PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Takeda, K; Yasumoto, K; Takada, R; Takada, S; Watanabe, K; Udono, T; Saito, H; Takahashi, K; Shibahara, S				Takeda, K; Yasumoto, K; Takada, R; Takada, S; Watanabe, K; Udono, T; Saito, H; Takahashi, K; Shibahara, S			Induction of melanocyte-specific microphthalmia-associated transcription factor by Wnt-3a	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WAARDENBURG SYNDROME TYPE-2; NEURAL CREST; HUMAN HOMOLOG; MITF GENE; MUTATIONS; PROTEIN; EXPRESSION; PROMOTER; ISOFORM; FAMILY	Microphthalmia-associated transcription factor (Mitf) plays a critical role in the development of neural crest-derived melanocytes. Here, we show that exogenously added Wnt-3a protein, an intercellular signaling molecule, up-regulates the expression of endogenous melanocyte-specific Mitf (Mitf-M) mRNA in cultured melanocytes. The melanocyte-specific promoter of the human MITF gene (MITF-M promoter) contains a functional LEF-1-binding site, which is bound in vitro by LEF-1 and confers the preferential expression on a reporter gene in melanocytes and melanoma cells, as judged by the transient transfection assays. Moreover, the LEF-1-binding site is required for the transactivation of a reporter gene by LEF-1, beta-catenin, or their combination. Exogenously added Wnt-3a protein also transactivates the MITF-M promoter via the LEF-1-binding site; this activation was abolished when a dominant-negative form of LEF-1 was coexpressed. These results suggest that Wnt-3a signaling recruits beta-catenin and LEF-1 to the LEF-1-binding site of the MITF-M promoter. Therefore, the present study identifies Mitf-M/MITF-M as a direct target of Wnt signaling.	Tohoku Univ, Sch Med, Dept Mol Biol & Appl Physiol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Japan Sci & Technol Corp, ERATO, Kondoh Differentiat Signaling Project, Sakyo Ku, Kyoto 6068305, Japan; Kyoto Univ, Grad Sch Sci, Ctr Mol & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan	Tohoku University; Japan Science & Technology Agency (JST); Kyoto University	Shibahara, S (corresponding author), Tohoku Univ, Sch Med, Dept Mol Biol & Appl Physiol, Aoba Ku, Sendai, Miyagi 9808575, Japan.		Shibahara, Shigeki/M-3644-2014; Takahashi, Kazuhiro/A-4887-2010	Takahashi, Kazuhiro/0000-0001-8943-1875; Takada, Shinji/0000-0003-4125-6056; Watanabe, Kenichi/0000-0002-5269-146X; Takada, Ritsuko/0000-0002-1615-056X; Yasumoto, Ken-ichi/0000-0002-8090-1161				Aksan I, 1998, MOL CELL BIOL, V18, P6930, DOI 10.1128/MCB.18.12.6930; Amae S, 1998, BIOCHEM BIOPH RES CO, V247, P710, DOI 10.1006/bbrc.1998.8838; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Dorsky RI, 1998, NATURE, V396, P370, DOI 10.1038/24620; Dorsky RI, 2000, GENE DEV, V14, P158; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; ERCOLANI L, 1988, J BIOL CHEM, V263, P15335; Fuse N, 1999, J BIOCHEM-TOKYO, V126, P1043, DOI 10.1093/oxfordjournals.jbchem.a022548; Fuse N, 1996, BIOCHEM BIOPH RES CO, V219, P702, DOI 10.1006/bbrc.1996.0298; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Ikeya M, 1997, NATURE, V389, P966, DOI 10.1038/40146; MOTOHASHI H, 1994, HEARING RES, V80, P10, DOI 10.1016/0378-5955(94)90003-5; Nakayama A, 1998, MECH DEVELOP, V70, P155, DOI 10.1016/S0925-4773(97)00188-3; Nobukuni Y, 1996, AM J HUM GENET, V59, P76; Price ER, 1998, J BIOL CHEM, V273, P33042, DOI 10.1074/jbc.273.49.33042; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SaintJeannet JP, 1997, P NATL ACAD SCI USA, V94, P13713, DOI 10.1073/pnas.94.25.13713; Shibamoto S, 1998, GENES CELLS, V3, P659; STECHSCHULTE DJ, 1987, J CELL PHYSIOL, V132, P565, DOI 10.1002/jcp.1041320321; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; TACHIBANA M, 1994, HUM MOL GENET, V3, P553, DOI 10.1093/hmg/3.4.553; Tachibana M, 1996, NAT GENET, V14, P50, DOI 10.1038/ng0996-50; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; TASSABEHJI M, 1995, HUM MOL GENET, V4, P2131, DOI 10.1093/hmg/4.11.2131; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; UDONO T, 2000, IN PRESS BIOCH BIOPH; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; Yajima I, 1999, HUM MOL GENET, V8, P1431, DOI 10.1093/hmg/8.8.1431; YASUMOTO K, 1995, J BIOCHEM-TOKYO, V118, P874, DOI 10.1093/jb/118.5.874; Yasumoto K, 1998, PIGM CELL RES, V11, P329, DOI 10.1111/j.1600-0749.1998.tb00491.x; Yasumoto K, 1997, J BIOL CHEM, V272, P503; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058	38	241	252	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14013	14016		10.1074/jbc.C000113200	http://dx.doi.org/10.1074/jbc.C000113200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10747853	hybrid			2022-12-27	WOS:000087006900003
J	Arakawa, H; Ahmad, R; Naoui, M; Tajmir-Riahi, HA				Arakawa, H; Ahmad, R; Naoui, M; Tajmir-Riahi, HA			A comparative study of calf thymus DNA binding to Cr(III) and Cr(VI) ions - Evidence for the guanine N-7-chromium-phosphate chelate formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; NUCLEIC-ACIDS; STRUCTURAL FORMS; CHROMIUM; POLY(DG-DC).POLY(DG-DC); CONFORMATION; POLY(DG-DC); CONDENSATION; REPLICATION; HYDRATION	Chromium(VI) salts are well known to be mutagens and carcinogens and to easily cross the cell membranes. Because they are powerful oxidizing agents, Cr(VD reacts with intracellular materials to reduce to trivalent form, which binds DNA. This study was designed to investigate the interaction of calf thymus DNA with Cr(VI) and Cr(IPI) in aqueous solution at pH 6.5-7.5, using Cr(VI)/DNA(P) molar ratios (r) of 1:20 to 2:1 and Cr(III)/DNA(P) molar ratios (r) of 1:80 to 1:2, W-visible and Fourier transform infrared (FTIR) difference spectroscopic methods were used to determine the metal ion-binding sites, binding constants, and the effect of cation complexation on DNA secondary structure. Spectroscopic results showed no interaction of Cr(VI) with DNA at low anion concentrations (r = 1:20 to 1:1), whereas some perturbations of DNA bases and backbone phosphate were observed at very high Cr(VI) contents (r > 1) with overall binding constant of K = 508 M-1. Cr(III) chelates DNA via guanine N-7 and the nearest PO2 group with overall binding constant of K = 3.15 x 10(3) m(-1) Evidence for cation chelate formation comes from major shiftings and intensity variations of the guanine band at 1717 and the phosphate asymmetric stretching vibration at 1222 cm(-1), At low Cr(III) concentration (r = 1:40), the number of Cr(III) ions bound to DNA were 6-7 cations/500 base pairs, and this increased to 30-35 cations/500 base pairs at high metal ion content (r = 1:4), DNA condensation occurred at high cation concentration (r = 1:10). No major alteration of DNA conformation was observed, and the biopolymer remained in the B family structure upon chromium complexation.	Univ Quebec, Dept Biol Chem, Trois Rivieres, PQ G9A 5H7, Canada	University of Quebec; University of Quebec Trois Rivieres	Tajmir-Riahi, HA (corresponding author), Univ Quebec, Dept Biol Chem, CP 500, Trois Rivieres, PQ G9A 5H7, Canada.							ALEX S, 1989, INORG CHIM ACTA, V157, P271, DOI 10.1016/S0020-1693(00)80552-6; BRAHMS S, 1974, ISRAEL J CHEM, V12, P153; BRIDGEWATER LC, 1994, MOL CARCINOGEN, V9, P122, DOI 10.1002/mc.2940090304; BRIDGEWATER LC, 1994, CARCINOGENESIS, V15, P2421, DOI 10.1093/carcin/15.11.2421; CONNETT PH, 1985, J AM CHEM SOC, V107, P4282, DOI 10.1021/ja00300a035; De Flora S, 1989, LIFE CHEM REPORTS, V7, P169; FLORO NA, 1984, BIOCHEM BIOPH RES CO, V124, P106, DOI 10.1016/0006-291X(84)90923-9; FORNACE AJ, 1981, CHEM-BIOL INTERACT, V36, P345, DOI 10.1016/0009-2797(81)90077-6; HNEIHEN AS, 1993, CARCINOGENESIS, V14, P1795, DOI 10.1093/carcin/14.9.1795; KELLER PB, 1986, NUCLEIC ACIDS RES, V14, P8167, DOI 10.1093/nar/14.20.8167; KLOTZ IM, 1971, BIOCHEMISTRY-US, V10, P3065, DOI 10.1021/bi00792a013; LOPRETE DM, 1993, BIOCHEMISTRY-US, V32, P4077, DOI 10.1021/bi00066a032; MALFOY B, 1981, NUCLEIC ACIDS RES, V9, P5659, DOI 10.1093/nar/9.21.5659; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; MOLLER A, 1981, P NATL ACAD SCI-BIOL, V78, P4777, DOI 10.1073/pnas.78.8.4777; Nakamoto K, 1963, INFRARED SPECTRA INO, P103; OSTERBERG R, 1984, J BIOMOL STRUCT DYN, V2, P285; PRESCOTT B, 1984, BIOPOLYMERS, V23, P235, DOI 10.1002/bip.360230206; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; SAGE E, 1980, P NATL ACAD SCI-BIOL, V77, P4597, DOI 10.1073/pnas.77.8.4597; SANTELLA RM, 1981, P NATL ACAD SCI-BIOL, V78, P1451, DOI 10.1073/pnas.78.3.1451; SEARLE CE, 1978, CHEM CARCINOGENESIS; SNOW ET, 1991, BIOCHEMISTRY-US, V30, P11238, DOI 10.1021/bi00111a007; Spiro T.G., 1987, BIOL APPL RAMAN SPEC, P83; STARIKOV EB, 1991, BIOPOLYMERS, V31, P255, DOI 10.1002/bip.360310302; Taillandier E., 1985, ADV INFRARED RAMAN S, P65; TAJMIRRIAHI HA, 1995, FEBS LETT, V370, P105, DOI 10.1016/0014-5793(95)00802-G; TSAPAKOS MJ, 1983, CANCER RES, V43, P5662; TSAPAKOS MJ, 1983, CARCINOGENESIS, V4, P959, DOI 10.1093/carcin/4.8.959; TSAPAKOS MJ, 1983, CHEM-BIOL INTERACT, V46, P265, DOI 10.1016/0009-2797(83)90034-0; Tsou TC, 1997, CHEM RES TOXICOL, V10, P962, DOI 10.1021/tx970040p; USHAY HM, 1982, NUCLEIC ACIDS RES, V10, P3573, DOI 10.1093/nar/10.11.3573; WEDRYCHOWSKI A, 1985, J BIOL CHEM, V260, P7150; WIDOM J, 1980, J MOL BIOL, V144, P431, DOI 10.1016/0022-2836(80)90330-7; WOLF T, 1989, CARCINOGENESIS, V10, P655, DOI 10.1093/carcin/10.4.655	35	248	260	3	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10150	10153		10.1074/jbc.275.14.10150	http://dx.doi.org/10.1074/jbc.275.14.10150			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744697	hybrid			2022-12-27	WOS:000086345600038
J	Carter, NS; Ben Mamoun, C; Liu, W; Silva, EO; Landfear, SM; Goldberg, DE; Ullman, B				Carter, NS; Ben Mamoun, C; Liu, W; Silva, EO; Landfear, SM; Goldberg, DE; Ullman, B			Isolation and functional characterization of the PfNT1 nucleoside transporter gene from Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALARIA-INFECTED ERYTHROCYTES; ADENOSINE TRANSPORTER; CLONING; PARASITES; EXPRESSION; MEMBRANE; ACID; PROTEINS; IDENTIFICATION; PERMEATION	Plasmodium falciparum, the causative agent of the most lethal form of human malaria, is incapable of de novo purine synthesis, and thus, purine acquisition from the host is an indispensable nutritional requirement. This purine salvage process is initiated by the transport of preformed purines into the parasite. We have identified a gene encoding a nucleoside transporter hom P. falciparum, PfNT1, and analyzed its function and expression during intraerythrocytic parasite development. PfNT1 predicts a polypeptide of 422 amino acids with 11 transmembrane domains that is homologous to other members of the equilibrative nucleoside transporter family. Southern analysis and BLAST searching of The Institute for Genomic Research (TIGR) malaria data base indicate that PfNT1 is a single copy gene located on chromosome 14, Northern analysis of RNA from intraerythrocytic stages of the parasite demonstrates that PfNT1 is expressed throughout the asexual life cycle but is significantly elevated during the early trophozoite stage. Functional expression of PfNT1 in Xenopus laevis oocytes significantly increases their ability to take up naturally occurring D-adenosine (K-m = 13.2 mu M) and D-inosine (K-m = 253 mu M) Significantly, PfNT1, unlike the mammalian nucleoside transporters, also has the capacity to transport the stereoisomer L-adenosine (K-m > 500 mu M). Inhibition studies with a battery of purine and pyrimidine nucleosides and bases as well as their analogs indicate that PfNT1 exhibits a broad substrate specificity for purine and pyrimidine nucleosides. These data provide compelling evidence that PfNT1 encodes a functional purine/pyrimidine nucleoside transporter whose expression is strongly developmentally regulated in the asexual stages of the P. falciparum life cycle. Moreover, the unusual ability to transport L-adenosine and the vital contribution of purine transport to parasite survival makes PfNT1 an attractive target for therapeutic evaluation.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med, St Louis, MO 63110 USA; Fed Univ Para, Dept Pathol, BR-66059 Belem, Para, Brazil	Oregon Health & Science University; Oregon Health & Science University; Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Universidade Federal do Para	Ullman, B (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.	ullmanb@ohsu.edu	Silva, Edilene O/B-8239-2015	Silva, Edilene/0000-0001-6555-6868	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044138, R01AI023682, R37AI023682] Funding Source: NIH RePORTER; NIAID NIH HHS [AI23682, AI44138] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARONOW B, 1987, MOL BIOCHEM PARASIT, V22, P29, DOI 10.1016/0166-6851(87)90066-1; Ben Mamoun C, 1999, P NATL ACAD SCI USA, V96, P8716, DOI 10.1073/pnas.96.15.8716; Beresford RM, 1995, P NZ PLAN P, V48, P89, DOI 10.30843/nzpp.1995.48.11498; CARTER NS, 1995, J BIOL CHEM, V270, P28153, DOI 10.1074/jbc.270.47.28153; CARTER NS, 1993, NATURE, V361, P173, DOI 10.1038/361173a0; Chiang CW, 1999, J BIOL CHEM, V274, P35255, DOI 10.1074/jbc.274.49.35255; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAIG JE, 1994, MOL MICROBIOL, V11, P1159, DOI 10.1111/j.1365-2958.1994.tb00392.x; Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; Fidock DA, 1997, P NATL ACAD SCI USA, V94, P10931, DOI 10.1073/pnas.94.20.10931; GATI WP, 1990, BIOCHEM J, V272, P277, DOI 10.1042/bj2720277; GERO AM, 1990, BLOOD CELLS, V16, P467; GERO AM, 1994, ADV EXP MED BIOL, V370, P493; Gero AM, 1999, NUCLEOS NUCLEOT, V18, P885, DOI 10.1080/15257779908041593; GERO AM, 1998, MOL BIOCHEM PARASIT, V27, P159; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; HALDAR K, 1986, P NATL ACAD SCI USA, V83, P8565, DOI 10.1073/pnas.83.22.8565; HANSEN SEW, 1987, EUR J BIOCHEM, V168, P385, DOI 10.1111/j.1432-1033.1987.tb13431.x; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; Keough DT, 1999, MOL BIOCHEM PARASIT, V98, P29, DOI 10.1016/S0166-6851(98)00139-X; KIRK K, 1994, J BIOL CHEM, V269, P3339; KIRK K, 1995, J BIOL CHEM, V270, P24270, DOI 10.1074/jbc.270.41.24270; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lauer SA, 1997, SCIENCE, V276, P1122, DOI 10.1126/science.276.5315.1122; Madani N, 1998, P NATL ACAD SCI USA, V95, P8005, DOI 10.1073/pnas.95.14.8005; Maniatis T., 1982, MOL CLONING; Maser P, 1999, SCIENCE, V285, P242, DOI 10.1126/science.285.5425.242; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PAJOR AM, 1992, J BIOL CHEM, V267, P3557; PASVOL G, 1992, BLOOD REV, V6, P183, DOI 10.1016/0268-960X(92)90014-H; Penny JI, 1998, MOL BIOCHEM PARASIT, V93, P81, DOI 10.1016/S0166-6851(98)00024-3; POUVELLE B, 1991, NATURE, V353, P73, DOI 10.1038/353073a0; REYES P, 1982, MOL BIOCHEM PARASIT, V5, P275, DOI 10.1016/0166-6851(82)90035-4; Saliba KJ, 1998, J BIOL CHEM, V273, P10190, DOI 10.1074/jbc.273.17.10190; Sanchez MA, 1999, J BIOL CHEM, V274, P30244, DOI 10.1074/jbc.274.42.30244; SCHWAB JC, 1995, MOL BIOCHEM PARASIT, V70, P59, DOI 10.1016/0166-6851(95)00005-L; Shi WX, 1999, BIOCHEMISTRY-US, V38, P9872, DOI 10.1021/bi990664p; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; UPSTON JM, 1995, BBA-BIOMEMBRANES, V1236, P249, DOI 10.1016/0005-2736(95)00055-8; Vasudevan G, 1998, P NATL ACAD SCI USA, V95, P9873, DOI 10.1073/pnas.95.17.9873; Vinkenoog R, 1998, MOL BIOCHEM PARASIT, V94, P1, DOI 10.1016/S0166-6851(98)00035-8; Wiser MF, 1997, P NATL ACAD SCI USA, V94, P9108, DOI 10.1073/pnas.94.17.9108; Woodrow CJ, 1999, J BIOL CHEM, V274, P7272, DOI 10.1074/jbc.274.11.7272; [No title captured]	50	115	121	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10683	10691		10.1074/jbc.275.14.10683	http://dx.doi.org/10.1074/jbc.275.14.10683			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744765	hybrid			2022-12-27	WOS:000086345600106
J	Mabuchi, T; Ichimura, Y; Takeda, M; Douglas, MMG				Mabuchi, T; Ichimura, Y; Takeda, M; Douglas, MMG			ASC1/RAS2 suppresses the growth defect on glycerol caused by the atp1-2 mutation in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; NUCLEOTIDE-BINDING DOMAIN; ALPHA-SUBUNIT; MITOCHONDRIAL ATPASE; PROTON-ATPASE; SUBMITOCHONDRIAL LOCALIZATION; ADENYLATE-CYCLASE; BETA-SUBUNIT; UNCA MUTANTS; RAS PROTEINS	To better define the regulatory role of the F-1-ATPase Lu-subunit in the catalytic cycle of the ATP synthase complex, we isolated suppressors of mutations occurring in ATP1, the gene for the alpha-subunit in Saccharomyces cerevisiae. First, two atp1 mutations (atp1-1 and atp1-2) mere characterized that prevent the growth of yeast on non-fermentable carbon sources. Both mutants contained full-length F-1 alpha-subunit proteins in mitochondria, but in lower amounts than that in the parental strain. Both mutants exhibited barely measurable F-1- ATPase activity. The primary mutations in atp1-1 and afp1-2 were identified as Thr(383)-->Ile and Gly(291)-->Asp, respectively. From recent structural data, position 383 lies within the catalytic site. Position 291 is located near the region affecting subunit-subunit interaction with the F(1)beta-subunit. An unlinked suppressor gene, ASC1 (alpha-subunit complementing) of the atp1-2 mutation (Gly(291) --> Asp) restored the growth defect phenotype on glycerol, but did not suppress either atp1-1 or the deletion mutant Delta atp1. Sequence analysis revealed that ASC1 was allelic with RAS2, a G-protein growth regulator. The introduction of ASC1/RAS2 into the atp1-2 mutant increased the F-1-ATPase enzyme activity in this mutant when the transformant was grown on glycerol, The possible mechanisms of ASC1/RAS2 suppression of atp1-2 are discussed; we suggest that RAS2 is part of the regulatory circuit involved ill the control of F-1-ATPase subunit levels in mitochondria.	Kumamoto Inst Technol, Dept Appl Microbial Technol, Ikeda, Kumamoto 8600082, Japan; Yamanashi Med Univ, Dept Biochem, Yamanashi 4093898, Japan; Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of Yamanashi; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Takeda, M (corresponding author), Kumamoto Inst Technol, Dept Appl Microbial Technol, Ikeda, Kumamoto 8600082, Japan.	takeda@bio.kumamoto-it.ac.jp	Peikertová, Pavlína/O-1756-2017	Peikertová, Pavlína/0000-0001-6272-2744	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036536] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM36536] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BOUTRY M, 1983, J BIOL CHEM, V258, P8524; BOYER PD, 1987, BIOCHEMISTRY-US, V26, P8503, DOI 10.1021/bi00400a001; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; BUSSEREAU F, 1992, CURR GENET, V21, P325, DOI 10.1007/BF00351690; CHANDRASEKARAN K, 1978, FEBS LETT, V87, P52, DOI 10.1016/0014-5793(78)80131-8; COX GB, 1992, MOL MECHANISMS BIOEN, P283; Cryer D R, 1975, Methods Cell Biol, V12, P39; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEFEOJONES D, 1983, NATURE, V306, P707, DOI 10.1038/306707a0; DOUGLAS MG, 1977, J BIOL CHEM, V252, P8333; DUNCAN TM, 1985, J BIOL CHEM, V260, P4901; DUPONT CH, 1990, CURR GENET, V17, P465, DOI 10.1007/BF00313073; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; FALSON P, 1991, J BIOL CHEM, V266, P287; FALSON P, 1993, BIOCHEMISTRY-US, V32, P10387, DOI 10.1021/bi00090a014; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GRESSER MJ, 1982, J BIOL CHEM, V257, P2030; HACK E, 1983, EMBO J, V2, P1783, DOI 10.1002/j.1460-2075.1983.tb01658.x; HARADA M, 1991, BIOCHIM BIOPHYS ACTA, V1056, P279, DOI 10.1016/S0005-2728(05)80059-3; LUIS AM, 1990, J BIOL CHEM, V265, P7713; MABUCHI T, 1993, ANAL BIOCHEM, V215, P158, DOI 10.1006/abio.1993.1569; MAGGIO MB, 1987, J BIOL CHEM, V262, P8981; MAHENDRAN R, 1991, NATURE, V349, P434, DOI 10.1038/349434a0; MCENTEE CM, 1993, MOL GEN GENET, V241, P213, DOI 10.1007/BF00280219; MORTIMER RK, 1992, YEAST, V8, P817, DOI 10.1002/yea.320081002; MUKHOPADHYAY A, 1994, FEBS LETT, V343, P160, DOI 10.1016/0014-5793(94)80310-2; MULLER G, 1987, YEAST, V3, P161, DOI 10.1002/yea.320030304; OMALLEY K, 1982, J BIOL CHEM, V257, P2097; PAGAN J, 1990, ARCH BIOCHEM BIOPHYS, V277, P283, DOI 10.1016/0003-9861(90)90580-R; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; PULLMAN ME, 1960, J BIOL CHEM, V235, P3322; RAO R, 1988, J BIOL CHEM, V263, P15957; RODEL G, 1985, J BACTERIOL, V161, P7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOGA S, 1989, ARCH BIOCHEM BIOPHYS, V268, P643, DOI 10.1016/0003-9861(89)90332-9; TAKEDA M, 1995, J BIOCHEM, V118, P607, DOI 10.1093/oxfordjournals.jbchem.a124953; Takeda M, 1999, YEAST, V15, P873, DOI 10.1002/(SICI)1097-0061(199907)15:10A<873::AID-YEA427>3.0.CO;2-A; TAKEDA M, 1986, J BIOL CHEM, V261, P5126; TATCHELL K, 1985, P NATL ACAD SCI USA, V82, P3785, DOI 10.1073/pnas.82.11.3785; THEVELEIN JM, 1992, ANTON LEEUW INT J G, V62, P109, DOI 10.1007/BF00584466; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; WISE JG, 1981, J BIOL CHEM, V256, P383; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; YUAN HB, 1992, J BIOL CHEM, V267, P14697	50	16	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10492	10497		10.1074/jbc.275.14.10492	http://dx.doi.org/10.1074/jbc.275.14.10492			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744740	hybrid, Green Published			2022-12-27	WOS:000086345600081
J	Yusof, R; Clum, S; Wetzel, M; Murthy, HMK; Padmanabhan, R				Yusof, R; Clum, S; Wetzel, M; Murthy, HMK; Padmanabhan, R			Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YELLOW-FEVER VIRUS; RNA-STIMULATED NTPASE; NS3 PROTEIN; NONSTRUCTURAL PROTEINS; STRUCTURAL PROTEINS; HELICASE ACTIVITY; KEX2 PROTEASE; IN-VITRO; PUTATIVE HELICASES; PROCESSING ENZYME	Dengue virus type 2 NS3, a multifunctional protein, has a serine protease domain (NS3pro) that requires the conserved hydrophilic domain of NS2B for protease activity in cleavage of the polyprotein precursor at sites following two basic amino acids. In this study, we report the expression of the NS2B-NS3pro precursor in Escherichia cole as a fusion protein with a histidine tag at the N terminus. The precursor was purified from insoluble inclusion bodies by Ni2+ affinity and gel filtration chromatography under denaturing conditions. The denatured precursor was refolded to yield a purified active protease complex. Biochemical analysis of the protease revealed that its activity toward either a natural substrate, NS4B-NS5 precursor, or the fluorogenic peptide substrates containing two basic residues at P1 and P2, was dependent on the presence of the NS2B domain. The peptide with a highly conserved Gly residue at P3 position was 3-fold more active as a substrate than a Gin residue at this position. The cleavage of a chromogenic substrate with a single Arg residue at P1 was NS2B-independent. These results suggest that heterodimerization of the NS3pro domain with NS2B generates additional specific interactions with the P2 and P3 residues of the substrates.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Univ Alabama Birmingham, Ctr Macromol Crystallog, Birmingham, AL 35294 USA	University of Kansas; University of Kansas Medical Center; University of Alabama System; University of Alabama Birmingham	Padmanabhan, R (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	rpadmana@kumc.edu	YUSOF, ROHANA/B-9589-2010	YUSOF, ROHANA/0000-0002-6591-3236	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032078, R21AI032078] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-32078] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMBERG SM, 1994, J VIROL, V68, P3794, DOI 10.1128/JVI.68.6.3794-3802.1994; ARIAS CF, 1993, VIROLOGY, V193, P888, DOI 10.1006/viro.1993.1198; BAZAN JF, 1989, VIROLOGY, V171, P637, DOI 10.1016/0042-6822(89)90639-9; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; BRENNER C, 1994, METHOD ENZYMOL, V244, P152; Brinkworth RI, 1999, J GEN VIROL, V80, P1167, DOI 10.1099/0022-1317-80-5-1167; CHAMBERS TJ, 1993, J VIROL, V67, P6797, DOI 10.1128/JVI.67.11.6797-6807.1993; CHAMBERS TJ, 1990, P NATL ACAD SCI USA, V87, P8898, DOI 10.1073/pnas.87.22.8898; Clum S, 1997, J BIOL CHEM, V272, P30715, DOI 10.1074/jbc.272.49.30715; DARKE PL, 1994, J BIOL CHEM, V269, P18708; FALGOUT B, 1993, J VIROL, V67, P2034, DOI 10.1128/JVI.67.4.2034-2042.1993; FALGOUT B, 1991, J VIROL, V65, P2467, DOI 10.1128/JVI.65.5.2467-2475.1991; FALGOUT B, 1995, J VIROL, V69, P7232, DOI 10.1128/JVI.69.11.7232-7243.1995; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P3889, DOI 10.1093/nar/17.10.3889; Gros C, 1996, VIROLOGY, V217, P367, DOI 10.1006/viro.1996.0125; IRIE K, 1989, GENE, V75, P197, DOI 10.1016/0378-1119(89)90266-7; JAN LR, 1995, J GEN VIROL, V76, P573, DOI 10.1099/0022-1317-76-3-573; Kadare G, 1997, J VIROL, V71, P2583; Kautner I, 1997, J PEDIATR-US, V131, P516, DOI 10.1016/S0022-3476(97)70054-4; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; KOONIN EV, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90338-A; Kuo MD, 1996, J GEN VIROL, V77, P2077, DOI 10.1099/0022-1317-77-9-2077; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li HT, 1999, J VIROL, V73, P3108, DOI 10.1128/JVI.73.4.3108-3116.1999; LIN C, 1993, J VIROL, V67, P2327, DOI 10.1128/JVI.67.4.2327-2335.1993; MARKOFF L, 1989, J VIROL, V63, P3345, DOI 10.1128/JVI.63.8.3345-3352.1989; MONATH TP, 1994, P NATL ACAD SCI USA, V91, P2395, DOI 10.1073/pnas.91.7.2395; Murthy HMK, 1999, J BIOL CHEM, V274, P5573, DOI 10.1074/jbc.274.9.5573; NESTOROWICZ A, 1994, VIROLOGY, V199, P114, DOI 10.1006/viro.1994.1103; NOWAK T, 1989, VIROLOGY, V169, P365, DOI 10.1016/0042-6822(89)90162-1; PREUGSCHAT F, 1991, VIROLOGY, V185, P689, DOI 10.1016/0042-6822(91)90540-R; PREUGSCHAT F, 1990, J VIROL, V64, P4364, DOI 10.1128/JVI.64.9.4364-4374.1990; RANDOLPH VB, 1990, VIROLOGY, V174, P450, DOI 10.1016/0042-6822(90)90099-D; RIKKONEN M, 1994, J VIROL, V68, P5804, DOI 10.1128/JVI.68.9.5804-5810.1994; Rockwell NC, 1998, BIOCHEMISTRY-US, V37, P3386, DOI 10.1021/bi972534r; Sali DL, 1998, BIOCHEMISTRY-US, V37, P3392, DOI 10.1021/bi972010r; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SARDANA VV, 1994, J BIOL CHEM, V269, P14337; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SPEIGHT G, 1989, VIROLOGY, V170, P299, DOI 10.1016/0042-6822(89)90383-8; Steinkuhler C, 1996, J BIOL CHEM, V271, P6367, DOI 10.1074/jbc.271.11.6367; Stocks CE, 1998, J VIROL, V72, P2141, DOI 10.1128/JVI.72.3.2141-2149.1998; SUZICH JA, 1993, J VIROL, V67, P6152, DOI 10.1128/JVI.67.10.6152-6158.1993; SVITKIN YV, 1984, VIROLOGY, V135, P536, DOI 10.1016/0042-6822(84)90207-1; Tai CL, 1996, J VIROL, V70, P8477, DOI 10.1128/JVI.70.12.8477-8484.1996; TAMURA JK, 1993, VIROLOGY, V193, P1, DOI 10.1006/viro.1993.1097; Teo KF, 1997, J GEN VIROL, V78, P337, DOI 10.1099/0022-1317-78-2-337; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Valle RPC, 1998, J VIROL, V72, P624, DOI 10.1128/JVI.72.1.624-632.1998; WARRENER P, 1993, J VIROL, V67, P989, DOI 10.1128/JVI.67.2.989-996.1993; WARRENER P, 1995, J VIROL, V69, P1720, DOI 10.1128/JVI.69.3.1720-1726.1995; WENGLER G, 1991, J GEN VIROL, V72, P851, DOI 10.1099/0022-1317-72-4-851; WENGLER G, 1991, VIROLOGY, V184, P707, DOI 10.1016/0042-6822(91)90440-M; YAMSHCHIKOV VF, 1993, VIROLOGY, V192, P38, DOI 10.1006/viro.1993.1006; ZHANG LW, 1992, J VIROL, V66, P7549, DOI 10.1128/JVI.66.12.7549-7554.1992	57	238	253	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					9963	9969		10.1074/jbc.275.14.9963	http://dx.doi.org/10.1074/jbc.275.14.9963			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744671	hybrid			2022-12-27	WOS:000086345600012
J	Argent, RH; Parrott, AM; Day, PJ; Roberts, LM; Stockley, PG; Lord, JM; Radford, SE				Argent, RH; Parrott, AM; Day, PJ; Roberts, LM; Stockley, PG; Lord, JM; Radford, SE			Ribosome-mediated folding of partially unfolded ricin A-chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA IDENTITY ELEMENTS; ALPHA-SARCIN LOOP; ENDOPLASMIC-RETICULUM; DIPHTHERIA-TOXIN; ESCHERICHIA-COLI; SYNTHETIC OLIGORIBONUCLEOTIDE; RETROGRADE TRANSPORT; TRANSMEMBRANE DOMAIN; PROTEIN-DEGRADATION; RIBONUCLEIC-ACID	After endocytic uptake by mammalian cells, the cytotoxic protein ricin is transported to the endoplasmic reticulum, whereupon the A-chain must cross the lumenal membrane to reach its ribosomal substrates. It is assumed that membrane traversal is preceded by unfolding of ricin A-chain, followed by refolding in the cytosol to generate the native, biologically active toxin. Here we describe biochemical and biophysical analyses of the unfolding of ricin A-chain and its refolding in vitro. We show that native ricin A-chain is surprisingly unstable at pH 7.0, unfolding non-cooperatively above 37 degrees C to generate a partially unfolded state, This species has conformational properties typical of a molten globule, and cannot be refolded to the native state by manip ulation of the buffer conditions or by the addition of a stem-loop dodecaribonucleotide or deproteinized Escherichia coli ribosomal RNA, both of which are substrates for ricin A-chain. By contrast, in the presence of salt-washed ribosomes, partially unfolded ricin A-chain regains full catalytic activity. The data suggest that the conformational stability of ricin A-chain is ideally poised for translocation from the endoplasmic reticulum, Within the cytosol, ricin A-chain molecules may then refold in the presence of ribosomes, resulting in ribosome depurination and cell death.	Univ Warwick, Dept Sci Biol, Coventry CV4 7AL, W Midlands, England; Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Fac Biol, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Warwick; University of Leeds; University of Leeds	Lord, JM (corresponding author), Univ Warwick, Dept Sci Biol, Coventry CV4 7AL, W Midlands, England.		PARROTT, ANDREW M/AAS-2111-2020	PARROTT, ANDREW M/0000-0002-7845-7479; Stockley, Peter/0000-0002-1360-2751; Radford, Sheena/0000-0002-3079-8039				ALLERSON CR, 1995, CHEM BIOL, V2, P667, DOI 10.1016/1074-5521(95)90030-6; ARGENT RH, 1994, J BIOL CHEM, V269, P26705; ARGENT RH, 1997, THESIS U WARWICK COV; BEAUMELLE B, 1993, J BIOL CHEM, V268, P23661; Bychkova VE, 1996, BIOCHEMISTRY-US, V35, P6058, DOI 10.1021/bi9522460; CHAN YL, 1983, J BIOL CHEM, V258, P2768; Chen XY, 1998, BIOCHEMISTRY-US, V37, P11605, DOI 10.1021/bi980990p; Das B, 1996, EUR J BIOCHEM, V235, P613, DOI 10.1111/j.1432-1033.1996.00613.x; DUMONT ME, 1988, J BIOL CHEM, V263, P2087; ENDO Y, 1987, J BIOL CHEM, V262, P8128; ENDO Y, 1991, J MOL BIOL, V221, P193, DOI 10.1016/0022-2836(91)90814-M; ENDO Y, 1988, J BIOL CHEM, V263, P7917; FEDOROV AN, 1992, J MOL BIOL, V228, P351, DOI 10.1016/0022-2836(92)90825-5; FUNATSU G, 1991, BIOCHIMIE, V73, P1157, DOI 10.1016/0300-9084(91)90160-3; GLUCK A, 1994, NUCLEIC ACIDS RES, V22, P321, DOI 10.1093/nar/22.3.321; GLUCK A, 1992, J MOL BIOL, V226, P414; GORDON VM, 1994, INFECT IMMUN, V62, P333, DOI 10.1128/IAI.62.2.333-340.1994; HARLEY SM, 1985, PLANT SCI, V41, P111, DOI 10.1016/0168-9452(85)90111-6; Hazes B, 1997, BIOCHEMISTRY-US, V36, P11051, DOI 10.1021/bi971383p; HU VW, 1984, J BIOL CHEM, V259, P2226; KATZIN BJ, 1991, PROTEINS, V10, P251, DOI 10.1002/prot.340100309; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Kudlicki W, 1997, FOLD DES, V2, P101, DOI 10.1016/S1359-0278(97)00014-X; LAMB FI, 1985, EUR J BIOCHEM, V148, P265, DOI 10.1111/j.1432-1033.1985.tb08834.x; Lord JM, 1998, J CELL BIOL, V140, P733; MARCHANT A, 1994, EUR J BIOCHEM, V226, P141, DOI 10.1111/j.1432-1033.1994.tb20035.x; MARCHANT A, 1995, J MOL BIOL, V254, P848, DOI 10.1006/jmbi.1995.0660; MAY MJ, 1989, EMBO J, V8, P301, DOI 10.1002/j.1460-2075.1989.tb03377.x; MURRAY JB, 1994, ANAL BIOCHEM, V218, P177, DOI 10.1006/abio.1994.1157; Olsnes S., 1988, IMMUNOTOXINS, P39; Orita M, 1996, NUCLEIC ACIDS RES, V24, P611, DOI 10.1093/nar/24.4.611; ORITA M, 1993, NUCLEIC ACIDS RES, V21, P5670, DOI 10.1093/nar/21.24.5670; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Rapak A, 1997, P NATL ACAD SCI USA, V94, P3783, DOI 10.1073/pnas.94.8.3783; ROBERTS L M, 1992, Current Opinion in Biotechnology, V3, P422, DOI 10.1016/0958-1669(92)90171-E; SANDVIG K, 1986, J BIOL CHEM, V261, P1639; SIMPSON JC, 1995, J BIOL CHEM, V270, P20078, DOI 10.1074/jbc.270.34.20078; Simpson JC, 1998, EXP CELL RES, V239, P293, DOI 10.1006/excr.1997.3921; Simpson JC, 1999, FEBS LETT, V459, P80, DOI 10.1016/S0014-5793(99)01222-3; Van Der Goot Francoise G., 1992, Trends in Cell Biology, V2, P343; WALES R, 1993, J BIOL CHEM, V268, P23986; WALES R, 1992, EXP CELL RES, V203, P1, DOI 10.1016/0014-4827(92)90032-4; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z; ZHAN HJ, 1994, BIOCHEMISTRY-US, V33, P11254, DOI 10.1021/bi00203a022; ZHAN HJ, 1995, BIOCHEMISTRY-US, V34, P4856, DOI 10.1021/bi00014a043	49	91	100	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9263	9269		10.1074/jbc.275.13.9263	http://dx.doi.org/10.1074/jbc.275.13.9263			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734065	hybrid			2022-12-27	WOS:000086206500029
J	Garcia, A; Cereghini, S; Sontag, E				Garcia, A; Cereghini, S; Sontag, E			Protein phosphatase 2A and phosphatidylinositol 3-kinase regulate the activity of Sp1-responsive promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SMALL-T-ANTIGEN; IMMUNODEFICIENCY-VIRUS TYPE-1; KINASE-C-ZETA; SV40 SMALL-T; TRANSCRIPTION FACTOR SP1; LONG TERMINAL REPEAT; DNA-BINDING ACTIVITY; SMALL TUMOR-ANTIGEN; GENE-EXPRESSION	The transcription factor Spl regulates the activity of a large number of eukaryotic gene promoters, including early SV40 and human immunodeficiency virus type 1 (HIV-1), Here, we report that expression of SV40 small tumor antigen (small t) in quiescent CV-1 cells transactivates two Spl-responsive promoters, including a deletion mutant of HIV-1 LTR, through specific inhibition of endogenous AC and AB alpha C forms of protein phosphatase 2A (PP2A). Expression of a small t mutant, lacking the PP2A-binding domain, failed to transactivate Spl. Overexpression of the B56 alpha, B56 beta, and B56 gamma 1 regulatory PP2A subunits strongly inhibited the ability of small t, but not the phosphatase inhibitor, okadaic acid, to enhance Spl-driven gene expression. Using inhibitors and co-expression of kinase-deficient mutants, we also show that functional phosphatidylinositol 3-kinase (PI 3-kinase) and atypical protein kinase C zeta are required for small t-induced Spl-dependent promoter transcriptional activation. Moreover, two inhibitors of PI 3-kinase, wortmannin and LY294002, inhibit the initiation of SV40 DNA replication in quiescent CV-1 cells. Taken together, these results suggest that PP2A and PI 3-kinase contribute to the ability of small t to regulate Spl activity, stimulate early SV40 DNA replication, and enhance the transformation of resting cells during SV40 infection.	Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Inst Necker, INSERM U423, F-75015 Paris, France; Inst Pasteur, Lab Signalisat Immunoparasitaire, URA CNRS 1960, Dept Immunol, F-75015 Paris, France	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Sontag, E (corresponding author), Univ Texas, SW Med Ctr, Dept Pathol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		SONTAG, ESTELLE/AAE-9805-2020		NIA NIH HHS [AG12300] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG012300] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BIKEL I, 1992, J VIROL, V66, P1489, DOI 10.1128/JVI.66.3.1489-1494.1992; BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; CHANG LJ, 1993, J VIROL, V67, P743, DOI 10.1128/JVI.67.2.743-752.1993; CICALA C, 1994, J VIROL, V68, P3138, DOI 10.1128/JVI.68.5.3138-3144.1994; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; GUNTHER M, 1995, MOL CELL BIOL, V15, P2490; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HARRICH D, 1989, J VIROL, V63, P2585, DOI 10.1128/JVI.63.6.2585-2591.1989; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAMIBAYASHI C, 1995, ADV PROT PHOSPHATASE, V9, P195; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KITADAI Y, 1992, BIOCHEM BIOPH RES CO, V189, P1342, DOI 10.1016/0006-291X(92)90221-6; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Lin SY, 1996, MOL CELL BIOL, V16, P1668; MARTIN RG, 1979, CELL, V17, P635, DOI 10.1016/0092-8674(79)90271-X; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; Mortensen ER, 1997, J BIOL CHEM, V272, P16540, DOI 10.1074/jbc.272.26.16540; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROSS EK, 1991, J VIROL, V65, P4350, DOI 10.1128/JVI.65.8.4350-4358.1991; Ruediger R, 1997, VIROLOGY, V238, P432, DOI 10.1006/viro.1997.8873; RUNDELL K, 1987, J VIROL, V61, P1240, DOI 10.1128/JVI.61.4.1240-1243.1987; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SHAO ZH, 1995, ONCOGENE, V10, P221; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SUNE C, 1995, J VIROL, V69, P6572; Tooze J, 1981, MOL BIOL TUMOR VIRUS; VIRSHUP DM, 1992, MOL CELL BIOL, V12, P4883, DOI 10.1128/MCB.12.11.4883; VLACH J, 1995, VIROLOGY, V208, P753, DOI 10.1006/viro.1995.1207; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WHEAT WH, 1994, MOL CELL BIOL, V14, P5881, DOI 10.1128/MCB.14.9.5881; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yurochko AD, 1997, J VIROL, V71, P4638, DOI 10.1128/JVI.71.6.4638-4648.1997	47	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9385	9389		10.1074/jbc.275.13.9385	http://dx.doi.org/10.1074/jbc.275.13.9385			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734082	hybrid			2022-12-27	WOS:000086206500046
J	Jabet, C; Sprague, ER; VanDemark, AP; Wolberger, C				Jabet, C; Sprague, ER; VanDemark, AP; Wolberger, C			Characterization of the N-terminal domain of the yeast transcriptional repressor Tup1 - Proposal for an association model of the repressor complex Tup1 center dot Ssn6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GLUCOSE REPRESSION; COILED COILS; BETA-SUBUNIT; TETRATRICOPEPTIDE REPEATS; COREPRESSOR COMPLEX; INVERTASE SYNTHESIS; GENERAL REPRESSOR; HOMEO DOMAIN; CO-REPRESSOR	The yeast Tup1 and Ssn6 proteins form a transcriptional repression complex that represses transcription of a broad array of genes. It has been shown that the N-terminal domain of the Tup1 protein interacts with a region of the Ssn6 protein that consists of 10 tandem copies of a tetratricopeptide motif. In this work, we use a surface plasmon resonance assay to measure the affinity of the N-terminal domain of Tup1 for a minimal 3-TPR domain of Saccharomyces cerevisiae SsnG that is sufficient for binding to Tup1. This domain of SsnG binds with comparable affinity to S. cerevisiae and Candida albicans Tup1, but with 100-fold lower affinity to Tup1 protein containing a point mutation that gives rise to a defect in repression in vivo. Results from studies using analytical ultracentrifugation, CD spectroscopy, limited proteolysis, and H-1 NMR show that this domain of Tup 1 is primarily alpha-helical and forms a stable tetramer that is highly nonglobular in shape. X-ray diffraction recorded from poorly ordered crystals of the Tup1 tetramerization domain contains fiber diffraction typical of a coiled coil. Our results are used to propose a model for the structure of the N-terminal domain of Tup1 and its interaction with the SsnG protein.	Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University	Wolberger, C (corresponding author), Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA.	cwolberg@jhmi.edu		VanDemark, Andrew/0000-0003-3424-4831; Sprague, Elizabeth/0000-0002-1603-3750; Wolberger, Cynthia/0000-0001-8578-2969				ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALASUBRAMANIAN B, 1993, MOL CELL BIOL, V13, P6071, DOI 10.1128/MCB.13.10.6071; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Braun BR, 1997, SCIENCE, V277, P105, DOI 10.1126/science.277.5322.105; CARLSON M, 1984, GENETICS, V107, P19; Carrico PM, 1998, GENETICS, V148, P637; Chen GQ, 1998, MOL CELL BIOL, V18, P7259, DOI 10.1128/MCB.18.12.7259; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COOPER JP, 1994, GENE DEV, V8, P1400, DOI 10.1101/gad.8.12.1400; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DELEAGE G, 1993, COMPUT APPL BIOSCI, V9, P197; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; ELLEDGE SJ, 1993, BIOESSAYS, V15, P333, DOI 10.1002/bies.950150507; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FLICK JS, 1990, MOL CELL BIOL, V10, P4757, DOI 10.1128/MCB.10.9.4757; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; HARTLEY DA, 1988, CELL, V55, P785, DOI 10.1016/0092-8674(88)90134-1; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; Komachi K, 1997, MOL CELL BIOL, V17, P6023, DOI 10.1128/MCB.17.10.6023; Kuchin S, 1998, MOL CELL BIOL, V18, P1163, DOI 10.1128/MCB.18.3.1163; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MUKAI Y, 1991, MOL CELL BIOL, V11, P3773, DOI 10.1128/MCB.11.7.3773; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; Parkhurst SM, 1998, TRENDS GENET, V14, P130, DOI 10.1016/S0168-9525(98)01407-3; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; RASMUSSEN R, 1991, P NATL ACAD SCI USA, V88, P561, DOI 10.1073/pnas.88.2.561; Redd MJ, 1997, J BIOL CHEM, V272, P11193; SCHULTZ J, 1990, MOL CELL BIOL, V10, P4744, DOI 10.1128/MCB.10.9.4744; SCHULTZ J, 1987, MOL CELL BIOL, V7, P3637, DOI 10.1128/MCB.7.10.3637; SMITH RL, 1995, GENE DEV, V9, P2903, DOI 10.1101/gad.9.23.2903; TANFORD C, 1961, PHYSICAL CHEM MACROM, P358; THRASHBINGHAM C, 1989, MOL CELL BIOL, V9, P809, DOI 10.1128/MCB.9.2.809; TREITEL MA, 1995, P NATL ACAD SCI USA, V92, P3132, DOI 10.1073/pnas.92.8.3132; TRUMBLY RJ, 1992, MOL MICROBIOL, V6, P15, DOI 10.1111/j.1365-2958.1992.tb00832.x; TRUMBLY RJ, 1986, J BACTERIOL, V166, P1123, DOI 10.1128/jb.166.3.1123-1127.1986; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; Varanasi US, 1996, MOL CELL BIOL, V16, P6707; Wahi M, 1998, COLD SPRING HARB SYM, V63, P447, DOI 10.1101/sqb.1998.63.447; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; ZHOU Z, 1992, GENETICS, V131, P851; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	54	34	36	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					9011	9018		10.1074/jbc.275.12.9011	http://dx.doi.org/10.1074/jbc.275.12.9011			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722750	hybrid			2022-12-27	WOS:000086507700100
J	Kim, JK; Gavrilova, O; Chen, Y; Reitmann, ML; Shulman, GI				Kim, JK; Gavrilova, O; Chen, Y; Reitmann, ML; Shulman, GI			Mechanism of insulin resistance in A-ZIP/F-1 fatless mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE FATTY-ACID; SKELETAL-MUSCLE; GLYCOGEN-SYNTHESIS; DIABETES-MELLITUS; GLUCOSE-UPTAKE; NIDDM; RATS; PATHOGENESIS; TRIGLYCERIDE; GLYCOLYSIS	Insulin resistance is a major factor in the pathogenesis of type 2 diabetes and may be related to alterations in fat metabolism, Fatless mice have been created using dominant-negative protein (A-ZIP/F-1) targeted gene expression in the adipocyte and shown to develop diabetes. To understand the mechanism responsible for the insulin resistance in these mice, we conducted hyperinsulinemic-euglycemic clamps in awake fatless and wild type littermates before the development of diabetes and examined insulin action and signaling in muscle and liver, We found the fatless mice to be severely insulin-resistant, which could be attributed to defects in insulin action in muscle and liver. Both of these abnormalities were associated with defects in insulin activation of insulin receptor substrate-1 and -2-associated phosphatidylinositol S-kinase activity and a 2-fold increase in muscle and liver triglyceride content. We also show that upon transplantation of fat tissue into these mice, triglyceride content in muscle and liver returned to normal as does insulin signaling and action, In conclusion, these results suggest that the development of insulin resistance in type 2 diabetes may be due to alterations in the partitioning of fat between the adipocyte and muscle/liver leading to accumulation of triglyceride in the latter tissues with subsequent impairment of insulin signaling and action.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst, New Haven, CT 06536 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06536 USA; NIDDKD, Diabet Branch, Bethesda, MD 20892 USA	Howard Hughes Medical Institute; Yale University; Yale University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Shulman, GI (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst, 295 Congress Ave,Box 9812,BCMM 254C, New Haven, CT 06536 USA.	gerald.shulman@yale.edu	Reitman, Marc/B-4448-2013; Shulman, Gerald I./P-7176-2019	Reitman, Marc/0000-0002-0426-9475; Shulman, Gerald I./0000-0003-1529-5668; Kim, Jason/0000-0002-7185-042X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK047031, R01DK040936, P30DK045735] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK040936, P30 DK-45735, R01 DK-40936] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Chalkley SM, 1998, METABOLISM, V47, P1121, DOI 10.1016/S0026-0495(98)90287-6; Cline GW, 1999, NEW ENGL J MED, V341, P240, DOI 10.1056/NEJM199907223410404; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; Gavrilova O, 2000, J CLIN INVEST, V105, P271, DOI 10.1172/JCI7901; Gavrilova O, 2000, NATURE, V403, P850, DOI 10.1038/35002663; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KELLEY DE, 1993, J CLIN INVEST, V92, P91, DOI 10.1172/JCI116603; Kim JK, 1996, DIABETES, V45, P446, DOI 10.2337/diabetes.45.4.446; Krssak M, 1999, DIABETOLOGIA, V42, P113, DOI 10.1007/s001250051123; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; OHSHIMA K, 1984, AM J PHYSIOL, V246, pE193, DOI 10.1152/ajpendo.1984.246.2.E193; Pan DA, 1997, DIABETES, V46, P983, DOI 10.2337/diabetes.46.6.983; Perseghin G, 1999, DIABETES, V48, P1600, DOI 10.2337/diabetes.48.8.1600; Petersen KF, 1998, DIABETES, V47, P381, DOI 10.2337/diabetes.47.3.381; Previs SF, 1999, DIABETES, V48, pA51; RANDLE PJ, 1963, LANCET, V1, P785; REAVEN GM, 1988, DIABETES, V37, P1020, DOI 10.2337/diabetes.37.8.1020; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; ROSSETTI L, 1990, J CLIN INVEST, V85, P1785, DOI 10.1172/JCI114636; ROTHMAN DL, 1995, P NATL ACAD SCI USA, V92, P983, DOI 10.1073/pnas.92.4.983; SchmitzPeiffer C, 1997, DIABETES, V46, P169, DOI 10.2337/diabetes.46.2.169; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280; VAAG AA, 1994, EUR J ENDOCRINOL, V130, P70, DOI 10.1530/eje.0.1300070; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; YOUN JH, 1994, DIABETES, V43, P564, DOI 10.2337/diabetes.43.4.564; ZORZANO A, 1985, BIOCHEM J, V232, P585, DOI 10.1042/bj2320585	32	331	342	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8456	8460		10.1074/jbc.275.12.8456	http://dx.doi.org/10.1074/jbc.275.12.8456			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722680	hybrid			2022-12-27	WOS:000086507700030
J	Sheng, SH; Li, JQ; McNulty, KA; Avery, D; Kleyman, TR				Sheng, SH; Li, JQ; McNulty, KA; Avery, D; Kleyman, TR			Characterization of the selectivity filter of the epithelial sodium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; SENSITIVE NA+ CHANNEL; CATION-PI INTERACTIONS; TOAD URINARY-BLADDER; POTASSIUM CHANNEL; ION SELECTIVITY; STRUCTURE PREDICTION; K+ CHANNEL; MEMBRANE TOPOLOGY; WEAVER MUTATION	The epithelial sodium channel (ENaC) is composed of three homologous subunits termed alpha, beta, and gamma. Previous studies suggest that selected residues within a hydrophobic region immediately preceding the second membrane-spanning domain of each subunit contribute to the conducting pore of ENaC. We probed the pore of mouse ENaC by systematically mutating all 24 amino acids within this putative pore region of the alpha-subunit to cysteine and co-expressing these mutants with wild type beta- and gamma-subunits of mouse ENaC in Xenopus laevis oocytes, Functional characteristics of these mutants were examined by two-electrode voltage clamp and single channel recording techniques. Two distinct domains were identified based on the functional changes associated with point mutations. An amino-terminal domain (alpha-Val(569)-alpha-Gly(579)) showed minimal changes in cation selectivity or amiloride sensitivity following cysteine substitution. In contrast, cysteine substitutions within the carboxyl-terminal domain (alpha-Ser(580)-alpha-Ser(592)) resulted in significant changes in cation selectivity and moderately altered amiloride sensitivity. The mutant channels containing alpha G587C or alpha S589C were permeable to K+, and mutation of a GSS tract (positions alpha 587-alpha 589) to GYG resulted in a moderately K+-selective channel. Our results suggest that the C-terminal portion of the pore region within the alpha-subunit contributes to the selectivity filter of ENaC.	Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; Vet Affairs Med Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center	Kleyman, TR (corresponding author), Div Renal, 700 Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.	kleyman@mail.med.upenn.edu	Sheng, Shaohu/G-7052-2016	Sheng, Shaohu/0000-0002-7198-1702	NIDDK NIH HHS [DK54354] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054354] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn YJ, 1999, AM J PHYSIOL-RENAL, V277, pF121, DOI 10.1152/ajprenal.1999.277.1.F121; BENOS DJ, 1980, J GEN PHYSIOL, V76, P233, DOI 10.1085/jgp.76.2.233; Busch AE, 1996, PFLUG ARCH EUR J PHY, V432, P760, DOI 10.1007/s004240050196; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Coscoy S, 1999, J BIOL CHEM, V274, P10129, DOI 10.1074/jbc.274.15.10129; Dart C, 1998, J PHYSIOL-LONDON, V511, P25, DOI 10.1111/j.1469-7793.1998.025bi.x; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Eskandari S, 1999, J BIOL CHEM, V274, P27281, DOI 10.1074/jbc.274.38.27281; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Frishman D, 1996, PROTEIN ENG, V9, P133, DOI 10.1093/protein/9.2.133; Fuller CM, 1997, BIOPHYS J, V72, P1622, DOI 10.1016/S0006-3495(97)78808-8; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; Guermeur Y, 1999, BIOINFORMATICS, V15, P413, DOI 10.1093/bioinformatics/15.5.413; HAMILTON KL, 1985, AM J PHYSIOL, V249, pC200, DOI 10.1152/ajpcell.1985.249.3.C200; Hoshi T, 1993, Curr Opin Neurobiol, V3, P283, DOI 10.1016/0959-4388(93)90119-J; Ismailov II, 1996, J BIOL CHEM, V271, P807, DOI 10.1074/jbc.271.2.807; Ismailov II, 1997, J PHYSIOL-LONDON, V504, P287, DOI 10.1111/j.1469-7793.1997.287be.x; Ismailov II, 1997, J BIOL CHEM, V272, P21075, DOI 10.1074/jbc.272.34.21075; Kellenberger S, 1999, P NATL ACAD SCI USA, V96, P4170, DOI 10.1073/pnas.96.7.4170; Kellenberger S, 1999, J GEN PHYSIOL, V114, P13, DOI 10.1085/jgp.114.1.13; King RD, 1996, PROTEIN SCI, V5, P2298, DOI 10.1002/pro.5560051116; Kofuji P, 1996, NEURON, V16, P941, DOI 10.1016/S0896-6273(00)80117-8; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; KUMPF RA, 1993, SCIENCE, V261, P1708, DOI 10.1126/science.8378771; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Moore DD, 1995, GLOB MOB SURV; PALMER LG, 1982, J MEMBRANE BIOL, V67, P91, DOI 10.1007/BF01868651; PALMER LG, 1990, RENAL PHYSIOL BIOCH, V13, P51; PALMER LG, 1987, J MEMBRANE BIOL, V96, P97, DOI 10.1007/BF01869236; PALMER LG, 1984, J MEMBRANE BIOL, V80, P153, DOI 10.1007/BF01868771; PATIL N, 1995, NAT GENET, V11, P126, DOI 10.1038/ng1095-126; PUOTI A, 1995, AM J PHYSIOL-CELL PH, V269, pC188, DOI 10.1152/ajpcell.1995.269.1.C188; RENARD S, 1994, J BIOL CHEM, V269, P12981; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; SHENG S, 1999, J AM SOC NEPHROL, V10, P43; Slesinger PA, 1996, NEURON, V16, P321, DOI 10.1016/S0896-6273(00)80050-1; Snyder PM, 1999, J BIOL CHEM, V274, P28484, DOI 10.1074/jbc.274.40.28484; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Tong YH, 1996, FEBS LETT, V390, P63, DOI 10.1016/0014-5793(96)00632-1; Tsushima RG, 1997, J GEN PHYSIOL, V109, P463, DOI 10.1085/jgp.109.4.463; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735; Williams K, 1998, MOL PHARMACOL, V53, P933; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	51	73	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8572	8581		10.1074/jbc.275.12.8572	http://dx.doi.org/10.1074/jbc.275.12.8572			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722696	hybrid			2022-12-27	WOS:000086507700046
J	Zhang, JH; Zhang, QY; Guo, JC; Zhou, YL; Ding, XX				Zhang, JH; Zhang, QY; Guo, JC; Zhou, YL; Ding, XX			Identification and functional characterization of a conserved, nuclear factor 1-like element in the proximal promoter region of CYP1A2 gene specifically expressed in the liver and olfactory mucosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOBARBITAL-RESPONSIVE ENHANCER; DNA-BINDING PROTEIN; CYTOCHROME P4501A2; MESSENGER-RNA; AH-RECEPTOR; REGULATORY ELEMENTS; FACTOR-I; TRANSCRIPTIONAL ACTIVATION; CONSTITUTIVE EXPRESSION; MOUSE	CYP1A2 is a major cytochrome P-450 isoform in the liver and the olfactory mucosa but is essentially not expressed in other tissues. A nuclear factor 1 (NF-1) -like element was identified in the proximal promoter region of rat, mouse, rabbit, and human CYP1A2 genes through data base analysis. In vitro DNase I footprinting with a -211 to +81 probe from the rat CYP1A2 gene and nuclear extracts from rat liver and olfactory mucosa revealed a single protected region corresponding to the NF-l-like element at -129 to -111, Protein binding to this NF-l-like element was tissue-selective and was confirmed by in vivo footprinting in native chromatin from rat liver. Multiple DNA-binding complexes were detected in gel-shift assays using the CYP1A2 NF-l-like element and nuclear extracts from liver and olfactory mucose, all of which were supershifted in the presence of an anti-NF1 antibody, The NF-l-like element was essential for transcriptional activity of the CYP1A2 gene in an in vitro transcription assay using nuclear extracts from the two tissues, Thus, members of the NF-1 family of transcription factors may play an important role in the tissue-selective expression of the CYP1A2 gene in the liver and olfactory mucosa.	New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA; SUNY Albany, Sch Publ Hlth, Dept Environm Hlth & Toxicol, Albany, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Ding, XX (corresponding author), New York State Dept Hlth, Wadsworth Ctr Labs & Res, Empire State Plaza,Box 509, Albany, NY 12201 USA.				NIDCD NIH HHS [DC-02640] Funding Source: Medline; NIEHS NIH HHS [ES-07642] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002640] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ADAMS AD, 1995, J BIOL CHEM, V270, P6975, DOI 10.1074/jbc.270.12.6975; AOYAMA T, 1990, ENDOCRINOLOGY, V126, P3101, DOI 10.1210/endo-126-6-3101; Baumeister H, 1999, MOL BRAIN RES, V72, P65, DOI 10.1016/S0169-328X(99)00210-7; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; CHUNG I, 1995, MOL PHARMACOL, V47, P677; Chung IJ, 1997, ARCH BIOCHEM BIOPHYS, V338, P220, DOI 10.1006/abbi.1996.9815; CHUNG IJ, 1994, ARCH BIOCHEM BIOPHYS, V314, P75, DOI 10.1006/abbi.1994.1413; Corcos L, 1998, FEBS LETT, V425, P293, DOI 10.1016/S0014-5793(98)00246-4; Dey A, 1999, BIOCHEM PHARMACOL, V58, P525, DOI 10.1016/S0006-2952(99)00110-0; DING X, 1993, CYTOCHROME P450 HDB, V105, P351; DING XX, 1992, DRUG METAB DISPOS, V20, P792; EATON DL, 1995, PHARMACOGENETICS, V5, P259, DOI 10.1097/00008571-199510000-00001; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; Fletcher CF, 1999, MAMM GENOME, V10, P390, DOI 10.1007/s003359901008; Gao B, 1998, J BIOL CHEM, V273, P31784, DOI 10.1074/jbc.273.48.31784; Genter MB, 1998, BIOCHEM PHARMACOL, V55, P1819, DOI 10.1016/S0006-2952(98)00004-5; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GILLNER M, 1987, CANCER RES, V47, P4150; Gonzalez FJ, 1996, FASEB J, V10, P1112, DOI 10.1096/fasebj.10.10.8751713; GONZALEZ FJ, 1985, J BIOL CHEM, V260, P5040; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P964, DOI 10.1128/MCB.5.5.964; GRONOSTAJSKI RM, 1987, NUCLEIC ACIDS RES, V15, P5545, DOI 10.1093/nar/15.14.5545; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Honkakoski P, 1997, J BIOL CHEM, V272, P14943, DOI 10.1074/jbc.272.23.14943; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; Huang JD, 1999, DRUG METAB DISPOS, V27, P98; IKEYA K, 1989, MOL ENDOCRINOL, V3, P1399, DOI 10.1210/mend-3-9-1399; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JONES KW, 1990, MOL CELL BIOL, V10, P5098, DOI 10.1128/MCB.10.10.5098; KIM J, 1991, BIOCHEMISTRY-US, V30, P10287, DOI 10.1021/bi00106a029; KIMURA S, 1986, MOL CELL BIOL, V6, P1471, DOI 10.1128/MCB.6.5.1471; LAETHEM RM, 1992, J PHARMACOL EXP THER, V262, P433; Liu SQ, 1998, DNA CELL BIOL, V17, P461, DOI 10.1089/dna.1998.17.461; Mace K, 1998, EUR J CANCER, V34, P914, DOI 10.1016/S0959-8049(98)00034-3; Maxam A M, 1980, Methods Enzymol, V65, P499; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL JP, 1989, SCIENCE, V245, P371; Morel Y, 1999, MOL CELL BIOL, V19, P6825; Morel Y, 1998, J BIOL CHEM, V273, P26969, DOI 10.1074/jbc.273.41.26969; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Nakajima M, 1999, J BIOCHEM-TOKYO, V125, P803, DOI 10.1093/oxfordjournals.jbchem.a022352; OWENS RA, 1990, BIOCHEM BIOPH RES CO, V172, P1109, DOI 10.1016/0006-291X(90)91561-6; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; PASCO DS, 1988, J BIOL CHEM, V263, P8671; QUATTROCHI LC, 1989, MOL PHARMACOL, V36, P66; QUATTROCHI LC, 1994, J BIOL CHEM, V269, P6949; Quattrochi LC, 1998, ARCH BIOCHEM BIOPHYS, V350, P41, DOI 10.1006/abbi.1997.0491; ROBERTS ES, 1992, MOL PHARMACOL, V41, P427; Ryu DY, 1996, MOL PHARMACOL, V50, P443; Sachse C, 1999, BRIT J CLIN PHARMACO, V47, P445, DOI 10.1046/j.1365-2125.1999.00898.x; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; SOGAWA K, 1985, J BIOL CHEM, V260, P5026; Stoltz C, 1999, BIOCHEM PHARMACOL, V57, P1073, DOI 10.1016/S0006-2952(98)00367-0; STROM DK, 1992, ARCH BIOCHEM BIOPHYS, V294, P707, DOI 10.1016/0003-9861(92)90745-I; Tamura Taka-Aki, 1996, Methods (Orlando), V10, P312, DOI 10.1006/meth.1996.0108; TUKEY RH, 1984, BIOCHEMISTRY-US, V23, P6003, DOI 10.1021/bi00320a016; UENO T, 1990, MOL CELL BIOL, V10, P4495, DOI 10.1128/MCB.10.9.4495; UENO T, 1990, NUCLEIC ACIDS RES, V18, P4623, DOI 10.1093/nar/18.15.4623; Wardlaw SA, 1998, CARCINOGENESIS, V19, P655, DOI 10.1093/carcin/19.4.655; WAXMAN DJ, 1988, ARCH BIOCHEM BIOPHYS, V263, P424, DOI 10.1016/0003-9861(88)90655-8; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; Welfare MR, 1999, PHARMACOGENETICS, V9, P367, DOI 10.1097/00008571-199906000-00012; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; Zhang JH, 1998, J BIOL CHEM, V273, P23454, DOI 10.1074/jbc.273.36.23454	68	26	26	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8895	8902		10.1074/jbc.275.12.8895	http://dx.doi.org/10.1074/jbc.275.12.8895			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722736	hybrid			2022-12-27	WOS:000086507700086
J	Doussau, F; Gasman, S; Humeau, Y; Vitiello, F; Popoff, M; Boquet, P; Bader, MF; Poulain, B				Doussau, F; Gasman, S; Humeau, Y; Vitiello, F; Popoff, M; Boquet, P; Bader, MF; Poulain, B			A Rho-related GTPase is involved in Ca2+-dependent neurotransmitter exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN-RHO; DIFFICILE TOXIN-B; SYNAPTIC VESICLES; ESCHERICHIA-COLI; LETHAL TOXIN; ADP-RIBOSYLTRANSFERASE; CHROMAFFIN CELLS; RAC; ACTIVATION; MEMBRANE	Rho, Rac, and Cdc42 monomeric GTPases are well known regulators of the actin cytoskeleton and phosphoinositide metabolism and have been implicated in hormone secretion in endocrine cells. Here, we examine their possible implication in Ca2+-dependent exocytosis of neurotransmitters. Using subcellular fractionation procedures, we found that RhoA,RhoB, Rac1, and Cdc42 are present in rat brain synaptosomes; however, only Rad was associates with highly purified synaptic vesicles. To determine the synaptic function of these GTPases, toxins that impair Rho-related proteins were microinjected into Aplysia neurons. We used lethal toxin from Clostridium sordellii, which inactivates Rac; toxin B from Clostridium difficile, which inactivates Rho, Rac, and Cdc42; and C3 exoenzyme from Clostridium bo;botulinum and cytotoxic necrotizing factor 1 from Escherichia coli, which mainly affect Rho. Analysis of the toxin effects on evoked acetylcholine release revealed that a member of the Rho family, most likely Rad, was implicated in the control of neurotransmitter release. Strikingly, blockage of acetylcholine release by lethal toxin and toxin B could be completely removed in <1 s by high frequency stimulation of nerve terminals. Further characterization of the inhibitory action produced by lethal toxin suggests that Rac1 protein regulates a late step in Ca2+-dependent neuroexocytosis.	CNRS, Lab Neurobiol Cellulaire, UPR 9009, F-67084 Strasbourg, France; INSERM, U338, F-67084 Strasbourg, France; Inst Pasteur, F-75724 Paris 15, France; INSERM U452, F-06107 Nice 2, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm)	Poulain, B (corresponding author), CNRS, Lab Neurobiol Cellulaire, UPR 9009, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.	poulain@neurochem.u-strasbg.fr	Bader, Marie-France/O-2098-2016; stéphane, gasman/Q-1145-2019; Gasman, Stephane/D-5113-2017	stéphane, gasman/0000-0001-8415-1276; Gasman, Stephane/0000-0001-8415-1276; Doussau, Frederic/0000-0002-3769-1402				Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Bajjalieh SM, 1999, CURR OPIN NEUROBIOL, V9, P321, DOI 10.1016/S0959-4388(99)80047-6; Bean AJ, 1997, NATURE, V385, P826, DOI 10.1038/385826a0; Bokoch GM, 1996, BIOCHEM J, V315, P775, DOI 10.1042/bj3150775; Brown AM, 1998, MOL BIOL CELL, V9, P1053, DOI 10.1091/mbc.9.5.1053; Calakos N, 1996, PHYSIOL REV, V76, P1; Cussac D, 1996, MOL CELL ENDOCRINOL, V119, P195, DOI 10.1016/0303-7207(96)03814-2; D'Silva NJ, 1998, AM J PHYSIOL-CELL PH, V274, pC1667, DOI 10.1152/ajpcell.1998.274.6.C1667; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Doussau F, 1998, J NEUROSCI, V18, P3147; Edwards RH, 1998, CURR BIOL, V8, pR883, DOI 10.1016/S0960-9822(07)00551-9; Fernandez-Chacon R, 1999, ANNU REV PHYSIOL, V61, P753, DOI 10.1146/annurev.physiol.61.1.753; Fiorentini C, 1997, J BIOL CHEM, V272, P19532, DOI 10.1074/jbc.272.31.19532; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; GARDNER D, 1971, SCIENCE, V173, P550, DOI 10.1126/science.173.3996.550; Gasman S, 1997, J BIOL CHEM, V272, P20564, DOI 10.1074/jbc.272.33.20564; Gasman S, 1998, J BIOL CHEM, V273, P16913, DOI 10.1074/jbc.273.27.16913; Geppert M, 1998, ANNU REV NEUROSCI, V21, P75, DOI 10.1146/annurev.neuro.21.1.75; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Johannes L, 1996, J CELL SCI, V109, P2875; JUST I, 1992, J BIOL CHEM, V267, P10274; Just I, 1996, J BIOL CHEM, V271, P10149, DOI 10.1074/jbc.271.17.10149; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KIM S, 1990, MOL CELL BIOL, V10, P2645, DOI 10.1128/MCB.10.6.2645; Klingauf J, 1998, NATURE, V394, P581, DOI 10.1038/29079; KLUO L, 1997, CURR OPIN NEUROBIOL, V7, P81; Kowluru A, 1997, BIOCHEM PHARMACOL, V54, P1097, DOI 10.1016/S0006-2952(97)00314-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lemichez E, 1997, MOL MICROBIOL, V24, P1061, DOI 10.1046/j.1365-2958.1997.4151781.x; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; MALLART A, 1968, J PHYSIOL-LONDON, V196, P593, DOI 10.1113/jphysiol.1968.sp008525; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; Martin Thomas F. J., 1994, Current Opinion in Neurobiology, V4, P626, DOI 10.1016/0959-4388(94)90002-7; Marvaud JC, 1998, MOL MICROBIOL, V29, P1009, DOI 10.1046/j.1365-2958.1998.00985.x; MATSUOKA I, 1990, BIOCHIM BIOPHYS ACTA, V1026, P99, DOI 10.1016/0005-2736(90)90338-O; MENARD L, 1992, EUR J BIOCHEM, V206, P537, DOI 10.1111/j.1432-1033.1992.tb16957.x; MIYAZAKI M, 1995, MOL BRAIN RES, V28, P29, DOI 10.1016/0169-328X(94)00180-M; MOCHIDA S, 1994, NEURON, V13, P1131, DOI 10.1016/0896-6273(94)90051-5; Morgan A, 1997, SEMIN CELL DEV BIOL, V8, P141, DOI 10.1006/scdb.1996.0133; NGSEE JK, 1991, J BIOL CHEM, V266, P2675; POPOFF MR, 1991, INFECT IMMUN, V59, P3673, DOI 10.1128/IAI.59.10.3673-3679.1991; POPOFF MR, 1987, INFECT IMMUN, V55, P35, DOI 10.1128/IAI.55.1.35-43.1987; Popoff MR, 1996, J BIOL CHEM, V271, P10217, DOI 10.1074/jbc.271.17.10217; Prepens U, 1996, J BIOL CHEM, V271, P7324, DOI 10.1074/jbc.271.13.7324; QUILLIAM LA, 1989, FEBS LETT, V247, P221, DOI 10.1016/0014-5793(89)81339-0; Ren XD, 1998, CURR OPIN GENET DEV, V8, P63, DOI 10.1016/S0959-437X(98)80063-4; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Sturani E, 1997, EXP CELL RES, V235, P117, DOI 10.1006/excr.1997.3660; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Taubenblatt P, 1999, J CELL SCI, V112, P3559; VOLKNANDT W, 1993, FEBS LETT, V317, P53, DOI 10.1016/0014-5793(93)81490-Q; Wang LY, 1998, NATURE, V394, P384, DOI 10.1038/28645	61	85	86	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7764	7770		10.1074/jbc.275.11.7764	http://dx.doi.org/10.1074/jbc.275.11.7764			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713089	hybrid			2022-12-27	WOS:000085913300049
J	Reckenfelderbaumer, N; Ludemann, H; Schmidt, H; Steverding, D; Krauth-Siegel, RL				Reckenfelderbaumer, N; Ludemann, H; Schmidt, H; Steverding, D; Krauth-Siegel, RL			Identification and functional characterization of thioredoxin from Trypanosoma brucei brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL HYDROPEROXIDE REDUCTASE; SEMI-DEFINED MEDIUM; RIBONUCLEOTIDE REDUCTASE; ESCHERICHIA-COLI; CRITHIDIA-FASCICULATA; TRYPANOTHIONE REDUCTASE; CRYSTAL-STRUCTURE; CLONING; EXPRESSION; PURIFICATION	Trypanosomes and Leishmania, the causative agents of several tropical diseases, lack the glultathione/glutathione reductase system but have trypanothione/ trypanothione reductase instead. The uniqueness of this thiol metabolism and the failure to detect thioredoxin reductases in these parasites have led to the suggestion that these protozoa lack a thioredoxin system. As presented here, this is not the case. A gene encoding thioredoxin has been cloned from Trypanosoma brucei, the causative agent of African sleeping sickness. The single copy gene, which encodes a protein of 107 amino acid residues, is expressed in all developmental stages of the parasite. The deduced protein sequence is 56% identical with a putative thioredoxin revealed by the genome pro ject of Leishmania major. The relationship to other thioredoxins is low. T. brucei thioredoxin is unusual in having a calculated pi value of 8.5. The gene has been overexpressed in Escherichia coli. The recombinant protein is a substrate of human thioredoxin reductase with a K-m value of 6 mu M but is not reduced by trypanothione reductase, T. brucei thioredoxin catalyzes the reduction of insulin by dithioerythritol, and functions as an electron donor for T. brucei ribonucleotide reductase. The parasite protein is the first classical thioredoxin of the order Kinetoplastida characterized so far.	Heidelberg Univ, Zentrum Biochem, D-69120 Heidelberg, Germany; Heidelberg Univ, Inst Hyg, Abt Parasitol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Krauth-Siegel, RL (corresponding author), Heidelberg Univ, Zentrum Biochem, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	krauth-siegel@urz.uni-heidelberg.de	Steverding, Dietmar/A-6947-2010; Steverding, Dietmar/ABD-9452-2021	Steverding, Dietmar/0000-0002-0050-7771				Andersen JF, 1997, BIOCHEMISTRY-US, V36, P13979, DOI 10.1021/bi971004s; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; BALTZ T, 1985, EMBO J, V4, P1273, DOI 10.1002/j.1460-2075.1985.tb03772.x; Brown DM, 1996, MOL BIOCHEM PARASIT, V83, P211, DOI 10.1016/S0166-6851(96)02776-4; BRUN R, 1979, ACTA TROP, V36, P289; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHEN NY, 1989, J GEN MICROBIOL, V135, P2931; CHOMCZYNSKI P, 1996, CURRENT PROTOCOLS MO, V1; Dormeyer M, 1997, FEBS LETT, V414, P449, DOI 10.1016/S0014-5793(97)01036-3; EKLUND H, 1984, EMBO J, V3, P1443, DOI 10.1002/j.1460-2075.1984.tb01994.x; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; ENGSTROM Y, 1979, BIOCHEMISTRY-US, V18, P2941, DOI 10.1021/bi00581a004; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; Gasdaska PY, 1999, FEBS LETT, V442, P105, DOI 10.1016/S0014-5793(98)01638-X; Gladyshev VN, 1999, BIOCHEM BIOPH RES CO, V259, P244, DOI 10.1006/bbrc.1999.0765; GLEASON FK, 1992, PROTEIN SCI, V1, P609, DOI 10.1002/pro.5560010507; Gommel DU, 1997, EUR J BIOCHEM, V248, P913, DOI 10.1111/j.1432-1033.1997.t01-1-00913.x; HALL DE, 1971, EUR J BIOCHEM, V23, P328, DOI 10.1111/j.1432-1033.1971.tb01625.x; HIRUMI H, 1980, PARASITOLOGY, V80, P371, DOI 10.1017/S0031182000000822; Hofer A, 1997, P NATL ACAD SCI USA, V94, P6959, DOI 10.1073/pnas.94.13.6959; Hofer A, 1998, J BIOL CHEM, V273, P34098, DOI 10.1074/jbc.273.51.34098; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1968, EUR J BIOCHEM, V6, P475, DOI 10.1111/j.1432-1033.1968.tb00470.x; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Hotz HR, 1998, MOL BIOCHEM PARASIT, V91, P131, DOI 10.1016/S0166-6851(97)00196-5; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; Jeong JS, 1999, BIOCHEMISTRY-US, V38, P776, DOI 10.1021/bi9817818; JONES SW, 1988, J BIOL CHEM, V263, P9607; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; Krauth-Siegel RL, 1999, PARASITOL TODAY, V15, P404, DOI 10.1016/S0169-4758(99)01516-1; KRAUTHSIEGEL RL, 1993, FEBS LETT, V317, P105, DOI 10.1016/0014-5793(93)81501-P; KrauthSiegel RL, 1996, MOL BIOCHEM PARASIT, V80, P203, DOI 10.1016/0166-6851(96)02689-8; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; LAURENT TC, 1964, J BIOL CHEM, V239, P3436; Ludemann H, 1998, FEBS LETT, V431, P381, DOI 10.1016/S0014-5793(98)00793-5; MATSUI M, 1995, GENE, V152, P165, DOI 10.1016/0378-1119(94)00707-Y; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V59, P327, DOI 10.1016/0166-6851(93)90231-L; Montemartini M, 1998, J BIOL CHEM, V273, P4864, DOI 10.1074/jbc.273.9.4864; Myler PJ, 1999, P NATL ACAD SCI USA, V96, P2902, DOI 10.1073/pnas.96.6.2902; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; OBLONG JE, 1993, BIOCHEMISTRY-US, V32, P7271, DOI 10.1021/bi00079a025; Pedrajas JR, 1999, J BIOL CHEM, V274, P6366, DOI 10.1074/jbc.274.10.6366; RIVERAMADRID R, 1995, P NATL ACAD SCI USA, V92, P5620, DOI 10.1073/pnas.92.12.5620; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schoneck R, 1997, EUR J BIOCHEM, V243, P739, DOI 10.1111/j.1432-1033.1997.00739.x; SULLIVAN FX, 1991, MOL BIOCHEM PARASIT, V44, P145, DOI 10.1016/0166-6851(91)90231-T; Tetaud E, 1998, MOL BIOCHEM PARASIT, V96, P111, DOI 10.1016/S0166-6851(98)00120-0; van Meirvenne N., 1975, Annales Soc belge Med trop, V55, P1; Wang PF, 1999, BIOCHEMISTRY-US, V38, P3187, DOI 10.1021/bi982674g; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; WILLING A, 1988, EUR J BIOCHEM, V170, P603, DOI 10.1111/j.1432-1033.1988.tb13740.x; WOLLMAN EE, 1988, J BIOL CHEM, V263, P15506	55	64	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7547	7552		10.1074/jbc.275.11.7547	http://dx.doi.org/10.1074/jbc.275.11.7547			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713060	hybrid			2022-12-27	WOS:000085913300020
J	Rosado, JA; Jenner, S; Sage, SO				Rosado, JA; Jenner, S; Sage, SO			A role for the actin cytoskeleton in the initiation and maintenance of store-mediated calcium entry in human platelets - Evidence for conformational coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FURA-2-LOADED HUMAN PLATELETS; ACTIVATED CA2+ INFLOW; GTP-BINDING PROTEIN; PLASMA-MEMBRANE; TYROSINE PHOSPHORYLATION; ENDOTHELIAL-CELLS; ERM PROTEINS; POLYMERIZATION; INHIBITION; JASPLAKINOLIDE	The nature of the mechanism underlying store-mediated Ca2+ entry has been investigated in human platelets through a combination of cytoskeletal modifications, Inhibition of actin polymerization by cytochalasin D or latrunculin A had a biphasic time-dependent effect on Ca2+ entry, showing an initial potentiation followed by inhibition of Ca2+ entry. Moreover, addition of these agents after induction of store-mediated Ca2+ Entry inhibited the Ca2+ influx mechanism. Jasplakinolide, which reorganizes actin filaments into a tight cortical layer adjacent to the plasma membrane, prevented activation of store-mediated Ca2+ entry but did not modify this process after its activation. In addition, jasplakinolide prevented cytochalasin D-induced inhibition of store-mediated Ca2+ entry. Calyculin A, an inhibitor of protein serine/threonine phosphatases 1 and 2 which activates translocation of existing F-actin to the cell periphery without inducing actin polymerization, also prevented activation of store-mediated Ca2+ entry. Finally, inhibition of vesicular transport with brefeldin A inhibited activation of store-mediated Ca2+ entry but did not alter this mechanism once initiated. These data suggest that store-mediated Ca2+ entry in platelets may be mediated by a reversible trafficking and coupling of the endoplasmic reticulum with the plasma membrane, which shows close parallels to the events mediating secretion.	Univ Cambridge, Dept Physiol, Cambridge CB2 3EG, England	University of Cambridge	Sage, SO (corresponding author), Univ Cambridge, Dept Physiol, Downing St, Cambridge CB2 3EG, England.		Rosado, Juan A/H-3488-2015	Rosado, Juan A/0000-0002-9749-2325; Sage, Stewart/0000-0001-8578-3558				ALVAREZ J, 1991, BIOCHEM J, V274, P193, DOI 10.1042/bj2740193; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BUBB MR, 1994, J BIOL CHEM, V269, P14869; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; Dong JF, 1998, J BIOL CHEM, V273, P31449, DOI 10.1074/jbc.273.47.31449; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; Fernando KC, 1997, BIOCHEM J, V328, P463; FOX JEB, 1981, NATURE, V292, P650, DOI 10.1038/292650a0; GILL DL, 1993, HDB EXPT PHARM GTPAS, V108, P625; Gregory RB, 1996, BIOCHEM J, V319, P755, DOI 10.1042/bj3190755; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; Hartwig JH, 1996, J BIOL CHEM, V271, P32986, DOI 10.1074/jbc.271.51.32986; Hishiya A, 1999, J BIOL CHEM, V274, P26705, DOI 10.1074/jbc.274.38.26705; Holda JR, 1997, FEBS LETT, V403, P191, DOI 10.1016/S0014-5793(97)00051-3; Marriott I, 1996, J BIOL CHEM, V271, P26732, DOI 10.1074/jbc.271.43.26732; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; Molony L, 1996, BIOCHEM BIOPH RES CO, V223, P612, DOI 10.1006/bbrc.1996.0943; PANDOL SJ, 1990, J BIOL CHEM, V265, P12846; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Petersen CCH, 1996, PFLUG ARCH EUR J PHY, V432, P286, DOI 10.1007/s004240050135; RADRIAMAMPITA C, 1993, NATURE, V364, P809; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; Rosado JA, 1998, BBA-MOL CELL RES, V1404, P412, DOI 10.1016/S0167-4889(98)00072-X; ROSADO JA, 1999, J PHYSL, V520, P20; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; RYSSIKORA KE, 1994, J BIOL CHEM, V269, P31607; SAGE SO, 1990, BIOCHEM J, V265, P675, DOI 10.1042/bj2650675; SARGEANT P, 1993, J BIOL CHEM, V268, P18151; SHINOKI N, 1995, J CELL BIOCHEM, V59, P368, DOI 10.1002/jcb.240590308; Shurety W, 1998, MOL BIOL CELL, V9, P957, DOI 10.1091/mbc.9.4.957; SIMONESCU N, 1983, CARDIOVASCULAR SYSTE, P371; Somasundaram B, 1996, J BIOL CHEM, V271, P26096, DOI 10.1074/jbc.271.42.26096; SOMASUNDARAM B, 1995, BIOCHEM J, V309, P725, DOI 10.1042/bj3090725; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; URBANIK E, 1989, ARCH BIOCHEM BIOPHYS, V269, P181, DOI 10.1016/0003-9861(89)90098-2; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; Vuist WMJ, 1997, THROMB HAEMOSTASIS, pP1089; YANO Y, 1995, BIOCHEM J, V307, P439, DOI 10.1042/bj3070439; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5	45	173	176	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7527	7533		10.1074/jbc.275.11.7527	http://dx.doi.org/10.1074/jbc.275.11.7527			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713057	hybrid			2022-12-27	WOS:000085913300017
J	Silberg, JJ; Vickery, LE				Silberg, JJ; Vickery, LE			Kinetic characterization of the ATPase cycle of the molecular chaperone Hsc66 from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK COGNATE PROTEIN; ALKALINE-PHOSPHATASE; PEPTIDE BINDING; DNAK; GRPE; HSP70; SYSTEM; GENE; HSC70; DISSOCIATION	Hsc66 from Escherichia coli is a constitutively expressed hsp70 class molecular chaperone whose activity is coupled to ATP binding and hydrolysis. To better understand the mechanism and regulation of Hsc66, we investigated the kinetics of ATP hydrolysis and the interactions of Hsc66 with nucleotides. Steady-state experiments revealed that Hsc66 has a low affinity for ATP (K-m(ATP) = 12.7 mu M) compared with other hsp70 chaperones. The kinetics of nucleotide binding were determined by analyzing changes in the Hsc66 absorbance spectrum using stopped-flow methods at 23 degrees C, ATP binding results in a rapid, biphasic increase of Hsc66 absorbance at 280 nm; this is interpreted as arising from a two-step process in which ATP binding (k(a)(ATP) = 4.2 X 10(4) M-1 s(-1), K-d(ATP) = 1.1 S-1) is followed by a slow conformational change (k(conf) = 0.1 s(-1)). Under single turnover conditions, the ATP-induced transition decays exponentially with a rate (k(decay) = 0.0013 s(-1)) similar to that observed in both steady-state and single turnover ATP hydrolysis experiments (k(hyd) - 0.0014 s(-1)). ADP binding to Hsc66 results in a monophasic transition in the absence (k(a)(ADP) = 7 x 10(5) M-1 s(-1), k(d)(ADP) = 60 S-1) and presence of physiological levels of inorganic phosphate (k(a)(ADP(Pi)) = 0.28 x 10(5) M-1 s(-1), k(d)(ADP(Pi)) = 9.1 S-1). These results indicate that ATP hydrolysis is the rate-limiting step under steady-state conditions and is >10(3)-fold slower than the rate of ADP/ATP exchange. Thus, in contrast to DnaK and eukaryotic forms of hsp70 that have been characterized to date, the R double left right arrow T equilibrium balance for Hsc66 is shifted in favor of the low peptide affinity T state, and regulation of the reaction cycle is expected to occur at the ATP hydrolysis step rather than at nucleotide exchange.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine	Vickery, LE (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.		Silberg, Jonathan J/A-3817-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054624] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54624, GM07311] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banecki B, 1996, J BIOL CHEM, V271, P6137, DOI 10.1074/jbc.271.11.6137; BOCK JL, 1978, J BIOL CHEM, V253, P4082; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; EPSTEIN W, 1965, J GEN PHYSIOL, V49, P221, DOI 10.1085/jgp.49.2.221; Farr CD, 1998, J BIOL CHEM, V273, P9744, DOI 10.1074/jbc.273.16.9744; Feifel B, 1996, EUR J BIOCHEM, V237, P318, DOI 10.1111/j.1432-1033.1996.0318n.x; FERSHT A, 1985, ENZYME STRUCTURE MEC, P131; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Ha JH, 1997, J BIOL CHEM, V272, P27796, DOI 10.1074/jbc.272.44.27796; HA JH, 1994, BIOCHEMISTRY-US, V33, P14625, DOI 10.1021/bi00252a031; HA JH, 1995, BIOCHEMISTRY-US, V34, P11635, DOI 10.1021/bi00036a040; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Hesterkamp T, 1998, EMBO J, V17, P4818, DOI 10.1093/emboj/17.16.4818; HOHFELD J, 1995, CELL, V83, P589; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; KAWULA TH, 1994, J BACTERIOL, V176, P610, DOI 10.1128/jb.176.3.610-619.1994; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Martin J, 1997, CURR OPIN STRUC BIOL, V7, P41, DOI 10.1016/S0959-440X(97)80006-1; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; Neuhard J, 1987, ESCHERICHIA COLI SAL, P445; OBRIEN MC, 1995, J BIOL CHEM, V270, P2247, DOI 10.1074/jbc.270.5.2247; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Pierpaoli EV, 1997, J MOL BIOL, V269, P757, DOI 10.1006/jmbi.1997.1072; Pierpaoli EV, 1998, J BIOL CHEM, V273, P6643, DOI 10.1074/jbc.273.12.6643; Press W.H., 1992, NUMERICAL RECIPES C, P683; RAO NN, 1993, J BACTERIOL, V175, P74, DOI 10.1128/JB.175.1.74-79.1993; Russell R, 1999, BIOCHEMISTRY-US, V38, P4165, DOI 10.1021/bi9824036; Russell R, 1998, BIOCHEMISTRY-US, V37, P596, DOI 10.1021/bi972025p; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SEATON BL, 1994, P NATL ACAD SCI USA, V91, P2066, DOI 10.1073/pnas.91.6.2066; SHULMAN RG, 1979, SCIENCE, V205, P160, DOI 10.1126/science.36664; Silberg JJ, 1998, J BACTERIOL, V180, P6617, DOI 10.1128/JB.180.24.6617-6624.1998; Slepenkov SV, 1998, BIOCHEMISTRY-US, V37, P1015, DOI 10.1021/bi9720484; Steinfeld JL, 1989, CHEM KINETICS DYNAMI, p[22, 124]; Takeda S, 1996, BIOCHEMISTRY-US, V35, P4636, DOI 10.1021/bi952903o; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; Vickery LE, 1997, PROTEIN SCI, V6, P1047, DOI 10.1002/pro.5560060511; WILBANKS SM, 1994, J BIOL CHEM, V269, P12893; WILLSKY GR, 1976, J BACTERIOL, V127, P595, DOI 10.1128/JB.127.1.595-609.1976; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264; ZIEGELHOFFER T, 1995, J BIOL CHEM, V270, P10412, DOI 10.1074/jbc.270.18.10412	48	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7779	7786		10.1074/jbc.275.11.7779	http://dx.doi.org/10.1074/jbc.275.11.7779			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713091	hybrid			2022-12-27	WOS:000085913300051
J	Zechiedrich, EL; Khodursky, AB; Bachellier, S; Schneider, R; Chem, DR; Lilley, DMJ; Cozzarelli, NR				Zechiedrich, EL; Khodursky, AB; Bachellier, S; Schneider, R; Chem, DR; Lilley, DMJ; Cozzarelli, NR			Roles of topoisomerases in maintaining steady-state DNA supercoiling in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; I MUTANTS; LEU-500 PROMOTER; CHROMOSOME SEGREGATION; BACTERIOPHAGE-LAMBDA; SUPERHELICAL TURNS; GYRASE GENES; PLASMID DNA; TRANSCRIPTION; REPLICATION	DNA supercoiling is essential for bacterial cell survival. We demonstrated that DNA topoisomerase IV acting in concert with topoisomerase I and gyrase, makes an important contribution to the steady-state level of supercoiling in Escherichia coli, Following inhibition of gyrase, topoisomerase IV alone relaxed plasmid DMA to a final supercoiling density (a) of -0.015 at an initial rate of 0.8 links min-l. Topoisomerase I relaxed DNA at a faster rate, 5 links min-l, but only to a a of -0.05, Inhibition of topoisomerase IV in wild-type cells increased supercoiling to approximately the same level as in a mutant lacking topoisomerase I activity (to sigma = -0.08). The role of topoisomerase IV was revealed by two functional assays. Removal of both topoisomerase 1 and topoisomerase IV caused the DNA to become hyper-negatively supercoiled (sigma = -0.09), greatly stimulating transcription from the supercoiling sensitive leu-500 promoter and increasing the number of supercoils trapped by A integrase site-specific recombination.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Biophys Grp, Berkeley, CA 94720 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Univ Dundee, Dept Biochem, Canc Res Campaign, Nucle Acid Struct Res Grp, Dundee DD1 4HN, Scotland; Univ Munich, Inst Genet & Mikrobiol, D-80638 Munich, Germany	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Baylor College of Medicine; University of Dundee; University of Munich	Zechiedrich, EL (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	elz@bcm.tmc.edu	Zechiedrich, Elizabeth Lynn/S-4720-2019; Bachellier-Bassi, Sophie/AAB-7981-2020	Bachellier-Bassi, Sophie/0000-0003-3970-4825; Zechiedrich, Lynn/0000-0003-0533-1637	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031657, R37GM031657] Funding Source: NIH RePORTER; Cancer Research UK [11722] Funding Source: Medline; NIEHS NIH HHS [ESO1890] Funding Source: Medline; NIGMS NIH HHS [GM 31657] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Cancer Research UK(Cancer Research UK); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; ARNOLD GF, 1986, J BACTERIOL, V170, P4266; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; Berger JM, 1998, CURR OPIN STRUC BIOL, V8, P26, DOI 10.1016/S0959-440X(98)80006-7; BLATTNER FR, 1993, NUCLEIC ACIDS RES, V21, P5408; BLISKA JB, 1991, J BIOL CHEM, V266, P2041; BLISKA JB, 1987, J MOL BIOL, V194, P205, DOI 10.1016/0022-2836(87)90369-X; BOLES TC, 1990, J MOL BIOL, V213, P931, DOI 10.1016/S0022-2836(05)80272-4; CHEN DR, 1992, P NATL ACAD SCI USA, V89, P8784, DOI 10.1073/pnas.89.18.8784; CHEN DR, 1993, BIOCHEMISTRY-US, V32, P13162, DOI 10.1021/bi00211a027; CHEN DR, 1994, J BACTERIOL, V176, P3757, DOI 10.1128/JB.176.12.3757-3764.1994; CRISONA NJ, 1994, J MOL BIOL, V243, P437, DOI 10.1006/jmbi.1994.1671; DIGATE RJ, 1989, J BIOL CHEM, V264, P17924; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; DORMAN CJ, 1989, MOL MICROBIOL, V3, P531, DOI 10.1111/j.1365-2958.1989.tb00199.x; Drlica K, 1997, MICROBIOL MOL BIOL R, V61, P377, DOI 10.1128/.61.3.377-392.1997; Eckstein F., 1995, NUCLEIC ACIDS MOL BI, P115; FREE A, 1994, MOL MICROBIOL, V14, P151, DOI 10.1111/j.1365-2958.1994.tb01275.x; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; Harmon FG, 1999, MOL CELL, V3, P611, DOI 10.1016/S1097-2765(00)80354-8; Hartsuiker E, 1998, MOL BIOL CELL, V9, P2739, DOI 10.1091/mbc.9.10.2739; Hiasa H, 1996, J BIOL CHEM, V271, P21529, DOI 10.1074/jbc.271.35.21529; HIGGINS NP, 1978, P NATL ACAD SCI USA, V75, P1773, DOI 10.1073/pnas.75.4.1773; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO J, 1992, J BIOL CHEM, V267, P25676; KATO JI, 1988, J BACTERIOL, V170, P3967, DOI 10.1128/jb.170.9.3967-3977.1988; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; KHODURSKY AB, 1995, P NATL ACAD SCI USA, V92, P11801, DOI 10.1073/pnas.92.25.11801; Khodursky AB, 1998, J BIOL CHEM, V273, P27668, DOI 10.1074/jbc.273.42.27668; KHODURSKY AB, 1997, THESIS U CALIFORNIA; Levine C, 1998, BBA-GENE STRUCT EXPR, V1400, P29, DOI 10.1016/S0167-4781(98)00126-2; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LOCKSHON D, 1983, NUCLEIC ACIDS RES, V11, P2999, DOI 10.1093/nar/11.10.2999; LYNCH AS, 1993, J BACTERIOL, V175, P1645, DOI 10.1128/JB.175.6.1645-1655.1993; MARIANS KJ, 1986, PROG NUCLEIC ACID RE, V33, P111, DOI 10.1016/S0079-6603(08)60021-5; Masse E, 1999, J BIOL CHEM, V274, P16654, DOI 10.1074/jbc.274.23.16654; MCNAIRN E, 1995, MOL MICROBIOL, V15, P507, DOI 10.1111/j.1365-2958.1995.tb02264.x; MENZEL R, 1983, CELL, V34, P105, DOI 10.1016/0092-8674(83)90140-X; MENZEL R, 1987, J BACTERIOL, V169, P1272, DOI 10.1128/jb.169.3.1272-1278.1987; MENZEL R, 1987, P NATL ACAD SCI USA, V84, P4185, DOI 10.1073/pnas.84.12.4185; MILLER JH, 1972, EXPT GENETICS; MIZUUCHI K, 1980, J MOL BIOL, V141, P485, DOI 10.1016/0022-2836(80)90256-9; MUSKHELISHVILI G, 1995, EMBO J, V14, P1446, DOI 10.1002/j.1460-2075.1995.tb07131.x; NASH HA, 1990, TRENDS BIOCHEM SCI, V15, P222, DOI 10.1016/0968-0004(90)90034-9; OGATA Y, 1994, MOL GEN GENET, V244, P451, DOI 10.1007/BF00583895; ORR E, 1979, MOL GEN GENET, V177, P103, DOI 10.1007/BF00267259; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; PRUSS GJ, 1985, J MOL BIOL, V185, P51, DOI 10.1016/0022-2836(85)90182-2; PRUSS GJ, 1986, P NATL ACAD SCI USA, V83, P8952, DOI 10.1073/pnas.83.23.8952; PRUSS GJ, 1989, CELL, V56, P521, DOI 10.1016/0092-8674(89)90574-6; PRUSS GJ, 1982, CELL, V31, P35, DOI 10.1016/0092-8674(82)90402-0; RAJI A, 1985, J BACTERIOL, V162, P1173, DOI 10.1128/JB.162.3.1173-1179.1985; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOFIELD MA, 1992, J BACTERIOL, V174, P5168, DOI 10.1128/JB.174.15.5168-5170.1992; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; SINGH H, 1991, Indian Journal of Pharmaceutical Sciences, V53, P1; STECK TR, 1984, CELL, V36, P1081, DOI 10.1016/0092-8674(84)90058-8; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; TSEDINH YC, 1985, NUCLEIC ACIDS RES, V13, P4751, DOI 10.1093/nar/13.13.4751; Uematsu N, 1997, MUTAT RES-DNA REPAIR, V383, P223, DOI 10.1016/S0921-8777(97)00005-0; Ullsperger C, 1996, J BIOL CHEM, V271, P31549, DOI 10.1074/jbc.271.49.31549; Vologodskii A, 1996, BIOPHYS J, V70, P2548, DOI 10.1016/S0006-3495(96)79826-0; VOLOGODSKII AV, 1994, ANNU REV BIOPH BIOM, V23, P609, DOI 10.1146/annurev.bb.23.060194.003141; VOLOGODSKII AV, 1992, TOPOLOGY PHSYICS CIR; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WASSERMAN SA, 1986, SCIENCE, V232, P951, DOI 10.1126/science.3010458; WHORISKEY SK, 1991, GENETICS, V127, P21; YOSHIDA H, 1988, MOL GEN GENET, V211, P1, DOI 10.1007/BF00338386; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x; Zechiedrich EL, 1997, GENE DEV, V11, P2580, DOI 10.1101/gad.11.19.2580; ZECHIEDRICH EL, 1995, GENE DEV, V9, P2859, DOI 10.1101/gad.9.22.2859	75	235	239	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8103	8113		10.1074/jbc.275.11.8103	http://dx.doi.org/10.1074/jbc.275.11.8103			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713132	hybrid			2022-12-27	WOS:000085913300092
J	LeRoy, G; Loyola, A; Lane, WS; Reinberg, D				LeRoy, G; Loyola, A; Lane, WS; Reinberg, D			Purification and characterization of a human factor that assembles and remodels chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE OCTAMER; IN-VITRO; NUCLEOSOME; COMPLEX; ISWI; TRANSCRIPTION; ELONGATION; NUCLEASE; PARTICLE; CHRAC	We have previously reported the isolation and characterization of a nucleosome remodeling and spacing factor, RSF. One of the RSF subunits is hSNF2h, a SNF2 homologue. Here we set out to isolate and characterize other hSNF2h-containing complexes. We have identified a novel hSNF2h complex that facilitates ATP-dependent chromatin assembly with the histone chaperone NAP-1. The complex possesses ATPase activity that is DNA-dependent and nucleosome-stimulated. This complex is capable of facilitating ATP-dependent nucleosome remodeling and transcription initiation from chromatin templates. In addition to hSNF2h, this complex also contains a 190-kDa protein encoded by the BAZ1A gene. Since both subunits are homologues of the Drosophila ACF complex (ATP-utilizing chromatin assembly and remodeling factor), we have named this factor human ACF or hACF.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucle Acid Enzymol,Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Harvard Univ, Harvard Microchem Facil, Cambridge, MA 02138 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Harvard University	Reinberg, D (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucle Acid Enzymol,Howard Hughes Med Inst, Piscataway, NJ 08854 USA.	reinbedf@umdnj.edu	Loyola, Alejandra/ABE-8337-2020	Reinberg, Danny/0000-0003-4288-2016	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037120, R37GM037120] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37120] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexiadis V, 1998, EMBO J, V17, P3428, DOI 10.1093/emboj/17.12.3428; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Bochar DA, 2000, P NATL ACAD SCI USA, V97, P1038, DOI 10.1073/pnas.97.3.1038; Bulger M., 1994, METH MOL G, V5, P241; Corona DFV, 1999, MOL CELL, V3, P239, DOI 10.1016/S1097-2765(00)80314-7; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Jones MH, 2000, GENOMICS, V63, P40, DOI 10.1006/geno.1999.6071; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; Lu XJ, 1998, GENOMICS, V54, P241, DOI 10.1006/geno.1998.5578; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mizuguchi G, 1997, MOL CELL, V1, P141, DOI 10.1016/S1097-2765(00)80015-5; NOLL M, 1977, J MOL BIOL, V109, P393, DOI 10.1016/S0022-2836(77)80019-3; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; SPADAFORA C, 1976, FEBS LETT, V69, P281, DOI 10.1016/0014-5793(76)80704-1; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; van Holde KE., 1989, SPRINGER SERIES MOL; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Wolffe A., 1995, CHROMATIN STRUCTURE; Yudkovsky N, 1999, GENE DEV, V13, P2369, DOI 10.1101/gad.13.18.2369; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	31	129	131	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14787	14790		10.1074/jbc.C000093200	http://dx.doi.org/10.1074/jbc.C000093200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10747848	hybrid			2022-12-27	WOS:000087128300003
J	Bretscher, LE; Abel, RL; Raines, RT				Bretscher, LE; Abel, RL; Raines, RT			A ribonuclease A variant with low catalytic activity but high cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE SEMINAL RIBONUCLEASE; SITE-DIRECTED MUTAGENESIS; AMINO-ACID-SEQUENCE; BIOLOGICAL-ACTIVITIES; STRUCTURAL BASIS; INHIBITOR; ANGIOGENIN; PROTEIN; MECHANISM; OOCYTES	Onconase(TM), a homolog of ribonuclease A (RNase A) with low ribonucleolytic activity, is cytotoxic and has efficacy as a cancer chemotherapeutic. Here variants of RNase A were used to probe the interplay between ribonucleolytic activity and evasion of the cytotoxic ribonuclease inhibitor protein (RI) in the cytotoxicity of ribonucleases. K41R/G88R RNase A is a less active catalyst than G88R RNase A but, surprisingly, is more cytotoxic. Like Onconase(TM), the K41R/G88R variant has a low affinity for RI, which apparently compensates for its low ribonucleolytic activity. In contrast, K41A/G88R RNase,which has the same affinity for RI as does the K41R/G88R variant, is not cytotoxic. The nontoxic K41A/G88R variant is a much less active catalyst than is the toxic K41R/G88R variant. These data indicate that maintaining sufficient ribonucleolytic activity in the presence of RI is a requirement for a homolog or variant of RNase A to be cytotoxic. This principle can guide the design of new chemotherapeutics based on homologs and variants of RNase A.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Raines, RT (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.	raines@biochem.wisc.edu	Raines, Ronald T./A-5009-2013	Raines, Ronald T./0000-0001-7164-1719	NATIONAL CANCER INSTITUTE [R01CA073808] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008293] Funding Source: NIH RePORTER; NCI NIH HHS [CA73808] Funding Source: Medline; NIGMS NIH HHS [GM08293] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARDELT W, 1991, J BIOL CHEM, V266, P245; Blackburn P, 1982, ENZYMES, VXV, P317; Boix E, 1996, J MOL BIOL, V257, P992, DOI 10.1006/jmbi.1996.0218; CAFARO V, 1995, FEBS LETT, V359, P31, DOI 10.1016/0014-5793(94)01450-F; DIDONATO A, 1994, J BIOL CHEM, V269, P17394; DOSTAL J, 1973, J REPROD FERTIL, V33, P263, DOI 10.1530/jrf.0.0330263; Floridi A, 1967, Boll Soc Ital Biol Sper, V43, P32; Kelemen BR, 1999, NUCLEIC ACIDS RES, V27, P3696, DOI 10.1093/nar/27.18.3696; KIM JS, 1995, J BIOL CHEM, V270, P10525, DOI 10.1074/jbc.270.18.10525; KIM JS, 1995, BIOCHEM J, V308, P547, DOI 10.1042/bj3080547; Kim JS, 1995, J BIOL CHEM, V270, P31097, DOI 10.1074/jbc.270.52.31097; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; Kobe B, 1996, J MOL BIOL, V264, P1028, DOI 10.1006/jmbi.1996.0694; KURACHI K, 1985, BIOCHEMISTRY-US, V24, P5494, DOI 10.1021/bi00341a032; LEE FS, 1989, BIOCHEMISTRY-US, V28, P225, DOI 10.1021/bi00427a031; Leland PA, 1998, P NATL ACAD SCI USA, V95, P10407, DOI 10.1073/pnas.95.18.10407; MESSMORE JM, 1995, J AM CHEM SOC, V117, P8057, DOI 10.1021/ja00136a001; MURTHY BS, 1992, BIOCHEM J, V281, P343, DOI 10.1042/bj2810343; Piccoli R, 1999, P NATL ACAD SCI USA, V96, P7768, DOI 10.1073/pnas.96.14.7768; Raines RT, 1998, CHEM REV, V98, P1045, DOI 10.1021/cr960427h; Raines RT, 1999, BIOM HLTH R, V27, P235; ROTH JS, 1967, METHOD CANCER RES, V3, P153; Rybak SM, 1999, EXP CELL RES, V253, P325, DOI 10.1006/excr.1999.4718; RYBAK SM, 1991, J BIOL CHEM, V266, P21202; SAXENA SK, 1991, J BIOL CHEM, V266, P21208; Saxena SK, 1996, J BIOL CHEM, V271, P20783, DOI 10.1074/jbc.271.34.20783; SELA M, 1957, BIOCHIM BIOPHYS ACTA, V26, P502, DOI 10.1016/0006-3002(57)90096-3; SHAPIRO R, 1989, BIOCHEMISTRY-US, V28, P1726, DOI 10.1021/bi00430a045; SHAPIRO R, 1987, P NATL ACAD SCI USA, V84, P2238, DOI 10.1073/pnas.84.8.2238; STRYDOM DJ, 1985, BIOCHEMISTRY-US, V24, P5486, DOI 10.1021/bi00341a031; Suzuki M, 1999, NAT BIOTECHNOL, V17, P265, DOI 10.1038/7010; Thompson JE, 1995, BIOORG CHEM, V23, P471, DOI 10.1006/bioo.1995.1033; TRAUTWEIN K, 1991, FEBS LETT, V281, P275, DOI 10.1016/0014-5793(91)80410-5; VICENTINI AM, 1990, BIOCHEMISTRY-US, V29, P8827, DOI 10.1021/bi00489a046; WU YN, 1995, J BIOL CHEM, V270, P17476, DOI 10.1074/jbc.270.29.17476; WU YN, 1993, J BIOL CHEM, V268, P10686; Youle R. J., 1997, RIBONUCLEASES STRUCT, P491	37	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					9893	9896		10.1074/jbc.275.14.9893	http://dx.doi.org/10.1074/jbc.275.14.9893			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744660	hybrid			2022-12-27	WOS:000086345600001
J	Cervellera, MN; Sala, A				Cervellera, MN; Sala, A			Poly(ADP-ribose) polymerase is a B-MYB coactivator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; HEMATOPOIETIC-CELLS; DEPENDENT-KINASE; GENE-EXPRESSION; LEUKEMIA-CELLS; S-PHASE; V-MYB; C-MYB; A-MYB; ACTIVATION	B-MYB is implicated in cell growth control, differentiation, and cancer and belongs to the MYB family of nuclear transcription factors. Evidence exists that cellular proteins bind directly to B-MYB, and it has been hypothesized that B-MYB transcriptional activity may be modulated by specific cofactors. In an attempt to isolate proteins that interact with the B-MYB DNA-binding domain, a modular domain that has the potential to mediate protein-protein interaction, we performed pull-down experiments with a glutathione S-transferase-B-MYB protein and mammalian protein extracts. We isolated a 110-kDa protein associated endogenously with B-MYB in the nuclei of HL60 cells. Microsequence analysis and immunoprecipitation experiments determined that the bound protein was poly(ADP-ribose) polymerase (PARP). Transient transfection assays showed that PARP enhanced B-MYB transactivation and that PARP enzymatic activity is not required for B-MYB-dependent transactivation. These results suggest that PARP, as a transcriptional cofactor of a potentially oncogenic protein, may play a role in growth control and cancer.	Consorzio Mario Negri Sud, Dept Mol Pharmacol & Pathol, I-66030 Santa Maria Imbaro, Chieti, Italy	Consorzio Mario Negri Sud	Sala, A (corresponding author), Consorzio Mario Negri Sud, Dept Mol Pharmacol & Pathol, Via Nazionale, I-66030 Santa Maria Imbaro, Chieti, Italy.	asala@cmns.mnegri.it	sala, arturo/C-4959-2008	Sala, Arturo/0000-0002-2841-7866				Althaus FR, 1999, MOL CELL BIOCHEM, V193, P5, DOI 10.1023/A:1006975002262; ARSURA M, 1992, BLOOD, V79, P2708; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Bhatia M, 1996, CELL GROWTH DIFFER, V7, P91; BHATIA M, 1995, BIOCHEM J, V308, P131, DOI 10.1042/bj3080131; Bies J, 1996, ONCOGENE, V12, P355; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dantzer F, 1998, NUCLEIC ACIDS RES, V26, P1891, DOI 10.1093/nar/26.8.1891; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; GOLAY J, 1991, BLOOD, V77, P149; Hibi K, 1998, CANCER RES, V58, P5690; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Jeggo PA, 1998, CURR BIOL, V8, pR49, DOI 10.1016/S0960-9822(98)70032-6; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; Kumari SR, 1998, CANCER RES, V58, P5075; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1992, ONCOGENE, V7, P1885; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; Mink S, 1996, MOL CELL BIOL, V16, P1316; Miyamoto T, 1999, MOL CELL BIOL, V19, P2644; Nie J, 1998, FEBS LETT, V424, P27, DOI 10.1016/S0014-5793(98)00131-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Oei SL, 1998, J BIOL CHEM, V273, P31644, DOI 10.1074/jbc.273.48.31644; Pfitzner E, 1998, P NATL ACAD SCI USA, V95, P5539, DOI 10.1073/pnas.95.10.5539; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Plaza S, 1999, ONCOGENE, V18, P1041, DOI 10.1038/sj.onc.1202406; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; Raschella G, 1999, CANCER RES, V59, P3365; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; Robinson C, 1996, ONCOGENE, V12, P1855; Rolli V, 1997, BIOCHEMISTRY-US, V36, P12147, DOI 10.1021/bi971055p; Sala A, 1999, ONCOGENE, V18, P1333, DOI 10.1038/sj.onc.1202421; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1999, J CELL PHYSIOL, V179, P245; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; TASHIRO S, 1995, ONCOGENE, V10, P1699; VanGool L, 1997, EUR J BIOCHEM, V244, P15; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	42	106	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10692	10696		10.1074/jbc.275.14.10692	http://dx.doi.org/10.1074/jbc.275.14.10692			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744766	hybrid			2022-12-27	WOS:000086345600107
J	Lee, W; Ryu, J; Hah, J; Tsujita, T; Jung, CY				Lee, W; Ryu, J; Hah, J; Tsujita, T; Jung, CY			Association of carboxyl esterase with facilitative glucose transporter isoform 4 (GLUT4) intracellular compartments in rat adipocytes and its possible role in insulin-induced GLUT4 recruitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT4-CONTAINING VESICLES; PHOSPHATIDYLINOSITOL 3-KINASE; ADIPOSE-TISSUE; DEPENDENT TRAFFICKING; 3T3-L1 ADIPOCYTES; MAJOR PROTEIN; MEMBRANE; TRANSLOCATION; CELL; RAB4	Facilitative glucose transporter isoform 4 (GLUT4) in rat adipocytes is largely sequestered in intracellular sites, and insulin recruits GLUT4 from these sites to the cell surface. The process is known to involve multiple intracellular compartments and associated proteins, many of which are yet to be identified. Recently, we purified three distinct insulin-sensitive intracellular GLUT4 compartments (G4T(L), G4H, and G4L) in rat adipocytes and unraveled several new resident proteins in these compartments. Here, we describe one of them, a 62-kDa protein, purified and identified as rat adipose tissue carboxyl esterase (p62/CE) by matrix-assisted laser desorption/ionization time of flight mass spectroscopy, reverse transcription-polymerase chain reaction, gene cloning, and immunological and enzymatic activity measurements. p62/CE in rat adipocytes was 80% cytosolic and 20% microsome-associated. It was found in all of the three insulin-sensitive intracellular GLUT4 compartments, and particularly enriched in G4T(L), a compartment thought to represent GLUT4 endocytic vesicles. Significantly, an antibody against p62/CE introduced into rat adipocytes completely abolished the insulin-induced GLUT4 recruitment to the plasma membrane in host cells without affecting the basal GLUT4 distribution. Together, these findings suggest that p62/CE plays a key role in insulin-induced GLUT4 recruitment in rat adipocytes, probably by hydrolyzing acylglycerols or acyl-CoA esters to the respective free acids that are required for GLUT4 transport vesicle budding and/or fusion.	SUNY Buffalo, Sch Med, Dept Physiol & Biophys, Vet Affairs Med Ctr,Biophys Lab, Buffalo, NY 14215 USA; Ehime Univ, Sch Med, Dept Med Biochem, Shigenobu, Ehime 79102, Japan	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ehime University	Jung, CY (corresponding author), SUNY Buffalo, Sch Med, Dept Physiol & Biophys, Vet Affairs Med Ctr,Biophys Lab, Buffalo, NY 14215 USA.	cyjung@acsu.buffalo.edu	Lee, Wan/B-6252-2013	Lee, Wan/0000-0002-5181-2135	NIDDK NIH HHS [R01 DK13376] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013376] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAIN CC, 1992, J BIOL CHEM, V267, P11681; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; CORMONT M, 1993, J BIOL CHEM, V268, P19491; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; DEVECCHIO RL, 1991, J BIOL CHEM, V266, P13278; DIPERSIO LP, 1991, J BIOL CHEM, V266, P4033; Ghosh S, 1995, BBA-LIPID LIPID MET, V1259, P305, DOI 10.1016/0005-2760(95)00184-0; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; Hornick CA, 1997, AM J PHYSIOL-CELL PH, V273, pC1075, DOI 10.1152/ajpcell.1997.273.3.C1075; HOSSAIN A, 1994, HORM METAB RES, V26, P19, DOI 10.1055/s-2007-1000766; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; Kandror KV, 1996, J BIOL CHEM, V271, P21703, DOI 10.1074/jbc.271.36.21703; Karnam P, 1997, J BIOL CHEM, V272, P6136, DOI 10.1074/jbc.272.10.6136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE SM, 1993, J BIOL CHEM, V268, P19110; Lee W, 1999, J BIOL CHEM, V274, P37755, DOI 10.1074/jbc.274.53.37755; Lin BZ, 1997, J BIOL CHEM, V272, P24145, DOI 10.1074/jbc.272.39.24145; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; LIU HZ, 1995, J BIOL CHEM, V270, P7869, DOI 10.1074/jbc.270.14.7869; Martin LB, 1998, J BIOL CHEM, V273, P1444, DOI 10.1074/jbc.273.3.1444; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; ROBBI M, 1990, BIOCHEM J, V269, P451, DOI 10.1042/bj2690451; RODBELL M, 1967, J BIOL CHEM, V242, P5744; Satoh T, 1998, ANNU REV PHARMACOL, V38, P257, DOI 10.1146/annurev.pharmtox.38.1.257; SCHOENLE EJ, 1984, J BIOL CHEM, V259, P2112; Shi YW, 1999, ARCH BIOCHEM BIOPHYS, V363, P323, DOI 10.1006/abbi.1998.1088; Shisheva A, 1997, BIOCHEMISTRY-US, V36, P6564, DOI 10.1021/bi970202g; Sleeman MW, 1998, J BIOL CHEM, V273, P3132, DOI 10.1074/jbc.273.6.3132; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; TSUJITA T, 1982, BIOCHIM BIOPHYS ACTA, V715, P181, DOI 10.1016/0304-4165(82)90357-9; TSUJITA T, 1992, J BIOL CHEM, V267, P23489; Yates JR, 1998, J MASS SPECTROM, V33, P1	37	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10041	10046		10.1074/jbc.275.14.10041	http://dx.doi.org/10.1074/jbc.275.14.10041			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744682	hybrid			2022-12-27	WOS:000086345600023
J	Mohan, R; Sivak, J; Ashton, P; Russo, LA; Pham, BQ; Kasahara, N; Raizman, MB; Fini, ME				Mohan, R; Sivak, J; Ashton, P; Russo, LA; Pham, BQ; Kasahara, N; Raizman, MB; Fini, ME			Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FACTOR GENE-EXPRESSION; ENDOTHELIAL-CELLS; TRANSCRIPTION FACTOR; DIETARY CURCUMIN; INFLAMMATORY CYTOKINES; PROMOTER ACTIVITY; OXIDATIVE STRESS; IV COLLAGENASE; COLON-CANCER	We have studied mechanisms controlling activation of the gelatinase B gene (matrix metalloproteinase-g) by fibroblast growth factor-a (FGF-2) during angiogenesis, and the effects of the natural product curcuminoids on this process. Using a transgenic mouse (line 3445) harboring a gelatinase B promoter/lacZ fusion gene, we demonstrate FC;F-S stimulation of reporter gene expression in endothelial cells of invading neocapillaries in the corneal micropocket assay. Using cultured corneal cells, we show that FGF-S stimulates DNA binding activity of transcription factor AP-1 but not NF-kappa B and that AP-1 stimulation is inhibited by curcuminoids, We further show that induction of gelatinase B transcriptional promoter activity in response to FGF-S is dependent on AP-1 but not NF-kappa B response elements and that promoter activity is also inhibited by curcuminoids. In rabbit corneas, the angiogenic response induced by implantation of an FGF-P pellet is inhibited by the coimplantation of a curcuminoid pellet, and this correlates with inhibition of endogenous gelatinase B expression induced by FGF-2. Angiostatic efficacy in the cornea is also observed when curcuminoids are provided to mice in the diet. Our findings provide evidence that curcuminoids target the FGF-2 ansogenic signaling pathway and inhibit expression of gelatinase B in the angiogenic process.	Tufts Univ, Sch Med, New England Eye Ctr, Vis Res Labs, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Boston, MA 02111 USA	Tufts University; Tufts University; Tufts University	Fini, ME (corresponding author), Tufts Univ, Sch Med, New England Eye Ctr, Vis Res Labs, 750 Washington St,Box 450, Boston, MA 02111 USA.	efini@opal.tufts.edu	Sivak, Jeremy/AAA-3467-2022; Kasahara, Niro/P-4631-2019; Kasahara, Niro/N-8865-2014	Sivak, Jeremy/0000-0002-8776-223X; Kasahara, Niro/0000-0003-4101-0304; Kasahara, Niro/0000-0003-4101-0304	NEI NIH HHS [EY12651] Funding Source: Medline; NIAMS NIH HHS [AR42981] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042981] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aho S, 1997, EUR J BIOCHEM, V247, P503, DOI 10.1111/j.1432-1033.1997.00503.x; BABU PS, 1995, MOL CELL BIOCHEM, V152, P13; Bierhaus A, 1997, THROMB HAEMOSTASIS, V77, P772; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Brown PD, 1995, ANN ONCOL, V6, P967, DOI 10.1093/oxfordjournals.annonc.a059091; Cao YH, 1999, NATURE, V398, P381, DOI 10.1038/18793; CHEN C, 1995, CANCER RES, V55, P4230; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; CONNEY AH, 1991, ADV ENZYME REGUL, V31, P385, DOI 10.1016/0065-2571(91)90025-H; Faris M, 1998, AIDS, V12, P19, DOI 10.1097/00002030-199801000-00003; FINI ME, 1994, J BIOL CHEM, V269, P28620; FINI ME, 1990, J CELL SCI, V97, P373; Fini ME, 1998, BIOL EXTRAC, P299; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GIRARD MT, 1991, INVEST OPHTH VIS SCI, V32, P2441; Gualandris A, 1996, CELL GROWTH DIFFER, V7, P147; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Huang MT, 1998, CARCINOGENESIS, V19, P1697, DOI 10.1093/carcin/19.9.1697; HUANG MT, 1994, CANCER RES, V54, P5841; HUANG TS, 1995, CANCER LETT, V96, P1, DOI 10.1016/0304-3835(95)03918-M; Itoh T, 1998, CANCER RES, V58, P1048; JAIN SK, 1994, CIBA F SYMP, V185, P153; Kelloff GJ, 1996, J CELL BIOCHEM, P54, DOI 10.1002/jcb.240630705; Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1625; Krishnaswamy K, 1998, INDIAN J MED RES, V108, P167; Lin LI, 1998, ONCOLOGY-BASEL, V55, P349, DOI 10.1159/000011876; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MATSUBARA M, 1991, INVEST OPHTH VIS SCI, V32, P3221; MATSUBARA M, 1991, DEV BIOL, V147, P425, DOI 10.1016/0012-1606(91)90300-R; Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621; Mohan R, 1998, J BIOL CHEM, V273, P25903, DOI 10.1074/jbc.273.40.25903; Nguyen M, 1998, J BIOL CHEM, V273, P5400, DOI 10.1074/jbc.273.9.5400; NGUYEN Q, 1993, BIOCHEM J, V295, P595, DOI 10.1042/bj2950595; Palmer HJ, 1997, NUTR REV, V55, P353, DOI 10.1111/j.1753-4887.1997.tb01561.x; Pendurthi UR, 1997, ARTERIOSCL THROM VAS, V17, P3406, DOI 10.1161/01.ATV.17.12.3406; POLVERINI PJ, 1995, CRIT REV ORAL BIOL M, V6, P230, DOI 10.1177/10454411950060030501; Rao CV, 1995, ANN NY ACAD SCI, V768, P201, DOI 10.1111/j.1749-6632.1995.tb12122.x; RUPEC RA, 1995, EUR J BIOCHEM, V234, P632, DOI 10.1111/j.1432-1033.1995.632_b.x; SATO H, 1993, J BIOL CHEM, V268, P23460; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Shono T, 1996, MOL CELL BIOL, V16, P4231; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Stoltz RA, 1996, P NATL ACAD SCI USA, V93, P2832, DOI 10.1073/pnas.93.7.2832; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Vu TH, 1998, BIOL EXTRAC, P115; WEICH HA, 1991, J CELL BIOCHEM, V47, P158, DOI 10.1002/jcb.240470209; Yamamoto H, 1998, GENE DEV, V12, P1315, DOI 10.1101/gad.12.9.1315; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997; Yokoo T, 1996, AM J PHYSIOL-RENAL, V270, pF123, DOI 10.1152/ajprenal.1996.270.1.F123; Yu AE, 1998, BIOL EXTRAC, P85	53	214	230	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10405	10412		10.1074/jbc.275.14.10405	http://dx.doi.org/10.1074/jbc.275.14.10405			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744729	hybrid			2022-12-27	WOS:000086345600070
J	Zhou, BBS; Chaturvedi, P; Spring, K; Scott, SP; Johanson, RA; Mishra, R; Mattern, MR; Winkler, JD; Khanna, KK				Zhou, BBS; Chaturvedi, P; Spring, K; Scott, SP; Johanson, RA; Mishra, R; Mattern, MR; Winkler, JD; Khanna, KK			Caffeine abolishes the mammalian G(2)/M DNA damage checkpoint by inhibiting ataxia-telangiectasia-mutated kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATES HUMAN CDC25C; CELL-CYCLE CHECKPOINTS; IONIZING-RADIATION; PROTEIN-KINASE; RADIOSENSITIZATION; ACTIVATION; SERINE-216; P53; ATM; PHOSPHATASE	Recent evidence indicates that arrest of mammalian cells at the G(2)/M checkpoint involves inactivation and translocation of Cdc25C, which is mediated by phosphorylation of Cdc25C on serine 216, Data obtained with a phospho-specific antibody against serine 216 suggest that activation of the DNA damage checkpoint is accompanied by an increase in serine 216 phosphorylated Cdc25C in the nucleus after exposure of cells to gamma-radiation. Prior treatment of cells with 2 mM caffeine inhibits such a change and markedly reduces radiation-induced ataxia-telangiectasia-mutated (ATM)-dependent Chk2/Cds1 activation and phosphorylation. Chk2/Cds1 is known to localize in the nucleus and to phosphorylate Cdc25C at serine 216 in vitro. Caffeine does not inhibit Chk2/Cds1 activity directly, but rather, blocks the activation of Chk2/Cds1 by inhibiting ATM kinase activity. In vitro, ATM phosphorylates Chk2/Cds1 at threonine 68 close to the N terminus, and caffeine inhibits this phosphorylation with an IC50 of approximately 200 mu M. Using a phospho-specific antibody against threonine 68, we demonstrate that radiation-induced, ATM-dependent phosphorylation of Chk2/Cds1 at this site is caffeine-sensitive. From these results, we propose a model wherein caffeine abrogates the G(2)/M checkpoint by targeting the ATM-Chk2/Cds1 pathway; by inhibiting ATM, it prevents the serine 216 phosphorylation of Cdc25C in the nucleus. Inhibition of ATM provides a molecular explanation for the increased radiosensitivity of caffeine-treated cells.	SmithKline Beecham Pharmaceut, Dept Oncol Res, King Of Prussia, PA 19406 USA; Univ Queensland, Queensland Inst Med Res, Royal Brisbane Hosp, Brisbane, Qld 4029, Australia	GlaxoSmithKline; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Queensland	Zhou, BBS (corresponding author), SmithKline Beecham Pharmaceut, Dept Oncol Res, 709 Swedeland Rd, King Of Prussia, PA 19406 USA.	Bin-Bing_S_Zhou@sbphrd.com	Khanna, Kum Kum/I-1747-2013	Khanna, Kum Kum/0000-0001-8650-5381; Spring, Kevin/0000-0003-0601-924X	NCI NIH HHS [CA-50771-09] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA050771, U01CA050771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; Lavin LF, 1999, INT J RADIAT BIOL, V75, P1201; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; OConnor PM, 1997, CANCER SURV, V29, P151; OGG S, 1994, J BIOL CHEM, V269, P30461; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; POWELL SN, 1995, CANCER RES, V55, P1643; RUSSELL KJ, 1995, CANCER RES, V55, P1639; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1999, CANCER RES, V59, P4375; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140	33	253	265	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10342	10348		10.1074/jbc.275.14.10342	http://dx.doi.org/10.1074/jbc.275.14.10342			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744722	hybrid			2022-12-27	WOS:000086345600063
J	Deeney, JT; Gromada, J; Hoy, M; Olsen, HL; Rhodes, CJ; Prentki, M; Berggren, PO; Corkey, BE				Deeney, JT; Gromada, J; Hoy, M; Olsen, HL; Rhodes, CJ; Prentki, M; Berggren, PO; Corkey, BE			Acute stimulation with long chain acyl-CoA enhances exocytosis in insulin secreting cells (HIT T-15 and NMRI beta-cells)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; DEPENDENT DIABETES-MELLITUS; METABOLIC COUPLING FACTORS; PANCREATIC B-CELLS; FATTY-ACIDS; MALONYL-COA; COENZYME-A; TRANSPORT VESICLES; CHROMAFFIN CELLS; GOLGI CISTERNAE	Non insulin-dependent diabetes mellitus is associated with, in addition to impaired insulin release, elevated levels of free fatty acids (FFA) in the blood. Insulin release is stimulated when beta-cells are acutely exposed to FFA whereas chronic exposure may inhibit glucose-induced insulin secretion. In the present study we investigated the direct effects of long chain acyl-CoA (LCCoA), the active intracellular form of FFA, on insulin exocytosis, Palmitoyl-CoA stimulated both insulin release from streptolysin-O-permeabilized HIT cells and fusion of secretory granules to the plasma membrane of mouse pancreatic beta-cells, as measured by cell capacitance, The LC-CoA effect was chain length-dependent, requiring chain lengths of at least 14 carbons. LC-CoA needed to be present to stimulate insulin release, and consequently there was no effect following its removal. The stimulatory effect was observed after inhibition of protein kinase activity and in the absence of ATP, even though both kinases and ATP, themselves, modulate exocytosis. The effect of LC-CoA was inhibited by cerulenin, which has been shown to block protein acylation. The data suggest that altered LC-CoA levels, resulting from FFA or glucose metabolism, may act directly on the exocytotic machinery to stimulate insulin release by a mechanism involving LC-CoA protein binding.	Karolinska Inst, Karolinska Hosp L102, Rolf Luft Ctr Diabet Res, Dept Mol Med, S-17176 Stockholm, Sweden; Boston Med Ctr, Evans Dept Med, Boston, MA 02118 USA; Novo Nordisk AS, Islet Discovery Res, Islet Cell Physiol, DK-2880 Bagsvaerd, Denmark; Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Montreal, Mol Nutr Unit, Dept Nutr, Montreal, PQ H2L 4M1, Canada	Karolinska Institutet; Boston Medical Center; Novo Nordisk; Universite de Montreal	Berggren, PO (corresponding author), Karolinska Inst, Karolinska Hosp L102, Rolf Luft Ctr Diabet Res, Dept Mol Med, S-17176 Stockholm, Sweden.	perolof@enk.ks.se	; Corkey, Barbara/E-7712-2015	Deeney, Jude/0000-0003-0988-9419; Corkey, Barbara/0000-0002-5467-1630; Berggren, Per-Olof/0000-0001-8991-413X	NIDDK NIH HHS [DK35914] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035914, R37DK035914, R56DK035914] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMMALA C, 1993, J PHYSIOL-LONDON, V472, P665, DOI 10.1113/jphysiol.1993.sp019966; BERNE C, 1975, BIOCHEM J, V152, P661, DOI 10.1042/bj1520661; BOUVIER M, 1995, BIOCHEM SOC T, V23, P116, DOI 10.1042/bst0230116; BOYLAN JG, 1992, BIOCHEMISTRY-US, V31, P557, DOI 10.1021/bi00117a037; Branstrom R, 1997, J BIOL CHEM, V272, P17390, DOI 10.1074/jbc.272.28.17390; Chapman ER, 1996, BIOCHEM BIOPH RES CO, V225, P326, DOI 10.1006/bbrc.1996.1174; CHEN SY, 1994, DIABETES, V43, P878, DOI 10.2337/diabetes.43.7.878; CORKEY BE, 1988, METHOD ENZYMOL, V166, P55; CORKEY BE, 1988, J BIOL CHEM, V263, P4247; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; COUVE A, 1995, P NATL ACAD SCI USA, V92, P5987, DOI 10.1073/pnas.92.13.5987; Deeney JT, 1996, J BIOL CHEM, V271, P18154, DOI 10.1074/jbc.271.30.18154; DEENEY JT, 1992, J BIOL CHEM, V267, P19840; DEWIT RJW, 1984, EUR J BIOCHEM, V142, P255; DUNLOP ME, 1985, BIOCHEM BIOPH RES CO, V132, P467, DOI 10.1016/0006-291X(85)91157-X; EASOM RA, 1989, BIOCHEM J, V264, P27, DOI 10.1042/bj2640027; Eliasson L, 1997, J PHYSIOL-LONDON, V503, P399, DOI 10.1111/j.1469-7793.1997.399bh.x; FRAZE E, 1985, J CLIN ENDOCR METAB, V61, P807, DOI 10.1210/jcem-61-5-807; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; HAMILTON JA, 1994, J BIOL CHEM, V269, P20852; HEINEMANN C, 1994, BIOPHYS J, V67, P2546, DOI 10.1016/S0006-3495(94)80744-1; HESS DT, 1992, J NEUROSCI, V12, P4634; IKEMOTO H, 1995, J NEUROSURG, V83, P1008, DOI 10.3171/jns.1995.83.6.1008; KAMP F, 1993, BIOCHEMISTRY-US, V32, P11074, DOI 10.1021/bi00092a017; KAMP F, 1992, P NATL ACAD SCI USA, V89, P11367, DOI 10.1073/pnas.89.23.11367; Larsson O, 1996, J BIOL CHEM, V271, P10623, DOI 10.1074/jbc.271.18.10623; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; LEWIS B, 1972, EUR J CLIN INVEST, V2, P445, DOI 10.1111/j.1365-2362.1972.tb00676.x; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MALAISSE WJ, 1983, ARCH BIOCHEM BIOPHYS, V224, P102, DOI 10.1016/0003-9861(83)90193-5; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; Moche M, 1999, J BIOL CHEM, V274, P6031, DOI 10.1074/jbc.274.10.6031; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; PERSAUD SJ, 1994, BIOCHEM SOC T, V22, pS208, DOI 10.1042/bst022208s; PFANNER N, 1990, J CELL BIOL, V110, P955, DOI 10.1083/jcb.110.4.955; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SAKO Y, 1990, ENDOCRINOLOGY, V127, P1580, DOI 10.1210/endo-127-4-1580; Smith RM, 1974, CRITICAL STABILITY C, V1-6; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VARA E, 1986, METABOLISM, V35, P266, DOI 10.1016/0026-0495(86)90212-X; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; WARNOTTE C, 1994, DIABETES, V43, P703, DOI 10.2337/diabetes.43.5.703; YANEY GC, 2000, IN PRESS ENDOCRINOLO; Zhang SY, 1998, CELL SIGNAL, V10, P35, DOI 10.1016/S0898-6568(97)00070-3	53	132	136	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9363	9368		10.1074/jbc.275.13.9363	http://dx.doi.org/10.1074/jbc.275.13.9363			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734079	hybrid			2022-12-27	WOS:000086206500043
J	Richardson, RM; Pridgen, BC; Haribabu, B; Snyderman, R				Richardson, RM; Pridgen, BC; Haribabu, B; Snyderman, R			Regulation of the human chemokine receptor CCR1 - Cross-regulation by CXCR1 and CXCR2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C5A CHEMOATTRACTANT RECEPTORS; PLATELET-ACTIVATING-FACTOR; PROTEIN-KINASE-A; INTERLEUKIN-8 RECEPTOR; DIFFERENTIAL REGULATION; FUNCTIONAL EXPRESSION; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; DESENSITIZATION; CELLS	To investigate the regulation of the CCR1 chemokine receptor, a rat basophilic leukemia (RBL-2H3) cell line was modified to stably express epitope-tagged receptor. These cells responded to RANTES (regulated upon activation normal T expressed and secreted), macrophage inflammatory protein-1 alpha, and monocyte chemotactic protein-a to mediate phospholipase C activation, intracellular Ca2+ mobilization and exocytosis. Upon activation, CCR1 underwent phosphorylation and desensitization as measured by diminished GTPase stimulation and Ca2+ mobilization. Alanine substitution of specific serine and threonine residues (S2 and S3) or truncation of the cytoplasmic tail (Delta CCR1) of CCR1 abolished receptor phosphorylation and desensitization of G protein activation but did not abolish desensitization of Ca2+ mobilization. S2, S3, and Delta CCR1 were also resistant to internalization, mediated greater phosphatidylinositol hydrolysis and sustained Ca2+ mobilization, and were only partially desensitized by RANTES, relative to S1 and CCR1. To study CCR1 cross-regulation, RBL cells co-expressing CCR1 and receptors for interleukin-8 (CXCR1, CXCR2, or a phosphorylation-deficient mutant of CXCR2, 331T) were produced. Interleukin-8 stimulation of CXCR1 or CXCR2 cross-phosphorylated CCR1 and cross-desensitized its ability to stimulate GTPase activity and Ca2+ mobilization. Interestingly, CCR1 cross-phosphorylated and cross-desensitized CXCR2, but not CXCR1. Ca2+ mobilization by S3 and Delta CCR1 were also cross-desensitized by CXCR1 and CXCR2 despite lack of receptor phosphorylation, In contrast to wild type CCR1, S3 and Delta CCR1, which produced sustained signals, cross-phosphorylated and cross-desensitized responses to CXCR1 as well as CXCR2, Taken together, these results indicate that CCR1-mediated responses are regulated at several steps in the signaling pathway, by receptor phosphorylation at the level of receptor/G protein coupling and by an unknown mechanism at the level of phospholipase C activation. Moreover selective cross-regulation among chemokine receptors is, in part, a consequence of the strength of signaling (i.e. greater phosphatidylinositol hydrolysis and sustained Ca2+ mobilization) which is inversely correlated with the receptor's susceptibility to phosphorylation, Since many chemokines activate multiple chemokine receptors, selective cross-regulation among such receptors may play a role in their immunomodulation.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	Duke University; Duke University	Richardson, RM (corresponding author), Duke Univ, Med Ctr, Dept Med, Box 3680, Durham, NC 27710 USA.		Bodduluri, Haribabu/A-2584-2010	Bodduluri, Haribabu/0000-0002-8261-3294	NIAID NIH HHS [AI-43184, AI-38910] Funding Source: Medline; NIDCR NIH HHS [DE-03738] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038910, R29AI043184, R29AI038910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE003738] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ali H, 1999, J BIOL CHEM, V274, P6027, DOI 10.1074/jbc.274.10.6027; Ali H, 1998, J BIOL CHEM, V273, P11012, DOI 10.1074/jbc.273.18.11012; Ali H, 1997, J BIOL CHEM, V272, P11706, DOI 10.1074/jbc.272.18.11706; ALI H, 1993, J BIOL CHEM, V268, P24247; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Aragay AM, 1998, P NATL ACAD SCI USA, V95, P2985, DOI 10.1073/pnas.95.6.2985; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Bacon KB, 1998, J IMMUNOL, V160, P1894; Bacon KB, 1997, DRUG NEWS PERSPECT, V10, P133; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Berger EA, 1997, AIDS, V11, pS3; DELPOZO MA, 1995, J CELL BIOL, V131, P495, DOI 10.1083/jcb.131.2.495; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Filtz TM, 1999, BIOCHEM J, V338, P257, DOI 10.1042/0264-6021:3380257; Franci C, 1996, J IMMUNOL, V157, P5606; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; Haribabu B, 1999, J BIOL CHEM, V274, P37087, DOI 10.1074/jbc.274.52.37087; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; MANTEL C, 1995, J IMMUNOL, V154, P2342; MUELLER SG, 1994, J BIOL CHEM, V269, P1973; Mueller SG, 1997, J BIOL CHEM, V272, P8207, DOI 10.1074/jbc.272.13.8207; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Prado GN, 1996, J BIOL CHEM, V271, P19186, DOI 10.1074/jbc.271.32.19186; RICHARDON RM, 1995, J BIOL CHEM, V270, P27829, DOI 10.1074/jbc.270.46.27829; Richardson RM, 1998, J BIOL CHEM, V273, P23830, DOI 10.1074/jbc.273.37.23830; Richardson RM, 1998, J BIOL CHEM, V273, P10690, DOI 10.1074/jbc.273.17.10690; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; Solari R, 1997, J BIOL CHEM, V272, P9617; TARDIF M, 1993, J IMMUNOL, V150, P3534; TOMHAVE E, 1994, J IMMUNOL, V154, P3267; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; Yue CP, 1998, J BIOL CHEM, V273, P18023, DOI 10.1074/jbc.273.29.18023	33	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9201	9208		10.1074/jbc.275.13.9201	http://dx.doi.org/10.1074/jbc.275.13.9201			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734056	hybrid			2022-12-27	WOS:000086206500020
J	Yu, R; Mandlekar, S; Tan, TH; Kong, ANT				Yu, R; Mandlekar, S; Tan, TH; Kong, ANT			Activation of p38 and c-Jun N-terminal kinase pathways and induction of apoptosis by chelerythrine do not require inhibition of protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; MAP KINASE; BENZOPHENANTHRIDINE ALKALOIDS; DIFFERENTIAL ACTIVATION; SELECTIVE ACTIVATION; GAMMA-RADIATION; CELL-DEATH; STRESS; PHOSPHORYLATION; JNK	Chelerythrine, a natural benzophenanthridine alkaloid, has been reported to mediate a variety of biological activities, including inhibition of protein kinase C (PKC), Here we report that chelerythrine induced time-and dose-dependent activation of JNK1 and p38 in HeLa cells, which was mediated the upstream kinases, MEKK1 and MKK4. However, treatment with two other potent and selective PKC inhibitors, GF-109203X and G66983, or down-regulation of PKC activity by prolonged treatment with phorbol 12-myristate 13-acetate had no effect on JNK1 and p38 activities. Furthermore, under the conditions where JNK1 and p38 were activated, we did not observe any significant inhibitory effect of chelerythrine on the activities of PKC isozymes present in HeLa cells. Interestingly, pretreatment with the antioxidants, N-acetyl-L-cysteine, dithiothreitol, and glutathione, impaired chelerythrine-induced JNK1 and p38 activation, In addition, chelerythrine induced apoptosis that was blocked by the antioxidants and the dominant-negative mutants of MEKK1, MKK4, JNK1, and p38, Together, these results uncover a novel biochemical property of chelerythrine, i.e. activation of MEKK1- and MKK4-dependent JNK1 and p38 pathways through an oxidative stress mechanism, which mediate the induction of apoptosis, but are independent of PKC inhibition.	Univ Illinois, Coll Pharm, Ctr Pharmaceut Biotechnol, Dept Pharmaceut & Pharmacodynam, Chicago, IL 60612 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Baylor College of Medicine	Kong, ANT (corresponding author), Univ Illinois, Coll Pharm, Ctr Pharmaceut Biotechnol, Dept Pharmaceut & Pharmacodynam, M-C870,900 S Ashland Ave, Chicago, IL 60612 USA.	KongT@uic.edu	Kong, Ah-Ng Tony/AAX-2828-2020; Tan, Tse-Hua/E-3983-2010; Tan, Tse-Hua/ABD-7080-2021	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038649] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA73647] Funding Source: Medline; NIAID NIH HHS [R01-AI38649] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; Chmura SJ, 1996, CANCER RES, V56, P2711; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Freemerman AJ, 1996, MOL PHARMACOL, V49, P788; Geng Y, 1996, J CLIN INVEST, V98, P2425, DOI 10.1172/JCI119056; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOPALAKRISHNA R, 1992, ANAL BIOCHEM, V206, P24, DOI 10.1016/S0003-2697(05)80006-5; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KO FN, 1990, BIOCHIM BIOPHYS ACTA, V1052, P360, DOI 10.1016/0167-4889(90)90144-3; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lee SK, 1998, J BIOL CHEM, V273, P19829, DOI 10.1074/jbc.273.31.19829; LENFELD J, 1981, PLANTA MED, V43, P161, DOI 10.1055/s-2007-971493; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; LOMBARDINI JB, 1995, BRAIN RES, V673, P194, DOI 10.1016/0006-8993(94)01369-S; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Militante JD, 1999, BRAIN RES, V818, P368, DOI 10.1016/S0006-8993(98)01318-3; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Morrison P, 1996, J BIOL CHEM, V271, P12891, DOI 10.1074/jbc.271.22.12891; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NISHIZUKA Y, 1992, C SCI, V258, P607; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Shi LJ, 1999, ARCH BIOCHEM BIOPHYS, V368, P40, DOI 10.1006/abbi.1999.1235; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Stempka L, 1997, J BIOL CHEM, V272, P6805, DOI 10.1074/jbc.272.10.6805; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VONSTEBUT E, 1994, AGENTS ACTIONS, V41, pC56; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; WOLFF J, 1993, BIOCHEMISTRY-US, V32, P13334, DOI 10.1021/bi00211a047; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798; Young PR, 1998, CYTOKINE GROWTH F R, V9, P239, DOI 10.1016/S1359-6101(98)00011-2; Yu R, 1997, J BIOL CHEM, V272, P28962, DOI 10.1074/jbc.272.46.28962; Yu R, 1996, CANCER LETT, V107, P73, DOI 10.1016/0304-3835(96)04345-5; Yu R, 1998, CANCER RES, V58, P402; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	70	95	98	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9612	9619		10.1074/jbc.275.13.9612	http://dx.doi.org/10.1074/jbc.275.13.9612			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734112	hybrid			2022-12-27	WOS:000086206500076
J	Benedict, MA; Hu, YM; Inohara, N; Nunez, G				Benedict, MA; Hu, YM; Inohara, N; Nunez, G			Expression and functional analysis of Apaf-1 isoforms - Extra WD-40 repeat is required for cytochrome c binding and regulated activation of procaspase-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; BCL-X-L; APOPTOSIS; CASPASE-9; ELEGANS; HOMOLOG; COMPLEX; DISEASE; CED-4	Apaf-1 is an important apoptotic signaling molecule that can activate procaspase-9 in a cytochrome c/dATP-dependent fashion. Alternative splicing can create an NH2-terminal Il-amino acid insert between the caspase recruitment domain and ATPase domains or an additional COOH-terminal WD-40 repeat. Recently, several Apaf-1 isoforms have been identified in tumor cell lines, but their expression in tissues and ability to activate procaspase-9 remain poorly characterized. We performed analysis of normal tissue mRNAs to examine the relative expression of the Apaf-1 forms and identified Apaf-1XL, containing both the NH2-terminal and COOH-terminal inserts, as the major RNA form expressed in all tissues tested. We also identified another expressed isoform, Apaf-1LN, containing the NH2-terminal insert, but lacking the additional WD-40 repeat. Functional analysis of all identified Apaf-1 isoforms demonstrated that only those with the additional WD-40 repeat activated procaspase 9 in vitro in response to cytochrome c and dATP, while the NH2-terminal insert was not required for this activity. Consistent with this result, in vitro binding assays demonstrated that the additional WD-40 repeat was also required for binding of cytochrome c, subsequent Apaf-1 self-association, binding to procaspase-9, and formation of active Apaf-1 oligomers, These experiments demonstrate the expression of multiple Apaf-1 isoforms and show that only those containing the additional WD-40 repeat bind and activate procaspase-9 in response to cytochrome c and dATP.	Univ Michigan, Sch Med, Ctr Comprehens Canc, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Cellular & Mol Biol Program, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Nunez, G (corresponding author), Univ Michigan, Sch Med, Ctr Comprehens Canc, Dept Pathol, Ann Arbor, MI 48109 USA.		Nuñez, Gabriel/A-7160-2014		NCI NIH HHS [CA-34556] Funding Source: Medline; NHLBI NIH HHS [2T32HL07517] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007517] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adrain C, 1999, J BIOL CHEM, V274, P20855, DOI 10.1074/jbc.274.30.20855; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Parniske M, 1997, CELL, V91, P821, DOI 10.1016/S0092-8674(00)80470-5; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stennicke HR, 1999, METHODS, V17, P313, DOI 10.1006/meth.1999.0745; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yuan JY, 1996, J CELL BIOCHEM, V60, P4, DOI 10.1002/(SICI)1097-4644(19960101)60:1<4::AID-JCB2>3.0.CO;2-1; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	24	111	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8461	8468		10.1074/jbc.275.12.8461	http://dx.doi.org/10.1074/jbc.275.12.8461			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722681	hybrid			2022-12-27	WOS:000086507700031
J	Imamura, Y; Scott, IC; Greenspan, DS				Imamura, Y; Scott, IC; Greenspan, DS			The pro-alpha 3(V) collagen chain - Complete primary structure, expression domains in adult and developing tissues, and comparison to the structures and expression domains of the other types V and XI procollagen chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EHLERS-DANLOS-SYNDROME; BONE MORPHOGENETIC PROTEIN-1; AMINO-TERMINAL PROPEPTIDE; ARGININE-RICH PROTEIN; HEPARIN-BINDING SITE; NH2-TERMINAL DOMAIN; FIBRILLAR COLLAGEN; GENE COL5A1; MOLECULAR-CLONING; ALPHA-1(V) CHAIN	The low abundance fibrillar collagen type V is widely distributed in tissues as an alpha 1(V)(2)alpha 2(V) heterotrimer that helps regulate the diameters of fibrils of the abundant collagen type I. Mutations in the alpha 1(V) and alpha 2(V) chain genes have been identified in some cases of classical Ehlers-Danlos syndrome (EDS), in which aberrant collagen fibrils are associated with connective tissue fragility, particularly in skin and joints, Type V collagen also exists as an alpha 1(V)alpha 2(V)alpha 3(V) heterotrimer that has remained poorly characterized chiefly due to inability to obtain the complete primary structure or nucleic acid probes for the alpha 3(V) chain or its biosynthetic precursor, pro-alpha 3(V), Here we provide human and mouse full-length pro-alpha 3(V) sequences. Pro-alpha 3(V) is shown to be closely related to the alpha 1(V) precursor, pro-alpha 1(V), but with marked differences in N-propeptide sequences, and collagenous domain features that provide insights into the low melting temperature of alpha 1(V)alpha 2(V)alpha 3(V) heterotrimers, lack of heparin binding by alpha 3(V) chains and the possibility that alpha 1(V)alpha 2(V)alpha 3(V) heterotrimers are incorporated into heterotypic fibrils, In situ hybridization of mouse embryos detects alpha 3(V) expression primarily in the epimysial sheaths of developing muscles and within nascent ligaments adjacent to forming bones and in joints. This distribution, and the association of alpha 1(V), alpha 2(V), and alpha 3(V) chains in heterotrimers, suggests the human alpha 3(V) gene COL5A3 as a candidate locus for at least some cases of classical EDS in which the alpha 1(V) and alpha 2(V) genes have been excluded, and for at least some cases of the hypermobility type of EDS, a condition marked by gross joint laxity and chronic musculoskeletal pain. COL5A3 is mapped to 19p13.2 near a polymorphic marker that should be useful in analyzing linkage with EDS and other disease phenotypes.	Univ Wisconsin, Dept Lab Med & Pathol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Greenspan, DS (corresponding author), Univ Wisconsin, Dept Lab Med & Pathol, Madison, WI 53706 USA.		Imamura, Yasutada/AAI-3078-2020	Imamura, Yasutada/0000-0001-6264-1709; Greenspan, Daniel/0000-0001-8096-7446	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043621] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR43621] Funding Source: Medline; NIGMS NIH HHS [GM46846] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEDIN MZ, 1982, BIOSCIENCE REP, V2, P493, DOI 10.1007/BF01115247; ADACHI E, 1986, CONNECT TISSUE RES, V14, P257, DOI 10.3109/03008208609017469; ANDRIKOPOULOS K, 1992, DEV DYNAM, V195, P113, DOI 10.1002/aja.1001950205; ANDRIKOPOULOS K, 1995, NAT GENET, V9, P31, DOI 10.1038/ng0195-31; Beighton P, 1998, AM J MED GENET, V77, P31, DOI 10.1002/(SICI)1096-8628(19980428)77:1<31::AID-AJMG8>3.3.CO;2-P; BEIGHTON P, 1993, MCKUSICKS HERITABLE, P189; BERNARD M, 1988, J BIOL CHEM, V263, P17159; BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999; BIRK DE, 1990, J CELL SCI, V95, P649; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BORK P, 1992, FEBS LETT, V307, P49, DOI 10.1016/0014-5793(92)80900-2; BRANDRIFF BF, 1994, GENOMICS, V23, P582, DOI 10.1006/geno.1994.1546; BROEK DL, 1985, J BIOL CHEM, V260, P555; BROWN RA, 1978, BIOCHEM BIOPH RES CO, V80, P866, DOI 10.1016/0006-291X(78)91324-4; BYERS PH, 1995, METABOLIC MOL BASES, P4029; Delacoux F, 1998, J BIOL CHEM, V273, P15069, DOI 10.1074/jbc.273.24.15069; DePaepe A, 1997, AM J HUM GENET, V60, P547; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P9383; DION AS, 1987, J MOL BIOL, V193, P127, DOI 10.1016/0022-2836(87)90632-2; EYRE D, 1987, STRUCTURE FUNCTION C, P2361; FESSLER JH, 1987, STRUCTURE FUNCTION C, P81; FICHARD A, 1994, MATRIX BIOL, V14, P515; GREENSPAN DS, 1991, J BIOL CHEM, V266, P24727; GREENSPAN DS, 1989, J BIOL CHEM, V264, P20683; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HARALSON MA, 1980, P NATL ACAD SCI-BIOL, V77, P5206, DOI 10.1073/pnas.77.9.5206; Imamura Y, 1998, J BIOL CHEM, V273, P27511, DOI 10.1074/jbc.273.42.27511; Jobsis GJ, 1996, NAT GENET, V14, P113, DOI 10.1038/ng0996-113; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KIMURA T, 1989, J BIOL CHEM, V264, P13910; KLEMAN JP, 1992, EUR J BIOCHEM, V210, P329, DOI 10.1111/j.1432-1033.1992.tb17425.x; KUMAMOTO CA, 1980, P NATL ACAD SCI-BIOL, V77, P6434, DOI 10.1073/pnas.77.11.6434; KUMAMOTO CA, 1981, J BIOL CHEM, V256, P7053; LEBARON RG, 1989, J BIOL CHEM, V264, P7950; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; LUI VCH, 1995, BIOCHEM J, V311, P511, DOI 10.1042/bj3110511; MADRI JA, 1982, COLLAGEN REL RES, V2, P19; MANN K, 1992, BIOL CHEM H-S, V373, P69, DOI 10.1515/bchm3.1992.373.1.69; MAYNE R, 1993, J BIOL CHEM, V268, P9381; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; Mizuno K, 1996, J BIOCHEM-TOKYO, V120, P934; MORADIAMELI M, 1994, EUR J BIOCHEM, V221, P987, DOI 10.1111/j.1432-1033.1994.tb18815.x; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; MORRIS NP, 1990, J BIOL CHEM, V265, P10081; NAH HD, 1992, J BIOL CHEM, V267, P22581; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; NEAME PJ, 1990, J BIOL CHEM, V265, P20401; Nicholls AC, 1996, J MED GENET, V33, P940, DOI 10.1136/jmg.33.11.940; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NIVIBIZI C, 1993, BIOCHIM BIOPHYS ACTA, V1203, P304; NIYIBIZI C, 1994, EUR J BIOCHEM, V224, P943, DOI 10.1111/j.1432-1033.1994.00943.x; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; NIYIBIZI C, 1984, J BIOL CHEM, V259, P4170; OXFORD JT, 1995, J BIOL CHEM, V270, P9478, DOI 10.1074/jbc.270.16.9478; RHODES RK, 1981, COLLAGEN REL RES, V1, P337; Richards AJ, 1998, J MED GENET, V35, P846, DOI 10.1136/jmg.35.10.846; Rousseau JC, 1996, J BIOL CHEM, V271, P23743, DOI 10.1074/jbc.271.39.23743; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; Ruggiero F, 1996, J CELL SCI, V109, P1865; SANDBERG MM, 1993, BIOCHEM J, V294, P595, DOI 10.1042/bj2940595; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; TAKAHARA K, 1995, GENOMICS, V29, P588, DOI 10.1006/geno.1995.9961; THOM JR, 1991, J BIOL CHEM, V266, P7262; Toriello HV, 1996, NAT GENET, V13, P361, DOI 10.1038/ng0796-361; TSUMAKI N, 1995, J BIOL CHEM, V270, P2372, DOI 10.1074/jbc.270.5.2372; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VUORISTO MM, 1995, J BIOL CHEM, V270, P22873, DOI 10.1074/jbc.270.39.22873; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; WEIL D, 1987, NUCLEIC ACIDS RES, V15, P181, DOI 10.1093/nar/15.1.181; Wenstrup RJ, 1996, HUM MOL GENET, V5, P1733, DOI 10.1093/hmg/5.11.1733; Wolfman NM, 1997, J CLIN INVEST, V100, P321, DOI 10.1172/JCI119537; WOODBURY D, 1989, J BIOL CHEM, V264, P2735; WU JJ, 1995, J BIOL CHEM, V270, P18865, DOI 10.1074/jbc.270.32.18865; Wu YL, 1998, BBA-GENE STRUCT EXPR, V1397, P275, DOI 10.1016/S0167-4781(98)00016-5; YAOI Y, 1990, BIOCHIM BIOPHYS ACTA, V1035, P139, DOI 10.1016/0304-4165(90)90108-9; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423; YOSHIOKA H, 1995, DEV DYNAM, V204, P41, DOI 10.1002/aja.1002040106; ZHIDKOVA NI, 1993, FEBS LETT, V326, P25, DOI 10.1016/0014-5793(93)81753-M; ZHIDKOVA NI, 1995, J BIOL CHEM, V270, P9486, DOI 10.1074/jbc.270.16.9486	83	66	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8749	8759		10.1074/jbc.275.12.8749	http://dx.doi.org/10.1074/jbc.275.12.8749			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722718	hybrid			2022-12-27	WOS:000086507700068
J	Kondo, T; Matsuda, T; Tashima, M; Umehara, H; Domae, N; Yokoyama, K; Uchiyama, T; Okazaki, T				Kondo, T; Matsuda, T; Tashima, M; Umehara, H; Domae, N; Yokoyama, K; Uchiyama, T; Okazaki, T			Suppression of heat shock protein-70 by ceramide in heat shock-induced NL-60 cell apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; STRESS-INDUCED APOPTOSIS; HL-60 CELLS; HSP70 EXPRESSION; PHORBOL ESTERS; ACTIVATION; KINASE; DEATH; PATHWAY; INHIBITION	Ceramide has emerged as a mediator of cell growth, differentiation, and apoptosis in many biological systems. Many kinds of stresses are reported to induce apoptosis with an increase of ceramide generation. Here we showed that the intracellular ceramide levels increased in parallel with heat shock (HS)-induced apoptosis in an intensity- and time-dependent manner, and synthetic N-acetylsphingosine (C-2-ceramide) synergistically enhanced MS-induced apoptosis in HL-60 cells. In order to know the role of ceramide generation in HS-induced apoptosis, we examined the effects of C-2-ceramide on the levels of mRNA and protein of heat shock proteins (HSPs). The increase of MSP-70 mRNA levels 1-2 h after HS at 42 degrees C for 30 min was suppressed by C-2-ceramide in a dose-dependent manner. In comparison with HSP-70, the levels of HSP-60 and -90 mRNAs were faintly suppressed by C-2-ceramide. Similarly, the increase in the protein levels of HSP-70 was significantly suppressed 4-8 h after HS by C-2-ceramide in a dose-dependent manner. Additionally, in 293 cells, which are constitutively overexpressing MSP-70 gene, the levels of HSP-70 mRNA were suppressed by C-2-ceramide in parallel with the increase of apoptotic cells. We next examined the mechanisms by which C-2-ceramide suppressed MS-increased MSP-70 expression. The treatment with C-2-ceramide did not affect both an activation of a nuclear transcription factor for HSP-70, heat shock factor-1, and an increased transcriptional rate of HSP-70 by MS, but increased the rates of MSP-70 mRNA degradation. In summary, ceramide may efficiently induce MS-induced apoptosis by suppressing anti-apoptotic MSP-70 through a post-transcriptional regulation.	Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Sakyo Ku, Kyoto 6068507, Japan; Osaka Dent Univ, Dept Med, Osaka 540, Japan; RIKEN, Tsukuba Life Sci Res Ctr, Gene Bank, Tsukuba, Ibaraki 3050074, Japan	Kyoto University; RIKEN	Okazaki, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Sakyo Ku, 54 Syogoin Kawaramachi, Kyoto 6068507, Japan.	toshiroo@kuhp.kyoto-u.ac.jp						BIRD TA, 1994, J BIOL CHEM, V269, P31836; Buzzard KA, 1998, J BIOL CHEM, V273, P17147, DOI 10.1074/jbc.273.27.17147; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; De Maio A, 1999, SHOCK, V11, P1, DOI 10.1097/00024382-199901000-00001; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; Elia G, 1996, J BIOL CHEM, V271, P16111, DOI 10.1074/jbc.271.27.16111; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Gamen S, 1996, FEBS LETT, V390, P233, DOI 10.1016/0014-5793(96)00666-7; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; Granerus M, 1996, CELL PROLIFERAT, V29, P309, DOI 10.1111/j.1365-2184.1996.tb01582.x; Hawkins CJ, 1996, P NATL ACAD SCI USA, V93, P13786, DOI 10.1073/pnas.93.24.13786; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JACQUIERSARLIN MR, 1995, J BIOL CHEM, V270, P14094, DOI 10.1074/jbc.270.23.14094; KIM DH, 1995, P NATL ACAD SCI USA, V92, P2126, DOI 10.1073/pnas.92.6.2126; KOLESNICK RN, 1994, BIOCHEM CELL BIOL, V72, P471, DOI 10.1139/o94-063; LASTER SM, 1988, J IMMUNOL, V141, P2629; LI GC, 1982, P NATL ACAD SCI-BIOL, V79, P3218, DOI 10.1073/pnas.79.10.3218; Liossis SNC, 1997, J IMMUNOL, V158, P5668; Lu ML, 1996, P NATL ACAD SCI USA, V93, P8977, DOI 10.1073/pnas.93.17.8977; Mansat V, 1997, CANCER RES, V57, P5300; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; Mizushima N, 1996, FEBS LETT, V395, P267, DOI 10.1016/0014-5793(96)01050-2; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Nishikawa A, 1995, DIFFERENTIATION, V59, P207, DOI 10.1046/j.1432-0436.1995.5940207.x; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; Reyes JG, 1996, J BIOL CHEM, V271, P21375, DOI 10.1074/jbc.271.35.21375; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; Sawai H, 1997, J BIOL CHEM, V272, P2452; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; THEODORAKIS NG, 1987, MOL CELL BIOL, V7, P4357, DOI 10.1128/MCB.7.12.4357; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; YANG ZH, 1993, J BIOL CHEM, V268, P20520; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	45	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8872	8879		10.1074/jbc.275.12.8872	http://dx.doi.org/10.1074/jbc.275.12.8872			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722733	hybrid			2022-12-27	WOS:000086507700083
J	Chinenov, Y; Henzl, M; Martin, ME				Chinenov, Y; Henzl, M; Martin, ME			The alpha and beta subunits of the GA-binding protein form a stable heterodimer in solution - Revised model of heterotetrameric complex assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; DNA-BINDING; IV GENE; POLYOMAVIRUS ENHANCER; INITIATOR ACTIVITY; E4TF1 SUBUNITS; ETS; ACTIVATION; PROMOTER; ELEMENTS	We have studied the assembly of GA-binding protein (GABP) in solution and established the sole of DNA in the assembly of the transcriptionally active GABP alpha(2)beta(2) heterotetrameric complex. GABP binds DNA containing a single PEA3/Ets-binding site (PEA3/EBS) exclusively as the ap heterodimer complex, but readily hinds as the GABP alpha(2)beta(2) heterotetramer complex on DNA containing two PEA3/EBSs. Positioning of the PEA3/EBSs on the same face of the DNA helix stabilizes heterotetramer complex binding. These observations suggest that GABP alpha beta heterodimers are the predominant molecular species in solution and that DNA containing two PEA3/ EBSs promotes formation of the GABP alpha(2)beta(2) heterotetrameric complex. We analyzed the assembly of GABP alpha(2)beta(2) heteromeric complexes in solution by analytical ultracentrifugation. GABP alpha exists as a monomer in solution while GABP beta exists in a monomer-dimer equilibrium (K-d = 1.8 +/- 0.27 mu M). In equimolar mixtures of the two subunits, GABP alpha and GABP beta formed a stable heterodimer, with no heterotetramer complex detected. Thus, GABP exists in solution as the heterodimer previously shown to be a weak transcriptional activator. Assembly of the transcriptionally active GABP alpha(2)beta(2) heterotetramer complex requires the presence of specific: DNA containing at least two PEA3/EBSs.	Univ Missouri, Dept Biochem, Columbia, MO 65212 USA	University of Missouri System; University of Missouri Columbia	Martin, ME (corresponding author), Univ Missouri, Dept Biochem, Columbia, MO 65212 USA.							Bachman NJ, 1996, ARCH BIOCHEM BIOPHYS, V333, P152, DOI 10.1006/abbi.1996.0376; Bannert N, 1999, P NATL ACAD SCI USA, V96, P1541, DOI 10.1073/pnas.96.4.1541; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTER RS, 1994, J BIOL CHEM, V269, P4381; Chinenov Y, 1998, J BIOL CHEM, V273, P6203, DOI 10.1074/jbc.273.11.6203; DELABROUSSE FC, 1994, GENE DEV, V8, P1853, DOI 10.1101/gad.8.15.1853; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; HANSEN JC, 1994, BIOCHEMISTRY-US, V33, P13155, DOI 10.1021/bi00249a001; Hoffmeyer A, 1998, J BIOL CHEM, V273, P10112, DOI 10.1074/jbc.273.17.10112; Kohler JJ, 1999, P NATL ACAD SCI USA, V96, P11735, DOI 10.1073/pnas.96.21.11735; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LAMARCO KL, 1989, GENE DEV, V3, P1372, DOI 10.1101/gad.3.9.1372; Laue TM, 1999, ANNU REV BIOPH BIOM, V28, P75, DOI 10.1146/annurev.biophys.28.1.75; Markiewicz S, 1996, J BIOL CHEM, V271, P14849, DOI 10.1074/jbc.271.25.14849; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; Martin ME, 1996, J BIOL CHEM, V271, P25617, DOI 10.1074/jbc.271.41.25617; MINTON AP, 1990, ANAL BIOCHEM, V190, P1, DOI 10.1016/0003-2697(90)90125-S; Pomerantz JL, 1998, BIOCHEMISTRY-US, V37, P965, DOI 10.1021/bi972464o; Rentzeperis D, 1999, NAT STRUCT BIOL, V6, P569; Rosmarin AG, 1998, J BIOL CHEM, V273, P13097, DOI 10.1074/jbc.273.21.13097; Sawa C, 1996, NUCLEIC ACIDS RES, V24, P4954, DOI 10.1093/nar/24.24.4954; SAWADA J, 1994, EMBO J, V13, P1396, DOI 10.1002/j.1460-2075.1994.tb06393.x; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; Shiio Y, 1996, ONCOGENE, V12, P1837; Sucharov C, 1995, GENE EXPRESSION, V5, P93; Suzuki F, 1998, J BIOL CHEM, V273, P29302, DOI 10.1074/jbc.273.45.29302; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; Villena JA, 1998, BIOCHEM J, V331, P121, DOI 10.1042/bj3310121; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; YOO WD, 1991, J VIROL, V65, P5391, DOI 10.1128/JVI.65.10.5391-5400.1991; Yu M, 1997, J BIOL CHEM, V272, P29060, DOI 10.1074/jbc.272.46.29060	36	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7749	7756		10.1074/jbc.275.11.7749	http://dx.doi.org/10.1074/jbc.275.11.7749			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713087	hybrid			2022-12-27	WOS:000085913300047
J	Fedele, M; Benvenuto, G; Pero, R; Majello, B; Battista, S; Lembo, F; Vollono, E; Day, PM; Santoro, M; Lania, L; Bruni, CB; Fusco, A; Chiariotti, L				Fedele, M; Benvenuto, G; Pero, R; Majello, B; Battista, S; Lembo, F; Vollono, E; Day, PM; Santoro, M; Lania, L; Bruni, CB; Fusco, A; Chiariotti, L			A novel member of the BTB/POZ family, PATZ, associates with the RNF4 RING finger protein and acts as a transcriptional repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; DNA-BINDING; POZ-DOMAIN; HMGI-C; REGULATED EXPRESSION; HISTONE DEACETYLASE; INTERACTION MOTIF; GENE; RECEPTOR; ALPHA	We have identified a novel human gene encoding a 59-kDa POZ-AT hook-zinc finger protein (PATZ) that interacts with RNF4, a mediator of androgen receptor activity, and acts as a transcriptional repressor. PATZ cDNA was isolated through a two-hybrid interaction screening using the RING finger protein RNF4 as a bait. In vitro and in vivo interaction between RNF4 and PATZ was demonstrated by protein-protein affinity chromatography and coimmunoprecipitation experiments. Such interaction occurred through a small region of PATZ containing an AT-hook DNA binding domain. Immunofluorescence staining and confocal microscopy showed that PATZ localizes in distinct punctate nuclear regions and colocalizes with RNF4. Functional analysis was pe;formed by cotransfection assays: PATZ acted as a transcriptional repressor, whereas its partner RNF4 behaved as a transcriptional activator. When both proteins were overexpressed a strong repression of the basal transcription was observed, indicating that the association of PATZ with RNF4 switches activation to repression, In addition, RNF4 was also found to associate with HMGI(Y), a chromatin-modeling factor containing AT-hook domains.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, CNR, Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Genet Biol Mol & Gen, I-80134 Naples, Italy; NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA; Univ Catanzaro Magna Graecia, Dipartimento Med Sperimentale & Clin G Salvatore, I-88100 Catanzaro, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Naples Federico II; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Magna Graecia University of Catanzaro	Chiariotti, L (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, CNR, Ctr Endocrinol & Oncol Sperimentale, Via S Pansini 5, I-80131 Naples, Italy.		Fedele, Monica/C-1417-2015; Chiariotti, Lorenzo/AAC-5262-2022; Battista, Sabrina/AAY-2981-2020; Pero, Raffaela/L-1461-2015	Fedele, Monica/0000-0002-9171-1312; Battista, Sabrina/0000-0001-5899-9759; Pero, Raffaela/0000-0003-2182-5530; CHIARIOTTI, Lorenzo/0000-0001-6097-4171; BENVENUTO, Giovanna/0000-0001-7155-2935; Fusco, Alfredo/0000-0003-3332-5197; Majello, Barbara/0000-0003-2789-3585				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; ASHAR HR, 1995, CELL, V82, P57; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chiariotti L, 1998, GENOMICS, V47, P258, DOI 10.1006/geno.1997.5105; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dhordain P, 1995, ONCOGENE, V11, P2689; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; Fedele M, 1998, ONCOGENE, V17, P413, DOI 10.1038/sj.onc.1201952; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KANNO M, 1995, EMBO J, V14, P5672, DOI 10.1002/j.1460-2075.1995.tb00254.x; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; KleinHessling S, 1996, P NATL ACAD SCI USA, V93, P15311, DOI 10.1073/pnas.93.26.15311; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Majello B, 1999, ONCOGENE, V18, P4598, DOI 10.1038/sj.onc.1202822; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NUMOTO M, 1993, NUCLEIC ACIDS RES, V21, P3767, DOI 10.1093/nar/21.16.3767; Okabe S, 1998, MOL CELL BIOL, V18, P4235, DOI 10.1128/MCB.18.7.4235; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SALVATORE P, 1995, FEBS LETT, V373, P159, DOI 10.1016/0014-5793(95)01032-A; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; Seyfert VL, 1996, ONCOGENE, V12, P2331; STAUFENBIEL M, 1984, J CELL BIOL, V98, P1886, DOI 10.1083/jcb.98.5.1886; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; WOLFFE AP, 1995, CELL, V83, P1091; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	46	71	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7894	7901		10.1074/jbc.275.11.7894	http://dx.doi.org/10.1074/jbc.275.11.7894			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713105	hybrid			2022-12-27	WOS:000085913300065
J	Wrigley, JDJ; Ahmed, T; Nevett, CL; Findlay, JBC				Wrigley, JDJ; Ahmed, T; Nevett, CL; Findlay, JBC			Peripherin/rds influences membrane vesicle morphology - Implications for retinopathies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT RETINITIS-PIGMENTOSA; RDS MUTANT MICE; RETINAL DEGENERATION; PHOTORECEPTOR PERIPHERIN/RDS; ROD PHOTORECEPTORS; DISK MEMBRANE; PROTEIN; ROM-1; GENE; LOCALIZATION	Peripherin/rds is an integral membrane glycoprotein found in the rim regions of vertebrate photoreceptor cell discs. Natural mutations of the encoding gene result in degenerative retinal disorders, such as retinitis pig mentosa. The retinal degeneration slow (rds) phenotype, observed in mice, is considered to be an appropriate model for peripherin/rds-mediated retinitis pigmentosa, Associated abnormalities in the outer segment of photoreceptor cells have implicated peripherin/rds in some aspect of disc morphology, yet it remains unclear whether such morphological effects are the cause or the result of this condition. Here we present the first direct evidence to support a role for peripherin/rds in maintaining the flattened vesicle morphology characteristic of photoreceptor outer segments. In vitro expression yields a 36-kDa immunoreactive species, which is inserted into membranes and undergoes N-glycosylation, inter- and intramolecular disulfide bonding, and dimerization, Electron microscopy reveals that peripherin/rds flattens microsomal vesicles. This effect appears to be dependent on disulfide bond formation but not N-glycosylation, The inability of two pathogenic peripherin/rds mutants (P216L and C165Y) to flatten membrane vesicles implicates such mutations as the primary cause of the retinal degeneration observed in retinitis pigmentosa.	Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Findlay, JBC (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England.							ARIKAWA K, 1992, J CELL BIOL, V116, P659, DOI 10.1083/jcb.116.3.659; BASCOM RA, 1992, NEURON, V8, P1171, DOI 10.1016/0896-6273(92)90137-3; Boesze-Battaglia K, 1998, BIOCHEMISTRY-US, V37, P9477, DOI 10.1021/bi980173p; CONNELL GJ, 1990, BIOCHEMISTRY-US, V29, P4691, DOI 10.1021/bi00471a025; Drummond D. G., 1950, J ROY MICROSCOPICAL, V70, P1; Goldberg AFX, 1998, BIOCHEMISTRY-US, V37, P680, DOI 10.1021/bi972036i; Goldberg AFX, 1996, BIOCHEMISTRY-US, V35, P6144, DOI 10.1021/bi960259n; GOLDBERG AFX, 1995, BIOCHEMISTRY-US, V34, P14213, DOI 10.1021/bi00043a028; HAWKINS RK, 1985, EXP EYE RES, V41, P701, DOI 10.1016/0014-4835(85)90179-4; HAYAT MA, 1986, BASIC TECHNIQUES TRA, P275; HOLZENBURG A, 1993, EUR J BIOCHEM, V213, P21, DOI 10.1111/j.1432-1033.1993.tb17730.x; JANSEN HG, 1984, J COMP NEUROL, V224, P71, DOI 10.1002/cne.902240107; KAJIWARA K, 1991, NATURE, V354, P480, DOI 10.1038/354480a0; Kedzierski W, 1997, INVEST OPHTH VIS SCI, V38, P498; Keen TJ, 1996, HUM MUTAT, V8, P297; MOLDAY RS, 1994, PROG RETIN EYE RES, V13, P271, DOI 10.1016/1350-9462(94)90013-2; MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; ROOF DJ, 1982, J CELL BIOL, V95, P487, DOI 10.1083/jcb.95.2.487; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; SOUIED E, 1995, VISION RES S, V35, P221; TRAVIS GH, 1989, NATURE, V338, P70, DOI 10.1038/338070a0; VANNIE R, 1978, TISSUE ANTIGENS, V12, P106, DOI 10.1111/j.1399-0039.1978.tb01305.x	23	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13191	13194		10.1074/jbc.C900853199	http://dx.doi.org/10.1074/jbc.C900853199			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10747861	hybrid			2022-12-27	WOS:000086925300008
J	Agarkova, I; Auerbach, D; Ehler, E; Perriard, JC				Agarkova, I; Auerbach, D; Ehler, E; Perriard, JC			A novel marker for vertebrate embryonic heart, the EH-myomesin isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOMERIC M-BAND; SKELETAL-MUSCLE; IMMUNOELECTRON MICROSCOPY; DILATED CARDIOMYOPATHY; GENE-EXPRESSION; MYOSIN-BINDING; M-PROTEIN; TITIN; ELASTICITY; CELLS	Myomesin is a structural component of the M-band that is expressed in all types of striated muscle. Its primary function may be the maintenance of the thick filament lattice and its anchoring to the elastic filament system composed of titin. Different myomesin isoforms have been described in chicken and mice, but no particular function has been assigned to them. Here we investigate the spatio-temporal expression pattern of myomesin isoforms by means of reverse transcriptase-polymerase chain reaction and isoform-specific antibodies. We find that two alternative splicing events give rise to four myomesin isoforms in chicken contrary to only one splicing event with two possible isoforms in mice. A splicing event at the C terminus results in two splice variants termed H-myomesin and S-myomesin, which represent the major myomesin species in heart and skeletal muscle of avian species, respectively. In contrast, in mammalian heart and skeletal muscle only S-myomesin is expressed. In embryonic heart of birds and mammals, alternative splicing in the central part of the molecule gives rise to the isoform that we termed EH-myomesin. It represents the major myomesin isoform at early embryonic stages of heart but is rapidly down-regulated around birth. Thus, the strict developmental regulation of the EH-myomesin makes it an ideally suited marker for embryonic heart.	Swiss Fed Inst Technol, Inst Cell Biol, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Perriard, JC (corresponding author), Swiss Fed Inst Technol, Inst Cell Biol, CH-8093 Zurich, Switzerland.	jcp@cell.biol.ethz.ch		Ehler, Elisabeth/0000-0001-5646-5964				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Auerbach D, 1999, MOL BIOL CELL, V10, P1297, DOI 10.1091/mbc.10.5.1297; Auerbach D, 1997, CELL STRUCT FUNCT, V22, P139, DOI 10.1247/csf.22.139; Bantle S, 1996, J BIOL CHEM, V271, P19042, DOI 10.1074/jbc.271.32.19042; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Ehler E, 1999, J CELL SCI, V112, P1529; FISCHMAN DA, 1967, J CELL BIOL, V32, P557, DOI 10.1083/jcb.32.3.557; GOODE D, 1975, CYTOBIOLOGIE, V11, P203; Gregorio CC, 1998, J CELL BIOL, V143, P1013, DOI 10.1083/jcb.143.4.1013; GROVE BK, 1985, J CELL BIOL, V101, P1413, DOI 10.1083/jcb.101.4.1413; GROVE BK, 1984, J CELL BIOL, V98, P518, DOI 10.1083/jcb.98.2.518; HAMBURGER V, 1992, DEV DYNAM, V195, P231, DOI 10.1002/dvdy.1001950404; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; Helfman DM, 1999, J CELL SCI, V112, P371; KELLY AM, 1976, DEV BIOL, V48, P421, DOI 10.1016/0012-1606(76)90103-2; Kenny PA, 1999, GENE, V232, P11, DOI 10.1016/S0378-1119(99)00122-5; Kolmerer B, 1996, J MOL BIOL, V256, P556, DOI 10.1006/jmbi.1996.0108; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li FQ, 1997, J MOL CELL CARDIOL, V29, P1541, DOI 10.1006/jmcc.1997.0381; Linke WA, 1998, P NATL ACAD SCI USA, V95, P8052, DOI 10.1073/pnas.95.14.8052; MESSERLI JM, 1993, CYTOMETRY, V14, P725, DOI 10.1002/cyto.990140705; MESSERLI JM, 1993, HISTOCHEMISTRY, V100, P193, DOI 10.1007/BF00269092; NADALGINARD B, 1991, ADV ENZYME REGUL, V31, P261, DOI 10.1016/0065-2571(91)90017-G; Obermann WMJ, 1997, EMBO J, V16, P211, DOI 10.1093/emboj/16.2.211; Obermann WMJ, 1996, J CELL BIOL, V134, P1441, DOI 10.1083/jcb.134.6.1441; OBERMANN WMJ, 1995, EUR J BIOCHEM, V233, P110, DOI 10.1111/j.1432-1033.1995.110_1.x; PERIASAMY M, 1984, J BIOL CHEM, V259, P3595; PRICE MG, 1987, J CELL BIOL, V104, P1325, DOI 10.1083/jcb.104.5.1325; PRICE MG, 1993, J BIOL CHEM, V268, P21800; Reddy KB, 1998, J BIOL CHEM, V273, P35039, DOI 10.1074/jbc.273.52.35039; REMANE A, 1979, SYSTEMATISCHE ZOOLOG, P571; RUMYANTSEV PP, 1977, INT REV CYTOL, V51, P187; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SEN A, 1988, J BIOL CHEM, V263, P19132; SMALL JV, 1992, EUR J BIOCHEM, V208, P559, DOI 10.1111/j.1432-1033.1992.tb17220.x; SMOLICH JJ, 1995, REPROD FERT DEVELOP, V7, P451, DOI 10.1071/RD9950451; SQUIRE JM, 1975, ANNU REV BIOPHYS BIO, V4, P137, DOI 10.1146/annurev.bb.04.060175.001033; Steiner F, 1999, GENOMICS, V56, P78, DOI 10.1006/geno.1998.5682; Sussman MA, 1998, J CLIN INVEST, V101, P51, DOI 10.1172/JCI1167; SUTHERLAND CJ, 1993, DEV DYNAM, V196, P25, DOI 10.1002/aja.1001960104; Tskhovrebova L, 1997, NATURE, V387, P308, DOI 10.1038/387308a0; Van der Ven PFM, 1999, J MUSCLE RES CELL M, V20, P569, DOI 10.1023/A:1005569225773; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; VINKEMEIER U, 1993, J CELL SCI, V106, P319; Wallimann T, 1985, Cell Muscle Motil, V6, P239; WEYDERT A, 1985, P NATL ACAD SCI USA, V82, P7183, DOI 10.1073/pnas.82.21.7183	49	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10256	10264		10.1074/jbc.275.14.10256	http://dx.doi.org/10.1074/jbc.275.14.10256			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744711	hybrid			2022-12-27	WOS:000086345600052
J	Bae, YS; Sung, JY; Kim, OS; Kim, YJ; Hur, KC; Kazlauskas, A; Rhee, SG				Bae, YS; Sung, JY; Kim, OS; Kim, YJ; Hur, KC; Kazlauskas, A; Rhee, SG			Platelet-derived growth factor-induced H2O2 production requires the activation of phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRTL-5 THYROID-CELLS; PROTEIN-KINASE-C; HYDROGEN-PEROXIDE; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; H2O2-GENERATING SYSTEM; RESPIRATORY BURST; PHOSPHOLIPASE-D; ANGIOTENSIN-II; NADPH OXIDASE	Autophosphorylation of the platelet-derived growth factor (PDGF) receptor triggers intracellular signaling cascades as a result of recruitment of Src homology 2 domain-containing enzymes, including phosphatidylinositol S-kinase (PI3K), the GTPase-activating protein of Pas (GAP), the protein-tyrosine phosphatase SHP-2, and phospholipase C-yl (PLC-gamma 1), to specific phosphotyrosine residues. The roles of these various effecters in PDGF-induced generation of H2O2 have now been investigated in HepG2 cells expressing various PDGF receptor mutants. These mutants included a kinase-deficient receptor and receptors in which various combinations of the tyrosine residues required for the binding of PI3K (Tyr(740) and Tyr(751)), GAP (Tyr(771)), SHP-2 (Tyr(1009)), Or PLC-gamma 1 (Tyr(1021)) were mutated to Phe. PDGF failed to increase H2O2 production in cells expressing either the kinase-deficient mutant or a receptor in which the two Tyr residues required for the binding of PI3K mere replaced by Phe. In contrast, PDGF-induced H2O2, production in cells expressing a receptor in which the binding sites for GAP, SHP-2, and PLC-gamma 1 were all mutated was slightly greater than that in cells expressing the wildtype receptor. Only the PI3K binding site was alone sufficient for PDGF-induced H2O2 production. The effect of PDGF on H2O2 generation was blocked by the PI3K inhibitors LY294002 and wortmannin or by overexpression of a dominant negative mutant of Rad. These results suggest that a product of PI3K is required for PDGF-induced production of H2O2 in nonphagocytic cells, and that Rad mediates signaling between the PI3K product and the putative NADPH oxidase.	Ewha Womans Univ, Ctr Cell Signaling Res, Div Mol Life Sci, Seodaemoon Gu, Seoul 120750, South Korea; Ewha Womans Univ, Dept Biol Sci, Seoul 120750, South Korea; Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA; NHLBI, Int Joint Res Lab, Ctr Cell Signaling Res, NIH, Bethesda, MD 20892 USA; NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA	Ewha Womans University; Ewha Womans University; Harvard University; Harvard Medical School; Schepens Eye Research Institute; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Rhee, SG (corresponding author), Ewha Womans Univ, Ctr Cell Signaling Res, Div Mol Life Sci, Seodaemoon Gu, 11-1 Daehyun Dong, Seoul 120750, South Korea.							Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHEN QL, 1995, J BIOL CHEM, V270, P28499, DOI 10.1074/jbc.270.48.28499; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; EMMENDORFFER A, 1993, EUR J HAEMATOL, V51, P223; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kim KS, 1998, J CLIN INVEST, V101, P1821, DOI 10.1172/JCI1830; KIMURA T, 1995, ENDOCRINOLOGY, V136, P116, DOI 10.1210/en.136.1.116; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Kourie JI, 1998, AM J PHYSIOL-CELL PH, V275, pC1, DOI 10.1152/ajpcell.1998.275.1.C1; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P549, DOI 10.1042/bj3070549; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P543, DOI 10.1042/bj3070543; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Lee ZW, 1998, J BIOL CHEM, V273, P12710, DOI 10.1074/jbc.273.21.12710; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; Min DS, 1998, J BIOL CHEM, V273, P29986, DOI 10.1074/jbc.273.45.29986; NATARAJAN V, 1993, J BIOL CHEM, V268, P930; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Nisimoto Y, 1997, J BIOL CHEM, V272, P18834, DOI 10.1074/jbc.272.30.18834; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Okajima F, 1997, ENDOCRINOLOGY, V138, P220, DOI 10.1210/en.138.1.220; Pagano PJ, 1997, P NATL ACAD SCI USA, V94, P14483, DOI 10.1073/pnas.94.26.14483; PAHL HL, 1994, BIOESSAYS, V16, P497, DOI 10.1002/bies.950160709; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; ROBERTSON FM, 1990, CANCER RES, V50, P6062; Sattler M, 1999, BLOOD, V93, P2928; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Thannickal VJ, 1998, J BIOL CHEM, V273, P23611, DOI 10.1074/jbc.273.36.23611; THELEN M, 1993, PHYSIOL REV, V73, P797, DOI 10.1152/physrev.1993.73.4.797; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Yeh LH, 1999, AM J PHYSIOL-CELL PH, V276, pC838, DOI 10.1152/ajpcell.1999.276.4.C838; Zafari AM, 1998, HYPERTENSION, V32, P488, DOI 10.1161/01.HYP.32.3.488; ZOR U, 1993, BIOCHEM J, V295, P879, DOI 10.1042/bj2950879	48	261	269	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10527	10531		10.1074/jbc.275.14.10527	http://dx.doi.org/10.1074/jbc.275.14.10527			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744745	hybrid			2022-12-27	WOS:000086345600086
J	Blakely, GW; Davidson, AO; Sherratt, DJ				Blakely, GW; Davidson, AO; Sherratt, DJ			Sequential strand exchange by XerC and XerD during site-specific recombination at dif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; INTEGRASE FAMILY; CELL-DIVISION; LAMBDA-INTEGRASE; TERMINUS REGION; IN-VITRO; RESOLUTION; CHROMOSOME; LOCUS; DNA	Successful segregation of circular chromosomes in Escherichia coli requires that dimeric replicons, produced by homologous recombination, are converted to monomers prior to cell division. The Xer site-specific recombination system uses two related tyrosine recombinases, XerC and XerD, to catalyze resolution of circular dimers at the chromosomal site, dif, A 33-base pair DNA fragment containing the 28-base pair minimal dif site is sufficient for the recombinases to mediate both inter- and intramolecular site-specific recombination in vivo. We show that Xer-mediated intermolecular recombination in vitro between nicked linear dif "suicide" substrates and supercoiled plasmid DNA containing dif is initiated by XerC, Furthermore, on the appropriate substrate, the nicked Holliday junction intermediate formed by XerC is converted to a linear product by a subsequent single XerD-mediated strand exchange. We also demonstrate that a XerC homologue from Pseudomonas aeruginosa stimulates strand cleavage by XerD on a nicked linear substrate and promotes initiation of strand exchange by XerD in an intermolecular reaction between linear and supercoiled DNA, thereby reversing the normal order of strand exchanges.	Univ Oxford, Dept Biochem, Div Mol Genet, Oxford OX1 3QU, England	University of Oxford	Sherratt, DJ (corresponding author), Univ Oxford, Dept Biochem, Div Mol Genet, S Parks Rd, Oxford OX1 3QU, England.							ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; Arciszewska L, 1997, EMBO J, V16, P3731, DOI 10.1093/emboj/16.12.3731; ARCISZEWSKA LK, 1995, EMBO J, V14, P2112, DOI 10.1002/j.1460-2075.1995.tb07203.x; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; Azaro MA, 1997, EMBO J, V16, P3744, DOI 10.1093/emboj/16.12.3744; Blakely G, 1996, GENE DEV, V10, P762, DOI 10.1101/gad.10.6.762; BLAKELY G, 1991, NEW BIOL, V3, P789; BLAKELY G, 1993, CELL, V75, P351, DOI 10.1016/0092-8674(93)80076-Q; Blakely GW, 1997, J MOL BIOL, V265, P30, DOI 10.1006/jmbi.1996.0709; Colloms SD, 1997, CELL, V88, P855, DOI 10.1016/S0092-8674(00)81931-5; Colloms SD, 1996, EMBO J, V15, P1172, DOI 10.1002/j.1460-2075.1996.tb00456.x; CORNET F, 1994, J BACTERIOL, V176, P3188, DOI 10.1128/jb.176.11.3188-3195.1994; DONACHIE WD, 1993, ANNU REV MICROBIOL, V47, P199, DOI 10.1146/annurev.mi.47.100193.001215; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; Guo F, 1999, P NATL ACAD SCI USA, V96, P7143, DOI 10.1073/pnas.96.13.7143; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; Hallet B, 1999, MOL CELL, V4, P949, DOI 10.1016/S1097-2765(00)80224-5; Hickman AB, 1997, CELL, V89, P227, DOI 10.1016/S0092-8674(00)80202-0; HOFTE M, 1994, MOL MICROBIOL, V14, P1011, DOI 10.1111/j.1365-2958.1994.tb01335.x; KITTS PA, 1988, J MOL BIOL, V204, P95, DOI 10.1016/0022-2836(88)90602-X; KUEMPEL PL, 1991, NEW BIOL, V3, P799; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; LANDY A, 1993, CURR OPIN GENET DEV, V3, P699, DOI 10.1016/S0959-437X(05)80086-3; LESLIE NR, 1995, EMBO J, V14, P1561, DOI 10.1002/j.1460-2075.1995.tb07142.x; Liu GW, 1998, MOL MICROBIOL, V29, P893, DOI 10.1046/j.1365-2958.1998.00986.x; Neilson L, 1999, MOL MICROBIOL, V31, P915, DOI 10.1046/j.1365-2958.1999.01231.x; NUNESDUBY SE, 1987, CELL, V50, P779, DOI 10.1016/0092-8674(87)90336-9; Recchia GD, 1999, EMBO J, V18, P5724, DOI 10.1093/emboj/18.20.5724; Sherratt DJ, 1998, CELL, V93, P149, DOI 10.1016/S0092-8674(00)81566-4; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; Steiner W, 1999, MOL MICROBIOL, V31, P579, DOI 10.1046/j.1365-2958.1999.01198.x; Steiner WW, 1998, MOL MICROBIOL, V27, P257, DOI 10.1046/j.1365-2958.1998.00651.x; STIRLING CJ, 1988, EMBO J, V7, P4389, DOI 10.1002/j.1460-2075.1988.tb03338.x; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; SUMMERS DK, 1984, CELL, V36, P1097, DOI 10.1016/0092-8674(84)90060-6; TECKLENBURG M, 1995, P NATL ACAD SCI USA, V92, P1352, DOI 10.1073/pnas.92.5.1352; TRASK DK, 1984, EMBO J, V3, P671, DOI 10.1002/j.1460-2075.1984.tb01865.x	37	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					9930	9936		10.1074/jbc.275.14.9930	http://dx.doi.org/10.1074/jbc.275.14.9930			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744667	hybrid			2022-12-27	WOS:000086345600008
J	Kimata, Y; Higashio, H; Kohno, K				Kimata, Y; Higashio, H; Kohno, K			Impaired proteasome function rescues thermosensitivity of yeast cells lacking the coatomer subunit epsilon-COP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI PROTEIN-TRANSPORT; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; COATED VESICLES; MEMBRANE-TRANSPORT; SECRETORY PATHWAY; DELTA-COP; ZETA-COP; ER; INHIBITORS	Formation of COPI-coated transport vesicles requires a cytosolic protein complex consisting of seven subunits: alpha-, beta-, beta'-, gamma-, delta-, epsilon-, and zeta-COP, collectively designated coatomer. The yeast Saccharomyces cerevisiae gene encoding the E-COP subunit is known as SEC28/ ANU2. anu2 null mutant cells (anu2 Delta) are temperature-sensitive, and LU-COP is rapidly degraded in these cells when they are shifted to the restrictive temperature. We isolated extragenic suppressors that rescue the temperature-sensitive growth defect of anu-2 Delta cells. Genetic analysis revealed that one of the suppressors is allelic to PRE8 (PRS4), which encodes a 20 S proteasome subunit. In the presence of a proteasome inhibitor, MG132, anu2 Delta cells did not cease growth even at the restrictive temperature. Furthermore, MG132 inhibited the rapid decrease of cu-COP levels in anu2 Delta cells shifted to the restrictive temperature. However, secretion of certain proteins by these cells was impaired even in the presence of MG132. In conclusion, impairment of proteasome-dependent proteolysis rescued some, but not all, temperature-sensitive defects of anu2 Delta cells. These results are discussed in terms of evidence that E-COP plays a critical role in maintaining the structural integrity of alpha-COP.	Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Ikoma, Nara 6300101, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1010062, Japan	Nara Institute of Science & Technology; Japan Science & Technology Agency (JST)	Kohno, K (corresponding author), Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, 8916-5 Takayama, Ikoma, Nara 6300101, Japan.		Kohno, Kenji/AAZ-6573-2020	Kohno, Kenji/0000-0002-3503-6551				BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Cosson P, 1996, EMBO J, V15, P1792, DOI 10.1002/j.1460-2075.1996.tb00528.x; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Daro E, 1997, J CELL BIOL, V139, P1747, DOI 10.1083/jcb.139.7.1747; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DUDEN R, 1994, J BIOL CHEM, V269, P24486; Duden R, 1998, EMBO J, V17, P985, DOI 10.1093/emboj/17.4.985; EMORI Y, 1991, MOL CELL BIOL, V11, P344, DOI 10.1128/MCB.11.1.344; Faulstich D, 1996, J CELL BIOL, V135, P53, DOI 10.1083/jcb.135.1.53; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; GERICH B, 1995, P NATL ACAD SCI USA, V92, P3229, DOI 10.1073/pnas.92.8.3229; GRAHAM TR, 1993, EMBO J, V12, P869, DOI 10.1002/j.1460-2075.1993.tb05727.x; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; Guo Q, 1996, J BIOL CHEM, V271, P11191, DOI 10.1074/jbc.271.19.11191; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; HOBBIE L, 1994, J BIOL CHEM, V269, P20958; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; Kaiser C., 1994, METHODS YEAST GENETI; Kimata Y, 1999, CELL STRUCT FUNCT, V24, P197, DOI 10.1247/csf.24.197; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lowe M, 1996, J BIOL CHEM, V271, P30725, DOI 10.1074/jbc.271.48.30725; Lowe M, 1995, J BIOL CHEM, V270, P31364, DOI 10.1074/jbc.270.52.31364; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SIKORSKI RS, 1989, GENETICS, V122, P19; STENBECK G, 1992, FEBS LETT, V314, P195, DOI 10.1016/0014-5793(92)80973-K; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; Yamazaki S, 1997, J BIOCHEM, V121, P8	35	10	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10655	10660		10.1074/jbc.275.14.10655	http://dx.doi.org/10.1074/jbc.275.14.10655			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744762	hybrid			2022-12-27	WOS:000086345600103
J	Landrieu, I; De Veylder, L; Fruchart, JS; Odaert, B; Casteels, P; Portetelle, D; Van Montagu, M; Inze, D; Lippens, G				Landrieu, I; De Veylder, L; Fruchart, JS; Odaert, B; Casteels, P; Portetelle, D; Van Montagu, M; Inze, D; Lippens, G			The Arabidopsis thaliana PIN1At gene encodes a single-domain phosphorylation-dependent peptidyl prolyl cis/trans isomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SUBSTRATE RECOGNITION; WW DOMAIN; PROTEIN; SEQUENCE; PHOSPHOPROTEINS; ISOMERIZATION; SPECTROSCOPY; CALCITONIN; PARVULIN	A homologue of the human site-specific prolyl cis/trans isomerase PIN1 was identified in Arabidopsis thaliana. The PIN1At gene encodes a protein of 119 amino acids that is 53% identical with the catalytic domain of the human PIN1 parvulin. Steady-state PIN1At mRNA is found in all plant tissues tested. We show by two-dimensional NMR spectroscopy that the PIN1At is a prolyl cis/trans isomerase with specificity for phosphoserine-proline bonds. PIN1At is the first example of an eukaryotic parvulin without N- or C-terminal extensions. The N-terminal WW domain of 40 amino acids, typical of all the phosphorylation-dependent eukaryotic parvulins, is absent. However, triple-resonance NMR experiments showed that PIN1At contained a hydrophobic helix similar to the al helix observed in PIN1 that could mediate the protein-protein interactions.	Fac Univ Sci Agron Gembloux, Unite Microbiol, B-5030 Gembloux, Belgium; State Univ Ghent VIB, Dept Plant Genet, B-9000 Ghent, Belgium; Inst Pasteur, Inst Biol Lille, CNRS, UMR 8525, F-59019 Lille, France	University of Liege; Flanders Institute for Biotechnology (VIB); Ghent University; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Landrieu, I (corresponding author), Fac Univ Sci Agron Gembloux, Unite Microbiol, B-5030 Gembloux, Belgium.	isabelle.landrieu@pastair-lille.fr; guy.lippens@pasteur-lelle.fr	Inzé, Dirk/AAW-6381-2021; de veylder, lieven/AAM-9909-2020; Landrieu, Isabelle/AAF-8495-2019	Inzé, Dirk/0000-0002-3217-8407; de veylder, lieven/0000-0003-1150-4426; Landrieu, Isabelle/0000-0002-4883-2637; Lippens, Guy/0000-0002-8236-0901				AMODEO P, 1994, BIOCHEMISTRY-US, V33, P10754, DOI 10.1021/bi00201a024; An YQ, 1996, PLANT J, V10, P107, DOI 10.1046/j.1365-313X.1996.10010107.x; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; HANES SD, 1989, YEAST, V5, P55, DOI 10.1002/yea.320050108; Hani J, 1999, J BIOL CHEM, V274, P108, DOI 10.1074/jbc.274.1.108; HANI J, 1995, FEBS LETT, V365, P198, DOI 10.1016/0014-5793(95)00471-K; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KERN D, 1993, FEBS LETT, V323, P198, DOI 10.1016/0014-5793(93)81338-Z; Kops O, 1998, J BIOL CHEM, V273, P31971, DOI 10.1074/jbc.273.48.31971; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 1999, NATURE, V399, P784; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Maleszka R, 1996, P NATL ACAD SCI USA, V93, P447, DOI 10.1073/pnas.93.1.447; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; RAHFELD JU, 1994, FEBS LETT, V352, P180, DOI 10.1016/0014-5793(94)00932-5; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Sambrook J., 2002, MOL CLONING LAB MANU; Schutkowski M, 1998, BIOCHEMISTRY-US, V37, P5566, DOI 10.1021/bi973060z; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Staub O, 1996, STRUCTURE, V4, P495, DOI 10.1016/S0969-2126(96)00054-8; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; TRAAS JA, 1992, PLANT J, V2, P723, DOI 10.1111/j.1365-313X.1992.tb00141.x; Uchida T, 1999, FEBS LETT, V446, P278, DOI 10.1016/S0014-5793(99)00239-2; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957	27	50	51	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10577	10581		10.1074/jbc.275.14.10577	http://dx.doi.org/10.1074/jbc.275.14.10577			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744752	hybrid			2022-12-27	WOS:000086345600093
J	Leung, YM; Zeng, WZ; Liou, HH; Solaro, CR; Huang, CL				Leung, YM; Zeng, WZ; Liou, HH; Solaro, CR; Huang, CL			Phosphatidylinositol 4,5-bisphosphate and intracellular pH regulate the ROMK1 potassium channel via separate but interrelated mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-ATP CHANNELS; PROTEIN-KINASE; BETA-GAMMA; NA+ IONS; PIP2; PHOSPHORYLATION; SENSITIVITY; ACTIVATION; CELLS	ROMK channels are responsible for K+ secretion in kidney. The activity of ROMK is regulated by intracellular pH (pH(i)) with acidification causing channel closure (effective pK(a) similar to 6.9). Recently, we and others reported that a direct interaction of the channels with phosphatidyl-1,5-bisphosphate (PIP2) is critical for opening of the inwardly rectifying K+ channels. Here, we investigate the relationship between the mechanisms for regulation of ROMK by PIP2 and by pH(i), We find that disruption of PIP2-ROMK1 interaction not only decreases single-channel open probability (P-o) but gives rise to a ROMK1 subconductance state. This state has an increased sensitivity to intracellular protons (effective pK(a) shifted to pH similar to 7.8), such that the subconductance channels are relatively quiescent at physiological pH(i) Open probability for the subconductance channels can then be increased by intracellular alkalinization to supra-physiological pH. This increase in P-o for the subconductance channels by alkalinization is not associated with an increase in PIP2-channel interaction. Thus, direct interaction with PIP2 is critical for ROMK1 to open at full conductance. Disruption of this interaction increases pH(i) sensitivity for the channels via emergence of the subconductance state. The control of open probability of ROMK1 by pH(i) occurs via a mechanism distinct from the regulation by PIP2.	Univ Texas, SW Med Ctr, Dept Med, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Huang, CL (corresponding author), Univ Texas, SW Med Ctr, Dept Med, H5-112,MC-8856,5323 Harry Hines Blvd, Dallas, TX 75235 USA.	chuan1@mednet.swmed.edu		Liou, Horng-Huei/0000-0001-6537-5346	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054368, T32DK007257] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK-54368, T32 DK-07257] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; BOIM MA, 1995, AM J PHYSIOL-RENAL, V268, pF1132, DOI 10.1152/ajprenal.1995.268.6.F1132; CASSOLA AC, 1993, AM J PHYSIOL, V264, pF502, DOI 10.1152/ajprenal.1993.264.3.F502; Choe H, 1997, AM J PHYSIOL-RENAL, V273, pF516, DOI 10.1152/ajprenal.1997.273.4.F516; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Fakler B, 1996, EMBO J, V15, P4093, DOI 10.1002/j.1460-2075.1996.tb00784.x; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; FRIEDMAN ZY, 1993, J PHARMACOL EXP THER, V267, P617; FUKAMI K, 1988, P NATL ACAD SCI USA, V85, P9057, DOI 10.1073/pnas.85.23.9057; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; HILLE B, 1992, IONIC CHANNELS EXCIT, P390; Ho IHM, 1999, J PHYSIOL-LONDON, V520, P645, DOI 10.1111/j.1469-7793.1999.00645.x; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; LEIPZIGER J, 2000, IN PRESS AM J PHYSL; Liou HH, 1999, P NATL ACAD SCI USA, V96, P5820, DOI 10.1073/pnas.96.10.5820; MacGregor GG, 1998, AM J PHYSIOL-RENAL, V275, pF415, DOI 10.1152/ajprenal.1998.275.3.F415; MATSUDA H, 1993, J PHYSIOL-LONDON, V460, P311, DOI 10.1113/jphysiol.1993.sp019473; MCNICHOLAS CM, 1994, P NATL ACAD SCI USA, V91, P8077, DOI 10.1073/pnas.91.17.8077; McNicholas CM, 1998, AM J PHYSIOL-RENAL, V275, pF972, DOI 10.1152/ajprenal.1998.275.6.F972; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; SCHLATTER E, 1994, PFLUG ARCH EUR J PHY, V428, P631, DOI 10.1007/BF00374587; Schulte U, 1998, J BIOL CHEM, V273, P34575, DOI 10.1074/jbc.273.51.34575; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; TSAI TD, 1995, AM J PHYSIOL-CELL PH, V268, pC1173, DOI 10.1152/ajpcell.1995.268.5.C1173; WANG WH, 1991, P NATL ACAD SCI USA, V88, P9722, DOI 10.1073/pnas.88.21.9722; WANG WH, 1990, AM J PHYSIOL, V259, pF494, DOI 10.1152/ajprenal.1990.259.3.F494; WANG WH, 1992, ANNU REV PHYSIOL, V54, P81; WANG WH, 1994, AM J PHYSIOL-RENAL, V267, pF599, DOI 10.1152/ajprenal.1994.267.4.F599; Xu ZC, 1996, J BIOL CHEM, V271, P9313, DOI 10.1074/jbc.271.16.9313; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103; ZHOU H, 1994, AM J PHYSIOL, V266, pC809, DOI 10.1152/ajpcell.1994.266.3.C809	34	69	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10182	10189		10.1074/jbc.275.14.10182	http://dx.doi.org/10.1074/jbc.275.14.10182			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744702	hybrid			2022-12-27	WOS:000086345600043
J	Martin, JB; Laussmann, T; Bakker-Grunwald, T; Vogel, G; Klein, G				Martin, JB; Laussmann, T; Bakker-Grunwald, T; Vogel, G; Klein, G			neo-Inositol polyphosphates in the amoeba Entamoeba histolytica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE-LIVING AMEBA; SCYLLO-INOSITOL; TETRAKISPHOSPHATE; IDENTIFICATION; DICTYOSTELIUM; PHOSPHATES; C-13-NMR; SPECTRA; NMR; PENTAKISPHOSPHATE	We have reexamined the structure of inositol phosphates resent in trophozoites of the parasitic amoeba Entamoeba histolytica and show here that, rather than being myo-inositol derivatives (Martin, J.-B., Bakker-Grunwald, T., and Klein, G. (1993) fur. J, Biochem 214, 711-718), these compounds belong to a new class of inositol phosphates in which the cyclitol isomer is neo-inositol. The structures of neo-inositol hexakisphosphate, 2-diphospho-neo-inositol pentakisphosphate, and 2,5-bisdiphospho-neo-inositol tetrakisphosphate, which are present in E. histolytica at concentrations of 0.08-0.36 mM, were solved by two-dimensional P-31-H-1 NMR spectroscopy. No evidence for the co-existence of their myo-inositol counterparts has been found. These neo-inositol compounds were not substrates of 6-diphospho-inositol pentakisphosphate Fi-kinase, an enzyme purified from Dictyostelium discoideum that phosphorylates 6-diphospho-myo-inositol pentakisphosphate and more slowly also myo-inositol hexakisphosphate, specifically on position 5. Because preliminary data indicate that large amounts of the same neo-inositol phosphate and diphosphate esters are also present in another primitive amoeba, Phreatamoeba balamuthi, the occurrence of high concentrations of neo-inositol polyphosphates may be much more general than previously thought.	CEA, Lab Biochim & Biophys Syst Integres, DBMS, BBSI, F-38054 Grenoble 9, France; Berg Univ Gesamthsch Wuppertal, Fachbereich Chem 6, D-42119 Wuppertal, Germany; Univ Osnabruck, Abt Mikrobiol, D-49069 Osnabruck, Germany	CEA; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); University of Wuppertal; University Osnabruck	Klein, G (corresponding author), CEA, Lab Biochim & Biophys Syst Integres, DBMS, BBSI, 17 Rue Martyrs, F-38054 Grenoble 9, France.	gklein@cea.fr		Laussmann, Tim/0000-0002-0180-3513				ANGYAL SJ, 1982, CARBOHYD RES, V100, P43, DOI 10.1016/S0008-6215(00)81024-1; [Anonymous], 1989, BIOCHEM J, V258, P1; BAX A, 1981, J MAGN RESON, V42, P501, DOI 10.1016/0022-2364(81)90272-9; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CANDY DJ, 1967, BIOCHEM J, V103, P666, DOI 10.1042/bj1030666; CAVALIERSMITH T, 1991, BIOSYSTEMS, V25, P25, DOI 10.1016/0303-2647(91)90010-I; CHAVEZ LA, 1986, J PROTOZOOL, V33, P397, DOI 10.1111/j.1550-7408.1986.tb05630.x; COSGROVE DJ, 1963, NATURE, V200, P568, DOI 10.1038/200568b0; FALCK JR, 1995, J AM CHEM SOC, V117, P12172, DOI 10.1021/ja00154a017; FLEISCHER B, 1994, J BIOL CHEM, V269, P17826; Giri B, 1996, FEBS LETT, V393, P109, DOI 10.1016/0014-5793(96)00866-6; GLENNON MC, 1993, BIOCHEM J, V293, P583, DOI 10.1042/bj2930583; GRIBBESTAD IS, 1994, NMR BIOMED, V7, P181, DOI 10.1002/nbm.1940070405; HIPPS PP, 1977, BIOCHEM BIOPH RES CO, V77, P340, DOI 10.1016/S0006-291X(77)80202-7; HUDLICKY T, 1994, J CHEM SOC PERK T 1, P1553, DOI 10.1039/p19940001553; IRVING GCJ, 1982, COMMUN SOIL SCI PLAN, V13, P957, DOI 10.1080/00103628209367324; *IUPAC IUB JOINT C, 1975, EUR J BIOCHEM, V57, P1; KESSLER H, 1990, MAGN RESON CHEM, V28, P62, DOI 10.1002/mrc.1260280112; LAIRD MH, 1976, ARCH BIOCHEM BIOPHYS, V175, P384, DOI 10.1016/0003-9861(76)90525-7; Laussmann T, 1997, BIOCHEM J, V322, P31, DOI 10.1042/bj3220031; Laussmann T, 1996, BIOCHEM J, V315, P715, DOI 10.1042/bj3150715; Laussmann T, 1998, FEBS LETT, V426, P145, DOI 10.1016/S0014-5793(98)00329-9; Lohia A, 1999, MOL BIOCHEM PARASIT, V98, P67, DOI 10.1016/S0166-6851(98)00147-9; MARTIN JB, 1987, BIOCHIM BIOPHYS ACTA, V931, P16, DOI 10.1016/0167-4889(87)90045-0; MARTIN JB, 1995, J EUKARYOT MICROBIOL, V42, P183, DOI 10.1111/j.1550-7408.1995.tb01560.x; MARTIN JB, 1993, EUR J BIOCHEM, V214, P711, DOI 10.1111/j.1432-1033.1993.tb17972.x; MAYR GW, 1988, BIOCHEM J, V254, P585, DOI 10.1042/bj2540585; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; MICHAELIS T, 1993, NMR BIOMED, V6, P105, DOI 10.1002/nbm.1940060116; RAHA S, 1995, FEBS LETT, V362, P316, DOI 10.1016/0014-5793(95)00265-B; Safrany ST, 1999, BIOL CHEM, V380, P945, DOI 10.1515/BC.1999.117; Seaquist ER, 1998, MAGNET RESON MED, V39, P313, DOI 10.1002/mrm.1910390220; SHEARS SB, 1995, J BIOL CHEM, V270, P10489, DOI 10.1074/jbc.270.18.10489; Shears SB, 1998, BBA-MOL CELL BIOL L, V1436, P49, DOI 10.1016/S0005-2760(98)00131-3; SHERMAN WR, 1978, COMP BIOCHEM PHYS B, V59, P201, DOI 10.1016/0305-0491(78)90246-8; SHERMAN WR, 1971, BIOCHEMISTRY-US, V10, P3491, DOI 10.1021/bi00795a002; STEPHENS L, 1993, J BIOL CHEM, V268, P4009; Taguchi R, 1997, ARCH BIOCHEM BIOPHYS, V342, P161, DOI 10.1006/abbi.1997.9991; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564	39	31	32	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10134	10140		10.1074/jbc.275.14.10134	http://dx.doi.org/10.1074/jbc.275.14.10134			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744695	hybrid			2022-12-27	WOS:000086345600036
J	Nagai, Y; Tucker, T; Ren, HZ; Kenan, DJ; Henderson, BS; Keene, JD; Strittmatter, WJ; Burke, JR				Nagai, Y; Tucker, T; Ren, HZ; Kenan, DJ; Henderson, BS; Keene, JD; Strittmatter, WJ; Burke, JR			Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-LOCALIZATION; ESCHERICHIA-COLI; DOMAIN PROTEINS; IN-VITRO; HUNTINGTIN; DISEASE; INTERACTS; TRACT; PATHOGENESIS; EXPANSION	Proteins with expanded polyglutamine domains cause eight inherited neurodegenerative diseases, including Huntington's, but the molecular mechanism(s) responsible for neuronal degeneration are not yet established. Expanded Polyglutamine domain proteins process properties that distinguish them from the same proteins with shorter glutamine repeats. Unlike proteins with short polyglutamine domains, proteins with expanded polyglutamine domains display unique protein interactions, form intercellular aggregates, and adopt a novel conformation that can be recognized by monoclonal antibodies. Any of these polyglutamine length-dependent properties could be responsible for the pathogenic effects of expanded polyglutamine proteins. To identify peptides that interfere with pathogenic polyglutamine interactions, we screened a combinatorial peptide library expressed on M13 phage pIII protein to identify proteins that preferentially bind pathologic-length polyglutamine domains. We identified six tryptophan-rich that preferentially bind pathologic-length polyglutamine domain proteins. Polyglutamine-binding peptide 1 (QBP1) potently inhibits polyglutamine protein aggregation in an in vitro assay, while a scrambled sequence has no effect on aggregation. QBP1 and a tandem repeat of QBP1 also inhibit aggregation of polyglutamine-yellow fluorescent fusion protein in transfected COS-7 cells. Expression of QBP1 potently inhibits polyglutamine-induced cell death. Selective inhibition of pathologic interactions of expanded polyglutamine domains with themselves or other proteins may be useful strategy for preventing disease onset or for slowing progression of the polyglutamine repeat diseases.	Duke Univ, Med Ctr, Deane Lab, Durham, NC 27710 USA; Duke Univ, Med Ctr, Div Neurol, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University; Duke University	Burke, JR (corresponding author), Duke Univ, Med Ctr, Dept Med Neurol, Box 2900, Durham, NC 27710 USA.		Burke, James R/E-4245-2016	Burke, James R/0000-0002-3408-7787				ADEY NB, 1996, PHAGE DISPLAY PEPTID, P66; Bao J, 1996, P NATL ACAD SCI USA, V93, P5037, DOI 10.1073/pnas.93.10.5037; Burke JR, 1996, NAT MED, V2, P347, DOI 10.1038/nm0396-347; Chai YH, 1999, J NEUROSCI, V19, P10338; Ellenberg J, 1999, TRENDS CELL BIOL, V9, P52, DOI 10.1016/S0962-8924(98)01420-2; Faber PW, 1998, HUM MOL GENET, V7, P1463, DOI 10.1093/hmg/7.9.1463; Georgalis Y, 1998, P NATL ACAD SCI USA, V95, P6118, DOI 10.1073/pnas.95.11.6118; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Hackam AS, 1998, J CELL BIOL, V141, P1097, DOI 10.1083/jcb.141.5.1097; Hsiao PW, 1999, J BIOL CHEM, V274, P20229, DOI 10.1074/jbc.274.29.20229; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; ISACSON O, 1995, NAT MED, V1, P1189, DOI 10.1038/nm1195-1189; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Koshy BT, 1997, BRAIN PATHOL, V7, P927, DOI 10.1111/j.1750-3639.1997.tb00894.x; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; LEVESQUE A, 1995, J IMMUNOL METHODS, V178, P71, DOI 10.1016/0022-1759(94)00243-P; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; Matilla A, 1997, NATURE, V389, P974, DOI 10.1038/40159; Nagai Y, 1999, EXP NEUROL, V155, P195, DOI 10.1006/exnr.1998.6991; Onodera O, 1996, FEBS LETT, V399, P135, DOI 10.1016/S0014-5793(96)01301-4; Onodera O, 1997, BIOCHEM BIOPH RES CO, V238, P599, DOI 10.1006/bbrc.1997.7337; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; Paulson HL, 1999, AM J HUM GENET, V64, P339, DOI 10.1086/302269; Perez MK, 1998, J CELL BIOL, V143, P1457, DOI 10.1083/jcb.143.6.1457; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; PIKE CJ, 1995, J BIOL CHEM, V270, P23895, DOI 10.1074/jbc.270.41.23895; Rubinsztein DC, 1996, AM J HUM GENET, V59, P16; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Sittler A, 1998, MOL CELL, V2, P427, DOI 10.1016/S1097-2765(00)80142-2; SLOBODA RD, 1976, BIOCHEMISTRY-US, V15, P4497, DOI 10.1021/bi00665a026; Sparks Andrew B., 1996, P227, DOI 10.1016/B978-012402380-2/50015-0; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Wood JD, 1998, MOL CELL NEUROSCI, V11, P149, DOI 10.1006/mcne.1998.0677; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328	39	151	163	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10437	10442		10.1074/jbc.275.14.10437	http://dx.doi.org/10.1074/jbc.275.14.10437			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744733	hybrid			2022-12-27	WOS:000086345600074
J	Schweickart, VL; Epp, A; Raport, CJ; Gray, PW				Schweickart, VL; Epp, A; Raport, CJ; Gray, PW			CCR11 is a functional receptor for the monocyte chemoattractant protein family of chemokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CC-CHEMOKINE; MOLECULAR-CLONING; CHEMOTACTIC CYTOKINES; INFLAMMATION; EXPRESSION; EOSINOPHILS; MICE; ATHEROSCLEROSIS; IDENTIFICATION; CHROMOSOME-3	Chemokines mediate their diverse activities through G protein-coupled receptors. The human homolog of the bovine orphan receptor PPR1 shares significant similarity to chemokine receptors. Transfection of this receptor into murine L1.2 cells resulted in responsiveness to monocyte chemoattractant protein (MCP)-4, MCP-2, and MCP-1 in chemotaxis assays. Binding studies with radio-labeled MCP-4 demonstrated a single high affinity binding site with an IC50 of 0.14 nM. As shown by competition binding, other members of the MCP family also recognized this receptor. MCP-2 was the next most potent ligand, with an IC50 of 0.45 nM, Surprisingly, eotaxin (IC50 = 6.7 nM) and MCP-3 (IC50 = 4.1 nM) bind with greater affinity than MCP-1 (IC50 = 10.7 nM) but only act as agonists in chemotaxis assays at 100-fold higher concentrations. Because of high affinity binding and functional chemotactic responses, we have termed this receptor CCR11. The gene for CCR11 was localized to human chromosome 3q22, which is distinct from most CC chemokine receptor genes at 3p21. Northern blot hybridization was used to identify CCR11 expression in heart, small intestine, and lung. Thus CCR11 shares functional similarity to CCR2 because it recognizes members of the MCP family, but CCR11 has a distinct expression pattern.	ICOS Corp, Bothell, WA 98021 USA	Icos Corporation	Gray, PW (corresponding author), ICOS Corp, 22021 20th Ave SE, Bothell, WA 98021 USA.	pgray@icos.com						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Campbell JJ, 1999, J IMMUNOL, V163, P2353; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; Chantry D, 1998, J LEUKOCYTE BIOL, V64, P49, DOI 10.1002/jlb.64.1.49; Chantry David, 1999, Blood, V94, P1890; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; COMBADIERE C, 1995, J BIOL CHEM, V270, P29671; Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894; GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613; Gerard C, 1998, NATURE, V395, P217, DOI 10.1038/26104; Godiska R, 1997, J LEUKOCYTE BIOL, V61, P353, DOI 10.1002/jlb.61.3.353; Godiska R, 1997, J EXP MED, V185, P1595, DOI 10.1084/jem.185.9.1595; Gong WH, 1998, J BIOL CHEM, V273, P4289, DOI 10.1074/jbc.273.8.4289; Gong XQ, 1997, J BIOL CHEM, V272, P11682, DOI 10.1074/jbc.272.18.11682; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; Grewal IS, 1997, J IMMUNOL, V159, P401; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Heiber M, 1996, GENOMICS, V32, P462, DOI 10.1006/geno.1996.0143; Jung S, 1999, CURR OPIN IMMUNOL, V11, P319, DOI 10.1016/S0952-7915(99)80051-X; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; MATSUOKA I, 1993, BIOCHEM BIOPH RES CO, V194, P504, DOI 10.1006/bbrc.1993.1848; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Nomiyama H, 1999, J INTERF CYTOK RES, V19, P227, DOI 10.1089/107999099314153; Pevzner V, 1999, CURR TOP MICROBIOL, V246, P79; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Samson M, 1996, GENOMICS, V36, P522, DOI 10.1006/geno.1996.0498; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; Streblow DN, 1999, CELL, V99, P511, DOI 10.1016/S0092-8674(00)81539-1; Suzuki G, 1999, J IMMUNOL, V162, P5981; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Tang HL, 1999, SCIENCE, V284, P819, DOI 10.1126/science.284.5415.819; Wells TNC, 1999, INFLAMM RES, V48, P353, DOI 10.1007/s000110050472; Zlotnik A, 1999, CRIT REV IMMUNOL, V19, P1; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	45	58	73	1	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9550	9556		10.1074/jbc.275.13.9550	http://dx.doi.org/10.1074/jbc.275.13.9550			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734104	hybrid			2022-12-27	WOS:000086206500068
J	Uyemura, SA; Luo, SH; Moreno, SNJ; Docampo, R				Uyemura, SA; Luo, SH; Moreno, SNJ; Docampo, R			Oxidative phosphorylation, Ca2+ transport, and fatty acid-induced uncoupling in malaria parasites mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM; PLANT-MITOCHONDRIA; OXYGEN-CONSUMPTION; TOXOPLASMA-GONDII; ATOVAQUONE; PROTEINS; INSITU; CELLS; MECHANISM; RESISTANT	Respiration, oxidative phosphorylation, calcium uptake, and the mitochondrial membrane potential of trophozoites of the malaria parasite Plasmodium berghei were assayed in situ after permeabilization with digitonin, ADP promoted an oligomycin-sensitive transition from resting to phosphorylating respiration. Respiration was sensitive to antimycin A and cyanide. The capacity of trophozoites to sustain oxidative phosphorylation was additionally supported by the detection of an oligomycin-sensitive decrease in mitochondrial membrane potential induced by ADP, Phosphorylation of ADP could be obtained in permeabilized trophozoites in the presence of succinate, citrate, alpha-ketoglutarate, glutamate, malate, dihydroorotate, alpha-glycerophosphate, and N,N,N',N'-tetramethyl-p-phenylenediamine Ca2+ uptake caused membrane depolarization compatible with the existence of an electrogenically mediated Ca2+ transport system in these mitochondria, An uncoupling effect of fatty acids was partly reversed by bovine serum albumin, ATP, or GTP and not affected by atractyloside, ADP, glutamate, or malonate, Evidence for the presence of a mitochondrial uncoupling protein in P, berghei was also obtained by using antibodies raised against plant uncoupling mitochondrial protein. Together these results provide the first direct biochemical evidence of mitochondrial function in ATP synthesis and Ca2+ transport in a malaria parasite and suggest the presence of an H+ conductance in trophozoites similar to that produced by a mitochondrial uncoupling protein.	Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Urbana-Champaign	Docampo, R (corresponding author), Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, 2001 S Lincoln Ave, Urbana, IL 61802 USA.		Uyemura, Sergio/B-4656-2011	Uyemura, Sergio/0000-0001-5505-9817				AKERMAN KEO, 1976, FEBS LETT, V68, P191, DOI 10.1016/0014-5793(76)80434-6; ANDREYEV AY, 1988, FEBS LETT, V226, P265, DOI 10.1016/0014-5793(88)81436-4; ANDREYEV AY, 1989, EUR J BIOCHEM, V182, P585, DOI 10.1111/j.1432-1033.1989.tb14867.x; BEACH DH, 1977, J PARASITOL, V63, P62, DOI 10.2307/3280105; BEAVIS AD, 1992, J BIOL CHEM, V267, P3079; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; DESLAURIERS R, 1986, BIOCHIM BIOPHYS ACTA, V886, P319, DOI 10.1016/0167-4889(86)90166-7; DLUZEWSKI AR, 1984, T ROY SOC TROP MED H, V78, P622, DOI 10.1016/0035-9203(84)90221-9; Docampo R., 1984, FREE RADICAL BIO MED, V4, P243; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FRY M, 1992, BIOCHEM PHARMACOL, V43, P1545, DOI 10.1016/0006-2952(92)90213-3; FRY M, 1991, PARASITOLOGY, V102, P17, DOI 10.1017/S0031182000060297; Fry M., 1991, P154; Garlid KD, 1998, FEBS LETT, V438, P10, DOI 10.1016/S0014-5793(98)01246-0; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GUTTERIDGE WE, 1979, BIOCHIM BIOPHYS ACTA, V582, P390, DOI 10.1016/0304-4165(79)90131-4; HOLZ GG, 1977, B WORLD HEALTH ORGAN, V55, P237; HOLZ GG, 1977, J PROTOZOOL, V24, P566, DOI 10.1111/j.1550-7408.1977.tb01017.x; HOMEWOOD CA, 1976, ANN TROP MED PARASIT, V70, P249, DOI 10.1080/00034983.1976.11687119; HUDSON AT, 1993, PARASITOL TODAY, V9, P66, DOI 10.1016/0169-4758(93)90040-M; INESI G, 1980, J BIOL CHEM, V255, P3025; Jarmuszkiewicz W, 1999, J BIOL CHEM, V274, P23198, DOI 10.1074/jbc.274.33.23198; Jezek P, 1998, BBA-BIOENERGETICS, V1365, P319, DOI 10.1016/S0005-2728(98)00084-X; Luo SH, 1999, FEBS LETT, V460, P217, DOI 10.1016/S0014-5793(99)01353-8; Mitchell P, 1966, CHEMIOSMOTIC COUPLIN; Murphy AD, 1997, EXP PARASITOL, V87, P112, DOI 10.1006/expr.1997.4194; NICHOLLS DG, 1976, FEBS LETT, V61, P103, DOI 10.1016/0014-5793(76)81014-9; PFEFFERKORN ER, 1993, J PARASITOL, V79, P559, DOI 10.2307/3283383; PRESSMAN BC, 1956, BIOCHIM BIOPHYS ACTA, V21, P458, DOI 10.1016/0006-3002(56)90182-2; Scarpa A, 1979, Methods Enzymol, V56, P301; SCHWARZENBACH G, 1957, HELV CHIM ACTA, V40, P1886, DOI 10.1002/hlca.19570400640; Sherman Irwin W., 1998, P135; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Sluse FE, 1998, FEBS LETT, V433, P237, DOI 10.1016/S0014-5793(98)00922-3; SMARTSEV VN, 1997, FEBS LETT, V412, P179; SMARTSEV VN, 1997, BIOCHIM BIOPHYS ACTA, V1319, P251; Srivastava IK, 1999, ANTIMICROB AGENTS CH, V43, P1334, DOI 10.1128/AAC.43.6.1334; Srivastava IK, 1997, J BIOL CHEM, V272, P3961, DOI 10.1074/jbc.272.7.3961; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vaidya Akhil B., 1998, P355; VERCESI AE, 1991, J BIOL CHEM, V266, P14431; VERCESI AE, 1993, J BIOL CHEM, V268, P8564; Vercesi AE, 1998, J BIOL CHEM, V273, P31040, DOI 10.1074/jbc.273.47.31040; VERCESI AE, 1995, NATURE, V375, P24, DOI 10.1038/375024a0; VERCESI AE, 1992, MOL BIOCHEM PARASIT, V56, P251, DOI 10.1016/0166-6851(92)90174-I; VERCESI AE, 1992, BIOCHEM J, V284, P463, DOI 10.1042/bj2840463; WALLACE WR, 1966, AM J TROP MED HYG, V15, P811, DOI 10.4269/ajtmh.1966.15.811; Wieckowski MR, 1997, BIOCHEM BIOPH RES CO, V232, P414; 1997, TROPICAL DIS RES, P40	50	73	77	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9709	9715		10.1074/jbc.275.13.9709	http://dx.doi.org/10.1074/jbc.275.13.9709			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734123	hybrid			2022-12-27	WOS:000086206500087
J	Chen, YZ; McPhie, DL; Hirschberg, J; Neve, RL				Chen, YZ; McPhie, DL; Hirschberg, J; Neve, RL			The amyloid precursor protein-binding protein APP-BP1 drives the cell cycle through the S-M checkpoint and causes apoptosis in neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE BRAIN; FUSION PROTEINS; SURFACE; EXPRESSION; KINASE; DEATH; PHOSPHORYLATION; NEURODEGENERATION; PURIFICATION; INDUCTION	APP-BP1 binds to the amyloid precursor protein (APP) carboxyl-terminal domain. Recent work suggests that APP-BP1 participates in a novel ubiquitinylation-related pathway involving the ubiquitin-like molecule NEDD8. We show here that, in vivo in mammalian cells, APP-BP1 interacts with hUba3, its presumptive partner in the NEDD8 activation pathway, and that the APP-BP1 binding site for hUba3 is within amino acids 443-479. We also provide evidence that the human APP-BP1 molecule can rescue the ts41 mutation in Chinese hamster cells. This mutation previously has been shown to lead to successive S phases of the cell. cycle without intervening G(2), M, and G(1), suggesting that the product of this gene negatively regulates entry into the S phase and positively regulates entry into mitosis. We show that expression of APP-BP1 in ts41 cells drives the cell cycle through the S-M checkpoint and that this function requires both hUba3 and hUbc12. Overexpression of APP-BP1 in primary neurons causes apoptosis via the same pathway. A specific caspase-6 inhibitor blocks this apoptosis. These findings are discussed in the context of abnormalities in the cell cycle that have been observed in Alzheimer's disease.	Harvard Univ, Sch Med, Dept Psychiat, McLean Hosp, Belmont, MA 02478 USA; Hebrew Univ Jerusalem, Inst Life Sci, Dept Genet, IL-91904 Jerusalem, Israel	Harvard University; McLean Hospital; Hebrew University of Jerusalem	Neve, RL (corresponding author), Harvard Univ, Sch Med, Dept Psychiat, McLean Hosp, MRC 223,115 Mill St, Belmont, MA 02478 USA.	neve@helix.mgh.harvard.edu			NATIONAL INSTITUTE ON AGING [R01AG012954] Funding Source: NIH RePORTER; NIA NIH HHS [AG12954] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bursztajn S, 1998, J NEUROSCI, V18, P9790; Busser J, 1998, J NEUROSCI, V18, P2801; Cernac A, 1997, DEVELOPMENT, V124, P1583; Chow N, 1998, P NATL ACAD SCI USA, V95, P9620, DOI 10.1073/pnas.95.16.9620; Chow NW, 1996, J BIOL CHEM, V271, P11339, DOI 10.1074/jbc.271.19.11339; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; Haas AL, 1997, FASEB J, V11, P1257; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; Harlow E., 1988, ANTIBODIES LAB MANUA; HEINTZ N, 1993, TRENDS BIOCHEM SCI, V18, P157, DOI 10.1016/0968-0004(93)90103-T; HERRUP K, 1995, DEVELOPMENT, V121, P2385; HIRSCHBERG J, 1982, J CELL PHYSIOL, V113, P159, DOI 10.1002/jcp.1041130125; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; Illenberger S, 1998, MOL BIOL CELL, V9, P1495, DOI 10.1091/mbc.9.6.1495; Johnson PR, 1997, TRENDS CELL BIOL, V7, P408, DOI 10.1016/S0962-8924(97)01132-X; Jung SS, 1996, J NEUROSCI RES, V46, P336, DOI 10.1002/(SICI)1097-4547(19961101)46:3<336::AID-JNR7>3.3.CO;2-L; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Keane RW, 1997, J NEUROSCI RES, V48, P168, DOI 10.1002/(SICI)1097-4547(19970415)48:2<168::AID-JNR9>3.0.CO;2-A; KUMAR S, 1993, BIOCHEM BIOPH RES CO, V195, P393, DOI 10.1006/bbrc.1993.2056; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Liakopoulos D, 1999, P NATL ACAD SCI USA, V96, P5510, DOI 10.1073/pnas.96.10.5510; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; LIU WK, 1995, AM J PATHOL, V146, P228; MarquezSterling NR, 1997, J NEUROSCI, V17, P140, DOI 10.1523/JNEUROSCI.17-01-00140.1997; NEVE RL, 1995, METH NEUROSCI, V25, P163; Oishi M, 1997, MOL MED, V3, P111, DOI 10.1007/BF03401803; Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Pellegrini L, 1999, J BIOL CHEM, V274, P21011, DOI 10.1074/jbc.274.30.21011; Perez RG, 1997, J NEUROSCI, V17, P9407; POPE WB, 1994, EXP NEUROL, V126, P185, DOI 10.1006/exnr.1994.1057; QIU WQ, 1995, J NEUROSCI, V15, P2157, DOI 10.1523/JNEUROSCI.15-03-02157.1995; Selznick LA, 1999, J NEUROPATH EXP NEUR, V58, P1020, DOI 10.1097/00005072-199909000-00012; Storey E, 1996, BRAIN RES, V735, P59; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; Vincent I, 1996, J CELL BIOL, V132, P413, DOI 10.1083/jcb.132.3.413; Vincent I, 1997, J NEUROSCI, V17, P3588; Whitby FG, 1998, J BIOL CHEM, V273, P34983, DOI 10.1074/jbc.273.52.34983; Yamazaki T, 1997, J NEUROSCI, V17, P1004; Youssoufian H, 1998, BIOTECHNIQUES, V24, P198, DOI 10.2144/98242bm05	49	104	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8929	8935		10.1074/jbc.275.12.8929	http://dx.doi.org/10.1074/jbc.275.12.8929			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722740	hybrid			2022-12-27	WOS:000086507700090
J	Feng, X; Teitelbaum, SL; Quiroz, ME; Cheng, SL; Lai, CF; Avioli, LV; Ross, FP				Feng, X; Teitelbaum, SL; Quiroz, ME; Cheng, SL; Lai, CF; Avioli, LV; Ross, FP			Sp1/Sp3 and PU.1 differentially regulate beta(5) integrin gene expression in macrophages and osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PU.1; STIMULATING FACTOR-RECEPTOR; BONE-RESORPTION; BINDING-PROTEINS; OSTEOCLAST PRECURSORS; MOLECULAR MECHANISMS; SP1 TRANSACTIVATION; EPITHELIAL-CELLS; FAMILY PROTEINS; ALPHA(V) GENE	Murine osteoclast precursors and osteoblasts express the integrin alpha(v)beta(5), the appearance of which on the cell surface is controlled by the beta(5), and not the alpha(v), subunit, Here, we show that a 173-base pair proximal region of the beta(5) promoter mediates beta(5) basal transcription in macrophage (osteoclast precursor)-like and osteoblastlike cells. DNase I footprinting reveal four regions (FP1-FP4) within the 173-base pair region, protected by macrophage nuclear extracts. In contrast, osteoblast nuclear extracts protect only FP1, FP2, and FP3, FP1, FP2, and FP3 bind Sp1 and Sp3 from both macrophage and osteoblast nuclear extracts. FP4 does not bind osteoblast proteins but binds PU.1 from macrophages, Transfection studies show that FP1 and FP2 Sp1/Sp3 sites act as enhancers in both MC3T3-E1 (osteoblast-like) and J774 (macrophage-like) cell lines, whereas the FP3 Sp1/Sp3 site serves as a silencer. Mutation of the FP2 Sp1/Sp3 site totally abolishes promoter activity in J774 cells, with only partial reduction in MC3T3-E1 cells, Finally, we demonstrate that PU.1 acts as a beta(5) silencer in J774 cells but plays no role in MC3T3-E1 cells. Thus, three Sp1/Sp3 sites regulate beta(5) gene expression in macrophages and osteoblast-like cells, with each element exhibiting cell-type and/or activation-suppression specificity.	Washington Univ, Sch Med, Div Bone & Mineral Dis, St Louis, MO 63110 USA	Washington University (WUSTL)	Ross, FP (corresponding author), Washington Univ, Sch Med, Dept Pathol, Barnes Jewish Hosp N, 216 S Kingshighway, St Louis, MO 63110 USA.			Teitelbaum, Steven/0000-0002-4054-6679	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042404, R01AR032788] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42404, AR32788] Funding Source: Medline; NIDCR NIH HHS [DE05413] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Albert ML, 1998, J EXP MED, V188, P1359, DOI 10.1084/jem.188.7.1359; BARON R, 1986, AM J PATHOL, V122, P363; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BORRAS FE, 1995, J BIOL CHEM, V270, P24385, DOI 10.1074/jbc.270.41.24385; BOYLAN AM, 1995, J CLIN INVEST, V96, P1987, DOI 10.1172/JCI118246; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; CAO X, 1993, J BIOL CHEM, V268, P27371; Chiba M, 1996, J CELL BIOCHEM, V62, P467; CLOVER J, 1992, J CELL SCI, V103, P267; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; FALLON MD, 1983, LAB INVEST, V49, P159; Feng X, 1999, J BIOL CHEM, V274, P1366, DOI 10.1074/jbc.274.3.1366; GRONOWICZ GA, 1994, J BONE MINER RES, V9, P193, DOI 10.1002/jbmr.5650090208; Gronthos S, 1997, J BONE MINER RES, V12, P1189, DOI 10.1359/jbmr.1997.12.8.1189; GROSSCHEDL R, 1995, CURR OPIN CELL BIOL, V7, P362, DOI 10.1016/0955-0674(95)80091-3; GRZESIK WJ, 1994, J BONE MINER RES, V9, P487, DOI 10.1002/jbmr.5650090408; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; Hayashi R, 1997, J IMMUNOL, V159, P4145; Henkel GW, 1996, BLOOD, V88, P2917, DOI 10.1182/blood.V88.8.2917.bloodjournal8882917; HORTON MA, 1991, EXP CELL RES, V195, P368, DOI 10.1016/0014-4827(91)90386-9; HUGHES DE, 1993, J BONE MINER RES, V8, P527; HULTENBY K, 1993, EUR J CELL BIOL, V62, P86; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Inoue M, 1998, MOL ENDOCRINOL, V12, P1955, DOI 10.1210/me.12.12.1955; Kambe M, 1998, BBA-GENE STRUCT EXPR, V1395, P209, DOI 10.1016/S0167-4781(97)00152-8; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; Kucharczuk KL, 1997, METHOD CELL BIOL, V52, P439, DOI 10.1016/S0091-679X(08)60391-X; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; Li RG, 1996, J BIOL CHEM, V271, P18925, DOI 10.1074/jbc.271.31.18925; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; Lin CS, 1997, DNA CELL BIOL, V16, P929, DOI 10.1089/dna.1997.16.929; Liu XD, 1999, J BIOL CHEM, V274, P3285, DOI 10.1074/jbc.274.6.3285; LopezRodriguez C, 1997, EUR J IMMUNOL, V27, P1843, DOI 10.1002/eji.1830270804; LopezRodriguez C, 1997, J BIOL CHEM, V272, P29120, DOI 10.1074/jbc.272.46.29120; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; Moursi AM, 1996, J CELL SCI, V109, P1369; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Nerlov C, 1998, GENE DEV, V12, P2403, DOI 10.1101/gad.12.15.2403; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; Noti JD, 1996, MOL CELL BIOL, V16, P2940; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PANETTI TS, 1993, J BIOL CHEM, V268, P11492; Rodan SB, 1997, J ENDOCRINOL, V154, pS47; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; ROSS FP, 1993, J BIOL CHEM, V268, P9901; SATO M, 1990, J CELL BIOL, V111, P1713, DOI 10.1083/jcb.111.4.1713; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHEPPARD D, 1992, J BIOL CHEM, V267, P17409; SHINAR DM, 1993, J BONE MINER RES, V8, P403; Sinha RK, 1996, BONE, V18, P451, DOI 10.1016/8756-3282(96)00044-0; Sjottem E, 1997, J MOL BIOL, V267, P490, DOI 10.1006/jmbi.1997.0893; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; TEITELBAUM SL, 1995, J CELL BIOCHEM, V59, P1, DOI 10.1002/jcb.240590102; Teitelbaum SL, 1997, J LEUKOCYTE BIOL, V61, P381, DOI 10.1002/jlb.61.4.381; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; WICKHAM TJ, 1994, J CELL BIOL, V127, P257, DOI 10.1083/jcb.127.1.257; Wildhage I, 1999, ENDOCRINOLOGY, V140, P624, DOI 10.1210/en.140.2.624; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Ye JP, 1996, MOL CELL BIOL, V16, P6178; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; Ziober BL, 1996, J BIOL CHEM, V271, P22915, DOI 10.1074/jbc.271.37.22915; Zutter MM, 1997, BLOOD, V90, P678, DOI 10.1182/blood.V90.2.678.678_678_689	73	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8331	8340		10.1074/jbc.275.12.8331	http://dx.doi.org/10.1074/jbc.275.12.8331			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722663	hybrid			2022-12-27	WOS:000086507700013
J	Matsushita, N; Nishi, N; Seki, M; Matsumoto, R; Kuwabara, I; Liu, FT; Hata, Y; Nakamura, T; Hirashima, M				Matsushita, N; Nishi, N; Seki, M; Matsumoto, R; Kuwabara, I; Liu, FT; Hata, Y; Nakamura, T; Hirashima, M			Requirement of divalent galactoside-binding activity of ecalectin/galectin-9 for eosinophil chemoattraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY CRYSTAL-STRUCTURE; CHEMOKINE RECEPTORS; MOLECULAR CHARACTERIZATION; FUNCTIONAL-HETEROGENEITY; CHEMOTACTIC LYMPHOKINES; ANIMAL LECTINS; CC-CHEMOKINE; CELL LINE; GALECTIN-9; PROTEIN	We have previously isolated and cloned a novel eosinophil chemoattractant (ECA) from a human T-cell-derived expression library. This EGA, termed ecalectin, is a variant of human galectin-9, a member of a beta-galactoside binding animal lectin family, which contains two conserved carbohydrate recognition domains (CRDs), In the present study, we addressed whether carbohydrate binding activity is required for the ECA activity of ecalectin and whether both CRDs are essential for this activity. Recombinant full-length wild-type ecalectin (ecalectin-WT) and N-terminal and C-terminal CRD (ecalectin-NT and -CT, respectively) were generated. All of these recombinant proteins exhibited affinity for lactose, a property shared by galectins, but ecalectin-WT exhibited substantially higher hemagglutination activities than ecalectin-NT and -CT. Furthermore, ecalectin-WT showed over 100-fold higher ECA activity than ecalectin-NT and -CT; combination of recombinant domain fragments did not reconstitute the ECA and hemagglutination activities of the full-length protein. ECA activity of ecalectin-WT was inhibited by lactose in a dose-dependent manner. Site-directed mutation of positions Arg(65) Of ecalectin-NT and Arg(239) Of ecalectin-CT to an aspartic acid residue resulted in the loss of both lactose-binding and ECA activities. We conclude that divalent galactoside-binding activity is required for eosinophil chemoattraction by ecalectin.	Kagawa Med Sch, Dept Immunol & Immunopathol, Miki, Kagawa 7610793, Japan; Kagawa Med Sch, Dept Plast & Reconstruct Surg, Miki, Kagawa 7610793, Japan; Kagawa Med Sch, Dept Endocrinol, Miki, Kagawa 7610793, Japan; Mayo Clin, Dept Immunol, Rochester, MN 55905 USA; La Jolla Inst Allergy & Immunol, San Diego, CA 92124 USA	Kagawa University; Kagawa University; Kagawa University; Mayo Clinic; La Jolla Institute for Immunology	Hirashima, M (corresponding author), Kagawa Med Sch, Dept Immunol & Immunopathol, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.		Liu, FU-TONG/A-5749-2019	Liu, FU-TONG/0000-0002-3354-1001; Nishi, Nozomu/0000-0001-7050-3226				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Arata Y, 1997, J BIOCHEM-TOKYO, V121, P1002, DOI 10.1093/oxfordjournals.jbchem.a021686; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; COULAND PO, 1989, J BIOL CHEM, V264, P1310; Dyer KD, 1996, LIFE SCI, V58, P2073, DOI 10.1016/0024-3205(96)00201-9; Elsner J, 1997, EUR J IMMUNOL, V27, P2892, DOI 10.1002/eji.1830271122; FEIZI T, 1994, BIOCHEMISTRY-US, V33, P6342, DOI 10.1021/bi00186a038; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Gabius HJ, 1997, EUR J BIOCHEM, V243, P543, DOI 10.1111/j.1432-1033.1997.t01-1-00543.x; GITT MA, 1992, J BIOL CHEM, V267, P10601; GITT MA, 1995, J BIOL CHEM, V270, P5032, DOI 10.1074/jbc.270.10.5032; Gitt MA, 1997, TRENDS GLYCOSCI GLYC, V9, P87, DOI 10.4052/tigg.9.87; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; HIRASHIMA M, 1992, LYMPHOKINE CYTOK RES, V11, P331; HIRASHIMA M, 1991, LYMPHOKINE CYTOK RES, V10, P481; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kaplan AP, 1998, ALLERGY, V53, P27, DOI 10.1111/j.1398-9995.1998.tb04936.x; Kita H, 1996, J EXP MED, V183, P2421, DOI 10.1084/jem.183.6.2421; KNIBBS RN, 1993, J BIOL CHEM, V268, P14940; LEFFLER H, 1986, J BIOL CHEM, V261, P119; LEOIDAS DD, 1995, STRUCTURE, V3, P1379; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; MAGALDO T, 1995, DEV BIOL, V168, P259; Matsumoto R, 1998, J BIOL CHEM, V273, P16976, DOI 10.1074/jbc.273.27.16976; Nickel R, 1999, J ALLERGY CLIN IMMUN, V104, P723, DOI 10.1016/S0091-6749(99)70281-2; NOWAK TP, 1976, BIOCHEM BIOPH RES CO, V68, P650, DOI 10.1016/0006-291X(76)91195-5; ODA Y, 1993, J BIOL CHEM, V268, P5929; POST TW, 1995, J IMMUNOL, V155, P5299; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; Sabroe I, 1998, J IMMUNOL, V161, P6139; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; Seetharaman J, 1998, J BIOL CHEM, V273, P13047, DOI 10.1074/jbc.273.21.13047; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; TUERECI O, 1997, J BIOL CHEM, V272, P6416; Wada J, 1997, J CLIN INVEST, V99, P2452, DOI 10.1172/JCI119429; Wada J, 1997, J BIOL CHEM, V272, P6078, DOI 10.1074/jbc.272.9.6078; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; Wells TNC, 1998, TRENDS PHARMACOL SCI, V19, P376, DOI 10.1016/S0165-6147(98)01247-4	43	121	128	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8355	8360		10.1074/jbc.275.12.8355	http://dx.doi.org/10.1074/jbc.275.12.8355			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722666	hybrid			2022-12-27	WOS:000086507700016
J	Santella, L; Kyozuka, K; Genazzani, AA; De Riso, L; Carafoli, E				Santella, L; Kyozuka, K; Genazzani, AA; De Riso, L; Carafoli, E			Nicotinic acid adenine dinucleotide phosphate-induced Ca2+ release - Interactions among distinct Ca2+ mobilizing mechanisms in starfish oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; CYCLIC-ADP-RIBOSE; INOSITOL TRISPHOSPHATE; NAADP; ACTIVATION; FERTILIZATION; MATURATION; INACTIVATION; MOBILIZATION; TRIGGERS	An intracellular mechanism activated by nicotinic acid adenine dinucleotide phosphate (NAADP(+)) contributes to intracellular Ca2+ release alongside inositol 1,4,5-trisphosphate (Ins-P-3) and ryanodine receptors. The NAADP(+)-sensitive mechanism has been shown to be operative in sea urchin eggs, ascidian eggs, and pancreatic acinar cells. Furthermore, most mammalian cell types can synthesize NAADP(+), with nicotinic acid and NADP(+) as precursors. In this contribution, NAADP(+) induced Ca2+ release has been investigated in starfish oocytes. Uncaging of injected NAADP(+) induced Ca2+ mobilization in both immature oocytes and in oocytes matured by the hormone 1-methyladenine (1-MA), The role of extracellular Ca2+ in NAADP(+)-induced Ca2+ mobilization, which was minor in immature oocytes, was instead essential in mature oocytes, Thus, the NAADP(+)-sensitive Ca2+ pool, which is known to be distinct from those sensitive to inositol 1,4,5-trisphosphate or cyclic ADPribose, apparently migrated closer to (or became part of) the plasma membrane during the maturation process. Inhibition of both Ins-P-3 and ryanodine receptors, but not of either alone, substantially inhibited NAADP(+)-induced Ca2+ mobilization in both immature and mature oocytes. The data also suggest that NAADP(+)-induced Ca2+ mobilization acted as a trigger for Ca2+ release via Ins-P-3 and ryanodine receptors.	Univ Padua, Dept Biochem, I-35121 Padua, Italy; Staz Zool Anton Dohrn, Cell Biol Lab, I-80121 Naples, Italy; Asamushi Marine Biol Stn, Asamushi, Aomori 0393501, Japan; Univ Cambridge, Dept Pharmacol, Cambridge CB2 1QJ, England	University of Padua; Stazione Zoologica Anton Dohrn di Napoli; University of Cambridge	Carafoli, E (corresponding author), Univ Padua, Dept Biochem, Viale G Colombo 3, I-35121 Padua, Italy.		Genazzani, Armando/AAI-8280-2020; Carafoli, Ernesto/K-5192-2016; Santella, Luigia/AAM-3524-2020	Carafoli, Ernesto/0000-0002-7826-0094; Santella, Luigia/0000-0001-7159-0499; Genazzani, Armando/0000-0003-1923-7430	Telethon [963] Funding Source: Medline	Telethon(Fondazione Telethon)		Aarhus R, 1996, J BIOL CHEM, V271, P8513, DOI 10.1074/jbc.271.15.8513; Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; Albrieux M, 1998, J BIOL CHEM, V273, P14566, DOI 10.1074/jbc.273.23.14566; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; CHIBA K, 1990, DEV BIOL, V140, P300, DOI 10.1016/0012-1606(90)90080-3; CHINI EN, 1995, J BIOL CHEM, V270, P3216, DOI 10.1074/jbc.270.7.3216; CHINI EN, 1995, BIOCHEM BIOPH RES CO, V209, P167, DOI 10.1006/bbrc.1995.1485; CRETON R, 1995, DEV GROWTH DIFFER, V37, P703; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; Genazzani AA, 1997, TRENDS PHARMACOL SCI, V18, P108, DOI 10.1016/S0165-6147(96)01036-X; Genazzani AA, 1997, BRIT J PHARMACOL, V121, P1489, DOI 10.1038/sj.bjp.0701295; Genazzani AA, 1996, BIOCHEM J, V315, P721, DOI 10.1042/bj3150721; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; KANATANI H, 1969, NATURE, V221, P273, DOI 10.1038/221273a0; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; Lee HC, 1997, J BIOL CHEM, V272, P4172, DOI 10.1074/jbc.272.7.4172; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; Lee Hon Cheung, 1998, Cell Biochemistry and Biophysics, V28, P1, DOI 10.1007/BF02738306; Longo F.J., 1997, FERTILIZATION; MIYAZAKI S, 1979, DEV BIOL, V70, P327, DOI 10.1016/0012-1606(79)90031-9; MOHRI T, 1995, DEV BIOL, V172, P139, DOI 10.1006/dbio.1995.0011; MOREAU M, 1978, NATURE, V272, P251, DOI 10.1038/272251a0; PerezTerzic CM, 1995, BIOCHEM J, V312, P955, DOI 10.1042/bj3120955; Santella L, 1998, BIOCHEM BIOPH RES CO, V252, P1, DOI 10.1006/bbrc.1998.9583; Santella L, 1999, EXP CELL RES, V248, P567, DOI 10.1006/excr.1999.4425; SANTELLA L, 1994, BIOCHEM BIOPH RES CO, V203, P674, DOI 10.1006/bbrc.1994.2235; SCHROEDER TE, 1983, DEV BIOL, V98, P373, DOI 10.1016/0012-1606(83)90366-4; STRICKER SA, 1995, DEV BIOL, V170, P496, DOI 10.1006/dbio.1995.1232; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y	29	91	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8301	8306		10.1074/jbc.275.12.8301	http://dx.doi.org/10.1074/jbc.275.12.8301			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722659	hybrid			2022-12-27	WOS:000086507700009
J	Thuresson, ED; Lakkides, KM; Smith, WL				Thuresson, ED; Lakkides, KM; Smith, WL			Different catalytically competent arrangements of arachidonic acid within the cyclooxygenase active site of prostaglandin endoperoxide H synthase-1 lead to the formation of different oxygenated products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ANTI-INFLAMMATORY DRUGS; SELECTIVE-INHIBITION; CRYSTAL-STRUCTURE; GENE-EXPRESSION; BINDING-SITES; ASPIRIN; BIOSYNTHESIS; FIBROBLASTS; PURIFICATION	Arachidonic acid is converted to prostaglandin G(2) (PGG(2)) by the cyclooxygenase activities of prostaglandin endoperoxide H synthases (PGHSs) 1 and 2, The initial, rate-limiting step is abstraction of the 13-proS hydrogen from arachidonate which, for PGG(2) formation, is followed by insertion of O-2 at C-11, cyclization, and a second O-2 insertion at C-15, As an accompaniment to ongoing structural studies designed to determine the orientation of arachidonate in the cyclooxygenase site, we analyzed the products formed from arachidonate by (a solubilized, partially purified ovine to) PGHS-1; (b) membrane-associated, recombinant oPGHS-1; and (c) a membrane-associated, recombinant active site mutant (V349L oPGHS-1) and determined kinetic values for formation of each product. Native forms of oPGHS-1 produced primarily PGG(2) but also several monohydroxy acids, which, in order of abundance, were 11R-hydroxy-5Z,8Z,12E,14Z-eicosatetraenoic acid (11R-HETE), 15S-hydroxy-5Z, 8Z,11Z,13E-eicosatetraenoic acid (15S-HETE), and 15R-HETE, V349L oPGHS-1 formed primarily PGG(2), 15S-HETE, and 15R-HETE but only trace amounts of 11R-HETE, With native enzyme, the K-m values for PGG(2), 11-METE, and 15-METE formation were each different (5.5, 12.1, and 19.4 mu M, respectively); similarly, the K-m, values for PGG(2) and 15-METE formation by V349L oPGHS-1 were different (11 and 5 mu M, respectively). These results establish that arachidonate can assume at least three catalytically productive arrangements within the cyclooxygenase site of oPGHS-1 leading to PGG(2), 11R-HETE, and 15S-HETE and/or 15R-HETE, respectively. IC50 values for inhibition of formation of the individual products by the competitive inhibitor, ibuprofen, were determined and found to be the same for a given enzyme form (i.e. 175 mu M for oPGHS-1 and 15 mu M for V349L oPGHS-1), These latter results are most simply rationalized by a kinetic model in which arachidonate forms various catalytically competent arrangements only after entering the cyclooxygenase active site.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University	Smith, WL (corresponding author), Michigan State Univ, Dept Biochem, 513 Biochem Bldg, E Lansing, MI 48824 USA.				NIGMS NIH HHS [P01 GM57323] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM057323] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; DeWitt DL, 1999, MOL PHARMACOL, V55, P625; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; EVETT GE, 1993, ARCH BIOCHEM BIOPHYS, V306, P169, DOI 10.1006/abbi.1993.1496; FOEGH ML, 1989, PROSTAGLANDINS CLIN, P131; GIERSE JK, 1995, BIOCHEM J, V305, P479, DOI 10.1042/bj3050479; Hamberg M, 1998, J BIOL CHEM, V273, P13080, DOI 10.1074/jbc.273.21.13080; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HECKER M, 1987, EUR J BIOCHEM, V169, P113, DOI 10.1111/j.1432-1033.1987.tb13587.x; HULKOWER KI, 1994, ARTHRITIS RHEUM-US, V37, P653, DOI 10.1002/art.1780370508; Juranek I, 1999, BBA-MOL CELL BIOL L, V1436, P509, DOI 10.1016/S0005-2760(98)00159-3; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1994, J BIOL CHEM, V269, P5527; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LANDS WEM, 1978, PROSTAG LEUKOTR ESS, V1, P117, DOI 10.1016/0161-4630(78)90037-X; LANEUVILLE O, 1995, J BIOL CHEM, V270, P19330, DOI 10.1074/jbc.270.33.19330; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; Li Y, 1998, J BIOL CHEM, V273, P29830, DOI 10.1074/jbc.273.45.29830; LOLL PJ, 1995, NAT STRUCT BIOL, V2, P637, DOI 10.1038/nsb0895-637; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Marnett LJ, 1999, J BIOL CHEM, V274, P22903, DOI 10.1074/jbc.274.33.22903; MARSHALL PJ, 1988, ARCH BIOCHEM BIOPHYS, V266, P162, DOI 10.1016/0003-9861(88)90246-9; MATIJEVICALEKSIC N, 1995, BBA-MOL CELL RES, V1269, P167, DOI 10.1016/0167-4889(95)00116-A; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MIZUNO K, 1982, PROSTAGLANDINS, V23, P743; OLIW EH, 1993, ARCH BIOCHEM BIOPHYS, V305, P288, DOI 10.1006/abbi.1993.1425; OTTO JC, 1994, J BIOL CHEM, V269, P19868; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; PORTER NA, 1980, BIOCHEM BIOPH RES CO, V92, P349, DOI 10.1016/0006-291X(80)90340-X; RAZ A, 1990, ADV PROSTAG THROMB L, V20, P22; Rieke CJ, 1999, J BIOL CHEM, V274, P17109, DOI 10.1074/jbc.274.24.17109; ROME LH, 1975, P NATL ACAD SCI USA, V72, P4863, DOI 10.1073/pnas.72.12.4863; Schneider C, 2000, J BIOL CHEM, V275, P4743, DOI 10.1074/jbc.275.7.4743; SHIMOKAWA T, 1992, J BIOL CHEM, V267, P12387; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; SMITH WL, 2000, IN PRESS ANN REV BIO; Spencer AG, 1999, J BIOL CHEM, V274, P32936, DOI 10.1074/jbc.274.46.32936; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; TSAI AL, 1995, J BIOL CHEM, V270, P10503, DOI 10.1074/jbc.270.18.10503; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; Wendt KU, 1997, SCIENCE, V277, P1811, DOI 10.1126/science.277.5333.1811; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742	48	85	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8501	8507		10.1074/jbc.275.12.8501	http://dx.doi.org/10.1074/jbc.275.12.8501			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722687	hybrid			2022-12-27	WOS:000086507700037
J	Toker, A; Newton, AC				Toker, A; Newton, AC			Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; AKT PROTOONCOGENE; ACTIVATION; PHOSPHORYLATION; MECHANISM; SUBFAMILY; S6-KINASE; PRODUCT	The function of Akt (protein kinase B) is regulated by phosphorylation on two sites conserved within the AGC kinase family: the activation loop (Thr-308) in the kinase core and a hydrophobic phosphorylation site on the carboxyl terminus (Ser-473). Thr-308 is phosphorylated by the phosphoinositide-dependent kinase-l, (PDK-1), whereas the mechanism of phosphorylation of the hydrophobic site, tentatively referred to as the PDK-2 site, is unknown. Here we report that phosphorylation of the hydrophobic motif requires catalytically competent Akt. First we show that a kinase-inactive construct of Akt fails to incorporate phosphate at Ser-473 following IGF-1 stimulation in vivo but does incorporate phosphate at Thr-308 and a second carboxyl-terminal site, Thr-450; this ligand triggers the phosphorylation of both sites in wild-type enzyme, Neither does a catalytically inactive construct in which phosphorylation at the activation loop is blocked, T308A, become phosphorylated on the hydrophobic site in response to stimulation. Second, we show that Akt autophosphorylates on the hydrophobic site in vitro: phosphorylation of the activation loop by PDK-1 triggers the phosphorylation of the hydrophobic site in kinase-active, but not thermally inactivated, Akt cu. Thus, Akt is regulated by autophosphorylation at the Ser-473 hydrophobic site.	Boston Biomed Res Inst, Signal Transduct Grp, Boston, MA 02114 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	Boston Biomedical Research Institute; University of California System; University of California San Diego	Toker, A (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave,RN-237, Boston, MA 02215 USA.				NATIONAL CANCER INSTITUTE [R01CA075134] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043154, R01GM043154] Funding Source: NIH RePORTER; NCI NIH HHS [CA 75134] Funding Source: Medline; NIGMS NIH HHS [GM 43154] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Behn-Krappa A, 1999, CURR BIOL, V9, P728, DOI 10.1016/S0960-9822(99)80332-7; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; BELLACOSA A, 1993, ONCOGENE, V8, P745; Brodbeck D, 1999, J BIOL CHEM, V274, P9133, DOI 10.1074/jbc.274.14.9133; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; ONO Y, 1986, FEBS LETT, V203, P111, DOI 10.1016/0014-5793(86)80724-4; ORR JW, 1992, J BIOL CHEM, V267, P15263; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sweatt JD, 1998, J NEUROCHEM, V71, P1075; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4	34	420	454	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8271	8274		10.1074/jbc.275.12.8271	http://dx.doi.org/10.1074/jbc.275.12.8271			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722653	hybrid			2022-12-27	WOS:000086507700003
J	Wu, GY; Bogatkevich, GS; Mukhin, YV; Benovic, JL; Hildebrandt, JD; Lanier, SM				Wu, GY; Bogatkevich, GS; Mukhin, YV; Benovic, JL; Hildebrandt, JD; Lanier, SM			Identification of G beta gamma binding sites in the third intracellular loop of the M-3-muscarinic receptor and their role in receptor regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; MUSCARINIC ACETYLCHOLINE-RECEPTOR; INSECT-CELL MEMBRANES; DEPENDENT PHOSPHORYLATION; ALPHA(2A)-ADRENERGIC RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; CHOLINERGIC RECEPTORS; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; CLATHRIN ADAPTER	G beta gamma binds directly to the third intracellular (i3) loop subdomain of the M-3-muscarinic receptor (RIPE), In this report, we identified the G beta gamma binding motif and G-protein-coupled receptor kinase (GRK2) phosphorylation sites in the M-3-MR i3 loop via a strategy of deletional and site-directed mutagenesis. The G beta gamma binding domain was localized to Cys(289)-His(330) within the M-3-MR-Arg(252)Gin(490) i3 loop, and the binding properties (affinity, influence of ionic strength) of the M-3-MR-Cys(289)-Ris(330) i3 loop subdomain were similar to those observed for the entire i3 loop. Site-directed mutagenesis of the M-3-MR-Cys(289)-His(330) i3 loop subdomain indicated that Phe(312) Phe(314) and a negatively charged region (Glu(324)-Asp(329)) were required for interaction with G beta gamma, Generation of the full-length M-3-MR-Arg(252)-Gln(490) i3 peptides containing the F312A mutation mere also deficient in G beta gamma binding and exhibited a reduced capacity for phosphorylation by GRK2. A similar, parallel strategy resulted in identification of major residues ((SSS333)-S-331 (318)SASS(351)) phosphorylated by GRK2, which were just downstream of the G beta gamma binding motif, Full-length M-3-MR constructs lacking the 42-amino acid G beta gamma binding domain (Cys(289)-His(330)), containing the F312A mutation exhibited ligand recognition properties similar to wild type receptor and also effectively mediated agonist-induced increases in intracellular calcium following receptor expression in Chinese hamster ovary and/or COS 7 cells. However, the M-3-MR Delta Cys(289)-His(330) and M-3-MR(F312A) constructs mere deficient in agonist-induced sequestration, indicating a key role for the G beta gamma-MR i3 loop interaction in receptor regulation and signal processing.	Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29425 USA; Med Univ S Carolina, Div Nephrol, Charleston, SC 29425 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Medical University of South Carolina; Medical University of South Carolina; Jefferson University	Lanier, SM (corresponding author), Med Univ S Carolina, Dept Pharmacol, 171 Ashley Ave, Charleston, SC 29425 USA.	laniersm@musc.edu		Lanier, Stephen/0000-0002-2740-7607	NIDDK NIH HHS [DK37219] Funding Source: Medline; NIGMS NIH HHS [GM44944] Funding Source: Medline; NINDS NIH HHS [NS24821] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821, R29NS024821] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; AUSIELLO DA, 1992, J BIOL CHEM, V267, P4759; Boekhoff I, 1997, J BIOL CHEM, V272, P4606, DOI 10.1074/jbc.272.7.4606; Bogatkewitsch GS, 1996, MOL PHARMACOL, V50, P424; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Budd DC, 1999, J BIOL CHEM, V274, P12355, DOI 10.1074/jbc.274.18.12355; Cismowski MJ, 1999, NAT BIOTECHNOL, V17, P878, DOI 10.1038/12867; COULTER S, 1992, P NATL ACAD SCI USA, V89, P5842, DOI 10.1073/pnas.89.13.5842; DEBBURMAN SK, 1995, MOL PHARMACOL, V47, P224; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; DINGUS J, 1994, METHOD ENZYMOL, V237, P457; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; HAGA K, 1992, J BIOL CHEM, V267, P2222; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; HALPERN JL, 1987, BIOCHEMISTRY-US, V26, P1655, DOI 10.1021/bi00380a025; Hildebrandt JD, 1997, BIOCHEM PHARMACOL, V54, P325, DOI 10.1016/S0006-2952(97)00269-4; HIROFUMI T, 1998, J PHARMACOL EXP THER, V284, P1218; Ito K, 1999, EUR J BIOCHEM, V260, P112, DOI 10.1046/j.1432-1327.1999.00125.x; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KIM CM, 1993, J BIOL CHEM, V268, P15412; KIM CM, 1993, RECEPTOR, V3, P39; Klein U, 1997, J BIOL CHEM, V272, P19099, DOI 10.1074/jbc.272.31.19099; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KURSTJENS NP, 1991, EUR J BIOCHEM, V197, P167, DOI 10.1111/j.1432-1033.1991.tb15895.x; LANIER SM, 1991, J BIOL CHEM, V266, P10470; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lee KB, 1998, J BIOL CHEM, V273, P12967, DOI 10.1074/jbc.273.21.12967; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Lin HC, 1998, P NATL ACAD SCI USA, V95, P5057, DOI 10.1073/pnas.95.9.5057; Luo Y, 1999, J BIOL CHEM, V274, P10685, DOI 10.1074/jbc.274.16.10685; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Maggio R, 1996, J BIOL CHEM, V271, P31055, DOI 10.1074/jbc.271.49.31055; Makhlouf M, 1996, BBA-MOL CELL RES, V1312, P163, DOI 10.1016/0167-4889(96)00019-5; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; MOCHIZUKI N, 1995, FEBS LETT, V373, P155, DOI 10.1016/0014-5793(95)01031-9; Mochizuki N, 1996, GENE, V181, P39, DOI 10.1016/S0378-1119(96)00456-8; MORO O, 1993, J BIOL CHEM, V268, P6862; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; Porter RHP, 1999, BRIT J PHARMACOL, V128, P13, DOI 10.1038/sj.bjp.0702751; Richardson M, 1999, J BIOL CHEM, V274, P13525, DOI 10.1074/jbc.274.19.13525; ROYCHOWDHURY S, 1993, BIOCHEMISTRY-US, V32, P4955, DOI 10.1021/bi00069a034; Sato M, 1996, J BIOL CHEM, V271, P30052, DOI 10.1074/jbc.271.47.30052; SATO M, 1995, J BIOL CHEM, V270, P15269, DOI 10.1074/jbc.270.25.15269; Schroeder K.S., 1996, J BIOMOL SCREEN, V1, P75, DOI DOI 10.1177/108705719600100205; STRITTMATTER SM, 1991, J BIOL CHEM, V266, P22465; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; TAYLOR JM, 1994, J BIOL CHEM, V269, P27618; Tobin AB, 1997, J BIOL CHEM, V272, P20844, DOI 10.1074/jbc.272.33.20844; VAILLANCOURT RR, 1990, P NATL ACAD SCI USA, V87, P3645, DOI 10.1073/pnas.87.10.3645; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Wu GY, 1998, J BIOL CHEM, V273, P7197, DOI 10.1074/jbc.273.13.7197; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157	61	87	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					9026	9034		10.1074/jbc.275.12.9026	http://dx.doi.org/10.1074/jbc.275.12.9026			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722752	hybrid			2022-12-27	WOS:000086507700102
J	Bera, AK; Smith, JL; Zalkin, H				Bera, AK; Smith, JL; Zalkin, H			Dual role for the glutamine phosphoribosylpyrophosphate amidotransferase ammonia channel - Interdomain signaling and intermediate channeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SITE	Glutamine phosphoribosylpyrophosphate (PRPP) amidotransferase catalyzes the first reaction of de novo purine nucleotide synthesis in two steps at two sites. Glutamine is hydrolyzed to glutamate plus NH, at an N-terminal glutaminase site, and NH, is transferred through a 20-Angstrom hydrophobic channel to a distal PRPP site for synthesis of phosphoribosylamine. Binding of PRPP is required to activate the glutaminase site (termed interdomain signaling) to prevent the wasteful hydrolysis of glutamine in the absence of phosphoribosylamine synthesis. Mutations were constructed to analyze the function of the NH, channel. In time wild type enzyme, NH, derived from glutamine hydrolysis was transferred to the PRPP site, and little or none was released. Replacement of Leu-415 at the PRPP end of the channel with an alanine resulted in a leaky channel and release of NH, to the solvent. Mutations in five amino acids that line the channel and two other residues required for the reorganization of phosphoribosyltransferase domain "flexible loop" that leads to formation of the channel perturbed channel function as well as interdomain signaling. The data emphasize the role of the NH, channel in coupling interdomain signaling and NH, transfer.	Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA; Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Zalkin, H (corresponding author), Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA.		Bera, Aloke Kumar/AAD-9541-2022		NIDDK NIH HHS [R37 DK042303, DK42303] Funding Source: Medline; NIGMS NIH HHS [GM24658] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042303, R37DK042303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024658, R37GM024658] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bera AK, 1999, J BIOL CHEM, V274, P36498, DOI 10.1074/jbc.274.51.36498; Chen SH, 1999, BIOCHEMISTRY-US, V38, P11659, DOI 10.1021/bi991060o; Kim JH, 1996, J BIOL CHEM, V271, P15549, DOI 10.1074/jbc.271.26.15549; Krahn JM, 1997, BIOCHEMISTRY-US, V36, P11061, DOI 10.1021/bi9714114; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MESSENGER LJ, 1979, J BIOL CHEM, V254, P3382; Miles BW, 1998, BIOCHEMISTRY-US, V37, P16773, DOI 10.1021/bi982018g; Miles EW, 1999, J BIOL CHEM, V274, P12193, DOI 10.1074/jbc.274.18.12193; Muchmore CRA, 1998, PROTEIN SCI, V7, P39, DOI 10.1002/pro.5560070104; SCHENDEL FJ, 1988, BIOCHEMISTRY-US, V27, P2614, DOI 10.1021/bi00407a052; Smith JL, 1998, CURR OPIN STRUC BIOL, V8, P686, DOI 10.1016/S0959-440X(98)80087-0; Zalkin H, 1998, ADV ENZYMOL RAMB, V72, P87	12	44	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7975	7979		10.1074/jbc.275.11.7975	http://dx.doi.org/10.1074/jbc.275.11.7975			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713115	hybrid			2022-12-27	WOS:000085913300075
J	Galko, MJ; Tessier-Lavigne, M				Galko, MJ; Tessier-Lavigne, M			Biochemical characterization of netrin-synergizing activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; GUIDANCE; BRAIN; AXONS; PROTEINS	The netrin-1 protein elicits spinal commissural axon outgrowth and turning in vitro and has been shown to be required for commissural axon guidance in vivo in the developing spinal cord. Biochemical observations made during the purification of netrin-1 suggest that this ligand and its receptor, DCC, may not function alone in directing commissural axon guidance. Recombinant netrin-1 protein is similar to 10 times more active in eliciting axon outgrowth from embryonic day (E) 13 rat dorsal spinal cord explants than from Ell rat dorsal spinal cord explants (Serafini, T., Kennedy, T. E,, Galko, M. J., Mirzayan, C., Jessell, T. M., and Tessier-Lavigne, M, (1994) Cell 78, 409-424) even though the starting material for the netrin purification, a high salt extract of E10 chicken brain membranes, is equally active on E13 and E11 explants. We previously reported an activity termed netrin-synergizing activity (NSA) that can potentiate the outgrowth-promoting activity of netrin-1 on E11 explants (Serafini et al.), Here we report a biochemical characterization of NSA in netrin-depleted high salt extracts of E10 chicken brain membranes. We provide evidence that NSA is composed of a denaturation-resistant basic protein(s) in the 25-35-kDa size range. We also provide evidence that the activity may be heterogeneous, splitting into three species that may be distinct or related. The results reported here should facilitate purification of this activity from a more abundant source or identification of the activity based on similarity to known proteins that share its distinctive biochemical properties.	Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Tessier-Lavigne, M (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA.			Galko, Michael/0000-0002-3759-2017				BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; Goodman CS, 1996, ANNU REV NEUROSCI, V19, P341, DOI 10.1146/annurev.ne.19.030196.002013; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Mueller BK, 1999, ANNU REV NEUROSCI, V22, P351, DOI 10.1146/annurev.neuro.22.1.351; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Shirasaki R, 1996, NEURON, V17, P1079, DOI 10.1016/S0896-6273(00)80241-X; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7; WEBER K, 1971, J BIOL CHEM, V246, P4504; YAMAMOTO M, 1986, J NEUROSCI, V6, P3576	19	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7832	7838		10.1074/jbc.275.11.7832	http://dx.doi.org/10.1074/jbc.275.11.7832			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713098	hybrid			2022-12-27	WOS:000085913300058
J	German, Z; Chambliss, KL; Pace, MC; Arnet, UA; Lowenstein, CJ; Shaul, PW				German, Z; Chambliss, KL; Pace, MC; Arnet, UA; Lowenstein, CJ; Shaul, PW			Molecular basis of cell-specific endothelial nitric-oxide synthase expression in airway epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG LIQUID PRODUCTION; IMMUNOCYTOCHEMICAL LOCALIZATION; IDENTIFICATION; HYPERRESPONSIVENESS; PROMOTER; OXYGEN; GENE	Nitric oxide (NO) plays an important role in airway function, and endothelial NO synthase (eNOS) is expressed in airway epithelium. To determine the basis of cell-specific eNOS expression in airway epithelium, studies were performed in NCI-H441 human bronchiolar epithelial cells transfected with the human eNOS promoter fused to luciferase. Transfection with 1624 base pairs of sequence 5' to the initiation ATG (position -1624) yielded a 19-fold increase in promoter activity versus vector alone. No activity was found in lung fibroblasts, which do not express eNOS. 5' deletions from -1624 to -279 had modest effects on promoter activity in H441 cells. Further deletion to -248 reduced activity by 65%, and activity was lost with deletion to -79, Point mutations revealed that the GATA binding motif at -254 is mandatory for promoter activity and that the positive regulatory element between -248 and -79 is the Spl binding motif at -125. Electrophoretic mobility shift assays yielded two complexes with the GATA site and three with the Spl site. Immunodepletion with antiserum to GATA-2 prevented formation of the slowest migrating GATA complex, and antiserum to Spl supershifted the slowest migrating Spl complex, An electrophoretic mobility shift assay with H441 versus fibroblast nuclei revealed that the slowest migrating GATA complex is unique to airway epithelium. Thus, cell-specific eNOS expression in airway epithelium is dependent on the interaction of GATA-2 with the core eNOS promoter, and the proximal Spl binding site is also an important positive regulatory element.	Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21287 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Johns Hopkins University	Shaul, PW (corresponding author), Univ Texas, SW Med Ctr, Dept Pediat, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Lowenstein, Charles/0000-0003-0485-7514	NHLBI NIH HHS [HL30276, HL63399] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL063399] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arnet UA, 1996, J BIOL CHEM, V271, P15069, DOI 10.1074/jbc.271.25.15069; BARNES PJ, 1995, ANN MED, V27, P389, DOI 10.3109/07853899509002592; Chatterjee S, 1996, HISTOCHEM J, V28, P715, DOI 10.1007/BF02409009; Cummings JJ, 1997, J APPL PHYSIOL, V83, P1538, DOI 10.1152/jappl.1997.83.5.1538; CUMMINGS JJ, 1995, J APPL PHYSIOL, V79, P1212, DOI 10.1152/jappl.1995.79.4.1212; Dweik RA, 1998, J CLIN INVEST, V101, P660, DOI 10.1172/JCI1378; FOLKERTS G, 1995, J CLIN INVEST, V95, P26, DOI 10.1172/JCI117649; GASTON B, 1994, AM J RESP CRIT CARE, V149, P538, DOI 10.1164/ajrccm.149.2.7508323; GIAID A, 1995, NEW ENGL J MED, V333, P214, DOI 10.1056/NEJM199507273330403; Guillot PV, 1999, J CLIN INVEST, V103, P799, DOI 10.1172/JCI6017; Gumina RJ, 1997, BLOOD, V89, P1260, DOI 10.1182/blood.V89.4.1260; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; HARKEMA JR, 1991, LUNG BIOL HLTH DIS, V0055, P00003; Jakupaj M, 1997, AM J PHYSIOL-LUNG C, V273, pL531, DOI 10.1152/ajplung.1997.273.3.L531; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; MacRitchie AN, 1997, CIRC RES, V81, P355, DOI 10.1161/01.RES.81.3.355; NIJKAMP FP, 1995, ARCH INT PHARMACOD T, V329, P81; OREILLY MA, 1988, BIOCHIM BIOPHYS ACTA, V970, P194, DOI 10.1016/0167-4889(88)90179-6; OW DW, 1986, SCIENCE, V234, P856, DOI 10.1126/science.234.4778.856; Potter CF, 1997, PEDIATR RES, V41, P886, DOI 10.1203/00006450-199706000-00014; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SHAUL PW, 1994, AM J RESP CELL MOL, V11, P432, DOI 10.1165/ajrcmb.11.4.7522486; SHAUL PW, 1994, J CLIN INVEST, V94, P2231, DOI 10.1172/JCI117585; Shaul PW, 1997, SEMIN PERINATOL, V21, P381, DOI 10.1016/S0146-0005(97)80004-3; Sherman TS, 1999, AM J PHYSIOL-LUNG C, V276, pL383, DOI 10.1152/ajplung.1999.276.2.L383; Snedecor GW, 1980, STAT METHODS, V7th; Stamler, 1993, ENDOTHELIUM, V1, P87; Teichert AM, 1998, BBA-GENE STRUCT EXPR, V1443, P352, DOI 10.1016/S0167-4781(98)00236-X; TRACEY WR, 1994, AM J PHYSIOL, V266, pC22, DOI 10.1152/ajpcell.1994.266.1.C22; UJIIE K, 1994, AM J PHYSIOL, V267, P296; VOORHOUT WF, 1992, J HISTOCHEM CYTOCHEM, V40, P1589, DOI 10.1177/40.10.1527377; Xue C, 1996, AM J PHYSIOL-LUNG C, V270, pL88, DOI 10.1152/ajplung.1996.270.1.L88; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320; Zini A, 1996, BIOL REPROD, V55, P935, DOI 10.1095/biolreprod55.5.935	34	38	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8183	8189		10.1074/jbc.275.11.8183	http://dx.doi.org/10.1074/jbc.275.11.8183			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713142	hybrid			2022-12-27	WOS:000085913300102
J	Nykvist, P; Tu, HM; Ivaska, J; Kapyla, J; Pihlajaniemi, T; Heino, JH				Nykvist, P; Tu, HM; Ivaska, J; Kapyla, J; Pihlajaniemi, T; Heino, JH			Distinct recognition of collagen subtypes by alpha(1)beta(1) and alpha(2)beta(1) integrins - alpha(1)beta(1) mediates cell adhesion to type XIII collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; EXTRACELLULAR-MATRIX PROTEINS; I-DOMAIN; CRYSTAL-STRUCTURE; LIGAND-BINDING; A-DOMAIN; ALPHA-1-BETA-1 INTEGRIN; ALPHA-2-BETA-1 VLA-2; GENE-EXPRESSION; MELANOMA-CELLS	Two integrin-type collagen receptors, alpha(1)beta(1) and alpha(2)beta(1), are structurally very similar. However, cells can concomitantly express the both receptors and they might have independent functions. Here, Chinese hamster ovary (CHO) cells, which lack endogenous collagen receptors, were transfected with either alpha(1) or alpha(2) integrin cDNA Cells were allowed to adhere to various collagen types and their integrin function was tested by observing the progression of cell spreading. The cells expressing alpha(1)beta(1) integrin could spread on collagen types I, III, IV, and V but not on type II, while alpha(2)beta(1) integrin could mediate cell spreading on collagen types I-V. Type XIII is a transmembrane collagen and its interaction with the integrins has not been previously studied. CHO-alpha 1 beta 1 cells could spread on human recombinant type XIII collagen, unlike CHO-alpha 2 beta 1 cells. Integrins alpha(1)beta(1) and alpha(2)beta(1) recognize collagens with the specific alpha I domains. The alpha(1)I and alpha(2)I domains were produced as recombinant proteins, labeled with europium and used in a sensitive solid-phase binding assay based on time-resolved fluorescence. alpha(1)I domain, unlike the alpha(2)I domain, could attach to type XIII collagen. The results indicate, that alpha(1)beta(1) and alpha(2)beta(1) have different ligand binding specificity. Distinct recognition of different collagen subtypes by the aI domains can partially explain the differences seen in cell spreading. However, despite the fact that CHO-alpha 1 beta 1 cells could not spread on type II collagen alpha(1)I domain could bind to this collagen type. Thus, the cell spreading on collagens may also be regulated by factors other than the integrins.	Univ Jyvaskyla, Dept Biol & Environm Sci, FIN-40351 Jyvaskyla, Finland; Univ Turku, Dept Med Biochem, FIN-20520 Turku, Finland; Univ Turku, MediCity Res Lab, FIN-20520 Turku, Finland; Univ Oulu, Bioctr, Collagen Res Unit, FIN-90220 Oulu, Finland; Univ Oulu, Dept Med Biochem, FIN-90220 Oulu, Finland	University of Jyvaskyla; University of Turku; University of Turku; University of Oulu; University of Oulu	Heino, JH (corresponding author), Univ Jyvaskyla, Dept Biol & Environm Sci, POB 35, FIN-40351 Jyvaskyla, Finland.			Kapyla, Jarmo/0000-0003-3036-713X; Ivaska, Johanna/0000-0002-6295-6556; Pihlajaniemi, Taina/0000-0002-1664-9045				BELKIN VM, 1990, J CELL BIOL, V111, P2159, DOI 10.1083/jcb.111.5.2159; Bienkowska J, 1997, J BIOL CHEM, V272, P25162, DOI 10.1074/jbc.272.40.25162; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; Dickeson SK, 1999, J BIOL CHEM, V274, P32182, DOI 10.1074/jbc.274.45.32182; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; ELENIUS K, 1990, J BIOL CHEM, V265, P17837; Emsley J, 1998, J BIOL CHEM, V273, P10396, DOI 10.1074/jbc.273.17.10396; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Gardner H, 1999, J CELL SCI, V112, P263; Gotwals PJ, 1996, J CLIN INVEST, V97, P2469, DOI 10.1172/JCI118693; Hagg P, 1998, J BIOL CHEM, V273, P15590, DOI 10.1074/jbc.273.25.15590; Huizinga EG, 1997, STRUCTURE, V5, P1147, DOI 10.1016/S0969-2126(97)00266-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ivaska J, 1999, J CELL BIOL, V147, P401, DOI 10.1083/jcb.147.2.401; Ivaska J, 1999, J BIOL CHEM, V274, P3513, DOI 10.1074/jbc.274.6.3513; JUVONEN M, 1992, J BIOL CHEM, V267, P24693; JUVONEN M, 1992, J BIOL CHEM, V267, P24700; Kamata T, 1999, J BIOL CHEM, V274, P32108, DOI 10.1074/jbc.274.45.32108; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; Kapyla J, 2000, J BIOL CHEM, V275, P3348, DOI 10.1074/jbc.275.5.3348; Kern A, 1998, J CELL PHYSIOL, V176, P634, DOI 10.1002/(SICI)1097-4652(199809)176:3<634::AID-JCP20>3.3.CO;2-J; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; KERN A, 1994, J BIOL CHEM, V269, P22811; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; Knutson JR, 1996, MOL BIOL CELL, V7, P383, DOI 10.1091/mbc.7.3.383; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; Lamberg A, 1996, J BIOL CHEM, V271, P11988, DOI 10.1074/jbc.271.20.11988; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; Nolte M, 1999, FEBS LETT, V452, P379, DOI 10.1016/S0014-5793(99)00666-3; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; Pentikainen O, 1999, J BIOL CHEM, V274, P31493, DOI 10.1074/jbc.274.44.31493; PFAFF M, 1993, EXP CELL RES, V206, P167, DOI 10.1006/excr.1993.1134; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; Racine-Samson L, 1997, J BIOL CHEM, V272, P30911, DOI 10.1074/jbc.272.49.30911; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Rich RL, 1999, J BIOL CHEM, V274, P24906, DOI 10.1074/jbc.274.35.24906; RIIKONEN T, 1995, BIOCHEM BIOPH RES CO, V209, P205, DOI 10.1006/bbrc.1995.1490; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; RIIKONEN T, 1995, J BIOL CHEM, V270, P376, DOI 10.1074/jbc.270.1.376; RUGGIERO F, 1994, EXP CELL RES, V210, P215, DOI 10.1006/excr.1994.1032; SAELMAN EUM, 1994, BLOOD, V83, P1244; Salminen TA, 1999, ACTA CRYSTALLOGR D, V55, P1365, DOI 10.1107/S0907444999006009; SANDBERG M, 1989, J CELL BIOL, V109, P1371, DOI 10.1083/jcb.109.3.1371; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; Tuckwell DS, 1996, EUR J BIOCHEM, V241, P732, DOI 10.1111/j.1432-1033.1996.00732.x; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; Vihinen P, 1996, CELL GROWTH DIFFER, V7, P439; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; ZUTTER MM, 1990, AM J PATHOL, V137, P113	57	139	146	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8255	8261		10.1074/jbc.275.11.8255	http://dx.doi.org/10.1074/jbc.275.11.8255			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713152	hybrid			2022-12-27	WOS:000085913300112
J	Osterhout, JL; Shuttleworth, TJ				Osterhout, JL; Shuttleworth, TJ			A Ca2+-independent activation of a type IV cytosolic phospholipase A(2) underlies the receptor stimulation of arachidonic acid-dependent noncapacitative calcium entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROLYZING PHOSPHOLIPASE-A2; MUSCARINIC RECEPTORS; CA-2+ OSCILLATIONS; PROTEIN-KINASE; CA2+ ENTRY; PHOSPHORYLATION; INHIBITION; TRANSLOCATION; MACROPHAGES; MECHANISM	The oscillatory [Ca2+](i) signals typically seen following physiologically relevant stimulation of phospholipase C-linked receptors are associated with a receptor-activated entry of Ca2+, which plays a critical role in driving the oscillations and influencing their frequency. We have recently shown that this receptor-activated entry of Ca2+ does not conform to the widely accepted "capacitative" model and, instead, reflects the activity of a distinct, novel Ca2+ entry pathway regulated by arachidonic acid (Shuttleworth, T. J., and Thompson, J. L. (1998) J. Biol. Chem. 273, 32636-32643). We now show that the generation of arachidonic acid under these conditions results from the activity of a type IV cytosolic phospholipase A(2) (cPLA(2)). Although cPLA(2) activation commonly involves a Ca2+-dependent translocation to the membrane, at these low agonist concentrations cPLA(2) activation was independent of increases in [Ca2+](i), and no detectable translocation to the membrane occurs. Nevertheless, stimulation of cPLA(2) activity was confined to the membrane fraction, where an increase in phosphorylation of the enzyme was observed. We suggest that, at the low agonist concentrations associated with oscillatory [Ca2+](i) signals, cPLA(2) activation involves an increased phosphorylation of a discrete pool of the total cellular cPLA(2) that is already localized within the membrane fraction at resting [Ca2+](i).	Univ Rochester, Sch Med & Dent, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA	University of Rochester	Shuttleworth, TJ (corresponding author), Univ Rochester, Sch Med & Dent, Med Ctr, Dept Physiol & Pharmacol, Box 711,601 Elmwood Ave, Rochester, NY 14642 USA.				NIGMS NIH HHS [GM 40457] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMANN EJ, 1995, BBA-LIPID LIPID MET, V1259, P125, DOI 10.1016/0005-2760(95)00143-Z; ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; ATRI A, 1993, BIOPHYS J, V65, P1727, DOI 10.1016/S0006-3495(93)81191-3; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Bayon Y, 1997, BIOCHEM J, V323, P281, DOI 10.1042/bj3230281; BERRIDGE MJ, 1994, BIOCHEM J, V302, P545, DOI 10.1042/bj3020545; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BUCKLEY BJ, 1994, BIOCHEM J, V300, P449, DOI 10.1042/bj3000449; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; EXTON JH, 1990, J BIOL CHEM, V265, P1; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; GIRARD S, 1993, SCIENCE, V260, P229, DOI 10.1126/science.8385801; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; KAWANISHI T, 1989, J BIOL CHEM, V264, P12859; Kohn EC, 1996, J BIOL CHEM, V271, P17476, DOI 10.1074/jbc.271.29.17476; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; Kramer RM, 1997, FEBS LETT, V410, P49, DOI 10.1016/S0014-5793(97)00322-0; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Morgan AJ, 1996, BIOCHEM J, V320, P505; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; Ramanadham S, 1999, J BIOL CHEM, V274, P13915, DOI 10.1074/jbc.274.20.13915; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; Schalkwijk CG, 1996, BIOCHEM J, V313, P91, DOI 10.1042/bj3130091; SCHALKWIJK CG, 1995, EUR J BIOCHEM, V231, P593, DOI 10.1111/j.1432-1033.1995.tb20737.x; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SHARP JD, 1991, J BIOL CHEM, V266, P14850; Shuttleworth TJ, 1999, J BIOL CHEM, V274, P31174, DOI 10.1074/jbc.274.44.31174; Shuttleworth TJ, 1998, J BIOL CHEM, V273, P32636, DOI 10.1074/jbc.273.49.32636; Shuttleworth TJ, 1996, J BIOL CHEM, V271, P21720, DOI 10.1074/jbc.271.36.21720; Shuttleworth TJ, 1996, BIOCHEM J, V313, P815, DOI 10.1042/bj3130815; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Wotta DR, 1998, PHARMACOLOGY, V56, P175, DOI 10.1159/000028196	46	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8248	8254		10.1074/jbc.275.11.8248	http://dx.doi.org/10.1074/jbc.275.11.8248			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713151	hybrid			2022-12-27	WOS:000085913300111
J	Su, YH; Liebhaber, SA; Cooke, NE				Su, YH; Liebhaber, SA; Cooke, NE			The human growth hormone gene cluster locus control region supports position-independent pituitary- and placenta-specific expression in the transgenic mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBIN GENE; GIANT-CELLS; LACTOGEN-I; LOCALIZATION; TISSUE; MICE; IDENTIFICATION; TRANSCRIPTION; PROLIFERIN; CHROMATIN	The human growth hormone (hGH) cluster contains five genes. The hGH-N gene is predominantly expressed in pituitary somatotropes, whereas the remaining four genes, the chorionic somatomammotropin genes hCS-L, hCS-A, and hCS-B and hGH-V, are expressed selectively in the placenta. In contrast, the mouse genome contains a single pituitary-specific GR gene and lacks any GH-related CS genes. Activation of the hGH transgene in the mouse is dependent on its linkage to a previously described, locus control region (LCR) located -15 to -32 kilobases upstream of the hGH cluster. The sporadic, nonreproducible expression of hCS transgenes lacking the LCR suggests that they may be dependent on hGH LCR activity as well. To determine whether the hCS genes could be expressed with appropriate placental specificity, a series of five transgenic mouse lines carrying an 87-kilobase human genomic insert encompassing the majority of the hGH gene cluster and the entire contiguous LCR was established. All of the hGH cluster genes were appropriately expressed in each of these lines, High level expression of hGH was restricted to the pituitary and hCS to the labyrinthine layer of the placenta. The expression of the GH cluster genes in their respective tissues paralleled transgene copy numbers irrespective of the transgene insertion site in the host mouse genome. These studies have extended the utility of the transgenic mouse model for the analysis of the full spectrum of hGH gene cluster activation. Further, they support a role for the hGH LCR in placental hCS, as well as pituitary hGH gene activation, and expression.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania	Cooke, NE (corresponding author), 752B Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19103 USA.				NICHD NIH HHS [R01 HD25147] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD025147] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BENIRSCHKE K., 1995, PATHOLOGY HUMAN PLAC; Bennani-Baiti IM, 1998, P NATL ACAD SCI USA, V95, P10655, DOI 10.1073/pnas.95.18.10655; BONIFER C, 1991, J CELL BIOCHEM, V47, P99, DOI 10.1002/jcb.240470203; BONIFER C, 1990, EMBO J, V9, P2843, DOI 10.1002/j.1460-2075.1990.tb07473.x; Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; CHEN EY, 1989, GENOMICS, V4, P479, DOI 10.1016/0888-7543(89)90271-1; Cooke N E, 1995, Vitam Horm, V50, P385, DOI 10.1016/S0083-6729(08)60659-7; COOKE NE, 1982, NATURE, V297, P603, DOI 10.1038/297603a0; Dai GL, 1998, ENDOCRINOLOGY, V139, P5157, DOI 10.1210/en.139.12.5157; DUNCAN SA, 1994, P NATL ACAD SCI USA, V91, P7598, DOI 10.1073/pnas.91.16.7598; FARIA TN, 1991, BIOL REPROD, V44, P327, DOI 10.1095/biolreprod44.2.327; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HALL J, 1984, J HISTOCHEM CYTOCHEM, V32, P379, DOI 10.1177/32.4.6368678; HAMMER RE, 1984, NATURE, V311, P65, DOI 10.1038/311065a0; Higgs DR, 1998, CELL, V95, P299, DOI 10.1016/S0092-8674(00)81761-4; JONES BK, 1995, MOL CELL BIOL, V15, P7010; LAMMING GE, 1994, MARSHALLS PHYSL REPR, V3, P233; LEE SJ, 1988, ENDOCRINOLOGY, V122, P1761, DOI 10.1210/endo-122-5-1761; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; Liebhaber SA, 1996, MOL CELL BIOL, V16, P2637; LIEBHABER SA, 1989, J CLIN INVEST, V83, P1985, DOI 10.1172/JCI114108; Lin JD, 1997, ENDOCRINOLOGY, V138, P5535, DOI 10.1210/en.138.12.5535; Linzer DIH, 1999, MOL ENDOCRINOL, V13, P837, DOI 10.1210/me.13.6.837; LIPKIN SM, 1993, GENE DEV, V7, P1674, DOI 10.1101/gad.7.9.1674; MACLEOD JN, 1992, J BIOL CHEM, V267, P14219; MCWILLIAMS D, 1980, ENDOCRINOLOGY, V107, P761, DOI 10.1210/endo-107-3-761; MEYUHAS O, 1980, GENE, V10, P113, DOI 10.1016/0378-1119(80)90129-8; MISRAPRESS A, 1994, J BIOL CHEM, V269, P23220; Muller H, 1998, BIOL REPROD, V58, P45, DOI 10.1095/biolreprod58.1.45; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; RAMSEY EM, 1982, PLACENTA HUMAN ANIMA, P7; Schwarzler P, 1997, J CLIN ENDOCR METAB, V82, P3337, DOI 10.1210/jc.82.10.3337; STERNBERG NL, 1992, TRENDS GENET, V8, P11, DOI 10.1016/0168-9525(92)90018-Y; Untergasser G, 1997, MOL CELL ENDOCRINOL, V130, P53, DOI 10.1016/S0303-7207(97)00073-7; WALKER WH, 1991, ENDOCR REV, V12, P316, DOI 10.1210/edrv-12-4-316; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; YAMAGUCHI M, 1994, BIOL REPROD, V51, P1188, DOI 10.1095/biolreprod51.6.1188; Yoshizato H, 1998, ENDOCRINOLOGY, V139, P2545, DOI 10.1210/en.139.5.2545	40	72	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7902	7909		10.1074/jbc.275.11.7902	http://dx.doi.org/10.1074/jbc.275.11.7902			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713106	hybrid			2022-12-27	WOS:000085913300066
J	Danilkovitch-Miagkova, A; Angeloni, D; Skeel, A; Donley, S; Lerman, M; Leonard, EJ				Danilkovitch-Miagkova, A; Angeloni, D; Skeel, A; Donley, S; Lerman, M; Leonard, EJ			Integrin-mediated RON growth factor receptor phosphorylation requires tyrosine kinase activity of both the receptor and c-Src	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE-STIMULATING PROTEIN; FOCAL ADHESION KINASE; PDGF-BETA-RECEPTORS; ALPHA(V)BETA(3) INTEGRIN; CELL-ADHESION; ACTIVATION; MIGRATION; IDENTIFICATION; FIBROBLASTS; MODULATION	Cooperation between integrins and growth factor receptors plays an important role in the regulation of cell growth, differentiation, and survival. The function of growth factor receptor tyrosine kinases (RTKs) can be regulated by cell adhesion to extracellular matrix (ECM) even in the absence of ligand, We investigated the pathway involved in integrin-mediated RTK activation, using RON, the receptor for macrophage-stimulating protein. Adhesion of RON-expressing epithelial cells to ECM caused phosphorylation of RON, which depended on the kinase activity of both RON itself and c-Src. This conclusion is based on these observations: 1) ECM-induced RON phosphorylation was inhibited in cells expressing kinase-inactive c-Src; 2) active c-Src could phosphorylate immunoprecipitated RON from ECM-stimulated cells but not from unstimulated cells; and 3) ECM did not cause RON phosphorylation in cells expressing kinase-dead RON, nor could active c-Src phosphorylate RON immunoprecipitated from these cells. The data fit a pathway in which ECM-induced integrin aggregation causes both c-Src activation and RON oligomerization followed by RON kinase-dependent autophosphorylation; this results in RON becoming a target for activated c-Src, which phosphorylates additional tyrosines on RON. Integrin-induced epidermal growth factor receptor (EGFR) phosphorylation also depended on both EGFR and c-Src kinase activities. This sequence appears to be a general pathway for integrin-dependent growth factor RTK activation.	NCI, Frederick Canc Res & Dev Ctr, Immunobiol Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Danilkovitch-Miagkova, A (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Immunobiol Lab, Bldg 560,Rm 1246, Frederick, MD 21702 USA.			Angeloni, Debora/0000-0002-3850-5392				Aplin AE, 1999, J CELL SCI, V112, P695; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; CYBULSKY AV, 1994, J CLIN INVEST, V94, P68, DOI 10.1172/JCI117350; Danilkovitch A, 1999, EXP CELL RES, V248, P575, DOI 10.1006/excr.1999.4429; Danilkovitch A, 2000, MOL CELL BIOL, V20, P2218, DOI 10.1128/MCB.20.6.2218-2227.2000; DeMali KA, 1999, J BIOL CHEM, V274, P19551, DOI 10.1074/jbc.274.28.19551; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Juliano Rudy, 1996, Bioessays, V18, P911, DOI 10.1002/bies.950181110; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; Li J, 1999, J BIOL CHEM, V274, P11209, DOI 10.1074/jbc.274.16.11209; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; Porter JC, 1998, TRENDS CELL BIOL, V8, P390, DOI 10.1016/S0962-8924(98)01344-0; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; Woodard AS, 1998, J CELL SCI, V111, P469	31	77	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14783	14786		10.1074/jbc.C000028200	http://dx.doi.org/10.1074/jbc.C000028200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10747844	Green Submitted, hybrid			2022-12-27	WOS:000087128300002
J	Kvint, K; Farewell, A; Nystrom, T				Kvint, K; Farewell, A; Nystrom, T			RpoS-dependent promoters require guanosine tetraphosphate for induction even in the presence of high levels of sigma(s)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-CELLS; RNA-POLYMERASE; 5'-DIPHOSPHATE 3'-DIPHOSPHATE; INORGANIC POLYPHOSPHATE; HISTIDINE OPERON; LAC OPERON; EXPRESSION; PPGPP; GENE; TRANSCRIPTION	RpoS-dependent promoters require ppGpp for induction in the stationary phase. This has been thought to be a simple consequence of sigma(S) itself requiring ppGpp for its production. By using four model promoters requiring sigma(S) for normal induction in the stationary phase, we demonstrate that sigma(3)-dependent promoters require ppGpp even in the presence of high levels of sigma(S) produced ectopically. Similar to sigma(70)-dependent promoters under positive control by ppGpp, the requirement of sigma(S)-dependent promoters for this alarmone is bypassed by specific "stringent" mutations in the beta-subunit of RNA polymerase. The results suggest that stationary phase induction of both sigma(S)- and sigma(70)-dependent genes requires the stringent control modulon and that stringency confers dual control on the RpoS regulon by affecting promoter activity and the levels of the required alpha-factor.	Univ Gothenburg, Dept Cell & Mol Biol Microbiol, S-40530 Gothenburg, Sweden	University of Gothenburg	Nystrom, T (corresponding author), Univ Gothenburg, Dept Cell & Mol Biol Microbiol, Box 462, S-40530 Gothenburg, Sweden.		Farewell, Anne/M-2618-2016; Farewell, Anne/O-4167-2019	Farewell, Anne/0000-0002-0841-4908; Farewell, Anne/0000-0002-0841-4908; Kvint, Kristian/0000-0001-9291-7526				ALBERTSON NH, 1994, FEMS MICROBIOL LETT, V117, P181, DOI 10.1111/j.1574-6968.1994.tb06762.x; Bartlett MS, 1998, J MOL BIOL, V279, P331, DOI 10.1006/jmbi.1998.1779; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; Chatterji D, 1998, GENES CELLS, V3, P279, DOI 10.1046/j.1365-2443.1998.00190.x; Choy HE, 2000, J BIOL CHEM, V275, P6783, DOI 10.1074/jbc.275.10.6783; DING QQ, 1995, MOL MICROBIOL, V16, P649, DOI 10.1111/j.1365-2958.1995.tb02427.x; DIRUSSO CC, 1993, MOL MICROBIOL, V7, P311, DOI 10.1111/j.1365-2958.1993.tb01122.x; Eichel J, 1999, J BACTERIOL, V181, P572, DOI 10.1128/JB.181.2.572-576.1999; Farewell A, 1998, MOL MICROBIOL, V29, P1039, DOI 10.1046/j.1365-2958.1998.00990.x; Farewell A, 1998, J BACTERIOL, V180, P6140; GENTRY DR, 1993, J BACTERIOL, V175, P7982, DOI 10.1128/JB.175.24.7982-7989.1993; Gourse RL, 1998, COLD SPRING HARB SYM, V63, P131, DOI 10.1101/sqb.1998.63.131; HERNANDEZ VJ, 1995, J MOL BIOL, V252, P536; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; Kusano S, 1996, J BIOL CHEM, V271, P1998, DOI 10.1074/jbc.271.4.1998; Kvint K, 2000, MOL MICROBIOL, V35, P435, DOI 10.1046/j.1365-2958.2000.01714.x; LANGE R, 1995, J BACTERIOL, V177, P4676, DOI 10.1128/jb.177.16.4676-4680.1995; LANGE R, 1991, J BACTERIOL, V173, P4474, DOI 10.1128/JB.173.14.4474-4481.1991; Miller JH, 1972, EXPT MOL GENETICS, P201; MULVEY MR, 1988, GENE, V73, P337, DOI 10.1016/0378-1119(88)90498-2; NYSTROM T, 1994, MOL GEN GENET, V245, P355, DOI 10.1007/BF00290116; OHLSEN KL, 1992, MOL MICROBIOL, V6, P2243, DOI 10.1111/j.1365-2958.1992.tb01400.x; PRIMAKOFF P, 1979, P NATL ACAD SCI USA, V76, P1726, DOI 10.1073/pnas.76.4.1726; Rao NN, 1998, J BACTERIOL, V180, P2186, DOI 10.1128/JB.180.8.2186-2193.1998; RIGGS DL, 1986, P NATL ACAD SCI USA, V83, P9333, DOI 10.1073/pnas.83.24.9333; Sambrook J., 2002, MOL CLONING LAB MANU; SANDS MK, 1952, J BACTERIOL, V63, P505, DOI 10.1128/JB.63.4.505-511.1952; Shiba T, 1997, P NATL ACAD SCI USA, V94, P11210, DOI 10.1073/pnas.94.21.11210; STENT GS, 1961, P NATL ACAD SCI USA, V47, P2005, DOI 10.1073/pnas.47.12.2005; STEPHENS JC, 1975, P NATL ACAD SCI USA, V72, P4389, DOI 10.1073/pnas.72.11.4389; WANG AY, 1994, MOL MICROBIOL, V11, P1009, DOI 10.1111/j.1365-2958.1994.tb00379.x; WANNER BL, 1977, J BACTERIOL, V130, P212, DOI 10.1128/JB.130.1.212-222.1977; XIAO H, 1991, J BIOL CHEM, V266, P5980; Zgurskaya HI, 1997, MOL MICROBIOL, V24, P643, DOI 10.1046/j.1365-2958.1997.3961742.x; Zhou YN, 1998, P NATL ACAD SCI USA, V95, P2908, DOI 10.1073/pnas.95.6.2908	35	110	113	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14795	14798		10.1074/jbc.C000128200	http://dx.doi.org/10.1074/jbc.C000128200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10747855	hybrid			2022-12-27	WOS:000087128300005
J	Abe, K; Rossman, KL; Liu, B; Ritola, KD; Chiang, D; Campbell, SL; Burridge, K; Der, CJ				Abe, K; Rossman, KL; Liu, B; Ritola, KD; Chiang, D; Campbell, SL; Burridge, K; Der, CJ			Vav2 is an activator of Cdc42, Rac1, and RhoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; JNK/SAPK SIGNALING PATHWAY; BINDING PROTEIN-RHO; ACTIN STRESS FIBERS; RAS TRANSFORMATION; DBL FAMILY; TRANSCRIPTIONAL ACTIVATION; STRUCTURAL SIMILARITIES; EXPRESSION CLONING; FOCAL ADHESIONS	Vav and Vav2 are members of the Dbl family of proteins that act as guanine nucleotide exchange factors (GEFs) for Rho family proteins. Whereas Vav expression is restricted to cells of hematopoietic origin, Vav2 is widely expressed. Although Vav and Vav2 share highly related structural similarities and high sequence identity in their Dbl homology domains, it has been reported that they are active GEFs with distinct substrate specificities toward Rho family members. Whereas Vav displayed GEF activity for Rac1, Cdc42, RhoA, and RhoG, Vav2 was reported to exhibit GEF activity for RhoA, RhoB, and RhoG but not for Rad or Cdc42. Consistent with their distinct substrate targets, it was found that constitutively activated versions of Vav and Vav2 caused distinct transformed phenotypes when expressed in NIH 3T3 cells. In contrast to the previous findings, we found that Vav2 can act as a potent GEF for Cdc42, Rac1, and RhoA in vitro. Furthermore, we found that NH2-terminally truncated and activated Vav and Vav2 caused indistinguishable transforming actions in NIH 3T3 cells that required Cdc42, Rad, and RhoA function. In addition, like Vav and Rad, we found that Vav2 activated the Jun NH2-terminal kinase cascade and also caused the formation of lamellipodia and membrane ruffles in NIH 3T3 cells. Finally, Vav2-transformed NIH 3T3 cells showed up-regulated levels of Rac-GTP. We conclude that Vav2 and Vav share overlapping downstream targets and are activators of multiple Rho family proteins. Therefore, Vav2 may mediate the same cellular consequences in nonhematopoietic cells as Vav does in hematopoietic cells.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Der, CJ (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, CB 7295, Chapel Hill, NC 27599 USA.	cjder@med.unc.edu	Chiang, Donyau/AFK-1742-2022; Chiang, Donyau/AAF-9096-2022	campbell, sharon/0000-0003-0311-409X; Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA63071, CA55008, CA42978] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055008, R01CA063071, R01CA042978] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe R, 1999, J BIOL CHEM, V274, P30410, DOI 10.1074/jbc.274.43.30410; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bustelo XR, 1996, CRIT REV ONCOGENESIS, V7, P65, DOI 10.1615/CritRevOncog.v7.i1-2.50; CAMPBELLBURK SL, 1995, METHOD ENZYMOL, V255, P3; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1996, ONCOGENE, V13, P455; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HAUSER CA, 1994, METHOD ENZYMOL, V238, P271; HENSKE EP, 1995, ANN HUM GENET, V59, P25, DOI 10.1111/j.1469-1809.1995.tb01603.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Liu BP, 1998, CELL ADHES COMMUN, V5, P249, DOI 10.3109/15419069809040295; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schuebel KE, 1996, ONCOGENE, V13, P363; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead IP, 1998, MOL CELL BIOL, V18, P4689, DOI 10.1128/MCB.18.8.4689; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	49	216	217	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10141	10149		10.1074/jbc.275.14.10141	http://dx.doi.org/10.1074/jbc.275.14.10141			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744696	Green Published, hybrid			2022-12-27	WOS:000086345600037
J	Deterding, LJ; Prasad, R; Mullen, GP; Wilson, SH; Tomer, KB				Deterding, LJ; Prasad, R; Mullen, GP; Wilson, SH; Tomer, KB			Mapping of the 5 '-2-deoxyribose-5-phosphate lyase active site in DNA polymerase beta by mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; N-TERMINAL DOMAIN; DEOXYRIBOSE PHOSPHATE EXCISION; CATALYTIC MECHANISM; IMINO INTERMEDIATE; 8-KDA DOMAIN; PROTEIN; BINDING; IDENTIFICATION; SEQUENCE	The mechanism of the 5'-2-deoxyribose-5-phosphate lyase reaction catalyzed by mammalian DNA beta-polymerase (beta-pol) was investigated using a cross-linking methodology in combination with mass spectrometric analyses. The approach included proteolysis of the covalently cross-linked protein-DNA complex with trypsin, followed by isolation, peptide mapping, and mass spectrometric and tandem mass spectrometric analyses. The 8-kDa domain of beta-pol was covalently cross-linked to a 5'-2-deoxyribose-5-phosphate-containing DNA substrate by sodium borohydride reduction. Using tandem mass spectrometry, the location of the DNA adduct on the 8-kDa domain was unequivocally determined to be at the Lys(72) as the sole Schiff base nucleophile in the 8-kDa domain of beta-pol. These results provide the first direct evidence in support of a catalytic mechanism involving nucleophilic attack by Lys(72) at the abasic site.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06032 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Connecticut	Tomer, KB (corresponding author), NIEHS, Struct Biol Lab, NIH, POB 12233 MD F0-03,111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.		Tomer, Kenneth B/E-8018-2013; Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050127, ZIAES050127, ZIAES050158, Z01ES050158] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barr DP, 1996, J BIOL CHEM, V271, P15498, DOI 10.1074/jbc.271.26.15498; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; Borchers C, 1999, J CHROMATOGR A, V854, P119, DOI 10.1016/S0021-9673(99)00479-3; CASASFINET JR, 1991, J BIOL CHEM, V266, P19618; DETERDING LJ, 1989, ANAL CHEM, V61, P2504, DOI 10.1021/ac00197a011; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; Feng JA, 1998, BIOCHEMISTRY-US, V37, P9605, DOI 10.1021/bi9808619; FISHER EH, 1958, J AM CHEM SOC, V80, P2906; Forsina G., 1996, J BIOL CHEM, V271, P9573; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; FRIDOVICH I, 1962, J AM CHEM SOC, V84, P3208, DOI 10.1021/ja00875a050; KIM SJ, 1994, J MOL BIOL, V244, P224, DOI 10.1006/jmbi.1994.1720; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAR A, 1990, J BIOL CHEM, V265, P2124; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; LIU DJ, 1994, BIOCHEMISTRY-US, V33, P9537, DOI 10.1021/bi00198a020; Liu DJ, 1996, BIOCHEMISTRY-US, V35, P6188, DOI 10.1021/bi952656o; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Matsumoto Y, 1998, BIOCHEMISTRY-US, V37, P6456, DOI 10.1021/bi9727545; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mullen GP, 1997, TETRAHEDRON, V53, P12057, DOI 10.1016/S0040-4020(97)00768-0; MULLEN GP, 1997, BASE EXCISION REPAIR, P121; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PIERSEN CE, 1995, J BIOL CHEM, V270, P23475, DOI 10.1074/jbc.270.40.23475; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; PRASAD R, 1993, J BIOL CHEM, V268, P22746; Prasad R, 1998, J BIOL CHEM, V273, P11121, DOI 10.1074/jbc.273.18.11121; Prasad R, 1998, J BIOL CHEM, V273, P15263, DOI 10.1074/jbc.273.24.15263; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; WARREN S, 1966, BIOCHEMISTRY-US, V5, P817, DOI 10.1021/bi00867a002; WILSON S, 1988, BIOCHIM BIOPHYS ACTA, V949, P149, DOI 10.1016/0167-4781(88)90078-4; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199	46	64	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10463	10471		10.1074/jbc.275.14.10463	http://dx.doi.org/10.1074/jbc.275.14.10463			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744736	hybrid			2022-12-27	WOS:000086345600077
J	Kim, Y; Bang, H; Kim, D				Kim, Y; Bang, H; Kim, D			TASK-3, a new member of the tandem pore K+ channel family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL EXPRESSION; PH; DOMAINS; CLONING; SEQUENCE; BRAIN	We have isolated from the rat cerebellum cDNA library a complementary DNA encoding a new member of the tandem pore KC channel family. Its amino acid sequence shares 54% identity with that of TASK-1, but less than 30% with those of TASK-8 and other tandem pore K+ channels (TWIK, TREK, TRAAK), Therefore, the new clone was named TASK-3. Reverse transcriptase-polymerase chain reaction analysis showed that TASK-3 mRNA is expressed in many rat tissues including brain, kidney, liver, lung, colon, stomach, spleen, testis, and skeletal muscle, and at very low levels in the heart and small intestine. When expressed in COS-7 cells, TASK-3 exhibited a time-independent, noninactivating K+-selective current. Single-channel conductance was 27 pS at -60 mV and 17 pS at 60 mV in symmetrical 140 mM KCI, TASK-3 current was highly sensitive to changes in extracellular pH (pH(o)) a hallmark of the TASK family of K+ channels. Thus, a change in pH, from 7.2 to 6.4 and 6.0 decreased TASK-3 current by 74 and 96%, respectively. Mutation of histidine at position 98 to aspartate abolished pH, sensitivity. TASK-3 was blocked by barium (57%, 3 mM), quinidine (37%, 100 mu M), and lidocaine (62%, 1 mM). Thus, TASK-3 is a new member of the acid-sensing K+ channel subfamily (TASK).	Finch Univ Hlth Sci, Dept Physiol & Biophys, Chicago Med Sch, Chicago, IL 60064 USA	Chicago Medical School	Kim, D (corresponding author), Finch Univ Hlth Sci, Dept Physiol & Biophys, Chicago Med Sch, 3333 Green Bay Rd, Chicago, IL 60064 USA.				NHLBI NIH HHS [HL55363] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055363] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAKER M, 1987, J PHYSIOL-LONDON, V383, P45; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chavez RA, 1999, J BIOL CHEM, V274, P7887, DOI 10.1074/jbc.274.12.7887; CHESLER M, 1990, PROG NEUROBIOL, V34, P401, DOI 10.1016/0301-0082(90)90034-E; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; Goldstein SAN, 1998, J MOL MED-JMM, V76, P13, DOI 10.1007/s109-1998-8100-0; Goldstein SAN, 1996, P NATL ACAD SCI USA, V93, P13256, DOI 10.1073/pnas.93.23.13256; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; Kim D, 1998, CIRC RES, V82, P513, DOI 10.1161/01.RES.82.4.513; Kim Y, 1999, AM J PHYSIOL-HEART C, V277, pH1669, DOI 10.1152/ajpheart.1999.277.5.H1669; KOH DS, 1992, J MEMBRANE BIOL, V130, P149; KOYANO K, 1992, J PHYSIOL-LONDON, V454, P231, DOI 10.1113/jphysiol.1992.sp019262; KRISHTAL OA, 1987, BRAIN RES, V436, P352, DOI 10.1016/0006-8993(87)91678-7; KYTE J, 1982, J MOL BIOL, V157, P162; Leonoudakis D, 1998, J NEUROSCI, V18, P868; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; Lesage F, 1996, J BIOL CHEM, V271, P4183; Maingret F, 1999, J BIOL CHEM, V274, P1381, DOI 10.1074/jbc.274.3.1381; O'Kelly I, 1999, AM J PHYSIOL-LUNG C, V276, pL96, DOI 10.1152/ajplung.1999.276.1.L96; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; PONGS O, 1992, PHYSIOL REV, V72, P569; Pountney DJ, 1999, FEBS LETT, V450, P191, DOI 10.1016/S0014-5793(99)00495-0; Reid JD, 1996, RECEPTOR CHANNEL, V4, P51; Reyes R, 1998, J BIOL CHEM, V273, P30863, DOI 10.1074/jbc.273.47.30863; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; Salinas M, 1999, J BIOL CHEM, V274, P11751, DOI 10.1074/jbc.274.17.11751; SHEN KZ, 1992, J PHYSIOL-LONDON, V445, P581, DOI 10.1113/jphysiol.1992.sp018941; SIESJO BK, 1985, J CEREBR BLOOD F MET, V5, P47, DOI 10.1038/jcbfm.1985.7; Wang ZW, 1999, ANN NY ACAD SCI, V868, P286, DOI 10.1111/j.1749-6632.1999.tb11294.x; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8	38	298	309	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9340	9347		10.1074/jbc.275.13.9340	http://dx.doi.org/10.1074/jbc.275.13.9340			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734076	hybrid			2022-12-27	WOS:000086206500040
J	Asano, S; Kawada, H; Kimura, T; Grishin, AV; Caplan, MJ; Takeguchi, N				Asano, S; Kawada, H; Kimura, T; Grishin, AV; Caplan, MJ; Takeguchi, N			The roles of carbohydrate chains of the beta-subunit on the functional expression of gastric H+,K+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CDNA CLONING; H+/K+-ATPASE; H,K-ATPASE; IDENTIFICATION; NA,K-ATPASE; BINDING; PROTEIN; GLYCOSYLATION; BIOSYNTHESIS	Gastric H+,K+-ATPase consists of alpha and beta-subunits. The alpha-subunit is the catalytic subunit, and the beta-subunit is a glycoprotein stabilizing the alpha/beta complex in the membrane as a functional enzyme. There are seven putative N-glycosylation sites on the beta-subunit. In this study, we examined the roles of the carbohydrate chains of the beta-subunit by expressing the alpha-subunit together with the beta-subunit in which one, several, or all of the asparagine residues in the N-glycosylation sites were replaced by glutamine. Removing any one of seven carbohydrate chains from the beta-subunit retained the H+,K+-ATPase activity. The effects of a series of progressive removals of carbohydrate chains on the H+,K+-ATPase activity were cumulative, and removal of all carbohydrate chains resulted in the complete loss of H+,K+-ATPase activity. Removal of any single carbohydrate chain did not affect the alpha/beta assembly; however, Little alpha/beta assembly was observed after removal of all the carbohydrate chains from the beta-subunit. In contrast, removal of three carbohydrate chains inhibited the surface delivery of the beta-subunit and the alpha-subunit assembled with the alpha-subunit, indicating that the surface delivery mechanism is more dependent on the carbohydrate chains than the expression of the H+,K+-ATPase activity and alpha/beta assembly.	Toyama Med & Pharmaceut Univ, Mol Genet Res Ctr, Toyama 9300194, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Toyama 9300194, Japan; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA	University of Toyama; University of Toyama; Yale University	Asano, S (corresponding author), Toyama Med & Pharmaceut Univ, Mol Genet Res Ctr, 2630 Sugitani, Toyama 9300194, Japan.			Caplan, Michael/0000-0001-5768-4405				ASANO S, 1994, BIOCHEM J, V299, P59, DOI 10.1042/bj2990059; Asano S, 1999, J BIOL CHEM, V274, P22257, DOI 10.1074/jbc.274.32.22257; Asano S, 1997, J BIOL CHEM, V272, P17668, DOI 10.1074/jbc.272.28.17668; Asano S, 1996, J BIOL CHEM, V271, P2740, DOI 10.1074/jbc.271.5.2740; Beggah AT, 1997, J BIOL CHEM, V272, P10318; CANFIELD VA, 1990, J BIOL CHEM, V265, P19878; CHOW DC, 1992, AM J PHYSIOL, V263, pC39, DOI 10.1152/ajpcell.1992.263.1.C39; Chowrira GM, 1998, TRANSGENIC RES, V7, P265, DOI 10.1023/A:1008874129407; GOTTARDI CJ, 1993, J BIOL CHEM, V268, P14342; Grishin AV, 1996, AM J PHYSIOL-RENAL, V271, pF539, DOI 10.1152/ajprenal.1996.271.3.F539; KEELING DJ, 1989, J BIOL CHEM, V264, P5552; Klaassen CHW, 1997, BIOCHEM J, V321, P419, DOI 10.1042/bj3210419; KLAASSEN CHW, 1993, FEBS LETT, V329, P277, DOI 10.1016/0014-5793(93)80237-O; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambrecht N, 1998, J BIOL CHEM, V273, P13719, DOI 10.1074/jbc.273.22.13719; MA JY, 1991, BIOCHEM BIOPH RES CO, V180, P39; MATHEWS PM, 1995, AM J PHYSIOL-CELL PH, V268, pC1207, DOI 10.1152/ajpcell.1995.268.5.C1207; OKAMOTO CT, 1990, BIOCHIM BIOPHYS ACTA, V1037, P360, DOI 10.1016/0167-4838(90)90038-H; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; SHULL GE, 1990, J BIOL CHEM, V265, P12123; SHULL GE, 1986, J BIOL CHEM, V261, P6788; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; TAKEDA K, 1988, FEBS LETT, V238, P201, DOI 10.1016/0014-5793(88)80256-4; TAMKUN MM, 1986, J BIOL CHEM, V261, P1009; TOH BH, 1990, P NATL ACAD SCI USA, V87, P6418, DOI 10.1073/pnas.87.16.6418; Tyagarajan K, 1996, BIOCHEMISTRY-US, V35, P3238, DOI 10.1021/bi952303p; Tyagarajan K, 1997, BIOCHEMISTRY-US, V36, P10200, DOI 10.1021/bi9706125; WALDERHAUG MO, 1985, J BIOL CHEM, V260, P3852; YODA A, 1970, BIOCHEM BIOPH RES CO, V40, P880, DOI 10.1016/0006-291X(70)90985-X; ZAMOFING D, 1989, AM J PHYSIOL, V256, pC959	30	38	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8324	8330		10.1074/jbc.275.12.8324	http://dx.doi.org/10.1074/jbc.275.12.8324			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722662	hybrid			2022-12-27	WOS:000086507700012
J	Ciufo, LF; Boyd, A				Ciufo, LF; Boyd, A			Identification of a lumenal sequence specifying the assembly of Emp24p into p24 complexes in the yeast secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPII-COATED VESICLES; LUMINAL ER PROTEINS; ENDOPLASMIC-RETICULUM; TRANSPORT VESICLES; GOLGI TRANSPORT; COMPONENT; COATOMER; MEMBRANE; VECTORS; FAMILY	The p24 proteins are transmembrane proteins of the endomembrane system that play a poorly defined role in vesicle traffic between the endoplasmic reticulum and the Golgis apparatus. Various lines of evidence indicate that p24 proteins fall into four subfamilies (alpha, beta, gamma, and delta) and that tetramers are assembled containing one representative from each subfamily; however, the nature of the protein-protein interactions within these hetero-oligomers is unknown. We have identified a lumenal segment of yeast p24 beta (Emp24p) that is necessary for its assembly into p24 complexes. Replacement of 52 C-terminal residues of Emp24p with the corresponding sequence from Erv25p (p24 delta) generates a chimeric protein able to replace Emp24p in p24 complexes that retain partial function in vivo, ruling out a role for the transmembrane and cytosolic domains in specifying p24 interactions. Substitution of a further 50 residues, encompassing a heptad repeat region, abolishes the ability of the chimera to replace Emp24p but instead creates a protein that resembles its Erv25p parent in its requirement for stabilization by Emp24p. These data point to a role for coiled-coil interactions in directing subfamily-specific assembly of p24 oligomers that project into the lumen of transport vesicles, where they may act to exclude secretory cargo from coat protein complex type I-coated retrograde transport vesicles.	Univ Edinburgh, Dept Biomed Sci, Edinburgh EH8 9XD, Midlothian, Scotland	University of Edinburgh	Boyd, A (corresponding author), Univ Edinburgh, Dept Biomed Sci, Hugh Robson Bldg,George Sq, Edinburgh EH8 9XD, Midlothian, Scotland.	alan.boyd@ed.ac.uk						ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Aridor M, 1996, TRENDS CELL BIOL, V6, P315, DOI 10.1016/0962-8924(96)10027-1; Aridor M, 1999, J BIOL CHEM, V274, P4389, DOI 10.1074/jbc.274.7.4389; Bednarek SY, 1996, TRENDS CELL BIOL, V6, P468, DOI 10.1016/0962-8924(96)84943-9; Belden WJ, 1996, J BIOL CHEM, V271, P26939, DOI 10.1074/jbc.271.43.26939; Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; Campbell JL, 1997, P NATL ACAD SCI USA, V94, P837, DOI 10.1073/pnas.94.3.837; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; ElrodErickson MJ, 1996, MOL BIOL CELL, V7, P1043, DOI 10.1091/mbc.7.7.1043; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Fullekrug J, 1999, MOL BIOL CELL, V10, P1939, DOI 10.1091/mbc.10.6.1939; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Kaiser C, 1998, CURR OPIN CELL BIOL, V10, P477, DOI 10.1016/S0955-0674(98)80062-8; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; KUSTERS JG, 1989, NUCLEIC ACIDS RES, V17, P8007, DOI 10.1093/nar/17.19.8007; Lavoie C, 1999, J CELL BIOL, V146, P285, DOI 10.1083/jcb.146.2.285; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Martinez-Menarguez JA, 1999, CELL, V98, P81, DOI 10.1016/S0092-8674(00)80608-X; Marzioch M, 1999, MOL BIOL CELL, V10, P1923, DOI 10.1091/mbc.10.6.1923; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Nickel W, 1997, P NATL ACAD SCI USA, V94, P11393, DOI 10.1073/pnas.94.21.11393; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WADA I, 1991, J BIOL CHEM, V266, P19599; ZUECO J, 1992, GENE, V121, P181, DOI 10.1016/0378-1119(92)90180-W	31	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8382	8388		10.1074/jbc.275.12.8382	http://dx.doi.org/10.1074/jbc.275.12.8382			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722670	hybrid			2022-12-27	WOS:000086507700020
J	Stewart, S; Guan, KL				Stewart, S; Guan, KL			The dominant negative Ras mutant, N17Ras, can inhibit signaling independently of blocking Ras activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NUCLEOTIDE EXCHANGE FACTORS; TERNARY COMPLEX-FORMATION; MAP KINASE; GROWTH-FACTOR; REGULATED KINASE-2; FACTOR P62TCF; PHOSPHORYLATION; TRANSCRIPTION; PATHWAYS	Ras plays an important role in a variety of cellular functions, including growth, differentiation, and oncogenic transformation. For instance, Ras participates in the activation of Raf, which phosphorylates and activates mitogen-activated protein kinase kinase (MEK), which then phosphorylates and activates extracellular signal-regulated kinase (ERK), a mitogen-activated protein (MAP) kinase. Activation of MAP kinase appears to be essential for propagating a wide variety of extracellular signals from the plasma membrane to the nucleus. N17Ras, a GDP-bound dominant negative mutant, is used widely as an interfering mutant to assess Ras function in vivo, Surprisingly, me observed that expression of N17Ras inhibited the activity and phosphorylation of Elk-1, a physiological substrate of MAP kinases, in response to phorbol myristate acetate, The activity and phosphorylation of the MAP kinase hemagglutinin epitope (HA)-ERK1 were not affected by N17Ras in response to the same stimulus, Additionally, expression of N17Ras, but not L61S186Ras, a GTP-bound interfering mutant, inhibited MEK-induced Elk-1 phosphorylation, suggesting that inhibition of Elk-1 may be unique to GDP-bound Res mutants, Finally, we observed that V12Ras-induced focus formation in NIH3T3 cells is inhibited by coexpression of GDP-bound Ras mutants, such as N17, A15, and N17N69. Therefore, N17Ras and V12 Ras may be codominant with respect to Elk-1 activation and cellular transformation. These results indicate that N17Ras appears to have at least two distinguishable functions: interference with endogenous Ras activation and inhibition of Elk-1 and transfomation, Furthermore, our data imply the possibility that GDP-bound Ras, Like N17Ras, may have a direct role in signal transduction.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Inst Gerontol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Guan, KL (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, M5416 Med Sci 1,12301 Catherine Rd, Ann Arbor, MI 48109 USA.				NATIONAL CANCER INSTITUTE [T32CA009676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051586] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA09676] Funding Source: Medline; NIGMS NIH HHS [GM51586] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHEN SY, 1994, ONCOGENE, V9, P2691; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Cool RH, 1999, MOL CELL BIOL, V19, P6297; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIAMOND LE, 1988, MOL CELL BIOL, V8, P2233, DOI 10.1128/MCB.8.5.2233; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GUERRERO I, 1985, P NATL ACAD SCI USA, V82, P7810, DOI 10.1073/pnas.82.23.7810; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HART M, 1995, METHOD ENZYMOL, V255, P129; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; JOHN J, 1993, J BIOL CHEM, V268, P923; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MICHAELI T, 1989, EMBO J, V8, P3039, DOI 10.1002/j.1460-2075.1989.tb08454.x; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; Park HO, 1997, P NATL ACAD SCI USA, V94, P4463, DOI 10.1073/pnas.94.9.4463; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; RIOU G, 1988, ONCOGENE, V3, P329; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Waters SB, 1996, J BIOL CHEM, V271, P18224, DOI 10.1074/jbc.271.30.18224; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WOTTON D, 1993, J BIOL CHEM, V268, P17975; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773; ZHENG CF, 1994, J BIOL CHEM, V269, P19947; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	51	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8854	8862		10.1074/jbc.275.12.8854	http://dx.doi.org/10.1074/jbc.275.12.8854			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722731	hybrid			2022-12-27	WOS:000086507700081
J	Bernardo, K; Krut, O; Wiegmann, K; Kreder, D; Micheli, M; Schafer, R; Sickman, A; Schmidt, WE; Schroder, JM; Meyer, HE; Sandhoff, K; Kronke, M				Bernardo, K; Krut, O; Wiegmann, K; Kreder, D; Micheli, M; Schafer, R; Sickman, A; Schmidt, WE; Schroder, JM; Meyer, HE; Sandhoff, K; Kronke, M			Purification and characterization of a magnesium-dependent neutral sphingomyelinase from bovine brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ACID SPHINGOMYELINASE; ACTIVATED PROTEIN-KINASE; NIEMANN-PICK DISEASE; RAT-BRAIN; CELL-DIFFERENTIATION; DEFICIENT MICE; CERAMIDE; ELECTROPHORESIS; METABOLISM; RECEPTOR	The magnesium-dependent, plasmamembrane-associated neutral sphingomyelinase (N-SMase) catalyzes hydrolysis of membrane sphingomyelin to form ceramide, a lipid signaling molecule implied in intracellular signaling. We report here the biochemical purification to apparent homogeneity of N-SMase from bovine brain. Proteins from Nonidet P-40 extracts of brain membranes were subjected to four purification steps yielding a N-SMase preparation that exhibited a specific enzymatic activity 23,330-fold increased over the brain homogenate, When analyzed by two-dimensional gel electrophoresis, the purified enzyme presented as two major protein species of 46 and 97 kDa, respectively; Matrix-assisted laser desorption/ionization-mass spectrometry analysis of tryptic peptides revealed at least partial identity of these two proteins, Amino acid sequenciny of tryptic peptides showed no apparent homologies of bovine N-SMase to any known protein. Peptidespecific antibodies recognized a single 97-kDa protein in Western blot analysis of cell lysates, The purified enzyme displayed a K-m of 40 mu M for sphingomyelin with an optimal activity at pH 7-8. Bovine brain N-SMase was strictly dependent on Mg2+, whereas Zn2+ and Ca2+ proved inhibitory. The highly purified bovine N-SMase was effectively blocked by glutathione and scyphostatin. Scyphostatin proved to be a potent inhibitor of N-SMase with 95% inhibition observed at 20 mu M scyphostatin. The results of this study define a N-SMase that fulfills the biochemical and functional criteria characteristic of the tumor necrosis factor-responsive membrane-bound N-SMase.	Univ Cologne, Inst Med Microbiol & Hyg, Med Ctr, D-50935 Cologne, Germany; Ruhr Univ Bochum, Inst Physiol Chem, D-44780 Bochum, Germany; Univ Kiel, Med Ctr, Dept Dermatol, D-24105 Kiel, Germany; Univ Kiel, Med Ctr, Dept Internal Med, D-24105 Kiel, Germany; Univ Bonn, Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany	University of Cologne; Ruhr University Bochum; University of Kiel; University of Kiel; University of Bonn	Kronke, M (corresponding author), Univ Cologne, Inst Med Microbiol & Hyg, Med Ctr, Goldenfels Str 19-21, D-50935 Cologne, Germany.	Martin.Kroenke@medizin.uni-koeln.de	Sickmann, Albert/A-1010-2011; Schäfer, Heiner/C-1055-2011	Sickmann, Albert/0000-0002-2388-5265; 				Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Albi E, 1997, BIOCHEM BIOPH RES CO, V236, P29, DOI 10.1006/bbrc.1997.6803; Auge N, 1998, J BIOL CHEM, V273, P12893, DOI 10.1074/jbc.273.21.12893; BRADY RO, 1966, P NATL ACAD SCI USA, V55, P366, DOI 10.1073/pnas.55.2.366; CARRE JB, 1989, J NEUROCHEM, V52, P1294, DOI 10.1111/j.1471-4159.1989.tb01878.x; CHATTERJEE S, 1989, J BIOL CHEM, V264, P12554; DUAN RD, 1995, BBA-LIPID LIPID MET, V1259, P49, DOI 10.1016/0005-2760(95)00137-2; FERLINZ K, 1994, BIOCHEM J, V301, P855, DOI 10.1042/bj3010855; GORG A, 1988, ELECTROPHORESIS, V9, P531, DOI 10.1002/elps.1150090913; Heinrich M, 1999, EMBO J, V18, P5252, DOI 10.1093/emboj/18.19.5252; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; HOSTETLER KY, 1979, J LIPID RES, V20, P456; JENO P, 1995, ANAL BIOCHEM, V224, P75, DOI 10.1006/abio.1995.1010; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kreder D, 1999, EMBO J, V18, P2472, DOI 10.1093/emboj/18.9.2472; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; Liu B, 1998, J BIOL CHEM, V273, P34472, DOI 10.1074/jbc.273.51.34472; Liu B, 1997, SEMIN CELL DEV BIOL, V8, P311, DOI 10.1006/scdb.1997.0153; Liu B, 1997, J BIOL CHEM, V272, P16281, DOI 10.1074/jbc.272.26.16281; Longo CA, 1997, AM J RESP CELL MOL, V16, P605, DOI 10.1165/ajrcmb.16.5.9160843; MARUYAMA EN, 1989, J NEUROCHEM, V52, P611, DOI 10.1111/j.1471-4159.1989.tb09163.x; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; Muller G, 1998, EMBO J, V17, P732, DOI 10.1093/emboj/17.3.732; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; OTTERBACH B, 1995, CELL, V81, P1053, DOI 10.1016/S0092-8674(05)80010-8; QUINTERN LE, 1989, EMBO J, V8, P2469, DOI 10.1002/j.1460-2075.1989.tb08382.x; RAO BG, 1976, J LIPID RES, V17, P506; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schissel SL, 1998, J BIOL CHEM, V273, P18250, DOI 10.1074/jbc.273.29.18250; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Suchard SJ, 1997, BLOOD, V89, P2139, DOI 10.1182/blood.V89.6.2139; TAMIYAKOIZUMI K, 1989, J BIOCHEM, V106, P593, DOI 10.1093/oxfordjournals.jbchem.a122901; Tanaka M, 1997, J AM CHEM SOC, V119, P7871, DOI 10.1021/ja9713385; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; YAMAGUCHI S, 1978, J BIOL CHEM, V253, P4090; YAMAGUCHI S, 1977, J BIOL CHEM, V252, P3805; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	45	66	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7641	7647		10.1074/jbc.275.11.7641	http://dx.doi.org/10.1074/jbc.275.11.7641			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713073	hybrid			2022-12-27	WOS:000085913300033
J	Epperson, TR; Patel, KD; McEver, RP; Cummings, RD				Epperson, TR; Patel, KD; McEver, RP; Cummings, RD			Noncovalent association of P-selectin glycoprotein ligand-1 and minimal determinants for binding to P-selectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHILS; FUNCTIONAL-CHARACTERIZATION; CHROMOSOMAL LOCALIZATION; ACTIVATED PLATELETS; TYROSINE SULFATION; MOLECULAR-CLONING; AMINO-TERMINUS; MYELOID CELLS; PSGL-1; EXPRESSION	P-selectin glycoprotein ligand-1 (PSGL-1) is a disulfide-bonded, homodimeric mucin (similar to 250 kDa) on leukocytes that binds to P-selectin on platelets and endothelial cells during the initial steps in inflammation. Because it has been proposed that only covalently dimerized PSGL-1 can bind P-selectin, we investigated the factors controlling dimerization of PSGL-Y and reexamined whether covalent dimers are required for binding its P-selectin. Recombinant forms of PSGL-1 were created in which the single extracellular Cys (Cys(320)) was replaced with either Ser (C320S-PSGL-1) or Ala (C320A-PSGL-1). Both recombinants migrated as monomeric species of similar to 120 kDa under bath nonreducing and reducing conditions on SDS-polyacrylamide gel electrophoresis. P-selectin bound similarly to cells expressing either wild type or mutated forms of PSGL-1 in both flow cytometric and rolling adhesion assays. Unexpectedly, chemical cross-linking studies revealed that both C320S- and C320A-PSGL-1 noncovalently associate in the plasma membrane and cross-linking generates dimeric species. Chimeric recombinants of PSGL-1 in which the transmembrane domain in PSGL-1 was replaced with the transmembrane domain of CD43 (CD43TMD-PSGL-1) could not be chemically crosslinked, suggesting that residues within the transmembrane domain of PSGL-1 are required for noncovalent association. Cells expressing CD43TMD-PSGL-1 bound P-selectin. To further address the ability of P-selectin to bind monomeric derivatives of PSGL-1, intact HL-60 cells were trypsin-treated, which generated a soluble similar to 25-kDa NHz-terminal fragment of PSGL-1 that bound to immobilized P-selectin. Because N-glycosylation of PSGL-1 hinders trypsin cleavage, a recombinant form of PSGL-1 was generated in which all three potential N-glycosylation sites were mutated (Delta N-PSGL-1). Cells expressing Delta N-PSGL-1 bound P-selectin, and trypsin treatment of the cells generated NH2-terminal monomeric fragments (<10 kDa) of PSGL-1 that bound to P-selectin. These results demonstrate that Cys(320)-dependent dimerization of PSGL-1 is not required for binding to P-selectin and that a small monomeric fragment of PSGL-1 is sufficient for P-selectin recognition.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, WK Warren Med Res Inst, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation	Cummings, RD (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, 975 NW 10th St,BRC Rm 417, Oklahoma City, OK 73104 USA.		Patel, Kamala D/AAX-1245-2021		NHLBI NIH HHS [P01 HL 54804] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054804] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bruehl RE, 1997, J LEUKOCYTE BIOL, V61, P489, DOI 10.1002/jlb.61.4.489; DELUCA M, 1995, J BIOL CHEM, V270, P26734, DOI 10.1074/jbc.270.45.26734; Ellies LG, 1998, IMMUNITY, V9, P881, DOI 10.1016/S1074-7613(00)80653-6; Evangelista V, 1999, BLOOD, V93, P876, DOI 10.1182/blood.V93.3.876.403k25_876_885; Fujimoto TT, 1996, INT J HEMATOL, V64, P231; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; Guyer DA, 1996, BLOOD, V88, P2415, DOI 10.1182/blood.V88.7.2415.bloodjournal8872415; Hidari KIPJ, 1997, J BIOL CHEM, V272, P28750, DOI 10.1074/jbc.272.45.28750; Kumar R, 1996, BLOOD, V88, P3872, DOI 10.1182/blood.V88.10.3872.bloodjournal88103872; Leppanen A, 1999, J BIOL CHEM, V274, P24838, DOI 10.1074/jbc.274.35.24838; Li FG, 1996, J BIOL CHEM, V271, P6342, DOI 10.1074/jbc.271.11.6342; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; Liu W, 1998, J BIOL CHEM, V273, P7078, DOI 10.1074/jbc.273.12.7078; LORANT DE, 1995, J CLIN INVEST, V96, P171, DOI 10.1172/JCI118018; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; McEver RP, 1997, GLYCOCONJUGATE J, V14, P585, DOI 10.1023/A:1018584425879; Mehta P, 1998, J BIOL CHEM, V273, P32506, DOI 10.1074/jbc.273.49.32506; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; Patel KD, 1995, J CELL BIOL, V131, P1893, DOI 10.1083/jcb.131.6.1893; PATEL KD, 1995, J CLIN INVEST, V96, P1887, DOI 10.1172/JCI118234; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Snapp KR, 1998, J CELL BIOL, V142, P263, DOI 10.1083/jcb.142.1.263; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; Tu LL, 1996, J IMMUNOL, V157, P3995; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; VELDMAN GM, 1995, J BIOL CHEM, V270, P16470, DOI 10.1074/jbc.270.27.16470; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; WASLEY LC, 1993, J BIOL CHEM, V268, P8458; Weyrich AS, 1996, J CLIN INVEST, V97, P1525, DOI 10.1172/JCI118575; WEYRICH AS, 1995, J CLIN INVEST, V95, P2297, DOI 10.1172/JCI117921; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Yang J, 1996, BLOOD, V87, P4176, DOI 10.1182/blood.V87.10.4176.bloodjournal87104176	43	61	67	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7839	7853		10.1074/jbc.275.11.7839	http://dx.doi.org/10.1074/jbc.275.11.7839			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713099	hybrid			2022-12-27	WOS:000085913300059
J	Luo, ZQ; Qin, YP; Farrand, SK				Luo, ZQ; Qin, YP; Farrand, SK			The antiactivator TraM interferes with the autoinducer-dependent binding of TraR to DNA by interacting with the C-terminal region of the quorum-sensing activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMID CONJUGAL TRANSFER; LUXR-LUXI FAMILY; TI-PLASMID; AGROBACTERIUM-TUMEFACIENS; TRANSCRIPTIONAL REGULATORS; GENE; LOCALIZATION; ELEMENTS; BACTERIA	Conjugal transfer of Agrobacterium tumefaciens Ti plasmids is regulated by quorum sensing via the transcriptional activator TraR and the acyl-homoserine lactone Agrobacterium autoinducer (AAI). Unique to this system, the activity of TraR is negatively modulated by an antiactivator called TraM, Analyses from yeast two-hybrid studies suggest that TraM directly interacts with the activator, but the conditions under which these components interact and the region of TraR responsible for this interaction are not known, Induction of traM in a strain in which TraR was activating transcription of a reporter system led to rapid cessation of gene expression. As assessed by a genetic assay that measures AAI-dependent DNA binding, TraM inhibited TraR function before and after the transcription factor had bound to its DNA recognition site. Consistent with this observation, in gel retardation assays, purified TraM abolished the DNA binding activity of TraR in a concentration-dependent manner. Such inhibition occurred independent of the order of addition of the reactants. As assessed by far Western analyses TraM interacts with TraR by directly binding the activator. TraM in its native form interacted with native TraR and also with heat-treated TraR but only when SDS was included with the denatured protein. TraM interacted with TraR on blots prepared with total lysates of cells grown in the presence and absence of AAI. Far Western analysis of N- and C-terminal deletion mutants localized a domain of TraR contributing to TraM binding to the e-terminal portion of the activator protein. Random mutagenesis by hydroxylamine treatment and error-prone polymerase chain reaction identified several residues in this region of TraR important for interacting with TraM as well as for transcriptional activation or/and DNA binding. We conclude that TraM inhibits TraR by binding to the activator at a domain within or close to the helix-turn-helix motif located at the C terminus of the protein.	Univ Illinois, Dept Crop Sci, Edward R Madigan Lab 240, Urbana, IL 61801 USA; Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Farrand, SK (corresponding author), Univ Illinois, Dept Crop Sci, Edward R Madigan Lab 240, 1201 W Gregory Dr, Urbana, IL 61801 USA.	stephenf@uiuc.edu		Luo, Zhao-Qing/0000-0001-8890-6621	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052465] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arthur TM, 1998, J BIOL CHEM, V273, P31381, DOI 10.1074/jbc.273.47.31381; CANGELOSI GA, 1991, METHOD ENZYMOL, V204, P384; CHILTON MD, 1974, P NATL ACAD SCI USA, V71, P3672, DOI 10.1073/pnas.71.9.3672; Farrand S. K, 1998, RHIZOBIACEAE MOL BIO, P199, DOI DOI 10.1007/978-94-011-5060-6; Farrand SK, 1996, J BACTERIOL, V178, P4233, DOI 10.1128/jb.178.14.4233-4247.1996; Fuqua C, 1996, MOL MICROBIOL, V20, P1199, DOI 10.1111/j.1365-2958.1996.tb02640.x; Fuqua C, 1996, J BACTERIOL, V178, P435, DOI 10.1128/jb.178.2.435-440.1996; FUQUA C, 1995, J BACTERIOL, V177, P1367, DOI 10.1128/jb.177.5.1367-1373.1995; Fuqua C, 1996, ANNU REV MICROBIOL, V50, P727, DOI 10.1146/annurev.micro.50.1.727; FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; FUQUA WC, 1994, J BACTERIOL, V176, P2796, DOI 10.1128/JB.176.10.2796-2806.1994; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Hwang IY, 1999, MOL MICROBIOL, V34, P282, DOI 10.1046/j.1365-2958.1999.01595.x; HWANG IY, 1995, J BACTERIOL, V177, P449, DOI 10.1128/jb.177.2.449-458.1995; Iyoda S, 1995, MOL GEN GENET, V249, P417; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; KONG LY, 1994, P NATL ACAD SCI USA, V91, P5793, DOI 10.1073/pnas.91.13.5793; Luo ZQ, 1999, P NATL ACAD SCI USA, V96, P9009, DOI 10.1073/pnas.96.16.9009; Luo ZQ, 1999, J BACTERIOL, V181, P618, DOI 10.1128/JB.181.2.618-626.1999; Miller J. H, 1972, EXPT MOL GENETICS; Oger P, 1998, MOL MICROBIOL, V27, P277, DOI 10.1046/j.1365-2958.1998.00671.x; Piper KR, 2000, J BACTERIOL, V182, P1080, DOI 10.1128/JB.182.4.1080-1088.2000; PIPER KR, 1993, NATURE, V362, P448, DOI 10.1038/362448a0; Piper KR, 1999, MOL MICROBIOL, V32, P1077, DOI 10.1046/j.1365-2958.1999.01422.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sharma UK, 1999, J BACTERIOL, V181, P5855, DOI 10.1128/JB.181.18.5855-5859.1999; Shaw PD, 1997, P NATL ACAD SCI USA, V94, P6036, DOI 10.1073/pnas.94.12.6036; SLOCK J, 1990, J BACTERIOL, V172, P3974, DOI 10.1128/jb.172.7.3974-3979.1990; VONBODMAN SB, 1992, P NATL ACAD SCI USA, V89, P643, DOI 10.1073/pnas.89.2.643; ZHANG LH, 1993, NATURE, V362, P446, DOI 10.1038/362446a0; ZHANG LH, 1991, J BACTERIOL, V173, P1867, DOI 10.1128/jb.173.6.1867-1872.1991; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052; Zhu J, 1999, P NATL ACAD SCI USA, V96, P4832, DOI 10.1073/pnas.96.9.4832	33	72	77	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7713	7722		10.1074/jbc.275.11.7713	http://dx.doi.org/10.1074/jbc.275.11.7713			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713083	hybrid			2022-12-27	WOS:000085913300043
J	Muller, S; Da'dara, A; Luersen, K; Wrenger, C; Das Gupta, R; Madhubala, R; Walter, RD				Muller, S; Da'dara, A; Luersen, K; Wrenger, C; Das Gupta, R; Madhubala, R; Walter, RD			In the human malaria parasite Plasmodium falciparum, polyamines are synthesized by a bifunctional ornithine decarboxylase, S-adenosylmethionine decarboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCTASE-THYMIDYLATE SYNTHASE; DIHYDROFOLATE-REDUCTASE; ESCHERICHIA-COLI; ALPHA-DIFLUOROMETHYLORNITHINE; MOLECULAR-CLONING; GENE; EXPRESSION; SEQUENCE; ENZYME; INHIBITORS	The polyamines putrescine, spermidine, and spermine are crucial for cell differentiation and proliferation. Interference with polyamine biosynthesis by inhibition of the rate-limiting enzymes ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (AdoMetDC) has been discussed as a potential chemotherapy of cancer and parasitic infections. Usually both enzymes are individually transcribed and highly regulated as monofunctional proteins. We have isolated a cDNA from the malaria parasite Plasmodium falciparum that encodes both proteins on a single open reading frame, with the AdoMetDC domain in the N-terminal region connected to a C-terminal ODC domain by a hinge region. The predicted molecular mass of the entire transcript is 166 kDa. The ODC/AdoMetDC coding region was subcloned into the expression vector pASK IBA3 and transformed into the AdoMetDC- and ODC-deficient Escherichia coli cell line EWH331. The resulting recombinant protein exhibited both AdoMetDC and ODC activity and co-eluted after gel filtration on Superdex S-200 at similar to 333 kDa, which is in good agreement with the molecular mass of similar to 326 kDa determined for the native protein from isolated P. falciparum, SDS-polyacrylamide gel electrophoresis analysis of the recombinant ODC/AdoMetDC revealed a heterotetrameric structure of the active enzyme indicating processing of the AdoMetDC domain. The data presented describe the occurrence of a unique bifunctional ODC/AdoMetDC in P. falciparum, an organization which is possibly exploitable for the design of new antimalarial drugs.	Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Jawaharlal Nehru Univ, Sch Life Sci, New Delhi 110067, India	Bernhard Nocht Institut fur Tropenmedizin; Harvard University; Harvard T.H. Chan School of Public Health; Jawaharlal Nehru University, New Delhi	Walter, RD (corresponding author), Bernhard Nocht Inst Trop Med, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.	walter@bni.uni-hamburg.de	Wrenger, Carsten/E-4110-2013; madhubala, Rentala/C-3445-2015	Wrenger, Carsten/0000-0001-5987-1749; Da'dara, Akram/0000-0003-3318-9623; madhubala, rentala/0000-0002-0034-399X				ASSARAF YG, 1984, BIOCHEM J, V222, P815, DOI 10.1042/bj2220815; ASSARAF YG, 1988, EXP PARASITOL, V67, P20, DOI 10.1016/0014-4894(88)90004-5; Bacchi C.J., 1987, P317; BALKELY RL, 1984, FOLATES PTERIDINES, P191; BITONTI AJ, 1987, EXP PARASITOL, V64, P237, DOI 10.1016/0014-4894(87)90148-2; BITONTI AJ, 1989, P NATL ACAD SCI USA, V86, P651, DOI 10.1073/pnas.86.2.651; BONNEFOY S, 1994, MOL BIOCHEM PARASIT, V67, P157, DOI 10.1016/0166-6851(94)90105-8; BRETON CB, 1990, RES IMMUNOL, V141, P743, DOI 10.1016/0923-2494(90)90005-J; BZIK DJ, 1987, P NATL ACAD SCI USA, V84, P8360, DOI 10.1073/pnas.84.23.8360; COLEMAN CS, 1994, J BIOL CHEM, V269, P3155; DADara AA, 1996, BIOCHEM J, V320, P519, DOI 10.1042/bj3200519; GAMARRO F, 1995, MOL BIOCHEM PARASIT, V72, P11, DOI 10.1016/0166-6851(95)00059-A; GHODA L, 1990, J BIOL CHEM, V265, P11823; GIESECKE H, 1991, BIOCHEM BIOPH RES CO, V180, P1350, DOI 10.1016/S0006-291X(05)81344-0; GRUMONT R, 1986, P NATL ACAD SCI USA, V83, P5387, DOI 10.1073/pnas.83.15.5387; GUPTA M, 1985, J BIOL CHEM, V260, P2941; HAFNER EW, 1979, J BIOL CHEM, V254, P2419; HANSON S, 1992, J BIOL CHEM, V267, P2350; HAYASHI S, 1989, ORNITHINE DECARBOXYL, P47; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; HOLLINGDALE MR, 1985, EXP PARASITOL, V60, P111, DOI 10.1016/S0014-4894(85)80028-X; HUGHES DE, 1989, MOL BIOCHEM PARASIT, V34, P155, DOI 10.1016/0166-6851(89)90007-8; IVANETICH KM, 1990, FASEB J, V4, P1591, DOI 10.1096/fasebj.4.6.2180768; KAHANA C, 1985, J BIOL CHEM, V260, P5390; KAPPES B, 1998, MOL BIOCHEM PARASIT, V72, P163; KITANI T, 1983, J BIOL CHEM, V258, P235; LU L, 1991, BIOCHEM J, V277, P671, DOI 10.1042/bj2770671; Luersen K, 1999, MOL BIOCHEM PARASIT, V98, P131, DOI 10.1016/S0166-6851(98)00161-3; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; Niemann G, 1996, BIOCHEM J, V317, P135, DOI 10.1042/bj3170135; OSTERMAN AL, 1995, J BIOL CHEM, V270, P11797, DOI 10.1074/jbc.270.20.11797; PAJUNEN A, 1988, J BIOL CHEM, V263, P17040; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1989, ENZYMES AS TARGETS FOR DRUG DESIGN, P157; PEGG AE, 1983, BIOCHEM J, V213, P495, DOI 10.1042/bj2130495; PERRYMAN SM, 1986, MOL BIOL EVOL, V3, P313; Persson K, 1998, BIOCHEM J, V333, P527, DOI 10.1042/bj3330527; Persson L, 1988, Adv Exp Med Biol, V250, P261; PORTER CW, 1986, ANTICANCER RES, V6, P525; POULIN R, 1992, J BIOL CHEM, V267, P150; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROM E, 1993, DNA CELL BIOL, V12, P499, DOI 10.1089/dna.1993.12.499; RUSSELL DH, 1969, MOL PHARMACOL, V5, P253; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEELY JE, 1982, BIOCHEMISTRY-US, V21, P3394, DOI 10.1021/bi00257a023; SHANTZ LM, 1992, BIOCHEM J, V288, P511, DOI 10.1042/bj2880511; STANLEY BA, 1991, J BIOL CHEM, V266, P18502; STANLEY BA, 1989, J BIOL CHEM, V264, P21073; STANLEY BA, 1994, J BIOL CHEM, V269, P7901; Svensson F, 1997, P NATL ACAD SCI USA, V94, P397, DOI 10.1073/pnas.94.2.397; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; TABOR H, 1964, PHARMACOL REV, V16, P245; TOBIAS KE, 1993, BIOCHEMISTRY-US, V32, P5842, DOI 10.1021/bi00073a017; TOBIAS KE, 1993, EUR J BIOCHEM, V218, P245, DOI 10.1111/j.1432-1033.1993.tb18371.x; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TRIGLIA T, 1994, P NATL ACAD SCI USA, V91, P7149, DOI 10.1073/pnas.91.15.7149; WRIGHT PS, 1991, BIOCHEM PHARMACOL, V41, P1713, DOI 10.1016/0006-2952(91)90174-4	58	77	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8097	8102		10.1074/jbc.275.11.8097	http://dx.doi.org/10.1074/jbc.275.11.8097			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713131	hybrid			2022-12-27	WOS:000085913300091
J	O'Kelly, I; Lewis, A; Peers, C; Kemp, PJ				O'Kelly, I; Lewis, A; Peers, C; Kemp, PJ			O-2 sensing by airway chemoreceptor-derived cells - Protein kinase C activation reveals functional evidence for involvement of NADPH oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIC PULMONARY VASOCONSTRICTION; RAT CAROTID-BODY; K+ CHANNEL; ION CHANNELS; I CELLS; EXPRESSION; CALCIUM; CLONING; ACID; PH	Accumulating evidence suggests that neuroepithelial bodies are airway O-2 sensors. Recently, we have established the H-146 small cell lung carcinoma line as a suitable model to study the biochemical basis of neuroepithelial body cell chemotransduction. Here we explore the possibility that hypoxic modulation of K+ channels is intimately linked to activity of NADPH oxidase. Graded hypoxia caused graded inhibition of whole cell K+ currents, which correlated well with membrane depolarization. Pretreatment with the phorbol esi;er, O-tetradecanoyl (TPA), inhibited K+ currents at all potentials, Although 4 alpha-phorbol 12,13-didecanoate and TPA in the presence of bisindolyhmaleimide were also able to depress K+ currents, only TPA could significantly ameliorate hypoxic depression of these currents, Thus, protein kinase C (PKC) activation modulates the sensitivity of these cells to changes in pO(2). Furthermore, because the addition of H2O2, a downstream product of NADPH oxidase, could only activate K+ currents during hypoxia (when endogenous H2O2 production is suppressed), if; appears likely that PKC modulates the affinity of NADPN oxidase for O-2 potentially via phosphorylation of the p47(phox) subunit, which is present in these cells. These data show that PKC is an important regulator of the O-2-transduction pathway and suggests that NADPH oxidase represents a significant component of the airway O-2 sensor.	Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Cardiovasc Res Inst, Leeds LS2 9JT, W Yorkshire, England	University of Leeds; University of Leeds	Kemp, PJ (corresponding author), Univ Leeds, Sch Biomed Sci, Worsley Med & Dent Bldg, Leeds LS2 9JT, W Yorkshire, England.	p.z.kemp@leeds.ac.uk		Peers, Chris/0000-0002-8354-346X				BUCKLER KJ, 1994, J PHYSIOL-LONDON, V476, P423, DOI 10.1113/jphysiol.1994.sp020143; Cutz E, 1999, RESP PHYSIOL, V115, P201, DOI 10.1016/S0034-5687(99)00018-3; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; FRANCOOBREGON A, 1995, P NATL ACAD SCI USA, V92, P4715, DOI 10.1073/pnas.92.10.4715; Fu XW, 1999, J PHYSIOL-LONDON, V514, P139, DOI 10.1111/j.1469-7793.1999.139af.x; GAZDAR AF, 1988, CANCER RES, V48, P4078; HOCKBERGER P, 1989, NATURE, V338, P340, DOI 10.1038/338340a0; LAUWERYNS JM, 1973, Z ZELLFORSCH MIK ANA, V145, P521, DOI 10.1007/BF00306722; LEACH RM, 1992, CLIN SCI, V82, P55, DOI 10.1042/cs0820055; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; Lopez-Barneo J, 1999, RESP PHYSIOL, V115, P215, DOI 10.1016/S0034-5687(99)00016-X; LopezBarneo J, 1996, TRENDS NEUROSCI, V19, P435; Marshall C, 1996, AM J RESP CELL MOL, V15, P633, DOI 10.1165/ajrcmb.15.5.8918370; O'Kelly I, 1998, AM J PHYSIOL-LUNG C, V275, pL709, DOI 10.1152/ajplung.1998.275.4.L709; O'Kelly I, 1999, AM J PHYSIOL-LUNG C, V276, pL96, DOI 10.1152/ajplung.1999.276.1.L96; PANCRAZIO JJ, 1989, CANCER RES, V49, P5901; Peers C, 1998, J PHYSIOL-LONDON, V512, P743, DOI 10.1111/j.1469-7793.1998.743bd.x; Peers C, 1997, TRENDS PHARMACOL SCI, V18, P405; Reyes R, 1998, J BIOL CHEM, V273, P30863, DOI 10.1074/jbc.273.47.30863; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; RODAWAY ARF, 1990, MOL CELL BIOL, V10, P5388, DOI 10.1128/MCB.10.10.5388; Tardif M, 1998, J IMMUNOL, V161, P6885; Wang DS, 1996, P NATL ACAD SCI USA, V93, P13182, DOI 10.1073/pnas.93.23.13182; WEIR EK, 1995, FASEB J, V9, P183, DOI 10.1096/fasebj.9.2.7781921; YOUNGSON C, 1993, NATURE, V365, P153, DOI 10.1038/365153a0	28	61	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7684	7692		10.1074/jbc.275.11.7684	http://dx.doi.org/10.1074/jbc.275.11.7684			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713079	hybrid			2022-12-27	WOS:000085913300039
J	Daniel, C; Salvekar, A; Schindler, U				Daniel, C; Salvekar, A; Schindler, U			A gain-of-function mutation in STAT6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE SIGNAL-TRANSDUCTION; GERMLINE EPSILON-PROMOTER; RECEPTOR-ALPHA-CHAIN; HUMAN IL-4 RECEPTOR; CONSTITUTIVE ACTIVATION; INTERLEUKIN-4 RECEPTOR; T-CELLS; TRANSCRIPTION FACTOR; GAMMA-INTERFERON; GENE-EXPRESSION	Interleukin-4 (IL-4) is a cytokine that plays a crucial role in the pathophysiology of asthma and allergic diseases. IL-1-induced gene expression is largely mediated through the activation of the latent transcription factor STAT6. We identified a STAT6 mutant (STAT6VT)) that is activated independently of IL-4 stimulation. STAT6VT carries two amino acid changes in the SH2 domain that affect the overall structure and stability of the monomeric and dimeric protein. When overexpressed in mammalian cells, STAT6VT undergoes tyrosine phosphorylation, binds DNA, and activates transcription in the absence of IL-4 stimulation. Using the Jak1- and Jak3-deficient fibroblast line U4A, we demonstrate that phosphorylation is mediated by an IL-1-independent tyrosine kinase that is not able to activate the wild-type STAT6 protein. These results suggest that small changes in STAT6 could result in hyperactivation of the protein and constitutive expression of STAT6-dependent genes. Such a mutation, if found in vivo, could cause genetic predisposition for atopic diseases.	Tularik Inc, San Francisco, CA 94080 USA		Schindler, U (corresponding author), Tularik Inc, 2 Corp Dr, San Francisco, CA 94080 USA.	uli@tularik.com						Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138; Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; Barnes KC, 1998, IMMUNOL TODAY, V19, P325, DOI 10.1016/S0167-5699(97)01241-3; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Campbell GS, 1997, J BIOL CHEM, V272, P2591, DOI 10.1074/jbc.272.5.2591; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Deichmann KA, 1999, J MED GENET, V36, P379; Deichmann KA, 1998, CLIN EXP ALLERGY, V28, P151; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; Haque SJ, 1997, P NATL ACAD SCI USA, V94, P8563, DOI 10.1073/pnas.94.16.8563; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Hoey T, 1998, CURR OPIN GENET DEV, V8, P582, DOI 10.1016/S0959-437X(98)80015-4; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Izuhara K, 1999, INT J MOL MED, V3, P3; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kruse S, 1999, IMMUNOLOGY, V96, P365; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Linehan LA, 1998, J IMMUNOL, V161, P302; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Marsh DG, 1996, ADV EXP MED BIOL, V409, P43; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Mikita T, 1998, J BIOL CHEM, V273, P17634, DOI 10.1074/jbc.273.28.17634; Mikita T, 1998, J IMMUNOL, V161, P1822; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Mitsuyasu H, 1999, J IMMUNOL, V162, P1227; Miyata S, 1999, CLIN EXP ALLERGY, V29, P114; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Ryan JJ, 1996, IMMUNITY, V4, P123, DOI 10.1016/S1074-7613(00)80677-9; Sampath D, 1999, J CLIN INVEST, V103, P1353, DOI 10.1172/JCI6130; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; Shuai K, 1996, MOL CELL BIOL, V16, P4932; Stavnezer J, 1996, ADV IMMUNOL, V61, P79, DOI 10.1016/S0065-2776(08)60866-4; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Wang HY, 1999, J IMMUNOL, V162, P4385; Wang HY, 1996, IMMUNITY, V4, P113, DOI 10.1016/S1074-7613(00)80676-7	49	50	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14255	14259		10.1074/jbc.C000129200	http://dx.doi.org/10.1074/jbc.C000129200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10747856	hybrid			2022-12-27	WOS:000087006900035
J	Dutil, EM; Newton, AC				Dutil, EM; Newton, AC			Dual role of pseudosubstrate in the coordinated regulation of protein kinase C by phosphorylation and diacylglycerol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; ACTIVATION; PDK1; TRANSLOCATION; DOMAIN	The activity of protein kinase C is reversibly regulated by an autoinhibitory pseudosubstrate, which blocks the active site of the enzyme in the absence of activators. However, before it can be allosterically regulated, protein kinase C must first be processed by three ordered phosphorylations, the first of which is modification of the activation loop catalyzed by the phosphoinositide-dependent kinase-l (PDK-1), Here we use limited proteolysis to show that 1) newly synthesized protein kinase C adopts a conformation in which its pseudosubstrate sequence is removed from the active site, and 2) this exposure is essential to allow PDK-1 to phosphorylate the enzyme. Precursor (unphosphorylated) protein kinase C beta II obtained by 1) in vitro transcription and translation, 2) expression of a phosphorylation-deficient mutant (T500V), or 3) in vivo labeling with a pulse of [S-35]cysteine/methionine is cleaved at the amino-terminal pseudosubstrate by the endoproteinase Arg-C. In marked contrast to mature (phosphorylated) enzyme, proteolysis occurs in the absence of lipid activators, revealing that precursor protein kinase C has its pseudosubstrate sequence removed constitutively. Additionally, we show that PDK-1 is unable to phosphorylate protein kinase C when the active site is sterically blocked by a peptide substrate. Neither can mature enzyme be dephosphorylated when the active site is blocked by binding either the pseudosubstrate sequence or a heterologous substrate. Thus, the accessibility of the activation loop to both phosphorylation and dephosphorylation requires an exposed pseudosubstrate, In summary, newly synthesized protein kinase C adopts a conformation in which its pseudosubstrate sequence is removed from the active site, rendering the activation loop accessible to phosphorylation by PDK-1. Phosphorylation serves as a conformational switch to position the pseudosubstrate so that it blocks the active site, a conformation that is maintained until stimulus-dependent membrane binding releases it, thus activating the enzyme.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Newton, AC (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.				NIGMS NIH HHS [2 T32 GM07752-21, GM 43154] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007752, R01GM043154, R37GM043154] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Behn-Krappa A, 1999, CURR BIOL, V9, P728, DOI 10.1016/S0960-9822(99)80332-7; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; MASAYUKI M, 1999, J BIOL CHEM, V273, P21473; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; ORR JW, 1994, J BIOL CHEM, V269, P27715; ORR JW, 1994, J BIOL CHEM, V269, P8383; ORR JW, 1992, J BIOL CHEM, V267, P15263; POEHLING HM, 1981, ELECTROPHORESIS, V2, P141, DOI 10.1002/elps.1150020304; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621	26	75	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10697	10701		10.1074/jbc.275.14.10697	http://dx.doi.org/10.1074/jbc.275.14.10697			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744767	hybrid			2022-12-27	WOS:000086345600108
J	Lewis, J; Devin, A; Miller, A; Lin, Y; Rodriguez, Y; Neckers, L; Liu, ZG				Lewis, J; Devin, A; Miller, A; Lin, Y; Rodriguez, Y; Neckers, L; Liu, ZG			Disruption of Hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALS CELL-DEATH; HEAT-SHOCK-PROTEIN; INDUCED APOPTOSIS; MOLECULAR CHAPERONE; CONTAINS 2; COMPLEX; INHIBITION; ALPHA; IDENTIFICATION; PHOSPHORYLATION	The death domain kinase, receptor interacting protein (RIP), is one of the major components of the tumor necrosis factor receptor 1 (TNFR1) complex and plays an essential role in tumor necrosis factor (TNF)-mediated nuclear factor kappa B (NF-kappa B) activation. The activation of NF-kappa B protects cells against TNF-induced apoptosis. Heat-shock proteins (Hsps) are chaperone molecules that confer protein stability and help to restore protein native folding following heat shock and other stresses. The most abundant Hsp, Hsp90, is also involved in regulating the stability and function of a number of cell-signaling molecules. Here we report that RTP is a novel Hsp90-associated kinase and that disruption of Hsp90 function by its specific inhibitor, geldanamycin (GA), selectively causes RIP degradation and the subsequent inhibition of TNF-mediated I kappa B kinase and NP-kappa B activation. MG-132, a specific proteasome inhibitor, abrogated GA-induced degradation of RIP but failed to restore the activation of I kappa B kinase by TNF, perhaps because, in the presence of GA and MG-132, RIP accumulated in a detergent-insoluble subcellular fraction. Most importantly, the degradation of RIP sensitizes cells to TNF-induced apoptosis. These data indicate that Hsp90 plays an important role in TNF-mediated NF-kappa B activation by modulating the stability and solubility of RIP. Thus, inhibition of NF-kappa B activation by GA may be a critical component of the anti-tumor activity of this drug.	NCI, Dept Cell & Canc Biol, Med Branch, Div Clin Sci,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Liu, ZG (corresponding author), NCI, Dept Cell & Canc Biol, Med Branch, Div Clin Sci,NIH, Bldg 10,6N105,9000 Rockville Pike, Bethesda, MD 20892 USA.				DIVISION OF CLINICAL SCIENCES - NCI [Z01SC010276] Funding Source: NIH RePORTER	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ding SZ, 1997, BIOCHEM BIOPH RES CO, V240, P561, DOI 10.1006/bbrc.1997.7699; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; GROSS V, 1995, GASTROENTEROLOGY, V108, P653, DOI 10.1016/0016-5085(95)90436-0; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ITOH N, 1993, J BIOL CHEM, V268, P10932; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Mori N, 1999, BLOOD, V93, P2360; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Neckers L, 1999, HANDB EXP PHARM, V136, P9; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Scheibel T, 1998, BIOCHEM PHARMACOL, V56, P675, DOI 10.1016/S0006-2952(98)00120-8; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Schulte TW, 1999, MOL ENDOCRINOL, V13, P1435, DOI 10.1210/me.13.9.1435; SEPPLORENZINO L, 1995, J BIOL CHEM, V270, P16580, DOI 10.1074/jbc.270.28.16580; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang WX, 1999, CLIN CANCER RES, V5, P119; WHITE JR, 1993, AGENTS ACTIONS, V39, P73; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	60	280	300	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10519	10526		10.1074/jbc.275.14.10519	http://dx.doi.org/10.1074/jbc.275.14.10519			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744744	hybrid			2022-12-27	WOS:000086345600085
J	Shahan, TA; Sorenson, WG; Simpson, J; Kefalides, NA; Lewis, DM				Shahan, TA; Sorenson, WG; Simpson, J; Kefalides, NA; Lewis, DM			Tyrosine kinase activation in response to fungal spores is primarily dependent on endogenous reactive oxygen production in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; BACTERIAL LIPOPOLYSACCHARIDE; ALVEOLAR MACROPHAGES; TRANSCRIPTION-FACTOR; MEMBRANE SKELETON; SUPEROXIDE; INFLAMMATION; ASSOCIATION; MESSENGERS; EXPRESSION	Studies from our laboratory (Shahan, T. A., Sorenson, W. G., and Lewis, D. M. (1994) Environ. Res. 67, 98-104) demonstrated that spores from different fungal species differentially activate rat alveolar macrophages as detected by the measurement of superoxide anion and cytokine production (Shahan, T. A., Siegel, P. D., Sorenson, W. G,, Kuschner, W. G., and Lewis, D. M. (1998) Am. J. Respir. Cell MoL Biol. 18, 435-441). Spores from Aspergillus candidus stimulated production of the highest levels of superoxide anion (5.2 nmol/1.0 x 10(6) alveolar macrophages (AMs)/30 min), followed by those from Aspergillus niger (2.4 nmol/1.0 x 10(6) AMs/30 min) and Eurotium amstelodami (0.4 nmol/1.0 x 10(6) AMs/30 min). The mechanism of this differential activation was studied. Our data demonstrate that the tyrosine kinases p56(Hck) p72(Syk), p77(Btk), p62(Yes), p56(Lck), and p59(Fyn) mere specifically activated in response to spores from A. candidus, whereas spores from either A. niger or E. amstelodami activated p56(Hck), p72(Syk), and p77(Btk). Kinetic analysis of specific tyrosine kinases demonstrated that p56(Hck) p72(Syk), and p77(Btk) were activated faster and to a greater extent by spores from A. candidus as compared with spores from E. amstelodami, These data suggest a relationship between reactive oxygen species and tyrosine kinase activation. Treatment of AMs with H2O2 (1 mM) caused the activation of p72(Syk) only, whereas treatment with superoxide dismutase and catalase before treatment with the spores had no effect on tyrosine kinase activation, Incubation with NADPH oxidase inhibitors inhibited both superoxide anion production and the activation of p56(Hck), p72(Syk), and p77(Btk) in response to fungal spores. These data indicate that endogenous reactive oxygen species are necessary for the activation of p56(Hck), P72(Syk), and p77(Btk) by spores; they also indicate that some species of spores are capable of activating tyrosine kinases independent of superoxide anion.	Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Ctr Dis Control & Prevent, Hlth Effects Lab Div, Assessment Sect, Morgantown, WV 26505 USA; Univ City Sci Ctr, Connect Tissue Res Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Centers for Disease Control & Prevention - USA	Shahan, TA (corresponding author), Univ Penn, Connect Tissue Res Inst, 3624 Market St,Suite 5-E, Philadelphia, PA 19104 USA.							Allen RG, 1999, J CELL PHYSIOL, V180, P114, DOI 10.1002/(SICI)1097-4652(199907)180:1<114::AID-JCP13>3.0.CO;2-0; Baeuerle PA, 1996, PATHOL BIOL, V44, P29; Biggs TE, 1999, J MOL BIOL, V290, P21, DOI 10.1006/jmbi.1999.2849; Blackwell TS, 1996, J IMMUNOL, V157, P1630; BRUMELL JH, 1994, AM J PHYSIOL-CELL PH, V267, pC1574, DOI 10.1152/ajpcell.1994.267.6.C1574; BURKHARDT AL, 1993, CURRENT PROTOCOLS IM, V11, P1; Crowley MT, 1997, J EXP MED, V186, P1027, DOI 10.1084/jem.186.7.1027; Doussiere J, 1999, BIOCHEMISTRY-US, V38, P3694, DOI 10.1021/bi9823481; DOWDY S, 1983, STAT RES, P32; FOX JEB, 1993, J BIOL CHEM, V268, P25973; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Hauses M, 1998, J BIOL CHEM, V273, P31844, DOI 10.1074/jbc.273.48.31844; Hii CST, 1999, INFECT IMMUN, V67, P1297, DOI 10.1128/IAI.67.3.1297-1302.1999; Hirji NS, 1999, INT ARCH ALLERGY IMM, V118, P180, DOI 10.1159/000024060; Irani K, 1998, BIOCHEM PHARMACOL, V55, P1339; JIAN ZJ, 1995, INFLAMMATION, V19, P637, DOI 10.1007/BF01534568; KATAGIRI K, 1991, J IMMUNOL, V146, P701; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Miller RA, 1997, CLIN MICROBIOL REV, V10, P1; NATHAN C, 1994, J BIOL CHEM, V269, P13725; SCHIEVEN GL, 1993, J BIOL CHEM, V268, P16688; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHAHAN TA, 1994, ENVIRON RES, V67, P98, DOI 10.1006/enrs.1994.1067; Shahan TA, 1998, AM J RESP CELL MOL, V18, P435, DOI 10.1165/ajrcmb.18.3.2856; SORENSON WG, 1993, PRACTICAL APPL ENV R, P94; WARD PA, 1986, ANN NY ACAD SCI, V456, P26; ZIEGLER SF, 1988, J EXP MED, V168, P1801, DOI 10.1084/jem.168.5.1801	31	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10175	10181		10.1074/jbc.275.14.10175	http://dx.doi.org/10.1074/jbc.275.14.10175			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744701	hybrid			2022-12-27	WOS:000086345600042
J	Tietge, UJF; Maugeais, C; Cain, W; Grass, D; Glick, JM; de Beer, FC; Rader, DJ				Tietge, UJF; Maugeais, C; Cain, W; Grass, D; Glick, JM; de Beer, FC; Rader, DJ			Overexpression of secretory phospholipase A(2) causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; SERUM AMYLOID-A; ACTIVE RHEUMATOID-ARTHRITIS; ACUTE-PHASE RESPONSE; DISEASE-ACTIVITY; TRANSGENIC MICE; HEART-DISEASE; PLASMA; HDL; METABOLISM	Plasma levels of high density lipoprotein (HDL) cholesterol and its major protein component apolipoprotein (apo) A-I are significantly reduced in both acute and chronic inflammatory conditions, but the basis for this phenomenon is not well. understood, We hypothesized that secretory phospholipase A(2) (sPLA(2)), an acute phase protein that has been found in association with HDL, promotes HDL catabolism. A series of HDL metabolic studies were performed in transgenic mice that specifically overexpress human sPLA(2) but have no evidence of local or systemic inflammation, We found that HDL isolated from these mice have a significantly lower phospholipid and cholesteryl ester and significantly greater triglyceride content. The fractional catabolic rate (FCR) of I-125-HDL was significantly faster in sPLA(2) transgenic mice (4.08 +/- 0.01 pools/day) compared with control wildtype littermates (2.16 +/- 0.48 pools/day). I-125-HDL isolated from sPLA(2) transgenic mice was catabolized significantly faster than I-131-HDL isolated from wild-type mice after injection in wild-type mice (p < 0.001), Injection of I-125-tyramine-cellobiose-HDL demonstrated significantly greater degradation of HDL apolipoproteins in the kidneys of sPLA(2) transgenic mice compared with control mice (p < 0.05), The fractional catabolic rate of [H-3]cholesteryl ether HDL was significantly faster in sPLA(2)-overexpressing mice (6.48 +/- 0.24 pools/day) compared with controls (4.80 +/- 0.72 pools/day). Uptake of [H-3] cholesteryl ether into the livers and adrenals of sPLA(2) transgenic mice was significantly enhanced compared with control mice. In summary, these data demonstrate that overexpression of sPLA(2) alone in the absence of inflammation causes profound alterations of HDL metabolism in vivo and are consistent with the hypothesis that sPLA(2) may promote HDL catabolism in acute and chronic inflammatory conditions.	Univ Penn, Med Ctr, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Mol & Cellular Engn, Philadelphia, PA 19104 USA; Univ Delaware, Dept Biol, Newark, DE 19716 USA; Chrysalis DNX Transgen Sci, Princeton, NJ 08540 USA; Univ Kentucky, Dept Internal Med, Lexington, KY 40536 USA; Vet Affairs Med Ctr, Lexington, KY 40536 USA	University of Pennsylvania; University of Pennsylvania; University of Delaware; University of Kentucky; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center	Rader, DJ (corresponding author), Univ Penn, Med Ctr, Dept Med, 614 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.				NHLBI NIH HHS [HL55323] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055323, R37HL055323] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACTON S, 1996, SCIENCE, V271, P460; Barrett PHR, 1998, METABOLISM, V47, P484, DOI 10.1016/S0026-0495(98)90064-6; BAUSSERMAN LL, 1988, EUR J CLIN INVEST, V18, P619, DOI 10.1111/j.1365-2362.1988.tb01277.x; BRESLOW JL, 1993, ANN NY ACAD SCI, V676, P157; BRINTON EA, 1989, J CLIN INVEST, V84, P262, DOI 10.1172/JCI114149; BRINTON EA, 1991, J CLIN INVEST, V87, P536, DOI 10.1172/JCI115028; BROUSSEAU T, 1993, CLIN CHEM, V39, P960; Cabana VG, 1996, J LIPID RES, V37, P2662; COLLET X, 1990, BIOCHIM BIOPHYS ACTA, V1043, P301, DOI 10.1016/0005-2760(90)90031-R; deBeer FC, 1997, J LIPID RES, V38, P2232; EMANCIPATOR K, 1992, INFECT IMMUN, V60, P596, DOI 10.1128/IAI.60.2.596-601.1992; ETTINGER WH, 1987, AM J MED, V83, P503, DOI 10.1016/0002-9343(87)90762-5; FLEGEL WA, 1993, INFECT IMMUN, V61, P5140, DOI 10.1128/IAI.61.12.5140-5146.1993; Foger B, 1997, J BIOL CHEM, V272, P27393, DOI 10.1074/jbc.272.43.27393; GIJON MA, 1995, BIOCHEM J, V306, P167, DOI 10.1042/bj3060167; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; Goldbourt U, 1997, ARTERIOSCL THROM VAS, V17, P107, DOI 10.1161/01.ATV.17.1.107; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; Gorshkova IN, 1996, BBA-LIPID LIPID MET, V1300, P103, DOI 10.1016/0005-2760(95)00237-5; Grass DS, 1996, J CLIN INVEST, V97, P2233, DOI 10.1172/JCI118664; GYLLING H, 1992, J LIPID RES, V33, P1527; HOFFMAN JS, 1982, J BIOL CHEM, V257, P510; HOMCY CJ, 1982, AM J CARDIOL, V49, P478, DOI 10.1016/0002-9149(82)90528-8; HOROWITZ BS, 1993, J CLIN INVEST, V91, P1743, DOI 10.1172/JCI116384; Hosoai H, 1999, J LIPID RES, V40, P648; HurtCamejo E, 1997, ARTERIOSCL THROM VAS, V17, P300, DOI 10.1161/01.ATV.17.2.300; IKEWAKI K, 1993, J LIPID RES, V34, P2207; ILOWITE NT, 1989, J PEDIATR-US, V114, P823, DOI 10.1016/S0022-3476(89)80148-9; Ivandic B, 1999, ARTERIOSCL THROM VAS, V19, P1284, DOI 10.1161/01.ATV.19.5.1284; Krieger M, 1998, P NATL ACAD SCI USA, V95, P4077, DOI 10.1073/pnas.95.8.4077; LAGOCKI PA, 1980, J BIOL CHEM, V255, P3701; LAKATOS J, 1988, CLIN BIOCHEM, V21, P93, DOI 10.1016/S0009-9120(88)80094-8; LAZAREVIC MB, 1992, SEMIN ARTHRITIS RHEU, V22, P172, DOI 10.1016/0049-0172(92)90017-8; Lee RT, 1997, ARTERIOSCL THROM VAS, V17, P1859, DOI 10.1161/01.ATV.17.10.1859; LEVINE DM, 1993, P NATL ACAD SCI USA, V90, P12040, DOI 10.1073/pnas.90.24.12040; Lin MKS, 1996, J RHEUMATOL, V23, P1162; Lindhorst E, 1997, BBA-PROTEIN STRUCT M, V1339, P143, DOI 10.1016/S0167-4838(96)00227-0; MALLE E, 1993, ATHEROSCLEROSIS, V102, P131, DOI 10.1016/0021-9150(93)90155-N; Menschikowski M, 1995, ATHEROSCLEROSIS, V118, P173, DOI 10.1016/0021-9150(95)05604-1; MENSCHIKOWSKI M, 1995, ATHEROSCLEROSIS, V117, P159, DOI 10.1016/0021-9150(95)05565-E; NAKAMURA H, 1995, J CLIN INVEST, V95, P1062, DOI 10.1172/JCI117752; NAKANO T, 1990, FEBS LETT, V261, P171, DOI 10.1016/0014-5793(90)80663-4; NAKANO T, 1990, FEBS LETT, V273, P23, DOI 10.1016/0014-5793(90)81042-M; NEVALAINEN T, 1993, CLIN CHEM, V39, P228; Nevalainen TJ, 1997, J HISTOCHEM CYTOCHEM, V45, P1109, DOI 10.1177/002215549704500808; Pajkrt D, 1996, J EXP MED, V184, P1601, DOI 10.1084/jem.184.5.1601; PETRI M, 1992, AM J MED, V93, P513, DOI 10.1016/0002-9343(92)90578-Y; Pittman R C, 1986, Methods Enzymol, V129, P612; Plump AS, 1997, J LIPID RES, V38, P1033; Pruzanski W, 1998, J LIPID RES, V39, P2150; PRUZANSKI W, 1988, J RHEUMATOL, V15, P1351; RADER DJ, 1993, LANCET, V342, P1455, DOI 10.1016/0140-6736(93)92933-K; Rader DJ, 1996, CURR OPIN LIPIDOL, V7, P117, DOI 10.1097/00041433-199606000-00002; RADER DJ, 1991, J LIPID RES, V32, P1849; REILLY PA, 1990, ANN RHEUM DIS, V49, P363, DOI 10.1136/ard.49.6.363; Ridker PM, 1998, CIRCULATION, V98, P731, DOI 10.1161/01.CIR.98.8.731; Ridker PM, 1998, LANCET, V351, P88, DOI 10.1016/S0140-6736(97)09032-6; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; Romano M, 1998, ARTERIOSCL THROM VAS, V18, P519, DOI 10.1161/01.ATV.18.4.519; ROSSNER S, 1978, ATHEROSCLEROSIS, V31, P93, DOI 10.1016/0021-9150(78)90041-2; SCHAEFER EJ, 1982, J LIPID RES, V23, P850; Situnayake RD, 1997, ANN RHEUM DIS, V56, P341, DOI 10.1136/ard.56.6.341; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; SVENSON KLG, 1987, ARCH INTERN MED, V147, P1912, DOI 10.1001/archinte.147.11.1912; Tsukamoto K, 1997, J CLIN INVEST, V100, P107, DOI 10.1172/JCI119501; WINKLER E, 1993, J LAB CLIN MED, V121, P774	67	137	141	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10077	10084		10.1074/jbc.275.14.10077	http://dx.doi.org/10.1074/jbc.275.14.10077			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744687	hybrid			2022-12-27	WOS:000086345600028
J	Boullier, A; Gillotte, KL; Horkko, S; Green, SR; Friedmann, P; Dennis, EA; Witztum, JL; Steinberg, D; Quehenberger, O				Boullier, A; Gillotte, KL; Horkko, S; Green, SR; Friedmann, P; Dennis, EA; Witztum, JL; Steinberg, D; Quehenberger, O			The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are associated with both the lipid and protein moieties of the lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCAVENGER RECEPTOR; MACROPHAGE RECEPTOR; HOST-DEFENSE; RECOGNITION; IDENTIFICATION; EXPRESSION; LIGAND; LDL; PURIFICATION; SPECIFICITY	There is growing evidence that CD36 has an important physiological function in the uptake of oxidized low density lipoprotein (OxLDL) by macrophages, However, the ligand specificity and the nature of the ligands on OxLDL that mediate the binding to CD36 remain ill defined, Results from recent studies suggested that some of the macrophage scavenger receptors involved in the uptake of OxLDL recognized both the lipid and the protein moieties of OxLDL, but there was no conclusive direct evidence for this. The present studies were undertaken to test whether a single, well characterized OzLDL receptor, CD36, could bind both the lipid and protein moieties of OxLDL, COS-7 cells transiently transfected with mouse CD36 cDNA bound intact OxLDL with high affinity. This binding was very effectively inhibited (similar to 50%) both by the reconstituted apoB from OxLDL and by microemulsions prepared from OxLDL lipids. The specific binding of both moieties to CD36 was further confirmed by direct ligand binding analysis and by demonstrating reciprocal inhibition, i.e. apoB from OxLDL inhibited the binding of the OxLDL lipids and vice versa. Furthermore, a monoclonal mouse antibody that recognizes oxidation-specific epitopes in OxLDL inhibited the binding of intact OxLDL and also that of its purified protein and lipid moieties to CD36, This antibody recognizes the phospholipid l-palmitoyl 2-(5'-oxovaleroyl) phosphatidylcholine, This model of an oxidized phospholipid was also an effective competitor for the CD36 binding of both the resolubilized apoB and the lipid microemulsions from OxLDL, Our results demonstrate that oxidized phospholipids in the lipid phase or covalently attached to apoB serve as ligands for recognition by CD36 and, at least in part, mediate the high affinity binding of OxLDL to macrophages.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Quehenberger, O (corresponding author), Univ Calif San Diego, Dept Med, 0682,9500 Gilman Dr, La Jolla, CA 92093 USA.		Dennis, Edward A./M-5554-2019	Dennis, Edward A./0000-0003-3738-3140	NHLBI NIH HHS [HL56989] Funding Source: Medline; NIDDK NIH HHS [DK07044] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007044] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACTON SL, 1994, J BIOL CHEM, V269, P21003; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; Bird DA, 1999, P NATL ACAD SCI USA, V96, P6347, DOI 10.1073/pnas.96.11.6347; Chang MK, 1999, P NATL ACAD SCI USA, V96, P6353, DOI 10.1073/pnas.96.11.6353; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; FOGELMAN AM, 1980, P NATL ACAD SCI-BIOL, V77, P2214, DOI 10.1073/pnas.77.4.2214; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Han JH, 1999, J LIPID RES, V40, P830; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Horkko S, 1996, J CLIN INVEST, V98, P815, DOI 10.1172/JCI118854; Horkko S, 1999, J CLIN INVEST, V103, P117, DOI 10.1172/JCI4533; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Krieger M, 1997, CURR OPIN LIPIDOL, V8, P275, DOI 10.1097/00041433-199710000-00006; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARINETTI GV, 1962, J LIPID RES, V3, P1; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Navazo MDP, 1996, ARTERIOSCL THROM VAS, V16, P1033, DOI 10.1161/01.ATV.16.8.1033; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; OTTNAD E, 1995, P NATL ACAD SCI USA, V92, P1391, DOI 10.1073/pnas.92.5.1391; Palinski W, 1996, J CLIN INVEST, V98, P800, DOI 10.1172/JCI118853; PARTHASARATHY S, 1987, P NATL ACAD SCI USA, V84, P537, DOI 10.1073/pnas.84.2.537; Pearce SFA, 1998, J BIOL CHEM, V273, P34875, DOI 10.1074/jbc.273.52.34875; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; SALACINSKI PRP, 1981, ANAL BIOCHEM, V117, P136, DOI 10.1016/0003-2697(81)90703-X; SAMBRANO GR, 1994, P NATL ACAD SCI USA, V91, P3265, DOI 10.1073/pnas.91.8.3265; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; Terpstra V, 1998, P NATL ACAD SCI USA, V95, P1806, DOI 10.1073/pnas.95.4.1806; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YAGI K, 1976, BIOCHEM MED METAB B, V15, P212, DOI 10.1016/0006-2944(76)90049-1; Yamada Y, 1998, CELL MOL LIFE SCI, V54, P628, DOI 10.1007/s000180050191; Yoshida H, 1998, ARTERIOSCL THROM VAS, V18, P794, DOI 10.1161/01.ATV.18.5.794; Yoshida H, 1998, BIOCHEM J, V334, P9, DOI 10.1042/bj3340009	43	157	175	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9163	9169		10.1074/jbc.275.13.9163	http://dx.doi.org/10.1074/jbc.275.13.9163			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734051	hybrid, Green Published			2022-12-27	WOS:000086206500015
J	Abe, Y; Nakayama, K; Yamanaka, A; Sakurai, T; Goto, K				Abe, Y; Nakayama, K; Yamanaka, A; Sakurai, T; Goto, K			Subtype-specific trafficking of endothelin receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; AGONIST-INDUCED INTERNALIZATION; CARBOXYL-TERMINUS; SIGNAL-TRANSDUCTION; ETB RECEPTOR; B RECEPTOR; CYTOPLASMIC TAIL; OPIOID RECEPTOR; MESSENGER-RNA; A RECEPTOR	We investigated the subcellular localization of two endothelin receptors (ETAR and ETBR), To visualize these receptors directly, the C terminus of each receptor was fused to the N terminus of enhanced green fluorescent protein (designated as ETR-EGFP). When transiently expressed in various mammalian cell lines, ETAR-EGFP was predominantly localized on the plasma membrane. By contrast, ETBR-EGFP was, independent of Ligand stimulation, predominantly localized on the intracellular vesicular structures containing Lamp-1. immunoblot analyses revealed that at steady state ETBR-EGFP was highly degraded, and its degradation was inhibited by bafilomycin A,. Antibody uptake experiments suggested that the ETBR-EGFP molecules were internalized from the plasma membrane. It is therefore likely that ETBR is first transported to the plasma membrane and then internalized, irrespective of ligand stimulation, to lysosomes where it undergoes proteolytic degradation. Exchanging the C-terminal cytoplasmic tails of the two ETRs revealed that the cytoplasmic tail is responsible for both the intracellular localization and the degradation of the receptors. Deletion of the extreme C-terminal 35 amino acids from both receptors allowed the receptor proteins to localize predominantly in the intracellular vesicles and to degrade. These observations indicate that the cytoplasmic tail of ETAR determines its plasma membrane localization. Stimulation with endothelin-l increased the amount of intact ETR-EGFP fusion proteins without increasing their de novo synthesis, suggesting that binding of endothelin-l stabilizes the ETRs.	Univ Tsukuba, Inst Basic Med Sci, Dept Pharmacol, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Gene Expt Ctr, Tsukuba, Ibaraki 3058575, Japan	University of Tsukuba; University of Tsukuba; University of Tsukuba	Goto, K (corresponding author), Univ Tsukuba, Inst Basic Med Sci, Dept Pharmacol, Tsukuba, Ibaraki 3058575, Japan.		Abe, Yoichiro/J-5576-2013; Nakayama, Kazuhisa/ABF-2924-2020; Abe, Yoichiro/AAN-8801-2020; Yamanaka, Akihiro/AAD-8641-2021	Abe, Yoichiro/0000-0001-6163-8794; Abe, Yoichiro/0000-0001-6163-8794; Yamanaka, Akihiro/0000-0001-6099-7306; Nakayama, Kazuhisa/0000-0001-7701-7183				ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; Arai H, 1997, J BIOL CHEM, V272, P25037, DOI 10.1074/jbc.272.40.25037; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; BENYA RV, 1993, J BIOL CHEM, V268, P20285; Bohm SK, 1997, J BIOL CHEM, V272, P2363; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; CHABRY J, 1995, J BIOL CHEM, V270, P2439, DOI 10.1074/jbc.270.6.2439; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; CHUN MY, 1995, J BIOL CHEM, V270, P10855, DOI 10.1074/jbc.270.18.10855; CYR CR, 1993, J BIOL CHEM, V268, P26071; Dery O, 1999, J BIOL CHEM, V274, P18524, DOI 10.1074/jbc.274.26.18524; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; Fukushima Y, 1997, J BIOL CHEM, V272, P19464, DOI 10.1074/jbc.272.31.19464; Hama H, 1997, J NEUROSCI RES, V47, P590, DOI 10.1002/(SICI)1097-4547(19970315)47:6<590::AID-JNR4>3.0.CO;2-8; HAMA H, 1992, BIOCHEM BIOPH RES CO, V186, P355, DOI 10.1016/S0006-291X(05)80815-0; HEIN L, 1994, J BIOL CHEM, V269, P27719; Horstmeyer A, 1996, J BIOL CHEM, V271, P20811, DOI 10.1074/jbc.271.34.20811; Hukovic N, 1998, J BIOL CHEM, V273, P21416, DOI 10.1074/jbc.273.33.21416; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; Ivy DD, 1998, AM J PHYSIOL-LUNG C, V274, pL535, DOI 10.1152/ajplung.1998.274.4.L535; Jockers R, 1996, J BIOL CHEM, V271, P9355, DOI 10.1074/jbc.271.16.9355; KOSHIMIZU T, 1995, BIOCHEM BIOPH RES CO, V217, P354, DOI 10.1006/bbrc.1995.2784; KOZUKA M, 1991, J BIOL CHEM, V266, P16892; LAMEH J, 1992, J BIOL CHEM, V267, P13406; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; MORO O, 1993, J BIOL CHEM, V268, P6862; Muramatsu M, 1999, AM J PHYSIOL-LUNG C, V276, pL358, DOI 10.1152/ajplung.1999.276.2.L358; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; Okamoto Y, 1997, J BIOL CHEM, V272, P21589, DOI 10.1074/jbc.272.34.21589; Owe-Young R, 1999, BRIT J PHARMACOL, V126, P103, DOI 10.1038/sj.bjp.0702280; Ozawa F, 1997, J NEUROCHEM, V69, P562; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; Pohl M, 1997, J BIOL CHEM, V272, P18179, DOI 10.1074/jbc.272.29.18179; Roos M, 1998, J BIOL CHEM, V273, P924, DOI 10.1074/jbc.273.2.924; Roth A, 1997, DNA CELL BIOL, V16, P111, DOI 10.1089/dna.1997.16.111; SAITO Y, 1991, J BIOL CHEM, V266, P23433; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAKURAI T, 1992, BIOCHEM BIOPH RES CO, V186, P342, DOI 10.1016/S0006-291X(05)80813-7; Schwartkop CP, 1999, J NEUROCHEM, V72, P1275, DOI 10.1046/j.1471-4159.1999.0721275.x; Segredo V, 1997, J NEUROCHEM, V68, P2395; Shibasaki T, 1999, BIOCHEM MOL BIOL INT, V47, P569; SHIBATA K, 1995, BRAIN RES, V692, P71, DOI 10.1016/0006-8993(95)00670-L; TAKAGI Y, 1995, J BIOL CHEM, V270, P10072, DOI 10.1074/jbc.270.17.10072; TAKASUKA T, 1994, J BIOL CHEM, V269, P7509; TAKEDA M, 1994, AM J PATHOL, V144, P473; TAKIGAWA M, 1995, EUR J BIOCHEM, V228, P102, DOI 10.1111/j.1432-1033.1995.0102o.x; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; YOSHIMURA A, 1995, KIDNEY INT, V48, P1290, DOI 10.1038/ki.1995.413; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999	57	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8664	8671		10.1074/jbc.275.12.8664	http://dx.doi.org/10.1074/jbc.275.12.8664			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722707	hybrid			2022-12-27	WOS:000086507700057
J	Field, SJ; Dobbin, PS; Cheesman, MR; Watmough, NJ; Thomson, AJ; Richardson, DJ				Field, SJ; Dobbin, PS; Cheesman, MR; Watmough, NJ; Thomson, AJ; Richardson, DJ			Purification and magneto-optical spectroscopic characterization of cytoplasmic membrane and outer membrane multiheme c-type cytochromes from Shewanella frigidimarina NCIMB400	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTREFACIENS MR-1; NITROSOMONAS-EUROPAEA; HYDROXYLAMINE OXIDOREDUCTASE; FLAVOCYTOCHROME C(3); REDOX POTENTIOMETRY; CIRCULAR-DICHROISM; FUMARATE REDUCTASE; NITRATE; HEMOPROTEINS; ALTEROMONAS	Two membranous c-type cytochromes from the Fe(III)-respiring bacterium Shewanella frigidimarina NCIMB400, CymA and OmcA, have been purified and characterized by W-visible, magnetic circular dichroism, and electron paramagnetic resonance spectroscopies. The 20-kDa CymA is a member of the NapC/NirT family of multiheme cytochromes, which are invariably anchored to the cytoplasmic membrane of Gram-negative bacteria, and are postulated to mediate electron flow between quinols and periplasmic redox proteins. CymA was found to contain four low-spin c-hemes, each with bis-His axial ligation, and midpoint reduction potentials of +10, -108, -136, and -229 mV, The 85-kDa OmcA is located at the outer membrane of S, frigidimarina NCIMB400, and as such might function as a terminal reductase via interaction with insoluble Fe(III) substrates, This putative role is supported by the finding that the protein was released into solution upon incubation of harvested intact cells at 25 degrees C, suggesting an attachment to the exterior face of the outer membrane, OmcA was revealed by magneto-optical spectrocopies to contain 10 low-spin bis-His ligated c-hemes, with the redox titer indicating two sets of near iso-potential components centered at -243 and -324 mV.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ E Anglia, Sch Chem Sci, Ctr Met Prot Biol & Spect, Norwich NR4 7TJ, Norfolk, England	University of East Anglia; University of East Anglia	Richardson, DJ (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.	d.richardson@uea.ac.uk	Richardson, David J/E-2275-2011; Watmough, Nicholas J/A-6643-2010	Watmough, Nicholas J/0000-0001-5901-6750				AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; AKAGAWAMATSUSHITA M, 1992, J GEN MICROBIOL, V138, P2275, DOI 10.1099/00221287-138-11-2275; ARCIERO DM, 1991, BIOCHEMISTRY-US, V30, P11459, DOI 10.1021/bi00112a013; Bartsch R. G., 1971, METHODS ENZYMOL, V23, P344, DOI [10.1016/S0076-6879(71)23110-4, DOI 10.1016/S0076-6879(71)23110-4]; Beliaev AS, 1998, J BACTERIOL, V180, P6292; BERKS BC, 1994, EUR J BIOCHEM, V220, P117, DOI 10.1111/j.1432-1033.1994.tb18605.x; BLYTH DJ, 1995, ANALYST, V120, P2725, DOI 10.1039/an9952002725; CHEESMAN MR, 1991, ADV INORG CHEM, V36, P201, DOI 10.1016/S0898-8838(08)60040-9; COSTA C, 1990, J BIOL CHEM, V265, P14382; DEVRIES S, 1979, BIOCHIM BIOPHYS ACTA, V546, P334; Dobbin PS, 1999, BIOCHEM J, V342, P439, DOI 10.1042/0264-6021:3420439; GADSBY PMA, 1990, J AM CHEM SOC, V112, P5003, DOI 10.1021/ja00169a002; Igarashi N, 1997, NAT STRUCT BIOL, V4, P276, DOI 10.1038/nsb0497-276; Iverson TM, 1998, NAT STRUCT BIOL, V5, P1005, DOI 10.1038/2975; LOVLEY DR, 1989, APPL ENVIRON MICROB, V55, P700, DOI 10.1128/AEM.55.3.700-706.1989; Lovley DR, 1997, FEMS MICROBIOL REV, V20, P305, DOI 10.1111/j.1574-6976.1997.tb00316.x; MCKNIGHT J, 1993, EUR J BIOCHEM, V213, P683, DOI 10.1111/j.1432-1033.1993.tb17808.x; MOORE GR, 1985, BIOCHIM BIOPHYS ACTA, V829, P83, DOI 10.1016/0167-4838(85)90071-8; MORRIS CJ, 1990, FEMS MICROBIOL LETT, V69, P259; Moser DP, 1996, APPL ENVIRON MICROB, V62, P2100, DOI 10.1128/AEM.62.6.2100-2105.1996; MYERS CR, 1992, J BACTERIOL, V174, P3429, DOI 10.1128/JB.174.11.3429-3438.1992; Myers CR, 1997, BBA-BIOMEMBRANES, V1326, P307, DOI 10.1016/S0005-2736(97)00034-5; Myers CR, 1997, LETT APPL MICROBIOL, V25, P162, DOI 10.1046/j.1472-765X.1997.00196.x; Myers CR, 1997, J BACTERIOL, V179, P1143, DOI 10.1128/jb.179.4.1143-1152.1997; MYERS CR, 1988, SCIENCE, V240, P1319, DOI 10.1126/science.240.4857.1319; Myers JM, 1998, BBA-BIOMEMBRANES, V1373, P237, DOI 10.1016/S0005-2736(98)00111-4; PRINCE RC, 1983, FEBS LETT, V163, P25, DOI 10.1016/0014-5793(83)81154-5; Reid GA, 1999, INT J SYST BACTERIOL, V49, P189, DOI 10.1099/00207713-49-1-189; Reid GA, 1998, BIOCHEM SOC T, V26, P418, DOI 10.1042/bst0260418; REISKE JS, 1967, METHOD ENZYMOL, V10, P239; RIGBY SEJ, 1988, BIOCHEM J, V256, P571, DOI 10.1042/bj2560571; Roldan MD, 1998, J BIOL CHEM, V273, P28785, DOI 10.1074/jbc.273.44.28785; Sears HJ, 1997, MICROBIOL-UK, V143, P3767, DOI 10.1099/00221287-143-12-3767; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; Tsapin AI, 1996, J BACTERIOL, V178, P6386, DOI 10.1128/jb.178.21.6386-6388.1996; Turner KL, 1999, BIOCHEMISTRY-US, V38, P3302, DOI 10.1021/bi9826308; WALKER FA, 1986, J AM CHEM SOC, V108, P5288, DOI 10.1021/ja00277a038	38	89	92	3	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8515	8522		10.1074/jbc.275.12.8515	http://dx.doi.org/10.1074/jbc.275.12.8515			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722689	hybrid			2022-12-27	WOS:000086507700039
J	Flory, E; Kunz, M; Scheller, C; Jassoy, C; Stauber, R; Rapp, UR; Ludwig, S				Flory, E; Kunz, M; Scheller, C; Jassoy, C; Stauber, R; Rapp, UR; Ludwig, S			Influenza virus-induced NF-kappa B-dependent gene expression is mediated by overexpression of viral proteins and involves oxidative radicals and activation of I kappa B kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	International Congress of Virology (ICV)	AUG, 1999	SYDNEY, AUSTRALIA				HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSCRIPTIONAL REGULATION; RAF-1 KINASE; HBX PROTEIN; A VIRUSES; CELL; INFECTION; INDUCTION; INTERLEUKIN-8; SPECIFICITY	Influenza A viruses are capable of inducing the expression of a variety of cytokine and proapoptotic genes in infected cells. The promoter regions of most of these genes harbor binding sites for the transcription factor NF-kappa B which is an important mediator of immune and inflammatory responses. Our present study is based on an observation that influenza A virus infection of cells stimulates transcriptional activation of the HN-l long terminal repeat (LTR) which harbors two regulatory NF-kappa B elements, and is aimed at identifying the molecular mechanisms involved in this process. We found that the expression of influenza virus hemagglutinin (HA), matrix protein (RI), and nucleoprotein (NP), as single factors is sufficient to transcriptionally activate the HIV-1 LTR, This process is mediated by oxidative radicals because treatment of cells with pyrrolidine dithiocarbamate, a scavenger of such radicals, abolished the transactivating ability. Expression of different influenza proteins induces activation of NF-kappa B-dependent gene expression but not transcriptional activation of an AP-1/Ets-dependent promoter, indicating a selectivity for NF-kappa B transactivation, Furthermore, influenza protein expression induces activation of I kappa B kinase (IKK), Accordingly coexpression of a catalytically inactive mutant of IKK abolishes influenza protein induced activation of NF-kappa B as web as HIV-1 LTR-dependent reporter gene expression, suggesting that IKK is an important intermediate within this signaling process, Taken together, our results show that various influenza virus proteins act as viral transactivators to modulate transcriptional activity of kappa B-element harboring promoters such as the HIV-LTR.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, MSZ, D-97078 Wurzburg, Germany; Univ Rostock, Dermatol & Venereol Klin, D-18055 Rostock, Germany; Univ Wurzburg, Inst Virol & Immunbiol, D-97078 Wurzburg, Germany; Univ Erlangen Nurnberg, Inst Klin & Mol Virol, D-91054 Erlangen, Germany	University of Wurzburg; University of Rostock; University of Wurzburg; University of Erlangen Nuremberg	Ludwig, S (corresponding author), Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, MSZ, Versbacherstr 5, D-97078 Wurzburg, Germany.			Ludwig, Stephan/0000-0003-4490-3052; Stauber, Roland/0000-0002-1341-4523				Anchlan D, 1996, ARCH VIROL, V141, P1553, DOI 10.1007/BF01718254; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baumann B, 1998, J BIOL CHEM, V273, P11448, DOI 10.1074/jbc.273.19.11448; Brown IH, 1997, J GEN VIROL, V78, P553, DOI 10.1099/0022-1317-78-3-553; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHOI AMK, 1992, FEBS LETT, V309, P327, DOI 10.1016/0014-5793(92)80799-M; DETJEN BM, 1987, J VIROL, V61, P16, DOI 10.1128/JVI.61.1.16-22.1987; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; DORN P, 1990, J VIROL, V64, P1616, DOI 10.1128/JVI.64.4.1616-1624.1990; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Flory E, 1998, J VIROL, V72, P2788, DOI 10.1128/JVI.72.4.2788-2794.1998; Flory E, 1996, J VIROL, V70, P2260, DOI 10.1128/JVI.70.4.2260-2268.1996; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; GRILLI M, 1993, INT REV CYTOL, V143, P1; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; Hoffmeyer A, 1999, J BIOL CHEM, V274, P4319, DOI 10.1074/jbc.274.7.4319; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Israel N, 1997, CELL MOL LIFE SCI, V53, P864, DOI 10.1007/s000180050106; Jacque JM, 1996, J VIROL, V70, P2930; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; Knobil K, 1998, AM J PHYSIOL-LUNG C, V274, pL134, DOI 10.1152/ajplung.1998.274.1.L134; Krug RM., 1989, INFLUENZA VIRUSES, P39, DOI [10.1007/978-1-4613-0811-9_2, DOI 10.1007/978-1-4613-0811-9_2]; Lamb R. A., 1996, FIELDS VIROLOGY, P1353; LAMB RA, 1981, P NATL ACAD SCI-BIOL, V78, P4170, DOI 10.1073/pnas.78.7.4170; LAMB RA, 1980, P NATL ACAD SCI-BIOL, V77, P1857, DOI 10.1073/pnas.77.4.1857; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Ludwig S, 1999, VIRAL IMMUNOL, V12, P175, DOI 10.1089/vim.1999.12.175; LUDWIG S, 1995, VIROLOGY, V212, P555, DOI 10.1006/viro.1995.1513; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OCHIAI H, 1993, J VIROL, V67, P6811, DOI 10.1128/JVI.67.11.6811-6814.1993; PAHL HL, 1995, J VIROL, V69, P1480, DOI 10.1128/JVI.69.3.1480-1484.1995; Pahl HL, 1996, J CELL BIOL, V132, P511, DOI 10.1083/jcb.132.4.511; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RICHARDSON JC, 1991, ARCH VIROL, V116, P69, DOI 10.1007/BF01319232; SCHRECK R, 1992, J VIROL, V66, P6288, DOI 10.1128/JVI.66.11.6288-6293.1992; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sprenger H, 1996, J EXP MED, V184, P1191, DOI 10.1084/jem.184.3.1191; Stauber RH, 1999, BIOCHEM BIOPH RES CO, V258, P695, DOI 10.1006/bbrc.1999.0511; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Ueda A, 1997, J BIOL CHEM, V272, P31092, DOI 10.1074/jbc.272.49.31092; Zandi E, 1999, MOL CELL BIOL, V19, P4547	49	117	125	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8307	8314		10.1074/jbc.275.12.8307	http://dx.doi.org/10.1074/jbc.275.12.8307			8	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722660	hybrid			2022-12-27	WOS:000086507700010
J	Kang, JS; Kim, JS				Kang, JS; Kim, JS			Zinc finger proteins as designer transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; GENE-EXPRESSION; MAMMALIAN-CELLS; IN-VIVO; SELECTION; REPRESSION; SEQUENCE; PEPTIDE; SYSTEM; RECOGNITION	Recent progress in the design and selection of novel zinc finger proteins with desired DNA binding specificities now allows construction of tailor-made DNA-binding proteins that specifically recognize almost any predetermined DNA sequence. Such novel or "designer" zinc finger proteins with desired DNA binding specificities can serve as efficient transcription factors in various mammalian cell Lines. In addition, they may be broadly useful in the regulation of endogenous genes in transgenic organisms and eventually in gene therapy applications. In this report, we use a series of transient and stable transfection experiments to demonstrate that the expression of a target gene can be controlled by changing the in vivo concentration of designer zinc finger proteins in a dose-dependent manner. We also report that designer zinc finger proteins can access their binding sites integrated into the genome and function as potent transcription factors. Our results suggest that designer zinc finger transcription factors that specifically recognize appropriate sites in the promoter of a target gene may have broad applications in the post-genomic era.	Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Changan Ku, Suwon, South Korea; Sungkyunkwan Univ, Sch Med, Toolgen Inc, Changan Ku, Suwon, South Korea	Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU)	Kim, JS (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Changan Ku, 300 Chunchun Dong, Suwon, South Korea.	jinsookim@netsgo.com	KIM, Jin-Soo/M-6918-2013	KIM, Jin-Soo/0000-0003-4847-1306				Beerli RR, 1998, P NATL ACAD SCI USA, V95, P14628, DOI 10.1073/pnas.95.25.14628; Cepek KL, 1996, GENE DEV, V10, P2079, DOI 10.1101/gad.10.16.2079; Choo Y, 1997, J MOL BIOL, V273, P525, DOI 10.1006/jmbi.1997.1339; Choo Y, 1998, NUCLEIC ACIDS RES, V26, P554, DOI 10.1093/nar/26.2.554; CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; DESJARLAIS JR, 1992, PROTEINS, V12, P101, DOI 10.1002/prot.340120202; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Greisman HA, 1997, SCIENCE, V275, P657, DOI 10.1126/science.275.5300.657; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; Kamiuchi T, 1998, BIOCHEMISTRY-US, V37, P13827, DOI 10.1021/bi9811112; KIM JS, 1994, ANAL BIOCHEM, V219, P165, DOI 10.1006/abio.1994.1251; Kim JS, 1997, J BIOL CHEM, V272, P29795, DOI 10.1074/jbc.272.47.29795; Kim JS, 1998, P NATL ACAD SCI USA, V95, P2812, DOI 10.1073/pnas.95.6.2812; Kim JS, 1997, P NATL ACAD SCI USA, V94, P3616, DOI 10.1073/pnas.94.8.3616; KIM JS, 1993, PROTEIN SCI, V2, P348; Liu Q, 1997, P NATL ACAD SCI USA, V94, P5525, DOI 10.1073/pnas.94.11.5525; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; Rivera VM, 1996, NAT MED, V2, P1028, DOI 10.1038/nm0996-1028; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; Tu GC, 1998, J BIOL CHEM, V273, P25125, DOI 10.1074/jbc.273.39.25125; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344	28	47	81	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8742	8748		10.1074/jbc.275.12.8742	http://dx.doi.org/10.1074/jbc.275.12.8742			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722717	hybrid			2022-12-27	WOS:000086507700067
J	Papamichos-Chronakis, M; Conlan, RS; Gounalaki, N; Copf, T; Tzamarias, D				Papamichos-Chronakis, M; Conlan, RS; Gounalaki, N; Copf, T; Tzamarias, D			Hrs1/Med3 is a Cyc8-Tup1 corepressor target in the RNA polymerase II holoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXY-TERMINAL DOMAIN; TRANSCRIPTIONAL REGULATION; SACCHAROMYCES-CEREVISIAE; YEAST; COMPLEX; REPRESSION; PROTEINS; ACTIVATION; RECRUITMENT; MEDIATOR	The Srb/Mediator, a multisubunit subcomplex of the RNA polymerase II (RNA pol II) holoenzyme has been proposed to function as a control panel regulating transcription in response to gene-specific activator proteins. In this report, we identify the Mediator subunit Hrs1/Med3 as a physical target for Cyc8-Tup1, a yeast transcriptional corepressor. Two-hybrid and glutathione S-transferase interaction assays show that Hrs1 can associate directly with Cyc8-Tup1, Moreover, affinity chromatography experiments, using yeast protein extracts, reveal that Cyc8-Tup1 co-purifies with Hrs1 and with additional Mediator subunits in a Hrs1 dependent manner. These observations suggest that Cyc8-Tup1 contacts the Mediator complex via its interaction with the Hrs1 subunit, Further on, genetic analysis indicates that increased Hrs1 dosage can alleviate Cyc8-Tup1-mediated repression, suggesting that Hrs1/Mediator's function is inhibited upon its interaction with Cyc8-Tup1. Finally, artificial holoenzyme recruitment assays support a model by which the contact between the corepressor and the Hrs1/Mediator may prevent pol II holoenzyme recruitment to the core promoter. These data, together with previous genetic evidence, establish a functional and physical interaction between the Cyc8-Tup1 corepressor and the RNA pol II holoenzyme and support a central role of the Mediator complex in transcriptional repression.	Univ Crete, Inst Mol Biol & Biotechnol, Fdn Res & Technol, GR-71110 Iraklion, Crete, Greece; Univ Crete, Dept Biol, GR-71110 Iraklion, Crete, Greece	University of Crete; University of Crete	Tzamarias, D (corresponding author), Univ Crete, Inst Mol Biol & Biotechnol, Fdn Res & Technol, POB 1527,Vassilika Vouton, GR-71110 Iraklion, Crete, Greece.			Papamichos-Chronakis, Emmanouil/0000-0002-4144-2070; Conlan, Robert/0000-0002-2562-3461				BANIAHMAD C, 1994, BIOTECHNIQUES, V16, P194; Bjorklund S, 1996, TRENDS BIOCHEM SCI, V21, P335, DOI 10.1016/0968-0004(96)10051-7; Chao DM, 1996, NATURE, V380, P82, DOI 10.1038/380082a0; CHEN SM, 1993, MOL CELL BIOL, V13, P831, DOI 10.1128/MCB.13.2.831; Conlan RS, 1999, J BIOL CHEM, V274, P205, DOI 10.1074/jbc.274.1.205; COVITZ PA, 1994, GENETICS, V138, P577; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gaudreau L, 1998, MOL CELL, V1, P913, DOI 10.1016/S1097-2765(00)80090-8; Greenblatt J, 1997, CURR OPIN CELL BIOL, V9, P310, DOI 10.1016/S0955-0674(97)80002-6; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; Huang L, 1997, MOL CELL BIOL, V17, P6555, DOI 10.1128/MCB.17.11.6555; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; Keaveney M, 1998, MOL CELL, V1, P917, DOI 10.1016/S1097-2765(00)80091-X; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Komachi K, 1997, MOL CELL BIOL, V17, P6023, DOI 10.1128/MCB.17.10.6023; Kuchin S, 1998, MOL CELL BIOL, V18, P1163, DOI 10.1128/MCB.18.3.1163; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Lee YC, 1997, MOL CELL BIOL, V17, P4622, DOI 10.1128/MCB.17.8.4622; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; Piruat JI, 1997, GENETICS, V147, P1585; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Pugh BF, 1996, CURR OPIN CELL BIOL, V8, P303, DOI 10.1016/S0955-0674(96)80002-0; Ranish JA, 1999, GENE DEV, V13, P49, DOI 10.1101/gad.13.1.49; Song WJ, 1996, MOL CELL BIOL, V16, P115; Song WJ, 1998, EMBO J, V17, P5757, DOI 10.1093/emboj/17.19.5757; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; TREITEL MA, 1995, P NATL ACAD SCI USA, V92, P3132, DOI 10.1073/pnas.92.8.3132; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; WAHI M, 1995, GENETICS, V140, P79	43	83	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8397	8403		10.1074/jbc.275.12.8397	http://dx.doi.org/10.1074/jbc.275.12.8397			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722672	hybrid			2022-12-27	WOS:000086507700022
J	Ward, JL; Sherali, A; Mo, ZP; Tse, CM				Ward, JL; Sherali, A; Mo, ZP; Tse, CM			Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells - ENT2 exhibits a low affinity for guanosine and cytidine but a high affinity for inosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; ADENOSINE; LINE; EI; FIBROBLASTS; PROTEINS; GROWTH; PK-15; RAT	We stably transfected the cloned human equilibrative nucleoside transporters 1 and 2 (hENT1 and hENT2) into nucleoside transporter-deficient PK15NTD cells. Although hENT1 and hENT2 are predicted to be 50-kDa proteins, hENT1 runs as 40 kDa and hENT2 migrates as 50 and 47 kDa on SDS-polyacrylamide gel electrophoresis. Peptide N-glycosidase F and endoglycosidase H deglycosylate hENT1 to 37 kDa and hENT2 to 45 kDa, With hENT1 being more sensitive, there is a 7000-fold and 71-fold difference in sensitivity to nitrobenzylthioinosine (NBMPR) (IC50, 0.4 +/- 0.1 nM versus 2.8 +/- 0.3 mu M) and dipyridamole (IC50, 5.0 +/- 0.9 nM versus 356 +/- 13 nM), respectively. [H-3]NBMPR binds to ENT1 cells with a high affinity K-d of 0.377 +/- 0.098 nM, and each ENT1 cell has 34,000 transporters with a turnover number of 46 molecules/s for uridine, Although both transporters are broadly selective, hENT2 is a generally low affinity nucleoside transporter with 2.6-, 2.8-, 7.7-, and 19.3-fold lower affinity than hENT1 for thymidine, adenosine, cytidine, and guanosine, respectively. In contrast, the affinity of hENT2 for inosine is 4-fold higher than hENT1, The nucleobase hypoxanthine inhibits [H-3]uridine uptake by hENT2 but has minimal effect on hENT1, Taken together, these results suggest that hENT2 might be important in transporting adenosine and its metabolites (inosine and hypoxanthine) in tissues such as skeletal muscle where ENT2 is predominantly expressed.	Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21205 USA	Johns Hopkins University	Tse, CM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, 918 Ross Res Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.				NIDDK NIH HHS [K08DK02737] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002737] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAN JM, 1992, BIOCHIM BIOPHYS ACTA, V1108, P67, DOI 10.1016/0005-2736(92)90115-3; ARAN JM, 1992, BIOCHIM BIOPHYS ACTA, V1110, P51, DOI 10.1016/0005-2736(92)90293-U; BELT JA, 1988, J BIOL CHEM, V263, P13819; Cass CE, 1998, BIOCHEM CELL BIOL, V76, P761, DOI 10.1139/bcb-76-5-761; CRAWFORD CR, 1990, J BIOL CHEM, V265, P9732; Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; HAMMOND JR, 1992, BIOCHEM J, V287, P431, DOI 10.1042/bj2870431; HE YP, 1994, J NUTR, V124, P1942, DOI 10.1093/jn/124.10.1942; JARVIS SM, 1988, BIOCHEM J, V249, P383, DOI 10.1042/bj2490383; KWONG FYP, 1986, BIOCHEM J, V240, P349, DOI 10.1042/bj2400349; MACKINNON AM, 1973, BIOCHIM BIOPHYS ACTA, V319, P1, DOI 10.1016/0005-2787(73)90034-8; Mun EC, 1998, AM J PHYSIOL-GASTR L, V274, pG261, DOI 10.1152/ajpgi.1998.274.2.G261; Osses N, 1996, BIOCHEM J, V317, P843, DOI 10.1042/bj3170843; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V947, P405, DOI 10.1016/0304-4157(88)90002-0; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; SHI MM, 1984, BIOCHEM BIOPH RES CO, V118, P594, DOI 10.1016/0006-291X(84)91344-5; STROHMEIER GR, 1995, J BIOL CHEM, V270, P2387, DOI 10.1074/jbc.270.5.2387; Tally KJ, 1996, SURGERY, V120, P248, DOI 10.1016/S0039-6060(96)80295-9; TSE CM, 1994, BIOCHEMISTRY-US, V33, P12954, DOI 10.1021/bi00248a003; Vickers MF, 1999, BIOCHEM J, V339, P21, DOI 10.1042/0264-6021:3390021; Ward JL, 1999, BBA-BIOMEMBRANES, V1419, P15, DOI 10.1016/S0005-2736(99)00045-0; WILLIAMS JB, 1995, BIOCHEM BIOPH RES CO, V213, P325, DOI 10.1006/bbrc.1995.2133; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423; Yip JW, 1997, J BIOL CHEM, V272, P18473, DOI 10.1074/jbc.272.29.18473	27	238	245	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8375	8381		10.1074/jbc.275.12.8375	http://dx.doi.org/10.1074/jbc.275.12.8375			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722669	hybrid			2022-12-27	WOS:000086507700019
J	Cowley, DJ; Moore, YR; Darling, DS; Joyce, PBM; Gorr, SU				Cowley, DJ; Moore, YR; Darling, DS; Joyce, PBM; Gorr, SU			N- and C-terminal domains direct cell type-specific sorting of chromogranin A to secretory granules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; DISULFIDE-BONDED LOOP; CARBOXYPEPTIDASE-E; SECRETOGRANIN-II; REGULATED PATHWAY; PROTEIN SECRETION; AGGREGATION; RECEPTOR; PH; PROHORMONES	Chromogranins are a family of regulated secretory proteins that are stored in secretory granules in endocrine and neuroendocrine cells and released in response to extracellular stimulation (regulated secretion). A conserved N-terminal disulfide bond is necessary for sorting of chromogranins in neuroendocrine PC12 cells. Surprisingly, this disulfide bond is not necessary for sorting of chromogranins in endocrine GH4C1 cells, To investigate the sorting mechanism in GH4C1 cells, we made several mutant forms removing highly conserved N- and C-terminal regions of bovine chromogranin A. Removing the conserved N-terminal disulfide bond and the conserved C-terminal dimerization and tetramerization domain did not affect the sorting of chromogranin A to the regulated secretory pathway. In contrast, removing the C-terminal 90 amino acids of chromogranin A caused rerouting to the constitutive secretory pathway and impaired aggregation properties as compared with wildtype chromogranin A, Since this mutant was sorted to the regulated secretory pathway in PC12 cells, these results demonstrate that chromogranins contain independent N- and C-terminal sorting domains that function in a cell type-specific manner. Moreover, this is the first evidence that low pH/calcium-induced aggregation is necessary for sorting of a chromogranin to the regulated secretory pathway of endocrine cells.	Univ Louisville, Dept Mol Cellular & Craniofacial Biol, Louisville, KY 40292 USA; Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40292 USA; Concordia Univ, Dept Chem & Biochem, Montreal, PQ H3G 1M8, Canada; Concordia Univ, Ctr Struct & Funct Genomics, Montreal, PQ H3G 1M8, Canada	University of Louisville; University of Louisville; Concordia University - Canada; Concordia University - Canada	Gorr, SU (corresponding author), Univ Louisville, Dept Mol Cellular & Craniofacial Biol, Louisville, KY 40292 USA.		Darling, Douglas S/D-4573-2009; Joyce, Paul/K-3989-2013	Darling, Douglas/0000-0002-9039-1169	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007254] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053367] Funding Source: NIH RePORTER; NIDCR NIH HHS [2 T32 DE 07254-06] Funding Source: Medline; NIDDK NIH HHS [1 R01 DK 53367-01] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Canaff L, 1996, P NATL ACAD SCI USA, V93, P9483, DOI 10.1073/pnas.93.18.9483; CHANAT E, 1994, FEBS LETT, V351, P225, DOI 10.1016/0014-5793(94)00865-5; CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; COHN DV, 1995, J NUTR, V125, pS2015; Cool DR, 1998, MOL CELL ENDOCRINOL, V139, P7, DOI 10.1016/S0303-7207(98)00081-1; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; GERDES HH, 1989, J BIOL CHEM, V264, P12009; Glombik MM, 1999, EMBO J, V18, P1059, DOI 10.1093/emboj/18.4.1059; GORR SU, 1987, BONE MINER, V2, P251; Gorr SU, 1999, BIOCHEM BIOPH RES CO, V257, P545, DOI 10.1006/bbrc.1999.0504; Gorr SU, 1999, AM J PHYSIOL-CELL PH, V277, pC121, DOI 10.1152/ajpcell.1999.277.1.C121; GORR SU, 1995, FEBS LETT, V361, P8, DOI 10.1016/0014-5793(95)00142-V; Gorr SU, 1996, J BIOL CHEM, V271, P3575; GORR SU, 1989, AM J PHYSIOL, V257, pR247; HINKLE PM, 1992, ENDOCRINOLOGY, V130, P3503, DOI 10.1210/en.130.6.3503; JUNG LJ, 1993, J CELL BIOL, V121, P11, DOI 10.1083/jcb.121.1.11; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; Klumperman J, 1996, J NEUROSCI, V16, P7930; Kromer A, 1998, J CELL BIOL, V140, P1331, DOI 10.1083/jcb.140.6.1331; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Normant E, 1998, ENDOCRINOLOGY, V139, P2137, DOI 10.1210/en.139.4.2137; PARMER RJ, 1993, J CLIN INVEST, V92, P1042, DOI 10.1172/JCI116609; SACHS E, 1992, AM J PHYSIOL, V262, pG257, DOI 10.1152/ajpgi.1992.262.2.G257; SCAMMELL JG, 1986, ENDOCRINOLOGY, V119, P1543, DOI 10.1210/endo-119-4-1543; Shennan KIJ, 1996, BIOCHEM SOC T, V24, P535, DOI 10.1042/bst0240535; Thiele C, 1997, CURR BIOL, V7, pR496, DOI 10.1016/S0960-9822(06)00247-8; Thiele C, 1998, SEMIN CELL DEV BIOL, V9, P511, DOI 10.1006/scdb.1998.0259; Thiele C, 1998, J BIOL CHEM, V273, P1223, DOI 10.1074/jbc.273.2.1223; Turquier V, 1999, ENDOCRINOLOGY, V140, P4104, DOI 10.1210/en.140.9.4104; Yoo SH, 1996, J BIOL CHEM, V271, P17041, DOI 10.1074/jbc.271.29.17041; YOO SH, 1993, BIOCHEMISTRY-US, V32, P8816, DOI 10.1021/bi00085a012; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	36	44	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7743	7748		10.1074/jbc.275.11.7743	http://dx.doi.org/10.1074/jbc.275.11.7743			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713086	hybrid			2022-12-27	WOS:000085913300046
J	Godber, BLJ; Doel, JJ; Sapkota, GP; Blake, DR; Stevens, CR; Eisenthal, R; Harrison, R				Godber, BLJ; Doel, JJ; Sapkota, GP; Blake, DR; Stevens, CR; Eisenthal, R; Harrison, R			Reduction of nitrite to nitric oxide catalyzed by xanthine oxidoreductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAT-GLOBULE MEMBRANE; SUPEROXIDE-DISMUTASE; RHEUMATIC DISEASES; ESCHERICHIA-COLI; ELEVATED LEVELS; BINDING; NITRATE; LOCALIZATION; INHIBITORS; MOLYBDENUM	Xanthine oxidase (XO) was shown to catalyze the reduction of nitrite to nitric oxide (NO), under anaerobic conditions, in the presence of either NADH or xanthine as reducing substrate. NO production was directly demonstrated by ozone chemiluminescence and showed stoichiometry of approximately 2:1 versus NADH depletion. With xanthine as reducing substrate, the kinetics of NO production were complicated by enzyme inactivation, resulting from NO-induced conversion of XO to its relatively inactive desulfo-form. Steady-state kinetic parameters were determined spectrophotametrically for urate production and NADH oxidation catalyzed by XO and xanthine dehydrogenase in the presence of nitrite under anaerobic conditions. pH optima for anaerobic NO production catalyzed by XO in the presence of nitrite were 7.0 for NADH and less than or equal to 6.0 for xanthine. Involvement of the molybdenum site of XO in nitrite reduction was shown by the fact that alloxanthine inhibits xanthine oxidation competitively with nitrite. Strong preference for Mo=S over Mo=O was shown by the relatively very low NADH-nitrite reductase activity shown by desulfo-enzyme. The FAD site of XO was shown not to influence nitrite reduction in the presence of xanthine, although it was clearly involved when NADH was the reducing substrate, Apparent production of NO decreased with increasing oxygen tensions, consistent with reaction of NO with XO-generated superoxide, It is proposed that XO-derived NO fulfills a bactericidal role in the digestive tract.	Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; Univ Bath, Dept Postgrad Med, Bath BA2 7AY, Avon, England	University of Bath; University of Bath	Harrison, R (corresponding author), Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England.	bssrh@bath.ac.uk	Sapkota, Gopal/C-7300-2014	Sapkota, Gopal/0000-0001-9931-3338				ADACHI T, 1993, BIOCHEM J, V289, P523, DOI 10.1042/bj2890523; ADACHI T, 1992, ARCH BIOCHEM BIOPHYS, V297, P155, DOI 10.1016/0003-9861(92)90654-F; Arnet UA, 1996, J BIOL CHEM, V271, P15069, DOI 10.1074/jbc.271.25.15069; AVIS PG, 1956, J CHEM SOC, P1219, DOI 10.1039/jr9560001219; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BENJAMIN N, 1994, NATURE, V368, P502, DOI 10.1038/368502a0; BRAY RC, 1988, Q REV BIOPHYS, V21, P299, DOI 10.1017/S0033583500004479; Bray RC., 1975, ENZYMES, V12, P299, DOI DOI 10.1016/S1874-6047(08)60229-2; BRILEY MS, 1975, BIOCHEM J, V147, P417, DOI 10.1042/bj1470417; BULKLEY GB, 1994, LANCET, V344, P934, DOI 10.1016/S0140-6736(94)92276-4; Cole J, 1996, FEMS MICROBIOL LETT, V136, P1; CORNISHB.A, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143; Cote CG, 1996, AM J PHYSIOL-LUNG C, V271, pL869, DOI 10.1152/ajplung.1996.271.5.L869; Crawford MJ, 1998, J BIOL CHEM, V273, P12543, DOI 10.1074/jbc.273.20.12543; DEMOSS JA, 1991, J BACTERIOL, V173, P3303, DOI 10.1128/jb.173.11.3303-3310.1991; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; Dixon M, 1924, BIOCHEM J, V18, P989, DOI 10.1042/bj0180989; DUNCAN C, 1995, NAT MED, V1, P546, DOI 10.1038/nm0695-546; Fang FC, 1997, J CLIN INVEST, V99, P2818, DOI 10.1172/JCI119473; Farrell AJ, 1996, ANN RHEUM DIS, V55, P7, DOI 10.1136/ard.55.1.7; FARRELL AJ, 1992, ANN RHEUM DIS, V51, P1219, DOI 10.1136/ard.51.11.1219; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; FRIDOVICH I, 1962, J BIOL CHEM, V237, P916; GOLDSTEIN S, 1995, FREE RADICAL BIO MED, V19, P505, DOI 10.1016/0891-5849(95)00034-U; GRANGER DL, 1990, J CLIN INVEST, V85, P264, DOI 10.1172/JCI114422; HARRISON R, 1990, CARDIOSCIENCE, V1, P183; HASSOUN PM, 1995, AM J PHYSIOL-LUNG C, V268, pL809, DOI 10.1152/ajplung.1995.268.5.L809; HORECKER BL, 1948, J BIOL CHEM, V175, P385; Houston M, 1999, J BIOL CHEM, V274, P4985, DOI 10.1074/jbc.274.8.4985; HUNT J, 1992, J BIOL CHEM, V267, P21479; Ichimori K, 1999, J BIOL CHEM, V274, P7763, DOI 10.1074/jbc.274.12.7763; Jann K., 1997, P113; JARASCH ED, 1981, CELL, V25, P67, DOI 10.1016/0092-8674(81)90232-4; KHAN AU, 1995, CHEM BIOL, V2, P437; Kim SO, 1999, FEBS LETT, V445, P389, DOI 10.1016/S0014-5793(99)00157-X; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KOMAI H, 1969, J BIOL CHEM, V244, P1692; KOOIJ A, 1994, HEPATOLOGY, V19, P1488, DOI 10.1002/hep.1840190626; KOOIJ A, 1992, VIRCHOWS ARCH B, V62, P143, DOI 10.1007/BF02899676; MASSEY V, 1970, J BIOL CHEM, V245, P6595; MASSEY V, 1970, J BIOL CHEM, V245, P2837; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MIESEL R, 1993, INFLAMMATION, V17, P551, DOI 10.1007/BF00914193; Millar TM, 1998, FEBS LETT, V427, P225, DOI 10.1016/S0014-5793(98)00430-X; Miyamoto Y, 1996, P SOC EXP BIOL MED, V211, P366; Mohacsi A, 1996, BBA-MOL BASIS DIS, V1316, P210, DOI 10.1016/0925-4439(96)00027-0; MONCADA S, 1991, PHARMACOL REV, V43, P109; ODONNELL VB, 1994, MOL PHARMACOL, V46, P778; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; PARKS DA, 1986, ACTA PHYSIOL SCAND, V126, P87; Patetsios P, 1996, ANN NY ACAD SCI, V800, P243, DOI 10.1111/j.1749-6632.1996.tb33318.x; PATTON S, 1975, BIOCHIM BIOPHYS ACTA, V415, P273, DOI 10.1016/0304-4157(75)90011-8; PORRAS AG, 1982, J BIOL CHEM, V257, P1617; Radi R, 1997, ARCH BIOCHEM BIOPHYS, V339, P125, DOI 10.1006/abbi.1996.9844; ROBINS RK, 1985, J HETEROCYCLIC CHEM, V22, P601, DOI 10.1002/jhet.5570220303; Rouquette M, 1998, FEBS LETT, V426, P397, DOI 10.1016/S0014-5793(98)00385-8; ROWE JJ, 1994, MOL MICROBIOL, V12, P579, DOI 10.1111/j.1365-2958.1994.tb01044.x; Sanderson WG, 1997, AQUAT CONSERV, V7, P245; SERGEEV N S, 1985, Journal of Applied Biochemistry, V7, P86; SHAMMAA MH, 1973, DIGEST DIS, V18, P15; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; SWAIN J, 1995, FEBS LETT, V368, P513, DOI 10.1016/0014-5793(95)00726-P; VANDENMUNCKHOF RJM, 1995, HISTOCHEM J, V27, P897; VARANI J, 1994, SHOCK, V2, P311, DOI 10.1097/00024382-199411000-00001; Vickers S, 1998, SURGERY, V124, P551, DOI 10.1067/msy.1998.89892; WAHL RC, 1982, J BIOL CHEM, V257, P1354; WEINBROUM A, 1995, AM J PHYSIOL-GASTR L, V268, pG988, DOI 10.1152/ajpgi.1995.268.6.G988; WESTERFELD WW, 1959, J BIOL CHEM, V234, P1897; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; Winyard P G, 1997, Adv Pharmacol, V38, P403; Yamamoto T, 1996, J CHROMATOGR B, V681, P395, DOI 10.1016/0378-4347(96)00071-0; Zhang Z, 1998, BIOCHEM BIOPH RES CO, V249, P767, DOI 10.1006/bbrc.1998.9226	74	302	320	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7757	7763		10.1074/jbc.275.11.7757	http://dx.doi.org/10.1074/jbc.275.11.7757			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713088	hybrid			2022-12-27	WOS:000085913300048
J	Le Menuet, D; Viengchareun, S; Penfornis, P; Walker, F; Zennaro, MC; Lombes, M				Le Menuet, D; Viengchareun, S; Penfornis, P; Walker, F; Zennaro, MC; Lombes, M			Targeted oncogenesis reveals a distinct tissue-specific utilization of alternative promoters of the human mineralocorticoid receptor gene in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-2; ALDOSTERONE ACTION; EXPRESSION; CLONING; PROTEIN; TRANSCRIPTION; LOCALIZATION; MESSENGER; ISOFORMS; ENZYME	The human mineralocorticoid receptor (hMR) is a nuclear receptor mediating aldosterone action, whose expression is driven by two alternative promoters, P1 and P2, flanking the two first 5'-untranslated exons. In vivo characterization of hMR regulatory regions was performed by targeted oncogenesis in mice using PI or Pa directing expression of the large T antigen of SV40 (TAg). While transgenic P1.TAg founders rapidly developed lethal hibernomas from brown fat, cerebral primitive neuroectodermal tumors and facial leiomyosarcomas occurred in P2.TAg mice. Quantitative analyses of mouse MR (mMR) and transgene expression indicate that P1 promoter was transcriptionally active in all MR-expressing tissues, directing strong TAg expression in testis and salivary glands, moderate in lung brain, uterus, liver, and heart but, unlike mMR, rather low in colon and kidney. Importantly, the renal transgene expression colocalized with mMR in the distal nephron. In contrast, P2 promoter was approximately 10 times less potent than P1, with no activity in the brain and colon. Several immortalized cell lines were established from both neoplastic and normal tissues of transgenic mice. These cells exhibited differentiated characteristics and maintained MR expression, thus providing useful models for further studies exploring the widespread expression and functions of MR. Our results demonstrate that hMR gene expression in vivo is controlled by complex regulatory mechanisms involving distinct tissue-specific utilization of alternative promoters.	Fac Xavier Bichat, INSERM U478, Inst Federatif Rech Cellules Epitheliales, F-75870 Paris 18, France; Hop Bichat Claude Bernard, Serv Anatomopathol, F-75018 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite	Lombes, M (corresponding author), Fac Xavier Bichat, INSERM U478, Inst Federatif Rech Cellules Epitheliales, 16 Rue Henri Huchard,BP416, F-75870 Paris 18, France.	mlombes@bichat.inserm.fr	Zennaro, Maria-Christina/G-2841-2013; Viengchareun, Say/GOV-6812-2022; Viengchareun, Say/M-6612-2017; Le Menuet, Damien/B-1489-2019; Lombes, Marc/L-5933-2018; Penfornis, Patrice/J-2545-2016	Zennaro, Maria-Christina/0000-0001-5449-9191; Le Menuet, Damien/0000-0002-0802-7190; Lombes, Marc/0000-0003-3189-023X; viengchareun, say/0000-0003-4280-3250; Penfornis, Patrice/0000-0001-7703-0070				ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, pR11, DOI 10.1016/0303-7207(94)90176-7; ANDERSON NS, 1976, ENDOCRINOLOGY, V98, P676, DOI 10.1210/endo-98-3-676; ARMANINI D, 1985, AM J PHYSIOL, V248, pE388, DOI 10.1152/ajpendo.1985.248.3.E388; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; Bonvalet JP, 1998, KIDNEY INT, pS49; BRIAND P, 1995, KIDNEY INT, V47, P388, DOI 10.1038/ki.1995.51; Brown RW, 1996, ENDOCRINOLOGY, V137, P794, DOI 10.1210/en.137.2.794; Condon J, 1998, J CLIN ENDOCR METAB, V83, P4490, DOI 10.1210/jc.83.12.4490; Couette B, 1998, MOL ENDOCRINOL, V12, P855, DOI 10.1210/me.12.6.855; Couette B, 1996, BIOCHEM J, V315, P421, DOI 10.1042/bj3150421; Eckert RL, 1996, CELL DEATH DIFFER, V3, P373; EDWARDS CRW, 1988, LANCET, V2, P986, DOI 10.1016/S0140-6736(88)90742-8; Escoubet B, 1996, AM J PHYSIOL-CELL PH, V270, pC1343, DOI 10.1152/ajpcell.1996.270.5.C1343; Fagart J, 1998, EMBO J, V17, P3317, DOI 10.1093/emboj/17.12.3317; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; FUNG KM, 1995, J NEUROPATH EXP NEUR, V54, P285, DOI 10.1097/00005072-199505000-00001; Furth PA, 1998, DEV BIOL STAND, V94, P281; Jarrard JA, 1998, CANCER RES, V58, P5582; Kaabache T, 1995, ANAL BIOCHEM, V232, P225, DOI 10.1006/abio.1995.0011; KROZOWSKI ZS, 1989, ENDOCRINOLOGY, V125, P192, DOI 10.1210/endo-125-1-192; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LOMBES M, 1993, BIOCHEM J, V292, P577, DOI 10.1042/bj2920577; LOMBES M, 1995, CIRCULATION, V92, P175, DOI 10.1161/01.CIR.92.2.175; LOMBES M, 1990, P NATL ACAD SCI USA, V87, P1086, DOI 10.1073/pnas.87.3.1086; LOMBES M, 1992, CIRC RES, V71, P503, DOI 10.1161/01.RES.71.3.503; LOMBES M, 1994, ENDOCRINOLOGY, V135, P834, DOI 10.1210/en.135.3.834; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; NAGY P, 1994, J CELL BIOL, V126, P223, DOI 10.1083/jcb.126.1.223; PEARCE P, 1987, CLIN EXP PHARMACOL P, V14, P859, DOI 10.1111/j.1440-1681.1987.tb02422.x; ROSS SR, 1992, P NATL ACAD SCI USA, V89, P7561, DOI 10.1073/pnas.89.16.7561; SAMBROOK J, 1989, MOL CLOLING LAB MANU; SASANO H, 1992, J ENDOCRINOL, V132, P305, DOI 10.1677/joe.0.1320305; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; SPICER AP, 1991, J BIOL CHEM, V266, P15099; WILKIE TM, 1994, ONCOGENE, V9, P2889; Zennaro MC, 1998, J CLIN INVEST, V101, P1254, DOI 10.1172/JCI1915; ZENNARO MC, 1995, J BIOL CHEM, V270, P21016, DOI 10.1074/jbc.270.36.21016; Zennaro MC, 1997, J CLIN ENDOCR METAB, V82, P1345, DOI 10.1210/jc.82.5.1345; Zennaro MC, 1996, MOL ENDOCRINOL, V10, P1549, DOI 10.1210/me.10.12.1549	39	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7878	7886		10.1074/jbc.275.11.7878	http://dx.doi.org/10.1074/jbc.275.11.7878			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713103	hybrid			2022-12-27	WOS:000085913300063
J	Zhu, XL; Bansal, NP; Evans, JP				Zhu, XL; Bansal, NP; Evans, JP			Identification of key functional amino acids of the mouse fertilin beta (ADAM2) disintegrin loop for cell-cell adhesion during fertilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM-EGG FUSION; PLATELET-AGGREGATION; GENE FAMILY; MOLECULAR CHARACTERIZATION; METALLOPROTEASE DOMAIN; MEMBRANE-PROTEINS; VENOM; CLONING; ALPHA; BINDING	Fertilin beta (also known as ADAM2) is a cell adhesion molecule on the surface of mammalian sperm that participates in sperm-egg membrane binding. Fertilin beta is a member of the molecular family known as ADAMs or MDCs. These proteins have a disintegrin domain with homology to integrin ligands found in snake venoms; several of these snake proteins have an RGD tripeptide presented on an extended "disintegrin loop." However, fertilin beta lacks an RGD tripeptide and instead has the consensus sequence X(D/E)ECD (QDECD in mouse fertilin beta) in its putative disintegrin loop, and there is controversy over which amino acids comprise the active site of the fertilin beta disintegrin loop. We have used point-mutated versions of the sequence AQDECDVT and two bioassays to identify the key functional amino acids of this sequence from the mouse fertilin beta disintegrin domain. Amino acid substitutions for the terminal aspartic acid residue of the QDECD sequence result in dramatically reduced activities in the two assays for protein function, implicating the terminal aspartic acid residue as critical for protein function. Substitutions for the glutamic acid and the cysteine residues in the QDECD sequence result in slight reductions in activity, whereas substitution of the first aspartic acid has virtually no effect. These data suggest that the conserved ECD sequence of the mouse fertilin beta disintegrin loop, especially the terminal D residue, contributes more to the protein's activity than does the QDE sequence that aligns with the RGD tripeptide in other disintegrins.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biochem & Mol Biol, Div Reprod Biol, Baltimore, MD 21205 USA	Johns Hopkins University	Evans, JP (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, Div Reprod Biol, 615 N Wolfe St,Rm 3606A, Baltimore, MD 21205 USA.	jpevans@jhsph.edu	Evans, Janice/Q-8483-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD037696, R01HD037696] Funding Source: NIH RePORTER; NICHD NIH HHS [HD07276, HD37696] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; BJARNASON JB, 1995, METHOD ENZYMOL, V248, P345; Bronson RA, 1999, MOL HUM REPROD, V5, P433, DOI 10.1093/molehr/5.5.433; Chen H, 1999, CHEM BIOL, V6, P1, DOI 10.1016/S1074-5521(99)80015-5; DELUCA M, 1995, BIOCHEM BIOPH RES CO, V206, P570, DOI 10.1006/bbrc.1995.1081; DEUTZMANN R, 1990, EUR J BIOCHEM, V191, P513, DOI 10.1111/j.1432-1033.1990.tb19151.x; Evans Janice P., 1999, Frontiers in Bioscience, V4, pD114, DOI 10.2741/Evans; Evans JP, 1997, DEV BIOL, V187, P79, DOI 10.1006/dbio.1997.8611; EVANS JP, 1995, J CELL SCI, V108, P3267; Evans JP, 1998, BIOL REPROD, V59, P145, DOI 10.1095/biolreprod59.1.145; Gichuhi PM, 1997, INT J ANDROL, V20, P165, DOI 10.1046/j.1365-2605.1997.00058.x; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; Gupta SK, 1996, BIOCHEM BIOPH RES CO, V224, P318, DOI 10.1006/bbrc.1996.1027; HAAS TA, 1994, CURR OPIN CELL BIOL, V6, P656, DOI 10.1016/0955-0674(94)90091-4; Hardy CM, 1996, MOL REPROD DEV, V45, P107, DOI 10.1002/(SICI)1098-2795(199610)45:2&lt;107::AID-MRD1&gt;3.0.CO;2-X; Iba K, 1999, AM J PATHOL, V154, P1489, DOI 10.1016/S0002-9440(10)65403-X; Ivaska J, 1999, J BIOL CHEM, V274, P3513, DOI 10.1074/jbc.274.6.3513; Jia LG, 1996, TOXICON, V34, P1269, DOI 10.1016/S0041-0101(96)00108-0; Jia LG, 1997, J BIOL CHEM, V272, P13094, DOI 10.1074/jbc.272.20.13094; Kurakin A, 1998, J PEPT RES, V52, P331; McLane MA, 1998, P SOC EXP BIOL MED, V219, P109, DOI 10.3181/00379727-219-44322; McLaughlin EA, 1997, MOL HUM REPROD, V3, P801, DOI 10.1093/molehr/3.9.801; Murayama O, 1996, J BIOCHEM-TOKYO, V120, P445; Mwethera PG, 1999, CONTRACEPTION, V59, P131, DOI 10.1016/S0010-7824(99)00007-4; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; PAINE MJI, 1992, J BIOL CHEM, V267, P22869; PERRY ACF, 1995, BIOCHEM J, V307, P843, DOI 10.1042/bj3070843; Pyluck A, 1997, BIOORG MED CHEM LETT, V7, P1053, DOI 10.1016/S0960-894X(97)00160-1; Redkar AA, 1999, J ANDROL, V20, P500; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; Shilling FM, 1997, DEV BIOL, V186, P155, DOI 10.1006/dbio.1997.8586; Shimokawa K, 1997, ARCH BIOCHEM BIOPHYS, V343, P35, DOI 10.1006/abbi.1997.0133; TAKEYA H, 1992, J BIOL CHEM, V267, P14109; TAKEYA H, 1990, J BIOL CHEM, V265, P16068; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; van Huijsduijnen RH, 1998, GENE, V206, P273, DOI 10.1016/S0378-1119(97)00597-0; Vidaeus CM, 1997, MOL REPROD DEV, V46, P363; Waters SI, 1997, BIOL REPROD, V56, P1245, DOI 10.1095/biolreprod56.5.1245; Whitten WK, 1971, ADV BIOSCI, V6, P129, DOI DOI 10.1016/B978-0-08-017571-3.50013-9; WOLFSBERG TG, 1993, P NATL ACAD SCI USA, V90, P10783, DOI 10.1073/pnas.90.22.10783; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; Yamabhai M, 1997, ANAL BIOCHEM, V247, P143, DOI 10.1006/abio.1997.2040; Yuan RY, 1997, J CELL BIOL, V137, P105, DOI 10.1083/jcb.137.1.105; ZHOU Q, 1995, BIOCHEM J, V307, P411, DOI 10.1042/bj3070411; Zhou Q, 1996, BIOCHEM BIOPH RES CO, V219, P720, DOI 10.1006/bbrc.1996.0301	48	69	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7677	7683		10.1074/jbc.275.11.7677	http://dx.doi.org/10.1074/jbc.275.11.7677			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713078	hybrid			2022-12-27	WOS:000085913300038
J	Mizutani, A; Fukuda, M; Ibata, K; Shiraishi, Y; Mikoshiba, K				Mizutani, A; Fukuda, M; Ibata, K; Shiraishi, Y; Mikoshiba, K			SYNCRIP, a cytoplasmic counterpart of heterogeneous nuclear ribonucleoprotein R, interacts with ubiquitous synaptotagmin isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-POLYPHOSPHATE BINDING; RNA LOCALIZATION; INOSITOL-1,3,4,5-TETRAKISPHOSPHATE BINDING; SYNAPTIC VESICLES; C2B DOMAIN; PROTEINS; SNARE; IDENTIFICATION; FUSION; EXOCYTOSIS	Synaptotagmins (Syts) are a large family of membrane proteins consisted of at least 12 isoforms, They are categorized in neuron-specific isoforms (I-V, X, and XI) and ubiquitous isoforms (VI-M) based on their expression patterns. Syt-I, a neuron-specific and abundant isoform, has been well characterized and postulated to be the exocytotic Ca2+ sensor. However, the functions of other isoforms remain obscure. Here, we report that ubiquitous isoforms of synaptotagmins, Syt-VII, Syt-VIII, and Syt-IX interacted with a cytoplasmic RNA-binding protein, SYNCRIP (Synaptotagmin-binding, cytoplasmic RNA-interacting protein), through their C2B domains. SYNCRIP was originally found in the Syt-II C2AB domain bound fraction from the mouse brain lysate, cDNA cloning of SYNCRIP cDNA revealed that the protein was highly homologous to heterogeneous nuclear ribonucleoprotein R (hnRNP R) recently identified. SYNCRIP protein was ubiquitously and constantly expressed in various tissues of mice parallel to hnRNP R, SYNCRIP indeed bound RNA with preference to poly(A) RNA; however, in contrast to the nuclear localization of hnRNP R, SYNCRIP was distributed predominantly in the cytoplasm as judged by both biochemical fractionation and immunohistochemical studies. In vitro binding experiments showed the potential interaction of SYNCRIP with C2B domains of Syts except for those of Syt-V, -VI, and -X. Furthermore, the interaction between SYNCRIP and Syt-VII, -VIII, or -IX was revealed by coimmunoprecipitation experiments using COS cells transiently expressing each Syt isoform, These findings suggested that SYNCRIP was a target of ubiquitous type of Syts and implied the involvement of ubiquitous Syts in the regulation of dynamics of the cytoplasmic mRNA.	RIKEN, Brain Sci Inst, Inst Phys & Chem Res, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; RIKEN, Brain Sci Inst, Inst Phys & Chem Res, Mol Neurogenesis Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Inst Med Sci, Dept Mol Neurobiol, Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Corp, Exploratory Res Adv technol, Calciosignal Net Project, Bunkyo Ku, Tokyo 1130021, Japan	RIKEN; RIKEN; University of Tokyo; Japan Science & Technology Agency (JST)	Mizutani, A (corresponding author), RIKEN, Brain Sci Inst, Inst Phys & Chem Res, Dev Neurobiol Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Mizutani, Akihiro/GPS-4809-2022; Fukuda, MItsunori/I-1511-2015; Ibata, Keiji/L-5802-2013; Mikoshiba, Katsuhiko/N-7943-2015	Mizutani, Akihiro/0000-0003-4155-802X; Fukuda, MItsunori/0000-0002-8620-5853; 				Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; Augustine GJ, 1996, ANNU REV PHARMACOL, V36, P659, DOI 10.1146/annurev.pa.36.040196.003303; Bashirullah A, 1998, ANNU REV BIOCHEM, V67, P335, DOI 10.1146/annurev.biochem.67.1.335; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Butz S, 1999, J BIOL CHEM, V274, P18290, DOI 10.1074/jbc.274.26.18290; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Deshler JO, 1998, CURR BIOL, V8, P489, DOI 10.1016/S0960-9822(98)70200-3; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; Fukuda M, 1997, BIOESSAYS, V19, P593, DOI 10.1002/bies.950190710; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; Harris CE, 1999, J VIROL, V73, P72, DOI 10.1128/JVI.73.1.72-80.1999; Hassfeld W, 1998, NUCLEIC ACIDS RES, V26, P439, DOI 10.1093/nar/26.2.439; HUDSON AW, 1995, P NATL ACAD SCI USA, V92, P5895, DOI 10.1073/pnas.92.13.5895; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Ibata K, 1998, J BIOL CHEM, V273, P12267, DOI 10.1074/jbc.273.20.12267; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; MIKOSHIBA K, 1995, P NATL ACAD SCI USA, V92, P10703, DOI 10.1073/pnas.92.23.10703; Mizutani A, 1997, BIOCHEM BIOPH RES CO, V240, P128, DOI 10.1006/bbrc.1997.7578; Mochida S, 1997, NEUROSCIENCE, V77, P937; Nakielny S, 1997, ANNU REV NEUROSCI, V20, P269, DOI 10.1146/annurev.neuro.20.1.269; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OHARAIMAIZUMI M, 1997, P NATL ACAD SCI USA, V92, P10708; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHELLER RH, 1995, NEURON, V14, P893; Schiavo G, 1998, BIOCHEM BIOPH RES CO, V248, P1, DOI 10.1006/bbrc.1998.8527; Schnapp BJ, 1997, SEMIN CELL DEV BIOL, V8, P529, DOI 10.1006/scdb.1997.0178; SHCIAVO G, 1996, NATURE, V328, P733; Sheng ZH, 1997, P NATL ACAD SCI USA, V94, P5405, DOI 10.1073/pnas.94.10.5405; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	42	75	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9823	9831		10.1074/jbc.275.13.9823	http://dx.doi.org/10.1074/jbc.275.13.9823			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734137	hybrid			2022-12-27	WOS:000086206500101
J	Modrowski, D; Basle, M; Lomri, A; Maric, PJ				Modrowski, D; Basle, M; Lomri, A; Maric, PJ			Syndecan-2 is involved in the mitogenic activity and signaling of granulocyte-macrophage colony-stimulating factor in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; FIBROBLAST GROWTH-FACTOR; CELL-SURFACE; MOLECULAR-CLONING; GM-CSF; N-SYNDECAN; MEMBRANE; BINDING; KINASE; PHOSPHORYLATION	We previously showed that granulocyte-macrophage colony-stimulating factor (GM-CSF) binds to heparan sulfate proteoglycans expressed at the surface of osteoblastic cells and that the mitogenic activity of this cytokine is dependent on the presence of fully sulfated proteoglycans, In this study, we determined if GM-CSF interacts with syndecans, a family of cell surface heparan sulfate proteoglycans. Human primary osteoblasts were found to express syndecan-2 and -4 but few syndecan-1 transcripts and proteins. Recombinant human GM-CSF coupled to biotin was found to bind to syndecan-2. Immunocytochemical transmission electron microscope analysis showed co-localization of syndecan-2 and GM-CSF at the cell membrane surface. Syndecan-2 also co-localized at the cell surface and co-immunoprecipitated with the GM-CSF receptor alpha chain, suggesting a strong interaction between the cytokine, its receptor, and syndecan-2, Phosphorylation of tyrosine residues in syndecan-2 associated with the alpha chain of the GM-CSF receptor was increased after cell stimulation by GMCSF. Antisense oligonucleotides that reduced specifically the expression of syndecan-2 inhibited the mitogenic activity of GM-CSF and the activation of extracellular signal-regulated kinase-l induced by the cytokine. Our results indicate functional interactions between syndecan-2 and GM-CSF in osteoblasts, and we propose that syndecan-2 plays a role as a co-receptor for this cytokine.	Hop Lariboisiere, INSERM, CNRS, Unite 349, F-75475 Paris 10, France; Univ Angers, Lab Histol Embryol, F-49045 Angers, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite d'Angers	Modrowski, D (corresponding author), INSERM, U349, 2 Rue Ambroise Pare, F-75475 Paris 10, France.		Modrowski, Dominique/N-6578-2018	Modrowski, Dominique/0000-0003-1103-7127				AlvarezSilva M, 1996, J LEUKOCYTE BIOL, V59, P435, DOI 10.1002/jlb.59.3.435; ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; Aviezer D, 1997, MOL CELL BIOL, V17, P1938, DOI 10.1128/MCB.17.4.1938; BALDWIN GC, 1992, DEV BIOL, V151, P352, DOI 10.1016/0012-1606(92)90175-G; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BERNFIELD M, 1993, DEVELOPMENT, P205; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; Carey DJ, 1997, BIOCHEM J, V327, P1; CHIBA S, 1990, J BIOL CHEM, V265, P19777; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Couchman JR, 1996, J CELL BIOCHEM, V61, P578, DOI 10.1002/(SICI)1097-4644(19960616)61:4<578::AID-JCB11>3.0.CO;2-C; DAVID G, 1993, DEVELOPMENT, V119, P841; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; EVANS DB, 1989, BIOCHEM BIOPH RES CO, V160, P588, DOI 10.1016/0006-291X(89)92473-X; FELIX R, 1991, ENDOCRINOLOGY, V128, P661, DOI 10.1210/endo-128-2-661; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GomezCambronero J, 1996, LIFE SCI, V59, P2099, DOI 10.1016/S0024-3205(96)00414-6; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; HAYASHI K, 1987, J HISTOCHEM CYTOCHEM, V35, P1079, DOI 10.1177/35.10.2957423; Horowitz A, 1998, J BIOL CHEM, V273, P10914, DOI 10.1074/jbc.273.18.10914; HOROWITZ MC, 1989, J CLIN INVEST, V83, P149, DOI 10.1172/JCI113852; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Hurley Marja M., 1996, P627; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; Kinnunen T, 1998, J BIOL CHEM, V273, P10702, DOI 10.1074/jbc.273.17.10702; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Kosher RA, 1998, MICROSC RES TECHNIQ, V43, P123, DOI 10.1002/(SICI)1097-0029(19981015)43:2<123::AID-JEMT5>3.0.CO;2-G; Lomri A, 1999, CALCIFIED TISSUE INT, V64, P394, DOI 10.1007/PL00005821; MACHWATE M, 1995, MOL ENDOCRINOL, V9, P187, DOI 10.1210/me.9.2.187; MARIE PJ, 1989, IN VITRO CELL DEV B, V25, P373; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; Modrowski D, 1997, J CELL PHYSIOL, V170, P35; Molteni A, 1999, BONE, V24, P337, DOI 10.1016/S8756-3282(98)00191-4; OKUDA K, 1992, BLOOD, V79, P2880; Ott VL, 1998, J BIOL CHEM, V273, P35291, DOI 10.1074/jbc.273.52.35291; PIERCE A, 1992, J BIOL CHEM, V267, P3894; RAULO E, 1994, J BIOL CHEM, V269, P12999; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; THESLEFF I, 1995, INT J DEV BIOL, V39, P35	48	61	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9178	9185		10.1074/jbc.275.13.9178	http://dx.doi.org/10.1074/jbc.275.13.9178			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734053	hybrid			2022-12-27	WOS:000086206500017
J	Qi, QG; Rajala, RVS; Anderson, W; Jiang, C; Rozwadowski, K; Selvaraj, G; Sharma, R; Datla, R				Qi, QG; Rajala, RVS; Anderson, W; Jiang, C; Rozwadowski, K; Selvaraj, G; Sharma, R; Datla, R			Molecular cloning, genomic organization, and biochemical characterization of myristoyl-CoA : protein N-myristoyltransferase from Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; GENE FAMILY; SUBSTRATE SPECIFICITIES; CANDIDA-ALBICANS; BOVINE BRAIN; EXPRESSION; TRANSFERASE; PURIFICATION; BINDING	Myristoyl-CoA:protein N-myristoyltransferase (NMT, EC 2.3.1.97) catalyzes the co-translational addition of myristic acid to the amino-terminal glycine residue of a number of important proteins of diverse functions. We have isolated a full-length Arabidopsis thaliana cDNA encoding NMT (AtNMT1), the first described from a higher plant, This AtNMT1 cDNA clone has an open reading frame of 434 amino acids and a predicted molecular mass of 48,706 Da, The primary structure is 50% identical to the mammalian NMTs, Analyses of Southern blots, genomic clones, and database sequences suggested that the A. thaliana genome contains two copies of NMT gene, which are present on different chromosomes and have distinct genomic organizations. The recombinant AtMMT1 expressed in Escherichia coli exhibited a high catalytic efficiency for the peptides derived from putative plant myristoylated proteins AtCDPK6 and Fen kinase, The AtNMT was similar to the mammalian NMTs with respect to a relative specificity for myristoyl CoA amoung the acyl CoA donors and also inhibition by the bovine brain NMT inhibitor NIP71. The AtNMT1 expression profile indicated ubiquity in roots, stem, leaves, flowers, and siliques (approximate to 1.7 kb transcript and approximate to 50 kDa immunoreactive polypeptide) but a greater level in the younger tissue, which are developmentally very active, NMT activity was also evident in all these tissues. Subcellular distribution studies indicated that, in leaf extracts, similar to 60% of AtNMT activity was associated with the ribosomal fractions, whereas similar to 30% of the activity was observed in the cytosolic fractions. The NMT is biologically important to plants, as noted from the stunted development when the AtNMT1 was down-regulated in transgenic Arabidopsis under the control of an enhanced CaMV 35S promoter. The results presented in this study provide the first direct molecular evidence for plant protein N-myristoylation and a mechanistic basis for understanding the role of this protein modification in plants.	Natl Res Council Canada, Inst Plant Biotechnol, Saskatoon, SK S7N 0W9, Canada; Univ Saskatchewan, Dept Pathol, Saskatoon, SK S7N 4H4, Canada; Univ Saskatchewan, Saskatoon Canc Ctr, Saskatoon, SK S7N 4H4, Canada	National Research Council Canada; University of Saskatchewan; University of Saskatchewan	Datla, R (corresponding author), Natl Res Council Canada, Inst Plant Biotechnol, 110 Gymnasium Rd, Saskatoon, SK S7N 0W9, Canada.		Datla, Raju/AGR-7376-2022; Datla, Raju/H-3820-2011	Datla, Raju/0000-0003-0790-5569				ARFIN SM, 1995, P NATL ACAD SCI USA, V92, P7714, DOI 10.1073/pnas.92.17.7714; BECHTOLD N, 1993, C R ACAD SCI PARIS L, V316, P194; Bhatnagar RS, 1997, TRENDS CELL BIOL, V7, P14, DOI 10.1016/S0962-8924(97)10044-7; Bhatnagar RS, 1998, NAT STRUCT BIOL, V5, P1091, DOI 10.1038/4202; BOUTIN JA, 1993, EUR J BIOCHEM, V214, P853, DOI 10.1111/j.1432-1033.1993.tb17989.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREVIARIO D, 1995, PLANT MOL BIOL, V27, P953, DOI 10.1007/BF00037023; DATLA RSS, 1992, GENE, V122, P383, DOI 10.1016/0378-1119(92)90232-E; DATLA RSS, 1993, PLANT SCI, V94, P139, DOI 10.1016/0168-9452(93)90015-R; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; DURONIO RJ, 1992, P NATL ACAD SCI USA, V89, P4129, DOI 10.1073/pnas.89.9.4129; Fujisawa Y, 1999, P NATL ACAD SCI USA, V96, P7575, DOI 10.1073/pnas.96.13.7575; Fulda M, 1997, PLANT MOL BIOL, V33, P911, DOI 10.1023/A:1005780529307; Giang DG, 1998, J BIOL CHEM, V273, P6595, DOI 10.1074/jbc.273.12.6595; GLOVER CJ, 1995, J BIOL CHEM, V270, P23226, DOI 10.1074/jbc.270.39.23226; Glover CJ, 1997, J BIOL CHEM, V272, P28680, DOI 10.1074/jbc.272.45.28680; GRAHAM JM, 1993, BIOMEMBRANE PROTOCOL, V19, P1; HEUCKEROTH RO, 1988, J BIOL CHEM, V263, P2127; HIRAYAMA T, 1992, PLANT MOL BIOL, V20, P653, DOI 10.1007/BF00046450; Hong Y, 1996, PLANT MOL BIOL, V30, P1259, DOI 10.1007/BF00019557; Hooley R, 1999, PLANT PHYSIOL BIOCH, V37, P393, DOI 10.1016/S0981-9428(99)80045-X; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; Joshi CP, 1997, PLANT MOL BIOL, V35, P993, DOI 10.1023/A:1005816823636; JOURNET EP, 1985, PLANT PHYSIOL, V79, P458, DOI 10.1104/pp.79.2.458; Keddie JS, 1998, PLANT CELL, V10, P877, DOI 10.1105/tpc.10.6.877; KING MJ, 1991, ANAL BIOCHEM, V199, P149, DOI 10.1016/0003-2697(91)90082-5; KING MJ, 1993, BIOCHEM J, V291, P635, DOI 10.1042/bj2910635; KISHORE NS, 1993, J BIOL CHEM, V268, P4889; KNOLL LJ, 1992, J BIOL CHEM, V267, P5366; KUDIA J, 1999, P NATL ACAD SCI USA, V96, P4718; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LODGE JK, 1994, J BIOL CHEM, V269, P2996; MACDONALD FD, 1983, BIOCHIM BIOPHYS ACTA, V755, P81, DOI 10.1016/0304-4165(83)90276-3; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MARTIN GB, 1994, PLANT CELL, V6, P1543, DOI 10.1105/tpc.6.11.1543; MATTOO AK, 1987, P NATL ACAD SCI USA, V84, P1497, DOI 10.1073/pnas.84.6.1497; MCILHINNEY RAJ, 1994, EUR J BIOCHEM, V222, P137, DOI 10.1111/j.1432-1033.1994.tb18851.x; MCILHINNEY RAJ, 1990, J NEUROCHEM, V54, P110, DOI 10.1111/j.1471-4159.1990.tb13289.x; McIlhinney RAJ, 1996, EXP CELL RES, V223, P348, DOI 10.1006/excr.1996.0090; Merrifield RB, 1976, SCIENCE, V232, P341, DOI DOI 10.1126/SCIENCE.3961484; Ntwasa M, 1997, J CELL SCI, V110, P149; Pawlowski K, 1997, MOL PLANT MICROBE IN, V10, P656, DOI 10.1094/MPMI.1997.10.5.656; PESECKIS SM, 1994, J BIOL CHEM, V269, P30888; Raju RVS, 1999, METH MOL B, V116, P193; Raju RVS, 1998, EXP CELL RES, V241, P23, DOI 10.1006/excr.1998.4021; Raju RVS, 1996, PROTEIN EXPRES PURIF, V7, P431, DOI 10.1006/prep.1996.0064; Raju RVS, 1999, BIOCHEM BIOPH RES CO, V257, P284, DOI 10.1006/bbrc.1999.0439; RAJU RVS, 1994, J BIOL CHEM, V269, P12080; Raju RVS, 1997, ARCH BIOCHEM BIOPHYS, V348, P134, DOI 10.1006/abbi.1997.0333; RAJU RVS, 1995, MOL CELL BIOCHEM, V150, P191; RAJU VSR, 1998, BIOCHEMISTRY-US, V37, P14923; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; ROCQUE WJ, 1993, J BIOL CHEM, V268, P9964; ROMMENS CMT, 1995, PLANT CELL, V7, P249, DOI 10.1105/tpc.7.3.249; RUDNICK DA, 1992, J BIOL CHEM, V267, P23852; Saijo Y, 1997, BBA-GENE STRUCT EXPR, V1350, P109, DOI 10.1016/S0167-4781(96)00207-2; Sambrook J., 2002, MOL CLONING LAB MANU; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SPEDDING G, 1990, RIBOSOMES PROTEIN SY, P1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; Tregear JW, 1996, PLANT SCI, V117, P107, DOI 10.1016/0168-9452(96)04400-7; WIEGAND RC, 1992, J BIOL CHEM, V267, P8591; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978; WU SY, 1993, J BIOL CHEM, V268, P10796; Yoon GM, 1999, PLANT MOL BIOL, V39, P991, DOI 10.1023/A:1006170512542; Zhang LT, 1996, J BIOL CHEM, V271, P33131, DOI 10.1074/jbc.271.51.33131; Zwerner R K, 1979, Methods Enzymol, V58, P221	73	61	63	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9673	9683		10.1074/jbc.275.13.9673	http://dx.doi.org/10.1074/jbc.275.13.9673			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734119	hybrid			2022-12-27	WOS:000086206500083
J	Rosado, JA; Sage, SO				Rosado, JA; Sage, SO			Phosphoinositides are required for store-mediated calcium entry in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 4-KINASE; GROWTH-FACTOR; CA-2+ ENTRY; ACTIVATION; CELLS; CYTOSKELETAL; STIMULATION; DEPLETION; PATHWAY	We have recently observed that small GTP-binding proteins are important for mediation of store-mediated Ca2+ entry in human platelets through the reorganization of the actin cytoskeleton. Because it has been shown in platelets and other cells that small CTP-binding proteins regulate the activity of phosphatidylinositol S-kinase and phosphatidylinositol 4-kinase, whose products, phosphoinositides, play a key role in the reorganization of the actin cytoskeleton, we have investigated the role of these lipid kinases in store mediated Ca2+ entry. Treatment of platelets with LY294002, an inhibitor of phosphatidylinositol 3- and phosphatidylinositol I-kinases, resulted in a concentration-dependent inhibition of Ca2+ entry stimulated by thapsigargin or the physiological agonist, thrombin. In addition, wortmannin, another inhibitor of these kinases, which is structurally unrelated to LY294002, significantly reduced store-mediated Ca2+ entry. The inhibitory effect of LY294002 was not mediated either by blockage of Ca2+ channels or by modification of membrane potential. LY294002 inhibited actin polymerization stimulated by thrombin or thapsigargin. These results indicate that both phosphatidylinositol 3-kinase and phosphatidylinositol 4-kinase are required for activation of store-mediated Ca2+ entry in human platelets and that the mechanism could involve the reorganization of the actin cytoskeleton.	Univ Cambridge, Dept Physiol, Cambridge CB2 3EG, England	University of Cambridge	Sage, SO (corresponding author), Univ Cambridge, Dept Physiol, Downing St, Cambridge CB2 3EG, England.		Rosado, Juan A/H-3488-2015	Rosado, Juan A/0000-0002-9749-2325; Sage, Stewart/0000-0001-8578-3558				Banfic H, 1998, J BIOL CHEM, V273, P11630, DOI 10.1074/jbc.273.19.11630; BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; BIRD GS, 1993, J BIOL CHEM, V268, P21486; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; Cullen PJ, 1998, BBA-MOL CELL BIOL L, V1436, P35, DOI 10.1016/S0005-2760(98)00149-0; Downing GJ, 1996, BIOCHEMISTRY-US, V35, P3587, DOI 10.1021/bi9517493; Fox JEB, 1996, HAEMOSTASIS, V26, P102; Gasman S, 1998, J BIOL CHEM, V273, P16913, DOI 10.1074/jbc.273.27.16913; Gratacap MP, 1998, J BIOL CHEM, V273, P24314, DOI 10.1074/jbc.273.38.24314; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hartwig JH, 1996, J BIOL CHEM, V271, P32986, DOI 10.1074/jbc.271.51.32986; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Heraud JM, 1998, J BIOL CHEM, V273, P17817, DOI 10.1074/jbc.273.28.17817; Holda JR, 1997, FEBS LETT, V403, P191, DOI 10.1016/S0014-5793(97)00051-3; Irvine R, 1996, CURR BIOL, V6, P537, DOI 10.1016/S0960-9822(02)00536-5; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; Jenner S, 1996, FEBS LETT, V381, P249, DOI 10.1016/0014-5793(96)00130-5; Linseman DA, 1998, J NEUROCHEM, V70, P940; MAHAUTSMITH MP, 1990, J PHYSIOL-LONDON, V428, P723, DOI 10.1113/jphysiol.1990.sp018237; MEYERS R, 1997, BIOCHEM BIOPH RES CO, V188, P155; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Rosado JA, 2000, J BIOL CHEM, V275, P7527, DOI 10.1074/jbc.275.11.7527; ROSADO JA, 2000, IN PRESS BIOCH J, V346; SAGE SO, 1990, BIOCHEM J, V265, P675, DOI 10.1042/bj2650675; SARGEANT P, 1993, FEBS LETT, V315, P242, DOI 10.1016/0014-5793(93)81172-V; SARGEANT P, 1994, EXP PHYSIOL, V79, P269, DOI 10.1113/expphysiol.1994.sp003762; Sorensen SD, 1998, MOL PHARMACOL, V53, P827; WAY BA, 1993, J BIOL CHEM, V268, P26409; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5	30	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9110	9113		10.1074/jbc.275.13.9110	http://dx.doi.org/10.1074/jbc.275.13.9110			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734043	hybrid			2022-12-27	WOS:000086206500007
J	Spampinato, C; Modrich, P				Spampinato, C; Modrich, P			The MutL ATPase is required for mismatch repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENE-PRODUCT; HELICASE-II; RECOMBINATION; HETERODUPLEX; MUTAGENESIS; REPLICATION; INITIATION; MECHANISMS; MUTATIONS	Members of the MutL family contain a novel nucleotide binding motif near their amino terminus, and the Escherichia coli protein has been found to be a weak ATPase (Ban, C., and Yang, W. (1998) Cell 95, 541-552), Genetic analysis has indicated that substitution of Lys for Glu-32 within this motif of bacterial MutL results in a strong dominant negative phenotype (Aronshtam, A, and Marinus, M. G. (1996) Nucleic Acids Res. 24, 2498-2504), By in vitro comparison of MutL-E32K with the wild type protein, we show the mutant protein to be defective in DNA-activated ATP hydrolysis, as well as MutS- and MutL-dependent activation of the MutH d(GATC) endonuclease and the mismatch repair excision system. MutL-E32K also acts in dominant negative manner in the presence of wild type MutL in vitro, inhibiting the overall mismatch repair reaction, as well as MutH activation. As judged by protein affinity chromatography, MutL and MutL-E32K both support formation of ternary complexes that also contain MutS and MutH or MutS and DNA helicase II. These findings imply that the MutL nucleotide binding center is required for mismatch repair and suggest that the dominant negative behavior of the MutL-E32K mutation is due to the formation of dead-end complexes in which the MutL-E32K protein is unable to transduce a signal from MutS that otherwise results in mismatch-dependent activation of the MutH d(GATC) endonuclease or the unwinding activity of helicase II.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; Duke University; Howard Hughes Medical Institute	Modrich, P (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.			Modrich, Paul/0000-0001-8708-9885	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023719, R01GM023719] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23719] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Aronshtam A, 1996, NUCLEIC ACIDS RES, V24, P2498, DOI 10.1093/nar/24.13.2498; AU KG, 1992, J BIOL CHEM, V267, P12142; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Blackwell LJ, 1998, J BIOL CHEM, V273, P32049, DOI 10.1074/jbc.273.48.32049; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COOPER DL, 1993, J BIOL CHEM, V268, P11823; Dao V, 1998, J BIOL CHEM, V273, P9202, DOI 10.1074/jbc.273.15.9202; FANG WH, 1993, J BIOL CHEM, V268, P11838; Galio L, 1999, NUCLEIC ACIDS RES, V27, P2325, DOI 10.1093/nar/27.11.2325; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; Hall MC, 1999, J BIOL CHEM, V274, P1306, DOI 10.1074/jbc.274.3.1306; Hall MC, 1998, EMBO J, V17, P1535, DOI 10.1093/emboj/17.5.1535; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MESELSON M, 1988, RECOMBINATION GENETI, P91; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MODRICH P, 1989, J BIOL CHEM, V264, P6597; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Picard V, 1997, Methods Mol Biol, V67, P183; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; RADMAN M, 1995, PHILOS T ROY SOC B, V347, P97, DOI 10.1098/rstb.1995.0015; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; WELSH KM, 1987, J BIOL CHEM, V262, P15624; Wu TH, 1999, J BIOL CHEM, V274, P5948, DOI 10.1074/jbc.274.9.5948; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197	37	108	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9863	9869		10.1074/jbc.275.13.9863	http://dx.doi.org/10.1074/jbc.275.13.9863			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734142	hybrid			2022-12-27	WOS:000086206500106
J	Ton-That, H; Mazmanian, SK; Faull, KF; Schneewind, O				Ton-That, H; Mazmanian, SK; Faull, KF; Schneewind, O			Anchoring of surface proteins to the cell wall of Staphylococcus aureus - Sortase catalyzed in vitro transpeptidation reaction using LPXTG peptide and NH2-Gly(3) substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-ALANINE CARBOXYPEPTIDASES; GRAM-POSITIVE BACTERIA; PENICILLIN; SERINE; ENZYME; GENE	Staphylococcus aureus sortase anchors surface proteins to the cell wall envelope by cleaving polypeptides at the LPXTG motif, Surface proteins are linked to the peptidoglycan by an amide bond between the C-terminal carboxyl and the amino group of the pentaglycine cross bridge. We find that purified recombinant sortase hydrolyzed peptides bearing an LPXTG: motif at the peptide bond between threonine and glycine, In the presence of NH2-Gly(3), sortase catalyzed exclusively a transpeptidation reaction, linking the carboxyl group of threonine to the amino group of NH2-Gly(3). In the presence of amino group donors the rate of sortase mediated cleavage at the LPXTG motif was increased. Hydrolysis and transpeptidation required the sulfhydryl of cysteine 184, suggesting that sortase catalyzed the transpeptidation reaction of surface protein anchoring via the formation of a thioester acyl-enzyme intermediate.	Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Pasarow Mass Spect Lab, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Pasarow Mass Spect Lab, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Neuropsychiat, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Schneewind, O (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	olafs@ucla.edu	Ton-That, Hung/AAB-6155-2020; Mazmanian, Sarkis/ABD-7729-2021	Mazmanian, Sarkis/0000-0003-2713-1513; Ton-That, Hung/0000-0003-1611-0469	NIAID NIH HHS [AI 38897] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038897] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIEMANN K, 1987, SCIENCE, V237, P992, DOI 10.1126/science.3303336; Fersht A., 1985, ENZYME STRUCTURE MEC; Filippova IY, 1996, ANAL BIOCHEM, V234, P113, DOI 10.1006/abio.1996.0062; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; KOZARICH JW, 1978, J BIOL CHEM, V253, P1272; KOZARICH JW, 1977, J BIOL CHEM, V252, P7525; KREISWIRTH BN, 1983, NATURE, V305, P709, DOI 10.1038/305709a0; Lebrun M, 1996, MOL MICROBIOL, V21, P579, DOI 10.1111/j.1365-2958.1996.tb02566.x; MATSUHASHI M, 1965, P NATL ACAD SCI USA, V54, P587, DOI 10.1073/pnas.54.2.587; Mazmanian SK, 1999, SCIENCE, V285, P760, DOI 10.1126/science.285.5428.760; Navarre WW, 1996, J BACTERIOL, V178, P441, DOI 10.1128/jb.178.2.441-446.1996; Navarre WW, 1998, J BIOL CHEM, V273, P29135, DOI 10.1074/jbc.273.44.29135; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; NAVARRE WW, 1994, MOL MICROBIOL, V14, P115, DOI 10.1111/j.1365-2958.1994.tb01271.x; Piard JC, 1997, J BACTERIOL, V179, P3068, DOI 10.1128/jb.179.9.3068-3072.1997; POZZI G, 1992, INFECT IMMUN, V60, P1902, DOI 10.1128/IAI.60.5.1902-1907.1992; RASMUSSEN JR, 1978, P NATL ACAD SCI USA, V75, P84, DOI 10.1073/pnas.75.1.84; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133; Ton-That H, 1999, J BIOL CHEM, V274, P24316, DOI 10.1074/jbc.274.34.24316; Ton-That H, 1999, P NATL ACAD SCI USA, V96, P12424, DOI 10.1073/pnas.96.22.12424; TonThat H, 1997, J BIOL CHEM, V272, P22285, DOI 10.1074/jbc.272.35.22285; WALSH CT, 1993, SCIENCE, V261, P308, DOI 10.1126/science.8392747; Yeung MK, 1998, INFECT IMMUN, V66, P1482, DOI 10.1128/IAI.66.4.1482-1491.1998; YOCUM RR, 1979, P NATL ACAD SCI USA, V76, P2730, DOI 10.1073/pnas.76.6.2730	28	228	253	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9876	9881		10.1074/jbc.275.13.9876	http://dx.doi.org/10.1074/jbc.275.13.9876			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734144	Green Accepted, hybrid			2022-12-27	WOS:000086206500108
J	Walchli, S; Curchod, ML; Gobert, RP; Arkinstall, S; van Huijsduijnen, RH				Walchli, S; Curchod, ML; Gobert, RP; Arkinstall, S; van Huijsduijnen, RH			Identification of tyrosine phosphatases that dephosphorylate the insulin receptor - A brute force approach based on "substrate-trapping" mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PTP-PEST; EXPRESSION; LAR; KINASES; CELLS; MICE; 1B; OVEREXPRESSION; SPECIFICITY; MECHANISM	Many pharmacologically important receptors, including all cytokine receptors, signal via tyrosine (auto) phosphorylation, followed by resetting to their original state through the action of protein tyrosine phosphatases (PTPs). Establishing the specificity of PTPs for receptor substrates is critical both for understanding how signaling is regulated and for the development of specific PTP inhibitors that act as ligand mimetics, We have set up a systematic approach for finding PTPs that are specific for a receptor and have validated this approach with the insulin receptor kinase, We have tested nearly all known human PTPs (45) in a membrane binding assay, using "substrate-trapping" PTP mutants. These results, combined with secondary dephosphorylation tests, confirm and extend earlier findings that PTP-1b and T-cell PTP are physiological enzymes for the insulin receptor kinase. We demonstrate that this approach can rapidly reduce the number of PTPs that have a particular receptor or other phosphoprotein as their substrate.	Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland		van Huijsduijnen, RH (corresponding author), Serono Pharmaceut Res Inst, 14 Chem Aulx,1228 Plan Ouates, CH-1228 Geneva, Switzerland.		; Hooft van Huijsduijnen, Rob/B-3653-2009	Walchli, Sebastien/0000-0001-5869-1746; Hooft van Huijsduijnen, Rob/0000-0002-2261-9424				AHMAD F, 1995, J CLIN INVEST, V95, P2806, DOI 10.1172/JCI117985; Bell SD, 1998, J BIOL CHEM, V273, P14309, DOI 10.1074/jbc.273.23.14309; Cote JF, 1998, BIOCHEMISTRY-US, V37, P13128, DOI 10.1021/bi981259l; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; HERRERA R, 1988, J BIOL CHEM, V263, P5560; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; KISHIMOTO TK, 1995, AGENT ACTION SUPPL, V47, P121; KURODA K, 1986, EMBO J, V5, P1359, DOI 10.1002/j.1460-2075.1986.tb04367.x; LaMontagne KR, 1998, MOL CELL BIOL, V18, P2965, DOI 10.1128/MCB.18.5.2965; Li PM, 1996, CELL SIGNAL, V8, P467, DOI 10.1016/S0898-6568(96)00101-5; MATOZAKI T, 1994, J BIOL CHEM, V269, P2075; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; Mooney RA, 1997, BIOCHEM BIOPH RES CO, V235, P709, DOI 10.1006/bbrc.1997.6889; Morinville A, 1998, TRENDS PHARMACOL SCI, V19, P452, DOI 10.1016/S0165-6147(98)01257-7; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NG DHW, 1995, J IMMUNOL METHODS, V179, P177, DOI 10.1016/0022-1759(94)00281-Z; Norris K, 1997, FEBS LETT, V415, P243, DOI 10.1016/S0014-5793(97)01133-2; Pannifer ADB, 1998, J BIOL CHEM, V273, P10454, DOI 10.1074/jbc.273.17.10454; Ren JM, 1998, DIABETES, V47, P493, DOI 10.2337/diabetes.47.3.493; Schaapveld RQJ, 1997, DEV BIOL, V188, P134, DOI 10.1006/dbio.1997.8630; Seely BL, 1996, DIABETES, V45, P1379, DOI 10.2337/diabetes.45.10.1379; Seo Y, 1997, BIOCHEM BIOPH RES CO, V231, P705, DOI 10.1006/bbrc.1997.6139; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TADDEI N, 1994, FEBS LETT, V350, P328, DOI 10.1016/0014-5793(94)00805-1; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; van Huijsduijnen RH, 1998, GENE, V225, P1; Wishart MJ, 1998, TRENDS BIOCHEM SCI, V23, P301, DOI 10.1016/S0968-0004(98)01241-9; YouTen KE, 1997, J EXP MED, V186, P683, DOI 10.1084/jem.186.5.683; Zhang ZY, 1995, BIOCHEMISTRY-US, V34, P16088, DOI 10.1021/bi00049a024	37	151	159	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9792	9796		10.1074/jbc.275.13.9792	http://dx.doi.org/10.1074/jbc.275.13.9792			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734133	hybrid			2022-12-27	WOS:000086206500097
J	Ye, JJ; Xie, XP; Tarassishin, L; Horwitz, MS				Ye, JJ; Xie, XP; Tarassishin, L; Horwitz, MS			Regulation of the NF-kappa B activation pathway by isolated domains of FIP3/IKK gamma, a component of the I kappa B-alpha kinase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SITE-SPECIFIC PHOSPHORYLATION; CELL-DEATH; TRANSCRIPTION FACTOR; TRANSFECTED CELLS; INDUCED APOPTOSIS; ADAPTER MOLECULE; BINDING-SITE; PROTEIN; INDUCTION	FIP3, isolated as a type 2 adenovirus E3-14.7-kDa interacting protein, is an essential component of the multimeric I kappa B-alpha kinase (IKK) complex and has been shown to interact with various components (Fas receptor-interacting protein, NF-kappa B-inducing kinase, IKK beta) of the NF-kappa B activation pathway. FIP3 has also been shown to repress basal and tumor necrosis factor (TNF) alpha-induced NF-kappa B activity as well as to induce cell death when overexpressed, The adenovirus E3-14.7-kDa protein (E3-14.7K) is an inhibitor of TNF alpha-induced cell death. In the current study, we generated deletion mutants to map the domains of FIP3, which are responsible for its various functions, The NF-kappa B inhibitory activity and the E3-14.7K binding domains were mapped at the carboxyl half of the FIP3 protein. We also found that the carboxyl-terminal half of FIP3 blocked TNF alpha-induced I kappa B-alpha phosphorylation and subsequent degradation, which suggests that the stabilization of the cytoplasmic inhibitor of NF-kappa B underlies the FIP3 inhibition of NF-kappa B activity. The amino-terminal 119 amino acids were responsible for the FIP3-IKK beta and FIP3-IKK alpha interaction, and the middle of the protein (amino acids 201-300) appeared to be both the FIP3 self-association domain as well as the FIP3-Fas receptor-interacting protein interaction domain. Thus, FIP3 might serve as a scaffold protein to organize the various components of the I kappa B-alpha kinase complex. Whereas the full-length protein is required for efficient cell death, the amino-terminal 200 amino acids are sufficient to cause rounding and detachment of the cells from the monolayer.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Horwitz, MS (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			Tarassishin, Leonid/0000-0002-2649-5465	NCI NIH HHS [CA13330, R01 CA72963] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072963, P30CA013330] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad M, 1997, CANCER RES, V57, P615; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, COLD SPRING HARB SYM, V53, P789, DOI 10.1101/SQB.1988.053.01.089; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Burke JR, 1998, J BIOL CHEM, V273, P12041, DOI 10.1074/jbc.273.20.12041; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GRELL M, 1994, J IMMUNOL, V153, P1963; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HORTON TM, 1991, J VIROL, V65, P2629, DOI 10.1128/JVI.65.5.2629-2639.1991; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li YG, 1997, BIOTECHNIQUES, V23, P1026, DOI 10.2144/97236bm12; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; LINDHOLM P F, 1990, New Biologist, V2, P1034; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; MUNOZ E, 1995, IMMUNOBIOLOGY, V193, P128, DOI 10.1016/S0171-2985(11)80535-8; NELSEN B, 1988, MOL CELL BIOL, V8, P3526, DOI 10.1128/MCB.8.8.3526; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WIRTH T, 1988, EMBO J, V7, P3109, DOI 10.1002/j.1460-2075.1988.tb03177.x; WONG GHW, 1994, J IMMUNOL, V152, P1751; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	54	61	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9882	9889		10.1074/jbc.275.13.9882	http://dx.doi.org/10.1074/jbc.275.13.9882			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734145	hybrid			2022-12-27	WOS:000086206500109
J	Jemth, P; Mannervik, B				Jemth, P; Mannervik, B			Active site serine promotes stabilization of the reactive glutathione thiolate in rat glutathione transferase T2-2 - Evidence against proposed sulfatase activity of the corresponding human enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC ACTIVITY; THETA; DISCRIMINATION; DESIGN; ESTERS; ACIDS	Ser(11) in rat glutathione transferase T2-2 is important for stabilization of the reactive enzyme-bound glutathione thiolate in the reaction with 1-menaphthyl sulfate. The S11A mutation increased the pK(a) value for the pH dependence of the rate constant for pre-steady-state product formation, from 5.7 to 7.9, This pH dependence is proposed to reflect titration of enzyme-bound glutathione thiol, Further, the mutation lowered the k(cat) value but not because of the impaired stabilization of the glutathione thiolate, In fact, several steps on the reaction pathway were affected by the S11A mutation, and the cause of the decreased k(cat) for the mutant was found to be a slower product release. The data presented here contradict the hypothesis that glutathione transferase T2-2 could act as a sulfatase that is not dependent on Ser(11) for the catalytic activity, as proposed for the corresponding human enzyme (Tan, K.-L,, Chelvanayagam, G,, Parker, M. W., and Board, P, G, (1996) Biochem. J, 319, 315-321; Rossjohn, J,, McKinstry, W. J,, Oakley, A. J., Verger, D., Flanagan, J., Chelvanayagam, G,, Tan, K.-L,, Board, P, G., and Parker, M. W, (1998) Structure 6, 309-322). On the contrary, Ser(11) governs both chemical and physical steps of the catalyzed reaction.	Univ Uppsala, Ctr Biomed, Dept Biochem, S-75123 Uppsala, Sweden	Uppsala University	Mannervik, B (corresponding author), Univ Uppsala, Ctr Biomed, Dept Biochem, Box 576, S-75123 Uppsala, Sweden.							Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; BARDSLEY WG, 1995, COMPUT CHEM, V19, P75, DOI 10.1016/0097-8485(95)00007-F; BJORNESTEDT R, 1992, BIOCHEM J, V282, P505; BROUWER AC, 1982, BIOCHEMISTRY-US, V21, P1302, DOI 10.1021/bi00535a030; Caccuri AM, 1999, J BIOL CHEM, V274, P19276, DOI 10.1074/jbc.274.27.19276; CLAPP JJ, 1970, BIOCHEM J, V118, P765, DOI 10.1042/bj1180765; DANIELSON UH, 1985, BIOCHEM J, V231, P263, DOI 10.1042/bj2310263; Fersht A, 1999, STRUCTURE MECH PROTE, P132; GILLHAM B, 1971, BIOCHEM J, V121, P667, DOI 10.1042/bj1210667; Gustafsson A, 1999, J MOL BIOL, V288, P787, DOI 10.1006/jmbi.1999.2712; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HIRATSUKA A, 1990, J BIOL CHEM, V265, P11973; HYDE CW, 1968, BIOCHEM J, V107, P519, DOI 10.1042/bj1070519; Jemth P, 1996, BIOCHEM J, V316, P131, DOI 10.1042/bj3160131; Jemth P, 1999, BIOCHEMISTRY-US, V38, P9982, DOI 10.1021/bi983065b; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P35; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MANNERVIK B, 1982, METHOD ENZYMOL, V87, P370; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; Parsons JF, 1998, BIOCHEMISTRY-US, V37, P6286, DOI 10.1021/bi980219e; PRINCIPATO GB, 1988, FEBS LETT, V231, P155, DOI 10.1016/0014-5793(88)80722-1; Rossjohn J, 1998, STRUCTURE, V6, P309, DOI 10.1016/S0969-2126(98)00034-3; Tan KL, 1996, BIOCHEM J, V319, P315, DOI 10.1042/bj3190315; VINCE R, 1971, J MED CHEM, V14, P402, DOI 10.1021/jm00287a006; Xiao B, 1999, BIOCHEMISTRY-US, V38, P11887, DOI 10.1021/bi990468i	27	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8618	8624		10.1074/jbc.275.12.8618	http://dx.doi.org/10.1074/jbc.275.12.8618			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722701	hybrid			2022-12-27	WOS:000086507700051
J	Taghibiglou, C; Carpentier, A; Van Iderstine, SC; Chen, B; Rudy, D; Aiton, A; Lewis, GF; Adeli, K				Taghibiglou, C; Carpentier, A; Van Iderstine, SC; Chen, B; Rudy, D; Aiton, A; Lewis, GF; Adeli, K			Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance - Evidence for enhanced lipoprotein assembly, reduced intracellular apoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-B SECRETION; CULTURED RAT HEPATOCYTES; HEP G2 CELLS; LIPID-METABOLISM; ACID SYNTHESIS; HYPERINSULINEMIA; EXPRESSION; HYPERTRIGLYCERIDEMIA; CHOLESTEROL; INDIVIDUALS	A novel animal model of insulin resistance, the fructose-fed Syrian golden hamster, was employed to investigate the mechanisms mediating the overproduction of very low density Lipoprotein (VLDL) in the insulin resistant state. Fructose feeding for a a-week period induced significant hypertriglyceridemia and hyperinsulinemia, and the development of whole body insulin resistance was documented using the euglycemic-hyperinsulinemic clamp technique. In vivo Triton WR-1339 studies showed evidence of VLDL-apoB overproduction in the fructose-fed hamster. Fructose feeding induced a significant increase in cellular synthesis and secretion of total triglyceride (TG) as well as VLDL-TG by primary hamster hepatocytes, Increased TG secretion was accompanied by a 4.6-fold increase in VLDL-apoB secretion. Enhanced stability of nascent apoB in fructose-fed hepatocytes mas evident in intact cells as well as in a permeabilized cell system, Analysis of newly formed lipoprotein particles in hepatic microsomes revealed significant differences in the pattern and density of lipoproteins, with hepatocytes derived from fructose-fed hamsters having higher levels of luminal lipoproteins at a density of VLDL versus controls, Immunoblot analysis of the intracellular mass of microsomal triglyceride transfer protein, a key enzyme involved in VLDL assembly showed a striking 2.1-fold elevation in hepatocytes derived from fructose-fed versus control hamsters, Direct incubation of hamster hepatocytes with various concentrations of fructose failed to show any direct stimulation of its intracellular stability or extracellular secretion, further supporting the notion that the apoB overproduction in the fructose-fed hamster may be related to the fructose-induced insulin resistance in this animal model. In summary, hepatic VLDL-apoB overproduction in fructose-fed hamsters appears to result from increased intracellular stability of nascent apoB and an enhanced expression of MTP, which act to facilitate the assembly and secretion of apoB-containing lipoprotein particles.	Univ Toronto, Hosp Sick Children, Div Clin Biochem, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto Hosp, Dept Med, Div Endocrinol & Metab, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto	Adeli, K (corresponding author), Univ Toronto, Hosp Sick Children, Div Clin Biochem, Dept Lab Med & Pathobiol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Taghibiglou, Changiz/H-4590-2019	Adeli, Khosrow/0000-0002-5839-5709				ADELI K, 1994, J BIOL CHEM, V269, P9166; ADELI K, 1992, BIOCHEM CELL BIOL, V70, P1301, DOI 10.1139/o92-177; Adeli K, 1997, J BIOL CHEM, V272, P5031, DOI 10.1074/jbc.272.8.5031; [Anonymous], 1993, LAB ANIM, V27, P1, DOI DOI 10.1258/002367793781082412; ARBEENY CM, 1992, J LIPID RES, V33, P843; BERGMAN RN, 1985, ENDOCR REV, V6, P45, DOI 10.1210/edrv-6-1-45; BJORNSSON OG, 1992, BIOCHEM J, V281, P381; Boisfer E, 1999, J BIOL CHEM, V274, P11564, DOI 10.1074/jbc.274.17.11564; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1992, J BIOL CHEM, V267, P9858; BRETT DJ, 1995, BIOCHEM J, V310, P11, DOI 10.1042/bj3100011; CUMMINGS MH, 1995, DIABETOLOGIA, V38, P959, DOI 10.1007/s001250050378; DASHTI N, 1989, J LIPID RES, V30, P1365; Eisele B, 1997, J LIPID RES, V38, P564; Garg A, 1996, DIABETES CARE, V19, P387, DOI 10.2337/diacare.19.4.387; GARG A, 1988, METABOLISM, V37, P982, DOI 10.1016/0026-0495(88)90157-6; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; GRUNDY SM, 1979, J CLIN INVEST, V63, P1274, DOI 10.1172/JCI109422; HAGAN DL, 1994, J BIOL CHEM, V269, P28737; HOANG VQ, 1993, BIOCHIM BIOPHYS ACTA, V1210, P73, DOI 10.1016/0005-2760(93)90051-A; HOWARD BV, 1987, J LIPID RES, V28, P613; JACKSON B, 1990, BIOCHIM BIOPHYS ACTA, V1045, P21, DOI 10.1016/0005-2760(90)90199-8; KasimKarakas SE, 1996, J LAB CLIN MED, V128, P208, DOI 10.1016/S0022-2143(96)90013-X; KAZUMI T, 1986, AM J PHYSIOL, V250, pE325, DOI 10.1152/ajpendo.1986.250.3.E325; KAZUMI T, 1985, ENDOCRINOLOGY, V117, P1145, DOI 10.1210/endo-117-3-1145; KISSEBAH AH, 1981, METABOLISM, V30, P856, DOI 10.1016/0026-0495(81)90064-0; Kuriyama H, 1998, HEPATOLOGY, V27, P557, DOI 10.1002/hep.510270233; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS GF, 1995, J CLIN INVEST, V95, P158, DOI 10.1172/JCI117633; Lewis GF, 1996, DIABETES CARE, V19, P390, DOI 10.2337/diacare.19.4.390; LEWIS GF, 1993, DIABETES, V42, P833, DOI 10.2337/diabetes.42.6.833; Li XH, 1997, J LIPID RES, V38, P1277; LIN MCM, 1995, J LIPID RES, V36, P1073; LIU GL, 1991, COMP BIOCHEM PHYS A, V99, P223, DOI 10.1016/0300-9629(91)90263-C; Lovry O.H., 1951, J BIOL CHEM, V193, P265; Macri J, 1997, J BIOL CHEM, V272, P7328, DOI 10.1074/jbc.272.11.7328; Malmstrom R, 1997, ARTERIOSCL THROM VAS, V17, P1454, DOI 10.1161/01.ATV.17.7.1454; Malmstrom R, 1998, DIABETES, V47, P779, DOI 10.2337/diabetes.47.5.779; Malmstrom R, 1997, DIABETOLOGIA, V40, P454, DOI 10.1007/s001250050700; MILLER LL, 1973, ISOLATED LIVER PERFU, P11; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; MYKKANEN L, 1994, METABOLISM, V43, P523, DOI 10.1016/0026-0495(94)90088-4; NISTOR A, 1987, ATHEROSCLEROSIS, V68, P159, DOI 10.1016/0021-9150(87)90106-7; OLEFSKY JM, 1974, AM J MED, V57, P551, DOI 10.1016/0002-9343(74)90006-0; ONTKO JA, 1990, J LIPID RES, V31, P1983; PATSCH W, 1983, J CLIN INVEST, V71, P1161, DOI 10.1172/JCI110865; Phung TL, 1997, J BIOL CHEM, V272, P30693, DOI 10.1074/jbc.272.49.30693; REARDON MF, 1981, CLIN CHEM, V27, P892; REAVEN GM, 1993, J CLIN INVEST, V92, P141, DOI 10.1172/JCI116541; REAVEN GM, 1967, J CLIN INVEST, V46, P1756, DOI 10.1172/JCI105666; REAVEN GM, 1992, METABOLISM, V41, P16, DOI 10.1016/0026-0495(92)90088-R; REAVEN GM, 1988, DIABETES METAB REV, V4, P639, DOI 10.1002/dmr.5610040703; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Riches FM, 1998, INT J OBESITY, V22, P414, DOI 10.1038/sj.ijo.0800602; SALHANICK AI, 1991, METABOLISM, V40, P275, DOI 10.1016/0026-0495(91)90109-A; Simionescu N, 1993, Curr Top Pathol, V87, P1; SLEDER J, 1980, METABOLISM, V29, P303, DOI 10.1016/0026-0495(80)90001-3; SPARKS CE, 1986, METABOLISM, V35, P1128, DOI 10.1016/0026-0495(86)90026-0; SPARKS JD, 1989, BIOCHEM J, V261, P83, DOI 10.1042/bj2610083; Sparks JD, 1996, BIOCHEM J, V313, P567, DOI 10.1042/bj3130567; SPARKS JD, 1994, BIOCHEM BIOPH RES CO, V205, P417, DOI 10.1006/bbrc.1994.2681; SPARKS JD, 1990, J BIOL CHEM, V265, P8854; SPARKS JD, 1994, BBA-LIPID LIPID MET, V1215, P9, DOI 10.1016/0005-2760(94)90088-4; STEINER G, 1984, AM J PHYSIOL, V246, pE187, DOI 10.1152/ajpendo.1984.246.2.E187; Steiner G, 1996, DIABETES, V45, pS24, DOI 10.2337/diab.45.3.S24; SUGIYAMA Y, 1995, ATHEROSCLEROSIS, V118, P145, DOI 10.1016/0021-9150(95)05601-R; SULLIVAN MP, 1993, LAB ANIM SCI, V43, P575; TASKINEN MR, 1995, CURR OPIN LIPIDOL, V6, P153, DOI 10.1097/00041433-199506000-00007; THERIAULT A, 1992, CLIN BIOCHEM, V25, P321, DOI 10.1016/0009-9120(92)80007-4; TOBEY TA, 1982, METABOLISM, V31, P608, DOI 10.1016/0026-0495(82)90100-7; WETTERAU JR, 1992, SCIENCE, V258, P999; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WIGGINS D, 1992, BIOCHEM J, V284, P457, DOI 10.1042/bj2840457; WRIGHT DW, 1983, AM J CLIN NUTR, V38, P879, DOI 10.1093/ajcn/38.6.879; Yoshino G, 1997, ATHEROSCLEROSIS, V129, P33, DOI 10.1016/S0021-9150(96)06006-6; ZAVARONI I, 1980, METABOLISM, V29, P970, DOI 10.1016/0026-0495(80)90041-4	78	238	244	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8416	8425		10.1074/jbc.275.12.8416	http://dx.doi.org/10.1074/jbc.275.12.8416			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722675	hybrid			2022-12-27	WOS:000086507700025
J	Yamauchi, S; Mita, S; Matsubara, T; Fukuta, M; Habuchi, H; Kimata, K; Habuchi, O				Yamauchi, S; Mita, S; Matsubara, T; Fukuta, M; Habuchi, H; Kimata, K; Habuchi, O			Molecular cloning and expression of chondroitin 4-sulfotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; SULFATE PROTEOGLYCAN; BRACHYMORPHIC MICE; NEURITE OUTGROWTH; BRAIN; 6-SULFOTRANSFERASE; SULFOTRANSFERASE; NEURONS; RECEPTOR; MEMBRANE	Chondroitin 4-sulfotransferase (C4ST) catalyzes the transfer of sulfate from 3'-phosphoadenosine 5'-phosphosulfate to position 4 of N-acetylgalactosamine residue of chondroitin, The enzyme has been previously purified to apparent homogeneity from the serum-free culture medium of rat chondrosarcoma cells (Yamauchi, A, Hirahara, Y,, Usui, Il,, Takeda, Y,, Hoshino, M., Fukuta, M., Kimura, J, H., and Habuchi, O. (1999) J, Biol, Chem. 274, 2456-2463), The purified enzyme also catalyzed the sulfation of partially desulfated dermatan sulfate. We have now cloned the cDNA of the mouse C4ST on the basis of the amino acid sequences of peptides obtained from the purified enzyme by protease digestion. This cDNA contains a single open reading frame that predicts a protein composed of 352 amino acid residues. The protein predicts a Type II transmembrane topology, The predicted sequence of the protein contains all of the known amino acid sequence and four potential sites for N-glycosylation which corresponds to the observation that the purified C4ST is an N-linked glycoprotein. The amino acid sequence of mouse C4ST showed significant sequence homology to HNK-1 sulfotransferase. Comparison of the sequence of mouse C4ST with human HNK-1 sulfotransferase revealed similar to 29% identity and similar to 48% similarity at the amino acid level, When the cDNA was introduced in a eukaryotic expression vector and transfected in COS-7 cells, the sulfotransferase activity that catalyzes the transfer of sulfate to position 4 of GalNAc residue of both chondroitin and desulfated dermatan sulfate was overexpressed, Northern blot analysis showed that, among various mouse adult tissues, 5.7-kilobase message of C4ST was mainly expressed in the brain and kidney.	Aichi Univ Educ, Dept Life Sci, Kariya, Aichi 4488542, Japan; Aichi Med Univ, Inst Mol Med Sci, Nagakute, Aichi 4801195, Japan	Aichi University Education; Aichi Medical University	Habuchi, O (corresponding author), Aichi Univ Educ, Dept Life Sci, Kariya, Aichi 4488542, Japan.	ohabuchi@auecc.aichi-edu.ac.jp						ADANY R, 1990, J BIOL CHEM, V265, P11389; ARUFFO A, 1998, CURRENT PROTOCOLS S, V43; Bakker H, 1997, J BIOL CHEM, V272, P29942, DOI 10.1074/jbc.272.47.29942; DELFERT DM, 1985, J BIOL CHEM, V260, P4446; Dou CL, 1997, J NEUROCHEM, V68, P1021; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; HABUCHI H, 1986, J BIOL CHEM, V261, P1031; Habuchi H, 1998, J BIOL CHEM, V273, P9208, DOI 10.1074/jbc.273.15.9208; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kappler J, 1997, EUR J NEUROSCI, V9, P306, DOI 10.1111/j.1460-9568.1997.tb01401.x; Kawashima H, 1999, INT IMMUNOL, V11, P393, DOI 10.1093/intimm/11.3.393; KIMATA K, 1973, MOL CELL BIOCHEM, V1, P211, DOI 10.1007/BF01659331; Kitagawa H, 1997, J BIOL CHEM, V272, P31377, DOI 10.1074/jbc.272.50.31377; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kobayashi M, 1999, J BIOL CHEM, V274, P10474, DOI 10.1074/jbc.274.15.10474; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maeda N, 1996, DEVELOPMENT, V122, P647; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MICHAL F, 1996, SCIENCE, V272, P1502; NAUJOKAS MF, 1993, CELL, V74, P257, DOI 10.1016/0092-8674(93)90417-O; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; OOHIRA A, 1998, CONNECT TISSUE, V30, P49; PENNYPACKER JP, 1981, DEV BIOL, V81, P280, DOI 10.1016/0012-1606(81)90291-8; Rossi A, 1996, J BIOL CHEM, V271, P18456, DOI 10.1074/jbc.271.31.18456; ROUCH U, 1992, J BIOL CHEM, V267, P19536; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; Sartipy P, 1996, J BIOL CHEM, V271, P26307, DOI 10.1074/jbc.271.42.26307; SHIBATA S, 1995, J BIOL CHEM, V270, P13794, DOI 10.1074/jbc.270.23.13794; SUGAHARA K, 1982, ARCH BIOCHEM BIOPHYS, V214, P589, DOI 10.1016/0003-9861(82)90064-9; THOMAS GJ, 1995, KIDNEY INT, V48, P1278, DOI 10.1038/ki.1995.412; TOYAMASORIMACHI N, 1995, J BIOL CHEM, V270, P7434; Uchimura K, 1998, GLYCOBIOLOGY, V8, P489, DOI 10.1093/glycob/8.5.489; Wakabayashi H, 1999, J BIOL CHEM, V274, P5436, DOI 10.1074/jbc.274.9.5436; WATANABE E, 1995, J BIOL CHEM, V270, P26876, DOI 10.1074/jbc.270.45.26876; Yamada H, 1997, J NEUROSCI, V17, P7784; YAMADA H, 1994, J BIOL CHEM, V269, P10119; Yamauchi S, 1999, J BIOL CHEM, V274, P2456, DOI 10.1074/jbc.274.4.2456	49	91	96	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8975	8981		10.1074/jbc.275.12.8975	http://dx.doi.org/10.1074/jbc.275.12.8975			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722746	hybrid			2022-12-27	WOS:000086507700096
J	Zhao, JL; Austen, KF; Lam, DK				Zhao, JL; Austen, KF; Lam, DK			Cell-specific transcription of leukotriene C-4 synthase involves a Kruppel like transcription factor and Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5-LIPOXYGENASE GENE PROMOTER; GLUTATHIONE-S-TRANSFERASE; MOLECULAR-CLONING; BINDING PROTEIN; MAST-CELLS; SEQUENCE; ACTIVATION; ELEMENT; EOSINOPHILS; GENERATION	Leukotriene C-4 synthase (LTC4S) is responsible for the biosynthesis of cysteinyl leukotrienes that participate in allergic and asthmatic inflammation. We analyzed 2.1 kilobases of the 5'-flanking region of the human LTC4S gene, which contains three DNase I hypersensitivity sites, for its transcriptional activity when fused to a promoterless and enhancerless luciferase gene. Deletion analysis revealed a nonspecific basal promoter region between nucleotides -122 and -56 upstream of the translation start site which contains a consensus Spl binding site and a putative initiator element (Inr) and cell-specific enhancer regions further upstream. A single mutation of either the Spl binding site between nucleotides -120 and -115 or the Inr (CAGAC) between nucleotides -66 and -62 reduced the expression of the reporter gene by similar to 60%, whereas double mutations decreased the expression by similar to 80%. The incubation of nuclear extracts from THP-1 and K562 cells with a P-32-labeled oligonucleotide containing the Spl site or the Inr sequence gave gel-shifted complexes that mere blocked by their respective cold oligonueleotides, and antisera specific for Spl and Sp3 provided supershifts for the former. Linker-scanning mutations of a cell-specific regulatory region revealed that mutations from nucleotides -165 to -125 reduced reporter activity. This region contains a tandem CACCC repeat (at nucleotides -149 to -145 and -139 to -135), An oligonucleotide containing the distal CACCC motif was gel shifted by THP-1 cell nuclear extract and was supershifted by antisera to Spl and Sp3, Cotransfection of an Spl expression plasmid into Drosophila SL2 cells with a -228 to -3 LTC4S reporter construct transactivated the reporter gene, whereas mutations at the CACCC repeat region reduced Spl transactivation by similar to 66%. Similarly, the Kruppel-like factor Zf9/CPBP (core promoter-binding protein) transactivated the -228 construct in COS cells but not its CACCC mutant construct. These findings indicate the involvement of Spl and an Inr in non-cell-specific regulation and a Kruppel-like transcription factor and Spl in the cell-specific regulation of the LTC4S gene. These are the first such analyses of a member of a newly recognized superfamily of membrane-associated proteins involved in eicosanoid and glutathione metabolism, which contains key proteins involved in the generation of both prostanoids and cysteinyl leukotrienes.	Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Lam, DK (corresponding author), Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Smith Bldg,Rm 628,1 Jimmy Fund Way, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022531, R01AI022531, U01AI031599, U19AI031599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES006105] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-31599, AI-22531] Funding Source: Medline; NIEHS NIH HHS [ES-06105] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALI A, 1994, J IMMUNOL, V153, P776; Bellorini M, 1996, MOL CELL BIOL, V16, P503; Bigby TD, 1996, MOL MED, V2, P637, DOI 10.1007/BF03401647; Boyce JA, 1996, BLOOD, V88, P4338; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; Crossley M, 1996, MOL CELL BIOL, V16, P1695; Gupta N, 1999, FEBS LETT, V449, P66, DOI 10.1016/S0014-5793(99)00397-X; HOSHIKO S, 1990, P NATL ACAD SCI USA, V87, P9073, DOI 10.1073/pnas.87.23.9073; In KH, 1997, J CLIN INVEST, V99, P1130, DOI 10.1172/JCI119241; Jakobsson PJ, 1999, PROTEIN SCI, V8, P689, DOI 10.1110/ps.8.3.689; Jakobsson PJ, 1996, J BIOL CHEM, V271, P22203, DOI 10.1074/jbc.271.36.22203; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Koritschoner NP, 1997, J BIOL CHEM, V272, P9573; Lam BK, 1997, J BIOL CHEM, V272, P13923, DOI 10.1074/jbc.272.21.13923; Lo K, 1996, GENE, V182, P13, DOI 10.1016/S0378-1119(96)00438-6; MACGLASHAN DW, 1986, J IMMUNOL, V136, P2231; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; MANCINI JA, 1995, EUR J BIOCHEM, V231, P65, DOI 10.1111/j.1432-1033.1995.tb20671.x; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MURAKAMI M, 1995, J BIOL CHEM, V270, P22653, DOI 10.1074/jbc.270.39.22653; NICHOLSON DW, 1993, P NATL ACAD SCI USA, V90, P2015, DOI 10.1073/pnas.90.5.2015; Penrose JF, 1996, J BIOL CHEM, V271, P11356, DOI 10.1074/jbc.271.19.11356; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Ratziu V, 1998, P NATL ACAD SCI USA, V95, P9500, DOI 10.1073/pnas.95.16.9500; Riddick CA, 1999, J IMMUNOL, V162, P1101; Sabath DE, 1996, NUCLEIC ACIDS RES, V24, P4978, DOI 10.1093/nar/24.24.4978; Silverman ES, 1998, AM J RESP CELL MOL, V19, P316, DOI 10.1165/ajrcmb.19.2.3154; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; ZHANG YH, 1994, P NATL ACAD SCI USA, V91, P2225, DOI 10.1073/pnas.91.6.2225; Zhao JL, 1996, J EXP MED, V183, P777, DOI 10.1084/jem.183.3.777	31	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8903	8910		10.1074/jbc.275.12.8903	http://dx.doi.org/10.1074/jbc.275.12.8903			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722737	hybrid			2022-12-27	WOS:000086507700087
J	Yamauchi, J; Kawano, T; Nagao, M; Kaziro, Y; Itoh, H				Yamauchi, J; Kawano, T; Nagao, M; Kaziro, Y; Itoh, H			G(i)-dependent activation of c-Jun N-terminal kinase in human embryonal kidney 293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; G-BETA-GAMMA; HETEROTRIMERIC G-PROTEINS; TYROSINE-KINASE; SIGNALING PATHWAY; BINDING PROTEINS; ALPHA-SUBUNITS; CLONING; RAS; 3-KINASE-GAMMA	Heterotrimeric G proteins stimulate the activities of two stress-activated protein kinases, c-dun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase in mammalian cells. In this study, we examined whether alpha subunits of G(i) family activate JNK using transient expression system in human embryonal kidney 293 cells. Constitutively activated mutants of G alpha(il), G alpha(i2), and G alpha(i3) increased JNK activity. In contrast, constitutively activated C alpha(o) and G alpha(z) mutants did not stimulate JNK activity. To examine the mechanism of JNK activation by G alpha(i), kinase-deficient mutants of mitogen-activated protein kinase kinase 4 (MKK4) and 7 (MKK7), which are, known to be JNK activators, were transfected into the cells. However, G alpha(i)-induced JNK activation was not blocked effectively by kinase-deficient MKK4 and MKK7. In addition, activated G alpha(i) mutant failed to stimulate MKK4 and MKK7 activities. Furthermore, JNK activation by Gai was inhibited by dominant-negative Rho and Cdc42 and tyrosine kinase inhibitors, but not dominant-negative Rac and phosphatidylinositol 3-kinase inhibitors. These results indicate that G alpha(i) regulates JNK activity dependent on small GTPases Rho and Cdc42 and on tyrosine kinase but not on MKK4 and MKK7.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Itoh, H (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.							Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1996, J BIOL CHEM, V271, P3963; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Dhanasekaran N, 1998, ONCOGENE, V17, P1383, DOI 10.1038/sj.onc.1202242; Edamatsu H, 1998, FEBS LETT, V440, P231, DOI 10.1016/S0014-5793(98)01457-4; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Guo JH, 1998, J BIOL CHEM, V273, P16487, DOI 10.1074/jbc.273.26.16487; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; ITOH H, 1986, P NATL ACAD SCI USA, V83, P3776, DOI 10.1073/pnas.83.11.3776; ITOH H, 1988, J BIOL CHEM, V263, P6656; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lopez-Ilasaca M, 1998, J BIOL CHEM, V273, P2505, DOI 10.1074/jbc.273.5.2505; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; SEKINE A, 1989, J BIOL CHEM, V264, P8602; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Sun YJ, 1999, J BIOCHEM, V125, P515, DOI 10.1093/oxfordjournals.jbchem.a022315; Tournier C, 1999, MOL CELL BIOL, V19, P1569; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; Yamauchi J, 1999, J BIOL CHEM, V274, P1957, DOI 10.1074/jbc.274.4.1957; Yamauchi J, 1997, J BIOL CHEM, V272, P7602, DOI 10.1074/jbc.272.12.7602; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	43	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7633	7640		10.1074/jbc.275.11.7633	http://dx.doi.org/10.1074/jbc.275.11.7633			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713072	hybrid			2022-12-27	WOS:000085913300032
J	Batisson, I; Vartanian, MD				Batisson, I; Vartanian, MD			Extracellular DsbA-insensitive folding of Escherichia coli heat-stable enterotoxin STa in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; GUANYLYL CYCLASE-C; MONOCLONAL-ANTIBODIES; COLORECTAL TUMORS; FORMATION INVIVO; CS31A FIMBRIAE; TOXIN; SECRETION; SEQUENCE; PATHWAY	To study the folding of human Escherichia coli heat-stable enterotoxin STh, we used the major protein subunit of CS31A fimbriae (ClpG) as a marker of STh secretion and a provider of a signal peptide. We established that STh genetically fused to the N or C terminus of ClpG was able to mobilize ClpG to the culture supernatant while still retaining full enterotoxicity. These features indicate that the STh activity was not altered by the chimeric structure and suggest that spatial conformation of STh in the fusion is close to that of the native toxin, thus permitting recognition and activation of the intestinal STh receptor in vivo. In contrast to other studies, we showed that disulfide bond formation did not occur in the periplasm through the DsbA pathway and that there was no correlation between DsbA and secretion, folding, or activity. This discrepancy was not attributable to the chimeric nature of STh since there was no effect of dsbA or dsbB mutations on secretion and activity of recombinant STh from which ClpG had been deleted. Periplasmic and lysate fractions of dsbA(+) and dsbA(-) cells did not have any STh activity. In addition, the STh chimera was exclusively found in an inactive reduced form intracellularly and in an active oxidized form extracellularly, irrespective of the dsbA background, Subsequently, a time course experiment in regard to the secretion of STh from both dsbA and dsbA(-) cells indicated that the enterotoxin activity (proper folding) in the extracellular milieu increased with time. Overall, these findings provide evidence that STa toxins can be cell-released in an unfolded state before being completely disulfide-bonded outside the cell.	Ctr Rech Clermont Ferrand Theix, INRA, Microbiol Lab, F-63122 St Genes Champanelle, France	INRAE	Vartanian, MD (corresponding author), Ctr Rech Clermont Ferrand Theix, INRA, Microbiol Lab, F-63122 St Genes Champanelle, France.							ACHESON DWK, 1992, J INFECTION, V24, P225, DOI 10.1016/S0163-4453(05)80028-3; ALDERETE JF, 1978, INFECT IMMUN, V19, P1021, DOI 10.1128/IAI.19.3.1021-1030.1978; Bader M, 1998, J BIOL CHEM, V273, P10302, DOI 10.1074/jbc.273.17.10302; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; BRANDWEIN H, 1985, INFECT IMMUN, V47, P242, DOI 10.1128/IAI.47.1.242-246.1985; Carrithers SL, 1996, P NATL ACAD SCI USA, V93, P14827, DOI 10.1073/pnas.93.25.14827; Carrithers SL, 1996, DIS COLON RECTUM, V39, P171, DOI 10.1007/BF02068072; DERVARTANIAN M, 1994, GENE, V148, P23, DOI 10.1016/0378-1119(94)90229-1; FIELD M, 1978, P NATL ACAD SCI USA, V75, P2800, DOI 10.1073/pnas.75.6.2800; GARIEPY J, 1987, P NATL ACAD SCI USA, V84, P8907, DOI 10.1073/pnas.84.24.8907; GIANNELLA RA, 1976, INFECT IMMUN, V14, P95, DOI 10.1128/IAI.14.1.95-99.1976; GIRARDEAU JP, 1991, J BACTERIOL, V173, P7673, DOI 10.1128/jb.173.23.7673-7683.1991; GIRARDEAU JP, 1988, INFECT IMMUN, V56, P2180, DOI 10.1128/IAI.56.8.2180-2188.1988; GUERRANT RL, 1980, J INFECT DIS, V142, P220, DOI 10.1093/infdis/142.2.220; GUILHOT C, 1995, P NATL ACAD SCI USA, V92, P9895, DOI 10.1073/pnas.92.21.9895; GUZMANVERDUZCO LM, 1989, INFECT IMMUN, V57, P645, DOI 10.1128/IAI.57.2.645-648.1989; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; MARTIN C, 1991, MICROB PATHOGENESIS, V10, P429, DOI 10.1016/0882-4010(91)90108-M; Mechin MC, 1996, GENE, V179, P211, DOI 10.1016/S0378-1119(96)00348-4; OKAMOTO K, 1990, J BACTERIOL, V172, P5260, DOI 10.1128/jb.172.9.5260-5265.1990; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RASHEED JK, 1988, MICROB PATHOGENESIS, V5, P333, DOI 10.1016/0882-4010(88)90034-4; RASHEED JK, 1990, MOL MICROBIOL, V4, P265, DOI 10.1111/j.1365-2958.1990.tb00593.x; Rietsch A, 1998, ANNU REV GENET, V32, P163, DOI 10.1146/annurev.genet.32.1.163; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ J, 1993, FEBS LETT, V330, P265, DOI 10.1016/0014-5793(93)80885-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO T, 1994, BIOCHEMISTRY-US, V33, P8641, DOI 10.1021/bi00195a004; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SCOTLAND SM, 1989, J CLIN MICROBIOL, V27, P1697, DOI 10.1128/JCM.27.7.1697-1699.1989; SO M, 1980, P NATL ACAD SCI-BIOL, V77, P4011, DOI 10.1073/pnas.77.7.4011; SO M, 1979, NATURE, V277, P453, DOI 10.1038/277453a0; TAKEDA T, 1993, INFECT IMMUN, V61, P289, DOI 10.1128/IAI.61.1.289-294.1993; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Waldman SA, 1998, DIS COLON RECTUM, V41, P310, DOI 10.1007/BF02237484; YAMANAKA H, 1994, J BACTERIOL, V176, P2906, DOI 10.1128/JB.176.10.2906-2913.1994; Yamanaka H, 1997, J BACTERIOL, V179, P3383, DOI 10.1128/jb.179.11.3383-3390.1997; YANG Y, 1992, MOL MICROBIOL, V6, P3521, DOI 10.1111/j.1365-2958.1992.tb01787.x	43	8	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10582	10589		10.1074/jbc.275.14.10582	http://dx.doi.org/10.1074/jbc.275.14.10582			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744753	Green Published, hybrid			2022-12-27	WOS:000086345600094
J	Bedford, MT; Sarbassova, D; Xu, J; Leder, P; Yaffe, MB				Bedford, MT; Sarbassova, D; Xu, J; Leder, P; Yaffe, MB			A novel Pro-Arg motif recognized by WW domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-3 DOMAINS; YES-ASSOCIATED PROTEIN; PROLINE-RICH PEPTIDES; SH3 DOMAIN; BINDING PROTEIN; SWISS-MODEL; SEQUENCE; IDENTIFICATION; LIGANDS; EXPRESSION	WW domains mediate protein-protein interactions through binding to short proline-rich sequences. Two distinct sequence motifs, PPXY and PPLP, are recognized by different classes of WW domains, and another class binds to phospho-Ser-Pro sequences. We now describe a novel Pro-Arg sequence motif recognized by a different class of WW domains using data from oriented peptide library screening, expression cloning, and in vitro binding experiments. The prototype member of this group is the WW domain of formin-binding protein 30 (FBP30), a p53-regulated molecule whose WW domains bind to Pro-Arg-rich cellular proteins. This new Pro-Arg sequence motif re-classifies the organization of WW domains based on ligand specificity, and the Pro-Arg class now includes the WW domains of FBP21 and FE65, A structural model is presented which rationalizes the distinct motifs selected by the WW domains of YAP, Pin1, and FBP30, The Pro-Arg motif identified for WW domains often overlaps with SH3 domain motifs within protein sequences, suggesting that the same extended proline-rich sequence could form discrete SH3 or WW domain complexes to transduce distinct cellular signals.	Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Signal Transduct,Dept Med, Boston, MA 02215 USA; Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Yaffe, MB (corresponding author), Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Signal Transduct,Dept Med, Boston, MA 02215 USA.	myaffe@bidmc.harvard.edu	Bedford, Mark T/E-7856-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03601] Funding Source: Medline; NIGMS NIH HHS [GM56203] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; BANERJI J, 1990, P NATL ACAD SCI USA, V87, P2374, DOI 10.1073/pnas.87.6.2374; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Craven RC, 1999, J VIROL, V73, P3359, DOI 10.1128/JVI.73.4.3359-3365.1999; Depraetere V, 1999, CELL DEATH DIFFER, V6, P883, DOI 10.1038/sj.cdd.4400564; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Espanel X, 1999, J BIOL CHEM, V274, P17284, DOI 10.1074/jbc.274.24.17284; Faber PW, 1998, HUM MOL GENET, V7, P1463, DOI 10.1093/hmg/7.9.1463; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Gavva NR, 1997, J BIOL CHEM, V272, P24105, DOI 10.1074/jbc.272.39.24105; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harty RN, 1999, J VIROL, V73, P2921, DOI 10.1128/JVI.73.4.2921-2929.1999; Irusta PM, 1998, EMBO J, V17, P6912, DOI 10.1093/emboj/17.23.6912; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kanelis V, 1998, BIOCHEM CELL BIOL, V76, P341, DOI 10.1139/bcb-76-2-3-341; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KINGSTON R, 1994, CURRENT PROTOCOLS MO, V1; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Linn H, 1997, BIOL CHEM, V378, P531, DOI 10.1515/bchm.1997.378.6.531; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Rentschler S, 1999, BIOL CHEM, V380, P431, DOI 10.1515/BC.1999.057; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Sudol M, 1996, TRENDS BIOCHEM SCI, V21, P161, DOI 10.1016/0968-0004(96)30018-2; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; TROMPETER HI, 1989, FEBS LETT, V253, P63, DOI 10.1016/0014-5793(89)80930-5; Wang GL, 1999, MOL CELL BIOL, V19, P342; Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737; Waragai M, 1999, HUM MOL GENET, V8, P977, DOI 10.1093/hmg/8.6.977; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yaffe MB, 1999, NATURE, V402, P30; YAFFE MB, 1999, IN PRESS METHODS ENZ; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	53	65	67	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10359	10369		10.1074/jbc.275.14.10359	http://dx.doi.org/10.1074/jbc.275.14.10359			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744724	hybrid			2022-12-27	WOS:000086345600065
J	Boneca, IG; Huang, ZH; Gage, DA; Tomasz, A				Boneca, IG; Huang, ZH; Gage, DA; Tomasz, A			Characterization of Staphylococcus aureus cell wall glycan strands, evidence for a new beta-N-acetylglucosaminidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; METHICILLIN-RESISTANT; ESCHERICHIA-COLI; STRUCTURAL CHARACTERIZATION; STREPTOCOCCUS-PNEUMONIAE; PEPTIDOGLYCAN; STRAIN; MUROPEPTIDES; SEPARATION; AUTOLYSIN	Using sequential digestion with the glycyl-glycine endopeptidase lysostaphin followed by the pneumococcal N-acetylmuramyl-L-alanine amidase (amidase), the glycan strands of the peptidoglycan of Staphylococcus aureus were purified and analyzed by a combination of reverse-phase-high pressure Liquid chromatography (HPLC) and mass spectrometry. Reverse-phase-RPLC resolved the glycan strands to a family of major peaks, which represented oligosaccharides composed of repeating disaccharide units (N-acetylglucosamine-[beta-1,4]-N-acetylmuramic acid) with different degrees of polymerization and terminating with N-acetylmuramic acid residues at the reducing ends. The method allowed separation of strands up to 23-26 disaccharide units with a predominant length between 3 and 10 and an average degree of polymerization of similar to 6. Glycan strands with a higher degree of polymerization (>26 disaccharide units) represented 10-15% of the total UV absorbing glycan material. A unique feature of the staphylococcal glycan strands was the presence of minor satellite peaks that were present throughout the HPLC elution profile eluting either just prior or shortly after the major oligosaccharide peaks. A number of observations including mass spectrometric analysis suggest that the satellites are the products of an N-acetylglucosaminidase activity that differs from the atl gene product and that appears to be involved with modification of the glycan strand structure.	Rockefeller Univ, Microbiol Lab, New York, NY 10021 USA; Michigan State Univ, Dept Biochem, Natl Inst Hlth Mass Spectrometry Facil, E Lansing, MI 48824 USA	Rockefeller University; Michigan State University	Tomasz, A (corresponding author), Rockefeller Univ, Microbiol Lab, 1230 York Ave, New York, NY 10021 USA.	Tomasz@ROCKVAX.ROCKEFELLER.EDU	Boneca, Ivo G/H-1677-2014	Boneca, Ivo G/0000-0001-8122-509X; Tomasz, Alexander/0000-0003-1520-1983				Arthur M, 1996, TRENDS MICROBIOL, V4, P401, DOI 10.1016/0966-842X(96)10063-9; Boneca IG, 1997, J BIOL CHEM, V272, P29053, DOI 10.1074/jbc.272.46.29053; DEJONGE BLM, 1993, J BACTERIOL, V175, P2779, DOI 10.1128/JB.175.9.2779-2782.1993; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11248; DELL A, 1988, BIOMED ENVIRON MASS, V16, P19, DOI 10.1002/bms.1200160104; DiBerardino M, 1996, FEBS LETT, V392, P184, DOI 10.1016/0014-5793(96)00809-5; GARCIABUSTOS J, 1990, P NATL ACAD SCI USA, V87, P5415, DOI 10.1073/pnas.87.14.5415; GARCIABUSTOS JF, 1987, J BIOL CHEM, V262, P15400; GARCIABUSTOS JF, 1987, J BACTERIOL, V169, P447, DOI 10.1128/jb.169.2.447-453.1987; GARCIABUSTOS JF, 1987, ANTIMICROB AGENTS CH, V31, P178, DOI 10.1128/AAC.31.2.178; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; Goffin C, 1998, MICROBIOL MOL BIOL R, V62, P1079, DOI 10.1128/MMBR.62.4.1079-1093.1998; HARZ H, 1990, ANAL BIOCHEM, V190, P120, DOI 10.1016/0003-2697(90)90144-X; Hiramatsu K, 1997, J ANTIMICROB CHEMOTH, V40, P135, DOI 10.1093/jac/40.1.135; HOLTJE JV, 1975, J BACTERIOL, V124, P1067; MATSUHASHI M, 1994, N COMP BIOC, V27, P55; OSHIDA T, 1992, J BACTERIOL, V174, P4952, DOI 10.1128/JB.174.15.4952-4959.1992; OSHIDA T, 1995, P NATL ACAD SCI USA, V92, P285, DOI 10.1073/pnas.92.1.285; QUINTELA JC, 1995, FEMS MICROBIOL LETT, V125, P95, DOI 10.1016/0378-1097(94)00479-B; Severin A, 1997, MICROB DRUG RESIST, V3, P391, DOI 10.1089/mdr.1997.3.391; Sieradzki K, 1999, NEW ENGL J MED, V340, P517, DOI 10.1056/NEJM199902183400704; Spratt BG, 1996, MOL MICROBIOL, V19, P639, DOI 10.1046/j.1365-2958.1996.442924.x; TIPPER DJ, 1968, BIOCHEMISTRY-US, V7, P1441, DOI 10.1021/bi00844a029; TONIN E, 1986, ANTIMICROB AGENTS CH, V30, P577, DOI 10.1128/AAC.30.4.577; VANDERIJN I, 1980, INFECT IMMUN, V27, P444, DOI 10.1128/IAI.27.2.444-448.1980; WANG WT, 1984, ANAL BIOCHEM, V141, P366, DOI 10.1016/0003-2697(84)90057-5; WARD JB, 1973, BIOCHEM J, V133, P395, DOI 10.1042/bj1330395	27	87	89	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					9910	9918		10.1074/jbc.275.14.9910	http://dx.doi.org/10.1074/jbc.275.14.9910			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744664	hybrid			2022-12-27	WOS:000086345600005
J	Linstedt, AD; Jesch, SA; Mehta, A; Lee, TH; Garcia-Mata, R; Nelson, DS; Sztul, E				Linstedt, AD; Jesch, SA; Mehta, A; Lee, TH; Garcia-Mata, R; Nelson, DS; Sztul, E			Binding relationships of membrane tethering components - The giantin N terminus and the GM130 N terminus compete for binding to the p115 C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PROTEIN-TRANSPORT; MITOTIC GOLGI FRAGMENTS; ENDOPLASMIC-RETICULUM; REQUIRES USO1P; MATRIX PROTEIN; VESICLES; CISTERNAE; DOCKING; STACKING; GRASP65	By forming a molecular tether between two membranes, p115, giantin, and GM130 may mediate multiple Golgi-related processes including vesicle transport, cisternae formation, and cisternal stacking. The tether is proposed to involve the simultaneous binding of p115 to giantin on one membrane and to GM130 on another membrane. To explore this model, we tested for the presence of the putative santin-p115-GM130 ternary complex. We first mapped p115-binding site in giantin to a 70-amino acid coiled-coil domain at the extreme N terminus, a position that may exist up to 400 nm away from the Golgi membrane. We then generated glutathione S-transferase (GST) fusion proteins containing either giantin's or GM130's p115 binding site and tested whether ouch proteins could bind p115 and GM130 or bind p115 and giantin, respectively. Unexpectedly, GST fusions containing either the giantin or the GM130 p115 binding site efficiently bound p115, but the p115 bound to GST-giantin did not bind GM130, and the p115 bound to GST-GM130 did not bind giantin, To explain this result, we mapped the giantin binding site in p115 and found that it is located at the C-terminal acidic domain, the same domain involved in binding GM130. The presence of a single binding site in p115 for giantin and GM130 was confirmed by demonstration that giantin and GM130 compete for binding to p115, These results question a simple tethering model involving a ternary giantin-p115-GM130 complex and suggest that p115-giantin and p115-GM130 interactions might mediate independent membrane tethering events.	Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA; Univ Alabama, Sch Med, Dept Cell Biol, Birmingham, AL 35294 USA	Carnegie Mellon University; University of Alabama System; University of Alabama Birmingham	Linstedt, AD (corresponding author), Carnegie Mellon Univ, Dept Biol Sci, 4400 5th Ave, Pittsburgh, PA 15213 USA.			Garcia-Mata, Rafael/0000-0002-7116-4411				Alvarez C, 1999, J CELL BIOL, V147, P1205, DOI 10.1083/jcb.147.6.1205; Bannykh SI, 1998, TRENDS CELL BIOL, V8, P21, DOI 10.1016/S0962-8924(97)01184-7; Barr FA, 1998, EMBO J, V17, P3258, DOI 10.1093/emboj/17.12.3258; Barr FA, 1997, CELL, V91, P253, DOI 10.1016/S0092-8674(00)80407-9; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; LINSTEDT AD, 1995, P NATL ACAD SCI USA, V92, P5102, DOI 10.1073/pnas.92.11.5102; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Nelson DS, 1998, J CELL BIOL, V143, P319, DOI 10.1083/jcb.143.2.319; Orci L, 1998, P NATL ACAD SCI USA, V95, P2279, DOI 10.1073/pnas.95.5.2279; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Rabouille C, 1998, CELL, V92, P603, DOI 10.1016/S0092-8674(00)81128-9; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; SEELIG HP, 1994, MOL CELL BIOL, V14, P2564, DOI 10.1128/MCB.14.4.2564; Shorter J, 1999, J CELL BIOL, V146, P57, DOI 10.1083/jcb.146.1.57; SLUSAREWICZ P, 1994, J CELL BIOL, V124, P405, DOI 10.1083/jcb.124.4.405; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; Yamakawa H, 1996, J STRUCT BIOL, V116, P356, DOI 10.1006/jsbi.1996.0053	27	65	68	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10196	10201		10.1074/jbc.275.14.10196	http://dx.doi.org/10.1074/jbc.275.14.10196			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744704	hybrid			2022-12-27	WOS:000086345600045
J	Mallampalli, RK; Ryan, AJ; Salome, RG; Jackowski, S				Mallampalli, RK; Ryan, AJ; Salome, RG; Jackowski, S			Tumor necrosis factor-alpha inhibits expression of CTP : phosphocholine cytidylyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDP-CHOLINE PATHWAY; RAT-LIVER CTP; NF-KAPPA-B; PHOSPHATIDYLCHOLINE SYNTHESIS; MESSENGER-RNA; CHOLINEPHOSPHATE CYTIDYLYLTRANSFERASE; INTRACELLULAR PROTEIN; TERMINAL DOMAIN; GENE-EXPRESSION; PHOSPHOLIPASE-C	We investigated the effects of tumor necrosis factor cu (TNF alpha), a key cytokine involved in inflammatory lung disease, on phosphatidylcholine (PtdCho) biosynthesis in a murine alveolar type II epithelial cell line (MLE-12). TNF alpha significantly inhibited [H-3]choline incorporation into PtdCho after 24 h of exposure. TNF alpha reduced the activity of CTP:phosphocholine cytidylyltransferase (CCT), the rate-regulatory enzyme within the CDP-choline pathway, by 40% compared with control, but it did not alter activities of choline kinase or cholinephosphotransferase. Immunoblotting revealed that TNF alpha inhibition of CCT activity was associated with a uniform decrease in the mass of CCT alpha in total cell lysates, cytosolic, microsomal, and nuclear subfractions of RILE cells, Northern blotting revealed no effects of the cytokine on steady-state levels of CCT alpha mRNA, and CCT beta mRNA was not detected. Incorporation of [S-35]methionine into immunoprecipitable CCT alpha protein in pulse and pulse-chase studies revealed that TNF alpha did not alter de novo synthesis of enzyme, but it substantially accelerated turnover of CCTa. Addition of N-acetyl-Leu-Leu-Nle-CHO (ALLN), the calpain I inhibitor, or lactacystin, the 20 S proteasome inhibitor, blocked the inhibition of PtdCho biosynthesis mediated by TNF alpha. TNF alpha-induced degradation of CCTa protein was partially blocked by ALLN or lactacystin, CCT was ubiquitinated, and ubiquitination increased after TNF alpha exposure. m-Calpain degraded both purified CCT and CCT in cellular extracts. Thus, TNF alpha inhibits PtdCho synthesis by modulating CCT protein stability via the ubiquitin-proteasome and calpain-mediated proteolytic pathways.	Univ Iowa, Coll Med, Dept Internal Med, Div Pulm, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Vet Affairs Med Ctr, Iowa City, IA 52242 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38163 USA	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital	Mallampalli, RK (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, Div Pulm, Iowa City, IA 52242 USA.		RYAN, Anderson/ACG-0319-2022; Jackowski, Suzanne/N-8168-2018	RYAN, Anderson/0000-0001-6241-7969; Jackowski, Suzanne/0000-0002-6855-1429	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL055584, R01HL055584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045737] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55584] Funding Source: Medline; NIGMS NIH HHS [GM45737] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIASDIAZ J, 1993, EUR J SURG, V159, P535; ARIASDIAZ J, 1994, J CLIN INVEST, V94, P244, DOI 10.1172/JCI117313; BALIBREA CANTERO JL, 1994, AM J RESP CRIT CARE, V149, P699, DOI 10.1164/ajrccm.149.3.8118639; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; BELARDELLI F, 1989, INT J CANCER, V44, P116, DOI 10.1002/ijc.2910440121; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BEYNON RJ, 1986, AM J PHYSIOL, V251, pC141, DOI 10.1152/ajpcell.1986.251.2.C141; Bladergroen BA, 1999, EUR J BIOCHEM, V264, P152, DOI 10.1046/j.1432-1327.1999.00589.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; BOTBOL V, 1983, J BIOL CHEM, V258, P1942; CANDELA M, 1991, J EXP MED, V174, P1363, DOI 10.1084/jem.174.6.1363; CHALVARDJIAN A, 1970, ANAL BIOCHEM, V36, P225, DOI 10.1016/0003-2697(70)90352-0; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Coleman CS, 1997, J BIOL CHEM, V272, P12164, DOI 10.1074/jbc.272.18.12164; CORNELL RB, 1995, BIOCHEM J, V310, P699, DOI 10.1042/bj3100699; CRAIG L, 1994, J BIOL CHEM, V269, P3311; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Cui Z, 1995, BIOCHEM J, V312, P939, DOI 10.1042/bj3120939; Donato NJ, 1998, J BIOL CHEM, V273, P5067, DOI 10.1074/jbc.273.9.5067; ELVIRA M, 1993, J BIOL CHEM, V268, P14294; FELDMAN DA, 1980, BIOCHIM BIOPHYS ACTA, V620, P603, DOI 10.1016/0005-2760(80)90152-6; FELDMAN DA, 1981, BIOCHIM BIOPHYS ACTA, V665, P53, DOI 10.1016/0005-2760(81)90231-9; GILFILLAN AM, 1983, J LIPID RES, V24, P1651; GROBLEWSKI GE, 1995, J BIOL CHEM, V270, P1437, DOI 10.1074/jbc.270.3.1437; GROSS I, 1986, PEDIATR RES, V20, P473; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HERTZOG JH, 1994, CRIT CARE MED, V22, P1969; Hogan M, 1996, BIOCHEM J, V314, P799, DOI 10.1042/bj3140799; HOUWELING M, 1993, EUR J BIOCHEM, V214, P927, DOI 10.1111/j.1432-1033.1993.tb17996.x; JAMIL H, 1992, J BIOL CHEM, V267, P1752; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; KOLESNICK RN, 1994, BIOCHEM CELL BIOL, V72, P471, DOI 10.1139/o94-063; Llovera M, 1997, BIOCHEM BIOPH RES CO, V230, P238, DOI 10.1006/bbrc.1996.5827; Lykidis A, 1998, J BIOL CHEM, V273, P14022, DOI 10.1074/jbc.273.22.14022; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; Mallampalli RK, 1996, BIOCHEM J, V318, P333, DOI 10.1042/bj3180333; MALLAMPALLI RK, 1994, AM J PHYSIOL-LUNG C, V267, pL641, DOI 10.1152/ajplung.1994.267.6.L641; Mallampalli RK, 1999, AM J PHYSIOL-LUNG C, V276, pL481, DOI 10.1152/ajplung.1999.276.3.L481; Mallampalli RK, 1997, J CLIN INVEST, V99, P2020, DOI 10.1172/JCI119370; MELLGREN RL, 1993, J BIOL CHEM, V268, P653; MILLER JC, 1981, J BIOL CHEM, V256, P2662; MORAND JN, 1986, ANAL BIOCHEM, V159, P157, DOI 10.1016/0003-2697(86)90321-0; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; NIEDERMAN MS, 1990, CLIN CHEST MED, V11, P633; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; SAKLATVALA J, 1995, BRIT MED BULL, V51, P402, DOI 10.1093/oxfordjournals.bmb.a072969; Schoenwaelder SM, 1997, J BIOL CHEM, V272, P24876, DOI 10.1074/jbc.272.40.24876; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SEUBERT P, 1987, SYNAPSE, V1, P20, DOI 10.1002/syn.890010105; SHIRATORI Y, 1995, J BIOL CHEM, V270, P29894; SLOMIANY A, 1992, EXP CELL RES, V201, P321, DOI 10.1016/0014-4827(92)90280-L; SOHAL PS, 1990, J BIOL CHEM, V265, P11746; Suzuki Y, 1996, IMMUNOLOGY, V87, P396, DOI 10.1046/j.1365-2567.1996.431546.x; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; Viscardi RM, 1997, BBA-LIPID LIPID MET, V1349, P157, DOI 10.1016/S0005-2760(97)00124-0; WATKINS JD, 1990, J BIOL CHEM, V265, P2190; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; Wieprecht M, 1996, J BIOL CHEM, V271, P9955, DOI 10.1074/jbc.271.17.9955; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; Xie HQ, 1997, J NEUROCHEM, V69, P1020; YANG W, 1995, J BIOL CHEM, V270, P16503, DOI 10.1074/jbc.270.28.16503	66	71	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9699	9708		10.1074/jbc.275.13.9699	http://dx.doi.org/10.1074/jbc.275.13.9699			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734122	hybrid			2022-12-27	WOS:000086206500086
J	Schmitt, EK; Kuck, U				Schmitt, EK; Kuck, U			The fungal CPCR1 protein, which binds specifically to beta-lactam biosynthesis genes, is related to human regulatory factor X transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PCBAB-PCBC PROMOTER; B VIRUS ENHANCER; PENICILLIUM-CHRYSOGENUM; ASPERGILLUS-NIDULANS; ACREMONIUM-CHRYSOGENUM; RFX1; FAMILY; YEAST; TRANSACTIVATOR; ACTIVATION	Here we report the isolation and characterization of a novel transcription factor from the cephalosporin C-producing fungus Acremonium chrysogenum. We have identified a protein binding site in the promoter of the p-lactam biosynthesis gene pcbC, located 418 nucleotides upstream of the translational start. Using the yeast one-hybrid system, we succeeded in isolating a cDNA clone encoding a polypeptide, which binds specifically to the pcbC promoter, The polypeptid shows significant sequence homology to human transcription factors of the regulatory factor X (RFX) family and was designated CPCR1, A high degree of CPCR1 binding specificity was observed in in vivo and in vitro experiments using mutated versions of the DNA binding site. The A, chrysogenum RFX protein CPCR1 recognizes an imperfect palindrome, which resembles binding sites of human RFX transcription factors. One- and two-hybrid experiments with truncated versions of CPCR1 showed that the protein forms a DNA binding homodimer. Nondenaturing electrophoresis revealed that the CPCR1 protein exists in vitro solely in a multimeric, probably dimeric, state. Finally, we isolated a homologue of the cpcR1 gene from the penicillin-producing fungus Penicillium chrysogenum and determined about 60% identical amino acid residues in the DNA binding domain of both fungal RFX proteins, which show an overall amino acid sequence identity of 29%.	Ruhr Univ Bochum, Lehrstuhl Allgemeine & Mol Bot, D-44780 Bochum, Germany	Ruhr University Bochum	Kuck, U (corresponding author), Ruhr Univ Bochum, Lehrstuhl Allgemeine & Mol Bot, Univ Str 150, D-44780 Bochum, Germany.							Ausubel F., 1999, CURRENT PROTOCOLS MO; Barry JK, 1999, BIOCHEMISTRY-US, V38, P6520, DOI 10.1021/bi9900727; Brakhage AA, 1998, MICROBIOL MOL BIOL R, V62, P547, DOI 10.1128/MMBR.62.3.547-585.1998; D'Alessio G, 1999, PROG BIOPHYS MOL BIO, V72, P271, DOI 10.1016/S0079-6107(99)00009-7; DAVID E, 1995, J BIOL CHEM, V270, P8353, DOI 10.1074/jbc.270.14.8353; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; EFTINK MR, 1994, BIOCHEMISTRY-US, V33, P10220, DOI 10.1021/bi00200a002; Emery P, 1996, MOL CELL BIOL, V16, P4486; Emery P, 1996, NUCLEIC ACIDS RES, V24, P803, DOI 10.1093/nar/24.5.803; Espeso EA, 1996, J BIOL CHEM, V271, P28825, DOI 10.1074/jbc.271.46.28825; FEDEROFF N, 1983, PLANT MOL BIOL REP, V1, P27; HAAS H, 1995, CURR GENET, V28, P177, DOI 10.1007/BF00315785; HOGE JHC, 1982, EXP MYCOL, V6, P225, DOI 10.1016/0147-5975(82)90114-1; Iwama A, 1999, MOL CELL BIOL, V19, P3940; Jackson-Fisher AJ, 1999, BIOCHEMISTRY-US, V38, P11340, DOI 10.1021/bi990911p; James P, 1996, GENETICS, V144, P1425; Katan Y, 1997, NUCLEIC ACIDS RES, V25, P3621, DOI 10.1093/nar/25.18.3621; Katan-Khaykovich Y, 1998, J BIOL CHEM, V273, P24504, DOI 10.1074/jbc.273.38.24504; Litzka O, 1998, EUR J BIOCHEM, V251, P758, DOI 10.1046/j.1432-1327.1998.2510758.x; Martin JF, 1998, APPL MICROBIOL BIOT, V50, P1, DOI 10.1007/s002530051249; MENNE S, 1994, APPL MICROBIOL BIOT, V42, P57; Minuth W., 1982, CURR GENET, V25, P34; Papagiannopoulos P, 1996, MOL GEN GENET, V251, P412, DOI 10.1007/s004380050184; Penalva MA, 1998, TRENDS BIOTECHNOL, V16, P483, DOI 10.1016/S0167-7799(98)01229-3; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Radzio R, 1997, APPL MICROBIOL BIOT, V48, P58, DOI 10.1007/s002530051015; REITH W, 1994, MOL CELL BIOL, V14, P1230, DOI 10.1128/MCB.14.2.1230; ROSE M, 1983, METHOD ENZYMOL, V101, P167; SIEGRIST CA, 1993, MOL CELL BIOL, V13, P6375, DOI 10.1128/MCB.13.10.6375; SMITH DJ, 1989, MOL GEN GENET, V216, P492, DOI 10.1007/BF00334395; Suarez T, 1996, MOL MICROBIOL, V20, P529, DOI 10.1046/j.1365-2958.1996.5421065.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ulmasov T, 1997, SCIENCE, V276, P1865, DOI 10.1126/science.276.5320.1865; Villard J, 1997, HUM MUTAT, V10, P430; WALZ M, 1991, CURR GENET, V19, P73, DOI 10.1007/BF00326285; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; WU SY, 1995, MOL CELL BIOL, V15, P1479	37	42	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9348	9357		10.1074/jbc.275.13.9348	http://dx.doi.org/10.1074/jbc.275.13.9348			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734077	hybrid			2022-12-27	WOS:000086206500041
J	Sevetson, BR; Svaren, J; Milbrandt, J				Sevetson, BR; Svaren, J; Milbrandt, J			A novel activation function for NAB proteins in EGR-dependent transcription of the luteinizing hormone beta gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; NGFI-A EGR-1; TRANSFORMING GROWTH-FACTOR-BETA-1; RETINOBLASTOMA PROTEIN; DEVELOPING HINDBRAIN; EPITHELIAL-CELLS; NERVOUS-SYSTEM; BINDING-SITE; MICE LACKING; PC12 CELLS	The EGR1/NGFI-A transcription factor directly activates the luteinizing hormone beta (LH beta) subunit promoter, and female mice lacking EGR1 are infertile due to LH beta deficiency. The NGFI-A-binding proteins NAB1 and NABS are corepressors of EGrR1/NGFI-A and of the related proteins EGB2/Krox20 and EGR3, Here we report that at certain promoters, including LH beta, NAB proteins display a novel ability to stimulate EGR-directed transcription. NAB coactivation requires the conserved NCD2 protein domain, previously implicated in NAB corepression, is strictly dependent upon EGR binding to the LH beta proximal promoter and is independent of EGR activation domains. Furthermore, we report that NAB-activated promoters such as LH beta contain EGR consensus sites that are fewer in number and lower in binding affinity than those found at NAB-repressed promoters such as basic fibroblast growth factor. Analysis of mutant and synthetic promoters confirms that both the strength and multiplicity of EGR-binding sites influence the transcriptional outcome of NAB recruitment. These results suggest a novel means by which EGR target genes could be differentially regulated in cells where EGR and NAB proteins are coexpressed.	Washington Univ, Sch Med, Dept Pathol & Internal Med, Div Lab Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Milbrandt, J (corresponding author), Washington Univ, Sch Med, Dept Pathol & Internal Med, Div Lab Med, 660 S Euclid Ave, St Louis, MO 63110 USA.	jeff@milbrandt.wustl.edu	Svaren, John/A-1605-2010	Svaren, John/0000-0003-2963-7921; Milbrandt, Jeffrey/0000-0002-5477-7689	NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NCI NIH HHS [5 P01 CA49712-08] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANSARI AZ, 1995, NATURE, V374, P371; Beckmann AM, 1997, NEUROCHEM INT, V31, P477, DOI 10.1016/S0197-0186(96)00136-2; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; Brown JA, 1998, J ACQ IMMUN DEF SYND, V17, P9, DOI 10.1097/00042560-199801010-00002; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; Dorn C, 1999, J BIOL CHEM, V274, P13870, DOI 10.1074/jbc.274.20.13870; Fan WM, 1997, MOL ENDOCRINOL, V11, P1342, DOI 10.1210/me.11.9.1342; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Halvorson LM, 1998, J BIOL CHEM, V273, P14712, DOI 10.1074/jbc.273.24.14712; Harding HP, 1997, MOL ENDOCRINOL, V11, P1737, DOI 10.1210/me.11.11.1737; Hidalgo E, 1997, EMBO J, V16, P1056, DOI 10.1093/emboj/16.5.1056; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KIM KE, 1990, MOL CELL ENDOCRINOL, V74, P101, DOI 10.1016/0303-7207(90)90112-L; KIM SJ, 1994, J BIOL CHEM, V269, P3739; KIM SJ, 1989, J BIOL CHEM, V264, P402; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kraus RJ, 1996, NUCLEIC ACIDS RES, V24, P1531, DOI 10.1093/nar/24.8.1531; Kristjuhan A, 1995, EUR J BIOCHEM, V234, P827, DOI 10.1111/j.1432-1033.1995.827_a.x; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; Levi G, 1996, DEVELOPMENT, V122, P113; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Mannervik M, 1999, SCIENCE, V284, P606, DOI 10.1126/science.284.5414.606; Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744; Mittelstadt PR, 1999, J BIOL CHEM, V274, P3222, DOI 10.1074/jbc.274.5.3222; Monsalve M, 1997, MOL CELL, V1, P99, DOI 10.1016/S1097-2765(00)80011-8; MYERS RM, 1985, NUCLEIC ACIDS RES, V13, P3111, DOI 10.1093/nar/13.9.3111; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; O'Donovan KJ, 1998, J NEUROCHEM, V70, P1241; O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166-2236(98)01343-5; PAULSEN RE, 1992, J BIOL CHEM, V267, P16491; Qu ZC, 1998, J CELL BIOL, V142, P1075, DOI 10.1083/jcb.142.4.1075; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; Seitanidou T, 1997, MECH DEVELOP, V65, P31, DOI 10.1016/S0925-4773(97)00051-8; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Svaren J, 1998, EMBO J, V17, P6010, DOI 10.1093/emboj/17.20.6010; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; Swirnoff AH, 1998, MOL CELL BIOL, V18, P512, DOI 10.1128/MCB.18.1.512; Theil T, 1998, DEVELOPMENT, V125, P443; TONY Y, 1995, CURR BIOL, V5, P1; Topilko P, 1998, MOL ENDOCRINOL, V12, P107, DOI 10.1210/mend.12.1.0049; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Tourtellotte WG, 1999, DEVELOPMENT, V126, P5061; Tourtellotte WG, 1998, NAT GENET, V20, P87, DOI 10.1038/1757; Tremblay JJ, 1999, MOL CELL BIOL, V19, P2567; VANDERWOUDE MW, 1995, MOL MICROBIOL, V17, P303, DOI 10.1111/j.1365-2958.1995.mmi_17020303.x; Wallin JJ, 1998, SCIENCE, V279, P1961, DOI 10.1126/science.279.5358.1961; Wang D, 1997, ONCOGENE, V14, P2291, DOI 10.1038/sj.onc.1201069; WANG ZY, 1995, ONCOGENE, V10, P1243; Warner LE, 1999, HUM MOL GENET, V8, P1245, DOI 10.1093/hmg/8.7.1245; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Wolfe MW, 1999, MOL ENDOCRINOL, V13, P752, DOI 10.1210/me.13.5.752	63	78	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9749	9757		10.1074/jbc.275.13.9749	http://dx.doi.org/10.1074/jbc.275.13.9749			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734128	hybrid			2022-12-27	WOS:000086206500092
J	Rothermel, B; Vega, RB; Yang, J; Wu, H; Bassel-Duby, R; Williams, RS				Rothermel, B; Vega, RB; Yang, J; Wu, H; Bassel-Duby, R; Williams, RS			A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TRANSCRIPTIONAL PATHWAY; CARDIAC-HYPERTROPHY; GENE-REGULATION; CYCLOSPORINE-A; FAMILY MEMBER; FACTOR NFAT1; NF-AT; ACTIVATION; EXPRESSION; PHOSPHATASE	Here we describe a small family of proteins, termed MCIP1 and MCIP2 (for myocyte-enriched calcineurin interacting protein), that are expressed most abundantly in striated muscles and that form a physical complex with calcineurin A. MCIP1 is encoded by DSCR1, a gene located in the Down syndrome critical region, Expression of the MCIP family of proteins is up-regulated during muscle differentiation, and their forced overexpression inhibits calcineurin signaling to a muscle-specific target gene in a myocyte cell background. Binding of MCIP1 to calcineurin A requires sequence motifs that resemble calcineurin interacting domains found in NFAT proteins. The inhibitory action of MCIP1 involves a direct association with the catalytic domain of calcineurin, rather than interference with the function of downstream components of the calcineurin signaling pathway, The interaction between MCIP proteins and calcineurin may modulate calcineurin-dependent pathways that control hypertrophic growth and selective programs of gene expression in striated muscles.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Williams, RS (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd,NB11-200, Dallas, TX 75390 USA.							Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Ding B, 1999, CIRC RES, V84, P729, DOI 10.1161/01.RES.84.6.729; Dunn SE, 1999, J BIOL CHEM, V274, P21908, DOI 10.1074/jbc.274.31.21908; Epstein CJ, 1995, METABOLIC MOL BASES, VI, P749; FUENTES JJ, 1995, HUM MOL GENET, V4, P1935, DOI 10.1093/hmg/4.10.1935; Fuentes JJ, 1997, GENOMICS, V44, P358, DOI 10.1006/geno.1997.4866; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; GRAYSON J, 1995, MOL CELL BIOL, V15, P1870; Grayson J, 1998, J CELL BIOCHEM, V70, P366, DOI 10.1002/(SICI)1097-4644(19980901)70:3<366::AID-JCB10>3.3.CO;2-T; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Ho N, 1996, J EXP MED, V184, P101, DOI 10.1084/jem.184.1.101; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Kashishian A, 1998, J BIOL CHEM, V273, P27412, DOI 10.1074/jbc.273.42.27412; KINGSBURY TJ, 1998, YEAST GENETICS MOL M, P98; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; Liu SF, 1997, EMBO J, V16, P143, DOI 10.1093/emboj/16.1.143; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; Mao ZX, 1999, J BIOL CHEM, V274, P31102, DOI 10.1074/jbc.274.43.31102; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; MARBAN E, 1987, P NATL ACAD SCI USA, V84, P6005, DOI 10.1073/pnas.84.16.6005; Masuda ES, 1997, MOL CELL BIOL, V17, P2066, DOI 10.1128/MCB.17.4.2066; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857; Miyazaki T, 1996, J BIOL CHEM, V271, P14567, DOI 10.1074/jbc.271.24.14567; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Naya FJ, 1999, DEVELOPMENT, V126, P2045; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; Seidman CE, 1998, BASIC RES CARDIOL, V93, P13; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Yang Q, 1997, MOL CELL BIOL, V17, P5236, DOI 10.1128/MCB.17.9.5236; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Zhang WG, 1999, CIRC RES, V84, P722, DOI 10.1161/01.RES.84.6.722; Zhuo M, 1999, P NATL ACAD SCI USA, V96, P4650, DOI 10.1073/pnas.96.8.4650	52	353	370	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8719	8725		10.1074/jbc.275.12.8719	http://dx.doi.org/10.1074/jbc.275.12.8719			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722714	hybrid			2022-12-27	WOS:000086507700064
J	Tang, H; Zhao, ZZJ; Landon, EJ; Inagami, T				Tang, H; Zhao, ZZJ; Landon, EJ; Inagami, T			Regulation of calcium-sensitive tyrosine kinase Pyk2 by angiotensin II in endothelial cells - Roles of Yes tyrosine kinase and tyrosine phosphatase SHP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; GTPASE-ACTIVATING PROTEIN; FOCAL ADHESION; TERMINAL KINASE; GROWTH-FACTOR; SH2 DOMAINS; S6 KINASE; PHOSPHORYLATION; RECEPTOR; BETA	Calcium-sensitive tyrosine kinase Pyk2 has been implicated in the regulation of ion channels, cellular adhesion, and mitogenic and hypertrophic reactions. In this study, we have investigated the regulation of Pyk2 by angiotensin II (Ang II) in pulmonary vein endothelial cells. We found that the Ang II-induced tyrosine phosphorylation of Pyk2, which requires the activity of Src family kinase, was specifically regulated by the Src family kinase member, Yes kinase, Moreover, we identified for the first time the constitutive association of Pyk2 with an Src homology 2 (SH2) domain-containing tyrosine phosphatase SHP-2. SHP-2 interacts with Pyk2 through a region other than its SH2 domains. Pyk2 can be dephosphorylated in vitro in SHP-2 immunoprecipitates and in intact cells expressing an NH, terminus-truncated form of SHP-2, which lacks the two SH2 domains but has an enhanced phosphatase activity. Ang II activates the endogenous SHP-2, Finally, the SHP-2-mediated dephosphorylation of Pyk2 correlates with the negative effect of SHP-2 on the Ang II-induced activation of extracellular signal-regulated kinase and c-Jun NH2-terminal kinase. Thus, the balance of Pyk2 tyrosine phosphorylation in response to Ang II is controlled by Yes kinase and by a tyrosine phosphatase SHP-2 in endothelial cells.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Div Hematol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Inagami, T (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 663 Light Hall, Nashville, TN 37232 USA.	hua.tang@vanderbilt.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057393, R01HL058205, R37HL058205] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-57393, HL-58205] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ali MS, 1997, J BIOL CHEM, V272, P12373, DOI 10.1074/jbc.272.19.12373; Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; Andreev J, 1999, MOL CELL BIOL, V19, P2338; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; Berk BC, 1999, J AM SOC NEPHROL, V10, pS62; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Byon JCH, 1997, P SOC EXP BIOL MED, V216, P1; Deb TB, 1998, J BIOL CHEM, V273, P16643, DOI 10.1074/jbc.273.27.16643; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Eguchi S, 1999, HYPERTENSION, V33, P201, DOI 10.1161/01.HYP.33.1.201; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Ganju RK, 1998, BLOOD, V91, P791, DOI 10.1182/blood.V91.3.791.791_791_797; Goodfriend TL, 1996, NEW ENGL J MED, V334, P1649, DOI 10.1056/NEJM199606203342507; Graves LM, 1997, J BIOL CHEM, V272, P1920, DOI 10.1074/jbc.272.3.1920; Griendling KK, 1997, HYPERTENSION, V29, P366, DOI 10.1161/01.HYP.29.1.366; Guo XYD, 1998, BLOOD, V92, p253A; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Inagami T, 1999, J AM SOC NEPHROL, V10, pS57; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lakkakorpi PT, 1999, J BIOL CHEM, V274, P4900, DOI 10.1074/jbc.274.8.4900; LEDUC I, 1995, J BIOL CHEM, V270, P4401, DOI 10.1074/jbc.270.9.4401; Lev S, 1999, MOL CELL BIOL, V19, P2278; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; Liu ZY, 1997, J CLIN INVEST, V99, P1798, DOI 10.1172/JCI119344; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; Marrero MB, 1996, CELL SIGNAL, V8, P21, DOI 10.1016/0898-6568(95)02016-0; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Murasawa S, 1998, HYPERTENSION, V32, P668, DOI 10.1161/01.HYP.32.4.668; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Ohba T, 1998, BIOCHEM J, V330, P1249, DOI 10.1042/bj3301249; Pueyo ME, 1997, GEN PHARMACOL-VASC S, V29, P691, DOI 10.1016/S0306-3623(97)00021-9; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Sayeski PP, 1998, CIRC RES, V82, P1279, DOI 10.1161/01.RES.82.12.1279; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TANG H, 1995, CIRC RES, V77, P239, DOI 10.1161/01.RES.77.2.239; Tang H, 1999, J BIOL CHEM, V274, P12401, DOI 10.1074/jbc.274.18.12401; Tang H, 1998, CIRC RES, V82, P523, DOI 10.1161/01.RES.82.5.523; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P19772, DOI 10.1074/jbc.273.31.19772; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zhang ZY, 1999, J BIOL CHEM, V274, P25093, DOI 10.1074/jbc.274.35.25093; Zhao RX, 1999, BIOCHEM J, V338, P35, DOI 10.1042/0264-6021:3380035; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; Zhao ZZ, 1996, J BIOL CHEM, V271, P22251, DOI 10.1074/jbc.271.36.22251	61	70	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8389	8396		10.1074/jbc.275.12.8389	http://dx.doi.org/10.1074/jbc.275.12.8389			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722671	hybrid			2022-12-27	WOS:000086507700021
J	Hasegawa, T; Yamaguchi, K; Wada, T; Takeda, A; Itoyama, Y; Miyagi, T				Hasegawa, T; Yamaguchi, K; Wada, T; Takeda, A; Itoyama, Y; Miyagi, T			Molecular cloning of mouse ganglioside sialidase and its increased expression in Neuro2a cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; HUMAN NEUROBLASTOMA-CELLS; RAT-BRAIN; CYTOSOLIC SIALIDASE; PLASMA-MEMBRANE; PROTEIN-KINASE; MESSENGER-RNA; LYSOSOMAL SIALIDASE; NEURITE OUTGROWTH; BOVINE BRAIN	Ganglioside sialidases have been implicated in neuronal differentiation processes, including neurite outgrowth. To understand further the roles and regulation mechanisms of the sialidase in neuronal systems, we have cloned mouse ganglioside sialidase cDNA and observed its expression in Neuro2a cell differentiation. A 3339-base pair cDNA, cloned based on the sequence information of previously cloned enzymes, encodes 418 amino acids containing three Asp boxes characteristic of sialidases. Northern blot analysis revealed a 3.4-kilo-base transcript expressed highly in heart but also in several other tissues including brain. In situ hybridization of mouse brain demonstrated the mRNA to be present in the cerebral cortex, as well as in the granule cell layer, Purkinje cells, and deep cerebellar nucleus of the cerebellum. Transient expression of the cDNA in COS-1 cells resulted in over 300-fold increase in sialidase activity toward gangliosides compared with the control level, with a preference for ganglioside substrate. During 5-bromodeoxyuridine-induced Neuro2a cell differentiation, the expression of the sialidase was increased as assessed by activity assays and quantitative reverse transcription-polymerase chain reaction analyses. Stable transfection of the sialidase in Neuro2a cells resulted in accelerated neurite arborization following 5-bromodeoxyuridine treatment, indicating the direct participation of this ganglioside sialidase in neuronal cell differentiation.	Miyagi Prefectural Canc Ctr, Res Inst, Div Biochem, Natori, Miyagi 9811293, Japan; Tohoku Univ, Sch Med, Dept Neurol, Sendai, Miyagi 9808574, Japan	Tohoku University	Miyagi, T (corresponding author), Miyagi Prefectural Canc Ctr, Res Inst, Div Biochem, 47-1 Nodayama, Natori, Miyagi 9811293, Japan.		Hasegawa, Takafumi/I-6668-2017					AKIYAMA Y, 1998, P 9 GEN INF WORKSH G, P131; AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; Bonten E, 1996, GENE DEV, V10, P3156, DOI 10.1101/gad.10.24.3156; Carrillo MB, 1997, GLYCOBIOLOGY, V7, P975; CHATTERJEE D, 1992, BRAIN RES, V583, P31, DOI 10.1016/S0006-8993(10)80007-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIESIELSKITRESKA J, 1977, DIFFERENTIATION, V8, P31, DOI 10.1111/j.1432-0436.1977.tb00918.x; CUELLO AC, 1989, P NATL ACAD SCI USA, V86, P2056, DOI 10.1073/pnas.86.6.2056; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FACCI L, 1984, J NEUROCHEM, V42, P299, DOI 10.1111/j.1471-4159.1984.tb02678.x; FERRARI G, 1983, DEV BRAIN RES, V8, P215, DOI 10.1016/0165-3806(83)90006-8; FERRARI G, 1995, J BIOL CHEM, V270, P3074, DOI 10.1074/jbc.270.7.3074; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Fronda CL, 1999, BIOCHEM BIOPH RES CO, V258, P727, DOI 10.1006/bbrc.1999.0698; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; HAKOMORI S, 1993, BIOCHEM SOC T, V21, P583, DOI 10.1042/bst0210583; HARA S, 1986, J CHROMATOGR, V377, P111, DOI 10.1016/S0378-4347(00)80766-5; Hata K, 1998, J BIOCHEM-TOKYO, V123, P899; HILBUSH BS, 1991, P NATL ACAD SCI USA, V88, P5616, DOI 10.1073/pnas.88.13.5616; Igdoura SA, 1998, HUM MOL GENET, V7, P115, DOI 10.1093/hmg/7.1.115; IHARA Y, 1995, GLYCOCONJUGATE J, V12, P787, DOI 10.1007/BF00731240; KOJIMA N, 1994, J BIOL CHEM, V269, P30451; Kopitz J, 1996, GLYCOBIOLOGY, V6, P367, DOI 10.1093/glycob/6.3.367; KOPITZ J, 1994, BIOCHEM BIOPH RES CO, V199, P1188, DOI 10.1006/bbrc.1994.1356; KOTANI M, 1993, GLYCOBIOLOGY, V3, P137, DOI 10.1093/glycob/3.2.137; KOTANI M, 1994, GLYCOBIOLOGY, V4, P855, DOI 10.1093/glycob/4.6.855; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kozireski-Chuback D, 1999, J NEUROSCI RES, V55, P107, DOI 10.1002/(SICI)1097-4547(19990101)55:1<107::AID-JNR12>3.0.CO;2-E; LI RX, 1992, J NEUROCHEM, V59, P2297; Mahoney JA, 1997, BBA-BIOMEMBRANES, V1328, P30, DOI 10.1016/S0005-2736(97)00070-9; Marchesini S, 1998, FEBS LETT, V428, P115, DOI 10.1016/S0014-5793(98)00510-9; Milner CM, 1997, J BIOL CHEM, V272, P4549, DOI 10.1074/jbc.272.7.4549; MIYAGI T, 1985, J BIOL CHEM, V260, P6710; MIYAGI T, 1984, EUR J BIOCHEM, V141, P75, DOI 10.1111/j.1432-1033.1984.tb08159.x; MIYAGI T, 1990, J BIOCHEM-TOKYO, V107, P787, DOI 10.1093/oxfordjournals.jbchem.a123126; Miyagi T, 1999, J BIOL CHEM, V274, P5004, DOI 10.1074/jbc.274.8.5004; MIYAGI T, 1993, J BIOL CHEM, V268, P26435; Monti E, 1999, GENOMICS, V57, P137, DOI 10.1006/geno.1999.5749; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Palestini P, 1998, BIOCHEMISTRY-US, V37, P3143, DOI 10.1021/bi971838a; PITTO M, 1989, J NEUROCHEM, V53, P1464, DOI 10.1111/j.1471-4159.1989.tb08539.x; Pshezhetsky AV, 1997, NAT GENET, V15, P316, DOI 10.1038/ng0397-316; PURPURA D P, 1977, Nature (London), V266, P553, DOI 10.1038/266553a0; RAHMANN H, 1983, NEUROCHEM INT, V5, P539, DOI 10.1016/0197-0186(83)90044-X; RIBONI L, 1995, J NEUROCHEM, V64, P451; ROGGENTIN P, 1989, GLYCOCONJUGATE J, V6, P349, DOI 10.1007/BF01047853; ROISEN FJ, 1981, SCIENCE, V214, P577, DOI 10.1126/science.7291999; Rottier RJ, 1998, HUM MOL GENET, V7, P313, DOI 10.1093/hmg/7.2.313; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; SAITO M, 1992, J NEUROCHEM, V58, P83, DOI 10.1111/j.1471-4159.1992.tb09280.x; SAITO M, 1995, J NEUROSCI RES, V40, P401, DOI 10.1002/jnr.490400315; SCHENGRUND CL, 1970, J BIOL CHEM, V245, P6196; SCHUBERT D, 1970, P NATL ACAD SCI USA, V67, P247, DOI 10.1073/pnas.67.1.247; SKAPER SD, 1994, GLYCOBIOLOGY BRAIN, P213; SPIRMAN N, 1982, J NEUROCHEM, V39, P874, DOI 10.1111/j.1471-4159.1982.tb07974.x; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; SVENNERHOLM L, 1989, BIOCHIM BIOPHYS ACTA, V1005, P109, DOI 10.1016/0005-2760(89)90175-6; TSUJI S, 1983, J BIOCHEM-TOKYO, V94, P303, DOI 10.1093/oxfordjournals.jbchem.a134344; TSUJI S, 1988, J BIOCHEM, V104, P498, DOI 10.1093/oxfordjournals.jbchem.a122498; UEMURA K, 1991, J BIOCHEM-TOKYO, V110, P96, DOI 10.1093/oxfordjournals.jbchem.a123549; VANIER MT, 1971, J NEUROCHEM, V18, P581, DOI 10.1111/j.1471-4159.1971.tb11988.x; Wada T, 1999, BIOCHEM BIOPH RES CO, V261, P21, DOI 10.1006/bbrc.1999.0973; WU GS, 1991, J NEUROCHEM, V56, P95, DOI 10.1111/j.1471-4159.1991.tb02567.x; YEE HF, 1989, AM J PHYSIOL, V256, pC1267, DOI 10.1152/ajpcell.1989.256.6.C1267; YOHE HC, 1977, J BIOL CHEM, V252, P2412	65	108	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8007	8015		10.1074/jbc.275.11.8007	http://dx.doi.org/10.1074/jbc.275.11.8007			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713120	hybrid			2022-12-27	WOS:000085913300080
J	Kim, JW; Kim, K; Kang, K; Joe, CO				Kim, JW; Kim, K; Kang, K; Joe, CO			Inhibition of homodimerization of poly(ADP-ribose) polymerase by its C-terminal cleavage products produced during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; ADP-RIBOSYLATION; CALF THYMUS; PROTEIN; CELLS; TOPOISOMERASE; ASSOCIATION; STIMULATION; SUBSTRATE; PROTEASES	biochemical role of the C-terminal fragment of poly(ADP-ribose) polymerase (PARP) was investigated in HeLa cells undergoing UV-mediated apoptoisis. During the course of apoptosis, the C-terminal cleavage product of PARP interacted with intact PARP and down-regulated PARP activity by blocking the homodimerization of PARP. The basic leucine zipper motif in the auto-modification domain of the C-terminal fragment of PARP represented the site of association, and Leu(405) was critical to the ability of the basic leucine zipper motif to associate with intact PARP. The expression of the C-terminal fragment of PARP stimulated UV-mediated apoptosis. These results suggest that the C-terminal cleavage product of PARP produced during apoptosis blocks the homodimerization of PARP and inhibits the cellular PARP activity. The inhibition of the cellular PARP activity might prevent cellular NAD(+) depletion and stimulate apoptosis by maintaining the basal cellular energy level required for the completion of apoptosis.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Joe, CO (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.		KIM, JIN WOO/C-1655-2011; Kim, Karam/K-1412-2018	KIM, JIN WOO/0000-0003-0767-1918; Kim, Karam/0000-0002-1886-5163				BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BAUER PI, 1990, BIOCHEM J, V270, P17, DOI 10.1042/bj2700017; CLIMENT I, 1991, BIOCHEMISTRY-US, V30, P5164, DOI 10.1021/bi00235a008; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DARBY MK, 1985, EMBO J, V4, P2129, DOI 10.1002/j.1460-2075.1985.tb03903.x; Eguchi Y, 1999, CANCER RES, V59, P2174; FERRO AM, 1984, J BIOL CHEM, V259, P547; GRUBE K, 1991, ANAL BIOCHEM, V193, P236, DOI 10.1016/0003-2697(91)90015-L; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Herceg Z, 1999, MOL CELL BIOL, V19, P5124; HULETSKY A, 1985, EUR J BIOCHEM, V146, P277, DOI 10.1111/j.1432-1033.1985.tb08650.x; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; MENDOZAALVAREZ H, 1993, J BIOL CHEM, V268, P22575; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; NOSSERI C, 1994, EXP CELL RES, V212, P367, DOI 10.1006/excr.1994.1156; OHASHI Y, 1986, BIOCHEM BIOPH RES CO, V140, P666, DOI 10.1016/0006-291X(86)90783-7; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; RHUN JYL, 1998, BIOCHEM BIOPH RES CO, V245, P1; Rosenthal DS, 1997, EXP CELL RES, V232, P313, DOI 10.1006/excr.1997.3536; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Simbulan-Rosenthal CM, 1999, CANCER RES, V59, P2190; Smulson ME, 1998, CANCER RES, V58, P3495; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; UCHIDA K, 1993, P NATL ACAD SCI USA, V90, P3481, DOI 10.1073/pnas.90.8.3481; VanGool L, 1997, EUR J BIOCHEM, V244, P15; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WesierskaGadek J, 1996, BIOCHEM BIOPH RES CO, V224, P96, DOI 10.1006/bbrc.1996.0990; YOSHIDA S, 1994, MOL CELL BIOCHEM, V138, P39, DOI 10.1007/BF00928441; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	40	35	36	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8121	8125		10.1074/jbc.275.11.8121	http://dx.doi.org/10.1074/jbc.275.11.8121			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713134	hybrid			2022-12-27	WOS:000085913300094
J	Muthuswami, R; Truman, PA; Mesner, LD; Hockensmith, JW				Muthuswami, R; Truman, PA; Mesner, LD; Hockensmith, JW			A eukaryotic SWI2/SNF2 domain, an exquisite detector of double-stranded to single-stranded DNA transition elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SWI/SNF COMPLEX; SACCHAROMYCES-CEREVISIAE; PROTEINS; BINDING; FAMILY; SEQUENCE; MOT1	Many members of the SWI2/SNF2 family of adenosine triphosphatases participate in the assembly/disassembly of multiprotein complexes involved in the DNA metabolic processes of transcription, recombination, repair, and chromatin remodeling The DNA molecule serves as an essential effector or catalyst for most of the members of this particular class of proteins, and the structure of the DNA mag be more important than the nucleotide sequence. Inspection of the DNA structure at sites where multiprotein complexes are assembled/disassembled for these various DNA metabolic processes reveals the presence of a common element: a double-stranded to single-stranded transition region. We now show that; this DNA element is crucial for the ATP hydrolytic function of an SWI2/SNF2 family member: DNA-dependent ATPase A. We further demonstrate that a domain containing the seven helicase-related motifs that are common to the SWI2/SNF2 family of proteins mediates the interaction with the DNA, yielding specific DNA structural recognition. This study forms a primary step toward understanding the physico-biochemical nature of the interaction between a particular class of DNA-dependent ATPase and their DNA effecters. Furthermore, this study provides a foundation for development of mechanisms to specifically target this class of DNA-dependent ATPases.	Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Hockensmith, JW (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, POB 800733, Charlottesville, VA 22908 USA.	jwh6f@virginia.edu	Muthuswami, Rohini/Q-9841-2019	Muthuswami, Rohini/0000-0002-0559-9484	NIGMS NIH HHS [GM-43569, GM-08136] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HOCKENSMITH JW, 1986, BIOCHEMISTRY-US, V25, P7812, DOI 10.1021/bi00372a005; JARVIS TC, 1989, J BIOL CHEM, V264, P12717; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; MESNER LD, 1993, BIOCHEMISTRY-US, V32, P7772, DOI 10.1021/bi00081a024; MESNER LD, 1991, BIOCHEMISTRY-US, V30, P11490, DOI 10.1021/bi00113a002; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Pohler JRG, 1998, EMBO J, V17, P817, DOI 10.1093/emboj/17.3.817; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; Wang WD, 1998, P NATL ACAD SCI USA, V95, P492, DOI 10.1073/pnas.95.2.492; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181; ZUKER M, 1989, METHOD ENZYMOL, V180, P262	26	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7648	7655		10.1074/jbc.275.11.7648	http://dx.doi.org/10.1074/jbc.275.11.7648			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713074	hybrid			2022-12-27	WOS:000085913300034
J	Valentin, E; Ghomashchi, F; Gelb, MH; Lazdunski, M; Lambeau, G				Valentin, E; Ghomashchi, F; Gelb, MH; Lazdunski, M; Lambeau, G			Novel human secreted phospholipase A(2) with homology to the group III bee venom enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SNAKE-VENOM; RECEPTOR; PURIFICATION; EXPRESSION; MECHANISM; CLEAVAGE; PROTEIN; MUTANT	Venom and mammalian secreted phospholipases A, (sPLA(2)s) have been associated with numerous physiological, pathological, and toxic processes. So far, structurally related group I and II sPLA(2)s have been found in vertebrates such as mammals and snakes, whereas group In: sPLA(2)s have mainly been found in venom from invertebrates such as bees and scorpions Here we report the cloning and expression of a cDNA coding for a human group III (hGIII) sPLA(2). The full-length cDNA codes for a signal peptide of 19 residues followed by a protein of 490 amino acids made up of a central sPLA(2), domain (141 residues) flanked by large N- and C-terminal regions (130 and 219 residues, respectively). The sPLA(2) domain is 31% identical to bee venom sPLA(2) and displays all of the features of group III sPLA(2)s including 10 cysteines. The hGIII sPLA(2) gene consists of at least 7 exons and maps to chromosome 22q. By Northern blot analysis, a 4.4-kilobase hGIII transcript was found in kidney, heart, liver, and skeletal muscle. Transfection of hGIII sPLA(2) cDNA in COS cells led to accumulation of sPLA(2) activity in the culture medium, indicating that the cDNA codes for a secreted enzyme, Using small unilamellar vesicles as substrate, hGIII sPLA(2) was found to be a Ca2+-dependent enzyme showing an 11-fold preference for phosphatidylglycerol over phosphatidylcholine and optimal activity at pH 8.	Inst Pharmacol Mol & Cellulaire, CNRS UPR 411, F-06560 Valbonne, France; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Lazdunski, M (corresponding author), Inst Pharmacol Mol & Cellulaire, CNRS UPR 411, 660 Route Lucioles, F-06560 Valbonne, France.	ipmc@ipmc.cnrs.fr	Lambeau, Gerard/GRJ-5624-2022	gelb, michael/0000-0001-7000-5219; Lambeau, Gerard/0000-0002-9239-518X	NHLBI NIH HHS [HL36235] Funding Source: Medline; NIAID NIH HHS [AI28040, AI42940] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL036235, R37HL036235, R01HL036235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028040, R01AI042940, R21AI042940] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Baker SF, 1998, BIOCHEMISTRY-US, V37, P13203, DOI 10.1021/bi981223t; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; Conde R, 1999, FEBS LETT, V460, P447, DOI 10.1016/S0014-5793(99)01392-7; Cupillard L, 1999, J BIOL CHEM, V274, P7043, DOI 10.1074/jbc.274.11.7043; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DUDLER T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P201, DOI 10.1016/0005-2760(92)90188-2; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Fenard D, 1999, J CLIN INVEST, V104, P611, DOI 10.1172/JCI6915; FRANKEN PA, 1992, EUR J BIOCHEM, V203, P89, DOI 10.1111/j.1432-1033.1992.tb19832.x; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HALBAN PA, 1994, BIOCHEM J, V299, P1; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Hoffman DR, 1996, J ALLERGY CLIN IMMUN, V97, P812, DOI 10.1016/S0091-6749(96)80159-X; Ishizaki J, 1999, J BIOL CHEM, V274, P24973, DOI 10.1074/jbc.274.35.24973; KINI RM, 1989, TOXICON, V27, P613, DOI 10.1016/0041-0101(89)90013-5; KUCHLER K, 1989, EUR J BIOCHEM, V184, P249, DOI 10.1111/j.1432-1033.1989.tb15014.x; Kundu GC, 1997, J BIOL CHEM, V272, P2346; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; LOTAN A, 1995, NATURE, V375, P456, DOI 10.1038/375456a0; MARSHALL LA, 1992, BIOCHEM PHARMACOL, V44, P1849, DOI 10.1016/0006-2952(92)90081-S; MCINTOSH JM, 1995, J BIOL CHEM, V270, P3518, DOI 10.1074/jbc.270.8.3518; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OHARA O, 1995, PROG LIPID RES, V34, P117, DOI 10.1016/0163-7827(94)00009-B; Rufini S, 1996, BIOCHEM J, V320, P467, DOI 10.1042/bj3200467; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; SOSA BP, 1986, BIOCHEMISTRY-US, V25, P2927, DOI 10.1021/bi00358a029; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 1999, J BIOL CHEM, V274, P19152, DOI 10.1074/jbc.274.27.19152; VANDERMEERS A, 1991, EUR J BIOCHEM, V196, P537, DOI 10.1111/j.1432-1033.1991.tb15847.x; Verpy E, 1999, P NATL ACAD SCI USA, V96, P529, DOI 10.1073/pnas.96.2.529; Wang YX, 1998, P NATL ACAD SCI USA, V95, P15345, DOI 10.1073/pnas.95.26.15345; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0; YU BZ, 1993, BIOCHEMISTRY-US, V32, P6485, DOI 10.1021/bi00076a024; Zamudio FZ, 1997, J BIOL CHEM, V272, P11886, DOI 10.1074/jbc.272.18.11886	42	152	161	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7492	7496		10.1074/jbc.275.11.7492	http://dx.doi.org/10.1074/jbc.275.11.7492			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713052	hybrid			2022-12-27	WOS:000085913300012
J	Wu, JY; Means, AR				Wu, JY; Means, AR			Ca2+/calmodulin-dependent protein kinase IV is expressed in spermatids and targeted to chromatin and the nuclear matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING PROTEIN; CEREBELLAR GRANULE CELLS; GENE-EXPRESSION; MAMMALIAN SPERMATOZOA; MOLECULAR-CLONING; RAT; GR; SPERMATOGENESIS; SEQUENCE; BRAIN	Ca2+/calmodulin-dependent protein kinase IV and calspermin are two proteins encoded by the Camk4 gene. Both are highly expressed in the testis, where in situ hybridization studies in rat testes have demonstrated that CaMKIV mRNA is localized to pachytene spermatocytes, while calspermin mRNA is restricted to spermatids. We have examined the expression patterns of both CaMKIV and calspermin in mouse testis and unexpectedly find that CaMKIV is expressed in spermatogonia and spermatids but excluded from spermatocytes, while calspermin is found only in spermatids. CaMKIV and calspermin expression in the testis are stage-dependent and appear to be coordinately regulated. In germ cells, we find that CaMKIV is associated with the chromatin. We further demonstrate that a fraction of CaMKIV in spermatids is hyperphosphorylated and specifically localized to the nuclear matrix. These novel findings may implicate CaMKIV in chromatin remodeling during nuclear condensation of spermatids.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Means, AR (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.				NICHD NIH HHS [HD07503] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anderson KA, 1997, MOL ENDOCRINOL, V11, P725, DOI 10.1210/me.11.6.725; BALHORN R, 1982, J CELL BIOL, V93, P298, DOI 10.1083/jcb.93.2.298; Bayer KU, 1996, MOL CELL BIOL, V16, P29; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BLAND MM, 1994, GENE, V142, P191, DOI 10.1016/0378-1119(94)90260-7; CHAFOULEAS JG, 1979, J BIOL CHEM, V254, P262; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; COLLINGE M, 1992, MOL CELL BIOL, V12, P2359, DOI 10.1128/MCB.12.5.2359; DON J, 1994, MOL REPROD DEV, V38, P16, DOI 10.1002/mrd.1080380104; EARNSHAW WC, 1987, J CELL BIOL, V105, P1479, DOI 10.1083/jcb.105.4.1479; Eddy EM, 1998, SEMIN CELL DEV BIOL, V9, P451, DOI 10.1006/scdb.1998.0201; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; ERICKSON RP, 1990, TRENDS GENET, V6, P264, DOI 10.1016/0168-9525(90)90209-O; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; GLENNEY JR, 1980, J BIOL CHEM, V255, P551; Grasso P, 1997, ENDOCRINOLOGY, V138, P4215, DOI 10.1210/en.138.10.4215; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; KLEENE KC, 1984, DEV BIOL, V105, P71, DOI 10.1016/0012-1606(84)90262-8; KRUMMEN LA, 1989, ENDOCRINOLOGY, V125, P1630, DOI 10.1210/endo-125-3-1630; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MEANS AR, 1993, RECENT PROG HORM RES, V48, P79; Means AR, 1997, RECENT PROG HORM RES, V52, P389; Meistrich M., 1989, HISTONES OTHER BASIC, P165; Moroi S, 1998, AM J PHYSIOL-CELL PH, V274, pC1708, DOI 10.1152/ajpcell.1998.274.6.C1708; MOSIALOS G, 1994, J VIROL, V68, P1697, DOI 10.1128/JVI.68.3.1697-1705.1994; NAZIAN SJ, 1991, J ANDROL, V12, P264; OHMSTEDE CA, 1991, P NATL ACAD SCI USA, V88, P5784, DOI 10.1073/pnas.88.13.5784; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; ONO T, 1989, J BIOL CHEM, V264, P2081; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; Russell L.D., 1990, HISTOLOGICAL HISTOPA, P119; SAKAGAMI H, 1993, MOL BRAIN RES, V19, P215, DOI 10.1016/0169-328X(93)90029-O; SODERSTROM KO, 1976, MOL CELL ENDOCRINOL, V5, P181, DOI 10.1016/0303-7207(76)90082-4; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; SUN Z, 1996, P 9 EUR TEST WORKSH, P29; SUN ZM, 1995, MOL CELL BIOL, V15, P561, DOI 10.1128/MCB.15.1.561; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Vreugdenhil E, 1999, J NEUROBIOL, V39, P41, DOI 10.1002/(SICI)1097-4695(199904)39:1<41::AID-NEU4>3.0.CO;2-X; WARD WS, 1989, CHROMOSOMA, V98, P153, DOI 10.1007/BF00329678; WARD WS, 1991, BIOL REPROD, V44, P569, DOI 10.1095/biolreprod44.4.569	42	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7994	7999		10.1074/jbc.275.11.7994	http://dx.doi.org/10.1074/jbc.275.11.7994			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713118	hybrid			2022-12-27	WOS:000085913300078
J	Osmulski, PK; Gaczynska, M				Osmulski, PK; Gaczynska, M			Atomic force microscopy reveals two conformations of the 20 S proteasome from fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPY; RESOLUTION; BIOMOLECULES; PROTEINS	The proteasome is a major cytosolic proteolytic complex, indispensable in eukaryotic cells. The barrel-shaped core of this enzyme, the 20 S proteasome, is built from 28 subunits forming four stacked rings. The two inner beta-rings harbor active centers, whereas the two outer alpha-rings play a structural role. Crystal structure of the yeast 20 S particle showed that the entrance to the central channel was sealed. Because of this result, the path of substrates into the catalytic chamber has remained enigmatic. We have used tapping mode atomic force microscopy (AFM) in liquid to address the dynamic aspects of the 20 S proteasomes from fission yeast. We present here evidence that, when observed with AFM, the proteasome particles in top view position have either open or closed entrance to the central channel. The preferred conformation depends on the ligands present. Apparently, the addition of a substrate to the uninhibited proteasome shifts the equilibrium toward the open conformation. These results shed new light on the possible path of the substrate into the proteolytic chamber.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio	Gaczynska, M (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, 15355 Lambda Dr, San Antonio, TX 78245 USA.		Osmulski, Pawel/C-7751-2019	Osmulski, Pawel/0000-0002-5359-9200				BAUMEISTER W, 1988, FEBS LETT, V241, P239, DOI 10.1016/0014-5793(88)81069-X; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; BUSTAMANTE C, 1994, CURR OPIN STRUC BIOL, V4, P750, DOI 10.1016/S0959-440X(94)90175-9; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dorn IT, 1999, J MOL BIOL, V288, P1027, DOI 10.1006/jmbi.1999.2714; Engel A, 1999, TRENDS CELL BIOL, V9, P77, DOI 10.1016/S0962-8924(98)01415-9; FRITZ M, 1995, LANGMUIR, V11, P3529, DOI 10.1021/la00009a040; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Hansma HG, 1997, J STRUCT BIOL, V119, P99, DOI 10.1006/jsbi.1997.3855; Kisselev AF, 1999, MOL CELL, V4, P395, DOI 10.1016/S1097-2765(00)80341-X; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Muller DJ, 1996, J BACTERIOL, V178, P3025; Muller DJ, 1999, BIOPHYS J, V76, P1101, DOI 10.1016/S0006-3495(99)77275-9; Osmulski PA, 1998, CURR BIOL, V8, P1023, DOI 10.1016/S0960-9822(07)00423-X; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Walz J, 1998, J STRUCT BIOL, V121, P19, DOI 10.1006/jsbi.1998.3958; Yao TT, 1999, CURR BIOL, V9, pR551, DOI 10.1016/S0960-9822(99)80352-2	19	50	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13171	13174		10.1074/jbc.C901035199	http://dx.doi.org/10.1074/jbc.C901035199			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10747864	hybrid			2022-12-27	WOS:000086925300003
J	Rebhun, JF; Chen, HS; Quilliam, LA				Rebhun, JF; Chen, HS; Quilliam, LA			Identification and characterization of a new family of guanine nucleotide exchange factors for the Ras-related GTPase Ral	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; ADAPTER PROTEIN; ACTIVATION; BINDING; KINASE; SOS; CDC25; NCK; EFFECTOR; PATHWAY	Guanine nucleotide exchange factors (GEFs) are responsible for coupling cell surface receptors to Ras protein activation. Here we describe the characterization of a novel family of differentially expressed GEFs, identified by database sequence homology searching. These molecules share the core catalytic domain of other Pas family GEFs but lack the catalytic non-conserved (conserved non-catalytic/Ras exchange motif/structurally conserved region 0) domain that is believed to contribute to Sos1 integrity. In vitro binding and in vivo nucleotide exchange assays indicate that these GEFs specifically catalyze the GTP loading of the Ral GTPase when overexpressed in 293T cells. A central proline-rich motif associated with the Src homology (SH)2/SH3-containing adapter proteins Grb2 and Nck in vivo, whereas a pleckstrin homology (PH) domain was located at the GEF C terminus. We refer to these GEFs as RalGPS 1A, 1B, and 2 (Ral GEFs with PH domain and SH3 binding motif). The PH domain was required for in vivo GEF activity and could be functionally replaced by the Hi-Res C terminus, suggesting a role in membrane targeting. In the absence of the PH domain RalGPS 1B cooperated with Grb2 to promote Pal activation, indicating that SH3 domain interaction also contributes to RalGPS regulation. In contrast to the Ral guanine nucleotide dissociation stimulator family of Ral GEFs, the RalGPS proteins do not possess a Res-GTP-binding domain, suggesting that they are activated in a Res-independent manner.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Quilliam, LA (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr,MS-4053, Indianapolis, IN 46202 USA.		Rebhun, John F/H-7235-2019; Quilliam, Lawrence/Q-4987-2019; Quilliam, Lawrence/B-6447-2015	Rebhun, John F/0000-0002-0764-5210; 	NCI NIH HHS [CA63139] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA063139] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Braverman LE, 1999, J BIOL CHEM, V274, P5542, DOI 10.1074/jbc.274.9.5542; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; Hofer F, 1998, CURR BIOL, V8, P839, DOI 10.1016/S0960-9822(98)70327-6; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; Lemmon MA, 1998, CURR TOP MICROBIOL, V228, P39; Matsubara K, 1999, ONCOGENE, V18, P1303, DOI 10.1038/sj.onc.1202425; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Sone M, 1997, SCIENCE, V275, P543, DOI 10.1126/science.275.5299.543; SPARKS AB, 1996, P NATL ACAD SCI US, V93; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Wojcik J, 1999, BIOCHEM BIOPH RES CO, V259, P113, DOI 10.1006/bbrc.1999.0727; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748	33	60	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13406	13410		10.1074/jbc.C000085200	http://dx.doi.org/10.1074/jbc.C000085200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10747847	hybrid			2022-12-27	WOS:000086925300037
J	Boldin, SA; Futerman, AH				Boldin, SA; Futerman, AH			Up-regulation of glucosylceramide synthesis upon stimulation of axonal growth by basic fibroblast growth factor - Evidence for post-translational modification of glucosylceramide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; CERAMIDE GLUCOSYLTRANSFERASE; GLYCOSPHINGOLIPID SYNTHESIS; SPHINGOLIPID SYNTHESIS; HIPPOCAMPAL-NEURONS; GOLGI MEMBRANES; PROTEIN-KINASE; OUTGROWTH; INHIBITION; EXPRESSION	We have previously shown that ongoing glucosylceramide (GlcCer) synthesis is required for basic fibroblast growth factor (bFGF) and laminin to stimulate axonal growth in cultured hippocampal neurons (Boldin, S., and Futerman, A. H. (1997) J, Neurochem. 68, 882-885), We now demonstrate that stimulation of axonal growth by bFGF leads to an increase in the rate of GlcCer synthesis. Within minutes of incubation with bFGF, a significant increase in the rate of metabolism of [C-14]hexanoyl ceramide to [C-14]hexanoyl GlcCer is detected, but there are no changes in the rate of [C-14]hexanoyl sphingomyelin synthesis. lit vitro analysis of GlcCer synthase activity revealed an approximately 2-fold increase in the rate of [C-14]hexanoyl GlcCer synthesis upon incubation with either bFGF or laminin; other growth factors, which did not effect the rate of axon growth, had no effect on the rate of [C-14]hexanoyl GlcCer synthesis. The increased rate of [C-14]hexanoyl GlcCer synthesis was not affected by preincubation with either cycloheximide or actinomycin, and no elevation of GlcCer synthase mRNA levels was detected, suggesting that GlcCer synthase is up-regulated by a post-translational mechanism. The relevance of these results for understanding the regulation of axonal growth is discussed.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Futerman, AH (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	Tony.Futerman@weizmann.ac.il		Futerman, Anthony/0000-0003-0013-0115				Boldin S, 1997, J NEUROCHEM, V68, P882; Bourteele S, 1998, J BIOL CHEM, V273, P31245, DOI 10.1074/jbc.273.47.31245; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COSTE H, 1986, BIOCHIM BIOPHYS ACTA, V858, P6, DOI 10.1016/0005-2736(86)90285-3; CREUZET C, 1995, J NEUROCHEM, V64, P1541; Futerman AH, 1996, TRENDS NEUROSCI, V19, P144, DOI 10.1016/S0166-2236(96)80025-7; FUTERMAN AH, 1992, METHOD ENZYMOL, V209, P437; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; Goslin K., 1998, CULTURING NERVE CELL, P339; HAREL R, 1993, J BIOL CHEM, V268, P14476; Hirschberg K, 1996, J BIOL CHEM, V271, P14876, DOI 10.1074/jbc.271.25.14876; Ichikawa S, 1998, TRENDS CELL BIOL, V8, P198, DOI 10.1016/S0962-8924(98)01249-5; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Komori H, 1999, J BIOL CHEM, V274, P8981, DOI 10.1074/jbc.274.13.8981; Ledesma MD, 1999, EMBO J, V18, P1761, DOI 10.1093/emboj/18.7.1761; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Marks DL, 1999, J BIOL CHEM, V274, P451, DOI 10.1074/jbc.274.1.451; Meivar-Levy I, 1999, J BIOL CHEM, V274, P4607, DOI 10.1074/jbc.274.8.4607; Memon RA, 1999, J BIOL CHEM, V274, P19707, DOI 10.1074/jbc.274.28.19707; Paul P, 1996, J BIOL CHEM, V271, P2287, DOI 10.1074/jbc.271.4.2287; SANO M, 1992, J NEUROCHEM, V58, P837, DOI 10.1111/j.1471-4159.1992.tb09333.x; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; Schwarz A, 1997, J NEUROSCI, V17, P2929; Watanabe R, 1998, J BIOL CHEM, V273, P9651, DOI 10.1074/jbc.273.16.9651; Wu KJ, 1999, BIOCHEM J, V341, P395, DOI 10.1042/0264-6021:3410395	29	33	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					9905	9909		10.1074/jbc.275.14.9905	http://dx.doi.org/10.1074/jbc.275.14.9905			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744663	hybrid			2022-12-27	WOS:000086345600004
J	Maudsley, S; Pierce, KL; Zamah, AM; Miller, WE; Ahn, S; Daaka, Y; Lefkowitz, RJ; Luttrell, LM				Maudsley, S; Pierce, KL; Zamah, AM; Miller, WE; Ahn, S; Daaka, Y; Lefkowitz, RJ; Luttrell, LM			The beta(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CLATHRIN-COATED VESICLES; BETA-GAMMA-SUBUNITS; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; ION-CHANNEL; RGS-GAIP; ENDOCYTOSIS; PATHWAY; TRANSACTIVATION	Many G protein-coupled receptors (GPCRs) activate MAP kinases by stimulating tyrosine kinase signaling cascades. In some systems, GPCRs stimulate tyrosine phosphorylation by inducing the "transactivation" of a receptor tyrosine kinase (RTK), The mechanisms underlying GPCR-induced RTK transactivation have not been clearly defined. Here we report that GPCR activation mimics growth factor-mediated stimulation of the epidermal growth factor receptor (EGFR) with respect to many facets of RTK function. beta(2)-Adrenergic receptor (beta(2)AR) stimulation of COS-7 cells induces EGFR dimerization, tyrosine autophosphorylation, and EGFR internalization. Coincident with EGFR transactivation, isoproterenol exposure induces the formation of a multireceptor complex containing both the beta(2)AR and the "transactivated" EGFR. beta(2)AR-mediated EGFR phosphorylation and subsequent beta(2)AR stimulation of extracellular signal-regulated kinase (ERK) 1/2 are sensitive to selective inhibitors of both EGFR and Src kinases, indicating that both kinases are required for EGFR transactivation. beta(2)AR-dependent signaling to ERK1/2, like direct EGF stimulation of ERK1/2 activity, is sensitive to inhibitors of clathrin-mediated endocytosis, suggesting that signaling downstream of both the EGF-activated and the GPCR-transactivated EGFRs requires a productive engagement of the complex with the cellular endocytic machinery, Thus, RTK transactivation is revealed to be a process involving both association of receptors of distinct classes and the interaction of the transactivated RTK with the cells endocytic machinery.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3821, Durham, NC 27710 USA.		Maudsley, Stuart/Q-4782-2019; Lefkowitz, Robert/AAW-2649-2021; Maudsley, Stuart/AAV-9929-2021	Maudsley, Stuart/0000-0002-1868-184X; Luttrell, Louis/0000-0003-2805-6949	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002352, R01DK055524, R56DK055524] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline; NIDDK NIH HHS [DK02352, DK55524] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BARAK LS, 1994, J BIOL CHEM, V269, P2790; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; De Vries L, 1998, MOL BIOL CELL, V9, P1123, DOI 10.1091/mbc.9.5.1123; De Vries L, 1998, P NATL ACAD SCI USA, V95, P12340, DOI 10.1073/pnas.95.21.12340; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HAWES BE, 1995, J BIOL CHEM, V270, P17146; Ignatova EG, 1999, J NEUROSCI, V19, P56, DOI 10.1523/JNEUROSCI.19-01-00056.1999; Keely SJ, 1998, J BIOL CHEM, V273, P27111, DOI 10.1074/jbc.273.42.27111; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luo X, 1999, J BIOL CHEM, V274, P17684, DOI 10.1074/jbc.274.25.17684; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; PHONPHOK Y, 1991, FEBS LETT, V281, P188, DOI 10.1016/0014-5793(91)80390-O; Pol A, 1998, FEBS LETT, V441, P34, DOI 10.1016/S0014-5793(98)01517-8; Quijano VJ, 1998, J BIOL CHEM, V273, P1200, DOI 10.1074/jbc.273.2.1200; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAMAMA P, 1994, MOL PHARMACOL, V45, P290; Soeder KJ, 1999, J BIOL CHEM, V274, P12017, DOI 10.1074/jbc.274.17.12017; STERNBERG PE, 1997, BLOOD, V89, P2384; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767; Zwick E, 1999, J BIOL CHEM, V274, P20989, DOI 10.1074/jbc.274.30.20989	47	358	369	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9572	9580		10.1074/jbc.275.13.9572	http://dx.doi.org/10.1074/jbc.275.13.9572			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734107	hybrid			2022-12-27	WOS:000086206500071
J	Bergh, FT; Flinn, EM; Svaren, J; Wright, AP; Horz, W				Bergh, FT; Flinn, EM; Svaren, J; Wright, AP; Horz, W			Comparison of nucleosome remodeling by the yeast transcription factor Pho4 and the glucocorticoid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; NUCLEAR FACTOR-I; STEROID-HORMONE RECEPTORS; SACCHAROMYCES-CEREVISIAE; MMTV PROMOTER; GENE-EXPRESSION; TRANSACTIVATION DOMAIN; FACTOR-BINDING; DNA-BINDING; CHROMATIN	Chromatin reorganization of the PHO5 and murine mammary tumor virus (MMTV) promoters is triggered by binding of either Pho4 or the glucocorticoid receptor (GR), respectively. In order to compare the ability of Pho4 and GR to remodel chromatin and activate transcription, hybrid promoter constructs were created by insertion of the MMTV B nucleosome sequence into the PHO5 promoter and then transformed into a yeast strain expressing GR, Activation of either Pho4 (by phosphate depletion) or GR (by hormone addition) resulted in only slight induction of hybrid promoter activity. However, simultaneous activation of both Pho4 and GR resulted in synergistic activation to levels exceeding that of the wild type PHO5 promoter. Under these conditions, Pho4 completely disrupted the nucleosome containing its binding site. In contrast, GR had little effect on the stability of the MMTV B nucleosome. A minimal transactivation domain of the GR fused to the Pho4 DNA-binding domain is capable of efficiently disrupting the nucleosome with a Pho4-binding site, whereas the complementary hybrid protein (Pho4 activation domain, GR DNA-binding domain) does not labilize the B nucleosome. Therefore, we conclude that significant activation by Pho4 requires nucleosome disruption, whereas equivalent transcriptional activation by GR is not accompanied by overt perturbation of nucleosome structure. Our results show that the DNA-binding domains of the two factors play critical roles in determining how chromatin structure is modified during promoter activation.	Univ Munich, Inst Physiol Chem, D-80336 Munich, Germany; Karolinska Inst, Dept Biosci, Novum, S-14157 Huddinge, Sweden; Sodertorns Hogskola, S-14104 Huddinge, Sweden	University of Munich; Karolinska Institutet; Sodertorn University	Horz, W (corresponding author), Univ Munich, Inst Physiol Chem, Schillerstr 44, D-80336 Munich, Germany.	Hoerz@bio.med.uni-muenchen.de	Svaren, John/A-1605-2010; Wright, Anthony/J-8187-2015	Svaren, John/0000-0003-2963-7921; Wright, Anthony/0000-0003-1029-9969				ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Barbaric S, 1998, MOL CELL BIOL, V18, P2629, DOI 10.1128/MCB.18.5.2629; Barbaric S, 1996, NUCLEIC ACIDS RES, V24, P4479, DOI 10.1093/nar/24.22.4479; Beato M, 1996, STEROIDS, V61, P240, DOI 10.1016/0039-128X(96)00030-X; Beato M, 1996, J STEROID BIOCHEM, V56, P47, DOI 10.1016/0960-0760(95)00223-5; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; Candau R, 1996, J STEROID BIOCHEM, V57, P19, DOI 10.1016/0960-0760(96)00262-2; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHAVEZ S, 1995, MOL CELL BIOL, V15, P6987; Chavez S, 1997, P NATL ACAD SCI USA, V94, P2885, DOI 10.1073/pnas.94.7.2885; DAHLMANWRIGHT K, 1994, P NATL ACAD SCI USA, V91, P1619, DOI 10.1073/pnas.91.5.1619; FASCHER KD, 1990, EMBO J, V9, P2523, DOI 10.1002/j.1460-2075.1990.tb07432.x; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Fragoso G, 1998, MOL CELL BIOL, V18, P3633, DOI 10.1128/MCB.18.6.3633; HAGER G, 1995, CHROMATIN STRUCTURE, P89; HORVATH A, 1994, YEAST, V10, P1305, DOI 10.1002/yea.320101007; KINGSMAN SM, 1990, METHOD ENZYMOL, V185, P329; Krude T, 1996, CURR BIOL, V6, P511, DOI 10.1016/S0960-9822(02)00529-8; McAndrew PC, 1998, MOL CELL BIOL, V18, P5818, DOI 10.1128/MCB.18.10.5818; MIKSICEK R, 1987, EMBO J, V6, P1355, DOI 10.1002/j.1460-2075.1987.tb02375.x; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PERLMANN T, 1992, P NATL ACAD SCI USA, V89, P3884, DOI 10.1073/pnas.89.9.3884; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RUDOLPH H, 1987, P NATL ACAD SCI USA, V84, P1340, DOI 10.1073/pnas.84.5.1340; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; Shimizu T, 1997, EMBO J, V16, P4689, DOI 10.1093/emboj/16.15.4689; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; SVAREN J, 1994, J BIOL CHEM, V269, P9335; SVAREN J, 1994, EMBO J, V13, P4856, DOI 10.1002/j.1460-2075.1994.tb06812.x; Svaren J, 1997, TRENDS BIOCHEM SCI, V22, P93, DOI 10.1016/S0968-0004(97)01001-3; SVAREN J, 1995, METH MOL G, V6, P153; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; WRIGHT APH, 1992, J BIOL CHEM, V267, P11191; WRIGHT APH, 1990, J BIOL CHEM, V265, P14763	40	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					9035	9042		10.1074/jbc.275.12.9035	http://dx.doi.org/10.1074/jbc.275.12.9035			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722753	hybrid			2022-12-27	WOS:000086507700103
J	Groulx, I; Bonicalzi, ME; Lee, S				Groulx, I; Bonicalzi, ME; Lee, S			Ran-mediated nuclear export of the von Hippel-Lindau tumor suppressor protein occurs independently of its assembly with cullin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCT; MESSENGER-RNA; RENAL-CARCINOMA; HUMAN TISSUES; GROWTH-FACTOR; LEPTOMYCIN-B; REV PROTEIN; IN-VITRO; IMPORT; CYTOPLASM	Inactivating mutations of the von Hippel-Lindau (VHL) tumor suppressor gene cause the VHL cancer syndrome and sporadic renal clear cell carcinoma. VHL engages in a nucleocytoplasmic shuttle, which is required for its function. Here, we pursue our investigation to identify mechanisms by which VHL-green fluorescent protein (VHL-GFP) is exported from the nucleus. We show that nuclear export of VHL-GFP in living cells requires ongoing RNA polymerase II activity, and is mediated by mechanisms that are temperature-sensitive and energy-dependent. In vitro nuclear export of VHL-GFP is inhibited by nuclear pore-specific lectins, requires ATP hydrolysis and polyadenylated mRNAs, and occurs with kinetics that are similar to those of proteins containing a nuclear export signal. Biochemical fractionation has revealed that nuclear export of VHL-GFP occurs by way of a Ran-dependent pathway, Size exclusion column chromatography and deletion mutant analysis suggest that VHL-GFP does not require assembly with one of its associated proteins, cullin-2, to engage in nuclear export. These results demonstrate that nuclear export of VHL-GFP is Ran-mediated and ATP hydrolysis-dependent. They also suggest that sequences outside the elongin C binding box may function as a nuclear export domain, potentially providing a novel role for this region of VHL frequently mutated in renal cell carcinoma.	Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Lee, S (corresponding author), Univ Ottawa, Fac Med, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	slee@uottawa.ca						ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Afonina E, 1998, J BIOL CHEM, V273, P13015, DOI 10.1074/jbc.273.21.13015; Blankenship C, 1999, ONCOGENE, V18, P1529, DOI 10.1038/sj.onc.1202473; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Chatterjee S, 1998, BIOTECHNIQUES, V24, P668, DOI 10.2144/98244rr04; Corless CL, 1997, HUM PATHOL, V28, P459, DOI 10.1016/S0046-8177(97)90035-6; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Englmeier L, 1999, CURR BIOL, V9, P30, DOI 10.1016/S0960-9822(99)80044-X; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gnarra JR, 1996, BBA-REV CANCER, V1242, P201, DOI 10.1016/0304-419X(95)00012-5; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Gorospe M, 1999, MOL CELL BIOL, V19, P1289; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; Holaska JM, 1998, P NATL ACAD SCI USA, V95, P14739, DOI 10.1073/pnas.95.25.14739; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Knebelmann B, 1998, CANCER RES, V58, P226; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; Lee MS, 1997, CURR OPIN GENET DEV, V7, P212, DOI 10.1016/S0959-437X(97)80131-1; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; Lee S, 1999, MOL CELL BIOL, V19, P1486; Lieubeau-Teillet B, 1998, CANCER RES, V58, P4957; LINEHAN WM, 1995, JAMA-J AM MED ASSOC, V273, P564; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Los M, 1996, LAB INVEST, V75, P231; Love DC, 1998, P NATL ACAD SCI USA, V95, P10608, DOI 10.1073/pnas.95.18.10608; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MELCHIOR F, 1995, METHOD ENZYMOL, V257, P279; Melchior F, 1998, METH MOL B, V88, P265; Melchior F, 1998, TRENDS CELL BIOL, V8, P175, DOI 10.1016/S0962-8924(98)01252-5; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; Moroianu J, 1997, P NATL ACAD SCI USA, V94, P9699, DOI 10.1073/pnas.94.18.9699; Nakielny S, 1998, CURR BIOL, V8, P89, DOI 10.1016/S0960-9822(98)70039-9; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NISHI K, 1994, J BIOL CHEM, V269, P6320; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sandri-Goldin RM, 1998, GENE DEV, V12, P868, DOI 10.1101/gad.12.6.868; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; Siemeister G, 1996, CANCER RES, V56, P2299; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tsuchiya H, 1996, CANCER RES, V56, P2881; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yang J, 1997, J CELL BIOL, V137, P523, DOI 10.1083/jcb.137.3.523; Ye Y, 1998, INT J CANCER, V78, P62, DOI 10.1002/(SICI)1097-0215(19980925)78:1<62::AID-IJC11>3.0.CO;2-7	71	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8991	9000		10.1074/jbc.275.12.8991	http://dx.doi.org/10.1074/jbc.275.12.8991			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722748	hybrid			2022-12-27	WOS:000086507700098
J	Park, HS; Huh, SH; Kim, YH; Shim, JY; Lee, SH; Park, IS; Jung, YK; Kim, IY; Choi, EJ				Park, HS; Huh, SH; Kim, YH; Shim, JY; Lee, SH; Park, IS; Jung, YK; Kim, IY; Choi, EJ			Selenite negatively regulates caspase-3 through a redox mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA FRAGMENTATION; MORPHOLOGICAL-CHANGES; ACTIVATED DNASE; APOPTOTIC CELLS; INHIBITION; CLEAVAGE; SELENOCYSTEINE; BINDING; GLUTATHIONE; FIBROBLASTS	Selenium, an essential biological trace element, exerts its modulatory effects in a variety of cellular events including cell survival and death. In our study we observed that selenite protects HEK293 cells from cell death induced by ultraviolet B radiation (UVB), Exposure of HEK293 cells to UVB radiation resulted in the activation of caspase-3-like protease activity, and pretreatment of the cells with z-DEVD-fmk (N-benzyloxy-carbonyl-Asp-Glu-Val-Asp-fluoromethylketone) a caspase-3 inhibitor, prevented UVB-induced cell death. Interestingly, enzymatic activity of caspase-3-like protease in cell lysates of UVB-exposed cells was repressed in vitro by the presence of selenite. Selenite also inhibited the in vitro activity of purified recombinant caspase-3 in cleaving Ac-DEVD-pNA (N-acetyl-Asp-Glu-Asp-p-nitroanilide) or ICAD(L) (inhibitor of a caspase-activated deoxyribonuclease) and in the induction of DNA fragmentation. The inhibitory action of selenite on a recombinant active caspase-3 could be reversed by sulfhydryl reducing agents, such as dithiothreitol and beta-mercaptoethanol, Furthermore, pretreatment of cells with selenite suppressed the stimulation of the caspase-3-like protease activity in UVB-exposed cells, whereas dithiothreitol and beta-mercaptoethanol reversed this suppression of the enzymatic activity. Taken together, our data suggest that selenite inhibits caspase-3 like protease activity through a redox mechanism and that inhibition of caspase-3-like protease activity may be the mechanism by which selenite exerts its protective effect against UVB-induced cell death.	Korea Univ, Natl Creat Res Initiat Ctr Cell Death, Sungbuk Ku, Seoul 136701, South Korea; Korea Univ, Grad Sch Biotechnol, Sungbuk Ku, Seoul 136701, South Korea; Korea Canc Ctr Hosp, Div Med Res, Seoul 139706, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; Ewha Womans Univ, Ctr Cell Singaling Res, Seoul 120750, South Korea; Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju, South Korea	Korea University; Korea University; National Cancer Center - Korea (NCC); Ewha Womans University; Ewha Womans University; Gwangju Institute of Science & Technology (GIST)	Choi, EJ (corresponding author), Korea Univ, Natl Creat Res Initiat Ctr Cell Death, Sungbuk Ku, Seoul 136701, South Korea.			Jung, Yong-Keun/0000-0002-9686-3120				BERGAD PL, 1986, CURR EYE RES, V5, P919, DOI 10.3109/02713688608995172; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BOREK C, 1986, P NATL ACAD SCI USA, V83, P1490, DOI 10.1073/pnas.83.5.1490; Bosl MR, 1997, P NATL ACAD SCI USA, V94, P5531, DOI 10.1073/pnas.94.11.5531; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CEKAN E, 1985, ACTA RADIOL ONCOL, V24, P267, DOI 10.3109/02841868509134399; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Emonet N, 1997, J PHOTOCH PHOTOBIO B, V40, P84, DOI 10.1016/S1011-1344(97)00041-9; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Frutos S, 1999, J BIOL CHEM, V274, P10765, DOI 10.1074/jbc.274.16.10765; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Gopalakrishna R, 1997, ARCH BIOCHEM BIOPHYS, V348, P37, DOI 10.1006/abbi.1997.0335; GREEDER GA, 1980, SCIENCE, V209, P825, DOI 10.1126/science.7406957; HANDEL ML, 1995, P NATL ACAD SCI USA, V92, P4497, DOI 10.1073/pnas.92.10.4497; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Kim IY, 1997, P NATL ACAD SCI USA, V94, P12904, DOI 10.1073/pnas.94.24.12904; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; MATSUMURA H, 1991, P NATL ACAD SCI USA, V88, P9046, DOI 10.1073/pnas.88.20.9046; MCKEEHAN WL, 1976, P NATL ACAD SCI USA, V73, P2023, DOI 10.1073/pnas.73.6.2023; MILNER JA, 1981, CANCER RES, V41, P1652; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Preston GA, 1997, CANCER RES, V57, P537; Rafferty TS, 1998, BIOCHEM J, V332, P231, DOI 10.1042/bj3320231; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; ROTRUCK JT, 1972, J NUTR, V102, P689, DOI 10.1093/jn/102.5.689; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; SAKAHIRA H, 1998, NATURE, V391, P1652; SHI CY, 1995, HUM EXP TOXICOL, V14, P55, DOI 10.1177/096032719501400111; Shimizu H, 1999, J INVEST DERMATOL, V112, P769, DOI 10.1046/j.1523-1747.1999.00582.x; Simbulan-Rosenthal CM, 1999, MOL CELL BIOCHEM, V193, P137, DOI 10.1023/A:1006988832729; SPYROU G, 1995, FEBS LETT, V368, P59, DOI 10.1016/0014-5793(95)00599-5; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Stapleton SR, 1997, BBA-MOL CELL RES, V1355, P259, DOI 10.1016/S0167-4889(96)00140-1; Takahashi H, 1999, EXP CELL RES, V249, P291, DOI 10.1006/excr.1999.4476; TASHIMA Y, 1989, J BIOCHEM-TOKYO, V105, P358, DOI 10.1093/oxfordjournals.jbchem.a122668; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Zech B, 1999, J BIOL CHEM, V274, P20931, DOI 10.1074/jbc.274.30.20931	48	62	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8487	8491		10.1074/jbc.275.12.8487	http://dx.doi.org/10.1074/jbc.275.12.8487			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722685	hybrid			2022-12-27	WOS:000086507700035
J	Sommerfeld, MT; Schweigreiter, R; Barde, YA; Hoppe, E				Sommerfeld, MT; Schweigreiter, R; Barde, YA; Hoppe, E			Down-regulation of the neurotrophin receptor TrkB following ligand binding - Evidence for an involvement of the proteasome and differential regulation of TrkA and TrkB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; FACTOR BETA-RECEPTOR; PROTEIN-KINASE-C; MESSENGER-RNA; TYROSINE KINASE; PROTEOLYTIC PATHWAY; CORTICAL-NEURONS; IN-VIVO; DEGRADATION; UBIQUITIN	This study examines the mechanisms by which the tyrosine kinase receptor TrkB is down-regulated following binding of brain-derived neurotrophic factor (BDNF). In primary cultures of cerebellar granule neurons, BDNF-induced reduction of TrkB receptors was largely prevented by the addition of specific proteasome inhibitors. HN10 cells, a neuronal cell line that can be readily transfected, also showed a marked down-regulation of cell surface TrkB following BDNF exposure. In addition, me observed that prolonged exposure to nerve growth factor of TrkA-transfected cells did not lead to the down-regulation seen with BDNF and TrkB. TrkA and TrkB chimeric molecules were therefore expressed in HN10 cells and tested for ligand-induced regulation. These experiments led to the conclusion that the motives responsible for down-regulation are contained in the cytoplasmic domain of TrkB, and a short sequence in the juxtamembrane domain of TrkB was identified that confers nerve growth factor-induced down-regulation when inserted into TrkA.	Max Planck Inst Neurobiol, Dept Neurobiochem, D-82152 Planegg Martinsried, Germany	Max Planck Society	Barde, YA (corresponding author), Max Planck Inst Neurobiol, Dept Neurobiochem, Klopferspitz 18A, D-82152 Planegg Martinsried, Germany.	yves_barde@neuro.mpg.de	Hoppe, Edmund/X-6091-2019; Barde, Yves/F-6019-2011	Barde, Yves/0000-0002-7627-461X				Barde YA, 1999, HANDB EXP PHARM, V134, P1; Berninger B, 1996, CURR OPIN NEUROBIOL, V6, P324, DOI 10.1016/S0959-4388(96)80115-2; CARTER BD, 1995, J BIOL CHEM, V270, P21751, DOI 10.1074/jbc.270.37.21751; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Davies AM, 1996, PHILOS T ROY SOC B, V351, P389, DOI 10.1098/rstb.1996.0033; DECHANT G, 1993, DEVELOPMENT, V119, P545; ERNFORS P, 1992, EUR J NEUROSCI, V4, P1140, DOI 10.1111/j.1460-9568.1992.tb00141.x; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Frank L, 1996, EUR J NEUROSCI, V8, P1220, DOI 10.1111/j.1460-9568.1996.tb01290.x; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; GOTZ R, 1992, EUR J BIOCHEM, V204, P745, DOI 10.1111/j.1432-1033.1992.tb16689.x; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hefti F, 1997, NAT MED, V3, P497, DOI 10.1038/nm0597-497; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; Knusel B, 1997, NEUROSCIENCE, V78, P851, DOI 10.1016/S0306-4522(96)00616-1; LEE HJ, 1990, J NEUROSCI, V10, P1779; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Magnifico A, 1998, FEBS LETT, V422, P129, DOI 10.1016/S0014-5793(97)01612-8; MAYER U, 1994, EUR J BIOCHEM, V225, P573, DOI 10.1111/j.1432-1033.1994.00573.x; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; MIYAZAWA K, 1994, BLOOD, V83, P137; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; NG NFL, 1993, J BIOL CHEM, V268, P25329; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Schropel A, 1995, MOL CELL NEUROSCI, V6, P544, DOI 10.1006/mcne.1995.0006; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WIDMER HR, 1993, BRAIN RES, V614, P325, DOI 10.1016/0006-8993(93)91051-S; YEE NS, 1994, J BIOL CHEM, V269, P31991; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x; ZIRRGIEBEL U, 1995, J NEUROCHEM, V65, P2241	45	134	134	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8982	8990		10.1074/jbc.275.12.8982	http://dx.doi.org/10.1074/jbc.275.12.8982			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722747	hybrid			2022-12-27	WOS:000086507700097
J	Zybailov, B; van der Est, A; Zech, SG; Teutloff, C; Johnson, TW; Shen, GZ; Bittl, R; Stehlik, D; Chitnis, PR; Golbeck, JH				Zybailov, B; van der Est, A; Zech, SG; Teutloff, C; Johnson, TW; Shen, GZ; Bittl, R; Stehlik, D; Chitnis, PR; Golbeck, JH			Recruitment of a foreign quinone into the A(1) site of photosystem I - II. Structural and functional characterization of phylloquinone biosynthetic pathway mutants by electron paramagnetic resonance and electron-nuclear double resonance spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION CENTERS; BACTERIAL REACTION CENTERS; CORRELATED RADICAL PAIRS; SPIN POLARIZATION; BINDING-SITE; PULSED EPR; HYPERFINE COUPLINGS; SINGLE-CRYSTALS; TRIPLET-STATE; ACCEPTOR A(1)	Electron paramagnetic resonance (EPR) and electron-nuclear double resonance studies of the photosystem (PS) I quinone acceptor, A(1), in phylloquinone biosynthetic pathway mutants are described. Room temperature continuous wave EPR measurements at X-band of whole cells of menA and menB interruption mutants show a transient reduction and oxidation of an organic radical with a g-value and anisotropy characteristic of a quinone, In PS I complexes, the continuous wave EPR spectrum of the photoaccumulated Q(-) radical, measured at Q-band, and the electron spin polarized transient EPR spectra of the radical pair P700(+) Q(-), measured at X-, Q-, and W-bands, show three prominent features: (i) Q(-) has a larger g-anisotropy than native phylloquinone, (ii) Q(-) does not display the prominent methyl hyperfine couplings attributed to the a-methyl group of phylloquinone, and (iii) the orientation of Q(-) in the A(1) site as derived from the spin polarization is that of native phylloquinone in the wild type. Electron spin echo modulation experiments on P700(+) Q(-) show that the dipolar coupling in the radical pair is the same as in native PS I, i.e. the distance between P700(+) and Q(-) (25.3 +/- 0.3 Angstrom) is the same as between P700(+) and A(1)(-) in the wild type. Pulsed electron-nuclear double resonance studies show two sets of resolved spectral features with nearly axially symmetric hyperfine couplings. They are tentatively assigned to the two methyl groups of the recruited plastoquinone-9, and their difference indicates a strong inequivalence among the two groups when in the A(1) site. These results show that Q (i) functions in accepting an electron from A(0)(-) and in passing the electron forward to the iron-sulfur clusters, (ii) occupies the A(1) site with an orientation similar to that of phylloquinone in the wild type, and (iii) has spectroscopic properties consistent with its identity as plastoquinone-9.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Free Univ Berlin, Fachbereich Phys, D-14195 Berlin, Germany; Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA; Tech Univ Berlin, Max Volmer Inst, D-10623 Berlin, Germany	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Free University of Berlin; Iowa State University; Technical University of Berlin	Golbeck, JH (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.	JHG5@PSU.EDU	Bittl, Robert/I-8149-2013	Bittl, Robert/0000-0003-4103-3768; Zybailov, Boris/0000-0003-2432-9145				Bittl R, 1997, J PHYS CHEM B, V101, P1429, DOI 10.1021/jp962256q; Bittl R, 1997, BIOCHEMISTRY-US, V36, P12001, DOI 10.1021/bi971645n; Brettel K, 1997, BBA-BIOENERGETICS, V1318, P322, DOI 10.1016/S0005-2728(96)00112-0; BUDIL DE, 1991, BIOCHIM BIOPHYS ACTA, V1057, P1, DOI 10.1016/S0005-2728(05)80081-7; DINER BA, 1988, BIOCHIM BIOPHYS ACTA, V934, P47, DOI 10.1016/0005-2728(88)90118-1; Dzuba SA, 1997, CHEM PHYS LETT, V264, P238, DOI 10.1016/S0009-2614(96)01302-4; Dzuba SA, 1997, CHEM PHYS LETT, V278, P333, DOI 10.1016/S0009-2614(97)01044-0; Hanley J, 1997, BIOCHEMISTRY-US, V36, P11543, DOI 10.1021/bi971360a; Hore PJ, 1996, MOL PHYS, V89, P1195, DOI 10.1080/002689796173598; ITOH S, 1991, BIOCHEMISTRY-US, V30, P5340, DOI 10.1021/bi00236a003; IWAKI M, 1991, BIOCHEMISTRY-US, V30, P5347, DOI 10.1021/bi00236a004; Johnson TW, 2000, J BIOL CHEM, V275, P8523, DOI 10.1074/jbc.275.12.8523; Kamlowski A, 1998, J PHYS CHEM B, V102, P8266, DOI 10.1021/jp9817022; Kamlowski A, 1998, J PHYS CHEM B, V102, P8278, DOI 10.1021/jp9824611; Kandrashkin YE, 1998, APPL MAGN RESON, V15, P417, DOI 10.1007/BF03162027; Klughammer C, 1997, BBA-BIOENERGETICS, V1318, P133, DOI 10.1016/S0005-2728(96)00129-6; Klughammer C, 1999, BIOCHEMISTRY-US, V38, P3726, DOI 10.1021/bi982431o; Klukas O, 1999, J BIOL CHEM, V274, P7361, DOI 10.1074/jbc.274.11.7361; Lubitz W, 1999, APPL MAGN RESON, V17, P1, DOI 10.1007/BF03162067; MacMillan F, 1997, BIOCHEMISTRY-US, V36, P9297, DOI 10.1021/bi971097d; MACMILLAN F, 1995, BIOCHEMISTRY-US, V34, P8144, DOI 10.1021/bi00025a021; O'Malley PJ, 1999, BBA-BIOENERGETICS, V1411, P101, DOI 10.1016/S0005-2728(99)00036-5; O'Malley PJ, 1998, CHEM PHYS LETT, V285, P99, DOI 10.1016/S0009-2614(97)01456-5; O'Malley PJ, 1998, J AM CHEM SOC, V120, P5093, DOI 10.1021/ja974235v; OKAMURA MY, 1975, P NATL ACAD SCI USA, V72, P3491, DOI 10.1073/pnas.72.9.3491; Rigby SEJ, 1996, BIOCHEMISTRY-US, V35, P6651, DOI 10.1021/bi952619x; RUSTANDI RR, 1992, BIOCHIM BIOPHYS ACTA, V1101, P311, DOI 10.1016/0005-2728(92)90087-I; RUTHERFORD AW, 1990, BIOCHIM BIOPHYS ACTA, V1019, P128, DOI 10.1016/0005-2728(90)90133-O; Salikhov KM, 1992, APPL MAGN RESON, V3, P199, DOI 10.1007/BF03166790; Schubert WD, 1997, J MOL BIOL, V272, P741, DOI 10.1006/jmbi.1997.1269; SIECKMAN I, 1991, FEBS LETT, V284, P98, DOI 10.1016/0014-5793(91)80771-T; SIECKMANN I, 1993, BIOCHEMISTRY-US, V32, P4842, DOI 10.1021/bi00069a020; STEHLIK D, 1989, J PHYS CHEM-US, V93, P1612, DOI 10.1021/j100341a084; Tang J, 1996, CHEM PHYS LETT, V253, P293, DOI 10.1016/0009-2614(96)00176-5; Teutloff C, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P607; THURNAUER MC, 1985, PHOTOBIOCH PHOTOBIOP, V9, P29; Timmel CR, 1998, CHEM PHYS, V226, P271, DOI 10.1016/S0301-0104(97)00283-8; van der Est A, 1998, BBA-BIOENERGETICS, V1409, P87, DOI 10.1016/S0005-2728(98)00152-2; VANDEREST A, 1995, CHEM PHYS, V194, P349, DOI 10.1016/0301-0104(95)00046-Q; Yang F, 1998, J PHYS CHEM B, V102, P8288, DOI 10.1021/jp981952i; Zech SG, 1996, BER BUNSEN PHYS CHEM, V100, P2041, DOI 10.1002/bbpc.19961001220; Zech SG, 1997, BIOCHEMISTRY-US, V36, P9774, DOI 10.1021/bi970754z; Zheng M, 1996, BIOCHEMISTRY-US, V35, P8955, DOI 10.1021/bi9522209	43	71	80	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8531	8539		10.1074/jbc.275.12.8531	http://dx.doi.org/10.1074/jbc.275.12.8531			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722691	hybrid			2022-12-27	WOS:000086507700041
J	Altincicek, B; Tenbaum, SP; Dressel, U; Thormeyer, D; Renkawitz, R; Baniahmad, A				Altincicek, B; Tenbaum, SP; Dressel, U; Thormeyer, D; Renkawitz, R; Baniahmad, A			Interaction of the corepressor Alien with DAX-1 is abrogated by mutations of DAX-1 involved in adrenal hypoplasia congenita	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; RETINOIC ACID RECEPTOR; HYPOGONADOTROPIC HYPOGONADISM; V-ERBA; SILENCING DOMAIN; GENE-EXPRESSION; CO-REPRESSOR; ACTIVATION; BINDING; BETA	DAX-1 is an unusual member of the nuclear hormone receptor (NHR) superfamily. Lack of DAX-1-mediated silencing leads to adrenal hypoplasia congenita and hypogonadotropic hypogonadism, Gene silencing through NHRs such as the thyroid hormone receptor (TR) is mediated by corepressors. We have previously characterized a novel corepressor, termed Alien, which interacts with TR and the ecdysone receptor but not with the retinoic acid receptors RAR or RXR. Here, we show that DAX-1 interacts with the corepressor Alien but not with the corepressor SMRT. This interaction is mediated by the DAX-1-silencing domain. Naturally occurring mutants of the DAX-1 gene fail to interact with Alien and have lost silencing function. Because the silencing domain of DAX-1 is unusual for NHRs, we mapped the interaction of Alien with DAX-1 and with TR. We show that Alien exhibits different binding characteristics to DAX-1 and TR. Furthermore, Northern experiments demonstrate that Alien is expressed in the adrenal gland and testis in tissues where DAX-1 is specifically expressed. Interestingly, a novel adrenal gland-specific mRNA of Alien was discovered. Thus, the impairment of Alien binding seems to play an important role in the pathogenesis mediated by DAX-1 mutants.	Univ Giessen, Genet Inst, D-35392 Giessen, Germany	Justus Liebig University Giessen	Baniahmad, A (corresponding author), Univ Giessen, Genet Inst, Heinrich Buff Ring 58-62, D-35392 Giessen, Germany.		Altincicek, Boran/C-1191-2009; Dressel, Uwe/C-1555-2016	Altincicek, Boran/0000-0003-2019-452X; Dressel, Uwe/0000-0003-4505-7855				Auwerx J, 1999, CELL, V97, P161; BANIAHMAD A, 1992, P NATL ACAD SCI USA, V89, P10633, DOI 10.1073/pnas.89.22.10633; Baniahmad A, 1997, MOL CELL BIOL, V17, P4259, DOI 10.1128/MCB.17.8.4259; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BANIAHMAD A, 1994, NUCL HORMONE RECEPTO, P1; Busch K, 1997, MOL ENDOCRINOL, V11, P379, DOI 10.1210/me.11.3.379; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Crawford PA, 1998, MOL CELL BIOL, V18, P2949, DOI 10.1128/MCB.18.5.2949; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; Dressel U, 1999, MOL CELL BIOL, V19, P3383; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; GUO WW, 1995, BIOCHEM MOL MED, V56, P8, DOI 10.1006/bmme.1995.1049; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Habiby RL, 1996, J CLIN INVEST, V98, P1055, DOI 10.1172/JCI118866; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; Lalli E, 1997, MOL ENDOCRINOL, V11, P1950, DOI 10.1210/me.11.13.1950; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARTIN B, 1994, NUCLEIC ACIDS RES, V22, P4899; Meloni A, 1996, HUM MUTAT, V8, P183, DOI 10.1002/(SICI)1098-1004(1996)8:2<183::AID-HUMU12>3.3.CO;2-C; MUNOZ A, 1991, MOL ENDOCRINOL, V5, P273, DOI 10.1210/mend-5-2-273; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Nakae J, 1996, J CLIN ENDOCR METAB, V81, P3680, DOI 10.1210/jc.81.10.3680; Schaefer L, 1999, GENOMICS, V56, P310, DOI 10.1006/geno.1998.5728; Swain A, 1999, GENE DEV, V13, P755, DOI 10.1101/gad.13.7.755; Swain A, 1998, NATURE, V391, P761, DOI 10.1038/35799; Tenbaum S, 1997, INT J BIOCHEM CELL B, V29, P1325, DOI 10.1016/S1357-2725(97)00087-3; Tong GX, 1996, MOL CELL BIOL, V16, P1909; Wang J, 1999, J INVEST MED, V47, P232; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Yoh SM, 1997, MOL ENDOCRINOL, V11, P470, DOI 10.1210/me.11.4.470; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; Zazopoulos E, 1997, NATURE, V390, P311, DOI 10.1038/36899; Zhang YH, 1998, AM J HUM GENET, V62, P855, DOI 10.1086/301782	40	88	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7662	7667		10.1074/jbc.275.11.7662	http://dx.doi.org/10.1074/jbc.275.11.7662			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713076	hybrid			2022-12-27	WOS:000085913300036
J	Brandhorst, T; Klein, B				Brandhorst, T; Klein, B			Cell wall biogenesis of Blastomyces dermatitidis - Evidence for a novel mechanism of cell surface localization of a virulence-associated adhesin via extracellular release and reassociation with cell wall chitin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYPTOCOCCUS-NEOFORMANS GLUCURONOXYLOMANNAN; GENETICALLY RELATED STRAINS; SACCHAROMYCES-CEREVISIAE; MURINE MACROPHAGES; ALTERED EXPRESSION; CANDIDA-ALBICANS; YEASTS; PROTEIN; WI-1; RECOGNITION	Pathogenic yeast of Blastomyces dermatitidis express a surface protein adhesin, WI-1. Due to the crucial role of WI-1 in adherence and disease pathogenesis, we investigated how the protein localizes to the surface of B. dermatitidis, WI-1 released extracellularly by wild-type yeast coated the surfaces of co-cultured knockout yeast within 3 h of incubation, implying that secreted WI-1 provides a pathway for loading the protein onto the yeast cell wall. In radioligand binding assays, purified WI-1 bound saturably, specifically, and with high affinity (K-d = 8.3 x 10(-9)) to the cell surface of knockout yeast devoid of WI-1. WI-1 added exogenously, in vitro to knockout yeast was indistinguishable from native cell surface WI-1 by fluorescence staining and restored adhesivity to the knockout yeast in macrophage binding and phagocytosis assays. Analysis of interactions between WI-1 and elements of the yeast cell wall identified chitin as the anchor point for WI-1. This interaction was shown to hinge on the 24-amino acid tandem repeat sequence of WI-1, Efforts to extract surface WI-l from the yeast demonstrated that it is fastened to the wall by non-covalent interactions and covalent links between cysteine residues. We conclude that the yeast cell surface adhesin WI-1 localizes to the cell wall, in part, through extracellular release followed by high affinity binding back onto exposed chitin fibrils, These findings point to a novel pathway of cell wall biogenesis in yeast and an unanticipated role for chitin in anchoring and displaying a surface adhesin and virulence determinant.	Univ Wisconsin, Sch Med, Dept Pediat, Madison, WI 53792 USA; Univ Wisconsin, Sch Med, Dept Internal Med, Madison, WI 53792 USA; Univ Wisconsin, Sch Med, Dept Med Microbiol & Immunol, Madison, WI 53792 USA; Univ Wisconsin, Sch Med, Ctr Comprehens Canc, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Klein, B (corresponding author), Univ Wisconsin, Sch Med, Dept Pediat, 600 Highland Ave,Rm K4-434, Madison, WI 53792 USA.							Audet R, 1997, PROTEIN EXPRES PURIF, V11, P219, DOI 10.1006/prep.1997.0783; Brandhorst TT, 1999, J EXP MED, V189, P1207, DOI 10.1084/jem.189.8.1207; BRASS C, 1982, SABOURAUDIA, V20, P145; CHAN J, 1992, J EXP MED, V175, P1111, DOI 10.1084/jem.175.4.1111; Chang WL, 2000, INFECT IMMUN, V68, P502, DOI 10.1128/IAI.68.2.502-510.2000; CROWE HM, 1987, EXP MYCOL, V11, P159, DOI 10.1016/0147-5975(87)90050-8; deJong JLO, 1996, J IMMUNOL, V156, P1339; DYKE KGH, 1964, BIOCHIM BIOPHYS ACTA, V82, P374, DOI 10.1016/0304-4165(64)90309-5; Ebbole DJ, 1997, TRENDS MICROBIOL, V5, P405, DOI 10.1016/S0966-842X(97)01130-X; GREEN H, 1982, 82 ANN M AM SOC MICR, P337; HOGAN LH, 1994, INFECT IMMUN, V62, P3543, DOI 10.1128/IAI.62.8.3543-3546.1994; Hogan LH, 1995, J BIOL CHEM, V270, P30725, DOI 10.1074/jbc.270.51.30725; KLEIN BS, 1994, INFECT IMMUN, V62, P3536, DOI 10.1128/IAI.62.8.3536-3542.1994; KLEIN BS, 1990, J CLIN INVEST, V85, P152, DOI 10.1172/JCI114406; KLEIN BS, 1993, J CLIN INVEST, V92, P330, DOI 10.1172/JCI116571; KLEIN BS, 1986, NEW ENGL J MED, V314, P529, DOI 10.1056/NEJM198602273140901; Kolbe S, 1998, MICROBIOL-SGM, V144, P1291, DOI 10.1099/00221287-144-5-1291; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; LEUSCH HG, 1989, CURR MICROBIOL, V19, P193, DOI 10.1007/BF01568941; LEVITT M, 1978, BIOCHEMISTRY-US, V17, P4277, DOI 10.1021/bi00613a026; MENASHE M, 1986, J BIOL CHEM, V261, P5328; Mio T, 1996, J BACTERIOL, V178, P2416, DOI 10.1128/jb.178.8.2416-2419.1996; MUKHERJEE J, 1994, ANTIMICROB AGENTS CH, V38, P580, DOI 10.1128/AAC.38.3.580; MUKHERJEE S, 1995, INFECT IMMUN, V63, P573, DOI 10.1128/IAI.63.2.573-579.1995; NEWMAN SL, 1995, J IMMUNOL, V154, P753; PIERCE M, 1983, J BIOL CHEM, V258, P3576; RUIZHERRERA J, 1992, FUNGAL CELL WALL STR, P13; SCHREUDER MP, 1993, YEAST, V9, P399, DOI 10.1002/yea.320090410; SHAW JA, 1991, J CELL BIOL, V114, P111, DOI 10.1083/jcb.114.1.111; WINDHOLZ M, 1976, ENCY CHEM DRUGS, P2027; WORSHAM PL, 1988, J MED VET MYCOL, V26, P137; YANG LY, 1992, J BACTERIOL, V174, P1258, DOI 10.1128/jb.174.4.1258-1267.1992; ZEBEDEE SL, 1994, ANTIMICROB AGENTS CH, V38, P1507, DOI 10.1128/AAC.38.7.1507	33	42	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7925	7934		10.1074/jbc.275.11.7925	http://dx.doi.org/10.1074/jbc.275.11.7925			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713109	hybrid			2022-12-27	WOS:000085913300069
J	Branza-Nichita, N; Negroiu, G; Petrescu, AJ; Garman, EF; Platt, FM; Wormald, MR; Dwek, RA; Petrescu, SM				Branza-Nichita, N; Negroiu, G; Petrescu, AJ; Garman, EF; Platt, FM; Wormald, MR; Dwek, RA; Petrescu, SM			Mutations at critical N-glycosylation sites reduce tyrosinase activity by altering folding and quality control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN GLUCOSYLTRANSFERASE; LINKED OLIGOSACCHARIDES; UDP-GLC; CALNEXIN; GLUCOSYLATION; ASSOCIATION; GENE; CONFORMATION; PURIFICATION; CALRETICULIN	Tyrosinase is a copper-containing enzyme that regulates melanin biosynthesis in mammals. Mutations at a single N-glycosylation sequon of tyrosinase have been reported to be responsible for oculocutaneous albinism type IA in humans, characterized by inactive tyrosinase and the total absence of pigmentation. To probe the role that each N-glycosylation site plays in the synthesis of biologically active tyrosinase, we analyzed the calnexin mediated folding of tyrosinase N-glycosylation mutants, We have determined that four of the six potential glycosylation sites, including that associated with albinism, are occupied. Analysis of the folding pathway and activity of 15 tyrosinase mutants lacking one our more of the occupied N-glycosylation sites shows that glycans at any two N-glycosylation sites are sufficient to interact with calnexin and give partial activity, but a specific pair of sites (Asn(86) and Asn(371)) is required for full activity. The mutants with less than two N-glycosylation sites do not interact with calnexin and show a complete absence of enzyme activity. Copper analysis of selected mutants suggests that the observed partial activity is due to two populations with differential copper content. By correlating the degree of folding with the activity of tyrosinase, we propose a local folding mechanism for tyrosinase that can explain the mechanism of inactivation of tyrosinase N-glycosylation mutants found in certain pigmentation disorders.	Romanian Acad, Inst Biochem, Bucharest 77700 17, Romania; Univ Oxford, Dept Biochem, Oxford Glycobiol Inst, Oxford OX1 3QU, England; Univ Oxford, Dept Biochem, Biophys Lab, Oxford OX1 3QU, England	Romanian Academy of Sciences; Institute of Biochemistry, Bucharest; University of Oxford; University of Oxford	Petrescu, SM (corresponding author), Romanian Acad, Inst Biochem, Splaiul Independentei 296, Bucharest 77700 17, Romania.	Stefana.Petrescu@biochim.ro	Negroiu, Gabriela/G-4649-2016; Negroiu, Gabriela/AAO-3980-2020; Platt, Frances/G-1004-2010; Petrescu, Stefana M/I-9240-2012; Wormald, Mark R/G-2785-2011; Petrescu, Andrei-Jose J/G-4576-2016; Petrescu, Stefana/AAJ-9505-2021	Petrescu, Stefana M/0000-0002-4047-0811; Wormald, Mark R/0000-0002-4853-2773; Petrescu, Andrei-Jose J/0000-0002-4478-3946; Petrescu, Stefana/0000-0002-4047-0811; Garman, Elspeth/0000-0001-8329-5665; Negroiu, Gabriela/0000-0003-3712-7681; Platt, Frances/0000-0001-7614-0403				AROCA P, 1993, J BIOL CHEM, V268, P25650; Branza-Nichita N, 1999, BIOCHEM BIOPH RES CO, V261, P720, DOI 10.1006/bbrc.1999.1030; Fernandez F, 1998, EMBO J, V17, P5877, DOI 10.1093/emboj/17.20.5877; Garman E, 1999, STRUCT FOLD DES, V7, pR291, DOI 10.1016/S0969-2126(00)88335-5; HEARING VJ, 1987, METHOD ENZYMOL, V142, P154; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hebert DN, 1997, J CELL BIOL, V139, P613, DOI 10.1083/jcb.139.3.613; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; MULLER G, 1988, EMBO J, V7, P2723, DOI 10.1002/j.1460-2075.1988.tb03126.x; NEGRIOU G, 1999, IN PRESS BIOCH J; OHKURA T, 1984, ARCH BIOCHEM BIOPHYS, V235, P63, DOI 10.1016/0003-9861(84)90255-8; PARK KC, 1993, AM J HUM GENET, V52, P406; PARODI AJ, 1983, J BIOL CHEM, V258, P8260; Petrescu SM, 1997, J BIOL CHEM, V272, P15796, DOI 10.1074/jbc.272.25.15796; Rodan AR, 1996, EMBO J, V15, P6921, DOI 10.1002/j.1460-2075.1996.tb01084.x; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; SPRITZ RA, 1990, NEW ENGL J MED, V322, P1724, DOI 10.1056/NEJM199006143222407; Toyofuku K, 1999, J BIOCHEM, V125, P82, DOI 10.1093/oxfordjournals.jbchem.a022272; TROMBETTA SE, 1989, BIOCHEMISTRY-US, V28, P8108, DOI 10.1021/bi00446a022; WINDER A, 1994, CELL MOL BIOL RES, V40, P613; WITKOP CJ, 1989, CLIN DERMATOL, V7, P80, DOI 10.1016/0738-081X(89)90059-X; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3	23	94	102	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8169	8175		10.1074/jbc.275.11.8169	http://dx.doi.org/10.1074/jbc.275.11.8169			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713140	hybrid			2022-12-27	WOS:000085913300100
J	Jung, SM; Moroi, M				Jung, SM; Moroi, M			Signal-transducing mechanisms involved in activation of the platelet collagen receptor integrin alpha(2)beta(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; PROTEIN-KINASE; FIBRINOGEN; BINDING; ALPHA(IIB)BETA(3); EXPOSURE; TYROSINE; THROMBIN; BETA(3); ADP	Evidence was obtained about the mechanism responsible for platelet integrin alpha(2)beta activation by determining effects of various inhibitors on soluble collagen binding, a parameter to assess integrin alpha(2)beta(1), activation, in stimulated platelets, Agonists that can also activate platelet glycoprotein IIb/IIIa are able to activate integrin alpha(2)beta(1),, but those operating via glycoprotein Ib cannot. Activation of alpha(2)beta(1), induced by low thrombin or collagen-related peptide concentrations was almost completely inhibited by apyrase, and the inhibitors wortmannin, 4-amino-5-(chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine bisindolylmaleimide I,and SQ29548 significantly inhibited it. Activation induced by high thrombin or collagen-related peptide concentrations was far less sensitive to these inhibitors. However, only wortmannin markedly inhibited ADP-induced integrin alpha(2)beta(1) activation, and this was not ADP concentration-dependent, These results suggest that at the low agonist concentrations, the released ADP would be a primary inducer of integrin alpha(2)beta(1), activation, while act the high agonist concentrations, there would be several pathways through which integrin alpha(2)beta(1) activation can be induced. Kinetic analyses revealed that ADP-induced platelets had about the same number of binding sites (B-max) as thrombin-induced platelets, but their affinity (K-d) for soluble collagen was 3.7-12.7-fold lower, suggesting that activated integrin alpha(2)beta(1), induced by ADP is different from that induced by thrombin, The data are consistent with an activation mechanism involving released ADP and in which there exists two different states Of activated integrin. alpha(2)beta(1); these activated forms of integrin alpha(2)beta(1), would have different conformations that determine their ligand affinity.	Kurume Univ, Inst Life Sci, Dept Prot Biochem, Kurume, Fukuoka 8390861, Japan	Kurume University	Jung, SM (corresponding author), Kurume Univ, Inst Life Sci, Dept Prot Biochem, 2432-3 Aikawa Machi, Kurume, Fukuoka 8390861, Japan.							ABRAMAS C, 1997, ADV MOL CELL BIOL, P67; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; BENNETT JS, 1981, J CLIN INVEST, V68, P981, DOI 10.1172/JCI110352; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; CHAN BMC, 1991, J IMMUNOL, V147, P398; Chang DD, 1997, J CELL BIOL, V138, P1149, DOI 10.1083/jcb.138.5.1149; COPPOLINO M, 1995, J BIOL CHEM, V270, P23132, DOI 10.1074/jbc.270.39.23132; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; GAO JB, 1995, J IMMUNOL METHODS, V181, P55, DOI 10.1016/0022-1759(94)00329-U; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hers I, 1998, ARTERIOSCL THROM VAS, V18, P404, DOI 10.1161/01.ATV.18.3.404; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; Jung SM, 1998, J BIOL CHEM, V273, P14827, DOI 10.1074/jbc.273.24.14827; KAWAGUCHI S, 1994, MOL BIOL CELL, V5, P977, DOI 10.1091/mbc.5.9.977; Kritzik M, 1998, BLOOD, V92, P2382, DOI 10.1182/blood.V92.7.2382; KUNICKI TJ, 1993, BLOOD, V82, P2693; Lerea KM, 1999, J BIOL CHEM, V274, P1914, DOI 10.1074/jbc.274.4.1914; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MARGUERIE GA, 1983, ANN NY ACAD SCI, V408, P556, DOI 10.1111/j.1749-6632.1983.tb23272.x; MARGUERIE GA, 1987, PLATELETS BIOL PATHO, V3, P95; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; MUSTARD JF, 1978, BLOOD, V52, P453; Nagel W, 1998, J BIOL CHEM, V273, P14853, DOI 10.1074/jbc.273.24.14853; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PLOW EF, 1980, J BIOL CHEM, V255, P971; PLOW EF, 1980, BLOOD, V56, P553; SANO K, 1983, J BIOL CHEM, V258, P2010; Shattil SJ, 1997, THROMB HAEMOSTASIS, V78, P220; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; vanWilligen G, 1996, BIOCHEM J, V314, P769, DOI 10.1042/bj3140769; Wang RG, 1997, J CLIN INVEST, V100, P2393, DOI 10.1172/JCI119780; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265; ZUTTER MM, 1990, AM J PATHOL, V137, P113	43	89	95	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8016	8026		10.1074/jbc.275.11.8016	http://dx.doi.org/10.1074/jbc.275.11.8016			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713121	hybrid			2022-12-27	WOS:000085913300081
J	Sakahira, H; Iwamatsu, A; Nagata, S				Sakahira, H; Iwamatsu, A; Nagata, S			Specific chaperone-like activity of inhibitor of caspase-activated DNase for caspase-activated DNase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; GLUCOCORTICOID RECEPTOR; MOLECULAR CHAPERONES; CHROMATIN CONDENSATION; FRAGMENTATION FACTOR; APOPTOSIS; PROTEIN; HSP90; HSP70; TRANSLATION	Caspase-activated DNase (CAD) is the enzyme that causes DNA fragmentation during apoptosis. CAD forms aggregates when it is synthesized in the absence of an inhibitor of CAD (ICAD). Here, using renaturation systems of chemically denatured CAD, we report that ICAD-L, a long form of ICAD, has a chaperone-like activity specific for CAD. Murine CAD carries 14 cysteines, most of which were found to be in reduced form. Reducing agents enhanced the production of the functional CAD in an in vitro translation system, The denatured CAD could be efficiently renatured under highly reducing conditions only in the presence of ICAD-L. This process was ATP-independent. In contrast, reticulocyte lysates stimulated ICAD-L- and ATP-dependent renaturation of denatured CAD without requiring a high concentration of reducing agents. These results indicate that ICAD-L works not only as a specific inhibitor but also as a specific chaperone for CAD.	Osaka Univ, Sch Med, Dept Genet, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Suita, Osaka 5650871, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanagawa 2360004, Japan	Osaka University; Japan Science & Technology Agency (JST); Kirin Brewery Company Limited	Nagata, S (corresponding author), Osaka Univ, Sch Med, Dept Genet, B-3,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DENIS M, 1989, J BIOL CHEM, V264, P6005; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gu JJ, 1999, J BIOL CHEM, V274, P20759, DOI 10.1074/jbc.274.30.20759; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Iwamatsu A, 1996, J BIOCHEM-TOKYO, V120, P29; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Kawane K, 1999, CELL DEATH DIFFER, V6, P745, DOI 10.1038/sj.cdd.4400547; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; NAGATA S, 1997, CELL, V88, P855; Netzer WJ, 1998, TRENDS BIOCHEM SCI, V23, P68, DOI 10.1016/S0968-0004(97)01171-7; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Sakahira H, 1999, J BIOL CHEM, V274, P15740, DOI 10.1074/jbc.274.22.15740; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Siegers K, 1999, EMBO J, V18, P75, DOI 10.1093/emboj/18.1.75; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thulasiraman V, 1999, EMBO J, V18, P85, DOI 10.1093/emboj/18.1.85; Tschopp J, 1999, CURR BIOL, V9, pR381, DOI 10.1016/S0960-9822(99)80233-4; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; WEICH H, 1992, NATURE, V358, P169; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Xanthoudakis S, 1999, EMBO J, V18, P2049, DOI 10.1093/emboj/18.8.2049; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480	51	53	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8091	8096		10.1074/jbc.275.11.8091	http://dx.doi.org/10.1074/jbc.275.11.8091			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713130	hybrid			2022-12-27	WOS:000085913300090
J	Wilkinson, SR; Temperton, NJ; Mondragon, A; Kelly, JM				Wilkinson, SR; Temperton, NJ; Mondragon, A; Kelly, JM			Distinct mitochondrial and cytosolic enzymes mediate trypanothione-dependent peroxide metabolism in Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL HYDROPEROXIDE REDUCTASE; THIOL-SPECIFIC ANTIOXIDANT; CRITHIDIA-FASCICULATA; HYDROGEN-PEROXIDE; PROTEIN LOCALIZATION; LEISHMANIA-DONOVANI; OXIDATIVE STRESS; SHUTTLE VECTOR; EXPRESSION; CLONING	The American trypanosome Trypanosoma cruzi is exposed to toxic oxygen metabolites that are generated by drug metabolism and immune responses in addition to those produced by endogenous processes. However, much remains to be resolved about the parasite oxidative defense system, including the mechanism(s) of peroxide reduction. Here we show that reduction of peroxides in T. cruzi is catalyzed by two distinct trypanothione-dependent enzymes. These were localized to the cytosol and mitochondrion. Both are members of the peroxiredoxin family of antioxidant proteins and are characterized by the presence of two conserved domains containing redox active cysteines. The role of these proteins in protecting T. cruzi from peroxide-mediated damage was demonstrated following overexpression of enzyme activity. The parasite-specific features of T. cruzi cytoplasmic peroxiredoxin and T. cruzi mitochondrial peroxiredoxin may be exploitable in terms of drug development.	Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Wilkinson, SR (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.		Temperton, Nigel James/K-5158-2013; Temperton, Nigel James/M-1164-2019	Temperton, Nigel James/0000-0002-7978-3815; Temperton, Nigel James/0000-0002-7978-3815				ADLUNATE J, 1993, FREE RADICALS TROPIC; [Anonymous], 1990, Wkly Epidemiol Rec, V65, P257; BOVERIS A, 1977, EXPERIENTIA, V33, P1306, DOI 10.1007/BF01920148; CARNIERI EGS, 1993, MOL BIOCHEM PARASIT, V61, P79, DOI 10.1016/0166-6851(93)90160-Y; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; Chen ZF, 1998, J PHARMACOL EXP THER, V285, P608; CLARK D, 1994, MOL BIOCHEM PARASIT, V66, P143, DOI 10.1016/0166-6851(94)90045-0; DENICOLA A, 1993, ARCH BIOCHEM BIOPHYS, V304, P279, DOI 10.1006/abbi.1993.1350; DENICOLASEOANE A, 1992, MOL BIOCHEM PARASIT, V54, P43, DOI 10.1016/0166-6851(92)90093-Y; DOCAMPO R, 1990, CHEM-BIOL INTERACT, V73, P1, DOI 10.1016/0009-2797(90)90106-W; DOCAMPO R, 1984, FREE RADICALS BIOL, V6; Dumas C, 1997, EMBO J, V16, P2590, DOI 10.1093/emboj/16.10.2590; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P13349, DOI 10.1021/bi9713658; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; GIBSON WC, 1986, EMBO J, V5, P1299, DOI 10.1002/j.1460-2075.1986.tb04359.x; GIULIVI C, 1988, MOL BIOCHEM PARASIT, V30, P243, DOI 10.1016/0166-6851(88)90093-X; Gommel DU, 1997, EUR J BIOCHEM, V248, P913, DOI 10.1111/j.1432-1033.1997.t01-1-00913.x; HENDERSON GB, 1987, MOL BIOCHEM PARASIT, V24, P39, DOI 10.1016/0166-6851(87)90113-7; Henle ES, 1997, J BIOL CHEM, V272, P19095, DOI 10.1074/jbc.272.31.19095; Ismail SO, 1997, MOL BIOCHEM PARASIT, V86, P187, DOI 10.1016/S0166-6851(97)00032-7; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KELLY JM, 1992, NUCLEIC ACIDS RES, V20, P3963, DOI 10.1093/nar/20.15.3963; KELLY JM, 1993, EUR J BIOCHEM, V218, P29, DOI 10.1111/j.1432-1033.1993.tb18348.x; KELLY JM, 1994, MOL BIOCHEM PARASIT, V65, P51, DOI 10.1016/0166-6851(94)90114-7; KELLY JM, 1993, PROTOCOLS MOL PARASI; KELLY JM, 1995, METHODS MOL BIOL, V47; KENDALL G, 1990, EMBO J, V9, P2751, DOI 10.1002/j.1460-2075.1990.tb07462.x; KrauthSiegel RL, 1996, MOL BIOCHEM PARASIT, V80, P203, DOI 10.1016/0166-6851(96)02689-8; MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185; Montemartini M, 1998, J BIOL CHEM, V273, P4864, DOI 10.1074/jbc.273.9.4864; MORENO SNJ, 1984, J BIOL CHEM, V259, P6298; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; PENKETH PG, 1986, MOL BIOCHEM PARASIT, V20, P111, DOI 10.1016/0166-6851(86)90023-X; PENKETH PG, 1987, FEBS LETT, V221, P427, DOI 10.1016/0014-5793(87)80968-7; Salazar NA, 1996, MOL BIOCHEM PARASIT, V78, P127, DOI 10.1016/S0166-6851(96)02617-5; SMITH K, 1991, MOL BIOCHEM PARASIT, V48, P109, DOI 10.1016/0166-6851(91)90170-B; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Temperton NJ, 1996, MOL BIOCHEM PARASIT, V76, P339, DOI 10.1016/0166-6851(95)02553-7; Tetaud E, 1998, MOL BIOCHEM PARASIT, V96, P111, DOI 10.1016/S0166-6851(98)00120-0; TIBBETTS RS, 1995, EXP PARASITOL, V80, P572, DOI 10.1006/expr.1995.1071; Tomas AM, 1997, EUR J BIOCHEM, V244, P596, DOI 10.1111/j.1432-1033.1997.t01-1-00596.x; Tovar J, 1996, NUCLEIC ACIDS RES, V24, P2942, DOI 10.1093/nar/24.15.2942; Tovar J, 1998, MOL MICROBIOL, V29, P653, DOI 10.1046/j.1365-2958.1998.00968.x; VESPA GNR, 1994, INFECT IMMUN, V62, P5177, DOI 10.1128/IAI.62.11.5177-5182.1994; Viode C, 1999, BIOCHEM PHARMACOL, V57, P549, DOI 10.1016/S0006-2952(98)00324-4; Watabe S, 1997, EUR J BIOCHEM, V249, P52, DOI 10.1111/j.1432-1033.1997.t01-1-00052.x; *WHO, 1995, 12 UNDP WORLD BANK W	51	143	145	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8220	8225		10.1074/jbc.275.11.8220	http://dx.doi.org/10.1074/jbc.275.11.8220			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713147	hybrid			2022-12-27	WOS:000085913300107
J	Hotchin, NA; Cover, TL; Akhtar, N				Hotchin, NA; Cover, TL; Akhtar, N			Cell vacuolation induced by the VacA cytotoxin of Helicobacter pylori is regulated by the Rac1 GTPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; LIPID BILAYERS; TOXIN; RHO; MEMBRANE; PROTEINS; SENSITIVITY; EXPRESSION; ENTRY	Chronic gastric infection with the Gram-negative bacterium Helicobacter pylori is a major contributing factor in the development of duodenal ulcers and is believed to be a significant risk factor in the development of gastric tumors. The VacA cytotoxin of H. pylori is a 90-kDa secreted protein that forms trans-membrane ion channels. In epithelial cells, VacA activity is associated with the rapid formation of acidic vacuoles enriched for late endosomal and lysosomal markers. Rad is a member of the Rho family of small GTP-binding proteins that regulate reorganization of the actin cytoskeleton and intracellular signal transduction and are being shown increasingly to play a role in membrane trafficking events. In this study we report that: (i) green fluorescent-tagged Rad localizes around the perimeter of the vacuoles induced by VacA; (ii) expression of dominant negative Rad in epithelial cells inhibits vacuole formation; (iii) expression of constitutively active Rad potentiates the activity of VacA. Taken together, these data demonstrate a role for Rad in the regulation of VacA activity.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Vanderbilt Univ, Sch Med, Dept Med, Div Infect Dis, Nashville, TN 37232 USA	University of Birmingham; Vanderbilt University	Hotchin, NA (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.		Cover, Timothy/I-3814-2015	Cover, Timothy/0000-0001-8503-002X; Akhtar, Nasreen/0000-0002-5099-8767; Hotchin, Neil/0000-0002-1844-7607	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053623] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI-39657] Funding Source: Medline; NIDDK NIH HHS [DK-53623] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adam T, 1996, EMBO J, V15, P3315, DOI 10.1002/j.1460-2075.1996.tb00696.x; AKHTAR N, 2000, IN PRESS CELL ADH CO; Bretscher MS, 1998, CURR BIOL, V8, P721, DOI 10.1016/S0960-9822(98)70281-7; COVER TL, 1991, INFECT IMMUN, V59, P1264, DOI 10.1128/IAI.59.4.1264-1270.1991; COVER TL, 1992, ANNU REV MED, V43, P135, DOI 10.1146/annurev.me.43.020192.001031; Cover TL, 1996, MOL MICROBIOL, V20, P241, DOI 10.1111/j.1365-2958.1996.tb02612.x; Cover TL, 1997, J CELL BIOL, V138, P759, DOI 10.1083/jcb.138.4.759; Czajkowsky DM, 1999, P NATL ACAD SCI USA, V96, P2001, DOI 10.1073/pnas.96.5.2001; de Bernard M, 1998, TOXICOL LETT, V99, P109, DOI 10.1016/S0378-4274(98)00140-4; de Bernard M, 1998, FEBS LETT, V436, P218, DOI 10.1016/S0014-5793(98)01132-6; deBernard M, 1997, MOL MICROBIOL, V26, P665, DOI 10.1046/j.1365-2958.1997.5881952.x; Ellis S, 2000, TRENDS CELL BIOL, V10, P85, DOI 10.1016/S0962-8924(99)01710-9; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HOTCHIN NA, 1992, J BIOL CHEM, V267, P14852; Iwamoto H, 1999, FEBS LETT, V450, P101, DOI 10.1016/S0014-5793(99)00474-3; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; Mellor H, 1998, J BIOL CHEM, V273, P4811, DOI 10.1074/jbc.273.9.4811; Molinari M, 1997, J BIOL CHEM, V272, P25339, DOI 10.1074/jbc.272.40.25339; Mounier J, 1999, J CELL SCI, V112, P2069; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; Palovuori R, 2000, BIOCHEM BIOPH RES CO, V269, P247, DOI 10.1006/bbrc.2000.2276; Papini E, 1997, EMBO J, V16, P15, DOI 10.1093/emboj/16.1.15; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROBERTSON D, 1995, J HISTOCHEM CYTOCHEM, V43, P471, DOI 10.1177/43.5.7537292; Satin B, 1997, J BIOL CHEM, V272, P25022, DOI 10.1074/jbc.272.40.25022; Segal ED, 1996, P NATL ACAD SCI USA, V93, P1259, DOI 10.1073/pnas.93.3.1259; Tombola F, 1999, BIOPHYS J, V76, P1401, DOI 10.1016/S0006-3495(99)77301-7	33	54	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14009	14012		10.1074/jbc.C000153200	http://dx.doi.org/10.1074/jbc.C000153200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10747859	hybrid			2022-12-27	WOS:000087006900002
J	Blaschke, UK; Eikenberry, EF; Hulmes, DJS; Galla, HJ; Bruckner, P				Blaschke, UK; Eikenberry, EF; Hulmes, DJS; Galla, HJ; Bruckner, P			Collagen XI nucleates self-assembly and limits lateral growth of cartilage fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT PROCOLLAGEN-II; IX COLLAGEN; FIBRILLOGENESIS INVITRO; EPIPHYSEAL CARTILAGE; ALPHA-1(XI) COLLAGEN; ENZYMATIC CLEAVAGE; V COLLAGEN; IN-VITRO; MICE; DECORIN	Fibrils of embryonic cartilage are heterotypic alloys formed by collagens II, IX, and XI and have a uniform diameter of similar to 20 nm, The molecular basis of this lateral growth control is poorly understood. Collagen II subjected to fibril formation in vitro produced short and tapered tactoids with strong D-periodic banding. The maximal width of these tactoids varied over a broad range. By contrast, authentic mixtures of collagens II, ni and XI yielded long and weakly banded fibrils, which, strikingly, had a uniform width of about 20 nm, The same was true for mixtures of collagens II and XI lacking collagen IX as long as the molar excess of collagen II was less than 8-fold. At higher ratios, the proteins assembled into tactoids coexisting with cartilage-like fibrils, Therefore, diameter control is an inherent property of appropriate mixtures of collagens II and XI, Collagen IX is not essential for this feature but strongly increases the efficiency of fibril formation. Therefore, this protein may be an important stabilizing factor of cartilage fibrils.	Univ Munster, Dept Physiol Chem & Pathobiochem, D-48149 Munster, Germany; Univ Munster, Inst Biochem, D-48149 Munster, Germany; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pathol, Piscataway, NJ 08854 USA; Inst Biol & Chim Prot, CNRS UPR 412, F-69007 Lyon, France	University of Munster; University of Munster; Rutgers State University New Brunswick; Rutgers State University Medical Center; Centre National de la Recherche Scientifique (CNRS)	Bruckner, P (corresponding author), Univ Munster, Dept Physiol Chem & Pathobiochem, Waldeyerstr 15, D-48149 Munster, Germany.		Bruckner, Peter/F-4817-2019	Bruckner, Peter/0000-0002-5566-5611; Hulmes, David/0000-0002-0651-1317				BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; Birk D.E., 1994, EXTRACELL MATRIX ASS, P91, DOI [10.1016/b978-0-12-775170-2.50009-3, DOI 10.1016/B978-0-12-775170-2.50009-3]; BIRK DE, 1984, ARCH BIOCHEM BIOPHYS, V235, P178, DOI 10.1016/0003-9861(84)90266-2; BIRK DE, 1990, J CELL SCI, V95, P649; Blaschke UK, 1996, J BIOL CHEM, V271, P30347, DOI 10.1074/jbc.271.48.30347; BRUCKNER P, 1989, J CELL BIOL, V109, P2537, DOI 10.1083/jcb.109.5.2537; BRUCKNER P, 1994, MICROSC RES TECHNIQ, V28, P378, DOI 10.1002/jemt.1070280504; CHAPMAN JA, 1989, BIOPOLYMERS, V28, P1367, DOI 10.1002/bip.360280803; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; EIKENBERRY EF, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P133; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; FASSLER R, 1994, P NATL ACAD SCI USA, V91, P5070, DOI 10.1073/pnas.91.11.5070; Fertala A, 1996, J BIOL CHEM, V271, P14864, DOI 10.1074/jbc.271.25.14864; FERTALA A, 1994, J BIOL CHEM, V269, P11584; GAROFALO S, 1993, P NATL ACAD SCI USA, V90, P3825, DOI 10.1073/pnas.90.9.3825; Hagg R, 1997, J BIOL CHEM, V272, P20650, DOI 10.1074/jbc.272.33.20650; Hagg R, 1998, J CELL BIOL, V142, P285, DOI 10.1083/jcb.142.1.285; HARTMANN DJ, 1983, COLLAGEN REL RES, V3, P349; Hodge A, 1963, ASPECTS PROTEIN STRU, P289; Holmes DF, 1996, J MOL BIOL, V261, P93, DOI 10.1006/jmbi.1996.0443; HULMES DJS, 1989, J MOL BIOL, V210, P337, DOI 10.1016/0022-2836(89)90335-5; HULMES DJS, 1995, BIOPHYS J, V68, P1661, DOI 10.1016/S0006-3495(95)80391-7; Hunziker EB, 1997, MICROSC RES TECHNIQ, V37, P271; KADLER KE, 1990, ANN NY ACAD SCI, V580, P214, DOI 10.1111/j.1749-6632.1990.tb17930.x; KEENE DR, 1995, J HISTOCHEM CYTOCHEM, V43, P967, DOI 10.1177/43.10.7560887; LEE SL, 1983, COLLAGEN REL RES, V3, P305; LEE SL, 1983, COLLAGEN REL RES, V3, P89; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; Li YF, 1997, MATRIX BIOL, V16, P49, DOI 10.1016/S0945-053X(97)90071-8; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; MAYNE R, 1995, EXTRACELLULAR MATRIX; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; Moradi-Ameli M, 1998, MATRIX BIOL, V17, P393, DOI 10.1016/S0945-053X(98)90091-9; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; MULLERGLAUSER W, 1986, J CELL BIOL, V102, P1931, DOI 10.1083/jcb.102.5.1931; OXFORD JT, 1995, J BIOL CHEM, V270, P9478, DOI 10.1074/jbc.270.16.9478; Prockop DJ, 1998, MATRIX BIOL, V16, P399, DOI 10.1016/S0945-053X(98)90013-0; PROCKOP DJ, 1994, EXTRACELLULAR MATRIX, P47; Richards AJ, 1996, HUM MOL GENET, V5, P1339, DOI 10.1093/hmg/5.9.1339; Rimoin DL, 1998, AM J MED GENET, V79, P376; Rousseau JC, 1996, J BIOL CHEM, V271, P23743, DOI 10.1074/jbc.271.39.23743; SEEGMILLER R, 1971, J CELL BIOL, V48, P580, DOI 10.1083/jcb.48.3.580; SHEFFIELD VC, 1985, COLLAGEN REL RES, V5, P1; THOM JR, 1991, J BIOL CHEM, V266, P7262; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; VIKKULA M, 1995, CELL, V80, P431, DOI 10.1016/0092-8674(95)90493-X; WU JJ, 1992, J BIOL CHEM, V267, P23007; YANG CL, 1995, BIOCHEM J, V306, P871, DOI 10.1042/bj3060871; ZHIDKOVA NI, 1995, J BIOL CHEM, V270, P9486, DOI 10.1074/jbc.270.16.9486	51	169	177	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10370	10378		10.1074/jbc.275.14.10370	http://dx.doi.org/10.1074/jbc.275.14.10370			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744725	hybrid			2022-12-27	WOS:000086345600066
J	Maliartchouk, S; Debeir, T; Beglova, N; Cuello, AC; Gehring, K; Saragovi, HU				Maliartchouk, S; Debeir, T; Beglova, N; Cuello, AC; Gehring, K; Saragovi, HU			Genuine monovalent ligands of TrkA nerve growth factor receptors reveal a novel pharmacological mechanism of action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROOT GANGLION NEURONS; NEUROTROPHIC FACTOR; FACTOR-BINDING; PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; CROSS-LINKING; NGF RECEPTOR; P75; AFFINITY; DIMERIZATION	Developing small molecule agonistic ligands for tyrosine kinase receptors has been difficult, and it is generally thought that such ligands require bivalency. Moreover, multisubunit receptors are difficult to target, because each subunit contributes to ligand affinity, and each subunit may have distinct and sometimes opposing functions. Here, the nerve growth factor receptor subunits p75 and the tyrosine kinase TrkA were studied using artificial ligands that bind specifically to their extracellular domain. Bivalent TrkA Ligands afford robust signals. However, genuine monomeric and monovalent TrkA ligands afford partial agonism, activate the tyrosine kinase activity, cause receptor internalization, and induce survival and differentiation in cell lines and primary neurons. Monomeric and monovalent TrkA Ligands can synergize with ligands that bind the p75 subunit. However, the p75 ligands used in this study must be bivalent, and monovalent p75 ligands have no effect. These findings will be useful in designing and developing screens of small molecules selective for tyrosine kinase receptors and indicate that strategies for designing agonists of multisubunit receptors require consideration of the role of each subunit. Last, the strategy of using anti-receptor mAbs and small molecule hormone mimics as receptor ligands could be applied to the study of many other heteromeric cell surface receptors.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Ctr Canc, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; McGill University; McGill University	Saragovi, HU (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Drummond St 1320, Montreal, PQ H3G 1Y6, Canada.	Uri@pharma.mcgill.ca	Cuello, A. Claudio/N-8211-2015; Gehring, Kalle/I-4403-2013; Gehring, Kalle/N-2945-2019	Gehring, Kalle/0000-0001-6500-1184; Gehring, Kalle/0000-0001-6500-1184; Cuello, Claudio/0000-0003-2143-2745				ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; Arteaga CL, 1997, J BIOL CHEM, V272, P23247, DOI 10.1074/jbc.272.37.23247; Beglova N, 1998, J BIOL CHEM, V273, P23652, DOI 10.1074/jbc.273.37.23652; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; BOGENMANN E, 1995, ONCOGENE, V10, P1915; Bredesen DE, 1997, TRENDS NEUROSCI, V20, P287, DOI 10.1016/S0166-2236(96)01049-1; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; Chao M, 1998, BRAIN RES REV, V26, P295, DOI 10.1016/S0165-0173(97)00036-2; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CLARY DO, 1994, MOL BIOL CELL, V5, P549, DOI 10.1091/mbc.5.5.549; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; Debeir T, 1999, P NATL ACAD SCI USA, V96, P4067, DOI 10.1073/pnas.96.7.4067; Farooqui T, 1997, J NEUROCHEM, V68, P2348; Frade JM, 1998, NEURON, V20, P35, DOI 10.1016/S0896-6273(00)80432-8; Gargano N, 1997, J NEUROSCI RES, V50, P1; Germain RN, 1997, CURR BIOL, V7, pR640, DOI 10.1016/S0960-9822(06)00323-X; Haniu M, 1997, J BIOL CHEM, V272, P25296, DOI 10.1074/jbc.272.40.25296; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOYER D, 1993, TRENDS PHARMACOL SCI, V14, P270, DOI 10.1016/0165-6147(93)90129-8; JAEN JC, 1995, J MED CHEM, V38, P4439, DOI 10.1021/jm00022a008; Jiang GQ, 1999, CURR BIOL, V9, pR568, DOI 10.1016/S0960-9822(99)80357-1; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; Kaneko M, 1997, J MED CHEM, V40, P1863, DOI 10.1021/jm970031d; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; Kimpinski K, 1997, J NEUROBIOL, V33, P395, DOI 10.1002/(SICI)1097-4695(199710)33:4<395::AID-NEU5>3.0.CO;2-5; LeSauteur L, 1996, NAT BIOTECHNOL, V14, P1120, DOI 10.1038/nbt0996-1120; LESAUTEUR L, 1995, J BIOL CHEM, V270, P6564, DOI 10.1074/jbc.270.12.6564; LeSauteur L, 1996, J NEUROSCI, V16, P1308; Li HM, 1998, IMMUNOL REV, V163, P177, DOI 10.1111/j.1600-065X.1998.tb01196.x; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Longo FM, 1997, J NEUROSCI RES, V48, P1, DOI 10.1002/(SICI)1097-4547(19970401)48:1<1::AID-JNR1>3.0.CO;2-K; MacDonald JIS, 1996, MOL CELL NEUROSCI, V7, P371, DOI 10.1006/mcne.1996.0027; MacPhee IJ, 1997, J BIOL CHEM, V272, P23547, DOI 10.1074/jbc.272.38.23547; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; Maliartchouk S, 1997, J NEUROSCI, V17, P6031; MILLIGAN G, 1995, TRENDS PHARMACOL SCI, V16, P10, DOI 10.1016/S0165-6147(00)88963-4; Molliver DC, 1997, J COMP NEUROL, V381, P428, DOI 10.1002/(SICI)1096-9861(19970519)381:4<428::AID-CNE3>3.0.CO;2-4; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Ross AH, 1996, J CELL BIOL, V132, P945, DOI 10.1083/jcb.132.5.945; SARAGOVI H, 1988, J IMMUNOL, V141, P476; Saragovi HU, 1999, EXPERT OPIN THER PAT, V9, P737, DOI 10.1517/13543776.9.6.737; Saragovi HU, 1998, J BIOL CHEM, V273, P34933, DOI 10.1074/jbc.273.52.34933; Segal RA, 1996, J BIOL CHEM, V271, P20175, DOI 10.1074/jbc.271.33.20175; Strange PG, 1999, BIOCHEM PHARMACOL, V58, P1081; Szafer A, 1995, NMR BIOMED, V8, P289, DOI 10.1002/nbm.1940080704; TAUB R, 1992, BIOCHEMISTRY-US, V31, P7431, DOI 10.1021/bi00148a001; Tian SS, 1998, SCIENCE, V281, P257, DOI 10.1126/science.281.5374.257; Vogelbaum MA, 1998, J NEUROSCI, V18, P8928; Wells JA, 1996, SCIENCE, V273, P449, DOI 10.1126/science.273.5274.449; WINDISCH JM, 1995, J BIOL CHEM, V270, P28133; Zhang B, 1999, SCIENCE, V284, P974, DOI 10.1126/science.284.5416.974	57	57	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					9946	9956		10.1074/jbc.275.14.9946	http://dx.doi.org/10.1074/jbc.275.14.9946			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744669	hybrid			2022-12-27	WOS:000086345600010
J	Zhao, L; Cissell, MA; Henderson, E; Colbran, R; Stein, R				Zhao, L; Cissell, MA; Henderson, E; Colbran, R; Stein, R			The RIPE3b1 activator of the insulin gene is composed of a protein(s) of approximately 43 kDa, whose DNA binding activity is inhibited by protein phosphatase treatment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEODOMAIN TRANSCRIPTION FACTOR; PANCREATIC BETA-CELLS; ISLET CELLS; FACTOR-I; CONTROL ELEMENT; HIGH GLUCOSE; EXPRESSION; ENHANCER; DIFFERENTIATION; PHOSPHORYLATION	Glucose-stimulated and pancreatic islet beta cell-specific expression of the insulin gene is mediated in part by the C1 DNA-element binding complex, termed RIPE3b1. In this report, we define the molecular weight range of the protein(s) that compose this beta cell-enriched activator complex and show that protein phosphatase treatment inhibits RIPE3b1 DNA binding activity. Fractionation of beta cell nuclear extracts by sodium dodecyl sulfate-polyacrylamide gel electrophoresis indicated that RIPE3b1 binding was mediated by a protein(s) within the 37-49-kDa ranges, Direct analysis of the proteins within the RIPE3b1 complex by ultraviolet light cross-linking analysis identified three binding species of approximately 51, 45, and 38 kDa. Incubating beta cell nuclear extracts with either calf alkaline phosphatase or a rat brain phosphatase preparation dramatically reduced RIPE3b1 DNA complex formation. Phosphatase inhibition of RIPE3b1 binding was prevented by sodium pyrophosphate, a general phosphatase inhibitor. We discuss how changes in the phosphorylation status of the RIPE3b1 activator may influence its DNA binding activity.	Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Stein, R (corresponding author), Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA.		Colbran, Roger/AAU-7708-2021	Colbran, Roger/0000-0001-7401-8244	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049852] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037508] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49852, DK42502] Funding Source: Medline; NINDS NIH HHS [NS37508] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahlgren U, 1996, DEVELOPMENT, V122, P1409; ARONHEIM A, 1991, NUCLEIC ACIDS RES, V19, P3893, DOI 10.1093/nar/19.14.3893; BOULDEN AM, 1992, MOL CELL BIOL, V12, P4769, DOI 10.1128/MCB.12.10.4769; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; CROWE DT, 1989, MOL CELL BIOL, V9, P1784, DOI 10.1128/MCB.9.4.1784; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EFRAT S, 1991, J BIOL CHEM, V266, P11141; FABER M, 1990, J BIOL CHEM, V265, P22243; GERMAN MS, 1994, MOL CELL BIOL, V14, P4067, DOI 10.1128/MCB.14.6.4067; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; MACFARLANE WM, 1994, BIOCHEM J, V303, P625, DOI 10.1042/bj3030625; Macfarlane WM, 1999, J BIOL CHEM, V274, P1011, DOI 10.1074/jbc.274.2.1011; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; MacMillan LB, 1999, J BIOL CHEM, V274, P35845, DOI 10.1074/jbc.274.50.35845; Malecki MT, 1999, NAT GENET, V23, P323, DOI 10.1038/15500; Marshak S, 1999, DIABETES, V48, P1230, DOI 10.2337/diabetes.48.6.1230; Marshak S, 1996, P NATL ACAD SCI USA, V93, P15057, DOI 10.1073/pnas.93.26.15057; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Odagiri H, 1996, J BIOL CHEM, V271, P1909, DOI 10.1074/jbc.271.4.1909; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Olson LK, 1998, MOL ENDOCRINOL, V12, P207, DOI 10.1210/me.12.2.207; PESHAVARIA M, 1994, MOL ENDOCRINOL, V8, P806, DOI 10.1210/me.8.6.806; Petersen HV, 1998, FEBS LETT, V431, P362, DOI 10.1016/S0014-5793(98)00776-5; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; PEYTON M, 1994, J BIOL CHEM, V269, P25936; Poitout V, 1996, J CLIN INVEST, V97, P1041, DOI 10.1172/JCI118496; Rafiq I, 1998, J BIOL CHEM, V273, P23241, DOI 10.1074/jbc.273.36.23241; ROBINSON GLWG, 1994, J BIOL CHEM, V269, P2452; Sander M, 1997, J MOL MED, V75, P327, DOI 10.1007/s001090050118; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1468, DOI 10.1210/me.9.11.1468; SHARMA A, 1994, MOL CELL BIOL, V14, P871, DOI 10.1128/MCB.14.2.871; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1127, DOI 10.1210/me.9.9.1127; SHIEH SY, 1991, J BIOL CHEM, V266, P16708; SHIEH SY, 1995, J BIOL CHEM, V270, P21503, DOI 10.1074/jbc.270.37.21503; STEIN R, 1993, TRENDS ENDOCRIN MET, V4, P96, DOI 10.1016/1043-2760(93)90086-T; STEINER DF, 1985, ANNU REV GENET, V19, P463, DOI 10.1146/annurev.ge.19.120185.002335; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; WHELAN J, 1990, MOL CELL BIOL, V10, P1564, DOI 10.1128/MCB.10.4.1564; Zhou J, 1999, DIABETES, V48, P2358, DOI 10.2337/diabetes.48.12.2358	54	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10532	10537		10.1074/jbc.275.14.10532	http://dx.doi.org/10.1074/jbc.275.14.10532			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744746	hybrid			2022-12-27	WOS:000086345600087
J	Calzada, A; Sanchez, M; Sanchez, E; Bueno, A				Calzada, A; Sanchez, M; Sanchez, E; Bueno, A			The stability of the Cdc6 protein is regulated by cyclin-dependent kinase/cyclin B complexes in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGINS IN-VIVO; DNA-REPLICATION; S-PHASE; FISSION YEAST; BUDDING YEAST; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; MITOTIC INDUCER; INITIATION; MITOSIS	The Saccharomyces cerevisiae Cdc6 protein is necessary for the formation of prereplicative complexes that are a prerequisite for firing origins during DNA replication in the S phase. In budding yeast, the presence of Cdc6 protein is normally restricted to the G(1) phase of the cell cycle, at least partly because of its proteolytic degradation in the late G(1)/early S phase. Here we show that a Cdc28-dependent mechanism targets p57(CDC6) for degradation in mitotic arrested budding yeast cells. Consistent with this observation, Cdc6-7 and Cdc6-8 proteins, mutants lacking Cdc28 phosphorylation sites, are stabilized relative to wild-type Cdc6, Our data also suggest a correlation between the absence of Cdc28/Clb kinase activity and Cdc6 protein stabilization, because a drop in Cdc28/Clb-associated kinase activity allows mitotic-arrested cells to accumulate Cdc6 protein. Finally, we also show that cdc28 temperature-sensitive G(1) mutants accumulate Cdc6 protein because of a post-transcriptional mechanism. Our data suggest that budding yeast cells target Cdc6 for degradation through a Cdc28-dependent mechanism in each cell cycle.	Univ Salamanca, CSIC, Inst Microbiol Bioquim, Ctr Invest Canc,Dept Microbiol & Genet, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Bueno, A (corresponding author), Univ Salamanca, CSIC, Inst Microbiol Bioquim, Ctr Invest Canc,Dept Microbiol & Genet, Edificio Departamental,Campus Miguel De Unamuno, Salamanca 37007, Spain.	abn@gugu.usal.es	SANCHEZ, MAR/L-1898-2017; Bueno, Avelino/A-9505-2016; Calzada, Arturo/M-1168-2014; Sánchez, Elisa/Z-3780-2019	Bueno, Avelino/0000-0002-0362-4391; Calzada, Arturo/0000-0002-3190-688X; Sanchez, Maria del Mar/0000-0003-4438-0722				[Anonymous], 1991, Methods Enzymol, V194, P1; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; Chong JPJ, 1996, TRENDS BIOCHEM SCI, V21, P102, DOI 10.1016/0968-0004(96)10013-X; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; DESHAIES R, 1995, CURR OPIN CELL BIOL, V7, P781, DOI 10.1016/0955-0674(95)80061-1; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Elsasser S, 1996, MOL BIOL CELL, V7, P1723, DOI 10.1091/mbc.7.11.1723; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HUTTER KJ, 1979, J GEN MICROBIOL, V113, P369, DOI 10.1099/00221287-113-2-369; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; Kearsey SE, 1996, CURR OPIN GENET DEV, V6, P208, DOI 10.1016/S0959-437X(96)80052-9; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; Lopez-Girona A, 1998, MOL BIOL CELL, V9, P63, DOI 10.1091/mbc.9.1.63; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MuziFalconi F, 1996, CURR BIOL, V6, P229, DOI 10.1016/S0960-9822(02)00464-5; MuziFalconi M, 1996, P NATL ACAD SCI USA, V93, P1566, DOI 10.1073/pnas.93.4.1566; NEWLON CS, 1993, CURR OPIN GENET DEV, V3, P752, DOI 10.1016/S0959-437X(05)80094-2; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; REED SI, 1980, GENETICS, V95, P561; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sanchez M, 1999, J BIOL CHEM, V274, P9092, DOI 10.1074/jbc.274.13.9092; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; Wuarin J, 1996, CELL, V85, P785, DOI 10.1016/S0092-8674(00)81261-1; ZWERSCHKE W, 1994, J BIOL CHEM, V269, P23351	51	47	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9734	9741		10.1074/jbc.275.13.9734	http://dx.doi.org/10.1074/jbc.275.13.9734			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734126	hybrid			2022-12-27	WOS:000086206500090
J	Chou, JH; Jahn, R				Chou, JH; Jahn, R			Binding of Rab3A to synaptic vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; MEMBRANE; TRANSPORT; GTPASES; PURIFICATION; ASSOCIATION; DOCKING; GTP; EXOCYTOSIS; FUSION	Prenylated Rab GTPases cycle between membrane-bound and soluble forms. Membrane-bound GrDP-Rabs interact with GDP dissociation inhibitor (GDI), resulting in the dissociation of a Rab GDI complex, which in turn serves as a precursor for the membrane re-association of Rabs, We have now characterized the binding of Rab3A to synaptic vesicles in vitro using either purified completes or rat brain cytosol as source for GDI.Rab3A Binding of Rab3A results in the immediate release of GDI from the membrane. Furthermore, binding does not require the presence of additional guanine nucleotides (GDP or GTP) or of cytosolic factors. Although nucleotide exchange follows binding, binding is initially reversible, suggesting that binding of GDP-Rab3A and nucleotide exchange are separate and independent events. Comparison with the binding of Rab1B revealed that both Rab proteins bind preferentially to their respective resident membranes although some promiscuity was observable, Binding is saturable and involves a protease-sensitive binding site that is tightly associated with the vesicle membrane.	Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA	Max Planck Society; Howard Hughes Medical Institute; Yale University; Yale University; Yale University	Jahn, R (corresponding author), Max Planck Inst Biophys Chem, Dept Neurobiol, Fassberg, D-37077 Gottingen, Germany.			Jahn, Reinhard/0000-0003-1542-3498				AHNERTHILGER G, 1994, EUR J CELL BIOL, V65, P26; Ayad N, 1997, EMBO J, V16, P4497, DOI 10.1093/emboj/16.15.4497; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSE N, 1990, J BIOL CHEM, V265, P10604; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DiracSvejstrup AB, 1997, EMBO J, V16, P465, DOI 10.1093/emboj/16.3.465; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; FISCHER V, 1991, NATURE, V349, P79; Geppert M, 1998, ANNU REV NEUROSCI, V21, P75, DOI 10.1146/annurev.neuro.21.1.75; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; HELL JW, 1994, CELL BIOL LAB HDB, P567; HORIUCHI H, 1995, METHOD ENZYMOL, V257, P9; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; KIKUCHI A, 1995, METHOD ENZYMOL, V257, P57; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazar T, 1997, TRENDS BIOCHEM SCI, V22, P468, DOI 10.1016/S0968-0004(97)01150-X; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; LLEDO PM, 1994, TRENDS NEUROSCI, V17, P426, DOI 10.1016/0166-2236(94)90017-5; Luan P, 1999, J BIOL CHEM, V274, P14806, DOI 10.1074/jbc.274.21.14806; Martinez O, 1998, BBA-MOL CELL RES, V1404, P101, DOI 10.1016/S0167-4889(98)00050-0; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; NUOFFER C, 1995, METHOD ENZYMOL, V257, P3; OSSIG R, 1995, EMBO J, V14, P3645, DOI 10.1002/j.1460-2075.1995.tb00034.x; Park JB, 1997, J BIOL CHEM, V272, P20857, DOI 10.1074/jbc.272.33.20857; SASAKI T, 1990, J BIOL CHEM, V265, P2333; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLDATI T, 1995, J BIOL CHEM, V270, P25541, DOI 10.1074/jbc.270.43.25541; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; STAHL B, 1994, J BIOL CHEM, V269, P24770; Stenius K, 1995, J CELL BIOL, V131, P1801, DOI 10.1083/jcb.131.6.1801; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; VONMOLLARD GF, 1994, J BIOL CHEM, V269, P10971; VONMOLLARD GF, 1994, EUR J CELL BIOL, V65, P319; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; VONMOLLARD GF, 1993, GTPASES BIOL, V1, P477; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Yang XP, 1998, EMBO J, V17, P4954, DOI 10.1093/emboj/17.17.4954	49	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9433	9440		10.1074/jbc.275.13.9433	http://dx.doi.org/10.1074/jbc.275.13.9433			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734089	hybrid			2022-12-27	WOS:000086206500053
J	Eggink, LL; Hoober, JK				Eggink, LL; Hoober, JK			Chlorophyll binding to peptide maquettes containing a retention motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; CHLAMYDOMONAS-REINHARDTII; PROTEIN; DESIGN; A/B; 38-DEGREES-C; APOPROTEINS; CHLOROPLAST; MODEL	The motif Glu-X-X-His/Asn-X-Arg is conserved in the first and third membrane-spanning domains of all light-harvesting chlorophyll a/b- and ale-binding proteins in chloroplasts. Molecular modeling of synthetic peptides containing the sequence Glu-Ile-Val-His-Ser-Arg, a motif found in the apoprotein of the major light-harvesting complex in plants, generated a loop structure formed by intrapeptide, electrostatic attraction between Glu and Arg. His, Asn, and charge-compensated Glu-Arg pairs are known ligands of the magnesium atom in chlorophyll, The prediction that this structure should bind two molecules of chlorophyll was confirmed experimentally with an assay based on fluorescence resonance energy transfer between peptides and chlorophyll a. Motifs with both potential ligands bound approximately two times the amount of chlorophyll as one in which His was replaced by Ale. These results support the conclusion that formation of this intermediate, within membranes of the envelope, is a crucial step in assembly of light-harvesting complexes and a mechanism that regulates import of the apoproteins into the chloroplast.	Arizona State Univ, Dept Plant Biol, Tempe, AZ 85287 USA; Arizona State Univ, Ctr Study Early Events Photosynthesis, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	Hoober, JK (corresponding author), Arizona State Univ, Dept Plant Biol, Tempe, AZ 85287 USA.	khoober@asu.edu						Bassi R, 1999, P NATL ACAD SCI USA, V96, P10056, DOI 10.1073/pnas.96.18.10056; Funk C, 1999, NATO ASI 3 HIGH TECH, V64, P103; Gadella TWJ, 1999, TRENDS PLANT SCI, V4, P287, DOI 10.1016/S1360-1385(99)01426-0; GREEN BR, 1994, PHOTOSYNTH RES, V39, P149, DOI 10.1007/BF00029382; Heinemann B, 1999, BIOCHEMISTRY-US, V38, P14088, DOI 10.1021/bi991439a; Hoober JK, 1999, PHOTOSYNTH RES, V61, P197; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; KOHORN BD, 1987, J BIOL CHEM, V262, P12897; KOHORN BD, 1990, PLANT PHYSIOL, V93, P339, DOI 10.1104/pp.93.1.339; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; MALONEY MA, 1989, PLANT PHYSIOL, V91, P1100, DOI 10.1104/pp.91.3.1100; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; Mulholland SE, 1999, BIOCHEMISTRY-US, V38, P10442, DOI 10.1021/bi9908742; Munoz V, 1997, NATURE, V390, P196, DOI 10.1038/36626; Pagano A, 1998, J BIOL CHEM, V273, P17154, DOI 10.1074/jbc.273.27.17154; Park H, 1997, PHYSIOL PLANTARUM, V101, P135, DOI 10.1034/j.1399-3054.1997.1010118.x; PAULSEN H, 1993, EUR J BIOCHEM, V215, P809, DOI 10.1111/j.1432-1033.1993.tb18096.x; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; RamirezAlvarado M, 1996, NAT STRUCT BIOL, V3, P604, DOI 10.1038/nsb0796-604; REINERO A, 1991, PHOTOSYNTH RES, V30, P25, DOI 10.1007/BF00035679; RENGE I, 1985, PHOTOCHEM PHOTOBIOL, V42, P253, DOI 10.1111/j.1751-1097.1985.tb08939.x; ROBERTSON DE, 1994, NATURE, V368, P425, DOI 10.1038/368425a0; White RA, 1996, PHOTOSYNTH RES, V47, P267, DOI 10.1007/BF02184287	23	54	58	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9087	9090		10.1074/jbc.275.13.9087	http://dx.doi.org/10.1074/jbc.275.13.9087			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734037	hybrid			2022-12-27	WOS:000086206500001
J	Mignen, O; Shuttleworth, TJ				Mignen, O; Shuttleworth, TJ			I-ARC, a novel arachidonate-regulated, noncapacitative Ca2+ entry channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CALCIUM CURRENT; ENDOTHELIAL-CELLS; EXTRACELLULAR PH; MAST-CELLS; DEPLETION; INFLUX; TRP; OSCILLATIONS; JURKAT; STORES	Along with the inositol trisphosphate-induced release of stored Ca2+, a receptor-enhanced entry of Ca2+ is a critical component of intracellular Ca2+ signals generated by agonists acting at receptors coupled to the activation of phospholipase C. Although the simple emptying of the intracellular Ca2+ stores is known to be capable of activating Ca2+ entry via the so-called "capacitative" mechanism, recent evidence suggests that Ca2+ entry at physiological agonist concentrations, where oscillatory Ca2+ signals are typically observed, does not conform to such a model. Instead, a noncapacitative Ca2+ entry pathway regulated by arachidonic acid appears to be responsible for Ca2+ entry under these conditions. Using whole-cell patch clamp techniques we demonstrate that low concentrations of arachidonic acid activate a Ca2+-selective current that is superficially similar to the store-operated current I-CRAC, but which also demonstrates certain distinct features. We have named this novel current I-ARC (for arachidonate-regulated calcium current). Importantly, I-arc can be readily activated in cells whose Ca2+ stores have been maximally depleted. I-ARC represents a novel Ca2+ entry pathway that is entirely separate from those activated by store depletion and is specifically activated at physiological levels of stimulation.	Univ Rochester, Dept Pharmacol & Physiol, Ctr Med, Rochester, NY 14642 USA	University of Rochester	Shuttleworth, TJ (corresponding author), Univ Rochester, Dept Pharmacol & Physiol, Ctr Med, 601 Elmwood Ave,Box 722, Rochester, NY 14642 USA.		MIGNEN, Olivier/M-3258-2019	MIGNEN, Olivier/0000-0001-7913-6119	NIGMS NIH HHS [GM 40457] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMERS W, 1984, J PHYSIOL-LONDON, V353, P565, DOI 10.1113/jphysiol.1984.sp015351; BERS DM, 1994, METHOD CELL BIOL, V40, P3; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Broad LM, 1999, J PHYSIOL-LONDON, V517, P121, DOI 10.1111/j.1469-7793.1999.0121z.x; Chyb S, 1999, NATURE, V397, P255, DOI 10.1038/16703; Fasolato C, 1998, PFLUG ARCH EUR J PHY, V436, P69, DOI 10.1007/s004240050605; Fierro L, 1999, J MEMBRANE BIOL, V168, P9, DOI 10.1007/s002329900493; HARDIE RC, 1995, CELL CALCIUM, V18, P256, DOI 10.1016/0143-4160(95)90023-3; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Hug MJ, 1996, PFLUG ARCH EUR J PHY, V432, P278, DOI 10.1007/s004240050134; Kerschbaum HH, 1998, J GEN PHYSIOL, V111, P521, DOI 10.1085/jgp.111.4.521; Kerschbaum HH, 1999, SCIENCE, V283, P836, DOI 10.1126/science.283.5403.836; LeppleWienhues A, 1996, BIOPHYS J, V71, P787, DOI 10.1016/S0006-3495(96)79278-0; MALAYEV A, 1995, J MEMBRANE BIOL, V146, P101; MCDONALD TV, 1993, J BIOL CHEM, V268, P3889; MUALLEM S, 1989, AM J PHYSIOL, V257, pG917, DOI 10.1152/ajpgi.1989.257.6.G917; Munaron L, 1997, CELL CALCIUM, V22, P179, DOI 10.1016/S0143-4160(97)90011-7; NEGULESCU PA, 1995, AM J PHYSIOL-GASTR L, V269, pG770, DOI 10.1152/ajpgi.1995.269.5.G770; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Shuttleworth TJ, 1999, J BIOL CHEM, V274, P31174, DOI 10.1074/jbc.274.44.31174; Shuttleworth TJ, 1998, J BIOL CHEM, V273, P32636, DOI 10.1074/jbc.273.49.32636; Shuttleworth TJ, 1999, CELL CALCIUM, V25, P237, DOI 10.1054/ceca.1999.0022; Shuttleworth TJ, 1996, BIOCHEM J, V316, P819, DOI 10.1042/bj3160819; Shuttleworth TJ, 1996, J BIOL CHEM, V271, P21720, DOI 10.1074/jbc.271.36.21720; Wakabayashi I, 1996, BIOCHEM BIOPH RES CO, V221, P762, DOI 10.1006/bbrc.1996.0670; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6259	33	165	170	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9114	9119		10.1074/jbc.275.13.9114	http://dx.doi.org/10.1074/jbc.275.13.9114			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734044	hybrid			2022-12-27	WOS:000086206500008
J	Schwarzler, A; Kreienkamp, HJ; Richter, D				Schwarzler, A; Kreienkamp, HJ; Richter, D			Interaction of the somatostatin receptor subtype 1 with the human homolog of the Shk1 kinase-binding protein from yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FISSION YEAST; CLONING; IDENTIFICATION; GLUTAMATE; TERMINUS; DOMAIN; BRAIN; SKB1	Interaction between the C terminus of a G-protein-coupled receptor and intracellular constituents may represent a crucial step in regulating signal transduction, To identify potential interacting candidates the C terminus of the somatostatin receptor subtype 1 was used as bait in a yeast two hybrid screen of a human brain cDNA library. We identified the human Skb1 sequence (Skb1Hs) as interacting protein, which is homologous to the yeast protein known Skb1 to down regulate mitosis in Schizosaccharomyces pombe via binding to the Shk1 protein kinase; the latter is a homolog to the mammalian p21(cdc42/Rac)-activated protein kinases, Interaction required almost the entire C terminus of the somatostatin receptor subtype 1 including the conserved NPXYY motif of transmembrane region seven; in the case of the Skb1Hs most of the N terminus and an S-adenosylmethionine binding domain were mandatory, whereas the C terminus was not essential. Interaction was verified by coexpression experiments in human embryonic kidney cells. As revealed by immunocytochemical analysis Skb1Hs expressed alone aggregates in large cytosolic clusters. When coexpressed, receptor subtype 1 and Skb1Hs were colocalized at the cell surface; these cells showed a strong increase in somatostatin binding compared with cells expressing the receptor only. This may suggest that Skb1Hs acts like a chaperone by correctly targeting the receptor to the cell surface.	Univ Hamburg, Hosp Eppendorf, Inst Zellbiochem & Klin Neurobiol, D-20246 Hamburg, Germany	University of Hamburg	Richter, D (corresponding author), Univ Hamburg, Inst Zellbiochem & Klin Neurobiol, Martinistr 52, D-20246 Hamburg, Germany.	richter@uke.uni-hamburg.de						Aguilar RC, 1997, J BIOL CHEM, V272, P27160, DOI 10.1074/jbc.272.43.27160; Ahn AH, 1996, J BIOL CHEM, V271, P2724, DOI 10.1074/jbc.271.5.2724; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Foord SM, 1999, TRENDS PHARMACOL SCI, V20, P184, DOI 10.1016/S0165-6147(99)01347-4; FUJII Y, 1994, FEBS LETT, V355, P117, DOI 10.1016/0014-5793(94)01159-1; Gilbreth M, 1998, P NATL ACAD SCI USA, V95, P14781, DOI 10.1073/pnas.95.25.14781; Gilbreth M, 1996, P NATL ACAD SCI USA, V93, P13802, DOI 10.1073/pnas.93.24.13802; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Krapivinsky G, 1998, J BIOL CHEM, V273, P10811, DOI 10.1074/jbc.273.18.10811; KRAPIVINSKY GB, 1994, CELL, V76, P439, DOI 10.1016/0092-8674(94)90109-0; Kreienkamp H J, 1999, Results Probl Cell Differ, V26, P215; Kreienkamp HJ, 1997, FEBS LETT, V419, P92, DOI 10.1016/S0014-5793(97)01437-3; KREIENKAMP HJ, 1994, J BIOL CHEM, V269, P8108; Lanneau C, 1998, EUR J NEUROSCI, V10, P204, DOI 10.1046/j.1460-9568.1998.00041.x; Lopez F, 1997, J BIOL CHEM, V272, P24448, DOI 10.1074/jbc.272.39.24448; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; MEYER G, 1995, NEURON, V15, P563, DOI 10.1016/0896-6273(95)90145-0; MEYERHOF W, 1991, DNA CELL BIOL, V10, P689, DOI 10.1089/dna.1991.10.689; PATEL YC, 1994, BIOCHEM BIOPH RES CO, V198, P605, DOI 10.1006/bbrc.1994.1088; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; RENSDOMIANO S, 1992, MOL PHARMACOL, V42, P28; Roosterman D, 1998, FEBS LETT, V425, P137, DOI 10.1016/S0014-5793(98)00221-X; Roth A, 1997, J BIOL CHEM, V272, P23769, DOI 10.1074/jbc.272.38.23769; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Schwartkop CP, 1999, J NEUROCHEM, V72, P1275, DOI 10.1046/j.1471-4159.1999.0721275.x; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; Zitzer H, 1999, J BIOL CHEM, V274, P18153, DOI 10.1074/jbc.274.26.18153; Zitzer H, 1999, J BIOL CHEM, V274, P32997, DOI 10.1074/jbc.274.46.32997	29	20	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9557	9562		10.1074/jbc.275.13.9557	http://dx.doi.org/10.1074/jbc.275.13.9557			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734105	hybrid			2022-12-27	WOS:000086206500069
J	Dong, JW; Walker, J; Nitiss, JL				Dong, JW; Walker, J; Nitiss, JL			A mutation in yeast topoisomerase II that confers hypersensitivity to multiple classes of topoisomerase II poisons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI GYRA; DNA TOPOISOMERASE; EUKARYOTIC TOPOISOMERASE; FLUOROQUINOLONE RESISTANCE; SALMONELLA-TYPHIMURIUM; QUINOLONE-RESISTANCE; AMINO-ACID; DRUGS; CLEAVAGE; ETOPOSIDE	A mutation was constructed in the CAP homology domain of yeast topoisomerase II that resulted in hypersensitivity to the intercalating agent N-[4-(9-acridinylamino)-3-methoxy-phenyl]methanesulfonamide and the fluoroquinolone 6,8-difiuoro-7-(4'-hydroxyphenyl)-1-cyclopropyl-4-quinolone-3-carboxylic acid, but not to etoposide. This mutation, which changes threonine at position 744 to proline, also confers hypersensitivity to anti-bacterial fluoroquinolones. The purified T744P mutant protein had wild type enzymatic activity in the absence of drugs, and no alteration in drug-independent DNA cleavage. Enhanced DNA cleavage in the presence of N-[4-(9-acridinylamino)-3-methoxy-phenyl] sulfonamide and fluoroquinolones was observed, in agreement with the results observed in vivo. DNA cleavage was also seen in the presence of norfloxacin and oxolinic acid, two quinolones that are inactive against eukaryotic topoisomerase II. The hypersensitivity was not associated with heat-stable covalent complexes, as was seen in another drug-hypersensitive mutant. Molecular modeling suggests that the mutation in the GAP homology domain may displace amino acids that play important roles in catalysis by topoisomerase II and may explain the drug-hypersensitive phenotype.	St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38018 USA	St Jude Children's Research Hospital	Nitiss, JL (corresponding author), St Jude Childrens Res Hosp, Dept Mol Pharmacol, 332 N Lauderdale, Memphis, TN 38018 USA.		Nitiss, John/E-9974-2010	Nitiss, John/0000-0002-1013-4972	NCI NIH HHS [CA21765, CA52814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, R01CA052814] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Critchlow SE, 1996, BIOCHEMISTRY-US, V35, P7387, DOI 10.1021/bi9603175; ELSEA SH, 1995, J BIOL CHEM, V270, P1913, DOI 10.1074/jbc.270.4.1913; ELSEA SH, 1992, J BIOL CHEM, V267, P13150; Fass D, 1999, NAT STRUCT BIOL, V6, P322; Freudenreich CH, 1998, CANCER RES, V58, P1260; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P28018; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GENSBERG K, 1995, FEMS MICROBIOL LETT, V132, P57, DOI 10.1016/0378-1097(95)00287-F; GOOTZ TD, 1990, ANTIMICROB AGENTS CH, V34, P8, DOI 10.1128/AAC.34.1.8; HEISIG P, 1993, J ANTIMICROB CHEMOTH, V32, P367, DOI 10.1093/jac/32.3.367; HENDERSHOT EF, 1995, INFECT DIS CLIN N AM, V9, P715; HOOPER DC, 1991, NEW ENGL J MED, V324, P384, DOI 10.1056/NEJM199102073240606; HOSHINO K, 1994, ANTIMICROB AGENTS CH, V38, P2623, DOI 10.1128/AAC.38.11.2623; HSIUNG YC, 1995, J BIOL CHEM, V270, P20359, DOI 10.1074/jbc.270.35.20359; JANNATIPOUR M, 1993, J BIOL CHEM, V268, P18586; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; Kumagai Y, 1996, ANTIMICROB AGENTS CH, V40, P710, DOI 10.1128/AAC.40.3.710; Li ZY, 1998, ANTIMICROB AGENTS CH, V42, P3293, DOI 10.1128/AAC.42.12.3293; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1983, J BIOL CHEM, V258, P5365; Liu QY, 1998, J BIOL CHEM, V273, P20252, DOI 10.1074/jbc.273.32.20252; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; NITISS J, 1991, DNA TOPOISOMERASES C, P77; Nitiss JL, 1996, ANN NY ACAD SCI, V803, P32, DOI 10.1111/j.1749-6632.1996.tb26374.x; NITISS JL, 1993, CANCER RES, V53, P89; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; Nitiss JL, 1998, BIOCHEMISTRY-US, V37, P3078, DOI 10.1021/bi9723257; Nitiss JL, 1996, EUR J CANCER, V32A, P958, DOI 10.1016/0959-8049(96)00056-1; NITISS JL, 1992, CANCER RES, V52, P4467; NITISS JL, 1996, ANTICANCER DRUGS S3, V7, P27; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; Pan XS, 1996, J BACTERIOL, V178, P4060, DOI 10.1128/jb.178.14.4060-4069.1996; Pommier Y, 1996, SEMIN ONCOL, V23, P3; ROBINSON MJ, 1992, ANTIMICROB AGENTS CH, V36, P751, DOI 10.1128/AAC.36.4.751; ROBINSON MJ, 1990, BIOCHEMISTRY-US, V29, P2511, DOI 10.1021/bi00462a012; ROBINSON MJ, 1991, J BIOL CHEM, V266, P14585; Sabourin M, 1998, J BIOL CHEM, V273, P29086, DOI 10.1074/jbc.273.44.29086; TRASK DK, 1984, EMBO J, V3, P671, DOI 10.1002/j.1460-2075.1984.tb01865.x; Vila J, 1996, ANTIMICROB AGENTS CH, V40, P491, DOI 10.1128/AAC.40.2.491; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; YONEZAWA M, 1995, MICROBIOL IMMUNOL, V39, P243, DOI 10.1111/j.1348-0421.1995.tb02196.x; YOSHIDA H, 1991, ANTIMICROB AGENTS CH, V35, P1647, DOI 10.1128/AAC.35.8.1647	46	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7980	7987		10.1074/jbc.275.11.7980	http://dx.doi.org/10.1074/jbc.275.11.7980			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713116	hybrid			2022-12-27	WOS:000085913300076
J	Guo, L; Johnson, RS; Schuh, JCL				Guo, L; Johnson, RS; Schuh, JCL			Biochemical characterization of endogenously formed eosinophilic crystals in the lungs of mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHITINASE PROTEIN FAMILY; CHEMOTACTIC FACTOR; MAMMALIAN MEMBER; TRANSGENIC MICE; IDENTIFICATION; INFLAMMATION; MACROPHAGE; INFECTION; SEQUENCE; DATABASE	Crystals seldom form spontaneously within tissues of mammals, except in the urinary tract or in association with eosinophil-rich diseases in humans (Charcot-Leyden crystals). Endogenously formed eosinophilic: crystals have been reported in respiratory tract and other tissues of several strains of mice, but the biochemical characterization of these crystals has not been reported. In this study, eosinophilic crystal formation was examined in homozygous C57BL/6J viable motheaten mice, lung-specific surfactant apoprotein G promoter/soluble human tumor necrosis factor p75 receptor type II fusion protein transgenic mice (C57BL/6NTac x Sv/129), and CD40L-deficient mice with spontaneous Pneumocystis carinii infection. In viable motheaten but not wild type mice, rapidly developing crystals represented a major feature of the fatal lung injury induced by macrophage dysregulation. Conversely, eosinophilic crystals did not form until 4-8 months of age in transgenic and CD40L-deficient mice and were present in 10-30% of age-matched wild type controls. Mass spectrometry analysis of proteins from bronchoalveolar lavage fluid identified the crystals as Ym1, sometimes referred to as T-lymphocyte-derived eosinophil chemotactic factor. The Ym1 sequence was homologous to chitinase, and enzymatic assays indicated a 3-5-fold increase in chitinase activity compared with control mice. Intracellular and extracellular crystals associated with epithelial damage suggested that the crystals may contribute to lung inflammation through mechanical damage and enzymatic degradation.	Immunex Corp, Seattle, WA 98101 USA	Immunex Corporation	Schuh, JCL (corresponding author), Immunex Corp, 51 Univ St, Seattle, WA 98101 USA.	schuhj@immunex.com		Schuh, JoAnn C. L./0000-0002-2399-8518				ACKERMAN SJ, 1993, J IMMUNOL, V150, P456; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; ENNULAT D, 1998, VET PATHOL, V35, P456; Ernst H, 1996, PATHOBIOLOGY AGING M, P281; Green EU, 1942, CANCER RES, V2, P210; HAALAND M, 1905, ANN I PASTEUR, V19, P165; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; HOLLAK CEM, 1994, J CLIN INVEST, V93, P1288, DOI 10.1172/JCI117084; Hu B, 1996, J BIOL CHEM, V271, P19415, DOI 10.1074/jbc.271.32.19415; Huffnagle GB, 1998, J IMMUNOL, V160, P2393; Jin HM, 1998, GENOMICS, V54, P316, DOI 10.1006/geno.1998.5593; LEWIS DJ, 1984, J COMP PATHOL, V94, P263, DOI 10.1016/0021-9975(84)90045-8; MURRAY AB, 1990, VET PATHOL, V27, P274, DOI 10.1177/030098589002700409; Owhashi M, 1996, INT J PARASITOL, V26, P705, DOI 10.1016/0020-7519(96)00054-9; Owhashi M, 1998, PARASITOL RES, V84, P136, DOI 10.1007/s004360050370; PerezArellano JL, 1996, RESP MED, V90, P159, DOI 10.1016/S0954-6111(96)90158-4; Rankin JA, 1996, P NATL ACAD SCI USA, V93, P7821, DOI 10.1073/pnas.93.15.7821; Schubert MA, 1997, J BIOMED MATER RES, V34, P493, DOI 10.1002/(SICI)1097-4636(19970315)34:4<493::AID-JBM10>3.0.CO;2-E; Schuh JCL, 1999, TOXICOL PATHOL, V27, P115, DOI 10.1177/019262339902700122; SCHUH JCL, 1996, VET PATHOL, V33, P616; SCHUH JCL, 1997, VET PATHOL, V34, P493; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SHULTZ LD, 1994, HDB MOUSE MUTATIONS, P351; Smith S, 1998, AM J RESP CELL MOL, V19, P881, DOI 10.1165/ajrcmb.19.6.3146; Sueoka N, 1998, CYTOKINE, V10, P124, DOI 10.1006/cyto.1997.0267; Takamoto M, 1997, IMMUNOLOGY, V90, P511, DOI 10.1046/j.1365-2567.1997.00208.x; Taylor JA, 1997, RAPID COMMUN MASS SP, V11, P1067, DOI 10.1002/(SICI)1097-0231(19970615)11:9<1067::AID-RCM953>3.0.CO;2-L; Tyzzer EE, 1909, J MED RES, V21, P479; Volck B, 1998, P ASSOC AM PHYSICIAN, V110, P351; WARD JM, 1978, VET PATHOL, V15, P170, DOI 10.1177/030098587801500203; WATANABE T, 1993, J BIOL CHEM, V268, P18567; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; YANG YH, 1964, AM J PATHOL, V45, P337; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	35	108	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8032	8037		10.1074/jbc.275.11.8032	http://dx.doi.org/10.1074/jbc.275.11.8032			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713123	hybrid			2022-12-27	WOS:000085913300083
J	Wang, YJ; Morrow, JS				Wang, YJ; Morrow, JS			Identification and characterization of human SLP-2, a novel homologue of stomatin (Band 7.2b) present in erythrocytes and other tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; CAENORHABDITIS-ELEGANS; NUCLEOTIDE-SEQUENCE; CELL MEMBRANE; GENE; BINDS; SENSITIVITY; TRANSPORT; SPECTRIN; SITE	Human stomatin (band 7.2b) is a 31-kDa erythrocyte membrane protein of unknown function but implicated in the control of ion channel permeability, mechanoreception, and lipid domain organization, Although absent in erythrocytes from patients with hereditary stomatocytosis, stomatin is not linked to this disorder. A second stomatin homologue, termed SLP-1, has been identified in nonerythroid tissues, and other stomatin related proteins are found in Drosophila, Caenorhabditis elegans, and plants. We now report the cloning and characterization of a new and unusual stomatin homologue, human SLP-2 (Stomatin-like protein 2), SLP-2 is encoded by an similar to 1.5-kilobase mRNA (GenBank(TM) accession no. AF190167). The gene for human SLP-2, HUSLP2, is present on chromosome 9p13. Its derived amino acid sequence predicts a 38,537-kDa protein that is overall similar to 20% similar to human stomatin. Northern and Western blots for SLP-I and SLP-2 reveal a wide but incompletely overlapping tissue distribution. Unlike SLP-1, SLP-2 is also present in mature human erythrocytes (similar to 4,000 +/- 5,660 (+/- 2 S.D.) copies/cell). SLP-2 lacks a characteristic NH2-terminal hydrophobic domain found in other stomatin homologues and (unlike stomatin) is fully extractable from erythrocyte membranes by NaOH, pH 11. SLP-2 partitions into both Triton X-100-soluble and -insoluble pools in erythrocyte ghost membranes or when expressed in cultured COS cells and migrates anomalously on SDS-polyacrylamide gel electrophoresis analysis with apparent mobilities of similar to 45,500, 44,600, and 34,300 M-r,. The smallest of these protein bands is believed to represent the product of alternative translation initiated at AUGs beginning with nt 217 or 391, although this point has not been rigorously proven. Collectively, these findings identify a novel and unusual member of the stomatin gene superfamily that interacts with the peripheral erythrocyte cytoskeleton and presumably other integral membrane proteins but not directly with the membrane bilayer, We hypothesize that SLP-2 may link stomatin or other integral membrane proteins to the peripheral cytoskeleton and thereby play a role in regulating ion channel conductances or the organization of sphingolipid and cholesterol-rich lipid rafts.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	Yale University	Morrow, JS (corresponding author), Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA.				NHLBI NIH HHS [F32-HL09977] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009977] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGRE P, 1995, CURR OPIN CELL BIOL, V7, P472, DOI 10.1016/0955-0674(95)80003-4; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Barnes TM, 1996, J NEUROCHEM, V67, P46; BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Delaunay J, 1999, Curr Opin Hematol, V6, P110, DOI 10.1097/00062752-199903000-00009; Desneves J, 1996, BIOCHEM BIOPH RES CO, V224, P108, DOI 10.1006/bbrc.1996.0992; Devarajan P, 1996, J CELL BIOL, V133, P819, DOI 10.1083/jcb.133.4.819; GALLAGHER PG, 1995, J BIOL CHEM, V270, P26358, DOI 10.1074/jbc.270.44.26358; HEBBEL RP, 1991, BIOPHYS J, V60, P712, DOI 10.1016/S0006-3495(91)82100-2; HIEBLDIRSCHMIED CM, 1991, BIOCHIM BIOPHYS ACTA, V1065, P195, DOI 10.1016/0005-2736(91)90230-6; HIEBLDIRSCHMIED CM, 1991, BIOCHIM BIOPHYS ACTA, V1090, P123, DOI 10.1016/0167-4781(91)90047-P; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Ho Mei M., 1997, Biochemical Society Transactions, V25, p492S; HUANG MX, 1995, NATURE, V378, P292, DOI 10.1038/378292a0; Innes DS, 1999, AM J HEMATOL, V60, P72, DOI 10.1002/(SICI)1096-8652(199901)60:1<72::AID-AJH13>3.0.CO;2-8; KENNEDY SP, 1991, J CELL BIOL, V115, P267, DOI 10.1083/jcb.115.1.267; *KOD INT BIOT IND, 1992, TECHN B, V1; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCKUSICK V, 1997, ONLINE MENDELIAN INH; Moore RB, 1997, BIOCHEM BIOPH RES CO, V232, P294, DOI 10.1006/bbrc.1997.6278; *PIERC, 1994, PIERC CAT HDB, pT116; Rajaram S, 1998, P NATL ACAD SCI USA, V95, P8761, DOI 10.1073/pnas.95.15.8761; SALZER U, 1993, BIOCHIM BIOPHYS ACTA, V1151, P149, DOI 10.1016/0005-2736(93)90098-K; Sambrook J., 2002, MOL CLONING LAB MANU; SCHRIER SL, 1992, BLOOD, V79, P1586; Seidel G, 1998, GENE, V225, P23, DOI 10.1016/S0378-1119(98)00532-0; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Snyers L, 1997, EUR J CELL BIOL, V73, P281; Snyers L, 1999, FEBS LETT, V449, P101, DOI 10.1016/S0014-5793(99)00417-2; Snyers L, 1998, J BIOL CHEM, V273, P17221, DOI 10.1074/jbc.273.27.17221; STEWART GW, 1993, BIOCHIM BIOPHYS ACTA, V1225, P15, DOI 10.1016/0925-4439(93)90116-I; STEWART GW, 1992, BLOOD, V79, P1593, DOI 10.1182/blood.V79.6.1593.bloodjournal7961593; STEWART GW, 1993, RED CELL MEMBRANE AN, P167; Wang YJ, 1999, BLOOD, V94, p189A; WESTBERG JA, 1993, CYTOGENET CELL GENET, V63, P241, DOI 10.1159/000133542; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; You ZR, 1998, MICROBIOL-SGM, V144, P2619, DOI 10.1099/00221287-144-9-2619; Zhu YW, 1999, BLOOD, V93, P2404, DOI 10.1182/blood.V93.7.2404.407k13_2404_2410	41	92	112	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8062	8071		10.1074/jbc.275.11.8062	http://dx.doi.org/10.1074/jbc.275.11.8062			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713127	hybrid			2022-12-27	WOS:000085913300087
J	Chang, TLY; Peng, XB; Fu, XY				Chang, TLY; Peng, XB; Fu, XY			Interleukin-4 mediates cell growth inhibition through activation of Stat1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATORY FACTOR-I; JAK-3 JANUS KINASE; INSULIN-RECEPTOR; TRANSCRIPTION FACTOR; SIGNALING PATHWAYS; INTERFERON-ALPHA; MAST-CELLS; B-CELLS; T-CELLS; IL-4	Interleukin-4 (IL-4) activates State (signal transducer and activator of transcription 6) and plays multiple roles in regulation of the immune system. IL-4 also triggers phosphorylation of insulin receptor substrate (IRS), leading to stimulation of cell growth. Moreover, IL-4 inhibits proliferation of a variety of cells, but the molecular mechanism of its growth inhibitory effect is not understood, In this study, me demonstrated that IL-4 inhibited cell growth of colon carcinoma cell lines (HT29 and WiDr) but promoted cell growth of Burkitt's lymphoma cell lines (BL30 and BL41) in a dose-dependent manner. The growth inhibition was not dependent on Stat6 activation, because Stat6 was activated at similar levels in all cell lines in response to IL-4. Strikingly, IL-4 activated Stat1 in colon carcinoma cell lines but not in Burkitt's lymphoma cell lines. Therefore, these results suggest that IL-4 induced Stat1 activation, resulting in growth inhibition of colon carcinoma cell lines. Importantly, we present evidence that Stat1 is necessary for IL-4-mediated growth inhibition using Stat1-deficient and Stat1-reconstituted cells. The growth inhibitory effect of IL-4 was diminished in Stat1-deficient cells, whereas it was restored in Stat1-reconstituted cells. In addition, the expression of dominant-negative Stat1 in HT29 cells led to the loss of growth inhibition in response to IL-4. Taken together, our data suggest that IL-4 activates Stat1, leading to cell growth inhibition in colon cancer cells. Thus, this study demonstrates, for the first time, a molecular mechanism by which IL-4 inhibits cell growth.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Yale University	Fu, XY (corresponding author), Natl Inst Hlth, Bethesda, MD 20892 USA.				NIAID NIH HHS [R01AI34522] Funding Source: Medline; NIGMS NIH HHS [R01GM55590] Funding Source: Medline; ASPE HHS [KO4AE01356] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055590] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); ASPE HHS; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACKER JM, 1992, J BIOL CHEM, V267, P1367; Banchereau J, 1994, CYTOKINE HDB, P99; BOVOLENTA C, 1994, P NATL ACAD SCI USA, V91, P5046, DOI 10.1073/pnas.91.11.5046; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; BROWN M, 1988, J IMMUNOL, V141, P504; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; CONRAD DH, 1987, J IMMUNOL, V139, P2290; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; Hollingsworth SJ, 1996, BRIT J CANCER, V74, P6, DOI 10.1038/bjc.1996.308; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kaplan MH, 1998, MOL CELL BIOL, V18, P1996, DOI 10.1128/MCB.18.4.1996; KEEGAN AD, 1994, IMMUNOL TODAY, V15, P423, DOI 10.1016/0167-5699(94)90272-0; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; Leonard WJ, 1996, ANNU REV MED, V47, P229; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MILLER CL, 1990, J IMMUNOL, V144, P1331; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; Murata T, 1995, J BIOL CHEM, V270, P30829, DOI 10.1074/jbc.270.51.30829; Murata T, 1996, J IMMUNOL, V156, P2972; NOELLE R, 1984, P NATL ACAD SCI-BIOL, V81, P6149, DOI 10.1073/pnas.81.19.6149; PAUL WE, 1991, BLOOD, V77, P1859; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Pine R, 1997, NUCLEIC ACIDS RES, V25, P4346, DOI 10.1093/nar/25.21.4346; Puri R. K., 1995, CYTOKINES INTERLEUKI, P143; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SEDER RA, 1991, INT ARCH ALLER A IMM, V94, P137, DOI 10.1159/000235345; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SPITS H, 1987, J IMMUNOL, V139, P1142; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SWAIN SL, 1990, J IMMUNOL, V145, P3796; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Taniguchi T, 1997, BBA-REV CANCER, V1333, pM9, DOI 10.1016/S0304-419X(97)00014-0; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; TOI M, 1992, CANCER RES, V52, P275; VITETTA ES, 1985, J EXP MED, V162, P1726, DOI 10.1084/jem.162.5.1726; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0	51	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10212	10217		10.1074/jbc.275.14.10212	http://dx.doi.org/10.1074/jbc.275.14.10212			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744706	hybrid			2022-12-27	WOS:000086345600047
J	Kanda, S; Lerner, EC; Tsuda, S; Shono, T; Kanetake, H; Smithgall, TE				Kanda, S; Lerner, EC; Tsuda, S; Shono, T; Kanetake, H; Smithgall, TE			The nonreceptor protein-tyrosine kinase c-Fes is involved in fibroblast growth factor-2-induced chemotaxis of murine brain capillary endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR-1; POINT MUTATION; SIGNAL-TRANSDUCTION; TRANSGENIC MICE; ANGIOGENESIS; ACTIVATION; DIFFERENTIATION; DOMAIN; AUTOPHOSPHORYLATION; SRC	Fibroblast growth factor-a (FGF-a)-induced migration of endothelial cells is involved in angiogenesis in vivo. However, signal transduction pathways leading to FGF-2-induced chemotaxis of endothelial cells are largely unknown, Previous studies have shown that the cytoplasmic protein-tyrosine kinase c-Fes is expressed in vascular endothelial cells and may influence angiogenesis in vivo. To investigate the contribution of c-Fes to FGF-2 signaling, we expressed wild-type or kinase-inactive human c-Fes in the murine brain capillary endothelial cell line, IBE (Immortomouse brain endothelial cells). Wild-type c-Fes was tyrosine-phosphorylated upon FGF-P stimulation in transfected cells, whereas kinase-inactive c-Fes was not. Overexpression of wild-type c-Fes promoted FGF-a-independent tube formation of IBE cells. Tube formation was not observed with endothelial cells expressing kinase-inactive c-Fes, indicating a requirement for c-Fes kinase activity in this biological response, Expression of kinase-defective c-Fes suppressed endothelial cell migration following FGF-P treatment, suggesting that activation of endogenous c-Fes may be required for the chemotactic response. Expression of either wild-type c-Fes or the kinase-inactive mutant did not affect the tyrosine phosphorylation FRS2, Shc, or phospholipase C-gamma, nor did it influence the kinetics of mitogen-activated protein kinase activation, These results implicate c-Fes in FGF-a-induced chemotaxis of endothelial cells through signaling pathways not linked to mitogenesis.	Nagasaki Univ, Sch Med, Dept Urol, Nagasaki 8528501, Japan; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Nagasaki University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kanda, S (corresponding author), Nagasaki Univ, Sch Med, Dept Urol, 1-7-1 Sakamoto, Nagasaki 8528501, Japan.				NCI NIH HHS [CA58667] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058667] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARECES LB, 1994, MOL CELL BIOL, V14, P4606, DOI 10.1128/MCB.14.7.4606; Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; Cheng HY, 1999, MOL CELL BIOL, V19, P8335; ColvilleNash PR, 1997, MOL MED TODAY, V3, P14, DOI 10.1016/S1357-4310(96)10048-4; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; Haigh J, 1996, CELL GROWTH DIFFER, V7, P931; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HJERMSTAD SJ, 1993, ONCOGENE, V8, P2283; IZUHARA K, 1994, J BIOL CHEM, V269, P18623; Jucker M, 1997, J BIOL CHEM, V272, P2104; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; Klint P, 1999, ONCOGENE, V18, P3354, DOI 10.1038/sj.onc.1202680; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Klint Peter, 1999, Frontiers in Bioscience, V4, pD165, DOI 10.2741/Klint; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Landgren E, 1998, ONCOGENE, V17, P283, DOI 10.1038/sj.onc.1201936; Larsson H, 1999, J BIOL CHEM, V274, P25726, DOI 10.1074/jbc.274.36.25726; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Li JZ, 1998, J BIOL CHEM, V273, P13828, DOI 10.1074/jbc.273.22.13828; MANFREDINI R, 1993, J EXP MED, V178, P381, DOI 10.1084/jem.178.2.381; Manfredini R, 1997, BLOOD, V89, P135, DOI 10.1182/blood.V89.1.135.135_135_145; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; PARTANEN J, 1992, Progress in Growth Factor Research, V4, P69, DOI 10.1016/0955-2235(92)90005-3; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; Read RD, 1997, J BIOL CHEM, V272, P18498, DOI 10.1074/jbc.272.29.18498; Rogers JA, 1996, J BIOL CHEM, V271, P17519, DOI 10.1074/jbc.271.29.17519; Smithgall TE, 1998, CRIT REV ONCOGENESIS, V9, P43, DOI 10.1615/CritRevOncog.v9.i1.40; SOROKIN A, 1994, J BIOL CHEM, V269, P17056; YU G, 1989, J BIOL CHEM, V264, P10276; ZHAN X, 1994, J BIOL CHEM, V269, P20221	37	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10105	10111		10.1074/jbc.275.14.10105	http://dx.doi.org/10.1074/jbc.275.14.10105			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744691	hybrid			2022-12-27	WOS:000086345600032
J	Laajoki, LG; Francis, GL; Wallace, JC; Carver, JA; Keniry, MA				Laajoki, LG; Francis, GL; Wallace, JC; Carver, JA; Keniry, MA			Solution structure and backbone dynamics of long-[Arg(3)]insulin-like growth factor-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; IGF-I; BINDING-PROTEINS; 3-DIMENSIONAL STRUCTURE; ESCHERICHIA-COLI; INSULIN; NMR; RECEPTOR; DOMAIN; RELAXATION	Long-[Arg(3)]insulin-like growth factor-I (IGF-I) is a potent analog of insulin-like growth factor-I that has been modified by a Glu(3) --> Arg mutation and a 13-amino acid extension appended to the N terminus. We have determined the solution structure of N-15-labeled Long-[Arg(3)]IGF-I using high resolution NMR and restrained molecular dynamics techniques to a precision of 0.82 +/- 0.28 Angstrom root mean square deviation for the backbone heavy atoms in the three alpha-helices and 3.5 +/- 0.9 Angstrom root mean square deviation for all backbone heavy atoms excluding the 8 N-terminal residues and the 8 C-terminal eight residues. Overall, the structure of the IGF-I domain is consistent with earlier studies of IGF-I with some minor changes remote from the N terminus. The major variations in the structure, compared with IGF-I, occur at the N terminus with a substantial reorientation of the N-terminal three residues of the IGF-I domain. These results are interpreted in terms of the lower binding affinity for insulin-like growth factor-binding proteins. The backbone dynamics of Long-[Arg(3)]IGF-I were investigated using N-15 nuclear spin relaxation and the heteronuclear nuclear Overhauser enhancement (NOE), There is a considerable degree of flexibility in Long-[Arg(3)]IGF-I, even in the alpha-helices, as indicated by an average {H-1}N-15 NOE of 0.55 for the regions, The largest heteronuclear NOEs are observed in the helical regions, lower heteronuclear NOEs are observed in the C-domain loop separating helix 1 from helix 2, and negative heteronuclear NOEs are observed in the N-terminal extension and at the C terminus, Despite these data indicating conformational flexibity for the N-terminal extension, slow amide proton exchange was observed for some residues in this region, suggesting some transitory structure does exist, possibly a molten helix. A certain degree of flexibility may be necessary in all insulin-like growth factors to enable association with various receptors and binding proteins.	Australian Natl Univ, Res Sch Chem, Canberra, ACT 2601, Australia; GroPep Pty Ltd, Adelaide, SA 5000, Australia; Cooperat Res Ctr Tissue Growth & Repair, Adelaide, SA 5000, Australia; Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia; Univ Wollongong, Dept Chem, Wollongong, NSW 2522, Australia	Australian National University; University of Adelaide; University of Wollongong	Keniry, MA (corresponding author), Australian Natl Univ, Res Sch Chem, GPO Box 414, Canberra, ACT 2601, Australia.		Carver, John Adrian/J-3825-2014; , John/AAP-5150-2020	Carver, John Adrian/0000-0002-2441-8108; 				ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; BAGLEY CJ, 1989, BIOCHEM J, V259, P665, DOI 10.1042/bj2590665; BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; BALLARD FJ, 1988, BIOCHEM J, V249, P721, DOI 10.1042/bj2490721; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Carr PA, 1997, STRUCTURE, V5, P949, DOI 10.1016/S0969-2126(97)00248-7; CASCIERI MA, 1988, BIOCHEMISTRY-US, V27, P3228; Clemmons David R., 1997, Cytokine and Growth Factor Reviews, V8, P45, DOI 10.1016/S1359-6101(96)00053-6; COOKE RM, 1991, BIOCHEMISTRY-US, V30, P5484, DOI 10.1021/bi00236a022; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DeWolf E, 1996, PROTEIN SCI, V5, P2193; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FRANCIS GL, 1992, J MOL ENDOCRINOL, V8, P213, DOI 10.1677/jme.0.0080213; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GRASBERGER BL, 1993, J MOL BIOL, V230, P364, DOI 10.1006/jmbi.1993.1152; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hodgson DR, 1996, REGUL PEPTIDES, V66, P191, DOI 10.1016/S0167-0115(96)00102-4; Hua QX, 1996, J MOL BIOL, V259, P297, DOI 10.1006/jmbi.1996.0320; Hua QX, 1998, J MOL BIOL, V277, P103, DOI 10.1006/jmbi.1997.1574; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kalus W, 1998, EMBO J, V17, P6558, DOI 10.1093/emboj/17.22.6558; KING R, 1992, J MOL ENDOCRINOL, V8, P29, DOI 10.1677/jme.0.0080029; LAAJOKI LG, 1997, FEBS LETT, V420, P87; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; MILNER SJ, 1995, BIOCHEM J, V308, P865, DOI 10.1042/bj3080865; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; Rajaram S, 1997, ENDOCR REV, V18, P801, DOI 10.1210/er.18.6.801; SATO A, 1992, J BIOCHEM-TOKYO, V111, P529, DOI 10.1093/oxfordjournals.jbchem.a123791; SATO A, 1993, INT J PEPT PROT RES, V41, P433; SPENCER EM, 1988, GROWTH FACTORS OTHER, P103; TERASAWA H, 1994, EMBO J, V13, P5590, DOI 10.1002/j.1460-2075.1994.tb06896.x; TORRES AM, 1995, J MOL BIOL, V248, P385, DOI 10.1006/jmbi.1995.0229; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024	37	21	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10009	10015		10.1074/jbc.275.14.10009	http://dx.doi.org/10.1074/jbc.275.14.10009			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744677	hybrid			2022-12-27	WOS:000086345600018
J	Tom, S; Henricksen, LA; Bambara, RA				Tom, S; Henricksen, LA; Bambara, RA			Mechanism whereby proliferating cell nuclear antigen stimulates flap endonuclease 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC DNA-REPLICATION; BASE EXCISION-REPAIR; CALF RTH-1 NUCLEASE; PCNA BINDING; MAMMALIAN 5'-EXONUCLEASE; FEN-1; 3'-EXONUCLEASE; INHIBITOR; CLEAVAGE; PROTEINS	Human flap endonuclease 1 (FEN1), an essential DNA replication protein, cleaves substrates with unannealed 5'-tails. FEN1 apparently tracks along the flap from the 5'-end to the cleavage site. Proliferating cell nuclear antigen (PCNA) stimulates FEN1 cleavage 5-50-fold. To determine whether tracking, binding, or cleavage is enhanced by PCNA, we tested a variety of flap substrates, Similar levels of PCNA stimulation occur on both a cleavage-sensitive nicked substrate and a less sensitive gapped substrate. PCNA stimulates FEN1 irrespective of the flap length. Stimulation occurs on a pseudo-Y substrate that exhibits upstream primer-independent cleavage. A pseudo-P substrate with a sequence requiring an upstream primer for cleavage was not activated by PCNA, suggesting that PCNA does not compensate for substrate features that inhibit cleavage. A biotin streptavidin conjugation at the 5'-end of a flap structure prevents FEN1 loading. The addition of PCNA does not restore FEN1 activity. These results indicate that PCNA does not direct FEN1 to the cleavage site from solution. Kinetic analyses reveal that PCNA can lower the K-m for FEN1 by 11-12-fold. Overall, our results indicate that after FEN1 tracks to the cleavage site, PCNA enhances FEN1 binding stability, allowing for greater cleavage efficiency.	Univ Rochester, Med Ctr, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Ctr Canc, Sch Med & Dent, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Bambara, RA (corresponding author), Univ Rochester, Med Ctr, Sch Med & Dent, Dept Biochem & Biophys, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18961, GM24441] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; Barnes CJ, 1996, J BIOL CHEM, V271, P29624, DOI 10.1074/jbc.271.47.29624; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; Bornarth CJ, 1999, BIOCHEMISTRY-US, V38, P13347, DOI 10.1021/bi991321u; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; Gary R, 1999, MOL CELL BIOL, V19, P5373; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Henricksen LA, 1998, LEUKEMIA RES, V22, P1, DOI 10.1016/S0145-2126(97)00113-6; Hosfield DJ, 1998, J BIOL CHEM, V273, P27154, DOI 10.1074/jbc.273.42.27154; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Huang L, 1996, BIOCHEMISTRY-US, V35, P9266, DOI 10.1021/bi9603074; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1996, J BIOL CHEM, V271, P25888, DOI 10.1074/jbc.271.42.25888; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; ROBINS P, 1994, J BIOL CHEM, V269, P28535; Sayers JR, 1998, NAT STRUCT BIOL, V5, P668, DOI 10.1038/1358; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036	46	147	157	17	114	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10498	10505		10.1074/jbc.275.14.10498	http://dx.doi.org/10.1074/jbc.275.14.10498			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744741	hybrid			2022-12-27	WOS:000086345600082
J	Vinetz, JM; Valenzuela, JG; Specht, CA; Aravind, L; Langer, RC; Ribeiro, JMC; Kaslow, DC				Vinetz, JM; Valenzuela, JG; Specht, CA; Aravind, L; Langer, RC; Ribeiro, JMC; Kaslow, DC			Chitinases of the avian malaria parasite Plasmodium gallinaceum, a class of enzymes necessary for parasite invasion of the mosquito midgut	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YELLOW-FEVER MOSQUITO; AEDES-AEGYPTI; PERITROPHIC MEMBRANE; SERRATIA-MARCESCENS; ESCHERICHIA-COLI; SANDFLY VECTOR; TRANSMISSION; SEQUENCES; TRANSFORMATION; IMMUNIZATION	The Plasmodium ookinete produces chitinolytic activity that allows the parasite to penetrate the chitin-containing peritrophic matrix surrounding the blood meal in the mosquito midgut, Since the peritrophic matrix is a physical barrier that the parasite must cross to invade the mosquito, and the presence of allosamidin, a chitinase inhibitor, in a blood meal prevents the parasite from invading the midgut epithelium, chitinases (3.2.1.14) are potential targets of malaria parasite transmission-blocking interventions. We have purified a chitinase of the avian malaria parasite Plasmodium gallinaceum and cloned the gene, PgCHT1, encoding it. PgCHT1 encodes catalytic and substrate-binding sites characteristic of family 18 glycohydrolases, Expressed in Escherichia coli strain AD494 (DE3), recombinant PgCHT1 was found to hydrolyze polymeric chitin, native chitin oligosaccharides, and 4-methylumbelliferone derivatives of chitin oligosaccharides. Allosamidin inhibited recombinant PgCHT1 with an IC50 of 7 mu M and differentially inhibited two chromatographically separable P. gallinaceum ookinete-produced chitinase activities with IC50 values of 7 and 12 mu M, respectively, These two chitinase activities also had different pH activity profiles. These data suggest that the P, gallinaceum oo kinete uses products of more than one chitinase gene to initiate mosquito midgut invasion.	Univ Texas, Med Branch, Dept Pathol, WHO,Collaborating Ctr Trop Dis, Galveston, TX 77615 USA; NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA; NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20892 USA	University of Texas System; University of Texas Medical Branch Galveston; World Health Organization; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Boston University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Vinetz, JM (corresponding author), Univ Texas, Med Branch, WHO, Ctr Trop Dis,Dept Pathol, Keiller 2-138,301 Univ Blvd, Galveston, TX 77615 USA.	jovinetz@utmb.edu		Ribeiro, Jose/0000-0002-9107-0818; Vinetz, Joseph/0000-0001-8344-2004; Aravind, L/0000-0003-0771-253X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000810, ZIAAI000810] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brurberg MB, 1996, MICROBIOL-SGM, V142, P1581, DOI 10.1099/13500872-142-7-1581; CARTER R, 1976, NATURE, V263, P57, DOI 10.1038/263057a0; Coates CJ, 1998, P NATL ACAD SCI USA, V95, P3748, DOI 10.1073/pnas.95.7.3748; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; FLACH J, 1992, EXPERIENTIA, V48, P701, DOI 10.1007/BF02124285; FUHRMAN JA, 1985, MOL BIOCHEM PARASIT, V17, P93, DOI 10.1016/0166-6851(85)90130-6; GWADZ RW, 1976, SCIENCE, V193, P1150, DOI 10.1126/science.959832; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Hu B, 1996, J BIOL CHEM, V271, P19415, DOI 10.1074/jbc.271.32.19415; HUBER M, 1991, P NATL ACAD SCI USA, V88, P2807, DOI 10.1073/pnas.88.7.2807; Jasinskiene N, 1998, P NATL ACAD SCI USA, V95, P3743, DOI 10.1073/pnas.95.7.3743; KASLOW DC, 1993, CURR OPIN IMMUNOL, V5, P557, DOI 10.1016/0952-7915(93)90037-S; KASLOW DC, 1994, BIO-TECHNOL, V12, P494, DOI 10.1038/nbt0594-494; KAUSHAL DC, 1984, MOL BIOCHEM PARASIT, V11, P145, DOI 10.1016/0166-6851(84)90061-6; Keyhani NO, 1996, J BIOL CHEM, V271, P33414, DOI 10.1074/jbc.271.52.33414; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; McCutchan TF, 1996, P NATL ACAD SCI USA, V93, P11889, DOI 10.1073/pnas.93.21.11889; Ni XY, 1997, P NATL ACAD SCI USA, V94, P13116, DOI 10.1073/pnas.94.24.13116; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Renkema GH, 1998, EUR J BIOCHEM, V251, P504, DOI 10.1046/j.1432-1327.1998.2510504.x; ROBBINS PW, 1988, J BIOL CHEM, V263, P443; ROBERTS RL, 1982, ANAL BIOCHEM, V127, P402, DOI 10.1016/0003-2697(82)90194-4; SAUL A, 1990, MOL BIOCHEM PARASIT, V42, P55, DOI 10.1016/0166-6851(90)90112-Y; SCHLEIN Y, 1991, P ROY SOC B-BIOL SCI, V245, P121, DOI 10.1098/rspb.1991.0097; SCHLEIN Y, 1992, P NATL ACAD SCI USA, V89, P9944, DOI 10.1073/pnas.89.20.9944; Shahabuddin M, 1996, INFECT IMMUN, V64, P739, DOI 10.1128/IAI.64.3.739-743.1996; SHAHABUDDIN M, 1993, PARASITOL TODAY, V9, P252, DOI 10.1016/0169-4758(93)90069-R; SHAHABUDDIN M, 1993, P NATL ACAD SCI USA, V90, P4266, DOI 10.1073/pnas.90.9.4266; Shahabuddin M, 1998, PARASITOLOGY, V116, pS83, DOI 10.1017/S0031182000084973; Shakarian AM, 1998, GENE, V208, P315, DOI 10.1016/S0378-1119(98)00011-0; SIEBER KP, 1991, EXP PARASITOL, V72, P145, DOI 10.1016/0014-4894(91)90132-G; SINGH L, 1984, NUCLEIC ACIDS RES, V12, P5627, DOI 10.1093/nar/12.14.5627; Tellam RL, 1999, INSECT BIOCHEM MOLEC, V29, P87, DOI 10.1016/S0965-1748(98)00123-4; Venegas A, 1996, MOL BIOCHEM PARASIT, V78, P149, DOI 10.1016/S0166-6851(96)02620-5; VILLAGOMEZCASTRO JC, 1992, MOL BIOCHEM PARASIT, V52, P53, DOI 10.1016/0166-6851(92)90035-I; Vinetz JM, 1999, P NATL ACAD SCI USA, V96, P14061, DOI 10.1073/pnas.96.24.14061; Vinetz JM, 1998, EXP PARASITOL, V90, P199, DOI 10.1006/expr.1998.4322; WATERS AP, 1991, P NATL ACAD SCI USA, V88, P3140, DOI 10.1073/pnas.88.8.3140	40	95	99	0	15	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10331	10341		10.1074/jbc.275.14.10331	http://dx.doi.org/10.1074/jbc.275.14.10331			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744721	hybrid			2022-12-27	WOS:000086345600062
J	Fei, YJ; Romero, MF; Krause, M; Liu, JC; Huang, W; Ganapathy, V; Leibach, FH				Fei, YJ; Romero, MF; Krause, M; Liu, JC; Huang, W; Ganapathy, V; Leibach, FH			A novel H+-coupled oligopeptide transporter (OPT3) from Caenorhabditis elegans with a predominant function as a H+ channel and an exclusive expression in neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-GLUCOSE COTRANSPORTER; BETA-LACTAM ANTIBIOTICS; PEPTIDE TRANSPORTER; CLONING; INTESTINE; CULTURES; KIDNEY	We have cloned and functionally characterized a novel, neuron-specific, H+-coupled oligopeptide transporter (OPT3) from Caenorhabditis elegans that functions predominantly as a H+ channel. The opt3 gene is similar to 4.4 kilobases long and consists of 13 exons. The cDNA codes for a protein of 701 amino acids with 11 putative transmembrane domains. When expressed in mammalian cells and in Xenopus laevis oocytes, OPT3 cDNA induces H+-coupled transport of the dipeptide glycylsarcosine, Electrophysiological studies of the transport function of OPT3 in Xenopus oocytes show that this transporter, although capable of mediating H+-coupled peptide transport, functions predominantly as a H+ channel. The H+ channel activity of OPT3 is similar to 3-4-fold greater than the H+/peptide cotransport activity as determined by measurements of H+ gradient-induced inward currents in the absence and presence of the dipeptide using the two-microelectrode voltage clamp technique, A downhill influx of H+ was accompanied by a large intracellular acidification as evidenced from the changes in intracellular pH using an ion-selective microelectrode. The H+ channel activity exhibits a K-0.5(H) of 1.0 mu M at a membrane potential of -50 mV. At the level of primary structure, OPT3 has moderate homology with OPT1 and OPT2, two other Hf-coupled oligopeptide transporters previously cloned from C. elegans, Expression studies using the opt3::gfp fusion constructs in transgenic C. elegans demonstrate that opt3 gene is exclusively expressed in neurons. OPT3 may play an important physiological role as a pH balancer in the maintenance of H+ homeostasis in C. elegans.	Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Sch Med, Cleveland, OH 44106 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	University System of Georgia; Augusta University; Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Fei, YJ (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, 1120 15th St,CB2507, Augusta, GA 30912 USA.	yjfei@mail.mcg.edu		Krause, Michael/0000-0001-6127-3940	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028389] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 28389] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson P, 1995, METHOD CELL BIOL, V48, P31; Berger UV, 1999, ANAT EMBRYOL, V199, P439, DOI 10.1007/s004290050242; Betz A. Lorris, 1994, P681; Boll M, 1996, P NATL ACAD SCI USA, V93, P284, DOI 10.1073/pnas.93.1.284; BOLL M, 1994, PFLUG ARCH EUR J PHY, V429, P146, DOI 10.1007/BF02584043; BROWN R, 1994, NEUROPEPTIDES, V2, P266; BROWNSTEIN MJ, 1994, BASIC NEUROCHEMISTRY, P341; Chalfie M, 1995, Science, V270, P415; Chalfie M., 1988, NEMATODE CAENORHABDI, P337; Chen XZ, 1997, BIOPHYS J, V73, P2503, DOI 10.1016/S0006-3495(97)78278-X; Chen XZ, 1995, BIOPHYS J, V69, P2405, DOI 10.1016/S0006-3495(95)80110-4; Dieck ST, 1999, GLIA, V25, P10, DOI 10.1002/(SICI)1098-1136(19990101)25:1<10::AID-GLIA2>3.0.CO;2-Y; Dringen R, 1998, J NEUROCHEM, V71, P388; Fei YJ, 1998, BIOCHEM J, V332, P565, DOI 10.1042/bj3320565; Fei YJ, 1998, PROG NUCLEIC ACID RE, V58, P239; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; Ganapathy V, 1996, Curr Opin Nephrol Hypertens, V5, P395, DOI 10.1097/00041552-199609000-00003; GANAPATHY V, 1991, KIDNEY INT, V40, pS4; Ganapathy Vadivel, 1994, P1773; HODGKIN J, 1995, SCIENCE, V270, P410, DOI 10.1126/science.270.5235.410; Lewis JA, 1995, METHOD CELL BIOL, V48, P4; LIU W, 1995, BBA-BIOMEMBRANES, V1235, P461, DOI 10.1016/0005-2736(95)80036-F; LYNCH DR, 1986, ANNU REV BIOCHEM, V55, P773, DOI 10.1146/annurev.bi.55.070186.004013; Mackenzie B, 1996, J BIOL CHEM, V271, P5430, DOI 10.1074/jbc.271.10.5430; Mello C, 1995, METHOD CELL BIOL, V48, P451; Miyamoto K, 1996, BBA-GENE STRUCT EXPR, V1305, P34, DOI 10.1016/0167-4781(95)00208-1; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; Romero MF, 1998, AM J PHYSIOL-RENAL, V274, pF425, DOI 10.1152/ajprenal.1998.274.2.F425; RONG LA, 1995, J BIOL CHEM, V270, P6456, DOI 10.1074/jbc.270.12.6456; Saito H, 1996, BBA-BIOMEMBRANES, V1280, P173, DOI 10.1016/0005-2736(96)00024-7; Saito H, 1995, J PHARMACOL EXP THER, V275, P1631; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; STEINER HY, 1995, MOL MICROBIOL, V16, P825, DOI 10.1111/j.1365-2958.1995.tb02310.x; TROMBLEY PQ, 1990, J NEUROPHYSIOL, V64, P598, DOI 10.1152/jn.1990.64.2.598; UMBACH JA, 1990, BIOPHYS J, V57, P1217, DOI 10.1016/S0006-3495(90)82640-0; Wang H, 1998, AM J PHYSIOL-CELL PH, V275, pC967, DOI 10.1152/ajpcell.1998.275.4.C967	37	23	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9563	9571		10.1074/jbc.275.13.9563	http://dx.doi.org/10.1074/jbc.275.13.9563			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734106	hybrid			2022-12-27	WOS:000086206500070
J	Liu, D; Martino, G; Thangaraju, M; Sharma, M; Halwani, F; Shen, SH; Patel, YC; Srikant, CB				Liu, D; Martino, G; Thangaraju, M; Sharma, M; Halwani, F; Shen, SH; Patel, YC; Srikant, CB			Caspase-8-mediated intracellular acidification precedes mitochondrial dysfunction in somatostatin-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CYTOCHROME-C; PERMEABILITY TRANSITION; ACIDIC ENDONUCLEASE; SIGNALED APOPTOSIS; DNA FRAGMENTATION; ACTIVATION; BCL-2; INDUCTION; RELEASE	Activation of initiator and effector caspases, mitochondrial changes involving a reduction in its membrane potential and release of cytochrome c (cyt c) into the cytosol, are characteristic features of apoptosis, These changes are associated with cell acidification in some models of apoptosis, The hierarchical relationship between these events has, however, not been deciphered. We have shown that somatostatin (SST), acting via the Src homology 2 bearing tyrosine phosphatase SHP-1, exerts cytotoxic action in MCF-7 cells, and triggers cell acidification and apoptosis, We investigated the temporal sequence of apoptotic events linking caspase activation, acidification, and mitochondrial dysfunction in this system and report here that (i) SHP-1-mediated caspase-8 activation is required for SST-induced decrease in pH(i), (ii) Effector caspases are induced only when there is concomitant acidification. (iii) Decrease in pH, is necessary to induce reduction in mitochondrial membrane potential, cyt c release and caspase-9 activation and (iv) depletion of ATP ablates SST-induced cyt c release and caspase-9 activation, but not its ability to induce effector caspases and apoptosis, These data reveal that SHP-1-/caspase-8-mediated acidification occurs at a site other than the mitochondrion and that SST-induced apoptosis is not dependent on disruption of mitochondrial function and caspase-9 activation.	Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Fraser Labs, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Pathol, Montreal, PQ H3A 1A1, Canada; Natl Res Council Canada, Biotechnol Res Inst, Pharmaceut Sector, Montreal, PQ H4P 2R2, Canada	McGill University; Royal Victoria Hospital; McGill University; McGill University; National Research Council Canada	Srikant, CB (corresponding author), Royal Victoria Hosp, M3-15,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.							Angoli D, 1996, BIOCHEM BIOPH RES CO, V229, P681, DOI 10.1006/bbrc.1996.1863; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Eguchi Y, 1997, CANCER RES, V57, P1835; Eguchi Y, 1999, CANCER RES, V59, P2174; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Furlong IJ, 1998, CELL DEATH DIFFER, V5, P214, DOI 10.1038/sj.cdd.4400335; Furlong IJ, 1997, J CELL SCI, V110, P653; GOTTLIEB RA, 1995, P NATL ACAD SCI USA, V92, P5965, DOI 10.1073/pnas.92.13.5965; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hirsch T, 1997, BIOSCIENCE REP, V17, P67, DOI 10.1023/A:1027339418683; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kakutani T, 1998, BIOCHEM BIOPH RES CO, V247, P773, DOI 10.1006/bbrc.1998.8797; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kurokawa H, 1999, ONCOL REP, V6, P33; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; LEE CP, 1966, BIOCHEM BIOPH RES CO, V23, P176, DOI 10.1016/0006-291X(66)90524-9; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIU D, 1999, ANN M END SOC SAN DI, P353; MAIDORN RP, 1993, BRIT J CANCER, V67, P297, DOI 10.1038/bjc.1993.56; Marchetti P, 1996, J IMMUNOL, V157, P4830; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, BIOMED PHARMACOTHER, V52, P248, DOI 10.1016/S0753-3322(98)80009-7; Meisenholder GW, 1996, J BIOL CHEM, V271, P16260, DOI 10.1074/jbc.271.27.16260; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; NEWELL K, 1992, BRIT J CANCER, V66, P311, DOI 10.1038/bjc.1992.262; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Park HJ, 1996, EUR J CANCER, V32A, P540, DOI 10.1016/0959-8049(95)00606-0; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sharma K, 1998, INT J CANCER, V76, P259, DOI 10.1002/(SICI)1097-0215(19980413)76:2<259::AID-IJC14>3.0.CO;2-7; Sharma K, 1998, BIOCHEM BIOPH RES CO, V242, P134, DOI 10.1006/bbrc.1997.7933; Srikant CB, 1996, ENDOCRINOLOGY, V137, P3461, DOI 10.1210/en.137.8.3461; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Thangaraju M, 1999, CANCER RES, V59, P1649; Thangaraju M, 1999, J BIOL CHEM, V274, P29549, DOI 10.1074/jbc.274.41.29549; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; THORNBERRY NA, 1994, METHOD ENZYMOL, V244, P615; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Vier J, 1999, BIOCHEM BIOPH RES CO, V261, P71, DOI 10.1006/bbrc.1999.0942; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Wolf CM, 1999, BIOCHEM BIOPH RES CO, V254, P821, DOI 10.1006/bbrc.1998.0132; Wolf CM, 1997, EXP CELL RES, V230, P22, DOI 10.1006/excr.1996.3401; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zanke BW, 1998, CANCER RES, V58, P2801; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	57	93	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9244	9250		10.1074/jbc.275.13.9244	http://dx.doi.org/10.1074/jbc.275.13.9244			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734062	hybrid			2022-12-27	WOS:000086206500026
J	Verhoeven, AJM; Neve, BP; Jansen, H				Verhoeven, AJM; Neve, BP; Jansen, H			Intracellular activation of rat hepatic lipase requires transport to the Golgi compartment and is associated with a decrease in sedimentation velocity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; ENDOPLASMIC-RETICULUM; TRIGLYCERIDE LIPASE; LINKED GLYCOSYLATION; CATALYTIC ACTIVITY; BROWN ADIPOCYTES; HEPG2 CELLS; SECRETION; LIVER; GLYCOPROTEIN	Hepatic lipase (HL) is an N-glycoprotein that acquires triglyceridase activity somewhere during maturation and secretion. To determine where and how HL becomes activated, the effect of drugs that interfere with maturation and intracellular transport of HL protein was studied using freshly isolated rat hepatocytes. Carbonyl cyanide m-chlorophenyl hydrazone (CCCP), castanospermine, monensin, and colchicin all inhibited secretion of HL without affecting its specific enzyme activity. The specific enzyme activity of intracellular HL was decreased by 25-50% upon incubation with CCCP or castanospermine, and increased 2-fold with monensin and colchicin. Glucose trimming of HL protein was not affected by CCCP, as indicated by digestion of immunoprecipitates with jack bean cu mannosidase. Pulse labeling experiments with [S-35]methionine indicated that conversion of the 53-kDa precursor to the 58-kDa form, nor the development of endoglycosidase II-resistance, were essential for acquisition of enzyme activity. In sucrose gradients, HL protein from secretion media sedimented as a homogeneous band of about 5.8 S, whereas HL protein from the cell lysates migrated as a broad band extending from 5.8 S to more than 8 S. With both sources, HL activity was exclusively associated with the 5.8 S HL protein form. We conclude that glucose trimming of HL protein in the endoplasmic reticulum is not sufficient for activation; full activation occurs during or after transport from the endoplasmic reticulum to the Golgi and is associated with a decrease in sedimentation velocity.	Erasmus Univ, Dept Biochem, Inst Cardiovasc Res, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam	Verhoeven, AJM (corresponding author), Erasmus Univ, Dept Biochem, Inst Cardiovasc Res, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Verhoeven, Adrie J/H-4612-2011					BAMBERGER M, 1983, J LIPID RES, V24, P869; BARTH JD, 1987, ATHEROSCLEROSIS, V68, P51, DOI 10.1016/0021-9150(87)90093-1; BENZEEV O, 1992, J BIOL CHEM, V267, P6219; BENZEEV O, 1994, J LIPID RES, V35, P1511; Berryman DE, 1998, BBA-PROTEIN STRUCT M, V1382, P217, DOI 10.1016/S0167-4838(97)00150-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breedveld B, 1997, BIOCHEM J, V321, P425, DOI 10.1042/bj3210425; BURKHARDT JK, 1989, J CELL SCI, V92, P633; BUSCH SJ, 1994, J BIOL CHEM, V269, P16376; CHANG SY, 1993, BIOCHEM J, V293, P745, DOI 10.1042/bj2930745; DOMS RW, 1990, METHOD ENZYMOL, V191, P841; DOOLITTLE MH, 1987, J LIPID RES, V28, P1326; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; GRIFFITHS G, 1994, J CELL BIOL, V127, P1557, DOI 10.1083/jcb.127.6.1557; GROOT PHE, 1991, ARTERIOSCLER THROMB, V11, P653, DOI 10.1161/01.ATV.11.3.653; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Hill JS, 1996, J BIOL CHEM, V271, P22931, DOI 10.1074/jbc.271.37.22931; JACKSON RL, 1983, ENZYMES, V16, P141; JANSEN H, 1979, FEBS LETT, V98, P299, DOI 10.1016/0014-5793(79)80204-5; JENSEN GL, 1981, ANAL BIOCHEM, V113, P246, DOI 10.1016/0003-2697(81)90073-7; JI ZS, 1994, J BIOL CHEM, V269, P13429; KIHARA S, 1993, J LIPID RES, V34, P961; Krapp A, 1996, J LIPID RES, V37, P926; LAPOSATA EA, 1987, J BIOL CHEM, V262, P5333; LEITERSDORF E, 1984, BIOCHIM BIOPHYS ACTA, V794, P261, DOI 10.1016/0005-2760(84)90154-1; MARQUESVIDAL P, 1994, J LIPID RES, V35, P373; MASUNO H, 1991, BIOCHEM J, V277, P801, DOI 10.1042/bj2770801; Nebbia C, 1999, DRUG METAB DISPOS, V27, P1039; ODA K, 1990, BIOCHEM J, V265, P161, DOI 10.1042/bj2650161; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; Park JW, 1996, BIOCHEM J, V317, P125, DOI 10.1042/bj3170125; Park JW, 1997, BBA-LIPID LIPID MET, V1344, P132, DOI 10.1016/S0005-2760(96)00146-4; PATZELT C, 1977, J CELL BIOL, V73, P578, DOI 10.1083/jcb.73.3.578; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PETER F, 1992, J BIOL CHEM, V267, P10631; Pontow SE, 1996, J BIOL CHEM, V271, P30736, DOI 10.1074/jbc.271.48.30736; REDMAN CM, 1975, J CELL BIOL, V66, P42, DOI 10.1083/jcb.66.1.42; Sanan DA, 1997, J LIPID RES, V38, P1002; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Snedecor GW, 1980, STAT METHODS, V7th; SULTAN F, 1990, BIOCHIM BIOPHYS ACTA, V1042, P150, DOI 10.1016/0005-2760(90)90071-5; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; vanLeeuwen JEM, 1996, J BIOL CHEM, V271, P9660, DOI 10.1074/jbc.271.16.9660; Verhoeven AJM, 1999, BIOCHEM J, V337, P133, DOI 10.1042/0264-6021:3370133; VERHOEVEN AJM, 1991, BIOCHIM BIOPHYS ACTA, V1086, P49, DOI 10.1016/0005-2760(91)90153-9; VERHOEVEN AJM, 1990, J LIPID RES, V31, P1883; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; WOLLE J, 1993, J LIPID RES, V34, P2169	50	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9332	9339		10.1074/jbc.275.13.9332	http://dx.doi.org/10.1074/jbc.275.13.9332			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734075	Green Published, hybrid			2022-12-27	WOS:000086206500039
J	Clay, MA; Pyle, DH; Rye, KA; Barter, PJ				Clay, MA; Pyle, DH; Rye, KA; Barter, PJ			Formation of spherical, reconstituted high density lipoproteins containing both apolipoproteins A-I and A-II is mediated by lecithin : cholesterol acyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTER TRANSFER PROTEIN; PLASMA-LIPOPROTEINS; HDL PARTICLES; CELL-LINES; COMPLEXES; SIZE; DISPLACEMENT; CATABOLISM; MECHANISM; SURFACE	Previous studies have provided detailed information on the formation of spherical high density lipoproteins (HDL) containing apolipoprotein (apo) A-I but no apoA-II (A-I HDL) by an lecithin:cholesterol acyltransferase (LCAT)-mediated process. In this study we have investigated the formation of spherical HDL containing both apoA-I and apoA-II (A-I/A-II HDL). Incubations were carried out containing discoidal A-I reconstituted HDL (rHDL), discoidal A-II rHDL, and low density lipoproteins in the absence or presence of LCAT, After the incubation, the rHDL were reisolated and subjected to immunoaffinity chromatography to determine whether A-I/A-II rHDL were formed. In the absence of LCAT, the majority of the rHDL remained as either A-I rHDL or A-II rHDL, with only a small amount of A-I/A-II rHDL present. By contrast, when LCAT was present, a substantial proportion of the reisolated rHDL were A-I/A-II rHDL. The identity of the particles was confirmed using apoA-I rocket electrophoresis, The formation of the A-U A-LI rHDL was influenced by the relative concentrations of the precursor discoidal A-I and A-II rHDL, The A-U A-II rHDL included several populations of HDL-sized particles; the predominant population having a Stokes' diameter of 9.9 nm, The particles were spherical in shape and had an electrophoretic mobility slightly slower than that of the alpha-migrating HDL in human plasma. The apoA-I:apoA-II molar ratio of the A-I/A-II rHDL was 0,7:1, Their major lipid constituents were phospholipids, unesterified cholesterol, and cholesteryl esters, The results presented are consistent with LCAT promoting fusion of the A-I rHDL and A-II rHDL to form spherical A-YA-II rHDL, We suggest that this process may be an important source of A-YA-II HDL in human plasma.	Inst Med & Vet Sci, Hanson Ctr Canc Res, Lipid Res Lab, Adelaide, SA 5000, Australia; Univ Adelaide, Royal Adelaide Hosp, Dept Med, Adelaide, SA 5000, Australia; Univ Adelaide, Royal Adelaide Hosp, Cardiovasc Invest Unit, Adelaide, SA 5000, Australia	Institute Medical & Veterinary Science Australia; Royal Adelaide Hospital; University of Adelaide; Royal Adelaide Hospital; University of Adelaide	Clay, MA (corresponding author), Inst Med & Vet Sci, Hanson Ctr Canc Res, Lipid Res Lab, Frome Rd, Adelaide, SA 5000, Australia.							AMOUYEL P, 1993, ARTERIOSCLER THROMB, V13, P1640, DOI 10.1161/01.ATV.13.11.1640; ATMEH RF, 1990, J LIPID RES, V31, P1771; BEKAERT ED, 1992, BIOCHIM BIOPHYS ACTA, V1126, P105, DOI 10.1016/0005-2760(92)90223-I; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; CLAY MA, 1990, BIOCHIM BIOPHYS ACTA, V1044, P50, DOI 10.1016/0005-2760(90)90217-L; Clay MA, 1996, J LIPID RES, V37, P1722; Clay MA, 1999, BIOCHEM J, V337, P445, DOI 10.1042/0264-6021:3370445; Durbin DM, 1997, J BIOL CHEM, V272, P31333, DOI 10.1074/jbc.272.50.31333; EDELSTEIN C, 1982, J BIOL CHEM, V257, P7189; FORTE TM, 1989, J LIPID RES, V30, P817; FORTE TM, 1995, J LIPID RES, V36, P148; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; GREEN PHR, 1981, J LIPID RES, V22, P1153; HAMILTON RL, 1976, J CLIN INVEST, V58, P667, DOI 10.1172/JCI108513; IKEWAKI K, 1995, ARTERIOSCL THROM VAS, V15, P306, DOI 10.1161/01.ATV.15.3.306; JONAS A, 1984, J BIOL CHEM, V259, P6369; LEROY A, 1993, J BIOL CHEM, V268, P4798; LIANG HQ, 1994, J LIPID RES, V35, P1187; Liang HQ, 1996, J LIPID RES, V37, P1962; Lusa S, 1996, BIOCHEM J, V313, P275, DOI 10.1042/bj3130275; MATZ CE, 1982, J BIOL CHEM, V257, P4535; NICHOLS AV, 1985, BIOCHIM BIOPHYS ACTA, V834, P285, DOI 10.1016/0005-2760(85)90001-3; NORFELDT PIP, 1981, EUR J BIOCHEM, V118, P1, DOI 10.1111/j.1432-1033.1981.tb05478.x; OHTA T, 1988, J LIPID RES, V29, P721; OIKAWA S, 1993, BIOCHIM BIOPHYS ACTA, V1165, P327, DOI 10.1016/0005-2760(93)90144-X; OSBORNE JC, 1986, METHOD ENZYMOL, V128, P213; PARRA HJ, 1990, CLIN CHEM, V36, P1431; PIRAN U, 1979, J LIPID RES, V20, P1040; RADER DJ, 1994, J CLIN INVEST, V93, P321, DOI 10.1172/JCI116962; RAINWATER DL, 1992, J LIPID RES, V33, P1876; REDGRAVE TG, 1979, J CLIN INVEST, V64, P162, DOI 10.1172/JCI109435; ROSSENEU M, 1981, EUR J BIOCHEM, V117, P347, DOI 10.1111/j.1432-1033.1981.tb06344.x; RYE KA, 1993, BIOCHIM BIOPHYS ACTA, V1167, P316, DOI 10.1016/0005-2760(93)90235-2; Rye KA, 1996, J BIOL CHEM, V271, P4243; RYE KA, 1995, J BIOL CHEM, V270, P189, DOI 10.1074/jbc.270.1.189; RYE KA, 1992, J LIPID RES, V33, P215; Schultz Joshua R., 1994, Current Opinion in Lipidology, V5, P126, DOI 10.1097/00041433-199404000-00009; SCHULTZ JR, 1993, NATURE, V365, P762, DOI 10.1038/365762a0; ZANNIS VI, 1981, BIOCHEMISTRY-US, V20, P7089, DOI 10.1021/bi00528a006	41	55	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					9019	9025		10.1074/jbc.275.12.9019	http://dx.doi.org/10.1074/jbc.275.12.9019			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722751	hybrid			2022-12-27	WOS:000086507700101
J	Liu, RT; Lin, W; Karin, NJ; Bergh, JJ; Adler-Storthz, K; Farach-Carson, MC				Liu, RT; Lin, W; Karin, NJ; Bergh, JJ; Adler-Storthz, K; Farach-Carson, MC			Ribozyme ablation demonstrates that the cardiac subtype of the voltage-sensitive calcium channel is the molecular transducer of 1,25-dihydroxyvitamin D-3-stimulated calcium influx in osteoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT OSTEOSARCOMA CELLS; VITAMIN-D3 METABOLITES; RNA ENZYMES; U1 SNRNA; CURRENTS; D-3; COMPLEMENTARY; TRANSCRIPTS; ACTIVATION; EXPRESSION	1,25-Dihydroxyvitamin D-3 (1,25(OH)(2)D-3) stimulates transmembrane influx of Ca2+ through L-type voltage-sensitive Ca2+ channels (VSCCs) in ROS 17/2.8 osteoblastic cells. Ca2+ influx modulates osteoblastic activities including matrix deposition, hormone responsiveness, and Ca2+-dependent signaling. 1,25(OH)(2)D-3 also regulates transcript levels encoding VSCCs, L-type VSCCs are multisubunit complexes composed of a central pore-forming alpha(1) subunit and four additional subunits. The alpha(1) subunit is encoded by one gene in a multimember family, defining tissue-specific subtypes. Osteoblasts synthesize two splice variants of the alpha(1C) cardiac VSCC subtype; however, the molecular identity of the 1,25(OH)(2)D-3-regulated VSCC remained unknown. We created a ribozyme specifically cleaving alpha(1C) mRNA. To increase target ablation efficiency, the ribozyme was inserted into U1 small nuclear RNA (snRNA) by engineering the U1 snRNA expression cassette, conferring the ribozyme transcript with stabilizing stem-loops at both sides and the Sm binding site that facilitates localization into nucleoplasm. After transfection of ROS 17/2.8 cells with U1 ribozyme-encoding vector, stable clonal cells were selected in which the expression of alpha(1C) transcript and protein were strikingly reduced. Ca2+ influx assays in ribozyme transfectants showed selective attenuation of depolarization and 1,25(OH)(2)D-3-regulated Ca2+ responses. We conclude that the cardiac subtype of the L-type VSCC is the transducer of stimulated Ca2+ influx in ROS 17/2.8 osteoblastic cells.	Univ Delaware, Dept Biol Sci, Newark, DE 19716 USA; Univ Texas, Dept Basic Sci, Dent Branch, Houston, TX 77030 USA	University of Delaware; University of Texas System	Farach-Carson, MC (corresponding author), Univ Delaware, Dept Biol Sci, 304 Wolf Hall, Newark, DE 19716 USA.			Farach-Carson, Mary/0000-0002-4526-3088	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039273] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39273] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARRY ELR, 1995, P NATL ACAD SCI USA, V92, P10914, DOI 10.1073/pnas.92.24.10914; Birikh KR, 1997, EUR J BIOCHEM, V245, P1, DOI 10.1111/j.1432-1033.1997.t01-3-00001.x; CAFFREY JM, 1989, J BIOL CHEM, V264, P20265; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CHESNOYMARCHAIS D, 1988, J PHYSIOL-LONDON, V398, P291, DOI 10.1113/jphysiol.1988.sp017043; CHRISTOFFERSEN RE, 1994, J MOL STRUC-THEOCHEM, V311, P273; COLEMAN J, 1984, CELL, V37, P429, DOI 10.1016/0092-8674(84)90373-8; Duncan RL, 1998, SEMIN NEPHROL, V18, P178; Duncan RL, 1996, P NATL ACAD SCI USA, V93, P1864, DOI 10.1073/pnas.93.5.1864; FARACHCARSON MC, 1995, NEWS PHYSIOL SCI, V10, P198; French MM, 1999, J CELL BIOL, V145, P1103, DOI 10.1083/jcb.145.5.1103; Gaur R K, 1997, Methods Mol Biol, V74, P69; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HIRASHIMA A, 1986, P NATL ACAD SCI USA, V83, P7726, DOI 10.1073/pnas.83.20.7726; HUI A, 1991, NEURON, V7, P35, DOI 10.1016/0896-6273(91)90072-8; Karin NJ, 1999, BIOTECHNIQUES, V27, P681, DOI 10.2144/99274bm10; KHOURY R, 1994, ENDOCRINOLOGY, V135, P2446, DOI 10.1210/en.135.6.2446; KOIZUMI M, 1989, NUCLEIC ACIDS RES, V17, P7059, DOI 10.1093/nar/17.17.7059; LIEBERHERR M, 1987, J BIOL CHEM, V262, P13168; LOZA J, 1994, CALCIFIED TISSUE INT, V55, P128, DOI 10.1007/BF00297188; Loza JC, 1999, J BONE MINER RES, V14, P386, DOI 10.1359/jbmr.1999.14.3.386; MANSER T, 1981, Journal of Molecular and Applied Genetics, V1, P117; Meszaros JG, 1997, METHOD ENZYMOL, V282, P236; Meszaros JG, 1996, J BIOL CHEM, V271, P32981, DOI 10.1074/jbc.271.51.32981; Meszaros JG, 1996, CONNECT TISSUE RES, V35, P107, DOI 10.3109/03008209609029181; Montgomery RA, 1997, HUM MOL GENET, V6, P519, DOI 10.1093/hmg/6.4.519; NORMAN AW, 1992, J STEROID BIOCHEM, V41, P231, DOI 10.1016/0960-0760(92)90349-N; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; PEREZREYES E, 1995, KIDNEY INT, V48, P1111, DOI 10.1038/ki.1995.395; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; Safran JB, 1998, J BIOL CHEM, V273, P29935, DOI 10.1074/jbc.273.45.29935; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SKUZESKI JM, 1984, J BIOL CHEM, V259, P8345; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; Strom TM, 1998, NAT GENET, V19, P260, DOI 10.1038/940; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; YUKIHIRO S, 1994, J BIOL CHEM, V269, P23889; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	40	29	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8711	8718		10.1074/jbc.275.12.8711	http://dx.doi.org/10.1074/jbc.275.12.8711			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722713	hybrid			2022-12-27	WOS:000086507700063
J	Maiorano, D; Lemaitre, JM; Mechali, M				Maiorano, D; Lemaitre, JM; Mechali, M			Stepwise regulated chromatin assembly of MCM2-7 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION LICENSING SYSTEM; ORIGIN RECOGNITION COMPLEX; CELL-CYCLE REGULATION; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; NUCLEAR-PROTEIN; FISSION YEAST; FREE-EXTRACTS; XENOPUS EGGS; S-PHASE	Acquisition of the competence to replicate requires the assembly of the MCM2-7 (minichromosome maintenance) protein complex onto pre-replicative chromatin, a step of the licensing reaction. This step is thought to occur through binding of a heterohexameric MCM complex containing the six related MCM subunits. Here we show that assembly of the MCM complex onto pre-replicative chromatin occurs through sequential stabilization of specific MCM subunits. Inhibition of licensing with 6-dimethylaminopurine results in chromatin containing specifically bound MCM4 and MCM6. A similar result was obtained by interference of the assembly reaction with an MCM3 antibody. The presence of chromatin-bound MCM intermediates was confirmed by reconstitution experiments in vitro with purified proteins and by the observation of an ordered association of MCM subunits with chromatin. These results indicate that the assembly of the MCM complex onto pre-replicative chromatin is regulated at the level of distinct subunits, suggesting an additional regulatory step in the formation of pre-replication complexes.	Inst Human Genet, CNRS, Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Mechali, M (corresponding author), Inst Human Genet, CNRS, 141 Rue de la Cardonille, Montpellier 5, France.		Maiorano, Domenico/N-5755-2017; LEMAITRE, Jean-Marc/I-4989-2016	Maiorano, Domenico/0000-0003-4229-5903; LEMAITRE, Jean-Marc/0000-0002-6492-5219				Adachi Y, 1997, GENES CELLS, V2, P467, DOI 10.1046/j.1365-2443.1997.1350333.x; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; BUCCI S, 1993, INT J DEV BIOL, V37, P509; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Coue M, 1998, EXP CELL RES, V245, P282, DOI 10.1006/excr.1998.4271; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; DeRyckere D, 1999, GENETICS, V151, P1445; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Grallert B, 1996, GENE DEV, V10, P2644, DOI 10.1101/gad.10.20.2644; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; HU B, 1993, NUCLEIC ACIDS RES, V21, P5289, DOI 10.1093/nar/21.23.5289-a; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; Ishimi Y, 1996, J BIOL CHEM, V271, P24115, DOI 10.1074/jbc.271.39.24115; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Kearsey SE, 1998, BBA-GENE STRUCT EXPR, V1398, P113, DOI 10.1016/S0167-4781(98)00033-5; KUBOTA Y, 1993, J CELL BIOL, V123, P1321, DOI 10.1083/jcb.123.6.1321; Kubota Y, 1997, EMBO J, V16, P3320, DOI 10.1093/emboj/16.11.3320; Lei M, 1996, MOL CELL BIOL, V16, P5081; Lemaitre JM, 1998, J CELL BIOL, V142, P1159, DOI 10.1083/jcb.142.5.1159; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; Mahbubani HM, 1997, J CELL BIOL, V136, P125, DOI 10.1083/jcb.136.1.125; MECHALI M, 1982, CELL, V30, P93, DOI 10.1016/0092-8674(82)90015-0; MENUT S, 1988, ADV MOL BIOL COMP ME, P196; Munshi R, 1998, EXP CELL RES, V240, P321, DOI 10.1006/excr.1998.4019; Perkins G, 1998, MOL CELL, V2, P23, DOI 10.1016/S1097-2765(00)80110-0; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Romanowski P, 1996, P NATL ACAD SCI USA, V93, P10189, DOI 10.1073/pnas.93.19.10189; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; SAMBROOK J, 1991, MOL CLONING LAB MANA; Sherman DA, 1998, NUCLEIC ACIDS RES, V26, P3955, DOI 10.1093/nar/26.17.3955; Su TT, 1996, MOL BIOL CELL, V7, P319, DOI 10.1091/mbc.7.2.319; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Weinreich M, 1999, P NATL ACAD SCI USA, V96, P441, DOI 10.1073/pnas.96.2.441; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1; You ZY, 1999, MOL CELL BIOL, V19, P8003	43	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8426	8431		10.1074/jbc.275.12.8426	http://dx.doi.org/10.1074/jbc.275.12.8426			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722676	hybrid			2022-12-27	WOS:000086507700026
J	Miller, KA; Chung, J; Lo, D; Jones, JCR; Thimmapaya, B; Weitzman, SA				Miller, KA; Chung, J; Lo, D; Jones, JCR; Thimmapaya, B; Weitzman, SA			Inhibition of laminin-5 production in breast epithelial cells by overexpression of p300	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR; COACTIVATORS P300; CANCER-CELLS; CBP; TRANSCRIPTION; EXPRESSION; PROTEINS; GENE; CARCINOMA; RECEPTORS	The transcriptional coactivator p300 is essential for normal embryonic development and cellular differentiation. We have been studying the role of p300 in the transcription of a variety of genes, and we became interested in the role of this coactivator in the transcription of genes important in breast epithelial cell biology. From MCF-10A cells (spontaneously immortalized, nontransformed human breast epithelial cells), we developed cell lines that stably overexpress p300. These p300-overexpressing cells displayed reduced adhesion to culture dishes and were found to secrete an extracellular matrix deficient in laminin-5. Laminin-5 is the major extracellular matrix component produced by breast epithelium. Immunofluorescence studies, as well as experiments using normal matrix, confirmed that the decreased adhesion of p300-overexpressing cells is due to laminin-5-deficient extracellular matrix and not due to loss of laminin-5 receptors, Northern blots revealed markedly decreased levels of expression of two of the genes (designated LAMA3 and LAMC2) encoding the alpha 3 and gamma 2 chains of the laminin-5 heterotrimer in the cells that overexpress p300, whereas LAIMB3 mRNA, encoding the third or beta 3 chain of laminin-5, was not markedly reduced. Transient transfection experiments with a vector containing a murine LAMA3 promoter demonstrate that overexpressing p300 down-regulates the LAMA3 promoter. In summary, overexpression of p300 leads to down-regulation of laminin-5 production in breast epithelial cells, resulting in decreased adhesion.	Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Microbiol & Immunol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Lurie Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Northwestern University; Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Weitzman, SA (corresponding author), Olson 8524,303 E Chicago Ave, Chicago, IL 60611 USA.		Jones, Jonathan C R/T-9467-2017	Jones, Jonathan C R/0000-0002-1496-4922; Lo, David/0000-0002-1243-3036	NCI NIH HHS [CA74403, 5T32CA09560] Funding Source: Medline; NIDCR NIH HHS [DE12328] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074403, T32CA009560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012328] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aumailley M, 1999, MATRIX BIOL, V18, P19, DOI 10.1016/S0945-053X(98)00004-3; Bahadoran P, 1997, BRIT J DERMATOL, V136, P35, DOI 10.1111/j.1365-2133.1997.tb08743.x; Baker SE, 1996, EXP CELL RES, V228, P262, DOI 10.1006/excr.1996.0325; BANERJEE AC, 1994, ONCOGENE, V9, P1733; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; Chopra A, 1998, J INVEST DERMATOL, V110, P52, DOI 10.1046/j.1523-1747.1998.00089.x; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; ENGEL J, 1992, BIOCHEMISTRY-US, V31, P10643, DOI 10.1021/bi00159a001; ENGVALL E, 1993, KIDNEY INT, V43, P2, DOI 10.1038/ki.1993.2; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; Ferrigno O, 1997, J BIOL CHEM, V272, P20502, DOI 10.1074/jbc.272.33.20502; Fukushima Y, 1998, INT J CANCER, V76, P63, DOI 10.1002/(SICI)1097-0215(19980330)76:1<63::AID-IJC11>3.0.CO;2-H; GagnouxPalacios L, 1996, J BIOL CHEM, V271, P18437, DOI 10.1074/jbc.271.31.18437; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Gonzales M, 1999, MOL BIOL CELL, V10, P259, DOI 10.1091/mbc.10.2.259; GOSPODORAWICZ D, 1984, METHODS PREPARATIO S; HAGMEYER BM, 1995, BIOESSAYS, V17, P621, DOI 10.1002/bies.950170708; Hao JS, 1996, AM J PATHOL, V149, P1341; Henning K, 1999, HISTOPATHOLOGY, V34, P305; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; LANGHOFER M, 1993, J CELL SCI, V105, P753; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Martin KJ, 1998, MOL MED, V4, P602, DOI 10.1007/BF03401760; MOROSOV A, 1994, J BIOL CHEM, V269, P18434; Muraoka M, 1996, ONCOGENE, V12, P1565; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Orian-Rousseau V, 1998, J CELL SCI, V111, P1993; Ota M, 1998, CELL GROWTH DIFFER, V9, P989; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; PYKE C, 1995, CANCER RES, V55, P4132; PYKE C, 1994, AM J PATHOL, V145, P782; Qin P, 1998, EXP EYE RES, V66, P569, DOI 10.1006/exer.1997.0455; RIDDELLE KS, 1991, J CELL BIOL, V112, P159, DOI 10.1083/jcb.112.1.159; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SOULE HD, 1990, CANCER RES, V50, P6075; Stahl S, 1997, J CELL SCI, V110, P55; Tani T, 1997, AM J PATHOL, V151, P1289; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; Virolle T, 1998, J BIOL CHEM, V273, P17318, DOI 10.1074/jbc.273.28.17318; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang K, 1996, EXP CELL RES, V227, P309, DOI 10.1006/excr.1996.0280; Zhang K, 1996, CELL ADHES COMMUN, V4, P159, DOI 10.3109/15419069609014220	49	12	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8176	8182		10.1074/jbc.275.11.8176	http://dx.doi.org/10.1074/jbc.275.11.8176			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713141	hybrid			2022-12-27	WOS:000085913300101
J	Moolenaar, GF; Monaco, V; van der Marel, GA; van Boom, JH; Visse, R; Goosen, N				Moolenaar, GF; Monaco, V; van der Marel, GA; van Boom, JH; Visse, R; Goosen, N			The effect of the DNA flanking the lesion on formation of the UvrB-DNA preincision complex - Mechanism for the UvrA-mediated loading of UvrB onto a DNA damaged site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL REGION; ESCHERICHIA-COLI; (A)BC EXCINUCLEASE; EXCISION-REPAIR; ABC EXCINUCLEASE; PROTEIN COMPLEX; CATALYTIC SITE; ACTIVE-SITE; 5' INCISION; ENDONUCLEASE	The UvrB-DNA preincision complex plays a key role in nucleotide excision repair in Escherichia coli. To study the formation of this complex, derivatives of a DNA substrate containing a cholesterol adduct were constructed. Introduction of a single strand nick into either the top or the bottom strand at the 3' side of the adduct stabilized the UvrB-DNA complex, most Likely by the release of local stress in the DNA Removal of both DNA strands up to the 3' incision site still allowed formation of the preincision complex. Similar modifications at the 5' side of the damage, however, gave different results. The introduction of a single strand nick at the 5' incision site completely abolished the UvrA-mediated formation of the UvrB-DNA complex. Deletion of both DNA strands up to the 5' incision site also prevented the UvrA-mediated loading of UvrB onto the damaged site, but UvrB by itself could bind very efficiently, This demonstrates that the UvrB protein is capable of recognizing damage without the matchmaker function of the UvrA protein. Our results also indicate that the UvrA-mediated loading of the UvrB protein is an asymmetric process, which. starts at the 5' side of the damage.	Leiden Univ, Leiden Inst Chem, Gorlaeus Labs, Mol Genet Lab, NL-2300 RA Leiden, Netherlands; Leiden Univ, Leiden Inst Chem, Gorlaeus Labs, Lab Bioorgan Synth, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC	Goosen, N (corresponding author), Leiden Univ, Leiden Inst Chem, Gorlaeus Labs, Mol Genet Lab, POB 9502, NL-2300 RA Leiden, Netherlands.							Delagoutte E, 1997, J MOL BIOL, V266, P703, DOI 10.1006/jmbi.1996.0830; GOOSEN N, 1998, NUCL ACIDS MOL BIOL; HSU DS, 1995, J BIOL CHEM, V270, P8319, DOI 10.1074/jbc.270.14.8319; LIN JJ, 1992, J BIOL CHEM, V267, P17693; LIN JJ, 1992, J BIOL CHEM, V267, P17688; Moolenaar GF, 1998, J BIOL CHEM, V273, P34896, DOI 10.1074/jbc.273.52.34896; Moolenaar GF, 2000, J BIOL CHEM, V275, P8044, DOI 10.1074/jbc.275.11.8044; Moolenaar GF, 1998, NUCLEIC ACIDS RES, V26, P462, DOI 10.1093/nar/26.2.462; Moolenaar GF, 1995, J BIOL CHEM, V270, P30508, DOI 10.1074/jbc.270.51.30508; MOOLENAAR GF, 1994, J MOL BIOL, V240, P294, DOI 10.1006/jmbi.1994.1447; OH EY, 1989, NUCLEIC ACIDS RES, V17, P4145, DOI 10.1093/nar/17.11.4145; OH EY, 1989, J BIOL CHEM, V264, P1336; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; VANHOUTEN B, 1987, J BIOL CHEM, V262, P13180; VISSE R, 1991, J BIOL CHEM, V266, P7609; VISSE R, 1992, J BIOL CHEM, V267, P4820; VOIGT JM, 1989, J BIOL CHEM, V264, P5172; Zou Y, 1999, EMBO J, V18, P4889, DOI 10.1093/emboj/18.17.4889; Zou Y, 1997, J BIOL CHEM, V272, P4820, DOI 10.1074/jbc.272.8.4820	20	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8038	8043		10.1074/jbc.275.11.8038	http://dx.doi.org/10.1074/jbc.275.11.8038			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713124	hybrid, Green Published			2022-12-27	WOS:000085913300084
J	Boue-Grabot, E; Archambault, V; Seguela, P				Boue-Grabot, E; Archambault, V; Seguela, P			A protein kinase C site highly conserved in P2X subunits controls the desensitization kinetics of P2X(2) ATP-gated channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSORY NEURONS; P-2X RECEPTOR; ION CHANNELS; EXTRACELLULAR ATP; PHOSPHORYLATION; IDENTIFICATION; MODULATION; FAMILY; NMDA	P2X receptors are nonselective cation channels gated by extracellular ATP. Recombinant mammalian P2X subunits assemble in homomeric ionotropic ATP receptors that differ by their agonist sensitivity and desensitization rate in heterologous expression systems. Using site-directed mutagenesis and voltage clamp recording in Xenopus oocytes, we identified the highly conserved protein kinase C site TX(K/R) located in the intracellular N terminus of P2X subunits as a critical determinant of kinetics in slowly desensitizing (time constant, >1 min) rat P2X(2) receptors, Mutant receptors P2X(2)T18A, T18N, and K20T devoid of this consensus site exhibited quickly desensitizing properties (time constant, <1 s), In contrast with wild-type receptors, mutant P2X(2) receptors with truncated C terminus exhibited variable cell-specific kinetics with quickly desensitizing currents converted to slowly desensitizing currents by phorbol ester-mediated stimulation of protein kinase C, Phosphorylation of Thr(18) was demonstrated directly by immunodetection using specific monoclonal antibodies directed against the phosphothreonine-proline motif, Our data indicate that both phosphorylation of the conserved threonine residue in the N-terminal domain by protein kinase C and interaction between the two cytoplasmic domains of P2X(2) subunits are necessary for the full expression of slowly desensitizing ATP-gated channels.	McGill Univ, Montreal Neurol Inst, Cell Biol Excitable Tissue Res Grp, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada	McGill University	Seguela, P (corresponding author), McGill Univ, Montreal Neurol Inst, Cell Biol Excitable Tissue Res Grp, Dept Neurol & Neurosurg, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.		Boué-Grabot, Eric/AAQ-2061-2020	Boué-Grabot, Eric/0000-0003-2187-9037				BEAN BP, 1990, J NEUROSCI, V10, P11; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; Buell G, 1996, EUR J NEUROSCI, V8, P2221, DOI 10.1111/j.1460-9568.1996.tb00745.x; Burnstock G, 1996, LANCET, V347, P1604, DOI 10.1016/S0140-6736(96)91082-X; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; Chow YW, 1998, J NEUROCHEM, V70, P2606; Collo G, 1996, J NEUROSCI, V16, P2495; KELLENBERGER S, 1992, J BIOL CHEM, V267, P25660; Koshimizu T, 1999, J BIOL CHEM, V274, P37651, DOI 10.1074/jbc.274.53.37651; Koshimizu T, 1998, J BIOL CHEM, V273, P12853, DOI 10.1074/jbc.273.21.12853; KRISHEK BJ, 1994, NEURON, V12, P1081, DOI 10.1016/0896-6273(94)90316-6; Le KT, 1999, J BIOL CHEM, V274, P15415, DOI 10.1074/jbc.274.22.15415; Le KT, 1998, J NEUROSCI, V18, P7152; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; Paradiso K, 1998, J NEUROSCI, V18, P9227; ROGERS M, 1995, BIOPHYS J, V68, P501, DOI 10.1016/S0006-3495(95)80211-0; Seguela P, 1996, J NEUROSCI, V16, P448; Smart TG, 1997, CURR OPIN NEUROBIOL, V7, P358, DOI 10.1016/S0959-4388(97)80063-3; Smith FM, 1999, J PHYSIOL-LONDON, V520, P91, DOI 10.1111/j.1469-7793.1999.00091.x; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Torres GE, 1998, FEBS LETT, V425, P19, DOI 10.1016/S0014-5793(98)00179-3; Torres GE, 1998, MOL PHARMACOL, V54, P989, DOI 10.1124/mol.54.6.989; Ueno S, 1998, BRIT J PHARMACOL, V124, P1484, DOI 10.1038/sj.bjp.0701963; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Werner P, 1996, P NATL ACAD SCI USA, V93, P15485, DOI 10.1073/pnas.93.26.15485; Zhou Z, 1998, BIOCHEM BIOPH RES CO, V252, P541, DOI 10.1006/bbrc.1998.9689	29	148	151	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10190	10195		10.1074/jbc.275.14.10190	http://dx.doi.org/10.1074/jbc.275.14.10190			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744703	hybrid			2022-12-27	WOS:000086345600044
J	Carman, CV; Barak, LS; Chen, CG; Liu-Chen, LY; Onorato, JJ; Kennedy, SP; Caron, MG; Benovic, JL				Carman, CV; Barak, LS; Chen, CG; Liu-Chen, LY; Onorato, JJ; Kennedy, SP; Caron, MG; Benovic, JL			Mutational analysis of G beta gamma and phospholipid interaction with G protein-coupled receptor kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN-HOMOLOGY DOMAIN; HETEROTRIMERIC G-PROTEINS; MU-OPIOID RECEPTOR; CRYSTAL-STRUCTURE; BINDING-SITE; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; G(BETA-GAMMA) SUBUNITS; INOSITOL PHOSPHATES; PH DOMAIN; ACTIVATION	Agonist-dependent regulation of G protein-coupled receptors is dependent on their phosphorylation by G protein-coupled receptor kinases (GRKs). GRK2 and GRK3 are selectively regulated in vitro by free G-beta-gamma subunits and negatively charged membrane phospholipids through their pleckstrin homology (PH) domains. However, the molecular binding determinants and physiological role for these ligands remain unclear. To address these issues, we generated an array of site-directed mutants within the GRK2 PH domain and characterized their interaction with G-beta-gamma and phospholipids in vitro. Mutation of several residues in the loop 1 region of the PH domain, including Lys-567, Trp-576, Arg-578, and Arg-579, resulted in a loss of receptor phosphorylation, likely via disruption of phospholipid binding, that was reversed by G-beta-gamma. Alternatively, mutation of residues distral to the C-terminal amphipathic alpha-helix, including Lys-663, Lys-665, Lys-667, and Arg-669, resulted in decreased responsiveness to G-beta-gamma. Interestingly, mutation of Arg-587 in beta-sheet 3, a region not previously thought to interact with G-beta-gamma, resulted in a specific and profound loss of G-beta-gamma responsiveness. To further characterize these effects, two mutants (GRK2(K567E/R578E) and GRK2(R587Q)) were expressed in Sf9 cells and purified. Analysis of these mutants revealed that GRK2(K567E/R578E) was refractory to stimulation by negatively charged phospholipids but bound G-beta-gamma similar to wild type GRK2. In contrast, GRK2(R587Q) was stimulated by acidic phospholipids but failed to bind G-beta-gamma. In order to examine the role of phospholipid and G-beta-gamma interaction in cells, wild-type and mutant GRK2s were expressed with a beta-2-adrenergic receptor (beta-2AR) mutant that is responsive to GRK2 phosphorylation (beta-2AR(Y326A)). In these cells, GRK2 (K567E/R578E) and GRK2(R587Q) were largely defective in promoting agonist-dependent phosphorylation and internalization of beta-2AR(Y326A). Similarly, wild-type GRK2 but not GRK2(K567E/R578E) or GRK2(R587Q) promoted morphine dependent phosphorylation of the mu-opioid receptor in cells. Thus, we have (i) identified several specific GRK2 binding determinants for G-beta-gamma and phospholipids, and (ii) demonstrated the G-beta-gamma binding is the limiting step for GRK2-dependent receptor phosphorylation in cells.	Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Duke Univ, Howard Hughes Med Inst, Dept Cell Biol, Durham, NC 27710 USA; Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19140 USA; Univ Wisconsin, Dept Med, Madison, WI 53792 USA; Pfizer Inc, Div Cent Res, Groton, CT 06340 USA	Jefferson University; Duke University; Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Wisconsin System; University of Wisconsin Madison; Pfizer	Benovic, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, 233 S 10th St, Philadelphia, PA 19107 USA.	benovic@lac.jci.tju.edu	Carman, Christopher/L-8108-2016; Carman, Christopher V./AAX-8995-2020	Carman, Christopher/0000-0001-7358-2548; Carman, Christopher V./0000-0001-7358-2548	NATIONAL CANCER INSTITUTE [T32CA009662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NCI NIH HHS [5-T32-CA09662] Funding Source: Medline; NIGMS NIH HHS [GM44944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BOEKHOFF I, 1994, J BIOL CHEM, V269, P37; Bromann PA, 1997, J BIOL CHEM, V272, P16240, DOI 10.1074/jbc.272.26.16240; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Carman CV, 1999, J BIOL CHEM, V274, P8858, DOI 10.1074/jbc.274.13.8858; Carman CV, 1998, J BIOL CHEM, V273, P20308, DOI 10.1074/jbc.273.32.20308; Chen CG, 1996, J BIOL CHEM, V271, P21422, DOI 10.1074/jbc.271.35.21422; CHEN CY, 1993, J BIOL CHEM, V268, P7825; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5742, DOI 10.1074/jbc.270.11.5742; DebBurman SK, 1996, J BIOL CHEM, V271, P22552, DOI 10.1074/jbc.271.37.22552; DOWNING AK, 1994, CURR BIOL, V4, P884, DOI 10.1016/S0960-9822(00)00197-4; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Fukuda M, 1996, J BIOL CHEM, V271, P18838, DOI 10.1074/jbc.271.31.18838; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; Fushman D, 1998, J BIOL CHEM, V273, P2835, DOI 10.1074/jbc.273.5.2835; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Goldman PS, 1997, BIOCHEM BIOPH RES CO, V240, P425, DOI 10.1006/bbrc.1997.7674; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Haga K, 1998, EUR J BIOCHEM, V255, P363, DOI 10.1046/j.1432-1327.1998.2550363.x; HAGA K, 1994, J BIOL CHEM, V269, P12594; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Haske TN, 1996, J BIOL CHEM, V271, P2941, DOI 10.1074/jbc.271.6.2941; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KIM CM, 1993, J BIOL CHEM, V268, P15412; KIM CM, 1993, RECEPTOR, V3, P39; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Loew A, 1998, STRUCT FOLD DES, V6, P1007, DOI 10.1016/S0969-2126(98)00102-6; LUTHIN GR, 1988, MOL PHARMACOL, V34, P327; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; ONORATO JJ, 1995, J BIOL CHEM, V270, P21346, DOI 10.1074/jbc.270.36.21346; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; Touhara K, 1997, FEBS LETT, V417, P243, DOI 10.1016/S0014-5793(97)01294-5; TOUHARA K, 1995, J BIOL CHEM, V270, P17000, DOI 10.1074/jbc.270.28.17000; VIHINEN M, 1995, BIOCHEMISTRY-US, V34, P1475, DOI 10.1021/bi00005a002; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WISTEL R, 1995, P NATL ACAD SCI USA, V93, P2105; Yagisawa H, 1998, J BIOL CHEM, V273, P417, DOI 10.1074/jbc.273.1.417; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	58	97	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10443	10452		10.1074/jbc.275.14.10443	http://dx.doi.org/10.1074/jbc.275.14.10443			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744734	hybrid			2022-12-27	WOS:000086345600075
J	Heller, JI; Crowley, JR; Hazen, SL; Salvay, DM; Wagner, P; Pennathur, S; Heinecke, JW				Heller, JI; Crowley, JR; Hazen, SL; Salvay, DM; Wagner, P; Pennathur, S; Heinecke, JW			p-Hydroxyphenylacetaldehyde, an aldehyde generated by myeloperoxidase, modifies phospholipid amino groups of low density lipoprotein in human atherosclerotic intima	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHILS EMPLOY; PEROXIDE-CHLORIDE SYSTEM; L-TYROSINE OXIDATION; SMOOTH-MUSCLE CELLS; HYDROGEN-PEROXIDE; SCAVENGER RECEPTOR; REACTIVE ALDEHYDES; APOLIPOPROTEIN-B; ALPHA,BETA-UNSATURATED ALDEHYDES; OXIDIZED PHOSPHOLIPIDS	Oxidation of low density lipoprotein (LDL) may be of critical importance in the pathogenesis of atherosclerosis. Recent studies suggest that oxidized phospholipids render LDL atherogenic, However, both the structures and the physiologically relevant pathways for the formation of modified phospholipids in oxidized LDL remain poorly understood. We previously showed that p-hydroxyphenylacetaldehyde (pHA) is the major product of L-tyrosine oxidation by the myeloperoxidase/hydrogen peroxide/chloride system of phagocytes, In the current studies, we demonstrate that this reactive aldehyde targets the aminophospholipids of LDL in vitro and in vivo. Activated human neutrophils generated pHA-ethanolamine, the reduced adduct of pHA with the amino group of phosphatidylethanolamine, on LDL phospholipids by a reaction that required myeloperoxidase, H2O2, and L-tyrosine, The cellular system could be replaced by HOCl and L-tyrosine but not by a wide variety of other oxidation systems, indicating that pHA-ethanolamine is a specific marker for covalent modification of aminophospholipids by myeloperoxidase. To determine whether aldehydes modify aminophospholipids in vivo, we quantified levels of pHA-ethanolamine in acid hydrolysates of reduced lipid extracts through isotope dilution gas chromatography/mass spectrometry, Circulating LDL contained undetectable levels of pHA-modified phospholipid (<0.1 mmol/mol), In contrast, the concentration of pHA-ethanolamine in LDL isolated from human atherosclerotic lesions was strikingly elevated (4.5 mmol/mol), Collectively, these results demonstrate a novel, myeloperoxidase-based mechanism for modifying the amino group of LDL phospholipids. They also offer the first evidence that myeloperoxidase may damage LDL lipids in Ditto, raising the possibility that aldehyde-modified aminophospholipids play a role in inflammation and vascular disease.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Heinecke, JW (corresponding author), Div Atherosclerosis Nutr & Lipid Res, Box 8046,660 S Euclid Ave, St Louis, MO 63110 USA.		Hazen, Stanley L/ABD-5845-2021		NIA NIH HHS [AG12293, AG15013] Funding Source: Medline; NIDDK NIH HHS [DK02456] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG015013, R01AG012293] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson MM, 1999, J CLIN INVEST, V104, P103, DOI 10.1172/JCI3042; Anderson MM, 1997, J CLIN INVEST, V99, P424, DOI 10.1172/JCI119176; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; Bevers EM, 1998, BIOL CHEM, V379, P973; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWNLEE M, 1991, ANNU REV MED, V42, P159, DOI 10.1146/annurev.me.42.020191.001111; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FOGELMAN AM, 1980, P NATL ACAD SCI-BIOL, V77, P2214, DOI 10.1073/pnas.77.4.2214; Gniwotta C, 1997, ARTERIOSCL THROM VAS, V17, P3236, DOI 10.1161/01.ATV.17.11.3236; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HABERLAND ME, 1984, J BIOL CHEM, V259, P1305; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hazen SL, 1999, CHEM RES TOXICOL, V12, P19, DOI 10.1021/tx980147s; Hazen SL, 1998, BIOCHEMISTRY-US, V37, P6864, DOI 10.1021/bi972449j; Hazen SL, 1999, METHOD ENZYMOL, V300, P88; Hazen SL, 1997, J BIOL CHEM, V272, P16990, DOI 10.1074/jbc.272.27.16990; Hazen SL, 1998, J BIOL CHEM, V273, P4997, DOI 10.1074/jbc.273.9.4997; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hazen SL, 1996, J BIOL CHEM, V271, P1861, DOI 10.1074/jbc.271.4.1861; HEINECKE JW, 1984, J CLIN INVEST, V74, P1890, DOI 10.1172/JCI111609; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; Heinecke JW, 1999, METHOD ENZYMOL, V300, P124; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; Horkko S, 1999, J CLIN INVEST, V103, P117, DOI 10.1172/JCI4533; HUGGINS TG, 1993, J BIOL CHEM, V268, P12341; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; Kates M, 1986, LAB TECHNIQUES BIOCH, V3; KETTLE AJ, 1988, BIOCHEM J, V252, P529, DOI 10.1042/bj2520529; Klebanoff S.J., 1978, NEUTROPHIL FUNCTION; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; PARTHASARATHY S, 1987, P NATL ACAD SCI USA, V84, P537, DOI 10.1073/pnas.84.2.537; RAKITA RM, 1990, BIOCHEMISTRY-US, V29, P1075, DOI 10.1021/bi00456a033; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; STEINBRECHER UP, 1989, J BIOL CHEM, V264, P15216; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; Terpstra V, 1998, P NATL ACAD SCI USA, V95, P1806, DOI 10.1073/pnas.95.4.1806; Vance D. E., 1991, BIOCH LIPIDS LIPOPRO; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; Whitman SC, 1999, ARTERIOSCL THROM VAS, V19, P1238, DOI 10.1161/01.ATV.19.5.1238; WITZ G, 1989, FREE RADICAL BIO MED, V7, P333, DOI 10.1016/0891-5849(89)90137-8; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	54	69	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					9957	9962		10.1074/jbc.275.14.9957	http://dx.doi.org/10.1074/jbc.275.14.9957			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744670	hybrid			2022-12-27	WOS:000086345600011
J	Mo, HQ; Winter, HC; Goldstein, IJ				Mo, HQ; Winter, HC; Goldstein, IJ			Purification and characterization of a Neu5Ac alpha 2-6Gal beta 1-4Glc/GlcNAc-specific lectin from the fruiting body of the polypore mushroom Polyporus squamosus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2,6 SIALYLTRANSFERASE ACTIVITY; BINDING LECTIN; RAS ONCOGENE; CELL-LINES; EDIBLE MUSHROOM; HIGHER FUNGI; FR3T3 CELLS; ALPHA-2,3-SIALYLTRANSFERASE; ALPHA-2,6-SIALYLTRANSFERASE; CONCANAVALIN	A lectin has been purified from the carpophores of the mushroom Polyporus squamosus by a combination of affinity chromatography on beta-D-galactosyl-Synsorb and ion-exchange chromatography on DEAE-Sephacel. Gel filtration chromatography, SDS-polyacrylamide gel electrophoresis, and N-terminal amino acid sequencing indicated that the native lectin, designated P. squamosus agglutinin, is composed of two identical 28-kDa subunits associated by noncovalent bonds. P. squamosus agglutinin agglutinated human A, B, and O and rabbit red blood cells but precipitated only with human alpha(2)-macroglobulin, of many glycoproteins and polysaccharides tested. The detailed carbohydrate binding properties of the purified lectin were elucidated using three different approaches, ie. precipitation inhibition assay tin solution binding assay), fluorescence quenching studies, and glycolipid binding by lectin staining on high-performance thin layer chromatography (solid-phase binding assay). Based on the results obtained by these assays, we conclude that although the P. squamosus lectin binds P-D-galactosides, it has an extended carbohydrate-combining site that exhibits highest specificity and affinity toward nonreducing terminal Neu5Ac alpha 2,6Gal beta 1,4Glc/GlcNAc (6'-sialylated type II chain) of N-glycans (2000-fold stronger than toward galactose). The strict specificity of the lectin for alpha 2,6-linked sialic acid renders this lectin a valuable tool for glycobiological studies in biomedical and cancer research.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Goldstein, IJ (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.				NIGMS NIH HHS [GM29470] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029470] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CROWLEY JF, 1982, METHOD ENZYMOL, V83, P368; DALLOLIO F, 1989, INT J CANCER, V44, P434; DALLOLIO F, 1992, INT J CANCER, V50, P325; DALLOLIO F, 1991, INT J CANCER, V47, P291, DOI 10.1002/ijc.2910470220; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DEAN BR, 1973, BIOCHIM BIOPHYS ACTA, V322, P141, DOI 10.1016/0005-2795(73)90184-0; DELANNOY P, 1993, GLYCOCONJUGATE J, V10, P91, DOI 10.1007/BF00731192; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; GOLDSTEIN IJ, 1980, NATURE, V285, P66, DOI 10.1038/285066b0; Guillot J, 1997, BIOCHEM SYST ECOL, V25, P203, DOI 10.1016/S0305-1978(96)00110-X; HANAOKA K, 1989, J BIOL CHEM, V264, P9842; HASSING GS, 1970, EUR J BIOCHEM, V16, P549, DOI 10.1111/j.1432-1033.1970.tb01116.x; Irazoqui FJ, 1999, GLYCOBIOLOGY, V9, P59, DOI 10.1093/glycob/9.1.59; KAWAGISHI H, 1995, FOOD REV INT, V11, P63, DOI 10.1080/87559129509541019; KAWAGISHI H, 1990, BIOCHIM BIOPHYS ACTA, V1034, P247, DOI 10.1016/0304-4165(90)90045-X; Kocourek J., 1986, LECTINS PROPERTIES F, P1; KONSKA G, 1994, J BIOCHEM-TOKYO, V116, P519, DOI 10.1093/oxfordjournals.jbchem.a124555; LEHMANN J, 1998, CARBOHYDRATES STRUCT, P32; LEMARER N, 1995, GLYCOBIOLOGY, V5, P219, DOI 10.1093/glycob/5.2.219; LEMARER N, 1992, GLYCOBIOLOGY, V2, P49, DOI 10.1093/glycob/2.1.49; LIN JY, 1984, J BIOCHEM, V96, P35, DOI 10.1093/oxfordjournals.jbchem.a134826; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MO HQ, 1994, GLYCOCONJUGATE J, V11, P424, DOI 10.1007/BF00731278; MO HQ, 1994, J BIOL CHEM, V269, P7666; NOWAK TP, 1975, BIOCHIM BIOPHYS ACTA, V393, P115, DOI 10.1016/0005-2795(75)90221-4; PEMBERTON RT, 1994, MYCOL RES, V98, P277, DOI 10.1016/S0953-7562(09)80455-3; Pousset D, 1997, CANCER RES, V57, P4249; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8318; TAMURA T, 1994, ANAL BIOCHEM, V216, P335, DOI 10.1006/abio.1994.1050; VANDAMME V, 1992, BIOCHIMIE, V74, P89, DOI 10.1016/0300-9084(92)90188-K; Wang HX, 1997, ANTICANCER RES, V17, P419; Wang HX, 1998, MYCOL RES, V102, P897, DOI 10.1017/S0953756298006200; WARREN L, 1959, J BIOL CHEM, V234, P1971; WLASICHUK KB, 1993, J BIOL CHEM, V268, P13971; YAMASHITA K, 1992, BIOCHEMISTRY-US, V31, P11647, DOI 10.1021/bi00161a052; YU LG, 1993, CANCER RES, V53, P4627	38	89	93	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10623	10629		10.1074/jbc.275.14.10623	http://dx.doi.org/10.1074/jbc.275.14.10623			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744758	hybrid			2022-12-27	WOS:000086345600099
J	Xue, J; Wang, X; Malladi, CS; Kinoshita, M; Milburn, PJ; Lengyel, I; Rostas, JAP; Robinson, PJ				Xue, J; Wang, X; Malladi, CS; Kinoshita, M; Milburn, PJ; Lengyel, I; Rostas, JAP; Robinson, PJ			Phosphorylation of a new brain-specific septin, G-septin, by cGMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-3 DOMAINS; CEREVISIAE CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; GENE-PRODUCT; NERVOUS-SYSTEM; BUDDING SITE; SH3 DOMAIN; BUD NECK; LOCALIZATION; FILAMENTS	The septins are a family of GTPase enzymes, some of which are required for the cytokinesis stage of cell di vision and others of which are associated with exocytosis. me purified and cloned the cDNA for a 40-kDa protein from rat brain that is a substrate for type I cGMP-dependent protein kinase (PKG). The amino acid sequences of two tryptic peptides of P40 showed high homology to the septins. Molecular cloning revealed the 358-amino acid P40 to be a new member of the septin family. P40 was named G-septin, as it is phosphorylated in, vitro by PKG, but relatively poorly by the related cAMP dependent protein kinase and not by protein kinase C, Two splice variants of G-septin (alpha and beta) were found with distinct N and C termini, but a common GTPase domain. G-septin lacks the C-terminal coiled-coil domain characteristic of all other mammalian septins and uniquely has two predicted phosphorylation site motifs for type I PKG. Photoaffinity labeling with [alpha-P-32]GTP confirmed that G-septin is a GTP-binding protein. Northern blotting showed that G-septin mRNA (5.0 kilobases) is highly expressed in brain and undetectable in 12 other tissues, indicating that the G-septins are primarily neuronal proteins. Very low levels of 6.0-, 3.4-, and 2.6-kilobase transcripts were found in testis. Our results reveal a new class of brain-specific septins that may be regulated by PKG in neurons.	Childrens Med Res Inst, Cell Signalling Unit, Wentworthville, NSW 2145, Australia; Univ Newcastle, Dept Med Biochem, Fac Med & Hlth Sci, Newcastle, NSW 2308, Australia; Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Kyoto 606, Japan; Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 0200, Australia; Hungarian Acad Sci, Biol Res Ctr, Inst Biochem, H-6701 Szeged, Hungary	Children's Medical Research Institute - Australia; University of Newcastle; Kyoto University; Australian National University; John Curtin School of Medical Research; Hungarian Academy of Sciences; Hungarian Biological Research Center	Robinson, PJ (corresponding author), Childrens Med Res Inst, Cell Signalling Unit, Locked Bag 23, Wentworthville, NSW 2145, Australia.	phrobins@mail.usyd.edu.au	Rostas, John/B-5089-2008; Lengyel, Imre/B-5217-2009; Robinson, Phillip J/G-4008-2011	Lengyel, Imre/0000-0001-7467-2174; Robinson, Phillip J/0000-0002-7878-0313; KINOSHITA, MAKOTO/0000-0002-7592-2400; Malladi, Chandra/0000-0002-5882-8228				ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Beites CL, 1999, NAT NEUROSCI, V2, P434, DOI 10.1038/8100; Bernabeu R, 1997, NEUROREPORT, V8, P2221, DOI 10.1097/00001756-199707070-00026; Bi E, 1998, J CELL BIOL, V142, P1301, DOI 10.1083/jcb.142.5.1301; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BYERS B, 1976, J CELL BIOL, V69, P717, DOI 10.1083/jcb.69.3.717; Carroll CW, 1998, J CELL BIOL, V143, P709, DOI 10.1083/jcb.143.3.709; Chant J, 1996, CELL, V84, P187, DOI 10.1016/S0092-8674(00)80972-1; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Cooper JA, 1996, J CELL BIOL, V134, P1345, DOI 10.1083/jcb.134.6.1345; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Fares H, 1996, J CELL BIOL, V132, P399, DOI 10.1083/jcb.132.3.399; FARES H, 1995, MOL BIOL CELL, V6, P1843, DOI 10.1091/mbc.6.12.1843; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Field CM, 1996, J CELL BIOL, V133, P605, DOI 10.1083/jcb.133.3.605; Firestein BL, 1998, J NEUROCHEM, V71, P1846; FLESCHER EG, 1993, J CELL BIOL, V122, P373, DOI 10.1083/jcb.122.2.373; FORD SK, 1991, DEV GENET, V12, P281, DOI 10.1002/dvg.1020120405; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; HAARER BK, 1987, MOL CELL BIOL, V7, P3678, DOI 10.1128/MCB.7.10.3678; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; Hsu SC, 1998, NEURON, V20, P1111, DOI 10.1016/S0896-6273(00)80493-6; KATO K, 1992, TRENDS NEUROSCI, V15, P319, DOI 10.1016/0166-2236(92)90046-B; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; KIM HB, 1991, J CELL BIOL, V112, P535, DOI 10.1083/jcb.112.4.535; Kinoshita A, 1998, AM J PATHOL, V153, P1551, DOI 10.1016/S0002-9440(10)65743-4; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Lengyel I, 1999, NEUROSCIENCE, V90, P607, DOI 10.1016/S0306-4522(98)00452-7; LINCOLN TM, 1983, METHOD ENZYMOL, V99, P62; LOUGTINE MS, 1996, CURR OPIN CELL BIOL, V8, P106; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; McKie JM, 1997, HUM GENET, V101, P6, DOI 10.1007/s004390050576; Mino A, 1998, BIOCHEM BIOPH RES CO, V251, P732, DOI 10.1006/bbrc.1998.9541; Nagase T, 1995, DNA Res, V2, P167, DOI 10.1093/dnares/2.4.167; NAKATSURU S, 1994, BIOCHEM BIOPH RES CO, V202, P82, DOI 10.1006/bbrc.1994.1896; NEUFELD TP, 1994, CELL, V77, P371, DOI 10.1016/0092-8674(94)90152-X; NOTTENBURG C, 1990, GENE, V95, P279, DOI 10.1016/0378-1119(90)90372-X; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Pantazis NJ, 1998, J NEUROCHEM, V70, P1826; ROBINSON PJ, 1992, J BIOL CHEM, V267, P21637; ROBINSON PJ, 1983, J NEUROCHEM, V41, P909, DOI 10.1111/j.1471-4159.1983.tb09034.x; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Sequeira SM, 1999, NEUROSCI LETT, V261, P29, DOI 10.1016/S0304-3940(98)01002-7; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; TEGGE W, 1995, BIOCHEMISTRY-US, V34, P10569, DOI 10.1021/bi00033a032; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG X, 1995, J NEUROCHEM, V65, P595; Wang X, 1997, J NEUROCHEM, V68, P443; Wang X, 1999, EMBO J, V18, P4549, DOI 10.1093/emboj/18.16.4549; Wu JQ, 1998, J NEUROSCI, V18, P3589; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zieger B, 1997, J CLIN INVEST, V99, P520, DOI 10.1172/JCI119188	59	49	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10047	10056		10.1074/jbc.275.14.10047	http://dx.doi.org/10.1074/jbc.275.14.10047			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744683	hybrid			2022-12-27	WOS:000086345600024
J	Griffiss, JM; Brandt, BL; Saunders, NB; Zollinger, W				Griffiss, JM; Brandt, BL; Saunders, NB; Zollinger, W			Structural relationships and sialylation among meningococcal L1, L8, and L3,7 lipooligosaccharide serotypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEISSERIA-GONORRHOEAE LIPOOLIGOSACCHARIDES; LIPOPOLYSACCHARIDE CORE OLIGOSACCHARIDES; CELL-SURFACE LIPOOLIGOSACCHARIDES; OUTER-MEMBRANE PROTEIN; MONOCLONAL-ANTIBODIES; GROUP-B; GONOCOCCAL LIPOOLIGOSACCHARIDE; MOLECULAR CHARACTERIZATION; HAEMOPHILUS-INFLUENZAE; EPITOPE EXPRESSION	Eighteen of 34 endemic meningococcal case strains were of the L8 lipooligosaccharide (LOS) type; four of these were both L3 and L7 (L3,7), and seven were L1, L1 structures arose by alternative terminal Gal substitutions of lactosyl diheptoside L8 structures, as determined by electrospray ionization and other mass spectrometric techniques, and enzymatic and chemical degradations (Structures L1 and L1 alpha). [GRAPHICS] The more abundant molecule, designated L1, had a tri-hexose globosyl alpha chain; the less abundant one, designated L1a, had a beta-lactosyl alpha chain and a parallel alpha-lactosaminyl gamma chain. A p(k) globoside (Gal alpha 1-->4Gal beta 1--> 4 Glc-R) monoclonal antibody bound 9/10 L1 strains, but a P-1 globoside (Gal alpha 1-->4Gal beta 1-4GlcNAc-R) mAb bound none of them. alpha-Galactosidase caused loss of both L1 structures and creation of L8 structures; P-galactosidase caused loss of the L8 determinant. The L1/P-k glycose was partially sialylated. Some LOS also had unsubstituted basal beta-GlcNAc additions. These structural relationships explain co-expression of L8, L1, and L3,7 serotypes.	Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94121 USA; Univ Calif San Francisco, Ctr Immunochem, San Francisco, CA 94121 USA; Walter Reed Army Inst Res, Dept Bacterial Dis, Washington, DC 20307 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	Griffiss, JM (corresponding author), Vet Adm Med Ctr, 111W1,4150 Clement St, San Francisco, CA 94121 USA.	crapaud@vacom.ucsf.edu	Zollinger, Wendell/B-2887-2011		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021620, R01AI021171] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 21620, AI 21171] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APICELLA MA, 1994, METHOD ENZYMOL, V235, P242; BAKER CJ, 1983, PEDIATRICS, V71, P923; BERTRAM MA, 1976, J IMMUNOL, V116, P842; BOSLEGO J, 1995, VACCINE, V13, P821, DOI 10.1016/0264-410X(94)00037-N; BRODIN NT, 1988, INT J CANCER, V42, P185, DOI 10.1002/ijc.2910420208; BROUD DD, 1979, J INFECT DIS, V140, P465, DOI 10.1093/infdis/140.4.465; DELL A, 1990, CARBOHYD RES, V200, P59, DOI 10.1016/0008-6215(90)84182-T; DIFABIO JL, 1990, CAN J CHEM, V68, P1029, DOI 10.1139/v90-160; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; ESTABROOK MM, 1992, J INFECT DIS, V166, P1079, DOI 10.1093/infdis/166.5.1079; ESTABROOK MM, 1990, INFECT IMMUN, V58, P2204, DOI 10.1128/IAI.58.7.2204-2213.1990; FROSCH M, 1989, P NATL ACAD SCI USA, V86, P1669, DOI 10.1073/pnas.86.5.1669; GAMIAN A, 1992, J BIOL CHEM, V267, P922; GIBSON BW, 1993, J BACTERIOL, V175, P2702, DOI 10.1128/JB.175.9.2702-2712.1993; GIBSON BW, 1989, P NATL ACAD SCI USA, V86, P17, DOI 10.1073/pnas.86.1.17; GRIFFISS JM, 1988, REV INFECT DIS, V10, pS287; GRIFFISS JM, 1984, J INFECT DIS, V150, P71, DOI 10.1093/infdis/150.1.71; Griffiss JM, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P179; GRIFFISS JM, 1974, JAMA-J AM MED ASSOC, V229, P68, DOI 10.1001/jama.229.1.68; GRIFFISS JM, 1983, MED TROP-MARSEILLE, V45, P53; HARDY MR, 1989, METHOD ENZYMOL, V179, P76; HELANDER IM, 1988, EUR J BIOCHEM, V177, P483, DOI 10.1111/j.1432-1033.1988.tb14398.x; JENNINGS HJ, 1987, A VAN LEEUW J MICROB, V53, P519, DOI 10.1007/BF00415511; JOHN CM, 1991, J BIOL CHEM, V266, P19303; JONES DM, 1992, MICROB PATHOGENESIS, V13, P219, DOI 10.1016/0882-4010(92)90022-G; KERWOOD DE, 1992, BIOCHEMISTRY-US, V31, P12760, DOI 10.1021/bi00166a008; KIM JJ, 1994, INFECT IMMUN, V62, P1566, DOI 10.1128/IAI.62.5.1566-1575.1994; KIM JJ, 1988, INFECT IMMUN, V56, P2631, DOI 10.1128/IAI.56.10.2631-2638.1988; KULSHIN VA, 1992, J BACTERIOL, V174, P1793, DOI 10.1128/jb.174.6.1793-1800.1992; MANDRELL RE, 1992, INFECT IMMUN, V60, P3017, DOI 10.1128/IAI.60.7.3017-3020.1992; MANDRELL RE, 1991, J BACTERIOL, V173, P2823, DOI 10.1128/JB.173.9.2823-2832.1991; MANDRELL RE, 1988, J EXP MED, V168, P107, DOI 10.1084/jem.168.1.107; MICHON F, 1990, J BIOL CHEM, V265, P7243; PAVLIAK V, 1993, J BIOL CHEM, V268, P14146; PHILLIPS NJ, 1990, BIOMED ENVIRON MASS, V19, P731, DOI 10.1002/bms.1200191112; PHILLIPS NJ, 1992, BIOCHEMISTRY-US, V31, P4515, DOI 10.1021/bi00133a019; Saunders NB, 1998, INFECT IMMUN, V66, P3218, DOI 10.1128/IAI.66.7.3218-3222.1998; SCHNEIDER H, 1982, J GEN MICROBIOL, V128, P13; SCHNEIDER H, 1988, INFECT IMMUN, V56, P942, DOI 10.1128/IAI.56.4.942-946.1988; SCHNEIDER H, 1984, INFECT IMMUN, V45, P544, DOI 10.1128/IAI.45.3.544-549.1984; SCHNEIDER H, 1986, INFECT IMMUN, V54, P924, DOI 10.1128/IAI.54.3.924-927.1986; SCHNEIDER H, 1985, INFECT IMMUN, V50, P672, DOI 10.1128/IAI.50.3.672-677.1985; SCHNEIDER H, 1991, J EXP MED, V174, P1601, DOI 10.1084/jem.174.6.1601; SCHOLTEN RJPM, 1994, J MED MICROBIOL, V41, P236, DOI 10.1099/00222615-41-4-236; TAKAYAMA K, 1986, J BIOL CHEM, V261, P624; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Westphal O., 1965, METHODS CARBOHYDRATE, V5, P83, DOI DOI 10.1016/J.WATRES.2010.04.030; YAMASAKI R, 1988, MOL IMMUNOL, V25, P799, DOI 10.1016/0161-5890(88)90116-2; YAMASAKI R, 1993, J BACTERIOL, V175, P4565, DOI 10.1128/JB.175.14.4565-4568.1993; YAMASAKI R, 1991, MOL IMMUNOL, V28, P1233, DOI 10.1016/0161-5890(91)90010-H; YAMASAKI R, 1994, J BIOL CHEM, V269, P30345; YAMASAKI R, 1991, BIOCHEMISTRY-US, V30, P10566, DOI 10.1021/bi00107a028; ZOLLINGER WD, 1977, INFECT IMMUN, V18, P424, DOI 10.1128/IAI.18.2.424-433.1977; ZOLLINGER WD, 1983, INFECT IMMUN, V40, P257, DOI 10.1128/IAI.40.1.257-264.1983	54	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9716	9724		10.1074/jbc.275.13.9716	http://dx.doi.org/10.1074/jbc.275.13.9716			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734124	hybrid			2022-12-27	WOS:000086206500088
J	Singh, IS; Viscardi, RM; Kalvakolanu, I; Calderwood, S; Hasday, JD				Singh, IS; Viscardi, RM; Kalvakolanu, I; Calderwood, S; Hasday, JD			Inhibition of tumor necrosis factor-alpha transcription in macrophages exposed to febrile range temperature - A possible role for heat shock factor-1 as a negative transcriptional regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR GENE-EXPRESSION; HUMAN-MONOCYTES; BINDING ACTIVITY; PROTECTS MICE; CELL-LINE; LIPOPOLYSACCHARIDE; ACTIVATION; CACHECTIN; ENDOTOXIN; TNF	We previously reported that expression of tumor necrosis factor-alpha (TNF alpha) was attenuated in macrophages exposed to febrile range temperatures. In this study, we analyzed the influence of temperature on TNF alpha transcription in the Raw 264.7 macrophage cell line during incubation at 37 and 39.5 degrees C, The initial activation of TNF alpha transcription in response to endotoxin (LPS) was comparable in the 37 and 39.5 degrees C cell cultures, peaking within 10 min of LPS stimulation. However, the duration of transcriptional activation was markedly reduced in the 39.5 degrees C cells (30-60 min) compared with the 37 degrees C cells (2-4 h), Deletion mapping of the TNF alpha gene revealed that the proximal 85-nucleotide promoter sequence and the 5'-untranslated region were sufficient for temperature sensitivity. This sequence contains six heat shock response element (HRE) half-sites but no complete HREs, Electrophoretic mobility shift and immunoblot assays demonstrated that nuclear transclocation of heat shock factor (HSF) and its activation to a DNA-binding form occurred in the 39.5 degrees C cells in the absence of heat shock protein-70 gene activation. The proximal TNF alpha promoter/5'-untranslated region sequence competed for HSF binding to a classic HRE. Overexpression of HSF-1 reduced activity of the TNF alpha promoter. These data suggest that partial activation of HSF-I during exposure to febrile, sub-heat shock temperatures may block TNF alpha transcription by binding to its proximal promoter or 5'-untranslated region.	Baltimore VA Med Ctr, Med & Res Serv, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pediat, Div Neonatol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; Univ Maryland, Baltimore Cytoking Core Lab, Baltimore, MD 21201 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Joint Ctr Radiat Therapy, Boston, MA 02115 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Hasday, JD (corresponding author), Baltimore VA Med Ctr, Med & Res Serv, Rm 3D127,10 N Greene St, Baltimore, MD 21201 USA.		Viscardi, Rose Marie/AAH-8998-2021	Viscardi, Rose Marie/0000-0001-7451-6059				ADERKA D, 1989, J IMMUNOL, V143, P3517; BEMELMANS MHA, 1993, J IMMUNOL, V150, P2007; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BEUTLER B, 1995, J INVEST MED, V43, P227; BEUTLER B, 1992, AM J MED SCI, V303, P129, DOI 10.1097/00000441-199202000-00015; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BEUTLER B, 1990, ONCOGENESIS, V2, P9; BIRAGYN A, 1995, J IMMUNOL, V155, P674; Bruce JL, 1999, CELL STRESS CHAPERON, V4, P36, DOI 10.1054/csac.1999.0005; Cahill CM, 1996, J BIOL CHEM, V271, P24874; Chen CM, 1997, J BIOL CHEM, V272, P26803, DOI 10.1074/jbc.272.43.26803; CHOLLETMARTIN S, 1993, AM REV RESPIR DIS, V164, P990; Chu BY, 1998, J BIOL CHEM, V273, P18640, DOI 10.1074/jbc.273.29.18640; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; Crawford EK, 1997, J BIOL CHEM, V272, P21120, DOI 10.1074/jbc.272.34.21120; CROSS A, 1995, J CLIN INVEST, V96, P676, DOI 10.1172/JCI118110; CROSS AS, 1989, CLIN EXP IMMUNOL, V76, P159; CROSS AS, 1989, J EXP MED, V169, P2021, DOI 10.1084/jem.169.6.2021; DROUET C, 1991, J IMMUNOL, V147, P1694; ENSOR JE, 1994, AM J PHYSIOL, V266, pC967, DOI 10.1152/ajpcell.1994.266.4.C967; ENSOR JE, 1995, AM J PHYSIOL-CELL PH, V269, pC1140, DOI 10.1152/ajpcell.1995.269.5.C1140; ESSNER R, 1989, J IMMUNOL, V142, P3857; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; GEIST LJ, 1994, J CLIN INVEST, V93, P474, DOI 10.1172/JCI116995; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; Jiang QQ, 1999, INFECT IMMUN, V67, P1539; JONGENEEL CV, 1989, EUR J IMMUNOL, V19, P549; JONGENEEL CV, 1995, IMMUNOBIOLOGY, V193, P210, DOI 10.1016/S0171-2985(11)80545-0; KUNKEL SL, 1988, J BIOL CHEM, V263, P5380; KUPRASH DV, 1995, ONCOGENE, V11, P97; LIEBERMAN AP, 1990, J EXP MED, V172, P989, DOI 10.1084/jem.172.3.989; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; Sambrook J., 2002, MOL CLONING LAB MANU; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARIBAN E, 1988, J CLIN INVEST, V81, P1506, DOI 10.1172/JCI113482; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; TAFFET SM, 1989, CELL IMMUNOL, V120, P291, DOI 10.1016/0008-8749(89)90198-6; ULICH TR, 1991, AM J PATHOL, V138, P1097; VELASCO S, 1991, J CLIN INVEST, V87, P1674, DOI 10.1172/JCI115184	43	105	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9841	9848		10.1074/jbc.275.13.9841	http://dx.doi.org/10.1074/jbc.275.13.9841			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734139	hybrid			2022-12-27	WOS:000086206500103
J	Cho, JH; Mok, KH; Olivera, BM; McIntosh, JM; Park, KH; Han, KH				Cho, JH; Mok, KH; Olivera, BM; McIntosh, JM; Park, KH; Han, KH			Nuclear magnetic resonance solution conformation of alpha-conotoxin AuIB, an alpha(3)beta(4) subtype-selective neuronal nicotinic acetylcholine receptor antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL SOLUTION STRUCTURE; 1.1 ANGSTROM RESOLUTION; SUBUNIT INTERFACES; CRYSTAL-STRUCTURE; MOLECULAR DISSECTION; CONUS-EPISCOPATUS; IDENTIFICATION; SPECTRA; BINDING; NMR	The neuronal nicotinic acetylcholine receptors constitute a highly diverse group, with subtypes consisting of pentameric combinations of alpha and beta subunits. alpha-Conotoxins are a homologous series of small peptides that antagonize these receptors, We present the three-dimensional solution structure of alpha-conotoxin AuIB, the first 15-residue alpha-conotoxin known to selectively block the alpha(3)beta(4) nicotinic acetylcholine receptor subtype. The pairwise backbone and heavy-atom root mean square deviation for an ensemble of 20 structures are 0.269 and 0.720 Angstrom respectively. The overall fold of alpha-conotoxin AuIB closely resembles that of the alpha 4/7 subfamily alpha-conotoxins. However, the absence of Tyr(15), normally present in other alpha 4/7 members, results in tight bending of the backbone at the C terminus and effectively renders Asp(14) to assume the spatial location of Tyr(15) present in other neuronal alpha 4/7 alpha-conotoxins. Structural comparison of alpha-conotoxin AuIB with the alpha(3)beta(2) Subtype-specific alpha-conotoxin MII shows different electrostatic surface charge distributions, which may be important in differential receptor subtype recognition.	Korea Res Inst Biosci & Biotechnol, Prot Engn Lab, Taejon 305600, South Korea; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Psychiat, Salt Lake City, UT 84112 USA	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Han, KH (corresponding author), Korea Res Inst Biosci & Biotechnol, Prot Engn Lab, Yusong POB 115, Taejon 305600, South Korea.	khhan@biotech5.kribb.re.kr	Mok, K. Hun/C-2607-2009	Mok, K Hun/0000-0003-3663-2002				BILLETER M, 1982, J MOL BIOL, V155, P321, DOI 10.1016/0022-2836(82)90008-0; BORGIAS BA, 1989, METHOD ENZYMOL, V176, P169; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; Chiara DC, 1997, J BIOL CHEM, V272, P32940, DOI 10.1074/jbc.272.52.32940; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; FAINZILBER M, 1994, BIOCHEMISTRY-US, V33, P9523, DOI 10.1021/bi00198a018; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GUNTERT P, 1992, J MAGN RESON, V96, P403, DOI 10.1016/0022-2364(92)90095-O; Han KH, 1997, BIOCHEMISTRY-US, V36, P1669, DOI 10.1021/bi962301k; Harvey SC, 1997, MOL PHARMACOL, V51, P336, DOI 10.1124/mol.51.2.336; HAVEL TF, 1991, PROG BIOPHYS MOL BIO, V56, P43, DOI 10.1016/0079-6107(91)90007-F; Hill JM, 1998, BIOCHEMISTRY-US, V37, P15621, DOI 10.1021/bi981535w; Hu SH, 1996, STRUCTURE, V4, P417, DOI 10.1016/S0969-2126(96)00047-0; Hu SH, 1997, BIOCHEMISTRY-US, V36, P11323, DOI 10.1021/bi9713052; Hu SH, 1998, BIOCHEMISTRY-US, V37, P11425, DOI 10.1021/bi9806549; Hucho F, 1996, EUR J BIOCHEM, V239, P539, DOI 10.1111/j.1432-1033.1996.0539u.x; JOHNSON DS, 1995, MOL PHARMACOL, V48, P194; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KEEPERS JW, 1984, J MAGN RESON, V57, P404, DOI 10.1016/0022-2364(84)90257-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lindstrom J, 1997, MOL NEUROBIOL, V15, P193, DOI 10.1007/BF02740634; Loughnan M, 1998, J BIOL CHEM, V273, P15667, DOI 10.1074/jbc.273.25.15667; LUETJE CW, 1991, J NEUROSCI, V11, P837; Luo SQ, 1998, J NEUROSCI, V18, P8571; Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744; MARTINEZ JS, 1995, BIOCHEMISTRY-US, V34, P14519, DOI 10.1021/bi00044a030; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; Mok KH, 1999, BIOCHEMISTRY-US, V38, P11895, DOI 10.1021/bi990558n; MUELLER L, 1987, J MAGN RESON, V72, P191, DOI 10.1016/0022-2364(87)90188-0; NICHOLSON D, 1991, CHARACTERIZATION POR, V2, P11; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; OLIVERA BM, 1995, TRENDS BIOTECHNOL, V13, P422, DOI 10.1016/S0167-7799(00)88996-9; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; Shon KJ, 1997, BIOCHEMISTRY-US, V36, P15693, DOI 10.1021/bi971443r; SINE SM, 1991, J BIOL CHEM, V266, P19369; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; Sugiyama N, 1998, MOL PHARMACOL, V53, P787, DOI 10.1124/mol.53.4.787; THOMAS PD, 1991, P NATL ACAD SCI USA, V88, P1237, DOI 10.1073/pnas.88.4.1237; WISHART DS, 1994, METHOD ENZYMOL, V239, P363	42	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8680	8685		10.1074/jbc.275.12.8680	http://dx.doi.org/10.1074/jbc.275.12.8680			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722709	hybrid			2022-12-27	WOS:000086507700059
J	Decker, P; Isenberg, D; Muller, S				Decker, P; Isenberg, D; Muller, S			Inhibition of caspase-3-mediated poly(ADP-ribose) polymerase (PARP) apoptotic cleavage by human PARP autoantibodies and effect on cells undergoing apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE; DNA STRAND BREAKS; ULCERATIVE-COLITIS; ANTIBODIES; EPITOPES; DOMAIN; REPAIR; ZINC; IDENTIFICATION	Autoantibodies directed to nuclear antigens are serological hallmarks of autoimmune rheumatic diseases such as systemic lupus erythematosus. Although much more is known about the molecular identity and functions of targeted self-antigens, with few exceptions, evidence that autoantibodies to these targets have a particular function and contribute directly to the pathological process is lacking, Here we show that human autoantibodies reacting with the zinc fingers of poly(ADP-ribose) polymerase involved in the recognition of damaged DNA totally prevent the cleavage of poly(ADP-ribose) polymerase by caspase-3, a process that normally occurs during early apoptosis, Furthermore, these antibodies, which are frequent in certain autoimmune rheumatic and bowel diseases, affect the characteristic features of apoptosis and increase cell survival er vivo. This new observation is important, because failure to remove autoimmune or abnormal cells can give rise to prolonged autoimmune stimulation and tumor formation.	Inst Biol Mol & Cellulaire, Unite Propre Rech 9021, CNRS, F-67084 Strasbourg, France; UCL, Dept Med, Bloomsbury Rheumatol Unit, Ctr Rheumatol, London W1P 9PG, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of London; University College London	Muller, S (corresponding author), Inst Biol Mol & Cellulaire, Unite Propre Rech 9021, CNRS, 15 Rue R Descartes, F-67084 Strasbourg, France.	S.Muller@ibmc.u-strasbg.fr	Decker, Patrice/AAD-8624-2022; Muller, Sylviane/J-5319-2014	Isenberg, David/0000-0001-9514-2455; Decker, Patrice/0000-0002-8155-2792				BHUSATE LL, 1992, ANN RHEUM DIS, V51, P8, DOI 10.1136/ard.51.1.8; CARMICHAEL J, 1987, CANCER RES, V47, P936; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; Decker P, 1998, ARTHRITIS RHEUM-US, V41, P918, DOI 10.1002/1529-0131(199805)41:5<918::AID-ART20>3.0.CO;2-W; Decker P, 1999, CLIN CANCER RES, V5, P1169; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Dumortier H, 1999, INT IMMUNOL, V11, P249, DOI 10.1093/intimm/11.2.249; GINER H, 1992, GENE, V114, P279, DOI 10.1016/0378-1119(92)90588-G; GOLAN TD, 1991, CLIN IMMUNOL IMMUNOP, V58, P289, DOI 10.1016/0090-1229(91)90143-X; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; HAUG BL, 1994, J RHEUMATOL, V21, P851; Herrmann M, 1998, ARTHRITIS RHEUM-US, V41, P1241, DOI 10.1002/1529-0131(199807)41:7<1241::AID-ART15>3.0.CO;2-H; Koscec M, 1997, J IMMUNOL, V159, P2033; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Madaio MP, 1999, SEMIN NEPHROL, V19, P48; Mazel JA, 1999, CIRCULATION, V99, P1914, DOI 10.1161/01.CIR.99.14.1914; MIURA H, 1994, CLIN IMMUNOL IMMUNOP, V73, P290, DOI 10.1006/clin.1994.1201; MULLER S, 1994, CLIN IMMUNOL IMMUNOP, V73, P187, DOI 10.1006/clin.1994.1187; MURCIA JM, 1997, P NATL ACAD SCI USA, V94, P7303; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Ravirajan CT, 1998, EUR J IMMUNOL, V28, P339, DOI 10.1002/(SICI)1521-4141(199801)28:01<339::AID-IMMU339>3.0.CO;2-C; REICHLIN M, 1994, ARTHRITIS RHEUM, V37, P1698, DOI 10.1002/art.1780371120; REUMAUX D, 1995, CLIN IMMUNOL IMMUNOP, V77, P349, DOI 10.1006/clin.1995.1162; Ricchiuti V, 1997, J AUTOIMMUN, V10, P181, DOI 10.1006/jaut.1996.0122; Rosen A, 1999, CELL DEATH DIFFER, V6, P6, DOI 10.1038/sj.cdd.4400460; ROSENSTEIN BS, 1992, J INVEST DERMATOL, V98, P469, DOI 10.1111/1523-1747.ep12499859; Sanford KK, 1997, CANCER DETECT PREV, V21, P540; SIBLEY JT, 1989, ARTHRITIS RHEUM, V32, P1045, DOI 10.1002/anr.1780320815; Suzuki N, 1997, FASEB J, V11, P1033, DOI 10.1096/fasebj.11.12.9337156; TAN EM, 1991, CELL, V67, P841, DOI 10.1016/0092-8674(91)90356-4; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Utz PJ, 1998, ARTHRITIS RHEUM, V41, P1152, DOI 10.1002/1529-0131(199807)41:7<1152::AID-ART3>3.0.CO;2-L; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WOLFF DJ, 1991, J RHEUMATOL, V18, P837; YAMANAKA H, 1989, J CLIN INVEST, V83, P180, DOI 10.1172/JCI113856; YAMANAKA H, 1987, J CLIN INVEST, V80, P900, DOI 10.1172/JCI113150	41	104	121	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					9043	9046		10.1074/jbc.275.12.9043	http://dx.doi.org/10.1074/jbc.275.12.9043			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722754	hybrid			2022-12-27	WOS:000086507700104
J	Gong, K; Mailloux, L; Herzberg, MC				Gong, K; Mailloux, L; Herzberg, MC			Salivary film expresses a complex, macromolecular binding site for Streptococcus sanguis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN-A COMPLEX; HYDROXYAPATITE; ADHESION; PROTEIN; PELLICLE; DISEASES; AMYLASE; TISSUES; MUTANS	Teeth in the oral cavity are coated with a salivary film or pellicle, which lacks apparent intermolecular organization. This heterogeneous sim facilitates binding of early commensal colonizing bacteria, including Streptococcus sanguis, To test the hypothesis that sufficient intermolecular organization exists in salivary films to form binding sites for S, sanguis, an in vitro model of saliva-coated teeth was probed with murine anti-idio-typical monoclonal antibodies (mAb2, anti-ids). The anti-ids were harvested from hybridomas that were developed in response to first generation murine hybridomas that produced anti-S, sanguis adhesin monoclonal antibodies (mAb1), The anti-ids (i) reacted with experimental salivary films and inhibited S, sanguis adhesion in a dose-dependent fashion, In Western blots, the anti-ids (ii) recognized a high molecular weight salivary antigen and (iii) secretory IgA (sIgA) light chain and cu-amylase. After isolation by gel filtration from whole saliva or mixed secretory IgA and cr-amylase, the high molecular weight component, containing amylase activity and sIgA, bound to hydroxyapatite to promote adhesion of S, sanguis. Therefore, a complex enriched in secretory immunoglobulin A and cu-amylase forms a S, sanguis-binding site.	Univ Minnesota, Sch Dent, Dept Prevent Sci, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Herzberg, MC (corresponding author), Univ Minnesota, Sch Dent, Dept Prevent Sci, Minneapolis, MN 55455 USA.				NIDCR NIH HHS [DE08590, DE05501] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE005501, R01DE008590] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AGUIRRE A, 1987, ARCH ORAL BIOL, V32, P297, DOI 10.1016/0003-9969(87)90024-0; ALHASHIMI I, 1989, ARCH ORAL BIOL, V34, P289, DOI 10.1016/0003-9969(89)90070-8; BIESBROCK AR, 1991, INFECT IMMUN, V59, P3492, DOI 10.1128/IAI.59.10.3492-3497.1991; Bowden GHW, 1998, CRIT REV ORAL BIOL M, V9, P54, DOI 10.1177/10454411980090010401; BUSSCHER HJ, 1992, FEMS MICROBIOL LETT, V88, P199, DOI 10.1111/j.1574-6968.1992.tb04988.x; Dalton HM, 1998, CURR OPIN BIOTECH, V9, P252, DOI 10.1016/S0958-1669(98)80055-4; Ellen R P, 1997, Adv Dent Res, V11, P33; GERSHONI JM, 1983, ANAL BIOCHEM, V131, P1, DOI 10.1016/0003-2697(83)90128-8; Gibbons RJ, 1996, J DENT RES, V75, P866, DOI 10.1177/00220345960750030201; GIBBONS RJ, 1989, J DENT RES, V68, P750, DOI 10.1177/00220345890680050101; GIBBONS RJ, 1983, INFECT IMMUN, V39, P280, DOI 10.1128/IAI.39.1.280-289.1983; GIBBONS RJ, 1980, BACTERIAL ADHERENC B, V6, P62; GIBBONS RJ, 1990, ARCH ORAL BIOL, V35, P107; Gong K, 1998, INFECT IMMUN, V66, P5388, DOI 10.1128/IAI.66.11.5388-5392.1998; Gong K, 1997, INFECT IMMUN, V65, P3815, DOI 10.1128/IAI.65.9.3815-3821.1997; GONG K, 1995, INFECT IMMUN, V63, P3628, DOI 10.1128/IAI.63.9.3628-3633.1995; Iontcheva I, 1997, J DENT RES, V76, P734, DOI 10.1177/00220345970760030501; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KISHIMOTO E, 1989, INFECT IMMUN, V57, P3702, DOI 10.1128/IAI.57.12.3702-3707.1989; Lamkin MS, 1996, J DENT RES, V75, P803, DOI 10.1177/00220345960750021101; Liljemark WF, 1996, CRIT REV ORAL BIOL M, V7, P180, DOI 10.1177/10454411960070020601; LILJEMARK WF, 1981, INFECT IMMUN, V31, P935, DOI 10.1128/IAI.31.3.935-941.1981; NESBITT WE, 1982, INFECT IMMUN, V35, P157, DOI 10.1128/IAI.35.1.157-165.1982; NISONOFF A, 1991, J IMMUNOL, V147, P2429; Oho T, 1998, INFECT IMMUN, V66, P115, DOI 10.1128/IAI.66.1.115-121.1998; Palmer RJ, 1997, TRENDS MICROBIOL, V5, P435, DOI 10.1016/S0966-842X(97)01142-6; REMALEY AT, 1989, CLIN CHEM, V35, P2261; TELLEFSON LM, 1986, INFECT IMMUN, V51, P750, DOI 10.1128/IAI.51.3.750-759.1986; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	29	37	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8970	8974		10.1074/jbc.275.12.8970	http://dx.doi.org/10.1074/jbc.275.12.8970			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722745	hybrid			2022-12-27	WOS:000086507700095
J	Hirst, J; Goodin, DB				Hirst, J; Goodin, DB			Unusual oxidative chemistry of N-omega-hydroxyarginine and N-hydroxyguanidine catalyzed at an engineered cavity in a heme peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; NITRIC-OXIDE SYNTHASE; HYDROXY-L-ARGININE; NITROGEN-OXIDES; AB-INITIO; CONTAINING OXYGENASES; RELAXING FACTOR; AMINO-ACIDS; MECHANISM; MUTANT	Heme enzymes are capable of catalyzing a range of oxidative chemistry with high specificity, depending on the surrounding protein environment. We describe here a reaction catalyzed by a mutant of cytochrome c peroxidase, which is similar but distinct from those catalyzed by nitric-oxide synthase, In the R48A mutant, an expanded water-filled cavity was created above the distal heme face. N-Hydroxyguanidine (NHG) but not guanidine was shown to bind in the cavity with K-d = 8.5 mM, and coordinate to the heme to give a low spin state. Reaction of R48A with peroxide produced a Fe(IV)=O/Trp(.+) center capable of oxidizing either NHG or N-omega-hydroxyarginine (NHA), but not arginine or guanidine, by a multi-turnover catalytic process. Oxidation of either NHG or NRA by R48A did not result in the accumulation of NO, NO2-, NO3-, urea, or citrulline, but instead afforded a yellow product with absorption maxima of 257 and 400 nm. Mass spectrometry of the derivatized NHA products identified the yellow species as N-nitrosoarginine, We suggest that a nitrosylating agent, possibly derived from HNO, is produced by the oxidation of one molecule of substrate. This then reacts with a second substrate molecule to form the observed N-nitroso products. This complex chemistry illustrates how the active sites of enzymes such as nitric-oxide synthase may serve to prevent alternative reactions from occurring, in addition to enabling those desired.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Goodin, DB (corresponding author), Scripps Res Inst, Dept Mol Biol, MB8,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dbg@scripps.edu	Hirst, Judy/F-4803-2011	Hirst, Judy/0000-0001-8667-6797	NIGMS NIH HHS [GM41049, R01 GM041049] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041049, R01GM041049, R37GM041049] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbuSoud HM, 1997, BIOCHEMISTRY-US, V36, P10811, DOI 10.1021/bi971414g; Andersen JF, 1997, BIOCHEMISTRY-US, V36, P4423, DOI 10.1021/bi9628883; ANNI H, 1992, MET IONS BIOL SYST, V28, P219; ATKINS WM, 1989, J AM CHEM SOC, V111, P2715, DOI 10.1021/ja00189a057; BAKER MD, 1981, ANAL CHEM, V53, P1658, DOI 10.1021/ac00234a025; BARRICK D, 1994, BIOCHEMISTRY-US, V33, P6546, DOI 10.1021/bi00187a023; BAZYLINSKI DA, 1985, J AM CHEM SOC, V107, P7982, DOI 10.1021/ja00312a031; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BOUCHER JL, 1992, BIOCHEM BIOPH RES CO, V184, P1158, DOI 10.1016/S0006-291X(05)80004-X; BRUICE TC, 1991, ACCOUNTS CHEM RES, V24, P243, DOI 10.1021/ar00008a004; Caminiti R, 1996, J PHYS CHEM-US, V100, P10928, DOI 10.1021/jp960311p; Clague MJ, 1997, BIOCHEMISTRY-US, V36, P14465, DOI 10.1021/bi971024u; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; DEMONTELLANO PRO, 1987, ACCOUNTS CHEM RES, V20, P289; DEMONTELLANO PRO, 1992, ANNU REV PHARMACOL, V32, P89, DOI 10.1146/annurev.pharmtox.32.1.89; DENBLAAUWEN T, 1991, J AM CHEM SOC, V113, P5050, DOI 10.1021/ja00013a046; DUNFORD HB, 1982, ADV INORG BIOCHEM, V4, P41; ERIKSSON AE, 1992, NATURE, V355, P371, DOI 10.1038/355371a0; Erman JE, 1998, J BIOCHEM MOL BIOL, V31, P307; Everett SA, 1998, FREE RADICAL BIO MED, V24, P1, DOI 10.1016/S0891-5849(97)00203-7; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FITZGERALD MM, 1994, BIOCHEMISTRY-US, V33, P3807, DOI 10.1021/bi00179a004; Fukuto JM, 1996, METHOD ENZYMOL, V268, P365; FUKUTO JM, 1992, BIOCHEM PHARMACOL, V43, P607, DOI 10.1016/0006-2952(92)90584-6; FUKUTO JM, 1993, J MED CHEM, V36, P2666, DOI 10.1021/jm00070a010; Glaser R, 1996, J ORG CHEM, V61, P1047, DOI 10.1021/jo950783k; GOODIN DB, 1993, BIOCHEMISTRY-US, V32, P3313, DOI 10.1021/bi00064a014; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GREENBERG SS, 1995, LIFE SCI, V57, P1949, DOI 10.1016/0024-3205(95)02181-H; GROVES JT, 1985, J CHEM EDUC, V62, P928, DOI 10.1021/ed062p928; HALPERT JR, 1993, J BIOL CHEM, V268, P4453; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Jousserandot A, 1998, BIOCHEMISTRY-US, V37, P17179, DOI 10.1021/bi981175c; KNEIP TJ, 1983, SCIENCE, V221, P1045, DOI 10.1126/science.6879203; MANSUY D, 1995, BIOCHIMIE, V77, P661, DOI 10.1016/0300-9084(96)88181-8; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MCREE DE, 1994, P NATL ACAD SCI USA, V91, P12847, DOI 10.1073/pnas.91.26.12847; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MILLER MA, 1990, BIOCHEMISTRY-US, V29, P9978, DOI 10.1021/bi00494a031; MILLER VP, 1992, J BIOL CHEM, V267, P8936; MOLNARPERL I, 1994, J CHROMATOGR A, V661, P43, DOI 10.1016/0021-9673(94)85175-1; Musah RA, 1997, BIOCHEMISTRY-US, V36, P11665, DOI 10.1021/bi9708038; Musah RA, 1997, J AM CHEM SOC, V119, P9083, DOI 10.1021/ja9716766; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ozaki S, 1997, J AM CHEM SOC, V119, P6666, DOI 10.1021/ja970453c; Ozaki S, 1996, J AM CHEM SOC, V118, P9784, DOI 10.1021/ja961223l; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; POULOS TL, 1992, FASEB J, V6, P674, DOI 10.1096/fasebj.6.2.1537455; POULOS TL, 1988, ADV INORG BIOCHEM, V7, P1; PUFAHL RA, 1993, BIOCHEM BIOPH RES CO, V193, P963, DOI 10.1006/bbrc.1993.1719; PUFAHL RA, 1995, BIOCHEMISTRY-US, V34, P1930, DOI 10.1021/bi00006a014; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; SAPSE AM, 1981, CANCER RES, V41, P1824; SENNEQUIER N, 1995, TETRAHEDRON LETT, V36, P6059, DOI 10.1016/0040-4039(95)01242-A; Sheldrick GM, 1997, METHOD ENZYMOL, V276, P628, DOI 10.1016/S0076-6879(97)76083-X; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; Southan GJ, 1998, NITRIC OXIDE-BIOL CH, V2, P270, DOI 10.1006/niox.1998.0187; STERN MK, 1992, MANGANESE REDOX ENZY, P233; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; TRAYLOR TG, 1982, OXIDASES RELATED RED, V3, P565; VITELLO LB, 1993, BIOCHEMISTRY-US, V32, P9807, DOI 10.1021/bi00088a036; WANG JL, 1993, J BIOL CHEM, V268, P22255; Wilcox SK, 1998, BIOCHEMISTRY-US, V37, P16853, DOI 10.1021/bi9815039; [No title captured]	69	32	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8582	8591		10.1074/jbc.275.12.8582	http://dx.doi.org/10.1074/jbc.275.12.8582			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722697	hybrid			2022-12-27	WOS:000086507700047
J	Taverna, F; Xiong, ZG; Brandes, L; Roder, JC; Salter, MW; MacDonald, JF				Taverna, F; Xiong, ZG; Brandes, L; Roder, JC; Salter, MW; MacDonald, JF			The Lurcher mutation of an alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor subunit enhances potency of glutamate and converts an antagonist to an agonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAINATE RECEPTORS; NMDA RECEPTORS; CHANNEL; DESENSITIZATION; AMPA; MICE; EXPRESSION; ACTIVATION; BINDING; FAMILY	A point mutation of the GluR delta 2 (A654T) glutamate receptor subunit converts it into a functional channel, and a spontaneous mutation at this site is thought to be responsible for the neurodegeneration of neurons in the Lurcher mouse. This mutation is located in a hydrophobic region of the M3 domain of this subunit, and this alanine is conserved throughout many of the glutamate receptors. We show here that site-directed mutagenesis of the homologous alanine (A636T; GluR1-L-c) in the GluR1 AMPA receptor subunit alters its channel properties. The apparent potencies of both kainate and glutamate were increased 85- and 2000-fold, respectively. Furthermore, 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX)was converted from a competitive antagonist into a potent agonist, Our results demonstrate that a single amino acid within or near the putative second transmembrane region of the GluR1 subunit is critical for the binding/gating properties of this AMPA receptor.	Hosp Sick Children, Dept Physiol, Toronto, ON, Canada; Hosp Sick Children, Program Brain & Behav, Toronto, ON, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	MacDonald, JF (corresponding author), Univ Toronto, Dept Physiol, Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Roder, John/G-6468-2013					BENVENISTE M, 1995, J PHYSIOL-LONDON, V483, P367, DOI 10.1113/jphysiol.1995.sp020591; BERTRAND D, 1992, P NATL ACAD SCI USA, V89, P1261, DOI 10.1073/pnas.89.4.1261; BETTLER B, 1995, NEUROPHARMACOLOGY, V34, P123, DOI 10.1016/0028-3908(94)00141-E; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; KASHIWABUCHI N, 1995, CELL, V81, P245, DOI 10.1016/0092-8674(95)90334-8; LEONARD JP, 1990, NEURON, V4, P53, DOI 10.1016/0896-6273(90)90443-J; Logan SM, 1999, J NEUROSCI, V19, P974; LOMELI H, 1993, FEBS LETT, V315, P318, DOI 10.1016/0014-5793(93)81186-4; Mainen ZF, 1998, NAT NEUROSCI, V1, P579, DOI 10.1038/2812; Mano I, 1996, J BIOL CHEM, V271, P15299, DOI 10.1074/jbc.271.26.15299; MISHINA M, 1993, ANN NY ACAD SCI, V707, P136, DOI 10.1111/j.1749-6632.1993.tb38049.x; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; SAH P, 1989, SCIENCE, V246, P815, DOI 10.1126/science.2573153; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; Stern-Bach Y, 1998, NEURON, V21, P907, DOI 10.1016/S0896-6273(00)80605-4; Swanson GT, 1997, NEURON, V19, P913, DOI 10.1016/S0896-6273(00)80972-1; Zuo J, 1997, NATURE, V388, P769, DOI 10.1038/42009	19	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8475	8479		10.1074/jbc.275.12.8475	http://dx.doi.org/10.1074/jbc.275.12.8475			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722683	hybrid			2022-12-27	WOS:000086507700033
J	Akama, KT; Van Eldik, LJ				Akama, KT; Van Eldik, LJ			beta-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1 beta- and tumor necrosis factor-alpha (TNF alpha)-dependent, and involves a TNF alpha receptor-associated factor- and NF kappa B-inducing kinase-dependent signaling mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ISCHEMIC BRAIN INJURY; NEURONAL CELL-DEATH; ALZHEIMERS-DISEASE; INTERFERON-GAMMA; MICROGLIAL CELLS; MESANGIAL CELLS; EXPRESSION; INDUCTION; CYTOKINES	In Alzheimer's disease, beta-amyloid (AP) plaques are surrounded by activated astrocytes and microglia, A growing body of evidence suggests that these activated glia contribute to neurotoxicity through the induction of inflammatory cytokines such as interleukin (IL)-1 beta and tumor necrosis factor-ac (TNF alpha) and the production of neurotoxic free radicals, mediated in part by the expression of inducible nitric-oxide synthase (iNOS). Here, we address the possibility that A beta-stimulated iNOS expression might result from an initial induction of IL-1 beta and TNF alpha. We find that in A beta-stimulated astrocyte cultures, IL-1 beta and TNF alpha production occur before iNOS production, new protein synthesis is required for increased iNOS mRNA levels, and the IL-I receptor antagonist IL-1 beta can inhibit nitrite accumulation. Likewise, dominant-negative mutants of tumor necrosis factor-alpha receptor-associated factor (TRAF) 6, TRAF2, and NF kappa B-inducing kinase (NIK), intracellular proteins involved in IL-I and TNF alpha! receptor signaling cascades, inhibit A beta-stimulated iNOS promoter activity. Our data suggest that A beta stimulation of astrocyte iNOS is mediated in part by IL-1 beta and TNF alpha, and involves a TRAFG-, TRAF2-, and NIK-dependent signaling mechanism.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Northwestern Drug Discovery Program, Chicago, IL 60611 USA	Northwestern University; Northwestern University	Van Eldik, LJ (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Ward 4-202,303 E Chicago Ave, Chicago, IL 60611 USA.	vaneldik@nwu.edu			NATIONAL INSTITUTE ON AGING [R01AG013939, P01AG015501, R37AG013939] Funding Source: NIH RePORTER; NIA NIH HHS [AG13939, AG15501] Funding Source: Medline; NIGMS NIH HHS [GM08061] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akama KT, 1998, P NATL ACAD SCI USA, V95, P5795, DOI 10.1073/pnas.95.10.5795; ARAUJO DM, 1992, BRAIN RES, V569, P141, DOI 10.1016/0006-8993(92)90380-R; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Aschner M, 1999, ANNU REV PHARMACOL, V39, P151, DOI 10.1146/annurev.pharmtox.39.1.151; Awane M, 1999, J IMMUNOL, V162, P5337; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Baldassare JJ, 1999, J IMMUNOL, V162, P5367; Blom MAA, 1997, BRAIN RES, V777, P210, DOI 10.1016/S0006-8993(97)01204-3; Brosnan CF, 1997, BIOCHEM SOC T, V25, P679, DOI 10.1042/bst0250679; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Casado M, 1997, BIOCHEM J, V327, P819, DOI 10.1042/bj3270819; CHAO CC, 1994, MOL CHEM NEUROPATHOL, V23, P159, DOI 10.1007/BF02815409; Chao CC, 1996, J NEUROVIROL, V2, P234, DOI 10.3109/13550289609146886; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; Chao Chun C., 1998, Alzheimer's Disease Review, V3, P87; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; Eberhardt W, 1998, J IMMUNOL, V160, P4961; Fiebich B L, 1998, J Neural Transm Suppl, V54, P268; FORSTERMANN U, 1995, N-S ARCH PHARMACOL, V352, P351; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Geller DA, 1998, CANCER METAST REV, V17, P7, DOI 10.1023/A:1005940202801; GRIFFIN WST, 1993, ALTSCHUL SY, V2, P359; Griffin WST, 1998, BRAIN PATHOL, V8, P65; Hensley K, 1999, J NEUROCHEM, V72, P2053, DOI 10.1046/j.1471-4159.1999.0722053.x; Hu JG, 1998, BRAIN RES, V785, P195, DOI 10.1016/S0006-8993(97)01318-8; Hu JR, 1997, J NEUROCHEM, V69, P2294; Iadecola C, 1997, J NEUROSCI, V17, P9157; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Jobin C, 1999, J IMMUNOL, V162, P4447; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Koppal T, 1999, J NEUROCHEM, V72, P310, DOI 10.1046/j.1471-4159.1999.0720310.x; KUNZ D, 1994, P NATL ACAD SCI USA, V91, P5387, DOI 10.1073/pnas.91.12.5387; LEE SC, 1993, J NEUROIMMUNOL, V46, P19, DOI 10.1016/0165-5728(93)90229-R; Lee Sunhee C., 1996, Methods (Orlando), V10, P31, DOI 10.1006/meth.1996.0075; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Liu J, 1996, J IMMUNOL, V157, P3569; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; McDonald DR, 1998, J NEUROSCI, V18, P4451; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MRAK RE, 1995, HUM PATHOL, V26, P816, DOI 10.1016/0046-8177(95)90001-2; Murphy GM, 1998, J BIOL CHEM, V273, P20967, DOI 10.1074/jbc.273.33.20967; Murphy MP, 1998, GEN PHARMACOL, V31, P179, DOI 10.1016/S0306-3623(97)00418-7; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; ODA T, 1995, EXP NEUROL, V136, P22, DOI 10.1006/exnr.1995.1080; Pasinetti GM, 1996, NEUROBIOL AGING, V17, P707, DOI 10.1016/0197-4580(96)00113-3; Petrova TV, 1999, P NATL ACAD SCI USA, V96, P4668, DOI 10.1073/pnas.96.8.4668; Rossi F, 1996, BIOCHEM BIOPH RES CO, V225, P474, DOI 10.1006/bbrc.1996.1197; Schielke GP, 1998, J CEREBR BLOOD F MET, V18, P180, DOI 10.1097/00004647-199802000-00009; SHENG JG, 1995, NEUROPATH APPL NEURO, V21, P290, DOI 10.1111/j.1365-2990.1995.tb01063.x; Sheng JG, 1998, NEUROPATH APPL NEURO, V24, P278; Smith MA, 1997, J NEUROSCI, V17, P2653; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Terai K, 1996, BRAIN RES, V739, P343, DOI 10.1016/S0006-8993(96)01073-6; Wallace MN, 1997, EXP NEUROL, V144, P266, DOI 10.1006/exnr.1996.6373; Weldon DT, 1997, GERIATRICS, V52, pS13; Yang GY, 1997, BRAIN RES, V751, P181, DOI 10.1016/S0006-8993(96)01277-2; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	60	295	312	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7918	7924		10.1074/jbc.275.11.7918	http://dx.doi.org/10.1074/jbc.275.11.7918			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713108	hybrid			2022-12-27	WOS:000085913300068
J	Chanchevalap, S; Yang, ZJ; Cui, NG; Qu, ZQ; Zhu, GY; Liu, CX; Giwa, LR; Abdulkadir, L; Jiang, C				Chanchevalap, S; Yang, ZJ; Cui, NG; Qu, ZQ; Zhu, GY; Liu, CX; Giwa, LR; Abdulkadir, L; Jiang, C			Involvement of histidine residues in proton sensing of ROMK1 channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNELS; K(IR)1.1 CHANNELS; INTRACELLULAR PH; K+ CHANNEL; EXPRESSION; NEURONS	ROMK channels are inhibited by intracellular acidification, This pH sensitivity is related to several amino acid residues in the channel proteins such as Lys-61, Thr-51, and His-206 (in ROMK2), Unlike all other amino acids, histidine is titratable at pH 6-7 carrying a positive charge below pH 6, To test the hypothesis that certain histidine residues are engaged in CO2 and pH sensing of ROMK1, we performed experiments by systematic mutations of all histidine residues in the channel using the site-directed mutagenesis, There are two histidine residues in the N terminus. Mutations of His-23, His-31, or both together did not affect channel sensitivity to CO2. Six histidine residues are located in the C terminus. His-225, His-274, His-342, and His-354 were critical in CO2 and pH sensing. Mutation of either of them reduced CO2 and pH sensitivities by 20-50% and similar to 0.2 pH units, respectively. Simultaneous mutations of all of them eliminated the CO2 sensitivity and caused this mutant channel to respond to only extremely acidic pH, Similar mutations of His-280 had no effect. The role of His-270 in CO2 and pH sensing is unclear, because substitutions of this residue with either a neutral, negative, or positive amino acid did not produce any fumctional channel. These results therefore indicate that histidine residues contribute to the sensitivity of the ROMK1 channel to hypercapnia and intracellular acidosis.	Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA	University System of Georgia; Georgia State University	Jiang, C (corresponding author), Georgia State Univ, Dept Biol, 24 Peachtree Cent Ave, Atlanta, GA 30303 USA.			Yang, Zhenjiang/0000-0002-9315-154X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058410] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL058410, HL58410-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baukrowitz T, 1999, EMBO J, V18, P847, DOI 10.1093/emboj/18.4.847; Buckley JT, 1995, BIOCHEMISTRY-US, V34, P16450, DOI 10.1021/bi00050a028; Choe H, 1997, AM J PHYSIOL-RENAL, V273, pF516, DOI 10.1152/ajprenal.1997.273.4.F516; Doi T, 1996, J BIOL CHEM, V271, P17261, DOI 10.1074/jbc.271.29.17261; EK JF, 1994, CIRC RES, V74, P1058, DOI 10.1161/01.RES.74.6.1058; Fakler B, 1996, EMBO J, V15, P4093, DOI 10.1002/j.1460-2075.1996.tb00784.x; Hebert SC, 1997, WIEN KLIN WOCHENSCHR, V109, P471; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Hoth S, 1997, P NATL ACAD SCI USA, V94, P4806, DOI 10.1073/pnas.94.9.4806; JIANG C, 1994, J NEUROSCI, V14, P5590; JIANG C, 1992, J PHYSIOL-LONDON, V448, P697, DOI 10.1113/jphysiol.1992.sp019065; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; McNicholas CM, 1998, AM J PHYSIOL-RENAL, V275, pF972, DOI 10.1152/ajprenal.1998.275.6.F972; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; Qu ZQ, 1999, J BIOL CHEM, V274, P13783, DOI 10.1074/jbc.274.20.13783; SCHLATTER E, 1994, PFLUG ARCH EUR J PHY, V428, P631, DOI 10.1007/BF00374587; Schulte U, 1998, J BIOL CHEM, V273, P34575, DOI 10.1074/jbc.273.51.34575; TODT JC, 1992, BIOCHEMISTRY-US, V31, P10479, DOI 10.1021/bi00158a010; TSAI TD, 1995, AM J PHYSIOL-CELL PH, V268, pC1173, DOI 10.1152/ajpcell.1995.268.5.C1173; WANG TL, 1995, J NEUROSCI, V15, P7684; WANG WH, 1990, AM J PHYSIOL, V259, pF494, DOI 10.1152/ajprenal.1990.259.3.F494; Wang WH, 1997, ANNU REV PHYSIOL, V59, P413, DOI 10.1146/annurev.physiol.59.1.413; ZHOU H, 1994, AM J PHYSIOL, V266, pC809, DOI 10.1152/ajpcell.1994.266.3.C809; ZHOU XM, 1994, AM J PHYSIOL, V267, pF114, DOI 10.1152/ajprenal.1994.267.1.F114; Zhu GY, 1999, J BIOL CHEM, V274, P11643, DOI 10.1074/jbc.274.17.11643; Zhu GY, 1999, J PHYSIOL-LONDON, V516, P699, DOI 10.1111/j.1469-7793.1999.0699u.x	27	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7811	7817		10.1074/jbc.275.11.7811	http://dx.doi.org/10.1074/jbc.275.11.7811			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713095	hybrid			2022-12-27	WOS:000085913300055
J	Deng, LY; Kasper, DL; Krick, TP; Wessels, MR				Deng, LY; Kasper, DL; Krick, TP; Wessels, MR			Characterization of the linkage between the type III capsular polysaccharide and the bacterial cell wall of group B Streptococcus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESOLUTION NMR-SPECTROSCOPY; IMMUNOCHEMICAL CHARACTERIZATION; STRUCTURAL DETERMINATION; MICROCOCCUS-LUTEUS; CONJUGATE VACCINE; COVALENT LINKAGE; PEPTIDOGLYCAN; EXPRESSION; ANTIGEN; ARABINOGALACTAN	The capsular polysaccharide of group B Streptococcus is a key virulence factor and an important target for protective immune responses. Until now, the nature of the attachment between the capsular polysaccharide and the bacterial cell has been poorly defined. We isolated insoluble cell wall fragments from lysates of type III group B Streptococcus and showed that the complexes contained both capsular polysaccharide and group B carbohydrate covalently bound to peptidoglycan. Treatment with the endo-N-acetylmuramidase mutanolysin released soluble complexes of capsular polysaccharide linked to group B carbohydrate by peptidoglycan fragments. Capsular polysaccharide could be enzymatically cleaved from group B carbohydrate by treatment of the soluble complexes with beta-N-acetylglucosaminidase, which catalyzes hydrolysis of the beta-n-GlcNAc(1-->4)beta-D-MurNAc subunit produced by mutanolysin digestion of peptidoglycan. Evidence from gas chromatography/mass spectrometry and (31)p NMR analysis of the separated polysaccharides supports a model of the group B Streptococcus cell surface in which the group B carbohydrate and the capsular polysaccharide are independently linked to the glycan backbone of cell wall peptidoglycan; group B carbohydrate is linked to N-acetylmuramic acid, and capsular polysaccharide is linked via a phosphodiester bond and an oligosaccharide linker to N-acetylglucosamine.	Channing Lab, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Infect Dis, Boston, MA 02115 USA; Univ Minnesota, Dept Biochem, St Paul, MN 55108 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Minnesota System; University of Minnesota Twin Cities	Wessels, MR (corresponding author), Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.			Deng, Lingyi Lynn/0000-0002-1906-8457	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042940, R01AI028040, N01AI025152, R21AI042940] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28040, AI25152, AI42940] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKER CJ, 1974, JAMA-J AM MED ASSOC, V230, P1158, DOI 10.1001/jama.230.8.1158; DAFFE M, 1990, J BIOL CHEM, V265, P6734; DECUENINCK BJ, 1982, INFECT IMMUN, V35, P572, DOI 10.1128/IAI.35.2.572-581.1982; DENG LY, 1995, ANTIMICROB AGENTS CH, V39, P694, DOI 10.1128/AAC.39.3.694; DIFABIO JL, 1989, CAN J CHEM, V67, P877; DILLON HC, 1987, J PEDIATR-US, V110, P31, DOI 10.1016/S0022-3476(87)80283-4; GASSNER GT, 1990, J BACTERIOL, V172, P2273, DOI 10.1128/jb.172.5.2273-2279.1990; GORENSTEIN DG, 1975, BIOCHEM BIOPH RES CO, V65, P1073, DOI 10.1016/S0006-291X(75)80495-5; GOTSCHLICH EC, 1981, J BIOL CHEM, V256, P8915; HAKANSSON S, 1990, J INFECT DIS, V161, P741, DOI 10.1093/infdis/161.4.741; Harrison LH, 1998, J INFECT DIS, V177, P998, DOI 10.1086/515260; JENNINGS HJ, 1983, J BIOL CHEM, V258, P1793; JENNINGS HJ, 1983, BIOCHEMISTRY-US, V22, P1258, DOI 10.1021/bi00274a042; KARAKAWA WW, 1985, J CLIN MICROBIOL, V22, P445, DOI 10.1128/JCM.22.3.445-447.1985; KOGAN G, 1994, J CARBOHYD CHEM, V13, P1071, DOI 10.1080/07328309408011849; KOGAN G, 1995, CARBOHYD RES, V277, P1, DOI 10.1016/0008-6215(95)00195-Y; Kogan G, 1996, J BIOL CHEM, V271, P8786, DOI 10.1074/jbc.271.15.8786; KUO JSC, 1985, J BACTERIOL, V163, P769, DOI 10.1128/JB.163.2.769-773.1985; KUYPERS JM, 1989, INFECT IMMUN, V57, P3058, DOI 10.1128/IAI.57.10.3058-3065.1989; MARQUES MB, 1992, INFECT IMMUN, V60, P3986, DOI 10.1128/IAI.60.10.3986-3993.1992; MARQUES MB, 1994, INFECT IMMUN, V62, P1593, DOI 10.1128/IAI.62.5.1593-1599.1994; MCNEIL M, 1990, J BIOL CHEM, V265, P18200; MICHON F, 1987, BIOCHEMISTRY-US, V26, P476, DOI 10.1021/bi00376a020; MICHON F, 1988, BIOCHEMISTRY-US, V27, P5341, DOI 10.1021/bi00414a059; MICHON F, 1991, INFECT IMMUN, V59, P1690, DOI 10.1128/IAI.59.5.1690-1696.1991; MUNSON RS, 1981, BIOL CARBOHYDRATES, V1, P91; PAOLETTI LC, 1990, J BIOL CHEM, V265, P18278; RUBENS CE, 1987, P NATL ACAD SCI USA, V84, P7208, DOI 10.1073/pnas.84.20.7208; RUBENS CE, 1993, MOL MICROBIOL, V8, P843, DOI 10.1111/j.1365-2958.1993.tb01631.x; SORENSEN UBS, 1990, MICROB PATHOGENESIS, V8, P325, DOI 10.1016/0882-4010(90)90091-4; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; WESSELS MR, 1989, INFECT IMMUN, V57, P1089, DOI 10.1128/IAI.57.4.1089-1094.1989; WESSELS MR, 1991, J BIOL CHEM, V266, P6714; WESSELS MR, 1987, J BIOL CHEM, V262, P8262; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; WOLTERS PJ, 1990, J BACTERIOL, V172, P5154, DOI 10.1128/jb.172.9.5154-5159.1990; YEUNG MK, 1986, CURR MICROBIOL, V14, P205, DOI 10.1007/BF01568519; YOKOGAWA K, 1974, ANTIMICROB AGENTS CH, V6, P156, DOI 10.1128/AAC.6.2.156	38	61	69	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7497	7504		10.1074/jbc.275.11.7497	http://dx.doi.org/10.1074/jbc.275.11.7497			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713053	hybrid			2022-12-27	WOS:000085913300013
J	Kim, YN; Wiepz, GJ; Guadarrama, AG; Bertics, PJ				Kim, YN; Wiepz, GJ; Guadarrama, AG; Bertics, PJ			Epidermal growth factor-stimulated tyrosine phosphorylation of caveolin-1 - Enhanced caveolin-1 tyrosine phosphorylation following aberrant epidermal, growth factor receptor status	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOGENICALLY TRANSFORMED-CELLS; LIGAND-INDUCED INTERNALIZATION; ROUS-SARCOMA VIRUS; EGF RECEPTOR; KINASE-ACTIVITY; SELF-PHOSPHORYLATION; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; PROTO-ONCOGENE; ACTIVATION	Caveolin-1 is the major coat protein of caveolae and has been reported to interact with various intracellular signaling molecules including the epidermal growth factor (EGF) receptor. To investigate the involvement of caveolin-1 in EGF receptor action, we used mouse B82L fibroblasts transfected with (a) wild type EGF receptor, (b) a C-terminally truncated EGF receptor at residue 1022, (c) a C-terminally truncated EGF receptor at residue 973, or (d) a kinase-inactive EGF receptor (R721M). Following EGF treatment, there was a distinct electrophoretic mobility shift of the caveolin-1 present in cells expressing the truncated forms of the EGF receptor, but this shift was not detectable in cells bearing either normal levels of the wild type EGF receptor or a kinase-inactive receptor. This mobility shift wins also not observed following the addition of other cell stimuli, such as platelet-derived growth factor, insulin, basic fibroblast growth factor, or phorbol 12-myristate 13-acetate, Analysis of caveolin-1 immunoprecipitates from EGF-stimulated or nonstimulated cells demonstrated that the EGF-induced mobility shift of caveolin-1 was associated with its tyrosine phosphorylation in cells expressing truncated EGF receptors, Maximal caveolin-1 phosphorylation was achieved within 5 min after exposure to 10 nm EGF and remained elevated for at least 2 h. Additionally, several distinct phosphotyrosine-containing proteins (60, 45, 29, 24, and 20 kDa) were co-immunoprecipitated with caveolin-1 in an EGF-dependent Manner. Furthermore, the Src family kinase inhibitor, PP1, does not affect autophosphorylation of the receptor, but it does inhibit the EGF-induced mobility shift and phosphorylation of caveolin-1. Conversely, the MEK inhibitors PD98059 and UO126 could attenuate EGF-induced mitogen-activated protein kinase activation, they do not affect the EGF-induced mobility shift of caveolin-1. Because truncation and overexpression of the EGF receptor have been linked to cell transformation, these results provide the first evidence that the tyrosine phosphorylation of caveolin-1 occurs via an EGF-sensitive signaling pathway that can be potentiated by an aberrant activity or expression of various forms of the EGF receptor.	Univ Wisconsin, Dept Biomol Chem & Endocrinol, Madison, WI 53706 USA; Univ Wisconsin, Reprod Physiol Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Bertics, PJ (corresponding author), Univ Wisconsin, Dept Biomol Chem & Endocrinol, 1300 Univ Ave, Madison, WI 53706 USA.				NIGMS NIH HHS [R01 GM53271] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053271] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bates ME, 1998, AM J RESP CELL MOL, V18, P75, DOI 10.1165/ajrcmb.18.1.2766; Benlimame N, 1998, MOL BIOL CELL, V9, P1773, DOI 10.1091/mbc.9.7.1773; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BERTICS PJ, 1988, J BIOL CHEM, V263, P3610; BERTICS PJ, 1991, 73 ANN M WASH DC JUN, P487; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; DICKSON RB, 1993, ADV EXP MED BIOL, V330, P119; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Galbiati F, 1998, P NATL ACAD SCI USA, V95, P10257, DOI 10.1073/pnas.95.17.10257; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Gill G N, 1988, Adv Exp Med Biol, V234, P91; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GRONOWSKI AM, 1993, ENDOCRINOLOGY, V133, P2838, DOI 10.1210/en.133.6.2838; GRONOWSKI AM, 1995, ENDOCRINOLOGY, V136, P2198, DOI 10.1210/en.136.5.2198; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; Hsuan JJ, 1997, INT J BIOCHEM CELL B, V29, P415, DOI 10.1016/S1357-2725(96)00163-X; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; Ko YG, 1998, J CELL BIOCHEM, V71, P524, DOI 10.1002/(SICI)1097-4644(19981215)71:4<524::AID-JCB7>3.3.CO;2-2; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Li J, 1999, J BIOL CHEM, V274, P11209, DOI 10.1074/jbc.274.16.11209; Li SW, 1996, J BIOL CHEM, V271, P3863; LI X, 1997, THESIS U WISCONSIN M; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; MAIHLE N J, 1988, Biochimica et Biophysica Acta, V948, P287; Mastick CC, 1997, J BIOL CHEM, V272, P20706, DOI 10.1074/jbc.272.33.20706; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Nomura R, 1999, MOL BIOL CELL, V10, P975, DOI 10.1091/mbc.10.4.975; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Sasaoka T, 1996, J BIOL CHEM, V271, P20082, DOI 10.1074/jbc.271.33.20082; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONSEN CC, 1983, P NATL ACAD SCI USA, V80, P2485; Tiruppathi C, 1997, J BIOL CHEM, V272, P25968, DOI 10.1074/jbc.272.41.25968; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; Vepa S, 1997, FREE RADICAL BIO MED, V22, P25, DOI 10.1016/S0891-5849(96)00241-9; WALTON GM, 1990, J BIOL CHEM, V265, P1750; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wells A, 1998, MICROSC RES TECHNIQ, V43, P395, DOI 10.1002/(SICI)1097-0029(19981201)43:5<395::AID-JEMT6>3.0.CO;2-T; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Xie H, 1998, J CELL SCI, V111, P615	73	82	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7481	7491		10.1074/jbc.275.11.7481	http://dx.doi.org/10.1074/jbc.275.11.7481			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713051	hybrid			2022-12-27	WOS:000085913300011
J	Sugawara, M; Nakanishi, T; Fei, YJ; Huang, W; Ganapathy, ME; Leibach, FH; Ganapathy, V				Sugawara, M; Nakanishi, T; Fei, YJ; Huang, W; Ganapathy, ME; Leibach, FH; Ganapathy, V			Cloning of an amino acid transporter with functional characteristics and tissue expression pattern identical to that of system A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-BIOLOGY; OOCYTES; CELLS; GENE	We report here on the cloning and functional characterization of the protein responsible for the system A amino acid transport activity that is known to be expressed in most mammalian tissues. This transporter, designated ATA2 for amino acid transporter A2, was cloned from rat skeletal muscle. It is distinct from the neuron-specific glutamine transporter (GlnT/ATA1). Rat ATA2 consists of 504 amino acids and bears significant homology to GlnT/ATA1 and system N (SN1). ATA2-specific mRNA is ubiquitously expressed in rat tissues. When expressed in mammalian cells, ATA2 mediates Na+ - dependent transport of alpha-(methylamino)isobutyric acid, a specific model substrate for system A. The transporter is specific for neutral amino acids. It is pH-sensitive and Li+-intolerant. The Na+:amino acid stoichiometry is 1:1. When expressed in Xenopus laevis oocytes, transport of neutral amino acids via ATA2 is associated with inward currents. The substrate-induced current is Naf-dependent and ps-sensitive. The amino acid transport system A is particularly known for its adaptive and hormonal regulation, and therefore the successful cloning of the protein responsible for this transport activity represents a significant step toward understanding the function and expression of this transporter in various physiological and pathological states.	Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Med, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Ganapathy, V (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.	vganapat@mail.mcg.edu	Sugawara, Mitsuru/A-5274-2012; Nakanishi, Takeo/C-3891-2015	Sugawara, Mitsuru/0000-0001-5350-2950; Nakanishi, Takeo/0000-0002-6561-7138	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010045] Funding Source: NIH RePORTER; NICHD NIH HHS [HD33347] Funding Source: Medline; NIDA NIH HHS [DA10045] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BERTRAN J, 1991, J BIOL CHEM, V266, P798; Chaudhry FA, 1999, CELL, V99, P769, DOI 10.1016/S0092-8674(00)81674-8; CHRISTENSEN HN, 1985, J MEMBRANE BIOL, V84, P97, DOI 10.1007/BF01872207; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CHRISTENSEN HN, 1965, J BIOL CHEM, V240, P3609; CHRISTENSEN HN, 1989, METHOD ENZYMOL, V173, P576; Fei YJ, 2000, J BIOL CHEM, V275, P9563, DOI 10.1074/jbc.275.13.9563; Ganapathy ME, 1997, BBA-BIOMEMBRANES, V1324, P296, DOI 10.1016/S0005-2736(96)00234-9; GANAPATHY V, 1999, TXB GASTROENTEROLOGY, P456; HAUSSINGER D, 1992, MAMMALIAN AMINO ACID TRANSPORT, P113; KILBERG MS, 1986, FED PROC, V45, P2438; Mackenzie B, 1996, J BIOL CHEM, V271, P5430, DOI 10.1074/jbc.271.10.5430; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; MUNOZ P, 1992, J BIOL CHEM, V267, P10381; OXENDER DL, 1963, J BIOL CHEM, V238, P3686; PALACIN M, 1990, BIOCHEM J, V270, P189, DOI 10.1042/bj2700189; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Rajan DP, 1999, J BIOL CHEM, V274, P29005, DOI 10.1074/jbc.274.41.29005; SHOTWELL MA, 1983, BIOCHIM BIOPHYS ACTA, V737, P267, DOI 10.1016/0304-4157(83)90003-5; TARNUZZER RW, 1990, J BIOL CHEM, V265, P13914; Varoqui H, 2000, J BIOL CHEM, V275, P4049, DOI 10.1074/jbc.275.6.4049; Wang HP, 1999, J BIOL CHEM, V274, P14875, DOI 10.1074/jbc.274.21.14875; Wu X, 1998, J BIOL CHEM, V273, P32776, DOI 10.1074/jbc.273.49.32776; Wu X, 1999, J PHARMACOL EXP THER, V290, P1482	24	220	230	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16473	16477		10.1074/jbc.C000205200	http://dx.doi.org/10.1074/jbc.C000205200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10747860	hybrid			2022-12-27	WOS:000087392200012
J	De Sepulveda, P; Ilangumaran, S; Rottapel, R				De Sepulveda, P; Ilangumaran, S; Rottapel, R			Suppressor of cytokine signaling-1 inhibits VAV function through protein degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOCS-BOX MOTIF; BINDING-PROTEIN; LIGASE; ACTIVATION; COMPLEX; DOMAIN; INVOLVEMENT; RECEPTOR; FAMILY; CBL	Suppressor of cytokine signaling-1 (SOCS1) is an inducible Src homology 2 (SH2)-containing protein that negatively regulates cytokine and growth factor signaling required during thymic development. Recent evidence indicates that SOCS1 interacts with elongins B and C, which are components of a ubiquitin ligase complex, VCB (VHL/elonginC/B), based on the VHL (von Hippel Lindau) tumor suppressor protein. SOCS1 has previously been shown to operate as an inhibitor of Janus kinases. Here we show that SOCS1 has the distinct function of targeting the hematopoietic specific guanine nucleotide exchange factor, VAV, for ubiquitin-mediated protein degradation. VAV and SOCS1 form a protein complex through interactions between the VAV NH,terminal regulatory region and the SH2 domain of SOCS1 in a phosphotyrosine-independent manner. SOCS1 decreases the steady state levels of cotransfected VAV and onco-VAV and reduces the focus forming activity of onco-VAV. SOCS1 stimulates the polyubiquitination of VAV proteins in vivo, which was stabilized by proteasomal inhibitors. These results suggest that SOCS1 programs VAV degradation by acting as a substrate-specific recognition component of a VCB-like ubiquitin ligase complex.	Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Immunol & Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto	Rottapel, R (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	Rottapel@oci.utoronto.ca	De sepulveda, paulo/K-6043-2015	De sepulveda, paulo/0000-0001-8295-5414; Ilangumaran, Subburaj/0000-0002-7563-576X; Rottapel, Robert/0000-0002-6024-5558				Abe R, 1999, J BIOL CHEM, V274, P30410, DOI 10.1074/jbc.274.43.30410; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; De Sepulveda P, 1999, EMBO J, V18, P904; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Germani A, 1999, MOL CELL BIOL, V19, P3798; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	32	147	147	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2000	275	19					14005	14008		10.1074/jbc.C000106200	http://dx.doi.org/10.1074/jbc.C000106200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313NZ	10747851	hybrid			2022-12-27	WOS:000087006900001
J	Kilani, AF; Trang, P; Jo, S; Hsu, A; Kim, J; Nepomuceno, E; Liou, K; Liu, FY				Kilani, AF; Trang, P; Jo, S; Hsu, A; Kim, J; Nepomuceno, E; Liou, K; Liu, FY			RNase P ribozymes selected in vitro to cleave a viral mRNA effectively inhibit its expression in cell culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEASE-P; HAMMERHEAD RIBOZYME; ESCHERICHIA-COLI; HAIRPIN RIBOZYME; THERAPEUTIC AGENTS; INVITRO SELECTION; SUBSTRATE BINDING; GENE-EXPRESSION; CATALYTIC RNA; ENZYME	An in vitro selection procedure was used to select RNase P ribozyme variants that efficiently cleaved the sequence of the mRNA encoding thymidine kinase of herpes simplex virus 1. Of the 45 selected variants sequenced, 25 ribozymes carried a common mutation at nucleotides 224 and 225 of RNase P catalytic RNA from Escherichia coli (G(224)G(225) --> AA). These selected ribozymes exhibited at least 10 times higher cleavage efficiency (k(cat)/K-m) than that derived from the wild type ribozyme. Our results suggest that the mutated A(224)A(225) are in close proximity to the substrate and enhance substrate binding of the ribozyme. When these ribozyme variants were expressed in herpes simplex virus 1-infected cells, the levels of thymidine kinase mRNA and protein were reduced by 95-99%. Our study provides the first direct evidence that RNase P ribozyme variants isolated by the selection procedure can be used for the construction of gene-targeting ribozymes that are highly effective in tissue culture. These results demonstrate the potential for using RNase P ribozymes as gene-targeting agents against any mRNA sequences, and using the selection procedure as a general approach for the engineering of RNase P ribozymes.	Univ Calif Berkeley, Sch Publ Hlth, Program Infect Dis & Immun, Program Comparat Biochem, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Liu, FY (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Program Infect Dis & Immun, Program Comparat Biochem, 140 Warren Hall, Berkeley, CA 94720 USA.	liu_fy@uclink4.berkeley.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041927] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41927] Funding Source: Medline; NIGMS NIH HHS [GM54875] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altman S., 1999, RNA WORLD, P351; Bertrand E, 1997, RNA, V3, P75; BERTRAND EL, 1994, EMBO J, V13, P2904, DOI 10.1002/j.1460-2075.1994.tb06585.x; BERZALHERRANZ A, 1992, GENE DEV, V6, P129, DOI 10.1101/gad.6.1.129; BURKE JM, 1993, FASEB J, V7, P106, DOI 10.1096/fasebj.7.1.8422956; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Castanotto D, 1994, Adv Pharmacol, V25, P289, DOI 10.1016/S1054-3589(08)60435-4; Chen JL, 1998, EMBO J, V17, P1515, DOI 10.1093/emboj/17.5.1515; COETZEE T, 1994, GENE DEV, V8, P1575, DOI 10.1101/gad.8.13.1575; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; FORSTER AC, 1990, SCIENCE, V249, P783, DOI 10.1126/science.1697102; Frank DN, 1996, RNA, V2, P1179; FRANK DN, 1994, BIOCHEMISTRY-US, V33, P10800, DOI 10.1021/bi00201a030; Frank DN, 1997, P NATL ACAD SCI USA, V94, P14355, DOI 10.1073/pnas.94.26.14355; Frank DN, 1998, ANNU REV BIOCHEM, V67, P153, DOI 10.1146/annurev.biochem.67.1.153; GARDINER KJ, 1985, J BIOL CHEM, V260, P5415; Gold L., 1993, RNA WORLD, P497; GREEN R, 1990, NATURE, V347, P406, DOI 10.1038/347406a0; GUERRIERTAKADA C, 1986, BIOCHEMISTRY-US, V25, P1509, DOI 10.1021/bi00355a006; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; Haas ES, 1996, NUCLEIC ACIDS RES, V24, P1252, DOI 10.1093/nar/24.7.1252; Haas ES, 1998, NUCLEIC ACIDS RES, V26, P4093, DOI 10.1093/nar/26.18.4093; HAAS ES, 1994, P NATL ACAD SCI USA, V91, P2527, DOI 10.1073/pnas.91.7.2527; HERSCHLAG D, 1994, EMBO J, V13, P2913, DOI 10.1002/j.1460-2075.1994.tb06586.x; JOSEPH S, 1993, J BIOL CHEM, V268, P24515; Joyce GF, 1998, P NATL ACAD SCI USA, V95, P5845, DOI 10.1073/pnas.95.11.5845; JOYCE GF, 1992, SCI AM, V267, P90, DOI 10.1038/scientificamerican1292-90; JOYCE GF, 1989, NUCLEIC ACIDS RES, V17, P711, DOI 10.1093/nar/17.12.4885; Kawa D, 1998, RNA, V4, P1397, DOI 10.1017/S1355838298980918; Kilani AF, 1999, RNA, V5, P1235, DOI 10.1017/S1355838299990672; Kim JJ, 1997, RNA, V3, P613; Lan N, 1998, SCIENCE, V280, P1593, DOI 10.1126/science.280.5369.1593; Lee NS, 1999, RNA, V5, P1200, DOI 10.1017/S1355838299990246; LIU FY, 1991, J VIROL, V65, P5149, DOI 10.1128/JVI.65.10.5149-5156.1991; Liu FY, 1996, NUCLEIC ACIDS RES, V24, P2690, DOI 10.1093/nar/24.14.2690; LIU FY, 1995, GENE DEV, V9, P471, DOI 10.1101/gad.9.4.471; Massire C, 1998, J MOL BIOL, V279, P773, DOI 10.1006/jmbi.1998.1797; MCGEOCH DJ, 1989, ANNU REV MICROBIOL, V43, P235; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NAKAMAYE KL, 1994, BIOCHEMISTRY-US, V33, P1271, DOI 10.1021/bi00171a030; Pal BK, 1998, J VIROL, V72, P8349, DOI 10.1128/JVI.72.10.8349-8353.1998; Poeschla Eric, 1994, Current Opinion in Oncology, V6, P601, DOI 10.1097/00001622-199411000-00012; Pulitz JZ, 1999, J VIROL, V73, P5381, DOI 10.1128/JVI.73.7.5381-5387.1999; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; Rossi JJ, 1999, CHEM BIOL, V6, pR33, DOI 10.1016/S1074-5521(99)80001-5; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001; SMITH D, 1992, J BIOL CHEM, V267, P2429; SULLENGER BA, 1993, SCIENCE, V262, P1566, DOI 10.1126/science.8248806; Szostak J.W., 1993, RNA WORLD, P511; SZOSTAK JW, 1992, TRENDS BIOCHEM SCI, V17, P89, DOI 10.1016/0968-0004(92)90242-2; Tang J, 1997, RNA, V3, P914; Trang P, 1999, NUCLEIC ACIDS RES, V27, P4590, DOI 10.1093/nar/27.23.4590; TSUCHIHASHI Z, 1993, SCIENCE, V262, P99, DOI 10.1126/science.7692597; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; Yamada O, 1996, VIROLOGY, V220, P361, DOI 10.1006/viro.1996.0324; YU M, 1993, P NATL ACAD SCI USA, V90, P6340, DOI 10.1073/pnas.90.13.6340; Yu Q, 1998, J BIOL CHEM, V273, P23524, DOI 10.1074/jbc.273.36.23524; YUAN Y, 1992, P NATL ACAD SCI USA, V89, P8006, DOI 10.1073/pnas.89.17.8006	60	41	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10611	10622		10.1074/jbc.275.14.10611	http://dx.doi.org/10.1074/jbc.275.14.10611			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744757	hybrid			2022-12-27	WOS:000086345600098
J	Kozaki, A; Kamada, K; Nagano, Y; Iguchi, H; Sasaki, Y				Kozaki, A; Kamada, K; Nagano, Y; Iguchi, H; Sasaki, Y			Recombinant carboxyltransferase responsive to redox of pea plastidic acetyl-CoA carboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; PLANTS; CHLOROPLASTS; ENZYMES; PROTEIN; SUBUNIT; LIGHT; FORMS	Acetyl-CoA carboxylase regulates the rate of fatty acid synthesis. This enzyme in plants is localized in plastids and is believed to be composed of biotin carboxyl carrier protein, biotin carboxylase, and carboxyltransferase made up of alpha and beta polypeptides, although the enzyme has not been purified yet. Accumulated evidence shows that pea plastidic acetyl-CoA carboxylase is activated by light and the activation is caused by light-dependent reduction of carboxyltransferase, but not of biotin carboxylase, via a redox cascade. To understand the reductive activation of carboxyltransferase at the molecular level here, we obtained the active enzyme composed of decahistidine-tagged (His tag) alpha and beta polypeptides through the expression of the pea plastidic carboxyltransferase gene in Escherichia coli. Gel filtration showed that the molecular size of the recombinant carboxyltransferase is in agreement with that of partially purified carboxyltransferase from pea chloroplasts, The catalytic activity of the recombinant enzyme was similar to that of native carboxyltransferase. These results indicate that the molecular structure and conformation of recombinant carboxyltransferase resemble those of its native counterpart and that native carboxyltransferase is indeed composed of alpha and beta polypeptides. This recombinant enzyme was activated by dithiothreitol, a known reductant of S-S bonds, with a profile similar to that of its native counterpart. The recombinant enzyme was activated by reduced thioredoxin-f, a signal transducer of redox potential in chloroplasts under irradiation. Thus, this enzyme was redox-regulated, like that of the native carboxyltransferase.	Nagoya Univ, Grad Sch Agr Sci, Plant Mol Biol Lab, Nagoya, Aichi 4648601, Japan	Nagoya University	Sasaki, Y (corresponding author), Nagoya Univ, Grad Sch Agr Sci, Plant Mol Biol Lab, Nagoya, Aichi 4648601, Japan.		Nagano, Yukio/H-8734-2019	Nagano, Yukio/0000-0001-5030-676X				Blanchard CZ, 1998, J BIOL CHEM, V273, P19140, DOI 10.1074/jbc.273.30.19140; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; Carninci P, 1998, P NATL ACAD SCI USA, V95, P520, DOI 10.1073/pnas.95.2.520; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; Hunter SC, 1998, ARCH BIOCHEM BIOPHYS, V359, P170, DOI 10.1006/abbi.1998.0900; KONISHI T, 1994, P NATL ACAD SCI USA, V91, P3598, DOI 10.1073/pnas.91.9.3598; Konishi T, 1996, PLANT CELL PHYSIOL, V37, P117, DOI 10.1093/oxfordjournals.pcp.a028920; Kozaki A, 1999, BIOCHEM J, V339, P541, DOI 10.1042/0264-6021:3390541; LI SJ, 1992, J BIOL CHEM, V267, P16841; NAGANO Y, 1991, CURR GENET, V20, P431, DOI 10.1007/BF00317074; OHLROGGE J, 1995, PLANT CELL, V7, P957, DOI 10.1105/tpc.7.7.957; Qian DQ, 1996, PLANT CELL, V8, P2381, DOI 10.1105/tpc.8.12.2381; Reverdatto S, 1999, PLANT PHYSIOL, V119, P961, DOI 10.1104/pp.119.3.961; SASAKI Y, 1995, PLANT PHYSIOL, V108, P445, DOI 10.1104/pp.108.2.445; SASAKI Y, 1993, J BIOL CHEM, V268, P25118; Sasaki Y, 1997, P NATL ACAD SCI USA, V94, P11096, DOI 10.1073/pnas.94.20.11096; SAUER A, 1984, Z NATURFORSCH C, V39, P268; Savage LJ, 1999, PLANT J, V18, P521, DOI 10.1046/j.1365-313X.1999.00478.x; Shorrosh BS, 1996, PLANT J, V10, P261, DOI 10.1046/j.1365-313X.1996.10020261.x; Sugiura M, 1998, ANNU REV GENET, V32, P437, DOI 10.1146/annurev.genet.32.1.437; YANG YR, 1993, PROTEIN SCI, V2, P1013, DOI 10.1002/pro.5560020614	21	31	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10702	10708		10.1074/jbc.275.14.10702	http://dx.doi.org/10.1074/jbc.275.14.10702			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744768	hybrid			2022-12-27	WOS:000086345600109
J	Nakajima, K; Takahashi, A; Yaoita, Y				Nakajima, K; Takahashi, A; Yaoita, Y			Structure, expression, and function of the Xenopus laevis caspase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; DEATH GENE CED-3; PROGRAMMED CELL-DEATH; PROTEIN-KINASE-B; THYROID-HORMONE; MOLECULAR-CLONING; IL-1-BETA-CONVERTING ENZYME; CYSTEINE PROTEASES; APOPTOTIC ACTIVITY; MAMMALIAN HOMOLOG	Caspases, a family of cysteine proteases, have been recognized as the central executors of programmed cell death. Nonetheless, the information on the caspase family has been Limited to mammals, Drosophila, and nematodes. To examine the structure and characterization of the Xenopus caspase family, we have cloned the cDNAs encoding caspase-2 and -6-10 in addition to caspase-1 and -3, which we characterized previously (Yaoita, Y., and Nakajima, K. (1997) J, Biol. Chem, 272, 5122-5127), First, the existence of these caspases in frog suggests that the caspase cascades clarified in mammals are conserved at least from Amphibia, Interestingly, Xenopus caspase-1, -8, and -10 (especially caspase-8) showed a lower degree of identity to human equivalents than the other caspases, Second, mRNAs of many caspases increased during the climax of metamorphosis in regressing organs, tail, and intestine, where programmed cell death occurs, but not in apoptotic tail-derived cultured cells (XLT-15-11) treated with thyroid hormone, showing that new RNA synthesis of caspases is dispensable to programmed cell death. Third, comparison of human and Xenopus caspase sequences implies that some proposed regulations of human caspases are not conserved in frog.	Tokyo Metropolitan Inst Neurosci, Dept Mol Neurobiol, Fuchu, Tokyo 1838526, Japan; Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Kyoto 6068397, Japan	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Kyoto University	Yaoita, Y (corresponding author), Tokyo Metropolitan Inst Neurosci, Dept Mol Neurobiol, 2-6 Musashidai, Fuchu, Tokyo 1838526, Japan.							Ahmad M, 1998, CANCER RES, V58, P5201; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Allet B, 1996, J CELL BIOL, V135, P479, DOI 10.1083/jcb.135.2.479; Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Colussi PA, 1998, J BIOL CHEM, V273, P26566, DOI 10.1074/jbc.273.41.26566; Cope FO., 1991, APOPTOSIS MOL BASIS, P47; DODD MHI, 1976, PHYSIOLOGY AMPHIBIA, V3, P467; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; Fraser AG, 1997, EMBO J, V16, P6192, DOI 10.1093/emboj/16.20.6192; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Humke EW, 1998, J BIOL CHEM, V273, P15702, DOI 10.1074/jbc.273.25.15702; ISHIZUYAOKA A, 1987, ANAT ANZEIGER, V164, P81; ISHIZUYAOKA A, 1992, J MORPHOL, V213, P185, DOI 10.1002/jmor.1052130205; Johnson AL, 1997, GENE, V192, P227, DOI 10.1016/S0378-1119(97)00068-1; KAUFMAN J, 1990, IMMUNOL REV, V113, P83, DOI 10.1111/j.1600-065X.1990.tb00038.x; KERR JFR, 1974, J CELL SCI, V14, P571; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; KOLLROS JJ, 1985, J COMP NEUROL, V233, P481, DOI 10.1002/cne.902330407; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; Lund LR, 1996, DEVELOPMENT, V122, P181; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1996, CURR BIOL, V6, P1241, DOI 10.1016/S0960-9822(02)70706-9; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NETT MA, 1992, J IMMUNOL, V149, P3254; NIEUWKOOP PD, 1956, NORMAL TADPOLE XENOP; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Sakamaki K, 1998, EUR J BIOCHEM, V253, P399, DOI 10.1046/j.1432-1327.1998.2530399.x; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Van de Craen M, 1998, J MOL BIOL, V284, P1017, DOI 10.1006/jmbi.1998.2226; Van de Craen M, 1998, CELL DEATH DIFFER, V5, P838, DOI 10.1038/sj.cdd.4400444; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang SY, 1996, J BIOL CHEM, V271, P20580, DOI 10.1074/jbc.271.34.20580; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Yamashita K, 1999, BLOOD, V93, P674, DOI 10.1182/blood.V93.2.674.402k26_674_685; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; YAOITA Y, 1990, GENE DEV, V4, P1917, DOI 10.1101/gad.4.11.1917; Yaoita Y, 1997, J BIOL CHEM, V272, P5122, DOI 10.1074/jbc.272.8.5122; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	76	70	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10484	10491		10.1074/jbc.275.14.10484	http://dx.doi.org/10.1074/jbc.275.14.10484			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744739	hybrid			2022-12-27	WOS:000086345600080
J	Palestini, P; Pitto, M; Tedeschi, G; Ferraretto, A; Parenti, M; Brunner, J; Masserini, M				Palestini, P; Pitto, M; Tedeschi, G; Ferraretto, A; Parenti, M; Brunner, J; Masserini, M			Tubulin anchoring to glycolipid-enriched, detergent-resistant domains of the neuronal plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; MELANOMA B16 CELLS; GM1 GANGLIOSIDE; NEUROBLASTOMA-CELLS; SIGNAL-TRANSDUCTION; RAT-BRAIN; PROTEIN; CULTURE; GLUTAMATE; CAVEOLAE	After incubation of intact living cultured rat cerebellar granule cells at 37 degrees C with a new GM1 ganglioside analog, carrying a diazirine group and labeled with I-125 in the ceramide moiety, followed by photoactivation, a relatively small number of radiolabeled proteins mere detected in a membrane-enriched fraction. A protein of about 55 kDa with a pI of about 5 carried a large portion of the radioactivity even if incubation and cross-linking were performed at 4 degrees C and in the presence of inhibitors of endocytosis, suggesting that it is cross-linked at the plasma membrane. Immunoprecipitation and Western blotting experiments showed the positivity of this protein for tubulin, Trypsin treatment of intact cells ruled out the involvement of a plasma membrane surface tubulin. Release of radioactivity from cross-linked tubulin after I(OH treatment (but not hydroxylamine treatment) suggested that the photoactivated ganglioside reacts with an ester-linked fatty acid anchor of tubulin, Low buoyancy, detergent-resistant membrane fractions, isolated from cells after incubation with the GM1 analogue and photoactivation, proved their enrichment in endogenous and radioactive GM1 ganglioside, sphingomyelin, cholesterol, signal transduction proteins, and tubulin. It is noteworthy that radioactive tubulin was also detected in this fraction, indicating the presence of tubulin molecules carrying a fatty acid anchor in detergent-resistant, ganglioside-enriched domains of the plasma membrane, Parallel experiments carried out with a phosphatidylcholine analogue, also carrying a diazirine group and labeled with I-125 in the fatty acid moiety, showed the specificity of tubulin interaction with GM1. Taken together, these results indicate that some tubulin molecules are associated with a lipid anchor to detergent-resistant glycolipid-enriched domains of the plasma membrane. This novel feature of membrane do mains can provide a key for a better understanding of their biological role.	Univ Milan, Hosp S Gerardo, Sch Med, Dept Expt Environm Med & Biotechnol, I-20052 Monza, Italy; Univ Milan, Dept Med Chem & Biochem, I-20133 Milan, Italy; Univ Milan, Inst Vet Physiol, I-20133 Milan, Italy; Swiss Fed Inst Technol, CH-8092 Zurich, Switzerland	University of Milan; University of Milan; University of Milan; Swiss Federal Institutes of Technology Domain; ETH Zurich	Palestini, P (corresponding author), Univ Milan, Sch Med, Via Saldini 50, I-20133 Milan, Italy.	paola.palestini@unimib.it	Palestini, PAOLA/AAD-9376-2019; Tedeschi, Gabriella/I-6247-2017; Ferraretto, Anita/L-3543-2016	Palestini, PAOLA/0000-0002-1045-8838; Tedeschi, Gabriella/0000-0003-2082-6443; Ferraretto, Anita/0000-0002-3637-5002				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BABITCH JA, 1981, J NEUROCHEM, V37, P1394, DOI 10.1111/j.1471-4159.1981.tb06307.x; BIZZOZERO OA, 1994, NEUROCHEM RES, V19, P923, DOI 10.1007/BF00968702; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BREMER EG, 1984, J BIOL CHEM, V259, P6818; CAIMI L, 1989, J NEUROCHEM, V52, P1722, DOI 10.1111/j.1471-4159.1989.tb07250.x; Caron JM, 1997, MOL BIOL CELL, V8, P621, DOI 10.1091/mbc.8.4.621; Chigorno V, 1985, GLYCOCONJUGATE J, VV2, P279; DESSI F, 1994, BRAIN RES, V654, P27, DOI 10.1016/0006-8993(94)91567-9; Eichler J, 1997, EMBO J, V16, P2188, DOI 10.1093/emboj/16.9.2188; ESTRIDGE M, 1977, NATURE, V268, P60, DOI 10.1038/268060a0; FAVARON M, 1988, P NATL ACAD SCI USA, V85, P7351, DOI 10.1073/pnas.85.19.7351; Fernandez MN, 1997, MOL CELL BIOCHEM, V170, P91; FISHMAN PH, 1988, FIDIA RES SER, V14, P183; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; FUESHKO SM, 1992, J NEUROCHEM, V59, P527, DOI 10.1111/j.1471-4159.1992.tb09402.x; GALLO V, 1982, P NATL ACAD SCI-BIOL, V79, P7919, DOI 10.1073/pnas.79.24.7919; Garner J, 1998, J BIOL CHEM, V273, P5167, DOI 10.1074/jbc.273.9.5167; GHIDONI R, 1981, J LIPID RES, V22, P1286; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; GUNDERSEN GG, 1988, P NATL ACAD SCI USA, V85, P5946, DOI 10.1073/pnas.85.16.5946; Hakomori S, 1998, GLYCOBIOLOGY, V8, pXI; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Hope HR, 1996, MOL BIOL CELL, V7, P843, DOI 10.1091/mbc.7.6.843; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Iwabuchi K, 1998, J BIOL CHEM, V273, P33766, DOI 10.1074/jbc.273.50.33766; Kaech S, 1996, NEURON, V17, P1189, DOI 10.1016/S0896-6273(00)80249-4; KARLSSON KA, 1986, CHEM PHYS LIPIDS, V42, P153, DOI 10.1016/0009-3084(86)90050-2; Kasahara K, 1997, J BIOL CHEM, V272, P29947, DOI 10.1074/jbc.272.47.29947; KUHN CS, 1992, BIOCONJUGATE CHEM, V3, P230, DOI 10.1021/bc00015a005; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU SC, 1990, J BIOL CHEM, V265, P16088; Masserini M, 1999, J NEUROCHEM, V73, P1, DOI 10.1046/j.1471-4159.1999.0730001.x; Oehrlein SA, 1996, BIOCHEM J, V317, P219, DOI 10.1042/bj3170219; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; Pitto M, 1998, FEBS LETT, V439, P93, DOI 10.1016/S0014-5793(98)01344-1; Ravindra R, 1997, ENDOCRINE, V7, P127, DOI 10.1007/BF02778134; Rebbaa A, 1996, GLYCOBIOLOGY, V6, P399, DOI 10.1093/glycob/6.4.399; RIBONI L, 1991, FEBS LETT, V287, P42, DOI 10.1016/0014-5793(91)80012-R; SAQR HE, 1993, J NEUROCHEM, V61, P395; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHWARZMANN G, 1990, BIOCHEMISTRY-US, V29, P10865, DOI 10.1021/bi00501a001; Shapiro RE, 1997, J BIOL CHEM, V272, P30380, DOI 10.1074/jbc.272.48.30380; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sofer A, 1996, J CELL SCI, V109, P2111; SONNINO S, 1989, BIOCHEMISTRY-US, V28, P77, DOI 10.1021/bi00427a012; SONNINO S, 1984, J LIPID RES, V25, P620; SONNINO S, 1992, NEUROCHEM INT, V20, P315, DOI 10.1016/0197-0186(92)90046-T; SONNINO S, 1992, J LIPID RES, V33, P1221; STEPHENS RE, 1986, BIOL CELL, V57, P95, DOI 10.1111/j.1768-322X.1986.tb00467.x; TETTAMAN.G, 1973, BIOCHIM BIOPHYS ACTA, V296, P160, DOI 10.1016/0005-2760(73)90055-6; TETTAMANTI G, 1994, PROG BRAIN RES, V101, P77; TIEMEYER M, 1989, J BIOL CHEM, V264, P1671; VACCARINO F, 1987, P NATL ACAD SCI USA, V84, P8707, DOI 10.1073/pnas.84.23.8707; WEBER T, 1995, J AM CHEM SOC, V117, P3084, DOI 10.1021/ja00116a013; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554; ZISAPEL N, 1980, J NEUROCHEM, V34, P26, DOI 10.1111/j.1471-4159.1980.tb04617.x	61	63	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					9978	9985		10.1074/jbc.275.14.9978	http://dx.doi.org/10.1074/jbc.275.14.9978			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744673	hybrid			2022-12-27	WOS:000086345600014
J	Scharnhorst, V; Dekker, P; van der Eb, AJ; Jochemsen, AG				Scharnhorst, V; Dekker, P; van der Eb, AJ; Jochemsen, AG			Physical interaction between Wilms tumor 1 and p73 proteins modulates their functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENYS-DRASH SYNDROME; WT1 GENE-PRODUCT; ZINC FINGER PROTEIN; SUPPRESSOR GENE; DNA-BINDING; P53 HOMOLOG; INDUCE APOPTOSIS; FRASIER-SYNDROME; MDM2 EXPRESSION; MUTATIONS	The WT1 gene, which is heterozygously mutated or deleted in congenital anomaly syndromes and homozygously mutated in about 15% of all Wilms tumors, encodes tissue-specific developmental regulators. Through alternative mRNA splicing, four main WT1 protein isoforms are synthesized, All isoforms can bind to DNA via their zinc fingers, albeit with different affinities and specificities, and thereby modulate the transcriptional activity of their target genes. Several proteins bind to and alter the transcription regulatory properties of the WT1 proteins, including the product of the tumor suppressor gene p53, interaction between WT1 and p53 was shown to modulate their ability to regulate the transcription of their respective target genes. Here, we report that all four isoforms of WT1 bind to p73, a recently cloned homologue of p53, p73 binds to the zinc finger region of WT1 and thereby inhibits DNA binding and transcription activation by WT1. Similarly, WT1 inhibits p73-induced transcription activation in reporter assays and counteracts p73-induced expression of endogenous Mdm2. This, taken together with our finding that WT1 also interacts with p63/KET, another p53 homologue, suggests that association between WT1 and the members of the p53 family of proteins may be an important determinant of their functions in cell growth and differentiation.	Leiden Univ, Med Ctr, Mol Carcinogenesis Lab, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Ctr Biomed Genet, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Jochemsen, AG (corresponding author), Leiden Univ, Med Ctr, Mol Carcinogenesis Lab, POB 9503, NL-2300 RA Leiden, Netherlands.			Scharnhorst, Volkher/0000-0002-1243-9251				Almog Nava, 1998, Biochimica et Biophysica Acta, V1378, pR43; ARMSTRONG JF, 1993, MECH DEVELOP, V40, P85, DOI 10.1016/0925-4773(93)90090-K; Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GOODYER P, 1995, ONCOGENE, V10, P1125; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Herzer U, 1999, CURR BIOL, V9, P837, DOI 10.1016/S0960-9822(99)80369-8; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Johnstone RW, 1998, J BIOL CHEM, V273, P10880, DOI 10.1074/jbc.273.18.10880; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kennedy D, 1996, NAT GENET, V12, P329, DOI 10.1038/ng0396-329; Klamt B, 1998, HUM MOL GENET, V7, P709, DOI 10.1093/hmg/7.4.709; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; LITTLE M, 1995, HUM MOL GENET, V4, P351, DOI 10.1093/hmg/4.3.351; MACHIN GA, 1984, HISTOPATHOLOGY, V8, P35, DOI 10.1111/j.1365-2559.1984.tb02320.x; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Menke AL, 1998, INT REV CYTOL, V181, P151, DOI 10.1016/S0074-7696(08)60418-0; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MIYASHITA T, 1995, CELL, V80, P293; Moore AW, 1999, DEVELOPMENT, V126, P1845; Moore AW, 1998, MECH DEVELOP, V79, P169, DOI 10.1016/S0925-4773(98)00188-9; MORRIS JF, 1991, ONCOGENE, V6, P2339; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RACKLEY RR, 1993, CELL GROWTH DIFFER, V4, P1023; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; Scharnhorst V, 1999, J BIOL CHEM, V274, P23456, DOI 10.1074/jbc.274.33.23456; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; SLATER RM, 1992, CANCER GENET CYTOGEN, V61, P111, DOI 10.1016/0165-4608(92)90071-F; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; van der Eb A J, 1980, Methods Enzymol, V65, P826; VANHEYNINGEN V, 1990, P NATL ACAD SCI USA, V87, P5383, DOI 10.1073/pnas.87.14.5383; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768	63	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10202	10211		10.1074/jbc.275.14.10202	http://dx.doi.org/10.1074/jbc.275.14.10202			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744705	hybrid			2022-12-27	WOS:000086345600046
J	Arar, M; Xu, YC; Elshihabi, I; Barnes, JL; Choudhury, GG; Abboud, HE				Arar, M; Xu, YC; Elshihabi, I; Barnes, JL; Choudhury, GG; Abboud, HE			Platelet-derived growth factor receptor beta regulates migration and DNA synthesis in metanephric mesenchymal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESANGIAL CELLS; SIGNAL-TRANSDUCTION; PDGF-RECEPTOR; EXPRESSION; CHEMOTAXIS; KINASE; KIDNEY; INDUCTION; ISOFORMS; MICE	Platelet-derived growth factor (PDGF) B-chain and PDGF receptor beta (PDGFR beta) are essential for glomerulogenesis, Mice deficient in PDGF B-chain or PDGFR beta exhibit an abnormal glomerular phenotype characterized by total lack of mesangial cells. In this study, we localized PDGFR beta in the developing rat kidney and explored the biological effects of PDGF in metanephric mesenchymal cells in an attempt to determine the mechanism by which PDGF regulates mesangial cell development. Immunohistochemical and in situ hybridization studies of rat embryonic kidneys reveal that PDGFR beta localizes to undifferentiated metanephric mesenchyme and is later expressed in the cleft of the comma-shaped and S-shaped bodies and in more mature glomeruli in a mesangial distribution. We also isolated and characterized cells from rat metanephric mesenchyme. Metanephric mesenchymal cells express vimentin and alpha-smooth muscle actin but not cytokeratin, These cells also express functional PDGFR beta, as demonstrated by autophosphorylation of the receptor as well as activation of phosphatidylinositol 3 kinase in response to PDGF B-chain homodimer, PDGF B-chain also induces migration and proliferation of metanephric mesenchymal cells. Taken together with the fact that PDGF B-chain is expressed in the glomerular epithelium and mesangial area, as demonstrated in the human embryonic kidney, we suggest that PDGF B-chain acts in a paracrine fashion to stimulate the migration and proliferation of mesangial cell precursors from undifferentiated metanephric mesenchyme to the mesangial area. PDGF B-chain also likely stimulates proliferation of mesangial cell precursors in an autocrine fashion once these cells migrate to the glomerular tuft.	Univ Texas, Hlth Sci Ctr, Dept Pediat, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Internal Med, San Antonio, TX 78229 USA; S Texas Dept Vet Affairs Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Geriatric Research Education & Clinical Center	Arar, M (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pediat, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	arar@uthscsa.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033665, R01DK033665, R01DK050190, R29DK050190] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK50190, DK33665] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abboud Hanna E., 1995, P573; ABBOUD HE, 1995, ANNU REV PHYSIOL, V57, P297; ABBOUD HE, 1994, J CELL PHYSIOL, V158, P140, DOI 10.1002/jcp.1041580118; ALPERS CE, 1992, KIDNEY INT, V42, P390, DOI 10.1038/ki.1992.300; BARNES JL, 1994, AM J PATHOL, V145, P585; BARNES JL, 1990, LAB INVEST, V62, P379; Barnes JL, 1999, J HISTOCHEM CYTOCHEM, V47, P533, DOI 10.1177/002215549904700412; CHOUDHURY GG, 1994, KIDNEY INT, V46, P37, DOI 10.1038/ki.1994.242; Choudhury GG, 1997, AM J PHYSIOL-RENAL, V273, pF931, DOI 10.1152/ajprenal.1997.273.6.F931; COUGHLIN SR, 1989, SCIENCE, V243, P1191; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HERZLINGER D, 1992, DEVELOPMENT, V114, P565; HERZLINGER D, 1994, DEV BIOL, V166, P815, DOI 10.1006/dbio.1994.1360; Higaki M, 1996, J BIOL CHEM, V271, P29342, DOI 10.1074/jbc.271.46.29342; HYINK DP, 1996, AM J PHYSIOL, V39, pF886; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; SAXEN L, ADV MORPHOGENESIS, V7, P251; Seifert RA, 1998, KIDNEY INT, V54, P731, DOI 10.1046/j.1523-1755.1998.00046.x; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; STOKER M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P81, DOI 10.1016/0304-419X(91)90008-9; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WENNSTROM S, 1994, ONCOGENE, V9, P651	26	28	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9527	9533		10.1074/jbc.275.13.9527	http://dx.doi.org/10.1074/jbc.275.13.9527			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734101	hybrid			2022-12-27	WOS:000086206500065
J	Brunner, T; Kasibhatla, S; Pinkoski, MJ; Frutschi, C; Yoo, NJ; Echeverri, F; Mahboubi, A; Green, DR				Brunner, T; Kasibhatla, S; Pinkoski, MJ; Frutschi, C; Yoo, NJ; Echeverri, F; Mahboubi, A; Green, DR			Expression of Fas ligand in activated T cells is regulated by c-Myc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; ORNITHINE DECARBOXYLASE; DNA-BINDING; E-BOX; PROTEIN; GENE; MAX; RECEPTOR; DEATH; LYMPHOCYTES	The transcription factor c-Myc is important for the control of cell cycle progression, neoplasia, and apoptotic cell death. c-Myc dimerizes with its partner Max to form an active transcription factor complex. Little is known, however, about the transcriptional targets of c-Myc and their roles in c-Myc-induced cell death. Here we demonstrate that T cell activation-induced expression of Fas ligand (FasL, CD95-L, APO-1-L), which can induce apoptotic cell death in many different cell types, is regulated by c-Myc, Down-modulation of c-Myc protein via antisense oligonucleotides blocked activation-induced Fast mRNA and protein expression and functional Fast expression in activated T cells and T cell lines. Further, Fast promoter activity in T cells is driven by overexpression of c-Myc and inhibited by expression of dominant-negative mutants of c-Myc and Max. Our findings indicate that c-Myc controls apoptotic cell death in T cells through regulation of Fast expression.	La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA; Univ Bern, Inst Pathol, Div Immunopathol, CH-3010 Bern, Switzerland	La Jolla Institute for Immunology; University of Bern	Green, DR (corresponding author), La Jolla Inst Allergy & Immunol, Div Cellular Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.		Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417	NIGMS NIH HHS [GM52735] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM052735, R01GM052735] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ANEL A, 1994, EUR J IMMUNOL, V24, P2469, DOI 10.1002/eji.1830241032; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BAHNE H, 1996, SCIENCE, V274, P1363; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BISSONETTE RP, 1994, APOPTOSIS 2 MOL BASI, P327; BISSONNETTE RP, 1994, J EXP MED, V180, P2413, DOI 10.1084/jem.180.6.2413; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bonfoco E, 1998, IMMUNITY, V9, P711, DOI 10.1016/S1074-7613(00)80668-8; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Brunner T, 1996, INT IMMUNOL, V8, P1017, DOI 10.1093/intimm/8.7.1017; Brunner T, 1996, Behring Inst Mitt, P161; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Genestier L, 1999, J EXP MED, V189, P231, DOI 10.1084/jem.189.2.231; GESESTIER L, 1999, J EXP MED, V189, P231; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; HARRIS T, 1994, SOUTH CULT, V1, P120, DOI 10.1353/scu.1994.0022; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Jones RM, 1996, MOL CELL BIOL, V16, P4754; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Latinis KM, 1997, J IMMUNOL, V158, P4602; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; Niehans GA, 1997, CANCER RES, V57, P1007; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; RUSSELL JH, 1991, P NATL ACAD SCI USA, V88, P2151, DOI 10.1073/pnas.88.6.2151; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; TILLMAN JB, 1993, MOL CELL ENDOCRINOL, V95, P101, DOI 10.1016/0303-7207(93)90034-H; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yagita H, 1996, NATURE, V379, P682, DOI 10.1038/379682a0; ZHANG XH, 1995, J EXP MED, V182, P699, DOI 10.1084/jem.182.3.699	50	72	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9767	9772		10.1074/jbc.275.13.9767	http://dx.doi.org/10.1074/jbc.275.13.9767			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734130	Green Submitted, hybrid			2022-12-27	WOS:000086206500094
J	Huang, CS; Mattjus, P; Ma, WY; Rincon, M; Chen, NY; Brown, RE; Dong, ZG				Huang, CS; Mattjus, P; Ma, WY; Rincon, M; Chen, NY; Brown, RE; Dong, ZG			Involvement of nuclear factor of activated T cells activation in UV response - Evidence from cell culture and transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NFATP; NF-KAPPA-B; CYCLOSPORINE-A; GROWTH-FACTOR; PROTEIN-KINASE; INTERLEUKIN-2 PROMOTER; AP-1 TRANSACTIVATION; LYMPHOCYTES-T; CALCINEURIN; FAMILY	Mammalian cells respond to UV radiation by signaling cascades leading to activation of transcription factors, such as activated protein 1, NF kappa B, and p53, a process known as the "UV response." Nuclear factor of activated T cells (NFAT) was first identified as an inducible nuclear factor in immune response and subsequently found to be expressed in other tissues and cells. To date, however, the regulation and function of NFAT in tissues and cells, other than the immune system, are not well understood. In this study, we demonstrate that UV radiation activates NEAT-dependent transcription through a calcium-dependent mechanism in mouse epidermal JB6 cell lines, as well as in the skin of NFAT-luciferase reporter transgenic mice. Exposure of JB6 cells to UV radiation leads to the transactivation of NEAT in a dose-dependent manner. A23187 had a synergistic effect with UV for NFAT induction, whereas pretreatment of cells with nifedipine, a calcium channel blocker, dramatically impaired the NFAT activity induced by either UV or UV plus A23187, Calcium-dependent activation of NEAT by UV was further confirmed by an in vivo study using NFAT-luciferase reporter transgenic mice. These results demonstrated that UV radiation is a strong activator for skin NFAT transactivation through calcium-dependent pathways, suggesting that NEAT activation may be a part of the UV response.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Univ Vermont, Dept Med, Program Immunobiol, Burlington, VT 05405 USA	University of Minnesota System; University of Vermont	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.		Mattjus, Peter/ABE-3596-2021; Mattjus, Peter/AAQ-7531-2021	Mattjus, Peter/0000-0001-8991-5933; Brown, Rhoderick/0000-0002-7337-3604; Huang, Chuanshu/0000-0003-4133-5096	NATIONAL CANCER INSTITUTE [R01CA077646, R01CA081064, R37CA081064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045928] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA081064, CA81064, R37 CA081064, R01 CA077646, CA77646] Funding Source: Medline; NIGMS NIH HHS [R01 GM045928-07, R01 GM045928-08, R01 GM045928, GM45928] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER V, 1995, CELL GROWTH DIFFER, V6, P1437; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Boss V, 1998, J BIOL CHEM, V273, P19664, DOI 10.1074/jbc.273.31.19664; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COCKERILL GW, 1995, BLOOD, V86, P2689; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; Dong ZG, 1998, ONCOGENE, V17, P1845, DOI 10.1038/sj.onc.1202084; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HO AM, 1994, J BIOL CHEM, V269, P28181; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Huang CS, 1998, CANCER RES, V58, P4102; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1997, P NATL ACAD SCI USA, V94, P11957, DOI 10.1073/pnas.94.22.11957; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1997, J BIOL CHEM, V272, P26325, DOI 10.1074/jbc.272.42.26325; Huang CS, 1997, ONCOGENE, V14, P1945, DOI 10.1038/sj.onc.1201056; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JIANG H, 1993, CARCINOGENESIS, V14, P67, DOI 10.1093/carcin/14.1.67; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lara-Pezzi E, 1998, EMBO J, V17, P7066, DOI 10.1093/emboj/17.23.7066; Luo C, 1996, MOL CELL BIOL, V16, P3955; Masuda ES, 1998, CELL SIGNAL, V10, P599, DOI 10.1016/S0898-6568(98)00019-9; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MATSUI MS, 1990, CARCINOGENESIS, V11, P229, DOI 10.1093/carcin/11.2.229; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PARK J, 1996, J BIOL CHEM, V271, P29014; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rincon M, 1997, MOL CELL BIOL, V17, P1522, DOI 10.1128/MCB.17.3.1522; Rincon M, 1996, MOL CELL BIOL, V16, P1074; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SERFLING E, 1995, BBA-GENE STRUCT EXPR, V1263, P181, DOI 10.1016/0167-4781(95)00112-T; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SINGH RK, 1995, CANCER RES, V55, P3669; Smith ML, 1997, P NATL ACAD SCI USA, V94, P12255, DOI 10.1073/pnas.94.23.12255; Tsatsanis C, 1998, ONCOGENE, V17, P2609, DOI 10.1038/sj.onc.1202460; Weiss DL, 1996, MOL CELL BIOL, V16, P228	54	51	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9143	9149		10.1074/jbc.275.13.9143	http://dx.doi.org/10.1074/jbc.275.13.9143			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734048	Green Accepted, hybrid			2022-12-27	WOS:000086206500012
J	Vikstrom, S; Li, L; Wieslander, A				Vikstrom, S; Li, L; Wieslander, A			The nonbilayer/bilayer lipid balance in membranes - Regulatory enzyme in Acholeplasma laidlawii is stimulated by metabolic phosphates, activator phospholipids, and double-stranded DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE ENERGY-CHARGE; PROTON MOTIVE FORCE; ESCHERICHIA-COLI; 1,2-DIACYLGLYCEROL 3-GLUCOSYLTRANSFERASE; MOLLICUTES MYCOPLASMAS; CELLS; PHASE; PHOSPHATIDYLGLYCEROL; MECHANISM; CALCIUM	In membranes of Acholeplasma laidlawii a single glucosyltransferase step between the major, nonbilayer-prone monoglucosyl-diacylglycerol (MGlcDAG) and the bilayer-forming diglucosyl-diacylglycerol (DGlcDAG) is important for maintenance of lipid phase equilibria and curvature packing stress. This DGlcDAG synthase is activated in a cooperative fashion by phosphatidylglycerol (PG), but in vivo PG amounts are not enough for efficient DGlcDAG synthesis. In vitro, phospholipids with an sn-glycero-3 phosphate backbone, and no positive head group charge, functioned as activators. Different metabolic, soluble phosphates could supplement PG for activation, depending on type, amount, and valency. Especially efficient were the glycolytic intermediates fructose 1,6-bisphosphate and ATP, active at cellular concentrations on the DGlcDAG but not on the preceding MGlcDAG synthase, Potencies of different phosphatidylinositol (foreign lipid) derivatives differed with numbers and positions of their phosphate moieties, A selective stimulation of the DGlcDAC, but not the MGlcDAG synthase, by minor amounts of double-stranded DNA was additive to the best phospholipid activators. These results support two types of activator sites on the enzyme: (i) lipid-phosphate ones close to the membrane interphase, and (ii) soluble (or particulate)-phosphate ones further out from the surface. Thereby, the nonbilayer (MGlcDAG) to bilayer (DGlcDAG) lipid balance may be integrated with the metabolic status of the cell and potentially also to membrane and cell division.	Umea Univ, Dept Biochem, S-90187 Umea, Sweden	Umea University	Vikstrom, S (corresponding author), Umea Univ, Dept Biochem, S-90187 Umea, Sweden.							BEAMAN KD, 1983, J GEN MICROBIOL, V129, P3103; BEVERS EM, 1977, BIOCHEMISTRY-US, V16, P1290, DOI 10.1021/bi00626a008; BEVERS EM, 1978, BIOCHIM BIOPHYS ACTA, V511, P509, DOI 10.1016/0005-2736(78)90285-7; Birch NG, 1993, MAGNESIUM CELL; Bond DR, 1998, APPL ENVIRON MICROB, V64, P976; CHANG CF, 1986, J BACTERIOL, V167, P935, DOI 10.1128/jb.167.3.935-939.1986; CLEMENTZ T, 1987, BIOCHIM BIOPHYS ACTA, V898, P299, DOI 10.1016/0005-2736(87)90070-8; CLEMENTZ T, 1986, BIOCHEMISTRY-US, V25, P823, DOI 10.1021/bi00352a014; Dahan-Grobgeld E, 1998, J BIOL CHEM, V273, P30232, DOI 10.1074/jbc.273.46.30232; DAHLQVIST A, 1992, BIOCHIM BIOPHYS ACTA, V1105, P131, DOI 10.1016/0005-2736(92)90171-H; DAHLQVIST A, 1995, BIOCHEMISTRY-US, V34, P13381, DOI 10.1021/bi00041a015; EGAN W, 1986, FEBS LETT, V204, P373, DOI 10.1016/0014-5793(86)80846-8; EPAND R, 1997, LIPID POLYMORPHISM M; Epand RM, 1998, BBA-REV BIOMEMBRANES, V1376, P353, DOI 10.1016/S0304-4157(98)00015-X; FARREN SB, 1983, BIOCHEM BIOPH RES CO, V111, P675, DOI 10.1016/0006-291X(83)90359-5; Gruner S. M., 1992, STRUCTURE BIOL MEMBR, P211; HUECK CJ, 1995, MOL MICROBIOL, V15, P395, DOI 10.1111/j.1365-2958.1995.tb02252.x; KAHANE I, 1973, J BACTERIOL, V113, P666, DOI 10.1128/JB.113.2.666-671.1973; Karlsson OP, 1997, J BIOL CHEM, V272, P929, DOI 10.1074/jbc.272.2.929; Karlsson OP, 1996, BIOCHEMISTRY-US, V35, P10094, DOI 10.1021/bi9602876; KARLSSON OP, 1994, J BIOL CHEM, V269, P23484; KILLIAN JA, 1994, BBA-BIOMEMBRANES, V1189, P225; LAJEUNESSE D, 1984, CAN J BIOCHEM CELL B, V62, P1041, DOI 10.1139/o84-133; LAU A, 1981, BIOCHIM BIOPHYS ACTA, V645, P279, DOI 10.1016/0005-2736(81)90199-1; Li L, 1997, J BIOL CHEM, V272, P29602, DOI 10.1074/jbc.272.47.29602; MASON PW, 1981, J BIOL CHEM, V256, P1861; McElhaney Ronald N., 1992, P113; MCLAUGHLIN S, 1989, ANNU REV BIOPHYS BIO, V18, P113, DOI 10.1146/annurev.biophys.18.1.113; Mileykovskaya E, 1998, J BACTERIOL, V180, P4252, DOI 10.1128/JB.180.16.4252-4257.1998; Morein S, 1996, J BIOL CHEM, V271, P6801, DOI 10.1074/jbc.271.12.6801; Mosior M, 1998, BIOCHEMISTRY-US, V37, P17271, DOI 10.1021/bi981344t; NEIMARK H, 1973, J BACTERIOL, V114, P1025, DOI 10.1128/JB.114.3.1025-1033.1973; NYSTROM S, 1992, EUR J BIOCHEM, V204, P231, DOI 10.1111/j.1432-1033.1992.tb16629.x; OSTERBERG F, 1995, BBA-LIPID LIPID MET, V1257, P18, DOI 10.1016/0005-2760(95)00042-B; OTTO R, 1984, ARCH MICROBIOL, V139, P338, DOI 10.1007/BF00408376; PASCHER I, 1992, BIOCHIM BIOPHYS ACTA, V1113, P339, DOI 10.1016/0304-4157(92)90006-V; PIERINGER RA, 1989, MICROBIAL LIPIDS, P51; Pollack JD, 1997, CRIT REV MICROBIOL, V23, P269, DOI 10.3109/10408419709115140; Razin S, 1998, MICROBIOL MOL BIOL R, V62, P1094, DOI 10.1128/MMBR.62.4.1094-1156.1998; Record MT, 1998, TRENDS BIOCHEM SCI, V23, P143, DOI 10.1016/S0968-0004(98)01196-7; RIETVELD AG, 1993, J BIOL CHEM, V268, P12427; Rilfors L, 1993, Subcell Biochem, V20, P109; SEELIG J, 1987, BIOCHEMISTRY-US, V26, P7535, DOI 10.1021/bi00398a001; STEINICK LE, 1980, J BACTERIOL, V143, P1200, DOI 10.1128/JB.143.3.1200-1207.1980; TILCOCK CPS, 1988, BIOCHEMISTRY-US, V27, P1415, DOI 10.1021/bi00405a004; Vikstrom S, 1999, BIOCHEMISTRY-US, V38, P5511, DOI 10.1021/bi982532m; WIESLANDER A, 1995, EUR J BIOCHEM, V227, P734, DOI 10.1111/j.1432-1033.1995.tb20196.x	47	23	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9296	9302		10.1074/jbc.275.13.9296	http://dx.doi.org/10.1074/jbc.275.13.9296			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734070	hybrid			2022-12-27	WOS:000086206500034
J	Enomoto, H; Enomoto-Iwamoto, M; Iwamoto, M; Nomura, S; Himeno, M; Kitamura, Y; Kishimoto, T; Komori, T				Enomoto, H; Enomoto-Iwamoto, M; Iwamoto, M; Nomura, S; Himeno, M; Kitamura, Y; Kishimoto, T; Komori, T			Cbfa1 is a positive regulatory factor in chondrocyte maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR OSF2/CBFA1; COLLAGEN GENE-EXPRESSION; OSTEOBLAST DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; X COLLAGEN; CELL-LINE; OSTEOCALCIN GENE; BONE-DEVELOPMENT; IN-VITRO; SEQUENCES	Cbfa1 is a transcription factor that belongs to the runt domain gene family. Cbfa1-deficient mice showed a complete lack of bone formation due to the maturational arrest of osteoblasts, demonstrating that Cbfa1 is an essential factor for osteoblast differentiation. Further, chondrocyte maturation was severely disturbed in Cbfa1-deficient mice. In this study, we examined the possibility that Cbfa1 is also involved in the regulation of chondrocyte differentiation. mRNAs for both Cbfa1 isotypes, type I Cbfa1 (Pebp2 alpha A/Cbfa1) and type II Cbfa1 (Osf2/Cbfa1 or til-l), which are different in N-terminal domain, were expressed in terminal hypertrophic chondrocytes as well as osteoblasts. In addition, mRNA for type I Cbfa1 was expressed in other hypertrophic chondrocytes and prehypertrophic chondropcytes, In a chondrogenic cell line, ATDC5, the expression of type I Cbfa1 was elevated prior to differentiation to the hypertrophic phenotype, which is characterized by type X collagen expression. Treatment with antisense oligonucleotides for type I Cbfa1 severely reduced type X collagen expression in ATDC5 cells. Retrovirally forced expression of either type I or type II Cbfa1 in chick immature chondrocytes induced type X collagen and MMP13 expression, alkaline phosphatase activity, and extensive cartilage-matrix mineralization, These results indicate that Cbfa1 is an important regulatory factor in chondrocyte maturation.	Osaka Univ, Sch Med, Dept Mol Med, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan; Osaka Univ, Fac Dent, Dept Biochem, Suita, Osaka 5650871, Japan; Osaka Univ, Fac Dent, Dept Oral Anat & Dev Biol, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, Form & Funct Precursory Res Embryon Sci & Technol, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Komori, T (corresponding author), Osaka Univ, Sch Med, Dept Mol Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Kishimoto, Tadamitsu/C-8470-2009					Akiyama H, 1996, J BONE MINER RES, V11, P22; APTE SS, 1993, MATRIX, V13, P165, DOI 10.1016/S0934-8832(11)80075-2; ATSUMI T, 1990, CELL DIFFER DEV, V30, P109, DOI 10.1016/0922-3371(90)90079-C; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; CELI FS, 1993, NUCLEIC ACIDS RES, V21, P1047, DOI 10.1093/nar/21.4.1047; DAHL LK, 1952, P SOC EXP BIOL MED, V80, P474, DOI 10.3181/00379727-80-19661; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; Gerstenfeld L.C., 1991, J CELL BIOL, V104, P1435; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.0.CO;2-W; IWAMOTO M, 1993, EXP CELL RES, V205, P213, DOI 10.1006/excr.1993.1079; IWAMOTO M, 1993, J BIOL CHEM, V268, P9645; Jimenez MJG, 1999, MOL CELL BIOL, V19, P4431; JOHNSONWINT B, 1982, ANAL BIOCHEM, V122, P338, DOI 10.1016/0003-2697(82)90292-5; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Kawabe Y, 1999, BBA-MOL CELL BIOL L, V1436, P307, DOI 10.1016/S0005-2760(98)00119-2; Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925-4773(98)00210-X; Komori T, 1998, CURR OPIN GENET DEV, V8, P494, DOI 10.1016/S0959-437X(98)80123-8; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; KOSHER RA, 1986, J CELL BIOL, V102, P1151, DOI 10.1083/jcb.102.4.1151; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LEBOY PS, 1989, J BIOL CHEM, V264, P17281; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Lei HQ, 1999, BIOL REPROD, V60, P183, DOI 10.1095/biolreprod60.1.183; LU J, 1995, MOL CELL BIOL, V15, P1651; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; NEUGEBAUER BM, 1995, J BONE MINER RES, V10, P157; NOMURA S, 1993, ACTA HISTOCHEM CYTOC, V26, P303, DOI 10.1267/ahc.26.303; OETTINGER HF, 1990, EXP CELL RES, V191, P292, DOI 10.1016/0014-4827(90)90017-5; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; Shukunami C, 1997, J BONE MINER RES, V12, P1174, DOI 10.1359/jbmr.1997.12.8.1174; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Tsuji K, 1998, BONE, V22, P87, DOI 10.1016/S8756-3282(97)00267-6; VASIOS G, 1988, J BIOL CHEM, V263, P2324	40	336	351	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8695	8702		10.1074/jbc.275.12.8695	http://dx.doi.org/10.1074/jbc.275.12.8695			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722711	hybrid			2022-12-27	WOS:000086507700061
J	Le Roch, K; Sestier, C; Dorin, D; Waters, N; Kappes, B; Chakrabarti, D; Meijer, L; Doerig, C				Le Roch, K; Sestier, C; Dorin, D; Waters, N; Kappes, B; Chakrabarti, D; Meijer, L; Doerig, C			Activation of a Plasmodium falciparum cdc2-related kinase by heterologous p25 and cyclin H - Functional characterization of a P. falciparum cyclin homologue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; DEPENDENT KINASE-5; CELL-CYCLE; MECHANISMS; INHIBITORS; EXPRESSION; PHOSPHORYLATION; CLONING; CDK5; CAK	Several Plasmodium falciparum genes encoding cdc2-related protein kinases have been identified, but the modalities of their regulation remains largely unexplored. Zn the present study, we investigated the regulation in vitro of PfPK5, a putative homologue of Cdk1 (cdc2) in P. falciparum. We show that (i) PfPK5 is efficiently activated by heterologous (human) cyclin H and p25, a cyclin-like molecule that specifically activates human Cdk5; (ii) the activated enzyme can be inhibited by chemical Cdk inhibitors; (iii) Pfmrk, a putative P. falciparum homologue of the Cdk-activating kinase, does neither activate nor phosphorylate PfPK5; and (iv) PfPK5 is able to autophosphorylate in the presence of a cyclin, Taken together, these results suggest that the regulation of Plasmodium Cdks may differ in important aspects from that of their human counterparts. Furthermore, we cloned an open reading frame encoding a novel P. falciparum protein possessing maximal homology to cyclin H from various organisms, and we show that this protein, called Pfcyc-1, is able to activate recombinant PfPK5 in vitro with an efficiency similar to that of human cyclin H and p25, This work opens the way to the development of screening procedures aimed at identifying compounds that specifically target the parasite Cdks.	INSERM, U511, F-75013 Paris, France; Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Div Expt Therapeut, Washington, DC 20307 USA; Heidelberg Univ, Ctr Biochem, D-69120 Heidelberg, Germany; Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32016 USA; CNRS, Stn Biol Roscoff, F-29682 Roscoff, France	Institut National de la Sante et de la Recherche Medicale (Inserm); United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center; Ruprecht Karls University Heidelberg; State University System of Florida; University of Central Florida; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Doerig, C (corresponding author), INSERM, U511, 91 Bd Hop, F-75013 Paris, France.	doerig@ext.jussieu.fr	Doerig, Christian/Q-9900-2019	Doerig, Christian/0000-0002-3188-094X				Arnot DE, 1998, ANN TROP MED PARASIT, V92, P361, DOI 10.1080/00034989859357; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DOERIG C, 1995, MOL BIOCHEM PARASIT, V70, P167, DOI 10.1016/0166-6851(95)00033-W; Dorin D, 1999, J BIOL CHEM, V274, P29912, DOI 10.1074/jbc.274.42.29912; Espinoza FH, 1996, SCIENCE, V273, P1714, DOI 10.1126/science.273.5282.1714; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; Gomez EB, 1998, MOL BIOCHEM PARASIT, V91, P337, DOI 10.1016/S0166-6851(97)00218-1; Graeser R, 1996, MOL BIOCHEM PARASIT, V79, P125, DOI 10.1016/0166-6851(96)02643-6; Graeser R, 1996, MOL BIOCHEM PARASIT, V82, P37, DOI 10.1016/0166-6851(96)02716-8; Gray N, 1999, CURR MED CHEM, V6, P859; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Heitz F, 1997, BIOCHEMISTRY-US, V36, P4995, DOI 10.1021/bi962349y; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; Huang DQ, 1998, MOL CELL BIOL, V18, P3289, DOI 10.1128/MCB.18.6.3289; Kappes B, 1999, PARASITOL TODAY, V15, P449, DOI 10.1016/S0169-4758(99)01527-6; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Li JL, 1996, EUR J BIOCHEM, V241, P805, DOI 10.1111/j.1432-1033.1996.00805.x; Measday V, 1997, MOL CELL BIOL, V17, P1212, DOI 10.1128/MCB.17.3.1212; Meijer L, 2000, CHEM BIOL, V7, P51, DOI 10.1016/S1074-5521(00)00063-6; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MOTTRAM JC, 1994, PARASITOL TODAY, V10, P253, DOI 10.1016/0169-4758(94)90136-8; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; ROSSMACDONALD PB, 1994, EUR J BIOCHEM, V220, P693, DOI 10.1111/j.1432-1033.1994.tb18670.x; Sharma P, 1999, P NATL ACAD SCI USA, V96, P11156, DOI 10.1073/pnas.96.20.11156; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; Tang D, 1996, Prog Cell Cycle Res, V2, P205; Tang DM, 1997, J BIOL CHEM, V272, P12318, DOI 10.1074/jbc.272.19.12318; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Waters AP, 1997, METHODS, V13, P134, DOI 10.1006/meth.1997.0506; WATERS NC, 1999, IN PRESS MOL BIOCH P; White NJ, 1998, ANN TROP MED PARASIT, V92, P449, DOI 10.1080/00034989859429; [No title captured]	34	88	91	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8952	8958		10.1074/jbc.275.12.8952	http://dx.doi.org/10.1074/jbc.275.12.8952			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722743	Green Submitted, hybrid			2022-12-27	WOS:000086507700093
J	Van Hellemond, JJ; Neuville, P; Schwarz, RT; Matthews, KR; Mottram, JC				Van Hellemond, JJ; Neuville, P; Schwarz, RT; Matthews, KR; Mottram, JC			Isolation of Trypanosoma brucei CYC2 and CYC3 cyclin genes by rescue of a yeast G(1) cyclin mutant - Functional characterization of CYC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDC2-RELATED PROTEIN-KINASES; MITOTIC-LIKE CYCLIN; HISTONE H1 KINASE; RNA-POLYMERASE-II; LEISHMANIA-MEXICANA; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; DEPENDENT KINASES; DESTRUCTION BOX	Two Trypanosoma brucei cyclin genes, CYC2 and CYC3, have been isolated by rescue of the Saccharomyces cerevisiae mutant DL1, which is deficient in CLN G(1) cyclin function. CYC2 encodes a 24-kDa protein that has sequence identity to the Neurospora crassa PREG1 and the S. cerevisiae PHO80 cyclin. CYC3 has the most sequence identity to mitotic B-type cyclins from a variety of organisms. Both CYC2 and CYC3 are single-copy genes and expressed in all life cycle stages of the parasite. To determine if CYC2 is found in a complex with previously identified trypanosome cdc2-related kinases (CRKs), the CYC2 gene was fused to the TY epitope tag, integrated into the trypanosome genome, and expressed under inducible control. CYC2ty was found to associate with an active trypanosome CRK complex since CYC2ty bound to leishmanial p12(cks1), and histone H1 kinase activity was detected in CYC2ty immune-precipitated fractions. Gene knockout experiments provide evidence that CYC2 is an essential gene, and co-immune precipitations together with a two-hybrid interaction assay demonstrated that CYC2 interacts with CRK3. The CRK3 . CYC2ty complex, the first cyclin-dependent kinase complex identified in trypanosomes, was localized by immune fluorescence to the cytoplasm throughout the cell cycle.	Univ Glasgow, Wellcome Ctr Mol Parasitol, Anderson Coll, Glasgow G11 6NU, Lanark, Scotland; Univ Marburg, Zentrum Hyg & Med Mikrobiol, D-35037 Marburg, Germany; Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Glasgow; Philipps University Marburg; University of Manchester	Mottram, JC (corresponding author), Univ Glasgow, Wellcome Ctr Mol Parasitol, Anderson Coll, 56 Dumbarton Rd, Glasgow G11 6NU, Lanark, Scotland.	j.mottram@udcf.gla.ac.uk	van Hellemond, Jaap/T-7555-2019	van Hellemond, Jaap/0000-0003-4862-7796; Matthews FRS FMedSci FRSE, Professor Keith/0000-0003-0309-9184; Mottram, Jeremy/0000-0001-5574-3766				AFFRANCHINO JL, 1993, GENE, V132, P75, DOI 10.1016/0378-1119(93)90516-6; AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; Andrews B, 1998, TRENDS GENET, V14, P66, DOI 10.1016/S0168-9525(97)01322-X; Arnaud L, 1998, CHROMOSOMA, V107, P424, DOI 10.1007/s004120050326; Barrett MP, 1999, TRENDS MICROBIOL, V7, P82, DOI 10.1016/S0966-842X(98)01433-4; Bastin P, 1996, MOL BIOCHEM PARASIT, V77, P235, DOI 10.1016/0166-6851(96)02598-4; BERBEROF M, 1995, EMBO J, V14, P2925, DOI 10.1002/j.1460-2075.1995.tb07292.x; Biebinger S, 1997, MOL BIOCHEM PARASIT, V85, P99, DOI 10.1016/S0166-6851(96)02815-0; Bochar DA, 1999, J BIOL CHEM, V274, P13162, DOI 10.1074/jbc.274.19.13162; BROWN L, 1992, NUCLEIC ACIDS RES, V20, P5451, DOI 10.1093/nar/20.20.5451; BROWN NR, 1995, STRUCTURE, V3, P1235, DOI 10.1016/S0969-2126(01)00259-3; BRUN R, 1979, ACTA TROP, V36, P289; Colgan DF, 1998, EMBO J, V17, P1053, DOI 10.1093/emboj/17.4.1053; Day IS, 1996, PLANT MOL BIOL, V30, P565, DOI 10.1007/BF00049332; Docampo R, 1999, PARASITOL TODAY, V15, P443, DOI 10.1016/S0169-4758(99)01531-8; Furger A, 1997, MOL CELL BIOL, V17, P4372, DOI 10.1128/MCB.17.8.4372; GLASSSMITH G, 1997, THESIS U GLASGOW; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gomez EB, 1998, MOL BIOCHEM PARASIT, V91, P337, DOI 10.1016/S0166-6851(97)00218-1; Grant KM, 1998, J BIOL CHEM, V273, P10153, DOI 10.1074/jbc.273.17.10153; HARDIE DG, 1994, CELL SIGNAL, V6, P813; Harlow E., 1988, ANTIBODIES LAB MANUA; Hautbergue G, 1999, MOL CELL BIOL, V19, P2527; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Hotz HR, 1998, MOL BIOCHEM PARASIT, V91, P131, DOI 10.1016/S0166-6851(97)00196-5; Hua SB, 1997, MOL BIOCHEM PARASIT, V84, P255, DOI 10.1016/S0166-6851(96)02804-6; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KANG S, 1993, GENETICS, V133, P193; Klotzbucher A, 1996, EMBO J, V15, P3053, DOI 10.1002/j.1460-2075.1996.tb00668.x; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Leclerc V, 1996, MOL BIOL CELL, V7, P505, DOI 10.1091/mbc.7.4.505; Lenburg ME, 1996, TRENDS BIOCHEM SCI, V21, P383, DOI 10.1016/S0968-0004(96)90127-9; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; Levine K, 1999, MOL CELL, V4, P353, DOI 10.1016/S1097-2765(00)80337-8; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATTHEWS KR, 1994, PARASITOL TODAY, V10, P473, DOI 10.1016/0169-4758(94)90159-7; MazhariTabrizi R, 1996, BIOCHEM J, V316, P853, DOI 10.1042/bj3160853; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V59, P327, DOI 10.1016/0166-6851(93)90231-L; Melville SE, 1998, MOL BIOCHEM PARASIT, V94, P155, DOI 10.1016/S0166-6851(98)00054-1; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTTRAM JC, 1994, PARASITOL TODAY, V10, P253, DOI 10.1016/0169-4758(94)90136-8; Mottram JC, 1996, BIOCHEM J, V316, P833, DOI 10.1042/bj3160833; Mottram JC, 1996, MOL MICROBIOL, V22, P573, DOI 10.1046/j.1365-2958.1996.00136.x; MOTTRAM JC, 1995, GENE, V162, P147, DOI 10.1016/0378-1119(95)00350-F; MOTTRAM JC, 1993, J BIOL CHEM, V268, P21044; MUHICH ML, 1988, MOL CELL BIOL, V8, P3837, DOI 10.1128/MCB.8.9.3837; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; ONEILL EM, 1995, NATURE, V374, P121, DOI 10.1038/374121a0; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; Rickert P, 1996, ONCOGENE, V12, P2631; Rodrigues CO, 1999, MOL CELL BIOL, V19, P7712; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHERMAN DR, 1991, EMBO J, V10, P3379, DOI 10.1002/j.1460-2075.1991.tb04902.x; Sogin ML, 1991, CURR OPIN GENET DEV, V1, P457, DOI 10.1016/S0959-437X(05)80192-3; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TURNER CMR, 1989, PARASITOLOGY, V99, P67, DOI 10.1017/S0031182000061035; Urbina JA, 1999, J BIOL CHEM, V274, P33609, DOI 10.1074/jbc.274.47.33609; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; VICKERMAN K, 1985, BRIT MED BULL, V41, P105, DOI 10.1093/oxfordjournals.bmb.a072036; Voit R, 1999, EMBO J, V18, P1891, DOI 10.1093/emboj/18.7.1891; Wang YX, 1998, MOL BIOCHEM PARASIT, V96, P139, DOI 10.1016/S0166-6851(98)00121-2; WIRTZ E, 1995, SCIENCE, V268, P1179, DOI 10.1126/science.7761835; WOODWARD R, 1990, J CELL SCI, V95, P49; Yamano H, 1996, EMBO J, V15, P5268, DOI 10.1002/j.1460-2075.1996.tb00912.x; Yamano H, 1998, EMBO J, V17, P5670, DOI 10.1093/emboj/17.19.5670; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zhao WQ, 1998, MOL CELL BIOL, V18, P5010, DOI 10.1128/MCB.18.9.5010	74	45	45	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8315	8323		10.1074/jbc.275.12.8315	http://dx.doi.org/10.1074/jbc.275.12.8315			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722661	hybrid			2022-12-27	WOS:000086507700011
J	Yahata, T; de Caestecker, MP; Lechleider, RJ; Andriole, S; Roberts, AB; Isselbacher, KJ; Shioda, T				Yahata, T; de Caestecker, MP; Lechleider, RJ; Andriole, S; Roberts, AB; Isselbacher, KJ; Shioda, T			The MSG1 non-DNA-binding transactivator binds to the p300/CBP coactivators, enhancing their functional link to the Smad transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOCYTE-SPECIFIC GENE; B-CELL COACTIVATOR; MOLECULAR-CLONING; TUMOR-SUPPRESSOR; NUCLEAR-PROTEIN; ACTIVATION; PROMOTER; DOMAIN; SMAD4/DPC4; EXPRESSION	The MSG1 nuclear protein has a strong transcriptional activating activity but does not bind directly to DNA, When cotransfected, MSG1 enhances transcription mediated by the Smad transcription factors in mammalian cells in a manner dependent on ligand-induced Smad hetero-oligomerization. However, the mechanism of this MSG1 effect has been unknown. We now show that MSG1 directly binds to the p300/cAMP-response element-binding protein-binding protein (CBP) transcriptional coactivators, which in turn bind to the Smads, and enhances Smad-mediated transcription in a manner dependent on p300/CBP, The C-terminal transactivating domain of MSG1 is required for binding to p300/CBP and enhancement of Smad-mediated transcription; the viral VP16 transactivating domain could not substitute for it. In the N-terminal region of MSG1, we identified a domain that is necessary and sufficient to direct the specific interaction of MSG1 with Smads, We also found that the Hsc70 heat-shock cognate protein also forms complex with MSG1 in vivo suppressing both binding of MSG1 to p300/CBP and enhancement of Smad-mediated transcription by MSG1, These results indicate that MSG1 interacts with both the DNA-binding Smad proteins and the p300/CBP coactivators through its N- and C-terminal regions, respectively, and enhances the functional link between Smads and p300/CBP.	Massachusetts Gen Hosp E, Ctr Canc, Lab Tumor Biol, Charlestown, MA 02129 USA; NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Shioda, T (corresponding author), Ctr Canc, Lab Tumor Biol, Bldg 149,7th Floor,13th St, Charlestown, MA 02129 USA.	shioda@helix.mgh.harvard.edu			NCI NIH HHS [R01 CA82230] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; CARTER D, 1997, FEBS LETT, V13, P81; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Datto MB, 1999, MOL CELL BIOL, V19, P2495; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Dunwoodie SL, 1998, MECH DEVELOP, V72, P27, DOI 10.1016/S0925-4773(98)00011-2; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Fenner MH, 1998, GENOMICS, V51, P401, DOI 10.1006/geno.1998.5383; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FRY CJ, 1999, J BIOL CHEM, V274, P25983; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; Glenn DJ, 1999, J BIOL CHEM, V274, P36159, DOI 10.1074/jbc.274.51.36159; Gstaiger M, 1996, EMBO J, V15, P2781, DOI 10.1002/j.1460-2075.1996.tb00638.x; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Johnson K, 1999, J BIOL CHEM, V274, P20709, DOI 10.1074/jbc.274.29.20709; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Li HC, 1998, EXP CELL RES, V242, P478, DOI 10.1006/excr.1998.4123; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; PEIFER M, 1997, SCIENCE, V275, P1049; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Shioda T, 1998, P NATL ACAD SCI USA, V95, P9785, DOI 10.1073/pnas.95.17.9785; Shioda T, 1996, P NATL ACAD SCI USA, V93, P12298, DOI 10.1073/pnas.93.22.12298; Shioda T, 1997, GENE, V204, P235, DOI 10.1016/S0378-1119(97)00551-9; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; WALKER S, 1994, CELL, V79, P841, DOI 10.1016/0092-8674(94)90073-6; Waltzer L, 1999, EMBO J, V18, P1630, DOI 10.1093/emboj/18.6.1630; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YAVUZER U, 1995, ONCOGENE, V10, P123; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	50	101	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8825	8834		10.1074/jbc.275.12.8825	http://dx.doi.org/10.1074/jbc.275.12.8825			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722728	hybrid			2022-12-27	WOS:000086507700078
J	Marty, I; Thevenon, D; Scotto, C; Groh, S; Sainnier, S; Robert, M; Grunwald, D; Villaz, M				Marty, I; Thevenon, D; Scotto, C; Groh, S; Sainnier, S; Robert, M; Grunwald, D; Villaz, M			Cloning and characterization of a new isoform of skeletal muscle triadin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL SARCOPLASMIC-RETICULUM; RYANODINE RECEPTOR; DIHYDROPYRIDINE RECEPTOR; FOOT PROTEIN; BIOCHEMICAL-CHARACTERIZATION; GLYCOPROTEIN TRIADIN; CALSEQUESTRIN; LOCALIZATION; COMPLEX; PURIFICATION	We have shown that several isoforms of triadin, a protein involved in calcium release process through the ryanodine receptor, are expressed in rat skeletal muscle, and we have cloned two of these isoforms. One is the rat homolog of the 95-kDa triadin identified in rabbit skeletal muscle, and the second one, shorter, is a truncated form of the previous one, but with a new unique COOH-terminal end. We propose to name the two proteins identified here Trisk 95 and Trisk 51. We have produced antibodies specific to each isoform. Using these antibodies, we have shown that the newly identified protein, Trisk 51, is actually expressed in adult rat skeletal muscle and also in rat embryo skeletal muscle. Immunofluorescent labeling of rat skeletal muscle with anti-Trisk 95, anti-Trisk 51, or anti-ryanodine receptor antibodies shows a similar localization of these proteins, in the tissue. Transfection of L6 cells with cDNA of Trisk 51 or Trisk 95 leads to the expression of proteins with the expected molecular weight, identical to those detected in rat skeletal muscle. Both proteins appear during differentiation of satellite cells in myotubes which may indicate the involvement of these two isoforms in the building of a functional calcium, release machinery.	Commissariat Energie Atom, INSERM, E9931, Dept Biol Mol & Struct Canaux Ion & Signalisat, F-38054 Grenoble, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Marty, I (corresponding author), Commissariat Energie Atom, INSERM, E9931, Dept Biol Mol & Struct Canaux Ion & Signalisat, 17 Rue Martyrs, F-38054 Grenoble, France.	imarty@cea.fr	Marty, Isabelle/N-7114-2017; Marty, Isabelle/ABF-5362-2020	Marty, Isabelle/0000-0003-3625-913X				BRANDT NR, 1990, J MEMBRANE BIOL, V113, P237, DOI 10.1007/BF01870075; Caswell AH, 1999, BIOCHEMISTRY-US, V38, P90, DOI 10.1021/bi981306+; CASWELL AH, 1991, BIOCHEMISTRY-US, V30, P7507, DOI 10.1021/bi00244a020; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CHAUDHARI N, 1993, DEV BIOL, V155, P507, DOI 10.1006/dbio.1993.1048; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; FAN HR, 1995, BIOCHEMISTRY-US, V34, P14902, DOI 10.1021/bi00045a035; Froemming GR, 1999, BBA-BIOMEMBRANES, V1418, P197, DOI 10.1016/S0005-2736(99)00024-3; Groh S, 1999, J BIOL CHEM, V274, P12278, DOI 10.1074/jbc.274.18.12278; Guo W, 1996, J BIOL CHEM, V271, P458, DOI 10.1074/jbc.271.1.458; GUO W, 1995, J BIOL CHEM, V270, P9027, DOI 10.1074/jbc.270.16.9027; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P1740; Jones LR, 1995, J BIOL CHEM, V270, P30787, DOI 10.1074/jbc.270.51.30787; KIM KC, 1990, BIOCHEMISTRY-US, V29, P9281, DOI 10.1021/bi00491a025; KNUDSON CM, 1993, J BIOL CHEM, V268, P12637; KNUDSON CM, 1993, J BIOL CHEM, V268, P12646; Kobayashi YM, 1999, J BIOL CHEM, V274, P28660, DOI 10.1074/jbc.274.40.28660; KOENIG J, 1982, DEV BIOL, V92, P188, DOI 10.1016/0012-1606(82)90162-2; KYSELOVIC J, 1994, J BIOL CHEM, V269, P21770; LAI FA, 1987, BIOCHEM BIOPH RES CO, V143, P704, DOI 10.1016/0006-291X(87)91411-2; MARTY I, 1994, P NATL ACAD SCI USA, V91, P2270, DOI 10.1073/pnas.91.6.2270; MARTY I, 1995, BIOCHEM J, V307, P769, DOI 10.1042/bj3070769; Ohkura M, 1998, BIOCHEMISTRY-US, V37, P12987, DOI 10.1021/bi972803d; PENG M, 1994, FEBS LETT, V348, P17, DOI 10.1016/0014-5793(94)00556-7; Rannou F, 1996, CARDIOVASC RES, V32, P258, DOI 10.1016/0008-6363(96)00095-8; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; SUTKO JL, 1991, J CELL BIOL, V113, P793, DOI 10.1083/jcb.113.4.793; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; YANO K, 1994, MOL CELL BIOCHEM, V135, P61, DOI 10.1007/BF00925961; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389	33	44	45	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8206	8212		10.1074/jbc.275.11.8206	http://dx.doi.org/10.1074/jbc.275.11.8206			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713145	hybrid			2022-12-27	WOS:000085913300105
J	Reilly, JF; Mickey, G; Maher, PA				Reilly, JF; Mickey, G; Maher, PA			Association of fibroblast growth factor receptor 1 with the adaptor protein Grb14 - Characterization of a new receptor binding partner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELIMINATES PHOSPHATIDYLINOSITOL HYDROLYSIS; PLECKSTRIN HOMOLOGY DOMAINS; SH2 DOMAIN; INSULIN-RECEPTOR; TYROSINE KINASE; POINT MUTATION; CLONING; ACTIVATION; FAMILY; CELLS	Using the cytoplasmic domain of fibroblast growth factor receptor 1 (FGFR1) as bait in a yeast two-hybrid screen, Grb14 was identified as a FGFR1 binding partner. A kinase-inactive mutant of FGFR1 failed to interact with Grb14, indicating that activation of FGFR1 is necessary for binding. Deletion of the C-tail or mutation of both C-tail tyrosine residues of FGFR1 to phenylalanine abolished binding and deletion of the juxtamembrane domain of the receptor reduced binding, suggesting that Grb14 binds to FGFR1 at multiple sites. Co. immunoprecipitation and in vitro binding assays demonstrated that binding of Grb14 to FGFR1 in mammalian cells was dependent on receptor activation by fibroblast growth factor-2 (FGF-2), Deletion of the Src homology 2 (SH2) domain of Grb14 reduced but did not block binding to FGFR1 and eliminated dependence on receptor activation. The SH2 domain alone bound both FGFR1 and platelet-derived growth factor receptor, whereas full-length Grb14 bound only FGFR1, suggesting that regions upstream of the SH2 domain confer specificity for FGFR1. Grb14 was phosphorylated on serine and threonine residues in unstimulated cells, and treatment with FGF-2 enhanced this phosphorylation. Expression of exogenous Grb14 inhibited FGF-2-induced cell proliferation, whereas a point-mutated form of Grb14 incapable of binding to FGFR1 enhanced FGF-2-induced mitogenesis, These data demonstrate an interaction between activated FGFR1 and Grb14 and suggest a role for Grb14 in FGF signaling.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Maher, PA (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd,CAL-3, La Jolla, CA 92037 USA.	pmaher@scripps.edu		Reilly, John/0000-0002-7164-0246	NIGMS NIH HHS [GM 54604] Funding Source: Medline; NINDS NIH HHS [NS 28121] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054604] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS028121] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baird Andrew, 1994, Current Opinion in Neurobiology, V4, P78, DOI 10.1016/0959-4388(94)90035-3; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; Dong LQ, 1998, J BIOL CHEM, V273, P17720, DOI 10.1074/jbc.273.28.17720; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Jones N, 1999, J BIOL CHEM, V274, P30896, DOI 10.1074/jbc.274.43.30896; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; Kasus-Jacobi A, 1998, J BIOL CHEM, V273, P26026, DOI 10.1074/jbc.273.40.26026; Keegan K, 1996, ONCOGENE, V12, P1537; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Mano H, 1998, GENES CELLS, V3, P431, DOI 10.1046/j.1365-2443.1998.00201.x; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Morrione A, 1997, J BIOL CHEM, V272, P26382, DOI 10.1074/jbc.272.42.26382; Morrione A, 1996, CANCER RES, V56, P3165; Morrione A, 1999, J BIOL CHEM, V274, P24094, DOI 10.1074/jbc.274.34.24094; Moutoussamy S, 1998, J BIOL CHEM, V273, P15906, DOI 10.1074/jbc.273.26.15906; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OOI J, 1995, ONCOGENE, V10, P1621; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; PASQUALE EB, 1988, J CELL PHYSIOL, V137, P146, DOI 10.1002/jcp.1041370118; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; Raffel GD, 1996, J BIOL CHEM, V271, P4640; SOROKIN A, 1994, J BIOL CHEM, V269, P17056; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Wang J, 1999, MOL CELL BIOL, V19, P6217; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942	48	59	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7771	7778		10.1074/jbc.275.11.7771	http://dx.doi.org/10.1074/jbc.275.11.7771			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713090	hybrid			2022-12-27	WOS:000085913300050
J	Baerends, RJS; Faber, KN; Kram, AM; Kiel, JAKW; van der Klei, IJ; Veenhuis, M				Baerends, RJS; Faber, KN; Kram, AM; Kiel, JAKW; van der Klei, IJ; Veenhuis, M			A stretch of positively charged amino acids at the N terminus of Hansenula polymorpha Pex3p is involved in incorporation of the protein into the peroxisomal membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; METHANOL METABOLISM; MATRIX PROTEIN; GENE ENCODES; BIOGENESIS; YEAST; IMPORT; PROLIFERATION; OXIDASE	Pex3p is a peroxisomal membrane protein that is essential for peroxisome biogenesis, Here, we show that a conserved stretch of positively charged amino acids (Arg(11)-X-Lys-Lys-Lys(15)) in the N terminus of Hansenula polymorpha Pex3p is involved in incorporation of the protein into its target membrane. Despite the strong conservation, this sequence shows a high degree of redundancy. Substitution of either Arg(11), Lys(13), Lys(14), Or Lys(15) with uncharged or negatively charged amino acids did not interfere with Pex3p location and function. However, a mutant Pex3p, carrying negatively charged amino acids at position 13 and 15 (K13E/K15E), caused moderate but significant defects in peroxisome assembly and matrix protein import. Additional changes in the N terminus of Pex3p, e.g. replacing three or four of the positively charged amino acids with negatively charged ones, led to a typical pex3 phenotype, i.e. accumulation of peroxisomal matrix proteins in the cytosol and absence of peroxisomal remnants. Also, in these cases, the mutant Pex3p levels mere reduced. Remarkably, mutant Pex3p proteins mere mislocalized to mitochondria or the cytosol, depending on the nature of the mutation, Furthermore, in case of reduced amounts of Pex3p, the levels of other peroxisomal membrane proteins, e.g Pex10p and Pex14p, were also diminished, suggesting that Pex3p maybe involved in the recruitment or stabilization of these proteins tin the membrane).	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Veenhuis, M (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.		van der Klei, Ida J/D-1919-2012	Van der Klei, Ida J./0000-0001-7165-9679				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Baerends RJS, 1997, YEAST, V13, P1437; Baerends RJS, 1996, J BIOL CHEM, V271, P8887, DOI 10.1074/jbc.271.15.8887; Baerends RJS, 1997, YEAST, V13, P1449, DOI 10.1002/(SICI)1097-0061(199712)13:15<1449::AID-YEA191>3.0.CO;2-Q; BRAVERMAN N, 1995, HUM MOL GENET, V4, P1791, DOI 10.1093/hmg/4.suppl_1.1791; DOUMA AC, 1985, ARCH MICROBIOL, V143, P237, DOI 10.1007/BF00411242; Dyer JM, 1996, J CELL BIOL, V133, P269, DOI 10.1083/jcb.133.2.269; Elgersma Y, 1997, EMBO J, V16, P7326, DOI 10.1093/emboj/16.24.7326; Erdmann R, 1997, TRENDS CELL BIOL, V7, P400, DOI 10.1016/S0962-8924(97)01126-4; FABER KN, 1995, FEBS LETT, V357, P115, DOI 10.1016/0014-5793(94)01317-T; FABER KN, 1992, J GEN MICROBIOL, V138, P2405, DOI 10.1099/00221287-138-11-2405; FABER KN, 1994, CURR GENET, V25, P305, DOI 10.1007/BF00351482; GLEESON MA, 1988, YEAST, V4, P293, DOI 10.1002/yea.320040407; Huhse B, 1998, J CELL BIOL, V140, P49, DOI 10.1083/jcb.140.1.49; Kammerer S, 1998, FEBS LETT, V429, P53, DOI 10.1016/S0014-5793(98)00557-2; Kiel JAKW, 1995, FEBS LETT, V377, P434, DOI 10.1016/0014-5793(95)01385-7; Kiel JAKW, 1999, YEAST, V15, P1059, DOI 10.1002/(SICI)1097-0061(199908)15:11<1059::AID-YEA434>3.0.CO;2-I; Komori M, 1999, FEBS LETT, V457, P397, DOI 10.1016/S0014-5793(99)01087-X; Komori M, 1997, EMBO J, V16, P44, DOI 10.1093/emboj/16.1.44; KRAUSE T, 1995, THESIS RUHR U BOCHUM; Kunau WH, 1998, CURR OPIN MICROBIOL, V1, P232, DOI 10.1016/S1369-5274(98)80016-7; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; McNew JA, 1996, TRENDS BIOCHEM SCI, V21, P54, DOI 10.1016/S0968-0004(96)80181-2; MERCKELBACH A, 1993, APPL MICROBIOL BIOT, V40, P361, DOI 10.1007/BF00170393; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Sambrook J., 2002, MOL CLONING LAB MANU; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; Subramani S, 1997, NAT GENET, V15, P331, DOI 10.1038/ng0497-331; TAN XQ, 1995, J CELL BIOL, V128, P307, DOI 10.1083/jcb.128.3.307; van der Klei IJ, 1997, TRENDS MICROBIOL, V5, P502, DOI 10.1016/S0966-842X(97)01156-6; van der Klei IJ, 1998, CURR GENET, V34, P1, DOI 10.1007/s002940050360; van der Klei IJ, 1998, EMBO J, V17, P3608, DOI 10.1093/emboj/17.13.3608; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VANDERKLEI IJ, 1991, ARCH MICROBIOL, V156, P15, DOI 10.1007/BF00418181; VANDIJKEN JP, 1976, ARCH MICROBIOL, V111, P137; VERDUYN C, 1984, J MICROBIOL METH, V2, P15, DOI 10.1016/0167-7012(84)90027-7; WATERHAM HR, 1994, J CELL BIOL, V127, P737, DOI 10.1083/jcb.127.3.737; Wiemer EAC, 1996, J BIOL CHEM, V271, P18973, DOI 10.1074/jbc.271.31.18973	41	126	130	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					9986	9995		10.1074/jbc.275.14.9986	http://dx.doi.org/10.1074/jbc.275.14.9986			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744674	hybrid, Green Published			2022-12-27	WOS:000086345600015
J	Gehring, S; Rottmann, S; Menkel, AR; Mertsching, J; Krippner-Heidenreich, A; Luscher, B				Gehring, S; Rottmann, S; Menkel, AR; Mertsching, J; Krippner-Heidenreich, A; Luscher, B			Inhibition of proliferation and apoptosis by the transcriptional repressor Mad1 - Repression of Fas-induced caspase-8 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE ACTIVITY; MYC ANTAGONIST MAD1; CASEIN KINASE-II; C-MYC; DNA-BINDING; E-BOX; CELL-GROWTH; N-COR; EPIDERMAL DIFFERENTIATION; RAS COTRANSFORMATION	Mad1 is a member of the Myc/Max/Mad network of transcriptional regulators that play a central role in the control of cellular behavior. Mad proteins are thought to antagonize Myc functions at least in part by repressing gene transcription. To systematically examine the function of Mad1 in growth control and during apoptosis, we have generated U2OS cell clones that express Mad1 under a tetracyline-regulatable promoter (UTA-Mad1). Mad1 was induced rapidly and efficiently, localized to the nucleus, and bound to DNA as a heterodimer with Max. The induction of Mad1 reduced cellular growth and, more profoundly, inhibited colony formation of UTA-Mad1 cells. Conditioned medium neutralized this inhibitory effect implying that Mad1 function is regulated by extracellular signals. In addition Mad1 interfered with Fas-, TRAIL-, and UV-induced apoptosis, which coincided with a reduced activation of caspase-8 during Fas-mediated apoptosis in response to Mad1 expression. Furthermore, microinjection of Mad1-expressing plasmids into fibroblasts inhibited apoptosis induced by the oncoproteins c-Myc and E1A. Thus, Mad1 not only interferes with cellular proliferation but also with apoptosis, which defines a novel aspect of Mad1 function.	Hannover Med Sch, Inst Mol Biol, D-30625 Hannover, Germany	Hannover Medical School	Luscher, B (corresponding author), Hannover Med Sch, Inst Mol Biol, OE 5250,Carl Neuberg Str 1, D-30625 Hannover, Germany.	luscher.bernard@mh-hannover.de	Luscher, Bernhard/A-7330-2011	Luscher, Bernhard/0000-0002-9622-8709				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOUSSET K, 1994, CELL MOL BIOL RES, V40, P501; CERNI C, 1995, ONCOGENE, V11, P587; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Cultraro CM, 1997, MOL CELL BIOL, V17, P2353, DOI 10.1128/MCB.17.5.2353; Dang CV, 1999, MOL CELL BIOL, V19, P1; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jones RM, 1996, MOL CELL BIOL, V16, P4754; Kasten MM, 1996, MOL CELL BIOL, V16, P4215; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KROOTH RS, 1964, COLD SPRING HARB SYM, V29, P189, DOI 10.1101/SQB.1964.029.01.024; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LARSSON LG, 1994, ONCOGENE, V9, P1247; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; OELGESCHLAGER M, 1995, MOL CELL BIOL, V15, P5966; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; ROY B, 1995, CELL BIOL INT, V19, P307, DOI 10.1006/cbir.1995.1073; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Sommer A, 1998, J BIOL CHEM, V273, P6632, DOI 10.1074/jbc.273.12.6632; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	70	44	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10413	10420		10.1074/jbc.275.14.10413	http://dx.doi.org/10.1074/jbc.275.14.10413			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744730	hybrid			2022-12-27	WOS:000086345600071
J	Hueber, AO; Zornig, M; Bernard, AM; Chautan, M; Evan, G				Hueber, AO; Zornig, M; Bernard, AM; Chautan, M; Evan, G			A dominant negative Fas-associated death domain protein mutant inhibits proliferation and leads to impaired calcium mobilization in both T-cells and fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; SIGNAL-TRANSDUCTION PATHWAYS; TNF RECEPTOR; INDUCED APOPTOSIS; INTERLEUKIN-2 RECEPTOR; ACTIVATION SIGNALS; CD95 FAS/APO-1; NUCLEAR FACTOR; MICE LACKING; FADD	Death domain-containing members of the tumor necrosis factor (TNF) receptor family ("death receptors") can induce apoptosis upon stimulation by their naural ligands or by agonistic antibodies. Activated death receptors recruit death domain adapter proteins like Fas-associated death domain protein (FADD), and this ultimately leads to proteolytic activation of the caspase cascade and cell death. Recently, FADD has also been implicated in the regulation of proliferation; functional inhibition of FADD results in p53-dependent impairment of proliferation in activated T-cells. In this study we have further analyzed T-cells derived from transgenic mice expressing a dominant negative FADD mutant (FADD DN) under control of lck promoter in vitro so as to identify the signaling pathways that become engaged upon T-cell receptor stimulation and that are regulated by death receptors. FADD DN expression inhibits T-cell proliferation, both at the G(0)-S transition and in the G(1) phase of continuously proliferating cells.	Imperial Canc Res Fund, London WC2A 3PX, England	Cancer Research UK	Hueber, AO (corresponding author), CNRS, INSERM, Ctr Immuno, Case 906, F-13288 Marseille 9, France.	hueber@ciml.univ-mrs.fr	Anne-Odile, Hueber/G-4352-2013; Anne-Odile, Hueber/P-9860-2019	Anne-Odile, Hueber/0000-0003-3816-2446; Anne-Odile, Hueber/0000-0003-3816-2446				AGGARWAL BB, 1995, FEBS LETT, V364, P5, DOI 10.1016/0014-5793(95)00339-B; ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Avdonin V, 1998, P NATL ACAD SCI USA, V95, P11703, DOI 10.1073/pnas.95.20.11703; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; CHARLESWORTH A, 1994, J BIOL CHEM, V269, P32528; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Decker EL, 1998, J BIOL CHEM, V273, P26923, DOI 10.1074/jbc.273.41.26923; Desbarats J, 1998, NAT MED, V4, P1377, DOI 10.1038/3965; Dustin ML, 1999, SCIENCE, V283, P649, DOI 10.1126/science.283.5402.649; GOLSTEIN P, 1995, CELL, V81, P185, DOI 10.1016/0092-8674(95)90327-5; Golstein P, 1997, CURR BIOL, V7, pR750, DOI 10.1016/S0960-9822(06)90000-1; GOUY H, 1990, EUR J IMMUNOL, V20, P2269, DOI 10.1002/eji.1830201016; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; Hoffmeyer A, 1999, J BIOL CHEM, V274, P4319, DOI 10.1074/jbc.274.7.4319; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; ITOH N, 1993, J BIOL CHEM, V268, P10932; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; LEDEIST F, 1995, BLOOD, V85, P1053, DOI 10.1182/blood.V85.4.1053.bloodjournal8541053; Lepple-Wienhues A, 1999, P NATL ACAD SCI USA, V96, P13795, DOI 10.1073/pnas.96.24.13795; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Magnusson C, 1999, IMMUNOL CELL BIOL, V77, P41, DOI 10.1046/j.1440-1711.1999.00800.x; Matsuda S, 1998, J BIOL CHEM, V273, P12378, DOI 10.1074/jbc.273.20.12378; MUSTELIN T, 1998, FRONT BIOSCI, V1, pD1060; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; NOVAK EJ, 1994, CYTOMETRY, V17, P135, DOI 10.1002/cyto.990170205; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PARTISETI M, 1994, J BIOL CHEM, V269, P32327; Penner R, 1993, Curr Opin Neurobiol, V3, P368, DOI 10.1016/0959-4388(93)90130-Q; Peterson EJ, 1998, CURR OPIN IMMUNOL, V10, P337, DOI 10.1016/S0952-7915(98)80173-8; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Rovere P, 1996, J IMMUNOL, V156, P4631; Sakata K, 1998, EUR J IMMUNOL, V28, P2648, DOI 10.1002/(SICI)1521-4141(199809)28:09<2648::AID-IMMU2648>3.0.CO;2-M; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Soares LRB, 1998, J IMMUNOL, V161, P209; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wallach D, 1996, Behring Inst Mitt, P144; Walsh CM, 1998, IMMUNITY, V8, P439, DOI 10.1016/S1074-7613(00)80549-X; WATERS CM, 1990, ONCOGENE, V5, P669; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Wells AD, 1997, J CLIN INVEST, V100, P3173, DOI 10.1172/JCI119873; Wiest DL, 1996, IMMUNITY, V4, P495, DOI 10.1016/S1074-7613(00)80415-X; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zornig M, 1998, CURR BIOL, V8, P467, DOI 10.1016/S0960-9822(98)70182-4	71	63	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10453	10462		10.1074/jbc.275.14.10453	http://dx.doi.org/10.1074/jbc.275.14.10453			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744735	hybrid			2022-12-27	WOS:000086345600076
J	Tarabykina, S; Moller, AL; Durussel, I; Cox, J; Berchtold, MW				Tarabykina, S; Moller, AL; Durussel, I; Cox, J; Berchtold, MW			Two forms of the apoptosis-linked protein ALG-2 with different Ca2+ affinities and target recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EF-HAND; GENE ALG-3; CALCIUM; ACTIVATION; INHIBITORS; THYMOCYTES; CALPAIN; FAMILY; CELLS; CA-2+	The apoptosis-linked gene ALG-2 encodes a Ca2+-binding protein of the penta EF-hand family, To investigate the Ca2+ binding properties of the recombinant ALG-2 protein, Re have cloned ALG-2 cDNA from mouse liver mRNA. Sequence analysis showed that two types of clones were present. One (named ALG-2,5) corresponds to the published ALG-2 sequence (Vito, P., Lacana, E., and D'Adamio, L. (1996) Science 271, 521-525); the second (named ALG-2,1) is 6 nucleotides shorter, and the corresponding protein lacks the amino acid residues Gly(121) and Phe(122), Both transcripts are present in mouse tissues in the same 2:1 molar ratio, The ALG-2,5 and ALG-2,1 recombinant proteins are fully soluble in the metal-free form but can be precipitated from bacterial lysates by Ca2+. In the presence of TR een the Ca2+ binding profiles display two high affinity sites with [Ca2+](0.5) values of 1.2 and 3.1 mu M for ALG-2,5 and ALG-2,1, respectively, plus one low affinity site. Using the yeast two-hybrid system we demonstrate that both proteins have a strong tendency to form homo- and heterodimers. In contrast to ALG-2,5, the ALG-2,1 isoform does not interact with the target protein AIP-1, earlier described to play a role in apoptosis (Vito, P., Pellegrini, L., Guiet, C., and D'Adamio, L. (1999) J. Biol, Chem. 274, 1533-1540), We propose that the minor sequence difference between ALG-2,5 and ALG-2,1 affects the Ca2+ binding properties and function of the proteins.	Univ Copenhagen, Inst Mol Biol, Dept Mol Cell Biol, DK-1353 Copenhagen, Denmark; Univ Geneva, Dept Biochem, CH-1211 Geneva, Switzerland	University of Copenhagen; University of Geneva	Berchtold, MW (corresponding author), Univ Copenhagen, Inst Mol Biol, Dept Mol Cell Biol, Oster Farimagsgade 2A, DK-1353 Copenhagen, Denmark.		Berchtold, Martin/L-1695-2014	Berchtold, Martin/0000-0001-8995-9047				Blanchard H, 1997, NAT STRUCT BIOL, V4, P532, DOI 10.1038/nsb0797-532; BOYHAN A, 1992, J BIOL CHEM, V267, P2928; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN JJ, 1984, J IMMUNOL, V132, P38; COHEN P, 1988, CALMODULIN, V5; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; COX JA, 1995, GUIDEBOOK CALCIUM BI, P1; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRANKFURT OS, 1995, CANCER LETT, V97, P149, DOI 10.1016/0304-3835(95)03970-8; Heizmann CW, 1998, BIOMETALS, V11, P383, DOI 10.1023/A:1009212521172; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; Kawai T, 1999, ONCOGENE, V18, P3471, DOI 10.1038/sj.onc.1202701; Kitaura Y, 1999, BIOCHEM BIOPH RES CO, V263, P68, DOI 10.1006/bbrc.1999.1189; Krebs J, 1998, BIOMETALS, V11, P375, DOI 10.1023/A:1009226316146; Lacana E, 1997, J IMMUNOL, V158, P5129; Lo KWH, 1999, BIOCHEMISTRY-US, V38, P7498, DOI 10.1021/bi990034n; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maki M, 1998, J BIOCHEM, V124, P1170, DOI 10.1093/oxfordjournals.jbchem.a022235; Maki M, 1997, BIOCHEM J, V328, P718; MCCONKEY DJ, 1989, J IMMUNOL, V143, P1801; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; Missotten M, 1999, CELL DEATH DIFFER, V6, P124, DOI 10.1038/sj.cdd.4400456; Nelson MR, 1998, BIOMETALS, V11, P297, DOI 10.1023/A:1009253808876; NICOTERA P, 1990, CHEM RES TOXICOL, V3, P484, DOI 10.1021/tx00018a001; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schwaller B, 1997, J BIOL CHEM, V272, P29663, DOI 10.1074/jbc.272.47.29663; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Squier MKT, 1999, J CELL PHYSIOL, V178, P311, DOI 10.1002/(SICI)1097-4652(199903)178:3<311::AID-JCP5>3.3.CO;2-K; TESHAN CG, 1992, BIOCHEM J, V286, P549; VANDERBLIEK AM, 1986, EMBO J, V5, P3201, DOI 10.1002/j.1460-2075.1986.tb04630.x; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zamparelli C, 1997, FEBS LETT, V409, P1, DOI 10.1016/S0014-5793(97)00464-X	37	45	46	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10514	10518		10.1074/jbc.275.14.10514	http://dx.doi.org/10.1074/jbc.275.14.10514			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744743	hybrid			2022-12-27	WOS:000086345600084
J	Bai, ST; Shi, XM; Yang, XL; Cao, X				Bai, ST; Shi, XM; Yang, XL; Cao, X			Smad6 as a transcriptional corepressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA FAMILY MEMBERS; MAD-RELATED PROTEIN; TUMOR-SUPPRESSOR; MESSENGER-RNA; DNA-BINDING; ANTAGONIST; GENE; DIFFERENTIATION; INDUCTION; RECEPTOR	Smad6 and Smad7, a subgroup of Smad proteins, antagonize the signals elicited by transforming growth factor-beta, These two Smads, induced by transforming growth factor-beta or bone morphogenetic protein (BMP) stimulation, form stable associations with their activated type I receptors, blocking phosphorylation of receptor-regulated Smads in the cytoplasm, Here we show that Smad6 interacts with homeobox (Hox) c-8 as a transcriptional corepressor, inhibiting BMP signaling in the nucleus. The interaction between Smad6 and Hoxc-8 was identified by a yeast two-hybrid approach and further demonstrated by co immunoprecipitation assays in cells. Gel shift assays show that Smad6, but not Smad7, interacts with both Hoxc-8 and Hoxa-9 as a heterodimer when binding to DNA. More importantly, the Smad6-Hoxc-8 complex inhibits interaction of Smad1 with Hoxc-8- and Smad1-induced transcription activity. These data indicate that Smad6 interacts with Hox transcription factors as part of the negative feedback circuit in the BMP signaling pathway.	Univ Alabama, Sch Med, Dept Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Cao, X (corresponding author), 1670 Univ Blvd,VH G002, Birmingham, AL 35294 USA.			Elefteriou, Xiangli/0000-0002-2333-8747	NIDDK NIH HHS [DK53757] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053757] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; Cao X, 1996, J BIOL CHEM, V271, P20650, DOI 10.1074/jbc.271.34.20650; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359-6101(97)00036-1; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; LEMOUELLIC H, 1988, GENE DEV, V2, P125, DOI 10.1101/gad.2.1.125; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nakayama T, 1998, GENES CELLS, V3, P387, DOI 10.1046/j.1365-2443.1998.00196.x; Nakayama T, 1998, DEVELOPMENT, V125, P857; Newfeld SJ, 1999, GENETICS, V152, P783; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; Sakou T, 1999, J BONE MINER RES, V14, P1145, DOI 10.1359/jbmr.1999.14.7.1145; Shi XM, 1999, J BIOL CHEM, V274, P13711, DOI 10.1074/jbc.274.19.13711; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; SIMEONE A, 1987, P NATL ACAD SCI USA, V84, P4914, DOI 10.1073/pnas.84.14.4914; STERNER JM, 1995, J BIOL CHEM, V270, P9281, DOI 10.1074/jbc.270.16.9281; Takase M, 1998, BIOCHEM BIOPH RES CO, V244, P26, DOI 10.1006/bbrc.1998.8200; Yang XL, 2000, J BIOL CHEM, V275, P1065, DOI 10.1074/jbc.275.2.1065; Yueh YG, 1998, P NATL ACAD SCI USA, V95, P9956, DOI 10.1073/pnas.95.17.9956	30	117	126	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8267	8270		10.1074/jbc.275.12.8267	http://dx.doi.org/10.1074/jbc.275.12.8267			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722652	hybrid			2022-12-27	WOS:000086507700002
J	Hurt, E; Strasser, K; Segref, A; Bailer, S; Schlaich, N; Presutti, C; Tollervey, D; Jansen, R				Hurt, E; Strasser, K; Segref, A; Bailer, S; Schlaich, N; Presutti, C; Tollervey, D; Jansen, R			Mex67p mediates nuclear export of a variety of RNA polymerase II transcripts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASH1 MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; NUCLEOCYTOPLASMIC TRANSPORT; PORE COMPLEX; POLY(A)(+) RNA; YEAST; GENE; LOCALIZATION; ACCUMULATION; TRAFFICKING	Mex67p is essential for nuclear poly(A)(+) RNA export in yeast, but which specific transcripts are transported by Mex67p is not known, We observed that thermosensitive mex67-5 cells do not produce a heat shock response at 37 degrees C but will induce heat shock proteins (Hsp) (e.g, Hsp104p and Hsp70p) when shifted back from the restrictive to permissive temperature (30 degrees C). This memory of a previous heat stress in mex67-5 cells could be explained if HSP mRNAs accumulated inside the nucleus during heat shock and mere exported and translated in the cytoplasm on return to the permissive temperature. To test this hypothesis, nuclear export of heat shock mRNAs was directly analyzed by in situ hybridization using fluorescent-labeled oligonucleotide probes specific for SSA transcripts. This revealed that Mex67p is required for nuclear export of heat shock mRNAs. Furthermore, other polymerase II transcripts encoding the transcriptional repressor ASH1 and the glycolytic enzyme PGK1 are shown to require Mex67p for their export into the cytoplasm, Thus, Mex67p is an mRNA export factor for a broad range of polymerase II transcripts.	Heidelberg Univ, BZH, D-69120 Heidelberg, Germany; ZMBH, D-69120 Heidelberg, Germany; Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of Edinburgh	Hurt, E (corresponding author), Heidelberg Univ, BZH, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	cg5@ix.urz.uni-heidelberg.de	Ed Hurt, Dr./AAE-8874-2019; Tollervey, David/AAR-6662-2020; Segref, Alexandra/C-8325-2011	Ed Hurt, Dr./0000-0002-4535-8255; Tollervey, David/0000-0003-2894-2772; Strasser, Katja/0000-0003-3533-5516; PRESUTTI, Carlo/0000-0003-3837-2275; Segref, Alexandra/0000-0001-8095-4469				AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; Bertrand E, 1998, MOL CELL, V2, P437, DOI 10.1016/S1097-2765(00)80143-4; Bobola N, 1996, CELL, V84, P699, DOI 10.1016/S0092-8674(00)81048-X; BOORSTEIN WR, 1990, J BIOL CHEM, V265, P18912; Cole CN, 1998, CURR BIOL, V8, pR368, DOI 10.1016/S0960-9822(98)70239-8; Dasso M, 1998, AM J HUM GENET, V63, P311, DOI 10.1086/301990; Fabre E, 1997, ANNU REV GENET, V31, P277, DOI 10.1146/annurev.genet.31.1.277; Goldstein AL, 1996, MOL BIOL CELL, V7, P917, DOI 10.1091/mbc.7.6.917; Heath CV, 1995, J CELL BIOL, V131, P1677, DOI 10.1083/jcb.131.6.1677; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; KADOWAKI T, 1994, J CELL BIOL, V126, P649, DOI 10.1083/jcb.126.3.649; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; Liu Y, 1999, P NATL ACAD SCI USA, V96, P6739, DOI 10.1073/pnas.96.12.6739; Long RM, 1995, RNA, V1, P1071; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; MANIATIS T, 1982, MOL CLONING LAB MANA; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; NEHRBASS U, 1993, EUR J CELL BIOL, V62, P1; NICOLET CM, 1991, METHOD ENZYMOL, V194, P710; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Saavedra C, 1996, GENE DEV, V10, P1608, DOI 10.1101/gad.10.13.1608; Saavedra CA, 1997, GENE DEV, V11, P2845, DOI 10.1101/gad.11.21.2845; Santos-Rosa H, 1998, MOL CELL BIOL, V18, P6826, DOI 10.1128/MCB.18.11.6826; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Siniossoglou S, 1996, CELL, V84, P265, DOI 10.1016/S0092-8674(00)80981-2; Stutz F, 1997, GENE DEV, V11, P2857, DOI 10.1101/gad.11.21.2857; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3	31	71	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8361	8368		10.1074/jbc.275.12.8361	http://dx.doi.org/10.1074/jbc.275.12.8361			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722667	hybrid			2022-12-27	WOS:000086507700017
J	Wakabayashi, S; Pang, TX; Su, XH; Shigekawa, M				Wakabayashi, S; Pang, TX; Su, XH; Shigekawa, M			A novel topology model of the human Na+/H+ exchanger isoform 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE TOPOLOGY; MOLECULAR-CLONING; GROWTH; NHE1; ANTIPORTER; DOMAIN; PH; IDENTIFICATION; EXPRESSION; MUTATION	The membrane topology of the human Na+/H+ exchanger isoform 1 (NHE1) was assessed by substituted cysteine accessibility analysis. Eighty-three cysteine residues were individually introduced into a functional cysteineless NHE1, and these mutants were expressed in the exchanger-deficient PS120 cells. The topological disposition of introduced cysteines was determined by labeling with a biotinyIated maleimide in the presence or absence of preincubation with the membrane-impermeable sulfhydryI reagent, 2-trimethylammoniumethyl-methanethiosulfonate in streptolysin O-permeabilized or nonpermeabilized cells. We proposed a new model for the topology of NHE1 that is significantly different from the model derived from hydropathy analysis. In this model, NHE1 is composed of 12 transmembrane segments (TMs) with the N and C termini located in the cytosol. The large, last extracellular loop in the membrane domain of the original model was suggested to comprise an intracellular loop, a new transmembrane segment (TM11), and an extraceIlular loop in the new model. Interestingly, cysteines at 183 and 184 and at 324 and 325 mapped to intracellular loops connecting TMs 4 and 5 (IL2) and TMs 8 and 9 (IL4), respectively, were accessible to sulfhydryl reagents hom the outside. Furthermore, exchange activities of two mutants, R180C and Q181C, within IL2 were markedly inhibited by external MTSET. These data suggest that part of IL2 or IL4 may be located in a pore-lining region that is accessible from either side of the membrane and involved in ion transport.	Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Suita, Osaka 565, Japan	National Cerebral & Cardiovascular Center - Japan	Wakabayashi, S (corresponding author), Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Suita, Osaka 565, Japan.							Baird NR, 1999, J BIOL CHEM, V274, P4377, DOI 10.1074/jbc.274.7.4377; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; Biemesderfer D, 1998, J BIOL CHEM, V273, P12391, DOI 10.1074/jbc.273.20.12391; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; Counillon L, 1997, BIOCHEMISTRY-US, V36, P2951, DOI 10.1021/bi9615405; COUNILLON L, 1994, BIOCHEMISTRY-US, V33, P10463, DOI 10.1021/bi00200a030; COUNILLON L, 1993, P NATL ACAD SCI USA, V90, P4508, DOI 10.1073/pnas.90.10.4508; Fujinaga J, 1999, J BIOL CHEM, V274, P6626, DOI 10.1074/jbc.274.10.6626; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Ikeda T, 1997, J BIOCHEM-TOKYO, V121, P295; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; Orlowski J, 1996, J BIOL CHEM, V271, P19922, DOI 10.1074/jbc.271.33.19922; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; Rothman A, 1996, J BIOL CHEM, V271, P32288, DOI 10.1074/jbc.271.50.32288; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; Shrode LD, 1998, AM J PHYSIOL-CELL PH, V275, pC431, DOI 10.1152/ajpcell.1998.275.2.C431; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE CM, 1993, J BIOL CHEM, V268, P11917; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; Wakabayashi S, 1997, BIOCHEMISTRY-US, V36, P12854, DOI 10.1021/bi9715472; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; WANG DH, 1995, AM J PHYSIOL-CELL PH, V269, pC392, DOI 10.1152/ajpcell.1995.269.2.C392	31	189	193	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7942	7949		10.1074/jbc.275.11.7942	http://dx.doi.org/10.1074/jbc.275.11.7942			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713111	hybrid			2022-12-27	WOS:000085913300071
J	Chesla, SE; Li, P; Nagarajan, S; Selvaraj, P; Zhu, C				Chesla, SE; Li, P; Nagarajan, S; Selvaraj, P; Zhu, C			The membrane anchor influences ligand binding two-dimensional kinetic rates and three-dimensional affinity of Fc gamma RIII (CD16)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-3; NATURAL-KILLER-CELLS; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; ADHESION MOLECULE; RECEPTOR-LIGAND; CARBOHYDRATE BOND; LATERAL DIFFUSION; FLOW-CYTOMETRY; LINKED FORM; P-SELECTIN	Kinetic rates and affinity are essential determinants for biological processes that involve receptor-ligand binding. By using a micropipette method, we measured the kinetics of human Fc gamma receptor III (CD16) interacting with IgG when the two molecules were bound to apposing cellular membranes. CD16 is one of only four eukaryotic receptors known to exist natively in both the transmembrane (TM, CD16b) and glycosylphosphatidylinositol (GPI, CD16b) isoforms, The biological significance of this anchor isoform coexistence is not clear. Here we showed that the anchor influenced kinetic rates; compared with CD16a-TM, CD16a-GPI bound faster and with higher affinities to human and rabbit IgGs but slower and with lower affinity to murine IgG2a. The same differential affinity patterns were observed using soluble IgG ligands, A monoclonal antibody bound CD16a-GPI with higher affinity than CD16a-TM, whereas another monoclonal antibody reacted strongly with CD16a-TM but weakly with CD16a-GPI, No major differential glycosylation between the two CD16a isoforms was detected by SDS-polyacrylamide gel electrophoresis analysis. We suggest a conformational difference as the mechanism underlying the observed anchor effect, as it cannot be explained by the differing diffusivity, flexibility, orientation, height, distribution, or clustering of the two molecules on the cell membrane. These data demonstrate that a covalent modification of an Ig superfamily receptor at the carboxyl terminus of the ectodomain can have an impact on ligand binding kinetics.	Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA 30332 USA; Georgia Inst Technol, Dept Biomed Engn, Atlanta, GA 30332 USA; Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology; Emory University	Zhu, C (corresponding author), Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA 30332 USA.		Zhu, Cheng/A-5724-2011	Zhu, Cheng/0000-0002-1718-565X	NIAID NIH HHS [AI30631, AI38282] Funding Source: Medline; NIGMS NIH HHS [GM08433] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI030631, R56AI038282, R01AI038282, R29AI038282] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008433] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; CHAN PY, 1992, MOL BIOL CELL, V3, P157, DOI 10.1091/mbc.3.2.157; CHAN PY, 1991, J CELL BIOL, V115, P245, DOI 10.1083/jcb.115.1.245; Chesla SE, 1998, BIOPHYS J, V75, P1553, DOI 10.1016/S0006-3495(98)74074-3; CROSS GAM, 1987, CELL, V48, P179, DOI 10.1016/0092-8674(87)90419-3; DEHAAS M, 1996, J IMMUNOL, V156, P3948; DUSTIN ML, 1987, NATURE, V329, P846, DOI 10.1038/329846a0; EDBERG JC, 1989, J IMMUNOL, V143, P1642; Edberg JC, 1997, J IMMUNOL, V159, P3849; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FLEIT HB, 1989, LEUKOCYTE TYPING, V4, P579; Hasslen SR, 1996, J HISTOCHEM CYTOCHEM, V44, P1115, DOI 10.1177/44.10.8813076; HE HT, 1987, J CELL BIOL, V105, P2489, DOI 10.1083/jcb.105.6.2489; HOROVITZ A, 1987, P NATL ACAD SCI USA, V84, P6654, DOI 10.1073/pnas.84.19.6654; KAPLANSKI G, 1993, BIOPHYS J, V64, P1922, DOI 10.1016/S0006-3495(93)81563-7; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOFLER R, 1977, J IMMUNOL METHODS, V16, P201, DOI 10.1016/0022-1759(77)90198-3; Kukulansky T, 1999, J IMMUNOL, V162, P5993; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; LANIER LL, 1991, J IMMUNOL, V146, P1571; Lauffenburger D. A., 1993, RECEPTORS MODELS BIN; LEBOUTEILLER PP, 1983, J IMMUNOL METHODS, V61, P301, DOI 10.1016/0022-1759(83)90224-7; LOW MG, 1987, BIOCHEM J, V244, P1; LYLES JM, 1984, J CELL BIOL, V98, P2077, DOI 10.1083/jcb.98.6.2077; Miller KL, 1996, J EXP MED, V183, P2227, DOI 10.1084/jem.183.5.2227; MOY P, 1993, J BIOL CHEM, V268, P8835; NAGARAJAN S, 1995, J BIOL CHEM, V270, P25762, DOI 10.1074/jbc.270.43.25762; Patel KD, 1995, J CELL BIOL, V131, P1893, DOI 10.1083/jcb.131.6.1893; PERUSSIA B, 1989, LEUKOCYTE TYPING, V4, P590; POO H, 1995, J MOL BIOL, V247, P597; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; SanchezMateos P, 1996, SEMIN CANCER BIOL, V7, P99, DOI 10.1006/scbi.1996.0015; SCALLON BJ, 1989, P NATL ACAD SCI USA, V86, P5079, DOI 10.1073/pnas.86.13.5079; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SELVARAJ P, 1989, J IMMUNOL, V143, P3283; SELVARAJ P, 1988, NATURE, V333, P565, DOI 10.1038/333565a0; SELVARAJ P, 1987, J EXP MED, V166, P1011, DOI 10.1084/jem.166.4.1011; SELVARAJ P, 1989, LEUKOCYTE TYPING, V4, P595; Serke S, 1998, CYTOMETRY, V33, P179, DOI 10.1002/(SICI)1097-0320(19981001)33:2<179::AID-CYTO12>3.0.CO;2-R; Tamm A, 1996, J IMMUNOL, V157, P1576; Tamm A, 1996, J BIOL CHEM, V271, P3659; Tees DFJ, 1996, BIOPHYS J, V71, P1102, DOI 10.1016/S0006-3495(96)79312-8; TERRY RW, 1993, P NATL ACAD SCI USA, V90, P5919, DOI 10.1073/pnas.90.13.5919; TOZEREN A, 1992, J CELL BIOL, V116, P997, DOI 10.1083/jcb.116.4.997; UEDA E, 1989, J IMMUNOL, V143, P1274; van de Winkel JG, 1996, HUMAN IGG FC RECEPTO; VANCE BA, 1993, J IMMUNOL, V151, P6429; Wong JY, 1997, SCIENCE, V275, P820, DOI 10.1126/science.275.5301.820; Wu JM, 1997, J CLIN INVEST, V100, P1059, DOI 10.1172/JCI119616; ZHANG F, 1991, J CELL BIOL, V115, P75, DOI 10.1083/jcb.115.1.75	53	52	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10235	10246		10.1074/jbc.275.14.10235	http://dx.doi.org/10.1074/jbc.275.14.10235			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744709	hybrid			2022-12-27	WOS:000086345600050
J	Tanaka, S; Uehara, T; Nomura, Y				Tanaka, S; Uehara, T; Nomura, Y			Up-regulation of protein-disulfide isomerase in response to hypoxia/brain ischemia and its protective effect against apoptotic cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELAYED NEURONAL DEATH; INTERLEUKIN-1-BETA CONVERTING-ENZYME; HUMAN PROLYL 4-HYDROXYLASE; SITE-DIRECTED MUTAGENESIS; CULTURED RAT ASTROCYTES; ANTI-CHAPERONE ACTIVITY; GIANT GELS; EXPRESSION; BRAIN; HIPPOCAMPUS	We isolated and identified a stress protein that is upregulated in response to hypoxia in primary-cultured glial cells. Protein-disulfide isomerase (PDI) was up-regulated not only by hypoxia in glia in vitro, but also by transient forebrain ischemia in rats in vivo, To determine whether newly synthesized PDI is involved in tolerance to ischemic stress, me carried out two procedures to induce PDI gene expression in human neuroblastoma SK-N-MC cells, as well as intrahippocampal injection following electroporation of an expression vector capable of overexpressing PDI in rats. Overexpression of this gene resulted in attenuation of the loss of cell viability induced by hypoxia in neuroblastoma SK-N-MC cells and a reduction in the number of DNA-fragmented cells in the CA1 area of the hippocampus in brain ischemic rats, respectively. These findings suggest that up-regulated PDI may play a critical role in resistance to ischemic damage, and that the elevation of levels of this protein in the brain may have beneficial effects against brain stroke.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sapporo, Hokkaido 0600812, Japan	Hokkaido University	Nomura, Y (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sapporo, Hokkaido 0600812, Japan.			Uehara, Takashi/0000-0002-8545-4006				Araya R, 1998, FEBS LETT, V439, P168, DOI 10.1016/S0014-5793(98)01363-5; Chen J, 1998, J NEUROSCI, V18, P4914; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; FERRER I, 1994, BRAIN PATHOL, V4, P115, DOI 10.1111/j.1750-3639.1994.tb00821.x; FREEDMAN RB, 1984, BIOCHEM SOC T, V12, P929, DOI 10.1042/bst0120929; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hara H, 1997, J CEREBR BLOOD F MET, V17, P370, DOI 10.1097/00004647-199704000-00002; HAWKINS HC, 1991, BIOCHEM J, V275, P335, DOI 10.1042/bj2750335; HORI O, 1994, J NEUROCHEM, V62, P1489; Hori O, 1996, J NEUROCHEM, V66, P973; KEMMINK J, 1995, PROTEIN SCI, V4, P2587, DOI 10.1002/pro.5560041216; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Kuwabara K, 1996, J BIOL CHEM, V271, P5025; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; Loddick SA, 1996, NEUROREPORT, V7, P1465, DOI 10.1097/00001756-199606170-00004; LYLES MM, 1994, J BIOL CHEM, V269, P30946; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Matsuo N, 1997, J BIOL CHEM, V272, P16438, DOI 10.1074/jbc.272.26.16438; MATSUO N, 1995, J BIOL CHEM, V270, P28216, DOI 10.1074/jbc.270.47.28216; NITATORI T, 1995, J NEUROSCI, V15, P1001; Ozawa K, 1999, J BIOL CHEM, V274, P6397, DOI 10.1074/jbc.274.10.6397; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; Primm TP, 1996, J BIOL CHEM, V271, P33664, DOI 10.1074/jbc.271.52.33664; PUIG A, 1994, J BIOL CHEM, V269, P7764; ROTH RA, 1981, BIOCHEMISTRY-US, V20, P6594, DOI 10.1021/bi00526a012; Schielke GP, 1998, J CEREBR BLOOD F MET, V18, P180, DOI 10.1097/00004647-199802000-00009; SIMONS ML, 1992, J NEUROCHEM, V59, P897; SONG JL, 1995, EUR J BIOCHEM, V231, P312, DOI 10.1111/j.1432-1033.1995.tb20702.x; SWANSON RA, 1993, J CEREBR BLOOD F MET, V13, P162, DOI 10.1038/jcbfm.1993.19; Uehara T, 1999, J BIOL CHEM, V274, P15875, DOI 10.1074/jbc.274.22.15875; Uehara T, 1999, BRAIN RES, V823, P226, DOI 10.1016/S0006-8993(99)01178-6; VORIS BP, 1980, ANAL BIOCHEM, V104, P478, DOI 10.1016/0003-2697(80)90103-7; VUORI K, 1992, J BIOL CHEM, V267, P7211; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; Xu DG, 1997, NAT MED, V3, P997, DOI 10.1038/nm0997-997; YOUNG DA, 1983, METHOD ENZYMOL, V91, P190	38	223	230	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10388	10393		10.1074/jbc.275.14.10388	http://dx.doi.org/10.1074/jbc.275.14.10388			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744727	hybrid			2022-12-27	WOS:000086345600068
J	van der Spoel, A; Bonten, E; d'Azzo, A				van der Spoel, A; Bonten, E; d'Azzo, A			Processing of lysosomal beta-galactosidase - The C-terminal precursor fragment is an essential domain of the mature enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTECTIVE PROTEIN; CATHEPSIN-A; INTRAMOLECULAR CHAPERONES; NEURAMINIDASE DEFICIENCY; QUALITY-CONTROL; ACID; PURIFICATION; EXPRESSION; CDNA; GALACTOSIALIDOSIS	Lysosomal beta-D galactosidase (beta-gal), the enzyme deficient in the autosomal recessive disorders G(M1) gangliosidosis and Morquio B, is synthesized as an 85-kDa precursor that is C-terminally processed into a 64-66-kDa mature form. The released similar to 20-kDa proteolytic fragment was thought to be degraded. We now present evidence that it remains associated to the 64-kDa chain after partial proteolysis of the precursor. This polypeptide was found to copurify with beta-gal and protective protein/cathepsin A from mouse liver and Madin-Darby bovine kidney cells and was immunoprecipitated from human fibroblasts but not from fibroblasts of a G(M1) gangliosidosis and a galactosialidosis patient. Uptake of wild-type protective protein/cathepsin A by galactosialidosis fibroblasts resulted in a significant increase of mature and active beta-gal and its C-terminal fragment. Expression in COS-1 cells of mutant cDNAs encoding either the N-terminal or the C-terminal domain of beta-gal resulted in the synthesis of correctly sized polypeptides without catalytic activity. Only when co-expressed, the two subunits associate and become catalytically active. Our results suggest that the C terminus of beta-gal is an essential domain of the catalytically active enzyme and provide evidence that lysosomal beta-galactosidase is a two-subunit molecule. These data may give new significance to mutations in G(M1) gangliosidosis patients found in the C-terminal part of the molecule.	St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA	St Jude Children's Research Hospital	d'Azzo, A (corresponding author), St Jude Childrens Res Hosp, Dept Genet, 332 N Lauderdale, Memphis, TN 38105 USA.			van der Spoel, Aarnoud/0000-0002-2338-5316				Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BONTEN EJ, 1995, J BIOL CHEM, V270, P26441, DOI 10.1074/jbc.270.44.26441; BOUSTANY RM, 1993, AM J HUM GENET, V53, P881; Brooks DA, 1997, FEBS LETT, V409, P115, DOI 10.1016/S0014-5793(97)00423-7; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cygler M, 1996, STRUCTURE, V4, P405, DOI 10.1016/S0969-2126(96)00046-9; D'Azzo A, 1995, METABOLIC MOL BASES, V2, P2825; DAZZO A, 1982, P NATL ACAD SCI-BIOL, V79, P4535, DOI 10.1073/pnas.79.15.4535; EDER J, 1995, MOL MICROBIOL, V16, P609, DOI 10.1111/j.1365-2958.1995.tb02423.x; FORNEROD M, 1995, ONCOGENE, V10, P1739; GALJAARD H, 1980, GENETIC METABOLIC DI; GALJART NJ, 1988, CELL, V54, P755, DOI 10.1016/S0092-8674(88)90999-3; GALJART NJ, 1991, J BIOL CHEM, V266, P14754; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Gutshall K, 1997, J BACTERIOL, V179, P3064, DOI 10.1128/jb.179.9.3064-3067.1997; Hahn CN, 1997, HUM MOL GENET, V6, P205, DOI 10.1093/hmg/6.2.205; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HIRSCHHORN R, 1995, METABOLIC MOL BASIS, V2, P2443; ISLAM MR, 1993, J BIOL CHEM, V268, P22627; Ito Y, 1997, BIOSCI BIOTECH BIOCH, V61, P1270, DOI 10.1271/bbb.61.1270; Kleijer WJ, 1996, PEDIATR RES, V39, P1067, DOI 10.1203/00006450-199606000-00022; LI H, 1990, J BIOL CHEM, V265, P14732; MACH L, 1994, J BIOL CHEM, V269, P13036; MORREAU H, 1989, J BIOL CHEM, V264, P20655; MORRONE A, 1997, AM J HUM GENET, V61, P1499; NORDEN AGW, 1974, J BIOL CHEM, V249, P7969; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; OSHIMA A, 1988, BIOCHEM BIOPH RES CO, V157, P238, DOI 10.1016/S0006-291X(88)80038-X; Oshima M., 1995, METABOLIC MOL BASES, V2, P2785; Pshezhetsky AV, 1996, J BIOL CHEM, V271, P28359, DOI 10.1074/jbc.271.45.28359; PSHEZHETSKY AV, 1994, ARCH BIOCHEM BIOPHYS, V313, P64, DOI 10.1006/abbi.1994.1359; RUSCONI S, 1990, GENE, V89, P211, DOI 10.1016/0378-1119(90)90008-F; SCHEIBE R, 1990, BIOMED BIOCHIM ACTA, V49, P547; SCHEIBE R, 1985, BIOMED BIOCHIM ACTA, V44, P1279; SHINDE U, 1994, J BIOCHEM, V115, P629, DOI 10.1093/oxfordjournals.jbchem.a124386; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TAKIYAMA N, 1993, BIOCHEM BIOPH RES CO, V193, P526, DOI 10.1006/bbrc.1993.1655; TARON CH, 1995, GLYCOBIOLOGY, V5, P603, DOI 10.1093/glycob/5.6.603; THOMAS GH, 1995, METABOLIC MOL BASIS, V2, P2529; VANDIGGELEN OP, 1982, BIOCHIM BIOPHYS ACTA, V703, P69, DOI 10.1016/0167-4838(82)90012-7; VERHEIJEN F, 1982, BIOCHEM BIOPH RES CO, V108, P868, DOI 10.1016/0006-291X(82)90911-1; VERHEIJEN FW, 1985, EUR J BIOCHEM, V149, P315, DOI 10.1111/j.1432-1033.1985.tb08928.x; YAMAMOTO Y, 1987, INT J BIOCHEM, V19, P435, DOI 10.1016/0020-711X(87)90064-4; YAMAMOTO Y, 1990, DNA CELL BIOL, V9, P119, DOI 10.1089/dna.1990.9.119; YAMAMOTO Y, 1982, J BIOCHEM, V92, P13, DOI 10.1093/oxfordjournals.jbchem.a133910; ZHOU XY, 1991, EMBO J, V10, P4041, DOI 10.1002/j.1460-2075.1991.tb04980.x; Zhou XY, 1996, HUM MOL GENET, V5, P1977, DOI 10.1093/hmg/5.12.1977	50	33	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10035	10040		10.1074/jbc.275.14.10035	http://dx.doi.org/10.1074/jbc.275.14.10035			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744681	hybrid			2022-12-27	WOS:000086345600022
J	Zhai, J; Schmidt, AG; Hoit, BD; Kimura, Y; MacLennan, DH; Kranias, EG				Zhai, J; Schmidt, AG; Hoit, BD; Kimura, Y; MacLennan, DH; Kranias, EG			Cardiac-specific overexpression of a superinhibitory pentameric phospholamban mutant enhances inhibition of cardiac function in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; ION-CHANNEL; TRANSGENIC MICE; LIPID BILAYERS; MOUSE HEARTS; AMINO-ACIDS; COILED-COIL; CA2+ PUMP; IN-VIVO; PHOSPHORYLATION	Phospholamban is a regulator of the Ca2+ affinity of the cardiac sarcoplasmic reticulum Ca2+ ATPase (SERCA2d) and of cardiac contractility, In vitro expression studies have shown that several mutant phospholamban monomers are superinhibitory, suggesting that monomeric phospholamban is the active species. However, a phospholamban Asn(27) --> Ala (N27A) mutant, which maintained a normal pentamer to monomer ratio, was shown to act as a superinhibitor of SERCA2a Ca2+ affinity, To determine whether the pentameric N27A mutant is superinhibitory in vivo, transgenic mice with cardiac-specific overexpression of mutant phospholamban mere generated. Quantitative immunoblotaing revealed a 61 +/- 6% increase in total phospholamban in mutant hearts, with 90% of the overexpressed protein being pentameric, The EC,, value for Ca2+ dependence of Ca2+ uptake was 0.69 +/- 0.07 mu m in mutant hearts, compared with 0.29 +/- 0.02 mu M in wild-type hearts or 0.43 +/- 0.03 mu M in hearts overexpressing wild-type PLB by 2-fold. Myocytes from phospholamban N27A mutant hearts also exhibited more depressed contractile parameters than wild-type phospholamban overexpressing cells. The shortening fraction was 52%, rates of shortening and relengthening were 46% and 38% respectively, and time for 80% decay of the Ca2+ signal was 146%, compared with wild-types (100%). Langendorff-perfuse mutant hearts also demonstrated depressed contractile parameters, Furthermore, in vivo echocardiography showed a depression in the ratio of early to late diastolic transmitral velocity and a 79% prolongation of the isovolumic relaxation time. Isoproterenol stimulation did not fully relieve the depressed contractile parameters at the cellular, organ, and intact animal levels. Thus, pentameric phospholamban N27A mutant can act as a superinhibitor of the affinity of SERCA2a for Ca2+ and of cardiac contractility in vivo.	Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; Case Western Reserve Univ, Div Cardiol, Cleveland, OH 44106 USA; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada	University of Cincinnati; Case Western Reserve University; University of Toronto	Kranias, EG (corresponding author), Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, 231 Bethesda Ave, Cincinnati, OH 45267 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR012358] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052318, R01HL026057, R37HL026057] Funding Source: NIH RePORTER; NCRR NIH HHS [P40RR12358] Funding Source: Medline; NHLBI NIH HHS [HL-26057, HL-52318] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARKIN IT, 1995, J MOL BIOL, V248, P824, DOI 10.1006/jmbi.1995.0263; ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; Autry JM, 1997, J BIOL CHEM, V272, P15872, DOI 10.1074/jbc.272.25.15872; BOWMAN S, 1990, Technique (Philadelphia), V2, P254; Chu GX, 1997, CIRC RES, V81, P485, DOI 10.1161/01.RES.81.4.485; Chu GX, 1998, J BIOL CHEM, V273, P33674, DOI 10.1074/jbc.273.50.33674; Chu GX, 1996, CIRC RES, V79, P1064, DOI 10.1161/01.RES.79.6.1064; Cornea RL, 1997, BIOCHEMISTRY-US, V36, P2960, DOI 10.1021/bi961955q; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; DRAGO GA, 1994, J BIOL CHEM, V269, P25073; FUJII J, 1989, J BIOL CHEM, V264, P12950; FUJII J, 1987, J CLIN INVEST, V79, P301, DOI 10.1172/JCI112799; FUJII J, 1986, BIOCHEM BIOPH RES CO, V138, P1044, DOI 10.1016/S0006-291X(86)80387-4; HARRER JM, 1994, MOL CELL BIOCHEM, V140, P185, DOI 10.1007/BF00926757; HOIT BD, 1995, CIRC RES, V77, P632, DOI 10.1161/01.RES.77.3.632; Jones WK, 1996, J CLIN INVEST, V98, P1906, DOI 10.1172/JCI118992; Ju YK, 1999, J PHYSIOL-LONDON, V516, P793, DOI 10.1111/j.1469-7793.1999.0793u.x; Kadambi VJ, 1997, BIOCHEM BIOPH RES CO, V239, P1, DOI 10.1006/bbrc.1997.7340; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; Kimura Y, 1996, J BIOL CHEM, V271, P21726, DOI 10.1074/jbc.271.36.21726; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Kimura Y, 1998, J BIOL CHEM, V273, P14238, DOI 10.1074/jbc.273.23.14238; Kiss E, 1997, AM J PHYSIOL-HEART C, V272, pH785, DOI 10.1152/ajpheart.1997.272.2.H785; KOSS KL, 1995, CIRC RES, V77, P342, DOI 10.1161/01.RES.77.2.342; KOVACS RJ, 1988, J BIOL CHEM, V263, P18364; LAMERS JMJ, 1980, BIOCHIM BIOPHYS ACTA, V624, P443, DOI 10.1016/0005-2795(80)90086-0; Li M, 1999, BIOPHYS J, V76, P2587, DOI 10.1016/S0006-3495(99)77411-4; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; Malashkevich VN, 1996, SCIENCE, V274, P761, DOI 10.1126/science.274.5288.761; Pollesello P, 1999, BIOPHYS J, V76, P1784, DOI 10.1016/S0006-3495(99)77339-X; Reddy LG, 1999, BIOCHEMISTRY-US, V38, P3954, DOI 10.1021/bi981795d; SASAKI T, 1992, J BIOL CHEM, V267, P1674; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; Wolska BM, 1996, AM J PHYSIOL-CELL PH, V271, pC391, DOI 10.1152/ajpcell.1996.271.1.C391	40	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10538	10544		10.1074/jbc.275.14.10538	http://dx.doi.org/10.1074/jbc.275.14.10538			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744747	hybrid			2022-12-27	WOS:000086345600088
J	Su, HP; Brugnera, E; Van Criekinge, W; Smits, E; Hengartner, M; Bogaert, T; Ravichandran, KS				Su, HP; Brugnera, E; Van Criekinge, W; Smits, E; Hengartner, M; Bogaert, T; Ravichandran, KS			Identification and characterization of a dimerization domain in CED-6, an adapter protein involved in engulfment of apoptotic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; IN-VIVO; SHC; PHAGOCYTOSIS; RECOGNITION; RECEPTOR; ELEGANS; DEATH	Phagocytosis of apoptotic cells is a key step in the completion of programmed cell death that occurs throughout life in multicellular organisms. The molecular events involved in clearance of apoptotic cells are just beginning to be elucidated. Recently, CED-6, an adapter protein involved in engulfment has been cloned in Caenorhabditis elegans and in humans. CED-6 is composed of a phosphotyrosine-binding (PTB) domain and a proline-rich C-terminal domain with no apparent catalytic domain. Since PTB domains, originally identified in Shc, mediate intracellular signaling downstream of cell surface receptors, CED-6 has also been proposed to mediate intracellular signals leading to engulfment. In this report, we demonstrate that CED-6 dimerizes through a leucine zipper domain that is immediately adjacent to the PTB domain, Several lines of evidence based on co-immunoprecipitation studies, yeast two-hybrid assays, and gel filtration studies suggest that CED-B exists as a dimer in vivo. Through mutational analyses, we show that the leucine zipper is necessary and sufficient for CED-6 dimerization and that this dimerization is conserved among C. elegans, rodent, and human CED-6 proteins. We propose that dimerization may have unique implications for ligand binding via CED-6 and its function during the phagocytosis of apoptotic cells.	Univ Virginia, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; DEVGEN NV, B-9052 Ghent, Belgium; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	University of Virginia; University of Virginia; Cold Spring Harbor Laboratory	Ravichandran, KS (corresponding author), Univ Virginia, Carter Immunol Ctr, Bldg MR4,RM4012F, Charlottesville, VA 22908 USA.	kr4h@virginia.edu	Hengartner, Michael O/E-6235-2011; Hengartner, Michael O/A-7058-2008	Hengartner, Michael/0000-0002-7584-596X; Su, Hua-Poo/0000-0003-3808-7837				Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; Bartkiewicz M, 1999, J BIOL CHEM, V274, P30887, DOI 10.1074/jbc.274.43.30887; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Borg JP, 1998, CURR TOP MICROBIOL, V228, P23; ELLIS RE, 1991, GENETICS, V129, P79; Fadok VA, 1999, J MAMMARY GLAND BIOL, V4, P203, DOI 10.1023/A:1011384009787; Gumienny TL, 1999, DEVELOPMENT, V126, P1011; Horvitz HR, 1999, CANCER RES, V59, p1701S; Howell BW, 1999, MOL CELL BIOL, V19, P5179; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Lamkin TD, 1997, J BIOL CHEM, V272, P10396; Liu QA, 1999, CURR BIOL, V9, P1347, DOI 10.1016/S0960-9822(00)80061-5; Liu QA, 1998, CELL, V93, P961, DOI 10.1016/S0092-8674(00)81202-7; Margolis B, 1996, J LAB CLIN MED, V128, P235, DOI 10.1016/S0022-2143(96)90022-0; Platt N, 1999, IMMUNOL LETT, V65, P15, DOI 10.1016/S0165-2478(98)00118-7; Platt N, 1998, BIOCHEM SOC T, V26, P639, DOI 10.1042/bst0260639; Platt N, 1996, P NATL ACAD SCI USA, V93, P12456, DOI 10.1073/pnas.93.22.12456; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; POLLARD JW, 1979, J CELL PHYSIOL, V98, P571, DOI 10.1002/jcp.1040980315; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; Savill J, 1997, BRIT MED BULL, V53, P491; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; Smits E, 1999, CURR BIOL, V9, P1351, DOI 10.1016/S0960-9822(00)80062-7; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	26	42	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9542	9549		10.1074/jbc.275.13.9542	http://dx.doi.org/10.1074/jbc.275.13.9542			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734103	hybrid, Green Accepted, Green Published			2022-12-27	WOS:000086206500067
J	Tsutsumi, T; Ushiro, H; Kosaka, T; Kayahara, T; Nakano, K				Tsutsumi, T; Ushiro, H; Kosaka, T; Kayahara, T; Nakano, K			Proline- and alanine-rich Ste20-related kinase associates with F-actin and translocates from the cytosol to cytoskeleton upon cellular stresses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; PHEROMONE RESPONSE; BINDING PROTEIN; HOMOLOG; CLONING; CASCADE; PATHWAY; ACTIVATION; COMPLEX; STE20P	Proline- and alanine-rich Ste20-related kinase (PASK) is a Ste20-related protein kinase isolated from rat brain. Cell fractionation studies showed that PASK was present both in the cytosol and in Triton X-100-insoluble cytoskeletal fraction in rat tissues. In brain, PASK associated with protein complexes that contained actin and tubulin, confirming the association of PASK with the cytoskeleton in vivo. Glutathione S-transferase-PASK fusion protein cosedimented with F-actin, indicating that PASK binds to F-actin, In contrast to rat tissues, PASK was detected only in the Triton X-100-soluble cytosolic fraction in cultured PC12 and NIR 3T3 cells. Cytosolic PASK translocated to the cytoskeleton when these cells were stimulated with severe cellular stresses such as hypertonic sodium chloride, hydrogen peroxide, and heat shock at 45 degrees C, Our results suggest that PASK may be involved in the regulation of the cytoskeleton in response to cellular stresses such as hyperosmotic shock.	Mie Univ, Sch Med, Dept Anat, Tsu, Mie 5148507, Japan	Mie University	Ushiro, H (corresponding author), Mie Univ, Sch Med, Dept Anat, Edobashi 2-174, Tsu, Mie 5148507, Japan.							Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Eichinger L, 1998, J BIOL CHEM, V273, P12952, DOI 10.1074/jbc.273.21.12952; Fujita A, 1997, BIOCHEM J, V328, P769, DOI 10.1042/bj3280769; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harden N, 1996, MOL CELL BIOL, V16, P1896; Hayashi H, 1997, J BACTERIOL, V179, P4246, DOI 10.1128/jb.179.13.4246-4253.1997; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MOORE D, 1992, SHORT PROTOCOLS MOL; Nakhost A, 1998, J NEUROCHEM, V71, P1221; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; Ushiro H, 1998, ARCH BIOCHEM BIOPHYS, V355, P233, DOI 10.1006/abbi.1998.0736; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984	26	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9157	9162		10.1074/jbc.275.13.9157	http://dx.doi.org/10.1074/jbc.275.13.9157			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734050	hybrid			2022-12-27	WOS:000086206500014
J	Tumova, S; Woods, A; Couchman, JR				Tumova, S; Woods, A; Couchman, JR			Heparan sulfate chains from glypican and syndecans bind the Hep II domain of fibronectin similarly despite minor structural differences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CELL-SURFACE PROTEOGLYCAN; GPI-ANCHORED PROTEINS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; CYTOPLASMIC DOMAIN; SKIN FIBROBLASTS; FINE-STRUCTURE; CORE PROTEIN; IN-VITRO; ADHESION	Numerous functions of heparan sulfate proteoglycans are mediated through interactions between their heparan sulfate glycosaminoglycan chains and extracellular ligands, Ligand binding specificity for some molecules, including many growth factors, is determined by complex heparan sulfate fine structure, where highly sulfated, iduronate-rich domains alternate with N-acetylated domains. Syndecan-4, a cell surface heparan sulfate proteoglycan, has a distinct role in cell adhesion, suggesting its chains may differ from those of other cell surface proteoglycans. To determine whether the specific role of syndecan-4 correlates with a distinct heparan sulfate structure, we have analyzed heparan sulfate chains from the different surface proteoglycans of a single fibroblast strain and compared their ability to bind the Hep II domain of fibronectin, a ligand known to promote focal adhesion formation through syndecan-4. Despite distinct molecular masses of glypican and syndecan glycosaminoglycans and minor differences in disaccharide composition and sulfation pattern, the overall proportion and distribution of sulfated regions and the affinity for the Hep II domain were similar. Therefore, adhesion regulation requires core protein determinants of syndecan-4.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol & Cell Adhes, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Matrix Res Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Couchman, JR (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, 1670 Univ Blvd,VH 201A, Birmingham, AL 35294 USA.	jrcouchman@cellbio.bhs.uab.edu	Tumova, Sarka/AAD-6353-2019	Tumova, Sarka/0000-0003-2044-4998	NIDDK NIH HHS [DK54605] Funding Source: Medline; NIGMS NIH HHS [GM50194] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054605] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAME KJ, 1993, J BIOL CHEM, V268, P19956; BENTLEY KL, 1985, J BIOL CHEM, V260, P7250; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; Bloom L, 1999, MOL BIOL CELL, V10, P1521, DOI 10.1091/mbc.10.5.1521; Carey DJ, 1997, BIOCHEM J, V327, P1; Couchman JR, 1999, J CELL SCI, V112, P3415; Couchman JR, 1996, J CELL BIOCHEM, V61, P578, DOI 10.1002/(SICI)1097-4644(19960616)61:4<578::AID-JCB11>3.0.CO;2-C; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; Echtermeyer F, 1999, J CELL SCI, V112, P3433; Edgren G, 1997, GLYCOBIOLOGY, V7, P103, DOI 10.1093/glycob/7.1.103; Feyzi E, 1998, J BIOL CHEM, V273, P13395, DOI 10.1074/jbc.273.22.13395; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Horowitz A, 1998, J BIOL CHEM, V273, P25548, DOI 10.1074/jbc.273.40.25548; INGHAM KC, 1990, BIOCHEM J, V272, P605, DOI 10.1042/bj2720605; Jayson GC, 1998, J BIOL CHEM, V273, P51, DOI 10.1074/jbc.273.1.51; KATO M, 1994, J BIOL CHEM, V269, P18881; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Lee D, 1998, J BIOL CHEM, V273, P13022, DOI 10.1074/jbc.273.21.13022; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2678; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; Liu W, 1998, J BIOL CHEM, V273, P22825, DOI 10.1074/jbc.273.35.22825; Longley RL, 1999, J CELL SCI, V112, P3421; LORIES V, 1992, J BIOL CHEM, V267, P1116; Lyon M, 1998, MATRIX BIOL, V17, P485, DOI 10.1016/S0945-053X(98)90096-8; McFall AJ, 1998, J BIOL CHEM, V273, P28270, DOI 10.1074/jbc.273.43.28270; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; RAPRAEGER A, 1985, J BIOL CHEM, V260, P4103; Rapraeger AC, 1998, CURR OPIN CELL BIOL, V10, P620, DOI 10.1016/S0955-0674(98)80038-0; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SANANTONIO JD, 1993, BIOCHEMISTRY-US, V32, P4746, DOI 10.1021/bi00069a008; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; SCHMIDTCHEN A, 1990, GLYCOCONJUGATE J, V7, P563, DOI 10.1007/BF01189077; SCHMIDTCHEN A, 1992, EUR J BIOCHEM, V208, P537, DOI 10.1111/j.1432-1033.1992.tb17218.x; Schofield KP, 1999, BIOCHEM J, V343, P663, DOI 10.1042/0264-6021:3430663; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; Tumova S, 1997, J BIOL CHEM, V272, P9078; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; Woods A, 2000, ARCH BIOCHEM BIOPHYS, V374, P66, DOI 10.1006/abbi.1999.1607; WOODS A, 1992, J CELL SCI, V101, P277; Woods A, 1998, TRENDS CELL BIOL, V8, P189, DOI 10.1016/S0962-8924(98)01244-6; YAMADA KM, 1980, J BIOL CHEM, V255, P6055; YANAGISHITA M, 1984, J BIOL CHEM, V259, P270; Zimmermann P, 1999, FASEB J, V13, pS91	54	96	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9410	9417		10.1074/jbc.275.13.9410	http://dx.doi.org/10.1074/jbc.275.13.9410			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734086	hybrid			2022-12-27	WOS:000086206500050
J	Belzar, KJ; Dafforn, TR; Petitou, M; Carrell, RW; Huntington, JA				Belzar, KJ; Dafforn, TR; Petitou, M; Carrell, RW; Huntington, JA			The effect of a reducing-end extension on pentasaccharide binding by antithrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDURONATE 2-SULFATE RESIDUES; HEPARIN-BINDING; CONFORMATIONAL CHANGE; REACTIVE CENTER; POTENTIOMETRIC TITRATION; ACTIVATION; MECHANISM; SEQUENCE; AFFINITY; ACCELERATION	Antithrombin requires heparin for efficient inhibition of the final two proteinases of the blood coagulation cascade, factor Xa and thrombin, Antithrombin binds heparin via a specific pentasaccharide domain in a two-step mechanism whereby initial weak binding is followed by a conformational change and subsequent tight binding. The goal of this study is to investigate the role of a reducing-end extension in the binding of the longer oligosaccharides that contain the cognate pentasaccharide sequence. We determined the antithrombin binding properties of a synthetic heptasaccharide containing the natural pentasaccharide sequence (DEFGH) and an additional reducing-end disaccharide (DEFGHG'H'). Binding at low ionic strength is unaffected by the disaccharide addition, but at ionic strengths greater than or equal to 0.2 the mode of heptasaccharide binding changes resulting in a a-fold increase in affinity due to a decrease in the off-rate caused by a greater nonionic contribution to binding, Molecular modeling of possible binding modes for the heptasaccharide at high ionic strength indicates a possible shift in position of the pentasaccharide domain to occupy the extended heparin-binding site. This conclusion supports the likely presence of a range of sequences that can bind to and activate antithrombin in the natural heparan sulfates that line the vascular endothelium.	Univ Cambridge, Cambridge Inst Med Res, Wellcome Trust Ctr Study Mol Mechanisms Dis, Dept Haematol, Cambridge CB2 2XY, England; Sanofi Rech, Dept Res Haematol, F-31036 Toulouse, France	University of Cambridge; Sanofi-Aventis; Sanofi France	Huntington, JA (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Wellcome Trust Ctr Study Mol Mechanisms Dis, Dept Haematol, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	jah52@cam.ac.uk	Dafforn, Tim/A-9072-2015	Dafforn, Tim/0000-0003-2257-6679				Bloomfield VA, 1996, CURR OPIN STRUC BIOL, V6, P334, DOI 10.1016/S0959-440X(96)80052-2; Desai UR, 1998, BIOCHEMISTRY-US, V37, P13033, DOI 10.1021/bi981426h; Desai UR, 1998, J BIOL CHEM, V273, P7478, DOI 10.1074/jbc.273.13.7478; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; GETTINS PGW, 1993, BIOCHEMISTRY-US, V32, P8385, DOI 10.1021/bi00084a001; GRANT D, 1992, BIOCHEM J, V287, P849, DOI 10.1042/bj2870849; GRANT D, 1992, BIOCHEM J, V285, P477, DOI 10.1042/bj2850477; Huntington JA, 1998, BIOCHEMISTRY-US, V37, P3272, DOI 10.1021/bi972182o; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIBERTI PA, 1967, ARCH BIOCHEM BIOPHYS, V119, P510, DOI 10.1016/0003-9861(67)90485-7; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Meagher JL, 1996, J BIOL CHEM, V271, P29353, DOI 10.1074/jbc.271.46.29353; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1992, ADV EXP MED BIOL, V313, P155; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; Petitou M, 1997, J MED CHEM, V40, P1600, DOI 10.1021/jm960726z; Petitou M, 1997, GLYCOBIOLOGY, V7, P323, DOI 10.1093/glycob/7.3.323-e; Pike RN, 1997, J BIOL CHEM, V272, P19652, DOI 10.1074/jbc.272.32.19652; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; Turk B, 1997, BIOCHEMISTRY-US, V36, P6682, DOI 10.1021/bi9702492; TURNBULL JE, 1991, BIOCHEM J, V277, P297, DOI 10.1042/bj2770297; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; VANBOECKEL CAA, 1994, NAT STRUCT BIOL, V1, P423, DOI 10.1038/nsb0794-423; WEDLOCK DJ, 1980, BIOCHIM BIOPHYS ACTA, V629, P530, DOI 10.1016/0304-4165(80)90158-0; YUAN L, 1972, BIOPOLYMERS, V11, P2079, DOI 10.1002/bip.1972.360111008	30	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8733	8741		10.1074/jbc.275.12.8733	http://dx.doi.org/10.1074/jbc.275.12.8733			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722716	hybrid			2022-12-27	WOS:000086507700066
J	Watabe, M; Kakeya, H; Onose, R; Osada, H				Watabe, M; Kakeya, H; Onose, R; Osada, H			Activation of MST/Krs and c-jun N-terminal kinases by different signaling pathways during cytotrienin A-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE-MEDIATED ACTIVATION; LEUKEMIA HL-60 CELLS; PROTEIN-KINASE; STE20-LIKE KINASE; CYTOCHROME-C; ELEGANS; DEATH; CLONING; ENCODES; TUMORS	We found that antitumor drugs such as cytotrienin A, camptothecin, taxol, and 5-fluorouracil induced the activation of a 36-kDa protein kinase (p36 myelin basic protein (MBP) kinase) during apoptosis in human promyelocytic leukemia HL-60 cells. This p36 MBP kinase, which phosphorylates MBP in an in-gel kinase assay, results from the caspase-3-mediated proteolytic cleavage of MST/Krs protein, a mammalian Ste20-like serine/threonine kinase. Herein the correlation between cytotrienin A-induced apoptosis and the activation of MST/Krs proteins was examined in human tumor cell lines, including leukemia-, lung, epidermoid-, cervix-, stomach-, and brain-derived cell lines. In cytotrienin A-sensitive cell lines, we observed a strong activation of p36 MBP kinase by cleavage of the C-terminal regulatory domain of full-length MST/Krs proteins by caspase-3. When the kinase-inactive mutant form of MST/Krs protein was overexpressed in cytotrienin A-sensitive HL-60 cells, the cytotrienin A-induced apoptosis was partially inhibited. Because cytotrienin A also activated c-Jun N-terminal kinase, Foe examined the effect of the expression of dominant negative c-Jun on cytotrienin A-induced apoptosis. The expression of dominant negative c-Jun also partially inhibited cytotrienin A-induced apoptosis. Furthermore, coexpression of kinase-inactive MST/Krs protein and dominant negative c-Jun completely suppressed cytotrienin A-induced apoptosis. These findings suggest that the proteolytic activation of MST/Krs and c-Jun N-terminal kinase activation are involved in cytotrienin A-induced apoptosis in human tumor cell lines.	RIKEN, Antibiot Lab, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan	RIKEN	Osada, H (corresponding author), RIKEN, Antibiot Lab, Inst Phys & Chem Res, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Osada, Hiroyuki/AAY-6254-2020; Osada, Hiroyuki/N-4305-2014; Kakeya, Hideaki/B-3527-2012	Kakeya, Hideaki/0000-0002-4293-7331				Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; Chresta CM, 1996, CANCER RES, V56, P1834; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Kakeya H, 1997, J MED CHEM, V40, P391, DOI 10.1021/jm960719a; Kakeya H, 1997, J ANTIBIOT, V50, P370, DOI 10.7164/antibiotics.50.370; Kakeya H, 1998, CANCER RES, V58, P4888; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MEYN RE, 1995, ANTI-CANCER DRUG, V6, P443, DOI 10.1097/00001813-199506000-00013; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; Watabe M, 1999, ONCOGENE, V18, P5211, DOI 10.1038/sj.onc.1202901; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhang HP, 1997, TETRAHEDRON LETT, V38, P1789, DOI 10.1016/S0040-4039(97)00170-6; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	24	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8766	8771		10.1074/jbc.275.12.8766	http://dx.doi.org/10.1074/jbc.275.12.8766			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722720	hybrid			2022-12-27	WOS:000086507700070
J	Elsner, J; Mack, M; Bruhl, H; Dulkys, Y; Kimmig, D; Simmons, G; Clapham, PR; Schlondorff, D; Kapp, A; Wells, TNC; Proudfoot, AEI				Elsner, J; Mack, M; Bruhl, H; Dulkys, Y; Kimmig, D; Simmons, G; Clapham, PR; Schlondorff, D; Kapp, A; Wells, TNC; Proudfoot, AEI			Differential activation of CC chemokine receptors by AOP-RANTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EOSINOPHIL EOTAXIN RECEPTOR; PROTEIN-COUPLED RECEPTORS; CHEMOTACTIC RESPONSIVENESS; MOLECULAR-CLONING; T-LYMPHOCYTES; ANTAGONIST; EXPRESSION; INFLAMMATION; DESENSITIZATION; INTERNALIZATION	RANTES (regulated on activation normal T cell expressed) has been found at elevated levels in biological fluids from patients with a wide range of allergic and autoimmune diseases and is able to attract several subtypes of leukocytes including eosinophils and monocytes into inflamed tissue. Amino-terminal modifications of RANTES produce receptor antagonists which are candidates for blocking this cellular recruitment. Met-RANTES has been shown to modulate inflammation in vivo, while AOP-RANTES is a potent inhibitor of R5 human immunodeficiency virus type 1 (HIV-1) strains and has been shown to down-modulate CCR5 and prevent recycling of the receptor. We have studied the effect of AOP-RANTES in eosinophil activation and have found that it is able to efficiently elicit eosinophil effector functions through CCR3, as measured by the release of reactive oxygen species and calcium mobilization, whereas Met-RANTES is inactive in these assays. AOP-RANTES is found to inhibit CCR3-mediated HIV-1 infection with moderate potency, in contrast to its potent inhibition of CCR5-mediated HIV-1 infection. Furthermore, we have investigated the abilities of these modified proteins to down-modulate CCR1 and CCR3 from the surface of monocytes and eosinophils. We show here that AOP-RANTES is much less effective than RANTES in down-modulation of CCR1. Surprisingly, recycling of CCR1 was minimal after incubation with RANTES while there was complete recycling with AOP-RANTES. In the case of CCR3, no significant difference was found between RANTES and AOP-RANTES in down-modulation and recycling. It therefore appears that trafficking of RANTES receptors follows different patterns, which opens up potential new targets for therapeutic intervention.	Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland; Hannover Med Sch, Dept Dermatol & Allergol, D-30449 Hannover, Germany; Univ Munich, Med Poliklin, D-80336 Munich, Germany; UCL, Sch Med, Dept Mol Pathol & Clin Biochem, Wohl Vir Ctr, London W1P 6DB, England	Hannover Medical School; University of Munich; University of London; University College London; UCL Medical School	Proudfoot, AEI (corresponding author), Serono Pharmaceut Res Inst, 14 Chemin Aulx, CH-1228 Geneva, Switzerland.	amanda.proudfoot@serono.com	Simmons, Graham/G-3523-2012	Simmons, Graham/0000-0002-9615-7023; Kapp, Alexander/0000-0002-1748-6276; Wells, Timothy/0000-0001-9796-847X				Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Berger EA, 1997, AIDS, V11, pS3; Bohm SK, 1997, BIOCHEM J, V322, P1; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Bonecchi R, 1999, J IMMUNOL, V162, P474; Chen SH, 1998, J EXP MED, V188, P193, DOI 10.1084/jem.188.1.193; CLAPHAM PR, 1992, J VIROL, V66, P3531, DOI 10.1128/JVI.66.6.3531-3537.1992; Dairaghi DJ, 1997, J BIOL CHEM, V272, P28206, DOI 10.1074/jbc.272.45.28206; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; Elsner J, 1996, J CELL PHYSIOL, V167, P548, DOI 10.1002/(SICI)1097-4652(199606)167:3<548::AID-JCP18>3.3.CO;2-Y; ELSNER J, 1994, EUR J IMMUNOL, V24, P518, DOI 10.1002/eji.1830240304; Elsner J, 1997, EUR J IMMUNOL, V27, P2892, DOI 10.1002/eji.1830271122; Elsner J, 1996, EUR J IMMUNOL, V26, P1919, DOI 10.1002/eji.1830260837; Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521; Gong JH, 1997, J EXP MED, V186, P131, DOI 10.1084/jem.186.1.131; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; GRONE HJ, 2000, IN PRESS FASEB J; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; Kledal TN, 1998, FEBS LETT, V441, P209, DOI 10.1016/S0014-5793(98)01551-8; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Lloyd CM, 1997, J LEUKOCYTE BIOL, V62, P676, DOI 10.1002/jlb.62.5.676; Lloyd GM, 1997, J EXP MED, V185, P1371, DOI 10.1084/jem.185.7.1371; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; Margolis L, 1999, NAT MED, V5, P592, DOI 10.1038/9418; Mueller SG, 1997, J BIOL CHEM, V272, P8207, DOI 10.1074/jbc.272.13.8207; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; PATTERSON BK, 1999, J APPL BIOMAT, V91, P254; PlaterZyberk C, 1997, IMMUNOL LETT, V57, P117, DOI 10.1016/S0165-2478(97)00075-8; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Proudfoot AEI, 1999, J BIOL CHEM, V274, P32478, DOI 10.1074/jbc.274.45.32478; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Solari R, 1997, J BIOL CHEM, V272, P9617; Struyf S, 1998, EUR J IMMUNOL, V28, P1262, DOI 10.1002/(SICI)1521-4141(199804)28:04<1262::AID-IMMU1262>3.0.CO;2-G; Teixeira MM, 1997, J CLIN INVEST, V100, P1657, DOI 10.1172/JCI119690; Wells TNC, 1999, IMMUNOL LETT, V65, P35, DOI 10.1016/S0165-2478(98)00121-7; Wells TNC, 1998, TRENDS PHARMACOL SCI, V19, P376, DOI 10.1016/S0165-6147(98)01247-4; Zhang SM, 1999, J IMMUNOL, V162, P4938; Zimmermann N, 1999, J BIOL CHEM, V274, P12611, DOI 10.1074/jbc.274.18.12611	46	68	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7787	7794		10.1074/jbc.275.11.7787	http://dx.doi.org/10.1074/jbc.275.11.7787			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713092	hybrid			2022-12-27	WOS:000085913300052
J	Gable, K; Slife, H; Bacikova, D; Monaghan, E; Dunn, TM				Gable, K; Slife, H; Bacikova, D; Monaghan, E; Dunn, TM			Tsc3p is an 80-amino acid protein associated with serine palmitoyltransferase and required for optimal enzyme activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SPHINGOLIPID SYNTHESIS; CA2+-SENSITIVE PHENOTYPE; CROSS-COMPLEMENTS; CSG1 MUTANTS; GENE; LCB1; BIOSYNTHESIS; CLONING; SUPPRESSORS	Serine palmitoyltransferase catalyzes the first step of sphingolipid synthesis, condensation of serine and palmitoyl CoA to form the long chain base 3-ketosphinganine, The LCB1/TSC2 and LCB2/TSC1 genes encode homologous proteins of the alpha-oxoamine synthase family required for serine palmitoyltransferase activity. The other alpha-oxoamine synthases are soluble homodimers, but serine palmitoyltransferase is a membrane-associated enzyme composed of at least two subunits, Lcb1p and Lcb2p, Here, we report the characterization of a third gene, TSC3, required for optimal 3-ketosphinganine synthesis in Saccharomyces cerevisiae. a cerevisiae cells lacking the TSC3 gene have a temperature-sensitive lethal phenotype that is reversed by supplying 3-ketosphinganine, dihydrosphingosine, or phytosphingosine in the growth medium. The tsc3 mutant cells have severely reduced serine palmitoyltransferase activity. The TSC3 gene encodes a novel 80-amino acid protein with a predominantly hydrophilic amino-terminal half and a hydrophobic carboxyl terminus that is membrane-associated. Tsc3p coimmunoprecipitates with Lcb1p and/or Lcb2p but does not bind as tightly as Lcb1p and Lcb2p bind to each other. Lcb1p and Lcb2p remain tightly associated with each other and localize to the membrane in cells lacking Tsc3p. However, Lcb2p is unstable in cells lacking Lcb1p and vice versa.	Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Dunn, TM (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.				NIGMS NIH HHS [GM 51891] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051891] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexeev D, 1998, J MOL BIOL, V284, P401, DOI 10.1006/jmbi.1998.2086; BEELER T, 1994, J BIOL CHEM, V269, P7279; Beeler T, 1998, J BIOL CHEM, V273, P30688, DOI 10.1074/jbc.273.46.30688; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; DiRusso CC, 1998, J BIOL CHEM, V273, P33652, DOI 10.1074/jbc.273.50.33652; Dunn TM, 1998, YEAST, V14, P311, DOI 10.1002/(SICI)1097-0061(19980315)14:4<311::AID-YEA220>3.0.CO;2-B; FU DD, 1994, YEAST, V10, P515, DOI 10.1002/yea.320100411; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Hanada K, 1997, J BIOL CHEM, V272, P32108, DOI 10.1074/jbc.272.51.32108; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; MANDON EC, 1991, EUR J BIOCHEM, V198, P667, DOI 10.1111/j.1432-1033.1991.tb16065.x; MANDON EC, 1992, J BIOL CHEM, V267, P11144; Nagiec MM, 1996, GENE, V177, P237, DOI 10.1016/0378-1119(96)00309-5; NAGIEC MM, 1994, P NATL ACAD SCI USA, V91, P7899, DOI 10.1073/pnas.91.17.7899; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SHERMAN F, 1986, METHOODS YEAST GENET; SIKORSKI RS, 1989, GENETICS, V122, P19; Weiss B, 1997, EUR J BIOCHEM, V249, P239, DOI 10.1111/j.1432-1033.1997.00239.x; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9; ZHAO C, 1994, J BIOL CHEM, V269, P21480	22	139	148	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7597	7603		10.1074/jbc.275.11.7597	http://dx.doi.org/10.1074/jbc.275.11.7597			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713067	Green Submitted, hybrid			2022-12-27	WOS:000085913300027
J	Xu, KM; Murphy, TJ				Xu, KM; Murphy, TJ			Reconstitution of angiotensin receptor mRNA down-regulation in vascular smooth muscle - Post-transcriptional control by protein kinase A but not mitogenic signaling directed by the 5 '-untranslated region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; GENE-EXPRESSION; NITRIC-OXIDE; II RECEPTOR; 3'-UNTRANSLATED REGION; OXIDATIVE STRESS; BINDING PROTEIN; MAMMALIAN-CELLS; IRON-METABOLISM; AT(1) RECEPTOR	Cell surface receptor activation generally leads to changes in mRNA abundance, which may involve regulatory targets in processes working at the post-transcriptional level. Many types of agonists down-regulate vascular smooth muscle angiotensin receptor (AT(1)-R) gene expression, but it is unclear which of these activate post-transcriptional mechanisms. To reconstitute faithfully the normal AT(1)-R mRNA regulatory environment, tetracycline-suppressible promoters drive highly accurate recombinant AT(1)-R mRNA mimics in vascular smooth muscle cells that co-express an endogenous AT(1)-R mRNA Down-regulation of the latter occurs shortly after stimulating mitogenic receptors or by using forskolin, but only cAMP signaling reduces expression of the recombinant AT(1)-R mRNA Transcription of the recombinant mRNA is unaffected by cAMP signaling. Deletions of the AT(1)-R mRNA 3'-untranslated region do not impair cAMP-mediated down-regulation, Both loss of function and gain of function mutants show the response is mediated by the 5'-untranslated region. These observations provide the first direct functional evidence for modulation of vascular AT(1)-R gene expression by a mechanism involving a protein kinase A-regulated post-transcriptional process.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA	Emory University	Murphy, TJ (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 5031 OW Rollins Res Bldg, Atlanta, GA 30322 USA.				NHLBI NIH HHS [HL56107, HL52810] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056107, R01HL052810] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams B, 1999, MOL PHARMACOL, V55, P1028, DOI 10.1124/mol.55.6.1028; ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; Beard SE, 1996, MUTAT RES-GENET TOX, V371, P1, DOI 10.1016/S0165-1218(96)90089-0; Bornfeldt KE, 1999, CELL SIGNAL, V11, P465, DOI 10.1016/S0898-6568(99)00020-0; Boss V, 1998, J BIOL CHEM, V273, P19664, DOI 10.1074/jbc.273.31.19664; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHEN X, 1994, EUR J PHARM-MOLEC PH, V267, P175, DOI 10.1016/0922-4106(94)90169-4; CHERRY LM, 1982, ENVIRON MUTAGEN, V4, P259, DOI 10.1002/em.2860040308; Danner S, 1998, J BIOL CHEM, V273, P3223, DOI 10.1074/jbc.273.6.3223; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; DUBOIS MF, 1994, J CELL PHYSIOL, V158, P417, DOI 10.1002/jcp.1041580305; Firulli AB, 1998, IN VITRO CELL DEV-AN, V34, P217; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1993, NUCLEIC ACIDS RES, V21, P4411, DOI 10.1093/nar/21.18.4411; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; Heaton JH, 1998, J BIOL CHEM, V273, P14261, DOI 10.1074/jbc.273.23.14261; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUANG LY, 1993, J BIOL CHEM, V268, P25769; JACKMAN J, 1994, CANCER RES, V54, P5656; KIMES BW, 1976, EXP CELL RES, V98, P349, DOI 10.1016/0014-4827(76)90446-8; LASSEGUE B, 1995, MOL PHARMACOL, V48, P601; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Matsusaka T, 1997, ANNU REV PHYSIOL, V59, P395, DOI 10.1146/annurev.physiol.59.1.395; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NICKENIG G, 1994, MOL PHARMACOL, V46, P653; Nickenig G, 1996, MOL PHARMACOL, V50, P743; PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267; Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781; PORT JD, 1992, J BIOL CHEM, V267, P24103; RASMUSSEN EB, 1993, P NATL ACAD SCI USA, V90, P7923, DOI 10.1073/pnas.90.17.7923; RegitzZagrosek V, 1996, J MOL MED, V74, P233; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SEISER C, 1995, J BIOL CHEM, V270, P29400, DOI 10.1074/jbc.270.49.29400; TAKEUCHI K, 1993, CIRC RES, V73, P612, DOI 10.1161/01.RES.73.4.612; Tian D, 1998, J BIOL CHEM, V273, P24861, DOI 10.1074/jbc.273.38.24861; Tian D, 1998, J BIOL CHEM, V273, P28454, DOI 10.1074/jbc.273.43.28454; Tillmann-Bogush M, 1999, J BIOL CHEM, V274, P1172, DOI 10.1074/jbc.274.2.1172; Ullian ME, 1997, AM J PHYSIOL-CELL PH, V273, pC1241, DOI 10.1152/ajpcell.1997.273.4.C1241; Wang XF, 1997, MOL PHARMACOL, V52, P781, DOI 10.1124/mol.52.5.781; Wang XF, 1998, MOL PHARMACOL, V54, P514, DOI 10.1124/mol.54.3.514; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922	47	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7604	7611		10.1074/jbc.275.11.7604	http://dx.doi.org/10.1074/jbc.275.11.7604			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713068	hybrid			2022-12-27	WOS:000085913300028
J	Iversen, LF; Andersen, HS; Branner, S; Mortensen, SB; Peters, GH; Norris, K; Olsen, OH; Jeppesen, CB; Lundt, BF; Ripka, W; Moller, KB; Moller, NPH				Iversen, LF; Andersen, HS; Branner, S; Mortensen, SB; Peters, GH; Norris, K; Olsen, OH; Jeppesen, CB; Lundt, BF; Ripka, W; Moller, KB; Moller, NPH			Structure-based design of a low molecular weight, nonphosphorus, nonpeptide, and highly selective inhibitor of protein-tyrosine phosphatase 1B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; INSULIN-RECEPTOR; SIGNAL-TRANSDUCTION; NEGATIVE REGULATOR; ALPHA; INTERMEDIATE; DOMAIN; VISUALIZATION; PURIFICATION; EXPRESSION	Several protein-tyrosine phosphatases (PTPs) have been proposed to act as negative regulators of insulin signaling. Recent studies have shown increased insulin sensitivity and resistance to obesity in PTP1B knockout mice, thus pointing to this enzyme as a potential drug target in diabetes. Structure-based design, guided by PTP mutants and x-ray protein crystallography, was used to optimize a relatively weak, nonphosphorus, nonpeptide general PTP inhibitor (2-(oxalyl-amino)-benzoic acid) into a highly selective PTP1B inhibitor. This was achieved by addressing residue 48 as a selectivity determining residue. Ey introducing a basic nitrogen in the core structure of the inhibitor, a salt bridge was formed to Asp-48 in PTP1B, In contrast, the basic nitrogen causes repulsion in other PTPs containing an asparagine in the equivalent position resulting in a remarkable selectivity for PTP1B, Importantly, this was accomplished while retaining the molecular weight of the inhibitor below 300 g/mol.	Novo Nordisk AS, Prot Chem, DK-2880 Bagsvaerd, Denmark; Novo Nordisk AS, Diabet Biol, DK-2880 Bagsvaerd, Denmark; Novo Nordisk AS, New Lead Discovery, DK-2880 Bagsvaerd, Denmark; Novo Nordisk AS, Signal Transduct, DK-2880 Bagsvaerd, Denmark; Novo Nordisk AS, Med Chem Res 1, DK-2760 Malov, Denmark; Novo Nordisk AS, Med Chem Res 4, DK-2760 Malov, Denmark; Tech Univ Denmark, Dept Chem, DK-2800 Lyngby, Denmark; Ontogen Corp, Carlsbad, CA 92009 USA	Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Technical University of Denmark	Iversen, LF (corresponding author), Novo Nordisk AS, Prot Chem, DK-2880 Bagsvaerd, Denmark.		Peters, Günther H.J./T-7100-2017	Peters, Günther H.J./0000-0001-9754-2663; Jeppesen, Claus Bekker/0000-0003-2878-4348				ANDERSEN HS, 2000, IN PRESS J BIOL CHEM, V275; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Burke TR, 1996, BIOCHEMISTRY-US, V35, P15989, DOI 10.1021/bi961256d; Byon JCH, 1998, MOL CELL BIOCHEM, V182, P101, DOI 10.1023/A:1006868409841; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; Cong LN, 1999, BIOCHEM BIOPH RES CO, V255, P200, DOI 10.1006/bbrc.1999.0183; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Evans J L, 1999, Expert Opin Investig Drugs, V8, P139, DOI 10.1517/13543784.8.2.139; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GEWALD K, 1966, CHEM BER-RECL, V99, P94, DOI 10.1002/cber.19660990116; GOLDSTEIN BJ, 1992, J CELL BIOCHEM, V48, P33, DOI 10.1002/jcb.240480107; Groves MR, 1998, BIOCHEMISTRY-US, V37, P17773, DOI 10.1021/bi9816958; Hoffmann KMV, 1997, J BIOL CHEM, V272, P27505, DOI 10.1074/jbc.272.44.27505; HOPPE E, 1994, EUR J BIOCHEM, V223, P1069, DOI 10.1111/j.1432-1033.1994.tb19085.x; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228; Jacob KK, 1998, J BIOL CHEM, V273, P4800, DOI 10.1074/jbc.273.8.4800; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; KOEGL M, 1994, BIOCHEM J, V302, P737, DOI 10.1042/bj3020737; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; Lammers R, 1998, BIOCHEM BIOPH RES CO, V242, P32, DOI 10.1006/bbrc.1997.7906; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pannifer ADB, 1998, J BIOL CHEM, V273, P10454, DOI 10.1074/jbc.273.17.10454; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; Sarmiento M, 1998, J BIOL CHEM, V273, P26368, DOI 10.1074/jbc.273.41.26368; Seely BL, 1996, DIABETES, V45, P1379, DOI 10.2337/diabetes.45.10.1379; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; Taing M, 1999, BIOCHEMISTRY-US, V38, P3793, DOI 10.1021/bi9813781; Vijayakumar M, 1999, PROTEINS, V34, P497, DOI 10.1002/(SICI)1097-0134(19990301)34:4<497::AID-PROT9>3.3.CO;2-7; Wrobel J, 1999, J MED CHEM, V42, P3199, DOI 10.1021/jm990260v; Yang J, 1998, J BIOL CHEM, V273, P28199, DOI 10.1074/jbc.273.43.28199; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007	43	169	182	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10300	10307		10.1074/jbc.275.14.10300	http://dx.doi.org/10.1074/jbc.275.14.10300			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744717	hybrid			2022-12-27	WOS:000086345600058
J	Moon, YS; Latasa, MJ; Kim, KH; Wang, D; Sul, HS				Moon, YS; Latasa, MJ; Kim, KH; Wang, D; Sul, HS			Two 5 '-regions are required for nutritional and insulin regulation of the fatty-acid synthase promoter in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-TRANSCRIPTION; HORMONAL-REGULATION; BINDING; ELEMENT; IDENTIFICATION; EXPRESSION; LIVER; SYNTHETASE; PROTEINS; SITES	We previously reported that 2.1 kilobase pairs of the 5'-flanking sequence are sufficient for tissue-specific and hormonal/metabolic regulation of the fatty-acid synthase (FAS) gene in transgenic mice. We also demonstrated that the -65 E-box is required for insulin regulation of the FAS promoter using 3T3-L1 adipocytes in culture. To further define sequences required for FAS gene expression, me generated transgenic mice carrying from -644, -444, -278, and -131 to +67 base pairs of the rat FAS 5'-flanking sequence fused to the chloramphenicol acetyltransferase (CAT) reporter gene. Similar to the expression observed with -2100-FAS-CAT transgenic mice, transgenic mice harboring -644-FAS-CAT and -444-FAS-CAT expressed high levels of CAT mRNA only in lipogenic tissues (liver and adipose tissue) in a manner identical to the endogenous FAS mRNA, In contrast, -278-FAS-CAT and -131-FAS-CAT transgenic mice did not show appreciable CAT expression in any of the tissues examined. When previously fasted mice were refed a high carbohydrate, fat-free diet, CAT mRNA expression in transgenic mice harboring -644-FAS-CAT and -444-FAS-CAT was induced dramatically in liver and adipose tissue. The induction was virtually identical to that observed in -2100-FAS-CAT transgenic mice and to the endogenous FAS mRNA In contrast, -278-FAS-CAT transgenic mice showed induction by feeding, but at a much lower magnitude in both liver and adipose tissue. The -131-FAS-CAT transgenic mice did not show any CAT expression either when fasted or refed a high carbohydrate diet. To study further the effect of insulin, we made these transgenic mice insulin-deficient by streptozotocin treatment. Insulin administration to the streptozotocin-diabetic mice increased CAT mRNA levels driven by the -644 FAS and -444 FAS promoters in liver and adipose tissue, paralleling the endogenous FAS mRNA levels. In the case of -278-FAS-CAT, the induction observed was at a much lower magnitude, and deletion to -131 base pairs did not show any increase in CAT expression by insulin. This study demonstrates that the sequence requirement for FAS gene regulation employing an in vitro culture system does not reflect the in vivo Situation and that two 5'-flanking regions are required for proper nutritional and insulin regulation of the FAS gene. Cotransfection of the upstream stimulatory factor and various FAS promoter-luciferase constructs as well as in vitro binding studies suggest a function for the upstream stimulatory factor at both the -65 and -332 E-box sequences.	Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Sul, HS (corresponding author), Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA.	hsul@nature.berkeley.edu	Han, Zaiqi/AAI-2233-2019; Latasa, Maria-Jesus/M-8704-2014	Latasa, Maria-Jesus/0000-0003-2840-8692	NIDDK NIH HHS [DK36264] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036264] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Casado M, 1999, J BIOL CHEM, V274, P2009, DOI 10.1074/jbc.274.4.2009; FOUFELLE F, 1995, BIOCHEM J, V308, P521, DOI 10.1042/bj3080521; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; LAKSHMAN.MR, 1972, P NATL ACAD SCI USA, V69, P3516, DOI 10.1073/pnas.69.12.3516; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; MOUSTAID N, 1993, BIOCHEM J, V292, P767, DOI 10.1042/bj2920767; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; Rangan VS, 1996, J BIOL CHEM, V271, P2307, DOI 10.1074/jbc.271.4.2307; Roder K, 1997, J BIOL CHEM, V272, P21616, DOI 10.1074/jbc.272.34.21616; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Soncini M, 1995, J BIOL CHEM, V270, P30339, DOI 10.1074/jbc.270.51.30339; Sul HS, 1998, ANNU REV NUTR, V18, P331, DOI 10.1146/annurev.nutr.18.1.331; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WANG D, 1995, J BIOL CHEM, V270, P28716, DOI 10.1074/jbc.270.48.28716; Wang D, 1997, J BIOL CHEM, V272, P26367, DOI 10.1074/jbc.272.42.26367	20	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10121	10127		10.1074/jbc.275.14.10121	http://dx.doi.org/10.1074/jbc.275.14.10121			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744693	hybrid			2022-12-27	WOS:000086345600034
J	Wang, LG; Miller, A; Kendall, DA				Wang, LG; Miller, A; Kendall, DA			Signal peptide determinants of SecA binding and stimulation of ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; MEMBRANE-VESICLES; POSITIVE CHARGE; PRESECRETORY PROTEINS; PRECURSOR PROTEINS; AMINO TERMINUS; REGION; SEQUENCES; HYDROPHOBICITY	A signal peptide is required for entry of a preprotein into the secretory pathway, but how it functions in concert with the other transport components is unknown. In Escherichia coli, SecA is a key component of the translocation machinery found in the cytoplasm and at membrane translocation sites. Synthetic signal peptides corresponding to the wild type alkaline phosphatase signal sequence and three sets of model signal sequences varying in hydrophobicity and amino-terminal charge were generated. These were used to establish the requirements for interaction with SecA, Binding to SecA, modulation of SecA conformations sensitive to protease, and stimulation of SecA-Lipid ATPase activity occur with functional signal sequences but not with transport-incompetent ones. The extent of SecA interaction is directly related to the hydrophobicity of the signal peptide core region. For signal peptides of moderate hydrophobicity, stimulation of the SecA-lipid ATPase activity is also dependent on amino-terminal charge. The results demonstrate unequivocally that the signal peptide, in the absence of the mature protein, interacts with SecA in aqueous solution and in a lipid bilayer. We show a clear parallel between the hierarchy of signal peptide characteristics that promote interaction with SecA in vitro and the hierarchy of those observed for function in vivo.	Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA	University of Connecticut	Kendall, DA (corresponding author), Univ Connecticut, Dept Mol & Cell Biol, Box U-44, Storrs, CT 06269 USA.	kendall@uconnvm.uconn.edu			NIGMS NIH HHS [GM37639] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037639] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKITA M, 1990, J BIOL CHEM, V265, P8164; Blanco J, 1998, EUR J BIOCHEM, V257, P472, DOI 10.1046/j.1432-1327.1998.2570472.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; DOUD SK, 1993, BIOCHEMISTRY-US, V32, P1251, DOI 10.1021/bi00056a008; FAUCHERE JL, 1988, INT J PEPT PROT RES, V32, P269; Fekkes P, 1999, MICROBIOL MOL BIOL R, V63, P161, DOI 10.1128/MMBR.63.1.161-173.1999; GENNITY J, 1990, J BIOENERG BIOMEMBR, V22, P233, DOI 10.1007/BF00763167; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HIKITA C, 1992, J BIOL CHEM, V267, P12375; INOUYE S, 1982, P NATL ACAD SCI-BIOL, V79, P3438, DOI 10.1073/pnas.79.11.3438; Izard JW, 1996, J BIOL CHEM, V271, P21579, DOI 10.1074/jbc.271.35.21579; IZARD JW, 1994, MOL MICROBIOL, V13, P765, DOI 10.1111/j.1365-2958.1994.tb00469.x; IZARD JW, 1995, BIOCHEMISTRY-US, V34, P9904, DOI 10.1021/bi00031a012; KIMURA E, 1991, J BIOL CHEM, V266, P6600; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V211, P324; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Miller A, 1998, J BIOL CHEM, V273, P11409, DOI 10.1074/jbc.273.19.11409; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; Mori H, 1997, BBA-BIOMEMBRANES, V1326, P23, DOI 10.1016/S0005-2736(97)00004-7; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; RUSCH SL, 1994, J CELL BIOCHEM, V55, P209, DOI 10.1002/jcb.240550208; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SELIGMAN SJ, 1993, ANAL BIOCHEM, V211, P324, DOI 10.1006/abio.1993.1277; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; VONHEIJNE G, 1981, EUR J BIOCHEM, V116, P419; Wickner W, 1996, J BIOL CHEM, V271, P29514, DOI 10.1074/jbc.271.47.29514	33	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10154	10159		10.1074/jbc.275.14.10154	http://dx.doi.org/10.1074/jbc.275.14.10154			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744698	hybrid			2022-12-27	WOS:000086345600039
J	Hajra, AK; Larkins, LK; Das, AK; Hemati, N; Erickson, RL; MacDougald, OA				Hajra, AK; Larkins, LK; Das, AK; Hemati, N; Erickson, RL; MacDougald, OA			Induction of the peroxisomal glycerolipid-synthesizing enzymes during differentiation of 3T3-L1 adipocytes - Role in triacylglycerol synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROXYACETONE PHOSPHATE ACYLTRANSFERASE; MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; ZELLWEGER SYNDROME; SELECTIVE CHANGES; GENE-EXPRESSION; CELL-LINE; BIOSYNTHESIS; LIVER; PREADIPOCYTES; DEFICIENCY	The glycerophosphate backbone for triglyceride synthesis is commonly believed to be created through the conversion of dihydroxyacetone phosphate (DHAP) by glycerophosphate dehydrogenase (GPD) to sn-glycerol 3-phosphate (GP), which is then converted by glycerophosphate acyltransferase (GPAT) to 1-acyl-GP. Consistent with this, GPD and GPAT are highly induced during differentiation of mouse 3T3-L1 preadipocytes. While the acyl dihydroxyacetone phosphate (acyl-DHAP) pathway for glycerolipid synthesis is commonly believed to be involved only in glycerol ether lipid synthesis, we report here that during conversion of 3T3 L1 preadipocytes to adipocytes, the specific activity of peroxisomal DHAP acyltransferase (DHAPAT) is increased by 9-fold in 6 days, while acyl-DHAP:NADPH reductase is induced by 5-fold. A parallel increase in the catalase (the peroxisomal marker enzyme) activity is also seen. In contrast, the specific activity of alkyl-DHAP synthase, the enzyme catalyzing the synthesis of the ether bond, is decreased by 60% during the same period. Unlike microsomal GPAT, the induced DHAPAT is found to have high activity at pH 5.5 and is resistant to inhibition by sulfhydryl agents, heat, and proteolysis, On subcellular fractionation, DHAPAT is found to be associated with microperoxisomes whereas GPAT activity is mainly present in microsomes, Northern blot analyses reveal that induction of DHAPAT can be largely explained through increases in DHAPAT mRNA A comparison of microsomal and peroxisomal glycerolipid synthetic pathways, using D-[3-H-3, U-C-14]glucose as the precursor of the lipid glycerol backbone shows that about 40 -50% of triglyceride is synthesized via the acyl-DHAP pathway. These results indicate that the acyl-DHAP pathway is important not only for the synthesis of ether lipids, but also for the synthesis of triacylglycerol and other non-ether glycerolipids.	Univ Michigan, Neurosci Lab, Dept Physiol, Ann Arbor, MI 48104 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48104 USA; Univ Michigan, Mental Hlth Res Inst, Ann Arbor, MI 48104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Hajra, AK (corresponding author), Univ Michigan, Neurosci Lab, Dept Physiol, 1103 E Huron St, Ann Arbor, MI 48104 USA.		Erickson, Robin/AAV-3405-2020	Erickson, Robin/0000-0002-3945-6158; Das, Arun/0000-0002-0883-1816; MacDougald, Ormond/0000-0001-6907-7960	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015747] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 51563] Funding Source: Medline; NINDS NIH HHS [NS 15747] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BATES EJ, 1979, BIOCHEM J, V182, P751, DOI 10.1042/bj1820751; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; Biermann J, 1999, EUR J BIOCHEM, V261, P492, DOI 10.1046/j.1432-1327.1999.00295.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURDETT K, 1991, J BIOL CHEM, V266, P12201; COLEMAN RA, 1980, J BIOL CHEM, V255, P7681; COLEMAN RA, 1978, J BIOL CHEM, V253, P7256; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; Das AK, 1996, J LIPID RES, V37, P2706; DATTA NS, 1984, NEW ENGL J MED, V311, P1080, DOI 10.1056/NEJM198410253111704; DEDUVE C, 1981, J CELL BIOL, V91, P2935; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; GREEN H, 1979, J CELL PHYSIOL, V101, P169, DOI 10.1002/jcp.1041010119; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GRIMALDI P, 1978, EUR J BIOCHEM, V84, P369, DOI 10.1111/j.1432-1033.1978.tb12177.x; Hajra AK, 1995, PROG LIPID RES, V34, P343, DOI 10.1016/0163-7827(95)00013-5; HAJRA AK, 1982, ANN NY ACAD SCI, V386, P170, DOI 10.1111/j.1749-6632.1982.tb21415.x; HAJRA AK, 1985, ANAL BIOCHEM, V148, P233, DOI 10.1016/0003-2697(85)90651-7; HAJRA AK, 1968, J BIOL CHEM, V243, P1617; HAJRA AK, 1997, METHOD ENZYMOL, V209, P402; HARJA AK, 1973, TUMOR LIPIDS, P183; Hemati N, 1997, J BIOL CHEM, V272, P25913, DOI 10.1074/jbc.272.41.25913; HEYMANS HSA, 1983, NATURE, V306, P69, DOI 10.1038/306069a0; HORIE S, 1992, METHOD ENZYMOL, V209, P385; James PF, 1997, J BIOL CHEM, V272, P23540, DOI 10.1074/jbc.272.38.23540; JERKINS AA, 1995, J BIOL CHEM, V270, P1416, DOI 10.1074/jbc.270.38.22135; JONES CL, 1980, J BIOL CHEM, V255, P8289; JONES KM, 1994, CLIN CHEM, V40, P946; Kennedy E. P., 1986, LIPIDS MEMBRANES PRE, P171; KURIHARCUCH W, 1977, J BIOL CHEM, V252, P2158; LABELLE EF, 1972, J BIOL CHEM, V247, P5825; LABELLE EF, 1972, J BIOL CHEM, V247, P5835; LEE CH, 1991, J NEUROCHEM, V56, P370, DOI 10.1111/j.1471-4159.1991.tb08161.x; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MONROY G, 1972, J BIOL CHEM, V247, P6884; NOVIKOFF AB, 1982, ANN NY ACAD SCI, V386, P138, DOI 10.1111/j.1749-6632.1982.tb21412.x; NOVIKOFF AB, 1980, J CELL BIOL, V87, P180, DOI 10.1083/jcb.87.1.180; Ofman R, 1998, HUM MOL GENET, V7, P847, DOI 10.1093/hmg/7.5.847; POLLOCK RJ, 1976, J BIOL CHEM, V251, P5149; PROCHAZKA M, 1989, J BIOL CHEM, V264, P4679; ROTHBLATT JA, 1983, J CELL BIOL, V97, P361; SHANTZ LM, 1989, P NATL ACAD SCI USA, V86, P3852, DOI 10.1073/pnas.86.10.3852; Thai TP, 1997, FEBS LETT, V420, P205, DOI 10.1016/S0014-5793(97)01495-6; VOET G, 1995, BIOCHEMISTRY-US, P617; WEBBER KO, 1993, ARCH BIOCHEM BIOPHYS, V300, P88, DOI 10.1006/abbi.1993.1013; WEBBER KO, 1992, METHOD ENZYMOL, V209, P92; WEBBER KO, 1987, FED PROC, V46, P2106; YET SF, 1995, BIOCHEMISTRY-US, V34, P7303, DOI 10.1021/bi00022a003	50	45	46	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9441	9446		10.1074/jbc.275.13.9441	http://dx.doi.org/10.1074/jbc.275.13.9441			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734090	hybrid			2022-12-27	WOS:000086206500054
J	Miano, JM; Carlson, MJ; Spencer, JA; Misra, RP				Miano, JM; Carlson, MJ; Spencer, JA; Misra, RP			Serum response factor-dependent regulation of the smooth muscle calponin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN GENE; ACTIN GENE; TRANSCRIPTIONAL REGULATION; CALDESMON GENE; CELL LINEAGES; EXPRESSION; PROMOTER; ELEMENTS; DIFFERENTIATION; ACTIVATION	Smooth muscle calponin is a multifunctional, thin filament-associated protein whose expression is restricted to smooth muscle cell lineages in developing and postnatal tissues. Although the physiology of smooth muscle calponin has been studied extensively, the cia-elements governing its restricted pattern of expression have yet to be identified. Here we report on smooth muscle-specific enhancer activity within the first intron of smooth muscle calponin. Sequence analysis revealed a proximal consensus intronic CArG box and two distal intronic CArG-like elements, each of which bound recombinant serum response factor (SRF) as well as immunoreactive SRF from smooth muscle nuclear extracts. Site-directed mutagenesis studies suggested that the consensus CArG box mediates much of the intronic enhancer activity; mutating all three CArG elements abolished the ability of SRF to confer enhancer activity on the smooth muscle calponin promoter. Cotransfecting a dominant-negative SRF construct attenuated smooth muscle-specific enhancer activity, and transducing smooth muscle cells with adenovirus harboring the dominant-negative SRF construct selectively reduced steady-state expression of endogenous smooth muscle calponin. These results demonstrate an important role for intronic CArG boxes and the SRF protein in the transcriptional control of smooth muscle calponin in vitro.	Med Coll Wisconsin, Dept Physiol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Miano, JM (corresponding author), Univ Rochester, Med Ctr, Cardiovasc Res Ctr, 601 Elmwood Ave,POB 679, Rochester, NY 14642 USA.		Miano, Joseph/L-5634-2018	Miano, Joseph/0000-0001-7522-3207	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS036256] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62572] Funding Source: Medline; NINDS NIH HHS [R29-NS36256] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aikawa M, 1997, CIRCULATION, V96, P82; Behre G, 1999, BIOTECHNIQUES, V26, P24, DOI 10.2144/99261bm03; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; Browning CL, 1998, DEV BIOL, V194, P18, DOI 10.1006/dbio.1997.8808; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; DUBAND JL, 1993, DIFFERENTIATION, V55, P1, DOI 10.1111/j.1432-0436.1993.tb00027.x; Firulli AB, 1998, IN VITRO CELL DEV-AN, V34, P217; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; GIMONA M, 1990, FEBS LETT, V274, P159, DOI 10.1016/0014-5793(90)81353-P; GOLDHAMER DJ, 1995, DEVELOPMENT, V121, P637; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hautmann MB, 1997, CIRC RES, V81, P600, DOI 10.1161/01.RES.81.4.600; Herring BP, 1997, AM J PHYSIOL-CELL PH, V272, pC1394, DOI 10.1152/ajpcell.1997.272.4.C1394; Horiuchi A, 1998, LAB INVEST, V78, P839; Hsieh CM, 1999, J BIOL CHEM, V274, P14344, DOI 10.1074/jbc.274.20.14344; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; JOLIET V, 1995, NATURE, V373, P632, DOI 10.1038/373632a0; KATOH Y, 1994, J BIOL CHEM, V269, P30538; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; KIMES BW, 1976, EXP CELL RES, V98, P349, DOI 10.1016/0014-4827(76)90446-8; Kitami Y, 1999, HYPERTENS RES-CLIN E, V22, P187, DOI 10.1291/hypres.22.187; Landerholm TE, 1999, DEVELOPMENT, V126, P2053; Lehmann U, 1999, J BIOL CHEM, V274, P1736, DOI 10.1074/jbc.274.3.1736; Leppard KN, 1998, SEMIN VIROL, V8, P301, DOI 10.1006/smvy.1997.0132; Li L, 1997, DEV BIOL, V187, P311, DOI 10.1006/dbio.1997.8621; Mack CP, 1999, CIRC RES, V84, P852; Madsen CS, 1997, J BIOL CHEM, V272, P6332, DOI 10.1074/jbc.272.10.6332; Mano T, 1999, CIRC RES, V84, P647, DOI 10.1161/01.RES.84.6.647; Miano JM, 1996, J BIOL CHEM, V271, P7095, DOI 10.1074/jbc.271.12.7095; Miano JM, 1997, GENE, V197, P215, DOI 10.1016/S0378-1119(97)00265-5; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; Momiyama T, 1998, BIOCHEM BIOPH RES CO, V242, P429, DOI 10.1006/bbrc.1997.7959; NAKANO Y, 1991, GENE, V99, P285; NG SY, 1989, NUCLEIC ACIDS RES, V17, P601, DOI 10.1093/nar/17.2.601; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Obata H, 1997, J BIOL CHEM, V272, P26643, DOI 10.1074/jbc.272.42.26643; OWENS GK, 1995, PHYSIOL REV, V75, P487; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; PRYWES R, 1992, NUCLEIC ACIDS RES, V20, P513, DOI 10.1093/nar/20.3.513; Qian J, 1996, DEV DYNAM, V207, P135; Raguz S, 1998, DEV BIOL, V201, P26, DOI 10.1006/dbio.1998.8964; ROTHMAN A, 1992, CIRCULATION, V86, P1977, DOI 10.1161/01.CIR.86.6.1977; Samaha FF, 1996, J BIOL CHEM, V271, P395, DOI 10.1074/jbc.271.1.395; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; Sobue K, 1999, MOL CELL BIOCHEM, V190, P105, DOI 10.1023/A:1006941621170; Sobue K, 1998, HORM RES, V50, P15, DOI 10.1159/000053119; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; SZUCSIK JC, 1995, GENOMICS, V28, P154, DOI 10.1006/geno.1995.1126; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; YANO H, 1995, J BIOL CHEM, V270, P23661, DOI 10.1074/jbc.270.40.23661; Zilberman A, 1998, CIRC RES, V82, P566, DOI 10.1161/01.RES.82.5.566	57	97	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9814	9822		10.1074/jbc.275.13.9814	http://dx.doi.org/10.1074/jbc.275.13.9814			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734136	hybrid			2022-12-27	WOS:000086206500100
J	Sakaguchi, K; Saito, S; Higashimoto, Y; Roy, S; Anderson, CW; Appella, E				Sakaguchi, K; Saito, S; Higashimoto, Y; Roy, S; Anderson, CW; Appella, E			Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase - Effect on Mdm2 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; TRANSACTIVATION DOMAIN; CELL-GROWTH; PROTEIN-DNA; I ISOFORM; SIGNALS; ACID; SITE	The p53 tumor suppressor protein is stabilized in response to ionizing radiation and accumulates in the nucleus. Stabilization is thought to involve disruption of the interaction between the p53 protein and Mdm2, which targets p53 for degradation. Here we show that the direct association between a p53 N-terminal peptide and Mdm2 is disrupted by phosphorylation of the peptide on Thr's but not by phosphorylation at other N-terminal sites, including Ser(15) and Ser(37). Thr(18) was phosphorylated in vitro by casein kinase (CK1); this process required the prior phosphorylation of Ser's Thr's was phosphorylated in vivo in response to DNA damage, and such phosphorylation required Ser's. Our results suggest that stabilization of p53 after ionizing radiation may result, in part, from an inhibition of Mdm(2) binding through a phosphorylation-phosphorylation cascade involving DNA damage-activated phosphorylation of p53 Ser(15) followed by phosphorylation of Thr(18).	NCI, Chem Immunol Sect, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Bose Inst, Dept Biophys, Kolkata 700054, W Bengal, India; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Department of Science & Technology (India); Bose Institute; United States Department of Energy (DOE); Brookhaven National Laboratory	Appella, E (corresponding author), NCI, Chem Immunol Sect, Cell Biol Lab, NIH, Bldg 37,Rm 1B03,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.	appellae@pop.nci.nih.gov		Higashimoto, Yuichiro/0000-0003-1382-8598; Sakaguchi, Kazuyasu/0000-0002-8434-4171	NATIONAL CANCER INSTITUTE [Z01BC003229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52825] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Christenson E, 1997, Recent Results Cancer Res, V143, P263; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Dietrich C, 1996, P NATL ACAD SCI USA, V93, P10815, DOI 10.1073/pnas.93.20.10815; FISCELLA M, 1993, ONCOGENE, V8, P1519; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Heyduk T, 1996, METHOD ENZYMOL, V274, P492; Ho Y, 1997, P NATL ACAD SCI USA, V94, P581, DOI 10.1073/pnas.94.2.581; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; KASTAN MB, 1991, CANCER RES, V51, P6304; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Longenecker KL, 1996, J MOL BIOL, V257, P618, DOI 10.1006/jmbi.1996.0189; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; Mayo LD, 1997, CANCER RES, V57, P5013; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; MILNE DM, 1992, ONCOGENE, V7, P1361; MITSUDOMI T, 1992, ONCOGENE, V7, P171; OTAKA A, 1995, TETRAHEDRON LETT, V36, P927, DOI 10.1016/0040-4039(94)02374-K; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; WEBER G, 1952, BIOCHEM J, V51, P145, DOI 10.1042/bj0510145	43	229	231	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9278	9283		10.1074/jbc.275.13.9278	http://dx.doi.org/10.1074/jbc.275.13.9278			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734067	hybrid			2022-12-27	WOS:000086206500031
J	Gan, XQ; Wang, JY; Yang, QH; Li, Z; Liu, F; Pei, G; Li, L				Gan, XQ; Wang, JY; Yang, QH; Li, Z; Liu, F; Pei, G; Li, L			Interaction between the conserved region in the C-terminal domain of GRK2 and rhodopsin is necessary for GRK2 to catalyze receptor phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PROTEIN-KINASE-C; ESCHERICHIA-COLI; ACTIVATION; MECHANISM; BINDING; RECOVERIN; PURIFICATION; INHIBITION; EXPRESSION	The C-terminal domain of G protein-coupled receptor kinases (GRKs) consists of a conserved region and a variable region, and the variable region has been shown to direct the membrane translocation of cytosolic enzymes. The present work has revealed that the C-terminal domain may also be involved in kinase-receptor interaction that is primarily mediated by the conserved region. Truncation of the C-terminal domain or deletion of the conserved region in this domain of GRK2 resulted in a complete loss of its ability to phosphorylate rhodopsin and in an obvious decrease in its sensitivity to receptor-mediated phosphorylation of a peptide substrate. On the contrary, deletion of the py subunit binding region in the C-terminal domain of GRK2 did not significantly alter the ability of the enzyme to phosphorylate rhodopsin, In addition, the recombinant proteins that represent the C-terminal domain and the conserved region of GRK2 could inhibit GRK2-mediated phosphorylation of rhodopsin and receptor-mediated activation of GRK2 but not GRK2-mediated phosphorylation of the peptide substrate. Furthermore, the conserved region as well as the C-terminal domain could directly bind rhodopsin in vitro, These results indicate that the C-terminal domain, or more precisely, the conserved region of this domain, is important for enzyme-receptor interaction and that this interaction is required for GRK2 to catalyze receptor phosphorylation.	Chinese Acad Sci, Shanghai Inst Biochem, Shanghai 200031, Peoples R China; Chinese Acad Sci, Shanghai Inst Cell Biol, Shanghai 200031, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China; Shanghai Res Ctr Life Sci, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Li, L (corresponding author), Chinese Acad Sci, Shanghai Inst Biochem, Shanghai 200031, Peoples R China.							BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; CALVERT PD, 1995, J BIOL CHEM, V270, P24127, DOI 10.1074/jbc.270.41.24127; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Carman CV, 1999, J BIOL CHEM, V274, P8858, DOI 10.1074/jbc.274.13.8858; Carman CV, 1998, J BIOL CHEM, V273, P20308, DOI 10.1074/jbc.273.32.20308; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; CHEN CY, 1993, J BIOL CHEM, V268, P7825; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; DebBurman SK, 1996, J BIOL CHEM, V271, P22552, DOI 10.1074/jbc.271.37.22552; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; KIM CM, 1993, J BIOL CHEM, V268, P15412; KIM CM, 1993, RECEPTOR, V3, P39; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PEI G, 1995, MOL PHARMACOL, V48, P173; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; Pronin AN, 1997, J BIOL CHEM, V272, P18273, DOI 10.1074/jbc.272.29.18273; Pronin AN, 1997, J BIOL CHEM, V272, P3806, DOI 10.1074/jbc.272.6.3806; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Weiss E R, 1998, Mol Vis, V4, P27; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105; Yang QH, 1997, PROTEIN EXPRES PURIF, V10, P320, DOI 10.1006/prep.1997.0749; Yu Q M, 1998, Cell Res, V8, P303; Zhao XY, 1998, J BIOL CHEM, V273, P5124, DOI 10.1074/jbc.273.9.5124	35	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8469	8474		10.1074/jbc.275.12.8469	http://dx.doi.org/10.1074/jbc.275.12.8469			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722682	hybrid			2022-12-27	WOS:000086507700032
J	Tevelev, A; Schatz, DG				Tevelev, A; Schatz, DG			Intermolecular V(D)J recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CODING JOINT FORMATION; CHROMOSOMAL TRANSLOCATIONS; SIGNAL SEQUENCES; MOUSE THYMOCYTES; DNA; RAG1; COMPLEX; REARRANGEMENT; CLEAVAGE; SYSTEM	V(D)J recombination plays a prominent role in the generation of the antigen receptor repertoires of B and T lymphocytes, It is also likely to be involved in the formation of chromosomal translocations, some of which may result from interchromosomal recombination, We have investigated the potential of the V(D)J recombination machinery to perform intermolecular recombination between two plasmids, either unlinked or linked by catenation, In either case, recombination occurs in trans to yield signal and coding joints, and the results do not support the existence of a mechanistic block to the formation of coding joints in trans. Instead, we observe that linearization of the substrate, which does not alter the cis or trans status of the recombination signals, causes a specific and dramatic reduction in coding joint formation. This unexpected result leads us to propose a "release and recapture" model for V(D)J recombination in which coding ends are frequently released from the postcleavage complex and the efficiency of coding joint formation is influenced by the efficiency with which such ends are recaptured by the complex. This implies the existence of mechanisms, operative during recombination of chromosomal substrates, that act to prevent coding end release or to facilitate coding end recapture.	Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University	Schatz, DG (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, 310 Cedar St,Box 208011, New Haven, CT 06520 USA.		Schatz, David/A-6748-2013	Schatz, David/0000-0002-5669-1176				Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Akamatsu Y, 1998, MOL CELL BIOL, V18, P4670, DOI 10.1128/MCB.18.8.4670; ASTER JC, 1992, J EXP MED, V175, P1773, DOI 10.1084/jem.175.6.1773; Bailey SN, 1997, MOL CELL BIOL, V17, P887, DOI 10.1128/MCB.17.2.887; BOEHM T, 1989, FASEB J, V3, P2344, DOI 10.1096/fasebj.3.12.2676678; BOEHM T, 1989, EUR J BIOCHEM, V185, P1, DOI 10.1111/j.1432-1033.1989.tb15074.x; BOOCOCK MR, 1995, EMBO J, V14, P5129, DOI 10.1002/j.1460-2075.1995.tb00195.x; DERBYSHIRE MK, 1994, MOL CELL BIOL, V14, P156, DOI 10.1128/MCB.14.1.156; Difilippantonio MJ, 1996, CELL, V87, P253, DOI 10.1016/S0092-8674(00)81343-4; DUGAICZYK A, 1975, J MOL BIOL, V96, P171, DOI 10.1016/0022-2836(75)90189-8; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; Eastman QM, 1999, MOL CELL BIOL, V19, P3788; GAUSS GH, 1993, MOL CELL BIOL, V13, P3900, DOI 10.1128/MCB.13.7.3900; GAUSS GH, 1992, GENE DEV, V6, P1553, DOI 10.1101/gad.6.8.1553; Grawunder U, 1997, NUCLEIC ACIDS RES, V25, P1375, DOI 10.1093/nar/25.7.1375; Han JO, 1999, MOL CELL, V3, P331, DOI 10.1016/S1097-2765(00)80460-8; Hempel WM, 1998, GENE DEV, V12, P2305, DOI 10.1101/gad.12.15.2305; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; Hiom K, 1997, CELL, V88, P65, DOI 10.1016/S0092-8674(00)81859-0; Hiom K, 1998, MOL CELL, V1, P1011, DOI 10.1016/S1097-2765(00)80101-X; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; LEU TMJ, 1995, MOL CELL BIOL, V15, P5657; Leu TMJ, 1997, IMMUNITY, V7, P303, DOI 10.1016/S1074-7613(00)80532-4; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; Li WH, 1997, MOL CELL BIOL, V17, P6932, DOI 10.1128/MCB.17.12.6932; Liao MJ, 1999, GENE DEV, V13, P1246, DOI 10.1101/gad.13.10.1246; Livak F, 1997, J MOL BIOL, V267, P1, DOI 10.1006/jmbi.1996.0834; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Mo XM, 1999, J BIOL CHEM, V274, P7025, DOI 10.1074/jbc.274.11.7025; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; Swanson PC, 1998, IMMUNITY, V9, P115, DOI 10.1016/S1074-7613(00)80593-2; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TYCKO B, 1990, CANCER CELL-MON REV, V2, P1; Vanasse GJ, 1999, J CLIN INVEST, V103, P1669, DOI 10.1172/JCI6658; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8	44	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8341	8348		10.1074/jbc.275.12.8341	http://dx.doi.org/10.1074/jbc.275.12.8341			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722664	hybrid			2022-12-27	WOS:000086507700014
J	Leung, GK; Veniant, MM; Kim, SK; Zlot, CH; Raabe, M; Bjorkegren, J; Neese, RA; Hellerstein, MK; Young, SG				Leung, GK; Veniant, MM; Kim, SK; Zlot, CH; Raabe, M; Bjorkegren, J; Neese, RA; Hellerstein, MK; Young, SG			A deficiency of microsomal triglyceride transfer protein reduces apolipoprotein B secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPOBETALIPOPROTEINEMIA; CONTAINING LIPOPROTEINS; EMBRYONIC LETHALITY; HEPATOMA-CELLS; MICE; BINDING; GENE; ABETALIPOPROTEINEMIA; HETEROZYGOTES; DEGRADATION	Microsomal triglyceride transfer protein (MTP) transfers lipids to apolipoprotein B (apoB) within the endoplasmic reticulum, a process that involves direct interactions between apoB and the large subunit of MTP, Recent studies with heterozygous MTP knockout mice have suggested that half-normal levels of MTP in the liver reduce apoB secretion. We hypothesized that reduced apoB secretion in the setting of half-normal MTP levels might be caused by a reduced MTP:apoB ratio in the endoplasmic reticulum, which would reduce the number of apoB-MTP interactions. If this hypothesis were true, half-normal levels of MTP might have little impact on lipoprotein secretion in the setting of half-normal levels of apoB synthesis (since the ratio of MTP to apoB would not be abnormally low) and might cause an exaggerated reduction in lipoprotein secretion in the setting of apoB overexpression (since the MTP apoB ratio would be even lower). To test this hypothesis, we examined the effects of heterozygous MTP deficiency on apoB metabolism in the setting of normal levels of apoB synthesis, half-normal levels of apoB synthesis (heterozygous Apob deficiency), and increased levels of apoB synthesis (transgenic overexpression of human apoB), Contrary to our expectations, half-normal levels of MTP reduced the plasma apoB100 levels to the same extent (similar to 25-35%) at each level of apoB synthesis. In addition, apoB secretion from primary hepatocytes was reduced to a comparable extent at each level of apoB synthesis. Thus, these results indicate that the concentration of MTP within the endoplasmic reticulum rather than the MTP:apoB ratio is the critical determinant of lipoprotein secretion. Finally, we found that heterozygosity for an apoB knockout mutation lowered plasma apoB100 levels more than heterozygosity for am MTP knockout allele, Consistent with that result, hepatic triglyceride accumulation was greater in heterozygous apoB knockout mice than in heterozygous MTP knockout mice.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Berkeley	Young, SG (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.			Young, Stephen/0000-0001-7270-3176	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47660] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bakillah A, 1998, BIOCHEMISTRY-US, V37, P3727, DOI 10.1021/bi972629t; Boren J, 1998, J CLIN INVEST, V101, P1197, DOI 10.1172/JCI1785; Bradbury P, 1999, J BIOL CHEM, V274, P3159, DOI 10.1074/jbc.274.5.3159; DIXON JL, 1991, J BIOL CHEM, V266, P5080; FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; Haghpassand M, 1996, J LIPID RES, V37, P1468; Hussain MM, 1998, J BIOL CHEM, V273, P25612, DOI 10.1074/jbc.273.40.25612; Hussain MM, 1997, BIOCHEMISTRY-US, V36, P13060, DOI 10.1021/bi971395a; Jung HR, 1999, BIOCHEM J, V343, P473, DOI 10.1042/0264-6021:3430473; Kane J.B., 1989, METABOLIC BASIS INHE, P1139; Kim E, 1998, J CLIN INVEST, V101, P1468; Kim E, 1998, J LIPID RES, V39, P703; Liang JS, 1998, J BIOL CHEM, V273, P35216, DOI 10.1074/jbc.273.52.35216; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; LINTON MF, 1993, J LIPID RES, V34, P521; Nicodeme E, 1999, J BIOL CHEM, V274, P1986, DOI 10.1074/jbc.274.4.1986; Nielsen LB, 1997, J BIOL CHEM, V272, P29752, DOI 10.1074/jbc.272.47.29752; Nielsen LB, 1998, CIRCULATION, V98, P13, DOI 10.1161/01.CIR.98.1.13; PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; Rusinol AE, 1997, J BIOL CHEM, V272, P8019, DOI 10.1074/jbc.272.12.8019; Segrest JP, 1999, J LIPID RES, V40, P1401; van Greevenbroek MMJ, 1998, J LIPID RES, V39, P173; Wang YW, 1997, J BIOL CHEM, V272, P12272, DOI 10.1074/jbc.272.19.12272; Wang YW, 1999, J BIOL CHEM, V274, P27793, DOI 10.1074/jbc.274.39.27793; WETTERAU JR, 1992, SCIENCE, V258, P999; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4; WHITE AL, 1992, J BIOL CHEM, V267, P15657; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; Wu XJ, 1996, J LIPID RES, V37, P1198; Young S G, 1996, J Atheroscler Thromb, V3, P62; YOUNG SG, 1986, CLIN CHEM, V32, P1484; Zlot CH, 1999, J LIPID RES, V40, P76	37	58	69	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7515	7520		10.1074/jbc.275.11.7515	http://dx.doi.org/10.1074/jbc.275.11.7515			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713055	hybrid			2022-12-27	WOS:000085913300015
J	Tian, L; Nelson, DL; Stewart, DM				Tian, L; Nelson, DL; Stewart, DM			Cdc42-interacting protein 4 mediates binding of the Wiskott-Aldrich syndrome protein to microtubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSKELETAL-ASSOCIATED PROTEIN; ACTIN-DEPOLYMERIZING PROTEIN; SRC HOMOLOGY-3 DOMAINS; N-WASP; SIGNALING PATHWAYS; TYROSINE KINASES; LIVING CELLS; T-CELLS; IDENTIFICATION; CDC42	The Wiskott-Aldrich syndrome is an inherited X-linked immunodeficiency characterized by thrombocytopenia, eczema, and a tendency toward lymphoid malignancy. Lymphocytes from affected individuals have cytoskeletal abnormalities, and monocytes show impaired motility. The Wiskott-Aldrich syndrome protein (WASP) is a multi-domain protein involved in cytoskeletal organization. In a two-hybrid screen, we identified the protein Cdc42-interacting protein 4 (CIP4) as a WASP interactor. CIP4, like WASP, is a Cdc42 effector protein involved in cytoskeletal organization. We found that the WASP-CIP4 interaction is mediated by the binding of the Src homology 3 domain of CIP4 to the proline-rich segment of WASP. Cdc42 was not required for this interaction. Go-expression of CIP4 and green fluorescent protein-WASP in COS-7 cells led to the association of WASP with microtubules. In vitro experiments showed that CIP4 binds to microtubules via its NH2 terminus. The region of CIP4 responsible for binding to active Cdc42 was localizes to amino acids 383-417, and the mutation I398S abrogated binding. Deletion of the Cdc42-binding domain of CIP4 did not affect the colocalization of WASP with microtubules in vivo. We conclude that CIP4 can mediate the association of WASP with microtubules. This may facilitate transport of WASP to sites of substrate adhesion in hematopoietic cells.	NCI, Metab Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Stewart, DM (corresponding author), NCI, Metab Branch, NIH, Rm 4N-115,Bldg 10,9000 Rockville Pike, Bethesda, MD 20892 USA.	dstew@helix.nih.gov						ALDRICH RA, 1954, PEDIATRICS, V13, P133; Allen WE, 1997, J CELL SCI, V110, P707; ALTMAN LC, 1974, J CLIN INVEST, V54, P486, DOI 10.1172/JCI107784; Aspenstrom P, 1997, CURR BIOL, V7, P479, DOI 10.1016/S0960-9822(06)00219-3; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; AVILA J, 1998, BRAIN MICROTUBULE AS; Babb SG, 1997, CELL MOTIL CYTOSKEL, V37, P308; Badolato R, 1998, J IMMUNOL, V161, P1026; Banin S, 1996, CURR BIOL, V6, P981, DOI 10.1016/S0960-9822(02)00642-5; Cory GOC, 1996, J IMMUNOL, V157, P3791; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; DERRY JMJ, 1994, CELL, V79, P923; Dowbenko D, 1998, J BIOL CHEM, V273, P989, DOI 10.1074/jbc.273.2.989; Downing KH, 1998, CURR OPIN CELL BIOL, V10, P16, DOI 10.1016/S0955-0674(98)80082-3; Facchetti F, 1998, J PATHOL, V185, P99, DOI 10.1002/(SICI)1096-9896(199805)185:1<99::AID-PATH48>3.0.CO;2-L; Finan PM, 1996, J BIOL CHEM, V271, P26291, DOI 10.1074/jbc.271.42.26291; Gallego MD, 1997, BLOOD, V90, P3089, DOI 10.1182/blood.V90.8.3089; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Joshi HC, 1998, CURR OPIN CELL BIOL, V10, P35, DOI 10.1016/S0955-0674(98)80084-7; Kato M, 1999, J BIOL CHEM, V274, P27225, DOI 10.1074/jbc.274.38.27225; Kaverina I, 1998, J CELL BIOL, V142, P181, DOI 10.1083/jcb.142.1.181; Kaverina I, 1999, J CELL BIOL, V146, P1033, DOI 10.1083/jcb.146.5.1033; KENNEY D, 1986, BLOOD, V68, P1329; Kinnon C, 1997, BIOCHEM SOC T, V25, P648, DOI 10.1042/bst0250648; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; KWAN SP, 1995, P NATL ACAD SCI USA, V92, P4706, DOI 10.1073/pnas.92.10.4706; Linder S, 1999, P NATL ACAD SCI USA, V96, P9648, DOI 10.1073/pnas.96.17.9648; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; MASSON D, 1993, J CELL BIOL, V123, P357, DOI 10.1083/jcb.123.2.357; Miki H, 1998, BIOCHEM BIOPH RES CO, V243, P73, DOI 10.1006/bbrc.1997.8064; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; MOLINA IJ, 1993, J IMMUNOL, V151, P4383; MOLINA IJ, 1992, J EXP MED, V176, P867, DOI 10.1084/jem.176.3.867; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Plomann M, 1998, EUR J BIOCHEM, V256, P201, DOI 10.1046/j.1432-1327.1998.2560201.x; Qualmann B, 1999, MOL BIOL CELL, V10, P501, DOI 10.1091/mbc.10.2.501; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; Ritter B, 1999, FEBS LETT, V454, P356, DOI 10.1016/S0014-5793(99)00830-3; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; ROSEN FS, 1995, NEW ENGL J MED, V333, P431, DOI 10.1056/NEJM199508173330707; She HY, 1997, MOL BIOL CELL, V8, P1709, DOI 10.1091/mbc.8.9.1709; SIMON HU, 1992, J CLIN INVEST, V90, P1396, DOI 10.1172/JCI116006; Stewart DM, 1996, J CLIN INVEST, V97, P2627, DOI 10.1172/JCI118712; Stewart DM, 1999, J IMMUNOL, V162, P5019; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8; Wu Y, 1998, J BIOL CHEM, V273, P30487, DOI 10.1074/jbc.273.46.30487; Wu Y, 1998, J BIOL CHEM, V273, P5765, DOI 10.1074/jbc.273.10.5765; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7; Yeung YG, 1998, J BIOL CHEM, V273, P30638, DOI 10.1074/jbc.273.46.30638; Zhu QL, 1997, BLOOD, V90, P2680, DOI 10.1182/blood.V90.7.2680.2680_2680_2689; Zicha D, 1998, BRIT J HAEMATOL, V101, P659, DOI 10.1046/j.1365-2141.1998.00767.x	57	137	144	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7854	7861		10.1074/jbc.275.11.7854	http://dx.doi.org/10.1074/jbc.275.11.7854			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713100	hybrid			2022-12-27	WOS:000085913300060
J	Zangger, K; Oz, G; Armitage, IM				Zangger, K; Oz, G; Armitage, IM			Re-evaluation of the binding of ATP to metallothionein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; NMR-SPECTROSCOPY; METAL REMOVAL; ZINC CLUSTERS; GLUTATHIONE	In recent paper Jiang ct al. (Jiang, L, J., Maret, W. & Vallee, B. L. (1998) Proc, Natl. Acad, Sci. U.S.A. 95, 9146-9149) reported that metallothionein interacts with adenosine triphosphate (ATP) to form a 1:1 complex with a dissociation constant of K-d = 176 +/- 33 mu M at pH: 7.4. In an effort to characterize further this interaction using nuclear magnetic resonance spectroscopy, titration calorimetry, gel-filtration chromatography, affinity chromatography, and ultrafiltration, we were unable to find any evidence for the binding of ATP to metallothionein.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Armitage, IM (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 6-155 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	armitage@bscl.msi.umn.edu	Oz, Gulin/L-1306-2016	Oz, Gulin/0000-0002-5769-183X; Zangger, Klaus/0000-0003-1682-1594	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018778] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18778] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROUWER M, 1991, ARCH BIOCHEM BIOPHYS, V290, P207, DOI 10.1016/0003-9861(91)90610-U; BROUWER M, 1993, BIOCHEM J, V294, P219, DOI 10.1042/bj2940219; DETERMANN H, 1968, NATURE, V219, P604, DOI 10.1038/219604a0; FUREY WF, 1986, SCIENCE, V231, P704, DOI 10.1126/science.3945804; GELOTTE B, 1960, J CHROMATOGR, V3, P330, DOI 10.1016/S0021-9673(01)97007-4; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; HUNZIKER PE, 1991, METHOD ENZYMOL, V205, P451; Jacob C, 1998, P NATL ACAD SCI USA, V95, P3489, DOI 10.1073/pnas.95.7.3489; JANSON JC, 1967, J CHROMATOGR, V28, P12, DOI 10.1016/S0021-9673(01)85920-3; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jiang LJ, 1998, P NATL ACAD SCI USA, V95, P3483, DOI 10.1073/pnas.95.7.3483; Jiang LJ, 1998, P NATL ACAD SCI USA, V95, P9146, DOI 10.1073/pnas.95.16.9146; Kagi J H, 1987, Experientia Suppl, V52, P25; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; Maret W, 1997, P NATL ACAD SCI USA, V94, P2233, DOI 10.1073/pnas.94.6.2233; NI F, 1994, PROG NUCL MAG RES SP, V26, P517, DOI 10.1016/0079-6565(94)90000-0; PALUMAA P, 1993, BIOCHEMISTRY-US, V32, P2874, DOI 10.1021/bi00062a019; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; ROBBINS AH, 1991, J MOL BIOL, V221, P1269, DOI 10.1016/0022-2836(91)90933-W; SCHERF T, 1993, BIOPHYS J, V64, P754, DOI 10.1016/S0006-3495(93)81436-X; SEBILLE B, 1990, J CHROMATOGR-BIOMED, V531, P51, DOI 10.1016/S0378-4347(00)82280-X; Sykes Brian D., 1993, Current Opinion in Biotechnology, V4, P392, DOI 10.1016/0958-1669(93)90003-F; VASAK M, 1991, METHOD ENZYMOL, V205, P452; VASAK M, 1985, BIOCHEMISTRY-US, V24, P740, DOI 10.1021/bi00324a031; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; [No title captured]	29	8	9	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7534	7538		10.1074/jbc.275.11.7534	http://dx.doi.org/10.1074/jbc.275.11.7534			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713058	hybrid			2022-12-27	WOS:000085913300018
J	Gambaletta, D; Marchetti, A; Benedetti, L; Mercurio, AM; Sacchi, A; Falcioni, R				Gambaletta, D; Marchetti, A; Benedetti, L; Mercurio, AM; Sacchi, A; Falcioni, R			Cooperative signaling between alpha(6)beta(4) integrin and ErbB-2 receptor is required to promote phosphatidylinositol 3-kinase-dependent invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; CARCINOMA-CELLS; MONOCLONAL-ANTIBODY; CYTOPLASMIC DOMAIN; BETA-4 INTEGRIN; ALPHA-6-BETA-4 INTEGRIN; LAMININ RECEPTOR; SUBUNIT; EXPRESSION; PROTEIN	We previously demonstrated that beta(4) integrin subunit overexpression increases in vitro invasiveness of NIH3T3 cells that have been transformed by ErbB-2 oncogene. We used this model to identify domains within the large beta(4) cytoplasmic domain that are involved in the interaction of alpha(6)beta(4) with ErbB-2, invasion, and phosphatidylinositol 3-kinase (PI3K) activation. For this purpose, we expressed deletion mutants of beta(4) that lacked either all or portions of the beta(4) cytoplasmic domain in NIH3T3/ErbB-2 cells. me also used an ecto-domain mutant in which most of the extracellular domain of beta(4) was replaced with a c-Myc tag, These transfectants were examined for their ability to invade Matrigel and their ability to activate PI3K, as well as for the ability of alpha(6)beta(4) to co-immunoprecipitate with ErbB-2, The results obtained revealed that a region of the beta(4) cytoplasmic domain between amino acids 854 and 1183 is critical for the ability of alpha(6)beta(4) integrin to increase invasion. Interestingly, the extracellular domain of beta(4) is not necessary for alpha(6)beta(4) to stimulate invasion. The association of alpha(6)beta(4) with ErbB-2 is dependent upon the beta(4) cytoplasmic domain and can occur in the absence of alpha(6)beta(4) heterodimerization, Finally, we observed strong activation of PI3K with beta(4) wild type and with those beta(4) deletion mutants that were able to stimulate invasion upon the expression in NIH3T3/ErbB-2 cells, In conclusion our results establish that there is cooperation between alpha(6)beta(4) and ErbB-2 in promoting PI3K-dependent invasion and implicate a specific region of the beta(4) cytoplasmic domain (amino acids 854-1183) in this event.	Regina Elena Inst Canc Res, Mol Oncogenesis Lab, I-00158 Rome, Italy; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Falcioni, R (corresponding author), Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Via Messi Oro, I-00158 Rome, Italy.	falcioni@crs.ifo.it	Falcioni, Rita/H-8869-2017; Marchetti, Alessandra/AAD-5498-2019	Falcioni, Rita/0000-0002-3745-4327; MARCHETTI, ALESSANDRA/0000-0001-9706-848X				ALBINI A, 1987, CANCER RES, V47, P3239; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Bachelder RE, 1999, J BIOL CHEM, V274, P20733, DOI 10.1074/jbc.274.29.20733; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BOTTINI C, 1993, INT J CANCER, V54, P261, DOI 10.1002/ijc.2910540217; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; Chao C, 1996, CANCER RES, V56, P4811; CLARKE AS, 1995, J BIOL CHEM, V270, P22673, DOI 10.1074/jbc.270.39.22673; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; FALCIONI R, 1988, CANCER RES, V48, P816; FALCIONI R, 1994, INT J ONCOL, V5, P573; Falcioni R, 1997, EXP CELL RES, V236, P76, DOI 10.1006/excr.1997.3695; Feltri ML, 1997, GENE, V186, P299, DOI 10.1016/S0378-1119(96)00725-1; GUNTHER AR, 1998, J CELL BIOL, V141, P290; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KENNEL SJ, 1986, CANCER RES, V46, P707; KENNEL SJ, 1991, CANCER RES, V51, P1529; KENNEL SJ, 1990, HYBRIDOMA, V9, P243, DOI 10.1089/hyb.1990.9.243; KIMMEL KA, 1986, CANCER RES, V46, P3614; LEE EC, 1992, J CELL BIOL, V117, P671, DOI 10.1083/jcb.117.3.671; LOTZ MM, 1990, CELL REGUL, V1, P249, DOI 10.1091/mbc.1.3.249; Mainiero F, 1996, J CELL BIOL, V134, P241, DOI 10.1083/jcb.134.1.241; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Niessen CM, 1997, J CELL SCI, V110, P1705; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; Quattrini A, 1996, GLIA, V17, P294, DOI 10.1002/(SICI)1098-1136(199608)17:4<294::AID-GLIA4>3.0.CO;2-#; Rabinovitz I, 1996, BIOCHEM CELL BIOL, V74, P811, DOI 10.1139/o96-087; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; Ram TG, 1996, CELL GROWTH DIFFER, V7, P551; Schaapveld RQJ, 1998, J CELL BIOL, V142, P271, DOI 10.1083/jcb.142.1.271; Serini G, 1996, J NATL CANCER I, V88, P442, DOI 10.1093/jnci/88.7.442; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; SONNENBERG A, 1990, J CELL SCI, V96, P207; Sonnenberg A, 1993, Curr Top Microbiol Immunol, V184, P7; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; SPINARDI L, 1993, MOL BIOL CELL, V4, P871, DOI 10.1091/mbc.4.9.871; SPINARDI L, 1995, J CELL BIOL, V129, P473, DOI 10.1083/jcb.129.2.473; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; Tan M, 1999, CANCER RES, V59, P1620; Tani T, 1996, AM J PATHOL, V149, P781; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VANVAES C, 1991, CANCER RES, V51, P2395; Vivinus-Nebot M, 1999, J CELL BIOL, V144, P563, DOI 10.1083/jcb.144.3.563	46	142	143	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10604	10610		10.1074/jbc.275.14.10604	http://dx.doi.org/10.1074/jbc.275.14.10604			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744756	hybrid			2022-12-27	WOS:000086345600097
J	Ouellette, MM; Liao, M; Herbert, BS; Johnson, M; Holt, SE; Liss, HS; Shay, JW; Wright, WE				Ouellette, MM; Liao, M; Herbert, BS; Johnson, M; Holt, SE; Liss, HS; Shay, JW; Wright, WE			Subsenescent telomere lengths in fibroblasts immortalized by limiting amounts of telomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DIPLOID FIBROBLASTS; NORMAL HUMAN-CELLS; CELLULAR SENESCENCE; LIFE-SPAN; MAINTENANCE; ELONGATION; YEAST; GENE; REPLICATION; EXPRESSION	Human fibroblasts expressing the catalytic component of human telomerase (hTERT) have been followed for 250-400 population doublings, As expected, telomerase activity declined in long term culture of stable transfectants, Supprisingly, however, clones with average telomere lengths several kilobases shorter than those of senescent parental cells continued to proliferate. Although the longest telomeres shortened, the size of the shortest telomeres was maintained. Cells with subsenescent telomere lengths proliferated for an additional 20 doublings after inhibiting telomerase activity with a dominant-negative hTERT mutant. These results indicate that, under conditions of limiting telomerase activity, cis-acting signals may recruit telomerase to act on the shortest telomeres, argue against the hypothesis that the mortality stage 1 mechanism of cellular senescence is regulated by telomere positional effects (in which subtelomeric loci silenced by long telomeres are expressed when telomeres become short), and suggest that catalytically active telomerase is not required to provide a protein-capping role at the end of very short telomeres.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pathol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Human Genet, Richmond, VA 23298 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Virginia Commonwealth University; Virginia Commonwealth University	Wright, WE (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Shay, Jerry W/F-7878-2011		NCI NIH HHS [N01-CN-85143] Funding Source: Medline; NIA NIH HHS [AG01228] Funding Source: Medline; DIVISION OF CANCER PREVENTION AND CONTROL [N01CN085143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG001228, R01AG001228] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAYNE RAL, 1994, HUM MOL GENET, V3, P539; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Holt Shawn E., 1996, Methods in Cell Science, V18, P237, DOI 10.1007/BF00132889; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LIN JH, 1994, GENE, V147, P287, DOI 10.1016/0378-1119(94)90083-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; Marcand S, 1999, EMBO J, V18, P3509, DOI 10.1093/emboj/18.12.3509; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Muniyappa K, 1998, CRIT REV BIOCHEM MOL, V33, P297, DOI 10.1080/10409239891204242; Norton JC, 1998, DNA CELL BIOL, V17, P217, DOI 10.1089/dna.1998.17.217; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Ouellette MM, 1999, BIOCHEM BIOPH RES CO, V254, P795, DOI 10.1006/bbrc.1998.0114; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; PLUTA AF, 1989, NATURE, V337, P429, DOI 10.1038/337429a0; Ray A, 1999, MOL CELL BIOL, V19, P31; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; Sprung CN, 1999, EXP CELL RES, V247, P29, DOI 10.1006/excr.1998.4293; Sprung CN, 1996, NUCLEIC ACIDS RES, V24, P4336, DOI 10.1093/nar/24.21.4336; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; Wright WE, 1996, DEV GENET, V18, P173; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; WRIGHT WE, 1995, TRENDS CELL BIOL, V5, P293, DOI 10.1016/S0962-8924(00)89044-3; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	44	210	212	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10072	10076		10.1074/jbc.275.14.10072	http://dx.doi.org/10.1074/jbc.275.14.10072			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744686	hybrid			2022-12-27	WOS:000086345600027
J	Sidorkina, OM; Laval, J				Sidorkina, OM; Laval, J			Role of the N-terminal proline residue in the catalytic activities of the Escherichia coli Fpg protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE; APURINIC APYRIMIDINIC SITES; SCHIFF-BASE INTERMEDIATE; ENDONUCLEASE-III; DIRECT IDENTIFICATION; REPAIR ENZYME; DAMAGED DNA; MECHANISM; MUTATIONS; EXCISION	The Escherichia coli Fpg protein is a DNA glycosylase/AP lyase. It removes, in DNA, oxidized purine residues, including the highly mutagenic Cg-oxo-guanine (8-oxoG). The catalytic mechanism is believed to involve the formation of a transient Schiff base intermediate formed between DNA containing an oxidized residue and the N-terminal proline of the Fpg protein. The importance and the role of this proline upon the various catalytic activities of the Fpg protein was examined by targeted mutagenesis, resulting in the construction of three mutant Fpg proteins: Pro-2 --> Gly (FpgP2G), Pro-2 --> Thr (FpgP2T), and Pro-2 --> Glu (FpgP2E). The formamidopyrimidine DNA glycosylase activities of FpgP2G and FpgP2T were comparable and accounted for 10% of the wild-type activity. FpgP2G and FpgP2T had barely detectable 8-oxoG-DNA glycosylase activity and produced minute Schiff base complex with 8-oxoG/C DNA. FpgP2G and FpgP2T mutants did not cleave a DNA containing preformed AP site but readily produced Schiff base complex with this substrate. FpgP2E was completely inactive in all the assays. The binding constants of the different mutants when challenged with a duplex DNA containing a tetrahydrofuran residue were comparable. The mutant Fpg proteins barely or did not complement in vivo the spontaneous transitions G/C --> T/A in E, coli BH990 (fpg mutY) cells. These results show the mandatory role of N-terminal proline in the 8-oxoG-DNA glycosylase activity of the Fpg protein in vitro and in vivo as well as in its AP lyase activity upon preformed AP site but less in the 2,6-diamino-4-hydroxy-5-N-methylformamidopyrimidine-DNA glycosylase activity.	Inst Gustave Roussy, CNRS, UMR 8532, Grp Reparat Les Radio & Chimio Induites, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Laval, J (corresponding author), Inst Gustave Roussy, CNRS, UMR 8532, Grp Reparat Les Radio & Chimio Induites, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	jlaval@igr.fr						Alamo MJP, 1998, NUCLEIC ACIDS RES, V26, P5199, DOI 10.1093/nar/26.22.5199; AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; BOITEUX S, 1989, MOL GEN GENET, V215, P300, DOI 10.1007/BF00339732; CASTAING B, 1992, NUCLEIC ACIDS RES, V20, P389, DOI 10.1093/nar/20.3.389; CHETSANGA CJ, 1979, NUCLEIC ACIDS RES, V6, P3673, DOI 10.1093/nar/6.11.3673; Coppel Y, 1997, BIOCHEMISTRY-US, V36, P4831, DOI 10.1021/bi962678q; CUPPLES CG, 1989, P NATL ACAD SCI USA, V86, P5345, DOI 10.1073/pnas.86.14.5345; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DUWAT P, 1995, MICROBIOL-UK, V141, P411, DOI 10.1099/13500872-141-2-411; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Jurado J, 1998, BIOCHEMISTRY-US, V37, P7757, DOI 10.1021/bi972982z; KOW YW, 1987, BIOCHEMISTRY-US, V26, P8200, DOI 10.1021/bi00399a027; Kuznetsov SV, 1998, EUR J BIOCHEM, V253, P413, DOI 10.1046/j.1432-1327.1998.2530413.x; LAVAL J, 1990, MUTAT RES, V233, P73, DOI 10.1016/0027-5107(90)90152-T; Laval J, 1998, MUTAT RES-FUND MOL M, V402, P93, DOI 10.1016/S0027-5107(97)00286-8; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; Nash HM, 1997, CHEM BIOL, V4, P693, DOI 10.1016/S1074-5521(97)90225-8; O'Connor T R, 1989, Ann Ist Super Sanita, V25, P27; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; Rabow LE, 1997, BIOCHEMISTRY-US, V36, P5084, DOI 10.1021/bi963005a; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sidorkina OM, 1998, NUCLEIC ACIDS RES, V26, P5351, DOI 10.1093/nar/26.23.5351; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; Thomas F, 1999, BIOCHEMISTRY-US, V38, P1930, DOI 10.1021/bi981770e; WARD WHJ, 1990, TRENDS PHARMACOL SCI, V11, P280, DOI 10.1016/0165-6147(90)90009-W; WEISS B, 1987, ADV ENZYMOL RAMB, V60, P1; Williams SD, 1998, NUCLEIC ACIDS RES, V26, P5123, DOI 10.1093/nar/26.22.5123; Wright PM, 1999, J BIOL CHEM, V274, P29011, DOI 10.1074/jbc.274.41.29011; Zharkov DO, 1998, BIOCHEMISTRY-US, V37, P12384, DOI 10.1021/bi981066y; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335	43	41	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					9924	9929		10.1074/jbc.275.14.9924	http://dx.doi.org/10.1074/jbc.275.14.9924			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744666	hybrid			2022-12-27	WOS:000086345600007
J	Winnay, JN; Bruning, JC; Burks, DJ; Kahn, CR				Winnay, JN; Bruning, JC; Burks, DJ; Kahn, CR			Gab-1-mediated IGF-1 signaling in IRS-1-deficient 3T3 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; FACTOR-I-RECEPTOR; PLECKSTRIN HOMOLOGY DOMAINS; GRB2 BINDING-SITE; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOTYROSINE PROTEIN; DOCKING PROTEIN; TYROSINE KINASE; SH2 DOMAIN	The insulin receptor substrate (IRS) family of proteins mediate a variety of intracellular signaling events by serving as signaling platforms downstream of several receptor tyrosine kinases including the insulin and insulin-like growth factor-1 (IGF-1) receptors. Recently, several new members of this family have been identified including IRS-3, IRS-4, and growth factor receptor-binding protein a-associated binder-1 (Gab-l). 3T3 cell lines derived from IRS-l-deficient embryos exhibit a 70-80% reduction in IGF-l-stimulated S-phase entry and a parallel decrease in the induction of the immediate-early genes c-fos and egr-1 but unaltered activation of the mitogen-activated protein kinases extracellular signal-regulated kinase-l and extracellular signal-regulated kinase-2. Reconstitution of IRS-1 expression in IRS-1-deficient fibroblasts by retroviral mediated gene transduction is capable of restoring these defects. Overexpression of Gab-l in IRS-l-deficient fibroblasts also results in the restoration of egr-1 induction to levels similar to those achieved by IRS-1 reconstitution and markedly increases IGF-l-stimulated S-phase progression. Gab-l is capable of regulating these biological end points despite the absence of IGF-1 stimulated tyrosine phosphorylation. These data provide evidence that Gab-l may serve as a unique signaling intermediate in insulin/IGF-1 signaling for induction of early gene expression and stimulation of mitogenesis without direct tyrosine phosphorylation.	Joslin Diabet Ctr, Div Cellular & Mol Physiol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Kahn, CR (corresponding author), Joslin Diabet Ctr, Div Cellular & Mol Physiol, Boston, MA 02215 USA.		Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NIDDK NIH HHS [DK36836, DK33201] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033201, P30DK036836] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; Burks DJ, 1997, J BIOL CHEM, V272, P27716, DOI 10.1074/jbc.272.44.27716; CHEATHAM B, 1996, DIABETES S1, V44, P81; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Fantin VR, 1998, J BIOL CHEM, V273, P10726, DOI 10.1074/jbc.273.17.10726; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KAHN CR, 1983, CURRENT THERAPY ENDO; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Lehr S, 1999, BIOCHEMISTRY-US, V38, P151, DOI 10.1021/bi9818265; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; MILARSKI KL, 1995, BIOCHEM J, V308, P579, DOI 10.1042/bj3080579; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; THOMPSON MJ, 1994, J BIOL CHEM, V269, P21127; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WATERS SB, 1993, J BIOL CHEM, V268, P22231; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WHITE MF, 1988, J BIOL CHEM, V263, P2969; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300	40	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10545	10550		10.1074/jbc.275.14.10545	http://dx.doi.org/10.1074/jbc.275.14.10545			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744748	hybrid			2022-12-27	WOS:000086345600089
J	Burow, ME; Weldon, CB; Collins-Burow, BM; Ramsey, N; McKee, A; Klippel, A; McLachlan, JA; Clejan, S; Beckman, BS				Burow, ME; Weldon, CB; Collins-Burow, BM; Ramsey, N; McKee, A; Klippel, A; McLachlan, JA; Clejan, S; Beckman, BS			Cross-talk between phosphatidylinositol 3-kinase and sphingomyelinase pathways as a mechanism for cell survival/death decisions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GROWTH-FACTOR-I; BREAST-CANCER CELLS; RADIATION-INDUCED APOPTOSIS; N-TERMINAL KINASE; MEDIATED APOPTOSIS; AKT KINASE; INHIBITS APOPTOSIS; MAP KINASE; KAPPA-B	Peptide hormones act to regulate apoptosis through activation of multiple pro- and anti-apoptotic signaling cascades of which lipid signaling events represent an important facet of the cellular rheostat that determines survival and death decisions. Activation of sphingomyelinase, which generates ceramide, is an intermediate in cellular stress responses and induction of apoptosis in many systems. Conversely, phosphatidylinositol 3-kinase (PI3K) is a critical signaling molecule involved in regulating cell survival and proliferation pathways. In the present study, we investigate cross-talk between the PI3K and sphingomyelinase pathways as a mechanism for regulation of cell survival/death decisions. We show that phorbol ester, insulin-like growth factor 1, and a constitutively active PI3K suppress both tumor necrosis factor-induced apoptosis and ceramide generation. Conversely, inhibition of the PI3K pathway with expression of a kinase-dead PI3K both prevented survival signaling and enhanced tumor necrosis factor-induced ceramide generation. The ability of exogenous sphingomyelinase to induce ceramide generation was partially suppressed by expression of constitutively active PI3K and enhanced by inhibition of PI3K suggesting that cross-talk between PI3K and ceramide generation within cells is regulated subsequent to activation of sphingomyelinase.	Tulane Univ, Med Ctr, Dept Pharmacol,Sch Med, Tulane Ctr Bioenvironm Res, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Dept Pathol & Lab Med, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Dept Surg, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Tulane Canc Ctr, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Dept Pharmacol, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Mol & Cellular Biol Program, New Orleans, LA 70112 USA; Chiron Corp, Emeryville, CA 94608 USA	Tulane University; Tulane University; Tulane University; Tulane University; Tulane University; Tulane University; Novartis	Beckman, BS (corresponding author), Tulane Univ, Med Ctr, Dept Pharmacol,Sch Med, Tulane Ctr Bioenvironm Res, 1430 Tulane Ave,SL-83, New Orleans, LA 70112 USA.	bbeckman@tmcpop.tmc.tulane.edu	Burow, Matthew/D-6351-2013	Burow, Matthew/0000-0002-0642-6630	NCI NIH HHS [1 T32 CA65436-01A3] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA065436] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alblas J, 1998, ONCOGENE, V16, P131, DOI 10.1038/sj.onc.1201485; Barboule N, 1999, FEBS LETT, V444, P32, DOI 10.1016/S0014-5793(99)00022-8; Blobe GC, 1996, CANCER SURV, V27, P213; Burow ME, 1998, CANCER RES, V58, P4940; Cai ZZ, 1997, J BIOL CHEM, V272, P6918, DOI 10.1074/jbc.272.11.6918; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; Clejan S, 1996, EXP CELL RES, V224, P16, DOI 10.1006/excr.1996.0107; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; DARBON JM, 1986, BIOCHEM PHARMACOL, V35, P2683, DOI 10.1016/0006-2952(86)90175-9; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; delPeso L, 1997, SCIENCE, V278, P687; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; Fenig E, 1997, CLIN CANCER RES, V3, P135; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Garzotto M, 1998, CANCER RES, V58, P2260; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Haimovitz-Friedman A, 1997, BRIT MED BULL, V53, P539; HAIMOVITZFRIEDMAN A, 1994, CANCER RES, V54, P2591; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hausler P, 1998, EUR J IMMUNOL, V28, P57, DOI 10.1002/(SICI)1521-4141(199801)28:01<57::AID-IMMU57>3.0.CO;2-8; Holmstrom TH, 1998, J IMMUNOL, V160, P2626; Hsuan JJ, 1997, INT J BIOCHEM CELL B, V29, P415, DOI 10.1016/S1357-2725(96)00163-X; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Huang CS, 1997, J BIOL CHEM, V272, P4187, DOI 10.1074/jbc.272.7.4187; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jung YK, 1996, J BIOL CHEM, V271, P5112; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kelly ML, 1998, BLOOD, V92, P416, DOI 10.1182/blood.V92.2.416.414k01_416_424; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; Manna SK, 1998, J BIOL CHEM, V273, P33333, DOI 10.1074/jbc.273.50.33333; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Parrizas M, 1997, J BIOL CHEM, V272, P154; Penninger JM, 1998, ADV IMMUNOL, V68, P51, DOI 10.1016/S0065-2776(08)60558-1; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; RuizRuiz MD, 1997, EUR J IMMUNOL, V27, P1442, DOI 10.1002/eji.1830270622; SANCHEZMARGALET V, 1994, BIOCHEM BIOPH RES CO, V204, P446, DOI 10.1006/bbrc.1994.2480; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Stadheim TA, 1998, BIOCHEM BIOPH RES CO, V245, P266, DOI 10.1006/bbrc.1998.8410; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wiegmann K, 1999, J BIOL CHEM, V274, P5267, DOI 10.1074/jbc.274.9.5267; Wu YL, 1996, J CELL PHYSIOL, V168, P499, DOI 10.1002/(SICI)1097-4652(199609)168:3<499::AID-JCP2>3.0.CO;2-K; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhang P, 1997, J BIOL CHEM, V272, P9609; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	68	57	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9628	9635		10.1074/jbc.275.13.9628	http://dx.doi.org/10.1074/jbc.275.13.9628			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734114	hybrid			2022-12-27	WOS:000086206500078
J	Lee, DK; Duan, HO; Chang, CS				Lee, DK; Duan, HO; Chang, CS			From androgen receptor to the general transcription factor TFIIH - Identification of cdk activating kinase (CAK) as an androgen receptor NH2-terminal associated coactivator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; CANCER DU145 CELLS; ESTROGEN-RECEPTOR; HISTONE ACETYLTRANSFERASE; COMPLEX; PHOSPHORYLATION; TRANSACTIVATION; DEACETYLASE; ENHANCEMENT; REPRESSION	The androgen receptor (AR), libe other steroid receptors, modulates the activity of the general transcription machinery on the core promoter to exert its function as a regulator, Co-immunoprecipitation of prostate cancer LNCaP cell extract using protein A-Sepharose coupled with anti-AR antibody indicates that the AR interacts with the general transcription factor TFIIH in a physiological condition. Co-transfection of cdk activating kinase (CAK), the kinase moiety of TFIIH, enhanced AR-mediated transcription in a ligand-dependent manner in human prostate cancer PC-3 and LNCaP cells, and in a ligand-independent manner in human prostate cancer DU145 cells. Detailed interaction studies further revealed that the AR NH2-terminal domain interacting with CAK was essential for the CAR-induced AR transactivation. Together, our data suggest that the AR may interact with TFIIH for efficient communication with the general transcription factors/RNA polymerase II on the core promoter.	Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Radiat Oncol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester	Chang, CS (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.	Chang@urmc.rochester.edu			NCI NIH HHS [CA68568, CA55639] Funding Source: Medline; NIDDK NIH HHS [DK51346] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA055639, R01CA055639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051346] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CULIG Z, 1994, CANCER RES, V54, P5474; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Hsiao PW, 1999, J BIOL CHEM, V274, P20229, DOI 10.1074/jbc.274.29.20229; Inamoto S, 1997, J BIOL CHEM, V272, P29852, DOI 10.1074/jbc.272.47.29852; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; Krstic MD, 1997, MOL CELL BIOL, V17, P3947, DOI 10.1128/MCB.17.7.3947; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P7379, DOI 10.1073/pnas.95.13.7379; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; OMALLEY BW, 1995, RECENT PROG HORM RES, V50, P333; ORYZKO VV, 1996, CELL, V90, P953; Picard D, 1997, BIOCHEM SOC T, V25, P597, DOI 10.1042/bst0250597; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; SOENCER TE, 1997, NATURE, V389, P3594; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; Trowbridge JM, 1997, P NATL ACAD SCI USA, V94, P10132, DOI 10.1073/pnas.94.19.10132; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Yeh SY, 1998, BIOCHEM BIOPH RES CO, V248, P361, DOI 10.1006/bbrc.1998.8974; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	42	86	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9308	9313		10.1074/jbc.275.13.9308	http://dx.doi.org/10.1074/jbc.275.13.9308			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734072	hybrid			2022-12-27	WOS:000086206500036
J	Paterno, GD; Ryan, PJ; Kao, KR; Gillespie, LL				Paterno, GD; Ryan, PJ; Kao, KR; Gillespie, LL			The VT+ and VT- isoforms of the fibroblast growth factor receptor type 1 are differentially expressed in the presumptive mesoderm of Xenopus embryos and differ in their ability to mediate mesoderm formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FGF RECEPTOR; CDNA CLONING; INDUCTION; COMPETENCE; TRANSITION; SIGNALS; PROTEIN; MUTANT; LAEVIS; TUMORS	Previously, we cloned a variant form of the type 1 fibroblast growth factor receptor (FGFR1), FGFR-VT-, from Xenopus embryos (Gillespie, L. L., Chen, G., and Paterno, G. D. (1995) J. Biol. Chem. 270, 22758-22763). This isoform differed from the reported FGFR1 sequence (FGFR-VT+) by a a-amino acid deletion, Val(423)-Thr(424), in the juxtamembrane region. This deletion arises from the use of an alternate 5' splice donor site, and the activity of the VT+ and VT- forms of the FGFR1 was regulated by phosphorylation at this site. We have now investigated the expression pattern and function of these two isoforms in mesoderm formation in Xenopus embryos. Cells within the marginal zone are induced to form mesoderm during blastula stages. RNase protection analysis of blastula stage embryos revealed that the VT+ isoform was expressed throughout the embryo but that the VT- isoform was expressed almost exclusively in the marginal zone. The ratio of VT+:VT- transcripts in the marginal zone indicated that the VT+ form was predominant throughout blastula stages except for a brief interval, coinciding with the start of zygotic transcription, when a dramatic increase in VT- expression levels was detected. This increase could be mimicked in part by treatment of animal cap explants with FGF-2, Overexpression of the VT+ isoform in Xenopus embryos resulted in development of tadpoles with severe reductions in trunk and tail structures, while embryos overexpressing the VT- isoform developed normally. A standard mesoderm induction assay revealed that a 10-fold higher concentration of FGF-2 was required to reach 50% induction in VT+-overexpressing animal cap explants compared with those overexpressing the VT-isoform, Furthermore, little or no expression of the pan-mesodermal marker Bratchyury (Xbra) was detected in VT+-overexpressing embryos, while VT- overexpressing embryos showed normal staining. This demonstrates that VT+ overexpression had a negative effect on mesoderm formation in vivo. These data are consistent with a model in which mesoderm formation in vivo is regulated, at least in part, by the relative expression levels of the VT+ and VT- isoforms.	Mem Univ Newfoundland, Div Basic Med Sci, Terry Fox Canc Res Labs, Fac Med, St Johns, NF A1B 3V6, Canada	Memorial University Newfoundland	Gillespie, LL (corresponding author), Mem Univ Newfoundland, Div Basic Med Sci, Terry Fox Canc Res Labs, Fac Med, St Johns, NF A1B 3V6, Canada.		Ryan, Patrick/HDO-1133-2022					AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; CORNELL RA, 1995, DEVELOPMENT, V121, P2429; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GILLESPIE LL, 1992, MECH DEVELOP, V38, P99, DOI 10.1016/0925-4773(92)90002-2; GILLESPIE LL, 1995, J BIOL CHEM, V270, P22758, DOI 10.1074/jbc.270.39.22758; GILLESPIE LL, 1989, DEVELOPMENT, V106, P203; GODSAVE SF, 1988, DEVELOPMENT, V102, P555; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; Isaacs HV, 1997, CELL MOL LIFE SCI, V53, P350, DOI 10.1007/PL00000611; Joseph EM, 1998, DEVELOPMENT, V125, P2677; KIMELMAN D, 1992, DEVELOPMENT, V116, P1; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KLINT P, 1999, FRONT BIOSCI, V4, P165; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; LaBonne C, 1997, DEV BIOL, V183, P9, DOI 10.1006/dbio.1996.8497; Masui Y, 1998, BIOL CELL, V90, P537, DOI 10.1016/S0248-4900(99)80011-2; McDowell N, 1999, SEMIN CELL DEV BIOL, V10, P311, DOI 10.1006/scdb.1999.0307; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Paterno GD, 1997, J BIOL CHEM, V272, P25591, DOI 10.1074/jbc.272.41.25591; Paterno GD, 1998, GENE, V222, P77, DOI 10.1016/S0378-1119(98)00473-9; RYAN PJ, 1994, DEV BIOL, V166, P101, DOI 10.1006/dbio.1994.1299; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SCHULTEMERKER S, 1995, CURR BIOL, V5, P62, DOI 10.1016/S0960-9822(95)00017-0; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; Szebenyi G, 1999, INT REV CYTOL, V185, P45; Yang SS, 1998, J BIOL CHEM, V273, P13746, DOI 10.1074/jbc.273.22.13746	32	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9581	9586		10.1074/jbc.275.13.9581	http://dx.doi.org/10.1074/jbc.275.13.9581			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734108	hybrid			2022-12-27	WOS:000086206500072
J	Reichert, M; Muller, T; Hunziker, W				Reichert, M; Muller, T; Hunziker, W			The PDZ domains of zonula occludens-1 induce an epithelial to mesenchymal transition of Madin-Darby canine kidney I cells - Evidence for a role of beta-catenin/Tcf/Lef signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; JUNCTION-ASSOCIATED PROTEIN; TRANSCRIPTION FACTOR LEF-1; POLYPOSIS-COLI PROTEIN; RAS TARGET AF-6; TIGHT JUNCTION; FUNCTIONAL INTERACTION; FORCED EXPRESSION; PLASMA-MEMBRANE; XENOPUS EMBRYOS	The integrity of cell-cell contacts such as adherens junctions (AJ) and tight junctions (TJ) is essential for the function of epithelia, During carcinogenesis, the increased motility and invasiveness of tumor cells reflect the loss of characteristic epithelial features, including cell adhesion. While beta-catenin, a component of AJ, plays a well characterized dual role in cell adhesion and signal transduction leading to epithelial cell transformation, little is known about possible roles of tight junction components in signaling processes. Here we show that mutants of the TJ protein zonula occludens protein-1 (ZO-1), which encode the PDZ domains (ZO-1 PDZ) but no longer localize at the plasma membrane, induce a dramatic epithelial to mesenchymal transition (EMT) of Madin-Darby canine kidney I (MDCKI) cells. The observed EMT of these MDCK-PDZ cells is characterized by a repression of epithelial marker genes, a restricted differentiation potential and a significantly induced tumorigenicity, Intriguingly, the beta-catenin signaling path way is activated in the cells expressing the ZO-1 PDZ protein. Ectopic expression of the adenomatous polyposis coli tumor suppressor gene, known to down-regulate activated beta-catenin signaling, reverts the transformed fibroblastoid phenotype of MDCK-PDZ cells. Thus, cytoplasmic localization of the ZO-1 PDZ domains induces an EMT in MDCKI cells, most likely by modulating beta-catenin signaling.	Univ Lausanne, CH-1015 Lausanne, Switzerland; Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland	University of Lausanne; Swiss Institute Experimental Cancer Research	Reichert, M (corresponding author), Univ Lausanne, CH-1015 Lausanne, Switzerland.		Hunziker, Walter/GSM-8190-2022; Hunziker, Walter/B-3140-2010	Hunziker, Walter/0000-0002-5265-4933				Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; BALDA MS, 1993, AM J PHYSIOL, V264, pC918, DOI 10.1152/ajpcell.1993.264.4.C918; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Cereijido M, 1998, ANNU REV PHYSIOL, V60, P161, DOI 10.1146/annurev.physiol.60.1.161; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN WC, 1991, J CELL BIOL, V114, P319, DOI 10.1083/jcb.114.2.319; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Easwaran V, 1999, J BIOL CHEM, V274, P16641, DOI 10.1074/jbc.274.23.16641; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Gallet A, 1999, EMBO J, V18, P2208, DOI 10.1093/emboj/18.8.2208; Gilles C, 1999, J CELL SCI, V112, P4615; Gottardi CJ, 1996, P NATL ACAD SCI USA, V93, P10779, DOI 10.1073/pnas.93.20.10779; Grisendi S, 1998, J CELL PHYSIOL, V176, P465, DOI 10.1002/(SICI)1097-4652(199809)176:3<465::AID-JCP3>3.0.CO;2-M; HANSSON GC, 1986, EMBO J, V5, P483, DOI 10.1002/j.1460-2075.1986.tb04237.x; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Hoover KB, 1998, AM J PATHOL, V153, P1767, DOI 10.1016/S0002-9440(10)65691-X; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; MAREEL M, 1995, CANCER DETECT PREV, V19, P451; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MCCREA PD, 1993, J CELL BIOL, V123, P477, DOI 10.1083/jcb.123.2.477; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NAKAZATO Y, 1989, BIOCHIM BIOPHYS ACTA, V1014, P57, DOI 10.1016/0167-4889(89)90240-1; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; Pollack AL, 1998, DEV BIOL, V204, P64, DOI 10.1006/dbio.1998.9091; Prieve MG, 1999, MOL CELL BIOL, V19, P4503; Romagnolo B, 1999, CANCER RES, V59, P3875; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Sheth B, 1997, DEVELOPMENT, V124, P2027; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Stevenson BR, 1998, ANNU REV CELL DEV BI, V14, P89, DOI 10.1146/annurev.cellbio.14.1.89; Takahisa M, 1996, GENE DEV, V10, P1783, DOI 10.1101/gad.10.14.1783; Taya S, 1998, J CELL BIOL, V142, P1053, DOI 10.1083/jcb.142.4.1053; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Yamamoto T, 1999, BIOCHEM BIOPH RES CO, V259, P103, DOI 10.1006/bbrc.1999.0731; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yu X, 1998, EMBO J, V17, P7021, DOI 10.1093/emboj/17.23.7021; ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700	66	131	140	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9492	9500		10.1074/jbc.275.13.9492	http://dx.doi.org/10.1074/jbc.275.13.9492			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734097	hybrid			2022-12-27	WOS:000086206500061
J	Smirnova, IV; Bittel, DC; Ravindra, R; Jiang, HM; Andrews, GK				Smirnova, IV; Bittel, DC; Ravindra, R; Jiang, HM; Andrews, GK			Zinc and cadmium can promote rapid nuclear translocation of metal response element-binding transcription factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE METALLOTHIONEIN-I; GENE-EXPRESSION; FACTOR MTF-1; DNA-BINDING; GLUCOCORTICOID RECEPTOR; LOCALIZATION SIGNAL; TRANSITION-METALS; HEAVY-METALS; INTERACTS; PROTEIN	Metal response element-binding transcription factor-1 (MTF-1) is a six-zinc finger protein that plays an essential role in activating metallothionein expression in response to the heavy metals zinc and cadmium. Low affinity interactions between zinc and specific zinc fingers in MTF-1 reversibly regulate its binding to the metal response elements in the mouse metallothionein-I promoter. This study examined the subcellular distribution and DNA binding activity of MTF-l in cells treated with zinc or cadmium. Immunoblot analysis of cytosolic and nuclear extracts demonstrated that in untreated cells, about 83% of MTF-1 is found in the cytosolic extracts and is not activated to bind to DNA. In sharp contrast, within 30 min of zinc treatment (100 mu M), MTF-1 is detected only in nuclear extracts and is activated to bind to DNA, The activation to bind to DNA and nuclear translocation of MTF-1 occurs in the absence of increased MTF-1 content in the cell. Furthermore, immunocytochemical localization and immunoblotting assays demonstrated that zinc induces the nuclear translocation of MTF-1-FLAG, expressed from the cytomegalovirus promoter in transiently transfected dko7 (MTF-1 double knockout) cells. Immunoblot analysis of cytosolic and nuclear extracts from cadmium-treated cells demonstrated that concentrations of cadmium (10 mu M) that actively induce metallothionein gene expression cause only a small increase in the amount of nuclear MTF-1, In contrast, an overtly toxic concentration of cadmium (50 mu M) rapidly induced the complete nuclear translocation and activation of DNA binding activity of MTF-1, These studies are consistent with the hypothesis that MTF-1 serves as a zinc sensor that responds to changes in cytosolic free zinc concentrations. In addition, these data suggest that cadmium activation of metallothionein gene expression may be accompanied by only small changes in nuclear MTF-1.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center	Andrews, GK (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.				NIEHS NIH HHS [F32 ES 05753, ES 05704] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005704, F32ES005753] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ali A, 1998, MOL CELL BIOL, V18, P4949, DOI 10.1128/MCB.18.9.4949; ANDERSEN RD, 1987, MOL CELL BIOL, V7, P3574, DOI 10.1128/MCB.7.10.3574; Andrews GK, 1999, J NUTR, V129, P1643, DOI 10.1093/jn/129.9.1643; ANDREWS GK, 1990, PROG FOOD NUTR SCI, V14, P193; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Bittel D, 1998, J BIOL CHEM, V273, P7127, DOI 10.1074/jbc.273.12.7127; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; BRUGNERA E, 1994, NUCLEIC ACIDS RES, V22, P3167, DOI 10.1093/nar/22.15.3167; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; Chen XH, 1999, BIOCHEMISTRY-US, V38, P12915, DOI 10.1021/bi9913000; Chen XH, 1998, BIOCHEMISTRY-US, V37, P11152, DOI 10.1021/bi980843r; Chu WA, 1999, J BIOL CHEM, V274, P5279, DOI 10.1074/jbc.274.9.5279; Dalton T, 1996, J NUTR, V126, P825, DOI 10.1093/jn/126.4.825; DALTON T, 1994, NUCLEIC ACIDS RES, V22, P5016, DOI 10.1093/nar/22.23.5016; Dalton TP, 1997, MOL CELL BIOL, V17, P2781, DOI 10.1128/MCB.17.5.2781; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Gunes C, 1998, EMBO J, V17, P2846, DOI 10.1093/emboj/17.10.2846; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; Hsieh JC, 1998, J CELL BIOCHEM, V70, P94, DOI 10.1002/(SICI)1097-4644(19980701)70:1<94::AID-JCB10>3.3.CO;2-Q; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KANG KI, 1994, P NATL ACAD SCI USA, V91, P340, DOI 10.1073/pnas.91.1.340; KOIZUMI S, 1991, CHEM-BIOL INTERACT, V80, P145, DOI 10.1016/0009-2797(91)90021-X; Koizumi S, 1999, EUR J BIOCHEM, V259, P635, DOI 10.1046/j.1432-1327.1999.00069.x; KOIZUMI S, 1992, EUR J BIOCHEM, V210, P555, DOI 10.1111/j.1432-1033.1992.tb17454.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; MATHENY C, 1994, J BIOL CHEM, V269, P8176; Maur AAD, 1999, BIOL CHEM, V380, P175, DOI 10.1515/BC.1999.026; MAYO KE, 1981, J BIOL CHEM, V256, P2621; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; Muller HP, 1995, SOMAT CELL MOLEC GEN, V21, P289, DOI 10.1007/BF02257464; Murphy BJ, 1999, CANCER RES, V59, P1315; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; PERROTAPPLANAT M, 1985, ENDOCRINOLOGY, V116, P1473, DOI 10.1210/endo-116-4-1473; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; RADTKE F, 1995, NUCLEIC ACIDS RES, V23, P2277, DOI 10.1093/nar/23.12.2277; Sackey FNA, 1996, MOL ENDOCRINOL, V10, P1191, DOI 10.1210/me.10.10.1191; SEGUIN C, 1987, SCIENCE, V235, P1383, DOI 10.1126/science.3103216; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; STUART GW, 1985, NATURE, V317, P828, DOI 10.1038/317828a0; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WAN M, 1993, BIOCHEM J, V292, P609, DOI 10.1042/bj2920609; WESTIN G, 1988, EMBO J, V7, P3763, DOI 10.1002/j.1460-2075.1988.tb03260.x; YAGLE MK, 1985, MOL CELL BIOL, V5, P291, DOI 10.1128/MCB.5.2.291; Yu CW, 1997, FEBS LETT, V420, P69, DOI 10.1016/S0014-5793(97)01489-0	48	183	186	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9377	9384		10.1074/jbc.275.13.9377	http://dx.doi.org/10.1074/jbc.275.13.9377			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734081	hybrid			2022-12-27	WOS:000086206500045
J	Choi, YC; Park, GT; Kim, TS; Sunwoo, IN; Steinert, PM; Kim, SY				Choi, YC; Park, GT; Kim, TS; Sunwoo, IN; Steinert, PM; Kim, SY			Sporadic inclusion body myositis correlates with increased expression and cross-linking by transglutaminases 1 and 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-AMYLOID PROTEIN; HUMAN NEUROMUSCULAR-JUNCTIONS; HUMAN EPIDERMAL-KERATINOCYTES; CORNIFIED CELL-ENVELOPE; TISSUE TRANSGLUTAMINASE; ALZHEIMERS-DISEASE; PEPTIDE; MUSCLE; ENZYME; IDENTIFICATION	Sporadic inclusion body myositis (SIBM) is characterized by vacuolar degeneration of muscle fibers and intrafiber clusters of paired helical filaments with abnormal amyloid deposition. Because of their potential involvement in other degenerative disorders, we have examined the expression of transglutaminases (TGases) in normal and SIBM tissues. We report that at least two different enzymes, the ubiquitous TGase 2 as well as the TGase 1 enzyme, are present in muscle tissues. However, in comparison with normal tissue, the expression of TGases 1 and 2 was increased 2.5- and 4-fold in SIBM, accompanied by about a 20-fold higher total TGase activity. By immunohistochemical staining, in normal muscle, TGase 2 expression was restricted to some endomysial connective tissue elements, whereas TGase 1 and beta-amyloid proteins were not detectable. In SIBM muscle, both TGases 1 and 2 as well as amyloid proteins were brightly expressed and co-localized in the vacuolated muscle fibers, but none of these proteins colocalized with inflammatory cell markers. Next, we isolated high molecular weight insoluble proteins from SIBM muscle tissue and showed that they were cross-linked by about 6 residues/1000 residues of the isopeptide bond. Furthermore, by amino acid sequencing of solubilized tryptic peptides, they contain amyloid and skeletal muscle proteins, Together, these findings suggest that elevated expression of TGases 1 and 2 participate in the formation of insoluble amyloid deposits in SIBM tissue and in this way may contribute to progressive and debilitating muscle disease.	Yonsei Univ, Coll Med, Dept Pathol, Seoul 135270, South Korea; NIAMS, Skin Biol Lab, NIH, Bethesda, MD 20892 USA; Yonsei Univ, Coll Med, Dept Neurol, Seoul 135270, South Korea	Yonsei University; Yonsei University Health System; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Yonsei University; Yonsei University Health System	Choi, YC (corresponding author), Yonsei Univ, Yongdong Severance Hosp, Coll Med, Dept Neurol, Seoul 135270, South Korea.	ycchoi@yumc.yonsei.ac.kr		Choi, Young-Chul/0000-0001-5525-6861				Aeschlimann D, 1998, J BIOL CHEM, V273, P3452, DOI 10.1074/jbc.273.6.3452; AESCHLIMANN D, 1995, J CELL BIOL, V129, P881, DOI 10.1083/jcb.129.3.881; AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; Aeschlimann Daniel, 1996, Seminars in Thrombosis and Hemostasis, V22, P437; ARAI H, 1990, P NATL ACAD SCI USA, V87, P2249, DOI 10.1073/pnas.87.6.2249; ASKANAS V, 1992, AM J PATHOL, V141, P31; ASKANAS V, 1993, ANN NEUROL, V34, P551, DOI 10.1002/ana.410340408; Askanas V, 1998, ANN NY ACAD SCI, V841, P28, DOI 10.1111/j.1749-6632.1998.tb10908.x; Askanas V, 1998, ARCH NEUROL-CHICAGO, V55, P915, DOI 10.1001/archneur.55.7.915; ASKANAS V, 1988, INCLUSION BODY MYOSI, P3; Candi E, 1999, J BIOL CHEM, V274, P7226, DOI 10.1074/jbc.274.11.7226; Carpenter S, 1996, J NEUROPATH EXP NEUR, V55, P1105, DOI 10.1097/00005072-199611000-00001; Di Luca M, 1998, ARCH NEUROL-CHICAGO, V55, P1195, DOI 10.1001/archneur.55.9.1195; DUDEK SM, 1994, BRAIN RES, V651, P129, DOI 10.1016/0006-8993(94)90688-2; Eligula L, 1998, BIOPHYS J, V74, P953, DOI 10.1016/S0006-3495(98)74018-4; ENGEL AG, 1984, ANN NEUROL, V16, P209, DOI 10.1002/ana.410160207; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; Gaudry CA, 1999, J BIOL CHEM, V274, P30707, DOI 10.1074/jbc.274.43.30707; GENTILE V, 1991, J BIOL CHEM, V266, P478; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GRIGGS RC, 1995, ANN NEUROL, V38, P705, DOI 10.1002/ana.410380504; HAND D, 1993, J NEUROCHEM, V61, P1064, DOI 10.1111/j.1471-4159.1993.tb03621.x; HAND D, 1993, INT J DEV NEUROSCI, V11, P709, DOI 10.1016/0736-5748(93)90060-Q; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; HO GJ, 1994, FEBS LETT, V349, P151, DOI 10.1016/0014-5793(94)00663-6; HOHL D, 1991, J BIOL CHEM, V266, P6626; IKURA K, 1993, FEBS LETT, V326, P109, DOI 10.1016/0014-5793(93)81772-R; KIM IG, 1992, J BIOL CHEM, V267, P7710; Kim SY, 1999, J BIOL CHEM, V274, P30715, DOI 10.1074/jbc.274.43.30715; KIM SY, 1995, J BIOL CHEM, V270, P18026, DOI 10.1074/jbc.270.30.18026; KIM SY, 1995, J INVEST DERMATOL, V104, P211, DOI 10.1111/1523-1747.ep12612769; KLEMAN JP, 1995, BIOCHEMISTRY-US, V34, P13768, DOI 10.1021/bi00042a007; KONIGSBERG WH, 1983, METHOD ENZYMOL, V91, P254; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; Marcon G, 1999, AM J PATHOL, V154, P1001, DOI 10.1016/S0002-9440(10)65352-7; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Melino G, 1998, FEBS LETT, V430, P59, DOI 10.1016/S0014-5793(98)00521-3; MELINO G, 1999, IN PRESS METHODS ENZ, V322; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nozawa H, 1997, COMP BIOCHEM PHYS B, V118, P313, DOI 10.1016/S0305-0491(97)00062-X; RAGHUNATHAN M, 1966, J CLIN INVEST, V98, P1174; RASMUSSEN LK, 1994, FEBS LETT, V338, P161, DOI 10.1016/0014-5793(94)80356-0; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; SARKOZI E, 1993, NEUROREPORT, V4, P815, DOI 10.1097/00001756-199306000-00055; SCHMIDT R, 1988, FEBS LETT, V229, P193, DOI 10.1016/0014-5793(88)80825-1; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SINGERSAM J, 1990, NUCLEIC ACIDS RES, V18, P1255, DOI 10.1093/nar/18.5.1255; Steinert PM, 1996, J BIOL CHEM, V271, P26242, DOI 10.1074/jbc.271.42.26242; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Steinert PM, 1996, BIOCHEM BIOPH RES CO, V221, P101, DOI 10.1006/bbrc.1996.0552; STERN RA, 1990, FEBS LETT, V264, P43; Thomazy VA, 1999, CELL DEATH DIFFER, V6, P146, DOI 10.1038/sj.cdd.4400464; UPCHURCH HF, 1991, J CELL PHYSIOL, V149, P375, DOI 10.1002/jcp.1041490304; Yang CC, 1998, NEUROSCI LETT, V254, P77, DOI 10.1016/S0304-3940(98)00657-0; YUNIS EJ, 1971, LAB INVEST, V25, P240; Zhang W, 1997, LIFE SCI, V60, P2323, DOI 10.1016/S0024-3205(97)00288-9	58	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8703	8710		10.1074/jbc.275.12.8703	http://dx.doi.org/10.1074/jbc.275.12.8703			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722712	hybrid, Green Submitted			2022-12-27	WOS:000086507700062
J	Kainulainen, V; Sundvall, M; Maatta, JA; Santiestevan, E; Klagsbrun, M; Elenius, K				Kainulainen, V; Sundvall, M; Maatta, JA; Santiestevan, E; Klagsbrun, M; Elenius, K			A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-RECEPTOR; PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; PUTATIVE RECEPTORS; FAMILY MEMBERS; DNA-SYNTHESIS; 3-OH KINASE; EXPRESSION	ErbB4 is a member of the epidermal growth factor receptor (ErbB) family that mediates cellular responses activated by neuregulins (NRG) and other epidermal growth factor-like growth factors. TWO naturally occurring ErbB4 isoforms, ErbB4 CYT-1 and ErbB4 CYT-2, have previously been identified. Unlike ErbB4 CYT-1, ErbB4 CYT-2 lacks a phosphoinositide 3-kinase (PIS-K)binding site and is incapable of activating PI3-K. We have now examined the consequences of the inability of this isoform to activate PI3-K on cell proliferation, survival, and chemotaxis in response to NRG-1 beta: (i) NRG-1 beta stimulated proliferation of cells expressing either ErbB4 CYT-1 or ErbB4 CYT-S, Consistent with the mitogenic responsiveness, analysis of downstream signaling showed that Shc and MAPK were phosphorylated after stimulating either isoform with NRG-1 beta. (ii) NRG-1 beta protected cells expressing ErbB4 CYT-1 but not cells expressing ErbB4 CYT-Q from starvation-induced apoptosis as measured by effects on cell number and 4',6-diamidino-2-phenylindole staining. Furthermore, in cells expressing ErbB4 CYT-2, Akt, a protein kinase that mediates cell survival, was not phosphorylated. (iii) NRG-1 beta stimulated chemotaxis and membrane ruffling in cells expressing ErbB4 CYT-1 but not in cells expressing ErbB4 CYT-8, In summary, ErbB4 CYT-8 can mediate proliferation but not chemotaxis or survival. These results suggest a novel mechanism by which cellular responses such as chemotaxis and survival may be regulated by the expression of alternative receptor-tyrosine kinase isoforms that differ in their coupling to PI3-K signaling.	Univ Turku, Medicity Res Labs, FIN-20520 Turku, Finland; Univ Turku, Dept Pediat, FIN-20520 Turku, Finland; Univ Turku, Dept Med Biochem & Mol Biol, FIN-20520 Turku, Finland; Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	University of Turku; University of Turku; University of Turku; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Elenius, K (corresponding author), Univ Turku, Medicity Res Labs, Tykistokatu 6 A, FIN-20520 Turku, Finland.	klaus.elenius@utu.fi	Elenius, Klaus/AAI-7594-2021	Elenius, Klaus/0000-0001-5700-0827; Maatta, Jorma/0000-0001-8752-6862; Sundvall, Maria H/0000-0002-0494-2965	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047397] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 47397] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CARPENTER G, 1991, PEPTIDE GROWTH FACTO, P69; Carroll SL, 1997, J NEUROSCI, V17, P1642; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Cohen BD, 1996, J BIOL CHEM, V271, P30897, DOI 10.1074/jbc.271.48.30897; Cohen BM, 1996, J BIOL CHEM, V271, P4813; COHEN S, 1980, J BIOL CHEM, V255, P4834; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dixon M, 1999, MOL CELL NEUROSCI, V13, P237, DOI 10.1006/mcne.1999.0749; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Elenius K, 1999, ONCOGENE, V18, P2607, DOI 10.1038/sj.onc.1202612; Fischbach GD, 1997, ANNU REV NEUROSCI, V20, P429, DOI 10.1146/annurev.neuro.20.1.429; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Furger C, 1998, CANCER RES, V58, P1773; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Gilbertson RJ, 1997, CANCER RES, V57, P3272; Harari D, 1999, ONCOGENE, V18, P2681, DOI 10.1038/sj.onc.1202631; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Klapper LN, 1999, P NATL ACAD SCI USA, V96, P4995, DOI 10.1073/pnas.96.9.4995; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Komurasaki T, 1997, ONCOGENE, V15, P2841, DOI 10.1038/sj.onc.1201458; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lim H, 1998, DEV BIOL, V204, P97, DOI 10.1006/dbio.1998.9072; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; MOSCOSO LM, 1995, DEV BIOL, V172, P158, DOI 10.1006/dbio.1995.0012; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PinkasKramarski R, 1997, ONCOGENE, V15, P2803, DOI 10.1038/sj.onc.1201466; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rio C, 1997, NEURON, V19, P39, DOI 10.1016/S0896-6273(00)80346-3; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Sawyer C, 1998, ONCOGENE, V17, P919, DOI 10.1038/sj.onc.1202015; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vartanian T, 1997, J CELL BIOL, V137, P211, DOI 10.1083/jcb.137.1.211; Vogt U, 1998, GENE, V223, P375, DOI 10.1016/S0378-1119(98)00454-5; Wang LM, 1998, P NATL ACAD SCI USA, V95, P6809, DOI 10.1073/pnas.95.12.6809; Welch H, 1998, J BIOL CHEM, V273, P11248, DOI 10.1074/jbc.273.18.11248; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WENNSTROM S, 1994, ONCOGENE, V9, P651; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhang K, 1996, J BIOL CHEM, V271, P3884; Zhao YY, 1999, CIRC RES, V84, P1380; Zhao YY, 1998, J BIOL CHEM, V273, P10261, DOI 10.1074/jbc.273.17.10261; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	84	138	144	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8641	8649		10.1074/jbc.275.12.8641	http://dx.doi.org/10.1074/jbc.275.12.8641			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722704	hybrid			2022-12-27	WOS:000086507700054
J	Sassetti, C; Van Zante, A; Rosen, SD				Sassetti, C; Van Zante, A; Rosen, SD			Identification of endoglycan, a member of the CD34/podocalyxin family of sialomucins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PODOCALYXIN-LIKE PROTEIN; ENDOTHELIAL-DERIVED LIGAND; STEM-CELL ANTIGEN; L-SELECTIN; MOLECULAR-CLONING; PASTEURELLA-HAEMOLYTICA; O-SIALOGLYCOPROTEINS; MAJOR SIALOPROTEIN; LEUKOCYTE ADHESION; ENCODING CD34	CD34 and podocalyxin are structurally related sialomucins, which are expressed in multiple tissues including vascular endothelium and hematopoietic progenitors, These glycoproteins have been proposed to be involved in processes as diverse as glomerular filtration, inhibition of stem cell differentiation, and leukocyte-endothelial adhesion. Using homologies present in the cytoplasmic tails of these proteins, me have identified a novel member of this family, which we designate endoglycan. This protein shares a similar overall domain structure with the other family members including a sialomucin domain, but also possesses an extremely acidic amino terminal region. In addition, endoglycan contains several potential glycosaminoglycan attachment sites and is modified with chondroitin sulfate. Endoglycan mRNA and protein were detected in both endothelial cells and CD34(+) bone marrow cells. Thus, CD34, podocalyxin, and endoglycan comprise a family of sialomucins sharing both structural similarity and sequence homology, which are expressed by both endothelium and multipotent hematopoietic progenitors. While the members of this family may perform overlapping functions at these sites, the unique structural features of endoglycan suggest distinct functions for this molecule.	Univ Calif San Francisco, Dept Anat, Program Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Inst Cardiovasc Res, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Rosen, SD (corresponding author), Univ Calif San Francisco, Dept Anat, Program Immunol, San Francisco, CA 94143 USA.	sdr@itsa.ucsf.edu		Rosen, Steven/0000-0002-6245-701X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023547] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM23547] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDULLAH KM, 1992, INFECT IMMUN, V60, P56, DOI 10.1128/IAI.60.1.56-62.1992; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDREWS PM, 1979, KIDNEY INT, V15, P376, DOI 10.1038/ki.1979.49; ANDREWS RG, 1986, BLOOD, V67, P842; Bannwarth S, 1998, J BIOL CHEM, V273, P1911, DOI 10.1074/jbc.273.4.1911; BARCLAY AN, 1993, LEUKOCYTE ANTIGEN FA; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BROWN J, 1991, INT IMMUNOL, V3, P175, DOI 10.1093/intimm/3.2.175; Bundgaard JR, 1997, J BIOL CHEM, V272, P21700, DOI 10.1074/jbc.272.35.21700; Carey DJ, 1997, BIOCHEM J, V327, P1; CIVIN CI, 1984, J IMMUNOL, V133, P157; CYSTER JG, 1991, EMBO J, V10, P893, DOI 10.1002/j.1460-2075.1991.tb08022.x; DEKAN G, 1991, P NATL ACAD SCI USA, V88, P5398, DOI 10.1073/pnas.88.12.5398; Derry CJ, 1999, EUR J IMMUNOL, V29, P419, DOI 10.1002/(SICI)1521-4141(199902)29:02<419::AID-IMMU419>3.0.CO;2-A; DOOLITTLE RF, 1986, URFS ORFS; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; Esko JD, 1996, CURR OPIN STRUC BIOL, V6, P663, DOI 10.1016/S0959-440X(96)80034-0; FACKLER MJ, 1990, J BIOL CHEM, V265, P11056; FACKLER MJ, 1995, BLOOD, V85, P3040, DOI 10.1182/blood.V85.11.3040.bloodjournal85113040; FINA L, 1990, BLOOD, V75, P2417; FISHER LW, 1990, J BIOL CHEM, V265, P2347; GIRARD JP, 1995, IMMUNOL TODAY, V16, P449, DOI 10.1016/0167-5699(95)80023-9; Harlow E., 1999, USING ANTIBODIES LAB; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4820, DOI 10.1021/bi00182a010; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; HOWELL SM, 1991, HUM GENET, V87, P625; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Kan M, 1999, J BIOL CHEM, V274, P15947, DOI 10.1074/jbc.274.22.15947; KATZ FE, 1985, LEUKEMIA RES, V9, P191, DOI 10.1016/0145-2126(85)90082-7; KERJASCHKI D, 1986, J CLIN INVEST, V78, P1142, DOI 10.1172/JCI112694; KERJASCHKI D, 1984, J CELL BIOL, V98, P1591, DOI 10.1083/jcb.98.4.1591; Kershaw DB, 1997, J BIOL CHEM, V272, P15708, DOI 10.1074/jbc.272.25.15708; Kershaw DB, 1997, GENOMICS, V45, P239, DOI 10.1006/geno.1997.4934; KERSHAW DB, 1995, J BIOL CHEM, V270, P29439, DOI 10.1074/jbc.270.49.29439; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Krause DS, 1996, BLOOD, V87, P1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEY K, 1993, BLOOD, V82, P1632; Li FG, 1996, J BIOL CHEM, V271, P6342, DOI 10.1074/jbc.271.11.6342; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; McNagny KM, 1997, J CELL BIOL, V138, P1395, DOI 10.1083/jcb.138.6.1395; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; Miettinen A, 1999, AM J PATHOL, V154, P813, DOI 10.1016/S0002-9440(10)65328-X; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MULLER WA, 1989, J EXP MED, V170, P399, DOI 10.1084/jem.170.2.399; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Petersen F, 1999, J BIOL CHEM, V274, P12376, DOI 10.1074/jbc.274.18.12376; PURI KD, 1995, J CELL BIOL, V131, P261, DOI 10.1083/jcb.131.1.261; RIBEIRO MJA, 1995, THROMB RES, V79, P153, DOI 10.1016/0049-3848(95)00101-V; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; Sassetti C, 1998, J EXP MED, V187, P1965, DOI 10.1084/jem.187.12.1965; SATTERTHWAITE AB, 1992, GENOMICS, V12, P788, DOI 10.1016/0888-7543(92)90310-O; SEILER MW, 1975, SCIENCE, V189, P390, DOI 10.1126/science.1145209; SIMMONS DL, 1992, J IMMUNOL, V148, P267; SIMMONS DL, 1993, CELLULAR INTERACTION, P93; SUTHERLAND DR, 1992, J IMMUNOL, V148, P1458; Weber KSC, 1999, EUR J IMMUNOL, V29, P700, DOI 10.1002/(SICI)1521-4141(199902)29:02<700::AID-IMMU700>3.0.CO;2-1; Wolff EA, 1999, J BIOL CHEM, V274, P2518, DOI 10.1074/jbc.274.4.2518; Zakrzewicz A, 1997, BLOOD, V89, P3228, DOI 10.1182/blood.V89.9.3228	62	82	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					9001	9010		10.1074/jbc.275.12.9001	http://dx.doi.org/10.1074/jbc.275.12.9001			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722749	hybrid			2022-12-27	WOS:000086507700099
J	Chikatsu, N; Fukumoto, S; Takeuchi, Y; Suzawa, M; Obara, T; Matsumoto, T; Fujita, T				Chikatsu, N; Fukumoto, S; Takeuchi, Y; Suzawa, M; Obara, T; Matsumoto, T; Fujita, T			Cloning and characterization of two promoters for the human calcium-sensing receptor (CaSR) and changes of CaSR expression in parathyroid adenomas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; EXTRACELLULAR CA2+-SENSING RECEPTOR; NEONATAL SEVERE HYPERPARATHYROIDISM; MESSENGER-RIBONUCLEIC-ACID; CELL-LINE; GENE; MUTATIONS; TISSUE; PEPTIDE; TRANSCRIPTION	Histological analyses showed that expression of the parathyroid calcium-sensing receptor (CaSR) is decreased in parathyroid adenomas, Because reduced expression of CaSR may result in insufficient suppression of parathyroid hormone secretion, the elucidation of regulatory mechanisms of CaSR expression is indispensable for understanding the pathogenesis of parapthyroid adenomas, Two cDNA clones for human CaSR with different 5'-untranslated regions have been isolated. However, the structure of the promoter region of human CaSR and the mechanisms of production of multiple CaSR mRNAs are unknown. We have cloned promoter regions of human CaSR by screening a genomic library. The human CaSR gene has two promoters and two 5'-untranslated exons (exons 1A and 1B), and alternative usage of these exons leads to production of multiple CaSR mRNAs, The upstream promoter has TATA and CAAT boxes, and the downstream promoter is GC-rich. Northern blot analysis showed that expression levels of exon 1A in parathyroid adenomas are significantly less than those in normal glands. However, expression of exon 1B was not different between adenomas and normal glands. Thus, specific reduction of the transcript driven by the upstream promoter was observed in parathyroid adenomas, Further analyses of factors that modulate the activity of the upstream promoter are necessary to clarify the pathogenesis of parathyroid adenomas.	Univ Tokyo, Branch Hosp, Dept Lab Med, Bunkyo Ku, Tokyo 1128688, Japan; Univ Tokyo, Branch Hosp, Dept Internal Med, Bunkyo Ku, Tokyo 1128688, Japan; Tokyo Womens Med Univ, Dept Endocrine Surg, Tokyo 1628666, Japan; Univ Tokushima, Dept Internal Med 1, Tokushima 7708503, Japan	University of Tokyo; University of Tokyo; Tokyo Women's Medical University; Tokushima University	Fukumoto, S (corresponding author), Univ Tokyo, Branch Hosp, Dept Lab Med, Bunkyo Ku, 3-28-6 Mejirodai, Tokyo 1128688, Japan.		Fukumoto, Seiji/B-7853-2015; Centeno, Patricia Pacios/O-8368-2016	Fukumoto, Seiji/0000-0003-3610-3469; 				BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CAMPOS RV, 1992, MOL ENDOCRINOL, V6, P1642, DOI 10.1210/me.6.10.1642; Chikatsu N, 1999, CLIN ENDOCRINOL, V50, P537, DOI 10.1046/j.1365-2265.1999.00729.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU YHW, 1995, AM J HUM GENET, V56, P1075; Farnebo F, 1997, J CLIN ENDOCR METAB, V82, P3481, DOI 10.1210/jc.82.10.3481; Freichel M, 1996, ENDOCRINOLOGY, V137, P3842, DOI 10.1210/en.137.9.3842; Fukumoto S, 1998, MOL CELL ENDOCRINOL, V141, P41, DOI 10.1016/S0303-7207(98)00092-6; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; Gogusev J, 1997, KIDNEY INT, V51, P328, DOI 10.1038/ki.1997.41; Heath H, 1996, J CLIN ENDOCR METAB, V81, P1312, DOI 10.1210/jcem.81.4.8636323; HOSOKAWA Y, 1995, J CLIN ENDOCR METAB, V80, P3107, DOI 10.1210/jc.80.11.3107; Joun H, 1997, ENDOCRINOLOGY, V138, P1742, DOI 10.1210/en.138.4.1742; Kaneko C, 1999, CALCIFIED TISSUE INT, V64, P271, DOI 10.1007/s002239900617; Kifor O, 1996, J CLIN ENDOCR METAB, V81, P1598, DOI 10.1210/jc.81.4.1598; MCCUAIG KA, 1995, NUCLEIC ACIDS RES, V23, P1948, DOI 10.1093/nar/23.11.1948; Pearce SHS, 1995, J CLIN INVEST, V96, P2683, DOI 10.1172/JCI118335; POLLAK MR, 1994, J CLIN INVEST, V93, P1108, DOI 10.1172/JCI117062; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; Sharp PA, 1997, CELL, V91, P875, DOI 10.1016/S0092-8674(00)80479-1; Southby J, 1996, ENDOCRINOLOGY, V137, P1349, DOI 10.1210/en.137.4.1349; Wada M, 1997, J CLIN INVEST, V100, P2977, DOI 10.1172/JCI119851; Yamaguchi T, 1998, J BONE MINER RES, V13, P1530, DOI 10.1359/jbmr.1998.13.10.1530; Yamaguchi T, 1998, ENDOCRINOLOGY, V139, P3561, DOI 10.1210/en.139.8.3561	24	71	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7553	7557		10.1074/jbc.275.11.7553	http://dx.doi.org/10.1074/jbc.275.11.7553			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713061	hybrid			2022-12-27	WOS:000085913300021
J	Lai, MC; Lin, RI; Huang, SY; Tsai, CW; Tarn, WY				Lai, MC; Lin, RI; Huang, SY; Tsai, CW; Tarn, WY			A human importin-beta family protein, transportin-SR2, interacts with the phosphorylated RS domain of SR proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA SPLICING FACTORS; SUBNUCLEAR LOCALIZATION; BINDING PROTEIN; GENE-EXPRESSION; NUCLEAR IMPORT; HNRNP A1; KINASE; IDENTIFICATION; CYTOPLASM; RECEPTOR	Serine/arginine-rich proteins (SR proteins) are mainly involved in the splicing of precursor mRNA. RS domains are also found in proteins that have influence on other aspects of gene expression. Proteins that contain an RS domain are often located in the speckled domains of the nucleus. Here we show that the RS domain derived from a human papillomavirus E2 transcriptional activator can target a heterologous protein to the nucleus, as it does in many other SR proteins, hut insufficient for localization in speckles. By using E2 as a bait in a yeast two-hybrid screen, we identified a human importin-beta family protein that is homologous to yeast Mtr10p and almost identical to human transportin-SR. This transportin-SR2 (TRN-SR2) protein can interact with several cellular SR proteins. More importantly, we demonstrated that TRN-SR2 can directly interact with phosphorylated, but not unphosphorylated, RS domains. Finally, an indirect immunofluoresence study revealed that a transiently expressed TRN-SR2 mutant lacking the N-terminal region becomes localized to the nucleus in a speckled pattern that coincides with the distribution of the SR protein SC35, Thus, our results likely reflect a role of TRN-SR2 in the cellular trafficking of phosphorylated SR proteins.	Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan	Academia Sinica - Taiwan	Tarn, WY (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Acad Rd,Sect 2, Taipei 11529, Taiwan.	wtarn@ibms.sinica.edu.tw	Tarn, Woan-Yuh/N-8464-2018					ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Chen HR, 1998, MOL CELL BIOL, V18, P2196, DOI 10.1128/MCB.18.4.2196; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; Floer M, 1999, J BIOL CHEM, V274, P16279, DOI 10.1074/jbc.274.23.16279; FU XD, 1995, RNA, V1, P663; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; HEDLEY ML, 1995, P NATL ACAD SCI USA, V92, P11524, DOI 10.1073/pnas.92.25.11524; Izaurralde E, 1998, RNA, V4, P351; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Kataoka N, 1999, J CELL BIOL, V145, P1145, DOI 10.1083/jcb.145.6.1145; Koizumi J, 1999, J BIOL CHEM, V274, P11125, DOI 10.1074/jbc.274.16.11125; Kuroyanagi N, 1998, BIOCHEM BIOPH RES CO, V242, P357, DOI 10.1006/bbrc.1997.7913; Lai MC, 1999, J BIOL CHEM, V274, P11832, DOI 10.1074/jbc.274.17.11832; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Mattaj IW, 1999, NATURE, V399, P208, DOI 10.1038/20322; MICHAEL WM, 1995, CELL, V83, P415; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; Nakielny S, 1998, CURR BIOL, V8, P89, DOI 10.1016/S0960-9822(98)70039-9; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Palmeri D, 1999, MOL CELL BIOL, V19, P1218; Paraskeva E, 1999, J CELL BIOL, V145, P255, DOI 10.1083/jcb.145.2.255; Paschal BM, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P305; Pemberton LF, 1997, J CELL BIOL, V139, P1645, DOI 10.1083/jcb.139.7.1645; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Ruegsegger U, 1998, MOL CELL, V1, P243, DOI 10.1016/S1097-2765(00)80025-8; Senger B, 1998, EMBO J, V17, P2196, DOI 10.1093/emboj/17.8.2196; Singer RH, 1997, CELL, V91, P291, DOI 10.1016/S0092-8674(00)80411-0; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Skiadopoulos MH, 1996, J VIROL, V70, P1117, DOI 10.1128/JVI.70.2.1117-1124.1996; Spector DL, 1996, EXP CELL RES, V229, P189, DOI 10.1006/excr.1996.0358; Truant R, 1999, MOL CELL BIOL, V19, P1210; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Yeakley JM, 1999, J CELL BIOL, V145, P447, DOI 10.1083/jcb.145.3.447; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837	45	149	152	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7950	7957		10.1074/jbc.275.11.7950	http://dx.doi.org/10.1074/jbc.275.11.7950			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713112	hybrid			2022-12-27	WOS:000085913300072
J	Jacob, R; Weiner, JR; Stadge, S; Naim, HY				Jacob, R; Weiner, JR; Stadge, S; Naim, HY			Additional N-glycosylation and its impact on the folding of intestinal lactase-phlorizin hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GONADOTROPIN BETA-SUBUNIT; PHLORHIZIN HYDROLASE; ENDOPLASMIC-RETICULUM; EPITHELIAL-CELLS; LINKED OLIGOSACCHARIDES; INTRACELLULAR-TRANSPORT; SUCRASE-ISOMALTASE; AMINOPEPTIDASE-N; ENZYME-ACTIVITY; LIGAND-BINDING	Lactase-phlorizin hydrolase (LPH) is a membrane bound intestinal hydrolase, with an extracellular domain comprising 4 homologous regions, LPH is synthesized as a large polypeptide precursor, pro-LPH, that undergoes several intra- and extracellular proteolytic steps to generate the final brush-border membrane form LPH beta(final). Pro-LPH is associated through homologous domain IV with the membrane through a transmembrane domain. A truncation of 236 amino acids at the (COOH terminus of domain IV (denoted LAC236) does not significantly influence the transport competence of the generated mutant LPH1646MACT (Panzer, P., Preuss, U,, Joberty, G., and Naim, H. Y. (1998) J. Biol. Chem. 273, 13861-13869), strongly suggesting that LAC236 is an autonomously folded domain that links the ectodomain with the transmembrane region. Here, we examine this hypothesis by engineering several N-linked glycosylation sites into LAC236. Transient expression of the cDNA constructs in COS-l cells confirm glycosylation of the introduced sites. The N-glycosyl pro-LPH mutants are transported to the Golgi apparatus at substantially reduced rates as compared with mild-type pro-LPH, Alterations in LAC236 appear to sterically hinder the generation of stable dimeric trypsin-resistant pro-LPH forms. Individual expression of chimeras containing LAC236, the transmembrane domain and cytoplasmic tail of pro-LPH and GFP as a reporter gene (denoted LAC236-GFP) lends strong support to this view: while LAC236-GFP is capable of forming dimers per se, its N-glycosyl variants are not, The data strongly suggest that the LAC236 is implicated in the dimerization process of pro-LPH, most Likely by nucleating the association of the ectodomains of the enzyme.	Hannover Sch Vet Med, Dept Physiol Chem, D-30559 Hannover, Germany	University of Veterinary Medicine Hannover, Foundation	Naim, HY (corresponding author), Hannover Sch Vet Med, Dept Physiol Chem, Bunteweg 17, D-30559 Hannover, Germany.		Jacob, Ralf/B-8163-2011					ALLEN S, 1995, J BIOL CHEM, V270, P4797, DOI 10.1074/jbc.270.9.4797; Asker N, 1998, J BIOL CHEM, V273, P18857, DOI 10.1074/jbc.273.30.18857; BOLL W, 1991, AM J HUM GENET, V48, P889; Bonfanti L, 1998, CELL, V95, P993, DOI 10.1016/S0092-8674(00)81723-7; Cannon KS, 1996, J BIOL CHEM, V271, P14280, DOI 10.1074/jbc.271.24.14280; Chapman RL, 1997, J BIOL CHEM, V272, P8808, DOI 10.1074/jbc.272.13.8808; DAHLQVIST A, 1968, ANAL BIOCHEM, V22, P99, DOI 10.1016/0003-2697(68)90263-7; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; Fan H, 1997, EUR J BIOCHEM, V246, P243, DOI 10.1111/j.1432-1033.1997.00243.x; FENG W, 1995, J BIOL CHEM, V270, P11851, DOI 10.1074/jbc.270.20.11851; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRUNBERG J, 1995, ARCH BIOCHEM BIOPHYS, V323, P367, DOI 10.1006/abbi.1995.9952; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JACOB R, 1995, J BIOL CHEM, V270, P18678, DOI 10.1074/jbc.270.31.18678; Jacob R, 1996, EUR J BIOCHEM, V236, P789, DOI 10.1111/j.1432-1033.1996.t01-1-00789.x; LETOURNEUR O, 1995, J BIOL CHEM, V270, P8249, DOI 10.1074/jbc.270.14.8249; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; Muyan M, 1998, MOL ENDOCRINOL, V12, P766, DOI 10.1210/me.12.5.766; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NAIM HY, 1992, J BIOL CHEM, V267, P25494; NAIM HY, 1991, J BIOL CHEM, V266, P12313; NAIM HY, 1994, J BIOL CHEM, V269, P26933; Naim HY, 1996, EUR J CELL BIOL, V70, P198; OBERHOLZER T, 1993, FEBS LETT, V333, P127, DOI 10.1016/0014-5793(93)80389-C; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; Panzer P, 1998, J BIOL CHEM, V273, P13861, DOI 10.1074/jbc.273.22.13861; RICKERT KW, 1995, CHEM BIOL, V2, P751, DOI 10.1016/1074-5521(95)90103-5; RIEDERER MA, 1991, J BACTERIOL, V173, P3539, DOI 10.1128/jb.173.11.3539-3546.1991; ROBERTS PC, 1993, J VIROL, V67, P3048, DOI 10.1128/JVI.67.6.3048-3060.1993; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Shen F, 1997, BIOCHEM J, V327, P759, DOI 10.1042/bj3270759; VOGEL LK, 1992, FEBS LETT, V308, P14, DOI 10.1016/0014-5793(92)81039-O; WACKER H, 1992, J BIOL CHEM, V267, P18744; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; Wuthrich M, 1996, ARCH BIOCHEM BIOPHYS, V336, P27, DOI 10.1006/abbi.1996.0528; ZHANG R, 1995, J BIOL CHEM, V270, P21722, DOI 10.1074/jbc.270.37.21722; ZHANG Y, 1993, BIOCHEM J, V295, P841, DOI 10.1042/bj2950841	41	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10630	10637		10.1074/jbc.275.14.10630	http://dx.doi.org/10.1074/jbc.275.14.10630			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744759	hybrid			2022-12-27	WOS:000086345600100
J	Mengus, G; Gangloff, YG; Carre, L; Lavigne, AC; Davidson, I				Mengus, G; Gangloff, YG; Carre, L; Lavigne, AC; Davidson, I			The human transcription factor IID subunit human TATA-binding protein-associated factor 28 interacts in a ligand-reversible manner with the vitamin D-3 and thyroid hormone receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; HISTONE-LIKE TAFS; NUCLEAR RECEPTOR; ESTROGEN-RECEPTOR; ACETYLASE COMPLEX; HUMAN TAF(II)135; TFIID COMPLEX; RETINOIC ACID; CO-REPRESSOR; ACTIVATION	Using coexpression in COS cells, we have identified novel interactions between the human TATA-binding protein-associated factor 28 (hTAF(II)28) component of transcription factor LTD and the ligand binding domains (LBDs) of the nuclear receptors for vitamin D3 NDR) and thyroid hormone (TR alpha). Interaction between hTAF(II)28 and the VDR and TR LBDs was ligand-reversible, whereas no interactions between hTAF(II)28 and the retinoid X receptors (RXRs) or other receptors were observed. TAF(II)28 interacted with two regions of the VDR, a 40-amino acid region spanning alpha-helices H3-H5 and alpha-helix H8. Interactions were also observed with the H3-H5 region of the TR alpha but not with the equivalent highly related region of the RXR gamma. Fine mapping using RXR derivatives in which single amino acids of the RXR gamma LED have been replaced with their VDR counterparts shows that the determinants for interaction with hTAF(II)28 are located in alpha-helix H3 and are not identical to those previously identified for interactions with hTAF(II)55. We also describe a mutation in the H3-H5 region of the VDR LED, which abolishes transactivation, and we show that interaction of hTAF(II)28 with this mutant is no longer ligand-reversible.	Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, Illkirch, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Davidson, I (corresponding author), Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP-163-67404, Illkirch, France.		GANGLOFF, Yann-Gaël/I-2161-2014; Lavigne, Anne-Claire/O-8805-2015	GANGLOFF, Yann-Gaël/0000-0001-9031-1184; MENGUS, Gabrielle/0000-0002-2844-1778; Davidson, Irwin/0000-0001-5533-1171				ALI S, 1993, HYBRIDOMA, V12, P391, DOI 10.1089/hyb.1993.12.391; Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Bell B, 1999, EXP CELL RES, V246, P11, DOI 10.1006/excr.1998.4294; Birck C, 1998, CELL, V94, P239, DOI 10.1016/S0092-8674(00)81423-3; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; Caron C, 1997, P NATL ACAD SCI USA, V94, P3662, DOI 10.1073/pnas.94.8.3662; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; Davidson I, 1998, COLD SPRING HARB SYM, V63, P233, DOI 10.1101/sqb.1998.63.233; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Fondell JD, 1996, MOL CELL BIOL, V16, P281; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Grant PA, 1998, NATURE, V396, P410, DOI 10.1038/24723; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Komarnitsky PB, 1999, GENE DEV, V13, P2484, DOI 10.1101/gad.13.19.2484; Kraichely DM, 1999, J BIOL CHEM, V274, P14352, DOI 10.1074/jbc.274.20.14352; Latchman DS, 1996, INT J BIOCHEM CELL B, V28, P1081, DOI 10.1016/1357-2725(96)00050-7; Lavigne AC, 1996, J BIOL CHEM, V271, P19774, DOI 10.1074/jbc.271.33.19774; Lavigne AC, 1999, MOL CELL BIOL, V19, P5486; Lavigne AC, 1999, MOL CELL BIOL, V19, P5050; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Manley JL, 1996, PHILOS T ROY SOC B, V351, P517, DOI 10.1098/rstb.1996.0050; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; May M, 1996, EMBO J, V15, P3093, DOI 10.1002/j.1460-2075.1996.tb00672.x; Mazzarelli JM, 1997, J VIROL, V71, P7978, DOI 10.1128/JVI.71.10.7978-7983.1997; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Natarajan K, 1998, MOL CELL, V2, P683, DOI 10.1016/S1097-2765(00)80166-5; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; Saluja D, 1998, MOL CELL BIOL, V18, P5734, DOI 10.1128/MCB.18.10.5734; Sanders SL, 1999, J BIOL CHEM, V274, P18847, DOI 10.1074/jbc.274.27.18847; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P206; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; Yamit-Hezi A, 1998, EMBO J, V17, P5161, DOI 10.1093/emboj/17.17.5161; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	54	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10064	10071		10.1074/jbc.275.14.10064	http://dx.doi.org/10.1074/jbc.275.14.10064			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744685	Green Published, hybrid			2022-12-27	WOS:000086345600026
J	Stillemark, P; Boren, J; Andersson, M; Larsson, T; Rustaeus, S; Karlsson, KA; Olofsson, SO				Stillemark, P; Boren, J; Andersson, M; Larsson, T; Rustaeus, S; Karlsson, KA; Olofsson, SO			The assembly and secretion of apolipoprotein B-48-containing very low density lipoproteins in McA-RH7777 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; RAT-LIVER; APO-B; RESIDENT CHAPERONES; HEP G2; PROTEIN; DEGRADATION; APOPROTEIN; B100; HEAT-SHOCK-PROTEIN-70	We have used an extraction procedure, which released membrane-bound apoB-100, to study the assembly of apoB-48 VLDL (very low density lipoproteins), This procedure released apoB-48, but not integral membrane proteins, from microsomes of McA-RH7777 cells. Upon gradient ultracentrifugation, the extracted apoB-48 migrated in the same position as the dense apoB-48-containing lipoprotein (apoB-48 HDL thigh density lipoprotein) secreted into the medium. Labeling studies with [H-3]glycerol demonstrated that the HDL-like particle extracted from the microsomes contains both triglycerides and phosphatidylcholine, The estimated molar ratio between triglyceride and phosphatidylcholine was 0.70 +/- 0.09, supporting the possibility that the particle has a neutral lipid core. Pulse-chase experiments indicated that microsomal apoB-48 HDL can either be secreted as apoB-48 HDL or converted to apoB-48 VLDL, These results support the two-step model of VLDL assembly. To determine the size of apoB required to assemble HDL and VLDL, we produced apoB polypeptides of various lengths and followed their ability to assemble VLDL, Small amounts of apoB-40 were associated with VLDL, but most of the nascent chains associated with VLDL ranged from apoB-48 to apoB-100, Thus, efficient VLDL assembly requires apoB chains of at least apoB-48 size. Nascent polypeptides as small as apoB-20 were associated with particles in the HDL density range, Thus, the structural requirements of apoB to form HDL-like first-step particles differ from those to form second-step VLDL, Analysis of proteins in the d < 1.006 g/ml fraction after ultracentrifugation of the luminal content of the cells identified five chaperone proteins: binding protein, protein disulfide isomerase, calcium-binding protein 2, calreticulin, and glucose regulatory protein 94. Thus, intracellular VLDL is associated with a network of chaperones involved in protein folding. Pulse-chase and subcellular fractionation studies showed that apoB-48 VLDL did not accumulate in the rough endoplasmic reticulum, This finding indicates either that the two steps of apoB lipoprotein assembly occur in different compartment or that the assembled VLDL is transferred rapidly out of the rough endoplasmic reticulum.	Gothenburg Univ, Dept Med Biochem, S-40530 Gothenburg, Sweden; Gothenburg Univ, Wallenberg Lab Cardiovasc Res, S-40530 Gothenburg, Sweden	University of Gothenburg; University of Gothenburg	Olofsson, SO (corresponding author), Gothenburg Univ, Dept Med Biochem, Box 440, S-40530 Gothenburg, Sweden.		Adiels, Martin/C-9278-2011					ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; ANDERSSON M, 1994, J LIPID RES, V35, P535; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1994, J BIOL CHEM, V269, P25879; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; CRESSWELL P, 1997, CURR BIOL, V7, P552; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Ginsberg HN, 1997, CLIN EXP PHARMACOL P, V24, pA29, DOI 10.1111/j.1440-1681.1997.tb03051.x; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; Hamilton RL, 1998, J LIPID RES, V39, P1543; Liao W, 1998, J BIOL CHEM, V273, P27225, DOI 10.1074/jbc.273.42.27225; Linnik KM, 1998, J BIOL CHEM, V273, P21368, DOI 10.1074/jbc.273.33.21368; LODISH HF, 1987, J CELL BIOL, V104, P221, DOI 10.1083/jcb.104.2.221; McLeod RS, 1996, J BIOL CHEM, V271, P18445, DOI 10.1074/jbc.271.31.18445; OLEGARD R, 1970, ACTA PAEDIATR SCAND, V59, P637, DOI 10.1111/j.1651-2227.1970.tb17698.x; Olofsson SO, 1999, CURR OPIN LIPIDOL, V10, P341, DOI 10.1097/00041433-199908000-00008; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; RUSTAEUS S, 1995, J BIOL CHEM, V270, P28879, DOI 10.1074/jbc.270.48.28879; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; SWIFT LL, 1995, J LIPID RES, V36, P395; TATU U, 1995, EMBO J, V14, P1340, DOI 10.1002/j.1460-2075.1995.tb07120.x; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; WETTESTEN M, 1985, EUR J BIOCHEM, V149, P461, DOI 10.1111/j.1432-1033.1985.tb08947.x; ZHOU MY, 1995, J BIOL CHEM, V270, P25220, DOI 10.1074/jbc.270.42.25220; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	33	60	60	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10506	10513		10.1074/jbc.275.14.10506	http://dx.doi.org/10.1074/jbc.275.14.10506			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744742	hybrid			2022-12-27	WOS:000086345600083
J	Kam, JL; Miura, K; Jackson, TR; Gruschus, J; Roller, P; Stauffer, S; Clark, J; Aneja, R; Randazzo, PA				Kam, JL; Miura, K; Jackson, TR; Gruschus, J; Roller, P; Stauffer, S; Clark, J; Aneja, R; Randazzo, PA			Phosphoinositide-dependent activation of the ADP-ribosylation factor GTPase-activating protein ASAP1 - Evidence for the pleckstrin homology domain functioning as an allosteric site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; BRUTONS TYROSINE KINASE; PHOSPHOLIPASE-D; PH DOMAIN; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; CHOLERA-TOXIN; FACTOR ARNO; ARF; BINDING	The ADP-ribosylation factor (Arf) family of GTP-binding proteins are regulators of membrane traffic and the actin cytoskeleton. Both negative and positive regulators of Arf, the centaurin beta family of Arf GTPase-activating proteins (GAPs) and Arf guanine nucleotide exchange factors, contain pleckstrin homology (PH) domains and are activated by phosphoinositides, To understand how the activities are coordinated, we have examined the role of phosphoinositide binding for Arf GAP function using ASAP1/centaurin beta 4 as a model, In contrast to Arf exchange factors, phosphatidylinositol 4,5-bisphosphate (PtdIns-4,5-P(2)) specifically activated Arf GAP, D3 phosphorylated phosphoinositides were less effective. Activation involved PtdIns-4,5-P(2) binding to the PH domain; however, in contrast to the Arf exchange factors and contrary to predictions based on the current paradigm for PH domains as independently functioning recruitment signals, we found the following: (i) the PH domain was dispensable for targeting to PDGF-induced ruffles; (ii) activation and recruitment could be uncoupled; (iii) the PH domain was necessary for activity even in the absence of phospholipids; and (iv) the Arf GAP domain influenced localization and lipid binding of the PH domain. Furthermore, PtdIns-4,5-P(2) binding to the PH domain caused a conformational change in the Arf GAP domain detected by limited proteolysis. Thus, these data demonstrate that PH domains can function as allosteric sites. In addition, differences from the published properties of the Arf exchange factors suggest a model in which feedforward and feedback loops involving lipid metabolites coordinate GTP binding and hydrolysis by Arf.	NCI, Div Basic Sci, Cellular Oncol Lab, Bethesda, MD 20892 USA; NHLBI, NIH, Bethesda, MD 20892 USA; UCL Royal Free & Univ Coll Med Sch, London NW3 2PF, England; Nutrimed Biotech, Langmuir Lab, Ithaca, NY 14850 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of London; University College London; UCL Medical School	Randazzo, PA (corresponding author), NCI, Div Basic Sci, Cellular Oncol Lab, 37 Convent Dr MSC 4255, Bethesda, MD 20892 USA.	randazzo@helix.nih.gov			NATIONAL CANCER INSTITUTE [Z01BC007365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R43GM051138, R43GM049594, R44GM049594] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 51138, GM 49594] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Andreev J, 1999, MOL CELL BIOL, V19, P2338; ANEJA R, 1970, BIOCHIM BIOPHYS ACTA, V218, P102, DOI 10.1016/0005-2760(70)90097-4; ANEJA R, 1974, Biochemical Society Transactions, V2, P38; ANEJA R, 1999, ACS SYM SER, V718, P224; Aneja SG, 1997, TETRAHEDRON LETT, V38, P803, DOI 10.1016/S0040-4039(96)02486-0; Bottomley MJ, 1998, BBA-MOL CELL BIOL L, V1436, P165, DOI 10.1016/S0005-2760(98)00141-6; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; Bromann PA, 1997, J BIOL CHEM, V272, P16240, DOI 10.1074/jbc.272.26.16240; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fensome A, 1996, CURR BIOL, V6, P730, DOI 10.1016/S0960-9822(09)00454-0; FERGUSON KM, 1995, NAT STRUCT BIOL, V2, P715, DOI 10.1038/nsb0995-715; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Frank SR, 1998, MOL BIOL CELL, V9, P3133, DOI 10.1091/mbc.9.11.3133; Fushman D, 1998, J BIOL CHEM, V273, P2835, DOI 10.1074/jbc.273.5.2835; HONG JX, 1994, J BIOL CHEM, V269, P9743; Hyvonen M, 1997, EMBO J, V16, P3396, DOI 10.1093/emboj/16.12.3396; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; KAHN RA, 1986, J BIOL CHEM, V261, P7906; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; Martin A, 1996, J BIOL CHEM, V271, P17397, DOI 10.1074/jbc.271.29.17397; Nagel W, 1998, J BIOL CHEM, V273, P14853, DOI 10.1074/jbc.273.24.14853; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Randazzo PA, 1997, BIOCHEM J, V324, P413, DOI 10.1042/bj3240413; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; RANDAZZO PA, 1995, METHOD ENZYMOL, V250, P394; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; Randazzo PA, 1997, J BIOL CHEM, V272, P7688; RANDAZZO PA, 1994, J BIOL CHEM, V269, P29490; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Song J, 1998, J CELL SCI, V111, P2257; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Venkateswarlu K, 1999, BIOCHEM J, V340, P359, DOI 10.1042/0264-6021:3400359; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2	49	101	105	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9653	9663		10.1074/jbc.275.13.9653	http://dx.doi.org/10.1074/jbc.275.13.9653			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734117	hybrid			2022-12-27	WOS:000086206500081
J	Katayose, Y; Li, M; Al-Murrani, SWK; Shenolikar, S; Damuni, Z				Katayose, Y; Li, M; Al-Murrani, SWK; Shenolikar, S; Damuni, Z			Protein phosphatase 2A inhibitors, I-1(PP2A) and I-2(PP2A), associate with and modify the substrate specificity of protein phosphatase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; MYELOID LEUKEMOGENESIS; PUTATIVE ONCOGENE; KINASE-ACTIVITY; CELLS; SET; BINDING; IDENTIFICATION; CONFORMATION; CANTHARIDIN	Recombinant I-1(PP2A) and I-2(PP2A) did not affect the activity of the catalytic subunit of protein phosphatase 1 (PP1(C)) with P-32-labeled myelin basic protein, histone Hi, and phosphorylase when assayed in the absence of divalent cations, However, in the presence of Mn2+, I-1(PP2A) and I-2(PP2A) stimulated PP1(C), activity by 15-20-fold with myelin basic protein and histone H1 but not phosphorylase. Half-maximal stimulation occurred at 2 and 4 nM I-1(PP2A) and I-2(PP2A), respectively. Moreover, I-1(PP2A) and I-2(PP2A) reduced the Mn2+ requirement by about 30-fold to 10 mu M In contrast, PP1(C) activity was unaffected by I-1(PP2A) and I-2(PP2A), the presence of Co3+ (0,1 mM), Mg2+ (2 mM), Ca2+ (0.5 mM), and Zn2+ (0.1 mM), Following gel filtration chromatography on Sephacryl S-200 in the presence of Mn2+ PP1(C) coeluted with I-1(PP2A) and I-2(PP2A) in the void volume. However, when I-1(PP2A) and I-2(PP2A) Or Mn2+ were omitted, PP1(C) emerged with a V-e/V-0, of similar to 1.6, The results demonstrate that I-1(PP2A) and I-2(PP2A) associate with and modify the substrate specificity of PP1(C), in the presence of physiological concentrations of Mn2+. A novel role is suggested for I-1(PP2A) and I-2(PP2A) in the reciprocal regulation of two major mammalian serine/threonine phosphatases, PPI and PP2A.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Cellular & Mol Physiol H166, Hershey, PA 17033 USA; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Duke University	Damuni, Z (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Cellular & Mol Physiol H166, POB 850, Hershey, PA 17033 USA.	zdamuni@psu.edu						Adler HT, 1997, J BIOL CHEM, V272, P28407, DOI 10.1074/jbc.272.45.28407; Al-Murrani SWK, 1999, BIOCHEM J, V341, P293, DOI 10.1042/0264-6021:3410293; ALESSI DR, 1993, EUR J BIOCHEM, V213, P1055, DOI 10.1111/j.1432-1033.1993.tb17853.x; AMICK GD, 1992, BIOCHEM J, V287, P1019, DOI 10.1042/bj2871019; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carlson SG, 1998, J AM SOC NEPHROL, V9, P1873; Chajry N, 1996, EUR J BIOCHEM, V235, P97, DOI 10.1111/j.1432-1033.1996.00097.x; Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; Chen TH, 1996, MOL BIOL CELL, V7, P2045, DOI 10.1091/mbc.7.12.2045; Chu YF, 1996, J BIOL CHEM, V271, P2574, DOI 10.1074/jbc.271.5.2574; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; Connor JH, 1998, J BIOL CHEM, V273, P27716, DOI 10.1074/jbc.273.42.27716; De Luca JP, 1999, AM J PHYSIOL-HEART C, V276, pH1520, DOI 10.1152/ajpheart.1999.276.5.H1520; Deibler G E, 1984, Prog Clin Biol Res, V146, P249; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; Endo S, 1997, BIOCHEMISTRY-US, V36, P6986, DOI 10.1021/bi970418i; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GORIS J, 1988, BIOCHEM J, V256, P1029, DOI 10.1042/bj2561029; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; Gusev Y, 1996, CELL PROLIFERAT, V29, P643, DOI 10.1111/j.1365-2184.1996.tb00978.x; GUY GR, 1995, EUR J BIOCHEM, V229, P503, DOI 10.1111/j.1432-1033.1995.0503k.x; HONKANEN RE, 1993, FEBS LETT, V330, P283, DOI 10.1016/0014-5793(93)80889-3; HUANG XC, 1995, J NEUROCHEM, V65, P2131; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Hurn B A, 1980, Methods Enzymol, V70, P104; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Kloeker S, 1999, J BIOL CHEM, V274, P5339, DOI 10.1074/jbc.274.9.5339; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; LI YM, 1992, P NATL ACAD SCI USA, V89, P11867, DOI 10.1073/pnas.89.24.11867; MacKintosh C, 1996, FEBS LETT, V397, P235, DOI 10.1016/S0014-5793(96)01175-1; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; Nishito Y, 1999, FEBS LETT, V447, P29, DOI 10.1016/S0014-5793(99)00256-2; Ortmeyer HK, 1998, HORM METAB RES, V30, P705, DOI 10.1055/s-2007-978963; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Quintaje SB, 1996, BIOCHEM BIOPH RES CO, V221, P539, DOI 10.1006/bbrc.1996.0632; REUSCH JEB, 1994, ENDOCRINOLOGY, V135, P2418, DOI 10.1210/en.135.6.2418; Scrimgeour AG, 1999, J BIOL CHEM, V274, P20949, DOI 10.1074/jbc.274.30.20949; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SRINIVASAN M, 1994, J BIOL CHEM, V269, P12514; VAESEN M, 1994, BIOL CHEM H-S, V375, P113, DOI 10.1515/bchm3.1994.375.2.113; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; WALENSKY LD, 1993, CANCER RES, V53, P4720; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484	53	44	44	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9209	9214		10.1074/jbc.275.13.9209	http://dx.doi.org/10.1074/jbc.275.13.9209			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734057	hybrid			2022-12-27	WOS:000086206500021
J	Moloney, DJ; Shair, LH; Lu, FM; Xia, J; Locke, R; Matta, KL; Haltiwanger, RS				Moloney, DJ; Shair, LH; Lu, FM; Xia, J; Locke, R; Matta, KL; Haltiwanger, RS			Mammalian Notch1 is modified with two unusual forms of O-linked glycosylation found on epidermal growth factor-like modules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; HUMAN FACTOR-IX; UDP-D-XYLOSE; N-ACETYLGLUCOSAMINE; STRUCTURAL-ANALYSIS; DROSOPHILA DEVELOPMENT; CYTOPLASMIC PROTEINS; GENE-PRODUCT; LINE HEPG2; CHO CELLS	Notch is a large cell-surface receptor known to be an essential player in a wide variety of developmental cascades, Here we show that Notch1 endogenously expressed in Chinese hamster ovary cells is modified with O-linked fucose and O-linked glucose saccharides, two unusual forms of O-linked glycosylation found on epidermal growth factor-like (EGF) modules. Interestingly, both modifications occur as monosaccharide and oligosaccharide species, Through exoglycosidase digestions we determined that the O-linked fucose oligosaccharide is a tetrasaccharide with a structure identical to that found on human clotting factor IX: Sia-alpha 2,3-Gal-beta 1,4-GlcNAc-beta 1,3-Fuc-alpha 1-O-Ser/Thr. The elongated form of O-linked glucose appears to be a trisaccharide. Notch1 is the first membrane-associated protein identified with either O-linked fucose or O-linked glucose modifications. It also represents the second protein discovered with an elongated form of O-linked fucose, The sites of glycosylation, which fall within the multiple EGF modules of Notch, are highly conserved across species and within Notch homologs, Since Notch is known to interact with its ligands through subsets of EGF modules, these results suggest that the O-linked carbohydrate modifications of these modules may influence receptor-ligand interactions.	SUNY Stony Brook, Dept Biochem & Cell Biol, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA; Harvard Univ, Sch Med, Dept Pediat, Childrens Hosp, Boston, MA 02115 USA; Roswell Pk Canc Inst, Buffalo, NY 14263 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Harvard University; Boston Children's Hospital; Harvard Medical School; Roswell Park Cancer Institute	Haltiwanger, RS (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA.							APPELLA E, 1987, J BIOL CHEM, V262, P4437; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; Fleming RJ, 1997, TRENDS CELL BIOL, V7, P437, DOI 10.1016/S0962-8924(97)01161-6; Frydman M, 1996, PRENATAL DIAG, V16, P266, DOI 10.1002/(SICI)1097-0223(199603)16:3<266::AID-PD845>3.3.CO;2-R; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; Haltiwanger RS, 1997, J BIOL CHEM, V272, P8752, DOI 10.1074/jbc.272.13.8752; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; HARRIS RJ, 1993, BIOCHEMISTRY-US, V32, P6539, DOI 10.1021/bi00077a007; HOKKE CH, 1995, EUR J BIOCHEM, V228, P981, DOI 10.1111/j.1432-1033.1995.tb20350.x; HOLT GD, 1986, J BIOL CHEM, V261, P8049; JACOB GS, 1994, METHOD ENZYMOL, V230, P280; JOHANSEN KM, 1989, J CELL BIOL, V109, P2427, DOI 10.1083/jcb.109.5.2427; Johnston SH, 1997, DEVELOPMENT, V124, P2245; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Kao YH, 1999, BIOCHEMISTRY-US, V38, P7097, DOI 10.1021/bi990234z; KMIECIK D, 1995, GLYCOBIOLOGY, V5, P483, DOI 10.1093/glycob/5.5.483; Koopman JL, 1998, J BIOL CHEM, V273, P33267, DOI 10.1074/jbc.273.50.33267; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Kornfeld S, 1998, J CLIN INVEST, V101, P1293, DOI 10.1172/JCI3140; LIEBER T, 1992, NEURON, V9, P847, DOI 10.1016/0896-6273(92)90238-9; LIN AI, 1994, GLYCOBIOLOGY, V4, P895, DOI 10.1093/glycob/4.6.895; Lu FM, 1996, P NATL ACAD SCI USA, V93, P5663, DOI 10.1073/pnas.93.11.5663; Minamida S, 1996, J BIOCHEM-TOKYO, V120, P1002; Moloney DJ, 1999, GLYCOBIOLOGY, V9, P679, DOI 10.1093/glycob/9.7.679; Moloney DJ, 1997, J BIOL CHEM, V272, P19046, DOI 10.1074/jbc.272.30.19046; NISHIMURA H, 1989, J BIOL CHEM, V264, P20320; NISHIMURA H, 1992, J BIOL CHEM, V267, P17520; Omichi K, 1997, EUR J BIOCHEM, V245, P143, DOI 10.1111/j.1432-1033.1997.00143.x; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; SCHNAPER HW, 1995, J CELL PHYSIOL, V165, P107, DOI 10.1002/jcp.1041650114; Shao L, 1998, GLYCOBIOLOGY, V8, P1110; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; STANLEY P, 1992, GLYCOBIOLOGY, V2, P99, DOI 10.1093/glycob/2.2.99; STANLEY P, 1981, MOL CELL BIOL, V1, P687, DOI 10.1128/MCB.1.8.687; STANLEY P, 1987, METHOD ENZYMOL, V138, P443; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; VARKI A, 1994, METHOD ENZYMOL, V230, P16; Wang Y, 1998, J BIOL CHEM, V273, P8112, DOI 10.1074/jbc.273.14.8112; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; Yuan YP, 1997, CELL, V88, P9, DOI 10.1016/S0092-8674(00)81852-8	47	276	285	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9604	9611		10.1074/jbc.275.13.9604	http://dx.doi.org/10.1074/jbc.275.13.9604			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734111	hybrid			2022-12-27	WOS:000086206500075
J	Papapetropoulos, A; Fulton, D; Mahboubi, K; Kalb, RG; O'Connor, DS; Li, FZ; Altieri, DC; Sessa, WC				Papapetropoulos, A; Fulton, D; Mahboubi, K; Kalb, RG; O'Connor, DS; Li, FZ; Altieri, DC; Sessa, WC			Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIE2; ANGIOGENESIS; EXPRESSION; MECHANISMS; ACTIVATION; SURVIVIN; RECEPTOR	A productive angiogenic response must couple to the survival machinery of endothelial cells to preserve the integrity of newly formed vessels. Angiopoietin-1 (Ang-l) is an endothelium-specific ligand essential for embryonic vascular stabilization, branching morphogenesis, and post-natal angiogenesis, but its contribution to endothelial cell survival has not been completely elucidated. Here we show that Ang-l acting via the Tie 2 receptor induces phosphorylation of the survival serine-threonine kinase, Akt (or protein kinase B). This is associated with up-regulation of the apoptosis inhibitor, survivin, in endothelial cells and protection of endothelium from death-inducing stimuli. Moreover, dominant negative survivin negates the ability of Ang-l to protect cells from undergoing apoptosis, The activation of antiapoptotic pathways mediated by Akt and survivin in endothelial cells may contribute to Ang-l stabilization of vascular structures during angiogenesis, in vivo.	Yale Univ, Sch Med, Boyer Ctr Mol Med 436D, Dept Pharmacol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pathol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Neurol, New Haven, CT 06536 USA	Yale University; Yale University; Yale University	Sessa, WC (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med 436D, Dept Pharmacol, 295 Congress Ave, New Haven, CT 06536 USA.		Andreas, Papapetropoulos/AAJ-3089-2020; Sessa, William C/B-6844-2011; Li, Fengzhi/GXF-0115-2022	Sessa, William C/0000-0001-5759-1938; Papapetropoulos, Andreas/0000-0002-4253-5930	NHLBI NIH HHS [HL61372, HL57665] Funding Source: Medline; PHS HHS [T32 L10183] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057665] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Fryer HJL, 2000, J NEUROCHEM, V74, P582, DOI 10.1046/j.1471-4159.2000.740582.x; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Grossman D, 1999, LAB INVEST, V79, P1121; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Jones N, 1999, J BIOL CHEM, V274, P30896, DOI 10.1074/jbc.274.43.30896; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; OCONNOR DS, 2000, IN PRESS AM J PATHOL, V156; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; Papapetropoulos A, 1999, LAB INVEST, V79, P213; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514	23	476	527	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9102	9105		10.1074/jbc.275.13.9102	http://dx.doi.org/10.1074/jbc.275.13.9102			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734041	hybrid			2022-12-27	WOS:000086206500005
J	Renold, A; Cescato, R; Beuret, N; Vogel, LK; Wahlberg, JM; Brown, JL; Fiedler, K; Spiess, M				Renold, A; Cescato, R; Beuret, N; Vogel, LK; Wahlberg, JM; Brown, JL; Fiedler, K; Spiess, M			Basolateral sorting signals differ in their ability to redirect apical proteins to the basolateral cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; POLARIZED MDCK CELLS; INFLUENZA-VIRUS HEMAGGLUTININ; HUMAN TRANSFERRIN RECEPTOR; PLASMA-MEMBRANE PROTEINS; HUMAN AMINOPEPTIDASE-N; ASIALOGLYCOPROTEIN RECEPTOR; CYTOPLASMIC DOMAIN; EPITHELIAL-CELLS	Polarized sorting of membrane proteins in epithelial cells is mediated by cytoplasmic basolateral signals or by apical signals in the transmembrane or exoplasmic domains. Basolateral signals were generally found to be dominant over apical determinants. We have generated chimeric proteins with the cytoplasmic domain of either the asialoglycoprotein receptor H1 or the transferrin receptor, two basolateral proteins, fused to the transmembrane and exoplasmic segments of aminopeptidase N, an apical protein, and analyzed them in Madin-Darby canine kidney cells. Whereas both cytoplasmic sequences induced endocytosis of the chimeras, only that of the transferrin receptor mediated basolateral expression in steady state. The H1 fusion protein, although still largely sorted to the basolateral side in biosynthetic surface transport, was subsequently resorted to the apical cell surface. We tested whether the difference in sorting between trimeric wild-type ill and the dimeric aminopeptidase chimera was caused by the number of sorting signals presented in the oligomers, Consistent with this hypothesis, the H1 signal was fully functional in a tetrameric fusion protein with the transmembrane and exoplasmic domains of influenza neuraminidase. The results suggest that basolateral signals per se need not be dominant over apical determinants for steady-state polarity and emphasize an important contribution of the valence of signals in polarized sorting.	Univ Basel, Biozentrum, Dept Biochem, CH-4056 Basel, Switzerland; Univ Copenhagen, Dept Med Biochem & Genet, Panum Inst, DK-2200 Copenhagen N, Denmark; Univ Colorado, Hlth Sci Ctr, Dept Biochem Biophys & Genet, Denver, CO 80262 USA	University of Basel; University of Copenhagen; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Spiess, M (corresponding author), Univ Basel, Biozentrum, Dept Biochem, Klingelbergstr 70, CH-4056 Basel, Switzerland.			Fiedler, Klaus/0000-0001-9398-1116; Spiess, Martin/0000-0001-7139-0550; Vogel, Lotte K./0000-0001-9920-0982				ARNESON LS, 1995, J CELL BIOL, V129, P1217, DOI 10.1083/jcb.129.5.1217; AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; Bider MD, 1996, J BIOL CHEM, V271, P31996, DOI 10.1074/jbc.271.50.31996; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; CORBEIL D, 1992, J BIOL CHEM, V267, P2798; DANIELSEN EM, 1990, J BIOL CHEM, V265, P14566; DANIELSEN EM, 1994, BIOCHEMISTRY-US, V33, P1599, DOI 10.1021/bi00172a041; DARGEMONT C, 1993, EMBO J, V12, P1713, DOI 10.1002/j.1460-2075.1993.tb05816.x; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; FUTTER CE, 1995, J BIOL CHEM, V270, P10999, DOI 10.1074/jbc.270.18.10999; Futter CE, 1998, J CELL BIOL, V141, P611, DOI 10.1083/jcb.141.3.611; GEFFEN I, 1991, P NATL ACAD SCI USA, V88, P8425, DOI 10.1073/pnas.88.19.8425; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; GONZALEZ A, 1993, J BIOL CHEM, V268, P6662; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; HANSEN SH, 1992, EXP CELL RES, V199, P19, DOI 10.1016/0014-4827(92)90457-J; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; Jacob R, 1999, J BIOL CHEM, V274, P8061, DOI 10.1074/jbc.274.12.8061; KITAGAWA Y, 1994, EXP CELL RES, V213, P449, DOI 10.1006/excr.1994.1222; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KUNDU A, 1994, J VIROL, V68, P1812, DOI 10.1128/JVI.68.3.1812-1818.1994; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; Larsen JE, 1999, FEBS LETT, V451, P19, DOI 10.1016/S0014-5793(99)00526-8; LEITINGER B, 1994, J BIOL CHEM, V269, P8115; LEITINGER B, 1995, P NATL ACAD SCI USA, V92, P10109, DOI 10.1073/pnas.92.22.10109; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MARTINEZPALOMO A, 1980, J CELL BIOL, V87, P736, DOI 10.1083/jcb.87.3.736; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MONLAUZEUR L, 1995, J BIOL CHEM, V270, P12219, DOI 10.1074/jbc.270.20.12219; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; Odorizzi G, 1997, J CELL BIOL, V137, P1255, DOI 10.1083/jcb.137.6.1255; Ohno H, 1997, VIROLOGY, V238, P305, DOI 10.1006/viro.1997.8839; OZAKI K, 1993, J BIOCHEM-TOKYO, V113, P271, DOI 10.1093/oxfordjournals.jbchem.a124038; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; ROTHENBERGER S, 1987, CELL, V49, P423, DOI 10.1016/0092-8674(87)90295-9; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SCHNEIDER C, 1982, J BIOL CHEM, V257, P8516; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P1158, DOI 10.1073/pnas.86.4.1158; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VOGEL LK, 1992, J BIOL CHEM, V267, P2794; VOGEL LK, 1992, FEBS LETT, V308, P14, DOI 10.1016/0014-5793(92)81039-O; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WEISZ OA, 1992, J BIOL CHEM, V267, P22282; WESSELS HP, 1989, J BIOL CHEM, V264, P17; WESSELS HP, 1990, J CELL BIOL, V111, P2923, DOI 10.1083/jcb.111.6.2923; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929	64	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9290	9295		10.1074/jbc.275.13.9290	http://dx.doi.org/10.1074/jbc.275.13.9290			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734069	hybrid			2022-12-27	WOS:000086206500033
J	Rogakou, EP; Nieves-Neira, W; Boon, C; Pommier, Y; Bonner, WM				Rogakou, EP; Nieves-Neira, W; Boon, C; Pommier, Y; Bonner, WM			Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE-ACTIVATED DNASE; INTERLEUKIN-1-BETA-CONVERTING ENZYME; CHROMATIN CONDENSATION; MORPHOLOGICAL-CHANGES; HL-60 CELLS; PROTEIN; CLEAVAGE; FAMILY; FAS; ENDONUCLEASE	Histone H2AX is a ubiquitous member of the H2A histone family that differs from the other H2A histones by the presence of an evolutionarily conserved C-terminal motif, -KKATQASQEY. The serine residue in this motif becomes rapidly phosphorylated in cells and animals when DNA double-stranded breaks are introduced into their chromatin by various physical and chemical means. In the present communication we show that this phosphorylated form of H2AX, referred to as gamma-H2AX, appears during apoptosis concurrently with the initial appearance of high molecular weight DNA fragments. gamma-H2AX forms before the appearance of internucleosomal DNA fragments and the externalization of phosphatidylserine to the outer membrane leaflet. gamma-H2AX formation is inhibited by N-benzyloxycarbonyl-Val-AlaAsp-fluoromethyl ketone and the inhibitor of caspase-activated DNase, and it is induced when DNase I and restriction enzymes are introduced into cells, suggesting that any apoptotic endonuclease is sufficient to induce gamma-H2AX formation. These results indicate that gamma-H2AX formation is an early chromatin modification following initiation of DNA fragmentation during apoptosis.	NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rogakou, EP (corresponding author), NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bldg 37,Rm 5D21, Bethesda, MD 20892 USA.	emrog@helix.nih.gov			NATIONAL CANCER INSTITUTE [Z01BC006140, ZIABC006140] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; BERTRAND R, 1995, DRUG DEVELOP RES, V34, P138, DOI 10.1002/ddr.430340206; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BICKNELL GR, 1994, J CELL SCI, V107, P2483; BONNER WM, 1980, EUR J BIOCHEM, V109, P17, DOI 10.1111/j.1432-1033.1980.tb04762.x; BRADBURY EM, 1974, NATURE, V247, P257, DOI 10.1038/247257a0; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Famulski KS, 1999, CELL DEATH DIFFER, V6, P281, DOI 10.1038/sj.cdd.4400495; Gohring F, 1997, EMBO J, V16, P7361, DOI 10.1093/emboj/16.24.7361; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; Han ZY, 1996, J BIOL CHEM, V271, P25035, DOI 10.1074/jbc.271.40.25035; Hughes FM, 1998, CELL DEATH DIFFER, V5, P1017; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MANNIRONI C, 1989, NUCLEIC ACIDS RES, V17, P9113, DOI 10.1093/nar/17.22.9113; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; Morgan W F, 1995, Methods Mol Biol, V48, P63; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Naito M, 1997, BLOOD, V89, P2060, DOI 10.1182/blood.V89.6.2060; Nieves-Neira W, 1999, INT J CANCER, V82, P396, DOI 10.1002/(SICI)1097-0215(19990730)82:3<396::AID-IJC13>3.0.CO;2-Z; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PEITSCH MC, 1993, NUCLEIC ACIDS RES, V21, P4206, DOI 10.1093/nar/21.18.4206; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Samejima K, 1999, PHILOS T ROY SOC B, V354, P1591, DOI 10.1098/rstb.1999.0503; Schneider P, 1997, J BIOL CHEM, V272, P18827, DOI 10.1074/jbc.272.30.18827; Shao RG, 1997, EXP CELL RES, V234, P388, DOI 10.1006/excr.1997.3650; SOLARY E, 1994, LEUKEMIA LYMPHOMA, V15, P21, DOI 10.3109/10428199409051674; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; SUGAR K, 1997, NATURE, V389, P251; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; van Holde KE., 1989, SPRINGER SERIES MOL; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; WALKER PR, 1994, BIOCHEM CELL BIOL, V72, P615, DOI 10.1139/o94-081; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WEST MHP, 1980, BIOCHEMISTRY-US, V19, P3238, DOI 10.1021/bi00555a022; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; WU RS, 1986, CRIT REV BIOCHEM MOL, V20, P201, DOI 10.3109/10409238609083735; Wyllie A, 1998, NATURE, V391, P20, DOI 10.1038/34040; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yoshida A, 1998, CANCER RES, V58, P2576; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480	62	564	577	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9390	9395		10.1074/jbc.275.13.9390	http://dx.doi.org/10.1074/jbc.275.13.9390			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734083	hybrid			2022-12-27	WOS:000086206500047
J	Ma, Q; Baldwin, KT				Ma, Q; Baldwin, KT			2,3,7,8-tetrachlorodibenzo-p-dioxin-induced degradation of aryl hydrocarbon receptor (AhR) by the ubiquitin-proteasome pathway - Role of the transcription activaton and DNA binding of AhR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; NUCLEAR TRANSLOCATOR; GENE-EXPRESSION; HEPATOMA-CELLS; MICE LACKING; PROTEIN; DIOXIN; INDUCTION; ENHANCER; TOXICITY	Activation of the aryl hydrocarbon receptor (AhR) by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a potent agonist of AhR, induces a marked reduction in steady state AhR, To analyze the mechanism of regulation of ligand-activated AhR, we examined the biochemical pathway and function of the down-regulation of the receptor by TCDD, Pulse-chase experiments reveal that TCDD shortens the half-life (t(1/2)) of AhR from 28 to 3 h in mouse hepatoma cells. Inhibitors of the 26 S proteasome, lacta-cystin and MG132, block the TCDD-induced turnover of AhR. The TCDD-induced degradation of AhR involves ubiquitination of the AhR protein, because (a) TCDD induces formation of high molecular weight, ubiquitinated AhR and (b) degradation of AhR is inhibited in ts20 cells, which bear a temperature-sensitive mutation in the ubiquitin-activating enzyme El, at a nonpermissive temperature. Inhibition of proteasomal degradation of AhR increases the amount of the nuclear AhR.Arnt complex and "superinduces" the expression of endogenous CYP1A1 gene by TCDD, indicating that the proteasomal degradation of AhR serves as a mechanism for controlling the activity of the activated receptor. We also show that deletion of the transcription activation domain of AhR abolishes the degradation, whereas a mutation in the DNA-binding region of AhR or Amt reduces the degradation; these data implicate the transcription activation domain and DNA binding in AhR degradation. Our findings provide new insights into the regulation of TCDD-activated AhR through ubiquitin-mediated protein degradation.	NIOSH, CDC, HELD, TMBB,Mol Toxicol Lab, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Ma, Q (corresponding author), NIOSH, CDC, HELD, TMBB,Mol Toxicol Lab, Mailstop 3014,1095 Willowdale Rd, Morgantown, WV 26505 USA.							Adams J, 1996, ANNU REP MED CHEM, V31, P279, DOI 10.1016/S0065-7743(08)60467-4; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Carver LA, 1997, J BIOL CHEM, V272, P11452; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Davarinos NA, 1999, J BIOL CHEM, V274, P28708, DOI 10.1074/jbc.274.40.28708; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; Dong LQ, 1996, J BIOL CHEM, V271, P7942, DOI 10.1074/jbc.271.14.7942; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FernandezSalguero PM, 1996, TOXICOL APPL PHARM, V140, P173, DOI 10.1006/taap.1996.0210; Gao L, 1998, J BIOL CHEM, V273, P15358, DOI 10.1074/jbc.273.25.15358; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; KHISSIIN A, 1999, FEBS LETT, V448, P160; Ko HSP, 1996, MOL CELL BIOL, V16, P430; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; KULKA RG, 1988, J BIOL CHEM, V263, P15726; Li H, 1996, J BIOL CHEM, V271, P21262, DOI 10.1074/jbc.271.35.21262; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; LUSTER M, 1979, ANN NY ACAD SCI, V31, P473; MA Q, 1995, J BIOL CHEM, V270, P12697, DOI 10.1074/jbc.270.21.12697; Ma Q, 1997, J BIOL CHEM, V272, P8878; Ma Q, 1996, MOL CELL BIOL, V16, P2144; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; MILLER AG, 1983, J BIOL CHEM, V258, P3523; Mimura J, 1997, GENES CELLS, V2, P645, DOI 10.1046/j.1365-2443.1997.1490345.x; NumayamaTsuruta K, 1997, EUR J BIOCHEM, V246, P486, DOI 10.1111/j.1432-1033.1997.00486.x; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1980, MOL PHARMACOL, V17, P86; POLAND A, 1988, ARCH BIOCHEM BIOPHYS, V261, P103, DOI 10.1016/0003-9861(88)90109-9; Pollenz RS, 1996, MOL PHARMACOL, V49, P391; REICK M, 1994, MOL CELL BIOL, V14, P5653, DOI 10.1128/MCB.14.9.5653; Reiners JJ, 1999, J BIOL CHEM, V274, P2502, DOI 10.1074/jbc.274.4.2502; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; SassoneCorsi P, 1997, NATURE, V389, P443, DOI 10.1038/38904; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; Whitlock JP, 1996, FASEB J, V10, P809, DOI 10.1096/fasebj.10.8.8666157	47	231	234	3	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8432	8438		10.1074/jbc.275.12.8432	http://dx.doi.org/10.1074/jbc.275.12.8432			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722677	hybrid			2022-12-27	WOS:000086507700027
J	Di Mauro, E; Kendrew, SG; Caserta, M				Di Mauro, E; Kendrew, SG; Caserta, M			Two distinct nucleosome alterations characterize chromatin remodeling at the Saccharomyces cerevisiae ADH2 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROGENASE-II ISOZYME; YEAST PHO5 PROMOTER; TRANSCRIPTIONAL ACTIVATION; ALCOHOL-DEHYDROGENASE; IN-VIVO; GENE; DOMAIN; GCN5; RNA; DISRUPTION	Glucose depletion derepresses the Saccharomyces cerevisiae ADH2 gene; this metabolic change is accompanied by chromatin structural modifications in the promoter region. We show that the ADR6/SWI1 gene is not necessary for derepression of the wild type chromosomal ADH2, whereas the transcription factor Adr1p, which regulates several S. cerevisiae functions, plays a major role in driving nucleosome reconfiguration and ADH2 expression. When we tested the effect of individual domains of the regulatory protein Adr1p on the chromatin structure of ADH2, a remodeling consisting of at least two steps was observed, Adr1p derivatives were analyzed in derepressing conditions, showing that the Adr1p DNA binding domain alone causes an alteration in chromatin organization in the absence of transcription. This alteration differs from the remodeling observed in the presence of the Adr1p activation domain when the promoter is transcriptionally active.	CNR, Ctr Studio Acidi Nucl, I-00185 Rome, Italy; Univ Rome La Sapienza, Dipartimento Genet & Biol Mol, Fdn Ist Pasteur, Fdn Cenci Bolognetti, I-00185 Rome, Italy; Univ Rome La Sapienza, Dipartimento Sci Biochim, I-00185 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Fondazione Cenci Bolognetti; Sapienza University Rome; Sapienza University Rome	Caserta, M (corresponding author), CNR, Ctr Studio Acidi Nucl, Ple Aldo Moro 5, I-00185 Rome, Italy.			Caserta, Micaela/0000-0003-1647-5118				ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; Balasubramanian B, 1999, MOL CELL BIOL, V19, P2977; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CAVALLI G, 1993, EMBO J, V12, P4603, DOI 10.1002/j.1460-2075.1993.tb06149.x; Chiang YC, 1996, J BIOL CHEM, V271, P32359, DOI 10.1074/jbc.271.50.32359; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; DENIS CL, 1981, J MOL BIOL, V148, P355, DOI 10.1016/0022-2836(81)90181-9; EISEN A, 1988, MOL CELL BIOL, V8, P4552, DOI 10.1128/MCB.8.10.4552; FEDOR MJ, 1989, MOL CELL BIOL, V9, P1721, DOI 10.1128/MCB.9.4.1721; Gaudreau L, 1997, CELL, V89, P55, DOI 10.1016/S0092-8674(00)80182-8; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; GRUNSTEIN M, 1990, TRENDS GENET, V6, P395, DOI 10.1016/0168-9525(90)90299-L; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HAPPEL AM, 1991, GENETICS, V128, P69; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; McAndrew PC, 1998, MOL CELL BIOL, V18, P5818, DOI 10.1128/MCB.18.10.5818; Moreira JMA, 1998, EMBO J, V17, P6028, DOI 10.1093/emboj/17.20.6028; MORSE RH, 1993, SCIENCE, V262, P1563, DOI 10.1126/science.8248805; PEREZORTIN JE, 1987, NUCLEIC ACIDS RES, V15, P6937; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PHAM TA, 1991, J BIOL CHEM, V266, P18179; Pollard KJ, 1998, BIOESSAYS, V20, P771, DOI 10.1002/(SICI)1521-1878(199809)20:9<771::AID-BIES10>3.0.CO;2-V; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Roberts SM, 1997, GENETICS, V147, P451; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SHUSTER J, 1986, MOL CELL BIOL, V6, P1894, DOI 10.1128/MCB.6.6.1894; Stafford GA, 1997, J BIOL CHEM, V272, P11526; Stargell LA, 1996, TRENDS GENET, V12, P311, DOI 10.1016/0168-9525(96)10028-7; SVAREN J, 1994, EMBO J, V13, P4856, DOI 10.1002/j.1460-2075.1994.tb06812.x; TAGUCHI AKW, 1987, GENETICS, V116, P531; TAGUCHI AKW, 1987, GENETICS, V116, P523; THUKRAL SK, 1989, MOL CELL BIOL, V9, P2360, DOI 10.1128/MCB.9.6.2360; Travers A, 1999, CELL, V96, P311, DOI 10.1016/S0092-8674(00)80543-7; TSKIYAMA T, 1999, GENE DEV, V13, P686; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; vanHolde K, 1996, BIOESSAYS, V18, P697, DOI 10.1002/bies.950180903; VENDITTI S, 1994, MOL GEN GENET, V242, P100, DOI 10.1007/BF00277353; Verdone L, 1997, J BIOL CHEM, V272, P30828, DOI 10.1074/jbc.272.49.30828; Verdone L, 1996, MOL CELL BIOL, V16, P1978; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Wolffe AP, 1998, PROG NUCLEIC ACID RE, V61, P379, DOI 10.1016/S0079-6603(08)60832-6; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; Young ET, 1998, J BIOL CHEM, V273, P32080, DOI 10.1074/jbc.273.48.32080	48	20	20	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7612	7618		10.1074/jbc.275.11.7612	http://dx.doi.org/10.1074/jbc.275.11.7612			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713069	hybrid			2022-12-27	WOS:000085913300029
J	Ingley, E; Sarna, MK; Beaumont, JG; Tilbrook, PA; Tsai, S; Takemoto, Y; Williams, JH; Klinken, SP				Ingley, E; Sarna, MK; Beaumont, JG; Tilbrook, PA; Tsai, S; Takemoto, Y; Williams, JH; Klinken, SP			HS1 interacts with Lyn and is critical for erythropoietin-induced differentiation of erythroid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; ANTIGEN-RECEPTOR; TRANSCRIPTION FACTOR; SH3 DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC LINEAGE; MAJOR SUBSTRATE; BINDING PROTEIN; STEM-CELLS; ASSOCIATION	Erythroid cells terminally differentiate in response to erythropoietin binding its cognate receptor. Previously we have shown that the tyrosine kinase Lyn associates with the erythropoietin receptor and is essential for hemoglobin synthesis in three erythroleukemic cell lines. To understand Lyn signaling events in erythroid cells, the yeast two-hybrid system was used to analyze interactions with other proteins. Here we show that the hemopoietic-specific protein HS1 interacted directly with the SH3 domain of Lyn, via its proline-rich region. A truncated HS1, bearing the Lye-binding domain, was introduced into J2E erythroleukemic cells to determine the impact upon responsiveness to erythropoietin. Truncated HS1 had a striking effect on the phenotype of the J2E line-the cells were smaller, more basophilic than the parental proerythoblastoid cells and had fewer surface erythropoietin receptors. Moreover, basal and erythropoietin-induced proliferation and differentiation were markedly suppressed. The inability of cells containing the truncated HS1 to differentiate maybe a consequence of markedly reduced levels of Lyn and GATA-1. In addition, erythropoietin stimulation of these cells resulted in rapid, endosome-mediated degradation of endogenous HS1. The truncated HS1 also suppressed the development of erythroid colonies from fetal liver cells. These data show that disrupting HS1 has profoundly influenced the ability of erythroid cells to terminally differentiate.	Univ Western Australia, Lab Canc Med, Dept Biochem, Perth, WA 6001, Australia; Royal Perth Hosp, Perth, WA 6001, Australia; Mt Sinai Sch Med, Inst Gene Therapy & Mol Med, New York, NY 10030 USA; Nippon Glaxo Ltd, Dept Mol Biol, Tsukuba Res Labs, Tsukuba, Ibaraki 30042, Japan	University of Western Australia; Royal Perth Hospital; University of Western Australia; Icahn School of Medicine at Mount Sinai; Eisai Co Ltd; GlaxoSmithKline	Klinken, SP (corresponding author), Univ Western Australia, Lab Canc Med, Dept Biochem, Level 6,MRF Bldg,Rear 50 Murray St, Perth, WA 6001, Australia.	pklinken@cyllene.uwa.edu.au	Sarna, Mohinder/GYR-3271-2022; Sarna, Mohinder/Q-7834-2016; Ingley, Evan/C-2401-2013; Sarna, Mohinder/AAO-9343-2020	Sarna, Mohinder/0000-0002-2448-1588; Ingley, Evan/0000-0002-8112-9134; Sarna, Mohinder/0000-0002-2448-1588; Williams, James/0000-0002-0950-1958				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BUSFIELD SJ, 1992, BLOOD, V80, P412; Chin H, 1998, BLOOD, V91, P3734; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; COOPER MC, 1974, P NATL ACAD SCI USA, V71, P1677, DOI 10.1073/pnas.71.5.1677; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; CORY S, 1991, CELL GROWTH DIFFER, V2, P165; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; FENG WC, 1994, J BIOL CHEM, V269, P1493; FUKAMACHI H, 1994, J IMMUNOL, V152, P642; Harlow E., 1988, ANTIBODIES LAB MANUA; HAWLEY RG, 1994, GENE THER, V1, P136; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KLINKEN SP, 1989, J VIROL, V63, P1489, DOI 10.1128/JVI.63.3.1489-1492.1989; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; Nagata Y, 1999, BLOOD, V93, P3347, DOI 10.1182/blood.V93.10.3347.410k06_3347_3354; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; PEVNY L, 1995, DEVELOPMENT, V121, P163; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; Ruzzene M, 1996, BIOCHEMISTRY-US, V35, P5327, DOI 10.1021/bi9528614; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Suzuki Y, 1997, J IMMUNOL, V158, P2736; Takemoto Y, 1998, J IMMUNOL, V161, P625; TAKEMOTO Y, 1995, EMBO J, V14, P3403, DOI 10.1002/j.1460-2075.1995.tb07346.x; Takemoto Y, 1996, INT IMMUNOL, V8, P1699, DOI 10.1093/intimm/8.11.1699; TANIUCHI I, 1995, EMBO J, V14, P3664, DOI 10.1002/j.1460-2075.1995.tb00036.x; Tilbrook PA, 1996, J BIOL CHEM, V271, P3453; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; TODOKORO K, 1987, P NATL ACAD SCI USA, V84, P4126, DOI 10.1073/pnas.84.12.4126; TORIGOE T, 1992, BLOOD, V80, P617; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; TROWBRIDGE IS, 1982, J CELL PHYSIOL, V112, P403, DOI 10.1002/jcp.1041120314; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Williams JH, 1999, EMBO J, V18, P5559, DOI 10.1093/emboj/18.20.5559; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; Yamanashi Y, 1997, J EXP MED, V185, P1387, DOI 10.1084/jem.185.7.1387; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	57	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7887	7893		10.1074/jbc.275.11.7887	http://dx.doi.org/10.1074/jbc.275.11.7887			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713104	hybrid, Green Published			2022-12-27	WOS:000085913300064
J	Kawanishi, M; Tamori, Y; Okazawa, H; Araki, S; Skinoda, H; Kasuga, M				Kawanishi, M; Tamori, Y; Okazawa, H; Araki, S; Skinoda, H; Kasuga, M			Role of SNAP23 in insulin-induced translocation of GLUT4 in 3T3-L1 adipocytes - Mediation of complex formation between syntaxin4 and VAMP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER GLUT4; RAT ADIPOSE-CELLS; SUBCELLULAR TRAFFICKING; RECOMBINANT ADENOVIRUS; PROTEIN SNAP-25; SNARE COMPLEX; CORE COMPLEX; EFFICIENT; MEMBRANE; VESICLES	Both syntaxin4 and VAMP2 are implicated in insulin regulation of glucose transporter-4 (GLUT4) trafficking in adipocytes as target (t) soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNARE) and vesicle (V)-SNARE proteins, respectively, which mediate fusion of GLUT4-containing vesicles with the plasma membrane. Synaptosome-associated 23-kDa protein (SNAP23) is a widely expressed isoform of SNAP25, the principal t-SNARE of neuronal cells, and colocalizes with syntaxin4 in the plasma membrane of 3T3-L1 adipocytes. In the present study, two SNAP23 mutants, SNAP23-Delta C8 (amino acids 1 to 202) and SNAP23-Delta C49 (amino acids 1 to 161), were generated to determine whether SNAP23 is required for insulin-induced translocation of GLUT4 to the plasma membrane in 3T3-L1 adipocytes. Wild-type SNAP23 (SNAP23-WT) promoted the interaction between syntaxin4 and VAMP2 both in vitro and in vivo. Although SNAP23-Delta C49 bound to neither syntaxin4 nor VAMP2, the SNAP23-Delta C8 mutant bound to syntaxin4 but not to VAMP2, In addition, although SNAP23-Delta C8 bound to syntaxin4, it did not mediate the interaction between syntaxin4 and VAMP2;. Moreover, overexpression of SNAP23-Delta C8 in 3T3-L1 adipocytes by adenovirus-mediated gene transfer inhibited insulin-induced translocation of GLUT4 but not that of GLUT1. In contrast, overexpression of neither SNAP23-WT nor SNAP23-Delta C49 in 3T3-L1 adipocytes affected the translocation of GLUT4 or GLUT1, Together, these results demonstrate that SNAP23 contributes to insulin-dependent trafficking of GLUT4 to the plasma membrane in 3T3-L1 adipocytes by mediating the interaction between t-SNARE (syntaxin4) and V-SNARE (VAMP2).	Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University	Tamori, Y (corresponding author), Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	tamori@med.kobe-u.ac.jp	Okazawa, Hideki/E-3055-2010; Okazawa, Hideki/C-3836-2011					Aguado F, 1996, EUR J CELL BIOL, V69, P351; Araki S, 1997, BIOCHEM BIOPH RES CO, V234, P257, DOI 10.1006/bbrc.1997.6560; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; Chen FS, 1997, BIOCHEMISTRY-US, V36, P5719, DOI 10.1021/bi962331n; El-Jack AK, 1999, MOL BIOL CELL, V10, P1581, DOI 10.1091/mbc.10.5.1581; Foster LJ, 1998, BIOCHEMISTRY-US, V37, P11089, DOI 10.1021/bi980253t; FROST SC, 1985, J BIOL CHEM, V260, P2646; HASHIRAMOTO M, 1992, J BIOL CHEM, V267, P17502; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; Jagadish MN, 1996, BIOCHEM J, V317, P945, DOI 10.1042/bj3170945; JHUN BH, 1992, J BIOL CHEM, V267, P17710; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; Macaulay SL, 1997, BIOCHEM BIOPH RES CO, V237, P388, DOI 10.1006/bbrc.1997.7143; Martin LB, 1998, J BIOL CHEM, V273, P1444, DOI 10.1074/jbc.273.3.1444; Martin S, 1997, J CELL SCI, V110, P2281; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Rea S, 1998, J BIOL CHEM, V273, P18784, DOI 10.1074/jbc.273.30.18784; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; ROTH D, 1994, FEBS LETT, V351, P207, DOI 10.1016/0014-5793(94)00833-7; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SADOUL K, 1995, J CELL BIOL, V128, P1019, DOI 10.1083/jcb.128.6.1019; SATOH S, 1993, J BIOL CHEM, V268, P17820; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tamori Y, 1996, BIOCHEM BIOPH RES CO, V220, P740, DOI 10.1006/bbrc.1996.0474; Tamori Y, 1998, J BIOL CHEM, V273, P19740, DOI 10.1074/jbc.273.31.19740; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Timmers KI, 1996, BIOCHEM J, V320, P429, DOI 10.1042/bj3200429; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; Wong PPC, 1997, BIOCHEM BIOPH RES CO, V230, P64, DOI 10.1006/bbrc.1996.5884; Wu-Wong JSR, 1999, J BIOL CHEM, V274, P8103, DOI 10.1074/jbc.274.12.8103; YANG J, 1993, J BIOL CHEM, V268, P4600	50	91	94	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8240	8247		10.1074/jbc.275.11.8240	http://dx.doi.org/10.1074/jbc.275.11.8240			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713150	hybrid			2022-12-27	WOS:000085913300110
J	O'Connell, L; Hongo, JA; Presta, LG; Tsoulfas, P				O'Connell, L; Hongo, JA; Presta, LG; Tsoulfas, P			TrkA amino acids controlling specificity for nerve growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH MOTIF; IMMUNOGLOBULIN-LIKE DOMAINS; TYROSINE KINASE RECEPTORS; FACTOR BINDING-SITE; NEUROTROPHIN RECEPTORS; EXTRACELLULAR DOMAIN; TISSUE DISTRIBUTION; NGF; FAMILY; EXPRESSION	Neurotrophins are important for the development and maintenance of the vertebrate nervous system, mediating their signal into the cell by specific interaction with tyrosine kinase receptors of the Trk family. The extracellular portion of the Trk receptors has been previously proposed to consist of a cysteine-rich motif, a leucine-rich motif, a second cysteine-rich motif followed by two immunoglobulin-like domains. Earlier studies have shown that a major neurotrophin-binding site in the Trk receptors resides in the second immunoglobulin-like domain. Although the individual amino acids in TrkA involved in binding to nerve growth factor (NGF) and those in TrkC involved in binding to neurotrophin-3 have been mapped in this domain, the Trk amino acids that provide specificity remained unclear. In this study, a minimum set of residues in the human TrkC second immunoglobulin-like domain, which does not bind nerve growth factor (NGF), were substituted with those from human TrkA. The resulting Trk variant recruited binding of NGF equivalent to TrkA, maintained neurotrophin-a binding equivalent to TrkC, and also bound brain-derived neurotrophin, although with lower affinity compared with TrkB. This implies that the amino acids in the second immunoglobulin-like domain that determine Trk specificity are distinct for each Trk.	Genentech Inc, Dept Immunol, S San Francisco, CA 94080 USA; Genentech Inc, Dept Antibody Technol, S San Francisco, CA 94080 USA; Univ Miami, Sch Med, Miami Project, Miami, FL 33135 USA; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33135 USA	Roche Holding; Genentech; Roche Holding; Genentech; University of Miami; University of Miami	Presta, LG (corresponding author), Genentech Inc, Dept Immunol, MS34,1 DNA Way, S San Francisco, CA 94080 USA.		Tsoulfas, Pantelis/GNH-1922-2022	Tsoulfas, Pantelis/0000-0003-1974-6366				Barbacid M, 1995, ANN NY ACAD SCI, V766, P442, DOI 10.1111/j.1749-6632.1995.tb26693.x; BARKER PA, 1993, J BIOL CHEM, V268, P15150; Belliveau DJ, 1997, J CELL BIOL, V136, P375, DOI 10.1083/jcb.136.2.375; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; Boeshore KL, 1999, J NEUROSCI, V19, P4739; Chao M, 1998, BRAIN RES REV, V26, P295, DOI 10.1016/S0165-0173(97)00036-2; CLARY DO, 1994, P NATL ACAD SCI USA, V91, P11133, DOI 10.1073/pnas.91.23.11133; Dechant G, 1997, CURR OPIN NEUROBIOL, V7, P413, DOI 10.1016/S0959-4388(97)80071-2; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Frade JM, 1998, BIOESSAYS, V20, P137, DOI 10.1002/(SICI)1521-1878(199802)20:2<137::AID-BIES6>3.0.CO;2-Q; Haniu M, 1997, J BIOL CHEM, V272, P25296, DOI 10.1074/jbc.272.40.25296; Holden PH, 1997, NAT BIOTECHNOL, V15, P668, DOI 10.1038/nbt0797-668; IBANEZ CF, 1991, EMBO J, V10, P2105, DOI 10.1002/j.1460-2075.1991.tb07743.x; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; IBANEZ CF, 1995, TRENDS BIOTECHNOL, V13, P217, DOI 10.1016/S0167-7799(00)88949-0; ILAG LL, 1994, J BIOL CHEM, V269, P19941; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; KAHLE P, 1992, J BIOL CHEM, V267, P22707; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kullander K, 1997, J BIOL CHEM, V272, P9300; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; MacDonald JIS, 1996, MOL CELL NEUROSCI, V7, P371, DOI 10.1006/mcne.1996.0027; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; Ninkina N, 1997, J BIOL CHEM, V272, P13019, DOI 10.1074/jbc.272.20.13019; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SHELTON DL, 1995, J NEUROSCI, V15, P477, DOI 10.1523/jneurosci.15-01-00477.1995; SHIH A, 1994, J BIOL CHEM, V269, P27679; Strohmaier C, 1996, EMBO J, V15, P3332, DOI 10.1002/j.1460-2075.1996.tb00698.x; Tam SY, 1997, BLOOD, V90, P1807, DOI 10.1182/blood.V90.5.1807; TANNAHILL L, 1995, EUR J NEUROSCI, V7, P1424, DOI 10.1111/j.1460-9568.1995.tb01136.x; Torcia M, 1996, CELL, V85, P345, DOI 10.1016/S0092-8674(00)81113-7; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; Tsoulfas P, 1996, J BIOL CHEM, V271, P5691, DOI 10.1074/jbc.271.10.5691; Ultsch MH, 1999, J MOL BIOL, V290, P149, DOI 10.1006/jmbi.1999.2816; URFER R, 1994, EMBO J, V13, P5896, DOI 10.1002/j.1460-2075.1994.tb06935.x; Urfer R, 1997, BIOCHEMISTRY-US, V36, P4775, DOI 10.1021/bi962877+; Urfer R, 1998, J BIOL CHEM, V273, P5829, DOI 10.1074/jbc.273.10.5829; URFER R, 1995, EMBO J, V14, P2795, DOI 10.1002/j.1460-2075.1995.tb07279.x; Wiesmann C, 1999, NATURE, V401, P184, DOI 10.1038/43705; WINDISCH JM, 1995, FEBS LETT, V374, P125, DOI 10.1016/0014-5793(95)01047-I; WINDISCH JM, 1995, BIOCHEMISTRY-US, V34, P11256, DOI 10.1021/bi00035a035; WINDISCH JM, 1995, J BIOL CHEM, V270, P28133	47	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7870	7877		10.1074/jbc.275.11.7870	http://dx.doi.org/10.1074/jbc.275.11.7870			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713102	hybrid			2022-12-27	WOS:000085913300062
J	Roth, AF; Davis, NG				Roth, AF; Davis, NG			Ubiquitination of the PEST-like endocytosis signal of the yeast a-factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; PHEROMONE RECEPTORS; ALPHA-FACTOR; PROTEIN; DEGRADATION; INTERNALIZATION; MUTANTS; SUBUNIT; CELLS	A 58-residue-long, PEST-like sequence within the yeast a-factor receptor (Ste3p) specifies the ubiquitination, endocytosis, and consequent vacuolar degradation of the receptor protein (Roth, A. F., Sullivan, D. M., and Davis, N, G. (1998) J. Cell Biol. 142, 949-961), The present work investigates three lysyl residues that map within this sequence as the potential ubiquitin acceptor sites. Lys --> Arg substitution mutants were tested for effects on both ubiquitination and endocytosis, Results indicate that the three lysines function redundantly; a severe blockade to both ubiquitination and endocytosis is seen only for receptors having all three lysines replaced. Of the three, Lys(432) plays the predominant role; ubiquitination and turnover are significantly impaired for receptors having just the K432R mutation. CNBr fragmentation of the receptor protein, used for the physical mapping of the ubiquitin attachment sites, showed PEST-like sequence lysines to be modified both with single ubiquitin moieties as well with short multi-ubiquitin chains, two or three ubiquitins long. Thus, in addition to being the signal for ubiquitination, the Ste3p PEST-like sequence also provides the site for ubiquitin attachment. To test if this endocytosis signal functions solely for ubiquitination, we have asked if the requirement for the PEST-like sequence in endocytosis might be bypassed through pre-attachment of ubiquitin to the receptor protein. Indeed, Ste3-ubiquitin translational fusions that have a ubiquitin moiety fused to the receptor in place of the PEST-like signal do undergo rapid endocytosis and vacuolar turnover. Wt? conclude that ubiquitin alone, with no required contribution from receptor sequences, provides the sufficient signal for initiating uptake. In addition, our results confirm conclusions originally drawn from studies with the cu-factor receptor (Terrell, J., Shih, S., Dunn, R., and Hicke, L. (1998) Mol. Cell 1, 193-202), namely that mono-ubiquitin, and not multi-ubiquitin chains provide the primary recognition determinant for uptake. Although mono-ubiquitination suffices, our results indicate that multi-ubiquitination serves to augment the rate of uptake.	Wayne State Univ, Sch Med, Dept Surg, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Davis, NG (corresponding author), Wayne State Univ, Sch Med, Dept Surg, Elliman Bldg,Rm 1205,421 E Canfield, Detroit, MI 48201 USA.							BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BENDER A, 1986, CELL, V47, P929, DOI 10.1016/0092-8674(86)90808-1; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Crook T, 1996, VIROLOGY, V217, P285, DOI 10.1006/viro.1996.0115; DAVIS NG, 1993, J CELL BIOL, V122, P53, DOI 10.1083/jcb.122.1.53; Dosil M, 1998, MOL CELL BIOL, V18, P5981, DOI 10.1128/MCB.18.10.5981; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Givan SA, 1997, MOL BIOL CELL, V8, P1317, DOI 10.1091/mbc.8.7.1317; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOU D, 1994, J BIOL CHEM, V269, P14244; Huang KM, 1999, EMBO J, V18, P3897, DOI 10.1093/emboj/18.14.3897; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Kolling R, 1997, EMBO J, V16, P2251, DOI 10.1093/emboj/16.9.2251; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Li Y, 1999, MOL CELL BIOL, V19, P3588; Marchal C, 1998, MOL CELL BIOL, V18, P314, DOI 10.1128/MCB.18.1.314; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; PAYNE GS, 1988, J CELL BIOL, V106, P1453, DOI 10.1083/jcb.106.5.1453; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Robinson CR, 1996, BIOCHEMISTRY-US, V35, P109, DOI 10.1021/bi9521194; ROHRER J, 1993, MOL BIOL CELL, V4, P511, DOI 10.1091/mbc.4.5.511; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Roth AF, 1998, J CELL BIOL, V142, P949, DOI 10.1083/jcb.142.4.949; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SIKORSKI RS, 1989, GENETICS, V122, P19; SILICIANO PG, 1984, CELL, V37, P969, DOI 10.1016/0092-8674(84)90431-8; Springael JY, 1999, J CELL SCI, V112, P1375; Tan PK, 1996, J CELL BIOL, V135, P1789, DOI 10.1083/jcb.135.6.1789; TAN PK, 1993, J CELL BIOL, V123, P1707, DOI 10.1083/jcb.123.6.1707; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9	40	81	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8143	8153		10.1074/jbc.275.11.8143	http://dx.doi.org/10.1074/jbc.275.11.8143			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713137	hybrid			2022-12-27	WOS:000085913300097
J	Kumar, S; McDonnell, PC; Lehr, R; Tierney, L; Tzimas, MN; Griswold, DE; Capper, EA; Tal-Singer, R; Wells, GI; Doyle, ML; Young, PR				Kumar, S; McDonnell, PC; Lehr, R; Tierney, L; Tzimas, MN; Griswold, DE; Capper, EA; Tal-Singer, R; Wells, GI; Doyle, ML; Young, PR			Identification and initial characterization of four novel members of the interleukin-1 family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; GAMMA INDUCING FACTOR; IL-1 RECEPTOR; CONVERTING-ENZYME; CRYSTAL-STRUCTURE; MESSENGER-RNA; CLONING; EXPRESSION; PROTEIN; CELLS	Interleukin-1 (IL-1), fibroblast growth factors (FGFs), and their homologues are secreted factors that share a common p-barrel structure and act on target cells by binding to cell surface receptors with immunoglobulinlike folds in their extracellular domain. While numerous members of the FGF family have been discovered, the IL-1 family has remained small and outnumbered by IL-1 receptor homologues, From expressed sequence tag data base searches, we have now identified four additional IL-1 homologues, IL-1H1, IL-1H2, IL-1H3, and IL-1H4. Like most other IL-1/FGFs, these proteins do not contain a hydrophobic leader sequence. IL-1H4 has a propeptide sequence, while IL-1H1, IL-1H2, and IL-1H3 encode only the mature protein. Circular dichroism spectra and thermal stability analysis suggest that 1H1 folds similarly to IL-1ra. The novel homologues are not widely expressed in mammals. IL-1H1 is constitutively expressed only in placenta and the squamous epithelium of the esophagus, However, IL-1H1 could be induced in vitro in keratinocytes by interferon-gamma and tumor necrosis factor-alpha and in vivo via a contact hypersensitivity reaction or herpes simplex virus infection. This suggests that IL-1H1 may be involved in pathogenesis of immune mediated disease processes. The addition of four novel IL-1 homologues suggests that the IL-1 family is significantly larger than previously thought.	SmithKline Beecham Pharmaceut, Dept Bone & Cartilage Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Mol Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Prot Biochem, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Toxicol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Pulm Pharmacol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Immunol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Mol Virol & Host Def, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Biol Struct, King Of Prussia, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Kumar, S (corresponding author), UW 2109,POB 1539,709 Swedeland Rd, King Of Prussia, PA 19406 USA.		Tal-Singer, Ruth/AAQ-2925-2021	Tal-Singer, Ruth/0000-0002-5275-8062; Doyle, Michael/0000-0003-4569-6315; Spudich, Elizabeth/0000-0002-6223-8271				Auron PE, 1998, CYTOKINE GROWTH F R, V9, P221, DOI 10.1016/S1359-6101(98)00018-5; Born TL, 1998, J BIOL CHEM, V273, P29445, DOI 10.1074/jbc.273.45.29445; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chang BS, 1996, BIOPHYS J, V71, P3399, DOI 10.1016/S0006-3495(96)79534-6; Dinarello CA, 1998, J LEUKOCYTE BIOL, V63, P658, DOI 10.1002/jlb.63.6.658; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; EISENBERG RJ, 1987, MICROB PATHOGENESIS, V3, P423, DOI 10.1016/0882-4010(87)90012-X; ENK AH, 1993, J IMMUNOL, V150, P3698; GRISWOLD DE, 1991, J INVEST DERMATOL, V97, P1019, DOI 10.1111/1523-1747.ep12492422; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; HASKILL S, 1991, P NATL ACAD SCI USA, V88, P3681, DOI 10.1073/pnas.88.9.3681; HILL TJ, 1975, J GEN VIROL, V28, P341, DOI 10.1099/0022-1317-28-3-341; HUZUDA D, 1989, J BIOL CHEM, V264, P1689; KLEMENZ R, 1989, P NATL ACAD SCI USA, V86, P5708, DOI 10.1073/pnas.86.15.5708; KUMAR S, 1995, J BIOL CHEM, V270, P27905, DOI 10.1074/jbc.270.46.27905; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P474, DOI 10.1006/bbrc.1997.6810; KUPPER TS, 1986, J EXP MED, V164, P2095, DOI 10.1084/jem.164.6.2095; Lovenberg TW, 1996, J NEUROIMMUNOL, V70, P113, DOI 10.1016/S0165-5728(96)00047-1; LU LH, 1994, CELL VISION, V1, P169; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MEYERS CA, 1987, J BIOL CHEM, V262, P11176; Mikloska Z, 1998, J INFECT DIS, V177, P827, DOI 10.1086/515236; MIZUTANI H, 1991, J CLIN INVEST, V87, P1066, DOI 10.1172/JCI115067; Mulero JJ, 1999, BIOCHEM BIOPH RES CO, V263, P702, DOI 10.1006/bbrc.1999.1440; Nishimura T, 1999, BBA-GENE STRUCT EXPR, V1444, P148, DOI 10.1016/S0167-4781(98)00255-3; Novick D, 1999, IMMUNITY, V10, P127, DOI 10.1016/S1074-7613(00)80013-8; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Ohbayashi N, 1998, J BIOL CHEM, V273, P18161, DOI 10.1074/jbc.273.29.18161; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V86, P9667, DOI 10.1073/pnas.86.24.9667; Rauschmayr T, 1997, P NATL ACAD SCI USA, V94, P5814, DOI 10.1073/pnas.94.11.5814; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Schreuder H, 1997, NATURE, V386, P194, DOI 10.1038/386194a0; Shornick LP, 1996, J EXP MED, V183, P1427, DOI 10.1084/jem.183.4.1427; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TOMINAGA S, 1989, FEBS LETT, V258, P301, DOI 10.1016/0014-5793(89)81679-5; Torigoe K, 1997, J BIOL CHEM, V272, P25737, DOI 10.1074/jbc.272.41.25737; Vigers GPA, 1997, NATURE, V386, P190, DOI 10.1038/386190a0; Webb EF, 1998, J INVEST DERMATOL, V111, P86, DOI 10.1046/j.1523-1747.1998.00239.x; Xu XL, 1999, CELL TISSUE RES, V296, P33, DOI 10.1007/s004410051264; Zhang YZ, 1999, GENE, V230, P69, DOI 10.1016/S0378-1119(99)00047-5; ZHENG H, 1995, IMMUNITY, V3, P9, DOI 10.1016/1074-7613(95)90154-X; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	45	256	321	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10308	10314		10.1074/jbc.275.14.10308	http://dx.doi.org/10.1074/jbc.275.14.10308			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744718	hybrid			2022-12-27	WOS:000086345600059
J	Feitsma, K; Hausser, H; Robenek, H; Kresse, H; Vischer, P				Feitsma, K; Hausser, H; Robenek, H; Kresse, H; Vischer, P			Interaction of thrombospondin-1 and heparan sulfate from endothelial cells - Structural requirements of heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN-FIBROBLASTS; PLATELET THROMBOSPONDIN; SECRETE THROMBOSPONDIN; EXTRACELLULAR-MATRIX; CARCINOMA-CELLS; FINE-STRUCTURE; GROWTH-FACTOR; BINDING; RECEPTOR; IDENTIFICATION	Cell surface-associated heparan sulfate proteoglycans, predominantly perlecan, are involved in the process of binding and endocytosis of thrombospondin-1 (TSP-1) by vascular endothelial cells. To investigate the structural properties of heparan sulfate (HS) side chains that mediate this interaction, the proteoglycans were isolated from porcine endothelial cells and HS chains obtained thereof by beta-elimination To characterize the structural composition of the HS chains and to identify the TSP-1-binding sequences, HS was disintegrated by specific chemical and enzymatic treatments. Cell layer-derived HS chains revealed the typical structural heterogeneity with domains of non-contiguously arranged highly sulfated disaccharides separated by extended sequences containing predominantly N-acetylated sequences of low sulfation, Affinity chromatography on immobilized TSP-1 demonstrated that nearly all intact HS chains possessed binding affinity, whereas after heparinase III treatment only a small proportion of oligosaccharides were bound with similar affinity to the column. Size fractioning of the bound and unbound oligosaccharides revealed that only a specific portion of deca- to tetradecasaccharides possessed TSP-l-binding affinity. The binding fraction contained over 40% di- and trisulfated disaccharide units and was enriched in the content of the trisulfated 2-O-sulfated L-iduronic acid-N-sulfated-6-O-sulfated glucosamine disaccharide unit. Comparison with the disaccharide composition of the intact HS chains and competition experiments with modified heparin species indicated the specific importance of N- and 6-O-sulfated glucosamine residues for binding. Further depolymerization of the binding oligosaccharides revealed that the glucosamine residues within the TSP-l-binding sequences are not continuously N-sulfated, The present findings implicate specific structural properties for the HS domain involved in TSP-1 binding and indicate that they are distinct from the binding sequence described for basic fibroblast growth factor, another HS ligand and a potential antagonist of TSP-1.	Univ Munster, Inst Arteriosclerosis Res, D-48149 Munster, Germany; Univ Munster, Inst Physiol Chem & Pathobiochem, D-48149 Munster, Germany	University of Munster; University of Munster	Vischer, P (corresponding author), Univ Munster, Inst Arteriosclerosis Res, Domagkstr 3, D-48149 Munster, Germany.	vicherp@uni-muenster.de						ADAMS JC, 1993, J CELL SCI, V104, P1061; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; BAGAVANDOSS P, 1990, BIOCHEM BIOPH RES CO, V170, P867, DOI 10.1016/0006-291X(90)92171-U; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; DIXIT VM, 1984, J BIOL CHEM, V259, P100; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; HOGG PJ, 1993, J BIOL CHEM, V268, P21811; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P817, DOI 10.1093/glycob/4.6.817; ISHIHARA M, 1995, J BIOCHEM-TOKYO, V118, P1255, DOI 10.1093/oxfordjournals.jbchem.a125015; JAFFE EA, 1985, BLOOD, V65, P79; JAFFE EA, 1983, P NATL ACAD SCI-BIOL, V80, P998, DOI 10.1073/pnas.80.4.998; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; KUSCHE M, 1990, J BIOL CHEM, V265, P7292; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1992, BIOCHEMISTRY-US, V31, P1173, DOI 10.1021/bi00119a029; LAWLER J, 1993, THROMBOSPONDIN, P275; LAWLER JW, 1978, J BIOL CHEM, V253, P8609; LI WX, 1993, J BIOL CHEM, V268, P16179; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINDBLOM A, 1990, GLYCOCONJUGATE J, V7, P545, DOI 10.1007/BF01189076; LYON M, 1994, J BIOL CHEM, V269, P11216; LYON M, 1994, J BIOL CHEM, V269, P11208; MAJACK RA, 1986, P NATL ACAD SCI USA, V83, P9050, DOI 10.1073/pnas.83.23.9050; MALMSTROM A, 1975, BIOCHEM J, V151, P477; MCPHERSON J, 1981, J BIOL CHEM, V256, P1330; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; Molist A, 1997, BIOCHEM BIOPH RES CO, V238, P874, DOI 10.1006/bbrc.1997.7192; MOSHER DF, 1990, ANNU REV MED, V41, P85; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; PHAN SH, 1989, BIOCHEM BIOPH RES CO, V163, P56, DOI 10.1016/0006-291X(89)92098-6; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; RAUGI GJ, 1982, J CELL BIOL, V95, P351, DOI 10.1083/jcb.95.1.351; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; SCHMIDT A, 1992, J BIOL CHEM, V267, P19242; SCHON P, 1992, EUR J CELL BIOL, V59, P329; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Stringer SE, 1997, J BIOL CHEM, V272, P20508, DOI 10.1074/jbc.272.33.20508; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TUSZYNSKI GP, 1993, J CELL BIOL, V120, P513, DOI 10.1083/jcb.120.2.513; Vischer P, 1997, EUR J CELL BIOL, V73, P332; VISCHER P, 1985, EXP CELL RES, V158, P15, DOI 10.1016/0014-4827(85)90427-6; VISCHER P, 1988, EUR J CELL BIOL, V47, P36; VOLKER W, 1991, J HISTOCHEM CYTOCHEM, V39, P1385, DOI 10.1177/39.10.1940309; YABKOWITZ R, 1991, CANCER RES, V51, P3648	56	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9396	9402		10.1074/jbc.275.13.9396	http://dx.doi.org/10.1074/jbc.275.13.9396			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734084	hybrid			2022-12-27	WOS:000086206500048
J	Kraus, RL; Sinnegger, MJ; Koschak, A; Glossmann, H; Stenirri, S; Carrera, P; Striessnig, J				Kraus, RL; Sinnegger, MJ; Koschak, A; Glossmann, H; Stenirri, S; Carrera, P; Striessnig, J			Three new familial hemiplegic migraine mutants affect P/Q-type Ca2+ channel kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; ALPHA(1A) SUBUNITS; EPISODIC ATAXIA; MESSENGER-RNAS; GENE; EXPRESSION; MUTATIONS	Missense mutations in the pore-forming human alpha(1A) subunit of neuronal P/Q-type Ca2+ channels are associated with familial hemiplegic migraine. We studied the functional consequences on P/Q-type Ca2+ channel function of three recently identified mutations, R583Q, D715E, and V1457L after introduction into rabbit alpha(1A) and expression in Xenopus laevis oocytes, The potential for half-maximal channel activation of Ba2+ inward currents was shifted by > 9 mV to more negative potentials in all three mutants. The potential for half-maximal channel inactivation was shifted by > 7 mV in the same direction in R583Q and D715E, Biexponential current inactivation during 3-s test pulses was significantly faster in D715E and slower in V1457L than in wild type. Mutations R583Q and V1457L delayed the time course of recovery from channel inactivation. The decrease of peak current through R583Q (30.2%) and D715E (30.1%) but not V1457L (18.7%) was more pronounced during l-Hz trains of 15 100-ms pulses than in wild type (18,2%), Our data demonstrate that the mutations R583Q, D715E, and V1457L, like the previously reported mutations T666M, V714A, and I1819L, affect P/Q-type Ca2+ channel gating, We therefore propose that altered channel gating represents a common pathophysiological mechanism in familial hemiplegic migraine.	Inst Biochem Pharmakol, A-6020 Innsbruck, Austria; Hosp San Raffaele, Clin Mol Biol Lab, I-20132 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Striessnig, J (corresponding author), Inst Biochem Pharmakol, Peter Mary Str 1, A-6020 Innsbruck, Austria.		Striessnig, Joerg/S-9334-2017; Glossmann, Hartmut/AAL-9790-2020	Striessnig, Joerg/0000-0002-9406-7120; Brauns, Martina/0000-0002-0547-2731; Carrera, Paola/0000-0001-7376-2119; glossmann, hartmut h./0000-0002-7392-3266				Armstrong CM, 1998, NEURON, V20, P371, DOI 10.1016/S0896-6273(00)80981-2; Battistini S, 1999, NEUROLOGY, V53, P38, DOI 10.1212/WNL.53.1.38; Carrera P, 1999, NEUROLOGY, V53, P26, DOI 10.1212/WNL.53.1.26; Denier C, 1999, NEUROLOGY, V52, P1816, DOI 10.1212/WNL.52.9.1816; Diener HC, 1996, CURR OPIN NEUROL, V9, P199, DOI 10.1097/00019052-199606000-00007; Ducros A, 1999, AM J HUM GENET, V64, P89, DOI 10.1086/302192; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; Garcia J, 1997, BIOPHYS J, V72, P2515, DOI 10.1016/S0006-3495(97)78896-9; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; Hans M, 1999, J NEUROSCI, V19, P1610; Hering S, 1996, J BIOL CHEM, V271, P24471, DOI 10.1074/jbc.271.40.24471; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Jen J, 1999, NEUROLOGY, V53, P34, DOI 10.1212/WNL.53.1.34; Kraus RL, 1998, J BIOL CHEM, V273, P5586, DOI 10.1074/jbc.273.10.5586; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; MAY A, 1995, HUM GENET, V96, P604, DOI 10.1007/BF00197420; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; Terwindt GM, 1998, NEUROLOGY, V50, P1105, DOI 10.1212/WNL.50.4.1105; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403; WHEELER DB, 1994, SCIENCE, V266, P828; Yue Q, 1998, AM J MED GENET, V77, P298, DOI 10.1002/(SICI)1096-8628(19980526)77:4<298::AID-AJMG9>3.0.CO;2-J; Yue Q, 1997, AM J HUM GENET, V61, P1078, DOI 10.1086/301613; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	31	106	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9239	9243		10.1074/jbc.275.13.9239	http://dx.doi.org/10.1074/jbc.275.13.9239			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734061	hybrid			2022-12-27	WOS:000086206500025
J	Takeda, K; Hatai, T; Hamazaki, TS; Nishitoh, H; Saitoh, M; Ichijo, H				Takeda, K; Hatai, T; Hamazaki, TS; Nishitoh, H; Saitoh, M; Ichijo, H			Apoptosis signal-regulating kinase 1 (ASK1) induces neuronal differentiation and survival of PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; MAP KINASE; C-JUN; PC-12 CELLS; PHOSPHORYLATION; INDUCTION; PATHWAYS; IDENTIFICATION; NEUROFILAMENTS	Apoptosis signal-regulating kinase 1 (ASK1) is a ubiquitously expressed mitogen-activated protein kinase kinase kinase that activates the c-dun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase signaling cascades, We report here that expression of constitutively active ASK1 (ASK1 Delta N) induces neurite outgrowth in the rat pheochromocytoma cell line PC12, We found that p38 and to a lesser extent JNK, but not ERK, were activated by the expression of ASK1 Delta N in PC12 cells. ASK1 Delta N-induced neurite outgrowth was strongly inhibited by treatment with the p38 inhibitor SB203580 but not with the MEK inhibitors, suggesting that activation of p38, rather than of ERK, is required for the neurite-inducing activity of ASK1 in PC12 cells. We also observed that ASK1 Delta N induced expression of several neuron-specific proteins and phosphorylation of neurofilament proteins, confirming that PC12 cells differentiated into mature neuronal cells by ASK1. Moreover, ASK1 Delta N-expressing PC12 cells survived in serum-starved condition. ASK1 thus appears to mediate signals leading to both differentiation and survival of PC12 cells. Together with previous reports indicating that ASI(1 functions as a pro-apoptotic signaling intermediate, these results suggest that ASK1 has a broad range of biological activities depending on cell types and/or cellular context.	Tokyo Med & Dent Univ, Dept Biomat Sci, Fac Dent, Bunkyo Ku, Tokyo 1138549, Japan	Tokyo Medical & Dental University (TMDU)	Takeda, K (corresponding author), Tokyo Med & Dent Univ, Dept Biomat Sci, Fac Dent, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.	takeda.det2@dent.tmd.ac.jp; ichijo.det2@dent.tmd.ac.jp		Ichijo, Hidenori/0000-0002-5005-6438; Takeda, Kohsuke/0000-0002-8359-8399; Nishitoh, Hideki/0000-0002-8652-4109				Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; ELHANANY E, 1994, J NEUROCHEM, V63, P2324; Giasson BI, 1997, J NEUROSCI, V17, P9466; Giasson BI, 1996, J BIOL CHEM, V271, P30404, DOI 10.1074/jbc.271.48.30404; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUAN RJ, 1991, J BIOL CHEM, V266, P8262; Heasley LE, 1996, MOL CELL BIOL, V16, P648; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Iwasaki S, 1996, J BIOL CHEM, V271, P17360, DOI 10.1074/jbc.271.29.17360; Iwasaki S, 1999, J BIOL CHEM, V274, P26503, DOI 10.1074/jbc.274.37.26503; Julien JP, 1998, PROG NUCLEIC ACID RE, V61, P1, DOI 10.1016/S0079-6603(08)60823-5; Kanamoto T, 2000, MOL CELL BIOL, V20, P196, DOI 10.1128/MCB.20.1.196-204.2000; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; LEE MK, 1990, CELL MOTIL CYTOSKEL, V17, P118, DOI 10.1002/cm.970170207; LEE VMY, 1987, J NEUROSCI, V7, P3474; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RODER HM, 1995, J NEUROCHEM, V64, P2203; SADOT E, 1995, J CELL SCI, V108, P2857; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sano M, 1998, BRAIN RES, V785, P299, DOI 10.1016/S0006-8993(97)01403-0; Sun DM, 1996, J BIOL CHEM, V271, P14245, DOI 10.1074/jbc.271.24.14245; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Veeranna, 1998, J NEUROSCI, V18, P4008; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Watson A, 1998, J NEUROSCI, V18, P751; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yao RJ, 1997, J BIOL CHEM, V272, P18261, DOI 10.1074/jbc.272.29.18261; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	48	140	148	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9805	9813		10.1074/jbc.275.13.9805	http://dx.doi.org/10.1074/jbc.275.13.9805			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734135	hybrid			2022-12-27	WOS:000086206500099
J	Kimura, K; Gelmann, EP				Kimura, K; Gelmann, EP			Tumor necrosis factor-alpha and Fas activate complementary Fas-associated death domain-dependent pathways that enhance apoptosis induced by gamma-irradiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROSTATIC-CARCINOMA; NF-KAPPA-B; JURKAT T-LYMPHOCYTES; INDUCED CELL-DEATH; MEDIATED APOPTOSIS; TNF-ALPHA; FAS/APO-1-MEDIATED APOPTOSIS; LAMIN-A; LNCAP; PROTEASE	Activation of either tumor necrosis factor receptor I or Fas induces a low level of programmed cell death in LNCaP human prostate cancer cells. We have shown that LNCaP cells are entirely resistant to gamma-radiation-induced apoptosis, but can be sensitized to irradiation by TNF-alpha. Fas activation also sensitized LNCaP cells to irradiation, causing nearly 40% cell death 72 h after irradiation. Caspase-8 was cleaved and activated after exposure to tumor necrosis factor (TNF)-alpha. However, after exposure to anti-Fas antibody caspase-8 cleavage occurred only between the 26-kDa N-terminal prodomain and the 28-kDa C-terminal region that contains the protease components. Although anti-Fas antibody plus irradiation induced apoptosis that could be blocked by the pancaspase inhibitor zVAD, there was no measurable caspase-8 activity after exposure to anti-Fas antibody. The effector caspases-6 and -7, and to a lesser extent caspase-3, were activated by TNF-alpha, but not by anti-Fas antibody. Anti-Fas antibody, like TNF-or also activated serine proteases that contributed to cell death. Exposure of LNCaP cells simultaneously to TNF-alpha and anti-Fas antibody CH-11 resulted in marked enhancement of apoptosis that occurred very rapidly and was still further augmented by irradiation. Rapid apoptosis that ensued from combined treatment with TNF-alpha, anti-Fas antibody, and irradiation was completely blocked either by zVAD or expression of dominant negative Fas-associated death domain. Our data shows that there are qualitative differences in caspase activation resulting from either TNF receptor 1 or Fas, Simultaneous activation of these receptors was synergistic and caused rapid epithelial cell apoptosis mediated by the caspase cascade.	Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20007 USA	Georgetown University	Gelmann, EP (corresponding author), Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20007 USA.				NCI NIH HHS [CA79912] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079912] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BERCHEM GJ, 1995, CANCER RES, V55, P735; Boix J, 1998, EXP CELL RES, V238, P422, DOI 10.1006/excr.1997.3852; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bowen C, 1999, CELL DEATH DIFFER, V6, P394, DOI 10.1038/sj.cdd.4400502; Chase W., 1997, GEN STAT; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; Deweese TL, 1998, J UROLOGY, V159, P591, DOI 10.1016/S0022-5347(01)63990-9; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; Grimm S, 1996, P NATL ACAD SCI USA, V93, P10923, DOI 10.1073/pnas.93.20.10923; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang Y, 1999, ONCOGENE, V18, P3431, DOI 10.1038/sj.onc.1202685; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jones RA, 1998, HEPATOLOGY, V27, P1632, DOI 10.1002/hep.510270624; Kimura K, 1999, CANCER RES, V59, P1606; Kobayashi T, 1999, ARTHRITIS RHEUM, V42, P519, DOI 10.1002/1529-0131(199904)42:3<519::AID-ANR17>3.0.CO;2-Q; Kokontis JM, 1998, MOL ENDOCRINOL, V12, P941, DOI 10.1210/me.12.7.941; Krammer P H, 1999, Adv Immunol, V71, P163; KWO P, 1995, AM J PHYSIOL-GASTR L, V268, pG613, DOI 10.1152/ajpgi.1995.268.4.G613; LEITH JT, 1994, PROSTATE, V24, P119, DOI 10.1002/pros.2990240304; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LIM DJ, 1993, PROSTATE, V22, P109, DOI 10.1002/pros.2990220203; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Mizushima N, 1996, FEBS LETT, V395, P267, DOI 10.1016/0014-5793(96)01050-2; MONTGOMERY BT, 1992, PROSTATE, V21, P63, DOI 10.1002/pros.2990210107; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Pflug BR, 1999, PROSTATE, V40, P269, DOI 10.1002/(SICI)1097-0045(19990901)40:4<269::AID-PROS9>3.0.CO;2-6; Quirk SM, 1998, ENDOCRINOLOGY, V139, P4860, DOI 10.1210/en.139.12.4860; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rokhlin OW, 1997, CANCER RES, V57, P1758; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; SHERWOOD ER, 1990, J BIOL RESP MODIF, V9, P44; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; Spanaus KS, 1998, EUR J IMMUNOL, V28, P4398, DOI 10.1002/(SICI)1521-4141(199812)28:12<4398::AID-IMMU4398>3.0.CO;2-Y; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Wallach D, 1997, FEBS LETT, V410, P96, DOI 10.1016/S0014-5793(97)00553-X; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WEIS M, 1995, EXP CELL RES, V219, P699, DOI 10.1006/excr.1995.1281	52	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8610	8617		10.1074/jbc.275.12.8610	http://dx.doi.org/10.1074/jbc.275.12.8610			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722700	hybrid			2022-12-27	WOS:000086507700050
J	Kobayashi, Y; Kume, A; Li, M; Doyu, M; Hata, M; Ohtsuka, K; Sobue, G				Kobayashi, Y; Kume, A; Li, M; Doyu, M; Hata, M; Ohtsuka, K; Sobue, G			Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BULBAR MUSCULAR-ATROPHY; MACHADO-JOSEPH-DISEASE; SPINOCEREBELLAR ATAXIA TYPE-2; HEAT-SHOCK PROTEINS; CAG REPEAT; INTRANUCLEAR INCLUSIONS; GLUTAMINE REPEATS; HUMAN HOMOLOG; NEURODEGENERATIVE DISEASES; TRINUCLEOTIDE REPEAT	Spinal and bulbar muscular atrophy (SBMA) is one of a group of human inherited neurodegenerative diseases caused by polyglutamine expansion. We have previously demonstrated that the SBMA gene product, the androgen receptor protein, is toxic and aggregates when truncated. Heat shock proteins function as molecular chaperones, which recognize and renaturate misfolded protein (aggregate). We thus assessed the effect of a variety of chaperones in a cultured neuronal cell model of SBMA. Overexpression of chaperones reduces aggregate formation and suppresses apoptosis in a cultured neuronal cell model of SBMA to differing degrees depending on the chaperones and their combinations. Combination of Hsp70 and Hsp40 was the most effective among the chaperones in reducing aggregate formation and providing cellular protection, reflecting that Hsp70 and Hsp40 act together in chaperoning mutant and disabled proteins. Although Hdj2/Hsdj chaperone has been previously reported to suppress expanded polyglutamine tract-formed aggregate, Hsdj/Hdj2 showed little Effect in our system. These findings indicate that chaperones may be one of the key factors in the developing of CAG repeat disease and suggested that increasing expression level or enhancing the function of chaperones will provide an avenue for the treatment of CAG repeat disease.	Nagoya Univ, Sch Med, Dept Neurol, Showa Ku, Nagoya, Aichi 4668550, Japan; Aichi Canc Ctr, Res Inst, Expt Radiol Lab, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Nagoya University; Aichi Cancer Center	Sobue, G (corresponding author), Nagoya Univ, Sch Med, Dept Neurol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	sobueg@med.nagoya-u.ac.jp						Bruening W, 1999, J NEUROCHEM, V72, P693, DOI 10.1046/j.1471-4159.1999.0720693.x; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Burke JR, 1996, NAT MED, V2, P347, DOI 10.1038/nm0396-347; Chai YH, 1999, HUM MOL GENET, V8, P673, DOI 10.1093/hmg/8.4.673; CHELLAIAH A, 1993, BIOCHIM BIOPHYS ACTA, V1174, P111, DOI 10.1016/0167-4781(93)90103-K; CIECHANOVER A, 1997, CELL, V91, P249; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; David G, 1997, NAT GENET, V17, P65, DOI 10.1038/ng0997-65; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DOYU M, 1992, ANN NEUROL, V32, P707, DOI 10.1002/ana.410320517; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; GREGORI L, 1995, J BIOL CHEM, V270, P19702, DOI 10.1074/jbc.270.34.19702; HATTORI H, 1992, CELL STRUCT FUNCT, V17, P77, DOI 10.1247/csf.17.77; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; IGARASHI S, 1992, NEUROLOGY, V42, P2300, DOI 10.1212/WNL.42.12.2300; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Kahlem P, 1996, P NATL ACAD SCI USA, V93, P14580, DOI 10.1073/pnas.93.25.14580; Kalchman MA, 1997, NAT GENET, V16, P44, DOI 10.1038/ng0597-44; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Kobayashi Y, 1998, BIOCHEM BIOPH RES CO, V252, P145, DOI 10.1006/bbrc.1998.9624; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; LASPADA AR, 1992, NAT GENET, V2, P301, DOI 10.1038/ng1292-301; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; Li I, 1998, AM J PATHOL, V153, P695, DOI 10.1016/S0002-9440(10)65612-X; Li M, 1998, ANN NEUROL, V44, P249, DOI 10.1002/ana.410440216; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Lu Z, 1998, J BIOL CHEM, V273, P5970, DOI 10.1074/jbc.273.10.5970; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; Matilla A, 1997, NATURE, V389, P974, DOI 10.1038/40159; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; Merry DE, 1998, HUM MOL GENET, V7, P693, DOI 10.1093/hmg/7.4.693; Michels AA, 1997, J BIOL CHEM, V272, P33283, DOI 10.1074/jbc.272.52.33283; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Miyashita T, 1997, J BIOL CHEM, V272, P29238, DOI 10.1074/jbc.272.46.29238; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; OH S, 1993, BIOCHIM BIOPHYS ACTA, V1174, P114, DOI 10.1016/0167-4781(93)90104-L; OHTSUKA K, 1986, RADIAT RES, V108, P34, DOI 10.2307/3576967; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Paulson HL, 1997, ANN NEUROL, V41, P453, DOI 10.1002/ana.410410408; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; Sanpei K, 1996, NAT GENET, V14, P277, DOI 10.1038/ng1196-277; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; Waragai M, 1999, HUM MOL GENET, V8, P977, DOI 10.1093/hmg/8.6.977; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	59	265	278	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8772	8778		10.1074/jbc.275.12.8772	http://dx.doi.org/10.1074/jbc.275.12.8772			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722721	hybrid			2022-12-27	WOS:000086507700071
J	Rodionov, DG; Nordeng, TW; Kongsvik, TL; Bakke, O				Rodionov, DG; Nordeng, TW; Kongsvik, TL; Bakke, O			The cytoplasmic tail of CD1d contains two overlapping basolateral sorting signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL ACID-PHOSPHATASE; POLARIZED MDCK CELLS; LEUCINE-BASED MOTIF; CLASS-II MOLECULES; KILLER T-CELLS; STRUCTURAL REQUIREMENTS; RAPID INTERNALIZATION; ANTIGEN PRESENTATION; MEMBRANE-PROTEINS; INVARIANT CHAIN	CD1d is a member of the CD1 polypeptide family that represents a new arm of host defense against invading pathogens. In our previous work (Rodionov, D. G., Nordeng, T. W., Pedersen, K., Balk, S. P., and Bakke, O. (1999) J. Immunol. 162, 1488-1495) we have shown that CD1d contained a classic tyrosine-based internalization signal (YQGV) in its short cytoplasmic tail. CD1d is expressed in polarized epithelial cells, and we found that the cytoplasmic tail of CDld also contained information for basolateral sorting. Interestingly, a mutation of the critical tyrosine residue of the endosomal sorting signal did not result in the loss of basolateral targeting of the mutant CDld, To search for a basolateral sorting signal we have constructed a full set of alanine mutants, but no single alanine substitution inactivated the signal. However, deletions or mutations of either the C-terminal valine/leucine pair or the critical tyrosine residue from the internalization signal and either residue from the C-terminal valine/leucine pair inactivated basolateral sorting. Our data thus suggest that the cytoplasmic tail contains two overlapping basolateral signals, one tyrosine- and the other leucine-based, each being sufficient to direct CDld to the basolateral membrane of polarized Madin-Darby canine kidney cells.	Univ Oslo, Dept Biol, MCB, Div Mol Cell Biol, N-0316 Oslo, Norway	University of Oslo	Bakke, O (corresponding author), Univ Oslo, Dept Biol, MCB, Div Mol Cell Biol, POB 1055 Blindern, N-0316 Oslo, Norway.			Bakke, Oddmund/0000-0003-4843-7626				Behar SM, 1999, J IMMUNOL, V162, P161; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Brossay L, 1998, J EXP MED, V188, P1521, DOI 10.1084/jem.188.8.1521; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; Eberl G, 1999, J IMMUNOL, V162, P6410; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Hofmann MW, 1999, J BIOL CHEM, V274, P36153, DOI 10.1074/jbc.274.51.36153; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Jackman RM, 1999, CRIT REV IMMUNOL, V19, P49; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; Nordeng TW, 1998, CURR TOP MICROBIOL, V232, P179; Odorizzi G, 1997, J CELL BIOL, V137, P1255, DOI 10.1083/jcb.137.6.1255; Ohno H, 1999, FEBS LETT, V449, P215, DOI 10.1016/S0014-5793(99)00432-9; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; OKAMOTO CT, 1994, J BIOL CHEM, V269, P15676; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; Porcelli SA, 1997, CURR BIOL, V7, pR508, DOI 10.1016/S0960-9822(06)00250-8; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Rodionov DG, 1999, J IMMUNOL, V162, P1488; Rodionov DG, 1998, J BIOL CHEM, V273, P6005, DOI 10.1074/jbc.273.11.6005; Salamero J, 1996, J BIOL CHEM, V271, P30318, DOI 10.1074/jbc.271.48.30318; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; Simmen T, 1999, MOL CELL BIOL, V19, P3136; Simonsen A, 1997, J CELL SCI, V110, P597; Simonsen A, 1998, EUR J CELL BIOL, V76, P25, DOI 10.1016/S0171-9335(98)80014-9; Singh N, 1999, J IMMUNOL, V163, P2373; Spada FM, 1998, J EXP MED, V188, P1529, DOI 10.1084/jem.188.8.1529; Sugita M, 1998, CLIN IMMUNOL IMMUNOP, V87, P8, DOI 10.1006/clin.1997.4500; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WONG SH, 1993, J BIOL CHEM, V268, P22853	43	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8279	8282		10.1074/jbc.275.12.8279	http://dx.doi.org/10.1074/jbc.275.12.8279			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722655	hybrid			2022-12-27	WOS:000086507700005
J	Chen, OS; Kaplan, J				Chen, OS; Kaplan, J			CCC1 suppresses mitochondrial damage in the yeast model of Friedreich's ataxia by limiting mitochondrial iron accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; FRATAXIN; TRANSPORTER; DEFICIENCY; HOMOLOG; GENE	Deletion of YFH1 in Saccharomyces cerevisiae leads to a loss of respiratory competence due to excessive miteochondrial iron accumulation. A suppressor screen identified a gene, CCC1, that maintained respiratory function in a Delta yfh1 yeast strain regardless of extracellular iron concentration. CCC1 expression prevented excessive mitochondrial iron accumulation by limiting mitochondrial iron uptake rather than by increasing mitochondrial iron egress, Expression of CCC1 did not result in sequestration of iron in membranous compartments or cellular iron export. CCC1 expression in wild type cells resulted in increased expression of the high affinity iron transport system, composed of FET3 and FTR1, suggesting that intracellular iron is not sensed by the iron-dependent transcription factor Aft1p. Introduction of AFT1(up), a constitutive allele of the iron transcription factor, AFT1, that also leads to increased high affinity iron transport did not prevent Delta yfh1 cells from becoming respiratory-incompetent, Although the mechanism by which CCC1 expression affects cytosolic iron is not known, the data suggest that excessive mitochondrial iron accumulation only occurs when cytosolic free iron levels are high.	Univ Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Kaplan, J (corresponding author), Univ Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA.				NIDDK NIH HHS [DK 52380] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052380] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; Davis-Kaplan SR, 1998, P NATL ACAD SCI USA, V95, P13641, DOI 10.1073/pnas.95.23.13641; Delatycki MB, 1999, ANN NEUROL, V45, P673, DOI 10.1002/1531-8249(199905)45:5<673::AID-ANA20>3.3.CO;2-H; Foury F, 1999, FEBS LETT, V456, P281, DOI 10.1016/S0014-5793(99)00961-8; FU DD, 1994, YEAST, V10, P515, DOI 10.1002/yea.320100411; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Korshunova YO, 1999, PLANT MOL BIOL, V40, P37, DOI 10.1023/A:1026438615520; Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345; LAMARCHE JB, 1980, CAN J NEUROL SCI, V7, P389, DOI 10.1017/S0317167100022927; Lapinskas PJ, 1996, MOL MICROBIOL, V21, P519, DOI 10.1111/j.1365-2958.1996.tb02561.x; LESUISSE E, 1991, BIOCHEM J, V280, P545, DOI 10.1042/bj2800545; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Sambrook J., 2002, MOL CLONING LAB MANU; SHERMAN F, 1989, METHODS YEAST GENETI; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; Wilson RB, 1997, NAT GENET, V16, P352, DOI 10.1038/ng0897-352; Wong A, 1999, HUM MOL GENET, V8, P425, DOI 10.1093/hmg/8.3.425	20	65	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7626	7632		10.1074/jbc.275.11.7626	http://dx.doi.org/10.1074/jbc.275.11.7626			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713071	hybrid			2022-12-27	WOS:000085913300031
J	Zhou, BP; Hu, MCT; Miller, SA; Yu, ZM; Xia, WY; Lin, SY; Hung, MC				Zhou, BP; Hu, MCT; Miller, SA; Yu, ZM; Xia, WY; Lin, SY; Hung, MC			HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappa B pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; OVARIAN-CANCER; KINASE; EXPRESSION; PROTOONCOGENE; ACTIVATION; RESISTANCE; ONCOGENE; RECEPTOR; GROWTH	Overexpression of HER-2/neu correlates with poor survival of breast and ovarian cancer patients and induces resistance to tumor necrosis factor (TNF), which causes cancer cells to escape from host immune defenses. The mechanism of HER-2/neu-induced TNF resistance is unknown. Here we report that HER-2/neu activates Akt and NF-KB without extracellular stimulation. Blocking of the Akt pathway by a dominant-negative Akt sensitizes the HER-2/neu-overexpressing cells to TNF-induced apoptosis and inhibites I kappa B kinases, I kappa B phosphorylation, and NF-KB activation. Our results suggested that HER-2/neu constitutively activates the Akt/NF-kappa B anti-apoptotic cascade to confer resistance to TNF on cancer cells and reduce host defenses against neoplasia.	Univ Texas, MD Anderson Canc Ctr, Breast Canc Basic Res Program, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Breast Canc Basic Res Program, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NATIONAL CANCER INSTITUTE [P30CA016672, R01CA077858, R01CA058880] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA58880, R01-CA77858, CA 16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEUAUD C, 1999, P NATL ACAD SCI USA, V96, P429; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HUDZIAK RM, 1988, P NATL ACAD SCI USA, V85, P5102, DOI 10.1073/pnas.85.14.5102; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; LICHTENSTEIN A, 1990, CANCER RES, V50, P7364; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Ozes ON, 1999, NATURE, V401, P82; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; PESO LD, 1997, SCIENCE, V278, P687; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; RUSSELL KS, 1992, CANCER RES, V52, P6624; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Tagliabue E, 1999, INT J BIOL MARKER, V14, P16, DOI 10.1177/172460089901400104; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; WANXG CY, 1996, SCIENCE, V274, P784; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4	29	333	351	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8027	8031		10.1074/jbc.275.11.8027	http://dx.doi.org/10.1074/jbc.275.11.8027			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713122	hybrid			2022-12-27	WOS:000085913300082
J	Bergo, MO; Leung, GK; Ambroziak, P; Otto, JC; Casey, PJ; Young, SG				Bergo, MO; Leung, GK; Ambroziak, P; Otto, JC; Casey, PJ; Young, SG			Targeted inactivation of the isoprenylcysteine carboxyl methyltransferase gene causes mislocalization of K-Ras in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; A-FACTOR; STE14 GENE; PROTEIN; METHYLATION; SEQUENCE; CAAX; MICE; ESTERIFICATION; TRAFFICKING	After isoprenylation and endoproteolytic processing, the Ras proteins are methylated at the carboxyl-terminal isoprenylcysteine, The importance of isoprenylation for targeting of Ras proteins to the plasma membrane is well established, but the importance of carboxyl methylation, which is carried out by isoprenylcysteine carboxyl methyltransferase (Icmt), is less certain. We used gene targeting to produce homozygous Icmt knockout embryonic stem cells (Icmt-/-). Lysates from Icmt-/-cells lacked the ability to methylate farnesyl-K-Ras4B or small-molecule Icmt substrates such as N-acetyl-S-geranylgeranyl-L-cysteine. To assess the impact of absent Icmt activity on the localization of K-Ras within cells, wild-type and Icmt-/- cells were transfected with a green fluorescent protein (GFP)-K-Ras fusion construct. As expected, virtually all of the GFP-K-Ras fusion in wild-type cells was localized along the plasma membrane. In contrast, a large fraction of the fusion in Icmt-/- cells was trapped within the cytoplasm, and fluorescence at the plasma membrane was reduced, Also, cell fractionation/Western blot studies revealed that a smaller fraction of the K-Ras in Icmt-/- cells was associated with the membranes. We conclude that carboxyl methylation of the isoprenylcysteine is important for proper K-Ras localization in mammalian cells.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Duke University	Bergo, MO (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.	mbergo@gladstone.ucsf.edu		Casey, Patrick/0000-0002-7366-9309; Young, Stephen/0000-0001-7270-3176	NHLBI NIH HHS [HL41633] Funding Source: Medline; NIA NIH HHS [AG15451] Funding Source: Medline; NIGMS NIH HHS [GM46372] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015451] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; Clarke S, 1993, CURR OPIN CELL BIOL, V5, P977, DOI 10.1016/0955-0674(93)90080-A; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; Desrosiers RR, 1999, BIOCHEM BIOPH RES CO, V261, P790, DOI 10.1006/bbrc.1999.0936; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; FUJIYAMA A, 1991, J BIOL CHEM, V266, P17926; GHOMASHCHI F, 1995, BIOCHEMISTRY-US, V34, P11910, DOI 10.1021/bi00037a032; Gibbs JB, 1997, CURR OPIN CHEM BIOL, V1, P197, DOI 10.1016/S1367-5931(97)80010-5; Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; Kim E, 1997, P NATL ACAD SCI USA, V94, P6132, DOI 10.1073/pnas.94.12.6132; Kim E, 1999, J BIOL CHEM, V274, P8383, DOI 10.1074/jbc.274.13.8383; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; Leventis R, 1998, BIOCHEMISTRY-US, V37, P7640, DOI 10.1021/bi973077h; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Otto JC, 1999, J BIOL CHEM, V274, P8379, DOI 10.1074/jbc.274.13.8379; PEREZSALA D, 1992, BIOCHEM J, V284, P835, DOI 10.1042/bj2840835; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; Romano JD, 1998, MOL BIOL CELL, V9, P2231, DOI 10.1091/mbc.9.8.2231; SAPPERSTEIN S, 1994, MOL CELL BIOL, V14, P1438, DOI 10.1128/MCB.14.2.1438; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; SMITHIES O, 1993, TRENDS GENET, V9, P112, DOI 10.1016/0168-9525(93)90204-U; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; TAMANOI F, 1993, TRENDS BIOCHEM SCI, V18, P349, DOI 10.1016/0968-0004(93)90072-U; TAN EW, 1991, J BIOL CHEM, V266, P10719; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; THOMAS KR, 1992, MOL CELL BIOL, V12, P2919, DOI 10.1128/MCB.12.7.2919; VOLKER C, 1991, FEBS LETT, V295, P189, DOI 10.1016/0014-5793(91)81415-5; VOLKER C, 1991, J BIOL CHEM, V266, P21515; YOUNG SG, 2000, IN PRESS ENZYMES LIP; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	40	132	138	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17605	17610		10.1074/jbc.C000079200	http://dx.doi.org/10.1074/jbc.C000079200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10747846	hybrid			2022-12-27	WOS:000087485000057
J	Oelkers, P; Tinkelenberg, A; Erdeniz, N; Cromley, D; Billheimer, JT; Sturley, SL				Oelkers, P; Tinkelenberg, A; Erdeniz, N; Cromley, D; Billheimer, JT; Sturley, SL			A lecithin cholesterol acyltransferase-like gene mediates diacylglycerol esterification in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COENZYME-A; TRIACYLGLYCEROL SYNTHESIS; SACCHAROMYCES-CEREVISIAE; IDENTIFICATION; TRANSFORMATION; METABOLISM; MICROSOMES; SECRETION; ENZYME; CELLS	The terminal step in triglyceride biosynthesis is the esterification of diacylglycerol. To study this reaction in the model eukaryote, Saccharomyces cerevisiae, we investigated five candidate genes with sequence conservation to mammalian acyltransferases. Four of these genes are similar to the recently identified acyl-CoA diacylglycerol acyltransferase and, when deleted, resulted in little or no decrease in triglyceride synthesis as measured by incorporation of radiolabeled oleate or glycerol. By contrast, deletion of LRO1, a homolog of human lecithin cholesterol acyltransferase, resulted in a dramatic reduction in triglyceride synthesis, whereas overexpression of LRO1 yielded a significant increase in triglyceride production. In vitro microsomal assays determined that Lro1 mediated the esterification of diacylglycerol using phosphatidylcholine as the acyl donor. The residual triglyceride biosynthesis that persists in the LRO1 deletion strain is mainly acyl-CoA-dependent and mediated by a gene that is structurally distinct from the previously identified mammalian diacylglycerol acyltransferase. These mechanisms may also exist in mammalian cells.	Columbia Univ Coll Phys & Surg, Inst Human Nutr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pediat Physiol & Cellular Biophys, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA; DuPont Pharmaceut Co, Expt Stn, Wilmington, DE 19880 USA	Columbia University; Columbia University; Columbia University; DuPont	Sturley, SL (corresponding author), Columbia Univ Coll Phys & Surg, Inst Human Nutr, 650 W 168th St, New York, NY 10032 USA.	sls37@columbia.edu		Oelkers, Peter/0000-0002-2421-472X	NHLBI NIH HHS [HL07343] Funding Source: Medline; NIDDK NIH HHS [DK07715] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accad MF, 1998, CIRCULATION, V98, P1; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BILLHEIMER JT, 1990, BIOCHIM BIOPHYS ACTA, V1046, P136, DOI 10.1016/0005-2760(90)90180-6; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; COLEMAN R, 1976, J BIOL CHEM, V251, P4537; CONVERSE CA, 1992, LIPROPROTEIN ANAL, P234; Cross FR, 1997, YEAST, V13, P647, DOI 10.1002/(SICI)1097-0061(19970615)13:7<647::AID-YEA115>3.0.CO;2-#; Daum G, 1999, YEAST, V15, P601, DOI 10.1002/(SICI)1097-0061(199905)15:7<601::AID-YEA390>3.0.CO;2-N; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Erdeniz N, 1997, GENOME RES, V7, P1174, DOI 10.1101/gr.7.12.1174; Gotto AM, 1998, AM J CARDIOL, V82, p22Q; GRIGOR MR, 1982, BIOCHIM BIOPHYS ACTA, V712, P464, DOI 10.1016/0005-2760(82)90273-9; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KENNEDY EP, 1961, FED PROC, V20, P934; KRAUSS RM, 1998, AM J MED S, V105, P58, DOI DOI 10.1016/S0002-9343(98)00213-7; LEHNER R, 1993, J BIOL CHEM, V268, P8781; Liang J, 1999, CIRCULATION, V100, P686; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCLEAN J, 1986, NUCLEIC ACIDS RES, V14, P9397, DOI 10.1093/nar/14.23.9397; Oelkers P, 1998, J BIOL CHEM, V273, P26765, DOI 10.1074/jbc.273.41.26765; OWEN M, 1997, BIOCH SOC T S, V25, P21; Owen MR, 1997, BIOCHEM J, V323, P17, DOI 10.1042/bj3230017; Peelman F, 1998, PROTEIN SCI, V7, P587, DOI 10.1002/pro.5560070307; Peelman F, 1999, J LIPID RES, V40, P59; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; RUSTAN AC, 1988, J LIPID RES, V29, P1417; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; Sturley SL, 1997, CURR OPIN LIPIDOL, V8, P167, DOI 10.1097/00041433-199706000-00007; Subramanian VS, 1999, BBA-MOL CELL BIOL L, V1439, P95, DOI 10.1016/S1388-1981(99)00072-4; Taskinen MR, 1997, DIABETES METAB REV, V13, P93, DOI 10.1002/(SICI)1099-0895(199706)13:2&lt;93::AID-DMR187&gt;3.0.CO;2-6; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353; YOKOYAMA S, 1977, J BIOCHEM-TOKYO, V82, P719, DOI 10.1093/oxfordjournals.jbchem.a131748; Yu CJ, 1996, J BIOL CHEM, V271, P24157, DOI 10.1074/jbc.271.39.24157; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	36	194	212	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15609	15612		10.1074/jbc.C000144200	http://dx.doi.org/10.1074/jbc.C000144200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10747858	hybrid			2022-12-27	WOS:000087291400003
J	Evans, TC; Martin, D; Kolly, R; Panne, D; Sun, L; Ghosh, I; Chen, LX; Benner, J; Liu, XQ; Xu, MQ				Evans, TC; Martin, D; Kolly, R; Panne, D; Sun, L; Ghosh, I; Chen, LX; Benner, J; Liu, XQ; Xu, MQ			Protein trans-splicing and cyclization by a naturally split intein from the dnaE gene of Synechocystis species PCC6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEAVAGE; LIGATION; ELEMENT	A naturally occurring split intein from the dnaE gene of Synechocystis sp. PCC6803 (Ssp DnaE intein) has been shown to mediate efficient in vivo and in vitro transsplicing in a foreign protein context. A cis-splicing Ssp DnaE intein construct displayed splicing activity similar to the trans-splicing form, which suggests that the Nand C-terminal intein fragments have a high affinity interaction. An in vitro trans-splicing system was developed that used a bacterially expressed N-terminal fragment of the Ssp DnaE intein and either a bacterially expressed or chemically synthesized intein C-terminal fragment. Unlike artificially split inteins, the Ssp DnaE intein fragments could be reconstituted in vitro under native conditions to mediate splicing as well as peptide bond cleavage. This property allowed the development of an on-column trans-splicing system that permitted the facile separation of reactants and products. Furthermore, the trans-splicing activity of the Ssp DnaE intein was successfully applied to the cyclization of proteins in vivo, Also, the isolation of the unspliced precursor on chitin resin allowed the cyclization reaction to proceed in vitro. The Ssp DnaE intein thus represents a potentially important protein for in vivo and in vitro protein manipulation.	New England Biolabs Inc, Beverly, MA 01915 USA; Univ Basel, Biozentrum, CH-4056 Basel, Switzerland; Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada	University of Basel; Dalhousie University	Xu, MQ (corresponding author), New England Biolabs Inc, 32 Tozer Rd, Beverly, MA 01915 USA.		Panne, Daniel/I-8368-2017; Wood, David W/B-2992-2012	Panne, Daniel/0000-0001-9158-5507; 				Camarero JA, 1999, J AM CHEM SOC, V121, P5597, DOI 10.1021/ja990929n; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Chong SR, 1998, NUCLEIC ACIDS RES, V26, P5109, DOI 10.1093/nar/26.22.5109; Chong SR, 1996, J BIOL CHEM, V271, P22159, DOI 10.1074/jbc.271.36.22159; Chong SR, 1997, GENE, V192, P271, DOI 10.1016/S0378-1119(97)00105-4; Cotton GJ, 1999, J AM CHEM SOC, V121, P1100, DOI 10.1021/ja983804b; DUPLAY P, 1984, J BIOL CHEM, V259, P606; Evans TC, 1999, J BIOL CHEM, V274, P3923, DOI 10.1074/jbc.274.7.3923; Evans TC, 1999, J BIOL CHEM, V274, P18359, DOI 10.1074/jbc.274.26.18359; Evans TC, 1998, PROTEIN SCI, V7, P2256, DOI 10.1002/pro.5560071103; Iwai H, 1999, FEBS LETT, V459, P166, DOI 10.1016/S0014-5793(99)01220-X; Mathys S, 1999, GENE, V231, P1, DOI 10.1016/S0378-1119(99)00103-1; Mills KV, 1998, P NATL ACAD SCI USA, V95, P3543, DOI 10.1073/pnas.95.7.3543; Muir TW, 1998, P NATL ACAD SCI USA, V95, P6705, DOI 10.1073/pnas.95.12.6705; Paulus H, 1998, CHEM SOC REV, V27, P375, DOI 10.1039/a827375z; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; Perler FB, 1998, CELL, V92, P1, DOI 10.1016/S0092-8674(00)80892-2; Scott CP, 1999, P NATL ACAD SCI USA, V96, P13638, DOI 10.1073/pnas.96.24.13638; Severinov K, 1998, J BIOL CHEM, V273, P16205, DOI 10.1074/jbc.273.26.16205; Shao Y, 1997, CHEM BIOL, V4, P187, DOI 10.1016/S1074-5521(97)90287-8; Southworth MW, 1998, EMBO J, V17, P918, DOI 10.1093/emboj/17.4.918; Southworth MW, 1999, BIOTECHNIQUES, V27, P110, DOI 10.2144/99271st04; WATANABE T, 1994, J BACTERIOL, V176, P4465, DOI 10.1128/JB.176.15.4465-4472.1994; Wood DW, 1999, NAT BIOTECHNOL, V17, P889, DOI 10.1038/12879; Wu H, 1998, BBA-PROTEIN STRUCT M, V1387, P422, DOI 10.1016/S0167-4838(98)00157-5; Wu H, 1998, P NATL ACAD SCI USA, V95, P9226, DOI 10.1073/pnas.95.16.9226; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x; Xu R, 1999, P NATL ACAD SCI USA, V96, P388, DOI 10.1073/pnas.96.2.388; Yamazaki T, 1998, J AM CHEM SOC, V120, P5591, DOI 10.1021/ja980776o	29	154	188	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9091	9094		10.1074/jbc.275.13.9091	http://dx.doi.org/10.1074/jbc.275.13.9091			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734038	hybrid			2022-12-27	WOS:000086206500002
J	Lostao, A; El Harrous, M; Daoudi, F; Romero, A; Parody-Morreale, A; Sancho, J				Lostao, A; El Harrous, M; Daoudi, F; Romero, A; Parody-Morreale, A; Sancho, J			Dissecting the energetics of the apoflavodoxin-FMN complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; GILL TITRATION CALORIMETER; OXIDIZED FLAVODOXIN; HEAT-CAPACITY; BINDING; RESOLUTION; REFINEMENT; PROTEINS; THERMODYNAMICS; ANABAENA-7120	Many flavoproteins are non-covalent complexes between FMN and an apoprotein. To understand better the stability of flavoproteins, we have studied the energetics of the complex between FMN and the apoflavodoxin from Anabaena PCC 7119 by a combination of site-directed mutagenesis, titration calorimetry, equilibrium binding constant determinations, and x-ray crystallography, Comparison of the strength of the wild type and mutant apoflavodoxin-FMN complexes and that of the complexes between wild type apoflavodoxin and shortened FMN analogues (riboflavin and lumiflavin) allows the dissection of the binding energy into contributions associated with the different parts of the FMN molecule. The estimated contribution of the phosphate is greatest, at 7 kcal mol(-1); that of the isoalloxazine is of around 5-6 kcal mol(-1) (mainly due to interaction with Trp-57 and Tyr-94 in the apoprotein) and the ribityl contributes least: around 1 kcal mol(-1). The stabilization of the complex is both enthalpic and entropic although the enthalpy contribution is dominant. Both the phosphate and the isoalloxazine significantly contribute to the enthalpy of binding. The ionic strength does not have a large effect on the stability of the FMN complex because, although it weakens the phosphate interactions, it strengthens the isoalloxazine-protein hydrophobic interactions. Phosphate up to 100 mM does not affect the strength of the riboflavin complex, which suggests the isoalloxazine and phosphate binding sites may be independent in terms of binding energy. Interestingly, we find crystallographic evidence of flexibility in one of the loops (57-62) involved in isoalloxazine binding.	Univ Zaragoza, Fac Ciencias, Dept Bioquim & Biol Mol & Celular, E-50009 Zaragoza, Spain; Univ Granada, Fac Ciencias, Dept Quim Fis, E-18071 Granada, Spain; Univ Granada, Fac Ciencias, Inst Biotecnol, E-18071 Granada, Spain; CSIC, Ctr Invest Biol, E-28006 Madrid, Spain	University of Zaragoza; University of Granada; University of Granada; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Sancho, J (corresponding author), Univ Zaragoza, Fac Ciencias, Dept Bioquim & Biol Mol & Celular, E-50009 Zaragoza, Spain.	jsancho@posta.unizar.es	Romero, Antonio/K-5754-2014; Sancho, javier/AAA-1225-2019; Lostao, Anabel/P-8693-2015	Romero, Antonio/0000-0002-6990-6973; Sancho, javier/0000-0002-2879-9200; Lostao, Anabel/0000-0001-7460-5916				AMZEL LM, 1977, PROTEIN-STRUCT FUNCT, V28, P144; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Bevington P. R, 1969, DATA REDUCTION ERROR; BRUNGER AT, 1991, ANNU REV PHYS CHEM, V42, P197, DOI 10.1146/annurev.pc.42.100191.001213; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; BURKHART BM, 1995, ACTA CRYSTALLOGR D, V51, P318, DOI 10.1107/S0907444994011716; Chang FC, 1999, BIOCHEMISTRY-US, V38, P7168, DOI 10.1021/bi982203u; DAquino JA, 1996, PROTEINS, V25, P143, DOI 10.1002/(SICI)1097-0134(199606)25:2<143::AID-PROT1>3.0.CO;2-J; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Druhan LJ, 1998, BIOCHEMISTRY-US, V37, P9668, DOI 10.1021/bi980770b; EDMONDSON DE, 1971, BIOCHEMISTRY-US, V10, P124; ElHarrous M, 1997, ANAL BIOCHEM, V254, P96, DOI 10.1006/abio.1997.2386; ELHARROUS M, 1994, MEAS SCI TECHNOL, V5, P1071, DOI 10.1088/0957-0233/5/9/007; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FILLAT MF, 1991, BIOCHEM J, V280, P187, DOI 10.1042/bj2800187; GAST R, 1976, BIOCHIM BIOPHYS ACTA, V446, P463, DOI 10.1016/0005-2795(76)90012-X; Genzor CG, 1996, NAT STRUCT BIOL, V3, P329, DOI 10.1038/nsb0496-329; Genzor CG, 1996, PROTEIN SCI, V5, P1376, DOI 10.1002/pro.5560050716; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOMEZ J, 1995, PROTEINS, V22, P404, DOI 10.1002/prot.340220410; Guinto ER, 1996, BIOCHEMISTRY-US, V35, P8800, DOI 10.1021/bi9608828; Hilser VJ, 1996, PROTEINS, V26, P123, DOI 10.1002/(SICI)1097-0134(199610)26:2<123::AID-PROT2>3.0.CO;2-H; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lostao A, 1997, BIOCHEMISTRY-US, V36, P14334, DOI 10.1021/bi971384h; LUDWIG ML, 1992, CHEM BIOCH FLAVOENZY, V3, P427; Maldonado S, 1998, BIOCHEMISTRY-US, V37, P10589, DOI 10.1021/bi980368x; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Mayhew S. G., 1992, CHEM BIOCH FLAVOENZY, V3, P389; Mewies M, 1998, PROTEIN SCI, V7, P7, DOI 10.1002/pro.5560070102; Minton A.P., 1994, MODERN ANAL ULTRACEN, P81; Muller F., 2017, CHEM BIOCH FLAVOENZY, V3; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nedler JA, 1965, COMPUT J, V7, P308; NICHOLLS A, 1991, BIOPHYS J, V239, P423; Otwinowski Z, 1993, DENZO FILM PROCESSIN; Pueyo JJ, 1996, BIOCHEM J, V313, P855, DOI 10.1042/bj3130855; RAO ST, 1992, PROTEIN SCI, V1, P1413, DOI 10.1002/pro.5560011103; ROUSSEL A, 1989, TURBO FRODO SILICON; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SMITH WW, 1983, J MOL BIOL, V165, P737, DOI 10.1016/S0022-2836(83)80277-0; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Steensma E, 1998, J MOL BIOL, V282, P653, DOI 10.1006/jmbi.1998.2045; STOCKMAN BJ, 1994, BIOCHEMISTRY-US, V33, P15298, DOI 10.1021/bi00255a011; SWENSON RP, 1994, BIOCHEMISTRY-US, V33, P8505, DOI 10.1021/bi00194a015; Tamura A, 1997, J MOL BIOL, V273, P1048, DOI 10.1006/jmbi.1997.1368; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V	46	65	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9518	9526		10.1074/jbc.275.13.9518	http://dx.doi.org/10.1074/jbc.275.13.9518			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734100	Green Published, hybrid			2022-12-27	WOS:000086206500064
J	Lupi, R; Corda, D; Di Girolamo, M				Lupi, R; Corda, D; Di Girolamo, M			Endogenous ADP-ribosylation of the G protein beta subunit prevents the inhibition of type 1 adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PASTEURELLA-MULTOCIDA TOXIN; SKELETAL-MUSCLE; RIBOSYLTRANSFERASE ACTIVITY; HUMAN-ERYTHROCYTES; BINDING-PROTEINS; GAMMA-SUBUNITS; ALPHA-SUBUNIT; CHOLERA-TOXIN; BREFELDIN-A; MEMBRANE	Mono-ADP-ribosylation is a post-translational modification of cellular proteins that has been implicated in the regulation of signal transduction, muscle cell differentiation, protein trafficking, and secretion. In several cell systems we have observed that the major substrate of endogenous mono-ADP-ribosylation is a 36-kDa protein. This ADP-ribosylated protein was both recognized in Western blotting experiments and selectively immunoprecipitated by a G protein beta subunit-specific polyclonal antibody, indicating that this protein is the G: protein beta subunit. The ADP-ribosylation of the beta subunit was due to a plasma membrane-associated enzyme, was sensitive to treatment with hydroxylamine, and was inhibited by meta-iodobenzylguanidine, indicating that the involved enzyme is an arsnine-specific mono-ADP-ribosyltransferase, By mutational analysis, the target arginine was located in position 129. The ADP-ribosylated beta subunit was also deribosylated by a cytosolic hydrolase, This ADP-ribosylation/deribosylation cycle might be an in vivo modulator of the interaction of py with specific effecters. Indeed, we found that the ADP-ribosylated beta gamma subunit is unable to inhibit calmodulin-stimulated type 1 adenylyl cyclase in cell membranes and that the endogenous ADP-ribosylation of the beta subunit occurs in intact Chinese hamster ovary cells, where the NAD(+) pool was labeled with [H-3]adenine. These results show that the ADP-ribosylation of the beta gamma subunit could represent a novel cellular mechanism in the regulation of G protein mediated signal transduction.	Consorzio Mario Negri Sud, Ist Ric Farmacol Mario Negri, Dept Cell Biol & Oncol, I-66030 Santa Maria Imbaro, Chieti, Italy	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Di Girolamo, M (corresponding author), Consorzio Mario Negri Sud, Ist Ric Farmacol Mario Negri, Dept Cell Biol & Oncol, Via Nazionale, I-66030 Santa Maria Imbaro, Chieti, Italy.	corda@cmns.mnegri.it; mdg@cmns.mnegri.it	Corda, Daniela/K-6385-2016	Corda, Daniela/0000-0002-3614-751X				CANALES J, 1995, BBA-PROTEIN STRUCT M, V1246, P167, DOI 10.1016/0167-4838(94)00191-I; CHANG YC, 1986, BIOCHEM BIOPH RES CO, V139, P932, DOI 10.1016/S0006-291X(86)80267-4; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Chen YB, 1997, P NATL ACAD SCI USA, V94, P2711, DOI 10.1073/pnas.94.6.2711; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Danner S, 1996, P NATL ACAD SCI USA, V93, P10145, DOI 10.1073/pnas.93.19.10145; DEMATTEIS MA, 1994, P NATL ACAD SCI USA, V91, P1114, DOI 10.1073/pnas.91.3.1114; DIGIROLAMO M, 1995, P NATL ACAD SCI USA, V92, P7065, DOI 10.1073/pnas.92.15.7065; DIGIROLAMO M, 1992, J BIOL CHEM, V267, P17397; EHRETHILBERER S, 1992, FEBS LETT, V309, P394, DOI 10.1016/0014-5793(92)80814-W; FRIEDMAN PJ, 1992, EMBO J, V11, P63; GETTYS TW, 1994, ANAL BIOCHEM, V220, P82, DOI 10.1006/abio.1994.1302; GILL DM, 1978, P NATL ACAD SCI USA, V75, P3050, DOI 10.1073/pnas.75.7.3050; HAAG F, 1997, ADP RIBOSYLATION ANI; HILTZ H, 1984, P NATL ACAD SCI USA, V81, P3929; HUANG HY, 1993, BIOCHEM BIOPH RES CO, V197, P570, DOI 10.1006/bbrc.1993.2517; Iyengar R, 1997, SCIENCE, V275, P42, DOI 10.1126/science.275.5296.42; KATADA T, 1982, P NATL ACAD SCI-BIOL, V79, P3129, DOI 10.1073/pnas.79.10.3129; KochNolte F, 1997, ADV EXP MED BIOL, V419, P1; KOTS AY, 1992, FEBS LETT, V300, P9, DOI 10.1016/0014-5793(92)80153-8; LEE AC, 1994, J BIOL CHEM, V269, P30974; LOESBERG C, 1990, BIOCHIM BIOPHYS ACTA, V1037, P92, DOI 10.1016/0167-4838(90)90106-P; MIRONOV A, 1997, J CELL BIOL, V139, P1; MORRIS D, 1990, BIOCHEMISTRY-US, V29, P9079, DOI 10.1021/bi00490a027; MOSS J, 1977, J BIOL CHEM, V252, P2455; Moss J, 1997, ADV EXP MED BIOL, V419, P25; MOSS J, 1992, J BIOL CHEM, V267, P10481; MOSS J, 1985, P NATL ACAD SCI USA, V82, P5603, DOI 10.1073/pnas.82.17.5603; MURAKAMI T, 1992, BIOCHEMISTRY-US, V31, P2905, DOI 10.1021/bi00126a009; NORTHUP JK, 1980, P NATL ACAD SCI-BIOL, V77, P6516, DOI 10.1073/pnas.77.11.6516; Okazaki IJ, 1996, J BIOL CHEM, V271, P22052, DOI 10.1074/jbc.271.36.22052; OKAZAKI IJ, 1994, BIOCHEMISTRY-US, V33, P12828, DOI 10.1021/bi00209a014; PLAGEMANN PGW, 1990, BIOCHIM BIOPHYS ACTA, V1022, P103, DOI 10.1016/0005-2736(90)90405-D; QUIST EE, 1994, J MOL CELL CARDIOL, V26, P251, DOI 10.1006/jmcc.1994.1028; SAXTY BA, 1995, BIOCHEM J, V310, P931, DOI 10.1042/bj3100931; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SMETS LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P49, DOI 10.1016/0167-4889(90)90204-Q; SOMAN G, 1984, BIOCHEM BIOPH RES CO, V120, P973, DOI 10.1016/S0006-291X(84)80202-8; STADDON JM, 1991, J CELL BIOL, V115, P949, DOI 10.1083/jcb.115.4.949; STADDON JM, 1992, J BIOL CHEM, V267, P25239; STERNWEIS PC, 1990, RECEPTOR EFFECTOR CO, P1; TAKADA T, 1993, J BIOL CHEM, V268, P17837; Tanaka T, 1999, PROTEIN EXPRES PURIF, V15, P207, DOI 10.1006/prep.1998.1011; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANUMA S, 1987, J BIOCHEM-TOKYO, V101, P821, DOI 10.1093/jb/101.3.821; THOMAS TC, 1993, BIOCHEMISTRY-US, V32, P8628, DOI 10.1021/bi00084a034; TSUCHIYA M, 1994, J BIOL CHEM, V269, P27541; VANDEKERCKHOVE J, 1988, J BIOL CHEM, V263, P696; VANNESS BG, 1980, J BIOL CHEM, V255, P710; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WATKINS PA, 1987, BIOCHEM J, V248, P749, DOI 10.1042/bj2480749; WIELAND T, 1993, J BIOL CHEM, V268, P18111; WINSLOW JW, 1986, J BIOL CHEM, V261, P7571; Yan K, 1996, J BIOL CHEM, V271, P17597, DOI 10.1074/jbc.271.30.17597; ZANG S, 1996, J BIOL CHEM, V271, P20208; ZOLKIEWSKA A, 1994, MOL CELL BIOCHEM, V138, P107, DOI 10.1007/BF00928450; ZOLKIEWSKA A, 1995, J BIOL CHEM, V270, P9227, DOI 10.1074/jbc.270.16.9227; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352	58	46	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9418	9424		10.1074/jbc.275.13.9418	http://dx.doi.org/10.1074/jbc.275.13.9418			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734087	hybrid			2022-12-27	WOS:000086206500051
J	Seghers, V; Nakazaki, M; DeMayo, F; Aguilar-Bryan, L; Bryan, J				Seghers, V; Nakazaki, M; DeMayo, F; Aguilar-Bryan, L; Bryan, J			Sur1 knockout mice - A model for K-ATP channel-independent regulation of insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA; PANCREATIC BETA-CELLS; MOUSE B-CELLS; SULFONYLUREA RECEPTOR; EXTRACELLULAR CA2+; GLUCOSE; RAT; RELEASE; ISLETS; STIMULATION	Sur1 knockout mouse beta-cells lack K-ATP channels and show spontaneous Ca2+ action potentials equivalent to those seen in patients with persistent hyperinsulinemic hypoglycemia of infancy, but the mice are normoglycemic unless stressed. Sur1(-/-) islets lack first phase insulin secretion and exhibit an attenuated glucose-stimulated second phase secretion, Loss of the first phase leads to mild glucose intolerance, whereas reduced insulin output is consistent with observed neonatal hyperglycemia. Loss of K-ATP channels impairs the rate of return to a basal secretory level after a fall in glucose concentration. This leads to increased hypoglycemia upon fasting and contributes to a very early, transient neonatal hypoglycemia. Whereas persistent hyperinsulinemic hypoglycemia of infancy underscores the importance of the K-ATP-dependent ionic pathway in control of insulin release, the Sur1(-/-) animals provide a novel model for study of K-ATP-independent pathways that regulate insulin secretion.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Bryan, J (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Rm 108C,1 Baylor Plaza, Houston, TX 77030 USA.		DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336	NIDDK NIH HHS [DK 50750] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK050750, R01DK050750] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; Aguilar-Bryan L, 1998, METHOD ENZYMOL, V292, P732; Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; Aguilar-Bryan L, 1996, DIABETES REV, V4, P336; Aizawa T, 1998, TRENDS PHARMACOL SCI, V19, P496, DOI 10.1016/S0165-6147(98)01273-5; Atwater Illani, 1996, P78; Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; Babenko AP, 1999, FEBS LETT, V445, P131, DOI 10.1016/S0014-5793(99)00102-7; BERGLUND O, 1980, ACTA ENDOCRINOL-COP, V93, P54, DOI 10.1530/acta.0.0930054; BEST L, 1992, BIOCHEM PHARMACOL, V43, P2483, DOI 10.1016/0006-2952(92)90330-L; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; COOK DL, 1997, ELLENBERG RIFKINS DI, P49; Drain P, 1998, P NATL ACAD SCI USA, V95, P13953, DOI 10.1073/pnas.95.23.13953; Dunne MJ, 1997, NEW ENGL J MED, V336, P703, DOI 10.1056/NEJM199703063361005; Eliasson L, 1996, SCIENCE, V271, P813, DOI 10.1126/science.271.5250.813; Fournet JC, 1998, ANN ENDOCRINOL-PARIS, V59, P485; GEMBAL M, 1993, J CLIN INVEST, V91, P871, DOI 10.1172/JCI116308; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; John SA, 1998, J PHYSIOL-LONDON, V510, P333, DOI 10.1111/j.1469-7793.1998.333bk.x; KAISER N, 1990, DIABETOLOGIA, V33, P482, DOI 10.1007/BF00405110; KAKEI M, 1993, BRIT J PHARMACOL, V109, P1226, DOI 10.1111/j.1476-5381.1993.tb13753.x; Kane C, 1996, NAT MED, V2, P1344, DOI 10.1038/nm1296-1344; Komatsu M, 1997, Jpn J Physiol, V47 Suppl 1, pS22; KOMATSU M, 1992, ENDOCRINOLOGY, V130, P221, DOI 10.1210/en.130.1.221; KOMATSU M, 1995, P NATL ACAD SCI USA, V92, P10728, DOI 10.1073/pnas.92.23.10728; Komatsu M, 1997, DIABETES, V46, P1928, DOI 10.2337/diabetes.46.12.1928; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; LENZEN S, 1979, AM J PHYSIOL, V236, pE391, DOI 10.1152/ajpendo.1979.236.4.E391; MA YH, 1995, EUR J ENDOCRINOL, V132, P370, DOI 10.1530/eje.0.1320370; Mikhailov MV, 1998, FEBS LETT, V429, P390, DOI 10.1016/S0014-5793(98)00640-1; Miki T, 1997, P NATL ACAD SCI USA, V94, P11969, DOI 10.1073/pnas.94.22.11969; Miki T, 1998, P NATL ACAD SCI USA, V95, P10402, DOI 10.1073/pnas.95.18.10402; PANTEN U, 1988, N-S ARCH PHARMACOL, V338, P459; PORTE D, 1991, DIABETES, V40, P166, DOI 10.2337/diabetes.40.2.166; SATO Y, 1992, DIABETES, V41, P438, DOI 10.2337/diabetes.41.4.438; Straub SG, 1998, DIABETES, V47, P1053, DOI 10.2337/diabetes.47.7.1053; Straub SG, 1998, DIABETES, V47, P758, DOI 10.2337/diabetes.47.5.758; SUTTON R, 1986, TRANSPLANTATION, V42, P689, DOI 10.1097/00007890-198612000-00022; Thornton PS, 1998, J PEDIATR-US, V132, P9, DOI 10.1016/S0022-3476(98)70477-9; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Verkarre V, 1998, J CLIN INVEST, V102, P1286, DOI 10.1172/JCI4495; ZAWALICH WS, 1995, ENDOCRINOLOGY, V136, P4903, DOI 10.1210/en.136.11.4903; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	44	300	309	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9270	9277		10.1074/jbc.275.13.9270	http://dx.doi.org/10.1074/jbc.275.13.9270			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734066	hybrid			2022-12-27	WOS:000086206500030
J	Yokoi, M; Masutani, C; Maekawa, T; Sugasawa, K; Ohkuma, Y; Hanaoka, F				Yokoi, M; Masutani, C; Maekawa, T; Sugasawa, K; Ohkuma, Y; Hanaoka, F			The xeroderma pigmentosum group C protein complex XPC-HR23B plays an important role in the recruitment of transcription factor IIH to damaged DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; RNA-POLYMERASE-II; FACTOR TFIIH; ESCHERICHIA-COLI; HUMAN HOMOLOGS; YEAST; XPC; NUCLEASE; RAD23; PURIFICATION	The xeroderma pigmentosum group C protein complex XPC-HR23B was first isolated as a factor that complemented nucleotide excision repair defects of XP-C cell extracts in vitro. Recent studies have revealed that this protein complex plays an important role in the early steps of global genome nucleotide excision repair, especially in damage recognition, open complex formation, and repair protein complex formation. However, the precise function of XPC-HR23B in global genome repair is still unclear. Here we demonstrate that XPC-HR23B interacts with general transcription factor IIH (TFIIH) both in vivo and in vitro. This interaction is thought to be mediated through the specific affinity of XPC for the TFIIH subunits XPB and/or p62, which are essential for both basal transcription and nucleotide excision repair, Interestingly, association of TFIIH with DNA was observed in both wild-type and XP-A cell extracts but not in XP-C cell extracts, and XPC-HR23B could restore the association of TFIIH with DNA in XP-C cell extracts. Moreover, we found that XPC-HR23B was necessary for efficient association of TFIIH with damaged DNA in cell-free extracts. We conclude that the XPC-HR23B protein complex plays a crucial role in the recruitment of TFIIH to damaged DNA in global genome repair.	Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan; RIKEN, Cellular Physiol Lab, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan; Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan	Osaka University; RIKEN; Osaka University	Hanaoka, F (corresponding author), Osaka Univ, Inst Mol & Cellular Biol, 1-3 Yamada Oka, Suita, Osaka 5650871, Japan.		Masutani, Chikahide/I-6160-2014	Masutani, Chikahide/0000-0002-8600-8227				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BARDWELL AJ, 1994, MOL CELL BIOL, V14, P3569, DOI 10.1128/MCB.14.6.3569; BOOTSMA D, 1997, GENETIC BASIS HUMAN, pCH9; Boulikas T, 1996, ANTICANCER RES, V16, P693; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; Evans E, 1997, EMBO J, V16, P6559, DOI 10.1093/emboj/16.21.6559; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; Guzder SN, 1996, J BIOL CHEM, V271, P8903, DOI 10.1074/jbc.271.15.8903; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; GUZDER SN, 1995, J BIOL CHEM, V270, P8385, DOI 10.1074/jbc.270.15.8385; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P173, DOI 10.1016/0168-9525(93)90164-D; Hoffmann A, 1996, J BIOL CHEM, V271, P18194, DOI 10.1074/jbc.271.30.18194; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li RY, 1998, J MOL BIOL, V281, P211, DOI 10.1006/jmbi.1998.1949; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; Masutani C, 1997, MOL CELL BIOL, V17, P6915, DOI 10.1128/MCB.17.12.6915; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; Mu D, 1997, J BIOL CHEM, V272, P7570, DOI 10.1074/jbc.272.12.7570; Mu D, 1997, J BIOL CHEM, V272, P28971, DOI 10.1074/jbc.272.46.28971; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; Nocentini S, 1997, J BIOL CHEM, V272, P22991, DOI 10.1074/jbc.272.37.22991; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; Okamoto T, 1998, J BIOL CHEM, V273, P19866, DOI 10.1074/jbc.273.31.19866; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; Reardon JT, 1996, J BIOL CHEM, V271, P19451, DOI 10.1074/jbc.271.32.19451; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SHIVJI MKK, 1994, J BIOL CHEM, V269, P22749; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Sugasawa K, 1997, MOL CELL BIOL, V17, P6924, DOI 10.1128/MCB.17.12.6924; Sugasawa K, 1996, MOL CELL BIOL, V16, P4852; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; vanderSpek PJ, 1996, NUCLEIC ACIDS RES, V24, P2551, DOI 10.1093/nar/24.13.2551; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; Wakasugi M, 1999, J BIOL CHEM, V274, P18759, DOI 10.1074/jbc.274.26.18759; Wakasugi M, 1998, P NATL ACAD SCI USA, V95, P6669, DOI 10.1073/pnas.95.12.6669; Winkler GS, 1998, J BIOL CHEM, V273, P1092, DOI 10.1074/jbc.273.2.1092; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031	46	209	217	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9870	9875		10.1074/jbc.275.13.9870	http://dx.doi.org/10.1074/jbc.275.13.9870			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734143	hybrid			2022-12-27	WOS:000086206500107
J	Afroze, T; Husain, M				Afroze, T; Husain, M			c-Myb-binding sites mediate G(1)/S-associated repression of the plasma membrane Ca2+-ATPase-1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; CA2+ PUMP; CRYPTIC PROMOTER; GENE-EXPRESSION; CALCIUM-PUMP; TRANSCRIPTION FACTORS; FUNCTIONAL DOMAINS; MESSENGER-RNA; DNA-BINDING; NUCLEAR-RNA	We demonstrate that two Myb-binding sites of the mouse plasma membrane Ca2+-ATPase-1 (PMCA1) promoter are required for G(1)/S cell cycle stage-associated repression of PMCA1 promoter activity. Nuclear run-on experiments revealed G(1)/S-associated repression of PMCA1 transcription. Ribonuclease protection assays revealed two transcription initiation sites between two Myb-binding sites in the PMCA1 promoter. Gel shift assays showed that c-Myb can bind to wild-type but not point mutated Myb binding sequences of the PMCA1 promoter. Transient transfection assays using cell cycle-synchronized vascular smooth muscle cells (VSMC) and PMCA1 promoter-luciferase constructs showed a a-fold decrease in reporter activity at G(1)/S as compared with G(0). Overexpression of wild-type c-Myb severely repressed PMCA1 promoter activity at both G(0) and G(1)/S while co-transfection of a dominant negative c-Myb, or a construct encoding an anti-c-Myb neutralizing antibody, completely abolished the repression seen at G(1)/S. Single nucleotide substitutions in the first, second, or both Myb-binding sites alleviated the G(1)/S-associated repression of PMCA1 promoter activity in transformed rat VSMC and primary mouse VSMC cultures. We conclude that c-Myb mediates G(1)/S-associated transcriptional repression of the PMCA1 Ca2+ pump in rodent VSMC by direct binding to the PMCA1 promoter.	Toronto Gen Hosp, Cardiovasc Res Ctr, Toronto, ON M5G 1L5, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Husain, M (corresponding author), Toronto Gen Hosp, EN 12-221,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.	mansoor.husain@utoronto.ca		Husain, Mansoor/0000-0002-3740-6739				Albanesi C, 1996, DEVELOPMENT, V122, P1291; ALSHAWI R, 1991, MOL CELL BIOL, V11, P4207, DOI 10.1128/MCB.11.8.4207; Bein K, 1998, J BIOL CHEM, V273, P21423, DOI 10.1074/jbc.273.33.21423; Bein K, 1997, J CELL PHYSIOL, V173, P319, DOI 10.1002/(SICI)1097-4652(199712)173:3<319::AID-JCP3>3.0.CO;2-Q; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BRANDT P, 1992, J BIOL CHEM, V267, P4376; Brandt TL, 1997, J BIOL CHEM, V272, P6278, DOI 10.1074/jbc.272.10.6278; BROWN KE, 1992, J BIOL CHEM, V267, P4625; CARAFOLI E, 1994, J NEUROBIOL, V25, P312, DOI 10.1002/neu.480250311; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; CUDDIHY AE, 1993, MOL CELL BIOL, V13, P3505, DOI 10.1128/MCB.13.6.3505; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DU YS, 1995, ARCH BIOCHEM BIOPHYS, V316, P302, DOI 10.1006/abbi.1995.1041; Elferink CJ, 1996, BIOTECHNIQUES, V20, P470; Firulli AB, 1997, TRENDS GENET, V13, P364, DOI 10.1016/S0168-9525(97)01171-2; FOUREL G, 1992, MOL CELL BIOL, V12, P5336, DOI 10.1128/MCB.12.12.5336; FURUKAWA KI, 1988, J BIOL CHEM, V263, P8058; Ganter B, 1997, ONCOGENE, V15, P193, DOI 10.1038/sj.onc.1201173; Guerini D, 1998, ACTA PHYSIOL SCAND, V163, P265; GUERRA J, 1995, BLOOD, V86, P1873, DOI 10.1182/blood.V86.5.1873.bloodjournal8651873; HILFIKER H, 1993, J BIOL CHEM, V268, P19717; Husain M, 1997, AM J PHYSIOL-CELL PH, V272, pC1947, DOI 10.1152/ajpcell.1997.272.6.C1947; Husain M, 1997, CIRC RES, V80, P617, DOI 10.1161/01.RES.80.5.617; IRNIGER S, 1992, NUCLEIC ACIDS RES, V20, P4733, DOI 10.1093/nar/20.18.4733; Kasono K, 1998, BIOCHEM BIOPH RES CO, V251, P124, DOI 10.1006/bbrc.1998.9259; KEETON TP, 1993, J BIOL CHEM, V268, P2740; Klempt M, 1998, IMMUNOBIOLOGY, V199, P148, DOI 10.1016/S0171-2985(98)80070-3; KU DH, 1993, J BIOL CHEM, V268, P2255; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUO TH, 1993, ARCH BIOCHEM BIOPHYS, V305, P428, DOI 10.1006/abbi.1993.1442; KUO TH, 1991, J BIOL CHEM, V266, P2520; LOCHELT M, 1995, VIROLOGY, V206, P601, DOI 10.1016/S0042-6822(95)80077-8; MELTON DW, 1986, CELL, V44, P319, DOI 10.1016/0092-8674(86)90766-X; MIZUGUCHI G, 1995, J BIOL CHEM, V270, P9384, DOI 10.1074/jbc.270.16.9384; MULLICK J, 1995, BIOCHEMISTRY-US, V34, P13729, DOI 10.1021/bi00042a003; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NEVINS JR, 1987, METHOD ENZYMOL, V152, P234; Penniston JT, 1998, J MEMBRANE BIOL, V165, P101, DOI 10.1007/s002329900424; Ponton A, 1997, PROSTAGLANDINS, V53, P49, DOI 10.1016/S0090-6980(96)00140-2; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAMSAY RG, 1992, J BIOL CHEM, V267, P5656; Ratajczak MZ, 1998, BLOOD, V91, P1934, DOI 10.1182/blood.V91.6.1934.1934_1934_1946; REDDY MA, 1994, J EXP MED, V180, P2309, DOI 10.1084/jem.180.6.2309; REILLY CF, 1990, J CELL PHYSIOL, V142, P342, DOI 10.1002/jcp.1041420217; Rolfe FG, 1997, J IMMUNOL METHODS, V202, P143, DOI 10.1016/S0022-1759(96)00245-1; Romero I, 1998, PLANT J, V14, P273, DOI 10.1046/j.1365-313X.1998.00113.x; Rosinski JA, 1998, J MOL EVOL, V46, P74, DOI 10.1007/PL00006285; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SIMONS M, 1995, AM J PHYSIOL-CELL PH, V268, pC856, DOI 10.1152/ajpcell.1995.268.4.C856; SIMONS M, 1993, J BIOL CHEM, V268, P627; Simpson ER, 1997, FASEB J, V11, P29, DOI 10.1096/fasebj.11.1.9034163; STAUFFER TP, 1995, J BIOL CHEM, V270, P12184, DOI 10.1074/jbc.270.20.12184; Stein GS, 1997, MOL BIOL REP, V24, P185, DOI 10.1023/A:1006803615430; TAKAHASHI N, 1991, JPN J CANCER RES, V82, P1239, DOI 10.1111/j.1349-7006.1991.tb01787.x; TRAVALI S, 1991, ONCOGENE, V6, P887; TROYANOVSKY SM, 1994, EUR J BIOCHEM, V225, P61, DOI 10.1111/j.1432-1033.1994.00061.x; Vandenbark GR, 1996, CELL GROWTH DIFFER, V7, P1383; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; Wei Y, 1996, J GEN VIROL, V77, P177, DOI 10.1099/0022-1317-77-2-177; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; ZOBEL A, 1992, BIOCHEM BIOPH RES CO, V186, P715, DOI 10.1016/0006-291X(92)90805-U	68	34	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					9062	9069		10.1074/jbc.275.12.9062	http://dx.doi.org/10.1074/jbc.275.12.9062			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722757	hybrid			2022-12-27	WOS:000086507700107
J	Mould, JA; Li, HC; Dudlak, CS; Lear, JD; Pekosz, A; Lamb, RA; Pinto, LH				Mould, JA; Li, HC; Dudlak, CS; Lear, JD; Pekosz, A; Lamb, RA; Pinto, LH			Mechanism for proton conduction of the M-2 ion channel of influenza A virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; M2 PROTEIN; A VIRUS; TRANSMEMBRANE DOMAIN; LIPID BILAYERS; INHIBITOR; CURRENTS; CELLS; FORMS	The M-2 integral membrane protein of influenza A virus forms a proton-selective ion channel. We investigated the mechanism for proton transport of the M-2 protein in Xenopus oocytes using a two-electrode voltage clamp and in CV-1 cells using the whole cell patch clamp technique. Membrane currents mere recorded while manipulating the external solution to alter either the total or free proton concentration or the solvent itself. Membrane conductance decreased by similar to 50% when D2O replaced H2O as the solvent. From this, me conclude that hydrogen ions do not pass through M-2 as hydronium ions, but instead must interact with titratable groups that line the pore of the channel. M-2 currents measured in solutions of low buffer concentration (<15 mM in oocytes and <0.15 mM in CV-1 cells) were smaller than those studied in solutions of high buffer concentration. Furthermore, the reversal voltage measured in low buffer was shifted to a more negative voltage than in high buffer. Also, at a given pH, M-2 current amplitude in 15 mar buffer decreased when pH-pK(a) was increased by changing the buffer pK(a). Collectively, these results demonstrate that M-2 currents can be limited by external buffer capacity. The data presented in this study were also used to estimate the maximum single channel current of the M-2 ion channel, which was calculated to be on the order of 1-10 fA.	Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA; Northwestern Univ, Dept Biochem, Evanston, IL 60208 USA; Northwestern Univ, Dept Biol Mol, Evanston, IL 60208 USA; Northwestern Univ, Dept Cell Biol, Evanston, IL 60208 USA; Northwestern Univ, Howard Hughes Med Inst, Evanston, IL 60208 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	Northwestern University; Northwestern University; Northwestern University; Northwestern University; Howard Hughes Medical Institute; Northwestern University; University of Pennsylvania	Pinto, LH (corresponding author), Northwestern Univ, Dept Neurobiol & Physiol, Hogan Hall,2153 N Campus Dr, Evanston, IL 60208 USA.			Pekosz, Andrew/0000-0003-3248-1761	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020201, R01AI031882, R37AI020201, R56AI020201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056423] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20201, AI-31882] Funding Source: Medline; NIGMS NIH HHS [GM56423-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BYERLY L, 1989, J PHYSIOL-LONDON, V413, P75, DOI 10.1113/jphysiol.1989.sp017642; Chizhmakov IV, 1996, J PHYSIOL-LONDON, V494, P329, DOI 10.1113/jphysiol.1996.sp021495; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DeCoursey TE, 1996, BIOPHYS J, V71, P182, DOI 10.1016/S0006-3495(96)79215-9; DeCoursey TE, 1997, J GEN PHYSIOL, V109, P415, DOI 10.1085/jgp.109.4.415; DUFF KC, 1992, VIROLOGY, V190, P485, DOI 10.1016/0042-6822(92)91239-Q; FERSHT A, 1985, ENZYME STRUCTURE MEC, P147; Gandhi CS, 1999, J BIOL CHEM, V274, P5474, DOI 10.1074/jbc.274.9.5474; GLASOE PK, 1960, J PHYS CHEM-US, V64, P188, DOI 10.1021/j100830a521; Hay A.J., 1992, SEMIN VIROL, V3, P21, DOI DOI 10.1016/J.BMC.2015.06.030; HILLE B, 1992, IONIC CHANNELS EXCIT, P261; HOLSINGER LJ, 1994, J VIROL, V68, P1551, DOI 10.1128/JVI.68.3.1551-1563.1994; HOLSINGER LJ, 1991, VIROLOGY, V183, P32, DOI 10.1016/0042-6822(91)90115-R; KURTZ S, 1995, ANTIMICROB AGENTS CH, V39, P2204, DOI 10.1128/AAC.39.10.2204; Lamb R. A., 1994, RECEPTOR MEDIATED VI, P303; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; LEAR JD, 1988, SCIENCE, V240, P1179; PANAYOTOV PP, 1992, VIROLOGY, V186, P352, DOI 10.1016/0042-6822(92)90096-8; Pinto LH, 1997, P NATL ACAD SCI USA, V94, P11301, DOI 10.1073/pnas.94.21.11301; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; Sakaguchi T, 1997, P NATL ACAD SCI USA, V94, P5000, DOI 10.1073/pnas.94.10.5000; SHIMBO K, 1996, BIOPHYS J, V70, P1336; STUHMER W, 1995, SINGLE CHANNEL RECOR, P344; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; TOSTESON MT, 1994, J MEMBRANE BIOL, V142, P117; Tu Q, 1996, J VIROL, V70, P4246, DOI 10.1128/JVI.70.7.4246-4252.1996; WANG C, 1995, BIOPHYS J, V69, P1363, DOI 10.1016/S0006-3495(95)80003-2; WANG C, 1994, VIROLOGY, V205, P133, DOI 10.1006/viro.1994.1628	28	123	125	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8592	8599		10.1074/jbc.275.12.8592	http://dx.doi.org/10.1074/jbc.275.12.8592			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722698	hybrid			2022-12-27	WOS:000086507700048
J	Wang, HC; Zentner, MD; Deng, HT; Kim, KJ; Wu, R; Yang, PC; Ann, DK				Wang, HC; Zentner, MD; Deng, HT; Kim, KJ; Wu, R; Yang, PC; Ann, DK			Oxidative stress disrupts glucocorticoid hormone-dependent transcription of the amiloride-sensitive epithelial sodium channel alpha-subunit in lung epithelial cells through ERK-dependent and thioredoxin-sensitive pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-DISTRESS-SYNDROME; NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; DNA-BINDING ACTIVITY; HYDROGEN-PEROXIDE; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; OXYGEN; INJURY; CLEARANCE	The amiloride-sensitive epithelial Na+ channel (ENaC) plays a critical role in the maintenance of alveolar fluid balance. It is generally accepted that reactive oxygen and nitrogen species can inhibit ENaC activity and aggravate acute lung injury; however, the molecular mechanism for free radical-mediated ENaC inhibition is unclear. Previously, Re showed that the expression of the alpha-subunit of ENaC, alpha-ENaC, which is indispensable for ENaC activity, is repressed by Ras activation in salivary epithelial cells. Here, we investigated whether exogenous H2O2 modulates alpha-ENaC gene expression in lung epithelial cells through a similar molecular mechanism. Utilizing transient transfection reporter assays and site-directed mutagenesis analyses, we found that the glucocorticoid response element (GRE), located at -1334 to -1306 base pairs of the alpha-ENaC 5'-flanking region, is the major enhancer for the stimulated alpha-ENaC expression in A549 lung epithelial cells. We further demonstrate that the presence of an intact GRE is necessary and sufficient for oxidants to repress alpha-ENaC expression. Consistent with our hypothesis, exogenous H2O2-mediated repression of alpha-ENaC GRE activity is partially blocked by either a specific inhibitor for extracellular signal-regulated kinase (ERK) pathway activation, U0126, or dominant negative ERK, suggesting that, in part, activated ERK may mediate the repressive effects of H2O2 on alpha-ENaC expression, In addition, overexpression of thioredoxin restored glucocorticoid receptor action on the alpha-ENaC GRE in the presence of exogenous H2O2. Taken together, we hypothesize that oxidative stress impairs Nat transport activity by inhibiting dexamethasone-dependent alpha-ENaC GRE activation via both ERK-dependent and thioredoxin-sensitive pathways. These results suggest a putative mechanism whereby cellular redox potentials modulate the glucocorticoid receptor/dexamethasone effect on alpha-ENaC expression in lung and other tight epithelia.	Univ So Calif, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA; Univ So Calif, Dept Physiol & Med Biophys, Los Angeles, CA 90033 USA; Univ So Calif, Dept Biomed Engn, Will Rogers Inst Pulm Res Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; Univ Calif Davis, Ctr Comparat Resp Biol & Med, Davis, CA 95616 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; National Taiwan University; National Taiwan University Hospital; University of California System; University of California Davis	Ann, DK (corresponding author), Univ So Calif, Sch Pharm, 1985 Zonal Ave, Los Angeles, CA 90033 USA.		Yang, Pan-Chyr/B-8808-2009	Wang, Hao-Chien/0000-0002-7528-7494; YANG, PAN-CHYR/0000-0001-6330-6048	NHLBI NIH HHS [HL64365, HL38658] Funding Source: Medline; NIDCR NIH HHS [DE07211] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064365, R01HL038658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007211] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adderley SR, 1999, J BIOL CHEM, V274, P5038, DOI 10.1074/jbc.274.8.5038; AN G, 1992, BIOCHEM BIOPH RES CO, V183, P170, DOI 10.1016/0006-291X(92)91624-Y; BERNARD GR, 1987, NEW ENGL J MED, V317, P1565, DOI 10.1056/NEJM198712173172504; Brun-Buisson C, 1998, JAMA-J AM MED ASSOC, V280, P182, DOI 10.1001/jama.280.2.182; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Chabot F, 1998, EUR RESPIR J, V11, P745; DAS KC, 1995, AM J PHYSIOL-LUNG C, V269, pL588, DOI 10.1152/ajplung.1995.269.5.L588; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Ding JW, 1998, AM J PHYSIOL-LUNG C, V274, pL378, DOI 10.1152/ajplung.1998.274.3.L378; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; Grant CM, 1999, MOL CELL BIOL, V19, P2650; GUYTON KZ, 1993, BRIT MED BULL, V49, P523, DOI 10.1093/oxfordjournals.bmb.a072628; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hartsfield CL, 1997, AM J PHYSIOL-LUNG C, V273, pL980; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; HUTCHISON KA, 1991, J BIOL CHEM, V266, P10505; Kaul N, 1996, FREE RADICAL BIO MED, V21, P401, DOI 10.1016/0891-5849(96)00178-5; Kaul N, 1998, ARCH BIOCHEM BIOPHYS, V350, P79, DOI 10.1006/abbi.1997.0487; Keel JBP, 1998, RESPIRATION, V65, P258, DOI 10.1159/000029273; KIM KJ, 1993, AM J PHYSIOL, V264, pL308, DOI 10.1152/ajplung.1993.264.3.L308; KLEBANOFF SJ, 1986, J IMMUNOL, V136, P4220; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; Lin HH, 1999, J BIOL CHEM, V274, P21544, DOI 10.1074/jbc.274.31.21544; LUCE JM, 1988, AM REV RESPIR DIS, V138, P62, DOI 10.1164/ajrccm/138.1.62; MATTHAY MA, 1990, AM REV RESPIR DIS, V142, P1250, DOI 10.1164/ajrccm/142.6_Pt_1.1250; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; Meduri GU, 1998, JAMA-J AM MED ASSOC, V280, P159, DOI 10.1001/jama.280.2.159; NAKAMURA H, 1994, IMMUNOL LETT, V42, P75, DOI 10.1016/0165-2478(94)90038-8; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; OBRODOVICH H, 1990, J APPL PHYSIOL, V68, P1758, DOI 10.1152/jappl.1990.68.4.1758; Olivieri D, 1998, RESPIRATION, V65, P256, DOI 10.1159/000029272; PAHL HL, 1994, BIOESSAYS, V16, P497, DOI 10.1002/bies.950160709; Papa S, 1997, MOL CELL BIOCHEM, V174, P305, DOI 10.1023/A:1006873518427; Rao GN, 1999, J BIOL CHEM, V274, P6003, DOI 10.1074/jbc.274.9.6003; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; SAKUMA T, 1994, AM J RESP CRIT CARE, V150, P305, DOI 10.1164/ajrccm.150.2.8049807; Sayegh R, 1999, J BIOL CHEM, V274, P12431, DOI 10.1074/jbc.274.18.12431; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shepherd V L, 1986, Semin Respir Infect, V1, P99; SPRAGG RG, 1991, LUNG SCI F, P2003; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; TCHEPICHEV S, 1995, AM J PHYSIOL-CELL PH, V269, pC805, DOI 10.1152/ajpcell.1995.269.3.C805; Tirosh A, 1999, J BIOL CHEM, V274, P10595, DOI 10.1074/jbc.274.15.10595; Tolwinski NS, 1999, J BIOL CHEM, V274, P6168, DOI 10.1074/jbc.274.10.6168; Torres M, 1999, ARCH BIOCHEM BIOPHYS, V366, P231, DOI 10.1006/abbi.1999.1225; van der Vliet A, 1998, J BIOL CHEM, V273, P31860, DOI 10.1074/jbc.273.48.31860; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Zentner MD, 1998, J BIOL CHEM, V273, P30770, DOI 10.1074/jbc.273.46.30770	58	58	61	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8600	8609		10.1074/jbc.275.12.8600	http://dx.doi.org/10.1074/jbc.275.12.8600			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722699	hybrid			2022-12-27	WOS:000086507700049
J	Hofmann, A; Proust, J; Dorowski, A; Schantz, R; Huber, R				Hofmann, A; Proust, J; Dorowski, A; Schantz, R; Huber, R			Annexin 24 from Capsicum annuum - X-ray structure and biochemical characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR REPLACEMENT; PHOSPHOLIPID-BINDING; PROTEIN; IDENTIFICATION; EXPRESSION; PROGRAM; GENE; P35	This work provides the first three-dimensional structure of a member of the plant annexin family and correlates these findings with biochemical properties of this protein. Annexin 24(Ca32) from Capsicum annuum was purified as a native protein fr om bell pepper and was also prepared by recombinant techniques. To overcome the problem of precipitation of the recombinant wildtype protein in crystallization trials, two mutants were designed. Whereas an N-terminal truncation mutant turned out to be an unstable protein, the N-terminal His-tagged annexin 24(Ca32) was crystallized, and the three-dimensional structure was determined by x-ray diffraction at 2.8 Angstrom resolution, The structure refined to an R-factor of 0.216 adopts the typical annexin fold; the detailed structure, however, is different from non-plant annexins, especially in domains I and III and in the membrane binding loops on the convex side. Within the unit cell there are two molecules per asymmetric unit, which differ in conformation of the LQB-loop. Both conformers show Trp-35 on the surface. The loop-out conformation is stabilized by tight interactions of this tryptophan with residue side chains of a symmetry-related molecule and enforced by a bound sulfate. Characterization of this plant annexin using biophysical methods revealed calcium-dependent binding to phospholipid vesicles with preference for phosphatidylcholine over phosphatidylserine and magnesium-dependent phosphodiesterase activity in vitro as shown with adenosine triphosphate as the substrate. A comparative unfolding study of recombinant annexin 24(Ca32) wild type and of the His-tag fusion protein indicates higher stability of the latter. The effect of this N-terminal modification is also visible from CD spectra. Both proteins were subjected to a FURA-2-based calcium influx assay, which gave high influx rates for the wild-type but greatly reduced influx rates for the fusion protein. We therefore conclude that the N-terminal domain is indeed a major regulatory element modulating different annexin properties by allosteric mechanisms.	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; CNRS, Inst Biol Mol Plantes, F-67084 Strasbourg, France	Max Planck Society; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Hofmann, A (corresponding author), NCI, Macromol Crystallog Lab, Program Struct Biol, FCRDC, Frederick, MD 21702 USA.		Hofmann, Andreas/B-9515-2008; Hofmann, Andreas/M-9870-2019	Hofmann, Andreas/0000-0003-4408-5467; Hofmann, Andreas/0000-0003-4408-5467				Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Battey NH, 1996, PLANT PHYSIOL, V112, P1391, DOI 10.1104/pp.112.3.1391; BERENDES R, 1993, FEBS LETT, V317, P131, DOI 10.1016/0014-5793(93)81507-V; BOUSTEAD CM, 1989, FEBS LETT, V244, P456, DOI 10.1016/0014-5793(89)80582-4; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1998, XPLOR SYSTEM XRAY CR; BURGER A, 1993, FEBS LETT, V329, P25, DOI 10.1016/0014-5793(93)80185-W; Calvert CM, 1996, PLANT CELL, V8, P333, DOI 10.1105/tpc.8.2.333; CLARK GB, 1995, PLANTA, V197, P376, DOI 10.1007/BF00202660; Delmer DP, 1997, CELL MOL LIFE SCI, V53, P546, DOI 10.1007/s000180050070; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; GEISOW MJ, 1986, NATURE, V320, P636, DOI 10.1038/320636a0; *GEN COMP GROUP, 1996, WISC PACK VERS 9 0; GOOSSENS ELJ, 1995, FEBS LETT, V359, P155, DOI 10.1016/0014-5793(95)00032-5; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hofmann A, 1998, J BIOL CHEM, V273, P2885, DOI 10.1074/jbc.273.5.2885; HOFMANN A, 1998, THESIS TU MUNCHEN; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1978, J APPL CRYSTALLOGR, V15, P24; Kovacs I, 1998, PLANT J, V15, P185, DOI 10.1046/j.1365-313X.1998.00194.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1994, PROCHECK PROGRAMS CH; LESLIE AGW, 1998, MOSFLM VERSION 5 51; Lim EK, 1998, J BIOL CHEM, V273, P34920, DOI 10.1074/jbc.273.52.34920; MCCLUNG AD, 1994, BIOCHEM J, V303, P709, DOI 10.1042/bj3030709; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Pace CN, 1995, METHOD ENZYMOL, V259, P538; Pigault C, 1999, BIOCHEM BIOPH RES CO, V254, P484, DOI 10.1006/bbrc.1998.9965; Proust J, 1999, PLANT MOL BIOL, V39, P361, DOI 10.1023/A:1006199814795; REEVES JP, 1969, J CELL PHYSIOL, V73, P49, DOI 10.1002/jcp.1040730108; SCHOEPFER R, 1993, GENE, V124, P83, DOI 10.1016/0378-1119(93)90764-T; Thonat C, 1997, PLANT PHYSIOL, V114, P981, DOI 10.1104/pp.114.3.981; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; TURK D, 1992, THESIS TU MUNCHEN; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; WILSCHUT J, 1980, BIOCHEMISTRY-US, V19, P6011, DOI 10.1021/bi00567a011; [No title captured]; 1996, ACTA CRYSTALLOGR D, V50, P760	41	80	93	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8072	8082		10.1074/jbc.275.11.8072	http://dx.doi.org/10.1074/jbc.275.11.8072			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713128	hybrid			2022-12-27	WOS:000085913300088
J	Xu, LW; Marians, KJ				Xu, LW; Marians, KJ			Purification and characterization of DnaC810, a primosomal protein capable of bypassing PriA function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI DNA-REPLICATION; SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; HOMOLOGOUS RECOMBINATION; PHI-X174-TYPE PRIMOSOME; GENE PRODUCT; HELICASE; FORM; CONVERSION; REPAIR	Escherichia coli strains lacking PriA are severely compromised in their ability to repair W-damaged DNA and to perform homologous recombination. These phenotypes arise because of a lack of PriA-directed replication fork assembly at recombination intermediates such as D-loops. Naturally arising suppressor mutations in dnaC restore strains carrying the priA2::kan nub allele to wild-type function. We have cloned one such gene, dnaC810, and overexpressed, purified, and characterized the DnaC810 protein. DnaC810 can support a PriA-independent synthesis of phi X174 complementary strand DNA This can be attributed to its ability, unlike wildtype DnaC, to catalyze a SSB-insensitive general priming reaction with DnaB and DnaG on any SSB-coated single-stranded DNA. Gel mobility shift analysis revealed that DnaC810 could load DnaB directly to SSB-coated single-stranded DNA as well as to D loop DNA. This explains the ability of DnaC810 to bypass the requirement for PriA, PriB, PriC, and DnaT during replication fork assembly at recombination intermediates.	Cornell Univ, Grad Sch Med Sci, Biochem & Struct Biol Grad Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center	Marians, KJ (corresponding author), Cornell Univ, Grad Sch Med Sci, Biochem & Struct Biol Grad Program, New York, NY 10021 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034557, R37GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34557, R37 GM034557] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI KI, 1981, P NATL ACAD SCI USA, V76, P4308; BOUCHE JP, 1975, J BIOL CHEM, V250, P5995; Cox MM, 1998, GENES CELLS, V3, P65, DOI 10.1046/j.1365-2443.1998.00175.x; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; Kogoma T, 1996, CELL, V85, P625, DOI 10.1016/S0092-8674(00)81229-5; Kogoma T, 1996, J BACTERIOL, V178, P1258, DOI 10.1128/jb.178.5.1258-1264.1996; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; Learn BA, 1997, P NATL ACAD SCI USA, V94, P1154, DOI 10.1073/pnas.94.4.1154; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE EH, 1991, P NATL ACAD SCI USA, V88, P3029, DOI 10.1073/pnas.88.8.3029; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; Liu J, 1999, J BIOL CHEM, V274, P25033, DOI 10.1074/jbc.274.35.25033; Liu JI, 1999, P NATL ACAD SCI USA, V96, P3552, DOI 10.1073/pnas.96.7.3552; Maniatis T., 1982, MOL CLONING LAB MANU; MARIANS KJ, 1984, CRC CR REV BIOCH MOL, V17, P153, DOI 10.3109/10409238409113604; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MASAI H, 1994, EMBO J, V13, P5338, DOI 10.1002/j.1460-2075.1994.tb06868.x; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MODEL P, 1974, J MOL BIOL, V83, P231, DOI 10.1016/0022-2836(74)90389-1; MOK M, 1987, J BIOL CHEM, V262, P16644; MORTON RM, 1989, GENE, V77, P61; Ng JY, 1996, J BIOL CHEM, V271, P15642, DOI 10.1074/jbc.271.26.15642; Ng JY, 1996, J BIOL CHEM, V271, P15649, DOI 10.1074/jbc.271.26.15649; Nurse P, 1999, J BIOL CHEM, V274, P25026, DOI 10.1074/jbc.274.35.25026; NURSE P, 1991, J BACTERIOL, V173, P6686, DOI 10.1128/jb.173.21.6686-6693.1991; Sandler SJ, 1999, MOL MICROBIOL, V34, P91, DOI 10.1046/j.1365-2958.1999.01576.x; Sandler SJ, 1996, GENETICS, V143, P5; SCHEKMAN R, 1975, J BIOL CHEM, V250, P5859; WAHLE E, 1989, J BIOL CHEM, V264, P2463; WICKNER RB, 1972, P NATL ACAD SCI USA, V69, P3233, DOI 10.1073/pnas.69.11.3233; WICKNER S, 1974, P NATL ACAD SCI USA, V71, P783, DOI 10.1073/pnas.71.3.783; WICKNER S, 1974, P NATL ACAD SCI USA, V71, P4120, DOI 10.1073/pnas.71.10.4120; WICKNER W, 1972, P NATL ACAD SCI USA, V69, P965, DOI 10.1073/pnas.69.4.965; WU CA, 1992, J BIOL CHEM, V267, P4030; ZAVITZ KH, 1991, MOL MICROBIOL, V5, P2869, DOI 10.1111/j.1365-2958.1991.tb01846.x; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933	40	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8196	8205		10.1074/jbc.275.11.8196	http://dx.doi.org/10.1074/jbc.275.11.8196			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713144	hybrid			2022-12-27	WOS:000085913300104
J	Kitazawa, T; Eto, M; Woodsome, TP; Brautigan, DL				Kitazawa, T; Eto, M; Woodsome, TP; Brautigan, DL			Agonists trigger G protein-mediated activation of the CPI-17 inhibitor phosphoprotein of myosin light chain phosphatase to enhance vascular smooth muscle contractility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-ASSOCIATED KINASE; SIGNAL-TRANSDUCTION; CALCIUM; BINDING; PHOSPHORYLATION; SENSITIVITY; SENSITIZATION; LOCALIZATION; INVOLVEMENT; CA-2+	Myosin light chain phosphatase (MLCP) plays a pivotal role in smooth muscle contraction by regulating Ca2+ sensitivity of myosin light chain phosphorylation. A smooth muscle phosphoprotein called CPI-17 specifically and potently inhibits MLCP in vitro and in situ and is activated when phosphorylated at Thr-38, which increases its inhibitory potency 1000-fold. We produced a phosphospecific antibody for this site in CPI-17 and used it to study in situ phosphorylation of endogenous CPI-17 in arterial smooth muscle in response to agonist stimulation. In the intact femoral artery, CPI-17 phosphorylation was negligible at the resting state and was not increased during contraction induced by K+ depolarization, The Ca2+-sensitizing agonists histamine and phenylephrine induced nearly equivalent contractions, but histamine generated significantly higher levels of CPI-17 phosphorylation, In alpha-toxin-permeabilized strips at pCa 6.7, contractile force and CPI-17 phosphorylation were proportional in response to histamine, guanosine 5'-O-(gamma-thiotriphosphate), and histamine plus guanyl-5'-yl thiophosphate, implying that histamine increased CPI-17 phosphorylation through activation of G proteins, Inhibitors of Rho-kinase (Y27632) and protein kinase C (PKC; GF109203X) reduced contraction and CPI-17 phosphorylation in parallel, suggesting that CPI-17 functions downstream of Rho kinases and PKC, The results show that agonists such as histamine signal through phosphorylation of CPI-17 to produce Ca2+ sensitization of smooth muscle contraction.	Georgetown Univ, Med Ctr, Dept Physiol & Biophys, Washington, DC 20007 USA; Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA	Georgetown University; University of Virginia	Kitazawa, T (corresponding author), Georgetown Univ, Med Ctr, Dept Physiol & Biophys, 3900 Reservoir Rd NW, Washington, DC 20007 USA.		Eto, Masumi/ABE-4700-2020	Eto, Masumi/0000-0002-0651-5836	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051824] Funding Source: NIH RePORTER; NCI NIH HHS [CA40042] Funding Source: Medline; NHLBI NIH HHS [HL51824] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADLEY AB, 1987, J PHYSIOL-LONDON, V385, P437, DOI 10.1113/jphysiol.1987.sp016500; Eto M, 1997, FEBS LETT, V410, P356, DOI 10.1016/S0014-5793(97)00657-1; ETO M, 1995, J BIOCHEM, V118, P1104, DOI 10.1093/oxfordjournals.jbchem.a124993; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; GONG MC, 1992, J BIOL CHEM, V267, P21492; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; Hartshorne DJ, 1998, J MUSCLE RES CELL M, V19, P325, DOI 10.1023/A:1005385302064; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HIRATA K, 1992, J BIOL CHEM, V267, P8719; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kitazawa T, 1999, J PHYSIOL-LONDON, V520, P139, DOI 10.1111/j.1469-7793.1999.00139.x; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; KUBOTA Y, 1992, AM J PHYSIOL, V262, pC405, DOI 10.1152/ajpcell.1992.262.2.C405; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Li L, 1998, J PHYSIOL-LONDON, V508, P871, DOI 10.1111/j.1469-7793.1998.871bp.x; Li S, 1998, BIOPHYS J, V74, pA152; Lucius C, 1998, J PHYSIOL-LONDON, V506, P83, DOI 10.1111/j.1469-7793.1998.083bx.x; MASUO M, 1994, J GEN PHYSIOL, V104, P265, DOI 10.1085/jgp.104.2.265; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; NISHIMURA J, 1988, BIOCHEM BIOPH RES CO, V157, P677, DOI 10.1016/S0006-291X(88)80303-6; Senba S, 1999, J BIOCHEM-TOKYO, V125, P354, DOI 10.1093/oxfordjournals.jbchem.a022294; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; TALIAN JC, 1983, J CELL BIOL, V97, P1277, DOI 10.1083/jcb.97.4.1277; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187	28	264	277	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					9897	9900		10.1074/jbc.275.14.9897	http://dx.doi.org/10.1074/jbc.275.14.9897			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744661	hybrid			2022-12-27	WOS:000086345600002
J	Laffitte, BA; Kast, HR; Nguyen, CM; Zavacki, AM; Moore, DD; Edwards, PA				Laffitte, BA; Kast, HR; Nguyen, CM; Zavacki, AM; Moore, DD; Edwards, PA			Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLETHANOLAMINE N-METHYLTRANSFERASE; PHOSPHOLIPID TRANSFER PROTEIN; THYROID-HORMONE RECEPTOR; RETINOIC ACID RECEPTORS; ECDYSONE RECEPTOR; NUCLEAR RECEPTOR; RESPONSE ELEMENTS; ORPHAN RECEPTORS; DIRECT REPEATS; FUNCTIONAL-CHARACTERIZATION	The farnesoid X-activated receptor (FXR; NR1H4) is a member of the nuclear hormone receptor superfamily and functions as a heterodimer with the 9-cis-retinoic acid receptor (RXR). In order to determine the optimal DNA binding sequence for the FXR/RXR heterodimer, we have utilized the selected and amplified binding sequence imprinting technique. This technique identified a number of related sequences that interacted with FXR /RXR in vitro. The consensus sequence contained an inverted repeat of the sequence AGGTCA with a 1-base pair spacing (IR-1). This sequence was shown to be a high affinity binding site for FXR/RXR in vitro and to confer Ligand-dependent transcriptional activation by FXR/RXR to a heterologous promoter. Electrophoretic mobility shift assays and transient transfection assays were used to investigate the importance of the core half-site sequences, spacing nucleotide, flanking sequences, and orientation and spacing of the core half-sites on DNA binding and ligand-dependent transcriptional activation by FXR/RXR. These studies demonstrated that the FXR/RXR heterodimer binds to the consensus IR-1 sequence with the highest affinity, although FXR/RXR can bind to and activate through a variety of elements including IR-1 elements with changes in the core half-site sequence, spacing nucleotide, and flanking nucleotides. In addition, FXR/RXR can bind to and transactivate through direct repeats. Three genes were identified that contain IR-1 sequences in their proximal promoters. These elements were shown to bind FXR/RXR in vitro and to confer FXR/RXR-dependent transcriptional activation to a heterologous promoter in response to a bile acid or synthetic retinoid, The endogenous mRNA levels of one of these genes, phospholipid transfer protein, were shown to be induced by FXR and FXR ligands. The identification of the IR-1 and related elements as high affinity binding sites and functional response elements for FXR/RXR and the identification of a target gene for FXR/RXR should assist in the identification of additional genes regulated by FXR/RXR.	Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Baylor College of Medicine	Edwards, PA (corresponding author), Univ Calif Los Angeles, Dept Biol Chem, CHS 33-257, Los Angeles, CA 90095 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30568] Funding Source: Medline; NIGMS NIH HHS [GM 07185] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antoniewski C, 1996, MOL CELL BIOL, V16, P2977; Auwerx J, 1999, CELL, V97, P161; BAETGE EE, 1988, P NATL ACAD SCI USA, V85, P3648, DOI 10.1073/pnas.85.10.3648; BAETGE EE, 1986, P NATL ACAD SCI USA, V83, P5454, DOI 10.1073/pnas.83.15.5454; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014; BRENT GA, 1989, J BIOL CHEM, V264, P178; Bruce C, 1998, ANNU REV NUTR, V18, P297, DOI 10.1146/annurev.nutr.18.1.297; CLARKE PRH, 1981, J BIOL CHEM, V256, P9861; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; CRETTAZ M, 1990, BIOCHEM J, V272, P391, DOI 10.1042/bj2720391; DAY JR, 1994, J BIOL CHEM, V269, P9388; Eaton S, 1996, BIOCHEM J, V320, P345, DOI 10.1042/bj3200345; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; HARDING HP, 1995, MOL CELL BIOL, V15, P4791; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; KANEDA N, 1988, J BIOL CHEM, V263, P7672; KOENIG RJ, 1987, P NATL ACAD SCI USA, V84, P5670, DOI 10.1073/pnas.84.16.5670; Lagrost L, 1998, CURR OPIN LIPIDOL, V9, P203, DOI 10.1097/00041433-199806000-00004; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MONTERMINI L, 1994, BBA-GENE STRUCT EXPR, V1219, P237, DOI 10.1016/0167-4781(94)90280-1; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; RIDDIHOUGH G, 1987, EMBO J, V6, P3729, DOI 10.1002/j.1460-2075.1987.tb02707.x; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; SUBAUSTE JS, 1994, J BIOL CHEM, V269, P30232; SUH YH, 1994, J NEUROCHEM, V63, P1603; THOMAS HE, 1993, NATURE, V362, P471, DOI 10.1038/362471a0; Tu AY, 1995, BIOCHEM BIOPH RES CO, V217, P705, DOI 10.1006/bbrc.1995.2830; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Vogtli M, 1998, NUCLEIC ACIDS RES, V26, P2407, DOI 10.1093/nar/26.10.2407; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wang SF, 1998, J BIOL CHEM, V273, P27531, DOI 10.1074/jbc.273.42.27531; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Willy PJ, 1997, GENE DEV, V11, P289, DOI 10.1101/gad.11.3.289; WILLY PJ, 1998, HORMONES SIGNALING, V1, P307; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Yan ZH, 1997, J BIOL CHEM, V272, P10565; YANG YZ, 1995, ENDOCRINOLOGY, V136, P2896, DOI 10.1210/en.136.7.2896; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909	48	227	231	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10638	10647		10.1074/jbc.275.14.10638	http://dx.doi.org/10.1074/jbc.275.14.10638			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744760	hybrid			2022-12-27	WOS:000086345600101
J	Rondinone, CM; Carvalho, E; Rahn, T; Manganiello, VC; Degerman, E; Smith, UP				Rondinone, CM; Carvalho, E; Rahn, T; Manganiello, VC; Degerman, E; Smith, UP			Phosphorylation of PDE3B by phosphatidylinositol 3-kinase associated with the insulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KM CAMP PHOSPHODIESTERASE; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; GLUCOSE-TRANSPORT; TYROSINE KINASES; HUMAN ADIPOCYTES; RAT ADIPOCYTES; SH2 DOMAINS; P85 SUBUNIT; FAT-CELLS	Phosphatidylinositol S-kinase mediates several actions of insulin including its antilipolytic effect. This effect is elicited by the insulin-stimulated serine phosphorylation and activation of cGMP-inhibited phosphodiesterase (PDE3B). In human adipocytes, we found that insulin differentially stimulated phosphatidylinositol S-kinase activity; the lipid kinase activity was associated with IRS-1, whereas the serine kinase activity was associated with the insulin receptor and phosphorylated a number of proteins including p85, p110, and a 135-kDa protein identified as PDE3B. PDE3B phosphorylation was associated with enzyme activation, thus initiating the antilipolytic effect of insulin. These results show a novel pathway for intracellular signaling through the insulin receptor leading to the serine phosphorylation of key proteins involved in insulin action.	NHLBI, Cellular Metab Lab, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA; Gothenburg Univ, Sahlgrens Hosp, Dept Internal Med, Lundberg Lab Diabetes Res, S-41345 Gothenburg, Sweden; Univ Lund, Dept Cell & Mol Biol, Sect Mol Signaling, S-22100 Lund, Sweden	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Sahlgrenska University Hospital; University of Gothenburg; Lund University	Smith, UP (corresponding author), NHLBI, Cellular Metab Lab, Pulm Crit Care Med Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.		Carvalho, Eugenia/AAV-6868-2021	Carvalho, Eugenia/0000-0001-6264-3632	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002540, ZIAHL002540, Z01HL000654] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; DEGERMAN E, 1990, P NATL ACAD SCI USA, V87, P533, DOI 10.1073/pnas.87.2.533; DEGERMAN E, 1988, SEC MESS PHOSPHOPROT, V12, P171; Degerman E, 1997, J BIOL CHEM, V272, P6823, DOI 10.1074/jbc.272.11.6823; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; LAM K, 1994, J BIOL CHEM, V269, P20648; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; LONNROTH P, 1986, BIOCHEM BIOPH RES CO, V141, P1157, DOI 10.1016/S0006-291X(86)80165-6; MANGANIELLO VC, 1971, J BIOL CHEM, V246, P2195; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OKADA T, 1994, J BIOL CHEM, V269, P3563; OKADA T, 1994, J BIOL CHEM, V269, P3568; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Rondinone CM, 1996, J BIOL CHEM, V271, P18148, DOI 10.1074/jbc.271.30.18148; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH U, 1972, J LIPID RES, V13, P822; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; SUNG CK, 1994, J BIOL CHEM, V269, P12503; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; Wijkander J, 1998, ENDOCRINOLOGY, V139, P219, DOI 10.1210/en.139.1.219	29	58	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10093	10098		10.1074/jbc.275.14.10093	http://dx.doi.org/10.1074/jbc.275.14.10093			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744689	hybrid			2022-12-27	WOS:000086345600030
J	Coussin, F; Macrez, N; Morel, JL; Mironneau, J				Coussin, F; Macrez, N; Morel, JL; Mironneau, J			Requirement of ryanodine receptor subtypes 1 and 2 for Ca(2+)induced Ca2+ release in vascular myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PORTAL-VEIN; MUSCLE SARCOPLASMIC-RETICULUM; CALCIUM-INDUCED RELEASE; PROTEIN-KINASE-C; SKELETAL-MUSCLE; SMOOTH-MUSCLE; MICE LACKING; CARDIAC MYOCYTES; ANGIOTENSIN-II; CHANNEL COMPLEX	While the roles of subtypes 1 and 2 of the ryanodine receptors (RYRs) have been studied in cellular systems expressing specifically one or the other of these subtypes (i.e. skeletal and cardiac muscle), the function of these receptors has not been evaluated in smooth muscles. We have previously reported RYR-mediated elementary (Ca2+ sparks) and global Ca2+ responses in rat portal vein myocytes, Here, we investigated the respective roles of all three RYR subtypes expressed in these cells as revealed by reverse transcriptase-polymerase chain reaction. Antisense oligonucleotides targeting each one of the three RYR subtypes were shown to specifically inhibit the expression of the corresponding mRNA and protein without affecting the other RYR subtypes. Confocal Ca2+ measurements revealed that depolarization-induced Ca2+ sparks and global Ca2+ responses were blocked when either RYR1 or RYR2 expression was suppressed. Caffeine-induced Ca2+ responses were partly inhibited by the same antisense oligonucleotides. Neither the corresponding scrambled oligonucleotides nor the antisense oligonucleotides targeting RYR3 affected depolarization- or caffeine induced Ca2+ responses. Our results show that, in vascular myocytes, the two RYR1 and RYR2 subtypes are required for Ca2+ release during Ca2+ sparks and global Ca2+ responses, evoked by activation of voltage-gated Ca2+ channels.	Univ Bordeaux 2, CNRS, UMR 5017, Lab Physiol Cellulaire & Pharmacol Mol, F-33076 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Macrez, N (corresponding author), Univ Bordeaux 2, CNRS, UMR 5017, Lab Physiol Cellulaire & Pharmacol Mol, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	nathalie.macrez@esa5017.u-bordeaux2.fr	Morel, Jean-Luc/AAY-9235-2020	MACREZ, Nathalie/0000-0002-3844-4403; morel, jean-luc/0000-0001-8079-6851				Arnaudeau S, 1997, CELL CALCIUM, V22, P399, DOI 10.1016/S0143-4160(97)90024-5; Arnaudeau S, 1996, BIOCHEM BIOPH RES CO, V222, P809, DOI 10.1006/bbrc.1996.0808; BENNETT CF, 1994, J IMMUNOL, V152, P3530; BERRIDGE MJ, 1993, NATURE, V365, P388, DOI 10.1038/365388a0; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; Bertocchini F, 1997, EMBO J, V16, P6956, DOI 10.1093/emboj/16.23.6956; Boittin FX, 1999, AM J PHYSIOL-CELL PH, V277, pC139, DOI 10.1152/ajpcell.1999.277.1.C139; BOSSE E, 1992, EMBO J, V11, P2033, DOI 10.1002/j.1460-2075.1992.tb05260.x; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; CANNELL MB, 1994, BIOPHYS J, V67, P1942, DOI 10.1016/S0006-3495(94)80677-0; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; Conklin MW, 1999, BIOPHYS J, V77, P1394, DOI 10.1016/S0006-3495(99)76988-2; ENDO M, 1970, NATURE, V228, P34, DOI 10.1038/228034a0; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; GANITKEVICH VY, 1995, J PHYSIOL-LONDON, V484, P287, DOI 10.1113/jphysiol.1995.sp020665; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; Holz GG, 1999, J BIOL CHEM, V274, P14147, DOI 10.1074/jbc.274.20.14147; JOSEPH SK, 1995, J BIOL CHEM, V270, P23310, DOI 10.1074/jbc.270.40.23310; Kamishima T, 1997, J PHYSIOL-LONDON, V501, P497, DOI 10.1111/j.1469-7793.1997.497bm.x; LAI FA, 1989, J BIOL CHEM, V264, P16776; Lipp P, 1996, PROG BIOPHYS MOL BIO, V65, P265, DOI 10.1016/S0079-6107(96)00014-4; MacrezLepretre N, 1996, J PHARMACOL EXP THER, V278, P468; MacrezLepretre N, 1997, J BIOL CHEM, V272, P5261, DOI 10.1074/jbc.272.8.5261; MARKS AR, 1989, P NATL ACAD SCI USA, V86, P8683, DOI 10.1073/pnas.86.22.8683; McGraw K, 1997, ANTI-CANCER DRUG DES, V12, P315; Mironneau J, 1996, CELL CALCIUM, V20, P153, DOI 10.1016/S0143-4160(96)90104-9; Morel JL, 1996, BRIT J PHARMACOL, V118, P73, DOI 10.1111/j.1476-5381.1996.tb15368.x; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; NEYLON CB, 1995, BIOCHEM BIOPH RES CO, V215, P814, DOI 10.1006/bbrc.1995.2536; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; Satoh H, 1997, HEART VESSELS, P58; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; Sonnleitner A, 1998, EMBO J, V17, P2790, DOI 10.1093/emboj/17.10.2790; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; Takeshima H, 1998, EMBO J, V17, P3309, DOI 10.1093/emboj/17.12.3309; TAKESHIMA H, 1995, EMBO J, V14, P2999, DOI 10.1002/j.1460-2075.1995.tb07302.x; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; Takeshima H, 1996, J BIOL CHEM, V271, P19649, DOI 10.1074/jbc.271.33.19649; Takimoto K, 1997, J MOL CELL CARDIOL, V29, P3035, DOI 10.1006/jmcc.1997.0532; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; WOJCIKIEWICZ RJH, 1995, BIOCHEM BIOPH RES CO, V213, P334, DOI 10.1006/bbrc.1995.2134; Zhang JJ, 1999, BRIT J PHARMACOL, V126, P1066, DOI 10.1038/sj.bjp.0702400; Zhang XJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1306, DOI 10.1152/ajpcell.1997.273.4.C1306	47	106	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9596	9603		10.1074/jbc.275.13.9596	http://dx.doi.org/10.1074/jbc.275.13.9596			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734110	hybrid			2022-12-27	WOS:000086206500074
J	Manivet, P; Mouillet-Richard, S; Callebert, J; Nebigil, CG; Maroteaux, L; Hosoda, S; Kellermann, O; Launay, JM				Manivet, P; Mouillet-Richard, S; Callebert, J; Nebigil, CG; Maroteaux, L; Hosoda, S; Kellermann, O; Launay, JM			PDZ-dependent activation of nitric-oxide syntheses by the serotonin 2B receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY PROTEIN PSD-95; CELL-LINE; 5-HT2B RECEPTOR; 5-HYDROXYTRYPTAMINE(2B) RECEPTOR; SIGNAL-TRANSDUCTION; CALCIUM-RELEASE; SYNTHASE; PATHWAY; INVOLVEMENT; EXPRESSION	Taking advantage of three cellular systems, we established that 5-HT2B receptors are coupled with NO signaling pathways. In the 1C11 serotonergic cell line and Mastomys natalensis carcinoid cells, which naturally express the 5-HT2B receptor, as well as in transfected LMTK- fibroblasts, stimulation of the 5-HT2B receptor triggers intracellular cGMP production through dual activation of constitutive nitric-oxide synthase (cNOS) and inducible NOS (iNOS). The group I PDZ motif at the C terminus of the 5-HT2B receptor is required for recruitment of the cNOS and iNOS transduction pathways. Indeed, the 5-HT2B receptor-mediated NO coupling is abolished not only upon introduction of a competitor C-terminal 5-HT2B peptide in the three cell types but also in LMTK- fibroblasts expressing a receptor C-terminally truncated or harboring a point mutation within the PDZ domain. The occurrence of a direct functional coupling between the receptor and cNOS activity is supported by highly significant correlations between the binding constants of drugs on the receptor and their effects on cNOS activity. The 5-HT2B/iNOS coupling mechanisms appear more complex because neutralization of endogenous G alpha(13) by specific antibodies cancels the cellular iNOS response while not interfering with cNOS activities. These findings may shed light on physiological links between the 5-HT2B receptor and NO and constitute the first demonstration that PDZ inter actions participate in downstream transductional pathways of a G protein-coupled receptor.	Hop Lariboisiere, Serv Biochim, AP HP,IFR 6, Ctr Rech Claude Bernard Pathol Expt & Commun Cell, F-75010 Paris, France; Inst Pasteur, URA 1960 CNRS, F-75724 Paris, France; Univ Strasbourg, IGBMC, CNRS, INSERM, F-67404 Illkirch, France; Aichi Canc Ctr, Res Inst, Pathol Lab, Nagoya, Aichi 464, Japan	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Aichi Cancer Center	Launay, JM (corresponding author), Hop Lariboisiere, Serv Biochim, AP HP,IFR 6, Ctr Rech Claude Bernard Pathol Expt & Commun Cell, 2 Rue Ambroise Pare, F-75010 Paris, France.		Maroteaux, Luc/H-4585-2019; Manivet, Philippe/AAA-1884-2021; Mouillet, Sophie/E-4960-2017; Nebigil, Canan/AAK-7162-2021; callebert, jacques/L-4569-2017	Maroteaux, Luc/0000-0002-9499-8603; Mouillet, Sophie/0000-0002-8950-1949; Nebigil, Canan/0000-0002-2035-5795; 				Bateson AN, 1996, EUR J PHARMACOL, V303, P141, DOI 10.1016/0014-2999(96)00099-4; BAXTER G, 1995, TRENDS PHARMACOL SCI, V16, P105, DOI 10.1016/S0165-6147(00)88991-9; BERTHOU L, 1992, EUR J CELL BIOL, V58, P377; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BUCCARON MH, 1990, P NATL ACAD SCI USA, V87, P1922, DOI 10.1073/pnas.87.5.1922; BUSH PA, 1992, BIOCHEM BIOPH RES CO, V185, P960, DOI 10.1016/0006-291X(92)91720-B; CABRAL JH, 1999, NATURE, V382, P649; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Choi DS, 1996, FEBS LETT, V391, P45, DOI 10.1016/0014-5793(96)00695-3; CLEMENTI E, 1995, J BIOL CHEM, V270, P22277, DOI 10.1074/jbc.270.38.22277; COX DA, 1995, LIFE SCI, V56, pPL333, DOI 10.1016/0024-3205(94)00097-2; COX DA, 1995, J PHARMACOL EXP THER, V272, P143; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; ELLIS ES, 1995, BRIT J PHARMACOL, V114, P400, DOI 10.1111/j.1476-5381.1995.tb13240.x; GANEM YJ, 1989, BIOGENIC AMINES, V6, P495; Gath I, 1996, FASEB J, V10, P1614, DOI 10.1096/fasebj.10.14.9002553; GEOFFROY C, 1983, J BIOL CHEM, V258, P9968; GLUSA E, 1993, N-S ARCH PHARMACOL, V347, P471, DOI 10.1007/BF00166737; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; KAGAYA A, 1995, J NEURAL TRANSM-GEN, V100, P27, DOI 10.1007/BF01276863; KAUFMAN MJ, 1995, J NEUROCHEM, V64, P199; Kellermann O, 1996, BRIT J PHARMACOL, V118, P1161, DOI 10.1111/j.1476-5381.1996.tb15519.x; Kitamura K, 1996, J BIOL CHEM, V271, P7412, DOI 10.1074/jbc.271.13.7412; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kroeze WK, 1998, BIOL PSYCHIAT, V44, P1128, DOI 10.1016/S0006-3223(98)00132-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Launay JM, 1996, J BIOL CHEM, V271, P3141, DOI 10.1074/jbc.271.6.3141; LORIC S, 1995, MOL PHARMACOL, V47, P458; Lucaites VL, 1996, LIFE SCI, V59, P1081, DOI 10.1016/0024-3205(96)00423-7; Marcoli M, 1997, J NEUROCHEM, V69, P427; Marietta M.A., 1993, J BIOL CHEM, V268, P12231; MEHTA JL, 1995, J LAB CLIN MED, V125, P370; MEULEMANS AL, 1993, N-S ARCH PHARMACOL, V348, P424; MONCADA S, 1991, PHARMACOL REV, V43, P109; PEROUTKA SJ, 1991, SEROTONIN RECEPTOR S; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Schmuck K, 1996, EUR J NEUROSCI, V8, P959, DOI 10.1111/j.1460-9568.1996.tb01583.x; Shimpo M, 1997, EUR J PHARMACOL, V338, P97, DOI 10.1016/S0014-2999(97)01314-9; Tournois C, 1998, J BIOL CHEM, V273, P17498, DOI 10.1074/jbc.273.28.17498; Ullmer C, 1996, BRIT J PHARMACOL, V117, P1081, DOI 10.1111/j.1476-5381.1996.tb16700.x; ULLMER C, 1995, FEBS LETT, V370, P215, DOI 10.1016/0014-5793(95)00828-W; Watts SW, 1996, J PHARMACOL EXP THER, V277, P1103	46	102	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9324	9331		10.1074/jbc.275.13.9324	http://dx.doi.org/10.1074/jbc.275.13.9324			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734074	hybrid			2022-12-27	WOS:000086206500038
J	Thodeti, CK; Adolfsson, J; Juhas, M; Sjolander, A				Thodeti, CK; Adolfsson, J; Juhas, M; Sjolander, A			Leukotriene D-4 triggers an association between G beta gamma subunits and phospholipase C-gamma 1 in intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SMOOTH-MUSCLE CELLS; TYROSINE PHOSPHORYLATION; INTRACELLULAR CA2+; BINDING PROTEIN; C ISOZYMES; ACTIVATION; KINASES; SRC; MOBILIZATION	The proinflammatory mediator leukotriene D-4 (LTD4) binds to the seven transmembrane receptor CYSLT1. Although this leukotriene plays an important biological role, its intracellular signaling pathways are only partly known. In previous experiments, we found that LTD, induced tyrosine phosphorylation and translocation of phospholipase (PLC)-gamma 1 to a plasma membrane fraction in a human epithelial cell line (Int 407). In the present study, we further examined these signaling events and found that LTD, induced a rapid interaction between G beta gamma subunits and PLC-gamma 1; results obtained with GST fusion proteins of PLC-gamma 1 suggest that this interaction is mediated via the pleckstrin homology domain of PLC-gamma 1. Moreover, LTD4 induced an increased association of c-Src with PLC-gamma 1, and the selective Src family tyrosine kinase inhibitor PP1 blocked both LTD4-induced tyro sine phosphorylation of PLC-gamma 1 and the association of PLC-gamma 1 with G beta gamma subunits. The relevance of these observations in intracellular calcium signaling was investigated by microinjecting cells with anti-Gp, anti-PLC-gamma 1, or anti-c-Src antibodies and by pretreatment with PPI, LTD4-induced calcium mobilization was blocked by each of the indicated antibodies (but not isotype-matched control antibodies) and by PP1, Our data suggest that G beta gamma subunits can, directly or indirectly, serve as membrane-bound partners for PLC-gamma 1 and c-Src and that each of these proteins is essential for LTD4-induced downstream PLC-gamma 1 signaling.	Univ Lund, Malmo Univ Hosp, Dept Lab Med, Div Expt Pathol, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital	Sjolander, A (corresponding author), Univ Lund, Malmo Univ Hosp, Dept Lab Med, Div Expt Pathol, Entrance 78,Floor 3, SE-20502 Malmo, Sweden.							Adolfsson JLP, 1996, BIOCHEM BIOPH RES CO, V226, P413, DOI 10.1006/bbrc.1996.1370; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; CROOKE ST, 1989, TRENDS PHARMACOL SCI, V10, P103, DOI 10.1016/0165-6147(89)90206-X; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; Gaudreau R, 1998, BIOCHEM J, V335, P15, DOI 10.1042/bj3350015; Gronroos E, 1996, BIOCHEM J, V316, P239; GRONROOS E, 1995, CELL CALCIUM, V17, P177, DOI 10.1016/0143-4160(95)90032-2; Hackam DJ, 1997, J EXP MED, V186, P955, DOI 10.1084/jem.186.6.955; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HENLE G, 1957, J IMMUNOL, V79, P54; INGLESE J, 1993, J BIOL CHEM, V268, P23735; JACKSON WT, 1996, PROG DRUG RES, V46, P116; Jiang HP, 1996, J BIOL CHEM, V271, P13430, DOI 10.1074/jbc.271.23.13430; Khare S, 1997, J CLIN INVEST, V99, P1831, DOI 10.1172/JCI119350; KIMIECIK TE, 1987, CELL, V49, P65; Lee ZW, 1998, J BIOL CHEM, V273, P12710, DOI 10.1074/jbc.273.21.12710; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LIAO F, 1993, BIOCHEM BIOPH RES CO, V191, P1028, DOI 10.1006/bbrc.1993.1320; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Lynch KR, 1999, NATURE, V399, P789; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; Myung CS, 1999, J BIOL CHEM, V274, P16595, DOI 10.1074/jbc.274.23.16595; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; Owman C, 1996, GENOMICS, V37, P187, DOI 10.1006/geno.1996.0541; PARK DG, 1993, J BIOL CHEM, V268, P4573; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; SATOH T, 1992, J BIOL CHEM, V267, P24149; Schneider T, 1997, TRENDS PHARMACOL SCI, V18, P8, DOI 10.1016/S0165-6147(96)01001-2; SJOLANDER A, 1990, J BIOL CHEM, V265, P20976; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Venema RC, 1998, J BIOL CHEM, V273, P7703, DOI 10.1074/jbc.273.13.7703; WATANABE T, 1990, J BIOL CHEM, V265, P21237; Wu GY, 1998, J BIOL CHEM, V273, P7197, DOI 10.1074/jbc.273.13.7197; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Zhu X, 1996, P NATL ACAD SCI USA, V93, P2827, DOI 10.1073/pnas.93.7.2827	44	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9849	9853		10.1074/jbc.275.13.9849	http://dx.doi.org/10.1074/jbc.275.13.9849			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734140	hybrid			2022-12-27	WOS:000086206500104
J	Tian, H; Sadoski, R; Zhang, L; Yu, CA; Yu, L; Durham, B; Millett, F				Tian, H; Sadoski, R; Zhang, L; Yu, CA; Yu, L; Durham, B; Millett, F			Definition of the interaction domain for cytochrome c on the cytochrome bc(1) complex - Steady-state and rapid kinetic analysis of electron transfer between cytochrome c and Rhodobacter sphaeroides cytochrome bc1 surface mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON TRANSLOCATION; ENERGY TRANSDUCTION; HEART-MITOCHONDRIA; CRYSTAL-STRUCTURE; BINDING-SITE; OXIDASE; PEROXIDASE; DERIVATIVES; REDUCTASE; RESIDUES	The interaction domain for cytochrome c on the cytochrome bc(1) complex was studied using a series of Rhodobacter sphaeroides cytochrome bc(1) mutants in which acidic residues on the surface of cytochrome c(1) were substituted with neutral or basic residues. Intracomplex electron transfer was studied using a cytochrome c derivative labeled with ruthenium trisbipyridine at lysine 72 (Ru-72-Cc), Flash photolysis of a 1:1 complex between Ru-72-Cc and cytochrome bc(1) at low ionic strength resulted in electron transfer from photoreduced heme c to cytochrome c(1) with a rate constant of k(et) = 6 x 10(4) s(-1). Compared with the wild-type enzyme, the mutants substituted at Glu-74, Glu-101, Asp-102, Glu-104, Asp-109, Glu-162, Glu-163, and Glu-168 have significantly lower k(et) values as well as significantly higher equilibrium dissociation constants and steady-state K-m values. Mutations at acidic residues 56, 79, 82, 83, 97, 98, 213, 214, 217, 220, and 223 have no significant effect on either rapid kinetics or steady-state kinetics, These studies indicate that acidic residues on opposite sides of the heme crevice of cytochrome c(1) are involved in binding positively charged cytochrome c. These acidic residues on the intramembrane surface of cytochrome c(1) direct the diffusion and binding of cytochrome c from the intramembrane space.	Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA; Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA	University of Arkansas System; University of Arkansas Fayetteville; Oklahoma State University System; Oklahoma State University - Stillwater	Millett, F (corresponding author), Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA.	millett@comp.uark.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030721, R01GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30721, GM20488] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED AJ, 1978, BIOCHEMISTRY-US, V17, P2479, DOI 10.1021/bi00606a003; BROGER C, 1983, EUR J BIOCHEM, V131, P349, DOI 10.1111/j.1432-1033.1983.tb07269.x; CAPALDI RA, 1972, FEBS LETT, V26, P261, DOI 10.1016/0014-5793(72)80587-8; CHIANG YL, 1976, J BIOL CHEM, V251, P29; DURHAM B, 1989, BIOCHEMISTRY-US, V28, P8659, DOI 10.1021/bi00447a057; GEREN LM, 1995, J BIOL CHEM, V270, P2466, DOI 10.1074/jbc.270.6.2466; GUTWENIGER HE, 1983, BIOCHEM BIOPH RES CO, V116, P272, DOI 10.1016/0006-291X(83)90411-4; HAHM S, 1992, BIOCHEMISTRY-US, V31, P3472, DOI 10.1021/bi00128a022; HALL J, 1987, BIOCHEMISTRY-US, V26, P4501, DOI 10.1021/bi00388a049; HALL J, 1989, BIOCHEMISTRY-US, V28, P2568, DOI 10.1021/bi00432a033; HEACOCK DH, 1993, J BIOL CHEM, V268, P27171; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; KONIG BW, 1980, FEBS LETT, V111, P395, DOI 10.1016/0014-5793(80)80835-0; LEMASTERS JJ, 1978, FEBS LETT, V88, P10, DOI 10.1016/0014-5793(78)80595-X; Mei HK, 1996, BIOCHEMISTRY-US, V35, P15800, DOI 10.1021/bi961487k; MILLER MA, 1994, BIOCHEMISTRY-US, V33, P8686, DOI 10.1021/bi00195a009; PAN LP, 1993, BIOCHEMISTRY-US, V32, P8492, DOI 10.1021/bi00084a014; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; RIEDER R, 1980, J BIOL CHEM, V255, P4732; SCHROEDL NA, 1977, BIOCHEMISTRY-US, V16, P4961, DOI 10.1021/bi00642a003; SMITH HT, 1981, J BIOL CHEM, V256, P4984; SPECK SH, 1979, P NATL ACAD SCI USA, V76, P155, DOI 10.1073/pnas.76.1.155; STONEHUERNER J, 1985, J BIOL CHEM, V260, P5392; Tian H, 1998, J BIOL CHEM, V273, P27953, DOI 10.1074/jbc.273.43.27953; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; Wang KF, 1996, BIOCHEMISTRY-US, V35, P15107, DOI 10.1021/bi9611117; WILLIE A, 1992, BIOCHEMISTRY-US, V31, P7237, DOI 10.1021/bi00147a005; WILLIE A, 1993, BIOCHEMISTRY-US, V32, P7519, DOI 10.1021/bi00080a025; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YU CA, 1983, BIOCHIM BIOPHYS ACTA, V736, P226, DOI 10.1016/0005-2736(83)90288-2; YU CA, 1973, J BIOL CHEM, V248, P528; Yu CA, 1996, BBA-BIOENERGETICS, V1275, P47, DOI 10.1016/0005-2728(96)00049-7; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	34	40	41	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9587	9595		10.1074/jbc.275.13.9587	http://dx.doi.org/10.1074/jbc.275.13.9587			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734109	hybrid			2022-12-27	WOS:000086206500073
J	Wesley, CS; Saez, L				Wesley, CS; Saez, L			Notch responds differently to Delta and Wingless in cultured Drosophila cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLIT COMPLEX GENES; LATERAL INHIBITION; RECEPTOR; PROTEIN; NEUROGENESIS; SUPPRESSOR; EXPRESSION; ENHANCER; ELEMENTS; SIGNAL	Notch, a cell surface receptor, is required for producing different types of cells during development of Drosophila melanogaster. Notch activates expression of one set of genes in response to ligand Delta and another set of genes in response to ligand Wingless. The means by which Notch initiates these different intracellular activities was examined in this study. Cultured cells expressing Notch were treated with Delta or Wingless, and the effect on Notch was examined by Western blotting. Treatment of cells with Delta resulted in accumulation of similar to 120-kDa Notch intracellular domain molecules in the cytoplasmic fraction. This form of Notch did not accumulate in cells treated with Wingless, but the similar to 350-kDa full-length Notch molecules accumulated. These results indicate that N responds differently to binding by Delta and Wingless, and suggest that although the Delta signal is transduced by the Notch intracellular domain released from the plasma membrane, the Wingless signal is transduced by the Notch intracellular domain associated with the plasma membrane.	Rockefeller Univ, Genet Lab, New York, NY 10021 USA	Rockefeller University	Wesley, CS (corresponding author), Rockefeller Univ, Genet Lab, Box 288,1230 York Ave, New York, NY 10021 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025103] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 25103] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Brennan K, 1999, DEV BIOL, V216, P210, DOI 10.1006/dbio.1999.9502; Brennan K, 1999, DEV BIOL, V216, P230, DOI 10.1006/dbio.1999.9501; Brennan K, 1999, CURR BIOL, V9, P707, DOI 10.1016/S0960-9822(99)80313-3; CABRERA CV, 1990, DEVELOPMENT, V109, P733; COUSO JP, 1994, CELL, V79, P259, DOI 10.1016/0092-8674(94)90195-3; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; Klein T, 1998, DEV BIOL, V194, P196, DOI 10.1006/dbio.1997.8829; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; LIEBER T, 1992, NEURON, V9, P847, DOI 10.1016/0896-6273(92)90238-9; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; Sambrook J., 2002, MOL CLONING LAB MANU; SKEATH JB, 1992, DEVELOPMENT, V114, P939; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Wesley CS, 1999, MOL CELL BIOL, V19, P5743; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096	26	28	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9099	9101		10.1074/jbc.275.13.9099	http://dx.doi.org/10.1074/jbc.275.13.9099			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734040	hybrid			2022-12-27	WOS:000086206500004
J	Wolff, EC; Wolff, J; Park, MH				Wolff, EC; Wolff, J; Park, MH			Deoxyhypusine synthase generates and uses bound NADH in a transient hydride transfer mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE ADENINE-DINUCLEOTIDE; ENZYME-SUBSTRATE INTERMEDIATE; EUKARYOTIC CELL-PROLIFERATION; LIVER ALCOHOL-DEHYDROGENASE; HYPUSINE DEPLETION; SPERMIDINE; FLUORESCENCE; INHIBITION; POLYAMINES; FEATURES	Deoxyhypusine is a modified lysine residue. It is formed posttranslationally in the precursor of eukaryotic initiation factor 5A (eIF5A) by deoxyhypusine synthase, employing spermidine as a butylamine donor. In the initial step of this reaction, deoxyhypusine synthase catalyzes the production of NADH through dehydrogenation of spermidine. Fluorescence measurements of this reaction revealed a -22-nm blue shift in the emission peak of NADH and a similar to 15-fold increase in peak intensity, characteristics of tightly bound NADH that were not seen by simply mixing NADH and enzyme. The fluorescent properties of the bound NADH can be ascribed to a hydrophobic environment and a rigidly held, open conformation of NADH, features in accord with the known crystal structure of the enzyme. Considerable fluorescence resonance energy transfer from tryptophan 327 in the active site to the dihydronicotinamide ring of NADH was seen. Upon addition of the eIF5A precursor, utilization of the enzyme-bound NADH for reduction of the eIF5A-imine intermediate to deoxyhypusine was reflected by a rapid decrease in the NADH fluorescence, indicating a transient hydride transfer mechanism as an integral part of the reaction. The number of NADH molecules bound approached four/enzyme tetramer; not all of the bound NADH was available for reduction of the eIF5A-imine intermediate.	NIDCR, NIH, Oral & Pharyngeal Canc Branch, Bethesda, MD 20892 USA; NIDDK, NIH, Lab Biochem & Genet, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wolff, EC (corresponding author), NIDCR, NIH, Oral & Pharyngeal Canc Branch, Bldg 30,Rm 211, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK034002, ZIHDK034002, ZIADK034002] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bell CE, 1997, PROTEIN SCI, V6, P2084; BHATTACHARYYA B, 1984, J BIOL CHEM, V259, P1836; Bhattacharyya U, 1999, J BIOL CHEM, V274, P14573, DOI 10.1074/jbc.274.21.14573; BOTTCHER F, 1994, CAN J CHEM, V72, P80, DOI 10.1139/v94-013; BYERS TL, 1992, BIOCHEM J, V287, P717, DOI 10.1042/bj2870717; BYERS TL, 1994, BIOCHEM J, V303, P363, DOI 10.1042/bj3030363; Chen KY, 1997, BIOL SIGNAL, V6, P105; CHEN KY, 1988, FEBS LETT, V229, P325, DOI 10.1016/0014-5793(88)81149-9; DAWBER JG, 1988, J CHEM SOC FARAD T 1, V84, P713, DOI 10.1039/f19888400713; EKLUND H, 1987, PYRIDINE NUCLEOTIDE, V1, P51; Frey P. A., 1987, PYRIDINE NUCLEOTIDE, P461; GAFNI A, 1976, BIOCHEMISTRY-US, V15, P3165, DOI 10.1021/bi00660a001; JAKUS J, 1993, J BIOL CHEM, V268, P13151; JOE YA, 1994, J BIOL CHEM, V269, P25916; JOE YA, 1995, J BIOL CHEM, V270, P22386, DOI 10.1074/jbc.270.38.22386; Joe YA, 1997, J BIOL CHEM, V272, P32679, DOI 10.1074/jbc.272.51.32679; Kaiser A, 1999, PLANT J, V19, P195, DOI 10.1046/j.1365-313X.1999.00509.x; Lee YB, 1999, BIOCHEM J, V340, P273, DOI 10.1042/0264-6021:3400273; Liao DI, 1998, STRUCTURE, V6, P23, DOI 10.1016/S0969-2126(98)00004-5; Liu YJ, 1997, BIOCHEMISTRY-US, V36, P10675, DOI 10.1021/bi970430a; MAXWELL ES, 1960, J BIOL CHEM, V235, P308; Park MH, 1998, J BIOL CHEM, V273, P1677, DOI 10.1074/jbc.273.3.1677; PARK MH, 1993, TRENDS BIOCHEM SCI, V18, P475, DOI 10.1016/0968-0004(93)90010-K; Park MH, 1997, BIOL SIGNAL, V6, P115; PARK MH, 1988, J BIOL CHEM, V263, P15264; Piersma SR, 1998, BIOCHEMISTRY-US, V37, P3068, DOI 10.1021/bi972115u; Piersma SR, 1997, ADV EXP MED BIOL, V414, P425; REICHARDT C, 1994, CHEM REV, V94, P2319, DOI 10.1021/cr00032a005; Rosorius O, 1999, J CELL SCI, V112, P2369; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; SCOTT TG, 1970, J AM CHEM SOC, V92, P687, DOI 10.1021/ja00706a043; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Tanner JJ, 1999, PROTEIN SCI, V8, P1725, DOI 10.1110/ps.8.9.1725; VELICK SF, 1958, J BIOL CHEM, V233, P1455; VISSER AJW, 1987, PYRIDINE NUCLEOTIDE, V1, P163; WOLFF EC, 1990, J BIOL CHEM, V265, P4793; Wolff EC, 1997, J BIOL CHEM, V272, P15865, DOI 10.1074/jbc.272.25.15865	38	25	26	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9170	9177		10.1074/jbc.275.13.9170	http://dx.doi.org/10.1074/jbc.275.13.9170			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734052	hybrid			2022-12-27	WOS:000086206500016
J	Zwerschke, W; Mannhardt, B; Massimi, P; Nauenburg, S; Pim, D; Nickel, W; Banks, L; Reuser, AJ; Jansen-Durr, P				Zwerschke, W; Mannhardt, B; Massimi, P; Nauenburg, S; Pim, D; Nickel, W; Banks, L; Reuser, AJ; Jansen-Durr, P			Allosteric activation of acid alpha-glucosidase by the human papillomavirus E7 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONKEY COS-1 CELLS; TYPE-16 E7; TRANSFORMING ACTIVITY; HUMAN KERATINOCYTES; GENE-EXPRESSION; CYCLIN-E; ONCOPROTEIN; TRANSACTIVATION; E7-PROTEIN; BINDING	Changes in the cellular carbohydrate metabolism are a hallmark of malignant transformation and represent one of the earliest discernible events in tumorigenesis. In the early stages of certain epithelial cancers, a metabolic switch is regularly observed, in which slowly growing glycogenotic cells are converted to highly proliferating basophilic cells. This step is accompanied by a rapid depletion of the intracellular glycogen stores, which in liver carcinogenesis results from the activation of the enzyme acid alpha-glucosidase by an as yet unknown mechanism. We show here that acid alpha-glucosidase is a target for the E7 protein encoded by human papillomavirus type 16, a human tumor virus that plays a key role in the genesis of cervical carcinoma. We show that expression of E7 induces the catalytic activity of acid alpha-glucosidase in vivo and wild type E7, but not ransformation-deficient mutants bind directly to acid cu-glucosidase and increase the catalytic activity of the enzyme in vitro. The data suggest that the E7 protein encoded by human papillomavirus type 16 can act as an allosteric activator of acid alpha-glucosidase.	Deutsch Krebsforschungszentrum, Forschungsschwerpunkt Angew Tumorvirol, Abt F0301, D-69120 Heidelberg, Germany; Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Heidelberg Univ, Biochem Zentrum Heidelberg, D-69120 Heidelberg, Germany; Erasmus Univ, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands	Helmholtz Association; German Cancer Research Center (DKFZ); International Center for Genetic Engineering & Biotechnology (ICGEB); Ruprecht Karls University Heidelberg; Erasmus University Rotterdam	Jansen-Durr, P (corresponding author), Austrian Acad Sci, Inst Biomed Alternsforsch, Rennweg 10, A-6020 Innsbruck, Austria.	P.Jansen-Duerr@oeaw.ac.at	Jansen-Dürr, Pidder/ABG-2466-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429; Zwerschke, Werner/0000-0003-1137-2953				Alani RM, 1998, J CLIN ONCOL, V16, P330, DOI 10.1200/JCO.1998.16.1.330; [Anonymous], 1934, AM J SURG; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; Ausubel F., 1999, CURRENT PROTOCOLS MO; Bannasch P, 1997, J BIOENERG BIOMEMBR, V29, P303, DOI 10.1023/A:1022438528634; BANNASCH P, 1998, CELL GROWTH ONCOGENE, P191; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; Bijvoet AGA, 1998, HUM MOL GENET, V7, P1815, DOI 10.1093/hmg/7.11.1815; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; DEFEOJONES D, 1993, J VIROL, V67, P716, DOI 10.1128/JVI.67.2.716-725.1993; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; Eigenbrodt E., 1992, Critical Reviews in Oncogenesis, V3, P91; Eigenbrodt E, 1994, BIOCH MOL ASPECTS SE, V2, P311; Franci C, 1996, BIOCHEM J, V314, P33, DOI 10.1042/bj3140033; FUJIKAWA K, 1994, VIROLOGY, V204, P789, DOI 10.1006/viro.1994.1594; Fuller M, 1995, EUR J BIOCHEM, V234, P903, DOI 10.1111/j.1432-1033.1995.903_a.x; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HACKER HJ, 1982, CARCINOGENESIS, V3, P1265, DOI 10.1093/carcin/3.11.1265; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HERMANS MMP, 1991, J BIOL CHEM, V266, P13507; HOEFSLOOT LH, 1988, EMBO J, V7, P1697, DOI 10.1002/j.1460-2075.1988.tb02998.x; HOWLEY PM, 1991, CANCER RES, V51, pS5019; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; KANDA T, 1991, VIROLOGY, V182, P723, DOI 10.1016/0042-6822(91)90613-G; KLIMEK F, 1989, VIRCHOWS ARCH B, V57, P245, DOI 10.1007/BF02899088; LELOIR LUIS F., 1967, NAT CANCER INST MONGR, V27, P3; Massimi P, 1997, J GEN VIROL, V78, P2607, DOI 10.1099/0022-1317-78-10-2607; Mazurek S, 1997, J BIOENERG BIOMEMBR, V29, P315, DOI 10.1023/A:1022490512705; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; MUNGER K, 1989, J VIROL, V63, P4417; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; OUDE ER, 1984, EUR J BIOCHEM, V139, P497; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Reed SI, 1996, BBA-REV CANCER, V1287, P151, DOI 10.1016/0304-419X(96)00006-6; SATO H, 1989, VIROLOGY, V170, P311, DOI 10.1016/0042-6822(89)90386-3; Schulze A, 1998, J VIROL, V72, P2323, DOI 10.1128/JVI.72.3.2323-2334.1998; SMOTKIN D, 1987, J VIROL, V61, P1686, DOI 10.1128/JVI.61.5.1686-1689.1987; VANDERPLOEG AT, 1991, J CLIN INVEST, V87, P513, DOI 10.1172/JCI115025; WEINHOUSE S, 1972, CANCER RES, V32, P2007; WISSELAAR HA, 1993, J BIOL CHEM, V268, P2223; Zatsepina O, 1997, ONCOGENE, V14, P1137, DOI 10.1038/sj.onc.1200946; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZerfassThome K, 1996, ONCOGENE, V13, P2323; Zwerschke W, 2000, ADV CANCER RES, V78, P1; Zwerschke W, 1996, ONCOGENE, V12, P213; Zwerschke W, 1999, P NATL ACAD SCI USA, V96, P1291, DOI 10.1073/pnas.96.4.1291	49	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9534	9541		10.1074/jbc.275.13.9534	http://dx.doi.org/10.1074/jbc.275.13.9534			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734102	hybrid			2022-12-27	WOS:000086206500066
J	Fax, P; Lipinski, KS; Esche, H; Brockmann, D				Fax, P; Lipinski, KS; Esche, H; Brockmann, D			CAMP-independent activation of the adenovirus type 12 E2 promoter correlates with the recruitment of CREB-1/ATF-1, E1A(12S), and CBP to the E2-CRE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING-PROTEIN; RNA-POLYMERASE-II; CYCLIC-AMP; E1A PROTEINS; TRANSCRIPTION FACTORS; ESCHERICHIA-COLI; ONCOGENIC ADENOVIRUS-TYPE-12; TRANSACTIVATION FUNCTION; GEL-ELECTROPHORESIS; MESSENGER-RNAS	Expression of the transcription unit early region 2 (E2) is of crucial importance for adenoviruses because this region encodes proteins essential for viral replication. Here, we demonstrate that the E1A(12S) protein of the oncogenic adenovirus serotype 12 activates the E2 promoter in dependence of the N terminus and the conserved region 1. Activation is mediated through a cAMP-response element that is bound by CREB-1 and ATF-1. Moreover, the Ad12 E2 promoter is inducible by protein kinase A and repressed by either a dominant-negative cAMP-response element-binding protein (CREB) mutant or the highly specific protein kinase A inhibitor protein underscoring the participation of CREB-1/ATF-1 in promoter activation. E1A(12S) binds to CREB-1 and ATF-1 in dependence of the N terminus and CR1 and is recruited to the E2 cAMP-response element through both cellular transcription factors. Most interestingly, point mutations revealed that E1A(12S) domains essential for binding to CREB-1/ATF-1 and for activation of the Ad12 E2 promoter are also essential for binding to the CREB-binding protein. Due to these data and results obtained in DNA-dependent protein-protein interaction assays, we propose a model in which the cAMP-independent activation of the Ad12 E2 promoter is mediated through a ternary complex consisting of CREB-1/ATF-1, E1A(12S) and CREB-binding protein, which assembles on the E2 cAMP-response element.	Univ Essen Gesamthsch, Sch Med, Inst Mol Biol Canc Res, D-45122 Essen, Germany	University of Duisburg Essen	Brockmann, D (corresponding author), Univ Essen Gesamthsch, Sch Med, Inst Mol Biol Canc Res, Hufelandstr 55, D-45122 Essen, Germany.	dieter.brockmann@uni-essen.de						Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKMANN D, 1990, VIROLOGY, V179, P585, DOI 10.1016/0042-6822(90)90125-B; BROCKMANN D, 1995, CURR TOP MICROBIOL, V199, P81; BROCKMANN D, 1995, J BIOL CHEM, V270, P10754, DOI 10.1074/jbc.270.18.10754; Canman CE, 1996, NATURE, V384, P213, DOI 10.1038/384213a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Lee BH, 1997, P NATL ACAD SCI USA, V94, P4481, DOI 10.1073/pnas.94.9.4481; Lee JS, 1996, J BIOL CHEM, V271, P17666, DOI 10.1074/jbc.271.30.17666; LEE KAW, 1989, MOL CELL BIOL, V9, P4390, DOI 10.1128/MCB.9.10.4390; Lipinski KS, 1999, VIROLOGY, V255, P94, DOI 10.1006/viro.1998.9583; Lipinski KS, 1998, VIRUS RES, V54, P99, DOI 10.1016/S0168-1702(98)00003-3; Lipinski KS, 1997, J GEN VIROL, V78, P413, DOI 10.1099/0022-1317-78-2-413; Loeken Mary R., 1993, Gene Expression, V3, P253; LUCHER LA, 1985, J VIROL, V56, P183, DOI 10.1128/JVI.56.1.183-193.1985; LUCHER LA, 1986, J VIROL, V58, P592, DOI 10.1128/JVI.58.2.592-599.1986; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MASSON N, 1993, NUCLEIC ACIDS RES, V21, P4166, DOI 10.1093/nar/21.18.4166; Melkonyan H, 1996, NUCLEIC ACIDS RES, V24, P4356, DOI 10.1093/nar/24.21.4356; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NEVINS JR, 1981, CELL, V26, P213, DOI 10.1016/0092-8674(81)90304-4; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; RICHTER JD, 1988, J VIROL, V62, P1948, DOI 10.1128/JVI.62.6.1948-1955.1988; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SASSONECORSI P, 1988, P NATL ACAD SCI USA, V85, P7192, DOI 10.1073/pnas.85.19.7192; Snowden AW, 1998, BIOCHEM PHARMACOL, V55, P1947, DOI 10.1016/S0006-2952(98)00020-3; SPRENGEL J, 1994, J VIROL, V68, P379, DOI 10.1128/JVI.68.1.379-389.1994; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; SWAMINATHAN S, 1995, CURR TOP MICROBIOL, V199, P177; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; WHITTAKER JL, 1984, MOL CELL BIOL, V4, P110, DOI 10.1128/MCB.4.1.110; WILLIAMS J, 1995, CURR TOP MICROBIOL, V199, P149; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	57	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8911	8920		10.1074/jbc.275.12.8911	http://dx.doi.org/10.1074/jbc.275.12.8911			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722738	hybrid			2022-12-27	WOS:000086507700088
J	Hoffert, JD; Leitch, V; Agre, P; King, LS				Hoffert, JD; Leitch, V; Agre, P; King, LS			Hypertonic induction of aquaporin-5 expression through an ERK-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CANINE KIDNEY-CELLS; WATER CHANNEL; EPITHELIAL-CELLS; ALDOSE REDUCTASE; OSMOTIC-STRESS; MESSENGER-RNA; RENAL-CELLS; MAP KINASE; GENE	Aquaporin-8 (AQPB) is a mater channel protein expressed in lung, salivary gland, and lacrimal gland epithelia. Each of these sites may experience fluctuations in surface liquid osmolarity; however, osmotic regulation of AQP5 expression has not been reported. This study demonstrates that AQP5 is induced by hypertonic stress and that induction requires activation of extracellular signal-regulated kinase (ERK), Incubation of mouse lung epithelial cells (MLE-15) in hypertonic medium produced a dose-dependent increase in AQP5 expression; AQPB protein peaked by 24 h and returned to baseline levels within hours of returning cells to isotonic medium. AQP5 induction was observed only with relatively impermeable solutes, suggesting an osmotic pressure gradient is required for induction. ERK was selectively activated in MLE-15 cells by hypertonic stress, and inhibition of ERR activation with two distinct mitogen-activated extracellular regulated kinase kinase (MEK) inhibitors, U0126 and PD98059, bloched AQP5 induction. AQP5 induction was also observed in the lung, salivary, and lacrimal glands of hyperosmolar rats, suggesting potential physiologic relevance for osmotic regulation of AQP5 expression. This report provides the first example of hypertonic induction of an extrarenal aquaporin, as well as the first association between mitogen-activated protein kinase signaling and aquaporin expression.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	King, LS (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Blalock 910,600 N Wolfe St, Baltimore, MD 21287 USA.	lsking@welch.jhu.edu			NATIONAL EYE INSTITUTE [R01EY011239] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033991, R37HL048268, R01HL048268] Funding Source: NIH RePORTER; NEI NIH HHS [EY11239] Funding Source: Medline; NHLBI NIH HHS [HL33991, HL48268] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON CJ, 1996, EUROPEAN J INT RELAT, V2, P175, DOI DOI 10.1177/1354066196002002002; ANDERSON SD, 1984, J ALLERGY CLIN IMMUN, V73, P660, DOI 10.1016/0091-6749(84)90301-4; ANDERSON SD, 1995, ASTHMA RHINITIS, P1178; Bai CX, 1999, J CLIN INVEST, V103, P555, DOI 10.1172/JCI4138; Berl T, 1997, AM J PHYSIOL-RENAL, V272, pF305, DOI 10.1152/ajprenal.1997.272.3.F305; Blomberg A, 1997, ELECTROPHORESIS, V18, P1429, DOI 10.1002/elps.1150180818; BOUCHER RC, 1981, J APPL PHYSIOL, V50, P613, DOI 10.1152/jappl.1981.50.3.613; BOWEN JW, 1992, AM J PHYSIOL, V262, pC845, DOI 10.1152/ajpcell.1992.262.4.C845; Burg MB, 1996, FASEB J, V10, P1598, DOI 10.1096/fasebj.10.14.9002551; COHEN DM, 1991, AM J PHYSIOL, V261, pC594, DOI 10.1152/ajpcell.1991.261.4.C594; COWLEY BD, 1990, AM J PHYSIOL, V258, pF154, DOI 10.1152/ajprenal.1990.258.1.F154; DAVIS JQ, 1984, J BIOL CHEM, V259, P3550; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; Delporte C, 1996, J BIOL CHEM, V271, P22070, DOI 10.1074/jbc.271.36.22070; Denkert C, 1998, ARCH BIOCHEM BIOPHYS, V354, P172, DOI 10.1006/abbi.1998.0661; Edwards YS, 1998, AM J PHYSIOL-LUNG C, V275, pL670, DOI 10.1152/ajplung.1998.275.4.L670; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; ITOH T, 1994, J CLIN INVEST, V93, P2387, DOI 10.1172/JCI117245; Jenq W, 1998, BIOCHEM BIOPH RES CO, V245, P804, DOI 10.1006/bbrc.1998.8518; King LS, 1996, J CLIN INVEST, V97, P2183, DOI 10.1172/JCI118659; King LS, 1997, AM J PHYSIOL-CELL PH, V273, pC1541, DOI 10.1152/ajpcell.1997.273.5.C1541; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Kultz D, 1998, J EXP BIOL, V201, P3015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHR JW, 1988, LIFE SCI, V43, P271, DOI 10.1016/0024-3205(88)90317-7; Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296; Ma TH, 1999, J BIOL CHEM, V274, P20071, DOI 10.1074/jbc.274.29.20071; MAN SFP, 1979, J APPL PHYSIOL, V46, P205, DOI 10.1152/jappl.1979.46.2.205; MARTIAL S, 1995, J AM SOC NEPHROL, V5, P1971; MCMANUS ML, 1995, NEW ENGL J MED, V333, P1260, DOI 10.1056/NEJM199511093331906; Miyai A, 1996, KIDNEY INT, V50, P819, DOI 10.1038/ki.1996.381; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; Miyakawa H, 1998, AM J PHYSIOL-RENAL, V274, pF753, DOI 10.1152/ajprenal.1998.274.4.F753; Moeckel GW, 1997, AM J PHYSIOL-RENAL, V272, pF100, DOI 10.1152/ajprenal.1997.272.1.F100; Nielsen S, 1997, AM J PHYSIOL-CELL PH, V273, pC1549, DOI 10.1152/ajpcell.1997.273.5.C1549; OLD SE, 1995, INVEST OPHTH VIS SCI, V36, P88; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; RAINA S, 1995, J BIOL CHEM, V270, P1908, DOI 10.1074/jbc.270.4.1908; Rim JS, 1998, J BIOL CHEM, V273, P20615, DOI 10.1074/jbc.273.32.20615; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; Sheikh-Hamad D, 1998, J BIOL CHEM, V273, P1832, DOI 10.1074/jbc.273.3.1832; SMARDO FL, 1992, AM J PHYSIOL, V262, pC776, DOI 10.1152/ajpcell.1992.262.3.C776; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; TERADA Y, 1994, J BIOL CHEM, V269, P31296; van der Wijk T, 1998, BIOCHEM J, V331, P863, DOI 10.1042/bj3310863; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; Wojtaszek PA, 1998, J CLIN INVEST, V102, P1874, DOI 10.1172/JCI4384; Zhang Z, 1998, AM J PHYSIOL-CELL PH, V275, pC1104, DOI 10.1152/ajpcell.1998.275.4.C1104	50	106	114	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					9070	9077		10.1074/jbc.275.12.9070	http://dx.doi.org/10.1074/jbc.275.12.9070			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722758	hybrid			2022-12-27	WOS:000086507700108
J	Lin, T; Genestier, L; Pinkoski, MJ; Castro, A; Nicholas, S; Mogil, R; Paris, F; Fuks, Z; Schuchman, EH; Kolesnick, RN; Green, DR				Lin, T; Genestier, L; Pinkoski, MJ; Castro, A; Nicholas, S; Mogil, R; Paris, F; Fuks, Z; Schuchman, EH; Kolesnick, RN; Green, DR			Role of acidic sphingomyelinase in Fas/CD95-mediated cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-FAS ANTIBODY; INDUCED APOPTOSIS; CD95 FAS/APO-1; IN-VIVO; B-CELLS; MEDIATED APOPTOSIS; CERAMIDE FORMATION; SIGNALING PATHWAY; LIGAND; ACTIVATION	Engagement of the Fas receptor has been reported to induce ceramide generation via activation of acidic sphingomyelinase (aSMase). However, the role of aSMase in Fas-mediated cell, death is controversial. Using genetically engineered mice deficient in the aSMase gene (aSMase(-/-)), we found that thymocytes, concanavalin A-activated T cells, and lipopolysaccharide-activated B cells derived from both aSMase(-/-) and aSMase(+/+) mice were equally sensitive to Fas-mediated cell death, triggered by either anti-Fas antibody or Fas ligand in vitro. Similarly, activation-induced apoptosis of T lymphocytes was unaffected by the status of aSMase, and aSMase(-/-) mice failed to show immunological symptoms seen in animals with defects in Fas function, In vivo, intravenous injection of 3 mu g/25 g mouse body weight of anti-Fas Jo2 antibody into asMase(-/-) mice failed to affect hepatocyte apoptosis or mortality, whereas massive hepatocyte apoptosis and animal death occurred in wild type littermates, Animals heterozygous for aSMase deficiency were also significantly protected. Susceptibility of aSMase(-/-) mice to anti-Fas antibody was demonstrated with higher antibody doses (greater than or equal to 4 mu g/25 g mouse). These data indicate a role for aSMase in Fas-mediated cell death in some but not all tissues.	La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA; Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA	La Jolla Institute for Immunology; Icahn School of Medicine at Mount Sinai; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Green, DR (corresponding author), La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA.	Dgreen5240@aol.com	Genestier, Laurent/H-6443-2016; Paris, francois E/L-4915-2015; Green, Douglas R/N-8083-2018	Genestier, Laurent/0000-0002-0527-4583; Paris, francois E/0000-0002-0176-7348; Green, Douglas R/0000-0002-7332-1417	NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002445] Funding Source: NIH RePORTER; NCI NIH HHS [CA69381, CA42385] Funding Source: Medline; NIDDK NIH HHS [DK02445] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boesen-de Cock JGR, 1998, J BIOL CHEM, V273, P7560, DOI 10.1074/jbc.273.13.7560; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brenner B, 1998, CELL DEATH DIFFER, V5, P29, DOI 10.1038/sj.cdd.4400307; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Brunner T, 1996, INT IMMUNOL, V8, P1017, DOI 10.1093/intimm/8.7.1017; Chang HY, 1999, P NATL ACAD SCI USA, V96, P1252, DOI 10.1073/pnas.96.4.1252; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; De Maria R, 1998, J EXP MED, V187, P897, DOI 10.1084/jem.187.6.897; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Fleck M, 1998, J IMMUNOL, V160, P3766; Gamen S, 1998, CELL DEATH DIFFER, V5, P241, DOI 10.1038/sj.cdd.4400344; Genestier L, 1998, J BIOL CHEM, V273, P5060, DOI 10.1074/jbc.273.9.5060; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Hsu SC, 1998, BLOOD, V91, P2658, DOI 10.1182/blood.V91.8.2658.2658_2658_2663; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Kishimoto H, 1998, J EXP MED, V187, P1427, DOI 10.1084/jem.187.9.1427; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin TS, 1998, J CLIN INVEST, V101, P570, DOI 10.1172/JCI896; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MOGIL RJ, 1995, INT IMMUNOL, V7, P1451, DOI 10.1093/intimm/7.9.1451; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1994, Semin Immunol, V6, P3, DOI 10.1006/smim.1994.1002; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OGASAWARA J, 1995, J EXP MED, V181, P485, DOI 10.1084/jem.181.2.485; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PENA LA, 2000, IN PRESS CANC RES; RATHMELL JC, 1995, NATURE, V376, P181, DOI 10.1038/376181a0; Rathmell JC, 1996, CELL, V87, P319, DOI 10.1016/S0092-8674(00)81349-5; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Sillence DJ, 1997, BIOCHEM J, V324, P29, DOI 10.1042/bj3240029; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Tonnetti L, 1999, J EXP MED, V189, P1581, DOI 10.1084/jem.189.10.1581; Walsh CM, 1998, IMMUNITY, V8, P439, DOI 10.1016/S1074-7613(00)80549-X; Watanabe D, 1995, INT IMMUNOL, V7, P1949, DOI 10.1093/intimm/7.12.1949; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9	51	115	117	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8657	8663		10.1074/jbc.275.12.8657	http://dx.doi.org/10.1074/jbc.275.12.8657			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722706	hybrid			2022-12-27	WOS:000086507700056
J	Kondo, T; Matsuda, T; Kitano, T; Takahashi, A; Tashima, M; Ishikura, H; Umehara, H; Domae, N; Uchiyama, T; Okazaki, T				Kondo, T; Matsuda, T; Kitano, T; Takahashi, A; Tashima, M; Ishikura, H; Umehara, H; Domae, N; Uchiyama, T; Okazaki, T			Role of c-jun expression increased by heat shock- and ceramide-activated caspase-3 in HL-60 cell apoptosis - Possible involvement of ceramide in heat shock-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FAS-INDUCED APOPTOSIS; ICE-LIKE PROTEASE; SACCHAROMYCES-CEREVISIAE; IONIZING-RADIATION; STRESS; DIFFERENTIATION; KINASE; INTERLEUKIN-1-BETA; REQUIREMENT	Ceramide has emerged as a lipid mediator in apoptosis induced by a variety of stresses. As we previously showed that the activation of AP-I, a nuclear transcription factor was indispensable to ceramide-induced apoptosis in human leukemia HL-60 cells (Sawai, H, Okazaki, T., Yamamoto, H., Okano, H., Takeda, Y., Tashima, M., Sawada, H., Okuma, M., Ishikura, H., Umehara, M., and Domae, N. (1995) J. Biol. Chem, 270, 27326-27331), the role and mechanism of heat shock (HS)-increased c-jun expression in apoptosis was here investigated. KS increased morphological changes compatible with apoptosis in human leukemia HL-60 cells, and induced ceramide generation and sphingomyelin hydrolysis with an increase of neutral magnesium-dependent sphingomyelinase activity. When MS failed to induce apoptosis in MS-resistant HL-60 cells, ceramide generation was not detected, suggesting that ceramide was involved in downstream signals required for MS-induced apoptosis. Both MS and N-acetylsphingosine (C-2-ceramide) increased the expression of c-jun/c-fos mRNAs with the peak 2 h after treatment. When we examined whether the inhibition of c-jun expression by its antisense oligodeoxynucleotides (AS) blocked HS- or C-2-ceramide-induced apoptosis, AS of c-jun gene inhibited apoptotic morphological changes and DNA fragmentation whereas did not sense oligodeoxynucleotides. Moreover, a synthetic tetrapeptide, acetyl-Asp-Met-Gln-Asp-aldehyde (DMQD-CRO), which inhibited the formation of active form of caspase-3 more efficiently than those of caspase-4, -6, -7, and -8, blocked both caspase-3 like activity, c-jun expression and apoptosis induced by MS or C,-ceramide, although DMQD-CHO did not affect HS-induced ceramide generation. These results suggested that the ceramide was generated through sphingomyelin hydrolysis by MS-activated neutral, magnesiun-dependent sphingomyelinase and that subsequent c-jun expression through activation of caspase-3 played a role in MS-induced ML-60 cell apoptosis.	Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Sakyo Ku, Kyoto 6068507, Japan; Osaka Den Univ, Dept Med, Cyuo Ku, Osaka 5400008, Japan; Shimane Med Univ, Transfus Div, Izumo, Shimane 6930027, Japan	Kyoto University; Shimane University	Okazaki, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Sakyo Ku, 54 Shogoin Kawaramachi, Kyoto 6068507, Japan.	toshiroo@kuhp.kyoto-u.jp.ac						AMIN V, 1995, NEUROSCI LETT, V200, P85, DOI 10.1016/0304-3940(95)12074-E; Buzzard KA, 1998, J BIOL CHEM, V273, P17147, DOI 10.1074/jbc.273.27.17147; Chang Y, 1995, P NATL ACAD SCI USA, V92, P12275, DOI 10.1073/pnas.92.26.12275; Chant ID, 1996, BRIT J HAEMATOL, V93, P898, DOI 10.1046/j.1365-2141.1996.d01-1737.x; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Darmon AJ, 1996, J BIOL CHEM, V271, P21699, DOI 10.1074/jbc.271.36.21699; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FIELD FJ, 1993, J CLIN INVEST, V92, P2609, DOI 10.1172/JCI116876; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Gamen S, 1996, FEBS LETT, V390, P233, DOI 10.1016/0014-5793(96)00666-7; Greidinger EL, 1996, FEBS LETT, V390, P299, DOI 10.1016/0014-5793(96)00678-3; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Iwamori M, 1996, ANAL BIOCHEM, V238, P29, DOI 10.1006/abio.1996.0245; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Kimura C, 1998, EXP CELL RES, V239, P411, DOI 10.1006/excr.1997.3912; KOLESNICK RN, 1994, BIOCHEM CELL BIOL, V72, P471, DOI 10.1139/o94-063; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Noguchi K, 1996, ONCOGENE, V13, P39; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; SJOHOLM A, 1995, FEBS LETT, V367, P283, DOI 10.1016/0014-5793(95)00470-T; SMITH MJ, 1992, BLOOD, V79, P2107; STRUM JC, 1994, J BIOL CHEM, V269, P15493; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; WANG H, 1987, CANCER RES, V47, P3341; Watts JD, 1997, P NATL ACAD SCI USA, V94, P7292, DOI 10.1073/pnas.94.14.7292; Wells GB, 1998, J BIOL CHEM, V273, P7235, DOI 10.1074/jbc.273.13.7235; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; YANG ZH, 1993, J BIOL CHEM, V268, P20520; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0	45	74	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7668	7676		10.1074/jbc.275.11.7668	http://dx.doi.org/10.1074/jbc.275.11.7668			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713077	hybrid, Green Submitted			2022-12-27	WOS:000085913300037
J	Moraga, F; Janciauskiene, S				Moraga, F; Janciauskiene, S			Activation of primary human monocytes by the oxidized form of alpha 1-antitrypsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-1-PROTEINASE INHIBITOR; LOW-DENSITY-LIPOPROTEIN; TUMOR-NECROSIS-FACTOR; ALPHA-1 PROTEINASE-INHIBITOR; SYNOVIAL-FLUID; OXIDATIVE REGULATION; ELASTASE; INACTIVATION; EXPRESSION; MACROPHAGES	The oxidation of methionine residues in many proteins, including the serine proteinase inhibitor alpha 1-antitrypsin (AAT), can result in functional inactivation. In this study we investigated the pro-inflammatory properties of oxidized AAT (oxAAT), specifically its ability to activate human monocytes in culture. Monocytes stimulated with oxAAT at concentrations up to 0.2 mg/ml for 24 h showed significant elevation in monocyte tractant;tractant protein-1, cytokine interleukin-6, and tumor necrosis factor-a expression and increased NADPH oxidase activity. Monocytes activated with oxAAT showed surprising effects on lipid metabolism. Expression of low density lipoprotein (LDL) receptors increased by up to 76% compared with controls but was not accompanied by any changes in I-125-labeled LDL binding and, paradoxically, decreased LDL uptake, degradation, and intracellular cholesterol synthesis. oxAAT also down-regulated the scavenger receptor CD36, which takes up and is up-regulated by oxidized LDL and is down-regulated by cholesterol efflux, As a by-product of oxidative events accompanying inflammation, oxAAT has multiple effects on cytokine expression, generation of reactive oxygen species,and on intracellular lipid metabolism. The up-regulation of monocyte-derived reactive oxygen by oxAAT could potentially result in self-amplification of AAT oxidation and, thereby, the other effects deriving from it. This implies that there are as yet unidentified regulatory processes that control this cycle.	Malmo Univ Hosp, Dept Med, Gastroenterol Hepatol Sect, S-20502 Malmo, Sweden	Lund University; Skane University Hospital	Janciauskiene, S (corresponding author), MAS, Wallenberg Lab, Dept Med, Div Gastroenterol Hepatol, Ing 46, S-20502 Malmo, Sweden.	Sabina.Janciauskiene@medforsk.mas.lu.se						ABBINK JJ, 1993, ARTHRITIS RHEUM, V36, P168, DOI 10.1002/art.1780360206; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BANDA MJ, 1988, J EXP MED, V167, P1608, DOI 10.1084/jem.167.5.1608; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BIERMAN EL, 1974, CIRC RES, V35, P136, DOI 10.1161/01.RES.35.1.136; Boskovic G, 1998, BBA-MOL CELL RES, V1403, P37, DOI 10.1016/S0167-4889(98)00018-4; CARP H, 1980, J CLIN INVEST, V66, P987, DOI 10.1172/JCI109968; CHIDWICK K, 1991, ANN RHEUM DIS, V50, P915, DOI 10.1136/ard.50.12.915; Dafforn TR, 1999, J BIOL CHEM, V274, P9548, DOI 10.1074/jbc.274.14.9548; DAVIS LG, 1986, BASIC METHODS MOL BI, P129; Draude G, 1999, AM J PHYSIOL-HEART C, V276, pH1144, DOI 10.1152/ajpheart.1999.276.4.H1144; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; GEBOES K, 1982, HISTOPATHOLOGY, V6, P55, DOI 10.1111/j.1365-2559.1982.tb02701.x; Han JH, 1999, J LIPID RES, V40, P830; Han JH, 1997, J BIOL CHEM, V272, P21654, DOI 10.1074/jbc.272.34.21654; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; ISAACSON P, 1981, J CLIN PATHOL, V34, P982, DOI 10.1136/jcp.34.9.982; Janciauskiene S, 1997, SCAND J CLIN LAB INV, V57, P325, DOI 10.3109/00365519709099406; Janciauskiene S, 1999, HEPATOLOGY, V29, P434, DOI 10.1002/hep.510290217; Janciauskiene S, 1999, ATHEROSCLEROSIS, V147, P263, DOI 10.1016/S0021-9150(99)00194-X; Janciauskiene S, 1998, EUR J BIOCHEM, V254, P460, DOI 10.1046/j.1432-1327.1998.2540460.x; JOHNSON D, 1978, J BIOL CHEM, V253, P7142; Jovinge S, 1996, ARTERIOSCL THROM VAS, V16, P1573, DOI 10.1161/01.ATV.16.12.1573; Kataoka H, 1999, AM J PATHOL, V154, P457, DOI 10.1016/S0002-9440(10)65292-3; Knoell DL, 1998, AM J RESP CRIT CARE, V157, P246, DOI 10.1164/ajrccm.157.1.9702033; Koyama H, 1998, THORAX, V53, pS10, DOI 10.1136/thx.53.2008.S10; Kubo N, 1997, FEBS LETT, V409, P177, DOI 10.1016/S0014-5793(97)00501-2; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; MATHESON NR, 1979, BIOCHEM BIOPH RES CO, V88, P402, DOI 10.1016/0006-291X(79)92062-X; Matsuura F, 1999, ATHEROSCLEROSIS, V142, P355, DOI 10.1016/S0021-9150(98)00260-3; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MICHAELIS J, 1990, BIOCHEM J, V270, P809, DOI 10.1042/bj2700809; MOHSENIN V, 1991, J APPL PHYSIOL, V70, P1456, DOI 10.1152/jappl.1991.70.4.1456; MORI T, 1995, AM HEART J, V129, P234, DOI 10.1016/0002-8703(95)90003-9; Nakagawa T, 1998, ARTERIOSCL THROM VAS, V18, P1350, DOI 10.1161/01.ATV.18.8.1350; Norusis M.J., 1993, SPSS WINDOWS VERSION; OSSANNA PJ, 1986, J CLIN INVEST, V77, P1939, DOI 10.1172/JCI112523; PERLMUTTER DH, 1988, J BIOL CHEM, V263, P16499; PERLMUTTER DH, 1985, P NATL ACAD SCI USA, V82, P795, DOI 10.1073/pnas.82.3.795; RAY MB, 1977, CELL TISSUE RES, V185, P63; RICKARD D, 1992, OSTEOPOROSIS INT, V2, P94, DOI 10.1007/BF01623843; SALTER AM, 1986, BIOCHEM J, V240, P549, DOI 10.1042/bj2400549; Scott LJ, 1999, BIOCHEM BIOPH RES CO, V255, P562, DOI 10.1006/bbrc.1999.0247; SEPPER R, 1995, J CLIN IMMUNOL, V15, P27, DOI 10.1007/BF01489487; SMITH EB, 1977, AM J PATHOL, V86, P665; Smith RE, 1997, J LEUKOCYTE BIOL, V62, P612, DOI 10.1002/jlb.62.5.612; SWAIM MW, 1988, J LEUKOCYTE BIOL, V43, P365, DOI 10.1002/jlb.43.4.365; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VOGT W, 1995, FREE RADICAL BIO MED, V18, P93, DOI 10.1016/0891-5849(94)00158-G; WALLAERT B, 1991, AM J RESP CELL MOL, V5, P437, DOI 10.1165/ajrcmb/5.5.437; Wawrzos I, 1996, ACTA BIOCHIM POL, V43, P481; Weber C, 1999, ATHEROSCLEROSIS, V145, P115, DOI 10.1016/S0021-9150(99)00021-0; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WONG PS, 1980, BIOCHEM BIOPH RES CO, V96, P1449, DOI 10.1016/0006-291X(80)90113-8; Yu KCW, 1997, BIOCHEM MOL BIOL INT, V41, P33; Zay K, 1999, AM J PHYSIOL-LUNG C, V276, pL269, DOI 10.1152/ajplung.1999.276.2.L269; ZHANG Z, 1993, FEBS LETT, V321, P274, DOI 10.1016/0014-5793(93)80123-C; ZHU XJ, 1987, BIOCHEM J, V246, P19, DOI 10.1042/bj2460019	59	64	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7693	7700		10.1074/jbc.275.11.7693	http://dx.doi.org/10.1074/jbc.275.11.7693			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713080	hybrid			2022-12-27	WOS:000085913300040
J	Kitaura, H; Shinshi, M; Uchikoshi, Y; Ono, T; Tsurimoto, T; Yoshikawa, H; Iguchi-Ariga, SMM; Ariga, H				Kitaura, H; Shinshi, M; Uchikoshi, Y; Ono, T; Tsurimoto, T; Yoshikawa, H; Iguchi-Ariga, SMM; Ariga, H			Reciprocal regulation via protein-protein interaction between c-myc and p21(cip1/waf1/sdi1) in DNA replication and transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; E-BOX; GROWTH ARREST; GENE; CYCLIN; TARGET; KINASE; ALPHA; ACTIVATION; INHIBITOR	The c-myc protooncogene product (c-Myc) is a transcription factor and is rapidly induced in resting cells following various mitogenic stimuli. c-Myc is thus suggested to play an important role in the transition from quiescence to proliferation. Despite numerous studies, including those on the connection between cyclin E/cyclin-dependent kinase 2 and c-Myc, little has been clarified about c-Myc in terms of the cell cycle regulation. Here we show that c-Myc can directly bind to the carboxyl-terminal region of the cyclin-dependent kinase inhibitor p(21cip1/waf1/sdi1) and thus partially relieves the p21 of the inhibitory effect on DNA synthesis directed by the proliferating cell nuclear antigen-dependent DNA polymerase delta. As for transcription, on the other hand, the p21 binding to the Myc box II region of c-Myc blocks c-Myc-Max complex formation on the E-box and thereby suppresses the transcriptional activation from the E-box by c-Myc. These results suggest that c-Myc activates DNA replication via inactivation of p21 and that p21, vice versa, represses the transcriptional activity of c-Myc. The balance of the reciprocal inactivation between c-Myc and p21 may determine the course of cellular processes such as cell proliferation, differentiation, and apoptosis.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Hokkaido Univ, Coll Med Technol, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Nara Inst Sci & Technol, Fac Biol Sci, Nara 6300101, Japan	Hokkaido University; Hokkaido University; Nara Institute of Science & Technology	Ariga, H (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Kita 12,Nishi 6, Sapporo, Hokkaido 0600812, Japan.	hiro@pharm.hokudai.ac.jp	Ariga, Hiroyoshi/B-5895-2013; Ariga, Sanae/H-9647-2013; Kitaura, Hideki/U-7277-2019	Ariga, Hiroyoshi/0000-0001-7384-2143; Tsurimoto, Toshiki/0000-0001-7597-2216; Ono, Takashi/0000-0002-1820-8040				ALEXANDROVA N, 1995, MOL CELL BIOL, V15, P5188; Amati Bruno, 1998, Frontiers in Bioscience, V3, pD250; Bao JX, 1996, ONCOGENE, V12, P2171; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; CLASSON M, 1990, ONCOGENE, V5, P1371; Dang CV, 1999, MOL CELL BIOL, V19, P1; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fotedar R, 1996, ONCOGENE, V12, P2155; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; Guo QB, 1998, P NATL ACAD SCI USA, V95, P9172, DOI 10.1073/pnas.95.16.9172; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; Hoffman B, 1996, CURR TOP MICROBIOL, V211, P17; Horikawa I, 1999, CANCER RES, V59, P826; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; Mori K, 1998, J BIOL CHEM, V273, P29794, DOI 10.1074/jbc.273.45.29794; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Prendergast GC, 1999, ONCOGENE, V18, P2914, DOI 10.1038/sj.onc.1202784; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Schuldiner O, 1996, P NATL ACAD SCI USA, V93, P7143, DOI 10.1073/pnas.93.14.7143; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Taira T, 1999, J BIOL CHEM, V274, P24270, DOI 10.1074/jbc.274.34.24270; Taira T, 1998, GENES CELLS, V3, P549, DOI 10.1046/j.1365-2443.1998.00206.x; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010	51	115	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10477	10483		10.1074/jbc.275.14.10477	http://dx.doi.org/10.1074/jbc.275.14.10477			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744738	hybrid			2022-12-27	WOS:000086345600079
J	Satoh-Horikawa, K; Nakanishi, H; Takahashi, K; Miyahara, M; Nishimura, M; Tachibana, K; Mizoguchi, A; Takai, Y				Satoh-Horikawa, K; Nakanishi, H; Takahashi, K; Miyahara, M; Nishimura, M; Tachibana, K; Mizoguchi, A; Takai, Y			Nectin-3, a new member of immunoglobulin-like cell adhesion molecules that shows homophilic and heterophilic cell-cell adhesion activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLIOVIRUS RECEPTOR GENE; SIMPLEX VIRUS TYPE-1; BINDING PROTEIN; HOMOLOG; LOCALIZATION; SUPERFAMILY; CLEAVAGE; CLONING; ENTRY	We have isolated a novel cell-cell adhesion system localized at cadherin-based adherens junctions (AJs), This system consists of at least nectin, a Ca2+ -independent immunoglobulin-like adhesion molecule, and afadin, an actin filament-binding protein, that connects nectin to the actin cytoskeleton, Nectin constitutes a family consisting of two members, nectin-1 and -2, We have isolated here a third member of the nectin family and named it nectin-3, Nectin-3 has three splicing variants, nectin-3 alpha (biggest), -3 beta (middle), and -3 gamma (smallest). Like nectin-1 and -2, nectin-3 alpha consists of three extracellular immunoglobulin-like domains, a transmembrane segment, and a cytoplasmic region with the C-terminal consensus motif for binding to the PDZ domain. Nectin-3 alpha formed a cis-homo-dimer and showed Ca2+ -independent trans-homo-interaction to cause hemophilic cell-cell adhesion. Nectin-3 alpha furthermore showed trans-hetero-interaction with nectin-1 or -2 but did not form a cis-hetero-dimer with nectin-1 or -2, Nectin-1 did not show trans-heterointeraction with nectin-2. The affinity of trans-heterointeraction of nectin-3 alpha with nectin-1 or -2 was higher than that of trans homo-interaction of nectin-1, -2, or -3 alpha. Nectin-2 and -3 were ubiquitously expressed, whereas nectin-1 was abundantly expressed in brain. Nectin-3 alpha was colocalized with nectin-2 at cadherin-based AJs and interacted with afadin, These results indicate that the nectin family consists of at least three members, nectin-1, -2, and -3, all of which show hemophilic and heterophilic cell-cell adhesion activities and are localized at cadherin-based AJs.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project,Nishi Ku, Kobe, Hyogo 6512241, Japan; Kyoto Univ, Fac Med, Dept Anat & Neurobiol, Kyoto 6068501, Japan	Osaka University; Japan Science & Technology Agency (JST); Kyoto University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.			Nakanishi, Hiroyuki/0000-0002-9765-0266				Aoki J, 1997, EXP CELL RES, V235, P374, DOI 10.1006/excr.1997.3685; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buchert M, 1999, J CELL BIOL, V144, P361, DOI 10.1083/jcb.144.2.361; CHADENEAU C, 1994, J BIOL CHEM, V269, P15601; Cocchi F, 1998, J VIROL, V72, P9992, DOI 10.1128/JVI.72.12.9992-10002.1998; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; HONIG MG, 1986, J CELL BIOL, V103, P171, DOI 10.1083/jcb.103.1.171; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; MANDELSOHN CL, 1989, CELL, V56, P855; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; MORRISON ME, 1992, J VIROL, V66, P2807, DOI 10.1128/JVI.66.5.2807-2813.1992; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; PRASAD R, 1993, CANCER RES, V53, P5624; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Sambrook J., 2002, MOL CLONING LAB MANU; SIEBER F, 1981, J CELL BIOL, V90, P55, DOI 10.1083/jcb.90.1.55; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Uemura T, 1998, CELL, V93, P1095, DOI 10.1016/S0092-8674(00)81452-X; Warner MS, 1998, VIROLOGY, V246, P179, DOI 10.1006/viro.1998.9218	29	240	253	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10291	10299		10.1074/jbc.275.14.10291	http://dx.doi.org/10.1074/jbc.275.14.10291			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744716	hybrid			2022-12-27	WOS:000086345600057
J	Weissman, JDJ; Howcroft, TK; Singer, DS				Weissman, JDJ; Howcroft, TK; Singer, DS			TAF(II)250-independent transcription can be conferred on a TAF(II)250-dependent basal promoter by upstream activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I GENE; RNA-POLYMERASE-II; NF-KAPPA-B; CELL-LINE; EXPRESSION; ELEMENTS; TBP; SEQUENCE; PROTEIN; BINDING	TAF(II)250, a component of the general transcription factor, TFIID, is required for the transcription of a subset of genes, including those involved in regulating cell cycle progression. The tsBN462 cell line, with a temperature-sensitive mutation of TAF(II)250, grows normally at 32 degrees C, but when grown at 39.5 degrees C, it differentially arrests transcription of many, but not all, genes. The present studies examine the basis for the requirement for TAF(II)250. We show that the basal promoter of a major histocompatibility complex class I gene requires TAF(II)250. This dependence can be overcome by select upstream regulatory elements but not by basal promoter elements. Thus, the coactivator CIITA rescues the basal promoter from the requirement for TAF(II)250, whereas introduction of a canonical TATAA box does not. Similarly, the SV40 basal promoter is shown to require TAF(II)250, and the presence of the 72-base pair enhancer overcomes this requirement. Furthermore, the SV40 72-base pair enhancer when placed upstream of the basal class I promoter renders it independent of TAF(II)250. These data suggest that the assembly of transcription initiation complexes is dynamic and can be modulated by specific transcription factors.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Singer, DS (corresponding author), NCI, Expt Immunol Branch, NIH, Bldg 10,Room 4B-36, Bethesda, MD 20892 USA.							ARNOSTI DN, 1993, EMBO J, V12, P157, DOI 10.1002/j.1460-2075.1993.tb05641.x; Carroll IR, 1998, MOL IMMUNOL, V35, P1171, DOI 10.1016/S0161-5890(98)00107-2; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EHRLICH R, 1988, MOL CELL BIOL, V8, P695, DOI 10.1128/MCB.8.2.695; FRANKLIN CC, 1995, BIOCHEM J, V305, P967, DOI 10.1042/bj3050967; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Guermah M, 1998, MOL CELL BIOL, V18, P3234, DOI 10.1128/MCB.18.6.3234; HAYASHIDA T, 1994, GENE, V141, P267; Howcroft TK, 1999, MOL CELL BIOL, V19, P4788; HOWCROFT TK, 1993, EMBO J, V12, P3163, DOI 10.1002/j.1460-2075.1993.tb05985.x; HOWCROFT TK, 1995, IMMUNITY, V3, P127; KOLLER BH, 1988, J IMMUNOL, V141, P897; LEONARD J, 1989, J VIROL, V63, P4919, DOI 10.1128/JVI.63.11.4919-4924.1989; MAGUIRE JE, 1992, MOL CELL BIOL, V12, P3078, DOI 10.1128/MCB.12.7.3078; Martin BK, 1997, IMMUNITY, V6, P591, DOI 10.1016/S1074-7613(00)80347-7; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Murphy C, 1996, J BIOL CHEM, V271, P30992, DOI 10.1074/jbc.271.48.30992; NAKASHIMA T, 1994, GENE, V141, P193; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; SAJI M, 1992, P NATL ACAD SCI USA, V89, P1944, DOI 10.1073/pnas.89.5.1944; Saji M, 1997, J BIOL CHEM, V272, P20096, DOI 10.1074/jbc.272.32.20096; Sekiguchi T, 1999, ONCOGENE, V18, P1797, DOI 10.1038/sj.onc.1202508; SINGER DS, 1990, CRIT REV IMMUNOL, V10, P235; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WEISSMAN JD, 1991, MOL CELL BIOL, V11, P4217, DOI 10.1128/MCB.11.8.4217; Weissman JD, 1998, P NATL ACAD SCI USA, V95, P11601, DOI 10.1073/pnas.95.20.11601; ZWILLING S, 1994, NUCLEIC ACIDS RES, V22, P1655, DOI 10.1093/nar/22.9.1655	31	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10160	10167		10.1074/jbc.275.14.10160	http://dx.doi.org/10.1074/jbc.275.14.10160			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744699	hybrid			2022-12-27	WOS:000086345600040
J	Arion, D; Sluis-Cremer, N; Parniak, MA				Arion, D; Sluis-Cremer, N; Parniak, MA			Mechanism by which phosphonoformic acid resistance mutations restore 3 '-azido-3 '-deoxythymidine (AZT) sensitivity to AZT-resistant HIV-1 reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HIGH-LEVEL RESISTANCE; MULTIPLE MUTATIONS; ZIDOVUDINE AZT; IN-VITRO; FOSCARNET; SITE; SUSCEPTIBILITY; PROCESSIVITY; CONTRIBUTES	The development of phosphonoformic acid (PFA) resistance against a background of 3'-azido-3'-deoxythymidine (AZT) resistance in human immunodeficiency virus type 1 (HIV-1) restores viral sensitivity to AZT, High level AZT resistance requires multiple mutations (D67N/K70R/T215F/K219Q). In order to characterize the mechanism of PFA resistance-mediated resensitization to AZT, the A114S mutation associated with PFA resistance was introduced into the reverse transcriptase (RT) of both wild type and drug-resistant virus. We previously showed that pyrophosphorolytic removal of chain-terminating AZT is the primary mechanism of the AZT resistance phenotype (Arion, D,, Kaushik, N,, McCormick, S., Borkow, G., and Parniak, M.A. (1998) Biochemistry 37, 15908-15917), Introduction of A114S into the AZT resistance background significantly diminishes both the enhanced pyrophosphorolytic activity and the DNA synthesis processivity associated with the AZT resistant RT, The A114S mutation also alters the nucleotide-dependent phosphorolysis activity associated with AZT resistance. The presence of the A114S mutation therefore severely impairs the mutant enzyme's ability to excise chain-terminating AZT, The decrease in phosphorolytic activity of RT conferred by the PFA resistance A114S mutation resensitizes AZT-resistant HIV-1 to AZT by allowing the latter to again function as a chain terminator of viral DNA synthesis. These data further underscore the importance of phosphorolytic removal of chain-terminating AZT as the primary mechanism of HIV-1 AZT resistance.	Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, AIDS Ctr, Sir Mortimer B Davis Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University	Parniak, MA (corresponding author), Lady Davis Inst Med Res, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.							Arion D, 1999, DRUG RESIST UPDATE, V2, P91, DOI 10.1054/drup.1999.0076; Arion D, 1996, J BIOL CHEM, V271, P19860, DOI 10.1074/jbc.271.33.19860; Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; ARTS EJ, 1994, J BIOL CHEM, V269, P14672; BOUCHER CAB, 1993, ANTIMICROB AGENTS CH, V37, P2231, DOI 10.1128/AAC.37.10.2231; Canard B, 1998, J BIOL CHEM, V273, P14596, DOI 10.1074/jbc.273.23.14596; Fletcher RS, 1996, PROTEIN EXPRES PURIF, V7, P27, DOI 10.1006/prep.1996.0004; Harrigan PR, 1996, J VIROL, V70, P5930, DOI 10.1128/JVI.70.9.5930-5934.1996; Harris D, 1998, J BIOL CHEM, V273, P33624, DOI 10.1074/jbc.273.50.33624; Hooker DJ, 1996, J VIROL, V70, P8010, DOI 10.1128/JVI.70.11.8010-8018.1996; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; LACEY SF, 1992, J BIOL CHEM, V267, P15789; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; MELLORS JW, 1995, ANTIMICROB AGENTS CH, V39, P1087, DOI 10.1128/AAC.39.5.1087; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471; SARAFIANOS SG, 1995, J BIOL CHEM, V270, P19729, DOI 10.1074/jbc.270.34.19729; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; Tachedjian G, 1998, ANTIMICROB AGENTS CH, V42, P3038, DOI 10.1128/AAC.42.11.3038; TACHEDJIAN G, 1995, VIROLOGY, V212, P58, DOI 10.1006/viro.1995.1453; Tachedjian G, 1996, J VIROL, V70, P7171, DOI 10.1128/JVI.70.10.7171-7181.1996	24	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9251	9255		10.1074/jbc.275.13.9251	http://dx.doi.org/10.1074/jbc.275.13.9251			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734063	hybrid			2022-12-27	WOS:000086206500027
J	Fukasawa, Y; Segawa, H; Kim, JY; Chairoungdua, A; Kim, DK; Matsuo, H; Cha, SH; Endou, H; Kanai, Y				Fukasawa, Y; Segawa, H; Kim, JY; Chairoungdua, A; Kim, DK; Matsuo, H; Cha, SH; Endou, H; Kanai, Y			Identification and characterization of a Na+-independent neutral amino acid transporter that associates with the 4F2 heavy chain and exhibits substrate selectivity for small neutral D- and L-amino acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY GLUTAMATE TRANSPORTER; MONOCLONAL-ANTIBODY 4F2; CELL-SURFACE ANTIGEN; RED-BLOOD-CELLS; FUNCTIONAL-CHARACTERIZATION; EXPRESSION CLONING; SYSTEM ASC; ERYTHROCYTES; PROTEIN; CD98	A cDNA was isolated from the mouse brain that encodes a novel Na+-independent neutral amino acid transporter. The encoded protein, designated as Asc-l (asc-type amino acid transporter 1), was found to be structurally related to recently identified mammalian amino acid transporters for the transport systems L, y(+)L, x(C)(-) and b(0,+), which are linked, via a disulfide bond, to the type II membrane glycoproteins, 4F2 heavy chain (4F2hc), or rBAT (related to b(0,+) amino acid transporter). Asc-l required 4F2hc for its functional expression. In Western blot analysis in the nonreducing condition, a 118-kDa band, which seems to correspond to the heterodimeric complex of Asc-l and 4F2hc, was detected in the mouse brain. The band shifted to 33 kDa in the reducing condition, confirming that Asc-1 and 4F2hc are linked via a disulfide bond. Asc-1-mediated transport was not dependent on the presence of Na+ or Cl-. Although Asc-1 showed a high sequence homology (66% identity at the amino acid level) to the Na+-independent broad scope neutral amino acid transporter LATE (Segawa, H., Fukasawa, Y., Miyamoto, K., Takeda, E., Endou, H., and Kanai, Y. (1999) J. Biol. Chem. 274, 19745-19751), Asc-1 also exhibited distinctive substrate selectivity and transport properties. Asc-1 preferred small neutral amino acids such as Gly, L-Ala, L-Ser, L-Thr, and L-Cys, and alpha-aminoisobutyric acid as substrates. Asc-1 also transported D-isomers of the small neutral amino acids, in particular D-Ser, a putative endogenous modulator of N-methyl-D-aspartate-type glutamate receptors, with high affinity. Asc-1 operated preferentially, although not exclusively, in an exchange mode. Asc-1 mRNA was detected in the brain, lung, small intestine, and placenta. The functional properties of Asc-1 seem to be consistent with those of a transporter subserving the Na+-independent small neutral amino acid transport system asc.	Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, Mitaka, Tokyo 1818611, Japan; Univ Tokushima, Sch Med, Dept Clin Nutr, Tokushima 7708503, Japan; Natl Def Med Coll, Dept Physiol 1, Tokorozawa, Saitama 3598513, Japan	Kyorin University; Tokushima University; National Defense Medical College - Japan	Kanai, Y (corresponding author), Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, 6-20-2 Shinkawa, Mitaka, Tokyo 1818611, Japan.			Matsuo, Hirotaka/0000-0003-4302-8719				ALBI JL, 1994, J MEMBRANE BIOL, V140, P189; ALTMAN A, 1984, P NATL ACAD SCI-BIOL, V81, P2176, DOI 10.1073/pnas.81.7.2176; Apiwattanakul N, 1999, MOL PHARMACOL, V55, P847; BARKER GA, 1990, EXP PHYSIOL, V75, P3, DOI 10.1113/expphysiol.1990.sp003382; Chairoungdua A, 1999, J BIOL CHEM, V274, P28845, DOI 10.1074/jbc.274.41.28845; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CHRISTENSEN HN, 1969, J BIOL CHEM, V244, P1510; Feliubadalo L, 1999, NAT GENET, V23, P52, DOI 10.1038/12652; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; FINCHAM DA, 1990, J EXP BIOL, V154, P355; FINCHAM DA, 1985, BIOCHEM J, V227, P13, DOI 10.1042/bj2270013; GALLARDO MA, 1993, J MEMBRANE BIOL, V134, P251; HARA H, 1976, AM J HEMATOL, V1, P453, DOI 10.1002/ajh.2830010410; Hashimoto A, 1997, PROG NEUROBIOL, V52, P325, DOI 10.1016/S0301-0082(97)00019-1; HAYNES BF, 1981, J IMMUNOL, V126, P1409; HEMLER ME, 1982, J IMMUNOL, V129, P623; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Isnard AD, 1996, J MOL BIOL, V262, P473, DOI 10.1006/jmbi.1996.0529; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; KANAI Y, 1992, AM J PHYSIOL, V263, pF1087, DOI 10.1152/ajprenal.1992.263.6.F1087; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; KUHLMANN MK, 1991, J BIOL CHEM, V266, P15042; Mannion BA, 1998, J BIOL CHEM, V273, P33127, DOI 10.1074/jbc.273.50.33127; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; NORMAN PSR, 1987, J MEMBRANE BIOL, V96, P153, DOI 10.1007/BF01869241; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Pfeiffer R, 1998, FEBS LETT, V439, P157, DOI 10.1016/S0014-5793(98)01359-3; Pfeiffer R, 1999, EMBO J, V18, P49, DOI 10.1093/emboj/18.1.49; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; QUACKENBUSH E, 1987, P NATL ACAD SCI USA, V84, P6526, DOI 10.1073/pnas.84.18.6526; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; UtsunomiyaTate N, 1997, FEBS LETT, V416, P312, DOI 10.1016/S0014-5793(97)01232-5; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; VADGAMA JV, 1985, J BIOL CHEM, V260, P2912; YAGITA H, 1986, CANCER RES, V46, P1478; YOUNG JD, 1976, BIOCHEM J, V154, P43, DOI 10.1042/bj1540043; YOUNG JD, 1977, BIOCHEM J, V162, P33, DOI 10.1042/bj1620033; Zerangue N, 1996, J PHYSIOL-LONDON, V493, P419, DOI 10.1113/jphysiol.1996.sp021393	46	209	219	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9690	9698		10.1074/jbc.275.13.9690	http://dx.doi.org/10.1074/jbc.275.13.9690			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734121	hybrid			2022-12-27	WOS:000086206500085
J	Hashimoto, Y; Nunoki, K; Kudo, H; Ishii, K; Taira, N; Yanagisawa, T				Hashimoto, Y; Nunoki, K; Kudo, H; Ishii, K; Taira, N; Yanagisawa, T			Changes in the inactivation of rat Kv1.4 K+ channels induced by varying the number of inactivation particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM-CHANNEL; SUBUNIT STOICHIOMETRY	N-type inactivation of rat Kv1,4 channels with one, two, or four inactivation balls was investigated using homogeneous populations of channels expressed in Xenopus oocytes, Tandem dimeric and tetrameric constructs of Kv1.4 were made, Channels encoded by tandem cDNAs Kv1.4-Rv1.4 Delta 1-145 and Kv1.4-[Kv1.4 Delta 1-145](3) have two or only one tethered inactivation ball, respectively, whereas Kv1,4 itself encodes channels having four inactivation balls. The time constants for inactivation of macroscopic currents were increased significantly as the number of inactivation balls was decreased, whereas the time constants for recovery from inactivation were not modified. The ratios of the rate constants of inactivation (k(inact)) of Kv1.4-Kv1.4 Delta 1-145 and Kv1.4-[Kv1.4 Delta-145](3) channels to that of the Kv1,4 channel were 0.65 and 0.4, respectively, whereas the ratios of the rate constant of recovery (k(rec)) of these channels to that of Kv1,4 were almost unity. The rate constants k(inact) for channels having two and four inactivation balls are smaller than those that would be expected if inactivation balls on each channel are independent, suggesting some interaction occurs between inactivation balls. Furthermore, noninactivating current became apparent as the number of inactivation balls on a channel was decreased.	Tohoku Univ, Sch Med, Dept Pharmacol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Yamagata Univ, Sch Med, Dept Pharmacol, Yamagata 9909585, Japan	Tohoku University; Yamagata University	Nunoki, K (corresponding author), Tohoku Univ, Sch Med, Dept Pharmacol, Aoba Ku, 2-1 Seiryomachi, Sendai, Miyagi 9808575, Japan.							CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CHRISTIE MJ, 1990, NEURON, V2, P405; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; COMER MB, 1994, AM J PHYSIOL-HEART C, V267, pH1383, DOI 10.1152/ajpheart.1994.267.4.H1383; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; GOMEZLAGUNAS F, 1995, BIOPHYS J, V68, P89, DOI 10.1016/S0006-3495(95)80162-1; HOPKINS WF, 1994, J NEUROSCI, V14, P1385, DOI 10.1523/JNEUROSCI.14-03-01385.1994; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Kondoh S, 1997, J BIOL CHEM, V272, P19333, DOI 10.1074/jbc.272.31.19333; LEE TE, 1994, BIOPHYS J, V66, P667, DOI 10.1016/S0006-3495(94)80840-9; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Liu DT, 1996, NEURON, V16, P983, DOI 10.1016/S0896-6273(00)80121-X; MACKINNON R, 1993, SCIENCE, V262, P757, DOI 10.1126/science.7694359; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; NUNOKI K, 1994, J BIOL CHEM, V269, P24138; OKADA H, 1992, BIOCHEM BIOPH RES CO, V189, P430, DOI 10.1016/0006-291X(92)91576-C; PO S, 1993, CIRC RES, V72, P1326, DOI 10.1161/01.RES.72.6.1326; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; RUSSELL SN, 1994, AM J PHYSIOL-CELL PH, V267, pC1729, DOI 10.1152/ajpcell.1994.267.6.C1729; SHEN NV, 1993, NEURON, V11, P67; TAGLIALATELA M, 1994, BIOPHYS J, V65, P179; TSENGCRANK J, 1993, J GEN PHYSIOL, V102, P1057, DOI 10.1085/jgp.102.6.1057; TYTGAT J, 1992, NATURE, V359, P420, DOI 10.1038/359420a0; Yang J, 1995, NEURON, V15, P1441, DOI 10.1016/0896-6273(95)90021-7	25	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9358	9362		10.1074/jbc.275.13.9358	http://dx.doi.org/10.1074/jbc.275.13.9358			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734078	hybrid			2022-12-27	WOS:000086206500042
J	Brar, BK; Jonassen, AK; Stephanou, A; Santilli, G; Railson, J; Knight, RA; Yellon, DM; Latchman, DS				Brar, BK; Jonassen, AK; Stephanou, A; Santilli, G; Railson, J; Knight, RA; Yellon, DM; Latchman, DS			Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICOTROPIN-RELEASING-FACTOR; GROWTH-FACTOR-I; CARDIAC MYOCYTES; FACTOR-RECEPTOR; SKELETAL-MUSCLE; MESSENGER-RNA; RAT MYOCYTES; KINASES; HEART; EXPRESSION	Urocortin (UCN) is a peptide related to hypothalamic corticotrophin-releasing hormone and binds with high affinity to corticotrophin-releasing hormone receptor-2 beta, which is expressed in the heart. In this study, we report that UCN prevented cell death when administered to primary cardiac myocyte cultures both prior to simulated hypoxia/ischemia and at the point of reoxygenation after simulated hypoxia/ischemia. UCN-mediated cell survival was measured by trypan blue exclusion, 3'-OH end labeling of DNA (TUNEL), annexin V, and fluorescence-activated cell sorting. To explore the mechanisms that could be responsible for this effect, we investigated the involvement of MAPK-dependent pathways. UCN caused rapid phosphorylation of ERK1/2-p42/44, and PD98059, which blocks the MEK1-ERK1/2-p42/44 cascade, also inhibited the survival-promoting effect of UCN. Most important, UCN reduced damage in isolated rat hearts ex vivo subjected to regional ischemia/reperfusion, with the protective effect being observed when UCN was given either prior to ischemia or at the time of reperfusion after ischemia. This suggests a novel function of UCN as a cardioprotective agent that could act when given after ischemia, at reperfusion.	Univ London, Inst Child Hlth, London WC1N 1EH, England; UCL Hosp & Med Sch, Hatter Inst Cardiol, London WC1E 6DB, England; Natl Heart & Lung Inst, Dept Cyst Fibrosis, London SW3 6LR, England	University of London; University College London; University of London; University College London; Imperial College London	Brar, BK (corresponding author), Univ London, Inst Child Hlth, 30 Guilford St, London WC1N 1EH, England.		Yellon, Derek M/ABD-5110-2021	Yellon, Derek/0000-0001-7791-9320				Adderley SR, 1999, J BIOL CHEM, V274, P5038, DOI 10.1074/jbc.274.8.5038; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Allen MP, 1999, MOL ENDOCRINOL, V13, P191, DOI 10.1210/me.13.2.191; ANDREE HAM, 1990, J BIOL CHEM, V265, P4923; Bamberger CM, 1998, J CLIN ENDOCR METAB, V83, P708, DOI 10.1210/jc.83.2.708; Brar BK, 1999, J MOL CELL CARDIOL, V31, P135, DOI 10.1006/jmcc.1998.0857; Brar BK, 1999, MOL CELL ENDOCRINOL, V158, P55, DOI 10.1016/S0303-7207(99)00183-5; BUERKE M, 1995, P NATL ACAD SCI USA, V92, P8031, DOI 10.1073/pnas.92.17.8031; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHANG CP, 1993, NEURON, V11, P1187, DOI 10.1016/0896-6273(93)90230-O; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; Clerk A, 1998, J BIOL CHEM, V273, P7228, DOI 10.1074/jbc.273.13.7228; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DeSouza EB, 1995, PSYCHONEUROENDOCRINO, V20, P789, DOI 10.1016/0306-4530(95)00011-9; Donaldson CJ, 1996, ENDOCRINOLOGY, V137, P2167, DOI 10.1210/en.137.5.2167; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ESUMI K, 1991, AM J PHYSIOL, V260, pH1743, DOI 10.1152/ajpheart.1991.260.6.H1743; FOX MW, 1993, STROKE, V24, P1072, DOI 10.1161/01.STR.24.7.1072; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Glynn BP, 1998, AM J OBSTET GYNECOL, V179, P533, DOI 10.1016/S0002-9378(98)70391-6; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Gottowik J, 1997, NEUROPHARMACOLOGY, V36, P1439, DOI 10.1016/S0028-3908(97)00098-1; Heldwein KA, 1996, ENDOCRINOLOGY, V137, P3631, DOI 10.1210/en.137.9.3631; Heldwein KA, 1997, MOL CELL ENDOCRINOL, V131, P167, DOI 10.1016/S0303-7207(97)00103-2; Hupf H, 1999, CIRC RES, V84, P365, DOI 10.1161/01.RES.84.3.365; Iino K, 1999, CLIN ENDOCRINOL, V50, P107, DOI 10.1046/j.1365-2265.1999.00624.x; JONASSEN AK, 2000, IN PRESS J MOL CELL; Kajstura J, 1996, LAB INVEST, V74, P86; KATZ AM, 1994, ANN INTERN MED, V121, P363, DOI 10.7326/0003-4819-121-5-199409010-00009; KISHIMOTO T, 1995, P NATL ACAD SCI USA, V92, P1108, DOI 10.1073/pnas.92.4.1108; Knight RJ, 1996, BIOCHEM BIOPH RES CO, V218, P83, DOI 10.1006/bbrc.1996.0016; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kunisada K, 1998, CIRCULATION, V98, P346, DOI 10.1161/01.CIR.98.4.346; LOVENBERG TW, 1995, P NATL ACAD SCI USA, V92, P836, DOI 10.1073/pnas.92.3.836; Mackay K, 1999, J BIOL CHEM, V274, P6272, DOI 10.1074/jbc.274.10.6272; Makino S, 1998, LIFE SCI, V62, P515, DOI 10.1016/S0024-3205(97)01147-8; Matsumura K, 1998, CIRCULATION, V97, P795, DOI 10.1161/01.CIR.97.8.795; Maulik N, 1996, FEBS LETT, V396, P233, DOI 10.1016/0014-5793(96)01109-X; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Okosi A, 1998, NEUROPEPTIDES, V32, P167, DOI 10.1016/S0143-4179(98)90033-6; Parkes DG, 1997, AM J PHYSIOL-HEART C, V272, pH2115, DOI 10.1152/ajpheart.1997.272.5.H2115; Petraglia F, 1996, J CLIN ENDOCR METAB, V81, P3807, DOI 10.1210/jc.81.10.3807; PLOTSKY PM, 1991, J NEUROENDOCRINOL, V3, P1, DOI 10.1111/j.1365-2826.1991.tb00231.x; Rossant CJ, 1999, ENDOCRINOLOGY, V140, P1525, DOI 10.1210/en.140.4.1525; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Sheng ZL, 1996, DEVELOPMENT, V122, P419; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; Shimizu N, 1998, CARDIOVASC RES, V38, P116, DOI 10.1016/S0008-6363(97)00327-1; SIMPSON P, 1982, CIRC RES, V50, P101, DOI 10.1161/01.RES.50.1.101; STENZEL P, 1995, MOL ENDOCRINOL, V9, P637, DOI 10.1210/me.9.5.637; Stephanou A, 1998, J MOL CELL CARDIOL, V30, P849, DOI 10.1006/jmcc.1998.0651; Torpy DJ, 1999, NEUROIMMUNOMODULAT, V6, P182, DOI 10.1159/000026380; UMANSKY SR, 1997, ADV PHARMACOL, V41, P308; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VAUGHAN J, 1995, NATURE, V378, P287, DOI 10.1038/378287a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yeh JH, 1998, J EXP MED, V188, P1795, DOI 10.1084/jem.188.10.1795; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943	59	221	230	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8508	8514		10.1074/jbc.275.12.8508	http://dx.doi.org/10.1074/jbc.275.12.8508			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722688	hybrid			2022-12-27	WOS:000086507700038
J	Gerhardstein, BL; Gao, TY; Bunemann, M; Puri, TS; Adair, A; Ma, H; Hosey, MM				Gerhardstein, BL; Gao, TY; Bunemann, M; Puri, TS; Adair, A; Ma, H; Hosey, MM			Proteolytic processing of the C terminus of the alpha(1C) subunit of L-type calcium channels and the role of a proline-rich domain in membrane tethering of proteolytic fragments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; NEURONAL CLASS-C; 2 SIZE FORMS; CA2+ CHANNELS; ALPHA-1 SUBUNIT; SUBCELLULAR-LOCALIZATION; FUNCTIONAL EXPRESSION; CARBOXYL-TERMINUS; PHOSPHORYLATION; DIHYDROPYRIDINE	Although most L-type calcium channel alpha(1C) subunits isolated from heart or brain are similar to 190-kDa proteins that lack similar to 50 kDa of the C terminus, the C-terminal domain is present in intact cells. To test the hypothesis that the C terminus is processed but remains functionally associated with the channels, expressed, full-length alpha(1C) subunits mere cleaved in vitro by chymotrypsin to generate a 190-kDa C-terminal truncated protein and C-terminal fragments of 30-56 kDa, These hydrophilic C-terminal fragments remained membrane-associated, A C-terminal proline-rich domain (PRD) was identified as the mediator of membrane association. The alpha(1C) PRD bound to SH3 domains in Src, Lyn, Hck, and the channel beta(2) subunit. Mutant alpha(1C) Subunits lacking either similar to 50 kDa of the C terminus or the PRD produced increased barium currents through the channels, demonstrating that these domains participate in the previously described (Wei, X., Neely, a., Lacerda, A. E, Olcese, r,, Stefani, E,, Perez-Reges, E., and Birnbaumer, L,, (1994) J. Biol. Chem. 269, 1635-1640) inhibition of channel function by the C terminus.	Northwestern Univ, Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA	Northwestern University	Hosey, MM (corresponding author), Northwestern Univ, Sch Med, Dept Mol Pharmacol & Biol Chem, 303 E Chicago Ave,S215, Chicago, IL 60611 USA.				NHLBI NIH HHS [R01 HL23306] Funding Source: Medline; NIDDK NIH HHS [T32-DK07169] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007169] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; Blair LAC, 1997, NEURON, V19, P421, DOI 10.1016/S0896-6273(00)80950-2; Blair LAC, 1999, J NEUROSCI, V19, P1940; BRAWLEY RM, 1992, J BIOL CHEM, V267, P18218; CHANG FC, 1988, J BIOL CHEM, V263, P18929; Chien AJ, 1998, J BIOL CHEM, V273, P23590, DOI 10.1074/jbc.273.36.23590; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; DeJongh KS, 1996, BIOCHEMISTRY-US, V35, P10392, DOI 10.1021/bi953023c; DEJONGH KS, 1991, P NATL ACAD SCI USA, V88, P10778, DOI 10.1073/pnas.88.23.10778; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gao TY, 1997, J BIOL CHEM, V272, P19401, DOI 10.1074/jbc.272.31.19401; HAASE H, 1991, EUR J PHARM-MOLEC PH, V207, P51, DOI 10.1016/S0922-4106(05)80037-9; HADDAD J, 1988, AM J PHYSIOL, V255, pC19, DOI 10.1152/ajpcell.1988.255.1.C19; HEATH R, 1987, BIOCHEM INT, V14, P675; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; Hell JW, 1996, P NATL ACAD SCI USA, V93, P3362, DOI 10.1073/pnas.93.8.3362; HELL JW, 1993, J BIOL CHEM, V268, P19451; Hu XQ, 1998, J BIOL CHEM, V273, P5337, DOI 10.1074/jbc.273.9.5337; IHARA Y, 1995, MOL ENDOCRINOL, V9, P121, DOI 10.1210/me.9.1.121; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453; MEYERS MB, 1995, J BIOL CHEM, V270, P26411, DOI 10.1074/jbc.270.44.26411; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Mitterdorfer J, 1996, BIOCHEMISTRY-US, V35, P9400, DOI 10.1021/bi960683o; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; Perets T, 1996, FEBS LETT, V384, P189, DOI 10.1016/0014-5793(96)00303-1; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Puri TS, 1997, BIOCHEMISTRY-US, V36, P9605, DOI 10.1021/bi970500d; PURI TS, 1998, THESIS NW U; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; STAUBER WT, 1986, BASIC APPL HISTOCHEM, V30, P147; WEI XY, 1994, J BIOL CHEM, V269, P1635; WU JC, 1989, J BIOL CHEM, V264, P7989; YOSHIDA A, 1992, FEBS LETT, V309, P343, DOI 10.1016/0014-5793(92)80804-P	38	92	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8556	8563		10.1074/jbc.275.12.8556	http://dx.doi.org/10.1074/jbc.275.12.8556			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722694	hybrid			2022-12-27	WOS:000086507700044
J	Noti, JD; Johnson, AK; Dillon, JD				Noti, JD; Johnson, AK; Dillon, JD			Structural and functional characterization of the leukocyte integrin gene CD11d - Essential role of Sp1 and Sp3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATES TRANSCRIPTIONAL ACTIVATION; PROMOTER DIRECTS EXPRESSION; FAMILY PROTEINS; ALPHA-SUBUNIT; MYELOID DIFFERENTIATION; MONOCLONAL-ANTIBODY; BINDING PROTEINS; TRANSGENIC MICE; ANTIGEN LFA-1; RB PROTEIN	CD11d encodes the latest alpha-subunit of the leukocyte integrin family to be discovered, and it is expressed predominantly in myelomonocytic cells. We have isolated a genomic clone that contains CD11d and showed this gene to be 11,461 bp downstream and oriented in the same direction as the related CD11c gene. CD11d transcription beans 69-79 nucleotides upstream of the ATG codon. Transfection analysis of CD11d-luc reporter constructs revealed that the -173 to +74 region is sufficient to confer leukocyte-specific expression of luciferase in myelomonocytic cells (THP1 and HL60), B cells (IM9), and T-cells (Jurkat). Transfection analysis showed that down-regulation of CD11d expression by phorbol ester was myelomonocyte-specific and is mediated by one or more cis-elements within the -173 to +74 region. In vitro DNase I footprint analysis and electrophoretic mobility shift analysis showed that Spl and Sp3 bind at -63 to -40. Deletion of the Sp-binding site significantly reduced CD11d promoter activity. Overexpression of either Spl or Sp3 in THP1 cells led to activation of the CD11d promoter even in the presence of phorbol ester, whereas down-regulation of either factor by antisense oligonucleotides decreased CD11d promoter activity. In contrast, overexpression of Sp3 in IM9 and Jurkat cells down-regulated CD11d promoter expression. In vivo genomic footprinting revealed that the -63 to -40 region is bound by a Sp protein in unstimulated HL60 cells but not in phorbol ester-stimulated HL60 cells. In contrast, this site is bound in both unstimulated and phorbol ester stimulated IM9 and Jurkat cells. Together, these results show that myelomonocyte-specific phorbol ester down-regulation of CD11d is mediated through both Spl and Sp3.	Guthrie Res Inst, Sayre, PA 18840 USA		Noti, JD (corresponding author), 1 Guthrie Sq, Sayre, PA 18840 USA.	jnoti@inet.guthrie.org						BACK A, 1995, BLOOD, V85, P1017, DOI 10.1182/blood.V85.4.1017.bloodjournal8541017; BACK AL, 1992, J IMMUNOL, V148, P710; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; DAVIGNON D, 1981, J IMMUNOL, V127, P590; Fischer A, 1988, Immunodefic Rev, V1, P39; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; HICKSTEIN DD, 1989, J BIOL CHEM, V264, P21812; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KEIZER GD, 1987, EUR J IMMUNOL, V17, P1317, DOI 10.1002/eji.1830170915; KEIZER GD, 1987, J IMMUNOL, V138, P3130; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KRADY JK, 1995, MOL CELL BIOL, V15, P524, DOI 10.1128/MCB.15.1.524; KURZINGER K, 1981, J IMMUNOL, V127, P596; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LAW SKA, 1987, EMBO J, V6, P915, DOI 10.1002/j.1460-2075.1987.tb04838.x; LOPEZCABRERA M, 1993, J BIOL CHEM, V268, P1187; LopezRodriguez C, 1997, EUR J IMMUNOL, V27, P1843, DOI 10.1002/eji.1830270804; LopezRodriguez C, 1995, EUR J IMMUNOL, V25, P3496, DOI 10.1002/eji.1830251243; LopezRodriguez C, 1997, J BIOL CHEM, V272, P29120, DOI 10.1074/jbc.272.46.29120; LUCA PD, 1996, J BIOL CHEM, V271, P8533; MARTZ E, 1987, HUM IMMUNOL, V18, P3, DOI 10.1016/0198-8859(87)90110-8; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MILLER LJ, 1986, J IMMUNOL, V137, P2891; MUELLER P, 1995, CURRENT PROTOCOLS MO; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; Noti JD, 1996, MOL IMMUNOL, V33, P115, DOI 10.1016/0161-5890(95)00140-9; Noti JD, 1996, BIOTECHNIQUES, V20, P174; NOTI JD, 1992, DNA CELL BIOL, V11, P123, DOI 10.1089/dna.1992.11.123; NOTI JD, 1995, MOL IMMUNOL, V32, P361, DOI 10.1016/0161-5890(94)00164-V; Noti JD, 1996, MOL CELL BIOL, V16, P2940; NUEDA A, 1993, J BIOL CHEM, V268, P19305; PAHL HL, 1992, BLOOD, V79, P865; PAHL HL, 1993, J BIOL CHEM, V268, P5014; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; RITCHIE KA, 1995, BLOOD, V86, P147, DOI 10.1182/blood.V86.1.147.bloodjournal861147; ROSMARIN AG, 1989, BLOOD, V73, P131; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; Shelley CS, 1998, GENOMICS, V49, P334, DOI 10.1006/geno.1998.5232; Sjottem E, 1996, J VIROL, V70, P188; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; SPRINGER TA, 1986, J IMMUNOL, V136, P240; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; Wong DA, 1996, GENE, V171, P291, DOI 10.1016/0378-1119(95)00869-1	57	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8959	8969		10.1074/jbc.275.12.8959	http://dx.doi.org/10.1074/jbc.275.12.8959			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722744	hybrid			2022-12-27	WOS:000086507700094
J	Wagner, BL; Bauer, A; Schutz, G; Montminy, M				Wagner, BL; Bauer, A; Schutz, G; Montminy, M			Stimulus-specific interaction between activator-coactivator cognates revealed with a novel complex-specific antiserum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR CREB; ELEMENT-BINDING PROTEIN; RNA-POLYMERASE-II; DEPENDENT ACTIVATOR; CD4 RECEPTOR; CAMP; KINASE; CBP; PHOSPHORYLATION; INDUCTION	A number of second messenger pathways propagate inductive signals via protein-protein interactions that are phosphorylation-dependent. The second messenger, cAMP, for example, promotes cellular gene expression via the protein kinase A-mediated phosphorylation of cAMP-response element-binding protein (CREB) at Ser(133), and this modification in turn stimulates the association of CREB with the co-activator, CREB-binding protein (CBP), The solution structure of the CREB CBP complex, using relevant interaction domains, kinase inducible domain and kinase-induced domain interacting domain, referred to as KID and KIX, respectively, shows that KID undergoes a coil to helix transition, upon binding to KM, that stabilizes complex formation. Whether such changes occur in the context of the full-length CREB and CBP proteins, however, is unclear. Here we characterize a novel antiserum that specifically binds to the CREB CBP complex but to neither protein individually, Epitope mapping experiments demonstrate that the CREB CEP antiserum detects residues in KID that undergo a conformational change upon binding to KIX, The ability of this antiserum to recognize full length CREB CBP complexes in a phospho-(Ser(133))-dependent manner demonstrates that the structural transition observed with the isolated KID domain also occurs in the context of the full-length CREB protein. To our knowledge, this is the first report documenting formation of endogenous cellular protein-protein complexes in situ.	Salk Inst Biol Studies, Peptide Biol Labs, La Jolla, CA 92037 USA; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Salk Institute; Helmholtz Association; German Cancer Research Center (DKFZ)	Montminy, M (corresponding author), Salk Inst Biol Studies, Peptide Biol Labs, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NIDDK NIH HHS [F32-DK09806] Funding Source: Medline; NIGMS NIH HHS [R01-GM37828] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009806] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037828] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; BRINDLE P, 1995, P NATL ACAD SCI USA, V92, P10521, DOI 10.1073/pnas.92.23.10521; CESARE DD, 1998, P NATL ACAD SCI USA, V95, P12202; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DEVICO AL, 1995, VIROLOGY, V211, P583; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Lee S, 1997, J VIROL, V71, P6037, DOI 10.1128/JVI.71.8.6037-6043.1997; McKenna NJ, 1998, P NATL ACAD SCI USA, V95, P11697, DOI 10.1073/pnas.95.20.11697; MONTMINY MR, 1986, J NEUROSCI, V6, P803; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Parker D, 1998, MOL CELL, V2, P353, DOI 10.1016/S1097-2765(00)80279-8; Pugazhenthi S, 1999, J BIOL CHEM, V274, P2829, DOI 10.1074/jbc.274.5.2829; QUINN PG, 1993, J BIOL CHEM, V268, P16999; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; Seternes OM, 1999, MOL ENDOCRINOL, V13, P1071, DOI 10.1210/me.13.7.1071; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594	27	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8263	8266		10.1074/jbc.275.12.8263	http://dx.doi.org/10.1074/jbc.275.12.8263			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722651	hybrid			2022-12-27	WOS:000086507700001
J	Zhang, ZM; Hong, ZL; Verma, DPS				Zhang, ZM; Hong, ZL; Verma, DPS			Phragmoplastin polymerizes into spiral coiled structures via intermolecular interaction of two self-assembly domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CONFORMATIONAL CHANGE; GLUTATHIONE-S-TRANSFERASE; DYNAMIN-LIKE PROTEIN; MOUSE MX1 PROTEIN; ARABIDOPSIS-THALIANA; FUSION PROTEINS; GTPASE; IDENTIFICATION; YEAST; OLIGOMERIZATION	Phragmoplastin, a high molecular weight GTPase belonging to the dynamin superfamily of proteins, becomes associated with the cell plate during cytokinesis in plants. Growth of the cell plate requires continuous fusion of vesicles, and phragmoplastin appears to play a role in the formation of vesicle-tubule-vesicle structures at the cell plate. In this study, we have demonstrated that two self-assembly domains (SA1 and SA2) are involved in polymerization of phragmoplastin. SA1 is about 42 amino acids long and is located near the N terminus overlapping with the GTP-binding region. SA2, containing at least 24 amino acids, is located in the middle of the molecule outside the GTP-binding domain. Peptides containing either SA1 or SA2 interact efficiently with the full-length phragmoplastin. The SA1 domain of one phragmoplastin molecule also binds to SA2 of another as confirmed in vitro by using radiolabeled peptides, This interaction leads to the formation of polymers with a staggered contoured spiral structure, Electron microscopy studies revealed that helical arrays of phragmoplastin can be induced by reducing salt concentration. Our results suggest that phragmoplastin may assemble into helical arrays that wrap around and squeeze vesicles into vesicle-tubule-vesicle structures observed on the forming cell plate.	Ohio State Univ, Ctr Plant Biotechnol, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Verma, DPS (corresponding author), Ohio State Univ, Ctr Plant Biotechnol, 1060 Carmack Rd, Columbus, OH 43210 USA.		Hong, Zonglie/F-5679-2010; Zhang, Zhongming/C-9728-2015	Hong, Zonglie/0000-0001-9057-4128; Zhang, Zhongming/0000-0003-1124-5989				Carr JF, 1997, J BIOL CHEM, V272, P28030, DOI 10.1074/jbc.272.44.28030; DOMBROWSKI JE, 1995, PLANT MOL BIOL, V28, P1121, DOI 10.1007/BF00032672; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gu XJ, 1996, EMBO J, V15, P695, DOI 10.1002/j.1460-2075.1996.tb00405.x; Gu XJ, 1997, PLANT CELL, V9, P157, DOI 10.1105/tpc.9.2.157; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Imoto M, 1998, J CELL SCI, V111, P1341; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; Kang SG, 1998, PLANT MOL BIOL, V38, P437, DOI 10.1023/A:1006099718761; Kim J, 1997, P NATL ACAD SCI USA, V94, P11786, DOI 10.1073/pnas.94.22.11786; Klein DE, 1998, J BIOL CHEM, V273, P27725, DOI 10.1074/jbc.273.42.27725; Lauber MH, 1997, J CELL BIOL, V139, P1485, DOI 10.1083/jcb.139.6.1485; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; McNiven MA, 1998, CELL, V94, P151, DOI 10.1016/S0092-8674(00)81414-2; MELEN K, 1992, J BIOL CHEM, V267, P25898; NAKAYAMA M, 1991, J BIOL CHEM, V266, P21404; NAKAYAMA M, 1993, J BIOL CHEM, V268, P15033; Nevels M, 1999, BIOTECHNIQUES, V26, P57, DOI 10.2144/99261bm08; Okamoto PM, 1999, J BIOL CHEM, V274, P10277, DOI 10.1074/jbc.274.15.10277; Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333; Park JM, 1998, EMBO J, V17, P859, DOI 10.1093/emboj/17.4.859; SAMUELS AL, 1995, J CELL BIOL, V130, P1345, DOI 10.1083/jcb.130.6.1345; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schumacher B, 1998, J BIOL CHEM, V273, P28365, DOI 10.1074/jbc.273.43.28365; Shin HW, 1999, J BIOL CHEM, V274, P2780, DOI 10.1074/jbc.274.5.2780; Shin HW, 1997, J BIOCHEM-TOKYO, V122, P525; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Smirnova E, 1999, J BIOL CHEM, V274, P14942, DOI 10.1074/jbc.274.21.14942; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377	35	37	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8779	8784		10.1074/jbc.275.12.8779	http://dx.doi.org/10.1074/jbc.275.12.8779			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722722	hybrid			2022-12-27	WOS:000086507700072
J	Chan, DW; Son, SC; Block, W; Ye, RQ; Khanna, KK; Wold, MS; Douglas, P; Goodarzi, AA; Pelley, J; Taya, Y; Lavin, MF; Lees-Miller, SP				Chan, DW; Son, SC; Block, W; Ye, RQ; Khanna, KK; Wold, MS; Douglas, P; Goodarzi, AA; Pelley, J; Taya, Y; Lavin, MF; Lees-Miller, SP			Purification and characterization of ATM from human placenta - A manganese-dependent, wortmannin-sensitive serine/threonine protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATAXIA-TELANGIECTASIA GENE; STRANDED DNA; PHOSPHATIDYLINOSITOL 3-KINASE; CATALYTIC SUBUNIT; KU-AUTOANTIGEN; P34 SUBUNIT; P53; PHOSPHORYLATION; BINDING; EXPRESSION	ATM is mutated in the human genetic disorder ataxia telangiectasia, which is characterized by ataxia, immune defects, and cancer predisposition. Cells that lack ATM exhibit delayed up-regulation of p53 in response to ionizing radiation. Serine 15 of p53 is phosphorylated in vivo in response to ionizing radiation, and antibodies to ATM immunoprecipitate a protein kinase activity that, in the presence of manganese, phosphorylates p53 at serine 15. Immunoprecipitates of ATM also phosphorylate PHAS-I in a manganese-dependent manner. Here we have purified ATM from human cells using nine chromatographic steps. Highly purified ATM phosphorylated PHAS-I, the 32-kDa subunit of RPA, serine 15 of p53, and Chk2 in vitro. The majority of the ATM phosphorylation sites in Chk2 were located in the amino-terminal 57 amino acids. In each case, phosphorylation was strictly dependent on manganese. ATM protein kinase activity was inhibited by wortmannin with an IC50 of approximately 100 nM. Phosphorylation of RPA, but not p53, Chk2, or PHAS-I, was stimulated by DNA. The related protein, DNA-dependent protein kinase catalytic subunit, also phosphorylated PHAS-I, RPA, and Chk2 in the presence of manganese, suggesting that the requirement for manganese is a characteristic of this class of enzyme.	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; PO Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Univ Iowa, Coll Med, Dept Biochem, Iowa City, IA USA; Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 104, Japan	University of Calgary; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Iowa; National Cancer Center - Japan	Lees-Miller, SP (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr 1 NW, Calgary, AB T2N 1N4, Canada.		Wold, Marc/F-5806-2010; Lavin, Martin F/F-5961-2014	Lavin, Martin F/0000-0002-5940-4769; Lees-Miller, Susan/0000-0001-5809-2516; Khanna, Kum Kum/0000-0001-8650-5381; Wold, Marc/0000-0002-4580-1624				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chan DW, 1996, BIOCHEM CELL BIOL, V74, P67, DOI 10.1139/o96-007; Chan DW, 1998, INT J RADIAT BIOL, V74, P217, DOI 10.1080/095530098141591; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; NAKAMURA Y, 1998, NAT GENET, V11, P1231; Niu HW, 1997, J BIOL CHEM, V272, P12634, DOI 10.1074/jbc.272.19.12634; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Scott SP, 1998, BIOCHEM BIOPH RES CO, V245, P144, DOI 10.1006/bbrc.1998.8137; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; Suzuki K, 1999, J BIOL CHEM, V274, P25571, DOI 10.1074/jbc.274.36.25571; Ting NSY, 1998, J BIOL CHEM, V273, P2136, DOI 10.1074/jbc.273.4.2136; Weinfeld M, 1997, RADIAT RES, V148, P22, DOI 10.2307/3579534; West RB, 1998, MOL CELL BIOL, V18, P5908, DOI 10.1128/MCB.18.10.5908; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; ZernikKobak M, 1997, J BIOL CHEM, V272, P23896, DOI 10.1074/jbc.272.38.23896; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	42	105	109	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7803	7810		10.1074/jbc.275.11.7803	http://dx.doi.org/10.1074/jbc.275.11.7803			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713094	hybrid			2022-12-27	WOS:000085913300054
J	Menetski, JP				Menetski, JP			The structure of the nuclear factor-kappa B protein-DNA complex varies with DNA-binding site sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSCRIPTIONAL ACTIVATION; TARGETED DISRUPTION; LAC REPRESSOR; T-CELLS; HOMODIMER; GENE; P50; RECOGNITION; INHIBITION	Transcriptional regulation of many immune responsive genes is under the control of the transcription factor NF-KB. This factor is found in cells as a dimer which can contain any two members of the Rel family of proteins (p50, p65, p52, c-Rel, and RelB). The different dimers show distinct preferences for DNA-binding site sequences. To-understand the relationship between the DNA binding properties of the dimer forms and transcriptional activation, the physical properties of the complexes of p50 and p65 with DNA have been analyzed. Comparison of apparent DNA binding affinity showed differences inselectivity of DNA-binding site sequence. The ionic strength dependence of apparent binding affinity has shown that the number of ionic interactions in the protein-DNA complex depends on the DNA-binding site sequence and the dimer form, which are consistent with changes in the structure of the protein-DNA complex. Using a fluorescent technique to measure DNA structure changes, protein binding does not appear to alter the structure of the DNA-binding site within the limits of detection. These results are consistent with a change in protein structure that may result in! activation differences due to alternative interactions with other transcription proteins.	Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Mol Biol, Ann Arbor, MI 48105 USA	Pfizer	Menetski, JP (corresponding author), Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Mol Biol, Ann Arbor, MI 48105 USA.							CASOLARO V, 1995, P NATL ACAD SCI USA, V92, P11623, DOI 10.1073/pnas.92.25.11623; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; DEHASETH PL, 1977, BIOCHEMISTRY-US, V16, P4783, DOI 10.1021/bi00641a004; Doi TS, 1997, J EXP MED, V185, P953, DOI 10.1084/jem.185.5.953; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GILMORE TD, 1992, CANCER SURV, V15, P69; GOHLKE C, 1994, P NATL ACAD SCI USA, V91, P11660, DOI 10.1073/pnas.91.24.11660; Heyduk E, 1997, J BIOL CHEM, V272, P19763, DOI 10.1074/jbc.272.32.19763; HEYDUK T, 1992, BIOCHEMISTRY-US, V31, P5165, DOI 10.1021/bi00137a011; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MENETSKI JP, 1992, J BIOL CHEM, V267, P10400; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; MUROI M, 1993, J BIOL CHEM, V268, P19534; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NILLER HH, 1991, NUCLEIC ACIDS RES, V19, P3715, DOI 10.1093/nar/19.13.3715; Parkhurst KM, 1996, BIOCHEMISTRY-US, V35, P7459, DOI 10.1021/bi9530301; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; SCHMID RM, 1994, J BIOL CHEM, V269, P32162; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; STARR DB, 1995, J MOL BIOL, V250, P434; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; URBAN MB, 1991, NEW BIOL, V3, P279; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6	32	22	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7619	7625		10.1074/jbc.275.11.7619	http://dx.doi.org/10.1074/jbc.275.11.7619			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713070	hybrid			2022-12-27	WOS:000085913300030
J	Revest, JM; DeMoerlooze, L; Dickson, C				Revest, JM; DeMoerlooze, L; Dickson, C			Fibroblast growth factor 9 secretion is mediated by a non-cleaved amino-terminal signal sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-2; FACTOR FAMILY; FACTOR-I; NUCLEAR-LOCALIZATION; SUBCELLULAR FATE; FGF FAMILY; PROTEIN; CELLS; SYNAPTOTAGMIN-1; IDENTIFICATION	Fibroblast growth factors are a family of intercellular signaling molecules with multiple and varied roles in animal development. Most are exported from cells by means of a classical amino-terminal signal sequence that is cleaved from the mature protein during its passage through the secretory pathway. Fibroblast growth factor-9 (Fgf-g) does not contain a recognizable signal sequence, although it is efficiently secreted. In this study, we show that Fgf-g enters the endoplasmic reticulum and traverses the Golgi complex in a similar manner to other constitutively secreted proteins.:Deletion and point mutation analysis has revealed an atypical non-cleaved signal sequence within the amino-terminal region of Fgf-9. Moreover, the first 28 amino acids of Fgf-9 can function as an efficient non-cleaved signal peptide when appended to the amino terminus of green fluorescent protein.	Imperial Canc Res Fund, London WC2A 3PX, England	Cancer Research UK	Dickson, C (corresponding author), Imperial Canc Res Fund, 44 Lincolns Inn Fields, London WC2A 3PX, England.							ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; DeMoerlooze L, 1997, CURR OPIN GENET DEV, V7, P378, DOI 10.1016/S0959-437X(97)80152-9; DEVORE DL, 1995, CELL, V83, P611, DOI 10.1016/0092-8674(95)90101-9; Florkiewicz RZ, 1998, J BIOL CHEM, V273, P544, DOI 10.1074/jbc.273.1.544; GENTON C, 1987, J CELL BIOL, V104, P705, DOI 10.1083/jcb.104.3.705; HECHT D, 1995, GROWTH FACTORS, V12, P223, DOI 10.3109/08977199509036882; Kalies KU, 1998, EUR J BIOCHEM, V254, P1, DOI 10.1046/j.1432-1327.1998.2540001.x; KEIFER P, 1993, EMBO J, V12, P4159; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; LaVallee TM, 1998, J BIOL CHEM, V273, P22217, DOI 10.1074/jbc.273.35.22217; LINGAPPA VR, 1979, NATURE, V281, P117, DOI 10.1038/281117a0; Liu HS, 1999, BIOCHEM BIOPH RES CO, V260, P712, DOI 10.1006/bbrc.1999.0954; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Miyakawa K, 1999, J BIOL CHEM, V274, P29352, DOI 10.1074/jbc.274.41.29352; Miyake A, 1998, BIOCHEM BIOPH RES CO, V243, P148, DOI 10.1006/bbrc.1998.8073; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; NIELSEN H, 1997, PROTEIN ENG, V12, P3; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; Sawin KE, 1999, CURR BIOL, V9, P1335, DOI 10.1016/S0960-9822(00)80058-5; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; Song JW, 1996, DEV DYNAM, V206, P427, DOI 10.1002/(SICI)1097-0177(199608)206:4<427::AID-AJA8>3.0.CO;2-K; TABE L, 1984, J MOL BIOL, V180, P645, DOI 10.1016/0022-2836(84)90031-7; Tarantini F, 1998, J BIOL CHEM, V273, P22209, DOI 10.1074/jbc.273.35.22209; VONHEIJNE G, 1991, J BIOL CHEM, V266, P15240; WOHLWEND A, 1987, J EXP MED, V165, P320, DOI 10.1084/jem.165.2.320; YAMAGUCHI TP, 1995, CURR OPIN GENET DEV, V5, P485, DOI 10.1016/0959-437X(95)90053-J; YE RD, 1988, J BIOL CHEM, V263, P4869; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N	30	54	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8083	8090		10.1074/jbc.275.11.8083	http://dx.doi.org/10.1074/jbc.275.11.8083			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713129	hybrid			2022-12-27	WOS:000085913300089
J	Tang, J; Frankel, A; Cook, RJ; Kim, S; Paik, WK; Williams, KR; Clarke, S; Herschman, HR				Tang, J; Frankel, A; Cook, RJ; Kim, S; Paik, WK; Williams, KR; Clarke, S; Herschman, HR			PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT 10-FORMYLTETRAHYDROFOLATE DEHYDROGENASE; FOLATE-BINDING-PROTEIN; S-ADENOSYLMETHIONINE; N-METHYLTRANSFERASE; DOMAIN-STRUCTURE; TERMINAL DOMAIN; LIVER CYTOSOL; IDENTIFICATION; PURIFICATION; METHYLATION	Type I protein arginine methyltransferases catalyze the formation of asymmetric omega-N-G,N-G-dimethylarginine residues by transferring methyl groups from S-adeno syl-L-methionine to guanidino groups of arginine residues in a variety of eucaryotic proteins. The predominant type I enzyme activity is found in mammalian cells as a high molecular weight complex (300-400 kDa). In a previous study, this protein arginine methyltransferase activity was identified as an additional activity of 10-formyltetrahydrofolate dehydrogenase (FDH) protein. However, immunodepletion of FDH activity in RAT1 cells and in murine tissue extracts with antibody to FDH does not diminish type I methyltransferase activity toward the methyl-accepting substrates glutathione S-transferase fibrillarin glycine arginine domain fusion protein or heterogeneous nuclear ribonucleoprotein Al. Similarly, immunodepletion with anti-FDH antibody does not remove the endogenous methylating activity for hypomethylated proteins present in extracts from adenosine dialdehyde-treated RAT1 cells. In contrast, anti-PRMT1 antibody can remove PRMT1 activity from RAT1 extracts, murine tissue extracts, and purified rat liver FDH preparations. Tissue extracts from FDH(+/+), FDH(+/-), and FDH(-/-) mice have similar protein arginine methyltransferase activities but high, intermediate, and undetectable FDH activities, respectively. Recombinant glutathione S-transferase-PRMT1, but not purified FDH, can be cross-linked to the methyl-donor substrate S-adenosyl-L-methionine. We conclude that PRMT1 contributes the major type I protein arginine methyltransferase enzyme activity present in mammalian cells and tissues.	Univ Calif Los Angeles, Mol Biol Inst 341A, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Korea Univ, Coll Med, Grad Sch Biotechnol, Dept Biochem, Seoul 136701, South Korea; Ajou Univ, Sch Med, Dept Biochem, Suwon 442749, South Korea; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Vanderbilt University; Korea University; Korea University Medicine (KU Medicine); Ajou University; Howard Hughes Medical Institute; Yale University	Herschman, HR (corresponding author), Univ Calif Los Angeles, Mol Biol Inst 341A, 611 Charles E Young Dr E, Los Angeles, CA 90095 USA.		Williams, Kenneth/B-5986-2016	Williams, Kenneth/0000-0001-7792-9588	NIDDK NIH HHS [DK15289] Funding Source: Medline; NIGMS NIH HHS [GM26020] Funding Source: Medline; NINDS NIH HHS [NS28660] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK015289, R01DK015289] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026020, R01GM026020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028660] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Altschuler L, 1999, J INTERF CYTOK RES, V19, P189, DOI 10.1089/107999099314333; CHAMPION KM, 1994, P NATL ACAD SCI USA, V91, P11388; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Clarke S, 1993, CURR OPIN CELL BIOL, V5, P977, DOI 10.1016/0955-0674(93)90080-A; COOK RJ, 1995, ARCH BIOCHEM BIOPHYS, V321, P336, DOI 10.1006/abbi.1995.1403; Cook RJ, 1997, METHOD ENZYMOL, V281, P129; COOK RJ, 1991, J BIOL CHEM, V266, P4965; COOK RJ, 1986, METHOD ENZYMOL, V122, P251; Frankel A, 1999, BIOCHEM BIOPH RES CO, V259, P391, DOI 10.1006/bbrc.1999.0779; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; GHOSH SK, 1988, J BIOL CHEM, V263, P19024; HURST JH, 1984, BIOCHEM BIOPH RES CO, V122, P499, DOI 10.1016/S0006-291X(84)80061-3; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; Kim SD, 1998, J BIOL CHEM, V273, P27374, DOI 10.1074/jbc.273.42.27374; Krupenko SA, 1997, J BIOL CHEM, V272, P10266; Krupenko SA, 1997, J BIOL CHEM, V272, P10273; LEE HW, 1977, BIOCHEMISTRY-US, V16, P78, DOI 10.1021/bi00620a013; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LIU Q, 1995, MOL CELL BIOL, V15, P2800; MIN H, 1988, BIOCHIM BIOPHYS ACTA, V967, P348, DOI 10.1016/0304-4165(88)90097-9; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; PAIK WK, 1967, BIOCHEM BIOPH RES CO, V29, P14, DOI 10.1016/0006-291X(67)90533-5; PAIK WK, 1968, J BIOL CHEM, V243, P2108; Pintucci G, 1996, MOL BIOL CELL, V7, P1249, DOI 10.1091/mbc.7.8.1249; RAWAL N, 1994, BIOCHEM J, V300, P483, DOI 10.1042/bj3000483; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; SCHIRCH D, 1994, J BIOL CHEM, V269, P24728; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; SCRUTTON MC, 1979, BIOCHEM J, V177, P833, DOI 10.1042/bj1770833; Shen YJ, 1998, MOL CELL NEUROSCI, V12, P79, DOI 10.1006/mcne.1998.0700; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; YOUNG PR, 1988, BIOCHEM J, V250, P221, DOI 10.1042/bj2500221; Zobel-Thropp P, 1998, J BIOL CHEM, V273, P29283, DOI 10.1074/jbc.273.45.29283	37	332	337	3	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7723	7730		10.1074/jbc.275.11.7723	http://dx.doi.org/10.1074/jbc.275.11.7723			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713084	hybrid			2022-12-27	WOS:000085913300044
J	Zhang, L; Tai, CH; Yu, L; Yu, CA				Zhang, L; Tai, CH; Yu, L; Yu, CA			pH-induced intramolecular electron transfer between the iron-sulfur protein and cytochrome c(1) in bovine cytochrome bc(1) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BC1 COMPLEX; MITOCHONDRIAL; OXIDATION; DERIVATIVES; INHIBITION; UBIQUINONE; BINDING; HEART	Structural analysis of the bc(1) complex suggests that the extramembrane domain of iron-sulfur protein (ISP) undergoes substantial movement during the catalytic: cycle. Binding of Qo site inhibitors to this complex affects the mobility of ISP, Taking advantage of the difference in the pH dependence of the redox midpoint potentials of cytochrome c(1) and ISP, we have measured electron transfer between the [2Fe-2S] cluster and heme c(1) in native and inhibitor-treated partially reduced cytochrome bc(1) complexes. The rate of the pH-induced cytochrome c(1) reduction can be estimated by conventional stopped-flow techniques (t(1/2), 1-2 ms), whereas the rate of cytochrome c(1) oxidation is too high for stopped-flow measurement, These results suggest that oxidized ISP has a higher mobility than reduced ISP and that the movement of reduced ISP may require an energy input from. another component. In the 5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole (UHDBT)-inhibited complex, the rate of cytochrome c(1) reduction is greatly decreased to a t(1/2) of approximately 2.8 s. An even lower rate is observed with the stigmatellin-treated complex, These results support the idea that UHDBT and stigmatellin arrest the [2Fe-2S] cluster at a fixed position, 31 Angstrom from heme c, making electron transfer very slow.	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA; Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA	Oklahoma State University System; Oklahoma State University - Stillwater; University of Oklahoma System; University of Oklahoma - Norman	Yu, CA (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, 255 NRC, Stillwater, OK 74078 USA.	cayuq@okstate.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030721, R01GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CROFTS AR, 1989, PHOTOSYNTH RES, V22, P69, DOI 10.1007/BF00114768; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; Link TA, 1997, FEBS LETT, V412, P257, DOI 10.1016/S0014-5793(97)00772-2; Link TA, 1996, BIOCHEMISTRY-US, V35, P7546, DOI 10.1021/bi960004+; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; Matsuno-Yagi A, 1999, J BIOL CHEM, V274, P9283, DOI 10.1074/jbc.274.14.9283; MCCURLEY JP, 1990, BIOCHIM BIOPHYS ACTA, V1020, P176, DOI 10.1016/0005-2728(90)90049-A; MOSER CC, 1995, J BIOENERG BIOMEMBR, V27, P263, DOI 10.1007/BF02110096; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; Tian H, 1999, J BIOL CHEM, V274, P7146, DOI 10.1074/jbc.274.11.7146; Tian H, 1998, J BIOL CHEM, V273, P27953, DOI 10.1074/jbc.273.43.27953; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1980, J BIOENERG BIOMEMBR, V12, P151, DOI 10.1007/BF00744680; TSAI AL, 1983, J BIOL CHEM, V258, P2122; Ugulava NB, 1998, FEBS LETT, V440, P409, DOI 10.1016/S0014-5793(98)01493-8; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; VONJAGOW G, 1985, FEBS LETT, V185, P311, DOI 10.1016/0014-5793(85)80929-7; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YANG FD, 1989, J BIOL CHEM, V264, P891; YU C, 1980, BIOCHIM BIOPHYS ACTA, V591, P409, DOI 10.1016/0005-2728(80)90172-3; YU CA, 1982, BIOCHEMISTRY-US, V21, P4096, DOI 10.1021/bi00260a028; Yu Chang-an, 1999, P263; YUN CA, 1996, BIOCHIM BIOPHYS ACTA, V1275, P47; ZHANG L, 1999, BIOPHYS J, V76, P255; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	27	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7656	7661		10.1074/jbc.275.11.7656	http://dx.doi.org/10.1074/jbc.275.11.7656			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713075	hybrid			2022-12-27	WOS:000085913300035
J	Mammoto, A; Sasaki, T; Kim, Y; Takai, Y				Mammoto, A; Sasaki, T; Kim, Y; Takai, Y			Physical and functional interaction of rabphilin-11 with mammalian Sec13 protein - Implication in vesicle trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; ADP-RIBOSYLATION FACTOR; ENDOPLASMIC-RETICULUM; GOLGI MEMBRANES; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; RAT-LIVER; TRANSPORT; RAB11; YEAST	Rab11a small G protein (Rab11p) is implicated in vesicle trafficking, especially vesicle recycling. We have previously isolated a downstream effector of Rab11p, named rabphilin-11. We found here that rabphilin-11 directly bound the mammalian counterpart of yeast Sec13 protein (mSec13p) in cell-free and intact cell systems. Yeast Sec13p is involved as a component of coat proteins II in the Sar1p-induced vesicle formation from the endoplasmic reticulum, but the precise role of mSec13p is unknown. The interaction of rabphilin-11 with mSec13p was enhanced by GTP-Rab11p. Rabphilin-11 localized on the vesicles in perinuclear regions and along microtubules oriented toward the plasma membrane, whereas mSec13p partly colocalized with rabphilin-11 in the perinuclear regions, most presumably the Golgi complex. Disruption of the rabphilin-11-mSec13p interaction by overexpression of the mSec13p-binding region of rabphilin-11 impaired vesicle trafficking. These results indicate that the rabphilin-11-mSec13p interaction is implicated in vesicle trafficking.	Osaka Univ, Grad Sch Med, Dept Mol Biol & Biochem, Fac Med, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Biol & Biochem, Fac Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; BERGMANN JE, 1989, LAB METHODS VESICULA, P375; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; Chen W, 1998, MOL BIOL CELL, V9, P3241, DOI 10.1091/mbc.9.11.3241; DENFERT C, 1991, MOL CELL BIOL, V11, P5727, DOI 10.1128/MCB.11.11.5727; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HUGHSON E, 1988, CENT S PAST I, P75; Kamei T, 1998, J BIOL CHEM, V273, P28341, DOI 10.1074/jbc.273.43.28341; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; Mammoto A, 1999, J BIOL CHEM, V274, P25517, DOI 10.1074/jbc.274.36.25517; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Miller J.H., 1972, EXPT MOL GENETICS; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OHMORI T, 1990, BIOCHEM BIOPH RES CO, V169, P816, DOI 10.1016/0006-291X(90)90404-B; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; PRYER NK, 1993, J CELL BIOL, V120, P865, DOI 10.1083/jcb.120.4.865; Ren MD, 1998, P NATL ACAD SCI USA, V95, P6187, DOI 10.1073/pnas.95.11.6187; Roberg KJ, 1997, J CELL BIOL, V137, P1469, DOI 10.1083/jcb.137.7.1469; SAKURADA K, 1991, BIOCHEM BIOPH RES CO, V177, P1224, DOI 10.1016/0006-291X(91)90672-T; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; Sambrook J., 2002, MOL CLONING LAB MANU; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; Tang BL, 1997, MOL CELL BIOL, V17, P256, DOI 10.1128/MCB.17.1.256; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; URBE S, 1993, FEBS LETT, V334, P175, DOI 10.1016/0014-5793(93)81707-7; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644; Zeng JB, 1999, P NATL ACAD SCI USA, V96, P2840, DOI 10.1073/pnas.96.6.2840	37	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13167	13170		10.1074/jbc.C000096200	http://dx.doi.org/10.1074/jbc.C000096200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10747849	hybrid			2022-12-27	WOS:000086925300002
J	Harwood, FG; Kasibhatla, S; Petak, I; Vernes, R; Green, DR; Houghton, JA				Harwood, FG; Kasibhatla, S; Petak, I; Vernes, R; Green, DR; Houghton, JA			Regulation of FasL by NF-kappa B and AP-1 in Fas-dependent thymineless death of human colon carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; MYELOID-LEUKEMIA CELLS; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS; GENE-EXPRESSION; NUCLEAR FACTOR; STRESS; LIGAND; DRUG; JNK	Cell death due to thymine (dThd) deficiency, associated with the cytotoxic action of 5-fluorouracil in colon cancer, is regulated in thymidylate synthase-deficient (TS-) human colon carcinoma cells via the Fas (CD95, APO-1) death receptor. This was demonstrated by inhibiting the loss in clonogenicity of TS- cells by anti-Fast and in enhanced survival of TS- clones selected for resistance to Fas-mediated apoptosis, following dThd deprivation, During thymineless stress in TS- cells, Fas ligand (FasL) is expressed, and its promoter (hFasLPr) is activated. Transactivation of hFasLPr, dependent upon dThd deficiency, was inhibited following mutation of the binding sites for NF-kappa B or AP-1 and by preventing NF-kappa B or AP-1 activation, which inhibited expression of Fast and enhanced clonogenic survival in stable transformants expressing I kappa B alpha M Or DN-MEKK, respectively. These results demonstrate the crucial roles for NF-kappa B and AP-1 in the regulation of Fast in Fas-mediated thymineless death of colon carcinoma cells.	St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA; Cytovia Inc, San Diego, CA 92121 USA; La Jolla Inst Allergy & Immunol, Dept Cellular Immunol, San Diego, CA 92121 USA	St Jude Children's Research Hospital; La Jolla Institute for Immunology	Houghton, JA (corresponding author), St Jude Childrens Res Hosp, Dept Mol Pharmacol, 332 N Lauderdale, Memphis, TN 38105 USA.		Petak, Istvan/X-3656-2019; Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417	NATIONAL CANCER INSTITUTE [R37CA032613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI044828, R01AI044828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052735, R37GM052735] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA 32613] Funding Source: Medline; NIAID NIH HHS [AI44828] Funding Source: Medline; NIGMS NIH HHS [GM 52735] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BESSHO R, 1994, BIOCHEM PHARMACOL, V48, P1883, DOI 10.1016/0006-2952(94)90586-X; Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; BRACH MA, 1992, BLOOD, V79, P728; BRACH MA, 1992, MOL PHARMACOL, V41, P60; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Faris M, 1998, J IMMUNOL, V160, P134; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Harwood FG, 1996, ONCOGENE, V12, P2057; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; Houghton JA, 1997, P NATL ACAD SCI USA, V94, P8144, DOI 10.1073/pnas.94.15.8144; Houghton JA, 1995, CLIN CANCER RES, V1, P723; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Lin BH, 1999, CELL DEATH DIFFER, V6, P570, DOI 10.1038/sj.cdd.4400528; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Piret B, 1996, NUCLEIC ACIDS RES, V24, P4242, DOI 10.1093/nar/24.21.4242; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Tillman DM, 1998, CELL DEATH DIFFER, V5, P450, DOI 10.1038/sj.cdd.4400369; Tillman DM, 1999, CLIN CANCER RES, V5, P425; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396	28	67	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10023	10029		10.1074/jbc.275.14.10023	http://dx.doi.org/10.1074/jbc.275.14.10023			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744679	hybrid			2022-12-27	WOS:000086345600020
J	Reidling, JC; Miller, MA; Steele, RE				Reidling, JC; Miller, MA; Steele, RE			Sweet Tooth, a novel receptor protein-tyrosine kinase with C-type lectin-like extracellular domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEIN; CELL-ADHESION MOLECULE; SPONGE GEODIA-CYDONIUM; CARBOHYDRATE-RECOGNITION; HYDRA-ATTENUATA; GENE; EXPRESSION; YEAST; IDENTIFICATION; DROSOPHILA	A gene encoding a novel type of receptor protein-tyrosine kinase was identified in Hydra vulgaris. The extracellular portion of this receptor (which we have named Sweet Tooth) contains four C-type lectin-like domains (CTLDs). Comparison of the sequences of these domains with the sequences of the carbohydrate recognition domains of various vertebrate C-type lectins shows that Sweet Tooth CTLD1 and CTLD4 have amino acids in common with those shown to be involved in carbohydrate binding by the lectins. Comparison of sequences encoding CTLD1 from the Sweet Tooth genes from different species of Hydra shows variation in some of the conserved residues that participate in carbohydrate binding in C-type lectins. The Sweet Tooth gene is expressed widely in the Hydra polyp, and expression is particularly high in the endoderm of the tentacles. Treatment of polyps with peptides corresponding to sequences in the Sweet Tooth CTLDs results in the disintegration of the animal. These same peptides do not block adhesion or morphogenesis of Hydra cell aggregates.	Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Ctr Dev Biol, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Steele, RE (corresponding author), Univ Calif Irvine, Dept Biol Chem, 240D Med Sci 1, Irvine, CA 92697 USA.			Miller, Michael/0000-0003-4872-7121	NCRR NIH HHS [R01-RR09755] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR009755] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALTINGMEES MA, 1992, METHOD ENZYMOL, V216, P483; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BODE HR, 1974, AM ZOOL, V14, P543; BOSCH TCG, 1989, MOL CELL BIOL, V9, P4141, DOI 10.1128/MCB.9.10.4141; BOSCH TCG, 1986, J EXP ZOOL, V238, P225, DOI 10.1002/jez.1402380212; Boyington JC, 1999, IMMUNITY, V10, P75, DOI 10.1016/S1074-7613(00)80008-4; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; BRIGGS JB, 1995, GLYCOBIOLOGY, V5, P583, DOI 10.1093/glycob/5.6.583; CAMPBELL RD, 1973, J CELL SCI, V13, P651; CAMPBELL RD, 1967, J MORPHOL, V121, P19, DOI 10.1002/jmor.1051210103; CHAN TA, 1994, ONCOGENE, V9, P1253; Davis R W, 1980, Methods Enzymol, V65, P404; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; GENG JG, 1992, J BIOL CHEM, V267, P19846; GIERER A, 1972, NATURE-NEW BIOL, V239, P98, DOI 10.1038/newbio239098a0; Grens A, 1995, DEVELOPMENT, V121, P4027; Gronwald W, 1998, BIOCHEMISTRY-US, V37, P4712, DOI 10.1021/bi972788c; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kolatkar AR, 1996, J BIOL CHEM, V271, P6679, DOI 10.1074/jbc.271.12.6679; LENHOFF H M, 1970, Laboratory Animals (London), V4, P139, DOI 10.1258/002367770781036463; LEUNG JO, 1985, J BIOL CHEM, V260, P2523; LIU HP, 1992, GENETICS, V132, P665; Loewen MC, 1998, BIOCHEMISTRY-US, V37, P17745, DOI 10.1021/bi9820513; Martinez DE, 1997, DEV BIOL, V192, P523, DOI 10.1006/dbio.1997.8715; Miura R, 1999, J BIOL CHEM, V274, P11431, DOI 10.1074/jbc.274.16.11431; OTTO JJ, 1977, J EXP ZOOL, V200, P417, DOI 10.1002/jez.1402000311; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; Ruvkun G, 1998, SCIENCE, V282, P2033, DOI 10.1126/science.282.5396.2033; SARRAS MP, 1994, DEV BIOL, V164, P312, DOI 10.1006/dbio.1994.1201; SCHACKE H, 1994, MOL MEMBR BIOL, V11, P101, DOI 10.3109/09687689409162227; Schaecke Heike, 1994, Journal of Molecular Recognition, V7, P273, DOI 10.1002/jmr.300070406; SHENK MA, 1993, DEVELOPMENT, V117, P657; Steele RE, 1996, DEV GENES EVOL, V206, P247, DOI 10.1007/s004270050050; Steele RE, 1999, GENE, V239, P91, DOI 10.1016/S0378-1119(99)00373-X; STEELE RE, 1989, J BIOL CHEM, V264, P10649; TECHNAU U, 1995, DEVELOPMENT, V121, P1273; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vasta Gerardo R., 1996, P189; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; ZHANG XM, 1994, DEV BIOL, V164, P10, DOI 10.1006/dbio.1994.1176	48	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10323	10330		10.1074/jbc.275.14.10323	http://dx.doi.org/10.1074/jbc.275.14.10323			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744720	hybrid			2022-12-27	WOS:000086345600061
J	Ren, HM; Allison, WS				Ren, HM; Allison, WS			Substitution of beta Glu(201) in the alpha(3)beta(3)gamma subcomplex of the F-1-ATPase from the thermophilic Bacillus PS3 increases the affinity of catalytic sites for nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE MITOCHONDRIAL F1-ATPASE; ESCHERICHIA-COLI F1-ATPASE; GLUTAMIC-ACID RESIDUE; ATP HYDROLYSIS; BETA-SUBUNIT; RHODOSPIRILLUM-RUBRUM; ADENOSINE-TRIPHOSPHATASE; INHIBITORY MGADP; BINDING-SITES; SLOW BINDING	In the crystal structure of bovine mitochondrial F-1-ATPase (MF1) (Abrahams, J, P,, Leslie, A. G, W., Lutter, R., and Walker, J, E, (1994) Nature 370, 621-628), the side chain oxygen of beta Thr(163) interacts directly with Mg2+ coordinated to 5'-adenylyl beta,gamma-imidodiphosphate or ADP bound to catalytic sites of beta subunits present in closed conformations. In the unliganded beta subunit present in an open conformation, the hydroxyl of beta Thr(163) is hydrogen-bonded to the carboxylate of beta Glu199. Substitution of beta Glu(201) (equivalent to beta Glu199 in MF1) in the alpha(3)beta(3)gamma subcomplex of the F-1-ATPase from the thermophilic Bacillus PS3 with cysteine or valine increases the propensity to entrap inhibitory MgADP in a catalytic site during hydrolysis of 50 mu M ATP, These substitutions lower K-m3 (the Michaelis constant for trisite ATP hydrolysis) relative to that of the wild type by 25- and 10-fold, respectively, Fluorescence quenching of alpha(3)(beta E201C/Y341W)(3)gamma and alpha(3)(beta Y341W)(3)gamma mutant subcomplexes showed that MgATP and MgADP bind to the third catalytic site of the double mutant with 8.4- and 4.4-fold higher affinity, respectively, than to the single mutant. These comparisons support the hypothesis that the hydrogen bond observed between the side chains of beta Thr(163) and beta Glu(199) in the unliganded catalytic site in the crystal structure of MF1 stabilizes the open conformation of the catalytic site during ATP hydrolysis.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Allison, WS (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.				NIGMS NIH HHS [GM16974] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Allison WS, 1995, BIOCHEM SOC T, V23, P752, DOI 10.1042/bst0230752; Allison WS, 1998, ACCOUNTS CHEM RES, V31, P819, DOI 10.1021/ar960257v; AMANO T, 1994, FEBS LETT, V348, P93, DOI 10.1016/0014-5793(94)00588-5; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CROSS RL, 1982, J BIOL CHEM, V257, P2101; Dou C, 1998, BIOCHEMISTRY-US, V37, P16757, DOI 10.1021/bi981717q; ESCH FS, 1981, J BIOL CHEM, V256, P9084; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; GUERRERO KJ, 1990, J BIOL CHEM, V265, P16280; HACKNEY DD, 1978, J BIOL CHEM, V253, P3164; HATEFI Y, 1982, P NATL ACAD SCI-BIOL, V79, P1756, DOI 10.1073/pnas.79.6.1756; HATEFI Y, 1993, EUR J BIOCHEM, V218, P759, DOI 10.1111/j.1432-1033.1993.tb18431.x; Jault JM, 1996, J BIOL CHEM, V271, P28818, DOI 10.1074/jbc.271.46.28818; Jault JM, 1995, BIOCHEMISTRY-US, V34, P16412, DOI 10.1021/bi00050a023; JAULT JM, 1993, J BIOL CHEM, V268, P1558; KAYALAR C, 1977, J BIOL CHEM, V252, P2486; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; MURATALIEV MB, 1992, BIOCHEMISTRY-US, V31, P12885, DOI 10.1021/bi00166a025; Nathanson L, 1998, J BIOL CHEM, V273, P10933, DOI 10.1074/jbc.273.18.10933; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; NORLING B, 1988, BIOCHIM BIOPHYS ACTA, V935, P123, DOI 10.1016/0005-2728(88)90209-5; Ren H, 1999, J BIOL CHEM, V274, P31366, DOI 10.1074/jbc.274.44.31366; SAKURAI H, 1989, SEIKAGAKU, V61, P1098; SENIOR AE, 1992, J BIOL CHEM, V267, P21471; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; Tsunoda SP, 1999, J BIOL CHEM, V274, P5701, DOI 10.1074/jbc.274.9.5701; VASILYEVA EA, 1982, BIOCHEM J, V202, P15, DOI 10.1042/bj2020015; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WEBER J, 1993, J BIOL CHEM, V268, P20126; WEISS S, 1994, J BIOENERG BIOMEMBR, V26, P573, DOI 10.1007/BF00762742; YOSHIDA M, 1981, J BIOL CHEM, V256, P148; YOSHIDA M, 1982, J BIOL CHEM, V257, P33	34	24	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10057	10063		10.1074/jbc.275.14.10057	http://dx.doi.org/10.1074/jbc.275.14.10057			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744684	hybrid			2022-12-27	WOS:000086345600025
J	Rensink, WA; Schnell, DJ; Weisbeek, PJ				Rensink, WA; Schnell, DJ; Weisbeek, PJ			The transit sequence of ferredoxin contains different domains for translocation across the outer and inner membrane of the chloroplast envelope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT MACHINERY; PRECURSOR PROTEINS; COMPONENTS; APPARATUS; IDENTIFICATION; EXPRESSION; INTERACT	Deletion mutants in the transit sequence of preferredoxin were used in label transfer cross-linking assays to map the interactions of the transit sequence with the import machinery. The deletion mutants gave distinct cross-linking patterns to the Toc and Tic components of the import machinery, consistent with the binding and import properties obtained in in vitro import assays. The cross-linking results revealed two separate properties of the transit peptide: first the presentation of specific binding domains for the initial interaction with outer membrane components, and second the presence of different domains for interaction with the outer and inner membrane components of the transport machinery for full envelope translocation. The N-terminal Delta 6-14 deletion blocked import of the precursor at the Toc components, whereas the more internal deletion Delta 15-25 blocked import at the Tic components. The information for association with the outer and inner membrane components therefore resides in two separate but partly overlapping domains in the first 25 amino acids of the transit sequence.	Univ Utrecht, Dept Mol Cell Biol, NL-3584 Utrecht, Netherlands; Rutgers State Univ, Dept Biol Sci, Newark, NJ 07102 USA	Utrecht University; Rutgers State University Newark; Rutgers State University New Brunswick	Rensink, WA (corresponding author), Univ Utrecht, Dept Mol Cell Biol, Padualaan 8, NL-3584 Utrecht, Netherlands.							Bolter B, 1998, FEBS LETT, V441, P59, DOI 10.1016/S0014-5793(98)01525-7; Caliebe A, 1997, EMBO J, V16, P7342, DOI 10.1093/emboj/16.24.7342; Chen KH, 2000, PLANT PHYSIOL, V122, P813, DOI 10.1104/pp.122.3.813; Chen XJ, 1999, TRENDS CELL BIOL, V9, P222, DOI 10.1016/S0962-8924(99)01554-8; CLINE K, 1985, J BIOL CHEM, V260, P3691; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; Keegstra K, 1999, PLANT CELL, V11, P557, DOI 10.1105/tpc.11.4.557; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; Kessler F, 1996, P NATL ACAD SCI USA, V93, P7684, DOI 10.1073/pnas.93.15.7684; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; Kouranov A, 1998, J CELL BIOL, V143, P991, DOI 10.1083/jcb.143.4.991; Kouranov A, 1997, J CELL BIOL, V139, P1677, DOI 10.1083/jcb.139.7.1677; KRAMER W, 1987, METHOD ENZYMOL, V154, P350; LEHENY EA, 1994, PLANT CELL, V6, P427, DOI 10.2307/3869762; Lubeck J, 1996, EMBO J, V15, P4230, DOI 10.1002/j.1460-2075.1996.tb00797.x; Ma YK, 1996, J CELL BIOL, V134, P315, DOI 10.1083/jcb.134.2.315; Nielsen E, 1997, EMBO J, V16, P935, DOI 10.1093/emboj/16.5.935; OBLONG JE, 1992, EMBO J, V11, P4401, DOI 10.1002/j.1460-2075.1992.tb05540.x; PAIN D, 1987, P NATL ACAD SCI USA, V84, P3288, DOI 10.1073/pnas.84.10.3288; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; PILON M, 1990, J BIOL CHEM, V265, P3358; PILON M, 1992, J BIOL CHEM, V267, P2548; PILON M, 1992, J BIOL CHEM, V267, P19907; PILON M, 1995, J BIOL CHEM, V270, P3882, DOI 10.1074/jbc.270.8.3882; Rensink WA, 1998, PLANT PHYSIOL, V118, P691, DOI 10.1104/pp.118.2.691; Schnell DJ, 1997, TRENDS CELL BIOL, V7, P303, DOI 10.1016/S0962-8924(97)01111-2; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TRANEL PJ, 1995, EMBO J, V14, P2436, DOI 10.1002/j.1460-2075.1995.tb07241.x; VANDERVERE PS, 1995, P NATL ACAD SCI USA, V92, P7177, DOI 10.1073/pnas.92.16.7177; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x; Wienk HLJ, 1999, FEBS LETT, V453, P318, DOI 10.1016/S0014-5793(99)00653-5; WU CB, 1994, J BIOL CHEM, V269, P32264	35	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10265	10271		10.1074/jbc.275.14.10265	http://dx.doi.org/10.1074/jbc.275.14.10265			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744712	hybrid			2022-12-27	WOS:000086345600053
J	Stewart, RJ; Fredenburgh, JC; Leslie, BA; Keyt, BA; Rischke, JA; Weitz, JI				Stewart, RJ; Fredenburgh, JC; Leslie, BA; Keyt, BA; Rischke, JA; Weitz, JI			Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYOCARDIAL-INFARCTION; THROMBOLYTIC PROPERTIES; GLU-PLASMINOGEN; LYS-PLASMINOGEN; (DD)E COMPLEX; VARIANT; DEGRADATION; KINETICS; THERAPY; FIBRINOGENOLYSIS	TNK-tissue plasminogen activator (TNK-t-PA), a bioengineered variant of tissue-type plasminogen activator (t-PA), has a longer half-life than t-PA because the glycosylation site at amino acid 117 (N117Q, abbreviated N) has been shifted to amino acid 103 (T103N, abbreviated T) and is resistant to inactivation by plasminogen activator inhibitor 1 because of a tetra-alanine substitution in the protease domain (K296A/H297A/R298A/R299A, abbreviated Ii), TNK-t-PA is more fibrin-specific than t-PA for reasons that are poorly understood. Previously, we demonstrated that the fibrin specificity of t-PA is compromised because t-PA binds to (DD)E, the major degradation product of cross-linked fibrin, with an affinity similar to that for fibrin, To investigate the enhanced fibrin specificity of TNK-t-PA, we compared the kinetics of plasminogen activation for t-PA, TNK-, T-, K-, TK-, and NK-t-PA in the presence of fibrin, (DD)E or fibrinogen, Although the activators have similar catalytic efficiencies in the presence of fibrin, the catalytic efficiency of TNK-t-PA is 15-fold lower than that for t-PA in the presence of (DD)E or fibrinogen. The T and K mutations combine to produce this reduction via distinct mechanisms because T-containing variants have a higher K-M, whereas K-containing variants have a lower k(cat) than t-PA, These results are supported by data indicating that T-containing variants bind (DD)E and fibrinogen with lower affinities than t-PA, whereas the Rand N mutations have no effect on binding. Reduced efficiency of plasminogen activation in the presence of (DD)E and fibrinogen but equivalent efficiency in the presence of fibrin explain why TNK-t-PA is more fibrin specific than t-PA.	Hamilton Civ Hosp, Res Ctr, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Hamilton, ON L8V 1C3, Canada; Genentech Inc, S San Francisco, CA 94080 USA	McMaster University; McMaster University; Roche Holding; Genentech	Weitz, JI (corresponding author), Hamilton Civ Hosp, Res Ctr, 711 Concess St, Hamilton, ON L8V 1C3, Canada.		Weitz, Jeffrey/AAD-1929-2019	Weitz, Jeffrey/0000-0002-1092-7550				BENEDICT CR, 1995, CIRCULATION, V92, P3032, DOI 10.1161/01.CIR.92.10.3032; Blanchoin L, 1996, J BIOL CHEM, V271, P12380, DOI 10.1074/jbc.271.21.12380; BOEYNAEMS JM, 1975, J CYCLIC NUCL PROT, V1, P123; Cannon CP, 1998, CIRCULATION, V98, P2805, DOI 10.1161/01.CIR.98.25.2805; Cannon CP, 1997, CIRCULATION, V95, P351; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; COLLEN D, 1986, HAEMOSTASIS, V16, P25; Collen D, 1997, THROMB HAEMOSTASIS, V78, P742; COLLEN D, 1994, THROMB HAEMOSTASIS, V72, P98; DELLENBACK RJ, 1970, P SOC EXP BIOL MED, V134, P353; DEVRIES C, 1990, J BIOL CHEM, V265, P13547; EASTMAN D, 1992, BIOCHEMISTRY-US, V31, P419, DOI 10.1021/bi00117a016; FRANCIS CW, 1980, BLOOD, V56, P456; FREDENBURGH JC, 1992, J BIOL CHEM, V267, P26150; HIGGINS DL, 1986, ARCH BIOCHEM BIOPHYS, V249, P418, DOI 10.1016/0003-9861(86)90018-4; HOLDEN RW, 1990, RADIOLOGY, V174, P993, DOI 10.1148/radiology.174.3.174-3-993; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2183; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; IKENO LC, 1981, J RADIOANAL CHEM, V65, P179, DOI 10.1007/BF02516102; KEYT BA, 1994, P NATL ACAD SCI USA, V91, P3670, DOI 10.1073/pnas.91.9.3670; KLEMENT G, 1995, THROMB HAEMOSTASIS, V73, P1339; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIJNEN HR, 1990, THROMB RES S10, V57, P45; MCFARLANE AS, 1965, BIOCHEM J, V62, P135; Modi NB, 1998, THROMB HAEMOSTASIS, V79, P134; Mosesson MW, 1998, THROMB HAEMOSTASIS, V79, P796; MOSKOWITZ KA, 1994, BIOCHEMISTRY-US, V33, P12937, DOI 10.1021/bi00248a001; NESHEIM M, 1990, J BIOL CHEM, V265, P21541; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NIEUWENHUIZEN W, 1983, BIOCHIM BIOPHYS ACTA, V755, P531, DOI 10.1016/0304-4165(83)90261-1; OLEXA SA, 1979, BIOCHEMISTRY-US, V18, P991, DOI 10.1021/bi00573a009; OLEXA SA, 1979, J BIOL CHEM, V254, P4925; PAONI NF, 1993, THROMB HAEMOSTASIS, V70, P307; RAO AK, 1988, J AM COLL CARDIOL, V11, P1; SHAFER JA, 1988, CRIT REV CL LAB SCI, V26, P1; Smalling RW, 1997, AM J HEALTH-SYST PH, V54, pS17, DOI 10.1093/ajhp/54.suppl_1.S17; STASSEN JM, 1991, FIBRINOLYSIS, V5, P165, DOI 10.1016/0268-9499(91)90018-Y; Stewart R. J., 1998, Blood Coagulation and Fibrinolysis, V9, P691, DOI 10.1097/00001721-199810000-00065; Stewart RJ, 1998, J BIOL CHEM, V273, P18292, DOI 10.1074/jbc.273.29.18292; STEWART RJ, 1996, BLOOD, V88, P521; Van de Werf F, 1999, LANCET, V354, P716, DOI 10.1016/S0140-6736(99)07403-6; VAUGHAN DE, 1987, CIRCULATION, V75, P1200, DOI 10.1161/01.CIR.75.6.1200; VERHEIJEN JH, 1982, THROMB RES, V27, P377, DOI 10.1016/0049-3848(82)90055-X; VONCLAUSS A, 1957, ACTA HAEMAT, V17, P237; WEITZ JI, 1993, J CLIN INVEST, V91, P1343, DOI 10.1172/JCI116335; Weitz JI, 1999, THROMB HAEMOSTASIS, V82, P974; WEITZ JI, 1991, J CLIN INVEST, V87, P1082, DOI 10.1172/JCI115069; WEITZ JI, 1986, BLOOD, V67, P1014; Werz W, 1998, J BIOTECHNOL, V61, P157, DOI 10.1016/S0168-1656(98)00022-4	49	40	48	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10112	10120		10.1074/jbc.275.14.10112	http://dx.doi.org/10.1074/jbc.275.14.10112			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744692	hybrid			2022-12-27	WOS:000086345600033
J	Alderton, JM; Steinhardt, RA				Alderton, JM; Steinhardt, RA			Calcium influx through calcium leak channels is responsible for the elevated levels of calcium-dependent proteolysis in dystrophic myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; FIBROBLAST GROWTH-FACTOR; SKELETAL-MUSCLE CELLS; PROTEIN-DEGRADATION; MDX MOUSE; CALPAIN INHIBITOR; IN-VITRO; PROTEASOME; MICE; DIFFERENTIATION	To estimate calpain proteolysis, we measured the hydrolysis rate of a fluorogenic calpain substrate in individual resting normal and dystrophic mdx mouse myotubes in culture. Hydrolysis rates were high during myoblast and myotube alignment and fusion, After alignment and fusion ceased, hydrolysis rates declined. For normal myotubes, hydrolysis remained low after the development of contractile activity. In contrast, after the development of contractile activity, dystrophic mdx myotubes had abnormally high levels of hydrolysis that were dependent on external calcium and that could be abolished by calpeptin, an inhibitor of calpain, We eliminated the direct effects of contraction during measurements of hydrolysis by the addition of tetrodotoxin, Substrate hydrolysis by lysosomes or proteosomes was controlled for using NH4Cl and clasto-lactacystin beta-lactone, respectively. Increased activity of the calcium-activated protease in mature mdx myotubes was linked to the abnormal activity of calcium-specific leak channels because an antagonist of these channels reduced the higher levels of hydrolysis in dystrophic myotubes to nearly normal levels. The abnormal activity of these channels is linked to an increased frequency of transient sarcolemmal disruptions in the more fragile mdx myotubes (1, 2). Treatment of mdx myotubes with a prodrug of methylprednisolone also reduced calpain substrate hydrolysis to nearly normal levels. However, this inhibition only required 2.5 h of pretreatment, which was not long enough to act by the known effects of prednisolone on calcium homeostasis.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Steinhardt, RA (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044066] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR44066] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akaishi T, 1995, BBA-GEN SUBJECTS, V1245, P331, DOI 10.1016/0304-4165(95)00122-0; ANDERSON BD, 1985, J PHARM SCI, V74, P375, DOI 10.1002/jps.2600740403; ANGELINI C, 1994, MUSCLE NERVE, V17, P386, DOI 10.1002/mus.880170405; BAKKER AJ, 1993, J PHYSIOL-LONDON, V460, P1; Barnoy S, 1996, BIOCHEM BIOPH RES CO, V220, P933, DOI 10.1006/bbrc.1996.0509; BERTORINI TE, 1982, NEUROLOGY, V32, P1088, DOI 10.1212/WNL.32.10.1088; Bi GQ, 1995, J CELL BIOL, V131, P1747, DOI 10.1083/jcb.131.6.1747; Bi GQ, 1997, J CELL BIOL, V138, P999, DOI 10.1083/jcb.138.5.999; CLARKE MSF, 1993, J CELL SCI, V106, P121; Combaret L, 1996, FEBS LETT, V393, P292, DOI 10.1016/0014-5793(96)00910-6; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; DIMARIO J, 1988, DIFFERENTIATION, V39, P42, DOI 10.1111/j.1432-0436.1988.tb00079.x; DUNCAN CJ, 1978, EXPERIENTIA, V34, P1531, DOI 10.1007/BF02034655; EBISUI C, 1994, BIOCHEM MOL BIOL INT, V32, P515; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FENICHEL GM, 1991, NEUROLOGY S1, V41, P1825; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FONG P, 1990, SCIENCE, V250, P673, DOI 10.1126/science.2173137; GEKLE M, 1995, AM J PHYSIOL-RENAL, V268, pF899, DOI 10.1152/ajprenal.1995.268.5.F899; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1987, SCIENCE, V238, P347, DOI 10.1126/science.3659917; Hopf FW, 1996, J BIOL CHEM, V271, P22358, DOI 10.1074/jbc.271.37.22358; HOPF FW, 1996, J AM PHYSL SOC, V271, pC1325; IMBERT N, 1995, CELL CALCIUM, V18, P177, DOI 10.1016/0143-4160(95)90062-4; JENKINS AB, 1979, BIOCHEM BIOPH RES CO, V86, P1014, DOI 10.1016/0006-291X(79)90218-3; Kang J, 1996, Rinsho Shinkeigaku, V36, P1338; KAWAI H, 1993, J NEUROL, V240, P181, DOI 10.1007/BF00857525; KHAN MA, 1993, J NEUROL SCI, V120, P8, DOI 10.1016/0022-510X(93)90017-S; KOVACS AL, 1982, EXP CELL RES, V137, P191, DOI 10.1016/0014-4827(82)90020-9; KWAK KB, 1993, FEBS LETT, V323, P151, DOI 10.1016/0014-5793(93)81468-F; MA CP, 1992, J BIOL CHEM, V267, P10515; MATSUDA R, 1995, J BIOCHEM-TOKYO, V118, P959, DOI 10.1093/jb/118.5.959; MCKANNA JA, 1979, P NATL ACAD SCI USA, V76, P5689, DOI 10.1073/pnas.76.11.5689; McNeil PL, 1997, J CELL BIOL, V137, P1, DOI 10.1083/jcb.137.1.1; METZINGER L, 1995, BRIT J PHARMACOL, V116, P2811, DOI 10.1111/j.1476-5381.1995.tb15930.x; MONGINI T, 1988, NEUROLOGY, V38, P476, DOI 10.1212/WNL.38.3.476; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; RIVETBASTIDE M, 1993, CELL CALCIUM, V14, P563, DOI 10.1016/0143-4160(93)90077-J; ROSSER BG, 1993, J BIOL CHEM, V268, P23593; SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737; SPENCER MJ, 1995, J BIOL CHEM, V270, P10909, DOI 10.1074/jbc.270.18.10909; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; TURNER PR, 1988, NATURE, V335, P735, DOI 10.1038/335735a0; TURNER PR, 1991, J CELL BIOL, V115, P1701, DOI 10.1083/jcb.115.6.1701; TURNER PR, 1993, J MEMBRANE BIOL, V133, P243; ZIMMERMAN M, 1977, ANAL BIOCHEM, V78, P47, DOI 10.1016/0003-2697(77)90006-9	50	150	155	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9452	9460		10.1074/jbc.275.13.9452	http://dx.doi.org/10.1074/jbc.275.13.9452			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734092	hybrid			2022-12-27	WOS:000086206500056
J	Huang, TT; Wuerzberger-Davis, SM; Seufzer, BJ; Shumway, SD; Kurama, T; Boothman, DA; Miyamoto, S				Huang, TT; Wuerzberger-Davis, SM; Seufzer, BJ; Shumway, SD; Kurama, T; Boothman, DA; Miyamoto, S			NF-kappa B activation by camptothecin - A linkage between nuclear DNA damage and cytoplasmic signaling events	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC PHOSPHORYLATION; UBIQUITIN-PROTEASOME PATHWAY; INDUCED CELL-DEATH; TOPOISOMERASE-I; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; KINASE-ACTIVITY; INDUCED DEGRADATION; ALPHA PROTEOLYSIS; DRUG CAMPTOTHECIN	Activation of the transcription factor NF-kappa B by extracellular signals involves its release from the inhibitor protein I kappa B alpha in the cytoplasm and subsequent nuclear translocation. NF-kappa B can also be activated by the anticancer agent camptothecin (CPT), which inhibits DNA topoisomerase (Topo) I activity and causes DNA double-strand breaks during DNA replication to induce S phase-dependent cytotoxicity. Here we show that CPT activates NF-kappa B by a mechanism that is dependent on initial nuclear DNA damage followed by cytoplasmic signaling events. NF-kappa B activation by CPT is dramatically diminished in cytoplasts and in CEM/C2 cells expressing a mutant Topo I protein that fails to bind CPT, This response is intensified in S phase cell populations and is prevented by the DNA polymerase inhibitor aphidicolin. In addition, CPT activation of NF-kappa B involves degradation of cytoplasmic I kappa B alpha by the ubiquitin-proteasome pathway in a manner that depends on the I kappa B kinase complex. Finally, inhibition of NF-kappa B activation augments CPT-induced apoptosis, These findings elucidate the progression of signaling events that initiates in the nucleus with CPT-Topo I interaction and continues in the cytoplasm resulting in degradation of I kappa B alpha and nuclear translocation of NF-kappa B to attenuate the apoptotic response.	Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53792 USA; Univ Wisconsin, Program Mol & Cellular Pharmacol, Madison, WI 53792 USA; Univ Wisconsin, Human Canc Biol Program, Madison, WI 53792 USA; Univ Wisconsin, Program Cellular & Mol Biol, Madison, WI 53792 USA; Case Western Reserve Univ, Dept Radiat Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Lab Mol Stress Responses, Cleveland, OH 44106 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Case Western Reserve University; Case Western Reserve University	Miyamoto, S (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, K4-554 Clin Sci Ctr,600 Highland Ave, Madison, WI 53792 USA.		Boothman, David/Q-7776-2019		NCI NIH HHS [R01 CA078530] Funding Source: Medline; NIGMS NIH HHS [T32GM07215] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078530] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chen F, 1997, ARCH BIOCHEM BIOPHYS, V342, P383, DOI 10.1006/abbi.1997.0132; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; COFFER PJ, 1995, ONCOGENE, V11, P561; COVEY JM, 1989, CANCER RES, V49, P5016; DARPA P, 1990, CANCER RES, V50, P6919; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Fujimori A, 1996, ONCOL RES, V8, P295; FUJIMORI A, 1995, CANCER RES, V55, P1339; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GIOVANELLA BC, 1989, SCIENCE, V246, P1046, DOI 10.1126/science.2555920; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; Herrlich P, 1997, BIOL CHEM, V378, P1217; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; HSIANG YH, 1988, CANCER RES, V48, P1722; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lin JH, 1995, ARCH BIOCHEM BIOPHYS, V324, P293, DOI 10.1006/abbi.1995.0042; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Miyamoto S., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P624; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; Piret B, 1996, NUCLEIC ACIDS RES, V24, P4242, DOI 10.1093/nar/24.21.4242; Piret B, 1999, ONCOGENE, V18, P2261, DOI 10.1038/sj.onc.1202541; POSTE G, 1972, EXP CELL RES, V73, P273, DOI 10.1016/0014-4827(72)90049-3; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Rothenberg ML, 1997, ANN ONCOL, V8, P837, DOI 10.1023/A:1008270717294; RYAN AJ, 1994, CARCINOGENESIS, V15, P823, DOI 10.1093/carcin/15.5.823; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SLICHENMYER WJ, 1993, JNCI-J NATL CANCER I, V85, P271, DOI 10.1093/jnci/85.4.271; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; STEIN B, 1989, J VIROL, V63, P4540, DOI 10.1128/JVI.63.11.4540-4544.1989; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tobin D, 1998, P NATL ACAD SCI USA, V95, P565, DOI 10.1073/pnas.95.2.565; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Tsukamoto N, 1999, P NATL ACAD SCI USA, V96, P1234, DOI 10.1073/pnas.96.4.1234; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Wuerzberger SM, 1998, CANCER RES, V58, P1876; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	82	146	152	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9501	9509		10.1074/jbc.275.13.9501	http://dx.doi.org/10.1074/jbc.275.13.9501			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734098	hybrid			2022-12-27	WOS:000086206500062
J	Marissen, WE; Guo, YW; Thomas, AAM; Matts, RL; Lloyd, RE				Marissen, WE; Guo, YW; Thomas, AAM; Matts, RL; Lloyd, RE			Identification of caspase 3-mediated cleavage and functional alteration of eukaryotic initiation factor 2 alpha in apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; POLYPEPTIDE-CHAIN INITIATION; DISEASE VIRUS-RNA; TRANSLATIONAL CONTROL; FACTOR-II; ALPHA-SUBUNIT; PHOSPHORYLATION; INTERFERON; CELLS; YEAST	Induction of apoptosis in a variety of cell types leads to inhibition of protein synthesis. Recently, the cleavage of eukaryotic translation initiation factor 4G (eIF4G) by caspase 3 was described as a possible event contributing to translation inhibition, Here, we report the cleavage of another initiation factor in apoptotic cells, eIF2 alpha, that could contribute to regulation of translation during apoptosis, This cleavage event could be completely inhibited by pretreatment of HeLa cells with Z-VAD-fmk, In vitro analysis using purified eIF2 and purified caspases showed cleavage of eIF2 alpha by caspase 3, 6, 8, and 10 but not 9, Caspase 3 most efficiently cleaved eIF2 alpha and this could be inhibited by addition of Ac-DEVD-CHO in vitro, Comparison of cleavage of phosphorylated versus nonphosphorylated eIF2 alpha revealed a modest preference of the caspases for the nonphosphorylated form, When eIF2.2B complex was used as substrate, only caspase 3 was capable of eIF2 alpha cleavage, which was not affected by phosphorylation of the cu subunit, The eIF2 GDP binary complex was cleaved much less efficiently by caspase 3. Sequence analysis of the cleavage fragment suggested that the cleavage site is located in the C-terminal portion of the protein. Analysis showed that after caspase cleavage, exchange of GDP bound to eIF2 was very rapid and no longer dependent upon eIF2B, Furthermore, in vitro translation experiments indicated that cleavage of eIF2 alpha results in functional alteration of the eIF2 complex, which no longer stimulated upstream AUG selection on a mRNA containing a viral internal ribosome entry site and was no longer capable of stimulating overall translation. In conclusion, we describe here the cleavage of a translation initiation factor, eIF2 alpha that could contribute to inhibition or alteration of protein synthesis during the late stages of apoptosis.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Univ Utrecht, Dept Dev Biol, NL-3584 CH Utrecht, Netherlands; Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol, Oklahoma City, OK 73190 USA	Baylor College of Medicine; Utrecht University; Oklahoma State University System; Oklahoma State University - Stillwater; University of Oklahoma System; University of Oklahoma Health Sciences Center	Lloyd, RE (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.				NIAID NIH HHS [AI27914] Funding Source: Medline; NIEHS NIH HHS [ES 042299] Funding Source: Medline; NIGMS NIH HHS [GM59803] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059803] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn YH, 1998, EXP NEUROL, V154, P47, DOI 10.1006/exnr.1998.6931; ANDREWS NC, 1985, J BIOL CHEM, V260, P7628; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; BELSHAM GJ, 1992, EMBO J, V11, P1105, DOI 10.1002/j.1460-2075.1992.tb05150.x; Benton PA, 1996, J VIROL, V70, P5525, DOI 10.1128/JVI.70.8.5525-5532.1996; BENTON PA, 1995, VIROLOGY, V213, P7, DOI 10.1006/viro.1995.1541; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CHEN JJ, 1993, TRANSLATIONAL REGULA, V2, P349; Clemens MJ, 1998, ONCOGENE, V17, P2921, DOI 10.1038/sj.onc.1202227; Coxon FP, 1998, MOL PHARMACOL, V54, P631; DASSO MC, 1990, EUR J BIOCHEM, V187, P361, DOI 10.1111/j.1432-1033.1990.tb15313.x; Datta B, 1999, EXP CELL RES, V246, P376, DOI 10.1006/excr.1998.4313; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; ETCHISON D, 1984, J VIROL, V51, P832, DOI 10.1128/JVI.51.3.832-837.1984; Goering PL, 1999, TOXICOL LETT, V105, P183, DOI 10.1016/S0378-4274(99)00002-8; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Lee SB, 1997, VIROLOGY, V231, P81, DOI 10.1006/viro.1997.8494; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; Marissen WE, 1998, MOL CELL BIOL, V18, P7565, DOI 10.1128/MCB.18.12.7565; MATTS RL, 1983, P NATL ACAD SCI-BIOL, V80, P2559, DOI 10.1073/pnas.80.9.2559; MAURIDES PA, 1989, ANAL BIOCHEM, V183, P144, DOI 10.1016/0003-2697(89)90182-6; Merrick WC., 1996, TRANSLATION CONTROL, P31; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; OLDFIELD S, 1992, EUR J BIOCHEM, V208, P73, DOI 10.1111/j.1432-1033.1992.tb17160.x; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; Satoh S, 1999, BIOCHEM J, V342, P65, DOI 10.1042/0264-6021:3420065; SCAFFIDI F, 1999, ANTICANCER RES, V274, P22532; SCHEPER GC, 1991, BIOCHIM BIOPHYS ACTA, V1089, P220, DOI 10.1016/0167-4781(91)90011-A; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; SIEKIERKA J, 1983, P NATL ACAD SCI-BIOL, V80, P1232, DOI 10.1073/pnas.80.5.1232; SIEKIERKA J, 1984, P NATL ACAD SCI-BIOL, V81, P352, DOI 10.1073/pnas.81.2.352; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Thomas AAM, 1996, J GEN VIROL, V77, P265, DOI 10.1099/0022-1317-77-2-265; TRACHSEL H, 1978, P NATL ACAD SCI USA, V75, P3654, DOI 10.1073/pnas.75.8.3654; VANDENHEUVEL J, 1995, BBA-GENE STRUCT EXPR, V1261, P337, DOI 10.1016/0167-4781(95)00026-D	42	62	66	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9314	9323		10.1074/jbc.275.13.9314	http://dx.doi.org/10.1074/jbc.275.13.9314			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734073	hybrid			2022-12-27	WOS:000086206500037
J	Nguyen, M; Arkell, J; Jackson, CJ				Nguyen, M; Arkell, J; Jackson, CJ			Activated protein C directly activates human endothelial gelatinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASE; PROGELATINASE-A; CATALYTIC DOMAIN; CELL-SURFACE; ANGIOGENESIS; TIMP-2; DEGRADATION; COLLAGENASE; EXPRESSION; MECHANISM	Angiogenesis (formation of new blood vessels) occurs in a number of diseases such as cancer and arthritis. The matrix metalloproteinase (MMP), gelatinase A, is secreted by endothelial cells and plays a vital role during angiogenesis, It is secreted as a latent enzyme and requires extracellular activation. We investigated whether activated protein C (APC), a pivotal molecule involved in the body's natural anti-coagulant system, could activate latent gelatinase A secreted by human umbilical vein endothelial cells (HUVEC), APC induced the fully active form of gelatinase A in a dose (100-300 nM)- and time (4-24 h)-responsive manner. The inactive zymogen, protein C, did not activate gelatinase A when used at similar concentrations. APC did not up-regulate membrane type 1 MMP (MT1-MMP) mRNA in HUVEC. In addition, the MMP inhibitor, 1,10-phenanthroline (10 nM), was unable to inhibit APC-induced activation. These results suggested that MT1-MMP was not involved in the activation process. APC activation of gelatinase A occurred in the absence of cells, indicating that it acts directly. APC may contribute to the physiological/pathological mechanism of gelatinase A activation, especially during angiogenesis.	Royal N Shore Hosp, Sutton Arthritis Res Lab, St Leonards, NSW 2065, Australia	Royal North Shore Hospital	Jackson, CJ (corresponding author), Royal N Shore Hosp, Sutton Arthritis Res Lab, St Leonards, NSW 2065, Australia.	cjackson@med.usyd.edu.au		Jackson, Christopher/0000-0002-9234-9116				Baker WF, 1999, SEMIN THROMB HEMOST, V25, P387, DOI 10.1055/s-2007-994942; Baramova EN, 1997, FEBS LETT, V405, P157, DOI 10.1016/S0014-5793(97)00175-0; Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; Bini A, 1996, BIOCHEMISTRY-US, V35, P13056, DOI 10.1021/bi960730c; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Cao J, 1998, J BIOL CHEM, V273, P34745, DOI 10.1074/jbc.273.52.34745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cicala C, 1998, LIFE SCI, V62, P1817, DOI 10.1016/S0024-3205(97)01167-3; Esmon CT, 1999, HAEMATOLOGICA, V84, P254; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; Foda HD, 1996, LAB INVEST, V74, P538; GEBHARD N, 1986, BIOCH APROTININ APRO, P375; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; HERRON GS, 1986, J BIOL CHEM, V261, P2814; Itoh T, 1998, CANCER RES, V58, P1048; Jackson CJ, 1997, INT J BIOCHEM CELL B, V29, P1167, DOI 10.1016/S1357-2725(97)00061-7; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; Nguyen M, 1999, LAB INVEST, V79, P467; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; Sato H, 1996, J BIOCHEM-TOKYO, V119, P209; SCHNAPER HW, 1993, J CELL PHYSIOL, V156, P235, DOI 10.1002/jcp.1041560204; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; ZUCKER S, 1995, J BIOL CHEM, V270, P23730, DOI 10.1074/jbc.270.40.23730; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	26	82	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9095	9098		10.1074/jbc.275.13.9095	http://dx.doi.org/10.1074/jbc.275.13.9095			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734039	hybrid			2022-12-27	WOS:000086206500003
J	Rosenkranz, S; Ikuno, Y; Leong, FL; Klinghoffer, RA; Miyake, S; Band, H; Kazlauskas, A				Rosenkranz, S; Ikuno, Y; Leong, FL; Klinghoffer, RA; Miyake, S; Band, H; Kazlauskas, A			Src family kinases negatively regulate platelet-derived growth factor alpha receptor-dependent signaling and disease progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA-RECEPTOR; TYROSINE KINASE; C-SRC; TRANSDUCTION; CBL; INTERNALIZATION; CELLS; PDGF; UBIQUITINATION; FIBROBLASTS	We tested the hypothesis that Src family kinases (SFK) contribute to c-Cbl-mediated degradation of the platelet-derived growth factor (PDGF) alpha receptor (alpha PDGFR), Using either a receptor mutant that does not engage SFKs (E72/74), or cells that that lack SFKs, we found that SFKs contributed to degradation of the alpha PDGFR. Overexpression of c-Cbl also reduced the receptor half-life, but only if the receptor was able to engage SFKs. In cultured cells, prolonging the half-life of the receptor correlated with enhanced signaling and more efficient S phase entry, whereas accelerating receptor degradation had the opposite effect. Consistent with these tissue culture findings, there was a statistically significant increase in the onset of a proliferative retinal disease when animals were injected with cells expressing the F72/74 receptor, as compared with cells expressing the WT receptor. Our findings suggest that SFKs cooperate with c-Cbl to negatively regulate the alpha PDGFR, and that the SFK/c-Cbl suppression of alpha PDGFR output is relevant to the onset and progression of a proliferative disease.	Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA; Fred Hutchinson Canc Res Ctr, Program Dev Biol, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp,Lymphocyte Biol Sect, Dept Med,Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Schepens Eye Research Institute; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Kazlauskas, A (corresponding author), Harvard Univ, Sch Med, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.	kazlauskas@vision.eri.harvard.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD008412] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011693] Funding Source: NIH RePORTER; NEI NIH HHS [EY11693] Funding Source: Medline; NICHD NIH HHS [HD-08412] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Andrews A, 1999, INVEST OPHTH VIS SCI, V40, P2683; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; Bergeron JJM, 1995, BIOSCIENCE REP, V15, P411, DOI 10.1007/BF01204345; Broome MA, 1999, ONCOGENE, V18, P2908, DOI 10.1038/sj.onc.1202873; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Campochiaro PA, 1997, ARCH OPHTHALMOL-CHIC, V115, P237, DOI 10.1001/archopht.1997.01100150239014; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; COATS SR, 1994, CELL GROWTH DIFFER, V5, P937; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; DeMali KA, 1999, EXP CELL RES, V253, P271, DOI 10.1006/excr.1999.4669; DeMali KA, 1998, MOL CELL BIOL, V18, P2014, DOI 10.1128/MCB.18.4.2014; FASTENBERG DM, 1982, AM J OPHTHALMOL, V93, P559, DOI 10.1016/S0002-9394(14)77369-6; Gelderloos JA, 1998, J BIOL CHEM, V273, P5908, DOI 10.1074/jbc.273.10.5908; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; Hooshmand-Rad R, 1998, J CELL SCI, V111, P607; Irusta PM, 1998, EMBO J, V17, P6912, DOI 10.1093/emboj/17.23.6912; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; MORI S, 1993, J BIOL CHEM, V268, P577; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; RAINES EW, 1993, PLATELET DERIVED GRO, V5, P74; ROBBINS SG, 1994, INVEST OPHTH VIS SCI, V35, P3649; Rosenkranz S, 1999, GROWTH FACTORS, V16, P201, DOI 10.3109/08977199909002130; Rosenkranz S, 1999, J BIOL CHEM, V274, P28335, DOI 10.1074/jbc.274.40.28335; SEIFERT RA, 1993, J BIOL CHEM, V268, P4473; Smit L, 1997, CRIT REV ONCOGENESIS, V8, P359, DOI 10.1615/CritRevOncog.v8.i4.50; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; Stofega MR, 1997, CELL GROWTH DIFFER, V8, P113; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Waltenberger J, 1997, CIRCULATION, V96, P4083; Waltenberger J, 1999, CIRC RES, V85, P12; Ware MF, 1997, J BIOL CHEM, V272, P30185, DOI 10.1074/jbc.272.48.30185; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	49	51	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9620	9627		10.1074/jbc.275.13.9620	http://dx.doi.org/10.1074/jbc.275.13.9620			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734113	hybrid			2022-12-27	WOS:000086206500077
J	Malecki, J; Polit, A; Wasylewski, Z				Malecki, J; Polit, A; Wasylewski, Z			Kinetic studies of cAMP-induced allosteric changes in cyclic AMP receptor protein from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL TRANSITIONS; BINDING; ACTIVATION; PROMOTERS; COMPLEX; GENE; SITE; DNA	Cyclic AMP receptor protein (CRP) regulates the expression of several genes in Escherichia coli. The ability of CRP to bind specific DNA sequences and stimulate transcription is achieved as result of binding of an allosteric Ligand: cAMP. Stopped-flow fluorimetry was employed to study the kinetics of the conformational changes in CRP induced by cAMP binding to high and low affinity receptor sites. Results of experiments using CRP labeled at Cys-178 with 1,5-I-AENS indicate change in conformation of the helix-turn-helix, occurring after the formation of CRP-cAMP(2) complex, i.e, after saturation of the high affinity sites. The observed conformational change occurs according to sequential model of allostery and is described by rate constants: k(c) = 9.7 +/- 0.1 s(-1) and k(-c) = 0.31 +/- 0.05 s(-1), for the forward and backward reaction, respectively. Results of experiments monitored using CRP intrinsic fluorescence suggest that conformational change precedes the formation of CRP-cAMP(4) complex and results from displacement of equilibrium between two forms of CRP-cAMP(2), caused by binding of cAMP to low affinity sites of one of these forms only. The observed conformational change occurs according to concerted model of allostery and is described by rate constants: k(on) = 28 +/- 1.5 s(-1) and k(off) = 75.5 +/- 3 s(-1). Results of experiments using single-tryptophan-containing CRP mutants indicate that Trp-85 is mainly responsible for the observed total change in intrinsic fluorescence of wild-type CRP.	Jagiellonian Univ, Inst Mol Biol, Dept Phys Biochem, PL-31120 Krakow, Poland	Jagiellonian University	Wasylewski, Z (corresponding author), Jagiellonian Univ, Inst Mol Biol, Dept Phys Biochem, Mickiewicza 3, PL-31120 Krakow, Poland.			Polit, Agnieszka/0000-0001-5811-9838; Malecki, Jedrzej/0000-0003-0825-7962				AIBA H, 1982, NUCLEIC ACIDS RES, V10, P1345, DOI 10.1093/nar/10.4.1345; Baichoo N, 1997, BIOCHEMISTRY-US, V36, P10830, DOI 10.1021/bi970714v; Cantor C. R., 1980, BIOPHYSICAL CHEM 3; CHENG XD, 1995, BIOCHEMISTRY-US, V34, P10816, DOI 10.1021/bi00034a014; DEGRAZIA H, 1990, BIOCHEMISTRY-US, V29, P3557, DOI 10.1021/bi00466a019; EILEN E, 1977, J MOL BIOL, V114, P47, DOI 10.1016/0022-2836(77)90282-0; Fersht A., 1985, ENZYME STRUCTURE MEC; GARGES S, 1988, J BACTERIOL, V170, P1417, DOI 10.1128/jb.170.4.1417-1422.1988; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HEYDUK E, 1992, J BIOL CHEM, V267, P3200; HEYDUK T, 1989, BIOCHEMISTRY-US, V28, P6914, DOI 10.1021/bi00443a021; HINDS MG, 1991, FEBS LETT, V283, P127, DOI 10.1016/0014-5793(91)80569-O; HUDSON EN, 1973, BIOCHEMISTRY-US, V12, P4154, DOI 10.1021/bi00745a019; KIM J, 1992, P NATL ACAD SCI USA, V89, P9700, DOI 10.1073/pnas.89.20.9700; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; Malecki J, 1997, EUR J BIOCHEM, V243, P660, DOI 10.1111/j.1432-1033.1997.00660.x; *MERCK CO INC, 1976, MERCK IND, P353; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Mukhopadhyay J, 1999, FEBS LETT, V453, P215, DOI 10.1016/S0014-5793(99)00719-X; Passner JM, 1997, P NATL ACAD SCI USA, V94, P2843, DOI 10.1073/pnas.94.7.2843; TAKAHASHI M, 1980, BIOCHEMISTRY-US, V19, P5124, DOI 10.1021/bi00563a029; TANIGUCHI T, 1979, P NATL ACAD SCI USA, V76, P5090, DOI 10.1073/pnas.76.10.5090; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; Williams RM, 1996, NUCLEIC ACIDS RES, V24, P1112, DOI 10.1093/nar/24.6.1112; WU CW, 1974, BIOCHEMISTRY-US, V13, P2573, DOI 10.1021/bi00709a016; WU FYH, 1974, BIOCHEMISTRY-US, V13, P2567, DOI 10.1021/bi00709a015	28	30	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8480	8486		10.1074/jbc.275.12.8480	http://dx.doi.org/10.1074/jbc.275.12.8480			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722684	hybrid			2022-12-27	WOS:000086507700034
J	Shibata, Y; Iwamatsu, T; Oba, Y; Kobayashi, D; Tanaka, M; Nagahama, Y; Suzuki, N; Yoshikuni, M				Shibata, Y; Iwamatsu, T; Oba, Y; Kobayashi, D; Tanaka, M; Nagahama, Y; Suzuki, N; Yoshikuni, M			Identification and cDNA cloning of alveolin, an extracellular metalloproteinase, which induces chorion hardening of medaka (Oryzias latipes) eggs upon fertilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 CONSTITUENT PROTEASES; HATCHING ENZYME; RAINBOW-TROUT; XENOPUS-LAEVIS; ONCORHYNCHUS-MYKISS; STRUCTURAL PROTEINS; VITELLINE ENVELOPE; TELEOST; POLYSPERMY; COMPONENT	Chorion hardening is triggered by the contents of cortical alveoli that are released upon fertilization of medaka (Oryzias latipes) eggs. We purified the chorion hardening-inducing activity as a single protein from the exudate of cortical alveoli of medaka eggs. This activity was co-purified with proteolytic activity of the chorion protein ZI-1,2. Based on the amino acid sequence of purified protein, we cloned the cDNA of this protein from a medaka ovarian cDNA library. Sequence analyses revealed typical sequence features, a zinc-binding motif and a methionine turn motif, of the astacin metalloproteinase family. We termed this protein "alveolin." Alveolin has a molecular mass of 21.5 kDa deduced by the amino acid sequence and neutral optimal pH range. Alveolin hydrolyzes ZI-1,2, Alveolin activity was strongly inhibited by metal-chelating agents but not by various proteinase inhibitors. To our knowledge, this is the first description of the isolation and identification of the chorion hardening-inducing factor from cortical alveoli exudate of teleost eggs.	Natl Inst Basic Biol, Dept Dev Biol, Reprod Biol Lab, Okazaki, Aichi 4448585, Japan; Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan; Aichi Univ Educ, Dept Biol, Kariya, Aichi 4488542, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Hokkaido University; Aichi University Education	Yoshikuni, M (corresponding author), Natl Inst Basic Biol, Dept Dev Biol, Reprod Biol Lab, 38 Nishigonaka, Okazaki, Aichi 4448585, Japan.			Kobayashi, Daisuke/0000-0001-9755-6168; TANAKA, MINORU/0000-0001-9100-1487				BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; BOND JS, 1995, PROTEIN SCI, V4, P1427; BRADEN AWH, 1954, AUST J BIOL SCI, V7, P391, DOI 10.1071/BI9540391; Dumont J N, 1985, Dev Biol (N Y 1985), V1, P235; HAGENMAIER HE, 1976, H-S Z PHYSIOL CHEM, V357, P1435, DOI 10.1515/bchm2.1976.357.2.1435; HAMAZAKI TS, 1987, J EXP ZOOL, V242, P343, DOI 10.1002/jez.1402420313; Hung CH, 1997, J BIOL CHEM, V272, P13772, DOI 10.1074/jbc.272.21.13772; HYLLNER SJ, 1991, J ENDOCRINOL, V131, P229, DOI 10.1677/joe.0.1310229; IUCHI I, 1991, DEV GROWTH DIFFER, V33, P85; Iuchi I, 1996, DEV GROWTH DIFFER, V38, P299, DOI 10.1046/j.1440-169X.1996.t01-2-00009.x; IWAMATSU T, 1984, DEV GROWTH DIFFER, V26, P533; IWAMATSU T, 1976, Annotationes Zoologicae Japonenses, V49, P28; IWAMATSU T, 1991, DEV GROWTH DIFFER, V33, P479; IWAMATSU T, 1995, DEV GROWTH DIFFER, V37, P747, DOI 10.1046/j.1440-169X.1995.t01-4-00012.x; IWAMATSU T, 1983, J EXP ZOOL, V228, P83, DOI 10.1002/jez.1402280109; Iwamatsu T., 1969, B AICHI U ED, V18, P43; JIANG WP, 1992, FEBS LETT, V312, P110, DOI 10.1016/0014-5793(92)80916-5; KAY ES, 1985, BIOL FERTILIZATION, V3, P45; KOBAYASHI W, 1981, J EXP ZOOL, V217, P265, DOI 10.1002/jez.1402170213; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KS, 1994, FEBS LETT, V339, P281, DOI 10.1016/0014-5793(94)80431-1; LINDSAY LL, 1989, DEV BIOL, V135, P202, DOI 10.1016/0012-1606(89)90170-X; MASUDA K, 1991, DEV GROWTH DIFFER, V33, P75; Matsuda K., 1995, FISH BIOL J MEDAKA, V7, P15, DOI 10.18999/ fisbjm.7.15.; NAKANO E, 1969, FERT COMP, V2, P295; Nakano E., 1956, EMBRYOLOGIA, V3, P89; OHTSUKA E, 1957, SIEBOLDIA, V2, P19; OPPENBERNTSEN DO, 1990, DEV BIOL, V137, P258, DOI 10.1016/0012-1606(90)90252-E; OPPENBERNTSEN DO, 1992, J ENDOCRINOL, V135, P293, DOI 10.1677/joe.0.1350293; Shibata Y, 1996, ZOOL SCI, V13, P271, DOI 10.2108/zsj.13.271; STOCKER W, 1995, PROTEIN SCI, V4, P823; SUGA N, 1963, EMBRYOLOGIA, V8, P63, DOI 10.1111/j.1440-169X.1963.tb00186.x; TARENTINO AL, 1995, ARCH BIOCHEM BIOPHYS, V319, P281, DOI 10.1006/abbi.1995.1293; Tian JD, 1997, DEV BIOL, V187, P143, DOI 10.1006/dbio.1997.8607; TITANI K, 1987, BIOCHEMISTRY-US, V26, P222, DOI 10.1021/bi00375a029; Togo T, 1997, DEV BIOL, V182, P219, DOI 10.1006/dbio.1996.8483; VACQUIER VD, 1973, EXP CELL RES, V80, P111, DOI 10.1016/0014-4827(73)90281-4; WYRICK RE, 1974, P NATL ACAD SCI USA, V71, P2067, DOI 10.1073/pnas.71.5.2067; YAMAGAMI K, 1992, INT REV CYTOL, V136, P51, DOI 10.1016/S0074-7696(08)62050-1; YAMAMOTO TADASHI S., 1957, JAPANESE JOUR ICHTHYOL, V6, P54; YAMAMOTO TO, 1961, INT REV CYTOL, V12, P361; YASUMASU S, 1989, J BIOCHEM-TOKYO, V105, P204, DOI 10.1093/oxfordjournals.jbchem.a122640; YASUMASU S, 1989, J BIOCHEM, V105, P212, DOI 10.1093/oxfordjournals.jbchem.a122641; YASUMASU S, 1992, DEV BIOL, V149, P349, DOI 10.1016/0012-1606(92)90290-W; YASUMASU S, 1992, DEV BIOL, V153, P250, DOI 10.1016/0012-1606(92)90110-3; ZOTIN AI, 1958, J EMBRYOL EXP MORPH, V6, P546	46	42	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8349	8354		10.1074/jbc.275.12.8349	http://dx.doi.org/10.1074/jbc.275.12.8349			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722665	hybrid			2022-12-27	WOS:000086507700015
J	Bouet, JY; Surtees, JA; Funnell, BE				Bouet, JY; Surtees, JA; Funnell, BE			Stoichiometry of P1 plasmid partition complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; ESCHERICHIA-COLI; PARB PROTEIN; F-PLASMID; DNA; BINDING; SITE; CHROMOSOME; SPECIFICITY; SEGREGATION	The P1 plasmid prophage is faithfully partitioned by a high affinity nucleoprotein complex assembled at the centromere-like parS site. This partition complex is composed of P1 ParB and Escherichia coli integration host factor (IHF), bound specifically to parS. We have investigated the assembly of ParB at parS and its stoichiometry of binding. Measured by gel mobility shift assays, ParB and IHF bind tightly to parS and form a specific complex, called I + B1. We observed that as ParB concentration was increased, a second, larger complex (I + B2) formed, followed by the formation of larger complexes, indicating that additional ParB molecules joined the initial complex. Shift Western blotting experiments indicated that the I + B2 complex contained twice as much ParB as the I + B1 complex. Using mixtures of ParB and a larger polyhistidine-tagged version of ParB (His-ParB) in DNA binding assays, we determined that the initial I + B1 complex contains one dimer of ParB. Therefore, one dimer of ParB binds to its recognition sequences that span an IHF-directed bend in parS. Once this complex forms, a second dimer can join the complex, but this assembly requires much higher ParB concentrations.	Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto	Funnell, BE (corresponding author), Univ Toronto, Dept Mol & Med Genet, Med Sci Bldg, Toronto, ON M5S 1A8, Canada.		BOUET, Jean-Yves/B-2688-2008; Bouet, Jean-Yves/H-8469-2019	Bouet, Jean-Yves/0000-0003-1488-5455; Funnell, Barbara/0000-0002-1828-6567				ABELES AL, 1985, J MOL BIOL, V185, P261, DOI 10.1016/0022-2836(85)90402-4; BIEK DP, 1995, J MOL BIOL, V246, P388, DOI 10.1006/jmbi.1994.0094; Bouet JY, 1999, EMBO J, V18, P1415, DOI 10.1093/emboj/18.5.1415; DAVIS MA, 1990, EMBO J, V9, P991, DOI 10.1002/j.1460-2075.1990.tb08201.x; DAVIS MA, 1988, EMBO J, V7, P1881, DOI 10.1002/j.1460-2075.1988.tb03021.x; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; Erdmann N, 1999, P NATL ACAD SCI USA, V96, P14905, DOI 10.1073/pnas.96.26.14905; FUNNELL BE, 1993, J BIOL CHEM, V268, P3616; FUNNELL BE, 1991, J BIOL CHEM, V266, P14328; FUNNELL BE, 1988, P NATL ACAD SCI USA, V85, P6657, DOI 10.1073/pnas.85.18.6657; FUNNELL BE, 1994, BIOCHIMIE, V76, P924, DOI 10.1016/0300-9084(94)90017-5; Gordon GS, 1997, CELL, V90, P1113, DOI 10.1016/S0092-8674(00)80377-3; HAYES F, 1994, J MOL BIOL, V243, P190, DOI 10.1006/jmbi.1994.1646; HIRAGA S, 1992, ANNU REV BIOCHEM, V61, P283; IRETON K, 1994, J BACTERIOL, V176, P5320, DOI 10.1128/JB.176.17.5320-5329.1994; Jensen RB, 1998, P NATL ACAD SCI USA, V95, P8550, DOI 10.1073/pnas.95.15.8550; Lin DCH, 1998, CELL, V92, P675, DOI 10.1016/S0092-8674(00)81135-6; Lobocka M, 1996, J MOL BIOL, V259, P366, DOI 10.1006/jmbi.1996.0326; LYNCH AS, 1994, J MOL BIOL, V236, P679, DOI 10.1006/jmbi.1994.1179; Niki H, 1997, CELL, V90, P951, DOI 10.1016/S0092-8674(00)80359-1; Radnedge L, 1996, EMBO J, V15, P1155, DOI 10.1002/j.1460-2075.1996.tb00454.x; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; Rodionov O, 1999, SCIENCE, V283, P546, DOI 10.1126/science.283.5401.546; Sambrook J., 2002, MOL CLONING LAB MANU; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; SPASSKY A, 1988, EMBO J, V7, P1871, DOI 10.1002/j.1460-2075.1988.tb03020.x; Surtees JA, 1999, J BACTERIOL, V181, P5898, DOI 10.1128/JB.181.19.5898-5908.1999; WILLIAMS DR, 1992, J GEN MICROBIOL, V138, P1; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	30	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8213	8219		10.1074/jbc.275.11.8213	http://dx.doi.org/10.1074/jbc.275.11.8213			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713146	hybrid			2022-12-27	WOS:000085913300106
J	Easton, RL; Patankar, MS; Lattanzio, FA; Leaven, TH; Morris, HR; Clark, GF; Dell, A				Easton, RL; Patankar, MS; Lattanzio, FA; Leaven, TH; Morris, HR; Clark, GF; Dell, A			Structural analysis of murine zone pellucida glycans - Evidence for the expression of core 2-type O-glycans and the Sd(a) antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED CARBOHYDRATE CHAINS; WHEAT-GERM-AGGLUTININ; SPERM-EGG BINDING; GLYCOPROTEIN FAMILY PZP3; GROUP CAD SPECIFICITY; MOUSE SPERM; TRANSGENIC MICE; AFFINITY-CHROMATOGRAPHY; GALACTOSYL RECEPTOR; IMMUNE-RESPONSES	Murine sperm initiate fertilization by binding to specific oligosaccharides linked to the zona pellucida, the specialized matrix coating the egg. Biophysical analyses have revealed the presence of both high mannose and complex-type N-glycans in murine zona pellucida, The predominant high mannose-type glycan had the composition Man(5)GlcNAc(2), but larger oligosaccharides of this type were also detected. Biantennary, triantennary, and tetraantennary complex-type N-glycans were found to be terminated with the following antennae: Gal beta 1-4GlcNAc, NeuAc alpha 2-3Gal beta 1-4GlcNAc, NeuGc alpha 2-3Gal beta 1-4GlcNAc, the Sd(a) antigen (NeuAc alpha 2-3[GalNAc beta 1-4]Gal beta 1-4GlcNAc, NeuGc alpha 2-3[GalNAc beta 1-4]Gal beta 1-4GlcNAc), and terminal GlcNAc, Polylactosamine-type sequence was also detected on a subset of the antennae. Analysis of the O-glycans indicated that the majority were core 2-type (Gal beta 1-4GlcNAc beta 1-6[Gal beta 1-3]GalNAc). The beta 1-linked branches attached to these Q-glycans were terminated with the same sequences as the N-glycans, except for terminal GlcNAc. Glycans bearing Gal beta 1-4GlcNAc beta 1-6 branches have previously been suggested to mediate initial murine gamete binding. Oligosaccharides terminated with GalNAc beta 1-4Gal have been implicated in the secondary binding interaction that occurs following the acrosome reaction. The significant implications of these observations are discussed.	Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England; Eastern Virginia Med Sch, Dept Physiol Sci, Norfolk, VA 23501 USA	Imperial College London; Eastern Virginia Medical School	Morris, HR (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England.							ABDULLAH M, 1989, J CELL BIOL, V108, P367, DOI 10.1083/jcb.108.2.367; ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8; Aviles M, 1997, BIOL REPROD, V57, P1155, DOI 10.1095/biolreprod57.5.1155; Aviles M, 1999, CELL TISSUE RES, V295, P269, DOI 10.1007/s004410051233; Banerjee M, 1997, MOL HUM REPROD, V3, P109, DOI 10.1093/molehr/3.2.109; BLANCHARD D, 1983, J BIOL CHEM, V258, P7691; BLANCHARD D, 1985, J BIOL CHEM, V260, P7813; BLEIL JD, 1988, DEV BIOL, V128, P376, DOI 10.1016/0012-1606(88)90299-0; BLEIL JD, 1988, P NATL ACAD SCI USA, V85, P6778, DOI 10.1073/pnas.85.18.6778; BLEIL JD, 1983, DEV BIOL, V95, P317, DOI 10.1016/0012-1606(83)90032-5; BOOKBINDER LH, 1995, SCIENCE, V269, P86, DOI 10.1126/science.7604284; CAHOVA M, 1992, J REPROD IMMUNOL, V21, P241, DOI 10.1016/0165-0378(92)90029-4; Chen J, 1998, P NATL ACAD SCI USA, V95, P6193, DOI 10.1073/pnas.95.11.6193; Clark GF, 1996, MOL HUM REPROD, V2, P513, DOI 10.1093/molehr/2.7.513; Clark GF, 1996, HUM REPROD, V11, P467, DOI 10.1093/HUMREP/11.3.467; CLARK GF, 1984, FED PROC, V43, P1696; CORNWALL GA, 1991, BIOL REPROD, V44, P913, DOI 10.1095/biolreprod44.5.913; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1235; DELL A, 1995, J BIOL CHEM, V270, P24116, DOI 10.1074/jbc.270.41.24116; DELL A, 1993, GLYCOBIOLOGY PRACTIC, P187; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; FUKUDA K, 1987, BIOCHIM BIOPHYS ACTA, V926, P132, DOI 10.1016/0304-4165(87)90229-7; GALLAGHER JT, 1985, BIOCHEM J, V231, P115, DOI 10.1042/bj2310115; GOLUBOFF ET, 1995, MOL REPROD DEV, V40, P460, DOI 10.1002/mrd.1080400410; GRINNELL BW, 1994, GLYCOBIOLOGY, V4, P221, DOI 10.1093/glycob/4.2.221; HANFLAND P, 1988, CARBOHYD RES, V178, P1, DOI 10.1016/0008-6215(88)80098-3; HAYES CE, 1974, J BIOL CHEM, V249, P1904; HIRANO T, 1993, EUR J BIOCHEM, V214, P763, DOI 10.1111/j.1432-1033.1993.tb17978.x; HOKKE CH, 1994, EUR J BIOCHEM, V221, P491, DOI 10.1111/j.1432-1033.1994.tb18762.x; HOKKE CH, 1993, FEBS LETT, V329, P29, DOI 10.1016/0014-5793(93)80186-X; Johnston DS, 1998, J BIOL CHEM, V273, P1888, DOI 10.1074/jbc.273.4.1888; Katsumata T, 1996, EUR J BIOCHEM, V240, P448, DOI 10.1111/j.1432-1033.1996.0448h.x; KINLOCH RA, 1991, J CELL BIOL, V115, P655, DOI 10.1083/jcb.115.3.655; Kudo K, 1998, EUR J BIOCHEM, V252, P492, DOI 10.1046/j.1432-1327.1998.2520492.x; LEFRANCOIS L, 1985, J IMMUNOL, V135, P374; LEFRANCOIS L, 1985, NATURE, V314, P449, DOI 10.1038/314449a0; LEFRANCOIS L, 1985, J EXP MED, V162, P1275, DOI 10.1084/jem.162.4.1275; LIU CY, 1995, MOL BIOL CELL, V6, P577, DOI 10.1091/mbc.6.5.577; Liu DY, 1997, MOL HUM REPROD, V3, P1015, DOI 10.1093/molehr/3.11.1015; Loeser CR, 1999, BIOL REPROD, V60, P94, DOI 10.1095/biolreprod60.1.94; Lu QX, 1997, DEVELOPMENT, V124, P4121; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; MONSIGNY M, 1980, EUR J BIOCHEM, V104, P147, DOI 10.1111/j.1432-1033.1980.tb04410.x; Mori E, 1997, BIOCHEM BIOPH RES CO, V238, P95, DOI 10.1006/bbrc.1997.7249; MORI E, 1991, BIOCHEMISTRY-US, V30, P2078, DOI 10.1021/bi00222a012; Mori E, 1998, GLYCOCONJUGATE J, V15, P447, DOI 10.1023/A:1006926801717; NAGDAS SK, 1994, BIOL REPROD, V51, P262, DOI 10.1095/biolreprod51.2.262; Nakano M, 1996, J Reprod Fertil Suppl, V50, P25; NOGUCHI S, 1992, EUR J BIOCHEM, V209, P883, DOI 10.1111/j.1432-1033.1992.tb17361.x; NOGUCHI S, 1993, BIOCHIM BIOPHYS ACTA, V1158, P217, DOI 10.1016/0304-4165(93)90018-4; NOGUCHI S, 1992, EUR J BIOCHEM, V204, P1089, DOI 10.1111/j.1432-1033.1992.tb16733.x; NOGUCHI S, 1992, EUR J BIOCHEM, V207, P1130; OEHNINGER S, 1995, FERTIL STERIL, V63, P377; OLSNES S, 1974, J BIOL CHEM, V249, P803; Ozgur K, 1998, MOL HUM REPROD, V4, P318, DOI 10.1093/molehr/4.4.318; PETERS BP, 1979, BIOCHEMISTRY-US, V18, P5505, DOI 10.1021/bi00591a038; RAVINDRANATH MH, 1985, J BIOL CHEM, V260, P8850; SANDOW BA, 1993, BIOL REPROD S1, V48, P166; SHUR BD, 1982, J CELL BIOL, V95, P574, DOI 10.1083/jcb.95.2.574; SKUTELSKY E, 1994, J REPROD FERTIL, V100, P35, DOI 10.1530/jrf.0.1000035; SMITH DF, 1987, J BIOL CHEM, V262, P12040; THALL AD, 1995, J BIOL CHEM, V270, P21437, DOI 10.1074/jbc.270.37.21437; Tsuboi S, 1998, J BIOL CHEM, V273, P30680, DOI 10.1074/jbc.273.46.30680; Tsuboi S, 1997, EMBO J, V16, P6364, DOI 10.1093/emboj/16.21.6364; UHLENBRUCK G, 1969, Z IMMUNITATSFORSCH, V138, P423; WANG WC, 1988, J BIOL CHEM, V263, P4576; WASSARMAN PM, 1990, DEVELOPMENT, V108, P1; YAMAGATA T, 1983, GLYCOCONJUGATES, P623; YAMASHITA K, 1985, J BIOL CHEM, V260, P4688; YAMASHITA K, 1987, J BIOL CHEM, V262, P1602; Yonezawa N, 1997, EUR J BIOCHEM, V248, P86, DOI 10.1111/j.1432-1033.1997.00086.x; Yonezawa N, 1999, EUR J BIOCHEM, V260, P57, DOI 10.1046/j.1432-1327.1999.00095.x; YONEZAWA N, 1995, EUR J BIOCHEM, V233, P35, DOI 10.1111/j.1432-1033.1995.035_1.x; YUREWICZ EC, 1991, MOL REPROD DEV, V30, P126, DOI 10.1002/mrd.1080300209	74	95	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7731	7742		10.1074/jbc.275.11.7731	http://dx.doi.org/10.1074/jbc.275.11.7731			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713085	hybrid			2022-12-27	WOS:000085913300045
J	Rocheville, M; Lange, DC; Kumar, U; Sasi, R; Patel, RC; Patel, YC				Rocheville, M; Lange, DC; Kumar, U; Sasi, R; Patel, RC; Patel, YC			Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE RECEPTOR; DIMERIZATION; CELLS; COEXPRESSION; DOMAIN; INTERNALIZATION; OLIGOMERIZATION; ACTIVATION; MICROSCOPY; EXPRESSION	The existence of receptor dimers has been proposed for several G protein-coupled receptors. However, the question of whether G protein-coupled receptor dimers are necessary for activating or modulating normal receptor function is unclear. We address this question with somatostatin receptors (SSTRs) of which there are five distinct subtypes. By using transfected mutant and wild type receptors, as well as endogenous receptors, we provide pharmacological, biochemical, and physical evidence, based on fluorescence resonance energy transfer analysis, that activation by ligand induces SSTR dimerization, both homo- and heterodimerization with other members of the SSTR family, and that dimerization alters the functional properties of the receptor such as ligand binding affinity and agonist-induced receptor internalization and up-regulation. Double label confocal fluorescence microscopy showed that when SSTR1 and SSTR5 subtypes were coexpressed in Chinese hamster ovary-K1 cells and treated with agonist they underwent internalisation and were colocalized in cytoplasmic vesicles. SSTR5 formed heterodimers with SSTR1 but not with SSTR4 suggesting that heterodimerization is a specific process that is restricted to some but not all receptor subtype combinations. Direct protein interaction between different members of the SSTR subfamily defines a new level of molecular cross-talk between subtypes of the SSTR and possibly related receptor families.	Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Fraser Labs, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Fraser Labs, Dept Pharmacol & Therapeut, Montreal, PQ H3A 1A1, Canada; McGill Univ, Fraser Labs, Dept Neurol & Neurosurg, Montreal, PQ H3A 1A1, Canada; Clarkson Univ, Dept Chem & Phys, Potsdam, NY 13676 USA	McGill University; Royal Victoria Hospital; McGill University; McGill University; McGill University; Clarkson University	Patel, YC (corresponding author), Royal Victoria Hosp, Rm M8-15,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.				NINDS NIH HHS [NS32160-04] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032160] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AbdAlla S, 1999, J BIOL CHEM, V274, P26079, DOI 10.1074/jbc.274.37.26079; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Clegg R. M, 1996, FLUORESCENCE IMAGING, V137, P179; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Forster T, 1948, NATURWISSENSCHAFTEN, V6, P166; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; George SR, 1998, J BIOL CHEM, V273, P30244, DOI 10.1074/jbc.273.46.30244; Gouldson PR, 1997, BIOCHEM SOC T, V25, P1066, DOI 10.1042/bst0251066; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; Greenwood MT, 1997, MOL PHARMACOL, V52, P807, DOI 10.1124/mol.52.5.807; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; HIRSCHFELD T, 1976, APPL OPTICS, V15, P3135, DOI 10.1364/AO.15.003135; Hukovic N, 1999, J BIOL CHEM, V274, P24550, DOI 10.1074/jbc.274.35.24550; Hukovic N, 1998, J BIOL CHEM, V273, P21416, DOI 10.1074/jbc.273.33.21416; Hukovic N, 1996, ENDOCRINOLOGY, V137, P4046, DOI 10.1210/en.137.9.4046; JONES KA, 1998, SCIENCE, V396, P674; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jovin T.M, 1989, CELL STRUCT FUNCT, P99; KATSUWADA T, 1992, NATURE, V358, P36; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Khare S, 1999, FASEB J, V13, P387, DOI 10.1096/fasebj.13.2.387; Koller KJ, 1997, ANAL BIOCHEM, V250, P51, DOI 10.1006/abio.1997.2190; Kumar U, 1999, DIABETES, V48, P77, DOI 10.2337/diabetes.48.1.77; Kumar U, 1997, ENDOCRINOLOGY, V138, P4473, DOI 10.1210/en.138.10.4473; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamberts SWJ, 1996, NEW ENGL J MED, V334, P246, DOI 10.1056/NEJM199601253340408; Liapakis G, 1996, J PHARMACOL EXP THER, V276, P1089; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; Marshall FH, 1999, TRENDS PHARMACOL SCI, V20, P396, DOI 10.1016/S0165-6147(99)01383-8; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; Onaran HO, 1999, TRENDS PHARMACOL SCI, V20, P274, DOI 10.1016/S0165-6147(99)01364-4; Osuga Y, 1997, J BIOL CHEM, V272, P25006, DOI 10.1074/jbc.272.40.25006; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; PATEL YC, 1994, J BIOL CHEM, V269, P1506; Reardon DB, 1997, MOL ENDOCRINOL, V11, P1062, DOI 10.1210/me.11.8.1062; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Sharma K, 1999, MOL ENDOCRINOL, V13, P82, DOI 10.1210/me.13.1.82; SRIKANT CB, 1987, SOMATOSTATIN BASIC C, P89; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Zeng FY, 1999, J BIOL CHEM, V274, P16629, DOI 10.1074/jbc.274.23.16629	44	426	438	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7862	7869		10.1074/jbc.275.11.7862	http://dx.doi.org/10.1074/jbc.275.11.7862			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713101	hybrid			2022-12-27	WOS:000085913300061
J	Jones, DH; Morris, JB; Morgen, CP; Kondo, H; Irvine, RF; Cockcroft, S				Jones, DH; Morris, JB; Morgen, CP; Kondo, H; Irvine, RF; Cockcroft, S			Type I phosphatidylinositol 4-phosphate 5-kinase directly interacts with ADP-ribosylation factor 1 and is responsible for phosphatidylinositol 4,5-bisphosphate synthesis in the Golgi compartment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-D ACTIVITY; EXCHANGE FACTOR; DOWNSTREAM EFFECTOR; LIPID KINASE; PROTEIN; ARF; SECRETION; CLONING; ISOFORMS; 4-KINASE	Phosphatidylinositol (PtdIns) 4,5-bisphosphate is involved in many aspects of membrane traffic, but the regulation of its synthesis is only partially understood. Golgi membranes contain PI 4-kinase activity and a pool of phosphatidylinositol phosphate (PIP), which is further increased by ADP-ribosylation factor 1 (ARF1). COS7 cells were transfected with alpha and beta forms of PI 4-kinase, and only membranes from COS7 cells transfected with PI 4-kinase beta increased their content of PIP when incubated with ARF1. PtdIns(4,5)P(2) content in Golgi membranes was nonexistent but could be increased to a small extent upon adding either cytosol or Type I or Type II PIP kinases. However, when ARF1 was present, Ptdins(4,5)P(2) levels increased dramatically when membranes were incubated in the presence of cytosol or Type I, but not Type II, PIP kinase. To examine whether ARF1 could directly activate Type I PIP 5-kinase, we used an in vitro assay consisting of phosphatidycholine-containing liposomes, ARF1, and PIP 5-kinase, ARF1 increased Type I PIP 5-kinase activity in a guanine nucleotide-dependent manner, identifying this enzyme as a direct effector for ARF1.	UCL, Dept Physiol, London WC1E 6JJ, England; Univ Cambridge, Dept Pharmacol, Cambridge CB2 1QJ, England; Tohoku Univ, Sch Med, Dept Anat, Sendai, Miyagi 980, Japan	University of London; University College London; University of Cambridge; Tohoku University	Cockcroft, S (corresponding author), UCL, Dept Physiol, London WC1E 6JJ, England.	S.Cockcroft@ucl.ac.uk	Cockcroft, Shamshad/F-9480-2011	Cockcroft, Shamshad/0000-0002-5731-476X				BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; COCKCROFT S, 1985, BIOCHIM BIOPHYS ACTA, V845, P163, DOI 10.1016/0167-4889(85)90173-9; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DIVECHA N, 1995, BIOCHEM J, V309, P715, DOI 10.1042/bj3090715; Fensome A, 1996, CURR BIOL, V6, P730, DOI 10.1016/S0960-9822(09)00454-0; Franco M, 1998, P NATL ACAD SCI USA, V95, P9926, DOI 10.1073/pnas.95.17.9926; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Godi A, 1998, P NATL ACAD SCI USA, V95, P8607, DOI 10.1073/pnas.95.15.8607; Hama H, 1999, J BIOL CHEM, V274, P34294, DOI 10.1074/jbc.274.48.34294; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; IRVINE RF, 1985, BIOCHEM J, V229, P505, DOI 10.1042/bj2290505; IRVINE RF, 1986, BIOCHEM J, V240, P301, DOI 10.1042/bj2400301; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Jones DH, 1999, BIOCHEM J, V341, P185, DOI 10.1042/0264-6021:3410185; Kanoh H, 1997, J BIOL CHEM, V272, P5421, DOI 10.1074/jbc.272.9.5421; Levine TP, 1998, CURR BIOL, V8, P729, DOI 10.1016/S0960-9822(98)70296-9; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; McEwen RK, 1999, J BIOL CHEM, V274, P33905, DOI 10.1074/jbc.274.48.33905; Monier S, 1998, J CELL SCI, V111, P3427; Morgan CP, 1997, BIOCHEM J, V325, P581, DOI 10.1042/bj3250581; Nakagawa T, 1996, J BIOL CHEM, V271, P12088, DOI 10.1074/jbc.271.20.12088; Nakagawa T, 1996, BIOCHEM J, V320, P643, DOI 10.1042/bj3200643; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Randazzo PA, 1997, J BIOL CHEM, V272, P7688; Sbrissa D, 1999, J BIOL CHEM, V274, P21589, DOI 10.1074/jbc.274.31.21589; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; Way G, 2000, BIOCHEM J, V346, P63, DOI 10.1042/0264-6021:3460063; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418	36	141	148	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13962	13966		10.1074/jbc.C901019199	http://dx.doi.org/10.1074/jbc.C901019199			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10747863	hybrid			2022-12-27	WOS:000086925300110
J	Celerier, J; Schmid, G; Le Caer, JP; Gimenez-Roqueplo, AP; Bur, D; Friedlein, A; Langen, H; Corvol, P; Jeunemaitre, X				Celerier, J; Schmid, G; Le Caer, JP; Gimenez-Roqueplo, AP; Bur, D; Friedlein, A; Langen, H; Corvol, P; Jeunemaitre, X			Characterization of a human angiotensinogen cleaved in its reactive center loop by a proteolytic activity from Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; HUMAN RENIN; COMPLEX-FORMATION; SERPIN; OVALBUMIN; PLASMA; RECOGNITION; EXPRESSION; SUBSTRATE; PROTEIN	Angiotensinogen, the renin (E.C. 3.4.23.15) substrate, belongs to the serpins superfamily and has been classified as a noninhibitory serpin, Using mass spectroscopy, angiotensinogen purified from Chinese hamster ovary cell supernatant shows a broad spectrum. The absence of protease inhibitors throughout the purification leads to an angiotensinogen cleaved within the reactive center loop, This cleavage does not affect the Ang I generation because kinetic parameters are similar to the values of the full-length angiotensinogen. Although cleavage is complete, the cleaved angiotensinogen migrates after deglycosylation on SDS-polyacrylamide gel electrophoresis as a doublet differing by 4 kDa. To test whether the circulating angiotensinogen is cleaved in the reactive center loop, it was purified from a pool of human plasma and was shown to be uncleaved. Its migration was obviously slower than of cleaved angiotensinogen but also consisted of two bands pointing to a so far unexplained residual heterogeneity. We then compared the heat-induced polymerization of full-length-and reactive center loop-cleaved angiotensinogens. Both monomers were able to aggregate, revealing a particular behavior of angiotensinogen distinct from that of reactive center loop-cleaved serpins, Lacking the three-dimensional structure of angiotensinogen, we propose and discuss a structural model of the serpin fold within the renin substrate.	Coll France, INSERM, U36, Chaire Med Expt & Endocrinol Renale, F-75005 Paris, France; F Hoffmann La Roche & Co Ltd, Pharmaceut Res Gene Technol, CH-4070 Basel, Switzerland; Ecole Super Phys & Chim Ind Ville Paris, Lab Neurobiol & Diversite Cellulaire, CNRS, UMR 7638, F-75231 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Roche Holding; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	Celerier, J (corresponding author), Coll France, INSERM, U36, Chaire Med Expt & Endocrinol Renale, 3 Rue Ulm, F-75005 Paris, France.	jerome.celerier@college-de-france.fr	GIMENEZ-ROQUEPLO, Anne-Paule/T-6752-2018; JEUNEMAITRE, Xavier/AAQ-4853-2021	GIMENEZ-ROQUEPLO, Anne-Paule/0000-0002-4816-670X; JEUNEMAITRE, Xavier/0000-0001-5925-381X				AERTGEERTS K, 1995, NAT STRUCT BIOL, V2, P891, DOI 10.1038/nsb1095-891; BECERRA SP, 1995, J BIOL CHEM, V270, P25992, DOI 10.1074/jbc.270.43.25992; CAMPBELL CJ, 1987, BIOCHEM J, V243, P121, DOI 10.1042/bj2430121; CLOUSTON W M, 1988, Genomics, V2, P240, DOI 10.1016/0888-7543(88)90008-0; Cohen P, 1996, J CLIN ENDOCR METAB, V81, P3505, DOI 10.1210/jc.81.10.3505; Corvol P, 1997, ENDOCR REV, V18, P662, DOI 10.1210/er.18.5.662; CUMIN F, 1987, BIOCHIM BIOPHYS ACTA, V913, P10, DOI 10.1016/0167-4838(87)90226-3; DECLERCK PJ, 1992, J BIOL CHEM, V267, P11693; DOOLITTLE RF, 1983, SCIENCE, V222, P417, DOI 10.1126/science.6604942; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; GAILLARD I, 1989, DNA-J MOLEC CELL BIO, V8, P87, DOI 10.1089/dna.1.1989.8.87; GENAIN C, 1984, J CLIN ENDOCR METAB, V59, P478, DOI 10.1210/jcem-59-3-478; GERBER PR, 1995, J COMPUT AID MOL DES, V9, P251, DOI 10.1007/BF00124456; Gimenez-Roqueplo AP, 1998, J BIOL CHEM, V273, P21232, DOI 10.1074/jbc.273.33.21232; Gimenez-Roqueplo AP, 1998, J BIOL CHEM, V273, P34480, DOI 10.1074/jbc.273.51.34480; GimenezRoqueplo AP, 1996, J BIOL CHEM, V271, P9838, DOI 10.1074/jbc.271.16.9838; GOULD AB, 1971, CARDIOVASC RES, V5, P86, DOI 10.1093/cvr/5.1.86; GrueningerLeitch F, 1996, PROTEIN SCI, V5, P2617, DOI 10.1002/pro.5560051224; HILL RE, 1987, NATURE, V326, P96, DOI 10.1038/326096a0; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KAGEYAMA R, 1984, BIOCHEMISTRY-US, V23, P3603, DOI 10.1021/bi00311a006; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LOMAS DA, 1995, J BIOL CHEM, V270, P5282, DOI 10.1074/jbc.270.10.5282; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; Mathews S, 1996, PROTEIN EXPRES PURIF, V7, P81, DOI 10.1006/prep.1996.0012; Mathialagan N, 1996, P NATL ACAD SCI USA, V93, P13653, DOI 10.1073/pnas.93.24.13653; MENARD J, 1972, ENDOCRINOLOGY, V90, P422, DOI 10.1210/endo-90-2-422; NAGASE M, 1994, BIOSCI BIOTECH BIOCH, V58, P1884, DOI 10.1271/bbb.58.1884; OHKUBO H, 1983, P NATL ACAD SCI-BIOL, V80, P2196, DOI 10.1073/pnas.80.8.2196; Patston PA, 1996, FEBS LETT, V383, P87, DOI 10.1016/0014-5793(96)00231-1; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; Streatfeild-James RMA, 1998, FEBS LETT, V436, P267, DOI 10.1016/S0014-5793(98)01145-4; TANAKA T, 1984, J BIOL CHEM, V259, P8063; TEWKSBURY DA, 1978, J BIOL CHEM, V253, P3817; TEWKSBURY DA, 1979, MOL CELL BIOCHEM, V27, P47, DOI 10.1007/BF00849278; TEWKSBURY DA, 1983, FED PROC, V42, P2724; TEWKSBURY DA, 1990, HYPERTENSION PATHOPH, V1, P1197; WEI L, 1988, BIOCHEM BIOPH RES CO, V156, P1103, DOI 10.1016/S0006-291X(88)80746-0; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	46	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10648	10654		10.1074/jbc.275.14.10648	http://dx.doi.org/10.1074/jbc.275.14.10648			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744761	hybrid			2022-12-27	WOS:000086345600102
J	Ma, XY; Cline, K				Ma, XY; Cline, K			Precursors bind to specific sites on thylakoid membranes prior to transport on the delta pH protein translocation system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPORT MACHINERY; CHLOROPLASTS; PATHWAYS; SEC; EXPORT; INTEGRATION; COMPONENT; HOMOLOG; ATP	The Delta pH pathway is one of two systems for protein transport to the thylakoid lumen. it is a novel transport system that requires only the thylakoidal Delta pH to power translocation, Several substrates of the Delta pH pathway, including the intermediate precursor form of OE17 (iOE17) and the truncated precursor form of OE17 (tOE17), were shown to bind to the membrane in the absence of the Delta pH and be transported into the lumen when the Delta pH was restored. finding occurred without energy or soluble factors, and efficient transport from the bound state (similar to 80-90%) required only the Delta pH, Binding is due to protein-protein interactions because protease pretreatment of thylakoids destroyed their binding capability, Precursors are bound to a specific site on the Delta pH pathway because binding was competed by saturating amounts of Delta pH pathway precursor proteins, but not by a Sec pathway precursor protein, These results suggested that precursor tOE17 binds to components of the Delta pathway translocation machinery. Hcf106 and Thai are two components of the Delta pH pathway machinery, Antibodies to Hcf106 or Tha4, when prebound to thylakoids, specifically inhibited precursor transport on the Delta pH pathway. However, only Hcf106 antibodies reduced the level of precursor binding. These results suggest that Hcf106 functions in early steps of the transport process.	Univ Florida, Dept Hort Sci, Hort Sci & Plant Mol & Cellular Biol Program, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Cline, K (corresponding author), Univ Florida, Dept Hort Sci, Hort Sci & Plant Mol & Cellular Biol Program, Fifield Hall, Gainesville, FL 32611 USA.		Cline, Kenneth/J-6238-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046951] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM46951] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; BROCK IW, 1995, J BIOL CHEM, V270, P1657, DOI 10.1074/jbc.270.4.1657; Bruce BD, 1998, PLANT MOL BIOL, V38, P223, DOI 10.1023/A:1006094308805; CLINE K, 1988, PLANT PHYSIOL, V86, P1120, DOI 10.1104/pp.86.4.1120; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; CLINE K, 1986, J BIOL CHEM, V261, P4804; Dalbey RE, 1999, TRENDS BIOCHEM SCI, V24, P17, DOI 10.1016/S0968-0004(98)01333-4; Henry R, 1997, J CELL BIOL, V136, P823, DOI 10.1083/jcb.136.4.823; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; Keegstra K, 1999, PLANT CELL, V11, P557, DOI 10.1105/tpc.11.4.557; Kouranov A, 1997, J CELL BIOL, V139, P1677, DOI 10.1083/jcb.139.7.1677; Mori H, 1999, J CELL BIOL, V146, P45, DOI 10.1083/jcb.146.1.45; NAKAI M, 1994, J BIOL CHEM, V269, P31338; Robinson D, 1996, PLANT J, V10, P149, DOI 10.1046/j.1365-313X.1996.10010149.x; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Schuenemann D, 1999, J BIOL CHEM, V274, P12177, DOI 10.1074/jbc.274.17.12177; Settles AM, 1998, TRENDS CELL BIOL, V8, P494, DOI 10.1016/S0962-8924(98)01387-7; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; VOELKER R, 1995, EMBO J, V14, P3905, DOI 10.1002/j.1460-2075.1995.tb00062.x; Walker MB, 1999, J CELL BIOL, V147, P267, DOI 10.1083/jcb.147.2.267; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633	23	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10016	10022		10.1074/jbc.275.14.10016	http://dx.doi.org/10.1074/jbc.275.14.10016			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744678	hybrid			2022-12-27	WOS:000086345600019
J	Mancuso, DJ; Jenkins, CM; Gross, RW				Mancuso, DJ; Jenkins, CM; Gross, RW			The genomic organization, complete mRNA sequence, cloning, and expression of a novel human intracellular membrane-associated calcium-independent phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMALOGEN-SELECTIVE PHOSPHOLIPASE-A2; ARACHIDONIC-ACID; MESSENGER-RNA; PLATELET PHOSPHOLIPASE-A2; CYTOSOLIC PHOSPHOLIPASE; MYOCARDIAL-ISCHEMIA; TUBER PROTEIN; SMOOTH-MUSCLE; ACTIVATION; IDENTIFICATION	During the sequencing of the long arm of chromosome 7 in the Human Genome Project, a predicted protein product of 40 kDa was identified, which contained two similar to 10-amino acid segments homologous to the ATP and lipase consensus sequences present in the founding members of a family of calcium-independent phospholipases A(2). Detailed inspection of the identified sequence (residues 79,671-109,912 GenBank(TM) accession no. AC005058) demonstrated that it represented only a partial sequence of a larger undefined polypeptide product. Accordingly, we identified the complete genomic organization of this putative phospholipase A, through analyses of previously published expressed sequence tags, PCR of human heart cDNA, and 5'-rapid amplification of cDNA ends. Polymerase chain reaction and Northern blotting demonstrated a 3.4-kilobase message, which encoded a polypeptide with a maximum calculated molecular weight of 88476.9, This 3,4-kilobase message was present in multiple human parenchymal tissues including heart, skeletal muscle, placenta, brain, liver, and pancreas. Cloning and expression of the protein encoded by this message in Sf9 cells resulted in the production of two proteins of apparent molecular masses of 77 and 63 kDa as assessed by Western analyses utilizing immunoaffinity-purified antibody. Membranes from Sf9 cells expressing recombinant protein released fatty acid from sn-2-radiolabeled phosphatidylcholine and plasmenylcholine up to 10-fold more rapidly than controls. The initial rate of fatty acid release from the membrane fraction was 0.3 nmol/mg min. The recombinant protein was entirely calcium-independent, had a pH optimum of 8.0, was inhibited by (E)-6-(bromomethylene)-3-(1-naphthalenyl)-2H-tetrahydropyran (IC50 = 3 mu M), and was predominantly present in the membrane-associated fraction. Collectively, these results describe the genomic organization, complete mRNA sequence, and sn-a-lipase activity of a novel intracellular calcium-independent membrane-associated phospholipase A(2).	Washington Univ, Sch Med, Div Bioorgan Chem & Mol Pharmacol, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Bioorgan Chem & Mol Pharmacol, Dept Chem & Mol Biol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Bioorgan Chem & Mol Pharmacol, Dept Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Gross, RW (corresponding author), Washington Univ, Sch Med, Div Bioorgan Chem & Mol Pharmacol, Dept Med, 660 S Euclid Ave,Campus Box 8020, St Louis, MO 63110 USA.				NHLBI NIH HHS [1 PO1 HL 57278-02, 2 R02 HL 41250-08A1] Funding Source: Medline; NIAAA NIH HHS [5R01 AA11094] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041250, P01HL057278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA011094] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALONSO F, 1986, BIOCHIM BIOPHYS ACTA, V878, P273, DOI 10.1016/0005-2760(86)90156-6; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDREWS DL, 1988, BIOCHEM J, V252, P199, DOI 10.1042/bj2520199; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BALLOU LR, 1986, J BIOL CHEM, V261, P3107; BEVAN M, 1986, NUCLEIC ACIDS RES, V14, P4625, DOI 10.1093/nar/14.11.4625; BILLS TK, 1977, J CLIN INVEST, V60, P1, DOI 10.1172/JCI108745; Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; BOWEN P, 1964, B JOHNS HOPKINS HOSP, V114, P402; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUCHER P, 1994, ISMB 94, P53; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; EVENBERG A, 1977, J BIOL CHEM, V252, P1189; Fisslthaler B, 1999, NATURE, V401, P493, DOI 10.1038/46816; FITZGERALD M, 1981, CELL, V24, P251, DOI 10.1016/0092-8674(81)90521-3; FORD DA, 1991, J CLIN INVEST, V88, P331, DOI 10.1172/JCI115296; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GROSS RW, 1993, BIOCHEMISTRY-US, V32, P327, DOI 10.1021/bi00052a041; GROSS RW, 1992, TRENDS CARDIOVAS MED, V2, P115, DOI 10.1016/1050-1738(92)90016-L; Gross RW, 1998, BIOCHEM SOC T, V26, P345, DOI 10.1042/bst0260345; GUBITOSIKLUG RA, 1995, J BIOL CHEM, V270, P2885, DOI 10.1074/jbc.270.7.2885; HAN XL, 1992, ANAL BIOCHEM, V200, P119, DOI 10.1016/0003-2697(92)90286-G; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HAZEN SL, 1991, J BIOL CHEM, V266, P5629; HAZEN SL, 1992, CIRC RES, V70, P486, DOI 10.1161/01.RES.70.3.486; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; HIRASHIMA Y, 1992, J NEUROCHEM, V59, P708, DOI 10.1111/j.1471-4159.1992.tb09426.x; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAMER RM, 1986, BIOCHIM BIOPHYS ACTA, V878, P394, DOI 10.1016/0005-2760(86)90248-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON FPK, 1999, EUR J BIOCHEM, V262, P575; Lazarow P. B., 1989, METABOLIC BASIS INHE, P1479; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LOEB LA, 1986, J BIOL CHEM, V261, P467; McHowat J, 1998, LIPIDS, V33, P1203, DOI 10.1007/s11745-998-0324-5; McHowat J, 1998, AM J PHYSIOL-CELL PH, V274, pC1727, DOI 10.1152/ajpcell.1998.274.6.C1727; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MIYAKE R, 1992, BIOCHIM BIOPHYS ACTA, V1165, P167, DOI 10.1016/0005-2760(92)90183-V; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SHARP JD, 1991, J BIOL CHEM, V266, P14850; Subramani S, 1996, J BIOL CHEM, V271, P32483, DOI 10.1074/jbc.271.51.32483; SUBRAMANI S, 1998, PHYSIOL REV, V78, P121; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Wolf MJ, 1996, J BIOL CHEM, V271, P30879, DOI 10.1074/jbc.271.48.30879; WOLF RA, 1985, J BIOL CHEM, V260, P7295; ZUPAN LA, 1993, J MED CHEM, V36, P95, DOI 10.1021/jm00053a012	64	177	181	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					9937	9945		10.1074/jbc.275.14.9937	http://dx.doi.org/10.1074/jbc.275.14.9937			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744668	hybrid			2022-12-27	WOS:000086345600009
J	McMahon, R; Murphy, M; Clarkson, M; Taal, M; Mackenzie, HS; Godson, C; Martin, F; Brady, HR				McMahon, R; Murphy, M; Clarkson, M; Taal, M; Mackenzie, HS; Godson, C; Martin, F; Brady, HR			IHG-2, a mesangial cell gene induced by high glucose, is human gremlin - Regulation by extracellular glucose concentration, cyclic mechanical strain, and transforming growth factor-beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIABETIC NEPHROPATHY; PATHOGENESIS; PROTEINS; RAT	We used cloning in silico coupled with polymerase chain reaction to demonstrate that IHG-2 is part of the 3'-untranslated region of gremlin, a member of the DAN family of secreted proteins that antagonize the bioactivities of members of the transforming growth factor (TGF)-beta superfamily, Mesangial cell gremlin mRNA levels were induced by high glucose, cyclic mechanical strain, and TGF-beta 1 in vitro, and gremlin mRNA levels were elevated in the renal cortex of rats with streptozotocin-induced diabetic nephropathy in vivo. gremlin expression was observed in parallel with induction of bone morphogenetic protein-2 (BMP-2), a target for gremlin in models of cell differentiation. Together these data indicate that (a) IHG-2 is gremlin, (b) gremlin is expressed in diabetic nephropathy in vivo, (c) both glycemic and mechanical strain stimulate mesangial cell gremlin expression in vitro, (d) high glucose induces gremlin, in part, through TGF beta-mediated pathways, and (e) Gremlin is a potential endogenous antagonist of BMPs within a diabetic glomerular milieu.	Univ Coll Dublin, Mater Misericordiae Hosp, Dept Med & Therapeut, Conway Inst Biomol & Biomed Res, Dublin 7, Ireland; Univ Coll Dublin, Mater Misericordiae Hosp, Dept Med & Therapeut, Ctr Mol Inflammat & Vasc Res, Dublin 7, Ireland; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Renal, Boston, MA 02115 USA; Univ Coll Dublin, Dept Pharmacol, Dublin 4, Ireland	Mater Misericordiae University Hospital; University College Dublin; Mater Misericordiae University Hospital; University College Dublin; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University College Dublin	Brady, HR (corresponding author), Univ Coll Dublin, Mater Misericordiae Hosp, Dept Med & Therapeut, Conway Inst Biomol & Biomed Res, 41 Eccles St, Dublin 7, Ireland.	hrbrady@mater.ie		Godson, Catherine/0000-0003-0655-1041; Taal, Maarten/0000-0002-9065-212X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Banfi S, 1998, TRENDS GENET, V14, P80, DOI 10.1016/S0168-9525(97)01354-1; BRADY HR, 1992, KIDNEY INT, V42, P480, DOI 10.1038/ki.1992.312; Choudhury GG, 1999, BIOCHEM BIOPH RES CO, V258, P490, DOI 10.1006/bbrc.1999.0599; Choundhury GG, 1999, J BIOL CHEM, V274, P10897; Cooper ME, 1998, LANCET, V352, P213, DOI 10.1016/S0140-6736(98)01346-4; Frazier JA, 1997, CURR BIOL, V7, pR414, DOI 10.1016/S0960-9822(06)00205-3; Hoffman BB, 1998, MINER ELECTROL METAB, V24, P190, DOI 10.1159/000057369; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; KREISBERG JI, 1993, KIDNEY INT, V43, P109, DOI 10.1038/ki.1993.18; Murphy M, 1999, J BIOL CHEM, V274, P5830, DOI 10.1074/jbc.274.9.5830; OZAKI T, 1995, CANCER RES, V55, P895; PARRING HH, 1996, BRENNER RECTORS KIDN, P1864; Pearce JJH, 1999, DEV BIOL, V209, P98, DOI 10.1006/dbio.1999.9240; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Riser BL, 2000, CURR OPIN NEPHROL HY, V9, P43, DOI 10.1097/00041552-200001000-00008; RISER BL, 1992, J CLIN INVEST, V90, P1932, DOI 10.1172/JCI116071; Sterzel R. Bernd, 1997, P595; Stewart FJ, 1996, CLIN GENET, V49, P152; Topol LZ, 1997, MOL CELL BIOL, V17, P4801, DOI 10.1128/MCB.17.8.4801; Yasuda T, 1999, NEPHROL DIAL TRANSPL, V14, P58, DOI 10.1093/ndt/14.suppl_1.58; Yazaki Y, 1998, ANTICANCER RES, V18, P2339; ZATZ R, 1985, P NATL ACAD SCI USA, V82, P5963, DOI 10.1073/pnas.82.17.5963; Zuniga A, 1999, NATURE, V401, P598, DOI 10.1038/44157	24	118	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					9901	9904		10.1074/jbc.275.14.9901	http://dx.doi.org/10.1074/jbc.275.14.9901			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744662	hybrid			2022-12-27	WOS:000086345600003
J	Talcott, B; Moore, MS				Talcott, B; Moore, MS			The nuclear import of RCC1 requires a specific nuclear localization sequence receptor, karyopherin alpha 3/Qip	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-TARGETING COMPLEX; ACTIVATING PROTEIN RANGAP1; TRANSPORT FACTORS; YEAST SRP1; IDENTIFICATION; ALPHA; RAN; HOMOLOG; EXPRESSION; INTERACTS	RCC1 is the only known guanine nucleotide exchange factor for the small GTPase Ran and is normally found inside the nucleus bound to chromatin, In order to analyze in more detail the nuclear import of RCC1, we created a fusion construct in which four IgG binding domains of protein A were fused to the amino terminus of human RCC1 (pA-RCC1), Surprisingly, we found that neither Xenopus ovarian cytosol nor a mixture of recombinant import factors (karyopherin alpha 2, karyopherin beta 1, Ran, and p19/NTF2) were able to support the import of pA-RCC1 into the nuclei of digitonin permeabilized cells. Both, in contrast, were capable of supporting the import of a construct containing another classical nuclear localization sequence (NLS), glutathione S-transferase-green fluorescent protein-NLS. Subsequently, me found that only one of the NLS receptors, karyopherin alpha 3 (Kap alpha 3/Qip), would support significant nuclear import of pA-RCC1 in permeabilized cells, while members of the other two main classes, Kap alpha 1 and Kap alpha 2, would not. Accordingly, in vitro binding studies revealed that only Kap alpha 3 showed significant binding to RCC1 (unlike Kap alpha 1 and Kap alpha 2) and that this binding was dependent on the basic amino acids present in the RCC1 NLS. In addition to Kap alpha 3, we found that the nuclear import of pA-RCC1 also required both karyopherin beta 1 and Ran.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Moore, MS (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053678] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-53678] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; Carazo-Salas RE, 1999, NATURE, V400, P178, DOI 10.1038/22133; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; FRASCH M, 1991, EMBO J, V10, P1225, DOI 10.1002/j.1460-2075.1991.tb08064.x; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Kalab P, 1999, CURR BIOL, V9, P481, DOI 10.1016/S0960-9822(99)80213-9; Kamei Y, 1999, J HISTOCHEM CYTOCHEM, V47, P363, DOI 10.1177/002215549904700310; KIEBE C, 1995, BIOCHEMISTRY-US, V34, P639; Kohler M, 1999, MOL CELL BIOL, V19, P7782; Kohler M, 1997, FEBS LETT, V417, P104, DOI 10.1016/S0014-5793(97)01265-9; KUSSEL P, 1995, MOL GEN GENET, V248, P351, DOI 10.1007/BF02191602; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Miyamoto Y, 1997, J BIOL CHEM, V272, P26375, DOI 10.1074/jbc.272.42.26375; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOORE MS, 2000, NUCL IMPORT DIGITONI; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Nachury MV, 1998, P NATL ACAD SCI USA, V95, P582, DOI 10.1073/pnas.95.2.582; Nadler SG, 1997, J BIOL CHEM, V272, P4310, DOI 10.1074/jbc.272.7.4310; NISHITANI H, 1990, J BIOCHEM-TOKYO, V107, P228, DOI 10.1093/oxfordjournals.jbchem.a123031; Ohba T, 1999, SCIENCE, V284, P1356, DOI 10.1126/science.284.5418.1356; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; ONEILL RE, 1995, J BIOL CHEM, V270, P22701, DOI 10.1074/jbc.270.39.22701; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Prieve MG, 1996, J BIOL CHEM, V271, P7654, DOI 10.1074/jbc.271.13.7654; Prieve MG, 1998, MOL CELL BIOL, V18, P4819, DOI 10.1128/MCB.18.8.4819; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; Schwoebel ED, 1998, J BIOL CHEM, V273, P35170, DOI 10.1074/jbc.273.52.35170; SEINO H, 1992, J CELL SCI, V102, P393; Seki T, 1997, BIOCHEM BIOPH RES CO, V234, P48, DOI 10.1006/bbrc.1997.6535; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Smith A, 1998, CURR BIOL, V8, P1403, DOI 10.1016/S0960-9822(98)00023-2; Takeda S, 1997, CYTOGENET CELL GENET, V76, P87, DOI 10.1159/000134521; Tsuji L, 1997, FEBS LETT, V416, P30, DOI 10.1016/S0014-5793(97)01092-2; Uetz P, 1996, ANAL BIOCHEM, V237, P161, DOI 10.1006/abio.1996.0220; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359; Zhang CM, 1999, J CELL SCI, V112, P2453	53	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10099	10104		10.1074/jbc.275.14.10099	http://dx.doi.org/10.1074/jbc.275.14.10099			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744690	hybrid			2022-12-27	WOS:000086345600031
J	Yun, CW; Ferea, T; Rashford, J; Ardon, O; Brown, PO; Botstein, D; Kaplan, J; Philpott, CC				Yun, CW; Ferea, T; Rashford, J; Ardon, O; Brown, PO; Botstein, D; Kaplan, J; Philpott, CC			Desferrioxamine-mediated iron uptake in Saccharomyces cerevisiae - Evidence for two pathways of iron uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR FACILITATOR SUPERFAMILY; TRANSPORT PROTEIN; USTILAGO-MAYDIS; REGULATED GENES; FET3 GENE; YEAST; SIDEROPHORES; EXPRESSION; REDUCTION; MEMBRANE	In the yeast Saccharomyces cerevisiae, uptake of iron is largely regulated by the transcription factor Aft1. cDNA microarrays were used to identify new iron and AFT1-regulated genes. Four homologous genes regulated as part of the AFT1-regulon (ARN1-4) were predicted to encode members of a subfamily of the major facilitator superfamily of transporters. These genes were predicted to encode proteins with 14 membrane spanning domains and were from 26 to 53% identical at the amino acid level. ARN3 is identical to SIT1, which is reported to encode a ferrioxamine B permease, Deletion of ARN3 did not prevent yeast from using ferrioxamine B as an iron source; however, deletion of ARN3 and FET3, a component of the high affinity ferrous iron transport system, did prevent uptake of ferrioxamine-bound iron and growth on ferrioxamine as an iron source. The siderophore-mediated transport system and the high affinity ferrous iron transport system were localized to separate cellular compartments. Epitope-tagged Arn3p was expressed in intracellular vesicles that co-sediment with the endosomal protein Pep12. In contrast, Fet3p was expressed on the plasma membrane and was digested by extracellular proteases, These data indicate that S. cerevisiae has two pathways for ferrrioxamine-mediated iron uptake, one occurring at the plasma membrane and the other occurring in an intracellular compartment.	NIDDK, Liver Dis Sect, NIH, Bethesda, MD 20892 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Biochem, Stanford, CA 94305 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Stanford University; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Stanford University	Philpott, CC (corresponding author), NIDDK, Liver Dis Sect, NIH, Bethesda, MD 20892 USA.	carolinep@intra.niddk.nih.gov		Ardon, Orly/0000-0001-8147-933X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK054507] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-305340] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aisen P, 1998, MET IONS BIOL SYST, V35, P585; Albrecht-Gary AM, 1998, MET IONS BIOL SYST, V35, P239; Ardon O, 1998, J BACTERIOL, V180, P2021, DOI 10.1128/JB.180.8.2021-2026.1998; Ardon O, 1997, MICROBIOL-UK, V143, P3625, DOI 10.1099/00221287-143-11-3625; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Askwith CC, 1998, J BIOL CHEM, V273, P22415, DOI 10.1074/jbc.273.35.22415; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; Braun V, 1998, MET IONS BIOL SYST, V35, P67; Byers BR, 1998, MET IONS BIOL SYST, V35, P37; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; DIX DR, 1994, J BIOL CHEM, V269, P26092; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; Goffeau A, 1997, YEAST, V13, P43, DOI 10.1002/(SICI)1097-0061(199701)13:1<43::AID-YEA56>3.0.CO;2-J; Leong SA, 1998, MET IONS BIOL SYST, V35, P147; LESUISSE E, 1987, J GEN MICROBIOL, V133, P3229; Lesuisse E, 1998, MICROBIOL-UK, V144, P3455, DOI 10.1099/00221287-144-12-3455; Lin SJ, 1997, J BIOL CHEM, V272, P9215; NEILANDS JB, 1995, J BIOL CHEM, V270, P26723, DOI 10.1074/jbc.270.45.26723; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; NOTHWEHR SF, 1995, J CELL BIOL, V129, P35, DOI 10.1083/jcb.129.1.35; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Philpott CC, 1998, EMBO J, V17, P5026, DOI 10.1093/emboj/17.17.5026; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; Schneider BL, 1996, YEAST, V12, P129, DOI 10.1002/(SICI)1097-0061(199602)12:2<129::AID-YEA891>3.0.CO;2-O; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Stearman R, 1998, GENE, V212, P197, DOI 10.1016/S0378-1119(98)00179-6; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x	34	163	168	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10709	10715		10.1074/jbc.275.14.10709	http://dx.doi.org/10.1074/jbc.275.14.10709			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744769	hybrid			2022-12-27	WOS:000086345600110
J	Dunstan, SL; Sala-Newby, GB; Fajardo, AB; Taylor, KM; Campbell, AK				Dunstan, SL; Sala-Newby, GB; Fajardo, AB; Taylor, KM; Campbell, AK			Cloning and expression of the bioluminescent photoprotein pholasin from the bivalve mollusc Pholas dactylus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DINOFLAGELLATE GONYAULAX-POLYEDRA; LUCIFERIN-BINDING-PROTEIN; INFLUENZA-VIRUS; GLYCOSYLATION; AEQUORIN; CELLS; GENE; HEMAGGLUTININ; CALSEQUESTRIN; REQUIREMENTS	Pholasin is the photoprotein responsible for luminescence in the bivalve Pholas dactylus and consists of a luciferin tightly bound to a glycosylated protein, It is a sensitive indicator of reactive oxygen species. A full-length clone encoding apopholasin was isolated from a P. dactylus light organ cDNA library. The unprocessed apoprotein contained 225 amino acids, starting with a signal peptide of 20 amino acids, 3 predicted N-linged glycosylation sites, 1 O-linked site, no histidines, and 7 cysteines, The recombinant apoprotein was expressed in cell extracts and insect cells. The size of the apoprotein expressed in cell extracts and the cytosol of insect cells was 26 kDa but that of the fully processed protein was 34 kDa, as was native pholasin. Both the processed and unprocessed recombinant apoproteins were recognized by a polyclonal antibody raised against native pholasin, Acid methanol extracts from Pholas added to recombinant apoprotein resulted in chemiluminescence triggered by sodium hypochlorite but not photoprotein formation. These results have important implications in understanding the molecular evolution of bioluminescence and will allow the development of recombinant pholasin as an intracellular indicator of reactive oxygen species.	Univ Wales, Coll Med, Dept Biochem Med, Cardiff CF14 4XN, S Glam, Wales	Cardiff University	Campbell, AK (corresponding author), Univ Wales, Coll Med, Dept Biochem Med, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.		Taylor, Kathryn M/O-3401-2014	Taylor, Kathryn M/0000-0002-9576-9490				Badminton MN, 1995, BIOCHEM BIOPH RES CO, V217, P950, DOI 10.1006/bbrc.1995.2862; BADMINTON MN, 1995, EXP CELL RES, V216, P236, DOI 10.1006/excr.1995.1030; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BASSOT JM, 1966, BIOLUMINESCENCE PROG, P559; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; Bellamacina CR, 1996, FASEB J, V10, P1257, DOI 10.1096/fasebj.10.11.8836039; Boettcher KJ, 1996, J COMP PHYSIOL A, V179, P65; BOWTELL D, 1987, ANAL BIOCHEM, V163, P391; Campbell A. K., 1994, BIOLUMINESCENCE CHEM; Campbell A.K., 1988, CHEMILUMINESCENCE PR; CAMPBELL AK, 1990, MAR BIOL, V104, P219, DOI 10.1007/BF01313261; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COTTON B, 1989, BIOCHEM SOC T, V17, P705, DOI 10.1042/bst0170705; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Dubois R, 1987, COMPT REND SOC BIOL, V39, P564; FINDLAY JBC, 1989, PROTEINS EQUENCING P; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; GALLAGHER PJ, 1992, J VIROL, V66, P7136, DOI 10.1128/JVI.66.12.7136-7145.1992; GROPPE JC, 1993, ANAL BIOCHEM, V210, P337, DOI 10.1006/abio.1993.1205; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; Harvey E.N., 1952, BIOLUMINESCENCE; HASTINGS JW, 1989, J BIOLUM CHEMILUM, V4, P12, DOI 10.1002/bio.1170040105; Hastings JW, 1996, GENE, V173, P5, DOI 10.1016/0378-1119(95)00676-1; HEARING J, 1989, J CELL BIOL, V108, P355, DOI 10.1083/jcb.108.2.355; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; HENRY JP, 1977, BIOCHEMISTRY-US, V16, P2517, DOI 10.1021/bi00630a031; HENRY JP, 1975, BIOCHEMISTRY-US, V14, P3458, DOI 10.1021/bi00686a026; Hsu TA, 1996, PROTEIN EXPRES PURIF, V7, P281, DOI 10.1006/prep.1996.0040; Johnson F.H., 1978, Methods in Enzymology, V57, P271; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; KENDALL JM, 1992, BIOCHEM BIOPH RES CO, V189, P1008, DOI 10.1016/0006-291X(92)92304-G; KORSMEYER SJ, 1995, BBA-MOL BASIS DIS, V1271, P63, DOI 10.1016/0925-4439(95)00011-R; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KUMAR S, 1990, FEBS LETT, V268, P287, DOI 10.1016/0014-5793(90)81029-N; KUROSE K, 1989, P NATL ACAD SCI USA, V86, P80, DOI 10.1073/pnas.86.1.80; LEE DH, 1993, J BIOL CHEM, V268, P8842; Li LM, 1998, PLANT MOL BIOL, V36, P275, DOI 10.1023/A:1005941421474; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Michelson A.M., 1978, Methods in Enzymology, V57, P385; MULLER T, 1990, J BIOLUM CHEMILUM, V5, P25, DOI 10.1002/bio.1170050106; NICOL JAC, 1960, J MAR BIOL ASSOC UK, V39, P109, DOI 10.1017/S002531540001314X; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Ohmiya Y, 1997, FEBS LETT, V404, P115, DOI 10.1016/S0014-5793(97)00105-1; OHNISHI M, 1987, BIOCHEMISTRY-US, V26, P7458, DOI 10.1021/bi00397a039; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; OSTWALD TJ, 1974, J BIOL CHEM, V249, P5867; Rees JF, 1998, J EXP BIOL, V201, P1211; RICHTER C, 1995, INT J BIOCHEM CELL B, V27, P647, DOI 10.1016/1357-2725(95)00025-K; ROBERTS PA, 1987, ANAL BIOCHEM, V160, P139, DOI 10.1016/0003-2697(87)90624-5; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SALANEWBY GB, 1994, BBA-PROTEIN STRUCT M, V1206, P155, DOI 10.1016/0167-4838(94)90084-1; SAMBROOK J, 1989, MOL CLONING LAB MANA; TAYLOR KM, 1994, IMMUNOLOGY, V83, P501; THOMPSON EM, 1989, P NATL ACAD SCI USA, V86, P6567, DOI 10.1073/pnas.86.17.6567; Thomson CM, 1997, J BIOLUM CHEMILUM, V12, P87, DOI 10.1002/(SICI)1099-1271(199703/04)12:2<87::AID-BIO438>3.0.CO;2-8; Tooze SA, 1998, BBA-MOL CELL RES, V1404, P231, DOI 10.1016/S0167-4889(98)00059-7; Wallace DC, 1998, NAT GENET, V19, P105, DOI 10.1038/448; WATKINS NJ, 1993, BIOCHEM J, V293, P181, DOI 10.1042/bj2930181; WINNEPENNINCKX B, 1993, TRENDS GENET, V9, P407	60	27	31	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9403	9409		10.1074/jbc.275.13.9403	http://dx.doi.org/10.1074/jbc.275.13.9403			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734085	hybrid, Green Accepted			2022-12-27	WOS:000086206500049
J	Melchor, JP; Van Nostrand, WE				Melchor, JP; Van Nostrand, WE			Fibrillar amyloid beta-protein mediates the pathologic accumulation of its secreted precursor in human cerebrovascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY CEREBRAL-HEMORRHAGE; ALZHEIMERS-DISEASE; FACTOR-IXA; ANGIOPATHY; NEUROTOXICITY; PEPTIDE; INVITRO; AGGREGATION; BINDING; QUANTITATION	Cerebrovascular deposition of the amyloid beta-protein (A beta) is a key pathologic lesion seen in patients with Alzheimer's disease and certain related disorders, including hereditary cerebral hemorrhage with amyloidosis of the Dutch type (HCHWA-D), The deposition of A beta has pronounced deleterious effects on smooth muscle cells within the cerebral vessel wall. We have previously shown that A beta(1-40) possessing the E22Q HCHWA-D mutation extensively assembles into fibrils on the surface of cultured human cerebrovascular smooth muscle (HCSM) cells. This cell-surface A beta fibril formation induces a series of pathologic responses in cultured HCSM cells, including a marked increase in the levels of cell-associated amyloid beta-protein precursor (A beta PP) and cell death. In the present study, we investigated the relationship between HCSM cell-surface A beta fibril formation and the striking increase in cell-associated A beta PP, Time course studies showed that cell-surface HCHWA-D A beta(1-40) fibril formation occurred rapidly, whereas both the increase in cell-associated A beta PP and loss of cell viability were delayed responses. Domain analysis using site-specific antibodies indicated that the vast majority of the increase in cell-associated A beta PP was secreted A beta PP (sA beta PP), Localization studies showed that the sA beta PP was present on the HCSM cell surface. This result raised the possibility that sA beta PP may bind back to HCSM cell-surface fibrils formed by HCHWA-D A beta(1-40). Indeed, binding of biotinylated sA beta PP to fibrillar HCHWA-D A beta(1-40) was demonstrated by transmission electron microscopy, Furthermore, solid-phase binding assays showed that biotinylated sA beta PP exhibited dose-dependent, saturable binding to fibrillar (but not soluble) HCHWA-D A beta(1-40) with k(d) approximate to 28 nM. Exon deletion experiments further defined a fragment of sA beta PP (A beta PP18-119), encoded by A beta PP exons 2 and 3, to contain the fibrillar A beta-binding domain. In addition, A beta PP18-119 effectively blocked the cell-surface accumulation of sA beta PP and subsequent cell death in HCSM cells treated with pathogenic A beta, Together, these findings could explain the accumulation of A beta PP in cerebrovascular A beta deposits observed both in vitro and in vivo and may contribute to the pathologic responses evoked by pathogenic forms of A beta in HCSM cells.	SUNY Stony Brook, Hlth Sci Ctr T15081, Dept Med, Stony Brook, NY 11794 USA; SUNY Stony Brook, Ctr Hlth Sci, Dept Pathol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Van Nostrand, WE (corresponding author), SUNY Stony Brook, Hlth Sci Ctr T15081, Dept Med, Stony Brook, NY 11794 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL003229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035781] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG016223] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03229] Funding Source: Medline; NIA NIH HHS [AG16223] Funding Source: Medline; NINDS NIH HHS [NS35781] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON JP, 1989, EMBO J, V8, P3627, DOI 10.1002/j.1460-2075.1989.tb08536.x; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURDICK D, 1992, J BIOL CHEM, V267, P546; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CORIA F, 1989, J NEUROPATH EXP NEUR, V48, P368, DOI 10.1097/00005072-198905000-00207; COTMAN CW, 1992, NEUROBIOL AGING, V13, P587, DOI 10.1016/0197-4580(92)90060-B; Davis J, 1999, AMYLOID, V6, P157, DOI 10.3109/13506129909007321; DAVISSALINAS J, 1995, J NEUROCHEM, V65, P931; DAVISSALINAS J, 1995, J BIOL CHEM, V270, P20887, DOI 10.1074/jbc.270.36.20887; FELDMANN E, 1991, STROKE, V22, P684; FRAUTSCHY SA, 1991, P NATL ACAD SCI USA, V563, P311; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Giulian D, 1998, J BIOL CHEM, V273, P29719, DOI 10.1074/jbc.273.45.29719; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; KANG J, 1987, NATURE, V324, P4245; KAWAI M, 1993, BRAIN RES, V623, P142, DOI 10.1016/0006-8993(93)90021-E; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; KOWALL NW, 1991, P NATL ACAD SCI USA, V88, P7247, DOI 10.1073/pnas.88.16.7247; KOWALL NW, 1992, NEUROBIOL AGING, V13, P537, DOI 10.1016/0197-4580(92)90053-Z; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; LUYENDIJK W, 1988, J NEUROL SCI, V85, P267, DOI 10.1016/0022-510X(88)90186-4; MAHDI F, 1995, J BIOL CHEM, V270, P23468, DOI 10.1074/jbc.270.40.23468; MARUYAMA K, 1990, STROKE, V21, P397, DOI 10.1161/01.STR.21.3.397; MULTHAUP G, 1994, BIOCHIMIE, V76, P304, DOI 10.1016/0300-9084(94)90163-5; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; OKAZAKI H, 1979, MAYO CLIN PROC, V54, P22; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327; ROZEMULLER AJM, 1993, AM J PATHOL, V142, P1449; SCHMAIER AH, 1995, BIOCHEMISTRY-US, V34, P1171, DOI 10.1021/bi00004a010; SCHMAIER AH, 1993, J CLIN INVEST, V92, P2540, DOI 10.1172/JCI116863; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; Van Nostrand WE, 1998, J NEUROCHEM, V70, P216; VANDUINEN SG, 1987, P NATL ACAD SCI USA, V84, P5991; VANLEY CT, 1981, HUM PATHOL, V12, P609, DOI 10.1016/S0046-8177(81)80044-5; VanNostrand WE, 1996, ANN NY ACAD SCI, V777, P297; VANNOSTRAND WE, 1994, AMYLOID, V1, P1, DOI 10.3109/13506129409148618; VANNOSTRAND WE, 1989, NATURE, V341, P546; VANNOSTRAND WE, 1992, ANN NY ACAD SCI, V674, P243; VANNOSTRAND WE, 1991, ANN NY ACAD SCI, V640, P140; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; VINTERS HV, 1987, STROKE, V18, P311, DOI 10.1161/01.STR.18.2.311; WATTENDORFF AR, 1995, J NEUROL NEUROSUR PS, V59, P699; WISNIEWSKI HM, 1994, AMYLOID, V1, P8, DOI 10.3109/13506129409148619; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077	49	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9782	9791		10.1074/jbc.275.13.9782	http://dx.doi.org/10.1074/jbc.275.13.9782			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734132	hybrid			2022-12-27	WOS:000086206500096
J	Murthy, S; Mathur, SN; Field, FJ				Murthy, S; Mathur, SN; Field, FJ			Tumor necrosis factor-alpha and interleukin-1 beta inhibit apolipoprotein B secretion in CaCo-2 cells via the epidermal growth factor receptor signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; INFLAMMATORY BOWEL-DISEASE; TYROSINE PHOSPHORYLATION; CARCINOMA-CELLS; KINASE-ACTIVITY; CELIAC-DISEASE; MESSENGER-RNA; CYTOKINES; EXPRESSION; PROTEIN	In inflammatory conditions of the gut, cytokines are released into the mucosa and submucosa propagating and sustaining the inflammatory response. In CaCo-2 cells, we have shown that various inflammatory cytokines interfere with the secretion of lipids, an effect that is likely caused by the release of a ligand to the epidermal growth factor (ECF) receptor. In the present study, the role of the EGF receptor signaling pathway and the effects of the cytokines tumor necrosis factor-alpha (TNF-alpha) and and interleukin 1 beta (Il-1 beta) on triacylglycerol-rich lipoprotein secretion were investigated, CaCo-2 cells were incubated with oleic acid to enhance triacylglycerol-rich lipoprotein secretion. TNF-alpha and IL-1 beta significantly decreased the basolateral secretion of apolipoprotein B (apoB) mass, with IL-1 beta being more potent. Tyrphostin, an inhibitor of the EGF receptor intrinsic tryosine kinase, prevented or markedly attenuated the decrease in apoB secretion by TNF-alpha or IL-1 beta. Both cytokines increased the phosphorylation of the EGF receptor by 30 min. Moreover, phosphotyrosine immunoblots of the EGF receptor demonstrated an increase in tyrosine residues phosphorylated by 0.5 and 6.5 h, At both these time points, TNF-alpha and IL-1 beta also decreased the binding of EGF to its cell surface receptor. At 6.5 h, activation of the EGF receptor was sustained, In contrast, the early activation of the receptor was only transient as receptor phosphorylation and binding of EGF to its receptor returned to basal levels by 2 h, Preventing ligand binding to the EGF receptor by a receptor-blocking antibody attenuated receptor activation observed after 6.5 h, This did not occur at 0.5 h, suggesting that early activation of the EGF receptor was non-ligand-mediated. Similarly, apoB secretion was inhibited by an early non-ligand-mediated process; whereas at the later time, inhibition of apoB secretion was ligand-mediated, Thus, the inflammatory cytokines TNF-alpha and IL-1 beta interfere with the secretion of triacylglycerol-rich lipoproteins by both early and delayed signaling events mediated by the EGF receptor signaling pathway.	Univ Iowa, Dept Internal Med & Vet Affairs, Iowa City, IA 52242 USA	University of Iowa	Murthy, S (corresponding author), Univ Iowa, Dept Internal Med & Vet Affairs, 200 Hawkins Dr, Iowa City, IA 52242 USA.				NHLBI NIH HHS [HL49264, HL56032] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056032, P01HL049264] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDOH A, 1993, J IMMUNOL, V151, P4239; BEIL WJ, 1995, J LEUKOCYTE BIOL, V58, P284, DOI 10.1002/jlb.58.3.284; BIRD AR, 1994, J NUTR, V124, P231, DOI 10.1093/jn/124.2.231; BIRD TA, 1989, J IMMUNOL, V142, P126; BISHOP WP, 1994, AM J PHYSIOL-GASTR L, V267, pG892, DOI 10.1152/ajpgi.1994.267.5.G892; BLAKE WL, 1992, BIOCHEM BIOPH RES CO, V186, P199, DOI 10.1016/S0006-291X(05)80793-4; BRAEGGER CP, 1994, ANN ALLERGY, V72, P135; BRYNSKOV J, 1992, SCAND J GASTROENTERO, V27, P897, DOI 10.3109/00365529209000160; DAVIS RJ, 1993, ADV LIPID RES, V25, P131; DONOWITZ M, 1994, AM J PHYSIOL, V266, pG647, DOI 10.1152/ajpgi.1994.266.4.G647; DOUCET JP, 1990, ANAL BIOCHEM, V190, P209, DOI 10.1016/0003-2697(90)90182-9; ECKMANN L, 1993, GASTROENTEROLOGY, V105, P1689, DOI 10.1016/0016-5085(93)91064-O; FAUCHER M, 1988, J BIOL CHEM, V263, P5319; FIELD FJ, 1993, J CLIN INVEST, V92, P2609, DOI 10.1172/JCI116876; FIELD FJ, 1988, J LIPID RES, V29, P1427; FIOCCHI C, 1991, IMMUNOL RES, V10, P239, DOI 10.1007/BF02919699; GILL GN, 1984, J BIOL CHEM, V259, P7755; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; HORVATH K, 1994, BBA-MOL CELL RES, V1222, P215, DOI 10.1016/0167-4889(94)90171-6; KAGNOFF MF, 1992, GASTROENTEROL CLIN N, V21, P405; KALTHOFF H, 1993, J BIOL CHEM, V268, P2762; KLEINBAUM DG, 1978, APPL REGRESSION ANAL, P15; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KONTUREK JW, 1991, J CLIN GASTROENTEROL, V13, pS88, DOI 10.1097/00004836-199112001-00015; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LEVY E, 1992, J LIPID RES, V33, P1607; LEVY E, 1994, BIOCHEM BIOPH RES CO, V204, P1340, DOI 10.1006/bbrc.1994.2610; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGEE DW, 1993, INFECT IMMUN, V61, P4637, DOI 10.1128/IAI.61.11.4637-4644.1993; MOLMENTI EP, 1993, J BIOL CHEM, V268, P14116; Murthy S, 1996, AM J PHYSIOL-GASTR L, V270, pG94, DOI 10.1152/ajpgi.1996.270.1.G94; Murthy S, 1997, J LIPID RES, V38, P206; MURTHY S, 1990, BIOCHIM BIOPHYS ACTA, V1045, P147, DOI 10.1016/0005-2760(90)90144-M; Opleta-Madsen K., 1991, AM J PHYSIOL, V260, P807; PRZEMIOSLO RT, 1994, GUT, V35, P1398, DOI 10.1136/gut.35.10.1398; RADEMA SA, 1991, GASTROENTEROLOGY, V100, P1180; Saklatvala J, 1996, PHILOS T ROY SOC B, V351, P151, DOI 10.1098/rstb.1996.0011; SARTOR RB, 1991, IMMUNOL RES, V10, P465, DOI 10.1007/BF02919743; SARTOR RB, 1994, GASTROENTEROLOGY, V106, P533, DOI 10.1016/0016-5085(94)90614-9; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; SCHMIEGEL W, 1993, P NATL ACAD SCI USA, V90, P863, DOI 10.1073/pnas.90.3.863; SCHUERERMALY CC, 1994, IMMUNOLOGY, V81, P85; SCHULTZ G, 1991, J CELL BIOCHEM, V45, P346, DOI 10.1002/jcb.240450407; SHIROTA K, 1990, VIRCHOWS ARCH B, V58, P303; Tarnawski AS, 1998, J CLIN GASTROENTEROL, V27, pS12, DOI 10.1097/00004836-199800001-00004; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALYINAGY I, 1992, J INVEST DERMATOL, V99, P350, DOI 10.1111/1523-1747.ep12616672; VIETOR I, 1993, J BIOL CHEM, V268, P18994; WAHL SM, 1989, IMMUNOL TODAY, V10, P258, DOI 10.1016/0167-5699(89)90136-9	50	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9222	9229		10.1074/jbc.275.13.9222	http://dx.doi.org/10.1074/jbc.275.13.9222			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734059	hybrid			2022-12-27	WOS:000086206500023
J	Sharma, MR; Jeyakumar, LH; Fleischer, S; Wagenknecht, T				Sharma, MR; Jeyakumar, LH; Fleischer, S; Wagenknecht, T			Three-dimensional structure of ryanodine receptor isoform three in two conformational states as visualized by cryo-electron microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; MUSCLE DIHYDROPYRIDINE RECEPTOR; SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; CA2+ RELEASE; CRYOELECTRON MICROSCOPY; 3-DIMENSIONAL ARCHITECTURE; FEET STRUCTURES; MICE LACKING; DOMAIN-III	Using cryo-electron microscopy and single particle image processing techniques, we present the first three-dimensional reconstructions of isoform 3 of the ryanodine receptor/calcium release channel (RyR3), Reconstructions were carried out on images obtained from a purified, detergent-solubilized receptor for two different buffer conditions, which were expected to favor open and closed functional states of the channel, As for the heart (RyR2) and skeletal muscle (RyR1) receptor isoforms, RyR3 is a homotetrameric complex comprising two main components, a multidomain cytoplasmic assembly and a smaller (similar to 20% of the total mass) transmembrane region. Although the isoforms show structural similarities, consistent with the similar to 70% overall sequence identity of the isoforms, detailed comparisons of RyR3 with RyR1 showed one region of highly significant difference between them. This difference indicated additional mass present in RyR1, and it likely corresponds to a region of the RyR1 sequence (residues 1303-1406, known as diversity region 2) that is absent from RyR3, The reconstructions of RyR3 determined under "open" and "closed" conditions were similar to each other in overall architecture. A difference map computed between the two reconstructions reveals subtle changes in conformation at several widely dispersed locations in the receptor, the most prominent of which is a similar to 4 degrees rotation of the transmembrane region with respect to the cytoplasmic assembly.	New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA; SUNY Albany, Dept Biomed Sci, Albany, NY 12201 USA; Vanderbilt Univ, Dept Mol Biol, Nashville, TN 37235 USA; Vanderbilt Univ, Dept Pharmacol, Sch Med, Nashville, TN 37232 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Vanderbilt University; Vanderbilt University	Sharma, MR (corresponding author), New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040615] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32711] Funding Source: Medline; NIAMS NIH HHS [AR40615] Funding Source: Medline; PHS HHS [IF32H20060-01A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; Chen SRW, 1998, J BIOL CHEM, V273, P14675, DOI 10.1074/jbc.273.24.14675; Chen SRW, 1997, J BIOL CHEM, V272, P24234, DOI 10.1074/jbc.272.39.24234; CHU A, 1990, MOL PHARMACOL, V37, P735; Conti A, 1996, BIOCHEM J, V316, P19, DOI 10.1042/bj3160019; Copello JA, 1999, BIOPHYS J, V76, pA469; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; Flucher BE, 1996, P NATL ACAD SCI USA, V93, P8101, DOI 10.1073/pnas.93.15.8101; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; INUI M, 1987, J BIOL CHEM, V262, P15637; INUI M, 1987, J BIOL CHEM, V262, P1740; Jeyakumar LH, 1998, J BIOL CHEM, V273, P16011, DOI 10.1074/jbc.273.26.16011; Leong P, 1998, J BIOL CHEM, V273, P7791, DOI 10.1074/jbc.273.14.7791; Leong P, 1998, BIOCHEM CELL BIOL, V76, P681, DOI 10.1139/bcb-76-5-681; Leong P, 1998, J BIOL CHEM, V273, P29958, DOI 10.1074/jbc.273.45.29958; Malhotra A, 1998, J MOL BIOL, V280, P103, DOI 10.1006/jmbi.1998.1859; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Murayama T, 1997, J BIOL CHEM, V272, P24030, DOI 10.1074/jbc.272.38.24030; Murayama T, 1999, J BIOL CHEM, V274, P17297, DOI 10.1074/jbc.274.24.17297; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Nakai J, 1997, P NATL ACAD SCI USA, V94, P1019, DOI 10.1073/pnas.94.3.1019; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; Ogawa Y, 1999, ADV BIOPHYS, V36, P27, DOI 10.1016/S0065-227X(99)80004-5; Orlova EV, 1996, NAT STRUCT BIOL, V3, P547, DOI 10.1038/nsb0696-547; Penczek PA, 1996, ULTRAMICROSCOPY, V63, P205, DOI 10.1016/0304-3991(96)00037-X; Qi Y, 1998, J BIOL CHEM, V273, P34813, DOI 10.1074/jbc.273.52.34813; Qi Y, 1998, BIOPHYS J, V74, pA322; RADERMACHER M, 1994, J CELL BIOL, V127, P411, DOI 10.1083/jcb.127.2.411; Samso M, 1999, J CELL BIOL, V146, P493, DOI 10.1083/jcb.146.2.493; Samso M, 1998, J STRUCT BIOL, V121, P172, DOI 10.1006/jsbi.1997.3955; Serysheva II, 1999, BIOPHYS J, V77, P1936, DOI 10.1016/S0006-3495(99)77035-9; SERYSHEVA II, 1995, NAT STRUCT BIOL, V2, P18, DOI 10.1038/nsb0195-18; Sharma MR, 1998, J BIOL CHEM, V273, P18429, DOI 10.1074/jbc.273.29.18429; Shoshan-Barmatz V, 1998, INT REV CYTOL, V183, P185, DOI 10.1016/S0074-7696(08)60145-X; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; SORRENTINO V, 1995, RYANODINE RECEPTORS, P85; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TAKESHIMA H, 1995, EMBO J, V14, P2999, DOI 10.1002/j.1460-2075.1995.tb07302.x; Takeshima H, 1996, J BIOL CHEM, V271, P19649, DOI 10.1074/jbc.271.33.19649; Tarroni P, 1997, J BIOL CHEM, V272, P19808, DOI 10.1074/jbc.272.32.19808; Wagenknecht T, 1997, J BIOL CHEM, V272, P32463, DOI 10.1074/jbc.272.51.32463; WAGENKNECHT T, 1995, FEBS LETT, V369, P43, DOI 10.1016/0014-5793(95)00581-S; Yamazawa T, 1996, EMBO J, V15, P6172, DOI 10.1002/j.1460-2075.1996.tb01005.x; Yamazawa T, 1997, J BIOL CHEM, V272, P8161, DOI 10.1074/jbc.272.13.8161	48	71	75	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9485	9491		10.1074/jbc.275.13.9485	http://dx.doi.org/10.1074/jbc.275.13.9485			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734096	hybrid			2022-12-27	WOS:000086206500060
J	Hanada, K; Hara, T; Nishijima, M				Hanada, K; Hara, T; Nishijima, M			Purification of the serine palmitoyltransferase complex responsible for sphingoid base synthesis by using affinity peptide chromatography techniques	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; ANCHORED PROTEIN; BIOSYNTHESIS; LCB1; SPHINGOLIPIDS; CHOLESTEROL; MEMBRANES; CLONING; MUTANT; ENZYME	Serine palmitoyltransferase (SPT), a membrane-bound enzyme of the endoplasmic reticulum, catalyzes the condensation of palmitoyl coenzyme A (CoA) and L-serine to produce 3-ketodihydrosphingosine. This enzyme contains at least two different subunits, named the LCB1 and LCBS proteins. In the present study, we expressed a FLAG- and His(6) peptide-tagged version of the hamster LCB1 protein in a Chinese hamster ovary cell mutant strain lacking the endogenous LCB1 subunit and purified SPT from the cells near to homogeneity by affinity peptide chromatography. The endogenous LCBS protein was co-purified with the tagged LCB1 protein in purification of SPT. In various aspects, including optimum pH, acyl-CoA specificity, and sphingofungin sensitivity, the activity of purified SPT was consistent with the activity detected in lysates of wild-type Chinese hamster ovary cells. The optimum concentration of palmitoyl-CoA for 3-ketodihydrosphingosine formation by purified SPT was similar to 25 mu M, and the apparent K-m of L-serine was 0.28 mM, Competition analysis of the SPT reaction with various serine analogs showed that all of the amino, carboxyl, and hydroxyl groups of L-serine were responsible for the substrate recognition of the enzyme. SDS-polyacrylamide gel electrophoretic analysis of purified SPT, together with immunoprecipitation analysis of metabolically labeled LCB proteins, strongly suggested that the SPT enzyme consisted of the LCB1 and LCB2 proteins with a stoichiometry of 1:1.	Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 1628640, Japan; Natl Inst Infect Dis, Japan Sci & Technol Corp, CREST, Shinjuku Ku, Tokyo 1628640, Japan	National Institute of Infectious Diseases (NIID); Japan Science & Technology Agency (JST); National Institute of Infectious Diseases (NIID)	Hanada, K (corresponding author), Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.			Hanada, Kentaro/0000-0003-1383-2781				Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BRAUN PE, 1968, J BIOL CHEM, V243, P3775; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; Chen JK, 1999, CHEM BIOL, V6, P221, DOI 10.1016/S1074-5521(99)80038-6; HANADA K, 1993, J BIOL CHEM, V268, P13820; HANADA K, 1992, J BIOL CHEM, V267, P23527; Hanada K, 1997, J BIOL CHEM, V272, P32108, DOI 10.1074/jbc.272.51.32108; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; HANADA K, 1990, J BIOL CHEM, V265, P22137; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; KARLSSON KA, 1970, CHEM PHYS LIPIDS, V5, P6, DOI 10.1016/0009-3084(70)90008-3; Kobayashi S, 1998, J AM CHEM SOC, V120, P908, DOI 10.1021/ja9730829; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANDON EC, 1992, J BIOL CHEM, V267, P11144; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; MERRILL AH, 1983, BIOCHIM BIOPHYS ACTA, V754, P284, DOI 10.1016/0005-2760(83)90144-3; Merrill Jr A. H., 1996, BIOCH LIPIDS LIPOPRO, P309; NAGIEC MM, 1994, P NATL ACAD SCI USA, V91, P7899, DOI 10.1073/pnas.91.17.7899; Naslavsky N, 1999, J BIOL CHEM, V274, P20763, DOI 10.1074/jbc.274.30.20763; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Stevens VL, 1997, J BIOL CHEM, V272, P18020, DOI 10.1074/jbc.272.29.18020; STOFFEL W, 1968, Z PHYSIOL CHEM, V349, P664; TARDI PG, 1992, LIPIDS, V27, P65, DOI 10.1007/BF02537062; Weiss B, 1997, EUR J BIOCHEM, V249, P239, DOI 10.1111/j.1432-1033.1997.00239.x; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9; ZHAO C, 1994, J BIOL CHEM, V269, P21480; ZWEERINK MM, 1992, J BIOL CHEM, V267, P25032	31	87	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8409	8415		10.1074/jbc.275.12.8409	http://dx.doi.org/10.1074/jbc.275.12.8409			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722674	hybrid			2022-12-27	WOS:000086507700024
J	Li, XL; Blackford, JA; Judge, CS; Liu, MJ; Xiao, WH; Kalvakolanu, DV; Hassel, BA				Li, XL; Blackford, JA; Judge, CS; Liu, MJ; Xiao, WH; Kalvakolanu, DV; Hassel, BA			RNase-L-dependent destabilization of interferon-induced mRNAs - A role for the 2-5A system in attenuation of the interferon response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; AU-RICH ELEMENT; MESSENGER-RNA; ENCEPHALOMYOCARDITIS VIRUS; 2-5A-DEPENDENT RNASE; 2'-5'-OLIGOADENYLATE SYNTHETASE; POSTTRANSCRIPTIONAL REGULATION; DIFFERENTIAL DISPLAY; MOLECULAR-CLONING; BINDING PROTEIN	The 2-5A system is an interferon-regulated RNA degradation pathway with antiviral, growth-inhibitory, and pro-apoptotic activities. RNase-L mediates the antiviral activity through the degradation of viral RNAs, and the anticellular effects of the 2-5A system are thought to be similarly mediated through the degradation of cellular transcripts. However, specific RNase-L-regulated cellular RNAs have not been identified. To isolate candidate RNase-L substrates, differential display was used to identify mRNAs that exhibited increased expression in RNase-L-deficient N1E-115 cells as compared with RNase-L-transfected cells. A novel interferon-stimulated gene encoding a 43-kDa ubiquitin-specific protease, designated ISG43, was identified in this screen. ISG43 expression is induced by interferon and negatively regulated by RNase-L. ISG43 induction is a primary response to interferon treatment and requires a functional JAK/STAT signaling pathway. The kinetics of ISG43 induction were identical in wild type and RNase-L knock-out fibroblasts; however, the decline in ISG43 mRNA following interferon treatment was markedly attenuated in RNase-L knock-out fibroblasts. The delayed shut-off kinetics of ISG43 mRNA corresponded to an increase in its half-life in RNase-L-deficient cells. ISG15 mRNA also displayed RNase-L-dependent regulation. These findings identify a novel role for the 2-5A system in the attenuation of the interferon response.	Univ Maryland, Greenbaum Canc Ctr, Program Oncol, Baltimore, MD 21201 USA; Univ Maryland, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; Univ Maryland, Cell & Mol Biol Program, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Hassel, BA (corresponding author), Univ Maryland, Greenbaum Canc Ctr, Program Oncol, 9th Floor BRB,655 W Baltimore St, Baltimore, MD 21201 USA.		Xiao, Weihua/N-2775-2013	Xiao, Weihua/0000-0001-9102-6326	NCI NIH HHS [CA71401, CA78282] Funding Source: Medline; NIAID NIH HHS [AI39608] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071401, R01CA078282] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI039608] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abe R, 1996, NUCLEIC ACIDS RES, V24, P4895, DOI 10.1093/nar/24.24.4895; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAGLIONI C, 1984, J VIROL, V52, P865, DOI 10.1128/JVI.52.3.865-871.1984; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; BLOMSTROM DC, 1986, J BIOL CHEM, V261, P8811; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Castelli JC, 1997, J EXP MED, V186, P967, DOI 10.1084/jem.186.6.967; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chernokalskaya E, 1997, NUCLEIC ACIDS RES, V25, P735, DOI 10.1093/nar/25.4.735; Chwetzoff S, 1997, FEBS LETT, V405, P148, DOI 10.1016/S0014-5793(97)00177-4; DALY C, 1995, J BIOL CHEM, V270, P23739, DOI 10.1074/jbc.270.40.23739; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DiazGuerra M, 1997, VIROLOGY, V236, P354, DOI 10.1006/viro.1997.8719; DiazGuerra M, 1997, VIROLOGY, V227, P220, DOI 10.1006/viro.1996.8294; DONG BH, 1995, J BIOL CHEM, V270, P4133, DOI 10.1074/jbc.270.8.4133; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; GRIBAUDO G, 1991, J VIROL, V65, P1748, DOI 10.1128/JVI.65.4.1748-1757.1991; Hartmann R, 1998, J BIOL CHEM, V273, P3236, DOI 10.1074/jbc.273.6.3236; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; Hoey T, 1998, CURR OPIN GENET DEV, V8, P582, DOI 10.1016/S0959-437X(98)80015-4; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; KHABAR K, 1999, J INTERFERON CYTOKIN, V19, P68; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Kren BT, 1996, CELL GROWTH DIFFER, V7, P1633; Lee CH, 1998, J BIOL CHEM, V273, P25261, DOI 10.1074/jbc.273.39.25261; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Li XL, 1998, J VIROL, V72, P2752, DOI 10.1128/JVI.72.4.2752-2759.1998; Li XS, 1996, CANCER RES, V56, P5055; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Liu LQ, 1999, MOL CELL BIOL, V19, P3029; LOEB KR, 1992, J BIOL CHEM, V267, P7806; MAITRA RK, 1994, VIROLOGY, V204, P823, DOI 10.1006/viro.1994.1601; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; Martinand C, 1998, J INTERF CYTOK RES, V18, P1031, DOI 10.1089/jir.1998.18.1031; Masumi A, 1999, MOL CELL BIOL, V19, P1810; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; NILSEN TW, 1979, P NATL ACAD SCI USA, V76, P2600, DOI 10.1073/pnas.76.6.2600; NOLANSORDEN NL, 1990, ANAL BIOCHEM, V184, P298, DOI 10.1016/0003-2697(90)90684-2; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Rani MRS, 1996, J BIOL CHEM, V271, P22878, DOI 10.1074/jbc.271.37.22878; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Schwartz AL, 1999, ANNU REV MED, V50, P57; SILVERMAN RH, 1983, J VIROL, V46, P1051, DOI 10.1128/JVI.46.3.1051-1055.1983; SILVERMAN RH, 1986, INTERFERONS CELL GRO, P143; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; SUN Y, 1994, CANCER RES, V54, P1139; Tnani M, 1998, J INTERF CYTOK RES, V18, P361, DOI 10.1089/jir.1998.18.361; TRAPANI JA, 1994, IMMUNOGENETICS, V40, P415; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; Zhang XX, 1999, VIROLOGY, V262, P152, DOI 10.1006/viro.1999.9914; Zhou AM, 1998, J INTERF CYTOK RES, V18, P953, DOI 10.1089/jir.1998.18.953; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355; Zuker M, 1994, Methods Mol Biol, V25, P267	61	96	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8880	8888		10.1074/jbc.275.12.8880	http://dx.doi.org/10.1074/jbc.275.12.8880			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722734	hybrid			2022-12-27	WOS:000086507700084
J	McLean, PJ; Kawamata, H; Ribich, S; Hyman, BT				McLean, PJ; Kawamata, H; Ribich, S; Hyman, BT			Membrane association and protein conformation of alpha-synuclein in intact neurons - Effect of Parkinson's disease-linked mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; LEWY BODIES; BINDING	Two missense mutations (Ala-30 --> Pro and Ala-53 --> Thr) in the gene encoding alpha-synuclein are associated with rare autosomal dominant forms of familial Parkinson's disease. In addition, alpha-synuclein is an abundant component of Lewy bodies in sporadic Parkinson's disease and diffuse Lewy body disease. However, the normal conformation of alpha-synuclein, its cellular localization in neurons, and the effects of the mutations remain to be determined. In the present study, we examine these questions using sensitive fluorescence resonance energy transfer techniques. Transient transfection of alpha-synuclein expression constructs into primary cortical neurons and counterstaining with the lipophilic fluorescent marker, DiI, demonstrates a close association between alpha-synuclein and cellular membranes. Both the Nand C-terminal regions of alpha-synuclein are tightly associated with membranes. A weak interaction also occurs between the N- and C termini themselves. The Parkinson's disease-associated mutations have no effect on membrane interaction however, the Ala-30 --> Pro mutation alters the three-dimensional conformation of alpha-synuclein, as measured by significantly increased fluorescence resonance energy transfer between the N- and C termini.	Massachusetts Gen Hosp E, Dept Neurol, Alzheimers Dis Res Unit, Charlestown, MA 02129 USA		Hyman, BT (corresponding author), Massachusetts Gen Hosp E, Dept Neurol, Alzheimers Dis Res Unit, 149 13th St, Charlestown, MA 02129 USA.			McLean, Pamela/0000-0003-4870-5715				Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Knowles RB, 1999, J NEUROPATH EXP NEUR, V58, P1090, DOI 10.1097/00005072-199910000-00007; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; SHAHROKH Z, 1991, J BIOL CHEM, V266, P12082; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; ULLMAN EF, 1976, J BIOL CHEM, V251, P4172; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Xia ZG, 1996, J NEUROSCI, V16, P5425	15	213	226	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8812	8816		10.1074/jbc.275.12.8812	http://dx.doi.org/10.1074/jbc.275.12.8812			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722726	hybrid			2022-12-27	WOS:000086507700076
J	Rep, M; Krantz, M; Thevelein, JM; Hohmann, S				Rep, M; Krantz, M; Thevelein, JM; Hohmann, S			The transcriptional response of Saccharomyces cerevisiae to osmotic shock - Hot1p and Msn2p/Msn4p are required for the induction of subsets of high osmolarity glycerol pathway-dependent genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; PROTEIN-KINASE-A; 0.7 M NACL; STRESS-RESPONSE; SALT TOLERANCE; GLYCEROL-3-PHOSPHATE DEHYDROGENASE; ZYGOSACCHAROMYCES-ROUXII; MULTISTRESS RESPONSE; 2 ISOENZYMES; ELEMENT STRE	We have analyzed the transcriptional response to osmotic shock in the yeast Saccharomyces cerevisiae. The mRNA level of 186 genes increased at least 3-fold after a shift to NaCl or sorbitol, whereas that of more than 100 genes was at least 1.5-fold diminished. Many induced genes encode proteins that presumably contribute to protection against different types of damage or encode enzymes in glycerol, trehalose, and glycogen metabolism. Several genes, which encode poorly expressed isoforms of enzymes in carbohydrate metabolism, were induced. The high osmolarity glycerol (HOG) pathway is required for full induction of many but not all genes, The recently characterized Hot1p transcription factor is required for normal expression of a subset of the HOG pathway-dependent responses. Stimulated expression of the genes that required the general stress-response transcription factors Msn2p and Msn4p was also reduced in a hog1 mutant, suggesting that Msn2p/Msn4p might be regulated by the HOG pathway. The expression of genes that are known to be controlled by the mating pheromone response pathway was stimulated by osmotic shock specifically in a hog1 mutant. Inappropriate activation of the mating response may contribute to the growth defect of a hog1 mutant in high osmolarity medium.	Univ Gothenburg, Dept Cell & Mol Biol Microbiol, S-40530 Gothenburg, Sweden; Katholieke Univ Leuven, Lab Mol Celbiol, B-3001 Louvain, Belgium	University of Gothenburg; KU Leuven	Hohmann, S (corresponding author), Univ Gothenburg, Dept Cell & Mol Biol Microbiol, Box 462, S-40530 Gothenburg, Sweden.		Thevelein, Johan M./AAK-4203-2021; Hohmann, Stefan/K-9895-2013; Thevelein, Johan M./A-7897-2013	Hohmann, Stefan/0000-0002-0809-1985; Thevelein, Johan M./0000-0002-2626-0180; Rep, Martijn/0000-0003-3608-6283				Akhtar N, 1997, FEBS LETT, V403, P173, DOI 10.1016/S0014-5793(97)00048-3; ALBERTYN J, 1994, CURR GENET, V25, P12, DOI 10.1007/BF00712960; ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; [Anonymous], [No title captured]; Ansell R, 1997, EMBO J, V16, P2179, DOI 10.1093/emboj/16.9.2179; BLOMBERG A, 1995, J BACTERIOL, V177, P3563, DOI 10.1128/jb.177.12.3563-3572.1995; Blomberg A, 1997, ELECTROPHORESIS, V18, P1429, DOI 10.1002/elps.1150180818; Boy-Marcotte E, 1998, J BACTERIOL, V180, P1044, DOI 10.1128/JB.180.5.1044-1052.1998; BREWSTER JL, 1994, YEAST, V10, P425, DOI 10.1002/yea.320100402; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; Cox KH, 1999, YEAST, V15, P703, DOI 10.1002/(SICI)1097-0061(19990615)15:8<703::AID-YEA413>3.0.CO;2-Z; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; DeWinde JH, 1996, EUR J BIOCHEM, V241, P633; ESTRUCH F, 1993, MOL CELL BIOL, V13, P3872, DOI 10.1128/MCB.13.7.3872; Fernandes L, 1997, MOL CELL BIOL, V17, P6982, DOI 10.1128/MCB.17.12.6982; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Fristedt U, 1996, ARCH BIOCHEM BIOPHYS, V330, P133, DOI 10.1006/abbi.1996.0235; Garay-Arroyo A, 1999, YEAST, V15, P879, DOI 10.1002/(SICI)1097-0061(199907)15:10A<879::AID-YEA428>3.3.CO;2-H; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Hall JP, 1996, MOL CELL BIOL, V16, P6715; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; HIRAYAMA T, 1995, MOL GEN GENET, V249, P127, DOI 10.1007/BF00290358; Hohmann S, 2000, TRENDS MICROBIOL, V8, P33, DOI 10.1016/S0966-842X(99)01645-5; Hohmann S., 1997, YEAST STRESS RESPONS, P101; HOSONO K, 1992, J GEN MICROBIOL, V138, P91, DOI 10.1099/00221287-138-1-91; Hounsa CG, 1998, MICROBIOL-UK, V144, P671, DOI 10.1099/00221287-144-3-671; Inoue Y, 1998, J BIOL CHEM, V273, P2977, DOI 10.1074/jbc.273.5.2977; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KRAAKMAN LS, 1993, MOL GEN GENET, V239, P196, DOI 10.1007/BF00281618; LARSSON K, 1993, MOL MICROBIOL, V10, P1101, DOI 10.1111/j.1365-2958.1993.tb00980.x; LASKO PF, 1981, J BACTERIOL, V148, P241, DOI 10.1128/JB.148.1.241-247.1981; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; Li BJ, 1999, MOL CELL BIOL, V19, P5393; LUYTEN K, 1995, EMBO J, V14, P1360, DOI 10.1002/j.1460-2075.1995.tb07122.x; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MAGER WH, 1995, MICROBIOL REV, V59, P506, DOI 10.1128/MMBR.59.3.506-531.1995; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; Marquez JA, 1996, FEBS LETT, V382, P89, DOI 10.1016/0014-5793(96)00157-3; Marquez JA, 1998, EMBO J, V17, P2543, DOI 10.1093/emboj/17.9.2543; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; MIRALLES VJ, 1995, MOL MICROBIOL, V17, P653, DOI 10.1111/j.1365-2958.1995.mmi_17040653.x; Moskvina E, 1998, YEAST, V14, P1041, DOI 10.1002/(SICI)1097-0061(199808)14:11<1041::AID-YEA296>3.0.CO;2-4; Moskvina E, 1999, MOL MICROBIOL, V32, P1263, DOI 10.1046/j.1365-2958.1999.01438.x; Nadkarni V, 1999, J BIOL CHEM, V274, P20185, DOI 10.1074/jbc.274.29.20185; Navarro-Avino JP, 1999, YEAST, V15, P829, DOI 10.1002/(SICI)1097-0061(199907)15:10A<829::AID-YEA423>3.0.CO;2-9; Norbeck J, 1996, FEMS MICROBIOL LETT, V137, P1; Norbeck J, 1996, J BIOL CHEM, V271, P13875, DOI 10.1074/jbc.271.23.13875; Norbeck J, 1997, J BIOL CHEM, V272, P5544, DOI 10.1074/jbc.272.9.5544; NORBECK J, 1995, ELECTROPHORESIS, V16, P149, DOI 10.1002/elps.1150160124; NWAKA S, 1995, J BIOL CHEM, V270, P10193, DOI 10.1074/jbc.270.17.10193; O'Rourke SM, 1998, GENE DEV, V12, P2874, DOI 10.1101/gad.12.18.2874; Parrou JL, 1999, YEAST, V15, P191, DOI 10.1002/(SICI)1097-0061(199902)15:3<191::AID-YEA358>3.0.CO;2-O; Parrou JL, 1997, MICROBIOL-UK, V143, P1891, DOI 10.1099/00221287-143-6-1891; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; POSAS F, 1995, J BIOL CHEM, V270, P13036, DOI 10.1074/jbc.270.22.13036; Posas F, 1998, MOL CELL BIOL, V18, P5788, DOI 10.1128/MCB.18.10.5788; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Posas F, 1998, CURR OPIN MICROBIOL, V1, P175, DOI 10.1016/S1369-5274(98)80008-8; Posas F, 1998, EMBO J, V17, P1385, DOI 10.1093/emboj/17.5.1385; Proft M, 1999, MOL CELL BIOL, V19, P537; Reiser V, 1999, GENE EXPRESSION, V7, P247; Reiser V, 1999, MOL BIOL CELL, V10, P1147, DOI 10.1091/mbc.10.4.1147; Rep M, 1999, MICROBIOL-UK, V145, P715, DOI 10.1099/13500872-145-3-715; Rep M, 1999, MOL CELL BIOL, V19, P5474; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; Serrano R, 1996, INT REV CYTOL, V165, P1, DOI 10.1016/S0074-7696(08)62219-6; Shinozaki K, 1996, CURR OPIN BIOTECH, V7, P161, DOI 10.1016/S0958-1669(96)80007-3; Siderius M, 1997, MICROBIOL-SGM, V143, P3241, DOI 10.1099/00221287-143-10-3241; Siderius M. H., 1997, YEAST STRESS RESPONS, P213; Simon JR, 1999, MOL MICROBIOL, V31, P823, DOI 10.1046/j.1365-2958.1999.01220.x; SPRAGUE GF, 1992, MOL CELLULAR BIOL YE, V2, P657; Tamas MJ, 1999, MOL MICROBIOL, V31, P1087, DOI 10.1046/j.1365-2958.1999.01248.x; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Treger JM, 1998, BIOCHEM BIOPH RES CO, V243, P13, DOI 10.1006/bbrc.1997.8061; USHIO K, 1991, J FERMENT BIOENG, V71, P390, DOI 10.1016/0922-338X(91)90249-G; VARELA JCS, 1995, MOL CELL BIOL, V15, P6232; WIELAND J, 1995, EMBO J, V14, P3870, DOI 10.1002/j.1460-2075.1995.tb00059.x; Winderickx J, 1996, MOL GEN GENET, V252, P470, DOI 10.1007/s004380050252; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; Yoshiba Y, 1997, PLANT CELL PHYSIOL, V38, P1095, DOI 10.1093/oxfordjournals.pcp.a029093; YUAN YLO, 1993, GENE DEV, V7, P1584, DOI 10.1101/gad.7.8.1584; Zahringer H, 1997, FEBS LETT, V412, P615, DOI 10.1016/S0014-5793(97)00868-5; ZHAO S, 1994, GENE, V146, P215, DOI 10.1016/0378-1119(94)90295-X	90	433	445	1	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8290	8300		10.1074/jbc.275.12.8290	http://dx.doi.org/10.1074/jbc.275.12.8290			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722658	hybrid			2022-12-27	WOS:000086507700008
J	Ridinger, K; Schafer, BW; Durussel, I; Cox, JA; Heizmann, CW				Ridinger, K; Schafer, BW; Durussel, I; Cox, JA; Heizmann, CW			S100A13 - Biochemical characterization and subcellular localization in different cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; FIBROBLAST-GROWTH-FACTOR; FACTOR-I; SMOOTH-MUSCLE; FAMILY; EXPRESSION; PURIFICATION; RELEASE; MEMBER; MACROPHAGES	S100 proteins became of major interest because of their divergent cell- and tissue-specific expression, their close association with a number of human diseases, and their importance for clinical diagnostics. Here, we report for the first time the purification and characterization of human recombinant S100A13. Flow dialysis revealed that the homodimeric S100A13 binds four Ca2+ in two sets of binding sites, both displaying positive cooperativity but of very different affinity. Fluorescence and difference spectrophotometry indicate that the Trp/Tyr signal changes are almost complete upon binding of Ca2+ to the two high affinity sites, which probably correspond to the C-terminal EF-hands in each subunit. The far-UV circular dichroic signal also changes upon binding of the first two Ca2+. So far, the tissue distribution of S100A13 has not been well characterized. Here, we show that S100A13 is widely expressed in various types of tissues with a high expression level in thyroid gland. Using specific antisera against S100A13, high protein expression was detected in follicle cells of thyroid, Leydig cells of testis, and specific cells of brain. In human smooth muscle cells, which co-express S100A2 in the nucleus and S100A1 in stress fibers, S100A13 shows a unique subcellular localization in the perinuclear area. These data suggest diverse functions for this protein in signal transduction.	Univ Geneva, Dept Biochem, CH-1211 Geneva 12, Switzerland; Univ Zurich, Dept Pediat, Div Clin Chem & Biochem, CH-8032 Zurich, Switzerland	University of Geneva; University of Zurich	Cox, JA (corresponding author), Univ Geneva, Dept Biochem, 30 Quai Ernest Ansermet, CH-1211 Geneva 12, Switzerland.	Jos.Cox@biochem.unige.ch		Schafer, Beat/0000-0001-5988-2915				Andersen K, 1998, ANTICANCER RES, V18, P3299; Barber KR, 1999, J BIOL CHEM, V274, P1502, DOI 10.1074/jbc.274.3.1502; BAUDIER J, 1986, J BIOL CHEM, V261, P8192; Boni R, 1997, BRIT J DERMATOL, V137, P39, DOI 10.1046/j.1365-2133.1997.17651853.x; Camby I, 1999, BRAIN PATHOL, V9, P1; Carreira CM, 1998, J BIOL CHEM, V273, P22224, DOI 10.1074/jbc.273.35.22224; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; Cox J.A., 1996, GUIDEBOOK CALCIUM BI, P1; DELLANGELICA EC, 1994, J BIOL CHEM, V269, P28929; FOHR UG, 1995, J BIOL CHEM, V270, P21056, DOI 10.1074/jbc.270.36.21056; FOHR UG, 1993, EUR J BIOCHEM, V215, P719, DOI 10.1111/j.1432-1033.1993.tb18084.x; Franz C, 1998, J BIOL CHEM, V273, P18826, DOI 10.1074/jbc.273.30.18826; GLENNEY JR, 1989, J CELL BIOL, V108, P569, DOI 10.1083/jcb.108.2.569; Gribenko A, 1998, PROTEIN SCI, V7, P211, DOI 10.1002/pro.5560070123; Heizmann CW, 1998, BIOMETALS, V11, P383, DOI 10.1023/A:1009212521172; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Ilg EC, 1996, INT J CANCER, V68, P325, DOI 10.1002/(SICI)1097-0215(19961104)68:3<325::AID-IJC10>3.0.CO;2-7; JACKSON A, 1995, J BIOL CHEM, V270, P33, DOI 10.1074/jbc.270.1.33; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; KIZAWA K, 1996, BIOCHIM BIOPHYS ACTA, V1313, P94; LEE SW, 1992, P NATL ACAD SCI USA, V89, P2504, DOI 10.1073/pnas.89.6.2504; Mandinova A, 1998, J CELL SCI, V111, P2043; MANI RS, 1990, BIOCHEMISTRY-US, V29, P1398, DOI 10.1021/bi00458a009; Millward TA, 1998, EMBO J, V17, P5913, DOI 10.1093/emboj/17.20.5913; Mueller A, 1999, HISTOCHEM CELL BIOL, V111, P453, DOI 10.1007/s004180050381; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; Oyama Y, 1997, BIOCHEM BIOPH RES CO, V240, P341, DOI 10.1006/bbrc.1997.7476; PEDROCCHI M, 1994, BIOCHEMISTRY-US, V33, P6732, DOI 10.1021/bi00187a045; PEDROCCHI M, 1994, INT J CANCER, V57, P684, DOI 10.1002/ijc.2910570513; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; Ridinger K, 1998, BBA-MOL CELL RES, V1448, P254, DOI 10.1016/S0167-4889(98)00137-2; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; SCHAFER BW, 1995, GENOMICS, V25, P638, DOI 10.1016/0888-7543(95)80005-7; Schwaller B, 1997, J BIOL CHEM, V272, P29663, DOI 10.1074/jbc.272.47.29663; Shao XG, 1997, NEURON, V18, P133, DOI 10.1016/S0896-6273(01)80052-0; Shishibori T, 1999, BIOCHEM J, V338, P583, DOI 10.1042/0264-6021:3380583; Vanderheeren G, 1998, BIOPHYS J, V75, P2195, DOI 10.1016/S0006-3495(98)77663-5; Vogl T, 1999, J BIOL CHEM, V274, P25291, DOI 10.1074/jbc.274.36.25291; WETERMAN MAJ, 1992, CANCER RES, V52, P1291; WHITE FP, 1980, NEUROSCIENCE, V5, P173, DOI 10.1016/0306-4522(80)90084-6; WHITE FP, 1990, NEUROCHEMISTRY, V35, P88; Wicki R, 1996, BIOCHEM BIOPH RES CO, V227, P594, DOI 10.1006/bbrc.1996.1551; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZWADLO G, 1988, CLIN EXP IMMUNOL, V72, P510	46	44	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8686	8694		10.1074/jbc.275.12.8686	http://dx.doi.org/10.1074/jbc.275.12.8686			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722710	hybrid			2022-12-27	WOS:000086507700060
J	Jones, M; Tussey, L; Athanasou, N; Jackson, DG				Jones, M; Tussey, L; Athanasou, N; Jackson, DG			Heparan sulfate proteoglycan isoforms of the CD44 hyaluronan receptor induced in human inflammatory macrophages can function as paracrine regulators of fibroblast growth factor action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE HOMING RECEPTOR; CELL-SURFACE; SYNOVIAL FIBROBLASTS; RHEUMATOID-ARTHRITIS; ADHESION MOLECULE; EPITHELIAL-CELLS; VARIANT ISOFORMS; SPLICE VARIANT; FACTOR-II; EXPRESSION	The CD44 glycoprotein is expressed in multiple isoforms on a variety of cell types where it functions as a receptor for hyaluronan-mediated motility. Recently, interest has centered on CD44 heparan sulfate proteoglycan (HSPG) isoforms because of their potential to sequester heparin-binding growth factors and chemokines. Expression of these isoforms on ectodermal cells has recently been shown to regulate limb morphogenesis via presentation of fibroblast growth factor (FGF) 4/FGF 8 while expression on tumor cells was shown to sequester hepatocyte growth factor and promote tumor dissemination. To date, however, CD44 HSPG expression in tissue macrophages and lymphocytes has not been adequately investigated, despite the fact these cells actively synthesize growth factors and chemokines and indirect evidence that monocyte CD44 sequesters macrophage inflammatory-protein-Ip. Here we show primary human monocytes rather than lymphocytes express CD44 HSPGs, but only following in vitro differentiation to macrophages or activation with the proin-flammatory cytokine interleukin-1 alpha or bacterial lipopolysaccharide. Furthermore, we show these isoforms are preferentially modified with heparan rather than chondroitin sulfate, bind the macrophage-derived growth factors FGF-2, vascular endothelial growth factor, and heparin-binding epidermal growth factor with varying affinities (K-d 25-330 nM) and in the case of FGF-2, can stimulate productive binding to the high affinity tyrosine kinase FGF receptor 1 (FGFR1). In contrast, we find no evidence for significant binding to C-C chemokines. Last, we confirm by immunofluorescent antibody staining that inflamed synovial membrane macrophages express CD44 HSPGs and that expression is greatest in cells containing high FGF-2 levels. These results suggest a paracrine role for macrophage CD44 HSPG isoforms in the regulation of growth factor action during inflammation.	Univ Oxford, Nuffield Dept Med, MRC, Human Immunol Unit,Inst Mol Med, Oxford OX3 9DU, England; John Radcliffe Hosp, Dept Cellular Sci, Oxford OX3 9DU, England; Nuffield Orthopaed Ctr, Oxford OX3 7LD, England	University of Oxford; University of Oxford; Nuffield Orthopaedic Centre	Jackson, DG (corresponding author), John Radcliffe Hosp, Nuffield Dept Med, MRC, Human Immunol Unit,Inst Mol Med, Oxford OX3 9DU, England.	djackson@enterpriseworf.molbiol.ox.ac.uk	Jones, Margaret/B-4083-2009	, david/0000-0002-4133-9364				ALOUANI S, 1995, EUR J BIOCHEM, V227, P328, DOI 10.1111/j.1432-1033.1995.tb20393.x; ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; AUGER MJ, 1992, MACROPHAGE; BENNETT KL, 1995, J CELL BIOL, V131, P1623, DOI 10.1083/jcb.131.6.1623; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Carey DJ, 1997, BIOCHEM J, V327, P1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clasper S, 1999, J BIOL CHEM, V274, P24113, DOI 10.1074/jbc.274.34.24113; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Croft DR, 1997, EUR J IMMUNOL, V27, P1680, DOI 10.1002/eji.1830270713; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Filla MS, 1998, J CELL PHYSIOL, V174, P310, DOI 10.1002/(SICI)1097-4652(199803)174:3<310::AID-JCP5>3.0.CO;2-R; Firestein GS, 1999, J CLIN INVEST, V103, P3, DOI 10.1172/JCI5929; Fitzgerald KA, 1999, J IMMUNOL, V162, P4920; Foster LC, 1998, J BIOL CHEM, V273, P20341, DOI 10.1074/jbc.273.32.20341; FOX SB, 1994, CANCER RES, V54, P4539; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; HAYNES BF, 1991, ARTHRITIS RHEUM, V34, P1434; HENDERSON KJ, 1994, ANN RHEUM DIS, V53, P729, DOI 10.1136/ard.53.11.729; JACKSON DG, 1992, J BIOL CHEM, V267, P4732; JACKSON DG, 1995, J CELL BIOL, V128, P673, DOI 10.1083/jcb.128.4.673; JACKSON DG, 1994, INT J CANCER, P110; JOHNSON BA, 1993, ARTHRITIS RHEUM, V36, P137, DOI 10.1002/art.1780360203; KOOPMAN G, 1993, J EXP MED, V177, P897, DOI 10.1084/jem.177.4.897; Koopmann W, 1999, J IMMUNOL, V163, P2120; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levesque MC, 1996, J IMMUNOL, V156, P1557; Levesque MC, 1999, CELL IMMUNOL, V193, P209, DOI 10.1006/cimm.1999.1456; LORIES V, 1992, J BIOL CHEM, V267, P1116; MACKAY CR, 1994, J CELL BIOL, V124, P71, DOI 10.1083/jcb.124.1.71; MIKECZ K, 1995, NAT MED, V1, P558, DOI 10.1038/nm0695-558; Mikecz K, 1999, ARTHRITIS RHEUM, V42, P659, DOI 10.1002/1529-0131(199904)42:4<659::AID-ANR8>3.0.CO;2-Z; Mohamadzadeh M, 1998, J CLIN INVEST, V101, P97, DOI 10.1172/JCI1604; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PULFORD K, 1992, IMMUNOLOGY, V75, P588; RICHARD C, 1995, J BIOL CHEM, V270, P24188, DOI 10.1074/jbc.270.41.24188; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SCREATON GR, 1993, J BIOL CHEM, V268, P12235; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; Sherman L, 1998, GENE DEV, V12, P1058, DOI 10.1101/gad.12.7.1058; Sleeman J, 1996, J CELL BIOL, V135, P1139, DOI 10.1083/jcb.135.4.1139; Solari R, 1997, J BIOL CHEM, V272, P9617; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; TURLEY H, 1994, J CLIN PATHOL, V47, P418, DOI 10.1136/jcp.47.5.418; van der Voort R, 1999, J BIOL CHEM, V274, P6499, DOI 10.1074/jbc.274.10.6499; VANFURTH R, 1992, MONONUCLEAR PHAGOCYT; VERDRENGH M, 1995, SCAND J IMMUNOL, V42, P353, DOI 10.1111/j.1365-3083.1995.tb03667.x; Weiss JM, 1997, J CELL BIOL, V137, P1137, DOI 10.1083/jcb.137.5.1137; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yonemura S, 1999, J CELL BIOL, V145, P1497, DOI 10.1083/jcb.145.7.1497	57	96	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7964	7974		10.1074/jbc.275.11.7964	http://dx.doi.org/10.1074/jbc.275.11.7964			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713114	hybrid			2022-12-27	WOS:000085913300074
J	Volchenboum, SL; Vockley, J				Volchenboum, SL; Vockley, J			Mitochondrial import and processing of wild type and type III mutant isovaleryl-CoA dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A DEHYDROGENASE; NUCLEOTIDE-SEQUENCE; LIVER MITOCHONDRIA; MOLECULAR-CLONING; PRECURSORS; SUBSTRATE; ACIDEMIA; TETRAMER; GENE	Isovaleric acidemia is a rare inborn error of metabolism caused by a deficiency of isovaleryl-CoA dehydrogenase (IVD), a nucleus-encoded, homotetrameric, mitochondrial flavoenzyme that catalyzes the conversion of isovaleryl-CoA to 3-methylcrotonyl-CoA We have previously identified a nucleotide deletion in the gene for IVD in fibroblasts from a patient with isovaleric acidemia leading to a shift in reading frame and premature termination of translation. The mutant IVD precursor is imported and processed to mature size, but no active enzyme is detected in mutant fibroblasts or expressed in Escherichia coli, Examination of the crystal structure of human IVD reveals that the C terminus is involved in tetramer stability. In vitro mitochondrial import experiment ts show that wild type IVD protein rapidly and stably forms mature homotetramer following import, whereas Type III mutant protein never forms stable oligomers. An additional series of mutant proteins with truncations and/or alterations in the C-terminal sequence implicates the C terminus of IVD in both enzyme activity and tetramer stability, Importantly, a dimeric intermediate in the folding pathway for wild type IVD has been identified in the in vitro mitochondrial import experiments, the first report of such an intermediate in the biogenesis of an acyl-CoA dehydrogenase.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med Genet, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Vockley, J (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.	vockley@mayo.edu	Vockley, Jerry/AAF-8523-2020; Vockley, Jerry/B-5210-2016	Vockley, Jerry/0000-0002-8180-6457; Vockley, Jerry/0000-0002-8180-6457	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045482] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK45482] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Battaile KP, 1996, BIOCHEMISTRY-US, V35, P15356, DOI 10.1021/bi961113r; BECKMANN JD, 1981, BIOCHEM BIOPH RES CO, V102, P1290, DOI 10.1016/S0006-291X(81)80151-9; DJORDJEVIC S, 1995, BIOCHEMISTRY-US, V34, P2163, DOI 10.1021/bi00007a009; IKEDA Y, 1985, P NATL ACAD SCI USA, V82, P7081, DOI 10.1073/pnas.82.20.7081; IKEDA Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P662, DOI 10.1016/0003-9861(87)90072-5; IKEDA Y, 1983, J BIOL CHEM, V258, P1077; INDO Y, 1991, GENOMICS, V11, P609, DOI 10.1016/0888-7543(91)90068-P; Kim JJP, 1994, FLAVINS AND FLAVOPROTEINS 1993, P273; KIM JJP, 1993, P NATL ACAD SCI USA, V90, P7523, DOI 10.1073/pnas.90.16.7523; KRAUS J P, 1987, Genomics, V1, P264, DOI 10.1016/0888-7543(87)90053-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUBARA Y, 1989, J BIOL CHEM, V264, P16321; Mohsen AA, 1998, BIOCHEMISTRY-US, V37, P10325, DOI 10.1021/bi973096r; MOHSEN AWA, 1995, BIOCHEMISTRY-US, V34, P10146, DOI 10.1021/bi00032a007; MOHSEN AWA, 1995, GENE, V160, P263, DOI 10.1016/0378-1119(95)00256-6; PARIMOO B, 1993, GENOMICS, V15, P582, DOI 10.1006/geno.1993.1111; SAIJO T, 1995, J BIOL CHEM, V270, P1899, DOI 10.1074/jbc.270.4.1899; SAIJO T, 1994, J BIOL CHEM, V269, P4401; TANAKA K, 1966, P NATL ACAD SCI USA, V56, P236, DOI 10.1073/pnas.56.1.236; Tiffany KA, 1997, BIOCHEMISTRY-US, V36, P8455, DOI 10.1021/bi970422u; VOCKLEY J, 1991, AM J HUM GENET, V40, P147; YOKOTA I, 1992, J BIOL CHEM, V267, P26004	22	11	11	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7958	7963		10.1074/jbc.275.11.7958	http://dx.doi.org/10.1074/jbc.275.11.7958			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713113	hybrid			2022-12-27	WOS:000085913300073
J	Widlak, P; Li, P; Wang, XD; Garrard, WT				Widlak, P; Li, P; Wang, XD; Garrard, WT			Cleavage preferences of the apoptotic endonuclease DFF40 (caspase-activated DNase or nuclease) on naked DNA and chromatin substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; RAT THYMOCYTES; MICROCOCCAL NUCLEASE; FRAGMENTATION FACTOR; IDENTIFICATION; DEGRADATION; INHIBITOR; DEOXYRIBONUCLEASE; CONDENSATION; PURIFICATION	Here we report the co-factor requirements for DNA fragmentation factor (DFF) endonuclease and characterize its cleavage sites on naked DNA and chromatin substrates. The endonuclease exhibits a pH optimum of 7.5, requires Mg2+, not Ca2+, and is inhibited by Zn2+. The enzyme generates blunt ends or ends with 1-base 5'-overhangs possessing 5'-phosphate and 3'-hydroxyl groups and is specific for double- and not single-stranded DNA or RNA. DFF endonuclease has a moderately greater sequence preference than micrococcal nuclease or DNase I, and the Bites attacked possess a dyed axis of symmetry with respect to purine and pyrimidine content. Using HeLa cell nuclei or chromatin reconstituted on a 5 S rRNA gene tandem array, we prove that the enzyme attacks chromatin in the internucleosomal linker, generating oligonucleosomal DNA ladders sharper than those created by micrococcal nuclease. Histone H1, high mobility group-1, and topoisomerase II activate DFF endonuclease activity on naked DNA substrates but much less so on chromatin substrates. We conclude that DFF is a useful reagent for chromatin research.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Garrard, WT (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	garrard@utsw.swmed.edu	Widlak, Piotr/AAL-8075-2021	Widlak, Piotr/0000-0001-5099-4726	NIGMS NIH HHS [GMRO1-55942] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; COMPTON MM, 1992, CANCER METAST REV, V11, P105, DOI 10.1007/BF00048058; DINGWALL C, 1981, NUCLEIC ACIDS RES, V9, P2659, DOI 10.1093/nar/9.12.2659; DREW HR, 1984, J MOL BIOL, V176, P535, DOI 10.1016/0022-2836(84)90176-1; DREW HR, 1984, CELL, V37, P491, DOI 10.1016/0092-8674(84)90379-9; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FERNANDES RS, 1993, ANTICANCER RES, V13, P1253; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; Gu JJ, 1999, J BIOL CHEM, V274, P20759, DOI 10.1074/jbc.274.30.20759; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; HORZ W, 1981, NUCLEIC ACIDS RES, V9, P2643, DOI 10.1093/nar/9.12.2643; Hughes FM, 1998, CELL DEATH DIFFER, V5, P1017; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Ivanchenko M, 1997, BIOPHYS J, V72, P1388, DOI 10.1016/S0006-3495(97)78785-X; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KAWABATA H, 1993, BIOCHEM BIOPH RES CO, V191, P247, DOI 10.1006/bbrc.1993.1209; Krieser RJ, 1998, J BIOL CHEM, V273, P30909, DOI 10.1074/jbc.273.47.30909; KRYLOV D, 1993, P NATL ACAD SCI USA, V90, P5052, DOI 10.1073/pnas.90.11.5052; Li TK, 1999, GENE DEV, V13, P1553, DOI 10.1101/gad.13.12.1553; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Montague JW, 1997, J BIOL CHEM, V272, P6677, DOI 10.1074/jbc.272.10.6677; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OJCIUS DM, 1991, EXP CELL RES, V197, P43, DOI 10.1016/0014-4827(91)90477-C; Pandey S, 1997, BIOCHEMISTRY-US, V36, P711, DOI 10.1021/bi962387h; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; PRICE PA, 1975, J BIOL CHEM, V250, P1981; RHODES D, 1989, METHOD ENZYMOL, V170, P575; Sakahira H, 1999, J BIOL CHEM, V274, P15740, DOI 10.1074/jbc.274.22.15740; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sakahira H, 1999, CURR BIOL, V9, P543, DOI 10.1016/S0960-9822(99)80240-1; Samejima K, 1998, EXP CELL RES, V243, P453, DOI 10.1006/excr.1998.4212; SEILIEV AA, 1992, RADIAT ENVIRON BIOPH, V31, P123, DOI 10.1007/BF01211210; SHIOKAWA D, 1994, EUR J BIOCHEM, V226, P23, DOI 10.1111/j.1432-1033.1994.tb20022.x; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; STEIN A, 1989, METHOD ENZYMOL, V170, P585; SUN DY, 1994, J EXP MED, V179, P559, DOI 10.1084/jem.179.2.559; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Toh SY, 1998, BIOCHEM BIOPH RES CO, V250, P598, DOI 10.1006/bbrc.1998.9369; Torriglia A, 1998, MOL CELL BIOL, V18, P3612, DOI 10.1128/MCB.18.6.3612; Urbano A, 1998, J BIOL CHEM, V273, P34820, DOI 10.1074/jbc.273.52.34820; van Holde K.E., 1988, CHROMATIN; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Widlak P, 1997, J BIOL CHEM, V272, P17654, DOI 10.1074/jbc.272.28.17654; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yakovlev AG, 1999, NUCLEIC ACIDS RES, V27, P1999, DOI 10.1093/nar/27.9.1999; Yoshida A, 1998, CANCER RES, V58, P2576; ZHANG CH, 1995, CELL IMMUNOL, V165, P161, DOI 10.1006/cimm.1995.1201; ZHANG J, 1999, IN PRESS J BIOL CHEM; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480	53	133	139	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8226	8232		10.1074/jbc.275.11.8226	http://dx.doi.org/10.1074/jbc.275.11.8226			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713148	hybrid			2022-12-27	WOS:000085913300108
J	Vazquez, G; de Boland, AR; Boland, RL				Vazquez, G; de Boland, AR; Boland, RL			Involvement of calmodulin in 1 alpha,25-dihydroxyvitamin D-3 stimulation of store-operated Ca2+ influx in skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CULTURED MYOBLASTS; VITAMIN-D; SIGNAL-TRANSDUCTION; CALCIUM-UPTAKE; ENTRY; RECEPTORS; CHANNELS; PATHWAY; BINDING	The steroid hormone 1 alpha,25-dihydroxyvitamin D-3 (1,25-(OH)(2)D-3) rapidly modulates Ca2+ homeostasis in avian skeletal muscle cells by driving a complex signal transduction mechanism, which promotes Ca2+ release from inner stores and cation influx from the outside through both L-type and store-operated Ca2+ (SOC) channels. In the present work, we evaluated the involvement of calmodulin (CAM) in 1,25-(OH)(2)D-3 regulation of SOC influx in chick skeletal muscle cells. Treatment with 10(-9) M 1,25-(OH)(2)D-3 in Ca2+-free medium resulted in a rapid but transient Ca2+ rise correlated with the sterol-induced inositol 1,4,5-trisphosphate (IP3) production. The SOC influx stimulated by the hormone was insensitive to both CAM antagonists (fluphenazine, trifluoperazine, chlorpromazine, compound 48/80) and the CAM-dependent protein kinase II (CAMKII) inhibitor KN-62 when added after the sterol-dependent Ca2+ transient, but it was completely abolished when added prior to the IP3-induced mobilization of Ca2+ from endogenous stores. Moreover, in cells microinjected with antisense oligonucleotides directed against the CAM mRNA the sterol-stimulated SOC influx was reduced up to 60% respect to uninjected cells. The present results suggest that the 1,25-(OH)(2)D-3-induced (IP3-mediated) cytosolic Ca2+ transient is required for CAM, activation which in turn activates SOC influx in a mechanism that seems to include CAMKII.	Univ Nacl Sur, Dept Biol Bioquim & Farmacia, RA-8000 Bahia Blanca, Argentina	National University of the South	Boland, RL (corresponding author), Univ Nacl Sur, Dept Biol Bioquim & Farmacia, San Juan 670, RA-8000 Bahia Blanca, Argentina.							ALBERT PR, 1994, TRENDS PHARMACOL SCI, V15, P250, DOI 10.1016/0165-6147(94)90320-4; BARSONY J, 1994, VITAMIN D, P345; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BOLAND R, 1995, MOL CELL ENDOCRINOL, V114, P1, DOI 10.1016/0303-7207(95)03650-V; BOLAND R, 1986, ENDOCR REV, V7, P434, DOI 10.1210/edrv-7-4-434; Cao YM, 1998, FEBS LETT, V424, P33, DOI 10.1016/S0014-5793(98)00133-1; Capiati DA, 1999, MOL CELL ENDOCRINOL, V153, P39, DOI 10.1016/S0303-7207(99)00093-3; Capiati DA, 1999, J CELL BIOCHEM, V74, P292, DOI 10.1002/(SICI)1097-4644(19990801)74:2<292::AID-JCB13>3.0.CO;2-M; CAPIATI DA, 1999, J CELL BIOCHEM, V74, P3000; Cochran W.G., 1967, STAT METHODS; DEBOLAND AR, 1994, CELL SIGNAL, V6, P717, DOI 10.1016/0898-6568(94)00042-5; DEBOLAND AR, 1988, CALCIFIED TISSUE INT, V43, P370, DOI 10.1007/BF02553281; DEBOLAND AR, 1987, ENDOCRINOLOGY, V120, P1858, DOI 10.1210/endo-120-5-1858; FERNANDEZ LM, 1990, CALCIFIED TISSUE INT, V47, P314, DOI 10.1007/BF02555915; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KALKBRENNER F, 1995, EMBO J, V14, P4728, DOI 10.1002/j.1460-2075.1995.tb00154.x; Kim YS, 1996, ENDOCRINOLOGY, V137, P3649, DOI 10.1210/en.137.9.3649; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI GD, 1992, MOL PHARMACOL, V42, P489; MORELLI S, 1993, BIOCHEM J, V289, P675, DOI 10.1042/bj2890675; Morelli S, 1996, MOL CELL ENDOCRINOL, V122, P207, DOI 10.1016/0303-7207(96)03886-5; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Vazquez G, 1999, BRIT J PHARMACOL, V126, P1815, DOI 10.1038/sj.bjp.0702451; VAZQUEZ G, 1993, BIOCHEM MOL BIOL INT, V31, P677; VAZQUEZ G, 1995, BBA-MOL CELL RES, V1269, P91, DOI 10.1016/0167-4889(95)00097-C; Vazquez G, 1997, BIOCHEM BIOPH RES CO, V234, P125, DOI 10.1006/bbrc.1997.6590; Vazquez G, 1996, BBA-MOL CELL RES, V1310, P157, DOI 10.1016/0167-4889(95)00158-1; Vazquez G, 1997, BIOCHEM BIOPH RES CO, V239, P562, DOI 10.1006/bbrc.1997.7501; XU X, 1995, J BIOL CHEM, V270, P29169, DOI 10.1074/jbc.270.49.29169; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	34	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					16134	16138		10.1074/jbc.C901008199	http://dx.doi.org/10.1074/jbc.C901008199			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10747862	hybrid			2022-12-27	WOS:000087291400072
J	Tu, CJ; Peterson, EC; Henry, R; Hoffman, NE				Tu, CJ; Peterson, EC; Henry, R; Hoffman, NE			The L18 domain of light-harvesting chlorophyll proteins binds to chloroplast signal recognition particle 43	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYLAKOID MEMBRANES; 54-KDA SUBUNIT; INSERTION; HOMOLOG; GTP; REQUIREMENT; INTEGRATION; POLYPEPTIDE; INTERACTS; TRANSPORT	Chloroplast signal recognition particle (cpSRP) is a novel type of SRP that contains a homolog of SRP54 and a 43-kDa subunit absent from all cytoplasmic SRPs but lacks RNA. It is also distinctive in its ability to posttranslationally interact with light-harvesting chlorophyll proteins (LHCP), hydrophobic proteins synthesized in the cytoplasm and targeted to the thylakoid via the stroma, LHCP integration into thylakoid membranes requires the two subunits of cpSRP, cpFtsY, GTP, and the membrane protein ALB3, It had previously been shown that the L18 domain, an 18-amino acid peptide between the second and third transmembrane domains, and a hydrophobic domain are required for interaction with cpSRP, In the present study we used a pull-down assay, with cpSRP43 or cpSRP54 fused to glutathione-transferase, to study interactions between cpSRP43, cpSRP54, LHCP, and cpFtsY. cpFtsY was not observed to form significant interactions with any of the proteins even in the presence of nonhydrolyzable GTP analogs. Our data indicate that cpSRP43 binds to the L18 domain, that cpSRP54 binds to the hydrophobic domain, and that LHCP and cpSRP54 independently bind to cpSRP43, These data confirm that the novel post-translational interaction between LHCP and cpSRP is mediated through binding to cpSRP43.	Paradigm Genet, Res Triangle Pk, NC 27709 USA; Univ Arkansas, Dept Biol Sci, Fayetteville, AR 72701 USA; Carnegie Inst Washington, Dept Plant Biol, Stanford, CA 94305 USA	University of Arkansas System; University of Arkansas Fayetteville; Carnegie Institution for Science	Hoffman, NE (corresponding author), Paradigm Genet, 104 alexander Dr, Res Triangle Pk, NC 27709 USA.		Peterson, Eric/I-3082-2013					ADAM Z, 1993, PLANT PHYSIOL, V102, P35, DOI 10.1104/pp.102.1.35; Amin P, 1999, PLANT PHYSIOL, V121, P61, DOI 10.1104/pp.121.1.61; CLINE K, 1989, J BIOL CHEM, V264, P14225; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; DeLille J, 2000, P NATL ACAD SCI USA, V97, P1926, DOI 10.1073/pnas.030395197; FRANKLIN AE, 1993, J BIOL CHEM, V268, P22175; HIGH S, 1991, J CELL BIOL, V113, P25, DOI 10.1083/jcb.113.1.25; High S, 1997, J BIOL CHEM, V272, P11622; HOFFMAN NE, 1994, PLANT PHYSIOL, V105, P295, DOI 10.1104/pp.105.1.295; Klimyuk VI, 1999, PLANT CELL, V11, P87, DOI 10.1105/tpc.11.1.87; Kogata N, 1999, FEBS LETT, V447, P329, DOI 10.1016/S0014-5793(99)00305-1; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; Moore M, 2000, J BIOL CHEM, V275, P1529, DOI 10.1074/jbc.275.3.1529; PAYAN LA, 1991, J CELL BIOL, V112, P603, DOI 10.1083/jcb.112.4.603; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; REED JE, 1990, EUR J BIOCHEM, V194, P33, DOI 10.1111/j.1432-1033.1990.tb19423.x; Schuenemann D, 1999, BIOCHEM BIOPH RES CO, V254, P253, DOI 10.1006/bbrc.1998.9923; Schuenemann D, 1998, P NATL ACAD SCI USA, V95, P10312, DOI 10.1073/pnas.95.17.10312; Tu CJ, 1999, J BIOL CHEM, V274, P27219, DOI 10.1074/jbc.274.38.27219; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511	21	72	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	2000	275	18					13187	13190		10.1074/jbc.C000108200	http://dx.doi.org/10.1074/jbc.C000108200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	312CH	10747852	hybrid			2022-12-27	WOS:000086925300007
J	Buhler, B; Schmid, A; Hauer, B; Witholt, B				Buhler, B; Schmid, A; Hauer, B; Witholt, B			Xylene monooxygenase catalyzes the multistep oxygenation of toluene and pseudocumene to corresponding alcohols, aldehydes, and acids in Escherichia coli JM101	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOL PLASMID PWW0; UPPER-PATHWAY OPERON; PSEUDOMONAS-PUTIDA; BENZYL ALCOHOL; ALKANE HYDROXYLASE; BENZALDEHYDE DEHYDROGENASE; DEGRADATION PATHWAY; SUBSTRATE RANGE; OXIDATION; OLEOVORANS	Xylene monooxygenase of Pseudomonas putida mt-2 catalyzes the methylgroup hydroxylation of toluene and xylenes. To investigate the potential of xylene monooxygenase to catalyze multistep oxidations of one methyl group, we tested recombinant Escherichia coli expressing the monooxygenase genes xylM and xylA under the control of the alh regulatory system of Pseudomonas oleovorans Gpo1, Expression of xylene monooxygenase genes could efficiently be controlled by n-octane and dicyclopropylketone. Xylene monooxygenase was found to catalyze the oxygenation of toluene, pseudocumene, the corresponding alcohols, and the corresponding aldehydes, For all three transformations O-18 incorporation provided stong evidence for a monooxygenation type of reaction, with gem-diols as the most likely reaction intermediates during the oxygenation of benzyl alcohols to benzaldehydes. To investigate the role of benzyl alcohol dehydrogenase (XylB) in the formation of benzaldehydes,;xylB was cloned behind and expressed in concert with xylMA. In comparison to E. coli expressing only xylMA, the presence of xylB lowered product formation rates and resulted in back formation of benzyl alcohol from benzaldehyde. In P. putida mt-2 XylB may prevent the formation of high concentrations of the particularly reactive benzaldehydes. In the case of high fluxes through the degradation pathways and low aldehyde concentrations, XylB may contribute to benzaldehyde formation via the energetically favorable dehydrogenation of benzyl alcohols. The results presented here characterize XylMA as an able to catalyze the multistep oxygenation of toluenes.	Swiss Fed Inst Technol, Inst Biotechnol, CH-8093 Zurich, Switzerland; BASF Corp, Res Fine Chem & Biotechnol, D-67056 Ludwigshafen, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; BASF	Schmid, A (corresponding author), Swiss Fed Inst Technol, Inst Biotechnol, ETH Honggerberg, CH-8093 Zurich, Switzerland.	andreas@biotech.biol.ethz.ch	Witholt, Bernard/A-7340-2012	Buhler, Bruno/0000-0001-6458-5739				ABRIL MA, 1989, J BACTERIOL, V171, P6782, DOI 10.1128/jb.171.12.6782-6790.1989; BAPTIST JN, 1963, BIOCHIM BIOPHYS ACTA, V69, P40, DOI 10.1016/0006-3002(63)91223-X; CHAKRABARTY AM, 1973, P NATL ACAD SCI USA, V70, P1137, DOI 10.1073/pnas.70.4.1137; Dean J.A., 1999, LANGES HDB CHEM; GRUND A, 1975, J BACTERIOL, V123, P546, DOI 10.1128/JB.123.2.546-556.1975; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARAYAMA S, 1992, ANNU REV MICROBIOL, V46, P565, DOI 10.1146/annurev.mi.46.100192.003025; HARAYAMA S, 1986, J BACTERIOL, V167, P455, DOI 10.1128/jb.167.2.455-461.1986; HARAYAMA S, 1989, J BACTERIOL, V171, P5048, DOI 10.1128/jb.171.9.5048-5055.1989; KEENER WK, 1994, APPL ENVIRON MICROB, V60, P1914, DOI 10.1128/AEM.60.6.1914-1920.1994; KOK M, 1989, J BIOL CHEM, V264, P5435; KUNZ DA, 1981, J BACTERIOL, V146, P179, DOI 10.1128/JB.146.1.179-191.1981; Lee K, 1996, APPL ENVIRON MICROB, V62, P3101, DOI 10.1128/AEM.62.9.3101-3106.1996; Leonardo MR, 1996, J BACTERIOL, V178, P6013, DOI 10.1128/jb.178.20.6013-6018.1996; MAVROVOUNIOTIS ML, 1990, BIOTECHNOL BIOENG, V36, P1070, DOI 10.1002/bit.260361013; MAVROVOUNIOTIS ML, 1991, J BIOL CHEM, V266, P14440; MAY SW, 1986, ENZYME MICROB TECH, V8, P17, DOI 10.1016/0141-0229(86)90004-9; NIEBOER M, 1993, MOL MICROBIOL, V8, P1039, DOI 10.1111/j.1365-2958.1993.tb01649.x; NIEBOER M, 1996, THESIS RIJKSUNIVERSI; Panke S, 1999, APPL ENVIRON MICROB, V65, P2324; Panke S, 1998, APPL ENVIRON MICROB, V64, P2032; Ramos JL, 1997, ANNU REV MICROBIOL, V51, P341, DOI 10.1146/annurev.micro.51.1.341; ROBERTSON JB, 1992, APPL ENVIRON MICROB, V58, P2643, DOI 10.1128/AEM.58.8.2643-2648.1992; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; Shanklin J, 1997, P NATL ACAD SCI USA, V94, P2981, DOI 10.1073/pnas.94.7.2981; SHAW JP, 1995, J FERMENT BIOENG, V79, P195, DOI 10.1016/0922-338X(95)90602-V; SHAW JP, 1990, EUR J BIOCHEM, V191, P705, DOI 10.1111/j.1432-1033.1990.tb19179.x; SHAW JP, 1992, BIOCHEM J, V283, P789, DOI 10.1042/bj2830789; SHAW JP, 1992, EUR J BIOCHEM, V209, P51, DOI 10.1111/j.1432-1033.1992.tb17260.x; SHAW JP, 1993, J BIOL CHEM, V268, P10842; SPAIN JC, 1989, APPL ENVIRON MICROB, V55, P2648, DOI 10.1128/AEM.55.10.2648-2652.1989; Staijen IE, 1999, J BACTERIOL, V181, P1610, DOI 10.1128/JB.181.5.1610-1616.1999; SUZUKI M, 1991, J BACTERIOL, V173, P1690, DOI 10.1128/jb.173.5.1690-1695.1991; Van Beilen Jan B., 1994, Biodegradation, V5, P161, DOI 10.1007/BF00696457; VAZ ADN, 1994, BIOCHEMISTRY-US, V33, P6442, DOI 10.1021/bi00187a008; Williams PA, 1997, MICROBIOL-SGM, V143, P101, DOI 10.1099/00221287-143-1-101; WUBBOLTS M, 1994, THESIS RIJKSUNIVERSI; Wubbolts MG, 1996, BIOTECHNOL BIOENG, V52, P301, DOI 10.1002/(SICI)1097-0290(19961020)52:2<301::AID-BIT10>3.0.CO;2-M; WUBBOLTS MG, 1994, ENZYME MICROB TECH, V16, P608, DOI 10.1016/0141-0229(94)90127-9; WUBBOLTS MG, 1994, ENZYME MICROB TECH, V16, P887, DOI 10.1016/0141-0229(94)90064-7; Yuste L, 1998, J BACTERIOL, V180, P5218, DOI 10.1128/JB.180.19.5218-5226.1998	42	64	73	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10085	10092		10.1074/jbc.275.14.10085	http://dx.doi.org/10.1074/jbc.275.14.10085			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744688	hybrid			2022-12-27	WOS:000086345600029
J	Mouillet-Richard, S; Mutel, V; Loric, S; Tournois, C; Launay, JM; Kellermann, O				Mouillet-Richard, S; Mutel, V; Loric, S; Tournois, C; Launay, JM; Kellermann, O			Regulation by neurotransmitter receptors of serotonergic or catecholaminergic neuronal cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F9 TERATOCARCINOMA CELLS; STEM-CELLS; PROGENITOR-CELL; RAT-BRAIN; IN-VITRO; LINE; EXPRESSION; NORADRENALINE; TRANSPORTERS; SIGNALS	The murine FS-derived 1C11 clone exhibits a stable epithelial morphology, expresses nestin, an early neuroectodermal marker, and expresses genes involved in neuroectodermal cell fate, Upon appropriate induction, 100% of 1C11 precursor cells develop neurite extensions and acquire neuronal markers (N-CAM, synaptophysin, gamma gamma-enolase, and neurofilament) as well as the general functions of either serotonergic (1C11*(/5HT)) (5HT, 5-hydroxytryptamine) or noradrenergic (1C11**(/NE)) (NE, norepinephrine) neurons. The two programs are shown to be mutually exclusive. 1C11 thus behaves as a neuroepithelial cell line with a dual bioaminergic fate. 1C11*(/5HT) cells implement a functional 5-HT transporter and thereby a complete serotonergic phenotype within a days, whereas 5-HT1B/D, 5-HT2B, and 5-HT2A receptors are sequentially induced. The accurate time schedule of catecholaminergic differentiation was defined. Catecholamine synthesis, storage, and catabolism are acquired within 4 days; the noradrenergic phenotype is complete at day 12 and includes a functional norepinephrine transporter and an alpha(1D)-adrenoreceptor (day 8). The time-dependent onset of neurotransmitter-associated functions proper to either program is similar to in vivo observations. Along each pathway, the selective induction of serotonergic or adrenergic receptors is shown to be an essential part of the differentiation program, since they promote an autoregulation of the corresponding phenotype.	Inst Pasteur, CNRS, URA 1960, F-75724 Paris 15, France; Hoffmann La Roche Ag, Pharma Res Dept, CH-40002 Basel, Switzerland; Hop Lariboisiere, CR Claude Bernard Pathol Expt & Commun Cellulaire, IFR 6, Serv Biochim, F-75010 Paris, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Roche Holding; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	Kellermann, O (corresponding author), Inst Pasteur, CNRS, URA 1960, 25 Rue Dr Roux, F-75724 Paris 15, France.		loric, sylvain/F-7224-2011; Mouillet, Sophie/E-4960-2017	Mouillet, Sophie/0000-0002-8950-1949				Alexander S, 1998, TRENDS PHARMACOL SCI, P1; BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; BronnerFraser M, 1997, CURR OPIN CELL BIOL, V9, P885, DOI 10.1016/S0955-0674(97)80092-0; BUCCARON MH, 1990, P NATL ACAD SCI USA, V87, P1922, DOI 10.1073/pnas.87.5.1922; Deacon T, 1998, EXP NEUROL, V149, P28, DOI 10.1006/exnr.1997.6674; Fleming RJ, 1997, TRENDS CELL BIOL, V7, P437, DOI 10.1016/S0962-8924(97)01161-6; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; Green S. H., 1995, Methods (Orlando), V7, P222, DOI 10.1006/meth.1995.1028; HOYER D, 1994, PHARMACOL REV, V46, P157; HYDE CE, 1994, BRAIN RES, V646, P118, DOI 10.1016/0006-8993(94)90063-9; JONAKAIT GM, 1985, DEV BIOL, V108, P6, DOI 10.1016/0012-1606(85)90003-X; KELLERMANN O, 1986, DIFFERENTIATION, V32, P74, DOI 10.1111/j.1432-0436.1986.tb00558.x; Kellermann O, 1996, BRIT J PHARMACOL, V118, P1161, DOI 10.1111/j.1476-5381.1996.tb15519.x; KIHMI Y, 1976, P NATL ACAD SCI USA, V73, P462; LAUDER JM, 1993, TRENDS NEUROSCI, V16, P233, DOI 10.1016/0166-2236(93)90162-F; LENDAHL U, 1990, TRENDS NEUROSCI, V13, P132, DOI 10.1016/0166-2236(90)90004-T; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LIESI P, 1983, NATURE, V306, P265, DOI 10.1038/306265a0; LORANG D, 1994, J NEUROSCI, V14, P4903; LORIC S, 1995, MOL PHARMACOL, V47, P458; MCPHERSON PA, 1995, METHODS COMP METHODS, V7, P238; MCQUEEN JK, 1987, BASIC CLIN ASPECTS N, V2, P7; OREILLY CA, 1988, J BIOL CHEM, V263, P6115; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; POLIARD A, 1995, J CELL BIOL, V130, P1461, DOI 10.1083/jcb.130.6.1461; ROWE SJ, 1993, DEVELOPMENT, V119, P1343; RUDGE JS, 1996, MOL CELL NEUROSCI, V7, P604; Russo AF, 1996, MOL NEUROBIOL, V13, P257, DOI 10.1007/BF02740626; Tournois C, 1998, J BIOL CHEM, V273, P17498, DOI 10.1074/jbc.273.28.17498; WESTLUND KN, 1985, SCIENCE, V230, P181, DOI 10.1126/science.3875898; Whittemore SR, 1996, MOL NEUROBIOL, V12, P13, DOI 10.1007/BF02740745; Ye WL, 1998, CELL, V93, P755, DOI 10.1016/S0092-8674(00)81437-3	33	67	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9186	9192		10.1074/jbc.275.13.9186	http://dx.doi.org/10.1074/jbc.275.13.9186			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734054	hybrid			2022-12-27	WOS:000086206500018
J	Subauste, MC; Von Herrath, M; Benard, V; Chamberlain, CE; Chuang, TH; Chu, KT; Bokoch, GM; Hahn, KM				Subauste, MC; Von Herrath, M; Benard, V; Chamberlain, CE; Chuang, TH; Chu, KT; Bokoch, GM; Hahn, KM			Rho family proteins modulate rapid apoptosis induced by cytotoxic T lymphocytes and Fas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; ACTIN-CYTOSKELETON; BCL-2 EXPRESSION; IN-VITRO; DEATH; CDC42; RAC; GTPASES; CELLS; ACTIVATION	Little is known about the role of Rho proteins in apoptosis produced by stimuli evolved specifically to produce apoptosis, such as granzymes from cytotoxic T lymphocytes (CTLs) and Fas, Here we demonstrate that all three Rho family members are involved in CTL- and Fas-induced killing. Dominant-negative mutants of each Rho family member and Clostridium difficile toxin B, an inhibitor of all family members, strongly inhibited the susceptibility of cells to CTL- and Fas-induced apoptosis. Fas-induced caspase-3 activation was inhibited by C, diflicile toxin, Activated mutants of each GTPase increased susceptibility to apoptosis, and activation of Cdc42 increased within 5 min of Fas stimulation. In contrast, during the time required for CTL and Fas killing, no apoptosis was produced by dominant-negative or activated mutants or by C, difficile toxin alone. Inhibition of actin polymerization using latrunculin A reduced the ability of constitutively active GTPase mutants to stimulate apoptosis and blocked Fas-induced activation of caspase-3. Furthermore, the ability of Rac to enhance apoptosis was decreased by point mutations reported to block Rac induction of actin polymerization, Rho family proteins may regulate apoptosis through their effects on the actin cytoskeleton.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Neuropharmacol, Div Virol, La Jolla, CA 92037 USA; Chiron Corp, Emeryville, CA 94608 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Novartis	Hahn, KM (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Chuang, Tsung-Hsien/F-9679-2010	Planat-Benard, Valerie/0000-0002-0712-4220; Hahn, Klaus/0000-0002-1970-7562	NATIONAL INSTITUTE ON AGING [R01AG015430] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG15430] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; AMIESEN J, 1994, IMMUNOL REV, V142, P9; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Castleman K. R., 1996, DIGITAL IMAGE PROCES; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Chicurel ME, 1998, CURR OPIN CELL BIOL, V10, P232, DOI 10.1016/S0955-0674(98)80145-2; CHU K, 1992, P NATL ACAD SCI USA, V92, P11894; Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687; COSA OA, 1995, CELL, V81, P1137; DRESCHEL DN, 1997, CURR BIOL, V7, P12; Dutartre H, 1996, J CELL SCI, V109, P367; Esteve P, 1998, ONCOGENE, V17, P1855, DOI 10.1038/sj.onc.1202082; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Fiorentini C, 1998, EXP CELL RES, V242, P341, DOI 10.1006/excr.1998.4057; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Glinsky GV, 1997, CANCER LETT, V115, P185, DOI 10.1016/S0304-3835(97)04738-1; Gomez J, 1997, EUR J IMMUNOL, V27, P2793, DOI 10.1002/eji.1830271108; Gulbins E, 1996, J BIOL CHEM, V271, P26389, DOI 10.1074/jbc.271.42.26389; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Henkart P A, 1997, Semin Immunol, V9, P85, DOI 10.1006/smim.1997.0064; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; JUST J, 1995, NATURE, V375, P500; Kong YY, 1998, J EXP MED, V188, P2099, DOI 10.1084/jem.188.11.2099; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LAMARCHE N, 1994, TRENDS GENET, V10, P346; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; McConkey David J., 1994, Trends in Cell Biology, V4, P370, DOI 10.1016/0962-8924(94)90087-6; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nishida K, 1999, ONCOGENE, V18, P407, DOI 10.1038/sj.onc.1202301; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Penninger JM, 1999, CELL, V96, P9, DOI 10.1016/S0092-8674(00)80954-X; Posey SC, 1999, J BIOL CHEM, V274, P4259, DOI 10.1074/jbc.274.7.4259; RAWSON CL, 1991, J CELL BIOL, V113, P671, DOI 10.1083/jcb.113.3.671; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; vonHerrath MG, 1996, J VIROL, V70, P1072, DOI 10.1128/JVI.70.2.1072-1079.1996; vonHerrath MG, 1995, IMMUNITY, V3, P727, DOI 10.1016/1074-7613(95)90062-4; Waters JB, 1996, J IMMUNOL, V157, P3396; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618; Zhou KM, 1998, J BIOL CHEM, V273, P16782, DOI 10.1074/jbc.273.27.16782	61	208	212	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9725	9733		10.1074/jbc.275.13.9725	http://dx.doi.org/10.1074/jbc.275.13.9725			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734125	hybrid			2022-12-27	WOS:000086206500089
J	Aguirre, V; Uchida, T; Yenush, L; Davis, R; White, MF				Aguirre, V; Uchida, T; Yenush, L; Davis, R; White, MF			The c-Jun NH2-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAY; PLECKSTRIN HOMOLOGY DOMAIN; TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; JUXTAMEMBRANE REGION; 3T3-L1 ADIPOCYTES; BRAIN INJURY; IN-VIVO	Tumor necrosis factor alpha (TNF alpha) inhibits insulin action, in part, through serine phosphorylation of IRS proteins; however, the phosphorylation sites that mediate the inhibition are unknown. TNF alpha promotes multipotential signal transduction cascades, including the activation of the Jun NH2-terminal kinase (JNK), Endogenous JNK associates with IRS-1 in Chinese hamster ovary cells. Anisomycin, a strong activator of JNK in these cells, stimulates the activity of JNK bound to IRS-1 and inhibits the insulin-stimulated tyrosine phosphorylation of IRS-I, Serine 307 is a major site of JNK phosphorylation in IRS-1, Mutation of serine 307 to alanine eliminates phosphorylation of IRS-1 by JNK and abrogates the inhibitory effect of TNF alpha on insulin-stimulated tyrosine phosphorylation of IRS-I. These results suggest that phosphorylation of serine 307 might mediate, at least partially, the inhibitory effect of proinflammatory cytokines like TNF alpha on IRS-I function.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Howard Hughes Med Inst, Boston, MA 02215 USA; Univ Massachusetts, Howard Hughes Med Inst, Dept Mol Med, Worcester, MA 01605 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Howard Hughes Medical Institute; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	White, MF (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Howard Hughes Med Inst, 1 Joslin Pl, Boston, MA 02215 USA.	morris.white@joslin.harvard.edu	Yenush, Lynne/J-8815-2014; Sancheti, Harsh/H-3538-2012	Yenush, Lynne/0000-0001-8589-7002; 	NIDDK NIH HHS [DK38712] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038712, R55DK038712, R29DK038712] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; Barthel A, 1998, BIOCHEM BIOPH RES CO, V243, P509, DOI 10.1006/bbrc.1998.8134; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CARBONI JM, 1995, ONCOGENE, V10, P1905; COMB DG, 1958, J BIOL CHEM, V232, P807; Costantino A, 1996, ENDOCRINOLOGY, V137, P4100, DOI 10.1210/en.137.10.4100; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; Delahaye L, 1998, ENDOCRINOLOGY, V139, P4911, DOI 10.1210/en.139.12.4911; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; FEENER EP, 1993, J BIOL CHEM, V268, P11256; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hani E, 1998, J CLIN INVEST, V101, P521, DOI 10.1172/JCI1403; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Ikezu T, 1997, J BIOL CHEM, V272, P25289, DOI 10.1074/jbc.272.40.25289; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lavine SD, 1998, J CEREBR BLOOD F MET, V18, P52, DOI 10.1097/00004647-199801000-00005; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Loddick SA, 1999, P NATL ACAD SCI USA, V96, P9449, DOI 10.1073/pnas.96.17.9449; LopezIlasaca M, 1997, BIOCHEM BIOPH RES CO, V232, P273, DOI 10.1006/bbrc.1997.6289; Miller BS, 1996, BIOCHEMISTRY-US, V35, P8769, DOI 10.1021/bi952651r; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P229, DOI 10.1097/00004647-199702000-00013; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018; PONS S, 1995, MOL CELL BIOL, V15, P4453; Qiao LY, 1999, J BIOL CHEM, V274, P10625, DOI 10.1074/jbc.274.15.10625; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rincon M, 1998, J EXP MED, V188, P1817, DOI 10.1084/jem.188.10.1817; Staubs PA, 1998, J BIOL CHEM, V273, P25139, DOI 10.1074/jbc.273.39.25139; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Vaxillaire M, 1997, HUM MOL GENET, V6, P583, DOI 10.1093/hmg/6.4.583; Venters HD, 1999, P NATL ACAD SCI USA, V96, P9879, DOI 10.1073/pnas.96.17.9879; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	66	1107	1159	1	61	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					9047	9054		10.1074/jbc.275.12.9047	http://dx.doi.org/10.1074/jbc.275.12.9047			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722755	hybrid			2022-12-27	WOS:000086507700105
J	Emsley, P; Fotinou, C; Black, I; Fairweather, NF; Charles, IG; Watts, C; Hewitt, E; Isaacs, NW				Emsley, P; Fotinou, C; Black, I; Fairweather, NF; Charles, IG; Watts, C; Hewitt, E; Isaacs, NW			The structures of the H-C fragment of tetanus toxin with carbohydrate subunit complexes provide insight into ganglioside binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BOTULINUM TOXINS; PROTEIN MODELS; REFINEMENT; NEUROTOXIN; RECEPTOR; REPLACEMENT; RECOGNITION; MEMBRANES; CHANNELS	The entry of tetanus neurotoxin into neuronal cells proceeds through the initial binding of the toxin to gangliosides on the cell surface. The carboxyl-terminal fragment of the heavy chain of tetanus neurotoxin contains the ganglioside-binding site, which has not yet been fully characterized. The crystal structures of native H-C and of H-C soaked with carbohydrates reveal a number of binding sites and protide insight into the possible mode of ganglioside binding.	Univ Glasgow, Dept Chem, Glasgow G12 8QQ, Lanark, Scotland; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AZ, England; Rayne Inst, Cruciform Project, London WC1E 6JJ, England; Univ Dundee, Dept Biochem, Dundee DD1 4HN, Scotland	University of Glasgow; Imperial College London; University of London; King's College London; University College London; University of Dundee	Isaacs, NW (corresponding author), Univ Glasgow, Dept Chem, Glasgow G12 8QQ, Lanark, Scotland.	N.Isaacs@chem.gla.ac.uk		Hewitt, Eric/0000-0002-6238-6303; Watts, Colin/0000-0001-6183-2087				ANDERSON MD, 1993, J MOL BIOL, V230, P673, DOI 10.1006/jmbi.1993.1181; ANGSTROM J, 1994, P NATL ACAD SCI USA, V91, P11859, DOI 10.1073/pnas.91.25.11859; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOQUET P, 1982, P NATL ACAD SCI-BIOL, V79, P7614, DOI 10.1073/pnas.79.24.7614; Cowtan KD, 1994, JOINT CCP4 ESF EACBM; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; EISEL U, 1986, EMBO J, V5, P2495, DOI 10.1002/j.1460-2075.1986.tb04527.x; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; FAIRWEATHER NF, 1986, NUCLEIC ACIDS RES, V14, P7809, DOI 10.1093/nar/14.19.7809; FIGUEIREDO D, 1995, INFECT IMMUN, V63, P3218, DOI 10.1128/IAI.63.8.3218-3221.1995; HALPERN JL, 1993, J BIOL CHEM, V268, P11188; Halpern JL, 1995, CURR TOP MICROBIOL, V195, P221; HOCH DH, 1985, P NATL ACAD SCI USA, V82, P1692, DOI 10.1073/pnas.82.6.1692; HOLMGREN J, 1980, EUR J BIOCHEM, V106, P371, DOI 10.1111/j.1432-1033.1980.tb04583.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamata Y, 1997, TOXICON, V35, P1337, DOI 10.1016/S0041-0101(97)00027-5; Kubota T, 1997, APPL ENVIRON MICROB, V63, P1214, DOI 10.1128/AEM.63.4.1214-1218.1997; Lacy DB, 1999, J MOL BIOL, V291, P1091, DOI 10.1006/jmbi.1999.2945; Lacy DB, 1998, NAT STRUCT BIOL, V5, P898, DOI 10.1038/2338; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JOINT CCP4 ESF EACM; MacKenzie CR, 1997, J BIOL CHEM, V272, P5533, DOI 10.1074/jbc.272.9.5533; MAKOFF AJ, 1989, NUCLEIC ACIDS RES, V17, P10191, DOI 10.1093/nar/17.24.10191; MONTECUCCO C, 1986, TRENDS BIOCHEM SCI, V11, P314, DOI 10.1016/0968-0004(86)90282-3; MONTECUCCO C, 1994, MOL MICROBIOL, V13, P1, DOI 10.1111/j.1365-2958.1994.tb00396.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; Shapiro RE, 1997, J BIOL CHEM, V272, P30380, DOI 10.1074/jbc.272.48.30380; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; Umland TC, 1997, NAT STRUCT BIOL, V4, P788, DOI 10.1038/nsb1097-788; VANHEYNI.WE, 1974, NATURE, V249, P415, DOI 10.1038/249415a0; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301	38	123	127	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8889	8894		10.1074/jbc.275.12.8889	http://dx.doi.org/10.1074/jbc.275.12.8889			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722735	hybrid			2022-12-27	WOS:000086507700085
J	Fang, SY; Jensen, JP; Ludwig, RL; Vousden, KH; Weissman, AM				Fang, SY; Jensen, JP; Ludwig, RL; Vousden, KH; Weissman, AM			Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; DNA-DAMAGE; IN-VITRO; DOMAIN; DEGRADATION; BINDING; PATHWAY; PHOSPHORYLATION; IDENTIFICATION; PROTEASOME	Mdm2 has been shown to regulate p53 stability by targeting the p53 protein for proteasomal degradation. We now report that Mdm2 is a ubiquitin protein ligase (E3) for p53 and that its activity is dependent on its RING finger. Furthermore, we show that Mdma mediates its own ubiquitination in a RING finger-dependent manner, which requires no eukaryotic proteins other than ubiquitin-activating enzyme (El) and an ubiquitin-conjugating enzyme (E2). It is apparent, therefore, that Mdma manifests an intrinsic capacity to mediate ubiquitination, Mutation of putative zinc coordination residues abrogated this activity, as did chelation of divalent cations. After cation chelation, the full activity could be restored by addition of zinc. We further demonstrate that the degradation of p53 and Mdma in cells requires additional potential zinc coordinating residues beyond those required for the intrinsic activity of Mdm2 in vitro. Replacement of the Mdm2 RING with that of another protein (Praja1) reconstituted ubiquitination and proteasomal degradation of Mdma. However, this RING was ineffective in ubiquitination and proteasomal targeting of p53, suggesting that there may be specificity at the level of the RING in the recognition of heterologous substrates.	NCI, Lab Immune Cell Biol, Div Basic Sci, NIH, Bethesda, MD 20892 USA; NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Weissman, AM (corresponding author), NCI, Lab Immune Cell Biol, Div Basic Sci, NIH, Bldg 10,Rm 1B34,9000 Rockville Pike, Bethesda, MD 20892 USA.	amw@nih.gov	Fang, Shengyun/H-3802-2011	Fang, Shengyun/0000-0001-7280-5463				Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; Bordallo J, 1999, FEBS LETT, V448, P244, DOI 10.1016/S0014-5793(99)00362-2; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; Duprez E, 1999, J CELL SCI, V112, P381; Everett RD, 1999, EMBO J, V18, P1526, DOI 10.1093/emboj/18.6.1526; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Hu G, 1999, MOL CELL BIOL, V19, P724; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; JAMAL S, 1995, ONCOGENE, V10, P2095; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Kutateladze TG, 1999, MOL CELL, V3, P805, DOI 10.1016/S1097-2765(01)80013-7; Kwon YT, 1998, P NATL ACAD SCI USA, V95, P7898, DOI 10.1073/pnas.95.14.7898; Lai ZH, 1998, BIOCHEMISTRY-US, V37, P17005, DOI 10.1021/bi980596r; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Meek DW, 1997, BIOCHEM SOC T, V25, P416, DOI 10.1042/bst0250416; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; Mishra L, 1997, ONCOGENE, V15, P2361, DOI 10.1038/sj.onc.1201405; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Parkinson J, 1999, J VIROL, V73, P650, DOI 10.1128/JVI.73.1.650-657.1999; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Roehm PC, 1997, BIOCHEMISTRY-US, V36, P10240, DOI 10.1021/bi970863d; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shumaker DK, 1998, CELL CALCIUM, V23, P151, DOI 10.1016/S0143-4160(98)90114-2; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Torii KU, 1999, J BIOL CHEM, V274, P27674, DOI 10.1074/jbc.274.39.27674; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	74	836	860	3	61	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8945	8951		10.1074/jbc.275.12.8945	http://dx.doi.org/10.1074/jbc.275.12.8945			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722742	hybrid			2022-12-27	WOS:000086507700092
J	Snellman, A; Keranen, MR; Hagg, PO; Lamberg, A; Hiltunen, JK; Kivirikko, KI; Pihlajaniemi, T				Snellman, A; Keranen, MR; Hagg, PO; Lamberg, A; Hiltunen, JK; Kivirikko, KI; Pihlajaniemi, T			Type XIII collagen forms homotrimers with three triple helical collagenous domains and its association into disulfide-bonded trimers is enhanced by prolyl 4-hydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BULLOUS PEMPHIGOID AUTOANTIGEN; MACROPHAGE SCAVENGER RECEPTORS; BACULOVIRUS EXPRESSION SYSTEM; MOLECULAR FLYPAPER; III PROCOLLAGEN; ALPHA-1 CHAIN; IX COLLAGEN; PROTEIN; IDENTIFICATION; CLONING	Type XIII collagen is a type II transmembrane protein predicted to consist of a short cytosolic domain, a single transmembrane domain, and three collagenous domains flanked by noncollagenous sequences. Previous studies on mRNAs indicate that the structures of the collagenous domain closest to the cell membrane, COL1, the adjacent noncollagenous domain, NC2, and the C-terminal domains COL3 and NC4 are subject to alternative splicing. In order to extend studies of type XIII collagen from cDNAs to the protein level we have produced it in insect cells by means of baculoviruses. Type XIII collagen alpha chains mere found to associate into disulfide-bonded trimers, and hydroxylation of proline residues dramatically enhanced this association. This protein contains altogether eight cysteine residues, and interchain disulfide bonds could be located in the NC1 domain and possibly at the junction of COL1 and NC2, while the two cysteine residues in NC4 are likely to form intrachain bonds. Pepsin and trypsin/chymotrypsin digestions indicated that the type XIII collagen alpha chains form homotrimers whose three collagenous domains are in triple helical conformation. The thermal stabilities (T-m) of the COL1, COL2, and COL3 domains were 38, 49 and 40 degrees C, respectively. The T-m of the central collagenous domain is unusually high, which in the light of this domain being invariant in terms of alternative splicing suggests that the central portion of the molecule may have an important role in the stability of the molecule. All in all, most of the type XIII collagen ectodomain appears to be present in triple helical conformation, which is in clear contrast to the short or highly interrupted triple helical domains of the other known collagenous transmembrane proteins.	Univ Oulu, Dept Med Biochem, FIN-90220 Oulu, Finland; Univ Oulu, Bioctr, Collagen Res Unit, FIN-90220 Oulu, Finland; Univ Oulu, Dept Biochem, FIN-90220 Oulu, Finland	University of Oulu; University of Oulu; Finland National Institute for Health & Welfare; University of Oulu	Pihlajaniemi, T (corresponding author), Univ Oulu, Dept Med Biochem, Kajaanintie 52 A, FIN-90220 Oulu, Finland.			Pihlajaniemi, Taina/0000-0002-1664-9045; Hiltunen, Kalervo/0000-0002-3073-9602				BACHINGER HP, 1981, J BIOL CHEM, V256, P3193; Bayes M, 1998, HUM MOL GENET, V7, P1661, DOI 10.1093/hmg/7.11.1661; Borradori L, 1996, CURR OPIN CELL BIOL, V8, P647, DOI 10.1016/S0955-0674(96)80106-2; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; Bulleid NJ, 1996, BIOCHEM J, V317, P195, DOI 10.1042/bj3170195; Burgeson RE, 1997, CURR OPIN CELL BIOL, V9, P651, DOI 10.1016/S0955-0674(97)80118-4; DOEGE KJ, 1986, J BIOL CHEM, V261, P8924; ELKHOURY J, 1994, J BIOL CHEM, V269, P10197; Elomaa O, 1998, J BIOL CHEM, V273, P4530, DOI 10.1074/jbc.273.8.4530; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; FESSLER LI, 1974, J BIOL CHEM, V249, P7637; FURTHMAYR H, 1971, ANAL BIOCHEM, V41, P510, DOI 10.1016/0003-2697(71)90173-4; GIUDICE GJ, 1991, J CLIN INVEST, V87, P734, DOI 10.1172/JCI115054; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; GRUENWALD S, 1993, BACULOVIRUS EXPRESSI; Hagg P, 1998, J BIOL CHEM, V273, P15590, DOI 10.1074/jbc.273.25.15590; Harlow E., 1988, ANTIBODIES LAB MANUA; JUVONEN M, 1992, J BIOL CHEM, V267, P24693; JUVONEN M, 1992, J BIOL CHEM, V267, P24700; JUVONEN M, 1993, LAB INVEST, V69, P541; KIVIRIKKO KI, 1967, ANAL BIOCHEM, V19, P249, DOI 10.1016/0003-2697(67)90160-1; KRIEGER M, 1992, TRENDS BIOCHEM SCI, V17, P141, DOI 10.1016/0968-0004(92)90322-Z; KRIEGER M, 1993, J BIOL CHEM, V268, P4569; Lamberg A, 1996, J BIOL CHEM, V271, P11988, DOI 10.1074/jbc.271.20.11988; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; LI K, 1991, J BIOL CHEM, V266, P24064; LUNSTRUM GP, 1992, J BIOL CHEM, V267, P20087; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; MAZZORANA M, 1993, J BIOL CHEM, V268, P3029; Mazzorana M, 1996, J BIOL CHEM, V271, P29003, DOI 10.1074/jbc.271.46.29003; Miles CA, 1998, J MOL BIOL, V277, P135, DOI 10.1006/jmbi.1997.1603; Myllyharju J, 1997, J BIOL CHEM, V272, P21824, DOI 10.1074/jbc.272.35.21824; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; Nokelainen M, 1998, MATRIX BIOL, V16, P329, DOI 10.1016/S0945-053X(98)90004-X; Peltonen S, 1997, DNA CELL BIOL, V16, P227, DOI 10.1089/dna.1997.16.227; Pihlajamaa T, 1999, J BIOL CHEM, V274, P22464, DOI 10.1074/jbc.274.32.22464; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P16922; PIHLAJANIEMI T, 1987, P NATL ACAD SCI USA, V84, P940, DOI 10.1073/pnas.84.4.940; PIHLAJANIEMI T, 1995, PROG NUCLEIC ACID RE, V50, P225, DOI 10.1016/S0079-6603(08)60816-8; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; REID KBM, 1985, BIOCHEM J, V231, P729, DOI 10.1042/bj2310729; SANDBERG M, 1989, J CELL BIOL, V109, P1371, DOI 10.1083/jcb.109.3.1371; TIKKA L, 1991, J BIOL CHEM, V266, P17713; VEIJOLA J, 1994, J BIOL CHEM, V269, P26746; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467	45	43	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8936	8944		10.1074/jbc.275.12.8936	http://dx.doi.org/10.1074/jbc.275.12.8936			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722741	hybrid			2022-12-27	WOS:000086507700091
J	Calvo, M; Pol, A; Lu, A; Ortega, D; Pons, M; Blasi, J; Enrich, C				Calvo, M; Pol, A; Lu, A; Ortega, D; Pons, M; Blasi, J; Enrich, C			Cellubrevin is present in the basolateral endocytic compartment of hepatocytes and follows the transcytotic pathway after IgA internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICAL PLASMA-MEMBRANE; CANINE KIDNEY-CELLS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; TRANS-CELLULAR TRANSPORT; 3 ENDOSOMAL FRACTIONS; POLARIZED MDCK CELLS; RAT-LIVER; EPITHELIAL-CELLS; CALMODULIN ANTAGONIST; RECYCLING ENDOSOMES	The endocytic compartment of polarized cells is organized in basolateral and apical endosomes plus those endocytic st structures specialized in recycling and transcytosis, which are still poorly characterized. The complexity of the various populations of endosomes has been demonstrated by the exquisite repertoire of endogenous proteins. In this study we examined the distribution of cellubrevin in the endocytic compartment of hepatocytes, since its intracellular location and function in polarized cells are largely unknown. Highly purified rat liver endosomes were isolated from estradiol-treated rats, and the early/sorting endosomal fraction was further subfractionated in a multistep sucrose density gradient, and studied. Analysis of dissected endosomal fractions showed that cellubrevin was located in early/sorting endosomes, with Rab4, annexins II and VI, and transferrin receptor, but in a specific subpopulation of these early endosomes with the same density range as pIgA and Raf-l, Interestingly, only in those isolated endosomal fractions, endosomes enriched in transcytotic: structures(of livers loaded with IgA), the polymeric immunoglobulin receptor specifically co-immunoprecipitated with cellubrevin. In addition, confocal and immuno-electron microscopy identification of cellubrevin in tubular structures underneath the sinusoidal plasma membrane together with the re-organization of cellubrevin, in the endocytic compartment, after the IgA loading, strongly suggest the involvement of cellubrevin in the transcytosis of pIgA.	Univ Barcelona, Fac Med, Dept Biol Cellular, Inst Invest Biomed August Pi & Sunyer, Barcelona 08036, Spain; Univ Barcelona, Fac Odontol, Dept Biol Cellular, Barcelona 08036, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona	Enrich, C (corresponding author), Univ Barcelona, Fac Med, Dept Biol Cellular, Inst Invest Biomed August Pi & Sunyer, Casanova 143, Barcelona 08036, Spain.	enrich@medicina.ub.es	Blasi, Juan/K-7943-2014; Pol, Albert/M-1865-2014; Pons, Monica/AAB-5309-2019; LU, ALBERT/AAB-6134-2019; Calvo, Maria/I-1872-2015	Blasi, Juan/0000-0002-0482-9444; Pol, Albert/0000-0002-1750-1085; LU, ALBERT/0000-0002-7507-3330; Calvo, Maria/0000-0002-7473-0474; Enrich, Carlos/0000-0003-0382-2993				ALI N, 1990, BIOCHEM J, V271, P193, DOI 10.1042/bj2710193; Apodaca G, 1996, EMBO J, V15, P1471, DOI 10.1002/j.1460-2075.1996.tb00491.x; APODACA G, 1994, J BIOL CHEM, V269, P19005; BARR VA, 1993, GASTROENTEROLOGY, V105, P554, DOI 10.1016/0016-5085(93)90734-T; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BELCHER JD, 1987, P NATL ACAD SCI USA, V84, P6785, DOI 10.1073/pnas.84.19.6785; BISSELL DM, 1973, J CELL BIOL, V59, P722; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHAO Y, 1979, J BIOL CHEM, V254, P1360; Chapin SJ, 1996, J BIOL CHEM, V271, P1336, DOI 10.1074/jbc.271.3.1336; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; Enrich C, 1999, HEPATOLOGY, V30, P1115, DOI 10.1002/hep.510300505; Enrich C, 1996, HEPATOLOGY, V24, P226, DOI 10.1002/hep.510240136; ENRICH C, 1989, EUR J CELL BIOL, V48, P344; Fujita H, 1998, BIOCHEM J, V329, P527, DOI 10.1042/bj3290527; Galli T, 1998, MOL BIOL CELL, V9, P1437, DOI 10.1091/mbc.9.6.1437; George CH, 1999, J BIOL CHEM, V274, P8678, DOI 10.1074/jbc.274.13.8678; Gibson A, 1998, J CELL BIOL, V143, P81, DOI 10.1083/jcb.143.1.81; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOPPE CA, 1985, J CELL BIOL, V101, P2113, DOI 10.1083/jcb.101.6.2113; HUNZIKER W, 1994, J BIOL CHEM, V269, P29003; Hunziker W, 1998, J BIOL CHEM, V273, P15734, DOI 10.1074/jbc.273.25.15734; JACKLE S, 1994, J BIOL CHEM, V269, P1026; JACKLE S, 1991, J LIPID RES, V32, P485; JACKLE S, 1991, J BIOL CHEM, V266, P1396; JACKLE S, 1993, HEPATOLOGY, V17, P455, DOI 10.1016/0270-9139(93)90058-U; JAECKLE S, 1989, P NATL ACAD SCI USA, V86, P1880, DOI 10.1073/pnas.86.6.1880; Jin MJ, 1996, J BIOL CHEM, V271, P30105, DOI 10.1074/jbc.271.47.30105; Kipp H, 1998, MOL BIOL CELL, V9, p209A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung SM, 1998, J BIOL CHEM, V273, P17732, DOI 10.1074/jbc.273.28.17732; Llorente A, 1996, EXP CELL RES, V227, P298, DOI 10.1006/excr.1996.0279; Low SH, 1998, J CELL BIOL, V141, P1503, DOI 10.1083/jcb.141.7.1503; Low SH, 1996, MOL BIOL CELL, V7, P2007, DOI 10.1091/mbc.7.12.2007; LUTCKE A, 1993, J CELL BIOL, V121, P553, DOI 10.1083/jcb.121.3.553; Luton F, 1999, MOL CELL, V4, P627, DOI 10.1016/S1097-2765(00)80213-0; Majo G, 1998, LIFE SCI, V62, P607, DOI 10.1016/S0024-3205(97)01156-9; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; NEVILLE DM, 1960, J BIOPHYS BIOCHEM CY, V8, P413, DOI 10.1083/jcb.8.2.413; Ortega D, 1998, J CELL SCI, V111, P261; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Pol A, 1997, BIOCHEM J, V327, P741, DOI 10.1042/bj3270741; Pol A, 1998, FEBS LETT, V441, P34, DOI 10.1016/S0014-5793(98)01517-8; Pol A, 1997, BIOCHEM J, V323, P435, DOI 10.1042/bj3230435; Pol A, 1997, ELECTROPHORESIS, V18, P2548, DOI 10.1002/elps.1150181410; Pol A, 1999, HEPATOLOGY, V29, P1848, DOI 10.1002/hep.510290602; QUINTART J, 1989, EUR J BIOCHEM, V184, P567, DOI 10.1111/j.1432-1033.1989.tb15051.x; REGAZZI R, 1995, EMBO J, V14, P2723, DOI 10.1002/j.1460-2075.1995.tb07273.x; STOORVOGEL W, 1991, CELL, V65, P417, DOI 10.1016/0092-8674(91)90459-C; SZTUL E, 1991, CELL, V64, P81, DOI 10.1016/0092-8674(91)90210-P; Teter K, 1998, J BIOL CHEM, V273, P19625, DOI 10.1074/jbc.273.31.19625; Tuma PL, 1999, J CELL BIOL, V145, P1089, DOI 10.1083/jcb.145.5.1089; van IJzendoorn SCD, 1998, J CELL BIOL, V142, P683, DOI 10.1083/jcb.142.3.683; Verges M, 1999, P NATL ACAD SCI USA, V96, P10146, DOI 10.1073/pnas.96.18.10146; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73	59	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7910	7917		10.1074/jbc.275.11.7910	http://dx.doi.org/10.1074/jbc.275.11.7910			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713107	Green Published, hybrid			2022-12-27	WOS:000085913300067
J	Janecki, AJ; Janecki, M; Akhter, S; Donowitz, M				Janecki, AJ; Janecki, M; Akhter, S; Donowitz, M			Basic fibroblast growth factor stimulates surface expression and activity of Na+/H+ exchanger NHE3 via mechanism involving phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; RAT ADIPOSE-CELLS; PHOSPHOINOSITIDE 3-KINASE; TRANSFERRIN RECEPTORS; 3T3-L1 ADIPOCYTES; NACL ABSORPTION; MEMBRANE; WORTMANNIN; ENDOCYTOSIS; TRAFFICKING	Na+/H+ exchanger NHE3 is a plasma membrane (PM) protein, which contributes to Na+ absorption in the intestine. Growth factors stimulate NHE3 via phosphatidylinositol 3-kinase (PI3-K), but mechanism of this process is not clear. To examine the hypothesis that growth factors stimulate NHE3 by modulating NHE3 recycling, and that PI3-K participates in this mechanism, we used PS120 fibroblasts expressing a fusion protein of NHE3 and green fluorescent protein. At steady state, similar to 25% of cellular NHE3 content was expressed at PM. Inhibition of PI3-K decreased PM expression of NHE3, which correlated with retention of the exchanger in recycling endosomal compartment. In contrast, basic fibroblast growth factor (bFGF) increased PM expression of NHE3, which was associated with a S-fold increase in rate constant for exit of the exchanger from the recycling compartment. Qualitatively similar effects of bFGF were observed in cells pretreated with PIS-K inhibitors, but their magnitude was only similar to 50% of that in intact cells. These data suggest that: (i) bFGF stimulates NHE3 by increasing PM expression of the exchanger; (ii) PI3-K mediates PM expression of NHE3 in both basal and bFGF-stimulated conditions, and (iii) not all of the effects of bFGF on NHE3 expression are mediated by PI3-K, suggesting additional regulatory mechanisms.	Univ Texas, Sch Med, Div Gastroenterol Hepatol & Nutr, Dept Med, Houston, TX 77030 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Div Gastroenterol, Baltimore, MD 21205 USA	University of Texas System; Johns Hopkins University; Johns Hopkins University	Janecki, AJ (corresponding author), Univ Texas, Sch Med, Div Gastroenterol Hepatol & Nutr, Dept Med, 6431 Fannin,4-234 MSB, Houston, TX 77030 USA.	ajaneck@heart.med.uth.tmc.edu			NIDDK NIH HHS [K08DK02557, P01DK44484, R01DK26523] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026523, K08DK002557, P01DK044484] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Betz WJ, 1996, CURR OPIN NEUROBIOL, V6, P365, DOI 10.1016/S0959-4388(96)80121-8; Biemesderfer D, 1997, AM J PHYSIOL-RENAL, V273, pF289, DOI 10.1152/ajprenal.1997.273.2.F289; Bretscher MS, 1998, CURR BIOL, V8, P721, DOI 10.1016/S0960-9822(98)70281-7; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHU SC, 1995, J GEN PHYSIOL, V105, P589, DOI 10.1085/jgp.105.5.589; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; DAVIS RJ, 1986, EMBO J, V5, P653, DOI 10.1002/j.1460-2075.1986.tb04263.x; DONOWITZ M, 1994, AM J PHYSIOL, V266, pG647, DOI 10.1152/ajpgi.1994.266.4.G647; DONOWITZ M, 1999, INTESTINAL MUCOSA IT, P89; DONOWITZ M, 1996, MOL BIOL MEMBRANE TR, P259; Gerdes HH, 1996, FEBS LETT, V389, P44, DOI 10.1016/0014-5793(96)00586-8; GHOSH RN, 1994, J CELL SCI, V107, P2177; HARDIN JA, 1993, AM J PHYSIOL, V264, pG312, DOI 10.1152/ajpgi.1993.264.2.G312; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; HENSLEY CB, 1989, AM J PHYSIOL, V257, pC637, DOI 10.1152/ajpcell.1989.257.4.C637; Hoogerwerf WA, 1996, AM J PHYSIOL-GASTR L, V270, pG29, DOI 10.1152/ajpgi.1996.270.1.G29; Janecki AJ, 1998, J BIOL CHEM, V273, P8790, DOI 10.1074/jbc.273.15.8790; Khurana S, 1996, J BIOL CHEM, V271, P9919, DOI 10.1074/jbc.271.17.9919; KNIGHT A, 1995, MOL BIOL CELL, V6, P597, DOI 10.1091/mbc.6.5.597; KOTYK A, 1975, CELL MEMBRANE TRANSP, P263; Kurashima K, 1998, J BIOL CHEM, V273, P20828, DOI 10.1074/jbc.273.33.20828; LAX Y, 1994, FEBS LETT, V339, P234, DOI 10.1016/0014-5793(94)80422-2; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; Malide D, 1997, FEBS LETT, V409, P461, DOI 10.1016/S0014-5793(97)00563-2; Malide D, 1997, J CELL SCI, V110, P2795; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Misra S, 1998, J BIOL CHEM, V273, P26638, DOI 10.1074/jbc.273.41.26638; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; OKADA T, 1994, J BIOL CHEM, V269, P3568; Park K, 1999, AM J PHYSIOL-GASTR L, V276, pG470, DOI 10.1152/ajpgi.1999.276.2.G470; Patterson GH, 1997, BIOPHYS J, V73, P2782, DOI 10.1016/S0006-3495(97)78307-3; PRESLEY JF, 1993, J CELL BIOL, V122, P1231, DOI 10.1083/jcb.122.6.1231; SHEPHERD PR, 1995, BIOCHEM BIOPH RES CO, V211, P535, DOI 10.1006/bbrc.1995.1846; Silviani V, 1996, PFLUG ARCH EUR J PHY, V432, P791, DOI 10.1007/s004240050200; Spiro DJ, 1996, MOL BIOL CELL, V7, P355, DOI 10.1091/mbc.7.3.355; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; VANDEURS B, 1989, INT REV CYTOL, V117, P131; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WILEY HS, 1984, P NATL ACAD SCI-BIOL, V81, P7456, DOI 10.1073/pnas.81.23.7456; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125; YUN CHC, 1995, P NATL ACAD SCI USA, V92, P10723, DOI 10.1073/pnas.92.23.10723; Zhang YB, 1996, AM J PHYSIOL-RENAL, V270, pF1004, DOI 10.1152/ajprenal.1996.270.6.F1004	46	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8133	8142		10.1074/jbc.275.11.8133	http://dx.doi.org/10.1074/jbc.275.11.8133			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713136	hybrid			2022-12-27	WOS:000085913300096
J	Mano, H; Kimura, C; Fujisawa, Y; Kameda, T; Watanabe-Mano, M; Kaneko, H; Kaneda, T; Hakeda, Y; Kumegawa, M				Mano, H; Kimura, C; Fujisawa, Y; Kameda, T; Watanabe-Mano, M; Kaneko, H; Kaneda, T; Hakeda, Y; Kumegawa, M			Cloning and function of rabbit peroxisome proliferator-activated receptor delta/beta in mature osteoclasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEROXIDE-H SYNTHASE-2; BONE-RESORPTION; PPAR-GAMMA; IN-VITRO; 5-LIPOXYGENASE METABOLITES; PARATHYROID-HORMONE; INHIBITORY FACTOR; GENE-EXPRESSION; STROMAL CELLS; OXIDIZED LDL	Osteoclasts modulate bone resorption under physiological and pathological conditions. Previously, we showed that both estrogens and retinoids regulated osteoclastic bone resorption and postulated that such regulation was directly mediated through their cognate receptors expressed in mature osteoclasts. In this study, we searched for expression of other members of the nuclear hormone receptor superfamily in osteoclasts, Using the low stringency homologous hybridization method, we isolated the peroxisome proliferator-activated receptor delta/beta (PPAR delta/beta) cDNA from mature rabbit osteoclasts. Northern blot analysis showed that PPAR delta/beta mRNA was highly expressed in highly enriched rabbit osteoclasts. Carbaprostacyclin, a prostacyclin analogue known to be a ligand for PPAR delta/beta, significantly induced both bone-resorbing activities of isolated mature rabbit osteoclasts and mRNA expression of the cathepsin K, carbonic anhydrase type II, and tartrate-resistant acid phosphatase genes in these cells. Moreover, the carbaprostacyclin-induced bone resorption was completely blocked by an antisense phosphothiorate oligodeoxynucleotide of PPAR delta/beta but not by the sense phosphothiorate oligodeoxynucleotide of the same DNA sequence. Our results suggest that PPAR delta/beta may be involved in direct modulation of osteoclastic bone resorption.	Meikai Univ, Sch Dent, Dept Oral Anat, Sakado, Saitama 35002, Japan; Tokyo Univ Agr, Fac Appl Biosci, Dept Biosci, Tokyo 156, Japan; Takeda Chem Ind Ltd, Pharmaceut Grp, Div Pharmaceut Res, Mol Pharmacol Lab, Osaka 532, Japan	Meikai University; Tokyo University of Agriculture; Takeda Chemical Industries	Kumegawa, M (corresponding author), Meikai Univ, Sch Dent, Dept Oral Anat, 1-1 Keyakidai, Sakado, Saitama 35002, Japan.							ADEBANJO OA, 1994, J ENDOCRINOL, V143, P375, DOI 10.1677/joe.0.1430375; Berger J, 1999, J BIOL CHEM, V274, P6718, DOI 10.1074/jbc.274.10.6718; BOIE Y, 1994, J BIOL CHEM, V269, P12173; Bonewald LF, 1997, ADV EXP MED BIOL, V433, P299; CHAMBERS TJ, 1985, ENDOCRINOLOGY, V116, P234, DOI 10.1210/endo-116-1-234; COLLINS DA, 1991, J BONE MINER RES, V6, P157; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Donahue Henry J., 1992, P207; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133; Flynn MA, 1999, CALCIFIED TISSUE INT, V64, P154, DOI 10.1007/s002239900595; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Fuller K, 1998, J ENDOCRINOL, V158, P341, DOI 10.1677/joe.0.1580341; GALLWITZ WE, 1993, J BIOL CHEM, V268, P10087; Garcia C, 1996, J BONE MINER RES, V11, P1619; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Hertz R, 1996, EUR J BIOCHEM, V235, P242, DOI 10.1111/j.1432-1033.1996.00242.x; Inui T, 1997, J BIOL CHEM, V272, P8109, DOI 10.1074/jbc.272.13.8109; Jimi E, 1996, ENDOCRINOLOGY, V137, P2187; Kakudo S, 1996, J BONE MINER METAB, V14, P129, DOI [10.1007/BF02239480, DOI 10.1007/BF02239480]; Kameda T, 1997, J EXP MED, V186, P489, DOI 10.1084/jem.186.4.489; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KLEIN DC, 1970, ENDOCRINOLOGY, V86, P1436, DOI 10.1210/endo-86-6-1436; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kobori M, 1998, GENES CELLS, V3, P459, DOI 10.1046/j.1365-2443.1998.00202.x; KODAMA H, 1991, J EXP MED, V173, P1291, DOI 10.1084/jem.173.5.1291; Lader CS, 1998, ENDOCRINOLOGY, V139, P3157, DOI 10.1210/en.139.7.3157; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mano H, 1996, BIOCHEM BIOPH RES CO, V223, P637, DOI 10.1006/bbrc.1996.0947; MANOLAGAS SC, 1995, BONE, V17, P63; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NAMBA T, 1994, J BIOL CHEM, V269, P9986; Pacifici R, 1996, J BONE MINER RES, V11, P1043; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; RIFKIN BR, 1993, BIOL PHYSL OSTEOCLAS; Roux S, 1997, ENDOCRINOLOGY, V138, P1476, DOI 10.1210/en.138.4.1476; SANESHIGE S, 1995, BIOCHEM J, V309, P721, DOI 10.1042/bj3090721; Sato T, 1996, J BONE MINER RES, V11, P392; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; TAKADA Y, 1992, BONE MINER, V17, P347, DOI 10.1016/0169-6009(92)90785-C; TEITELBAUM SL, 1995, J CELL BIOCHEM, V59, P1, DOI 10.1002/jcb.240590102; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; TEZUKA K, 1994, J BIOL CHEM, V269, P15006; TEZUKA K, 1992, BIOCHEM BIOPH RES CO, V186, P911, DOI 10.1016/0006-291X(92)90832-6; Tokushima T, 1997, ADV EXP MED BIOL, V433, P307; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Traianedes K, 1998, ENDOCRINOLOGY, V139, P3178, DOI 10.1210/en.139.7.3178; WALENGA RW, 1985, PROSTAGLANDINS, V29, P191, DOI 10.1016/0090-6980(85)90201-1; Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	51	62	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8126	8132		10.1074/jbc.275.11.8126	http://dx.doi.org/10.1074/jbc.275.11.8126			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713135	hybrid			2022-12-27	WOS:000085913300095
J	Rajagopal, V; Kreitman, RJ				Rajagopal, V; Kreitman, RJ			Recombinant toxins that bind to the urokinase receptor are cytotoxic without requiring binding to the alpha(2)-macroglobulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR RECEPTOR; PSEUDOMONAS EXOTOXIN-A; CIRCULARLY PERMUTED INTERLEUKIN-4; SINGLE-CHAIN IMMUNOTOXIN; CANCER CELL-LINES; DIPHTHERIA-TOXIN; KDEL RECEPTOR; ALPHA-2-MACROGLOBULIN RECEPTOR; MALIGNANT ASTROCYTOMA; TRANSFERRIN RECEPTOR	The alpha(2-)macroglobulin receptor (alpha(2)MR) has been reported to mediate the internalization of the urokinase plasminogen activator receptor (uPAR) via ligand binding to both receptors. To target malignant uPAR-expressing cells and to determine whether uPAR can internalize without ligand binding to alpha(2)MR, we engineered two recombinant toxins, ATF-PE38 and ATF-PE38KDEL. Each consists of the amino-terminal fragment (ATF) of human urokinase and a truncated form of Pseudomonas exotoxin (PE) devoid of domain Ia, which binds alpha(2)MR. ATF-PE38 and ATF-PE38KDEL were cytotoxic: toward malignant uPAR-bearing cells, with IC50 values as low as 0.02 ng/ml (0.3 pw). Cytotoxicity could be blocked using either recombinant urokinase or free ATF, indicating that the cytotoxicity of the recombinant toxins was specific. Radiolabeled ATF-PE38 had high affinity for uPAR (K-d = 0.4-8 nM) on a variety of different malignant cell types and internalized at a rate similar to that of ATF. The cytotoxicity was not diminished by receptor-associated protein, which binds and shields the alpha(2)MR from other proteins, or by incubation with phorbol myristate acetate, which is known to decrease the number of alpha(2)MRs in U937 cells or by antibodies to ar,MR. Therefore, these recombinant toxins appear to internalize via uPAR without association with the alpha(2)MR.	NCI, Mol Biol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kreitman, RJ (corresponding author), NCI, Mol Biol Lab, Div Basic Sci, NIH, 37-4B27,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.							Akamatsu Y, 1998, CLIN CANCER RES, V4, P2825; ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BATRA JK, 1989, P NATL ACAD SCI USA, V86, P8545, DOI 10.1073/pnas.86.21.8545; BATRA JK, 1991, MOL CELL BIOL, V11, P2200, DOI 10.1128/MCB.11.4.2200; Behrendt N, 1998, FIBRINOLYSIS PROTEOL, V12, P191, DOI 10.1016/S0268-9499(98)80013-1; BERGWERFF AA, 1995, EUR J BIOCHEM, V228, P1009; BLASI F, 1988, Fibrinolysis, V2, P73, DOI 10.1016/0268-9499(88)90370-0; BRETON J, 1995, EUR J BIOCHEM, V231, P563, DOI 10.1111/j.1432-1033.1995.tb20733.x; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; BRINKMANN U, 1995, P NATL ACAD SCI USA, V92, P10427, DOI 10.1073/pnas.92.22.10427; Carriero MV, 1997, CLIN CANCER RES, V3, P1299; CARROLL SF, 1987, J BIOL CHEM, V262, P8707; CAVALLARO U, 1993, J BIOL CHEM, V268, P23186; CAVALLARO U, 1995, SEMIN CANCER BIOL, V6, P269, DOI 10.1006/scbi.1995.0035; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; CHIRON MF, 1994, J BIOL CHEM, V269, P18167; CONESE M, 1995, FEBS LETT, V358, P73, DOI 10.1016/0014-5793(94)01399-L; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; CUBELLIS MV, 1986, J BIOL CHEM, V261, P5819; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; De Petro G, 1998, CANCER RES, V58, P2234; ELLIS V, 1989, J BIOL CHEM, V264, P2185; Fabbrini MS, 1997, FASEB J, V11, P1169, DOI 10.1096/fasebj.11.13.9367352; FRYLING C, 1992, INFECT IMMUN, V60, P497, DOI 10.1128/IAI.60.2.497-502.1992; GLADSON CL, 1995, AM J PATHOL, V146, P1150; GOODSON RJ, 1994, P NATL ACAD SCI USA, V91, P7129, DOI 10.1073/pnas.91.15.7129; Hessler JL, 1997, BIOCHEMISTRY-US, V36, P14577, DOI 10.1021/bi971447w; HOLLAS W, 1992, THROMB HAEMOSTASIS, V68, P662; Hudson MA, 1997, J NATL CANCER I, V89, P709, DOI 10.1093/jnci/89.10.709; HUNG PP, 1984, ADV EXP MED BIOL, V172, P281; HUSAIN SE, 1997, CANCER RES, V58, P3649; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; KENTZER EJ, 1990, BIOCHEM BIOPH RES CO, V171, P401, DOI 10.1016/0006-291X(90)91407-J; KIRCHHEIMER JC, 1989, BLOOD, V74, P1396; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KREITMAN RJ, 1995, CYTOKINE, V7, P311, DOI 10.1006/cyto.1995.0039; Kreitman RJ, 1999, INT J CANCER, V81, P148; Kreitman RJ, 1998, CANCER RES, V58, P968; KREITMAN RJ, 1993, BIOCONJUGATE CHEM, V4, P112, DOI 10.1021/bc00020a002; KREITMAN RJ, 1994, BLOOD, V83, P426; KREITMAN RJ, 1992, J IMMUNOL, V149, P2810; KREITMAN RJ, 1995, BIOCHEM J, V307, P29, DOI 10.1042/bj3070029; Kreitman RJ, 1997, BLOOD, V90, P252; Lanza F, 1998, BRIT J HAEMATOL, V103, P110; Laske DW, 1997, NAT MED, V3, P1362, DOI 10.1038/nm1297-1362; Lengyel E, 1997, ONCOGENE, V14, P2563, DOI 10.1038/sj.onc.1201098; Morita S, 1998, INT J CANCER, V78, P286, DOI 10.1002/(SICI)1097-0215(19981029)78:3<286::AID-IJC4>3.0.CO;2-R; Nykjaer A, 1998, J CELL BIOL, V141, P815, DOI 10.1083/jcb.141.3.815; NYKJAER A, 1994, J BIOL CHEM, V269, P31747; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OGATA M, 1992, J BIOL CHEM, V267, P25396; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; PLESNER T, 1994, AM J CLIN PATHOL, V102, P835, DOI 10.1093/ajcp/102.6.835; Ploug M, 1998, BIOCHEMISTRY-US, V37, P3612, DOI 10.1021/bi972787k; Puri RK, 1996, CANCER RES, V56, P5631; Ragno P, 1998, CANCER RES, V58, P1315; Rajagopal V, 1997, PROTEIN ENG, V10, P1453, DOI 10.1093/protein/10.12.1453; REITER Y, 1994, INT J CANCER, V58, P142, DOI 10.1002/ijc.2910580123; SEETHARAM S, 1991, J BIOL CHEM, V266, P17376; Shetty S, 1998, ARCH BIOCHEM BIOPHYS, V356, P265, DOI 10.1006/abbi.1998.0789; SIEGALL CB, 1989, J BIOL CHEM, V264, P14256; Sier CFM, 1998, CANCER RES, V58, P1843; Tagge E, 1996, J HISTOCHEM CYTOCHEM, V44, P159, DOI 10.1177/44.2.8609372; Taniguchi T, 1998, CANCER RES, V58, P4461; THEUER C, 1994, BIOCHEMISTRY-US, V33, P5894, DOI 10.1021/bi00185a029; THEUER CP, 1993, P NATL ACAD SCI USA, V90, P7774, DOI 10.1073/pnas.90.16.7774; van der Kaaden ME, 1998, FIBRINOLYSIS PROTEOL, V12, P251, DOI 10.1016/S0268-9499(98)80018-0; WEI Y, 1994, J BIOL CHEM, V269, P32380; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5; YAMAMOTO M, 1994, CANCER RES, V54, P5016; Yonemura Y, 1997, ONCOL REP, V4, P1229	74	44	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7566	7573		10.1074/jbc.275.11.7566	http://dx.doi.org/10.1074/jbc.275.11.7566			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713063	hybrid			2022-12-27	WOS:000085913300023
J	Camoni, L; Iori, V; Marra, M; Aducci, P				Camoni, L; Iori, V; Marra, M; Aducci, P			Phosphorylation-dependent interaction between plant plasma membrane H+-ATPase and 14-3-3 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL REGION; FUSICOCCIN RECEPTOR; BINDING; 14-3-3-PROTEINS; SYSTEM; DOMAIN; ROOTS	The H+-ATPase is a key enzyme for the establishment and maintenance of plasma membrane potential and energization of secondary active transport in the plant cell. The phytotoxin fusicoccin induces H+-ATPase activation by promoting the association of 14-3-3 proteins. It is still unclear whether 14-3-3 proteins can represent natural regulators of the proton pump, and factors regulating 14-3-3 binding to the H+-ATPase under physiological conditions are unknown as well. In the present study in vivo and in, vitro evidence is provided that 14-3-3 proteins can associate with the H+-ATPase from maize roots also in a fusicoccin-independent manner and that the interaction depends on the phosphorylation status of the proton pump. Furthermore, results indicate that phosphorylation of H+-ATPase influences also the fusicoccin-dependent interaction of 14-3-3 proteins. Finally, a protein phosphatase 2A able to impair the interaction between H+-ATPase and 14-3-3 proteins was identified and partially purified from maize root.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Univ Sannio, Dept Earth Sci, I-82100 Benevento, Italy	University of Rome Tor Vergata; University of Sannio	Aducci, P (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.		Camoni, Lorenzo/C-2584-2012					Bachmann M, 1996, FEBS LETT, V398, P26, DOI 10.1016/S0014-5793(96)01188-X; BALLIO A, 1968, Annali dell'Istituto Superiore di Sanita, V4, P317; Baunsgaard L, 1998, PLANT J, V13, P661, DOI 10.1046/j.1365-313X.1998.00083.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chung HJ, 1999, TRENDS PLANT SCI, V4, P367, DOI 10.1016/S1360-1385(99)01462-4; Fullone MR, 1998, J BIOL CHEM, V273, P7698, DOI 10.1074/jbc.273.13.7698; Jahn T, 1997, PLANT CELL, V9, P1805, DOI 10.1105/tpc.9.10.1805; JOHANSSON F, 1993, PLANT CELL, V5, P321, DOI 10.2307/3869599; JOHANSSON F, 1994, PHYSIOL PLANTARUM, V92, P389; KORTHOUT HAAJ, 1994, PLANT CELL, V6, P1681, DOI 10.1105/tpc.6.11.1681; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANFERMEIJER FC, 1994, PLANT PHYSIOL, V104, P1277, DOI 10.1104/pp.104.4.1277; Marra M, 1996, FEBS LETT, V382, P293, DOI 10.1016/0014-5793(96)00187-1; MARRA M, 1994, PLANT PHYSIOL, V106, P1497, DOI 10.1104/pp.106.4.1497; MARRA M, 1992, PLANT PHYSIOL, V98, P1029, DOI 10.1104/pp.98.3.1029; Moorhead G, 1996, CURR BIOL, V6, P1104, DOI 10.1016/S0960-9822(02)70677-5; Moorhead G, 1999, PLANT J, V18, P1, DOI 10.1046/j.1365-313X.1999.00417.x; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; OECKING C, 1994, FEBS LETT, V352, P163, DOI 10.1016/0014-5793(94)00949-X; Oecking C, 1997, PLANT J, V12, P441, DOI 10.1046/j.1365-313X.1997.12020441.x; Olsson A, 1998, PLANT PHYSIOL, V118, P551, DOI 10.1104/pp.118.2.551; Palmgren MG, 1998, ADV BOT RES, V28, P1; PALMGREN MG, 1991, J BIOL CHEM, V266, P20470; RASICALDOGNOV F, 1993, PLANT PHYSIOL, V103, P391, DOI 10.1104/pp.103.2.391; REGENBERG B, 1995, PLANT CELL, V7, P1655, DOI 10.1105/tpc.7.10.1655; SCHALLER GE, 1988, PLANTA, V173, P509, DOI 10.1007/BF00958964; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; Smith RD, 1996, ANNU REV PLANT PHYS, V47, P101, DOI 10.1146/annurev.arplant.47.1.101; Toroser D, 1998, FEBS LETT, V435, P110, DOI 10.1016/S0014-5793(98)01048-5; Xing T, 1996, PLANT CELL, V8, P555, DOI 10.2307/3870332; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	31	78	82	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					9919	9923		10.1074/jbc.275.14.9919	http://dx.doi.org/10.1074/jbc.275.14.9919			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744665	hybrid			2022-12-27	WOS:000086345600006
J	Funamoto, M; Fujio, Y; Kunisada, K; Negoro, S; Tone, E; Osugi, T; Hirota, H; Izumi, M; Yoshizaki, K; Walsh, K; Kishimoto, T; Yamauchi-Takihara, K				Funamoto, M; Fujio, Y; Kunisada, K; Negoro, S; Tone, E; Osugi, T; Hirota, H; Izumi, M; Yoshizaki, K; Walsh, K; Kishimoto, T; Yamauchi-Takihara, K			Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; STAT3 ACTIVATION; GENE-REGULATION; GP130; MICE; TRANSFORMATION; ANGIOGENESIS; PATHWAY; SRC	Activation of glycoprotein (gp) 130 transduces hypertrophic and cytoprotective signals in cardiac myocytes. In the present study, me have demonstrated that signals through gp130 increase the expression of vascular endothelial growth factor (VEGF) in cardiac myocytes via the signal transducer and activator of transcription (STAT) 3 pathway. After activation of gp130 with leukemia inhibitory factor (LIF), expression of VEGF mRNA rapidly increased with a peak at 3 h in cultured cardiac myocytes. Cardiotrophin-1 also enhanced VEGF mRNA expression in a dose-dependent manner. VEGF protein production and secretion to the medium were also enhanced by LIF and cardiotrophin-1 but not by interleukin-6, Adenovirus transfer of the dominant-negative form of STAT3 to cultured cardiac myocytes inhibited induction of VEGF expression induced by LIF, but neither PD98059 nor wortmannin was affected. In murine hearts, intravenous administration of LIF augmented expression of VEGF mRNA; however, the hearts of transgenic mice overexpressing dominant-negative STAT3 showed reduced expression of VEGF mRNA that mas not induced after LIF stimulation. These data provide the first evidence that a STAT family protein functions as a regulator of angiogenic growth factors and suggest that gp130/STAT signaling in cardiac myocytes can control vessel growth during cardiac remodeling.	Osaka Univ, Sch Med, Dept Mol Med, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Hlth & Sport Sci, Dept Med Sci 1, Suita, Osaka 5650871, Japan; Tufts Univ, St Elizabeths Med Ctr, Sch Med, Div Cardiovasc Res, Boston, MA 02135 USA	Osaka University; Osaka University; St. Elizabeth's Medical Center; Tufts University	Fujio, Y (corresponding author), Osaka Univ, Sch Med, Dept Mol Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Fujio, Yasushi/H-3421-2017; Kishimoto, Tadamitsu/C-8470-2009	Fujio, Yasushi/0000-0003-0828-2930; 				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Fujio Y, 1997, J CLIN INVEST, V99, P2898, DOI 10.1172/JCI119484; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; Hishinuma S, 1999, BIOCHEM BIOPH RES CO, V264, P436, DOI 10.1006/bbrc.1999.1535; Ikawa M, 1998, FEBS LETT, V430, P83, DOI 10.1016/S0014-5793(98)00593-6; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Kunisada K, 2000, P NATL ACAD SCI USA, V97, P315, DOI 10.1073/pnas.97.1.315; Kunisada K, 1996, CIRCULATION, V94, P2626, DOI 10.1161/01.CIR.94.10.2626; Kunisada K, 1998, CIRCULATION, V98, P346, DOI 10.1161/01.CIR.98.4.346; Matsui H, 1996, RES COMMUN MOL PATH, V93, P149; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; Palermo J, 1996, CIRC RES, V78, P504, DOI 10.1161/01.RES.78.3.504; Pan J, 1999, CIRC RES, V84, P1127, DOI 10.1161/01.RES.84.10.1127; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; Schirmacher P, 1998, AM J PATHOL, V153, P639, DOI 10.1016/S0002-9440(10)65605-2; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Wollert KC, 1997, J MOL MED-JMM, V75, P492, DOI 10.1007/s001090050134	28	132	139	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10561	10566		10.1074/jbc.275.14.10561	http://dx.doi.org/10.1074/jbc.275.14.10561			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744750	hybrid			2022-12-27	WOS:000086345600091
J	Hocking, DC; Sottile, J; Langenbach, KJ				Hocking, DC; Sottile, J; Langenbach, KJ			Stimulation of integrin-mediated cell contractility by fibronectin polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SKIN FIBROBLASTS; EXTRACELLULAR-MATRIX; COLLAGEN LATTICES; PROTEIN-KINASE; LYSOPHOSPHATIDIC ACID; PLASMA FIBRONECTIN; CYCLE PROGRESSION; WOUND CONTRACTION; FOCAL ADHESIONS; ASSEMBLY SITES	Ligation of integrins with extracellular matrix molecules induces the clustering of actin and actin-binding proteins to focal adhesions, which serves to mechanically couple the matrix with the cytoskeleton, During wound healing and development, matrix deposition and remodeling may impart additional tensile forces that modulate integrin-mediated cell functions, including cell migration and proliferation. We have utilized the ability of cells to contract floating collagen gels to determine the effect of fibronectin polymerization on mechanical tension generation by cells. Our data indicate that fibronectin polymerization promotes cell spreading in collagen gels and stimulates cell contractility by a Rho-dependent mechanism, Fibronectin-stimulated contractility was dependent on integrin ligation; however, integrin ligation by fibronectin fragments was not sufficient to induce either tension generation or cell spreading. Furthermore, treatment of cells with polyvalent RGD peptides or pre-polymerized fibronectin did not stimulate cell contractility. Fibronectin-induced contractility was blocked by agents that inhibit fibronectin polymerization, suggesting that the process of fibronectin polymerization is critical in triggering cytoskeletal tension generation. These data indicate that Rho-mediated cell contractility is regulated by the process of fibronectin polymerization and suggest a novel mechanism by which extracellular matrix fibronectin regulates cytoskeletal organization and cell function.	Univ Rochester, Dept Pharmacol & Physiol, Med Ctr, Rochester, NY 14642 USA; Albany Med Coll, Dept Cell Biol & Physiol, Albany, NY 12208 USA	University of Rochester; Albany Medical College	Hocking, DC (corresponding author), Univ Rochester, Dept Pharmacol & Physiol, Med Ctr, 601 Elmwood Ave,Box 711, Rochester, NY 14642 USA.	denise_hocking@urmc.rochester.edu	Hocking, Denise/H-7903-2012	Hocking, Denise/0000-0003-2337-0357	NHLBI NIH HHS [HL 64074, HL50549, HL60181] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL060181, R29HL050549, R01HL064074, R01HL060181] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLENHOFFMANN BL, 1987, J BIOL CHEM, V262, P14361; BALIAN G, 1980, J BIOL CHEM, V255, P3234; BELL E, 1981, SCIENCE, V211, P1052, DOI 10.1126/science.7008197; BELLOWS CG, 1982, J CELL SCI, V58, P125; Bloom L, 1999, MOL BIOL CELL, V10, P1521, DOI 10.1091/mbc.10.5.1521; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; BOUSQUET J, 1992, ALLERGY, V47, P3, DOI 10.1111/j.1398-9995.1992.tb02242.x; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CHECOVICH WJ, 1993, ARTERIOSCLER THROMB, V13, P1662, DOI 10.1161/01.ATV.13.11.1662; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; Chicurel ME, 1998, CURR OPIN CELL BIOL, V10, P232, DOI 10.1016/S0955-0674(98)80145-2; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; Clark RA., 1995, MOL CELLULAR BIOL WO, P3; Corbett SA, 1999, J BIOL CHEM, V274, P20943, DOI 10.1074/jbc.274.30.20943; EHRLICH HP, 1990, TISSUE CELL, V22, P407, DOI 10.1016/0040-8166(90)90070-P; ENGVALL E, 1978, J EXP MED, V147, P1584, DOI 10.1084/jem.147.6.1584; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FURCHT LT, 1980, J HISTOCHEM CYTOCHEM, V28, P1319, DOI 10.1177/28.12.7014712; Gotwals PJ, 1996, J CLIN INVEST, V97, P2469, DOI 10.1172/JCI118693; GRINNELL F, 1984, J CELL SCI, V66, P51; Grinnell F, 1999, J BIOL CHEM, V274, P918, DOI 10.1074/jbc.274.2.918; GUIDRY C, 1985, J CELL SCI, V79, P67; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; HARRIS AK, 1981, NATURE, V290, P249, DOI 10.1038/290249a0; Hocking DC, 1996, J CELL BIOL, V133, P431, DOI 10.1083/jcb.133.2.431; HOCKING DC, 1994, J BIOL CHEM, V269, P19183; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1990, FIBRONECTINS, P84; Hynes RO, 1990, FIBRONECTINS; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; Kreisberg JI, 1997, AM J PHYSIOL-RENAL, V273, pF283, DOI 10.1152/ajprenal.1997.273.2.F283; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; Lee KM, 1998, AM J PHYSIOL-HEART C, V274, pH76, DOI 10.1152/ajpheart.1998.274.1.H76; LITTLE CD, 1982, J CELL SCI, V55, P35; Magnusson MK, 1998, ARTERIOSCL THROM VAS, V18, P1363, DOI 10.1161/01.ATV.18.9.1363; MCDONALD JA, 1982, J CELL BIOL, V92, P485, DOI 10.1083/jcb.92.2.485; MCDONALD JA, 1980, J BIOL CHEM, V255, P8848; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; Mercurius KO, 1998, CIRC RES, V82, P548, DOI 10.1161/01.RES.82.5.548; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; Mosher, 1989, FIBRONECTIN, P1; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; OWENS RJ, 1986, EMBO J, V5, P2825, DOI 10.1002/j.1460-2075.1986.tb04575.x; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; Peters DMP, 1998, MICROSC MICROANAL, V4, P385, DOI 10.1017/S1431927698980369; PIERCE PF, 1981, CONT DIALYSIS, V2, P59; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; RODT SA, 1994, CIRC RES, V75, P942, DOI 10.1161/01.RES.75.5.942; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; Sechler JL, 1998, J BIOL CHEM, V273, P25533, DOI 10.1074/jbc.273.40.25533; Sechler JL, 1996, CELL ADHES COMMUN, V4, P413, DOI 10.3109/15419069709004458; SMALL JV, 1978, CYTOBIOLOGIE, V16, P308; SOMERS CE, 1993, J BIOL CHEM, V268, P22277; Sottile J, 1998, J CELL SCI, V111, P2933; SOTTILE J, 1994, J BIOL CHEM, V269, P17192; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; STOPAK D, 1982, DEV BIOL, V90, P383, DOI 10.1016/0012-1606(82)90388-8; Stupack DG, 1999, J CELL BIOL, V144, P777, DOI 10.1083/jcb.144.4.777; Suchard SJ, 1996, J CELL PHYSIOL, V168, P217, DOI 10.1002/(SICI)1097-4652(199607)168:1<217::AID-JCP26>3.0.CO;2-2; TINGSTROM A, 1992, J CELL SCI, V102, P315; TOMASEK JJ, 1992, ANAT REC, V232, P359, DOI 10.1002/ar.1092320305; VAHERI A, 1978, P NATL ACAD SCI USA, V75, P4944, DOI 10.1073/pnas.75.10.4944; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; WELCH MP, 1990, J CELL BIOL, V110, P133, DOI 10.1083/jcb.110.1.133; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; WOODS A, 1992, J CELL SCI, V101, P277; Wu CY, 1996, CELL ADHES COMMUN, V4, P149, DOI 10.3109/15419069609014219; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; Yang JT, 1996, MOL BIOL CELL, V7, P1737, DOI 10.1091/mbc.7.11.1737; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; ZARDI L, 1985, EUR J BIOCHEM, V146, P571, DOI 10.1111/j.1432-1033.1985.tb08690.x; Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415; ZHANG QH, 1994, J CELL BIOL, V127, P1447, DOI 10.1083/jcb.127.5.1447; Zhong CL, 1998, J CELL BIOL, V141, P539, DOI 10.1083/jcb.141.2.539	80	121	123	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10673	10682		10.1074/jbc.275.14.10673	http://dx.doi.org/10.1074/jbc.275.14.10673			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744764	hybrid			2022-12-27	WOS:000086345600105
J	Moroni, E; Mastrangelo, T; Razzini, R; Cairns, L; Moi, P; Ottolenghi, S; Giglioni, B				Moroni, E; Mastrangelo, T; Razzini, R; Cairns, L; Moi, P; Ottolenghi, S; Giglioni, B			Regulation of mouse p45 NF-E2 transcription by an erythroid-specific GATA-dependent intronic alternative promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBIN GENE-EXPRESSION; LOCUS-CONTROL REGION; LEUCINE ZIPPER PROTEIN; SMALL MAF PROTEINS; FACTOR EKLF GENE; CDNA CLONING; BINDING; ENHANCER; COMPLEX; FAMILY	The erythroid-enriched transcription factor NF-ES is composed of two subunits, p45 and p18, the former of which is mainly expressed in the hematopoietic system. We have isolated and characterized the mouse p45 NF-E2 gene; we show here that, similar to the human gene, the mouse gene has two alternative promoters, which are differentially active during development and in different hematopoietic cells. Transcripts from the distal promoter are present in both erythroid and myeloid cells; however, transcripts from an alternative proximal Ib promoter, lying in the first intron, are abundant in erythroid cells, but barely detectable in myeloid cells. During development, both transcripts are detectable in yolk sac, fetal liver, and bone marrow. Transfection experiments show that proximal promoter Ib has a strong activity in erythroid cells, which is completely dependent on the integrity of a palindromic GATA-1 binding site. In contrast, the distal promoter la is not active in this assay. When the promoter Ib is placed 3' to the promoter la and reporter gene, in an arrangement that resembles the natural one, it acts as an enhancer to stimulate the activity of the upstream promoter la.	Univ Milan, Ist Patol Gen, Ctr Studio Patol Cellulare, Consiglio Nazl Ric, I-20133 Milan, Italy; Univ Milan, Dipartimento Genet & Biol Microrganismi, I-20133 Milan, Italy; Ist Clin & Biol Eta Evolut, I-09121 Cagliari, Italy; Ist Ricerca Talassemie & Anemie Mediterranee, Consiglio Nazl Ric, I-09047 Cagliari, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Milan; University of Milan; Consiglio Nazionale delle Ricerche (CNR)	Moroni, E (corresponding author), Univ Milan, Ist Patol Gen, Ctr Studio Patol Cellulare, Consiglio Nazl Ric, Vi Mangiagalli 31, I-20133 Milan, Italy.		Moi, Paolo/AAC-3161-2019	MOI, Paolo/0000-0001-7879-8057	Telethon [A.048] Funding Source: Medline	Telethon(Fondazione Telethon)		Anderson KP, 1998, J BIOL CHEM, V273, P14347, DOI 10.1074/jbc.273.23.14347; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; Blank V, 1997, BLOOD, V89, P3925, DOI 10.1182/blood.V89.11.3925; BOCKAMP EO, 1995, BLOOD, P1503; CAIRNS LA, 1994, EMBO J, V13, P4577, DOI 10.1002/j.1460-2075.1994.tb06779.x; CALLIGARIS R, 1995, P NATL ACAD SCI USA, V92, P11598, DOI 10.1073/pnas.92.25.11598; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUI DHK, 1995, BIOCHEM BIOPH RES CO, V209, P40, DOI 10.1006/bbrc.1995.1467; CROSSLEY M, 1994, J BIOL CHEM, V269, P15440; Deveaux S, 1997, EMBO J, V16, P5654, DOI 10.1093/emboj/16.18.5654; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; Igarashi K, 1998, J BIOL CHEM, V273, P11783, DOI 10.1074/jbc.273.19.11783; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; Kuroha T, 1998, J BIOCHEM-TOKYO, V123, P376; Lecine P, 1998, J BIOL CHEM, V273, P7572, DOI 10.1074/jbc.273.13.7572; LECOINTE N, 1994, ONCOGENE, V9, P2623; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; Martin F, 1998, BLOOD, V91, P3459, DOI 10.1182/blood.V91.9.3459.3459_3459_3466; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Moroni E, 1997, BIOCHEM BIOPH RES CO, V231, P299, DOI 10.1006/bbrc.1997.6088; NAGAI T, 1994, BLOOD, V84, P1074, DOI 10.1182/blood.V84.4.1074.bloodjournal8441074; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; NICOLIS S, 1991, NUCLEIC ACIDS RES, V19, P5285, DOI 10.1093/nar/19.19.5285; Oyake T, 1996, MOL CELL BIOL, V16, P6083; PETERS LL, 1993, NATURE, V362, P768, DOI 10.1038/362768a0; PISCHEDDA C, 1995, P NATL ACAD SCI USA, V92, P3511, DOI 10.1073/pnas.92.8.3511; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; RONCHI AE, 1995, J BIOL CHEM, V270, P21934, DOI 10.1074/jbc.270.37.21934; Ronchi Antonella, 1997, Genes and Function, V1, P245; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; Takahashi S, 1998, BLOOD, V92, P434, DOI 10.1182/blood.V92.2.434.414k24_434_442; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; Toki T, 1996, BIOCHEM BIOPH RES CO, V219, P760, DOI 10.1006/bbrc.1996.0307; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Vyas P, 1999, BLOOD, V93, P2867; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145	56	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10567	10576		10.1074/jbc.275.14.10567	http://dx.doi.org/10.1074/jbc.275.14.10567			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744751	hybrid			2022-12-27	WOS:000086345600092
J	Piubelli, L; Aliverti, A; Arakaki, AK; Carrillo, N; Ceccarelli, EA; Karplus, PA; Zanetti, G				Piubelli, L; Aliverti, A; Arakaki, AK; Carrillo, N; Ceccarelli, EA; Karplus, PA; Zanetti, G			Competition between C-terminal tyrosine and nicotinamide modulates pyridine nucleotide affinity and specificity in plant ferredoxin-NADP(+) reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; COENZYME SPECIFICITY; NADP+ REDUCTASE; NADPH-CYTOCHROME-P-450 REDUCTASE; FLAVOPROTEIN REDUCTASES; ANGSTROM RESOLUTION; NITRATE REDUCTASE; ESCHERICHIA-COLI; DEHYDROGENASE; BINDING	Chloroplast ferredoxin-NADP+ reductase has a 32,000-fold preference for NADPH over NADH, consistent with its main physiological role of NADP+ photoreduction for de novo carbohydrate biosynthesis. Although it is distant from the 2'-phosphoryl group of NADP+, replacement of the C-terminal tyrosine (Tyr(308) in the pea enzyme) by Trp, Phe, Gly, and Ser produced enzyme forms in which the preference for NADPH over NADH was decreased about 2-, 10-, 300-, and 400-fold, respectively. Remarkably, in the case of the Y308S mutant, the k(cat) value for the NADH-dependent activity of the wild-type enzyme. Furthermore, difference spectra of the NAD+ complexes revealed that the nicotinamide ring of NAD+ binds at nearly full occupancy in the active site of both the Y308G and Y308S mutants. These results correlate well with the k(cat) values obtained with these mutants in the NADH-ferricyanide reaction. The data presented support the hypothesis that specific recognition of the 2'-phosphate group of NADP(H) is required but not sufficient to ensure a high degree of discrimmination against NAD(H) in ferredoxin-NADP+ reductase. Thus, the C-terminal tyrosine enhances the specificity of the reductase for NADP(H) by destabilizing the ineraction of a moiety common to both coenzymes, i.e. the nicotinamide.	Univ Milan, Dipartimento Fisiol & Biochim Gen, I-20133 Milan, Italy; Univ Nacl Rosario, Fac Quim & Farmaceut, Consejo Nacl Invest Cient & Tecn, Inst Mol & Cellular Biol,Mol Biol Div, RA-2000 Rosario, Santa Fe, Argentina; Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	University of Milan; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Rosario; Oregon State University	Zanetti, G (corresponding author), Univ Milan, Dipartimento Fisiol & Biochim Gen, Via Celoria 26, I-20133 Milan, Italy.		Ceccarelli, Eduardo A./V-2600-2019; Arakaki, Adrian K/C-6564-2008; Ceccarelli, Eduardo A./M-8699-2014; Aliverti, Alessandro/B-7875-2017	Ceccarelli, Eduardo A./0000-0001-5776-3306; Ceccarelli, Eduardo A./0000-0001-5776-3306; Aliverti, Alessandro/0000-0002-1226-3655; Karplus, Paul/0000-0001-8725-6292; PIUBELLI, LUCIANO/0000-0003-0805-5121				Aliverti A, 1998, J BIOL CHEM, V273, P34008, DOI 10.1074/jbc.273.51.34008; ALIVERTI A, 1995, BIOCHEMISTRY-US, V34, P8371, DOI 10.1021/bi00026a019; ALIVERTI A, 1993, BIOCHEMISTRY-US, V32, P6374, DOI 10.1021/bi00076a010; Arakaki AK, 1997, FASEB J, V11, P133, DOI 10.1096/fasebj.11.2.9039955; BATIE CJ, 1986, J BIOL CHEM, V261, P1214; BOCANEGRA JA, 1993, BIOCHEMISTRY-US, V32, P2737, DOI 10.1021/bi00062a001; BRUNS CM, 1995, J MOL BIOL, V247, P1125; CALCATERRA NB, 1995, BIOCHEMISTRY-US, V34, P12842, DOI 10.1021/bi00039a045; CHEN RD, 1995, P NATL ACAD SCI USA, V92, P11666, DOI 10.1073/pnas.92.25.11666; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; Didierjean C, 1997, J MOL BIOL, V268, P739, DOI 10.1006/jmbi.1997.0998; FAN F, 1991, BIOCHEMISTRY-US, V30, P6397, DOI 10.1021/bi00240a008; FEENEY R, 1990, BIOCHEM BIOPH RES CO, V166, P667, DOI 10.1016/0006-291X(90)90861-G; Ferscht A., 1998, STRUCTURE MECH PROTE, P116; HALL AV, 1994, J BIOL CHEM, V269, P33082; HANIU M, 1989, BIOCHEMISTRY-US, V28, P8639, DOI 10.1021/bi00447a054; Ingelman M, 1997, J MOL BIOL, V268, P147, DOI 10.1006/jmbi.1997.0957; KARPLUS PA, 1994, J BIOENERG BIOMEMBR, V26, P89, DOI 10.1007/BF00763221; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; Lesk AM, 1995, CURR OPIN STRUC BIOL, V5, P775, DOI 10.1016/0959-440X(95)80010-7; LU GG, 1994, STRUCTURE, V2, P809, DOI 10.1016/S0969-2126(94)00082-4; MITTL PRE, 1994, PROTEIN SCI, V3, P1504, DOI 10.1002/pro.5560030916; NISHIYAMA M, 1993, J BIOL CHEM, V268, P4656; ORELLANO EG, 1993, J BIOL CHEM, V268, P19267; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SEM DS, 1993, BIOCHEMISTRY-US, V32, P11548, DOI 10.1021/bi00094a011; Serre L, 1996, J MOL BIOL, V263, P20, DOI 10.1006/jmbi.1996.0553; SHIN M, 1965, J BIOL CHEM, V240, P1405; Shiraishi N, 1998, ARCH BIOCHEM BIOPHYS, V358, P104, DOI 10.1006/abbi.1998.0827; STAINTHORPE AC, 1990, GENE, V91, P27, DOI 10.1016/0378-1119(90)90158-N; TOMATSU S, 1989, GENE, V80, P353; ZANETTI G, 1991, CHEM BIOCH FLAVOENZY, V2, P305	34	80	81	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10472	10476		10.1074/jbc.275.14.10472	http://dx.doi.org/10.1074/jbc.275.14.10472			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744737	hybrid			2022-12-27	WOS:000086345600078
J	Rousseau, S; Houle, F; Kotanides, H; Witte, L; Waltenberger, J; Landry, J; Huot, J				Rousseau, S; Houle, F; Kotanides, H; Witte, L; Waltenberger, J; Landry, J; Huot, J			Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P38 MAP KINASE; SIGNAL-TRANSDUCTION PATHWAYS; PHOSPHOLIPASE-C-GAMMA; HEAT-SHOCK PROTEIN-27; GTP-BINDING PROTEIN; FACTOR RECEPTOR KDR; NITRIC-OXIDE; TYROSINE KINASE; CELL-MIGRATION; OXIDATIVE STRESS	In endothelial cells, vascular endothelial growth factor (VEGF) induces an accumulation of stress fibers associated with new actin polymerization and rapid formation of focal adhesions at the ventral surface of the cells. This cytoskeletal reorganization results in an intense motogenic activity. Using porcine endothelial cells expressing one or the other type of the VEGF receptors, VEGFR1 or VEGFR2, or human umbilical vein endothelial cells pretreated with a VEGFR2 neutralizing antibody, we show that VEGFR2 is responsible for VEGF-induced activation of the stress-activated protein kinase-2/p38 (SAPK2/p38), phosphorylation of focal adhesion kinase (FAK), and enhanced migratory activity. Activation of SAPK2/p38 triggered actin polymerization whereas FAX, which was phosphorylated independently of SAPK2/p38, initiated assembly of focal adhesions. Both processes contributed to the formation of stress fibers. Geldanamycin, an inhibitor of HSP90 blocked tyrosine phosphorylation of FAK, assembly of focal adhesions, actin reorganization, and cell, migration, all of which were reversed by overexpressing HSP90. We conclude that VEGFR2 mediates the physiological effect of VEGF on cell migration and that two independent pathways downstream of VEGFR2 regulate actin-based motility. One pathway involves SAPK2/p38 and leads to enhanced actin polymerization activity. The other involves HSP90 as a permissive signal transduction factor implicated in FAK phosphorylation and assembly of focal adhesions.	Univ Laval, Hotel Dieu Quebec, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada; Univ Ulm, Med Ctr, Dept Internal Med 2, D-89081 Ulm, Germany; ImClone Syst Inc, Dept Mol & Cell Biol, New York, NY 10014 USA	Laval University; Ulm University; Eli Lilly	Huot, J (corresponding author), Univ Laval, Hotel Dieu Quebec, Ctr Rech Cancerol, 11 Cote Palais, Quebec City, PQ G1R 2J6, Canada.	Jacques.Huot@phc.ulaval.ca	Rousseau, Simon/A-1800-2009; Waltenberger, Johannes/I-1813-2013	Waltenberger, Johannes/0000-0002-2417-9880; Rousseau, Simon/0000-0002-8773-575X				Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Barleon B, 1997, CANCER RES, V57, P5421; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Breier G, 1996, TRENDS CELL BIOL, V6, P454, DOI 10.1016/0962-8924(96)84935-X; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Carlier MF, 1997, J MOL BIOL, V269, P459, DOI 10.1006/jmbi.1997.1062; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V240, P635, DOI 10.1006/bbrc.1997.7719; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Guay J, 1997, J CELL SCI, V110, P357; Hannigan M, 1998, BIOCHEM BIOPH RES CO, V246, P55, DOI 10.1006/bbrc.1998.8570; Heuertz RM, 1999, J BIOL CHEM, V274, P17968, DOI 10.1074/jbc.274.25.17968; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Huot J, 1996, CANCER RES, V56, P273; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Ibitayo AI, 1999, AM J PHYSIOL-GASTR L, V277, pG445, DOI 10.1152/ajpgi.1999.277.2.G445; Jaakkola P, 1998, FASEB J, V12, P959, DOI 10.1096/fasebj.12.11.959; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Kroll J, 1998, BIOCHEM BIOPH RES CO, V252, P743, DOI 10.1006/bbrc.1998.9719; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; Landry J, 1999, BIOCHEM SOC SYMP, P79; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Liu ZY, 1997, BLOOD, V90, P2253, DOI 10.1182/blood.V90.6.2253.2253_2253_2259; MADRI JA, 1988, ENDOTHELIAL CELL BIO, P167; MARCEAU F, 1992, INT J IMMUNOPHARMACO, V14, P525, DOI 10.1016/0192-0561(92)90113-Y; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Morano KA, 1999, EMBO J, V18, P5953, DOI 10.1093/emboj/18.21.5953; Morbidelli L, 1996, AM J PHYSIOL-HEART C, V270, pH411, DOI 10.1152/ajpheart.1996.270.1.H411; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Noiri E, 1997, J BIOL CHEM, V272, P1747, DOI 10.1074/jbc.272.3.1747; NOIRI E, 1998, AM J PHYSIOL, V274, pR236; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Ochel HJ, 1999, MOL GENET METAB, V66, P24, DOI 10.1006/mgme.1998.2774; Ogura M, 1998, J IMMUNOL, V161, P3569; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; RIOUX F, 1994, J CARDIOVASC PHARM, V24, P229, DOI 10.1097/00005344-199424020-00006; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Sawano A, 1997, BIOCHEM BIOPH RES CO, V238, P487, DOI 10.1006/bbrc.1997.7327; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; STASIA MJ, 1991, BIOCHEM BIOPH RES CO, V180, P615, DOI 10.1016/S0006-291X(05)81110-6; Takahashi N, 1999, CIRC RES, V84, P1194, DOI 10.1161/01.RES.84.10.1194; TAKAISHI K, 1994, ONCOGENE, V9, P273; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; vanderZee R, 1997, CIRCULATION, V95, P1030; Waltenberger J, 1996, CIRCULATION, V94, P1647, DOI 10.1161/01.CIR.94.7.1647; Waltenberger J, 1996, J MOL CELL CARDIOL, V28, P1523, DOI 10.1006/jmcc.1996.0142; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Witte L, 1998, CANCER METAST REV, V17, P155, DOI 10.1023/A:1006094117427; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115; Zhu ZP, 1998, CANCER RES, V58, P3209	81	253	262	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10661	10672		10.1074/jbc.275.14.10661	http://dx.doi.org/10.1074/jbc.275.14.10661			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744763	hybrid			2022-12-27	WOS:000086345600104
J	Thotakura, SR; Karthikeyan, N; Smith, T; Liu, K; George, A				Thotakura, SR; Karthikeyan, N; Smith, T; Liu, K; George, A			Cloning and characterization of rat dentin matrix protein 1 (DMP1) gene and its 5 '-upstream region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOPONTIN; EXPRESSION; INDUCTION	Rat dentin matrix protein 1 (DMP1) is a highly acidic 58-kDa phosphoprotein, and DMP1 was the first gene to be cloned from the mineralized dentin matrix. It exists as a highly phosphorylated protein with a pi of 3 in the dentin matrix and, in that state, might have an important role in the mineralization process. The spatio-temporal distribution during development indicates that the expression of this gene is tightly regulated in the odontoblasts, It is now known that DMP1 is not unique to dentin but is present in other mineralized tissues like long bone, calvaria, and ameloblasts, To study the transcriptional regulation and the function of DMP1 in these tissues, a genomic clone with a functional promoter, introns, and exons was isolated. Sequence analysis showed that the rat DMP1 gene is comprised of six exons and five introns and spans similar to 13 kilobases (kb), Exon 1 contains the 5'-untranslated sequences. Exon 2 encodes a total of 18 amino acids including the 16 amino acids of the signal sequence. Exons 3-5 encode 16, 11, and 15 amino acids, respectively. Exon 6 contains 1.3 kb of the coding sequence with the RGD domain, stop codon, and the 5'-untranslated region (1.1 kb), We have mapped two transcription start sites within the DMP1 promoter that are 280 and 321 base pairs, respectively, from the ATG start codon, The location of functional elements within the 5'-upstream DMP1 DNA fragment was determined by cloning it into a luciferase reporter gene. Transient transfection and luciferase assays revealed that the 3 kb fragment has the ability to drive the luciferase gene. However, this promoter activity was restricted to MC3T3-E1 cells (an osteoblast cell lineage). The promoter was silent in Chinese hamster ovary cells (an epithelial cell lineage), indicating the necessity of tissue-specific factors to drive the transcription.	Univ Illinois, Dept Oral Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	George, A (corresponding author), Univ Illinois, Dept Oral Biol, M-C 690,801 S Paulina, Chicago, IL 60612 USA.		Narayanan, Karthikeyan/D-1957-2010	Narayanan, Karthikeyan/0000-0001-5136-2296; GEORGE, ANNE/0000-0002-9008-7642	NIDCR NIH HHS [DE11657] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R56DE011657] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Banine F, 1998, BBA-GENE STRUCT EXPR, V1398, P1, DOI 10.1016/S0167-4781(98)00042-6; Bleicher F, 1999, MATRIX BIOL, V18, P133, DOI 10.1016/S0945-053X(99)00007-4; Butler WT, 1998, EUR J ORAL SCI, V106, P204, DOI 10.1111/j.1600-0722.1998.tb02177.x; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; DSouza RN, 1997, J BONE MINER RES, V12, P2040, DOI 10.1359/jbmr.1997.12.12.2040; FRUSCIO MD, 1998, BIOCHIM BIOPHYS ACTA, V398, P9; George A, 1999, CONNECT TISSUE RES, V40, P49, DOI 10.3109/03008209909005277; GEORGE A, 1994, J HISTOCHEM CYTOCHEM, V42, P1527, DOI 10.1177/42.12.7983353; GEORGE A, 1993, J BIOL CHEM, V268, P12624; Hirst KL, 1997, GENOMICS, V42, P38, DOI 10.1006/geno.1997.4700; KULKARNI GV, 1999, IN PRESS P 6 INT C C; KULKARNI GV, 1999, IN PRESS ARCH ORAL B; Li YP, 1999, J BONE MINER RES, V14, P487, DOI 10.1359/jbmr.1999.14.4.487; Linde Anders, 1993, Critical Reviews in Oral Biology and Medicine, V4, P679; MacDougall M, 1998, J BONE MINER RES, V13, P422, DOI 10.1359/jbmr.1998.13.3.422; Peters H, 1999, TRENDS GENET, V15, P59, DOI 10.1016/S0168-9525(98)01662-X; RAFIDI K, 1994, GENE, V140, P163, DOI 10.1016/0378-1119(94)90540-1; Sambrook J., 2002, MOL CLONING LAB MANU; Thesleff I, 1996, CURR OPIN CELL BIOL, V8, P844, DOI 10.1016/S0955-0674(96)80086-X; Toyosawa S, 1999, GENE, V234, P307, DOI 10.1016/S0378-1119(99)00195-X; Toyosawa S, 1999, J MOL EVOL, V48, P160, DOI 10.1007/PL00006454; Veis A, 1985, CHEM BIOL MINERALIZE, P170	22	21	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10272	10277		10.1074/jbc.275.14.10272	http://dx.doi.org/10.1074/jbc.275.14.10272			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744713	hybrid			2022-12-27	WOS:000086345600054
J	Weernink, PAO; Schulte, P; Guo, YJ; Wetzel, J; Amano, M; Kaibuchi, K; Haverland, S; Voss, M; Schmidt, M; Mayr, GW; Jakobs, KH				Weernink, PAO; Schulte, P; Guo, YJ; Wetzel, J; Amano, M; Kaibuchi, K; Haverland, S; Voss, M; Schmidt, M; Mayr, GW; Jakobs, KH			Stimulation of phosphatidylinositol-4-phosphate 5-kinase by Rho-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-RHO; DIFFICILE TOXIN-B; SMALL GTPASE RHO; SERINE-THREONINE KINASE; 4-PHOSPHATE 5-KINASE; PHOSPHOLIPASE-D; PHOSPHOINOSITIDE KINASES; TYROSINE-PHOSPHORYLATION; SERINE/THREONINE KINASE; SIGNAL-TRANSDUCTION	The serine/threonine kinase Rho-kinase was recently identified as a downstream effector of the small GTPase Rho, mediating effects of Rho on the actin cytoskeleton. Also phosphatidylinositol 4,5-bisphosphate (PI(4,5)P-2) has been implicated in the regulation of actin polymerization. As the synthesis of PI(4,5)P-2 has been suggested to be affected by Rho proteins, me investigated whether Rho-kinase is involved in the control of PI(4,5)P-2 levels. Overexpression of RhoA in HEK-293 cells increased phosphatidylinositol 4-phosphate (PI4P) 5-kinase activity and concomitantly enhanced cellular PI(4,5)P-2 levels, whereas overexpression of the Rho-inactivating C3 transferase decreased both PI4P B-kinase activity and PI(4,5)P-2 levels. These effects of RhoA could be mimicked by overexpression of wild-type Rho-kinase and of the constitutively active catalytic domain of Rho-kinase, Rho-kinase-CAT. In contrast, a kinase-deficient mutant of Rho-kinase had no effect on PI4P 5-kinase activity. Importantly, the increase in PI4P 5-kinase activity and PI(4,5)P-2 levels by wild-type Rho-kinase, but not by Rho-kinase CAT, was completely prevented by coexpression of C3 transferase, indicating that the effect of Rho-kinase was under the control of endogenous Rho. In cell lysates, addition of recombinant RhoA and Rho-kinase-CAT stimulated PI4P B-kinase activity. Finally, the increase in PI(4,5)P-2 levels induced by both Rho-kinase-CAT and RhoA was reversed by the Rho-kinase inhibitor HA-1077. Our data suggest that Rho-kinase is involved in the Rho-controlled synthesis of PI(4,5)P-2 by PI4P S-kinase.	Univ Essen Gesamthsch Klinikum, Inst Pharmakol, D-45122 Essen, Germany; Nara Inst Sci & Technol, Div Signal Transduct, Nara 6300101, Japan; Univ Hamburg, Krankenhaus Eppendorf, Inst Med Biochem & Mol Biol, D-20246 Hamburg, Germany	University of Duisburg Essen; Nara Institute of Science & Technology; University of Hamburg	Weernink, PAO (corresponding author), Univ Essen Gesamthsch Klinikum, Inst Pharmakol, Hufelandstr 55, D-45122 Essen, Germany.		Amano, Mutsuki/M-4820-2014	Amano, Mutsuki/0000-0002-0662-1524				Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Asano T, 1998, CARDIOVASC DRUG REV, V16, P76, DOI 10.1111/j.1527-3466.1998.tb00346.x; CHILVERS ER, 1991, BIOCHEM J, V275, P373, DOI 10.1042/bj2750373; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COCHET C, 1991, J BIOL CHEM, V266, P637; Di Cunto F, 1998, J BIOL CHEM, V273, P29706, DOI 10.1074/jbc.273.45.29706; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; Fensome A, 1996, CURR BIOL, V6, P730, DOI 10.1016/S0960-9822(09)00454-0; Gehrmann T, 1999, BBA-MOL CELL BIOL L, V1437, P341, DOI 10.1016/S1388-1981(99)00029-3; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Hsuan JJ, 1998, ADV CANCER RES, V74, P167, DOI 10.1016/S0065-230X(08)60767-8; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; KAUFFMANNZEH A, 1995, SCIENCE, V268, P1188, DOI 10.1126/science.7761838; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; Loijens JC, 1996, ADV ENZYME REGUL, V36, P115, DOI 10.1016/0065-2571(95)00005-4; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Martin A, 1996, J BIOL CHEM, V271, P17397, DOI 10.1074/jbc.271.29.17397; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MAYR GW, 1990, METHODS INOSITIDE RE, P83; MORITZ A, 1992, J BIOL CHEM, V267, P7207; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Randazzo PA, 1997, J BIOL CHEM, V272, P7688; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; Rumenapp U, 1998, BIOCHEM J, V334, P625; Schmidt M, 1996, EUR J BIOCHEM, V240, P707, DOI 10.1111/j.1432-1033.1996.0707h.x; Schmidt M, 1996, N-S ARCH PHARMACOL, V354, P87, DOI 10.1007/BF00178707; SCHMIDT M, 1994, EUR J BIOCHEM, V225, P667, DOI 10.1111/j.1432-1033.1994.00667.x; Schmidt M, 1999, J BIOL CHEM, V274, P14648, DOI 10.1074/jbc.274.21.14648; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; STEPHENS L, 1993, BIOCHEM J, V296, P481, DOI 10.1042/bj2960481; Tolias KF, 1998, J BIOL CHEM, V273, P18040, DOI 10.1074/jbc.273.29.18040; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Tominaga T, 1998, EMBO J, V17, P4712, DOI 10.1093/emboj/17.16.4712; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105; ZHANG X, 1997, J BIOL CHEM, V272, P17759	56	85	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10168	10174		10.1074/jbc.275.14.10168	http://dx.doi.org/10.1074/jbc.275.14.10168			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744700	hybrid			2022-12-27	WOS:000086345600041
J	Avilan, L; Lebreton, S; Gontero, B				Avilan, L; Lebreton, S; Gontero, B			Thioredoxin activation of phosphoribulokinase in a bi-enzyme complex from Chlamydomonas reinhardtii chloroplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALVIN CYCLE ENZYMES; MULTIENZYME COMPLEXES; INFORMATION-TRANSFER; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; SPINACH-CHLOROPLASTS; CARBOXYLASE-OXYGENASE; FUNCTIONAL-PROPERTIES; REACTION-RATES; CO2 FIXATION; MODULATION	The activation of oxidized phosphoribulokinase either "free" or as part of a bi-enzyme complex by reduced thioredoxins during the enzyme reaction was studied. In the presence of reduced thioredoxin, the product of the reaction catalyzed by phosphoribulokinase within the bi-enzyme complex does not appear in a linear fashion. It follows a mono-exponential pattern that suggests a slow dissociation process of the bi-enzyme complex in the assay cuvette, A plot of the steady state of product appearance against thioredoxin concentration gave a sigmoid curve. On the basis of our experimental results, we propose a minimum model of the activation of phosphoribulokinase by reduced thioredoxin. Reduced thioredoxin may act on the phosphoribulokinase, either within the complex or in the dissociated metastable form, However, the time required to activate the enzyme as part of the complex is shorter (about 20 s) than that required to activate the dissociated form (about 10 min). This might be of physiological relevance, and we discuss the role of the interactions between phosphoribulokinase and glyceraldehyde-3-phosphate dehydrogenase in the regulation of the Calvin cycle.	Univ Paris 06, CNRS, UMR 7592, Inst Jacques Monod, F-75251 Paris 05, France; Univ Paris 07, CNRS, UMR 7592, Inst Jacques Monod, F-75251 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Gontero, B (corresponding author), Univ Paris 06, CNRS, UMR 7592, Inst Jacques Monod, 2 Pl Jussieu, F-75251 Paris 05, France.			lebreton, Sandrine/0000-0003-4772-9467; Avilan, Luisana/0000-0002-4774-8564				ANDERSON LE, 1995, PLANTA, V196, P245; Avilan L, 1997, EUR J BIOCHEM, V246, P78, DOI 10.1111/j.1432-1033.1997.00078.x; Avilan L, 1997, EUR J BIOCHEM, V250, P296, DOI 10.1111/j.1432-1033.1997.0296a.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandes HK, 1996, J BIOL CHEM, V271, P3333; BRANDES HK, 1993, J BIOL CHEM, V268, P18411; Buchanan Bob B., 1994, Seminars in Cell Biology, V5, P285, DOI 10.1006/scel.1994.1035; CHA S, 1968, J BIOL CHEM, V243, P820; CLARKE FM, 1974, BIOCHIM BIOPHYS ACTA, V1209, P101; CLASPER S, 1991, EUR J BIOCHEM, V202, P1239, DOI 10.1111/j.1432-1033.1991.tb16496.x; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; FARR TJ, 1994, PLANT PHYSIOL, V105, P1037, DOI 10.1104/pp.105.4.1037; GARDEMANN A, 1983, BIOCHIM BIOPHYS ACTA, V722, P51, DOI 10.1016/0005-2728(83)90156-1; GARDEMANN A, 1982, FEBS LETT, V137, P213, DOI 10.1016/0014-5793(82)80352-9; GONTERO B, 1993, EUR J BIOCHEM, V217, P1075, DOI 10.1111/j.1432-1033.1993.tb18339.x; GONTERO B, 1988, EUR J BIOCHEM, V173, P437, DOI 10.1111/j.1432-1033.1988.tb14018.x; GONTERO B, 1994, EUR J BIOCHEM, V226, P999, DOI 10.1111/j.1432-1033.1994.00999.x; GOODSELL DS, 1991, TRENDS BIOCHEM SCI, V16, P203, DOI 10.1016/0968-0004(91)90083-8; Harris EH, 1989, CHLAMYDOMONAS SOURCE, P25, DOI [DOI 10.1016/B978-0-12-326880-8.50007-9, DOI 10.1126/SCIENCE.246.4936.1503-A]; HENSLEY P, 1988, CURR TOP CELL REGUL, V29, P35; HOSUR MV, 1993, J MOL BIOL, V234, P1274, DOI 10.1006/jmbi.1993.1681; HUPPE HC, 1990, PLANTA, V180, P341, DOI 10.1007/BF01160389; Jacquot JP, 1997, NEW PHYTOL, V136, P543, DOI 10.1046/j.1469-8137.1997.00784.x; Jebanathirajah JA, 1998, PLANTA, V204, P177, DOI 10.1007/s004250050244; LAING WA, 1981, BIOCHIM BIOPHYS ACTA, V637, P348, DOI 10.1016/0005-2728(81)90174-2; Lebreton S, 1997, EUR J BIOCHEM, V246, P85, DOI 10.1111/j.1432-1033.1997.t01-2-00085.x; Lebreton S, 1997, EUR J BIOCHEM, V250, P286, DOI 10.1111/j.1432-1033.1997.0286a.x; Lebreton S, 1999, J BIOL CHEM, V274, P20879, DOI 10.1074/jbc.274.30.20879; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MILANEZ S, 1991, J BIOL CHEM, V266, P10694; MULLER B, 1972, Z NATURFORSCH PT B, VB 27, P925, DOI 10.1515/znb-1972-0814; NELDER JA, 1965, COMPUT J, V7, P308, DOI 10.1093/comjnl/7.4.308; OVADI J, 1978, EUR J BIOCHEM, V85, P157, DOI 10.1111/j.1432-1033.1978.tb12223.x; OVADI J, 1986, BIOCHEM BIOPH RES CO, V135, P852, DOI 10.1016/0006-291X(86)91006-5; PORTER MA, 1988, J BIOL CHEM, V263, P123; PRATGAY G, 1991, J BIOL CHEM, V266, P20913; RAULT M, 1991, EUR J BIOCHEM, V197, P791, DOI 10.1111/j.1432-1033.1991.tb15973.x; RAULT M, 1993, EUR J BIOCHEM, V217, P1065, DOI 10.1111/j.1432-1033.1993.tb18338.x; RICARD J, 1994, EUR J BIOCHEM, V226, P993, DOI 10.1111/j.1432-1033.1994.00993.x; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; SUSS KH, 1995, PLANT PHYSIOL, V107, P1387, DOI 10.1104/pp.107.4.1387; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; Wedel N, 1998, P NATL ACAD SCI USA, V95, P9699, DOI 10.1073/pnas.95.16.9699; WIRTZ W, 1982, FEBS LETT, V142, P223, DOI 10.1016/0014-5793(82)80139-7; WOLOSIUK RA, 1978, ARCH BIOCHEM BIOPHYS, V189, P97, DOI 10.1016/0003-9861(78)90119-4; WOLOSIUK RA, 1985, FEBS LETT, V189, P212, DOI 10.1016/0014-5793(85)81025-5	46	27	28	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9447	9451		10.1074/jbc.275.13.9447	http://dx.doi.org/10.1074/jbc.275.13.9447			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734091	hybrid			2022-12-27	WOS:000086206500055
J	Lai, CC; Henningson, C; DiMaio, D				Lai, CC; Henningson, C; DiMaio, D			Bovine papillomavirus E5 protein induces the formation of signal transduction complexes containing dimeric activated platelet-derived growth factor beta receptor and associated signaling proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE DOMAIN; PHOSPHOLIPASE C-GAMMA; TRANSFORMING PROTEIN; PDGF RECEPTOR; PHOSPHATIDYLINOSITOL-3 KINASE; CELLULAR-TRANSFORMATION; INDUCED DIMERIZATION; MUTATIONAL ANALYSIS; PHOSPHORYLATION; TRANSMEMBRANE	The bovine papillomavirus E5 protein binds to the cellular platelet-derived growth factor (PDGF) beta receptor, resulting in constitutive activation of the receptor and cell growth transformation. By subjecting extracts from EB-transformed or PDGF-treated cells to velocity sedimentation in sucrose gradients, activated PDGF beta receptor complexes were separated from monomeric, inactive receptor. Rapidly sedimenting activated complexes contained oligomeric (apparently dimeric), tyrosine-phosphorylated PDGF beta receptor, the E5 protein, and associated cellular signaling proteins including the p85 subunit of phosphoinositol S'-kinase, phospholipase C gamma, and Ras-GTPase activating protein. These signaling proteins made the major contribution to the increased sedimentation rate of the activated receptor complexes. Pairwise analysis of components of these complexes indicated that multiple signaling proteins and the E5 protein were simultaneously present in the activated complexes. Our results also showed that the E5 protein and PDGF activated only a small fraction of the total PDGF beta receptor, that not all receptor molecules associated with the E5 protein were tyrosine-phosphorylated, and that signaling proteins could bind to hemiphosphorylated receptor dimers, On the basis of these results, we propose a model for the assembly of multiprotein, activated PDGF beta receptor complexes in response to the E5 protein.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA	Yale University	DiMaio, D (corresponding author), Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA.				NATIONAL CANCER INSTITUTE [R37CA037157] Funding Source: NIH RePORTER; NCI NIH HHS [R37-CA37157] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; COHEN BD, 1993, J VIROL, V67, P5303, DOI 10.1128/JVI.67.9.5303-5311.1993; DeMali KA, 1997, J BIOL CHEM, V272, P9011; DeMali KA, 1998, MOL CELL BIOL, V18, P2014, DOI 10.1128/MCB.18.4.2014; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; ESCOBEDO JA, 1988, MOL CELL BIOL, V8, P5126, DOI 10.1128/MCB.8.12.5126; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GOLDSTEIN DJ, 1994, J VIROL, V68, P4432, DOI 10.1128/JVI.68.7.4432-4441.1994; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; HERBST R, 1995, BIOCHEMISTRY-US, V34, P5971, DOI 10.1021/bi00017a026; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Juang SH, 1996, ONCOGENE, V12, P1033; Kanagasundaram V, 1999, MOL CELL BIOL, V19, P4079; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KELLY JD, 1991, J BIOL CHEM, V266, P8987; Klein O, 1998, J VIROL, V72, P8921, DOI 10.1128/JVI.72.11.8921-8932.1998; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Lai CC, 1998, P NATL ACAD SCI USA, V95, P15241, DOI 10.1073/pnas.95.26.15241; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; NILSON LA, 1995, J VIROL, V69, P5869, DOI 10.1128/JVI.69.9.5869-5874.1995; NILSON LA, 1993, MOL CELL BIOL, V13, P4137, DOI 10.1128/MCB.13.7.4137; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; Petti LM, 1997, J VIROL, V71, P7318, DOI 10.1128/JVI.71.10.7318-7327.1997; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; STAEBLER A, 1995, J VIROL, V69, P6507, DOI 10.1128/JVI.69.10.6507-6517.1995; Surti T, 1998, PROTEINS, V33, P601; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Yeung YG, 1998, J BIOL CHEM, V273, P17128, DOI 10.1074/jbc.273.27.17128	40	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9832	9840		10.1074/jbc.275.13.9832	http://dx.doi.org/10.1074/jbc.275.13.9832			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734138	hybrid			2022-12-27	WOS:000086206500102
J	Lee, CI; Liu, XP; Zweier, JL				Lee, CI; Liu, XP; Zweier, JL			Regulation of xanthine oxidase by nitric oxide and peroxynitrite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE-RADICAL GENERATION; AMYOTROPHIC-LATERAL-SCLEROSIS; TYROSINE NITRATION; REPERFUSION INJURY; POSTISCHEMIC HEART; NADPH OXIDASE; SUPEROXIDE; MECHANISM; INACTIVATION; OXIDATION	Xanthine oxidase CXO) is a central mechanism of oxidative injury as occurs following ischemia. During the early period of reperfusion, both nitric oxide (NO.) and superoxide (Oa generation are increased leading to the formation of peroxynitrite (ONOO-); however, questions remain regarding the presence and nature of the interactions of NO. or ONOO- with XO and the role of this process in regulating oxidant generation. Therefore, we determined the dose-dependent effects of NO' and ONOO- on the O-2(-.) generation and enzyme activity of XO, respectively, by EPR spin trapping of O-2(-.) using 5-(diethoxyphosphoryl)-5-methyl-1-pyrroline-N and spectrophotometric assay, ONOO- markedly inhibited both O-2(-.) generation and XO activity in dose-dependent manner, while NO. from NO. gas in concentrations up to 200 mu M had no effect. Furthermore, we observed that NO' donors such as NOR-1 also inhibited O-2(-.) generation and XO activity; however, these effects were O-2(-.) dependent and blocked by superoxide dismutase or ONOO- scavengers. Finally, we found that ONOO- totally abolished the Mo(V) EPR spectrum. These changes were irreversible, suggesting oxidative disruption of the critical mo lybdenum center of the catalytic site. Thus, ONOO- formed in biological systems can feedback and downregulate XO activity and O-2(-.) generation, which in turn may serve to limit further ONOO- formation.	Johns Hopkins Med Inst, Mol & Cellular Biophys Labs, Dept Med, Div Cardiol, Baltimore, MD 21224 USA; Johns Hopkins Med Inst, Electron Paramagnet Resonance Ctr, Baltimore, MD 21224 USA; Kanagawa Dent Coll, Dept Pharmacol, Yokosuka, Kanagawa 2380003, Japan; Kanagawa Dent Coll, Electron Spin Resonance Ctr, Yokosuka, Kanagawa 2380003, Japan	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Kanagawa Dental College; Kanagawa Dental College	Zweier, JL (corresponding author), Johns Hopkins Asthma & Allergy Ctr, EPR Ctr, 5501 Johns Hopkins Bayview Circle, Baltimore, MD 21224 USA.		Liu, Xiaoping/A-4516-2008		NHLBI NIH HHS [HL-52315, HL-38324] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038324, P50HL052315, R29HL038324] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDELFATTAH AS, 1988, CIRCULATION, V78, P224; Abe K, 1997, NEUROL RES, V19, P124; ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BRAY RC, 1964, J BIOL CHEM, V239, P2667; Bray RC, 1997, BIOCHEM SOC T, V25, P762, DOI 10.1042/bst0250762; BRAY RC, 1961, BIOCHEM J, V81, P189, DOI 10.1042/bj0810189; Bruijn LI, 1997, P NATL ACAD SCI USA, V94, P7606, DOI 10.1073/pnas.94.14.7606; CLANCY RM, 1992, J CLIN INVEST, V90, P1116, DOI 10.1172/JCI115929; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Cote CG, 1996, AM J PHYSIOL-LUNG C, V271, pL869, DOI 10.1152/ajplung.1996.271.5.L869; Fujii H, 1997, J BIOL CHEM, V272, P32773, DOI 10.1074/jbc.272.52.32773; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; Gutierrez JA, 1997, J PHARMACOL EXP THER, V282, P1643; HASSOUN PM, 1995, AM J PHYSIOL-LUNG C, V268, pL809, DOI 10.1152/ajplung.1995.268.5.L809; HILLE R, 1995, FASEB J, V9, P995, DOI 10.1096/fasebj.9.11.7649415; Hooper DC, 1997, P NATL ACAD SCI USA, V94, P2528, DOI 10.1073/pnas.94.6.2528; Houston M, 1998, ARCH BIOCHEM BIOPHYS, V355, P1, DOI 10.1006/abbi.1998.0675; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Ichimori K, 1999, J BIOL CHEM, V274, P7763, DOI 10.1074/jbc.274.12.7763; IGNARRO LJ, 1987, CIRC RES, V61, P866, DOI 10.1161/01.RES.61.6.866; JENNINGS RB, 1985, ANNU REV PHYSIOL, V47, P727, DOI 10.1146/annurev.ph.47.030185.003455; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Kooy NW, 1997, CRIT CARE MED, V25, P812, DOI 10.1097/00003246-199705000-00017; Liu XP, 1998, J BIOL CHEM, V273, P18709, DOI 10.1074/jbc.273.30.18709; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; MALTHOUSE JPG, 1981, BIOCHEM J, V197, P421, DOI 10.1042/bj1970421; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORENO JJ, 1992, CHEM RES TOXICOL, V5, P425, DOI 10.1021/tx00027a017; Moriel P, 1997, BIOCHEM BIOPH RES CO, V232, P332, DOI 10.1006/bbrc.1997.6287; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; RADI R, 1991, J BIOL CHEM, V266, P4244; Roubaud V, 1997, ANAL BIOCHEM, V247, P404, DOI 10.1006/abio.1997.2067; SALGO MG, 1995, ARCH BIOCHEM BIOPHYS, V322, P500, DOI 10.1006/abbi.1995.1493; Smith MA, 1997, J NEUROSCI, V17, P2653; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; SZABO C, 1995, FEBS LETT, V372, P229, DOI 10.1016/0014-5793(95)00984-H; TARPEY MM, 1995, FEBS LETT, V364, P314, DOI 10.1016/0014-5793(95)00413-4; Wang PH, 1996, J BIOL CHEM, V271, P29223, DOI 10.1074/jbc.271.46.29223; XIA Y, 1995, J BIOL CHEM, V270, P18797, DOI 10.1074/jbc.270.32.18797; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804; ZWEIER JL, 1988, J BIOL CHEM, V263, P1353; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046; ZWEIER JL, 1995, J BIOL CHEM, V270, P304, DOI 10.1074/jbc.270.1.304	48	112	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9369	9376		10.1074/jbc.275.13.9369	http://dx.doi.org/10.1074/jbc.275.13.9369			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734080	hybrid			2022-12-27	WOS:000086206500044
J	Brinkman-Van der Linden, ECM; Varki, A				Brinkman-Van der Linden, ECM; Varki, A			New aspects of siglec binding specificities, including the significance of fucosylation and of the sialyl-Tn epitope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							MYELIN-ASSOCIATED GLYCOPROTEIN; POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; ALPHA-D-GALACTOSAMINE; I-TYPE LECTINS; OVINE SUBMAXILLARY MUCIN; GAL-BETA-1,3GALNAC-SPECIFIC GALNAC ALPHA-2,6-SIALYLTRANSFERASE; ADHESION MOLECULE CD22-BETA; O-LINKED GLYCOPROTEINS; BOVINE UDP-GALNAC; CELL-ADHESION	The siglecs (Sialic acid-binding immunoglobulin superfamily lectins) are immunoglobulin superfamily members recognizing sialylated ligands, Most prior studies of siglec specificities focused on alpha 2-3- and alpha 2-6-sialyllactos(amin)es and on one or two of the siglecs at a time. Here, we explore several new aspects of specificities of the first six reported siglecs, using sialylated glycans presented in multivalent form, on synthetic polyacrylamide backbones, or on mucin polypeptides. First, me report that binding of siglec-1 (sialoadhesin), siglec-3 (CD33), siglec-4a (myelin-associated glycoprotein), and siglec-5 to alpha 2-3 sialyllactosamine is affected markedly by the presence of an alpha 1-3-linked fucose. Thus, while siglecs may not interfere with selectin-mediated recognition, fucosylation could negatively regulate siglec binding. Second, in contrast to earlier studies, we find that siglec-3 prefers alpha 2-6-sialyllactose, Third, siglec-5 binds alpha 2-8-linked sialic acid, making it the siglec least specific for linkage recognition. Fourth, siglecs-2 (CD22), -3, -5, and -6 (obesity-binding protein 1) showed significant binding to sialyl-Tn (Neu5Ac alpha 2-6-GalNAc), a tumor marker associated with poor prognosis. Fifth, siglec-6 is an exception among siglecs in not requiring the glycerol side chain of sialic acid for recognition. Sixth, all siglecs require the carboxyl group of sialic acid for binding, Finally, the presentation of the sialyl-Tn epitope and/or more extended structures that include this motif may be important for optimal recognition by the siglecs, This was concluded from studies using ovine, bovine, and porcine submaxillary mucins and Chinese hamster ovary cells transfected with ST6GalNAc-I and/or the mucin polypeptide MUC1.	Univ Calif San Diego, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Varki, A (corresponding author), Univ Calif San Diego, Glycobiol Res & Training Ctr, CMM E, La Jolla, CA 92093 USA.	avarki@ucsd.edu			NHLBI NIH HHS [P01 HL57345] Funding Source: Medline; NIGMS NIH HHS [R01GM3273] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Barnes YC, 1999, BLOOD, V93, P1245, DOI 10.1182/blood.V93.4.1245.404k09_1245_1252; Bartsch S, 1997, BRAIN RES, V762, P231, DOI 10.1016/S0006-8993(97)00484-8; Bauer PH, 1999, J VIROL, V73, P5826, DOI 10.1128/JVI.73.7.5826-5832.1999; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; Bennett EP, 1998, J BIOL CHEM, V273, P30472, DOI 10.1074/jbc.273.46.30472; Bennett EP, 1999, J BIOL CHEM, V274, P25362, DOI 10.1074/jbc.274.36.25362; Bovin NV, 1998, GLYCOCONJUGATE J, V15, P431, DOI 10.1023/A:1006963717646; BRAESCHANDERSEN S, 1994, J BIOL CHEM, V269, P11783; Brinkman-Van der Linden ECM, 2000, J BIOL CHEM, V275, P8633, DOI 10.1074/jbc.275.12.8633; Brockhausen I, 1998, GLYCOCONJUGATE J, V15, P595, DOI 10.1023/A:1006967910803; Brockhausen I, 1998, ACTA ANAT, V161, P36; COCKS BG, 1995, NATURE, V376, P260, DOI 10.1038/376260a0; Collins BE, 1997, J BIOL CHEM, V272, P16889, DOI 10.1074/jbc.272.27.16889; Collins BE, 1997, J BIOL CHEM, V272, P1248, DOI 10.1074/jbc.272.2.1248; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; Crocker P R, 1998, Glycobiology, V8, pv; Crocker PR, 1996, BIOCHEM SOC T, V24, P150, DOI 10.1042/bst0240150; CROCKER PR, 1991, EMBO J, V10, P1661, DOI 10.1002/j.1460-2075.1991.tb07689.x; CROCKER PR, 1990, BLOOD, V76, P1131; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; DIAZ S, 1989, J BIOL CHEM, V264, P19416; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Falco M, 1999, J EXP MED, V190, P793, DOI 10.1084/jem.190.6.793; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; FRUTTIGER M, 1995, EUR J NEUROSCI, V7, P511, DOI 10.1111/j.1460-9568.1995.tb00347.x; GERKEN TA, 1989, BIOCHEMISTRY-US, V28, P5536, DOI 10.1021/bi00439a030; Hagen FK, 1997, J BIOL CHEM, V272, P13843, DOI 10.1074/jbc.272.21.13843; HAGEN FK, 1993, J BIOL CHEM, V268, P18960; HAISCH FG, 1999, J BIOL CHEM, V274, P9946; HANASAKI K, 1995, J BIOL CHEM, V270, P7533, DOI 10.1074/jbc.270.13.7533; Hennet T, 1998, P NATL ACAD SCI USA, V95, P4504, DOI 10.1073/pnas.95.8.4504; HILL HD, 1977, J BIOL CHEM, V252, P3791; HOMA FL, 1993, J BIOL CHEM, V268, P12609; ITZKOWITZ SH, 1990, CANCER-AM CANCER SOC, V66, P1960, DOI 10.1002/1097-0142(19901101)66:9<1960::AID-CNCR2820660919>3.0.CO;2-X; JASS JR, 1995, J PATHOL, V176, P143, DOI 10.1002/path.1711760207; JURCIC JG, 1995, CANCER RES, V55, pS5908; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kelm S, 1998, EUR J BIOCHEM, V255, P663, DOI 10.1046/j.1432-1327.1998.2550663.x; KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; Kelm S, 1997, INT REV CYTOL, V175, P137, DOI 10.1016/S0074-7696(08)62127-0; KOBAYASHI H, 1992, J CLIN ONCOL, V10, P95, DOI 10.1200/JCO.1992.10.1.95; KRISTENSEN JS, 1991, LEUKEMIA RES, V15, P693, DOI 10.1016/0145-2126(91)90071-Z; KUROSAWA N, 1994, J BIOL CHEM, V269, P19048; Kurosawa N, 1996, J BIOL CHEM, V271, P15109, DOI 10.1074/jbc.271.25.15109; KUROSAWA N, 1994, EUR J BIOCHEM, V219, P375, DOI 10.1111/j.1432-1033.1994.tb19949.x; LAW CL, 1994, IMMUNOL TODAY, V15, P442, DOI 10.1016/0167-5699(94)90275-5; Lee YC, 1999, J BIOL CHEM, V274, P11958, DOI 10.1074/jbc.274.17.11958; Leppanen A, 1999, J BIOL CHEM, V274, P24838, DOI 10.1074/jbc.274.35.24838; LLOYD KO, 1991, GLYCOCONJUGATE J, V8, P493, DOI 10.1007/BF00769849; LUNDJOHANSEN F, 1993, J LEUKOCYTE BIOL, V54, P47, DOI 10.1002/jlb.54.1.47; MANZI AE, 1990, J BIOL CHEM, V265, P13091; MUCHMORE EA, 1987, FASEB J, V1, P229, DOI 10.1096/fasebj.1.3.3623000; MUROI K, 1994, BLOOD, V83, P84; MURRAY MC, 1989, CARBOHYD RES, V186, P255, DOI 10.1016/0008-6215(89)84039-X; Nakase K, 1996, AM J CLIN PATHOL, V105, P761; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; OGATA S, 1995, CANCER RES, V55, P1869; Ogawa H, 1996, GYNECOL OBSTET INVES, V41, P278, DOI 10.1159/000292284; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Orntoft TF, 1999, ELECTROPHORESIS, V20, P362, DOI 10.1002/(SICI)1522-2683(19990201)20:2<362::AID-ELPS362>3.3.CO;2-M; Otipoby KL, 1996, NATURE, V384, P634, DOI 10.1038/384634a0; Patel N, 1999, J BIOL CHEM, V274, P22729, DOI 10.1074/jbc.274.32.22729; PIERELLI L, 1993, BRIT J HAEMATOL, V84, P24, DOI 10.1111/j.1365-2141.1993.tb03021.x; PODOLSKY DK, 1985, J BIOL CHEM, V260, P8262; POWELL LD, 1993, J BIOL CHEM, V268, P7019; POWELL LD, 1995, J BIOL CHEM, V270, P7523, DOI 10.1074/jbc.270.13.7523; POWELL LD, 1994, J BIOL CHEM, V269, P10628; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; Razi N, 1998, P NATL ACAD SCI USA, V95, P7469, DOI 10.1073/pnas.95.13.7469; Razi N, 1999, GLYCOBIOLOGY, V9, P1225, DOI 10.1093/glycob/9.11.1225; REUTER G, 1989, GLYCOCONJUGATE J, V6, P35, DOI 10.1007/BF01047888; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; SAVAGE AV, 1990, EUR J BIOCHEM, V192, P427, DOI 10.1111/j.1432-1033.1990.tb19244.x; Sawada N, 1999, CARBOHYD RES, V316, P1, DOI 10.1016/S0008-6215(99)00081-6; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Schauer R, 1982, SIALIC ACIDS CHEM ME, V10; Schnaar RL, 1998, ANN NY ACAD SCI, V845, P92, DOI 10.1111/j.1749-6632.1998.tb09664.x; Sgroi D, 1996, J BIOL CHEM, V271, P18803, DOI 10.1074/jbc.271.31.18803; SGROI D, 1993, J BIOL CHEM, V268, P7011; SGROI D, 1995, P NATL ACAD SCI USA, V92, P4026, DOI 10.1073/pnas.92.9.4026; Shi WX, 1996, J BIOL CHEM, V271, P31526, DOI 10.1074/jbc.271.49.31526; SHOGREN R, 1989, BIOCHEMISTRY-US, V28, P5525, DOI 10.1021/bi00439a029; Sjoberg ER, 1996, J BIOL CHEM, V271, P7450, DOI 10.1074/jbc.271.13.7450; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; SORENSEN T, 1995, J BIOL CHEM, V270, P24166, DOI 10.1074/jbc.270.41.24166; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; Strenge K, 1998, EUR J BIOCHEM, V258, P677, DOI 10.1046/j.1432-1327.1998.2580677.x; Tanaka N, 1999, EUR J BIOCHEM, V263, P27, DOI 10.1046/j.1432-1327.1999.00401.x; Tedder TF, 1997, ANNU REV IMMUNOL, V15, P481, DOI 10.1146/annurev.immunol.15.1.481; Ten Hagen KG, 1999, J BIOL CHEM, V274, P27867; Tropak MB, 1997, J NEUROCHEM, V68, P1753; TSUJI T, 1986, CARBOHYD RES, V151, P391, DOI 10.1016/S0008-6215(00)90358-6; VANDENBERG TK, 1992, J EXP MED, V176, P647, DOI 10.1084/jem.176.3.647; VANHALBEEK H, 1981, EUR J BIOCHEM, V118, P487; VANLENTEN L, 1971, J BIOL CHEM, V246, P1889; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; Varki A, 1997, J CLIN INVEST, V99, P158, DOI 10.1172/JCI119142; Varki A, 1999, ESSENTIALS GLYCOBIOL, P195; Vely F, 1997, J IMMUNOL, V159, P2075; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; Yang LJS, 1996, P NATL ACAD SCI USA, V93, P814, DOI 10.1073/pnas.93.2.814; ZANNETTINO ACW, 1995, BLOOD, V85, P3466, DOI 10.1182/blood.V85.12.3466.bloodjournal85123466; Zara J, 1996, BIOCHEM BIOPH RES CO, V228, P38, DOI 10.1006/bbrc.1996.1613; ZHANG SL, 1995, CANCER RES, V55, P3364	106	121	128	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8625	8632		10.1074/jbc.275.12.8625	http://dx.doi.org/10.1074/jbc.275.12.8625			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722702	hybrid			2022-12-27	WOS:000086507700052
J	Chang, JY; Li, L; Bulychev, A				Chang, JY; Li, L; Bulychev, A			The underlying mechanism for the diversity of disulfide folding pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; ANTICOAGULANT PEPTIDE TAP; BPTI; INTERMEDIATE; MUTANT	The disulfide folding pathway of bovine pancreatic trypsin inhibitor (BPTI) is characterized by the predominance of folding intermediates with native-like structures. Our laboratory has recently analyzed the folding pathway(s) of four 3-disulfide-containing proteins, including hirudin, potato carboxypeptidase inhibitor, epidermal growth factor, and tick anticoagulant peptide. Their folding mechanism(s) differ from that of BPTI by 1) a higher degree of heterogeneity of 1 and S-disulfide intermediates and 2) the presence of 3-disulfide scrambled isomers as folding intermediates. To search for the underlying causes of these diversities, we conducted kinetic analyses of the reductive unfolding of these five proteins. The experiment of reductive unfolding was designed to evaluate the relative stability and interdependence of disulfide bonds in the native protein. It is demonstrated here that among these five proteins, there exists a striking correlation between the mechanism(s) of reductive unfolding and that of oxidative folding. Those proteins with their native disulfide bonds reduced in a collective and simultaneous manner exhibit both a high degree of heterogeneity of folding intermediates and the accumulation of scrambled isomers along the folding pathway. A sequential reduction of the native disulfide bonds is associated with the presence of predominant intermediates with native-like structures.	Univ Texas, Inst Mol Med, Res Ctr Prot Chem, Houston, TX 77030 USA	University of Texas System	Chang, JY (corresponding author), Univ Texas, Inst Mol Med, Res Ctr Prot Chem, 2121 W Holcombe Blvd, Houston, TX 77030 USA.							CHANG JY, 1995, J BIOL CHEM, V270, P9207, DOI 10.1074/jbc.270.16.9207; CHANG JY, 1994, J BIOL CHEM, V269, P22087; Chang JY, 1996, BIOCHEMISTRY-US, V35, P11702, DOI 10.1021/bi9606915; CHANG JY, 1995, J BIOL CHEM, V270, P25661; CHANG JY, 1994, BIOCHEM J, V300, P643, DOI 10.1042/bj3000643; CHATRENET B, 1993, J BIOL CHEM, V268, P20988; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; CREIGHTON TE, 1992, SCIENCE, V256, P111, DOI 10.1126/science.1373519; EIGENBROT C, 1990, PROTEIN ENG, V3, P591, DOI 10.1093/protein/3.7.591; GOLDENBERG DP, 1993, BIOCHEMISTRY-US, V32, P2835, DOI 10.1021/bi00062a015; GOLDENBERG DP, 1988, BIOCHEMISTRY-US, V27, P2481, DOI 10.1021/bi00407a034; GOLDENBERG DP, 1992, TRENDS BIOCHEM SCI, V17, P247; KASSELL B, 1965, BIOCHEM BIOPH RES CO, V20, P463, DOI 10.1016/0006-291X(65)90601-7; KRESS LF, 1967, J BIOL CHEM, V242, P4925; LIMWILBY MSL, 1995, PROTEIN SCI, V4, P178; Mendes P, 1997, TRENDS BIOCHEM SCI, V22, P361, DOI 10.1016/S0968-0004(97)01103-1; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; STANLEY JP, 1992, P NATL ACAD SCI USA, V89, P1519; VANMIERLO CPM, 1991, J MOL BIOL, V222, P373, DOI 10.1016/0022-2836(91)90217-T; WEISSMAN JS, 1992, SCIENCE, V256, P112, DOI 10.1126/science.256.5053.112; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WU J, 1998, PROTEIN SCI, V7	23	53	55	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8287	8289		10.1074/jbc.275.12.8287	http://dx.doi.org/10.1074/jbc.275.12.8287			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722657	hybrid			2022-12-27	WOS:000086507700007
J	Korimilli, A; Gonzales, LW; Guttentag, SH				Korimilli, A; Gonzales, LW; Guttentag, SH			Intracellular localization of processing events in human surfactant protein B biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-FETAL LUNG; FIBROBLAST GROWTH-FACTOR; IMMUNOCYTOCHEMICAL LOCALIZATION; GLUCOCORTICOID REGULATION; STRUCTURAL REQUIREMENTS; GOLGI-APPARATUS; FACTOR RECEPTOR; NK-LYSIN; CELLS; COMPARTMENT	Surfactant protein B (SP-B) is essential to the function of pulmonary surfactant and to alveolar type 2 cell phenotype, Human SP-B is the 79-amino acid product of extensive post-translational processing of a 381-amino acid preproprotein. Processing involves modification of the primary translation product from 39 to 42 kDa and at least 3 subsequent proteolytic cleavages to produce the mature 8-kDa SP-B. To examine the intracellular sites of SP-B processing, we carried out immunofluorescence cytochemistry and inhibitor studies on human fetal lung in explant culture and isolated type 2 cells in monolayer culture using polyclonal antibodies to human SP-B, (Phe(201)-Met(279)) and specific epitopes within the N- (NFProx, Ser(145)-Leu(160); NFlank Gln(186)-Gln(200)) and C-terminal (CFlank, Gly(284)-Ser(304)) propeptides of pro-SP-B. Fluorescence immunocytochemistry using epitope-specific antisera showed colocalization of pro-SP-B with the endoplasmic reticulum resident protein BiP. The 25-kDa intermediate was partially endo H-sensitive, colocalized with the medial Golgi resident protein MG160, and shifted into the endoplasmic reticulum in the presence of brefeldin A, which interferes with anterograde transport from endoplasmic reticulum to Gel. The 9-kDa intermediate colocalized in part with MG160 but not with Lamp-1, a transmembrane protein resident in late endosomes and lamellar bodies. Brefeldin A induced a loss of colocalization between MG160 and NFlank, shifting NFlank immunostaining to a juxtanuclear tubular array. In pulse-chase studies, brefeldin A blocked all processing of 42-kDa pro-SP-B whereas similar studies using monensin blocked the final N-terminal processing event of 9 to 8 kDa SP-B. We conclude that: 1) the first enzymatic cleavage of pro-SP-B to the 25-kDa intermediate is in the brefeldin A-sensitive, medial Golgis; 2) cleavage of the 25-kDa intermediate to a 9-kDa form is a trans-Golgi event that is slowed but not blocked by monensin; 3) the final cleavage of 9 to 8 kDa SP-B is a monensin-sensitive, post-Golgi event occurring prior to transfer of SP-B to lamellar bodies.	Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Neonatol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Guttentag, SH (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Neonatol, 416G Abramson Res Bldg,34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.		Guttentag, Susan/ABE-7405-2020; Guttentag, Susan H/D-8705-2013	Guttentag, Susan/0000-0003-4420-5879; Guttentag, Susan H/0000-0003-4420-5879	NHLBI NIH HHS [1 RO1 HL-59959, 1 P50 HL-56401] Funding Source: Medline; NICHD NIH HHS [5 P30 HD-28815] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028815] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059959, P50HL056401] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akinbi HT, 1997, J BIOL CHEM, V272, P9640; Alcorn JL, 1997, AM J RESP CELL MOL, V17, P672, DOI 10.1165/ajrcmb.17.6.2858; ANDERSSON M, 1995, FEBS LETT, V362, P328, DOI 10.1016/0014-5793(95)00268-E; BEERS M, 2000, IN PRESS AM J RESP C, V22; BEERS MF, 1992, AM J PHYSIOL, V262, pL773, DOI 10.1152/ajplung.1992.262.6.L773; Beers MF, 1996, J BIOL CHEM, V271, P14361, DOI 10.1074/jbc.271.24.14361; BEERS MF, 1995, PEDIATR RES, V38, P668, DOI 10.1203/00006450-199511000-00007; BEERS MF, 1994, J BIOL CHEM, V269, P20318; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; GONATAS JO, 1995, J CELL SCI, V108, P457; GONZALES LW, 1986, J CLIN ENDOCR METAB, V62, P678, DOI 10.1210/jcem-62-4-678; Gonzales LW, 1999, PEDIATR RES, V45, p52A; Guttentag SH, 1998, AM J PHYSIOL-LUNG C, V275, pL559, DOI 10.1152/ajplung.1998.275.3.L559; Guttentag Susan H., 1998, Pediatric Research, V43, p49A; HAWGOOD S, 1993, AM J PHYSIOL, V264, pL290, DOI 10.1152/ajplung.1993.264.3.L290; HOOK VYH, 1994, FASEB J, V8, P1269, DOI 10.1096/fasebj.8.15.8001739; Korimilli A, 1999, PEDIATR RES, V45, p55A, DOI 10.1203/00006450-199904020-00331; Koval M, 1997, J CELL BIOL, V137, P847, DOI 10.1083/jcb.137.4.847; Laitusis AL, 1999, J BIOL CHEM, V274, P486, DOI 10.1074/jbc.274.1.486; Leonova T, 1996, J BIOL CHEM, V271, P17312, DOI 10.1074/jbc.271.29.17312; Liepinsh E, 1997, NAT STRUCT BIOL, V4, P793, DOI 10.1038/nsb1097-793; Lin S, 1996, BBA-MOL CELL RES, V1312, P177, DOI 10.1016/0167-4889(95)00201-4; Lin S, 1996, J BIOL CHEM, V271, P19689, DOI 10.1074/jbc.271.33.19689; OREILLY MA, 1989, BIOCHIM BIOPHYS ACTA, V1011, P140, DOI 10.1016/0167-4889(89)90201-2; PATON BC, 1990, EUR J CELL BIOL, V51, P157; QUI Z, 1995, J GEN VIROL, V76, P855; RABOUILLE C, 1995, J CELL SCI, V108, P1617; Sia MA, 1999, DEV GENET, V24, P111, DOI 10.1002/(SICI)1520-6408(1999)24:1/2&lt;111::AID-DVG11&gt;3.0.CO;2-P; SLUSAREWICZ P, 1994, J CELL BIOL, V124, P405, DOI 10.1083/jcb.124.4.405; Solarin KO, 1997, PEDIATR RES, V42, P356, DOI 10.1203/00006450-199709000-00017; STIEBER A, 1995, EXP CELL RES, V219, P562, DOI 10.1006/excr.1995.1265; TAMARU T, 1986, HISTOCHEMISTRY, V86, P195, DOI 10.1007/BF00493387; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; ULATOWSKI LM, 1993, J BIOL CHEM, V268, P7482; VACCARO AM, 1995, J BIOL CHEM, V270, P9953, DOI 10.1074/jbc.270.17.9953; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; VOORHOUT WF, 1992, AM J PHYSIOL, V263, pL479, DOI 10.1152/ajplung.1992.263.4.L479; VORBROKER DK, 1992, BIOCHIM BIOPHYS ACTA, V1105, P161, DOI 10.1016/0005-2736(92)90175-L; VORBROKER DK, 1995, AM J PHYSIOL, V268, P647; WASANO K, 1994, HISTOCHEMISTRY, V102, P329, DOI 10.1007/BF00268903; WEAVER TE, 1992, AM J PHYSIOL, V263, pL95, DOI 10.1152/ajplung.1992.263.1.L95; WHITSETT JA, 1995, PHYSIOL REV, V75, P749, DOI 10.1152/physrev.1995.75.4.749; WHITSETT JA, 1987, J BIOL CHEM, V262, P15618	43	57	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8672	8679		10.1074/jbc.275.12.8672	http://dx.doi.org/10.1074/jbc.275.12.8672			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722708	hybrid			2022-12-27	WOS:000086507700058
J	Perry, DK; Carton, J; Shah, AK; Meredith, F; Uhlinger, DJ; Hannun, YA				Perry, DK; Carton, J; Shah, AK; Meredith, F; Uhlinger, DJ; Hannun, YA			Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGANINE N-ACYLTRANSFERASE; SPHINGOLIPID BIOSYNTHESIS; CELL-DEATH; SACCHAROMYCES-CEREVISIAE; CULTURED NEURONS; INHIBITION; BCL-2; SYNTHASE; DISTINCT; TARGET	The de novo pathway of sphingolipid synthesis has been identified recently as a novel means of generating ceramide during apoptosis, Furthermore, it has been suggested that the activation of dihydroceramide synthase is responsible for increased ceramide production through this pathway, In this study, accumulation of ceramide mass in Molt-4 human leukemia cells by the chemotherapy agent etoposide was found to occur primarily due to activation of the de novo pathway, However, when the cells were labeled with a substrate for dihydroceramide synthase in the presence of etoposide, there was no corresponding increase in labeled ceramide. Further investigation using a labeled substrate for serine palmitoyltransferase, the rate-limiting enzyme in the pathways, resulted in an accumulation of label in ceramide upon etoposide treatment. This result suggests that the activation of serine palmitoyltransferase is the event responsible for increased ceramide generation during de novo synthesis initiated by etoposide, importantly, the ceramide generated from de novo synthesis appears to have a distinct function from that induced by sphingomyelinase action in that it is not involved in caspase-induced poly (ADP-ribose)polymerase proteolysis but does play a role in disrupting membrane integrity in this model system. These results implicate serine palmitoyltransferase as the enzyme controlling de novo ceramide synthesis during apoptosis and begin to define a unique function of ceramide generated from this pathway.	Med Univ S Carolina, Dept Biochem & Mol & Biol, Charleston, SC 29425 USA; Richard B Russell Agr Res Stn, Athens, GA 30604 USA; RW Johnson Pharmaceut Res Inst, Raritan, NJ 08869 USA	Medical University of South Carolina; Johnson & Johnson; Johnson & Johnson USA	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol & Biol, 173 Ashley Ave, Charleston, SC 29425 USA.							Bielawska A, 2000, METHOD ENZYMOL, V311, P518; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; Cabot MC, 1998, FEBS LETT, V431, P185, DOI 10.1016/S0014-5793(98)00744-3; CHEN GL, 1984, J BIOL CHEM, V259, P3560; Chigorno V, 1997, J LIPID RES, V38, P1163; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; Farrell AM, 1998, J LIPID RES, V39, P2031; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; Garzotto M, 1999, CANCER RES, V59, P5194; Garzotto M, 1998, CANCER RES, V58, P2260; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kaufmann SH, 1998, BBA-GENE STRUCT EXPR, V1400, P195, DOI 10.1016/S0167-4781(98)00136-5; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; MANDON EC, 1991, EUR J BIOCHEM, V198, P667, DOI 10.1111/j.1432-1033.1991.tb16065.x; MANDON EC, 1992, J BIOL CHEM, V267, P11144; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; Mizushima N, 1996, FEBS LETT, V395, P267, DOI 10.1016/0014-5793(96)01050-2; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; PATTON JL, 1992, J BACTERIOL, V174, P7180, DOI 10.1128/jb.174.22.7180-7184.1992; Paumen MB, 1997, J BIOL CHEM, V272, P3324, DOI 10.1074/jbc.272.6.3324; Perry DK, 1997, J BIOL CHEM, V272, P18530, DOI 10.1074/jbc.272.30.18530; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; Suzuki A, 1997, EXP CELL RES, V233, P41, DOI 10.1006/excr.1997.3498; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; VANVELDHOVEN PP, 1995, BIOCHEM MOL BIOL INT, V36, P21; WANG E, 1991, J BIOL CHEM, V266, P14486; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9; WILLIAMS RD, 1987, J LIPID RES, V28, P1478; Xu J, 1998, J BIOL CHEM, V273, P16521, DOI 10.1074/jbc.273.26.16521; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615	39	245	252	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					9078	9084		10.1074/jbc.275.12.9078	http://dx.doi.org/10.1074/jbc.275.12.9078			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722759	hybrid			2022-12-27	WOS:000086507700109
J	Ma, CC; Kanost, MR				Ma, CC; Kanost, MR			A beta 1,3-glucan recognition protein from an insect, Manduca sexta, agglutinates microorganisms and activates the phenoloxidase cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPOLYSACCHARIDE-BINDING PROTEIN; CRAYFISH PACIFASTACUS-LENIUSCULUS; BOMBYX-MORI; MOLECULAR-CLONING; PERIPLANETA-AMERICANA; INNATE IMMUNITY; GLUCAN-BINDING; PLASMA-PROTEIN; BETA-GLUCAN; PURIFICATION	Pattern recognition proteins function in innate immune responses by binding to molecules on the surface of invading pathogens and initiating host defense reactions. We report the purification and molecular cloning of a cDNA for a 53-kDa beta 1,3-glucan-recognition protein from the tobacco hornworm, Manduca sexta. This protein is constitutively expressed in fat body and secreted into hemolymph, The protein contains a region with sequence similarity to several glucanases, but it lacks glucanase activity. It binds to the surface of and agglutinates yeast, as well as Gram-negative and Gram-positive bacteria. beta 1,3-Glucan-recognition protein in the presence of laminarin, a soluble glucan, stimulated activation of prophenoloxidase in plasma, whereas laminarin alone did not. These results suggest that beta 1,3-glucan-recognition protein serves as a pattern recognition molecule for beta 1,3-glucan on the surface of fungal cell walls. After binding to pl,3-glucan, the protein may interact with a serine protease, leading to the activation of the prophenoloxidase cascade, a pathway in insects for defense against microbial infection.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Kanost, MR (corresponding author), Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA.	kanost@ksu.edu		Kanost, Michael/0000-0002-6827-0061	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041247, R37GM041247, R01GM041247] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41247, R37 GM041247] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ashida Masaaki, 1998, P135; Bachman ES, 1996, P NATL ACAD SCI USA, V93, P6808, DOI 10.1073/pnas.93.13.6808; BARRACCO MA, 1991, CELL TISSUE RES, V266, P491, DOI 10.1007/BF00318590; Beschin A, 1998, J BIOL CHEM, V273, P24948, DOI 10.1074/jbc.273.38.24948; CERENIUS L, 1994, J BIOL CHEM, V269, P29462; Chen CL, 1999, COMP BIOCHEM PHYS B, V122, P309, DOI 10.1016/S0305-0491(99)00020-6; Coligan JE, 1995, CURRENT PROTOCOLS PR; Dimopoulos G, 1997, P NATL ACAD SCI USA, V94, P11508, DOI 10.1073/pnas.94.21.11508; DUNN PE, 1983, J INVERTEBR PATHOL, V41, P77, DOI 10.1016/0022-2011(83)90238-0; DUVIC B, 1990, J BIOL CHEM, V265, P9327; *GENT COMP GROUP, 1991, PROGR MAN GCG PACK; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; HAHN M, 1995, J BIOL CHEM, V270, P3081, DOI 10.1074/jbc.270.7.3081; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Jiang H, 1996, INSECT MOL BIOL, V5, P31, DOI 10.1111/j.1365-2583.1996.tb00038.x; JOMORI T, 1992, FEBS LETT, V296, P283, DOI 10.1016/0014-5793(92)80305-Z; JOMORI T, 1991, J BIOL CHEM, V266, P13318; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Koizumi N, 1999, FEBS LETT, V443, P139, DOI 10.1016/S0014-5793(98)01701-3; LEE E, 1994, METHOD ENZYMOL, V237, P146; Lee WJ, 1996, P NATL ACAD SCI USA, V93, P7888, DOI 10.1073/pnas.93.15.7888; Medzhitov R, 1996, RES IMMUNOL, V147, P208, DOI 10.1016/0923-2494(96)87222-1; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Moore DD, 1995, GLOB MOB SURV; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; OCHIAI M, 1988, J BIOL CHEM, V263, P12056; SEKI N, 1994, J BIOL CHEM, V269, P1370; Shin SW, 1998, INSECT BIOCHEM MOLEC, V28, P827, DOI 10.1016/S0965-1748(98)00077-0; Simmen MW, 1998, P NATL ACAD SCI USA, V95, P4437, DOI 10.1073/pnas.95.8.4437; SODERHALL K, 1988, INSECT BIOCHEM, V18, P323, DOI 10.1016/0020-1790(88)90045-5; Tsuchiya M, 1996, FEMS IMMUNOL MED MIC, V15, P129, DOI 10.1016/0928-8244(96)00053-3; VargasAlbores F, 1996, DEV COMP IMMUNOL, V20, P299, DOI 10.1016/S0145-305X(96)00007-9; VargasAlbores F, 1997, COMP BIOCHEM PHYS B, V116, P453, DOI 10.1016/S0305-0491(96)00268-4; Vorup-Jensen T, 1998, IMMUNOBIOLOGY, V199, P348, DOI 10.1016/S0171-2985(98)80039-9; Wang Y, 1999, INSECT BIOCHEM MOLEC, V29, P1075, DOI 10.1016/S0965-1748(99)00086-7; YAHATA N, 1990, GENE, V86, P113, DOI 10.1016/0378-1119(90)90122-8; YOSHIDA H, 1986, INSECT BIOCHEM, V16, P539, DOI 10.1016/0020-1790(86)90031-4; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854; Yu XQ, 1999, INSECT BIOCHEM MOLEC, V29, P585, DOI 10.1016/S0965-1748(99)00036-3	41	192	215	1	20	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7505	7514		10.1074/jbc.275.11.7505	http://dx.doi.org/10.1074/jbc.275.11.7505			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713054	hybrid			2022-12-27	WOS:000085913300014
J	Palsson, EM; Popoff, M; Thelestam, M; O'Neill, LAJ				Palsson, EM; Popoff, M; Thelestam, M; O'Neill, LAJ			Divergent roles for Ras and Rap in the activation of p38 mitogen-activated protein kinase by interleukin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GLUCOSE DEFICIENCY; GTP-BINDING PROTEINS; NF-KAPPA-B; MAP KINASE; CLOSTRIDIUM-DIFFICILE; C-JUN; SELECTIVE ACTIVATION; TOXIN-B; SUPPRESSOR ACTIVITY; LETHAL TOXIN	We have found that lethal toxin from Clostridiam sordellii, which specifically inactivates the low molecular weight G proteins Ras, Rap, and Rac, inhibits the activation of p38 mitogen-activated protein kinase (MAPK) by interleukin-1 (IL-1) in EL4.NOB-1 cells and primary fibroblasts. The target protein involved appeared to be Ras, because transient transfections with dominant negative RasN17 inhibited p38 MAPK activation by IL-1. Furthermore, transfections of cells with constitutively active RasVHa-activated p38 MASH. Further evidence for Ras involvement came from the observation that IL-1 caused a rapid activation of Ras in the cells and from the inhibitory effects of the Ras inhibitors manumycin A and damnacanthal. Toxin B from Clostridium difficile, which inactivates Rac, Cdc42, and Rho, was without effect. Dominant negative versions of Rac (RacN17) or Bap (Rap1AN17) did not inhibit the response. Intriguingly, transfection of cells with dominant negative Rap1AN17 activated p38 MAPK, Furthermore, constitutively active Rap1AV12 inhibited p38 MAPK activation by IL-1, consistent with Rap antagonizing Ras function. IL-1 also activated Rap in the cells, but with slower kinetics than Ras. Our studies therefore provide clear evidence using multiple approaches for Ras as a signaling component in the activation of p38 MAPK by IL-1, with Rap having an inhibitory effect.	Univ Dublin Trinity Coll, Dept Biochem, Inst Biotechnol, Dublin 2, Ireland; Inst Pasteur, Unite Toxines Microbiennes, F-75724 Paris 15, France; Karolinska Inst, Microbiol & Tumorbiol Ctr, S-17177 Stockholm, Sweden	Trinity College Dublin; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Karolinska Institutet	O'Neill, LAJ (corresponding author), Univ Dublin Trinity Coll, Dept Biochem, Inst Biotechnol, Dublin 2, Ireland.			O'Neill, Luke/0000-0002-4333-2748				BIRD TA, 1994, J BIOL CHEM, V269, P31836; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; ChavesOlarte E, 1996, J BIOL CHEM, V271, P6925, DOI 10.1074/jbc.271.12.6925; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; Davis W, 1999, BIOCHEM J, V338, P387, DOI 10.1042/0264-6021:3380387; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Finch A, 1997, FEBS LETT, V418, P144, DOI 10.1016/S0014-5793(97)01364-1; FloresDiaz M, 1997, J BIOL CHEM, V272, P23784, DOI 10.1074/jbc.272.38.23784; FLORIN I, 1991, MICROB PATHOGENESIS, V11, P337, DOI 10.1016/0882-4010(91)90019-7; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; Grumbles RM, 1997, J CELL BIOCHEM, V67, P92; Guan ZH, 1998, J BIOL CHEM, V273, P28670, DOI 10.1074/jbc.273.44.28670; HARA M, 1993, P NATL ACAD SCI USA, V90, P2281, DOI 10.1073/pnas.90.6.2281; HATA Y, 1990, J BIOL CHEM, V265, P7104; He Q, 1999, HYPERTENSION, V33, P283, DOI 10.1161/01.HYP.33.1.283; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Hiwasa T, 1997, NEUROSCI LETT, V238, P115, DOI 10.1016/S0304-3940(97)00861-6; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; JUST I, 1994, J BIOL CHEM, V269, P10706; Kanakaraj P, 1998, J EXP MED, V187, P2073, DOI 10.1084/jem.187.12.2073; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOYNAGH PN, 1993, BIOCHEM J, V294, P343, DOI 10.1042/bj2940343; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; OLARTE EC, 1997, J CLIN INVEST, V100, P1734; Polverino AJ, 1997, J BIOL CHEM, V272, P7013, DOI 10.1074/jbc.272.11.7013; POPOFF MR, 1987, INFECT IMMUN, V55, P35, DOI 10.1128/IAI.55.1.35-43.1987; Popoff MR, 1996, J BIOL CHEM, V271, P10217, DOI 10.1074/jbc.271.17.10217; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rausch O, 1999, J BIOL CHEM, V274, P4096, DOI 10.1074/jbc.274.7.4096; SAKLATVALA J, 1993, FEBS LETT, V334, P189, DOI 10.1016/0014-5793(93)81709-9; SHOSHAN MC, 1990, EUR J CELL BIOL, V53, P357; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	52	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7818	7825		10.1074/jbc.275.11.7818	http://dx.doi.org/10.1074/jbc.275.11.7818			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713096	hybrid			2022-12-27	WOS:000085913300056
J	Verrecchio, A; Germann, MW; Schick, BP; Kung, B; Twardowski, T; San Antonio, JD				Verrecchio, A; Germann, MW; Schick, BP; Kung, B; Twardowski, T; San Antonio, JD			Design of peptides with high affinities for heparin and endothelial cell proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AQUEOUS-SOLUTION; SULFATE PROTEOGLYCANS; EXTRACELLULAR-MATRIX; BINDING SITES; GROWTH-FACTOR; I COLLAGEN; PROTEIN; GLYCOSAMINOGLYCANS; ANTITHROMBIN; SERGLYCIN	Proteoglycan-binding peptides were designed based on consensus sequences in heparin-binding proteins: XBBXBX and XBBBXXBX, where X and B are hydropathic and basic residues, respectively. initial peptide constructs included (AKKARA)(n) and (ARKKAAKA)(n) (n = 1-6), Affinity coelectrophoresis revealed that low M-r peptides (600-1300) had no affinities for low M-r heparin, but higher M-r peptides (2000-3500) exhibited significant affinities (K-d congruent to 50-150 nM), which increased with peptide M-r. Affinity was strongest when sequence arrays were contiguous and alanines and arginines occupied hydropathic and basic positions, but inclusion of prolines was disruptive. A peptide including a single consensus sequence of the serglycin proteoglycan core protein bound heparin strongly (K-d congruent to 200 nM), likely owing to dimerization through cysteine-cysteine linkages. circular dichroism showed that high affinity heparin-binding peptides converted from a charged coil to an alpha-helix upon heparin addition, whereas weak heparin-binding peptides did not. Higher M-r peptides exhibited high affinities for total endothelial cell proteoglycans (K-d congruent to 300 nM), and similar to 4-fold weaker affinities for their free glycosaminoglycan chains. Thus, peptides including concatamers of heparin-binding consensus sequences may exhibit strong affinities for heparin and proteoglycans. Such peptides may be applicable in promoting cell-substratum adhesion or in the design of drugs targeted to proteoglycan-containing cell surfaces and extracellular matrices.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Cardeza Fdn Hematol Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Drexel Univ, Dept Mat Engn, Philadelphia, PA 19104 USA	Jefferson University; Jefferson University; Jefferson University; Drexel University	San Antonio, JD (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, 1015 Walnut St, Philadelphia, PA 19107 USA.		German, Markus W/L-1531-2013	Twardowski, Thomas/0000-0002-9214-468X; Germann, Markus/0000-0002-1674-8166	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029282, R01HL053590, R29HL053590] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 29282, HL 53590] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER AJ, 1971, J PHYS CHEM-US, V75, P1516; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Conrad H. E., 1998, HEPARIN BINDING PROT; DELUCIA A, 1993, J VASC SURG, V18, P49, DOI 10.1067/mva.1993.42736; DOYLE BB, 1975, J MOL BIOL, V91, P79, DOI 10.1016/0022-2836(75)90373-3; FERRAN DS, 1992, BIOCHEMISTRY-US, V31, P5010, DOI 10.1021/bi00136a014; FROMM JR, 1995, ARCH BIOCHEM BIOPHYS, V323, P279, DOI 10.1006/abbi.1995.9963; GELMAN RA, 1973, ARCH BIOCHEM BIOPHYS, V159, P427, DOI 10.1016/0003-9861(73)90470-0; GELMAN RA, 1974, BIOPOLYMERS, V13, P139, DOI 10.1002/bip.1974.360130109; GELMAN RA, 1973, BIOPOLYMERS, V12, P541, DOI 10.1002/bip.1973.360120308; GIMBRONE MA, 1976, PROGR HEMATOLOGY THR, V2, P1; Hascall V.C., 1991, CELL BIOL EXTRACELLU, P149; Hiemenz P.C., 1984, POLYM CHEM BASIC CON; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; IOZZO RV, 1985, CANCER RES, V45, P5677; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JARVELAINEN HT, 1991, J BIOL CHEM, V266, P23274; JORDAN R, 1979, J BIOL CHEM, V254, P2902; LAURENT TC, 1978, BIOCHEM J, V175, P691, DOI 10.1042/bj1750691; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MCPHERSON JM, 1988, COLLAGEN REL RES, V1, P65; MERTENS G, 1992, J BIOL CHEM, V267, P20435; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; PERIN JP, 1988, BIOCHEM J, V255, P1007, DOI 10.1042/bj2551007; RACANELLI A, 1985, SEMIN THROMB HEMOST, V11, P176, DOI 10.1055/s-2007-1004373; SANANTONIO JD, 1994, GLYCOBIOLOGY, V4, P327; SANANTONIO JD, 1994, J CELL BIOL, V125, P1179, DOI 10.1083/jcb.125.5.1179; SANANTONIO JD, 1993, BIOCHEMISTRY-US, V32, P4746, DOI 10.1021/bi00069a008; SCHICK BP, 1995, J CELL PHYSIOL, V165, P96, DOI 10.1002/jcp.1041650113; Schick BP, 1997, J CELL PHYSIOL, V172, P87, DOI 10.1002/(SICI)1097-4652(199707)172:1<87::AID-JCP10>3.0.CO;2-L; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Starovasnik MA, 1997, P NATL ACAD SCI USA, V94, P10080, DOI 10.1073/pnas.94.19.10080; STIPP CS, 1994, J CELL BIOL, V124, P149, DOI 10.1083/jcb.124.1.149; TOOLE BP, 1976, J BIOL CHEM, V251, P895; TSILIBARY EC, 1988, J BIOL CHEM, V263, P19112; VARGAS FF, 1990, MEMBRANE BIOCHEM, V9, P83, DOI 10.3109/09687689009025831; WUNDERLICH B, 1973, MACROMOLECULAR PHYSI, V1	41	81	106	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7701	7707		10.1074/jbc.275.11.7701	http://dx.doi.org/10.1074/jbc.275.11.7701			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713081	hybrid			2022-12-27	WOS:000085913300041
J	Yuan, FH; Zhang, YB; Rajpal, DK; Wu, XH; Guo, DY; Wang, M; Taylor, JS; Wang, ZG				Yuan, FH; Zhang, YB; Rajpal, DK; Wu, XH; Guo, DY; Wang, M; Taylor, JS; Wang, ZG			Specificity of DNA lesion bypass by the yeast DNA polymerase eta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE GENE; ESCHERICHIA-COLI DINB; INDUCED MUTAGENESIS; HOMOLOG; PROTEIN; ENCODES; SEQUENCE; BINDING; DOMAINS; REV3	DNA polymerase eta (Pol eta, xeroderma pigmentosum variant, or Rad30) plays an important role in an error-free response to unrepaired UV damage during replication. It faithfully synthesizes DNA opposite a thymine-thymine cis-syn-cyclobutane dimer. We have purified the yeast Pol eta and studied its lesion bypass activity in vitro with various types of DNA damage. The yeast Pol eta lacked a nuclease or a proofreading activity. It efficiently bypassed 8-oxoguanine, incorporating C, A, and G opposite the lesion with a relative efficiency of similar to 100: 56:14, respectively. The yeast Pol eta efficiently incorporated a C opposite an acetylaminofluorene-modified G, and efficiently inserted a G or less frequently an A opposite an apurinic/apyrimidinic (AP) site but was unable to extend the DNA synthesis further in both cases. However, some continued DNA synthesis was observed in the presence of the yeast Pol zeta following the Pol eta action opposite an AP site, achieving true lesion bypass. In contrast, the yeast polo was able to bypass efficiently a template AP site, predominantly incorporating an A residue opposite the lesion, These results suggest that other than UV damage, Pol eta may also play a role in bypassing additional DNA lesions, some of which can be error-prone.	Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; Washington Univ, Dept Chem, St Louis, MO 63130 USA	University of Kentucky; Washington University (WUSTL)	Wang, ZG (corresponding author), Univ Kentucky, Grad Ctr Toxicol, 306 Hlth Sci Res Bldg, Lexington, KY 40536 USA.	zwang@pop.uky.edu	Yuan, Fenghua/F-8736-2011; Zhang, Yanbin/F-2998-2011; Taylor, John-Stephen/AAA-3218-2020	Zhang, Yanbin/0000-0002-7263-5510; Taylor, John-Stephen/0000-0002-8615-7257	NCI NIH HHS [CA40463] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040463, R01CA040463] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELGUISEVALLADIER P, 1995, J MOL BIOL, V249, P903, DOI 10.1006/jmbi.1995.0347; CHANET R, 1988, GENE, V74, P543, DOI 10.1016/0378-1119(88)90187-4; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gerlach VL, 1999, P NATL ACAD SCI USA, V96, P11922, DOI 10.1073/pnas.96.21.11922; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; JONES JS, 1988, NUCLEIC ACIDS RES, V16, P7119, DOI 10.1093/nar/16.14.7119; Kulaeva OI, 1996, MUTAT RES-FUND MOL M, V357, P245, DOI 10.1016/0027-5107(96)00164-9; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; LAWRENCE CW, 1985, MUTAT RES, V150, P211, DOI 10.1016/0027-5107(85)90117-4; LAWRENCE CW, 1985, MOL GEN GENET, V200, P80, DOI 10.1007/BF00383316; Lawrence CW, 1996, CANCER SURV, V28, P21; Lin WS, 1999, MUTAT RES-DNA REPAIR, V433, P89, DOI 10.1016/S0921-8777(98)00065-2; LIU W, 1999, NUCLEIC ACIDS RES, V27, P4468; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; McDonald JP, 1999, GENOMICS, V60, P20, DOI 10.1006/geno.1999.5906; McDonald JP, 1997, GENETICS, V147, P1557; McGregor WG, 1999, MOL CELL BIOL, V19, P147; MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; REYNOLDS P, 1985, P NATL ACAD SCI USA, V82, P168, DOI 10.1073/pnas.82.1.168; Roush AA, 1998, MOL GEN GENET, V257, P686; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Smith CA, 1998, J BIOL CHEM, V273, P21933, DOI 10.1074/jbc.273.34.21933; STRAUSS BS, 1991, BIOESSAYS, V13, P79, DOI 10.1002/bies.950130206; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Tang MJ, 1998, P NATL ACAD SCI USA, V95, P9755, DOI 10.1073/pnas.95.17.9755; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; WALKER GC, 1995, TRENDS BIOCHEM SCI, V20, P416, DOI 10.1016/S0968-0004(00)89091-X; Wang Zhigang, 1995, Methods (Orlando), V7, P177, DOI 10.1006/meth.1995.1023; Wu XH, 1999, BIOCHEMISTRY-US, V38, P2628, DOI 10.1021/bi982592s	35	140	145	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8233	8239		10.1074/jbc.275.11.8233	http://dx.doi.org/10.1074/jbc.275.11.8233			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713149	hybrid			2022-12-27	WOS:000085913300109
J	Anto, RJ; Maliekal, TT; Karunagaran, D				Anto, RJ; Maliekal, TT; Karunagaran, D			L-929 cells harboring ectopically expressed Re1A resist curcumin-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; KINASE-ACTIVITY; BREAST-CANCER; ACTIVATION; DEATH; INHIBITION; LINES; ALPHA; ANTITUMOR; DNA	Curcumin (diferuloyl methane), the yellow pigment in turmeric (Curcuma longa), is a potent chemopreventive agent. Curcumin induces apoptosis of several, but not all, cancer cells. Many cancer cells protect themselves against apoptosis by activating nuclear factor-kappa B (NF-kappa B)/Rel, a transcription factor that helps in cell survival. Signal-induced activation of NP-kappa B is known to be inhibited by curcumin. To understand the role of NF-kappa B in curcumin-induced apoptosis, we stably transfected relA gene encoding the p65/RelA subunit of NF-kappa B, into L-929 cells (mouse fibrosarcoma) and the relA-transfected cells were resistant to varying doses of curcumin (10(-6)-10(-4) M), whereas the parental cells underwent apoptosis in a time- and dose-dependent manner. The relA-transfected cells showed constitutive NF-kappa B DNA binding activity that could not be inhibited by curcumin and did not show nuclear condensation and DNA fragmentation upon treatment with curcumin. When a super-repressor form of I kappa B-alpha (known to inhibit NF-kappa B) was transfected transiently into relA-transfected cells, the cells were no longer resistant to curcumin. Our results highlight a critical anti-apoptotic role for NF-kappa B in curcumin-induced apoptosis.	Rajiv Gandhi Ctr Biotechnol, Div Canc Biol, Thiruvananthapuram 695014, Kerala, India	Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB)	Karunagaran, D (corresponding author), Rajiv Gandhi Ctr Biotechnol, Div Canc Biol, Thiruvananthapuram 695014, Kerala, India.	dkarunagaran@hotmail.com	Karunagaran, Devarajan/A-8148-2010	Karunagaran, Devarajan/0000-0001-9331-8947; Maliekal, Tessy/0000-0002-7311-7950				ALLEY MC, 1988, CANCER RES, V48, P589; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Anto RJ, 1996, INT J PHARMACEUT, V131, P1, DOI 10.1016/0378-5173(95)04254-7; Anto Ruby John, 1998, Pharmacy and Pharmacology Communications, V4, P103; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Gautam SC, 1998, BIOCHEM PHARMACOL, V55, P1333, DOI 10.1016/S0006-2952(98)00019-7; Hong RL, 1999, CLIN CANCER RES, V5, P1884; HUANG MT, 1994, CANCER RES, V54, P5841; HUANG MT, 1988, CANCER RES, V48, P5941; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jiang MC, 1996, NUTR CANCER, V26, P111, DOI 10.1080/01635589609514468; Jiang MC, 1996, ONCOGENE, V13, P609; Jobin C, 1999, J IMMUNOL, V163, P3474; KELLOFF GJ, 1994, CANCER EPIDEM BIOMAR, V3, P85; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; May MJ, 1999, SCIENCE, V284, P271, DOI 10.1126/science.284.5412.271; Mehta K, 1997, ANTI-CANCER DRUG, V8, P470, DOI 10.1097/00001813-199706000-00010; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Ozaki K, 1997, FEBS LETT, V410, P297, DOI 10.1016/S0014-5793(97)00653-4; Ramachandran C, 1999, BREAST CANCER RES TR, V54, P269, DOI 10.1023/A:1006170224414; RUBY AJ, 1995, CANCER LETT, V94, P79, DOI 10.1016/0304-3835(95)03827-J; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang WX, 1999, CLIN CANCER RES, V5, P119; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984	32	60	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2000	275	21					15601	15604		10.1074/jbc.C000105200	http://dx.doi.org/10.1074/jbc.C000105200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	318NX	10747850	hybrid			2022-12-27	WOS:000087291400001
J	Beard, MB; Olsen, AE; Jones, RE; Erdogan, S; Houslay, MD; Bolger, GB				Beard, MB; Olsen, AE; Jones, RE; Erdogan, S; Houslay, MD; Bolger, GB			UCR1 and UCR2 domains unique to the cAMP-specific phosphodiesterase family form a discrete module via electrostatic interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DROSOPHILA-MELANOGASTER; GENE; PHOSPHORYLATION; ACTIVATION; INHIBITION; ROLIPRAM; DUNCE; EXPRESSION; BINDING	The cAMP-specific phosphodiesterases (PDE4) enzymes contain unique "signature" regions of amino acid sequence, called upstream conserved regions 1 and 2 (UCR1 and UCR2), UCR1 and UCR2 are located between the extreme amino-terminal region and the catalytic region of the PDE4 enzymes. The UCR1 of the PDE4D3 isoform was used as a "bait" in a two-hybrid screen, which identified a PDE4D cDNA clone containing UCR2 and the catalytic region but not UCR1. Two-hybrid and "pull down" analysis of constructs incorporating various regions of the PDE4D3 cDNA demonstrated that the carboxyl terminal region of UCR1 interacted specifically with the amino-terminal region of UCR2, The interaction was blocked by mutations of two positively charged amino acids (Arg-98 and Arg-101 to alanine) located within an otherwise largely hydrophobic region of UCR1. Mutation of three negatively charged amino acids in UCR2 (Glu-146, Glu-147, and Asp-149, all to alanine) also blocked the interaction. The phosphorylation of UCR1 by cAMP-dependent protein kinase (PKA) in vitro attenuated the ability of UCR1 to interact with UCR2. Mutation of the PKA substrate site in UCR1 (Ser-54) to aspartic acid, which mimics the activation of PDE4D3 by PKA, profoundly reduced the interaction between UCR1 and UCR2. Our data are consistent with a model in which UCR1 and UCR2 act as independent domains whose interaction is determined by electrostatic interactions and which may be disrupted by PKA phosphorylation, We suggest that the UCR1 and UCR2 domains may form a module that interacts with and regulates the PDE4 catalytic region.	Univ Glasgow, Inst Biol & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland; Univ Utah, Ctr Hlth Sci, Vet Affairs Med Ctr, Huntsman Canc Inst,Dept Med,Div Oncol, Salt Lake City, UT 84132 USA; Univ Utah, Ctr Hlth Sci, Dept Oncol Sci, Salt Lake City, UT 84132 USA	University of Glasgow; Huntsman Cancer Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Bolger, GB (corresponding author), Dept Vet Affairs Med Ctr, 500 Foothill Blvd, Salt Lake City, UT 84148 USA.	Bolger@m.cc.utah.edu	Houslay, Miles D/A-6825-2011; Houslay, Miles/AAM-5281-2020	Houslay, Miles/0000-0002-3826-8091	NIGMS NIH HHS [R01-GM58553] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058553] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BOLGER G, 1993, MOL CELL BIOL, V13, P6558, DOI 10.1128/MCB.13.10.6558; Bolger GB, 1997, BIOCHEM J, V328, P539; Bolger GB, 1998, METH MOL B, V88, P101; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DUDAI Y, 1976, P NATL ACAD SCI USA, V73, P1684, DOI 10.1073/pnas.73.5.1684; ENGELS P, 1995, FEBS LETT, V358, P305, DOI 10.1016/0014-5793(94)01460-I; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GUAN C, 1988, GENE, V67, P21; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1990, ANTIBODIES LAB MANUA; Hoffmann R, 1998, BIOCHEM J, V333, P139, DOI 10.1042/bj3330139; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; Huston E, 1996, J BIOL CHEM, V271, P31334, DOI 10.1074/jbc.271.49.31334; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; MARCHMONT RJ, 1980, BIOCHEM J, V187, P381, DOI 10.1042/bj1870381; McPhee I, 1999, J BIOL CHEM, V274, P11796, DOI 10.1074/jbc.274.17.11796; MCPHEE I, 1995, BIOCHEM J, V310, P965, DOI 10.1042/bj3100965; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; QIU YH, 1991, J MOL BIOL, V222, P553, DOI 10.1016/0022-2836(91)90496-S; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P9245; SETTE C, 1994, J BIOL CHEM, V269, P18271; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909	30	94	97	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10349	10358		10.1074/jbc.275.14.10349	http://dx.doi.org/10.1074/jbc.275.14.10349			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744723	hybrid			2022-12-27	WOS:000086345600064
J	Di Noia, JM; D'Orso, I; Sanchez, DO; Frasch, ACC				Di Noia, JM; D'Orso, I; Sanchez, DO; Frasch, ACC			AU-rich elements in the 3 '-untranslated region of a new mucin-type gene family of Trypanosoma cruzi confers mRNA instability and modulates translation efficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; MESSENGER-RNA DEGRADATION; SIALIC-ACID; METACYCLIC TRYPOMASTIGOTES; MONOCLONAL-ANTIBODY; MAMMALIAN-CELLS; TRANS-SIALIDASE; PROTEIN GENES; EXPRESSION; SURFACE	Trypanosoma cruzi has a complex mucin gene family of 500 members with hypervariable regions expressed preferentially in vertebrate associated stages of the parasite. In this work, a novel mucin-type gene family is reported, composed of two groups of genes organized in independent tandems and having very short open reading frames, The structures of deduced proteins share the N and C termini but differ in central regions. One group has repeats with the consensus Lys-Asn-Thr(7)-Ser-Thr(3)-Ser(Ser/Lys)-Ala-Pro and the other a Thr-rich sequence of the type Asp-Gln-Thr(17-20)-Asn-Ala-Pro-Ala-Lys-Asp-Thr(5-7)-Asn-Ala-Pro-Ala-Lys. In both cases, expected mature core proteins are around 7 kDa, Both groups, named L and S, respectively, differ in the structure of genomic loci and mRNA, with differential blocks in the 3'-untranslated region, The highest mRNA level for S and L groups are in the epimastigote stage but they show distinct developmentally regulated patterns. Transcripts are short lived and their steady-state abundance is regulated post-transcriptionally with increased mRNA stability in insect stage epimastigote. AU-rich sequences, similar to ARE motives known to cause mRMA instability in higher eukaryotes, are present in the 3'-untranslated region of the transcripts. In transfection experiments this sequence is shown to be functional for the L group destabilizing its mRNA in a stage-specific manner. Furthermore, an effect of this AU-rich region on translation efficiency is shown, To our knowledge, this is the first time that a functional ARE sequence-dependent post-transcriptional regulation mechanism is reported in a lower eukaryote.	Univ Nacl Gen San Martin, Inst Invest Biotechnol, INTI, RA-1650 San Martin, Pcia Buenos Air, Argentina	Instituto Nacional de Tecnologia Industrial (INTI)	Frasch, ACC (corresponding author), Univ Nacl Gen San Martin, Inst Invest Biotechnol, INTI, Av Gral Paz S-N,Edificio 24,CC 30, RA-1650 San Martin, Pcia Buenos Air, Argentina.		Di Noia, Javier Marcelo/D-2285-2012	Di Noia, Javier Marcelo/0000-0003-2896-0321; Frasch, Alberto Carlos/0000-0001-7532-653X; sanchez, daniel/0000-0002-5427-7764	FDA HHS [GENBANK/AF203085, GENBANK/AF203105] Funding Source: Medline	FDA HHS		ACOSTA A, 1994, BRAZ J MED BIOL RES, V27, P439; ALMEIDA IC, 1994, BRAZ J MED BIOL RES, V27, P443; ASSONBATRES MA, 1994, P NATL ACAD SCI USA, V91, P1318, DOI 10.1073/pnas.91.4.1318; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CAPPA SMG, 1981, MEDICINA-BUENOS AIRE, V41, P119; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CAZZULO JJ, 1985, MOL BIOCHEM PARASIT, V16, P329, DOI 10.1016/0166-6851(85)90074-X; Charest H, 1996, J BIOL CHEM, V271, P17081, DOI 10.1074/jbc.271.29.17081; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CLAYTON CE, 1990, MOL CELL BIOL, V10, P3036, DOI 10.1128/MCB.10.6.3036; de Diego J, 1997, J IMMUNOL, V159, P4983; Di Noia JM, 1998, J BIOL CHEM, V273, P10843, DOI 10.1074/jbc.273.18.10843; DiNoia JM, 1996, J BIOL CHEM, V271, P32078, DOI 10.1074/jbc.271.50.32078; DINOIA JM, 1995, J BIOL CHEM, V270, P24146, DOI 10.1074/jbc.270.41.24146; Elias M. C. Q. B., 1998, Memorias do Instituto Oswaldo Cruz, V93, P57; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; FOURNEY RM, 1978, FOCUS, V10, P5; Franchin G, 1997, INFECT IMMUN, V65, P2548, DOI 10.1128/IAI.65.7.2548-2554.1997; FRASCH ACC, 1994, PARASITOLOGY, V108, pS37, DOI 10.1017/S0031182000075703; Freitas-Junior LHG, 1998, MOL BIOCHEM PARASIT, V93, P101, DOI 10.1016/S0166-6851(98)00025-5; Furger A, 1997, MOL CELL BIOL, V17, P4372, DOI 10.1128/MCB.17.8.4372; Hanke J, 1996, BIOTECHNIQUES, V21, P686; KELLY JM, 1992, NUCLEIC ACIDS RES, V20, P3963, DOI 10.1093/nar/20.15.3963; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Lee MGS, 1998, NUCLEIC ACIDS RES, V26, P4025, DOI 10.1093/nar/26.17.4025; Maranon C, 1998, MOL BIOCHEM PARASIT, V92, P313, DOI 10.1016/S0166-6851(98)00003-6; MartinezCalvillo S, 1997, GENE, V199, P71, DOI 10.1016/S0378-1119(97)00348-X; MERTZ LM, 1994, FOCUS, V16, P45; Morgenstern B, 1996, P NATL ACAD SCI USA, V93, P12098, DOI 10.1073/pnas.93.22.12098; MORTARA RA, 1992, INFECT IMMUN, V60, P4673, DOI 10.1128/IAI.60.11.4673-4678.1992; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; NILSEN TW, 1994, SCIENCE, V264, P1868, DOI 10.1126/science.7912006; NILSEN TW, 1995, MOL BIOCHEM PARASIT, V73, P1, DOI 10.1016/0166-6851(94)00107-X; Pays E, 1998, MOL BIOCHEM PARASIT, V91, P3, DOI 10.1016/S0166-6851(97)00183-7; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; PEREIRA MEA, 1981, SCIENCE, V211, P597, DOI 10.1126/science.7006082; Previato JO, 1998, J BIOL CHEM, V273, P14982, DOI 10.1074/jbc.273.24.14982; PREVIATO JO, 1994, BIOCHEM J, V301, P151, DOI 10.1042/bj3010151; REYES MB, 1994, GENE, V140, P139, DOI 10.1016/0378-1119(94)90745-5; Ruiz RC, 1998, BIOCHEM J, V330, P505; RUIZ RD, 1993, PARASITE IMMUNOL, V15, P121, DOI 10.1111/j.1365-3024.1993.tb00591.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAUER R, 1983, H-S Z PHYSIOL CHEM, V364, P1053, DOI 10.1515/bchm2.1983.364.2.1053; SCHENKMAN S, 1992, J EXP MED, V175, P1635, DOI 10.1084/jem.175.6.1635; SCHENKMAN S, 1993, MOL BIOCHEM PARASIT, V59, P293, DOI 10.1016/0166-6851(93)90227-O; SCHENKMAN S, 1994, ANNU REV MICROBIOL, V48, P499, DOI 10.1146/annurev.mi.48.100194.002435; SERRANO AA, 1995, J BIOL CHEM, V270, P27244, DOI 10.1074/jbc.270.45.27244; SHER A, 1982, NATURE, V300, P639, DOI 10.1038/300639a0; Sokolowski M, 1999, J VIROL, V73, P1080, DOI 10.1128/JVI.73.2.1080-1091.1999; STOECKLIN G, 1994, J BIOL CHEM, V269, P28591; TEIXEIRA SMR, 1994, J BIOL CHEM, V269, P20509; TEIXEIRA SMR, 1995, J BIOL CHEM, V270, P22586, DOI 10.1074/jbc.270.38.22586; Tomlinson S, 1998, PARASITOL TODAY, V14, P354, DOI 10.1016/S0169-4758(98)01295-2; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; Vazquez M. P., 1998, Memorias do Instituto Oswaldo Cruz, V93, P161; VAZQUEZ MP, 1994, MOL BIOCHEM PARASIT, V64, P327, DOI 10.1016/0166-6851(94)00026-3; Verdun RE, 1998, INFECT IMMUN, V66, P5393, DOI 10.1128/IAI.66.11.5393-5398.1998; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; YOSHIDA N, 1989, INFECT IMMUN, V57, P1663, DOI 10.1128/IAI.57.6.1663-1667.1989; Yoshida N, 1997, MOL BIOCHEM PARASIT, V84, P57, DOI 10.1016/S0166-6851(96)02783-1; Zingales B, 1997, ACTA TROP, V68, P159, DOI 10.1016/S0001-706X(97)00088-0; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	64	116	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10218	10227		10.1074/jbc.275.14.10218	http://dx.doi.org/10.1074/jbc.275.14.10218			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744707	hybrid			2022-12-27	WOS:000086345600048
J	Keiper, BD; Lamphear, BJ; Deshpande, AM; Jankowska-Anyszka, M; Aamodt, EJ; Blumenthal, T; Rhoads, RE				Keiper, BD; Lamphear, BJ; Deshpande, AM; Jankowska-Anyszka, M; Aamodt, EJ; Blumenthal, T; Rhoads, RE			Functional characterization of five eIF4E isoforms in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING-PROTEIN; SYNTHESIS INITIATION FACTOR-4F; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; C-ELEGANS; MALIGNANT TRANSFORMATION; ARABIDOPSIS-THALIANA; GENE; PROTEASES; SUBUNIT	Recognition of the 5'-cap structure of mRNA by eIF4E is a critical step in the recruitment of most mRNAs to the ribosome. In Caenorhabditis elegans, similar to 70% of mRNAs contain an unusual 2,2,7-trimethylguanosine cap structure as a result of trans-splicing onto the 5' end of the pre-mRNA, The characterization of three eIF4E isoforms in C. elegans (IFE-1, IFE-2, and IFE-3) was reported previously. The present study describes two more eIF4E isoforms expressed in C. elegans, IFE-4 and IFE-5. We analyzed the requirement of each isoform for viability by RNA interference. IFE-3, the most closely related to mammalian eIF4E-1, binds only 7-methylguanosine caps and is essential for viability. In contrast, three closely related isoforms (IFE-1, IFE-2, and IFE-8) bind 2,2,7-trimethylguanosine caps and are partially redundant, but at least one functional isoform is required for viability. IFE-4, which binds only 7-methylguanosine caps, is most closely related to an unusual eIF4E isoform found in plants (nCBP) and mammals (4E-HP) and is not essential for viability in any combination of IFE knockout. ife-2 ife-3 ife-4, and ife-5 mRNAs are themselves trans-spliced to SL1 spliced leaders. ife-1 mRNA is trans-spliced to an SL2 leader, indicating that its gene resides in a downstream position of an operon.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Univ Warsaw, Dept Chem, PL-02093 Warsaw, Poland	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Warsaw	Rhoads, RE (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway, Shreveport, LA 71130 USA.	rrhoad@lsumc.edu		Keiper, Brett/0000-0002-8621-9825	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM042432, R01GM042432] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42432, GM20818] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN ML, 1992, J BIOL CHEM, V267, P23232; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Blumenthal T, 1998, BIOESSAYS, V20, P480, DOI 10.1002/(SICI)1521-1878(199806)20:6&lt;480::AID-BIES6&gt;3.0.CO;2-Q; BLUMENTHAL T, 1997, C ELEGANS, V2, P117; BRENNER S, 1974, GENETICS, V77, P71; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Cai A, 1999, BIOCHEMISTRY-US, V38, P8538, DOI 10.1021/bi9830213; CONRAD R, 1991, MOL CELL BIOL, V11, P1921, DOI 10.1128/MCB.11.4.1921; DARZYNKIEWICZ E, 1988, NUCLEIC ACIDS RES, V16, P8953, DOI 10.1093/nar/16.18.8953; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; HARLOW E, 1988, ANTIBODIES LABORATOR, P72; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Jankowska-Anyszka M, 1998, J BIOL CHEM, V273, P10538, DOI 10.1074/jbc.273.17.10538; KEIPER BD, 1990, J BIOL CHEM, V265, P19397; Keiper BD, 1999, DEV BIOL, V206, P1, DOI 10.1006/dbio.1998.9131; Keiper BD, 1999, INT J BIOCHEM CELL B, V31, P37, DOI 10.1016/S1357-2725(98)00130-7; LAMOND AI, 1990, TRENDS BIOCHEM SCI, V15, P451, DOI 10.1016/0968-0004(90)90292-J; Lamphear BJ, 1996, BIOCHEMISTRY-US, V35, P15726, DOI 10.1021/bi961864t; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; LIOU RF, 1990, MOL CELL BIOL, V10, P1764, DOI 10.1128/MCB.10.4.1764; MacMorris MA, 1999, P NATL ACAD SCI USA, V96, P3813, DOI 10.1073/pnas.96.7.3813; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; McDermott JB, 1996, BIOCHEMISTRY-US, V35, P9415, DOI 10.1021/bi952646n; METZ AM, 1992, NUCLEIC ACIDS RES, V20, P4096, DOI 10.1093/nar/20.15.4096; Misquitta L, 1999, P NATL ACAD SCI USA, V96, P1451, DOI 10.1073/pnas.96.4.1451; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Rhoads RE, 1999, J BIOL CHEM, V274, P30337, DOI 10.1074/jbc.274.43.30337; Rodriguez CM, 1998, PLANT J, V13, P465, DOI 10.1046/j.1365-313X.1998.00047.x; Rom E, 1998, J BIOL CHEM, V273, P13104, DOI 10.1074/jbc.273.21.13104; Ruud KA, 1998, J BIOL CHEM, V273, P10325, DOI 10.1074/jbc.273.17.10325; RYCHLIK W, 1987, P NATL ACAD SCI USA, V84, P945, DOI 10.1073/pnas.84.4.945; RYCHLIK W, 1992, NUCLEIC ACIDS RES, V20, P6415, DOI 10.1093/nar/20.23.6415; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; SHATKIN AJ, 1987, BIOESSAYS, V7, P275, DOI 10.1002/bies.950070611; VANDOREN K, 1990, MOL CELL BIOL, V10, P1769, DOI 10.1128/MCB.10.4.1769; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; ZORIO DAR, 1994, NATURE, V372, P270, DOI 10.1038/372270a0	48	113	124	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10590	10596		10.1074/jbc.275.14.10590	http://dx.doi.org/10.1074/jbc.275.14.10590			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744754	hybrid			2022-12-27	WOS:000086345600095
J	Renz, M; Tomlinson, E; Hultgren, B; Levin, N; Gu, QM; Shimkets, RA; Lewin, DA; Stewart, TA				Renz, M; Tomlinson, E; Hultgren, B; Levin, N; Gu, QM; Shimkets, RA; Lewin, DA; Stewart, TA			Quantitative expression analysis of genes regulated by both obesity and leptin reveals a regulatory loop between leptin and pituitary-derived ACTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROOPIOMELANOCORTIN MESSENGER-RNA; EARLY-ONSET OBESITY; PROLACTIN SECRETION; GROWTH-HORMONE; DIFFERENTIAL DISPLAY; BODY-COMPOSITION; OB/OB MICE; METABOLISM; HUMANS; MUSCLE	Absence of the hormone leptin leads to dramatic increases in appetite, food intake, and adiposity, The primary site of action, at least with respect to appetite, is the hypothalamus. Leptin also has significant effects on the function(s) of peripheral organs involved in maintaining body composition. Some of these effects are mediated through direct interaction of leptin with its receptor on the target tissue, and some effects are indirectly mediated through secondary hormonal and neural pathways. Few of the genes that are responsible for regulating body composition and the peripheral effects of leptin are known. We have used a new gene profiling technology to characterize gene expression changes that occur in the pituitary, hypothalamus, fat, muscle, and liver in response to both obesity and treatment with exogenous leptin, These differences were then overlaid to allow the identification of genes that are regulated by obesity and at least partially normalized by leptin treatment. By using this process we have identified five genes (POMC, PC2, prolactin, HSGP25L2G, and one novel) that are both abnormally expressed in the pituitaries of obese mice and are sensitive to the effects of leptin, We also show that adrenocorticotropic hormone appears to be involved in a regulatory loop involving leptin.	Genentech Inc, Dept Endocrine Res, San Francisco, CA 94080 USA; CuraGen Corp, Gene Discovery, New Haven, CT 06511 USA	Roche Holding; Genentech	Stewart, TA (corresponding author), Genentech Inc, Dept Endocrine Res, 1 DNA Way, San Francisco, CA 94080 USA.	tas@gene.com						ALTOMONTE L, 1987, HORM RES, V27, P190, DOI 10.1159/000180818; AMATRUDA JM, 1982, INT J OBESITY, V6, P183; Arava Y, 1999, DIABETES, V48, P552, DOI 10.2337/diabetes.48.3.552; AVRUSKIN TW, 1985, J PEDIATR-US, V106, P373, DOI 10.1016/S0022-3476(85)80659-4; BARBIERI C, 1983, CLIN ENDOCRINOL, V19, P705, DOI 10.1111/j.1365-2265.1983.tb00048.x; BERTAGNA X, 1994, ENDOCRIN METAB CLIN, V23, P467, DOI 10.1016/S0889-8529(18)30079-3; BESHYAH SA, 1995, CLIN ENDOCRINOL, V42, P179, DOI 10.1111/j.1365-2265.1995.tb01860.x; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; CACCIARI E, 1981, ARCH DIS CHILD, V56, P386, DOI 10.1136/adc.56.5.386; Carulli JP, 1998, J CELL BIOCHEM, P286; CAVAGNINI F, 1981, J ENDOCRINOL INVEST, V4, P149, DOI 10.1007/BF03350443; Cawthorne MA, 1998, P NUTR SOC, V57, P449, DOI 10.1079/PNS19980064; Cheung CC, 1997, ENDOCRINOLOGY, V138, P4489, DOI 10.1210/en.138.10.4489; Cincotta AH, 1996, DIABETES CARE, V19, P667, DOI 10.2337/diacare.19.6.667; Clarke IJ, 1999, REV REPROD, V4, P48; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; Elmquist JK, 1998, NAT NEUROSCI, V1, P445, DOI 10.1038/2164; Foss MC, 1995, CLIN ENDOCRINOL, V43, P721, DOI 10.1111/j.1365-2265.1995.tb00541.x; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HOLTHUIS JCM, 1995, BIOCHEM J, V312, P205, DOI 10.1042/bj3120205; Houseknecht KL, 1998, J ANIM SCI, V76, P1405; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Kalra SP, 1999, ENDOCR REV, V20, P68, DOI 10.1210/er.20.1.68; KOPELMAN PG, 1979, LANCET, V1, P747; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; LARSON BA, 1976, ENDOCRINOLOGY, V98, P139, DOI 10.1210/endo-98-1-139; Levin N, 1996, P NATL ACAD SCI USA, V93, P1726, DOI 10.1073/pnas.93.4.1726; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Licinio J, 1997, NAT MED, V3, P575, DOI 10.1038/nm0597-575; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Luo SQ, 1998, NEUROENDOCRINOLOGY, V68, P1, DOI 10.1159/000054344; MARTIN RJ, 1977, HORM METAB RES, V9, P181, DOI 10.1055/s-0028-1093572; MICHAELS RL, 1987, DIABETES, V36, P1098, DOI 10.2337/diabetes.36.10.1098; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Peeke PM, 1995, ANN NY ACAD SCI, V771, P665, DOI 10.1111/j.1749-6632.1995.tb44719.x; Raber J, 1997, J BIOL CHEM, V272, P15057, DOI 10.1074/jbc.272.24.15057; REBUFFESCRIVE M, 1988, J CLIN ENDOCR METAB, V67, P1122, DOI 10.1210/jcem-67-6-1122; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; RODBELL M, 1964, J BIOL CHEM, V239, P375; SAITO M, 1984, AM J PHYSIOL, V246, pR20, DOI 10.1152/ajpregu.1984.246.1.R20; Sartorio A, 1997, J ENDOCRINOL INVEST, V20, P417, DOI 10.1007/BF03347994; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schwartz MW, 1997, DIABETES, V46, P2119, DOI 10.2337/diabetes.46.12.2119; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; Shimkets RA, 1999, NAT BIOTECHNOL, V17, P798, DOI 10.1038/11743; SINHA YN, 1975, ENDOCRINOLOGY, V97, P1386, DOI 10.1210/endo-97-6-1386; SORENSON RL, 1987, PANCREAS, V2, P283, DOI 10.1097/00006676-198705000-00006; Spinedi E, 1998, ENDOCRINOLOGY, V139, P4016, DOI 10.1210/en.139.9.4016; Thornton JE, 1997, ENDOCRINOLOGY, V138, P5063, DOI 10.1210/en.138.11.5063; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Vicent D, 1998, DIABETES, V47, P1451, DOI 10.2337/diabetes.47.9.1451; WADA I, 1991, J BIOL CHEM, V266, P19599; Weigle David S., 1996, Bioessays, V18, P867, DOI 10.1002/bies.950181105; Yaswen L, 1999, NAT MED, V5, P1066, DOI 10.1038/12506; Yu WH, 1997, P NATL ACAD SCI USA, V94, P1023, DOI 10.1073/pnas.94.3.1023; Zamorano PL, 1997, NEUROENDOCRINOLOGY, V65, P223, DOI 10.1159/000127276; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	58	30	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10429	10436		10.1074/jbc.275.14.10429	http://dx.doi.org/10.1074/jbc.275.14.10429			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744732	hybrid			2022-12-27	WOS:000086345600073
J	Gomez-Gallego, F; Garrido-Pertierra, A; Bautista, JM				Gomez-Gallego, F; Garrido-Pertierra, A; Bautista, JM			Structural defects underlying protein dysfunction in human glucose-6-phosphate dehydrogenase A(-) deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; DIFFERENTIAL SCANNING CALORIMETRY; GLYCOGEN-PHOSPHORYLASE-B; REACTIVE LYSYL RESIDUE; AMINO-ACID-COMPOSITION; ENZYME DEFICIENCY; PYRIDOXAL 5'-PHOSPHATE; QUATERNARY STRUCTURE; GENETIC-VARIANTS; ESCHERICHIA-COLI	The enzyme variant glucose-g-phosphate dehydrogenase (G6PD) A(-), which gives rise to human glucose-6-phosphate dehydrogenase deficiency, is a protein of markedly reduced structural stability. This variant differs from the normal enzyme, G6PD B, in two amino acid substitutions, A further nondeficient variant, G6PD G bears only one of these two mutations and is structurally stable. In this study, the synergistic structural defect in recombinant G6PD A(-) was reflected by reduced unfolding enthalpy due to loss of beta-sheet and alpha-helix interactions where both mutations are found. This was accompanied by changes in inner spatial distances between residues in the coenzyme domain and the partial disruption of tertiary structure with no significant loss of secondary structure. However, the secondary structure of G6PD A- was qualitatively affected by an increase in beta-sheets substituting beta-turns related to the lower unfolding enthalpy, The structural changes observed did not affect the active site of the mutant proteins, since its spatial position was unmodified. The final result is a loss of folding determinants leading to a protein with decreased intracellular stability. This is suggested as the cause of the enzyme deficiency in the red blood cell, which is unable to perform de novo protein synthesis.	Univ Complutense Madrid, Fac Vet, Dept Bioquim & Biol Mol 4, Madrid 28040, Spain	Complutense University of Madrid	Bautista, JM (corresponding author), Univ Complutense Madrid, Fac Vet, Dept Bioquim & Biol Mol 4, Ciudad Univ, Madrid 28040, Spain.		Bautista, José M./B-7899-2013; Gomez-Gallego, Felix/H-6925-2013; Gomez-Gallego, Felix/AAD-9617-2020	Bautista, José M./0000-0001-8926-881X; Gomez-Gallego, Felix/0000-0002-1968-1761; 				BABALOLA AOG, 1976, J BIOL CHEM, V251, P2993; BABALOLA O, 1972, P NATL ACAD SCI USA, V69, P946, DOI 10.1073/pnas.69.4.946; BALDWIN RL, 1989, TRENDS BIOCHEM SCI, V14, P291, DOI 10.1016/0968-0004(89)90067-4; BAUTISTA JM, 1995, FEBS LETT, V366, P61, DOI 10.1016/0014-5793(95)00474-N; BAUTISTA JM, 1992, BIOCHIM BIOPHYS ACTA, V1119, P74, DOI 10.1016/0167-4838(92)90237-8; Bautista JM, 1997, PROTEIN DYSFUNCTION, P33; BIENZLE U, 1972, LANCET, V1, P107; BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; Cai K, 1996, J BIOL CHEM, V271, P2987, DOI 10.1074/jbc.271.6.2987; CAMARDELLA L, 1981, BIOCHEM BIOPH RES CO, V103, P1384, DOI 10.1016/0006-291X(81)90276-X; CAMARDELLA L, 1988, EUR J BIOCHEM, V171, P485, DOI 10.1111/j.1432-1033.1988.tb13815.x; CENTENO F, 1992, J BIOENERG BIOMEMBR, V24, P625, DOI 10.1007/BF00762355; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CORTIJO M, 1971, J BIOL CHEM, V246, P933; COUTHON F, 1995, EUR J BIOCHEM, V234, P160, DOI 10.1111/j.1432-1033.1995.160_c.x; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P255; delPozo AM, 1996, BIOCHEMISTRY-US, V35, P2112, DOI 10.1021/bi9522211; DIJKSTRA BW, 1981, J MOL BIOL, V147, P97, DOI 10.1016/0022-2836(81)90081-4; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; Eisenhaber F, 1996, PROTEINS, V25, P157, DOI 10.1002/(SICI)1097-0134(199606)25:2<157::AID-PROT2>3.0.CO;2-F; Eisenhaber F, 1996, PROTEINS, V25, P169, DOI 10.1002/(SICI)1097-0134(199606)25:2<169::AID-PROT3>3.3.CO;2-5; FERSHT AR, 1994, BIOCHEM SOC T, V22, P267, DOI 10.1042/bst0220267; FISHER MT, 1992, J BIOL CHEM, V267, P1872; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GomezGallego F, 1996, FASEB J, V10, P153, DOI 10.1096/fasebj.10.1.8566536; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; GROSS M, 1995, BIOCHEMISTRY-US, V34, P10350, DOI 10.1021/bi00033a005; GROSS M, 1994, PROTEIN SCI, V3, P1058, DOI 10.1002/pro.5560030708; GUTIERREZMERINO C, 1989, BIOCHEMISTRY-US, V28, P3398, DOI 10.1021/bi00434a039; HIRONO A, 1988, P NATL ACAD SCI USA, V85, P3951, DOI 10.1073/pnas.85.11.3951; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; KAZUMAN W, 1959, ADV PROTEIN CHEM, V14, P1; KIM CWA, 1993, NATURE, V362, P267, DOI 10.1038/362267a0; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; Lakowicz J.R., 2013, PRINCIPLES FLUORESCE; LEVITT M, 1978, BIOCHEMISTRY-US, V17, P4277, DOI 10.1021/bi00613a026; LUZZATTO L, 1971, BIOCHEMISTRY-US, V10, P420, DOI 10.1021/bi00779a010; Naylor CE, 1996, BLOOD, V87, P2974, DOI 10.1182/blood.V87.7.2974.bloodjournal8772974; OTZEN DE, 1995, BIOCHEMISTRY-US, V34, P5718, DOI 10.1021/bi00017a003; Pace CN, 1996, FASEB J, V10, P75, DOI 10.1096/fasebj.10.1.8566551; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; PRIVALOV PL, 1974, J MOL BIOL, V86, P665, DOI 10.1016/0022-2836(74)90188-0; RUWENDE C, 1995, NATURE, V376, P246, DOI 10.1038/376246a0; Scopes DA, 1998, EUR J BIOCHEM, V251, P382, DOI 10.1046/j.1432-1327.1998.2510382.x; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SERRANO L, 1992, J MOL BIOL, V227, P544, DOI 10.1016/0022-2836(92)90906-Z; STRYER L, 1968, SCIENCE, V162, P526, DOI 10.1126/science.162.3853.526; T Forster, 1965, MODERN QUANTUM CHEMI, VIII, P93; Takano K, 1997, BIOCHEMISTRY-US, V36, P688, DOI 10.1021/bi9621829; TOWN M, 1992, HUM MOL GENET, V1, P171, DOI 10.1093/hmg/1.3.171; VULLIAMY T, 1992, TRENDS GENET, V8, P138, DOI 10.1016/0168-9525(92)90372-B; Vulliamy T, 1997, BLOOD CELL MOL DIS, V23, P302, DOI 10.1006/bcmd.1997.0147; VULLIAMY TJ, 1988, P NATL ACAD SCI USA, V85, P5171, DOI 10.1073/pnas.85.14.5171; YU MH, 1995, NAT STRUCT BIOL, V2, P363, DOI 10.1038/nsb0595-363	55	23	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9256	9262		10.1074/jbc.275.13.9256	http://dx.doi.org/10.1074/jbc.275.13.9256			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734064	hybrid			2022-12-27	WOS:000086206500028
J	Grosse, R; Schmid, A; Schoneberg, T; Herrlich, A; Muhn, P; Schultz, G; Gudermann, T				Grosse, R; Schmid, A; Schoneberg, T; Herrlich, A; Muhn, P; Schultz, G; Gudermann, T			Gonadotropin-releasing hormone receptor initiates multiple signaling pathways by exclusively coupling to G(q/11) proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL PHOSPHATE PRODUCTION; COMPLEMENTARY DEOXYRIBONUCLEIC-ACID; FIRST INTRACELLULAR LOOP; ALPHA-T3-1 CELL-LINE; SENSITIVE G-PROTEIN; LUTEINIZING-HORMONE; KINASE-C; PHOSPHOLIPASE-C; GNRH RECEPTOR; TRANSDUCTION PATHWAYS	The agonist-bound gonadotropin-releasing hormone (GnRH) receptor engages several distinct signaling cascades, and it has recently been proposed that coupling of a single type of receptor to multiple G proteins (G(q), G(s), and G(i)) is responsible for this behavior, GnRH-dependent signaling was studied in gonadotropic alpha T3-1 cells endogenously expressing the murine receptor and in CHO-K1 (CHO#3) and COS-7 cells transfected with the human GnRH receptor cDNA In all cell systems studied, GnRH-induced phospholipase C activation and Ca2+ mobilization was pertussis toxin-insensitive, as was GnRH-mediated extracellular signal-regulated kinase activation. Whereas the G(i)-coupled m2 muscarinic receptor interacted with a chimeric G(s) protein (G(s)i5) containing the C-terminal five amino acids of G alpha(12), the human GnRH receptor was unable to activate the G protein chimera. GnRH challenge of alpha T3-1, CHO#3 and of GnRH receptor-expressing COS-7 cells did not result in agonist-dependent cAMP formation. GnRH challenge of CHO#3 cells expressing a cAMP-responsive element-driven firefly luciferase did not result in increased reporter gene expression, However, coexpression of the human GnRH receptor and adenylyl cyclase I in COS-7 cells led to clearly discernible GnRH-dependent cAMP formation subsequent to GnRH-elicited rises in [Ca2+](i), In alpha T3-1 and CHO#3 cell membranes, addition of [alpha-P-32]GTP azidoanilide resulted in GnRH receptor-de pendent labeling of G alpha(q/11) but not of G alpha(i), G alpha(s), or G alpha(12/13) proteins. Thus, the murine and human GnRH receptors exclusively couple to G proteins of the G(q/11) family. Multiple GnRH-dependent signaling pathways are therefore initiated downstream of the receptor/G protein interface and are not indicative of a multiple G protein coupling potential of the GnRH receptor.	Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany; Schering AG, Forsch Lab, D-13342 Berlin, Germany	Free University of Berlin; Schering AG	Gudermann, T (corresponding author), Free Univ Berlin, Inst Pharmakol, Thielallee 69-73, D-14195 Berlin, Germany.	guderman@zedat.fu-berlin.de		Grosse, Robert/0000-0002-3380-5273				ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; ANTONI FA, 1995, J BIOL CHEM, V270, P28055; Arora KK, 1998, J BIOL CHEM, V273, P25581, DOI 10.1074/jbc.273.40.25581; BARNES SJ, 1993, ENDOCRINOLOGY, V133, P2756, DOI 10.1210/en.133.6.2756; Blomenrohr M, 1997, BIOCHEM BIOPH RES CO, V238, P517, DOI 10.1006/bbrc.1997.7331; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Childs G V, 1995, Vitam Horm, V50, P215, DOI 10.1016/S0083-6729(08)60657-3; Delahaye R, 1997, MOL CELL ENDOCRINOL, V135, P119, DOI 10.1016/S0303-7207(97)00194-9; Emons G, 1998, J STEROID BIOCHEM, V65, P199, DOI 10.1016/S0960-0760(97)00189-1; Flanagan C A, 1997, Rev Reprod, V2, P113; Grosse R, 1997, MOL ENDOCRINOL, V11, P1305, DOI 10.1210/me.11.9.1305; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; GUO CH, 1995, ENDOCRINOLOGY, V136, P3031, DOI 10.1210/en.136.7.3031; HAWES BE, 1993, ENDOCRINOLOGY, V132, P2124, DOI 10.1210/en.132.5.2124; HAWES BE, 1992, ENDOCRINOLOGY, V130, P2465, DOI 10.1210/en.130.5.2465; Heding A, 1998, J BIOL CHEM, V273, P11472, DOI 10.1074/jbc.273.19.11472; Herrlich A, 1996, J BIOL CHEM, V271, P16764, DOI 10.1074/jbc.271.28.16764; HIMMLER A, 1993, J RECEPTOR RES, V13, P79, DOI 10.3109/10799899309073647; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; HORN F, 1991, MOL ENDOCRINOL, V5, P347, DOI 10.1210/mend-5-3-347; HOTCHKISS J, 1994, PHYSL REPRODUCTION, V2, P711; HSIEH KP, 1992, MOL ENDOCRINOL, V6, P1673, DOI 10.1210/me.6.10.1673; IRMER G, 1995, CANCER RES, V55, P817; JANOVICK JA, 1993, ENDOCRINOLOGY, V132, P2131, DOI 10.1210/en.132.5.2131; Kaiser UB, 1997, ENDOCR REV, V18, P46, DOI 10.1210/er.18.1.46; Kakar SS, 1998, CANCER RES, V58, P4558; KAKAR SS, 1994, MOL CELL ENDOCRINOL, V106, P145, DOI 10.1016/0303-7207(94)90196-1; Kuhn B, 1996, MOL ENDOCRINOL, V10, P1697, DOI 10.1210/me.10.12.1697; KUPHAL D, 1994, ENDOCRINOLOGY, V135, P315, DOI 10.1210/en.135.1.315; LAUGWITZ KL, 1994, METHOD ENZYMOL, V237, P283; Lin XW, 1998, MOL ENDOCRINOL, V12, P161, DOI 10.1210/me.12.2.161; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; MACRAE MB, 1990, BIOCHEM J, V271, P635, DOI 10.1042/bj2710635; MCARDLE CA, 1992, MOL CELL ENDOCRINOL, V87, P95, DOI 10.1016/0303-7207(92)90237-Z; McArdle CA, 1996, TRENDS ENDOCRIN MET, V7, P168, DOI 10.1016/1043-2760(96)00051-3; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Pietruck F, 1997, N-S ARCH PHARMACOL, V355, P1; PINSKI J, 1994, INT J CANCER, V59, P51, DOI 10.1002/ijc.2910590112; Reiss N, 1997, ENDOCRINOLOGY, V138, P1673, DOI 10.1210/en.138.4.1673; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; SCHMID A, 1995, EUR J BIOCHEM, V228, P23, DOI 10.1111/j.1432-1033.1995.tb20223.x; SCHOMERUS E, 1994, ENDOCRINOLOGY, V134, P315, DOI 10.1210/en.134.1.315; Schoneberg T, 1997, J CLIN INVEST, V100, P1547, DOI 10.1172/JCI119678; SHAH BH, 1995, P NATL ACAD SCI USA, V92, P1886, DOI 10.1073/pnas.92.6.1886; SHAH BH, 1994, MOL PHARMACOL, V46, P1; SIM PJ, 1995, MOL CELL ENDOCRINOL, V112, P257, DOI 10.1016/0303-7207(95)03616-F; Stanislaus D, 1998, BIOL REPROD, V59, P579, DOI 10.1095/biolreprod59.3.579; Stanislaus D, 1998, MOL CELL ENDOCRINOL, V144, P1, DOI 10.1016/S0303-7207(98)00126-9; Stanislaus D, 1997, MOL ENDOCRINOL, V11, P738, DOI 10.1210/me.11.6.738; STOJILKOVIC SS, 1994, ENDOCR REV, V15, P462, DOI 10.1210/er.15.4.462; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; Sundaresan S, 1996, ENDOCRINOLOGY, V137, P304, DOI 10.1210/en.137.1.304; Ulloa-Aguirre A, 1998, ENDOCRINOLOGY, V139, P2472, DOI 10.1210/en.139.5.2472; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597; Wu V, 1997, J BIOL CHEM, V272, P9037; YANO T, 1994, P NATL ACAD SCI USA, V91, P7090, DOI 10.1073/pnas.91.15.7090	58	125	130	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9193	9200		10.1074/jbc.275.13.9193	http://dx.doi.org/10.1074/jbc.275.13.9193			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734055	hybrid			2022-12-27	WOS:000086206500019
J	Ikeda, Y; Taniguchi, N; Noguchi, T				Ikeda, Y; Taniguchi, N; Noguchi, T			Dominant negative role of the glutamic acid residue conserved in the pyruvate kinase M-1 isozyme in the heterotropic allosteric effect involving fructose-1,6-bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE RESIDUE; M-GENE; RAT; TRANSPEPTIDASE; SEQUENCE; MUTAGENESIS; EFFICIENT; BINDING; ENZYME	Pyruvate kinase M-1, a nonallosteric isozyme, lacks heterotropic allosteric effect involving fructose-1,6-bisphosphate (FBP). To explore the molecular basis for this, a series of mutants were prepared and characterized, in which the possible candidate, Glu-432, was replaced in the rat M-1 isozyme and its allosteric mutant with the replacement of Ala-398 by Arg. Although these single mutants of Glu-432 remained nearly fully active, similar to the wild type, only the mutants with replacements by Lys and Ala were more efficiently activated by FBP when the enzymes were inhibited by L-phenylalanine. Kinetic analyses and ligand-induced fluorescence quenching studies using the allosteric double mutants indicated that the loss of a negative charge at residue 432 led to a dramatic decrease in the apparent activation constant and apparent K-d for FBP. Furthermore, this enhancement was found to be associated with the modification of the FBP-binding site rather than the alteration of the subunit assembly. These findings suggest that Glu-432 hinders the heterotropic allosteric effect by preventing the binding of FBP through a repulsive electrostatic interaction and thereby contributes to its unique unregulated properties, independent of the shifted allosteric transition.	Fukui Med Univ, Dept Biochem, Matsuoka, Fukui 9101193, Japan; Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Chikusa Ku, Nagoya, Aichi 4648601, Japan	University of Fukui; Osaka University; Nagoya University	Noguchi, T (corresponding author), Fukui Med Univ, Dept Biochem, 23-3 Shimoaizuki, Matsuoka, Fukui 9101193, Japan.	tnoguchi@agr.nagoya-u.ac.jp	Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURKE RL, 1983, J BIOL CHEM, V258, P2193; Cheng XD, 1996, J BIOL CHEM, V271, P6313, DOI 10.1074/jbc.271.11.6313; COLLINS RA, 1992, BIOCHEM SOC T, V21, pS63; CONSLER TG, 1990, BIOCHEMISTRY-US, V29, P10765, DOI 10.1021/bi00500a007; CONSLER TG, 1989, BIOCHEMISTRY-US, V28, P8756, DOI 10.1021/bi00448a012; CONSLER TG, 1992, BIOCHEMISTRY-US, V31, P7870, DOI 10.1021/bi00149a018; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Friesen RHE, 1998, J BIOL CHEM, V273, P14772, DOI 10.1074/jbc.273.24.14772; Friesen RHE, 1998, BIOCHEMISTRY-US, V37, P2949, DOI 10.1021/bi971990c; GARDENAS JM, 1982, METHOD ENZYMOL, V90, P140; GARDENAS JM, 1975, ISOZYMES, V1, P523; IBSEN KH, 1977, CANCER RES, V37, P341; Ikeda Y, 1998, J BIOL CHEM, V273, P12227, DOI 10.1074/jbc.273.20.12227; IKEDA Y, 1995, P NATL ACAD SCI USA, V92, P126, DOI 10.1073/pnas.92.1.126; IKEDA Y, 1995, J BIOL CHEM, V270, P12471, DOI 10.1074/jbc.270.21.12471; IKEDA Y, 1995, J BIOL CHEM, V270, P22223, DOI 10.1074/jbc.270.38.22223; Ikeda Y, 1997, J BIOL CHEM, V272, P20495, DOI 10.1074/jbc.272.33.20495; IMAMURA K, 1982, METHOD ENZYMOL, V90, P150; IMAMURA K, 1986, MARKERS HUMAN NEUROE, P191; Jurica MS, 1998, STRUCTURE, V6, P195, DOI 10.1016/S0969-2126(98)00021-5; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN TM, 1994, BIOCHEMISTRY-US, V33, P6301, DOI 10.1021/bi00186a033; MCNALLY T, 1989, FEBS LETT, V247, P312, DOI 10.1016/0014-5793(89)81359-6; MCNALLY T, 1990, BIOCHEM SOC T, V18, P258, DOI 10.1042/bst0180258; MUIRHEAD H, 1986, EMBO J, V5, P475, DOI 10.1002/j.1460-2075.1986.tb04236.x; MUIRHEAD H, 1990, BIOCHEM SOC T, V18, P193, DOI 10.1042/bst0180193; MURCOTT THL, 1992, EMBO J, V11, P3811, DOI 10.1002/j.1460-2075.1992.tb05472.x; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; OBERFELDER RW, 1984, BIOCHEMISTRY-US, V23, P3813, DOI 10.1021/bi00312a004; PIWNICAWORMS H, 1987, CURRENT PROTOCOLS MO; TAKENAKA M, 1991, EUR J BIOCHEM, V198, P101, DOI 10.1111/j.1432-1033.1991.tb15991.x; TAKENAKA M, 1989, J BIOL CHEM, V264, P2363	35	33	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9150	9156		10.1074/jbc.275.13.9150	http://dx.doi.org/10.1074/jbc.275.13.9150			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734049	hybrid			2022-12-27	WOS:000086206500013
J	Nicolas, E; Morales, V; Magnaghi-Jaulin, L; Harel-Bellan, A; Richard-Foy, H; Trouche, D				Nicolas, E; Morales, V; Magnaghi-Jaulin, L; Harel-Bellan, A; Richard-Foy, H; Trouche, D			RbAp48 belongs to the histone deacetylase complex that associates with the retinoblastoma protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUSCEPTIBILITY GENE-PRODUCT; CHROMATIN ASSEMBLY FACTOR-1; TRANSCRIPTIONAL REPRESSION; CELL-CYCLE; NEGATIVE REGULATOR; BINDING PROTEIN; E2F-1; FAMILY; YEAST; PROLIFERATION	The retinoblastoma susceptibility gene product, the Rb protein, is a key regulator of mammalian cell proliferation. One of the major targets of Rb is the S phase inducing E2F transcription factor. Once bound to E2F, Rb represses the expression of E2F-regulated genes. Transcriptional repression by Rb is believed to be crucial for the proper control of cell growth. Recently, we and others showed that Rb represses transcription through the recruitment of a histone deacetylase. Interestingly, we show here that the Rb-associated histone deacetylase complex could deacetylate polynucleosomal substrates, indicating that other proteins could be present within this complex. The Rb-associated protein RbAp48 belongs to many histone deacetylase complexes. We show here that the histone deacetylase HDAC1 is able to mediate the formation of a ternary complex containing Rb and RbAp48. Moreover, less deacetylase activity was found associated with Rb in cell extracts depleted for RbAp48 containing complexes, demonstrating that Rb, histone deacetylase, and RbAp48 are physically associated in live cells. Taken together, these data indicate that RbAp48 is a component of the histone deacetylase complex recruited by Rb, Finally, we found that E2F1 and RbAp48 are physically associated in the presence of Rb and HDAC1, suggesting that RbAp48 could be involved in transcriptional repression of E2F-responsive genes.	CNRS, UPR 9006, Lab Biol Mol Eucaryote, F-31062 Toulouse, France; CNRS, UPR 9079, IFC01, F-94801 Villejuif, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Trouche, D (corresponding author), CNRS, UPR 9006, Lab Biol Mol Eucaryote, 118 Route Narbonne, F-31062 Toulouse, France.	trouche@ibcg.biotoul.fr	Trouche, Didier/B-2854-2008; Nicolas, Estelle/C-4425-2008; Harel-Bellan, Annick/M-9795-2015	Nicolas, Estelle/0000-0003-0412-8477; Trouche, Didier/0000-0003-1398-6481; Harel-Bellan, Annick/0000-0002-2339-153X				ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BULGER M, 1995, P NATL ACAD SCI USA, V92, P11726, DOI 10.1073/pnas.92.25.11726; Chow KNB, 1996, MOL CELL BIOL, V16, P7173; De Luca P, 1998, J CELL BIOCHEM, V70, P281, DOI 10.1002/(SICI)1097-4644(19980801)70:2<281::AID-JCB13>3.0.CO;2-Q; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Gdula DA, 1998, GENE DEV, V12, P3206, DOI 10.1101/gad.12.20.3206; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; Iavarone A, 1999, MOL CELL BIOL, V19, P916; Johnson BE, 1998, MATH MECH SOLIDS, V3, P447, DOI 10.1177/108128659800300405; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Laj A, 1999, MOL CELL BIOL, V19, P6632; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Le Cam L, 1999, EMBO J, V18, P1878, DOI 10.1093/emboj/18.7.1878; Lu XW, 1998, CELL, V95, P981, DOI 10.1016/S0092-8674(00)81722-5; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NEVINS JR, 1995, CURR TOP MICROBIOL, V199, P25; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Pearson A, 1997, ONCOGENE, V15, P2643, DOI 10.1038/sj.onc.1201451; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; QIN XQ, 1995, MOL CELL BIOL, V15, P742; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Sellers WR, 1997, J CLIN ONCOL, V15, P3301, DOI 10.1200/JCO.1997.15.11.3301; Stiegler P, 1998, CANCER RES, V58, P5049; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Trouche D, 1997, PATHOL BIOL, V45, P5; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	61	108	112	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9797	9804		10.1074/jbc.275.13.9797	http://dx.doi.org/10.1074/jbc.275.13.9797			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734134	hybrid			2022-12-27	WOS:000086206500098
J	Radaev, S; Dastidar, P; Patel, M; Woodard, RW; Gatti, DL				Radaev, S; Dastidar, P; Patel, M; Woodard, RW; Gatti, DL			Structure and mechanism of 3-deoxy-D-manno-octulosonate 8-phosphate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE REACTION INTERMEDIATE; AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; CATALYTIC MECHANISM; KDO8P SYNTHASE; 3-DEOXY-D-ARABINO-HEPTULOSONATE-7-PHOSPHATE SYNTHASE; 3-DEOXY-D-MANNO-2-OCTULOSONATE-8-PHOSPHATE SYNTHASE; PROTEIN STRUCTURES; STEREOCHEMISTRY; PURIFICATION	3-Deoxy-D-manno-octulosonate 8-phosphate (KDO8P) synthase catalyzes the condensation of phosphoenolpyruvate (PEP) with arabinose B-phosphate (A5P) to form KDO8P and inorganic phosphate, KDO8P is the phosphorylated precursor of 3-deoxy-D-manno-octulosonate, an essential sugar of the lipopolysaccharide of Gram-negative bacteria. The crystal structure of the Escherichia coli KDO8P synthase has been determined by multiple wavelength anomalous diffraction and the model has been refined to 2.4 Angstrom (R-factor, 19.9%; R-free, 23.9%). KDO8P synthase is a homotetramer in which each monomer has the fold of a (beta/alpha)(8) barrel. On the basis of the features of the active site, PEP and A5P are predicted to bind with their phosphate moieties 13 Angstrom apart such that KDO8P synthesis would proceed via a linear intermediate. A reaction similar to KDO8P synthesis, the condensation of phosphoenolpyruvate, and erythrose 4-phosphate to form 3-deoxy-D-arabino-heptulosonate 7-phosphate (DAH7P), is catalyzed by DAH7P synthase, In the active site of DAH7P synthase the two substrates PEP and erythrose 4-phosphate appear to bind in a configuration similar to that proposed for PEP and A5P in the active site of KDO8P synthase, This observation suggests that KDO8P synthase and DAH7P synthase evolved from a common ancestor and that they adopt the same catalytic strategy.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Univ Michigan, Coll Pharm, Interdepartmental Program Med Chem, Ann Arbor, MI 48109 USA	Wayne State University; University of Michigan System; University of Michigan	Gatti, DL (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA.			Woodard, Ronald/0000-0002-7472-3653	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI042868] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053069] Funding Source: NIH RePORTER; NIAID NIH HHS [AI42868] Funding Source: Medline; NIGMS NIH HHS [GM53069] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BAASOV T, 1993, EUR J BIOCHEM, V217, P991, DOI 10.1111/j.1432-1033.1993.tb18330.x; Babbitt PC, 1997, J BIOL CHEM, V272, P30591, DOI 10.1074/jbc.272.49.30591; BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; BOLOTIN A, 1995, MICROBIOL-SGM, V141, P2219, DOI 10.1099/13500872-141-9-2219; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DELEO AB, 1968, BIOCHEM BIOPH RES CO, V32, P873, DOI 10.1016/0006-291X(68)90322-7; DOTSON GD, 1995, J BIOL CHEM, V270, P13698, DOI 10.1074/jbc.270.23.13698; DOTSON GD, 1993, BIOCHEMISTRY-US, V32, P12392, DOI 10.1021/bi00097a017; DSouza FW, 1997, BIOORG MED CHEM LETT, V7, P2457, DOI 10.1016/S0960-894X(97)10019-1; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; HEDSTROM L, 1988, BIOCHEM BIOPH RES CO, V157, P816, DOI 10.1016/S0006-291X(88)80322-X; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; KOHEN A, 1993, BIOORG MED CHEM LETT, V3, P1577, DOI 10.1016/S0960-894X(00)80021-9; KOHEN A, 1992, EUR J BIOCHEM, V208, P443, DOI 10.1111/j.1432-1033.1992.tb17206.x; KOTANI S, 1990, ADV EXP MED BIOL, V256, P13; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAFORTELLE ED, 1997, CRYSTALLOGR COMPUT, V7, P1; LEVIN DH, 1959, J BIOL CHEM, V234, P2532; Liang PH, 1997, BIOORG MED CHEM LETT, V7, P2463; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAY PH, 1983, ACS SYM SER, V231, P141; RAY PH, 1980, J BACTERIOL, V141, P635, DOI 10.1128/JB.141.2.635-644.1980; RICK PD, 1982, J BACTERIOL, V150, P447, DOI 10.1128/JB.150.2.447-455.1982; RICK PD, 1984, REV INFECT DIS, V6, P455; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; Sheflyan GY, 1999, BIOCHEMISTRY-US, V38, P14320, DOI 10.1021/bi9829884; Sheflyan GY, 1998, J AM CHEM SOC, V120, P11027, DOI 10.1021/ja9816281; Shumilin IA, 1999, STRUCTURE, V7, P865, DOI 10.1016/S0969-2126(99)80109-9; STEC B, 1990, J MOL BIOL, V211, P235, DOI 10.1016/0022-2836(90)90023-F; STEPHENS CM, 1992, J BIOL CHEM, V267, P5762; STEPHENS CM, 1991, J BIOL CHEM, V266, P20810; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684; van den Akker F, 1999, ACTA CRYSTALLOGR D, V55, P206, DOI 10.1107/S0907444998007161; WOISETSCHLAGER M, 1986, J BACTERIOL, V168, P437, DOI 10.1128/jb.168.1.437-439.1986	43	96	97	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9476	9484		10.1074/jbc.275.13.9476	http://dx.doi.org/10.1074/jbc.275.13.9476			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734095	hybrid			2022-12-27	WOS:000086206500059
J	Rigby, LJ; Epa, VC; Mackay, GA; Hulett, MD; Sutton, BJ; Gould, HJ; Hogarth, PM				Rigby, LJ; Epa, VC; Mackay, GA; Hulett, MD; Sutton, BJ; Gould, HJ; Hogarth, PM			Domain one of the high affinity IgE receptor, Fc epsilon RI, regulates binding to IgE through its interface with domain two	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; GAMMA-RII; IDENTIFICATION; REGIONS; SITES; PHAGE	The high affinity receptor for IgE, FceRI, binds IgE through the second Ig-like domain of the alpha subunit. The role of the first Ig-like domain is not well understood, but it is required for optimal binding of IgE to FceRI, either through a minor contact interaction or in a supporting structural capacity. The results reported here demonstrate that domain one of FceRI plays a major structural role supporting the presentation of the ligand-binding site, by interactions generated within the interdomain interface. Analysis of a series of chimeric receptors and point mutants indicated that specific residues within the A' strand of domain one are crucial to the maintenance of the interdomain interface, and IgE binding. Mutation of the Arg(15) and Phe(17) residues caused loss in ligand binding, and utilizing a homology model of Fc epsilon RI-alpha based on the solved structure of Fc gamma RIIa, it appears likely that this decrease is brought about by collapse of the interface and consequently the IgE-binding site. In addition discrepancies in results of previous studies using chimeric IgE receptors comprising Fc epsilon RI alpha with either Fc gamma RIIa or Fc gamma RIIIA can be explained by the presence or absence of Arg(15) and its influence on the IgE-binding site. The data presented here suggest that the second domain of FceRI a is the only domain involved in direct contact with the IgE ligand and that domain one has a structural function of great importance in maintaining the integrity of the interdomain interface and, through it, the ligand-binding site.	Austin Repatriat Med Ctr, Helen M Schutt Lab Immunol, Austin Res Inst, Heidelberg, Vic 3084, Australia; Victoria Univ Technol, Ctr Bioproc & Food Technol, Werribee, Vic 3030, Australia; Biomol Res Inst, Parkville, Vic 3052, Australia; Kings Coll London, Randall Inst, London WC2B 5RL, England; Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Div Cellular Pathol, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Div Cellular Pathol, Albuquerque, NM 87131 USA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Victoria University; University of London; King's College London; University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center	Hogarth, PM (corresponding author), Austin Repatriat Med Ctr, Helen M Schutt Lab Immunol, Austin Res Inst, Kronheimer Bldg, Heidelberg, Vic 3084, Australia.	pm.hogarth@ari.unimelb.edu.au	Epa, Vidana C./D-2320-2013; Hulett, Mark D/C-4160-2012	Hulett, Mark/0000-0003-2072-5968; Hogarth, Mark/0000-0002-0360-7890; Gould, Hannah/0000-0003-0411-688X; Mackay, Graham/0000-0002-9083-1304				BEAVIL AJ, 1993, BIOCHEM SOC T, V21, P968, DOI 10.1042/bst0210968; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; Cook JPD, 1997, BIOCHEMISTRY-US, V36, P15579, DOI 10.1021/bi9713005; Frishman D, 1997, PROTEINS, V27, P329, DOI 10.1002/(SICI)1097-0134(199703)27:3<329::AID-PROT1>3.0.CO;2-8; Garman SC, 1998, CELL, V95, P951, DOI 10.1016/S0092-8674(00)81719-5; Hogarth P M, 1994, Immunomethods, V4, P17, DOI 10.1006/immu.1994.1003; HOGARTH PM, 1992, IMMUNOL REV, V125, P21, DOI 10.1111/j.1600-065X.1992.tb00623.x; HULETT MD, 1993, EUR J IMMUNOL, V23, P640, DOI 10.1002/eji.1830230310; Hulett MD, 1999, J BIOL CHEM, V274, P13345, DOI 10.1074/jbc.274.19.13345; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MALLAMACI MA, 1993, J BIOL CHEM, V268, P22076; Maxwell KF, 1999, NAT STRUCT BIOL, V6, P437; Nechansky A, 1998, FEBS LETT, V441, P225, DOI 10.1016/S0014-5793(98)01558-0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; RIGBY LJ, 1996, IGE RECEPTOR FCERI F, P7; ROBERTSON MW, 1993, J BIOL CHEM, V268, P12736; ROST B, 1994, CABIOS, V10, P266; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SAMBROOK J, 1989, MOL CLONING LAB MANU, V1, P42; SCARSELLI E, 1993, FEBS LETT, V329, P223, DOI 10.1016/0014-5793(93)80226-K; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; SITKOFF D, 1994, J PHYS CHEM-US, V98, P1978, DOI 10.1021/j100058a043; Sondermann P, 1999, EMBO J, V18, P1095, DOI 10.1093/emboj/18.5.1095; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353	25	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9664	9672		10.1074/jbc.275.13.9664	http://dx.doi.org/10.1074/jbc.275.13.9664			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734118	hybrid			2022-12-27	WOS:000086206500082
J	Brinkman-Van der Linden, ECM; Sjoberg, ER; Juneja, LR; Crocker, PR; Varki, N; Varki, A				Brinkman-Van der Linden, ECM; Sjoberg, ER; Juneja, LR; Crocker, PR; Varki, N; Varki, A			Loss of N-glycolylneuraminic acid in human evolution - Implications for sialic acid recognition by siglecs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; I-TYPE LECTINS; ADHESION MOLECULE CD22-BETA; IMMUNOGLOBULIN SUPERFAMILY; ACETYLNEURAMINIC ACID; CELL-ADHESION; B-CELLS; BINDING SPECIFICITIES; MICROBIAL RECOGNITION; SIALOADHESIN FAMILY	The common sialic acids of mammalian cells are N-acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc), Humans are an exception, because of a mutation in CMP-sialic acid hydroxylase, which occurred after our common ancestor with great apes, We asked if the resulting loss of Neu5Gc and increase in Neu5Ac in humans alters the biology of the siglecs, which are Ig superfamily members that recognize sialic acids. Human siglec-1 (sialoadhesin) strongly prefers Neu5Ac over Neu5Gc. Thus, humans have a higher density of siglec-1 ligands than great apes, Siglec-1-positive macrophages in humans are found primarily in the perifollicular zone, whereas in chimpanzees they also occur in the marginal zone and surrounding the periarteriolar lymphocyte sheaths. Although only a subset of chimpanzee macrophages express siglec-1, most human macrophages are positive. A known evolutionary difference is the strong preference of mouse siglec-2 (CD22) for Neu5Gc, contrasting with human siglec-2, which binds Neu5Ac equally well. To ask when the preference for Neu5Gc was adjusted in the human lineage, we cloned the first three extracellular domains of siglec-2 from all of the great apes and examined their preference. In fact, siglec-2 had evolved a higher degree of recognition flexibility before Neu5Gc was lost in humans. Human siglec-3 (CD33) and siglec-6 (obesity-binding protein 1) also recognize both Neu5Ac and Neu5Gc, and siglec-5 may have some preference for Neu5Gc, Others showed that siglec-4a (myelin-associated glycoprotein) prefers Neu5Ac over Neu5Gc, Thus, the human loss of Neu5Gc may alter biological processes involving siglec-1, and possibly, siglec-4a or -5.	Univ Calif San Diego, Glycobiol Res & Training Ctr, CMM East, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Cytel Inc, San Diego, CA 92093 USA; Taiyo Kagaku Co, Yokaichi 510, Japan; Univ Dundee, Dundee DD1 5EH, Scotland	University of California System; University of California San Diego; University of California System; University of California San Diego; TAIYO KAGAKU CO., LTD.; University of Dundee	Varki, A (corresponding author), Univ Calif San Diego, Glycobiol Res & Training Ctr, CMM East, La Jolla, CA 92093 USA.	avarki@ucsd.edu		Crocker, Paul/0000-0001-6230-0293	NIGMS NIH HHS [R01-GM3273] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREW SM, 1987, HISTOCHEM J, V19, P426, DOI 10.1007/BF01675753; Arnason U, 1996, J MOL EVOL, V43, P650, DOI 10.1007/BF02202113; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P10242, DOI 10.1073/pnas.89.21.10242; Barnes YC, 1999, BLOOD, V93, P1245, DOI 10.1182/blood.V93.4.1245.404k09_1245_1252; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BRAESCHANDERSEN S, 1994, J BIOL CHEM, V269, P11783; Brinkman-Van der Linden ECM, 2000, J BIOL CHEM, V275, P8625, DOI 10.1074/jbc.275.12.8625; CACCONE A, 1989, EVOLUTION, V43, P925, DOI 10.1111/j.1558-5646.1989.tb02540.x; Chou HH, 1998, P NATL ACAD SCI USA, V95, P11751, DOI 10.1073/pnas.95.20.11751; Collins BE, 1997, J BIOL CHEM, V272, P16889, DOI 10.1074/jbc.272.27.16889; Collins BE, 1997, J BIOL CHEM, V272, P1248, DOI 10.1074/jbc.272.2.1248; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; CROCKER PR, 1995, J CLIN INVEST, V95, P635, DOI 10.1172/JCI117708; Crocker PR, 1996, BIOCHEM SOC T, V24, P150, DOI 10.1042/bst0240150; CROCKER PR, 1991, EMBO J, V10, P1661, DOI 10.1002/j.1460-2075.1991.tb07689.x; CROCKER PR, 1990, BLOOD, V76, P1131; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; Crocker PR, 1998, GLYCOBIOLOGY, V8; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Falco M, 1999, J EXP MED, V190, P793, DOI 10.1084/jem.190.6.793; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; Gagneux P, 1999, GLYCOBIOLOGY, V9, P747, DOI 10.1093/glycob/9.8.747; GOODMAN M, 1983, NATURE, V303, P546, DOI 10.1038/303546a0; HANASAKI K, 1995, J BIOL CHEM, V270, P7533, DOI 10.1074/jbc.270.13.7533; HANASAKI K, 1995, J BIOL CHEM, V270, P7543, DOI 10.1074/jbc.270.13.7543; HIGA HH, 1985, J BIOL CHEM, V260, P8838; HIGASHIHARA T, 1991, INT ARCH ALLER A IMM, V95, P231, DOI 10.1159/000235434; HODSON HH, 1967, FOLIA PRIMATOL, V7, P1; Irie A, 1998, J BIOL CHEM, V273, P15866, DOI 10.1074/jbc.273.25.15866; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Karlsson KA, 1998, MOL MICROBIOL, V29, P1, DOI 10.1046/j.1365-2958.1998.00854.x; KARLSSON KA, 1995, CURR OPIN STRUC BIOL, V5, P622, DOI 10.1016/0959-440X(95)80054-9; KAWANO T, 1995, J BIOL CHEM, V270, P16458, DOI 10.1074/jbc.270.27.16458; Kelm S, 1998, EUR J BIOCHEM, V255, P663, DOI 10.1046/j.1432-1327.1998.2550663.x; KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; Kelm S, 1997, INT REV CYTOL, V175, P137, DOI 10.1016/S0074-7696(08)62127-0; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; KOZUTSUMI Y, 1990, J BIOCHEM, V108, P704, DOI 10.1093/oxfordjournals.jbchem.a123268; May AP, 1998, MOL CELL, V1, P719, DOI 10.1016/S1097-2765(00)80071-4; MCCLURE HM, 1972, FOLIA PRIMATOL, V18, P284, DOI 10.1159/000155484; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MERRICK JM, 1978, INT ARCH ALLER A IMM, V57, P477, DOI 10.1159/000232140; Muchmore EA, 1998, AM J PHYS ANTHROPOL, V107, P187, DOI 10.1002/(SICI)1096-8644(199810)107:2<187::AID-AJPA5>3.3.CO;2-M; MUCHMORE EA, 1989, J BIOL CHEM, V264, P20216; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; Odaka M, 1998, ANN NEUROL, V43, P829, DOI 10.1002/ana.410430619; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Otipoby KL, 1996, NATURE, V384, P634, DOI 10.1038/384634a0; Patel N, 1999, J BIOL CHEM, V274, P22729, DOI 10.1074/jbc.274.32.22729; POWELL LD, 1993, J BIOL CHEM, V268, P7019; POWELL LD, 1995, J BIOL CHEM, V270, P7523, DOI 10.1074/jbc.270.13.7523; POWELL LD, 1994, J BIOL CHEM, V269, P10628; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; Razi N, 1998, P NATL ACAD SCI USA, V95, P7469, DOI 10.1073/pnas.95.13.7469; SARICH VM, 1967, SCIENCE, V158, P1200, DOI 10.1126/science.158.3805.1200; Sato S, 1997, P NATL ACAD SCI USA, V94, P13158, DOI 10.1073/pnas.94.24.13158; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; Schauer R, 1982, SIALIC ACIDS CHEM ME, V10; Seko A, 1997, BBA-GEN SUBJECTS, V1335, P23, DOI 10.1016/S0304-4165(96)00118-3; SGROI D, 1993, J BIOL CHEM, V268, P7011; Sharon N, 1996, ADV EXP MED BIOL, V408, P1; SHAW L, 1988, BIOL CHEM H-S, V369, P477, DOI 10.1515/bchm3.1988.369.1.477; Shi WX, 1996, J BIOL CHEM, V271, P31526, DOI 10.1074/jbc.271.49.31526; SIBLEY CG, 1990, J MOL EVOL, V30, P202, DOI 10.1007/BF02099992; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; Steiniger B, 1997, IMMUNOLOGY, V92, P307, DOI 10.1046/j.1365-2567.1997.00328.x; Takahata N, 1997, P NATL ACAD SCI USA, V94, P4811, DOI 10.1073/pnas.94.9.4811; Tedder TF, 1997, ANNU REV IMMUNOL, V15, P481, DOI 10.1146/annurev.immunol.15.1.481; Tuscano JM, 1999, BLOOD, V94, P1382, DOI 10.1182/blood.V94.4.1382.416k14_1382_1392; VANDENBERG TK, 1992, J EXP MED, V176, P647, DOI 10.1084/jem.176.3.647; vanderMerwe PA, 1996, J BIOL CHEM, V271, P9273, DOI 10.1074/jbc.271.16.9273; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; Varki A, 1999, ESSENTIALS GLYCOBIOL, P195; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Yang LJS, 1996, P NATL ACAD SCI USA, V93, P814, DOI 10.1073/pnas.93.2.814	79	119	130	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8633	8640		10.1074/jbc.275.12.8633	http://dx.doi.org/10.1074/jbc.275.12.8633			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722703	hybrid			2022-12-27	WOS:000086507700053
J	Du, XL; Frei, H; Kim, SH				Du, XL; Frei, H; Kim, SH			The mechanism of GTP hydrolysis by Ras probed by fourier transform infrared spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-HA-RAS; TRANSITION-STATE; CRYSTAL-STRUCTURE; TYROSINE PHOSPHATASE; PHOSPHORYL-TRANSFER; ATP HYDROLYSIS; P21 PROTEINS; COMPLEX; GDP; NUCLEOTIDES	Time-resolved Fourier transform infrared spectroscopy (FTIR) in combination with photo-induced release of O-18-labeled caged nucleotide has been employed to address mechanistic issues of GTP hydrolysis by Ras protein. Infrared spectroscopy of Ras complexes with nitrophenylethyl (NPE)-[alpha-O-18(2)]GTP, NPE-[beta-O-18(4)]GTP, or NPE-[gamma-O-18(3)]GTP upon photolysis or during hydrolysis afforded a substantially improved mode assignment of phosphoryl group absorptions. Photolysis spectra of hydroxyphenylacyl-GTP and hydroxyphenylacyl-GDP bound to Ras and several mutants, Ras(Gly(12))-Mn2+, Ras(Pro(12)), Ras(Ala(12)), and Ras(Val(12)), mere obtained and yielded valuable information about structures of GTP or GDP bound to has mutants. IR spectra revealed stronger binding of GDP beta-PO32- moiety by Ras mutants with higher activity, suggesting that the transition state is largely GDP-like, Analysis of the photolysis and hydrolysis FTIR spectra of the [beta-nonbridge-O-18(2), alpha beta-bridge-O-18]GTP isotopomer allowed us to probe for positional isotope exchange. Such a reaction might signal the existence of metaphosphate as a discrete intermediate, a key species for a dissociative mechanism. No positional isotope exchange was observed. Overall, our results support a concerted mechanism, but the transition state seems to have a considerable amount of dissociative character. This work demonstrates that time-resolved FTIR is highly suitable for monitoring positional isotope exchange and advantageous in many aspects over previously used methods, such as P-31 NMR and mass spectrometry.	Univ Calif Berkeley, Biophys Grad Program, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Kim, SH (corresponding author), Univ Calif Berkeley, Melvin Calvin Lab, Room 220, Berkeley, CA 94720 USA.	SHKim@LBL.GOV						ADMIRAAL SJ, 1995, CHEM BIOL, V2, P729, DOI 10.1016/1074-5521(95)90101-9; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRUNGER AT, 1990, P NATL ACAD SCI USA, V87, P4849, DOI 10.1073/pnas.87.12.4849; Cepus V, 1998, BIOCHEMISTRY-US, V37, P10263, DOI 10.1021/bi973183j; CHAPMAN AC, 1964, SPECTROCHIM ACTA, V20, P937, DOI 10.1016/0371-1951(64)80094-1; CHUNG HH, 1993, SCIENCE, V259, P806, DOI 10.1126/science.8430333; COHN M, 1980, J AM CHEM SOC, V102, P913, DOI 10.1021/ja00523a003; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CULLIS PM, 1987, J CHEM SOC CHEM COMM, P783, DOI 10.1039/c39870000783; FEUERSTEIN J, 1989, J BIOL CHEM, V264, P6188; FEUERSTEIN J, 1987, EUR J BIOCHEM, V162, P49, DOI 10.1111/j.1432-1033.1987.tb10540.x; FOLEY CK, 1992, BIOCHEMISTRY-US, V31, P4951, DOI 10.1021/bi00136a005; FRECH M, 1994, BIOCHEMISTRY-US, V33, P3237, DOI 10.1021/bi00177a014; GEEVES MA, 1980, BIOCHEMISTRY-US, V19, P4748, DOI 10.1021/bi00562a005; Geyer M, 1996, BIOCHEMISTRY-US, V35, P10308, DOI 10.1021/bi952858k; Givens R S, 1998, Methods Enzymol, V291, P1; GOODY RS, 1982, ANAL BIOCHEM, V119, P322, DOI 10.1016/0003-2697(82)90592-9; HENGGE AC, 1995, BIOCHEMISTRY-US, V34, P13982, DOI 10.1021/bi00043a003; Hengge AC, 1996, BIOCHEMISTRY-US, V35, P7084, DOI 10.1021/bi960255i; Hengge AC, 1997, BIOCHEMISTRY-US, V36, P10185, DOI 10.1021/bi9706374; Hengge AC, 1997, BIOCHEMISTRY-US, V36, P7928, DOI 10.1021/bi970364c; HOARD DE, 1965, J AM CHEM SOC, V87, P1785, DOI 10.1021/ja01086a031; HOLLFELDER F, 1995, BIOCHEMISTRY-US, V34, P12255, DOI 10.1021/bi00038a021; Hu JS, 1997, BIOCHEMISTRY-US, V36, P5045, DOI 10.1021/bi963010e; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; LOWE G, 1978, J CHEM SOC PERK T 1, P1622, DOI 10.1039/p19780001622; Maegley KA, 1996, P NATL ACAD SCI USA, V93, P8160, DOI 10.1073/pnas.93.16.8160; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MIURA K, 1986, JPN J CANCER RES, V77, P45; MOKRASCH LC, 1960, BIOCHIM BIOPHYS ACTA, V37, P442, DOI 10.1016/0006-3002(60)90500-X; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Park CH, 1997, J AM CHEM SOC, V119, P2453, DOI 10.1021/ja9635589; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; RAUSHEL FM, 1988, CRC CR REV BIOCH MOL, V23, P1, DOI 10.3109/10409238809103118; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; Schweins T, 1996, BIOCHEMISTRY-US, V35, P14232, DOI 10.1021/bi961119g; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; Shimanouchi T., 1964, ADVANCES CHEMICAL PH, V7, P435; SLOAN JJ, 1989, ADV SPECTROSC, V18, P219; SMITHERS GW, 1990, ARCH BIOCHEM BIOPHYS, V280, P416, DOI 10.1016/0003-9861(90)90351-X; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; TAKEUCHI H, 1988, J AM CHEM SOC, V110, P392, DOI 10.1021/ja00210a013; THATCHER G, 1989, MECH CATALYSIS NUCLE, V25; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; TONGE PJ, 1990, BIOCHEMISTRY-US, V29, P10723, DOI 10.1021/bi00500a002; WALKER JW, 1989, METHOD ENZYMOL, V172, P288; Wang JH, 1998, BIOCHEMISTRY-US, V37, P11106, DOI 10.1021/bi980471m; WEBB MR, 1981, J BIOL CHEM, V256, P910; WEBB MR, 1980, BIOCHEMISTRY-US, V19, P4744, DOI 10.1021/bi00562a004	52	75	75	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8492	8500		10.1074/jbc.275.12.8492	http://dx.doi.org/10.1074/jbc.275.12.8492			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722686	hybrid			2022-12-27	WOS:000086507700036
J	Klausberger, T; Fuchs, K; Mayer, B; Ehya, N; Sieghart, W				Klausberger, T; Fuchs, K; Mayer, B; Ehya, N; Sieghart, W			GABA(A) receptor assembly - Identification and structure of gamma(2) sequences forming the intersubunit contacts with alpha(1) and beta(3) subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; ALLOSTERIC LIGANDS; NEURAL NETWORKS; A RECEPTORS; SUBTYPES; BINDING; STOICHIOMETRY; PHARMACOLOGY; EXPRESSION; SIGNALS	GABA(A) receptors are ligand-gated chloride channels composed of five homologous subunits that specifically recognize one another and assemble around an aqueous pore. To identify domains responsible for the specificity of subunit association, we constructed C-terminal truncated gamma(2) subunits, as well as mutated and chimeric fragments. From their ability to interfere with alpha(1)beta(3)gamma(2) receptor assembly and to associate with full-length subunits, we concluded that amino acid sequences gamma(2)-(91-104) and gamma(2)-(83-90) form the sites mediating assembly with alpha(1) and beta(3) subunits, respectively, Neural network-based secondary structure prediction, Monte Carlo optimization, and hydrophobicity analysis led to the conclusion that these sites also form the intersubunit contacts in the completely assembled receptor and provided important information on the benzodiazepine-binding site and structure of GABA(A) receptors.	Univ Vienna, Psychiat Clin, Sect Biochem Psychiat, A-1090 Vienna, Austria; Univ Vienna, Inst Theoret Chem & Radiat Chem, A-1090 Vienna, Austria	University of Vienna; University of Vienna	Sieghart, W (corresponding author), Univ Vienna, Psychiat Clin, Sect Biochem Psychiat, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Sieghart, Werner/A-4877-2013	Sieghart, Werner/0000-0002-0443-0302				Barnard EA, 1998, PHARMACOL REV, V50, P291; Chang YC, 1996, J NEUROSCI, V16, P5415; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Ebert V, 1999, NEUROCHEM INT, V34, P453, DOI 10.1016/S0197-0186(99)00039-X; Eertmoed AL, 1999, J NEUROSCI, V19, P6298; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FRITSCHY JM, 1992, P NATL ACAD SCI USA, V89, P6726, DOI 10.1073/pnas.89.15.6726; Hackam AS, 1997, J BIOL CHEM, V272, P13750, DOI 10.1074/jbc.272.21.13750; Hackam AS, 1998, J NEUROCHEM, V70, P40; IM WB, 1995, J BIOL CHEM, V270, P26063, DOI 10.1074/jbc.270.44.26063; Jechlinger M, 1998, J NEUROSCI, V18, P2449; KLEIN CT, 1996, THEOCHEM-J MOL STRUC, V370, P33; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; NAYEEM N, 1994, J NEUROCHEM, V62, P815; NEMETHY G, 1992, J PHYS CHEM-US, V96, P6472, DOI 10.1021/j100194a068; Nusser Z, 1998, J NEUROSCI, V18, P1693; PRITCHETT DB, 1989, P NATL ACAD SCI USA, V90, P7558; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SHEN NV, 1993, NEURON, V11, P67; Sieghart W, 1999, NEUROCHEM INT, V34, P379, DOI 10.1016/S0197-0186(99)00045-5; SIEGHART W, 1995, PHARMACOL REV, V47, P181; Sigel E, 1998, MOL PHARMACOL, V54, P1097, DOI 10.1124/mol.54.6.1097; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; SLANY A, 1995, EUR J PHARM-MOLEC PH, V291, P99, DOI 10.1016/0014-2999(95)90084-5; SLANY A, 1995, MOL PHARMACOL, V48, P385; Tretter V, 1997, J NEUROSCI, V17, P2728; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; WHITE BA, 1993, PCR PROTOCOLS, P251; WISDEN W, 1992, J NEUROSCI, V12, P1040; Zezula J, 1996, EUR J PHARMACOL, V301, P207, DOI 10.1016/0014-2999(96)00066-0; [No title captured]	34	66	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8921	8928		10.1074/jbc.275.12.8921	http://dx.doi.org/10.1074/jbc.275.12.8921			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722739	hybrid			2022-12-27	WOS:000086507700089
J	Minami, Y; Kawasaki, H; Minami, M; Tanahashi, N; Tanaka, K; Yahara, I				Minami, Y; Kawasaki, H; Minami, M; Tanahashi, N; Tanaka, K; Yahara, I			A critical role for the proteasome activator PA28 in the Hsp90-dependent protein refolding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; MOLECULAR CHAPERONES; HEAT-SHOCK; REACTION CYCLE; DNAJ HOMOLOG; ATP BINDING; HSP90; REGULATOR; SUBUNITS; PATHWAYS	The 90-kDa heat shock protein, Hsp90, was previously shown to capture firefly luciferase during thermal inactivation and prevent it from undergoing an irreversible off-pathway aggregation, thereby maintaining it in a folding-competent state. While Hsp90 by itself was not sufficient to refold the denatured luciferase, addition of rabbit reticulocyte lysate remarkably restored the luciferase activity. Here we demonstrate that Hsc70, Hsp40, and the 20 S proteasome activator PA28 are the effective components in reticulocyte lysate, Purified Hsc70, Hsp40, and PA28 were necessary and sufficient to fully reconstitute Hsp90-initiated refolding. Kinetics of substrate binding support the idea that PA28 acts as the molecular link between the Hsp90-dependent capture of unfolded proteins and the Hsc70- and ATP-dependent refolding process.	Oita Med Univ, Dept Biochem, Oita 8795593, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Oncol, Bunkyo Ku, Tokyo 1138613, Japan; Tokyo Metropolitan Inst Med Sci, Dept Cell Biol, Bunkyo Ku, Tokyo 1138613, Japan; Japan Sci & Technol Corp, CREST, Yokohama, Kanagawa, Japan	Oita University; Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science; Japan Science & Technology Agency (JST)	Minami, Y (corresponding author), Oita Med Univ, Dept Biochem, 1-1 Idaigaoka, Oita 8795593, Japan.		Kawasaki, Hiroshi/C-3048-2011	Kawasaki, Hiroshi/0000-0002-2517-159X				AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Bukau B, 1996, TRENDS CELL BIOL, V6, P480, DOI 10.1016/0962-8924(96)84946-4; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; Gottesman S, 1997, CELL, V91, P435, DOI 10.1016/S0092-8674(00)80428-6; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hendil KB, 1998, BIOCHEM J, V332, P749, DOI 10.1042/bj3320749; HOHFELD J, 1995, CELL, V83, P589; JACOB U, 1995, J BIOL CHEM, V270, P7288; JACOB U, 1994, TRENDS BIOCHEM SCI, V19, P205; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; Kandil E, 1997, IMMUNOGENETICS, V46, P337, DOI 10.1007/s002510050281; KAWASAKI H, 1990, ANAL BIOCHEM, V191, P332, DOI 10.1016/0003-2697(90)90227-Z; Knowlton JR, 1997, NATURE, V390, P639, DOI 10.1038/37670; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Maruya M, 1999, J MOL BIOL, V285, P903, DOI 10.1006/jmbi.1998.2349; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; MINAMI Y, 1994, MOL CELL BIOL, V14, P1459, DOI 10.1128/MCB.14.2.1459; Nathan DF, 1997, P NATL ACAD SCI USA, V94, P12949, DOI 10.1073/pnas.94.24.12949; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; Rassow J, 1997, TRENDS CELL BIOL, V7, P129, DOI 10.1016/S0962-8924(96)10056-8; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; SHUE GL, 1994, J BIOL CHEM, V269, P2707; Song XL, 1996, J BIOL CHEM, V271, P26410, DOI 10.1074/jbc.271.42.26410; Song XL, 1997, J BIOL CHEM, V272, P27994, DOI 10.1074/jbc.272.44.27994; Tanahashi N, 1997, GENES CELLS, V2, P195, DOI 10.1046/j.1365-2443.1997.d01-308.x; TANAKA K, 1988, J BIOL CHEM, V263, P16209; Terada K, 1997, J CELL BIOL, V139, P1089, DOI 10.1083/jcb.139.5.1089; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; Yonehara M, 1996, J BIOL CHEM, V271, P2641, DOI 10.1074/jbc.271.5.2641; Zhang ZG, 1999, BIOCHEMISTRY-US, V38, P5651, DOI 10.1021/bi990056+	49	70	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					9055	9061		10.1074/jbc.275.12.9055	http://dx.doi.org/10.1074/jbc.275.12.9055			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722756	hybrid			2022-12-27	WOS:000086507700106
J	Rensen, PCN; Jong, MC; van Vark, LC; van der Boom, H; Hendriks, WL; van Berkel, TJC; Biessen, EAL; Havekes, LM				Rensen, PCN; Jong, MC; van Vark, LC; van der Boom, H; Hendriks, WL; van Berkel, TJC; Biessen, EAL; Havekes, LM			Apolipoprotein E is resistant to intracellular degradation in vitro and in vivo - Evidence for retroendocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HEPARAN-SULFATE PROTEOGLYCANS; RECEPTOR-MEDIATED ENDOCYTOSIS; MOUSE PERITONEAL-MACROPHAGES; TRIGLYCERIDE-RICH LIPOPROTEIN; LDL-RECEPTOR; CHYLOMICRON REMNANTS; HUMAN-FIBROBLASTS; CULTURED-CELLS; HEPG2 CELLS	Apolipoprotein E (apoE) is an important determinant for the uptake of triglyceride-rich lipoproteins and emulsions by the liver, but the intracellular pathway of apoE following particle internalization is poorly defined. In the present study, we investigated whether retroendocytosis is a unique feature of apoE as compared with apoB by studying the intracellular fate of very low density lipoprotein-sized apoE-containing triglyceride-rich emulsion particles and LDL after LDLr-mediated uptake. Incubation of HepG2 cells with [B-3]cholesteryl oleate-labeled particles at 37 degrees C led to a rapid release of [H-3]cholesterol within 30 min for both LDL and emulsion particles. In contrast, emulsion-derived I-125-apoE was more resistant to degradation (greater than or equal to 120 min) than LDL-derived I-125-apoB (30 min). Incubation at 18 degrees C, which allows endosomal uptake but prevents lysosomal degradation, with subsequent incubation at 37 degrees C resulted in a time-dependent release of intact apoE from the cells (up to 14% of the endocytosed apoE at 4 h). The release of apoE was accelerated by the presence of protein-free emulsion (20%) or high density lipoprotein (26%). Retroendocytosis of intact particles could be excluded since little intact [H-3]cholesteryl oleate was released (<3%). In contrast, the degradation of LDL was complete with virtually no secretion of intact apoB into the medium. The intracellular stability of apoE was also demonstrated after hepatic uptake in C57Bl/6 mice. Intravenous injection of I-125-apoE and [H-3]cholesteryl oleate-labeled emulsions resulted in efficient LDLr-mediated uptake of both components by the liver (45-50% of the injected dose after 20 min). At 1 h after injection, only 15-20% of the hepatic I-125-apoE was degraded, whereas 75% of the [H-3]cholesteryl oleate was hydrolyzed. From these data we conclude that following LDLr-mediated internalization by liver cells, apoE can escape degradation and can be resecreted. This sequence of events may allow apoE to participate in its hypothesized intracellular functions such as mediator of the post-lysosomal trafficking of Lipids and very low density lipoprotein assembly.	Leiden Univ, Leiden Amsterdam Ctr Drug Res, Syllvius Lab, Div Biopharmaceut, NL-2300 RA Leiden, Netherlands; TNO Prevent & Hlth, Gaubius Lab, NL-2301 CE Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Cardiol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Gen Internal Med, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC; Netherlands Organization Applied Science Research; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Rensen, PCN (corresponding author), Leiden Univ, Leiden Amsterdam Ctr Drug Res, Syllvius Lab, Div Biopharmaceut, POB 9503, NL-2300 RA Leiden, Netherlands.		Rensen, Patrick C.N./D-7176-2018; Van Berkel, Theo/ABD-7677-2021	Rensen, Patrick C.N./0000-0002-8455-4988; 				AlHaideri M, 1997, BIOCHEMISTRY-US, V36, P12766, DOI 10.1021/bi9631024; AULINSKAS TH, 1985, ARTERIOSCLEROSIS, V5, P45, DOI 10.1161/01.ATV.5.1.45; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1995, CIRCULATION S, V92, P691; BIESSEN EAL, 1994, BIOCHEM J, V302, P283, DOI 10.1042/bj3020283; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN MS, 1979, P NATL ACAD SCI USA, V76, P3330, DOI 10.1073/pnas.76.7.3330; CHEN CM, 1997, CIRCULATION S1, V96, P346; CHEN CM, 1995, CIRCULATION S, V92, P691; CHOI SY, 1993, J BIOL CHEM, V268, P15804; DAHAN S, 1994, J CELL BIOL, V127, P1859, DOI 10.1083/jcb.127.6.1859; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; de Beer F, 1999, ARTERIOSCL THROM VAS, V19, P633, DOI 10.1161/01.ATV.19.3.633; DORY L, 1991, J LIPID RES, V32, P783; DUNN WA, 1980, J BIOL CHEM, V255, P5971; EISENBERG S, 1988, ARTERIOSCLEROSIS, V8, P480, DOI 10.1161/01.ATV.8.5.480; Fazio S, 1999, J BIOL CHEM, V274, P8247, DOI 10.1074/jbc.274.12.8247; GIANTURCO SH, 1983, J BIOL CHEM, V258, P4526; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; HAMILTON RL, 1990, J LIPID RES, V31, P1589; Heeren J, 1999, J CELL SCI, V112, P349; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Huang YD, 1998, J BIOL CHEM, V273, P26388, DOI 10.1074/jbc.273.41.26388; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; Ishibashi S, 1996, J BIOL CHEM, V271, P22422, DOI 10.1074/jbc.271.37.22422; JACKLE S, 1991, J BIOL CHEM, V266, P1396; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1993, J BIOL CHEM, V268, P10160; Ji ZS, 1998, J BIOL CHEM, V273, P13452, DOI 10.1074/jbc.273.22.13452; JI ZS, 1994, ARTERIOSCLER THROMB, V14, P2025, DOI 10.1161/01.ATV.14.12.2025; Kuipers F, 1997, J CLIN INVEST, V100, P2915, DOI 10.1172/JCI119841; LILLYSTAUDERMAN M, 1993, J LIPID RES, V34, P190; LOMBARDI P, 1993, BIOCHEM J, V290, P509, DOI 10.1042/bj2900509; LOMBARDI P, 1993, J BIOL CHEM, V268, P26113; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mahley RW, 1999, J LIPID RES, V40, P1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MORTIMER BC, 1995, J BIOL CHEM, V270, P28767, DOI 10.1074/jbc.270.48.28767; MYERS JN, 1993, J CELL BIOL, V123, P1389, DOI 10.1083/jcb.123.6.1389; PITAS RE, 1979, P NATL ACAD SCI USA, V76, P2311, DOI 10.1073/pnas.76.5.2311; PULCINI T, 1995, BBA-LIPID LIPID MET, V1254, P13, DOI 10.1016/0005-2760(94)00156-S; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; REDGRAVE TG, 1985, BIOCHIM BIOPHYS ACTA, V835, P104, DOI 10.1016/0005-2760(85)90036-0; RENSEN PCN, 1995, NAT MED, V1, P221, DOI 10.1038/nm0395-221; Rensen PCN, 1997, MOL PHARMACOL, V52, P445, DOI 10.1124/mol.52.3.445; Rensen PCN, 1997, J LIPID RES, V38, P1070; Rensen PCN, 1996, J BIOL CHEM, V271, P14791, DOI 10.1074/jbc.271.25.14791; Schmitt M, 1999, J LIPID RES, V40, P39; SCHWIEGELSHOHN B, 1995, J BIOL CHEM, V270, P1761, DOI 10.1074/jbc.270.4.1761; SHIMANO H, 1994, J CLIN INVEST, V93, P2215, DOI 10.1172/JCI117218; TABAS I, 1991, J CELL BIOL, V115, P1547, DOI 10.1083/jcb.115.6.1547; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; van Dijk KW, 1999, J LIPID RES, V40, P336; VANDIJK MCM, 1991, BIOCHEM J, V279, P863, DOI 10.1042/bj2790863; VOGEL T, 1985, P NATL ACAD SCI USA, V82, P8696, DOI 10.1073/pnas.82.24.8696; WEISGRABER KH, 1991, J BIOL CHEM, V266, P12029; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WINDLER E, 1980, J BIOL CHEM, V255, P8303; Windler E, 1996, HEPATOLOGY, V24, P344; WU AL, 1979, J BIOL CHEM, V254, P7316; YE SQ, 1992, J BIOL CHEM, V267, P21961	65	64	64	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8564	8571		10.1074/jbc.275.12.8564	http://dx.doi.org/10.1074/jbc.275.12.8564			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722695	Green Published, hybrid			2022-12-27	WOS:000086507700045
J	Schaloske, R; Schlatterer, C; Malchow, D				Schaloske, R; Schlatterer, C; Malchow, D			A xestospongin C-sensitive Ca2+ store is required for cAMP-induced Ca2+ influx and cAMP oscillations in Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; INTRACELLULAR CALCIUM; MOLECULAR-GENETICS; ACTIN-FILAMENTS; PLASMA-MEMBRANE; DISCOIDEUM; CELLS; MECHANISM; CYCLASE; RELEASE	Xestospongin C (XeC) is known to bind to the inositol 1,4,5-trisphosphate (IP3)-sensitive store in mammalian cells and to inhibit IP3- and thapsigargin-induced Ca2+ release. In this study we show that this is also true for Dictyostelium, In addition, XeC inhibited Ca2+ uptake into purified vesicle fractions and induced Ca2+ release. This suggests that, in the case of Dictyostelium, XeC opens rather than plugs the LP, receptor channel as was proposed for mammalian cells (Gafni, J., Munsch, J. A., Lam, T. H., Catlin, RI. C., Costa, L. G., Molinski, T, F., and Pessah, I. N. (1997) Neuron 19, 725-733), In order to elucidate the function of the XeC-sensitive Ca2+ store in Dictyostelium during differentiation, we applied XeC to the cells and found that it caused a time-dependent increase of basal [Ca2+](i) and inhibited cAMP-induced Ca2+ influx in single cells as well as in cell suspensions. Moreover, XeC blocked light scattering spikes and pulsatile cAMP signaling.	Univ Konstanz, Fac Biol, D-78457 Constance, Germany	University of Konstanz	Malchow, D (corresponding author), Univ Konstanz, Fac Biol, Postfach 55 60, D-78457 Constance, Germany.							BUMANN J, 1986, DIFFERENTIATION, V31, P85, DOI 10.1111/j.1432-0436.1986.tb00387.x; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; CONDEELIS J, 1982, J CELL BIOL, V94, P466, DOI 10.1083/jcb.94.2.466; Cubitt AB, 1998, DEV BIOL, V196, P77, DOI 10.1006/dbio.1997.8831; FLAADT H, 1993, J CELL SCI, V105, P1131; FRANKE J, 1992, CELL SIGNAL, V4, P471, DOI 10.1016/0898-6568(92)90016-2; FUTRELLE RP, 1982, J CELL BIOL, V92, P807, DOI 10.1083/jcb.92.3.807; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; GERISCH G, 1974, P NATL ACAD SCI USA, V71, P2118, DOI 10.1073/pnas.71.5.2118; GERISCH G, 1979, J EXP BIOL, V81, P33; GERISCH G, 1975, BIOCHEM BIOPH RES CO, V65, P364, DOI 10.1016/S0006-291X(75)80102-1; Gerisch G, 1976, Adv Cyclic Nucleotide Res, V7, P49; GOLDBETER A, 1977, P NATL ACAD SCI USA, V74, P1543, DOI 10.1073/pnas.74.4.1543; GOLLNICK F, 1991, EUR J CELL BIOL, V55, P262; Groner M, 1996, CELL CALCIUM, V19, P105, DOI 10.1016/S0143-4160(96)90079-2; Gu C, 1999, J BIOL CHEM, V274, P8012, DOI 10.1074/jbc.274.12.8012; Hurley JH, 1999, J BIOL CHEM, V274, P7599, DOI 10.1074/jbc.274.12.7599; Malchow D, 1996, BIOCHEM J, V319, P323, DOI 10.1042/bj3190323; MILNE JL, 1989, EXP CELL RES, V185, P21, DOI 10.1016/0014-4827(89)90033-5; Moniakis J, 1999, J CELL SCI, V112, P405; MONK PB, 1989, PHILOS T R SOC B, V323, P185, DOI 10.1098/rstb.1989.0005; Newell PC, 1995, EXPERIENTIA, V51, P1155, DOI 10.1007/BF01944733; OYAMA M, 1991, J BIOCHEM, V110, P928, DOI 10.1093/oxfordjournals.jbchem.a123691; Parent CA, 1996, ANNU REV BIOCHEM, V65, P411; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; ROONEY EK, 1992, P NATL ACAD SCI USA, V89, P8025, DOI 10.1073/pnas.89.17.8025; ROONEY EK, 1994, CELL CALCIUM, V16, P509, DOI 10.1016/0143-4160(94)90081-7; SCHAAP P, 1995, DEV BIOL, V168, P179, DOI 10.1006/dbio.1995.1070; Schaloske R, 1997, BIOCHEM J, V327, P233, DOI 10.1042/bj3270233; Schaloske R, 1998, BIOCHEM J, V332, P541, DOI 10.1042/bj3320541; Schlatterer C, 1996, BIOCHEM J, V313, P661, DOI 10.1042/bj3130661; SCHLATTERER C, 1994, J CELL SCI, V107, P2107; Soderbom F, 1998, TRENDS MICROBIOL, V6, P402, DOI 10.1016/S0966-842X(98)01348-1; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Thomason P, 1999, TRENDS GENET, V15, P15, DOI 10.1016/S0168-9525(98)01635-7; VANHAASTERT PJM, 1985, BIOCHIM BIOPHYS ACTA, V846, P324, DOI 10.1016/0167-4889(85)90002-3; VanHaastert PJM, 1995, EXPERIENTIA, V51, P1144; WURSTER B, 1987, J CELL SCI, V87, P723; YAMAMOTO K, 1982, J CELL BIOL, V95, P711, DOI 10.1083/jcb.95.3.711	39	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8404	8408		10.1074/jbc.275.12.8404	http://dx.doi.org/10.1074/jbc.275.12.8404			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722673	hybrid			2022-12-27	WOS:000086507700023
J	Topol, LZ; Bardot, B; Zhang, QY; Resau, J; Huillard, E; Marx, M; Calothy, G; Blair, DG				Topol, LZ; Bardot, B; Zhang, QY; Resau, J; Huillard, E; Marx, M; Calothy, G; Blair, DG			Biosynthesis, post-translation modification, and functional characterization of Drm/Gremlin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEINS; GROWTH-FACTOR; SPEMANN ORGANIZER; IDENTIFICATION; FIBROBLASTS; EXPRESSION; RECEPTORS; CERBERUS; CLEAVAGE; CLONING	Down-regulated by mos (Drm)/Gremlin is a highly conserved protein whose properties and expression pattern suggest a role in early development, tissue-specific differentiation, and cell transformation. We have investigated the biosynthesis and processing of Drm expressed endogenously in rat fibroblasts or overexpressed following transient or stable transfection. Analysis of metabolically labeled cells revealed that Drm exists in secreted and cell-associated forms that exhibit similar mobilities in SDS-polyacrylamide gel electrophoresis. Protein analysis indicated that Drm is present in two major species: a slow migrating glycosylated form and a nonglycosylated form. Both forms of Drm are able to undergo phosphorylation. Drm is released into the media within 30 min of synthesis and is detectable for up to 4-5 h, whereas the cell-associated form has a half-life of about 1 h, Confocal immunofluorescent microscopy indicates that Drm is present both on the external surface of expressing cells, as well as within the endoplasmic reticulum and the Golgi. Both glycosylated and nonglycosylated forms of Drm exhibit identical distributions and are able to antagonize bone morphogenetic protein signaling. Like the soluble form, the cell-associated forms are capable of binding I-125-bone morphogenetic protein-4. These properties are consistent with a role for Drm in interfering with signaling and indicate that Drm may act at the cell surface during tissue development and transformation.	NCI, Frederick Canc Res & Dev Ctr, Intramural Res Support Program, SAIC Frederick, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Basic Res Lab, Frederick, MD 21702 USA; Ctr Univ Orsay, Inst Curie, CNRS, UMR 146, F-91405 Orsay, France; NCI, Frederick Canc Res & Dev Ctr, Adv BioSci Labs Inc, Basic Res Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Blair, DG (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Intramural Res Support Program, SAIC Frederick, Frederick, MD 21702 USA.			Bardot, Boris/0000-0003-4976-9593	NCI NIH HHS [N01-CO-56000] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Biben C, 1998, DEV BIOL, V194, P135, DOI 10.1006/dbio.1997.8812; BOOWMEESTER T, 1996, NATURE, V382, P595; COUTENTE S, 1990, SCIENCE, V249, P797; DUKSIN D, 1982, J BIOL CHEM, V257, P3105; Ebendal T, 1998, J NEUROSCI RES, V51, P139, DOI 10.1002/(SICI)1097-4547(19980115)51:2<139::AID-JNR2>3.0.CO;2-E; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FROLIK CA, 1984, J BIOL CHEM, V259, P995; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; Golden JA, 1999, P NATL ACAD SCI USA, V96, P2439, DOI 10.1073/pnas.96.5.2439; GUM JR, 1992, J BIOL CHEM, V267, P21375; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; Harlow E., 1988, ANTIBODIES LAB MANUA; Hobman TC, 1998, MOL BIOL CELL, V9, P1265, DOI 10.1091/mbc.9.6.1265; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Iantosca MR, 1999, J NEUROSCI RES, V56, P248; ISAACS NW, 1995, CURR OPIN STRUC BIOL, V5, P391, DOI 10.1016/0959-440X(95)80102-2; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; Li H, 1999, DEV BIOL, V211, P64, DOI 10.1006/dbio.1999.9304; LIN XY, 1995, MOL CELL BIOL, V15, P2754; Mehler MF, 1997, TRENDS NEUROSCI, V20, P309, DOI 10.1016/S0166-2236(96)01046-6; MEITINGER T, 1993, NAT GENET, V5, P376, DOI 10.1038/ng1293-376; Merino R, 1999, DEVELOPMENT, V126, P5515; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nishitoh H, 1996, J BIOL CHEM, V271, P21345, DOI 10.1074/jbc.271.35.21345; NUNEZ E, 1994, J BIOL CHEM, V269, P16920; OZAKI T, 1993, P NATL ACAD SCI USA, V90, P2593, DOI 10.1073/pnas.90.7.2593; Pearce JJH, 1999, DEV BIOL, V209, P98, DOI 10.1006/dbio.1999.9240; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; Saraste J, 1992, Semin Cell Biol, V3, P343, DOI 10.1016/1043-4682(92)90020-V; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shimasaki S, 1999, P NATL ACAD SCI USA, V96, P7282, DOI 10.1073/pnas.96.13.7282; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Stanley E, 1998, MECH DEVELOP, V77, P173, DOI 10.1016/S0925-4773(98)00139-7; Topol LZ, 1997, MOL CELL BIOL, V17, P4801, DOI 10.1128/MCB.17.8.4801; Zuniga A, 1999, NATURE, V401, P598, DOI 10.1038/44157	36	109	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8785	8793		10.1074/jbc.275.12.8785	http://dx.doi.org/10.1074/jbc.275.12.8785			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722723	hybrid			2022-12-27	WOS:000086507700073
J	Bijur, GN; De Sarno, P; Jope, RS				Bijur, GN; De Sarno, P; Jope, RS			Glycogen synthase kinase-3 beta facilitates staurosporine- and heat shock-induced apoptosis - Protection by lithium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; BETA-CATENIN; PHOSPHATIDYLINOSITOL 3-KINASE; INTACT-CELLS; C-AKT; PHOSPHORYLATION; ACTIVATION; PATHWAY; DEATH; SURVIVAL	The potential role of glycogen synthase kinase-3 beta in modulating apoptosis was examined in human SH-SY5Y neuroblastoma cells. Staurosporine treatment caused time- and concentration-dependent increases in the activities of caspase-3 and caspase-9 but not caspase-1, increased proteolysis of poly(ADP-ribose) polymerase, and induced morphological changes consistent with apoptosis. Overexpression of glycogen synthase kinase-3 beta to levels 3.5 times that in control cells did not alter basal indices of apoptosis but potentiated staurosporine-induced activation of caspase-3, caspase-9, proteolysis of poly(ADP-ribose) polymerase, and morphological changes indicative of apoptosis, Inhibition of glycogen synthase kinase-3 beta by lithium attenuated the enhanced staurosporine-induced activation of caspase-3 in cells overexpressing glycogen synthase kinase-3 beta. In cells subjected to heat shock, caspase-3 activity was more than three times greater in glycogen synthase kinase-3 beta-transfected than control cells, and this potentiated response was inhibited by lithium treatment. Thus, glycogen synthase kinase-3 beta facilitated apoptosis induced by two experimental paradigms. These findings indicate that glycogen synthase kinase-3 beta may contribute to proapoptotic-signaling activity, that inhibition of glycogen synthase kinase-3 beta can contribute to anti-apoptotic-signaling mechanisms, and that the neuroprotective actions of lithium may be due in part to its inhibitory modulation of glycogen synthase kinase-3 beta.	Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, Sparks Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Jope, RS (corresponding author), Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, Sparks Ctr, Rm 1057, Birmingham, AL 35294 USA.	jope@uab.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH038752, R56MH038752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS010795] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG006569] Funding Source: NIH RePORTER; NIA NIH HHS [AG06569] Funding Source: Medline; NIMH NIH HHS [MH38752] Funding Source: Medline; NINDS NIH HHS [NS10795] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bijur G. N., 1999, Society for Neuroscience Abstracts, V25, P2015; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Centeno F, 1998, NEUROREPORT, V9, P4199, DOI 10.1097/00001756-199812210-00036; Chakravarthy BR, 1999, J NEUROCHEM, V72, P933, DOI 10.1046/j.1471-4159.1999.0720933.x; Chen RW, 1999, J BIOL CHEM, V274, P6039, DOI 10.1074/jbc.274.10.6039; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEGROOT RP, 1993, ONCOGENE, V8, P841; delPeso L, 1997, SCIENCE, V278, P687; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Gabai VL, 1998, FEBS LETT, V438, P1, DOI 10.1016/S0014-5793(98)01242-3; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; Hartigan JA, 1999, J BIOL CHEM, V274, P21395, DOI 10.1074/jbc.274.30.21395; Harvey KJ, 1998, MOL CELL BIOL, V18, P2912, DOI 10.1128/MCB.18.5.2912; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; INOUYE M, 1995, J RADIAT RES, V36, P203, DOI 10.1269/jrr.36.203; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Jope RS, 1999, MOL PSYCHIATR, V4, P117, DOI 10.1038/sj.mp.4000494; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kruman I, 1998, J NEUROSCI RES, V51, P293, DOI 10.1002/(SICI)1097-4547(19980201)51:3<293::AID-JNR3>3.0.CO;2-B; Lavoie L, 1999, J BIOL CHEM, V274, P28279, DOI 10.1074/jbc.274.40.28279; LI GC, 1982, P NATL ACAD SCI-BIOL, V79, P3218, DOI 10.1073/pnas.79.10.3218; Lin RZ, 1997, J BIOL CHEM, V272, P31196, DOI 10.1074/jbc.272.49.31196; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; Nonaka S, 1998, P NATL ACAD SCI USA, V95, P2642, DOI 10.1073/pnas.95.5.2642; Nonaka S, 1998, NEUROREPORT, V9, P2081, DOI 10.1097/00001756-199806220-00031; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; Posmantur R, 1997, J NEUROCHEM, V68, P2328; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Samali A, 1998, CELL STRESS CHAPERON, V3, P228, DOI 10.1379/1466-1268(1998)003<0228:HSPROS>2.3.CO;2; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Welsh GI, 1996, TRENDS CELL BIOL, V6, P274, DOI 10.1016/0962-8924(96)10023-4; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	57	281	295	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7583	7590		10.1074/jbc.275.11.7583	http://dx.doi.org/10.1074/jbc.275.11.7583			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713065	hybrid			2022-12-27	WOS:000085913300025
J	Cui, KY; Coutts, M; Stahl, J; Sytkowski, AJ				Cui, KY; Coutts, M; Stahl, J; Sytkowski, AJ			Novel interaction between the transcription factor CHOP (GADD153) and the ribosomal protein FTE/S3a modulates erythropoiesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR EIF-3; RAT-LIVER RIBOSOMES; GENE-EXPRESSION; CROSS-LINKING; MESSENGER-RNA; C-MYC; PHOSPHATIDYLINOSITOL 3-KINASE; ERYTHROID-DIFFERENTIATION; ERYTHROLEUKEMIA-CELLS; ALKYLATING GROUP	The transcription factor CHOP (GADD153) heterodimerizes with other C/EBP family members, especially CIEBP beta, thus preventing their homodimerization and binding to DNA sequences specific for the homodimers. Some CHOP-C/EBP heterodimers apparently bind to alternative DNA sequence and thereby regulate the transcription of other genes. Recently, we demonstrated that CHOP is up-regulated during certain stages of erythroid differentiation and that ectopic overexpression of CHOP enhances this process (Coutts, M., Cui, K., Davis, K. L.,Keutzer, J. C., and Sytkowski, A. J. (1999) Blood 93, 3369-3378). In the present study, we report that CHOP also interacts with another non-C/EBP protein designated v-fos transformation effector (FTE) (Kho, C. J., and Zarbl, H. (1992) Proc. Natl. Acad. Sci. U.S.A. 89, 2200-2204), which is identical to ribosomal protein S3a (Metspalu, A., Rebane, A, Hoth, S., Pooga, NI., Stahl, J., and Kruppa, J. (1992) Gene (Amst.) 119, 313-316). Bacterially expressed His-CHOP and in vitro translated S-35-labeled FTE/S3a-Gal4 fusion protein coimmunoprecipitated using anti-CHOP antibodies, and both anti-CHOP and anti-FTE/S3a antibodies co-immunoprecipitated CHOP and FTE/S3a from lysates of Rauscher murine erythroleukemia cells overexpressing both proteins. The in vivo interaction of CHOP and FTE/S3a was also demonstrated in cells overexpressing FTE/S3a but with endogenous expression levels of CHOP. Western blot analysis demonstrated co-localization of CHOP and FTE/S3a in both the cytosol and the nuclei of nontransfected cells. Overexpression of FTE/S3a inhibited differentiation of Rauscher cells induced either by erythropoietin or by dimethyl sulfoxide. This inhibition was reversed partially by simultaneous overexpression of CHOP or of antisense fte/S3a. FTE/s3a appears to be a bifunctional ribosomal protein that regulates CHOP and, hence, C/EBP function during erythropoiesis.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Lab Cell & Mol Biol, Boston, MA 02215 USA; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Sytkowski, AJ (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Lab Cell & Mol Biol, Boston, MA 02215 USA.	asytkows@caregroup.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038841, F32DK009201, F32DK008986] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38841, F32 DK08986, F32 DK09201] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BAILEY SC, 1991, J BIOL CHEM, V266, P24121; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CHERN YJ, 1991, BLOOD, V78, P991, DOI 10.1182/blood.V78.4.991.bloodjournal784991; CHERN YJ, 1991, J BIOL CHEM, V266, P2009; CHIBA T, 1991, NUCLEIC ACIDS RES, V19, P3843, DOI 10.1093/nar/19.14.3843; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHOI HS, 1987, J BIOL CHEM, V262, P2933; CHOI HS, 1990, J BIOL CHEM, V265, P4143; Coutts M, 1999, BLOOD, V93, P3369, DOI 10.1182/blood.V93.10.3369.410k11_3369_3378; DAMEN JE, 1993, BLOOD, V81, P3204; de Both N J, 1978, Nature, V272, P626, DOI 10.1038/272626a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; GORDON HM, 1992, J IMMUNOL, V148, P4021; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HADJIOLOV AA, 1985, CELL BIOL MONOGR, V12, P107; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KHO CJ, 1992, P NATL ACAD SCI USA, V89, P2200, DOI 10.1073/pnas.89.6.2200; Kho CJ, 1996, CELL GROWTH DIFFER, V7, P1157; KRANTZ SB, 1991, BLOOD, V77, P419; Li YK, 1996, J BIOL CHEM, V271, P27025, DOI 10.1074/jbc.271.43.27025; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; LUTSCH G, 1990, EUR J CELL BIOL, V51, P140; MALYGIN AA, 1994, EUR J BIOCHEM, V226, P715, DOI 10.1111/j.1432-1033.1994.tb20100.x; MAYEUX P, 1993, EUR J BIOCHEM, V216, P821, DOI 10.1111/j.1432-1033.1993.tb18203.x; METSPALU A, 1992, GENE, V119, P313, DOI 10.1016/0378-1119(92)90289-2; MIURA O, 1994, J BIOL CHEM, V269, P614; Musholt TJ, 1997, J SURG RES, V69, P94, DOI 10.1006/jsre.1997.5038; Nagahisa H, 1996, BLOOD, V87, P1309, DOI 10.1182/blood.V87.4.1309.bloodjournal8741309; NAORA H, 1995, IMMUNOLOGY, V85, P63; Naora H, 1996, BIOCHEM BIOPH RES CO, V224, P258, DOI 10.1006/bbrc.1996.1017; Naora H, 1998, LEUKEMIA, V12, P532, DOI 10.1038/sj.leu.2400979; Naora H, 1998, J CELL BIOL, V141, P741, DOI 10.1083/jcb.141.3.741; NYGARD O, 1981, ACTA CHEM SCAND B, V35, P57, DOI 10.3891/acta.chem.scand.35b-0057; NYGARD O, 1987, BIOCHIM BIOPHYS ACTA, V910, P245; PATEL HR, 1992, J BIOL CHEM, V267, P21300; Reynaud E, 1997, MOL GEN GENET, V256, P462, DOI 10.1007/s004380050590; RIFKIND RA, 1978, IN VITRO ASPECTS ERY, P266; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SPANGLER R, 1991, J BIOL CHEM, V266, P681; SPANGLER R, 1992, BLOOD, V79, P52; STAHL J, 1984, MOL BIOL REP, V9, P219, DOI 10.1007/BF00775350; STAHL J, 1981, FEBS LETT, V123, P269, DOI 10.1016/0014-5793(81)80305-5; STARKEY CR, 1995, INT J CANCER, V62, P325, DOI 10.1002/ijc.2910620316; SVOBODA AJ, 1978, BIOCHEM BIOPH RES CO, V81, P1145, DOI 10.1016/0006-291X(78)91256-1; SYTKOWSKI AJ, 1980, SCIENCE, V210, P74, DOI 10.1126/science.6932101; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TOLAN DR, 1981, J BIOL CHEM, V256, P129; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; WESTERMANN P, 1984, NUCLEIC ACIDS RES, V12, P8887, DOI 10.1093/nar/12.23.8887; WESTERMANN P, 1979, FEBS LETT, V97, P101, DOI 10.1016/0014-5793(79)80061-7; WESTERMANN P, 1981, NUCLEIC ACIDS RES, V9, P2387, DOI 10.1093/nar/9.10.2387; WESTERMANN P, 1983, BIOCHIM BIOPHYS ACTA, V741, P103, DOI 10.1016/0167-4781(83)90015-5; WESTERMANN P, 1986, STRUCTURE FUNCTIONS, P281; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Zhang H, 1999, KIDNEY INT, V56, P549, DOI 10.1046/j.1523-1755.1999.00561.x	60	46	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7591	7596		10.1074/jbc.275.11.7591	http://dx.doi.org/10.1074/jbc.275.11.7591			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713066	hybrid			2022-12-27	WOS:000085913300026
J	Miura, S; Li, CQ; Cao, ZF; Wang, HF; Wardell, MR; Sadler, JE				Miura, S; Li, CQ; Cao, ZF; Wang, HF; Wardell, MR; Sadler, JE			Interaction of von Willebrand factor domain A1 with platelet glycoprotein Ib alpha-(1-289) - Slow intrinsic binding kinetics mediate rapid platelet adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR; IB-IX; FACTOR MULTIMERS; FACTOR VWF; DISEASE; BOTROCETIN; MEMBRANE; PROTEIN; COMPLEX; RISTOCETIN	We investigated the crucial hemostatic interaction between von Willebrand factor (VWF) and platelet glycoprotein (GP) Ib alpha. Recombinant VWF A1 domain (residues Glu(497)-Pro(705) of VWF) bound stoichiometrically to a GrPIb alpha-calmodulin fusion protein (residues His(1)-Val(289) of GPIb alpha; GPIb alpha-CaM) immobilized on W-7-agarose with a K-d of 3.3 mu M. The variant VWF A1(R545A) bound to GPIb alpha-CaM 20-fold more tightly, mainly because the association rate constant k(on) increased from 1,100 to 8,800 M-1 s(-1). The GPIb alpha mutations G233V and M239V cause platelet-type pseudo-von Willebrand disease, and VWF A1 bound to GPIb alpha(G233V)-CaM and GPIb alpha(M239V)-CaM with a K-d of 1.0 and 0.63 mu M, respectively. The increased affinity of VWF A1 for GPIb alpha(M239V)-CaM was explained by an increase in k(on) to 4,580 M-1 s(-1) GPIb alpha-CaM bound with similar affinity to recombinant VWF A1, to multimeric plasma VWF, and to a fragment of dispase-digested plasma VWF (residues Leu(480)/Val(481)-Gly(718)). VWF A1 and A1(R545A) bound to platelets with affinities and rate constants similar to those for binding to GPIb alpha-CaM, and botrocetin had the expected positively cooperative effect on the binding of VWF A1 to GPIb alpha-CaM. Therefore, allosteric regulation by botrocetin of VWF A1 binding to GPIb alpha, and the increased binding affinity caused by mutations in VWF or GPIb alpha, are reproduced by isolated structural domains. The substantial increase in k(on) caused by mutations in either A1 or GPIb alpha suggests that productive interaction requires rate-limiting conformational changes in both binding sites. The exceptionally slow k(on) and k(off) provide important new constraints on models for rapid platelet tethering at high wall shear rates.	Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Sadler, JE (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, 660 S Euclid Ave,Box 8022, St Louis, MO 63110 USA.		Sadler, Evan/D-8556-2011	Sadler, J. Evan/0000-0001-5705-469X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060617] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60617] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AARTS PAMM, 1988, ARTERIOSCLEROSIS, V8, P819, DOI 10.1161/01.ATV.8.6.819; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8326, DOI 10.1021/bi00447a010; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; Borchiellini A, 1996, BLOOD, V88, P2951, DOI 10.1182/blood.V88.8.2951.bloodjournal8882951; CHRISTOPHE O, 1995, BRIT J HAEMATOL, V90, P195, DOI 10.1111/j.1365-2141.1995.tb03400.x; Cooney KA, 1996, BLOOD, V87, P2322, DOI 10.1182/blood.V87.6.2322.bloodjournal8762322; CRUZ MA, 1993, J BIOL CHEM, V268, P21238; CRUZ MA, 1995, J BIOL CHEM, V270, P10822, DOI 10.1074/jbc.270.18.10822; DEGROOT PG, 1988, J CLIN INVEST, V82, P65, DOI 10.1172/JCI113602; DONG ZG, 1994, J BIOL CHEM, V269, P6753; DU XP, 1987, BLOOD, V69, P1524; ENDO T, 1981, J BIOL CHEM, V256, P2485; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUJIMURA Y, 1991, BLOOD, V77, P113; FUJIMURA Y, 1991, BIOCHEMISTRY-US, V30, P1957, DOI 10.1021/bi00221a032; FUJIMURA Y, 1986, J BIOL CHEM, V261, P381; FUJIMURA Y, 1987, BLOOD, V70, P985; HOWARD MA, 1971, THROMB DIATH HAEMOST, V26, P362; KATAYAMA M, 1995, J BIOCHEM-TOKYO, V117, P331, DOI 10.1093/jb/117.2.331; KOHNERT U, 1992, PROTEIN ENG, V5, P93, DOI 10.1093/protein/5.1.93; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; Lu DS, 1999, J MOL BIOL, V292, P361, DOI 10.1006/jmbi.1999.3089; Marchese P, 1999, P NATL ACAD SCI USA, V96, P7837, DOI 10.1073/pnas.96.14.7837; MARCHESE P, 1995, J BIOL CHEM, V270, P9571, DOI 10.1074/jbc.270.16.9571; MATSUSHITA T, 1995, J BIOL CHEM, V270, P13406, DOI 10.1074/jbc.270.22.13406; Miyata S, 1996, J BIOL CHEM, V271, P9046, DOI 10.1074/jbc.271.15.9046; Miyata S, 1999, J BIOL CHEM, V274, P6586, DOI 10.1074/jbc.274.10.6586; MODDERMAN PW, 1992, J BIOL CHEM, V267, P364; MOORE PB, 1982, J BIOL CHEM, V257, P9663; MURATA M, 1991, J BIOL CHEM, V266, P15474; NICHOLS TC, 1995, P NATL ACAD SCI USA, V92, P2455, DOI 10.1073/pnas.92.7.2455; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PARETI FI, 1987, J BIOL CHEM, V262, P13835; READ MS, 1989, BLOOD, V74, P1031; Ruggeri ZM, 1999, THROMB HAEMOSTASIS, P682; RUGGERI ZM, 1987, BLOOD, V70, P895; Ruggeri ZM, 1997, J CLIN INVEST, V99, P559, DOI 10.1172/JCI119195; SABA HI, 1985, BLOOD, V66, P282; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; SADLER JE, 1995, METABOLIC MOL BASES, P3269; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SCOTT JP, 1991, J BIOL CHEM, V266, P8149; Siedlecki CA, 1996, BLOOD, V88, P2939, DOI 10.1182/blood.V88.8.2939.bloodjournal8882939; TAKAHASHI H, 1984, BLOOD, V64, P1254; TINOCO L, 1985, PHYSICAL CHEM PRINCI, P323; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; Tsuji S, 1996, BLOOD, V88, P3854, DOI 10.1182/blood.V88.10.3854.bloodjournal88103854; vanGenderen PJJ, 1996, BRIT J HAEMATOL, V93, P962, DOI 10.1046/j.1365-2141.1996.d01-1729.x; Vlot AJ, 1996, BLOOD, V87, P1809	52	93	103	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7539	7546		10.1074/jbc.275.11.7539	http://dx.doi.org/10.1074/jbc.275.11.7539			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713059	hybrid			2022-12-27	WOS:000085913300019
J	Noel, RJ; Reznikoff, WS				Noel, RJ; Reznikoff, WS			Structural studies of lacUV5-RNA polymerase interactions in vitro - Ethylation interference and missing nucleoside analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; PROMOTER DNA; NONTEMPLATE STRAND; SIGMA-70 SUBUNIT; RECOGNITION; BINDING; PROTEIN; FLEXIBILITY; CONTACTS; COMPLEX	Substantial effort has been made to investigate the interactions that the Escherichia coli RNA polymerase makes with promoter DNA during transcription initiation. The lacUV5 promoter has been the object of many of these studies, and to date, an incredible wealth of information exists on how RNA polymerase interacts with this promoter. We have sought to expand current knowledge by the use of two chemical interference protocols, phosphate ethylation and missing nucleoside. We have added to existing information with the identification of additional phosphates, for example, at the start site of the template strand Chat, when ethylated, perturb the binding of RNA polymerase. We have also discovered a number of positions, most remarkably -37 to -34 of the nontemplate strand, where nucleoside loss decreases binding. Finally, we have discovered positions of ethylation and/or nucleoside loss that can stimulate binding. In particular, missing nucleosides and phosphate ethylation near the transcription start site enhance RNA polymerase binding.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Reznikoff, WS (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32GM07215] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKWITH J, 1972, J MOL BIOL, V69, P155, DOI 10.1016/0022-2836(72)90031-9; Dombroski AJ, 1996, P NATL ACAD SCI USA, V93, P8858, DOI 10.1073/pnas.93.17.8858; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HAYES JJ, 1989, BIOCHEMISTRY-US, V28, P9521, DOI 10.1021/bi00450a041; Helmann JD, 1999, BIOCHEMISTRY-US, V38, P5959, DOI 10.1021/bi990206g; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; IPPEN K, 1968, NATURE, V217, P825, DOI 10.1038/217825a0; JORGENSEN ED, 1991, J BIOL CHEM, V266, P645; KOLB A, 1993, NUCLEIC ACIDS RES, V21, P319, DOI 10.1093/nar/21.2.319; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; Li XY, 1998, J BIOL CHEM, V273, P23558, DOI 10.1074/jbc.273.36.23558; LORIMER DD, 1986, NUCLEIC ACIDS RES, V14, P2921, DOI 10.1093/nar/14.7.2921; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; Negre D, 1997, NUCLEIC ACIDS RES, V25, P713, DOI 10.1093/nar/25.4.713; PETERSON ML, 1985, J MOL BIOL, V185, P535, DOI 10.1016/0022-2836(85)90070-1; Roberts CW, 1996, CELL, V86, P495; ROE JH, 1985, BIOCHEMISTRY-US, V24, P4721, DOI 10.1021/bi00339a002; SHANBLATT SH, 1986, J BIOL CHEM, V261, P885; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; SIEGELE DA, 1988, J MOL BIOL, V203, P29, DOI 10.1016/0022-2836(88)90088-5; WEREL W, 1991, EMBO J, V10, P2589, DOI 10.1002/j.1460-2075.1991.tb07800.x	24	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7708	7712		10.1074/jbc.275.11.7708	http://dx.doi.org/10.1074/jbc.275.11.7708			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713082	hybrid			2022-12-27	WOS:000085913300042
J	Petitclerc, E; Boutaud, A; Prestayko, A; Xu, JS; Sado, Y; Ninomiya, Y; Sarras, MP; Hudson, BG; Brooks, PC				Petitclerc, E; Boutaud, A; Prestayko, A; Xu, JS; Sado, Y; Ninomiya, Y; Sarras, MP; Hudson, BG; Brooks, PC			New functions for non-collagenous domains of human collagen type IV - Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONCOLLAGENOUS NC1 DOMAIN; ALPORT-SYNDROME; CELL ATTACHMENT; BASAL LAMINA; IN-VITRO; BINDING; EXPRESSION; MATRIX; CHAINS; VITRONECTIN	Collagen type IV is a major component of the basal lamina of blood vessels. Six genetically distinct collagen type IV chains have been identified and are distributed in a tissue-specific manner. Here we define a novel function for soluble non-collagenous (NC1) domains of the alpha 2(TV), alpha 3(IV), and alpha 6(IV) chains of human collagen type IV in the regulation of angiogenesis and tumor growth. These NC1 domains were shown to regulate endothelial cell adhesion and migration by distinct alpha(v) and beta(1) integrin-dependent mechanisms. Systemic administration of recombinant alpha 2(IV), alpha 3(IV), and alpha 6(IV) NC1 domains potently inhibit angiogenesis and tumor growth, whereas alpha 1(TV), alpha 4(TV), and alpha 5(IV) showed little if any effect. These findings suggest that specific NC1 domains of collagen type IV may represent an important new class of angiogenesis inhibitors.	Univ So Calif, Sch Med, Dept Biochem & Mol Biol, Norris Canc Ctr, Los Angeles, CA 90033 USA; BioStratum Inc, Durham, NC 27713 USA; Shigei Med Res Inst, Div Immunol, Okayama 701, Japan; Okayama Univ, Sch Med, Dept Mol Biol & Biochem, Okayama 700, Japan; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	University of Southern California; Okayama University; University of Kansas; University of Kansas Medical Center	Brooks, PC (corresponding author), Univ So Calif, Sch Med, Dept Biochem & Mol Biol, Norris Canc Ctr, Topping Tower Rm 6409,1441 Eastlake Ave, Los Angeles, CA 90033 USA.			Hudson, Billy/0000-0002-5420-4100	NATIONAL CANCER INSTITUTE [R29CA074132] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018381, R37DK018381] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA74132-01] Funding Source: Medline; NIDDK NIH HHS [DK18381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; Brooks PC, 1997, J CLIN INVEST, V99, P1390, DOI 10.1172/JCI119298; Brooks PC, 1999, METH MOL B, V129, P257; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Brooks PC, 1996, EUR J CANCER, V32A, P2423, DOI 10.1016/S0959-8049(96)00381-4; Carnemolla B, 1996, INT J CANCER, V68, P397, DOI 10.1002/(SICI)1097-0215(19961104)68:3<397::AID-IJC20>3.3.CO;2-D; CHELBERG MK, 1989, CANCER RES, V49, P4796; CHELBERG MK, 1990, J CELL BIOL, V111, P262; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; Cosgrove D, 1998, HEARING RES, V121, P84, DOI 10.1016/S0378-5955(98)00069-0; Davis GE, 1996, EXP CELL RES, V224, P39, DOI 10.1006/excr.1996.0109; Dehan P, 1997, AM J PATHOL, V151, P1097; DRAKE CJ, 1992, DEV DYNAM, V193, P83, DOI 10.1002/aja.1001930111; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; Fleischmajer R, 1998, ANN NY ACAD SCI, V857, P212, DOI 10.1111/j.1749-6632.1998.tb10118.x; Fleischmajer R, 1997, J INVEST DERMATOL, V109, P527, DOI 10.1111/1523-1747.ep12336696; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Gasparini G, 1997, CRIT REV ONCOL HEMAT, V26, P147, DOI 10.1016/S1040-8428(97)10001-4; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INGBER D, 1988, LAB INVEST, V59, P44; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; KUHN K, 1994, MATRIX BIOL, V14, P439; MADRI JA, 1980, LAB INVEST, V43, P303; MINER JH, 1994, J CELL BIOL, V127, P879, DOI 10.1083/jcb.127.3.879; Miner JH, 1996, J CELL BIOL, V135, P1403, DOI 10.1083/jcb.135.5.1403; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; Nakano S, 1999, LAB INVEST, V79, P281; Netzer KO, 1998, PROTEIN SCI, V7, P1340, DOI 10.1002/pro.5560070610; NINOMIYA Y, 1995, J CELL BIOL, V130, P1219, DOI 10.1083/jcb.130.5.1219; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PEISSEL B, 1995, J CLIN INVEST, V96, P1948, DOI 10.1172/JCI118241; PRATT BM, 1985, ANN NY ACAD SCI, V460, P274, DOI 10.1111/j.1749-6632.1985.tb51175.x; Ramchandran R, 1999, BIOCHEM BIOPH RES CO, V255, P735, DOI 10.1006/bbrc.1999.0248; RIES A, 1995, J BIOL CHEM, V270, P23790, DOI 10.1074/jbc.270.40.23790; ROSKELLEY CD, 1995, CURR OPIN CELL BIOL, V7, P736, DOI 10.1016/0955-0674(95)80117-0; Sado Y, 1998, KIDNEY INT, V53, P664, DOI 10.1046/j.1523-1755.1998.00795.x; Schittny JC, 1989, CURR OPIN CELL BIOL, V1, P983, DOI 10.1016/0955-0674(89)90069-0; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Setty S, 1998, J BIOL CHEM, V273, P12244, DOI 10.1074/jbc.273.20.12244; SIEBOLD B, 1987, EUR J BIOCHEM, V168, P569, DOI 10.1111/j.1432-1033.1987.tb13455.x; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TSILIBARY EC, 1988, J BIOL CHEM, V263, P4302; TSILIBARY EC, 1986, J CELL BIOL, V103, P2467, DOI 10.1083/jcb.103.6.2467; TSILIBARY EC, 1990, J CELL BIOL, V111, P1583, DOI 10.1083/jcb.111.4.1583; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; YURCHENCO PD, 1994, CURR OPIN CELL BIOL, V6, P674, DOI 10.1016/0955-0674(94)90093-0; ZHANG XM, 1994, DEV BIOL, V164, P10, DOI 10.1006/dbio.1994.1176; ZHOU J, 1993, SCIENCE, V261, pL167	59	252	274	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8051	8061		10.1074/jbc.275.11.8051	http://dx.doi.org/10.1074/jbc.275.11.8051			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713126	hybrid			2022-12-27	WOS:000085913300086
J	Piccoli, R; De Lorenzo, C; Dal Piaz, F; Pucci, P; D'Alessio, G				Piccoli, R; De Lorenzo, C; Dal Piaz, F; Pucci, P; D'Alessio, G			Trypsin sheds light on the singular case of seminal RNase, a dimer with two quaternary conformations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN STRUCTURES; RIBONUCLEASE-A; RESOLUTION; SITES	Dimeric seminal RNase presents the singular case of a dimer with access at equilibrium to two conformations: one in which the subunits exchange, or swap, their NH,terminal arms; the other with no exchange. Thus a continuous unfolding/refolding of structural elements into two alternative conformations takes place in the native protein at equilibrium. The phenomenon was investigated by kinetic and mass spectrometric: analyses of the effects of trypsin on the native protein, on its isolated quaternary forms, as well as on a monomeric derivative of the protein and on homologous dimeric RNase A The kinetics of tryptic action on the protein forms and on the protein derivatives, as well as the location of the tryptic cleavage sites, and their chronological sequence, led to the identification of relevant interconversion intermediates, to the description of a model for the interconversion process, and to a hypothesis for the unique phenomenon of the dual quaternary conformation of seminal RNase.	Univ Naples Federico II, Dipartimento Chim Organ & Biol, I-80134 Naples, Italy; Univ Naples Federico II, CNR, Ctr Int Serv Spettrometria Massa, I-80131 Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	D'Alessio, G (corresponding author), Univ Naples Federico II, Dipartimento Chim Organ & Biol, Via Mezzocannone 16, I-80134 Naples, Italy.	dalessio@unina.it	Dal Piaz, Fabrizio/D-1843-2010	Dal Piaz, Fabrizio/0000-0002-8643-5018; PUCCI, Pietro/0000-0002-5885-1495				ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BAKER D, 1994, BIOCHEMISTRY-US, V33, P7505, DOI 10.1021/bi00190a002; BEINTEMA JJ, 1988, PROG BIOPHYS MOL BIO, V51, P165, DOI 10.1016/0079-6107(88)90001-6; BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; CAFARO V, 1995, FEBS LETT, V359, P31, DOI 10.1016/0014-5793(94)01450-F; Catanzano F, 1997, BIOCHEMISTRY-US, V36, P14403, DOI 10.1021/bi971358j; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P2421; CRESTFIELD AM, 1962, ARCH BIOCHEM BIOPHYS, P217; D'Alessio G, 1999, EUR J BIOCHEM, V266, P699, DOI 10.1046/j.1432-1327.1999.00912.x; D'Alessio G., 1997, RIBONUCLEASES STRUCT, P383; DALESSIO G, 1975, BIOCHEMISTRY-US, V14, P1116, DOI 10.1021/bi00677a004; DALESSIO G, 1995, NAT STRUCT BIOL, V2, P11, DOI 10.1038/nsb0195-11; De Lorenzo C, 1998, PROTEIN SCI, V7, P2653; DIDONATO A, 1995, PROTEIN SCI, V4, P1470; Fontana A, 1997, FOLD DES, V2, pR17, DOI 10.1016/S1359-0278(97)00010-2; FRUCHTER RG, 1965, J BIOL CHEM, V240, P3868; FRUCHTER RG, 1965, J BIOL CHEM, V240, P3875; GRANDI C, 1979, BIOCHEMISTRY-US, V18, P3413, DOI 10.1021/bi00582a031; HIRS CHW, 1956, J BIOL CHEM, V219, P623; Hubbard SJ, 1998, PROTEIN ENG, V11, P349, DOI 10.1093/protein/11.5.349; KIM JS, 1995, J BIOL CHEM, V270, P10525, DOI 10.1074/jbc.270.18.10525; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu YS, 1998, P NATL ACAD SCI USA, V95, P3437, DOI 10.1073/pnas.95.7.3437; MAZZARELLA L, 1995, P NATL ACAD SCI USA, V92, P3799, DOI 10.1073/pnas.92.9.3799; MAZZARELLA L, 1993, ACTA CRYSTALLOGR D, V49, P389, DOI 10.1107/S0907444993003403; MURRAY AJ, 1995, P NATL ACAD SCI USA, V92, P7337, DOI 10.1073/pnas.92.16.7337; Nadig G, 1996, PROTEIN SCI, V5, P2104, DOI 10.1002/pro.5560051017; NODA Y, 1994, BIOPOLYMERS, V34, P217, DOI 10.1002/bip.360340208; OOI T, 1963, BIOCHEMISTRY-US, V2, P432, DOI 10.1021/bi00903a006; PARENTE A, 1985, EUR J BIOCHEM, V149, P381, DOI 10.1111/j.1432-1033.1985.tb08936.x; PARENTE A, 1977, ITAL J BIOCHEM, V26, P451; PICCOLI R, 1992, P NATL ACAD SCI USA, V89, P1870, DOI 10.1073/pnas.89.5.1870; PICCOLI R, 1988, BIOCHEM J, V253, P329, DOI 10.1042/bj2530329; RICHARDS FM, 1959, J BIOL CHEM, V234, P1459; Sica F, 1999, J CRYST GROWTH, V196, P305, DOI 10.1016/S0022-0248(98)00860-4; Sinclair A.R.E., 1977, AFRICAN BUFFALO STUD; TAMBURRINI M, 1986, ITAL J BIOCHEM, V35, P22; Zegers I, 1999, P NATL ACAD SCI USA, V96, P818, DOI 10.1073/pnas.96.3.818	39	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8000	8006		10.1074/jbc.275.11.8000	http://dx.doi.org/10.1074/jbc.275.11.8000			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713119	hybrid			2022-12-27	WOS:000085913300079
J	de la Iglesia, N; Mukhtar, M; Seoane, J; Guinovart, JJ; Agius, L				de la Iglesia, N; Mukhtar, M; Seoane, J; Guinovart, JJ; Agius, L			The role of the regulatory protein of glucokinase in the glucose sensory mechanism of the hepatocyte	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC GLYCOGEN-SYNTHESIS; METABOLIC CONTROL ANALYSIS; RAT HEPATOCYTES; HEXOKINASE-I; TRANSLOCATION; FRUCTOSE; LIVER; GLUCOSE-6-PHOSPHATE; GLYCOLYSIS; SYNTHASE	Glucokinase has a very high flux control coefficient (greater than unity) on glycogen synthesis from glucose in hepatocytes (Agius et al., J. BioL Chem, 271, 30479-30486, 1996). Hepatic glucokinase is inhibited by a 68 kDa glucokinase regulatory protein (GKRP) that is expressed in molar excess. To establish the relative control exerted by glucokinase and GKRP, we applied metabolic control analysis to determine the flux control coefficient of GKRP on glucose metabolism in hepatocytes. Adenovirus-mediated overexpression of GKRP (by up to 2-fold above endogenous levels) increased glucokinase binding and inhibited glucose phosphorylation, glycolysis, and glycogen synthesis over a wide range of concentrations of glucose and sorbitol, It decreased the affinity of glucokinase translocation for glucose and increased the control coefficient of glucokinase on glycogen synthesis. GKRP had a negative control coefficient of glycogen synthesis that is slightly greater than unity (-1.2) and a control coefficient on glycolysis of -0.5. The control coefficient of GKRP on glycogen synthesis decreased with increasing glucokinase overexpression (4-fold) at elevated glucose concentration (35 mM), which favors dissociation of glucokinase from GKRP, but not at 7.5 mM glucose. Under the latter conditions, glucokinase and GKRP have large and inverse control coefficients on glycogen synthesis, suggesting that a large component of the positive control coefficient of glucokinase is counterbalanced by the negative coefficient of GKRP. It is concluded that glucokinase and GKRP exert reciprocal control; therefore, mutations in GKRP affecting the expression or function of the protein may impact the phenotype even in the heterozygote state, similar to glucokinase mutations in maturity onset diabetes of the young type 2. Our results show that the mechanism comprising glucokinase and GKRP confers a markedly extended responsiveness and sensitivity to changes in glucose concentration on the hepatocyte.	Newcastle Univ, Sch Med, Dept Diabet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Barcelona, Fac Quim, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain	Newcastle University - UK; University of Barcelona	Agius, L (corresponding author), Newcastle Univ, Sch Med, Dept Diabet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	Loranne.Agius@ncl.ac.uk	de la Iglesia, Nuria/E-1420-2015; Mukhtar, Mohammed/AGY-4365-2022; Seoane, Joan/AAG-9173-2019	de la Iglesia, Nuria/0000-0002-1083-7715; Mukhtar, Mohammed/0000-0003-0671-2458; Seoane, Joan/0000-0002-6541-5974				Agius L, 1997, BIOCHEM J, V325, P667, DOI 10.1042/bj3250667; AGIUS L, 1990, BIOCHEM J, V266, P91, DOI 10.1042/bj2660091; AGIUS L, 1995, BIOCHEM J, V309, P711, DOI 10.1042/bj3090711; AGIUS L, 1993, BIOCHEM J, V296, P785, DOI 10.1042/bj2960785; Agius L, 1996, J BIOL CHEM, V271, P30479, DOI 10.1074/jbc.271.48.30479; AGIUS L, 1994, BIOCHEM J, V298, P237, DOI 10.1042/bj2980237; Aiston S, 1999, J BIOL CHEM, V274, P24559, DOI 10.1074/jbc.274.35.24559; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; BONTEMPS F, 1978, BIOCHEM J, V174, P603, DOI 10.1042/bj1740603; Brown KS, 1997, DIABETES, V46, P179, DOI 10.2337/diabetes.46.2.179; Cardenas M. L., 1995, GLUCOKINASE ITS REGU, P21; CLIFTON PM, 1988, ANAL BIOCHEM, V172, P165, DOI 10.1016/0003-2697(88)90426-5; CORNISHBOWDEN A, 1995, FUNDAMENTALS ENZYME, P249; de la Iglesia N, 1999, FEBS LETT, V456, P332, DOI 10.1016/S0014-5793(99)00971-0; FELL DA, 1992, BIOCHEM J, V286, P313, DOI 10.1042/bj2860313; Hattersley AT, 1998, DIABETIC MED, V15, P15, DOI 10.1002/(SICI)1096-9136(199801)15:1<15::AID-DIA562>3.0.CO;2-M; Hayward BE, 1997, BIOCHEM SOC T, V25, P140, DOI 10.1042/bst0250140; HEINRICH R, 1974, EUR J BIOCHEM, V42, P89, DOI 10.1111/j.1432-1033.1974.tb03318.x; HOLROYDE MJ, 1976, BIOCHEM J, V153, P351, DOI 10.1042/bj1530351; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; KACSER H, 1981, GENETICS, V97, P639; Kacser H, 1979, BIOCHEM SOC T, V7, P1149, DOI 10.1042/bst0071149; Kacser H, 1973, Symp Soc Exp Biol, V27, P65; MIWA I, 1990, PREP BIOCHEM, V20, P163, DOI 10.1080/00327489008050187; Niculescu L, 1997, BIOCHEM J, V321, P239, DOI 10.1042/bj3210239; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Rosa JL, 1997, HEPATOLOGY, V25, P324; Seoane J, 1996, J BIOL CHEM, V271, P23756, DOI 10.1074/jbc.271.39.23756; Thomas S, 1997, BIOCHEM J, V322, P119, DOI 10.1038/387119a0; VANDERCAMMEN A, 1993, BIOCHEM J, V294, P551, DOI 10.1042/bj2940551; VanSchaftingen E, 1997, BIOCHEM SOC T, V25, P136, DOI 10.1042/bst0250136; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P179; VANSCHAFTINGEN E, 1994, FASEB J, V8, P414, DOI 10.1096/fasebj.8.6.8168691; Velho G, 1996, J CLIN INVEST, V98, P1755, DOI 10.1172/JCI118974; VillarPalasi C, 1997, FASEB J, V11, P544, DOI 10.1096/fasebj.11.7.9212078	36	82	83	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10597	10603		10.1074/jbc.275.14.10597	http://dx.doi.org/10.1074/jbc.275.14.10597			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744755	hybrid			2022-12-27	WOS:000086345600096
J	McKenzie, DL; Kwok, KY; Rice, KG				McKenzie, DL; Kwok, KY; Rice, KG			A potent new class of reductively activated peptide gene delivery agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMID DNA; MASS-SPECTROMETRY; MAMMALIAN-CELLS; NUCLEIC-ACIDS; IN-VIVO; EXPRESSION; COMPLEXES; STABILITY; PARTICLES; CARRIERS	A new class of peptide gene delivery agents were developed by inserting multiple cysteine residues into short (dp 20) synthetic peptides, Substitution of one to four cysteine residues for lysine residues in Cys-Trp-Lys(18) resulted in low molecular weight DNA condensing peptides that spontaneously oxidize after binding to plasmid DNA to form interpeptide disulfide bonds. The stability of cross-linked peptide DNA condensates increased in proportion to the number of cysteines incorporated into the peptide. Disulfide bond formation led to a decrease in particle size relative to control peptide DNA condensates and prevented dissociation of peptide DNA condensates in concentrated sodium chloride. Cross-linked peptide DNA condensates were 5-60-fold more potent at mediating gene expression in HepG2 and COS 7 cells relative to uncross-linked peptide DNA condensates. The enhanced gene expression was dependent on the number of cysteine residues incorporated, with a peptide containing two cysteines mediating maximal gene expression. Cross-Linking peptides caused elevated gene expression without increasing DNA uptake by cells, suggesting a mechanism involving intracellular release of DNA triggered by disulfide bond reduction. The results establish cross-linking peptides as a novel class of potent gene delivery agents that enhance gene expression through a new mechanism of action.	Univ Michigan, Coll Pharm, Div Med Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Coll Pharm, Div Pharmaceut, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Rice, KG (corresponding author), Univ Michigan, Coll Pharm, Div Med Chem, 428 Church St, Ann Arbor, MI 48109 USA.				NIDCR NIH HHS [DE13004] Funding Source: Medline; NIGMS NIH HHS [GM48049] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013004] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048049, R29GM048049] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adami RC, 1999, J PHARM SCI, V88, P739, DOI 10.1021/js990042p; Adami RC, 1998, J PHARM SCI, V87, P678, DOI 10.1021/js9800477; ARNOTT D, 1993, CLIN CHEM, V39, P2005; Blessing T, 1998, P NATL ACAD SCI USA, V95, P1427, DOI 10.1073/pnas.95.4.1427; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIOU HC, 1994, NUCLEIC ACIDS RES, V22, P5439, DOI 10.1093/nar/22.24.5439; Collard WT, 2000, CARBOHYD RES, V323, P176; COLLARD WT, 2000, IN PRESS J PHARMACEU; Duguid JG, 1998, BIOPHYS J, V74, P2802, DOI 10.1016/S0006-3495(98)77987-1; FEENER EP, 1990, J BIOL CHEM, V265, P18780; Gottschalk S, 1996, GENE THER, V3, P448; HICKMAN MA, 1994, HUM GENE THER, V5, P1477, DOI 10.1089/hum.1994.5.12-1477; Kwoh DY, 1999, BBA-GENE STRUCT EXPR, V1444, P171, DOI 10.1016/S0167-4781(98)00274-7; Kwok KY, 1999, J PHARM SCI-US, V88, P996, DOI 10.1021/js990072s; LEWIS RJ, 1985, MACROMOLECULES, V18, P944, DOI 10.1021/ma00147a022; McKenzie DL, 1999, J PEPT RES, V54, P311, DOI 10.1034/j.1399-3011.1999.00104.x; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730; Ogris M, 1998, GENE THER, V5, P1425, DOI 10.1038/sj.gt.3300745; Plank C, 1999, HUM GENE THER, V10, P319, DOI 10.1089/10430349950019101; Plank C, 1996, HUM GENE THER, V7, P1437, DOI 10.1089/hum.1996.7.12-1437; Pouton CW, 1998, ADV DRUG DELIVER REV, V34, P3, DOI 10.1016/S0169-409X(98)00048-9; SMITH RD, 1990, ANAL CHEM, V62, P882, DOI 10.1021/ac00208a002; STANKOVICS J, 1994, HUM GENE THER, V5, P1095, DOI 10.1089/hum.1994.5.9-1095; Terebesi J, 1998, ANAL BIOCHEM, V263, P120, DOI 10.1006/abio.1998.2834; Thierry AR, 1997, GENE THER, V4, P226, DOI 10.1038/sj.gt.3300350; Toncheva V, 1998, BBA-GEN SUBJECTS, V1380, P354, DOI 10.1016/S0304-4165(98)00004-X; Trubetskoy VS, 1998, NUCLEIC ACIDS RES, V26, P4178, DOI 10.1093/nar/26.18.4178; Trubetskoy VS, 1999, BIOCONJUGATE CHEM, V10, P624, DOI 10.1021/bc9801530; Wadhwa MS, 1997, BIOCONJUGATE CHEM, V8, P81, DOI 10.1021/bc960079q; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; Wolfert MA, 1996, HUM GENE THER, V7, P2123, DOI 10.1089/hum.1996.7.17-2123; Wolfert MA, 1996, GENE THER, V3, P269; Wyman TB, 1997, BIOCHEMISTRY-US, V36, P3008, DOI 10.1021/bi9618474; Yang JP, 1997, GENE THER, V4, P950, DOI 10.1038/sj.gt.3300485; Zhang YP, 1997, PHARMACEUT RES, V14, P190, DOI 10.1023/A:1012000711033	37	211	244	3	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					9970	9977		10.1074/jbc.275.14.9970	http://dx.doi.org/10.1074/jbc.275.14.9970			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744672	hybrid			2022-12-27	WOS:000086345600013
J	Yue, HW; Devidas, S; Guggino, WB				Yue, HW; Devidas, S; Guggino, WB			The two halves of CFTR form a dual-pore ion channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS GENE; CHLORIDE CHANNEL; CL CHANNELS; LINING RESIDUES; PHOSPHORYLATION; IDENTIFICATION; HYDROLYSIS; STATES; CELLS	The cystic fibrosis transmembrane conductance regulator (CFTR) exhibits two conductance states, 9 picosiemens (pS) and 3 pS, To investigate the origin of these two distinct conductance states, we measured the single-channel activity of three truncated forms of CFTR. These include: TNR, which contains the first transmembrane domain, the first nucleotide binding domain, and the R domain; RT2N2, which contains the R domain, the second transmembrane domain, and the second nucleotide-binding domain; and T2N2, which contains only the second transmembrane domain and the second nucleotide-binding domain. The results show that TNR exhibits only the large conductance of 9.2 pS, whereas RT2N2 and T2N2 exhibit only the small conductance (3.8-4.0 pS), Go-expression of TNR with T2N2 resulted in a mixed pattern of two conductance states, which is similar to that observed in wild-type CFTR, In further studies, a "dual-R mutant," R334W and R347P in the transmembrane segment 6 of the first half of CFTR, severely impaired the large conductance channel without affecting the small conductance channel. The ion selectivity and gating behavior of the two conductance channels are different regardless of whether they are measured in wild-type CF-TR or in truncated CFTRs, The ion selectivity of the large conductance channel is Br- > Cl- > I-, whereas the ion selectivity of the small conductance channel is Br- = Cl- = I-. The open probability (P-o) of the large conductance is about 4-fold higher than that of the small conductance, Transition from closed to open states of the small conductance is not dependent upon the open or closed states of the large conductance. The independent behaviors of the two conductances in CFTR strongly suggest that CFTR may have two distinct pores. Thus, Like ClC0, CFTR is likely to be a double-barreled ion channel, with the first half of CFTR forming the large conductance and the second half forming the small conductance.	Johns Hopkins Univ, Sch Med, Dept Physiol & Pediat, Baltimore, MD 21205 USA	Johns Hopkins University	Guggino, WB (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol & Pediat, 725 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047122, P01HL051811] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47122, HL 51811] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; Arispe N, 1998, J BIOL CHEM, V273, P5727, DOI 10.1074/jbc.273.10.5727; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Cheung M, 1996, BIOPHYS J, V70, P2688, DOI 10.1016/S0006-3495(96)79838-7; Colquhoun David, 1995, P483; Devidas S, 1998, J BIOL CHEM, V273, P29373, DOI 10.1074/jbc.273.45.29373; GADSBY DC, 1995, ANNU REV PHYSIOL, V57, P387; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; Lansdell KA, 1998, J PHYSIOL-LONDON, V512, P751, DOI 10.1111/j.1469-7793.1998.751bd.x; Ludewig U, 1996, NATURE, V383, P340, DOI 10.1038/383340a0; MCCARTY NA, 1993, J GEN PHYSIOL, V102, P1, DOI 10.1085/jgp.102.1.1; MCDONOUGH S, 1994, NEURON, V13, P623, DOI 10.1016/0896-6273(94)90030-2; Middleton RE, 1996, NATURE, V383, P337, DOI 10.1038/383337a0; Morales MM, 1996, AM J PHYSIOL-RENAL, V270, pF1038, DOI 10.1152/ajprenal.1996.270.6.F1038; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; Schwiebert EM, 1998, P NATL ACAD SCI USA, V95, P2674, DOI 10.1073/pnas.95.5.2674; SHEPPARD DN, 1994, CELL, V76, P1091, DOI 10.1016/0092-8674(94)90385-9; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; Tao T, 1996, BIOPHYS J, V70, P743, DOI 10.1016/S0006-3495(96)79614-5; XIE JX, 1995, J BIOL CHEM, V270, P28084	25	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10030	10034		10.1074/jbc.275.14.10030	http://dx.doi.org/10.1074/jbc.275.14.10030			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744680	hybrid			2022-12-27	WOS:000086345600021
J	Cao, Y; Wang, CY				Cao, Y; Wang, CY			The COOH-terminal transactivation domain plays a key role in regulating the in vitro and in vivo function of Pax3 homeodomain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR ALVEOLAR RHABDOMYOSARCOMA; PAX3-FKHR FUSION PROTEIN; FACTOR-ALPHA RECEPTOR; PAIRED BOX GENE; DNA-BINDING; CHROMOSOMAL TRANSLOCATION; TRANSCRIPTION FACTOR; MOUSE MUTANT; SPLOTCH; MUTATION	Efficient transcription activation by Pax3 requires binding to a complex DNA sequence element containing binding sites for both the paired domain and the Prd type homeodomain. Previously, we have shown that this requirement is lost in PAX3-FKHR, the product of a t(2;13) chromosomal translocation associated with alveolar rhabdomyosarcoma. In contrast to Pax3, the chimeric PAX3-FKHR, which acts as an oncogene, can efficiently activate a DNA sequence element containing only a homeodomain binding site (TAATAN(2-3)ATTA), de spite the presence of an intact Pax3 paired domain, Here, we showed that this alteration in sequence-specific transcription activity was determined in part by the transactivation domain. First, we demonstrated that in intact Pax3, substitution of the Pax3 transactivation domain with an unrelated viral VP16 transactivation domain enabled Pax3 to transactivate homeodomain-specific DNA sequence, as well as to transform fibroblasts. Furthermore, we could abolish the homeodomain-dependent transcription and transforming activities of PAX3-FKHR by replacing its FKHR transactivation domain with Pax3 transactivation domain. Collectively, these results suggested that the transactivation domain influences the DNA binding specificity of Pax3. The translocation process increased the oncogenic potential of Pax3 by removing the inhibitory action of Pax3 transactivation domain on its homeodomain.	Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Wang, CY (corresponding author), Univ Illinois, Ctr Mol Biol Oral Dis, 801 S Paulina St, Chicago, IL 60612 USA.	chiayeng@tigger.uic.edu			NATIONAL CANCER INSTITUTE [R01CA074907, R29CA074907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R15NS036366] Funding Source: NIH RePORTER; NCI NIH HHS [CA-74907] Funding Source: Medline; NINDS NIH HHS [NS-36366] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CHALEPAKIS G, 1994, NUCLEIC ACIDS RES, V22, P3131, DOI 10.1093/nar/22.15.3131; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P3685, DOI 10.1073/pnas.91.9.3685; CHALEPAKIS G, 1993, J NEUROBIOL, V24, P1367, DOI 10.1002/neu.480241009; Daston G, 1996, DEVELOPMENT, V122, P1017; DOUGLASS EC, 1987, CYTOGENET CELL GENET, V45, P148, DOI 10.1159/000132446; ENZINGER FM, 1983, SOFT TISSUE TUMORS, P363; EPSTEIN DJ, 1993, P NATL ACAD SCI USA, V90, P532, DOI 10.1073/pnas.90.2.532; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; Fortin AS, 1998, NUCLEIC ACIDS RES, V26, P4574, DOI 10.1093/nar/26.20.4574; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HARMS D, 1995, CURR TOP PATHOL, V89, P292; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; HORN RC, 1958, CANCER, V11, P181, DOI 10.1002/1097-0142(195801/02)11:1<181::AID-CNCR2820110130>3.0.CO;2-I; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Maroto M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7; MERCOLA M, 1985, SCIENCE, V227, P266, DOI 10.1126/science.3917575; NEWTON WA, 1988, J CLIN ONCOL, V6, P67, DOI 10.1200/JCO.1988.6.1.67; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; SHAPIRO DN, 1993, CANCER RES, V53, P5108; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V19, P361, DOI 10.1016/0165-4608(86)90069-5; Underhill DA, 1997, J BIOL CHEM, V272, P14175, DOI 10.1074/jbc.272.22.14175; VOGAN KJ, 1993, GENOMICS, V17, P364, DOI 10.1006/geno.1993.1333; Wang CY, 1996, MOL CELL BIOL, V16, P712; Wang-Wuu S, 1988, Cancer Res, V48, P983; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9	41	27	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9854	9862		10.1074/jbc.275.13.9854	http://dx.doi.org/10.1074/jbc.275.13.9854			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734141	hybrid			2022-12-27	WOS:000086206500105
J	Grunewald, M; Kanner, BI				Grunewald, M; Kanner, BI			The accessibility of a novel reentrant loop of the glutamate transporter GLT-1 is restricted by its substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; RAT-BRAIN; MEMBRANE TOPOLOGY; ESCHERICHIA-COLI; FUNCTIONAL-CHARACTERIZATION; K+ CHANNEL; EXPRESSION; CLONING; REVEALS; RESIDUE	The excitatory neurotransmitter glutamate is removed from the synaptic cleft by several related sodium-and potassium-coupled transporters. They thereby restrict the neurotoxicity of this transmitter. Based on the accessibility of single cysteines to the large sulfhydryl reagent 3-N-maleimidyl(propionyl)biocytin, we have proposed a topological model for the astroglial glutamate transporter GLT-1 (Grunewald, M,, Bendahan, k and Kanner, B. I. (1998) Neuron 21, 623-632), Because of several unexpected observations, we have investigated the topological disposition of 19 cysteine residues engineered into a loop proposed to be intracellular. We have probed the accessibility of these cysteines to small and large sulfhydryl reagents. The impermeant hydrophilic sulfhydryl reagent [(2-trimethylammonium)ethyl] methanethiosulfonate inhibits transport activity only at two of these positions, weakly at G365C and potently at A364C, Glutamate and its nontransportable analogue dihydrokainate markedly protect A364C transporters against this impermeant reagent. Using a biotinylated maleimide, we found that, among the 14 mutants tested with it, only A364C is accessible to it from the extracellular side. This, together with our previous observations, indicates that the loop-including amino acid residues 354, 359, 373, and 379-is largely intracellular, but a short region of it forms a reentrant pore-loop-like structure, the accessibility of which is dependent ore the conformation of the transporter.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91010 Jerusalem, Israel	Hebrew University of Jerusalem	Kanner, BI (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, POB 12272, IL-91010 Jerusalem, Israel.							ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; Diamond JS, 1997, J NEUROSCI, V17, P4672; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GRUNEWALD M, 1995, J BIOL CHEM, V270, P17017, DOI 10.1074/jbc.270.28.17017; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KANNER BI, 1982, BIOCHEMISTRY-US, V21, P6327, DOI 10.1021/bi00267a044; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; Kekuda R, 1996, J BIOL CHEM, V271, P18657, DOI 10.1074/jbc.271.31.18657; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; Kuner T, 1996, NEURON, V17, P343, DOI 10.1016/S0896-6273(00)80165-8; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; NICOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462; Olami Y, 1997, J BIOL CHEM, V272, P1761, DOI 10.1074/jbc.272.3.1761; Otis TS, 1996, J NEUROSCI, V16, P1634, DOI 10.1523/jneurosci.16-05-01634.1996; PINES G, 1995, J BIOL CHEM, V270, P17093, DOI 10.1074/jbc.270.29.17093; PINES G, 1990, BIOCHEMISTRY-US, V29, P11209, DOI 10.1021/bi00503a008; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Seal RP, 1998, NEURON, V21, P1487, DOI 10.1016/S0896-6273(00)80666-2; SHAFQAT S, 1993, J BIOL CHEM, V268, P15351; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; Slotboom DJ, 1996, J BIOL CHEM, V271, P31317, DOI 10.1074/jbc.271.49.31317; Stephan MM, 1997, BIOCHEMISTRY-US, V36, P1322, DOI 10.1021/bi962150l; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Sun JZ, 1998, BIOCHEMISTRY-US, V37, P8020, DOI 10.1021/bi973192s; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; TOLNER B, 1995, J BACTERIOL, V177, P2863, DOI 10.1128/jb.177.10.2863-2869.1995; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; Wahle S, 1996, J CELL BIOL, V135, P1867, DOI 10.1083/jcb.135.6.1867; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; Zarbiv R, 1998, J BIOL CHEM, V273, P14231, DOI 10.1074/jbc.273.23.14231; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; Zhang YM, 1999, P NATL ACAD SCI USA, V96, P1710, DOI 10.1073/pnas.96.4.1710; Zhang YM, 1998, P NATL ACAD SCI USA, V95, P751, DOI 10.1073/pnas.95.2.751	52	119	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9684	9689		10.1074/jbc.275.13.9684	http://dx.doi.org/10.1074/jbc.275.13.9684			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734120	hybrid			2022-12-27	WOS:000086206500084
J	Mundorf, ML; Troyer, KP; Hochstetler, SE; Near, JA; Wightman, RM				Mundorf, ML; Troyer, KP; Hochstetler, SE; Near, JA; Wightman, RM			Vesicular Ca2+ participates in the catalysis of exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; SECRETORY VESICLE BIOGENESIS; SYNAPTIC VESICLES; CHROMOGRANIN-A; NEUROTRANSMITTER RELEASE; CATECHOLAMINE SECRETION; CONFORMATIONAL CHANGE; MONOAMINE TRANSPORT; RESERPINE BINDING; GRANULE MEMBRANES	Effects of vesicular monoamine transporter inhibitors on catecholamine release from bovine chromaffin cells have been examined at the level of individual exocytotic events. As expected for a depletion of vesicular stores, release evoked by depolarizing agents was decreased following 15-min incubations with reserpine and tetrabenazine, as evidenced by a decrease in exocytotic frequency and amount released per event. In contrast, two reserpine derivatives, methyl reserpate and reserpic acid, were much less effective. Surprisingly, the incubations also decreased the accompanying rise in intracellular Ca2+ evoked by depolarizing agents. Subcellular studies revealed that reserpine and tetrabenazine at concentrations near their Ri values not only could increase cytoplasmic catecholamines but also could displace Ca2+ from vesicles. Furthermore, transient exposure to tetrabenazine and reserpine, but not methyl reserpate and reserpic acid, induced exocytotic release of catecholamines, Reserpine induced a rise in intracellular Ca2+, as detected by whole-cell measurements with Fura-2, It could induce exocytosis, albeit at a lower frequency, in Ca2+-free solutions, supporting an internal Ca2+ source. Depletion of endoplasmic reticulum and mitochondrial Ca2+ pools did not eliminate the reserpine-activated release. These results indicate that vesicular Ca2+ can play an important role in exocytosis and under some conditions may be involved in initiating this process.	Univ N Carolina, Dept Comp Sci, Chapel Hill, NC 27599 USA; Indiana Univ, Sch Med, Med Sci Program, Bloomington, IN 47405 USA	University of North Carolina; University of North Carolina Chapel Hill; Indiana University System; Indiana University Bloomington	Wightman, RM (corresponding author), Univ N Carolina, Dept Comp Sci, Chapel Hill, NC 27599 USA.				NINDS NIH HHS [1R01 NS38879] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038879] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BURGOYNE RD, 1995, TRENDS NEUROSCI, V18, P191, DOI 10.1016/0166-2236(95)93900-I; CAHILL PS, 1995, ANAL CHEM, V67, P2599, DOI 10.1021/ac00111a017; CAUGHEY B, 1987, J NEUROCHEM, V49, P563, DOI 10.1111/j.1471-4159.1987.tb02901.x; CHAPLIN L, 1985, J BIOL CHEM, V260, P981; CHEEK TR, 1989, CELL CALCIUM, V10, P213, DOI 10.1016/0143-4160(89)90004-3; CHEEK TR, 1990, FEBS LETT, V266, P91, DOI 10.1016/0014-5793(90)81514-O; CHEEK TR, 1993, J BIOL CHEM, V268, P27076; DARCHEN F, 1989, BIOCHEMISTRY-US, V28, P1692, DOI 10.1021/bi00430a040; DORFMAN L, 1954, HELV CHIM ACTA, V37, P59, DOI 10.1002/hlca.19540370108; FINNEGAN JM, 1995, J BIOL CHEM, V270, P5353, DOI 10.1074/jbc.270.10.5353; Fitzpatrick S, 1996, MOL CELL BIOCHEM, V155, P121; FLOOR E, 1995, J NEUROCHEM, V64, P689; Fossier P, 1998, NEUROSCIENCE, V85, P85, DOI 10.1016/S0306-4522(97)00591-5; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; Goncalves PP, 1998, NEUROSCI LETT, V247, P87, DOI 10.1016/S0304-3940(98)00256-0; GRATZL M, 1981, BIOCHIM BIOPHYS ACTA, V649, P355, DOI 10.1016/0005-2736(81)90425-9; HAIGH JR, 1989, BIOCHEM J, V259, P485, DOI 10.1042/bj2590485; Han WP, 1999, J NEUROSCI, V19, P900; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; JANKOWSKI JA, 1993, J BIOL CHEM, V268, P14694; KAWAGOE KT, 1993, J NEUROSCI METH, V48, P225, DOI 10.1016/0165-0270(93)90094-8; Kozminski KD, 1998, ANAL CHEM, V70, P3123, DOI 10.1021/ac980129f; LESZCZYSZYN DJ, 1991, J NEUROCHEM, V56, P1855, DOI 10.1111/j.1471-4159.1991.tb03441.x; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Mahata M, 1996, HYPERTENSION, V28, P414, DOI 10.1161/01.HYP.28.3.414; MICHALKE W, 1990, N-S ARCH PHARMACOL, V342, P312; Mundorf ML, 1999, J NEUROCHEM, V73, P2397, DOI 10.1046/j.1471-4159.1999.0732397.x; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; PARTI R, 1987, J NEUROCHEM, V48, P949, DOI 10.1111/j.1471-4159.1987.tb05609.x; Petersen OH, 1996, TRENDS NEUROSCI, V19, P411; POULSEN JCJ, 1995, BIOCHEM J, V307, P749, DOI 10.1042/bj3070749; Powis DA, 1996, NEUROSCI LETT, V204, P165, DOI 10.1016/0304-3940(96)12346-6; Scheenen WJJM, 1998, J BIOL CHEM, V273, P19002, DOI 10.1074/jbc.273.30.19002; SCHERMAN D, 1980, BIOCHEM PHARMACOL, V29, P1883, DOI 10.1016/0006-2952(80)90098-2; SCHERMAN D, 1984, MOL PHARMACOL, V25, P113; SERCKHAN.G, 1973, BIOCHIM BIOPHYS ACTA, V307, P404, DOI 10.1016/0005-2736(73)90106-5; SUDHOF TC, 1983, BIOCHEM BIOPH RES CO, V116, P663; SULZER D, 1990, NEURON, V5, P797, DOI 10.1016/0896-6273(90)90339-H; Thomas DM, 1998, J NEUROSCI, V18, P3511; Troadec JD, 1998, BIOL CELL, V90, P339; UVNAS B, 1980, ACTA PHYSIOL SCAND, V109, P345, DOI 10.1111/j.1748-1716.1980.tb06606.x; vandePut FHMM, 1996, J BIOL CHEM, V271, P4999; Verkhratsky AJ, 1998, CELL CALCIUM, V24, P333, DOI 10.1016/S0143-4160(98)90057-4; VONRUDEN L, 1993, SCIENCE, V262, P1061, DOI 10.1126/science.8235626; WOODBURY DJ, 1995, MOL MEMBR BIOL, V12, P165, DOI 10.3109/09687689509027504; YOO SH, 1990, J BIOL CHEM, V265, P14414; Yoo SH, 1996, J BIOL CHEM, V271, P1558; YOO SH, 1995, J BIOL CHEM, V270, P12578, DOI 10.1074/jbc.270.21.12578; YOO SH, 1990, J BIOL CHEM, V265, P13446; ZALLAKIAN M, 1982, BIOCHEMISTRY-US, V21, P1051, DOI 10.1021/bi00534a035	51	49	50	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9136	9142		10.1074/jbc.275.13.9136	http://dx.doi.org/10.1074/jbc.275.13.9136			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734047	Green Published, hybrid			2022-12-27	WOS:000086206500011
J	Tang, DM; Lahti, JM; Kidd, VJ				Tang, DM; Lahti, JM; Kidd, VJ			Caspase-8 activation and bid cleavage contribute to MCF7 cellular execution in a caspase-3-dependent manner during staurosporine-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; PATHWAYS; FAS; MITOCHONDRIA; REQUIREMENT; RECEPTORS; PROTEIN; RELEASE; FADD	There are at least two distinct classes of caspases, initiators (e.g. caspases-8, -9, and -10) and effecters (e.g. caspase-3), Furthermore, it is believed that there are two distinct primary apoptotic signaling pathways, one of which is mediated by death receptors controlled by caspases-8/10, and the other by the release of cytochrome c and activation of a caspase-9/Apaf1/cytochrome c apoptosome. However, several recent reports have demonstrated that caspase-8, and its substrate Bid, are frequently activated in response to certain apoptotic stimuli in a death receptor-independent manner. These results suggest that significant cross talk may exist between these two distinct signaling arms, allowing each to take advantage of elements unique to the other. Here we provide evidence that activation of caspase-8, and subsequent Bid cleavage, does indeed participate in cytochrome c-mediated apoptosis, at least in certain circumstances and cell types. Furthermore, the participation of activated caspase-3 is essential for activation of caspase-8 and Bid processing to occur. Although caspase-8 activation is not required for the execution of a cytochrome c-mediated death signal, we found that it greatly shortens the execution time. Thus, caspase-8 involvement in cytochrome c-mediated cell death may help to amplify weaker death signals and ensure that apoptosis occurs within a certain time frame.	St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38101 USA	St Jude Children's Research Hospital	Kidd, VJ (corresponding author), St Jude Childrens Res Hosp, Dept Tumor Cell Biol, 332 N Lauderdale, Memphis, TN 38101 USA.		Tang, Damu/AAQ-1786-2021	Tang, Damu/0000-0002-3282-9521	NATIONAL CANCER INSTITUTE [P30CA021765, R01CA067938, R56CA067938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044088] Funding Source: NIH RePORTER; NCI NIH HHS [CA67938, CA21765] Funding Source: Medline; NIGMS NIH HHS [GM44088] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Choi KB, 1998, J BIOL CHEM, V273, P20185, DOI 10.1074/jbc.273.32.20185; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; FEARNHEAD H, 1997, P NATL ACAD SCI USA, V95, P13664; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Xanthoudakis S, 1999, EMBO J, V18, P2049, DOI 10.1093/emboj/18.8.2049; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	27	220	222	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9303	9307		10.1074/jbc.275.13.9303	http://dx.doi.org/10.1074/jbc.275.13.9303			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734071	hybrid			2022-12-27	WOS:000086206500035
J	Yauch, RL; Kazarov, AR; Desai, B; Lee, RT; Hemler, ME				Yauch, RL; Kazarov, AR; Desai, B; Lee, RT; Hemler, ME			Direct extracellular contact between integrin alpha(3)beta(1) and TM4SF protein CD151	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-VIRUS TYPE-1; MHC CLASS-II; TRANSMEMBRANE-4 SUPERFAMILY; MONOCLONAL-ANTIBODIES; T-CELLS; ELECTRON-MICROSCOPY; SIGNAL-TRANSDUCTION; SYNCYTIUM FORMATION; C33 ANTIGEN; ASSOCIATION	Previously we established that the alpha(3)beta(1) integrin shows stable, specific, and stoichiometric association with the TM4SF (tetraspannin) protein CD151. Here we used a membrane impermeable cross-linking agent to show a direct association between extracellular domains of alpha(3)beta(1) and CD151. The alpha(3)beta(1)-CD151 association site was then mapped using chimeric alpha(6)/alpha(3) integrins and CD151/NAG2 TM4SF proteins. Complex formation required an extracellular alpha(3) Site (amino acids (aa) 570-705) not previously known to be involved in specific integrin contacts with other proteins and a region (aa 186-217) within the large extracellular loop of CD151. Notably, the anti-CD151 monoclonal antibody TS151r binding epitope, previously implicated in alpha(3) integrin association, was mapped to the same region of CD151 (aa 186-217). Finally, we demonstrated that both NH2- and COOH-terminal domains of CD151 are located on the inside of the plasma membrane, thus confirming a long suspected model of TM4SF protein topology.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Hemler, ME (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Rm D-1430,44 Binney St, Boston, MA 02115 USA.			/0000-0002-3928-5854	NCI NIH HHS [CA86712] Funding Source: Medline; NIGMS NIH HHS [GM38903] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038903] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGELISOVA P, 1994, IMMUNOGENETICS, V39, P249; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; BELL GM, 1992, J EXP MED, V175, P527, DOI 10.1084/jem.175.2.527; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; Berditchevski F, 1997, J BIOL CHEM, V272, P29174, DOI 10.1074/jbc.272.46.29174; BERDITCHEVSKI F, 1995, J BIOL CHEM, V270, P17784, DOI 10.1074/jbc.270.30.17784; BERGELSON JM, 1994, CELL ADHES COMMUN, V2, P455, DOI 10.3109/15419069409004455; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.immunol.13.1.127; FITTER S, 1995, BLOOD, V86, P1348, DOI 10.1182/blood.V86.4.1348.bloodjournal8641348; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; Hasegawa H, 1996, J VIROL, V70, P3258, DOI 10.1128/JVI.70.5.3258-3263.1996; HEMLER ME, 1984, J IMMUNOL, V132, P3011; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; HEMLER ME, 1982, J IMMUNOL, V129, P2734; IMAI T, 1993, J IMMUNOL, V151, P6470; IMAI T, 1995, J IMMUNOL, V155, P1229; Jones PH, 1996, CELL ADHES COMMUN, V4, P297, DOI 10.3109/15419069609010773; KITAGAWA T, 1976, J BIOCHEM-TOKYO, V79, P233, DOI 10.1093/oxfordjournals.jbchem.a131053; LEE RT, 1995, CIRC RES, V76, P209, DOI 10.1161/01.RES.76.2.209; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Mannion BA, 1996, J IMMUNOL, V157, P2039; McCaffrey PG, 1997, BLOOD, V90, P2075, DOI 10.1182/blood.V90.5.2075; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; Nichols TC, 1998, EUR J IMMUNOL, V28, P4123, DOI 10.1002/(SICI)1521-4141(199812)28:12<4123::AID-IMMU4123>3.0.CO;2-G; Rubinstein E, 1997, EUR J IMMUNOL, V27, P1919, DOI 10.1002/eji.1830270815; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; Schmidt C, 1996, J NEUROSCI RES, V43, P12, DOI 10.1002/jnr.490430103; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Serru V, 1999, BIOCHEM J, V340, P103, DOI 10.1042/0264-6021:3400103; Shattil SJ, 1997, J CLIN INVEST, V100, pS91; Sincock PM, 1999, J CELL SCI, V112, P833; Sincock PM, 1997, J HISTOCHEM CYTOCHEM, V45, P515, DOI 10.1177/002215549704500404; Szollosi J, 1996, J IMMUNOL, V157, P2939; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; Tachibana I, 1999, J CELL BIOL, V146, P893, DOI 10.1083/jcb.146.4.893; Tanio Y, 1999, EXP HEMATOL, V27, P853, DOI 10.1016/S0301-472X(99)00011-9; Testa JE, 1999, CANCER RES, V59, P3812; TOMLINSON MG, 1993, EUR J IMMUNOL, V23, P136, DOI 10.1002/eji.1830230122; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751; YELTON DE, 1981, HYBRIDOMA, V1, P5, DOI 10.1089/hyb.1.1981.1.5	51	157	162	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9230	9238		10.1074/jbc.275.13.9230	http://dx.doi.org/10.1074/jbc.275.13.9230			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734060	hybrid			2022-12-27	WOS:000086206500024
J	Chauchereau, A; Georgiakaki, M; Perrin-Wolff, M; Milgrom, E; Loosfelt, H				Chauchereau, A; Georgiakaki, M; Perrin-Wolff, M; Milgrom, E; Loosfelt, H			JAB1 interacts with both the progesterone receptor and SRC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; TAT-MEDIATED TRANSACTIVATION; PROTEIN-PROTEIN-INTERACTION; CREB-BINDING-PROTEIN; ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS; GLUCOCORTICOID RECEPTOR; 26S PROTEASOME; C-JUN; TRANSCRIPTIONAL COACTIVATOR	JAB1 (Jun activation domain-binding protein-1) has previously been described as a coactivator of AP1 transcription factor. We show here, by yeast and mammalian two-hybrid analyses and by pull-down experiments, that JAB1 also interacts with both the progesterone receptor (PR) and the steroid receptor coactivator 1 (SRC-1) and that it stabilizes PR-SRC-1 complexes. We also show that JAB1 potentiates the activity of a variety of transcription factors known to associate with SRC-1 (nuclear receptors, activator protein-1, and nuclear factor KB). This occurs without any modification of PR or SRC-1 concentration. JAB1 is a subunit of a large multiprotein complex that has been called the COP9 signalosome. The latter is present in plant and animal cells and has been shown to be involved in a variety of cellular mechanisms including transcription regulation, cell cycle control, and phosphorylation cascades. We now show that it is also involved in the mechanisms of action of nuclear receptors and of their coactivators.	Hop Bicetre, INSERM U135, F-94275 Le Kremlin Bicetre, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Milgrom, E (corresponding author), Hop Bicetre, INSERM U135, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.	u135@kb.inserm.fr	Chauchereau, Anne/N-8880-2016; CHAUCHEREAU, Anne/B-1074-2009	Chauchereau, Anne/0000-0001-9447-3797; 				ADAMS A, 1997, METHODS YEAST GENETI, P148; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bamberger AM, 1996, P NATL ACAD SCI USA, V93, P6169, DOI 10.1073/pnas.93.12.6169; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chamovitz DA, 1996, CELL, V86, P115, DOI 10.1016/S0092-8674(00)80082-3; CHAUCHEREAU A, 1991, J BIOL CHEM, V266, P18280; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen HY, 1998, J BIOL CHEM, V273, P13165, DOI 10.1074/jbc.273.21.13165; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Dressel U, 1999, MOL CELL BIOL, V19, P3383; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GHOSH S, 1995, ANAL BIOCHEM, V225, P376, DOI 10.1006/abio.1995.1176; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Goubeaud A, 1996, MECH DEVELOP, V57, P59, DOI 10.1016/0925-4773(96)00532-1; GUIOCHONMANTEL A, 1995, MOL ENDOCRINOL, V9, P1791, DOI 10.1210/me.9.12.1791; GUIOCHONMANTEL A, 1988, NATURE, V336, P695, DOI 10.1038/336695a0; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; James P, 1996, GENETICS, V144, P1425; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; LEVINGER L, 1982, CELL, V28, P375, DOI 10.1016/0092-8674(82)90355-5; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; LOOSFELT H, 1986, P NATL ACAD SCI USA, V83, P9045, DOI 10.1073/pnas.83.23.9045; LORENZO F, 1988, EUR J BIOCHEM, V176, P53, DOI 10.1111/j.1432-1033.1988.tb14250.x; Mahalingam S, 1998, P NATL ACAD SCI USA, V95, P3419, DOI 10.1073/pnas.95.7.3419; McKenna NJ, 1998, P NATL ACAD SCI USA, V95, P11697, DOI 10.1073/pnas.95.20.11697; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Nichols M, 1998, EMBO J, V17, P765, DOI 10.1093/emboj/17.3.765; ONATE SA, 1995, SCIENCE, V270, P1354; Penney M, 1998, J BIOL CHEM, V273, P23938, DOI 10.1074/jbc.273.37.23938; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; SHIMANUKI M, 1995, J CELL SCI, V108, P569; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spain BH, 1996, MOL CELL BIOL, V16, P6698; SPARATO V, 1997, J BIOL CHEM, V272, P30470; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TRANSY C, 1995, MOL BIOL REP, V21, P119, DOI 10.1007/BF00986502; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WEI N, 1994, CELL, V78, P117, DOI 10.1016/0092-8674(94)90578-9; Wei N, 1999, TRENDS GENET, V15, P98, DOI 10.1016/S0168-9525(98)01670-9; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Xu JM, 1996, P NATL ACAD SCI USA, V93, P12195, DOI 10.1073/pnas.93.22.12195; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Zhang X, 1998, MOL ENDOCRINOL, V12, P513, DOI 10.1210/me.12.4.513; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	74	92	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8540	8548		10.1074/jbc.275.12.8540	http://dx.doi.org/10.1074/jbc.275.12.8540			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722692	hybrid, Green Submitted			2022-12-27	WOS:000086507700042
J	Denson, LA; Auld, KL; Schiek, DS; McClure, MH; Mangelsdorf, DJ; Karpen, SJ				Denson, LA; Auld, KL; Schiek, DS; McClure, MH; Mangelsdorf, DJ; Karpen, SJ			Interleukin-1 beta suppresses retinoid transactivation of two hepatic transporter genes involved in bile formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR LXR-ALPHA; NECROSIS-FACTOR-ALPHA; ACUTE-PHASE RESPONSE; BINDING-PROTEIN; X-RECEPTOR; RAT-LIVER; TRANSCRIPTION FACTORS; C/EBP-ALPHA; VITAMIN-A; ORPHAN RECEPTORS	Cytokines have been implicated in the pathogenesis of inflammatory cholestasis. This is due to transcriptional down-regulation of hepatic transporters including the Na+/bile acid cotransporter, ntcp, and the multispecific organic anion exporter, mrp2. We have recently shown that ntcp suppression by lipopolysaccharide in vivo is caused by down-regulation of transactivators including the previously uncharacterized Footprint B-binding protein. Both the ntcp FpB element and the mrp2 promoter contain potential retinoid-response elements. We hypothesized that retinoic acid receptor (RAR) and retinoid X receptor (RXR) heterodimers would activate these two genes and that cytokines that reduce bile flow might do so by suppressing nuclear levels of these transactivators. Retinoid transactivation and interleukin-1 beta down-regulation of the ntcp and mrp2 promoters were mapped to RXR alpha:RAR alpha-response elements. Gel mobility shift assays demonstrated specific binding of RXR alpha: RAR alpha heterodimers to the ntcp and mrp2 retinoid-response elements. The RXR alpha:RAR alpha complex was downregulated by IL-1 beta in HepG2 cells. An unexpected finding was that an adjacent CAAT-enhancer-binding protein element was required for maximal transactivation of the ntcp promoter by RXR alpha:RAR alpha. Taken together, these studies demonstrate regulation of two hepatobiliary transporter genes by RXR alpha:RAR alpha and describe a mechanism which likely contributes to their down-regulation during inflammation.	Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	Yale University; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Karpen, SJ (corresponding author), Yale Univ, Sch Med, Dept Pediat, 333 Cedar St, New Haven, CT 06520 USA.			Mangelsdorf, David/0000-0002-4355-0796	NICHD NIH HHS [HD-07388] Funding Source: Medline; NIDDK NIH HHS [R01 DK056239-02, R01 DK056239, DK-02318] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002318, R01DK056239] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adam-Stitah S, 1999, J BIOL CHEM, V274, P18932, DOI 10.1074/jbc.274.27.18932; ALLEGRETTO EA, 1995, J BIOL CHEM, V270, P23906, DOI 10.1074/jbc.270.41.23906; ANDUS T, 1991, HEPATOLOGY, V13, P364, DOI 10.1016/0270-9139(91)92454-G; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Bolder U, 1997, GASTROENTEROLOGY, V112, P214, DOI 10.1016/S0016-5085(97)70238-5; Crawford JM, 1997, CURR OPIN GASTROEN, V13, P175, DOI 10.1097/00001574-199705000-00002; Crestani M, 1998, J LIPID RES, V39, P2192; DAVIS BH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P318, DOI 10.1016/0167-4889(89)90055-4; DIEHL AM, 1994, GASTROENTEROLOGY, V106, P1625, DOI 10.1016/0016-5085(94)90420-0; DIEHL AM, 1994, HEPATOLOGY, V19, P447; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Gartung C, 1997, HEPATOLOGY, V25, P284; Green RM, 1996, GASTROENTEROLOGY, V111, P193, DOI 10.1053/gast.1996.v111.pm8698199; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; Hansen AJ, 1998, MOL PHARMACOL, V53, P1027; Hill D, 1997, CYTOKINES HLTH DIS, P401; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Karpen SJ, 1996, J BIOL CHEM, V271, P15211, DOI 10.1074/jbc.271.25.15211; Kauffmann HM, 1998, BIOCHEM BIOPH RES CO, V245, P325, DOI 10.1006/bbrc.1998.8340; Kubitz R, 1999, GASTROENTEROLOGY, V116, P401, DOI 10.1016/S0016-5085(99)70138-1; KUNO H, 1994, ENDOCRINOLOGY, V134, P2524, DOI 10.1210/en.134.6.2524; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; LEO MA, 1982, NEW ENGL J MED, V307, P597, DOI 10.1056/NEJM198209023071006; LEO MA, 1993, HEPATOLOGY, V17, P977; MACKIEWICZ A, 1991, J IMMUNOL, V146, P3032; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Moseley RH, 1997, GASTROENTEROLOGY, V112, P302, DOI 10.1016/S0016-5085(97)70250-6; Moshage H, 1997, J PATHOL, V181, P257, DOI 10.1002/(SICI)1096-9896(199703)181:3<257::AID-PATH756>3.0.CO;2-U; Nakamura J, 1999, BIOCHEM BIOPH RES CO, V255, P143, DOI 10.1006/bbrc.1999.0160; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; Ohata M, 1997, AM J PHYSIOL-GASTR L, V272, pG589, DOI 10.1152/ajpgi.1997.272.3.G589; ONG DE, 1987, HEPATOLOGY, V7, P253, DOI 10.1002/hep.1840070208; Park EA, 1997, BIOCHEM J, V322, P343, DOI 10.1042/bj3220343; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; PERLMUTTER DH, 1986, J CLIN INVEST, V78, P1349, DOI 10.1172/JCI112721; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; ROLLIER A, 1993, MOL BIOL CELL, V4, P59, DOI 10.1091/mbc.4.1.59; SCHINDLER R, 1988, INT J VITAM NUTR RES, V58, P146; Stroup D, 1997, J BIOL CHEM, V272, P9833; Sugawara A, 1998, ENDOCRINOLOGY, V139, P3030, DOI 10.1210/en.139.6.3030; Trauner M, 1998, J CLIN INVEST, V101, P2092, DOI 10.1172/JCI1680; Vos TA, 1998, HEPATOLOGY, V28, P1637, DOI 10.1002/hep.510280625; Vu-Dac N, 1998, J CLIN INVEST, V102, P625, DOI 10.1172/JCI1581; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; WHITING JF, 1995, HEPATOLOGY, V22, P1273, DOI 10.1016/0270-9139(95)90639-8; ZELEZNIKLE NJ, 1991, P NATL ACAD SCI USA, V88, P1873, DOI 10.1073/pnas.88.5.1873; Zou AH, 1997, J BIOL CHEM, V272, P19027, DOI 10.1074/jbc.272.30.19027	50	141	149	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8835	8843		10.1074/jbc.275.12.8835	http://dx.doi.org/10.1074/jbc.275.12.8835			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722729	hybrid			2022-12-27	WOS:000086507700079
J	Yang, HJ; Slupska, MM; Wei, YF; Tai, JH; Luther, WM; Xia, YR; Shih, DM; Chiang, JH; Baikalov, C; Fitz-Gibbon, S; Phan, IT; Conrad, A; Miller, JH				Yang, HJ; Slupska, MM; Wei, YF; Tai, JH; Luther, WM; Xia, YR; Shih, DM; Chiang, JH; Baikalov, C; Fitz-Gibbon, S; Phan, IT; Conrad, A; Miller, JH			Cloning and characterization of a new member of the nudix hydrolases from human and mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSE PYROPHOSPHATASE; NUCLEOSIDE TRIPHOSPHATE PYROPHOSPHOHYDROLASE; ESCHERICHIA-COLI MUTT; RADIATION HYBRID MAP; MOLECULAR-CLONING; CATALYTIC DOMAIN; RAT-LIVER; NUCLEOTIDE PYROPHOSPHATASE; STREPTOCOCCUS-PNEUMONIAE; IDENTIFICATION	Proteins containing the Nudix box "GX(5)EX(7)REUXEEXGU" (where U is usually Leu, Val, or lie) are Nudix hydrolases, which catalyze the hydrolysis of a variety of nucleoside diphosphate derivatives. Here we report cloning and characterization of a human cDNA encoding a novel nudix hydrolase NUDT5 for the hydrolysis of ADP-sugars. The deduced amino acid sequence of NUDT5 contains 219 amino acids, including a conserved Nudix hox sequence. The recombinant NUDT5 was expressed in Escherichia coli and purified to near homogeneity. At the optimal pH of 7, the purified recombinant NUTDT5 catalyzed hydrolysis of two major substrates, ADP-ribose and ADP-mannose with K-m values of 32 and 83 mu M, respectively; the V-max for ADP-mannose was about 1.5 times that with ADP-ribose. The murine NUDT5 homolog was also cloned and characterized. mNudT5 has 81% amino acid identity to NUDT5 with catalytic activities similar to NUDT5 under the optimal pH of 9. Both NUDT5 and mNudT5 transcripts were ubiquitously expressed in tissues analyzed with preferential abundance in liver. The genomic structures of both NUDT5 and mNudT5 were determined and located on human chromosome 10 and mouse chromosome 2, respectively. The role of NUDT5 in maintaining levels of free ADP-ribose in cells is discussed.	Univ Calif Los Angeles, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Div Cardiol, Los Angeles, CA 90095 USA; Human Genome Sci, Rockville, MD 20850 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; GlaxoSmithKline; Human Genome Sciences Inc	Miller, JH (corresponding author), Univ Calif Los Angeles, Dept Microbiol & Mol Genet, 1602 Mol Sci Bldg,405 Hilgard Ave, Los Angeles, CA 90095 USA.	jhmiller@mbi.ucla.edu			NCI NIH HHS [5-T32-CA009120] Funding Source: Medline; NIGMS NIH HHS [GM 32184] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009120] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEYGUNAWARDANA C, 1995, BIOCHEMISTRY-US, V34, P14997, DOI 10.1021/bi00046a006; AKIYAMA M, 1987, MOL GEN GENET, V206, P9, DOI 10.1007/BF00326530; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; AMES BN, 1960, J BIOL CHEM, V235, P769; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; BULLIONS LC, 1994, J BIOL CHEM, V269, P12339; CANALES J, 1995, BBA-PROTEIN STRUCT M, V1246, P167, DOI 10.1016/0167-4838(94)00191-I; Cartwright JL, 1999, J BIOL CHEM, V274, P8604, DOI 10.1074/jbc.274.13.8604; Cleland W W, 1979, Methods Enzymol, V63, P103; Conyers GB, 1999, J BIOL CHEM, V274, P1203, DOI 10.1074/jbc.274.3.1203; *DNASTAR INC, 1992, PROGR MAN ED SEQ PAC; Dunn CA, 1999, J BIOL CHEM, V274, P32318, DOI 10.1074/jbc.274.45.32318; Fernandez A, 1996, BBA-GEN SUBJECTS, V1290, P121, DOI 10.1016/0304-4165(96)00019-0; FRICK DN, 1995, J BIOL CHEM, V270, P1529, DOI 10.1074/jbc.270.4.1529; FRICK DN, 1995, J BIOL CHEM, V270, P24086, DOI 10.1074/jbc.270.41.24086; Gasmi L, 1999, BIOCHEM J, V344, P331, DOI 10.1042/0264-6021:3440331; *GEN COMP GROUP, 1991, PROGR MAN GCG PACK V; Glasgow BJ, 1998, BIOCHEMISTRY-US, V37, P2215, DOI 10.1021/bi9720888; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; Hankin S, 1997, INT J BIOCHEM CELL B, V29, P317, DOI 10.1016/S1357-2725(96)00153-7; JACOBSON EL, 1994, MOL CELL BIOCHEM, V138, P207, DOI 10.1007/BF00928463; Kim JS, 1998, INT J BIOCHEM CELL B, V30, P629, DOI 10.1016/S1357-2725(97)00142-8; LEE HC, 1994, MOL CELL BIOCHEM, V138, P229, DOI 10.1007/BF00928466; LEE TD, 1990, BIOMED ENVIRON MASS, V19, P639, DOI 10.1002/bms.1200191103; Maksel D, 1998, BIOCHEM J, V329, P313, DOI 10.1042/bj3290313; MATHEW N, 1995, BIOCHEM J, V311, P717, DOI 10.1042/bj3110717; McCarthy LC, 1997, GENOME RES, V7, P1153, DOI 10.1101/gr.7.12.1153; MCDONALD LJ, 1994, MOL CELL BIOCHEM, V138, P221, DOI 10.1007/BF00928465; McLennan AG, 1999, INT J MOL MED, V4, P79; MEJEAN V, 1994, MOL MICROBIOL, V11, P323, DOI 10.1111/j.1365-2958.1994.tb00312.x; Mildvan AS, 1999, ADV ENZYMOL RAMB, V73, P183, DOI 10.1002/9780470123195.ch6; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MIRO A, 1989, FEBS LETT, V244, P123, DOI 10.1016/0014-5793(89)81176-7; O'Handley SF, 1998, J BIOL CHEM, V273, P3192, DOI 10.1074/jbc.273.6.3192; OHandley SF, 1996, J BIOL CHEM, V271, P24649, DOI 10.1074/jbc.271.40.24649; Okazaki IJ, 1999, ANNU REV NUTR, V19, P485, DOI 10.1146/annurev.nutr.19.1.485; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Raffaelli N, 1999, FEBS LETT, V444, P222, DOI 10.1016/S0014-5793(99)00068-X; Safrany ST, 1999, J BIOL CHEM, V274, P21735, DOI 10.1074/jbc.274.31.21735; Safrany ST, 1998, EMBO J, V17, P6599, DOI 10.1093/emboj/17.22.6599; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sheikh S, 1998, J BIOL CHEM, V273, P20924, DOI 10.1074/jbc.273.33.20924; Sonnhammer ELL, 1998, NUCLEIC ACIDS RES, V26, P320, DOI 10.1093/nar/26.1.320; Swofford D.L., 1999, PAUP PHYLOGENETIC AN; VANIN EF, 1985, ANNU REV GENET, V19, P253, DOI 10.1146/annurev.genet.19.1.253	48	59	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8844	8853		10.1074/jbc.275.12.8844	http://dx.doi.org/10.1074/jbc.275.12.8844			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722730	hybrid			2022-12-27	WOS:000086507700080
J	Bergad, PL; Towle, HC; Berry, SA				Bergad, PL; Towle, HC; Berry, SA			Yin-yang 1 and glucocorticoid receptor participate in the Stat5-mediated growth hormone response of the serine protease inhibitor 2.1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-GLAND FACTOR; TYROSINE PHOSPHORYLATION; DNA-BINDING; TRANSCRIPTION FACTOR; GH RECEPTOR; SIGNAL TRANSDUCER; SEXUAL DIMORPHISM; NUCLEAR FACTOR; ACTIVATION; YY1	A growth hormone-inducible nuclear factor complex (GHINF), affinity-purified using the growth hormone response element (GHRE) from the promoter of rat serine protease inhibitor 2.1, was found to contain Stat5a and -5b, as well as additional components. The ubiquitous transcription factor yin-yang 1 (YY1) is present in GHINF.An antibody to YY1 inhibited the formation of the GHINF GHRE complex in an electrophoretic mobility shift assay. Furthermore, Stat5 was co-immunoprecipitated from rat hepatic nuclear extracts with antibodies to YY1. An examination of the GHRE shows that, in addition to two gamma-activated sites, it contains a putative YY1 binding site between the two gamma-activated sites, overlapping them both. Mutation of this putative YY1 site results in a decrease of GHINF GHRE complex formation in an electrophoretic mobility shift assay and a corresponding decrease in growth hormone (GH) response in functional assays. The glucocorticoid receptor was also present in GHINF, and StatB co-immunoprecipitates with glucocorticoid receptor in hepatic nuclear extracts from rats treated with GH, GH activation of serine protease inhibitor 2.1 requires the unique sequence of the GHRE encompassing the recognition sites of several transcription factors, and the interaction of these factors enhances the assembly of the transcription complex.	Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Berry, SA (corresponding author), Univ Minnesota, Dept Pediat, 420 Delaware St SE,Box 75, Minneapolis, MN 55455 USA.			Berry, Susan/0000-0001-7970-688X	NIDDK NIH HHS [DK32817] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032817] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709; BASU A, 1993, J BIOL CHEM, V268, P4188; BECKER KG, 1994, GENE, V150, P259, DOI 10.1016/0378-1119(94)90435-9; BERGAD PL, 1995, J BIOL CHEM, V270, P24903, DOI 10.1074/jbc.270.42.24903; BERRY SA, 1986, ENDOCRINOLOGY, V119, P2290, DOI 10.1210/endo-119-5-2290; BERRY SA, 1994, MOL ENDOCRINOL, V8, P1714, DOI 10.1210/me.8.12.1714; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; Gebert CA, 1997, MOL ENDOCRINOL, V11, P400, DOI 10.1210/me.11.4.400; Gronowski AM, 1996, ENDOCRINOLOGY, V137, P55, DOI 10.1210/en.137.1.55; GRONOWSKI AM, 1995, MOL ENDOCRINOL, V9, P171, DOI 10.1210/me.9.2.171; Hansen JA, 1997, J MOL ENDOCRINOL, V18, P213, DOI 10.1677/jme.0.0180213; HYDEDERUYSCHER RP, 1995, NUCLEIC ACIDS RES, V23, P4457, DOI 10.1093/nar/23.21.4457; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; JANSSON JO, 1985, ENDOCR REV, V6, P128, DOI 10.1210/edrv-6-2-128; Kim JS, 1996, NUCLEIC ACIDS RES, V24, P4341, DOI 10.1093/nar/24.21.4341; King APJ, 1996, J BIOL CHEM, V271, P18088, DOI 10.1074/jbc.271.30.18088; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Martin KA, 1997, DNA CELL BIOL, V16, P653, DOI 10.1089/dna.1997.16.653; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; RAUGHT B, 1994, MOL CELL BIOL, V14, P1752, DOI 10.1128/MCB.14.3.1752; ROSSI V, 1992, NUCLEIC ACIDS RES, V20, P1061, DOI 10.1093/nar/20.5.1061; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; SHIH HM, 1995, BIOTECHNIQUES, V18, P813; Silva CM, 1996, MOL ENDOCRINOL, V10, P508, DOI 10.1210/me.10.5.508; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; Smit LS, 1997, ENDOCRINOLOGY, V138, P3426, DOI 10.1210/en.138.8.3426; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Stoecklin E, 1997, MOL CELL BIOL, V17, P6708, DOI 10.1128/MCB.17.11.6708; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; VANDERKUUR JA, 1995, J BIOL CHEM, V270, P21738, DOI 10.1074/jbc.270.37.21738; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yi WS, 1996, MOL ENDOCRINOL, V10, P1425, DOI 10.1210/me.10.11.1425; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607	47	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8114	8120		10.1074/jbc.275.11.8114	http://dx.doi.org/10.1074/jbc.275.11.8114			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713133	hybrid			2022-12-27	WOS:000085913300093
J	Caputo, E; Manco, G; Mandrich, L; Guardiola, J				Caputo, E; Manco, G; Mandrich, L; Guardiola, J			A novel aspartyl proteinase from apocrine epithelia and breast tumors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SEMINAL PLASMA; ACTIN-BINDING PROTEIN; CD4-BINDING GLYCOPROTEIN; EXTRACELLULAR-MATRIX; MARKER PROTEIN; CANCER; CELLS; GENE; CARCINOMAS; EXPRESSION	GCDFP-15 gross cystic disease fluid protein, 15 kDa is a secretory marker of apocrine differentiation in breast carcinoma. In human breast cancer cell lines, gene expression is regulated by hormones, including androgens and prolactin. The protein is also known under different names in different body fluids such as gp17 in seminal plasma. GCDFP-15/gp17 is a ligand of CD4 and is a potent inhibitor of T-cell apoptosis induced by sequential CD4/T-cell receptor triggering. We now report that GCDFP-15/gp17 is a protease exhibiting structural properties relating it to the aspartyl proteinase superfamily. Unexpectedly, GCDFP-15/gp17 appears to be related to the retroviral members rather than to the known cellular members of this class. Site-specific mutagenesis of Asp(22) (predicted to be catalytically important for the active site) and pepstatin A inhibition confirmed that the protein is an aspartic-type protease. We also show that, among the substrates tested, GCDFP-15/gp17 is specific for fibronectin. The study of GCDFP-15/gp17-mediated proteolysis may provide a handle to understand phenomena as diverse as mammary tumor progression and fertilization.	CNR, Int Inst Genet & Biophys, I-80125 Naples, Italy; CNR, Inst Prot Biochem & Enzymol, I-80125 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR)	Caputo, E (corresponding author), CNR, Int Inst Genet & Biophys, Via Marconi 10, I-80125 Naples, Italy.	caputo@iigbna.iigb.na.cnr.it	Manco, Giuseppe/AAL-3777-2020; Caputo, Emilia/AAW-1300-2020; Mandrich, Luigi/AAH-9328-2020; MANDRICH, Luigi/L-7198-2019	Manco, Giuseppe/0000-0001-6191-3952; Mandrich, Luigi/0000-0002-0025-9544; MANDRICH, Luigi/0000-0002-0025-9544; CAPUTO, EMILIA/0000-0002-6485-8802				AKIYAMA K, 1990, BIOCHIM BIOPHYS ACTA, V1040, P206, DOI 10.1016/0167-4838(90)90077-S; ALITALO K, 1982, ADV CANCER RES, V37, P111, DOI 10.1016/S0065-230X(08)60883-0; AUTIERO M, 1991, EXP CELL RES, V197, P268, DOI 10.1016/0014-4827(91)90432-T; AUTIERO M, 1995, EUR J IMMUNOL, V25, P1461, DOI 10.1002/eji.1830250550; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; Bergamo P, 1997, HUM IMMUNOL, V58, P30, DOI 10.1016/S0198-8859(97)00213-9; Caputo E, 1999, EUR J BIOCHEM, V265, P664, DOI 10.1046/j.1432-1327.1999.00758.x; Caputo E, 1998, INT J CANCER, V78, P76, DOI 10.1002/(SICI)1097-0215(19980925)78:1<76::AID-IJC13>3.0.CO;2-3; CHAUHAN SS, 1991, CANCER RES, V51, P1478; CHEN LQ, 1992, ACTA CRYSTALLOGR B, V48, P476, DOI 10.1107/S0108768192001939; CUTFIELD S, 1993, J MOL BIOL, V234, P1266, DOI 10.1006/jmbi.1993.1679; FAIRBAIRN S, 1985, J CELL BIOL, V101, P1790, DOI 10.1083/jcb.101.5.1790; Fukai F, 1998, EXP CELL RES, V242, P92, DOI 10.1006/excr.1998.4076; Gaubin M, 1999, J IMMUNOL, V162, P2631; GRINDE B, 1992, J BIOL CHEM, V267, P9481; GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAAGENSEN DE, 1990, ANN NY ACAD SCI, V586, P161, DOI 10.1111/j.1749-6632.1990.tb17804.x; Hahnel R, 1996, VIRCHOWS ARCH, V429, P365; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HYNES RO, 1982, J CELL BIOL, V95, P369, DOI 10.1083/jcb.95.2.369; JONES PA, 1980, CANCER RES, V40, P3222; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Mann T, 1981, MALE REPROD FUNCTION; MAZOUJIAN G, 1983, AM J PATHOL, V110, P105; MILLER M, 1989, NATURE, V337, P576, DOI 10.1038/337576a0; MURPHY LC, 1987, J BIOL CHEM, V262, P15236; Orengo CA, 1999, NUCLEIC ACIDS RES, V27, P275, DOI 10.1093/nar/27.1.275; RATHMAN WM, 1989, J BIOL BUCCALE, V17, P199; ROST B, 1995, 3 INT C INT SYST MOL, P314; RUOSLAHTI E, 1984, CANCER METAST REV, V3, P43, DOI 10.1007/BF00047692; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCHENKELS LCPM, 1994, BIOL CHEM H-S, V375, P609; SHIU RPC, 1985, J BIOL CHEM, V260, P1307; SKALKA AM, 1989, CELL, V56, P911, DOI 10.1016/0092-8674(89)90621-1; TANG J, 1978, NATURE, V271, P618, DOI 10.1038/271618a0; WICK MR, 1989, HUM PATHOL, V20, P281, DOI 10.1016/0046-8177(89)90137-8; YAMADA KM, 1983, ANNU REV BIOCHEM, V52, P761, DOI 10.1146/annurev.bi.52.070183.003553	40	63	64	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7935	7941		10.1074/jbc.275.11.7935	http://dx.doi.org/10.1074/jbc.275.11.7935			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713110	hybrid			2022-12-27	WOS:000085913300070
J	Grimsby, J; Coffey, JW; Dvorozniak, MT; Magram, J; Li, GZ; Matschinsky, FM; Shiota, C; Kaur, S; Magnuson, MA; Grippo, JF				Grimsby, J; Coffey, JW; Dvorozniak, MT; Magram, J; Li, GZ; Matschinsky, FM; Shiota, C; Kaur, S; Magnuson, MA; Grippo, JF			Characterization of glucokinase regulatory protein-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETION; DIABETES-MELLITUS; GLUCOSE; LIVER; GENE; IDENTIFICATION; TRANSLOCATION; DISRUPTION; EXPRESSION; CELLS	The glucokinase regulatory protein (GKRP) inhibits glucokinase competitively with respect to glucose by forming a protein-protein complex with this enzyme. The physiological role of GKRP in controlling hepatic glucokinase activity was addressed using gene targeting to disrupt GKRP gene expression. Heterozygote and homozygote knockout mice have a substantial decrease in hepatic glucokinase expression and enzymatic activity as measured at saturating glucose concentrations when compared with wild-type mice, with no change in basal blood glucose levels. interestingly, when assayed under conditions to promote the association between glucokinase and GKRP,liver glucokinase activity in wild-type and nub mice displayed comparable glucose phosphorylation capacities at physiological glucose concentrations (5 mM). Thus, despite reduced hepatic glucokinase expression levels in the null mice, glucokinase activity in the liver homogenates was maintained at nearly normal levels due to the absence of the inhibitory effects of GKRP. However, following a glucose tolerance test, the homozygote knockout mice show impaired glucose clearance, indicating that they cannot recruit sufficient glucokinase due to the absence of a nuclear reserve. These data suggest both a regulatory and a stabilizing role for GKRP in maintaining adequate glucokinase in the liver. Furthermore, this study provides evidence for the important role GKRP plays in acutely regulating of hepatic glucose metabolism.	Hoffmann La Roche Inc, Dept Metab Dis, Nutley, NJ 07110 USA; OSI Pharmaceut Inc, Tarrytown, NY 10591 USA; Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Ctr Diabet Res, Philadelphia, PA 19104 USA; Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; DNX Transgen Sci, Cranbury, NJ 08512 USA	Roche Holding; Astellas Pharmaceuticals; OSI Pharmaceuticals; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Vanderbilt University	Grippo, JF (corresponding author), Hoffmann La Roche Inc, Dept Metab Dis, 340 Kingsland St, Nutley, NJ 07110 USA.	Joseph_F.Grippo@Roche.com	Magnuson, Mark A/B-1335-2009; Magnuson, Mark/AAY-7172-2021	Magnuson, Mark A/0000-0002-8824-6499; Magnuson, Mark/0000-0002-8824-6499				Agius L, 1998, ADV ENZYME REGUL, V38, P303, DOI 10.1016/S0065-2571(97)00001-0; Agius L, 1996, J BIOL CHEM, V271, P30479, DOI 10.1074/jbc.271.48.30479; ambrook J, 1989, MOL CLONING LAB MANU; BALI D, 1995, J BIOL CHEM, V270, P21464, DOI 10.1074/jbc.270.37.21464; Bell GI, 1996, ANNU REV PHYSIOL, V58, P171, DOI 10.1146/annurev.physiol.58.1.171; Brown KS, 1997, DIABETES, V46, P179, DOI 10.2337/diabetes.46.2.179; DAVIDSON AL, 1987, ARCH BIOCHEM BIOPHYS, V253, P156, DOI 10.1016/0003-9861(87)90648-5; Davis EA, 1999, DIABETOLOGIA, V42, P1175, DOI 10.1007/s001250051289; de la Iglesia N, 1999, FEBS LETT, V456, P332, DOI 10.1016/S0014-5793(99)00971-0; GRUPE A, 1995, CELL, V83, P69, DOI 10.1016/0092-8674(95)90235-X; IYNEDJIAN PB, 1986, P NATL ACAD SCI USA, V83, P1998, DOI 10.1073/pnas.83.7.1998; JETTON TL, 1994, J BIOL CHEM, V269, P3641; JETTON TL, 1992, P NATL ACAD SCI USA, V89, P2619, DOI 10.1073/pnas.89.7.2619; Matschinsky FM, 1998, DIABETES, V47, P307, DOI 10.2337/diabetes.47.3.307; Niswender KD, 1997, J BIOL CHEM, V272, P22570, DOI 10.1074/jbc.272.36.22570; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Shiota C, 1999, J BIOL CHEM, V274, P37125, DOI 10.1074/jbc.274.52.37125; Shiota M, 1998, DIABETES, V47, P867, DOI 10.2337/diabetes.47.6.867; STANLEY JC, 1984, BIOCHEM J, V224, P667, DOI 10.1042/bj2240667; Sweet IR, 1996, AM J PHYSIOL-ENDOC M, V271, pE606, DOI 10.1152/ajpendo.1996.271.3.E606; Terauchi Y, 1995, J BIOL CHEM, V270, P30253, DOI 10.1074/jbc.270.51.30253; VANDERCAMMEN A, 1990, EUR J BIOCHEM, V191, P483, DOI 10.1111/j.1432-1033.1990.tb19147.x; VANDERCAMMEN A, 1991, EUR J BIOCHEM, V200, P545, DOI 10.1111/j.1432-1033.1991.tb16217.x; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P173; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P179; VANSCHAFTINGEN E, 1994, FASEB J, V8, P414, DOI 10.1096/fasebj.8.6.8168691; Vionnet N, 1997, DIABETES, V46, P1062, DOI 10.2337/diabetes.46.6.1062; Wu CY, 1997, J IMMUNOL, V159, P1658; YIN L, 1992, DIABETES, V41, P792	29	101	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7826	7831		10.1074/jbc.275.11.7826	http://dx.doi.org/10.1074/jbc.275.11.7826			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713097	hybrid			2022-12-27	WOS:000085913300057
J	Ou, XM; Jafar-Nejad, H; Storring, JM; Meng, JH; Lemonde, S; Albert, PR				Ou, XM; Jafar-Nejad, H; Storring, JM; Meng, JH; Lemonde, S; Albert, PR			Novel dual repressor elements for neuronal cell-specific transcription of the rat 5-HT1A receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEROTONIN(1A) RECEPTOR; EXPRESSION; ANXIETY; DEPRESSION; SILENCER; BRAIN; MICE; DIFFERENTIATION; IDENTIFICATION; AUTORECEPTORS	The level of expression of the 5-HT1A receptor in the raphe and limbic systems is implicated in the etiology and treatment of major depression and anxiety disorders. The rat 5-HT1A receptor gene is regulated by a proximal TATA-driven promoter and by upstream repressors that inhibit gene expression. Deletion of a 71-base pair (bp) segment between -1590/-1519 bp of the 5-HT1A receptor gene induced over 10-fold enhancement of transcriptional activity in both 5-HT1A receptor-expressing (RN46A raphe and SN48 septal) cells and receptor-negative (L6 myoblast and C6 glioma) cells. A 31-bp segment of the repressor was protected from DNase I digestion by RN46A or L6 nuclear extracts. Within the 31-bp segment, a single protein complex was present in receptor-expressing cells that bound a novel 14-bp DNA element; in receptor-negative: cells, an additional complex bound an adjacent 12-bp sequence. In receptor-positive but not receptor-negative cells, mutation of the 14-bp element to eliminate protein binding abrogated repression to nearly the same extent as deletion of the -1590/-1519 bp segment. Additional mutation of both 14-bp and 12-bp elements abolished protein binding and repressor activity in receptor-negative cells. Thus a single protein-DNA complex at the 14-bp element represses the 5-HT1A receptor gene in 5-HT1A receptor-positive neuronal cells, whereas adjacent DNA elements provide a dual repression mechanism in 5-HT1A receptor-negative cells.	Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Med, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Neurosci Res Inst, Ottawa, ON K1H 8M5, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada	University of Ottawa; University of Ottawa; University of Ottawa; McGill University	Albert, PR (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.		Albert, Paul/E-4804-2010; Jafar-Nejad, Hamed/B-9216-2008	Albert, Paul/0000-0002-1809-3554; 				Albert PR, 1996, NEUROPSYCHOPHARMACOL, V14, P19, DOI 10.1016/S0893-133X(96)80055-8; BLIER P, 1994, TRENDS PHARMACOL SCI, V15, P220, DOI 10.1016/0165-6147(94)90315-8; CHAREST A, 1993, J NEUROSCI, V13, P5164, DOI 10.1523/JNEUROSCI.13-12-05164.1993; CHARNEY DS, 1990, ANNU REV MED, V41, P437; Chen ZF, 1998, NAT GENET, V20, P136, DOI 10.1038/2431; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; EATON MJ, 1995, DEV BIOL, V170, P169, DOI 10.1006/dbio.1995.1205; FANELLI RJ, 1992, SYNAPSE, V12, P75, DOI 10.1002/syn.890120109; HAMON M, 1994, TRENDS PHARMACOL SCI, V15, P36, DOI 10.1016/0165-6147(94)90104-X; Heisler LK, 1998, P NATL ACAD SCI USA, V95, P15049, DOI 10.1073/pnas.95.25.15049; HOYER D, 1994, PHARMACOL REV, V46, P157; LEE HJ, 1990, J NEUROSCI, V10, P1779; Lopez JF, 1998, BIOL PSYCHIAT, V43, P547, DOI 10.1016/S0006-3223(97)00484-8; MANDEL G, 1993, ANNU REV NEUROSCI, V16, P323, DOI 10.1146/annurev.ne.16.030193.001543; MIQUEL MC, 1992, MOL BRAIN RES, V14, P357, DOI 10.1016/0169-328X(92)90104-J; Mongeau R, 1997, BRAIN RES REV, V23, P145, DOI 10.1016/S0165-0173(96)00017-3; Ogbourne S, 1998, BIOCHEM J, V331, P1; Palm K, 1998, J NEUROSCI, V18, P1280; Parks CL, 1998, P NATL ACAD SCI USA, V95, P10734, DOI 10.1073/pnas.95.18.10734; PENINGTON NJ, 1993, J PHYSIOL-LONDON, V469, P887; Rajas F, 1998, BIOCHEM J, V333, P77, DOI 10.1042/bj3330077; Ramboz S, 1998, P NATL ACAD SCI USA, V95, P14476, DOI 10.1073/pnas.95.24.14476; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SCHOENHERR CJ, 1995, CURR OPIN NEUROBIOL, V5, P566, DOI 10.1016/0959-4388(95)80060-3; SHINTANI A, 1993, MOL BRAIN RES, V17, P129, DOI 10.1016/0169-328X(93)90081-Y; SOTELO C, 1990, EUR J NEUROSCI, V2, P1144, DOI 10.1111/j.1460-9568.1990.tb00026.x; Stockmeier CA, 1998, J NEUROSCI, V18, P7394; Storring JM, 1999, J NEUROCHEM, V72, P2238, DOI 10.1046/j.1471-4159.1999.0722238.x; Timmusk T, 1999, J BIOL CHEM, V274, P1078; TORK I, 1990, ANN NY ACAD SCI, V600, P34; Weber JRM, 1997, J NEUROSCI, V17, P7583; WELNER SA, 1989, SYNAPSE, V4, P347, DOI 10.1002/syn.890040410; WHITE LA, 1994, J NEUROSCI, V14, P6744	33	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8161	8168		10.1074/jbc.275.11.8161	http://dx.doi.org/10.1074/jbc.275.11.8161			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713139	hybrid			2022-12-27	WOS:000085913300099
J	Puzon-McLaughlin, W; Kamata, T; Takada, Y				Puzon-McLaughlin, W; Kamata, T; Takada, Y			Multiple discontinuous ligand-mimetic antibody binding sites define a ligand binding pocket in integrin alpha(IIb)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; MURINE MONOCLONAL-ANTIBODY; DEPENDENT ADHESION SITE; VON-WILLEBRAND-FACTOR; GPIIB-IIIA; PLATELET-AGGREGATION; IIB/IIIA COMPLEX; FIBRINOGEN BINDING; CRITICAL RESIDUES; BETA(3) INTEGRIN	Integrin alpha(IIb)beta(3), a platelet fibrinogen receptor, is critically involved in thrombosis and hemostasis. However, how ligands interact with alpha(IIb)beta(3) has been controversial, Ligand-mimetic anti-alpha(IIb)beta(3) antibodies (PAC-1, LJ-CP3, and OP-G2) contain the RGD-like RYD sequence in their CDR3 in the heavy chain and have structural and functional similarities to native ligands. We have located binding sites for ligand-mimetic antibodies in alpha(IIb) and beta(3) using human-to-mouse chimeras, which we expect to maintain functional integrity of alpha(IIb)beta(3). Here we report that these antibodies recognize several discontinuous binding sites;in both the alpha(IIb) and beta(3) subunits; these binding sites are located in residues 156-162 and 229-230 of alpha(IIb) and residues 179-183 of beta(3). In contrast, several nonligand-mimetic antibodies (e.g. 7E3) recognize single epitopes in either subunit, Thus, binding to several discontinuous sites in both subunits is unique to ligand-mimetic antibodies. Interestingly, these binding sites overlap with several (but not all) of the sequences that have been reported to be critical for fibrinogen binding (e.g. N-terminal repeats 2-3 but not repeats 4-7, of alpha(IIb)). These results suggest that ligand-mimetic antibodies and probably native ligands may make direct contact with these discontinuous binding sites in both subunits, which may constitute a ligand-binding pocket.	Scripps Res Inst, Dept Vasc Biol, CAL 10, La Jolla, CA 92037 USA	Scripps Research Institute	Takada, Y (corresponding author), Scripps Res Inst, Dept Vasc Biol, CAL 10, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	takada@scripps.edu		takada, yoshikazu/0000-0001-5481-9589	NIGMS NIH HHS [GM49899, GM47157] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047157, R01GM049899] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAJT ML, 1994, J BIOL CHEM, V269, P20913; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; Cierniewski CS, 1999, J BIOL CHEM, V274, P16923, DOI 10.1074/jbc.274.24.16923; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; COOK JJ, 1992, BIOCHIM BIOPHYS ACTA, V1119, P312, DOI 10.1016/0167-4838(92)90219-4; DECKMYN H, 1994, BRIT J HAEMATOL, V87, P562, DOI 10.1111/j.1365-2141.1994.tb08313.x; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; GOTO S, 1995, J BIOL CHEM, V270, P23352, DOI 10.1074/jbc.270.40.23352; GULINO D, 1992, J BIOL CHEM, V267, P1001; HARFENIST EJ, 1988, BLOOD, V71, P132; Honda S, 1998, J CLIN INVEST, V102, P1183, DOI 10.1172/JCI3206; Hu DD, 1999, J BIOL CHEM, V274, P4633, DOI 10.1074/jbc.274.8.4633; HUANG XZ, 1995, AM J RESP CELL MOL, V13, P245, DOI 10.1165/ajrcmb.13.2.7626292; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; Kamata T, 1996, J BIOL CHEM, V271, P18610, DOI 10.1074/jbc.271.31.18610; LASZ EC, 1993, BIOCHEM BIOPH RES CO, V190, P118, DOI 10.1006/bbrc.1993.1019; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lin ECK, 1997, J BIOL CHEM, V272, P14236, DOI 10.1074/jbc.272.22.14236; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; NIIYA K, 1987, BLOOD, V70, P475; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; PIDARD D, 1983, J BIOL CHEM, V258, P2582; PRAMMER KV, 1994, RECEPTOR, V4, P93; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; RINDERKNECHT H, 1962, NATURE, V193, P167, DOI 10.1038/193167b0; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; STEINER B, 1993, J BIOL CHEM, V268, P6870; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Takagi J, 1997, J BIOL CHEM, V272, P19794, DOI 10.1074/jbc.272.32.19794; Tokuhira M, 1996, THROMB HAEMOSTASIS, V76, P1038; TOMIYAMA Y, 1992, J BIOL CHEM, V267, P18085; TOMIYAMA Y, 1992, BLOOD, V79, P2303; Tozer EC, 1999, BLOOD, V93, P918, DOI 10.1182/blood.V93.3.918.403k26_918_924; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; WOODS VL, 1984, BLOOD, V63, P368; Xia Z, 1996, BRIT J HAEMATOL, V93, P204, DOI 10.1046/j.1365-2141.1996.445980.x; YLANNE J, 1988, BLOOD, V72, P1478; Yokoyama K, 1999, BIOCHEMISTRY-US, V38, P5872, DOI 10.1021/bi9827619	52	88	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7795	7802		10.1074/jbc.275.11.7795	http://dx.doi.org/10.1074/jbc.275.11.7795			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713093	hybrid			2022-12-27	WOS:000085913300053
J	Rio, C; Buxbaum, JD; Peschon, JJ; Corfas, G				Rio, C; Buxbaum, JD; Peschon, JJ; Corfas, G			Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; CARDIAC DEVELOPMENT; NEUREGULIN RECEPTOR; ERBB-4 RECEPTOR; PROTO-ONCOGENE; GENE; EXPRESSION; FAMILY; HEREGULIN	HER4 is a member of the epidermal growth factor receptor family and has an essential function in heart and neural development. Identification of two HER4 isoforms, HER4 JM-a and JM-b, which differ in their extracellular juxtamembrane region and in their susceptibility to cleavage after phorbol ester stimulation, showed that the juxtamembrane region of the receptor is critical for proteolysis. We now demonstrate that phorbol ester and pervanadate are effective stimuli for HER4 JM-a processing and that the HER4 JM-b isoform does not undergo cleavage in response to any of the stimuli studied. We also show that HER4 JM-a is not cleaved in cells lacking the metalloprotease tumor necrosis factor-alpha-converting enzyme (TACE) and that reexpression of TACE in these cells restores constitutive and regulated processing of HER4 JM-a. Moreover, we show that the sequence specific to the HER4 JM-a juxtamembrane region is sufficient to confer susceptibility to phorbol 12-myristate 13-acetate-induced cleavage of the HERS receptor. In conclusion, we provide evidence that TACE is essential for the regulated shedding of the HER4 JM-a receptor.	Harvard Univ, Childrens Hosp, Sch Med, Div Neurosci, Boston, MA 02115 USA; Mt Sinai Med Ctr, Dept Psychiat, New York, NY 10029 USA; Immunex Corp, Seattle, WA 98101 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Icahn School of Medicine at Mount Sinai; Immunex Corporation	Corfas, G (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Div Neurosci, 300 Longwood Ave, Boston, MA 02115 USA.		Río, Carlos/GQA-4045-2022; Buxbaum, Joseph D/G-6001-2010; Corfas, Gabriel/AAH-2378-2020	Río, Carlos/0000-0003-2666-7746; Corfas, Gabriel/0000-0001-5412-9473; Buxbaum, Joseph/0000-0001-8898-8313	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035884] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014996] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG14996] Funding Source: Medline; NICHD NIH HHS [P30-HD 18655] Funding Source: Medline; NINDS NIH HHS [R01 NS35884] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; Baulida J, 1996, J BIOL CHEM, V271, P5251; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Busfield SJ, 1997, MOL CELL BIOL, V17, P4007, DOI 10.1128/MCB.17.7.4007; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Cerretti DP, 1999, BIOCHEM SOC T, V27, P219, DOI 10.1042/bst0270219; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; Codony-Servat J, 1999, CANCER RES, V59, P1196; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Elenius K, 1999, ONCOGENE, V18, P2607, DOI 10.1038/sj.onc.1202612; Erickson SL, 1997, DEVELOPMENT, V124, P4999; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Graber HU, 1999, INT J CANCER, V84, P24, DOI 10.1002/(SICI)1097-0215(19990219)84:1<24::AID-IJC5>3.0.CO;2-2; Han B, 1999, J BIOL CHEM, V274, P26407, DOI 10.1074/jbc.274.37.26407; Harari D, 1999, ONCOGENE, V18, P2681, DOI 10.1038/sj.onc.1202631; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Komurasaki T, 1997, ONCOGENE, V15, P2841, DOI 10.1038/sj.onc.1201458; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; NATALI PG, 1990, INT J CANCER, V45, P457, DOI 10.1002/ijc.2910450314; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Riese DJ, 1996, ONCOGENE, V12, P345; Rosendahl MS, 1997, J BIOL CHEM, V272, P24588, DOI 10.1074/jbc.272.39.24588; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Srinivasan R, 1998, J PATHOL, V185, P236, DOI 10.1002/(SICI)1096-9896(199807)185:3<236::AID-PATH118>3.0.CO;2-7; Turner AJ, 1999, BIOCHEM SOC T, V27, P255, DOI 10.1042/bst0270255; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Vecchi M, 1998, J BIOL CHEM, V273, P20589, DOI 10.1074/jbc.273.32.20589; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562; ZIMONJIC DB, 1995, ONCOGENE, V10, P1235	56	254	261	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10379	10387		10.1074/jbc.275.14.10379	http://dx.doi.org/10.1074/jbc.275.14.10379			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744726	hybrid			2022-12-27	WOS:000086345600067
J	Simon, DI; Wei, Y; Zhang, L; Rao, NK; Xu, H; Chen, ZP; Liu, QM; Rosenberg, S; Chapman, HA				Simon, DI; Wei, Y; Zhang, L; Rao, NK; Xu, H; Chen, ZP; Liu, QM; Rosenberg, S; Chapman, HA			Identification of a urokinase receptor-integrin interaction site - Promiscuous regulator of integrin function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR RECEPTOR; LIGAND-BINDING; EXTRACELLULAR-MATRIX; MAC-1 CD11B/CD18; HUMAN MONOCYTES; I-DOMAIN; ADHESION; CELLS; NEUTROPHILS; MIGRATION	Adhesion and signaling by integrins require their dynamic association with nonintegrin membrane proteins. One such protein, the glycolipid-anchored urokinase receptor (uPAR), associates with and modifies the function of the beta(2)-integrin Mac-1 (CD11b/CD18). In this study, a critical non-I-domain binding site for uPAR on CD11b (M25; residues 424-440) is identified by homology with a phage display peptide known to bind uPAR, recombinant soluble uPAR and cells expressing uPAR bound to immobilized M25, binding being promoted by urokinase and blocked by soluble M25, but not a scrambled control or homologous peptides from other beta(2)-associated alpha-chains. Mac-1, but not a mutated Mac-1 in which M25 was replaced with the homologous sequence of CD11c, co-precipitated with uPAR, In the beta-propeller model of alpha-chain folding, M25 spans an exposed loop on the ligand-binding, upper surface of alpha M, identifying uPAR as an atypical alpha M ligand. Although not blocking ligand binding to Mac-1, M25 (25-100 mu M) inhibited leukocyte adhesion to fibrinogen, vitronectin, and cytokine-stimulated endothelial cells. M25 also blocked the association of uPAR with beta(1)-integrins and impaired beta(1)-integrin-dependent spreading and migration of human vascular smooth muscle cells on fibronectin and collagen. These observations indicate that uPAR associates with integrins directly and that disruption of this association broadly impairs integrin function, suggesting a novel strategy for regulation of integrins in the settings of inflammation and tumor progression.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Resp, Boston, MA 02115 USA; Amer Red Cross, Holland Lab, Rockville, MD 20855 USA; Chiron Corp, Emeryville, CA 94608 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; American Red Cross; Novartis	Simon, DI (corresponding author), Univ Calif San Francisco, Pulm & Crit Care Div, 505 Parnassus Ave, San Francisco, CA 94143 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL057506, R01HL061589, R01HL044712, R01HL057506] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44712, HL57506, R01 HL061589] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; CLYMAN RI, 1992, EXP CELL RES, V200, P272, DOI 10.1016/0014-4827(92)90173-6; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Hofmann R, 1996, CANCER, V78, P487; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Irie A, 1997, P NATL ACAD SCI USA, V94, P7198, DOI 10.1073/pnas.94.14.7198; Kindzelskii AL, 1997, BIOPHYS J, V73, P1777, DOI 10.1016/S0006-3495(97)78208-0; Kindzelskii AL, 1996, J IMMUNOL, V156, P297; LOIKE JD, 1991, P NATL ACAD SCI USA, V88, P1044, DOI 10.1073/pnas.88.3.1044; Lu HF, 1997, J CLIN INVEST, V99, P1340, DOI 10.1172/JCI119293; MAECKER HT, 1997, FASEB J, V11, P429; May AE, 1998, J EXP MED, V188, P1029, DOI 10.1084/jem.188.6.1029; Mesri M, 1998, J BIOL CHEM, V273, P744, DOI 10.1074/jbc.273.2.744; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; RONNE E, 1991, FEBS LETT, V288, P233, DOI 10.1016/0014-5793(91)81042-7; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Simon DI, 1996, BLOOD, V88, P3185, DOI 10.1182/blood.V88.8.3185.bloodjournal8883185; Sitrin RG, 1996, J CLIN INVEST, V97, P1942, DOI 10.1172/JCI118626; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Xue W, 1997, CANCER RES, V57, P1682; XUE W, 1994, J IMMUNOL, V152, P4360; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393; Zhang L, 1997, J BIOL CHEM, V272, P17558, DOI 10.1074/jbc.272.28.17558; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	35	184	191	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10228	10234		10.1074/jbc.275.14.10228	http://dx.doi.org/10.1074/jbc.275.14.10228			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744708	hybrid			2022-12-27	WOS:000086345600049
J	Urbaneja, MA; McGrath, CF; Kane, BP; Henderson, LE; Casas-Finet, JR				Urbaneja, MA; McGrath, CF; Kane, BP; Henderson, LE; Casas-Finet, JR			Nucleic acid binding properties of the simian immunodeficiency virus nucleocapsid protein NCp8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DETECTED MAGNETIC-RESONANCE; SINGLE-STRANDED POLYNUCLEOTIDES; MURINE LEUKEMIA-VIRUS; AROMATIC-AMINO-ACIDS; TRYPTOPHAN RESIDUES; ZINC FINGERS; STACKING INTERACTIONS; TYPE-1; FLUORESCENCE; TYROSINE	The nucleocapsid protein of simian immunodeficiency virus (SIV) NCp8 has two copies of conserved sequences (termed zinc fingers, ZF) of 14 amino acids with 4 invariant residues (CCHC) that coordinate Zn(II), Each of its two ZFs has a Trp residue. A significant quenching of NCp8 Trp fluorescence was seen in nucleic acid complexes, suggesting stacking of the indole ring with nucleobases and the simultaneous involvement of both ZFs in the binding process. Both ZFs contribute to the nucleic acid binding free energy of NCp8, albeit in a not additive manner. NCp8 exhibited a base preference analogous to that of NCp7: G similar to I > T > U > C > A. Alternating base sequences that bind HIV-1 NCp7 in a sequence-specific manner were also bound selectively by NCp8, Specific sequence recognition required at least five bases and the presence of bound Zn(II), The two ZFs account for the net displacement of 3 out of 4 sodium ions upon binding (2 by the first and one by the second finger), and for most (85%) of the hydrophobic stabilization in complex formation. Based on the sequence and functional similarity of SIV NCp8 and HIV-1 NCp7, and using available structural information for free and oligonucleotide bound NCp7, we propose a structural model for NCp8-oligonucleotide complexes.	NCI, FCRDC, AIDS Vaccine Program, SAIC Frederick, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Casas-Finet, JR (corresponding author), NCI, FCRDC, AIDS Vaccine Program, SAIC Frederick, Bldg 535,POB B, Ft Detrick, MD 21702 USA.							Arthur LO, 1998, AIDS RES HUM RETROV, V14, pS311; BESS JW, 1992, J VIROL, V66, P840, DOI 10.1128/JVI.66.2.840-847.1992; BRUN F, 1975, BIOCHEMISTRY-US, V14, P558, DOI 10.1021/bi00674a015; BUSCH LK, 1994, THESIS HOOD COLL FRE; Casas-Finet J. R., 1997, Biophysical Journal, V72, pA133; CASASFINET JR, 1987, FEBS LETT, V220, P347, DOI 10.1016/0014-5793(87)80844-X; CASASFINET JR, 1988, EUR J BIOCHEM, V178, P101, DOI 10.1111/j.1432-1033.1988.tb14434.x; CASASFINET JR, 1991, J MOL BIOL, V221, P693, DOI 10.1016/0022-2836(91)80081-5; CASASFINET JR, 1988, EUR J BIOCHEM, V172, P641, DOI 10.1111/j.1432-1033.1988.tb13937.x; CASASFINET JR, 1987, J BIOL CHEM, V262, P8574; CASASFINET JR, 1988, BIOCHEMISTRY-US, V27, P1172, DOI 10.1021/bi00404a016; Chertova E, 1997, TECH PROT CHEM, V8, P231, DOI 10.1016/S1080-8914(97)80025-7; Chertova EN, 1998, BIOCHEMISTRY-US, V37, P17890, DOI 10.1021/bi980907y; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; DEMENE H, 1994, J BIOMOL NMR, V4, P153, DOI 10.1007/BF00175244; Domagala J M, 1997, Drug Des Discov, V15, P49; Druillennec S, 1999, P NATL ACAD SCI USA, V96, P4886, DOI 10.1073/pnas.96.9.4886; Fisher RJ, 1998, J VIROL, V72, P1902, DOI 10.1128/JVI.72.3.1902-1909.1998; Gorelick RJ, 1999, VIROLOGY, V253, P259, DOI 10.1006/viro.1998.9513; GORELICK RJ, 1994, HUMAN RETROVIRUSES A, V3, P1; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; KARPEL RL, 1981, BIOCHEM BIOPH RES CO, V100, P760, DOI 10.1016/S0006-291X(81)80240-9; KUMAR NV, 1984, BIOPOLYMERS, V23, P2009, DOI 10.1002/bip.360231015; Lee BM, 1998, J MOL BIOL, V279, P633, DOI 10.1006/jmbi.1998.1766; MAURIZOT JC, 1978, BIOCHEMISTRY-US, V17, P2096, DOI 10.1021/bi00604a012; MAYER R, 1979, J BIOL CHEM, V254, P75; MCGHEE JD, 1976, J MOL BIOL, V103, P679; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MELY Y, 1993, BIOPHYS J, V65, P1513, DOI 10.1016/S0006-3495(93)81222-0; Mely Y, 1996, BIOCHEMISTRY-US, V35, P5175, DOI 10.1021/bi952587d; MORELLET N, 1992, EMBO J, V11, P3059, DOI 10.1002/j.1460-2075.1992.tb05377.x; MORELLET N, 1994, J MOL BIOL, V235, P287, DOI 10.1016/S0022-2836(05)80033-6; Morellet N, 1998, J MOL BIOL, V283, P419, DOI 10.1006/jmbi.1998.2098; RAJESWARI MR, 1987, BIOCHEMISTRY-US, V26, P6825, DOI 10.1021/bi00395a036; Record MT, 1998, ADV PROTEIN CHEM, V51, P281; Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0; RICE WG, 1995, SCIENCE, V270, P1194, DOI 10.1126/science.270.5239.1194; RICE WG, 1993, NATURE, V361, P473, DOI 10.1038/361473a0; RIZVI TA, 1993, J VIROL, V67, P2681, DOI 10.1128/JVI.67.5.2681-2688.1993; Rossio JL, 1998, J VIROL, V72, P7992, DOI 10.1128/JVI.72.10.7992-8001.1998; SHAMOO Y, 1994, BIOCHEMISTRY-US, V33, P8272, DOI 10.1021/bi00193a014; Sudhakar K, 1998, BIOPHYS J, V74, pA70; Sudhakar K, 1998, FASEB J, V12, pA1453; Urbaneja M. A., 1997, Biophysical Journal, V72, pA98; Urbaneja MA, 1999, J MOL BIOL, V287, P59, DOI 10.1006/jmbi.1998.2521; VOGT VM, 1998, RETROVIRUSES, P27; Wu JQ, 1997, BIOCHEMISTRY-US, V36, P12506, DOI 10.1021/bi970676f; Wu JQ, 1997, BIOCHEMISTRY-US, V36, P6115, DOI 10.1021/bi962951o; Wu TY, 1999, J VIROL, V73, P4794, DOI 10.1128/JVI.73.6.4794-4805.1999	49	18	18	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10394	10404		10.1074/jbc.275.14.10394	http://dx.doi.org/10.1074/jbc.275.14.10394			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744728	hybrid			2022-12-27	WOS:000086345600069
J	Weiss, RH; Joo, A; Randour, C				Weiss, RH; Joo, A; Randour, C			p21(Waf1/Cip1) is an assembly factor required for platelet-derived growth factor-induced vascular smooth muscle cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; CYCLE ARREST; P21 GENE; P27(KIP1); G(1); INDUCTION; OVEREXPRESSION; MITOGENESIS; FIBROBLASTS; EXPRESSION	The cyclin-dependent kinase inhibitors interact with cyclin-cdk complexes to arrest mitogen-stimulated transit through the cell cycle, but these proteins have recently been shown to have positive regulatory effects on cyclin-cdk complex activity as well. Most of the previous work in this area has focussed on the finding that overexpressed p21(Waf1/Cip1) causes growth arrest. However, mice lacking p21(Waf1/Cip1) showed normal development with no aberrancy in their cell cycles, and antisense p21(Waf1/Cip1) has only been shown to prevent cell cycle arrest, leading to the conclusion that the cyclin kinase inhibitors may not be required for cell cycle progression. We found that transfection of several lines of vascular smooth muscle cells with antisense oligodeoxynucleotide specific to p21(Waf1/Cip1) correlates with decreased cyclin D1/cdk 4, but not cyclin E/cdk 2, association, yet, unexpectedly, results in dose-dependent inhibition of platelet-derived growth factor-BB-stimulated DNA synthesis and cell proliferation. Our finding that p21(Waf1/Cip1) exhibits permissive effects on growth factor-induced vascular smooth muscle cell cycle progression, such that its presence is required for growth factor-induced proliferation, is the first such report and opens up a fertile area of research relevant to diseases involving vascular cell proliferation.	Univ Calif Davis, Div Nephrol, Dept Internal Med, Davis, CA 95616 USA; Univ Calif Davis, Cell & Dev Biol Grad Grp, Davis, CA 95616 USA; Dept Vet Affairs No Calif, Hlth Care Syst, Mather, CA 95655 USA	University of California System; University of California Davis; University of California System; University of California Davis	Weiss, RH (corresponding author), Univ Calif Davis, Div Nephrol, Dept Internal Med, TB-136, Davis, CA 95616 USA.							Al-Awqati Q, 1999, P NATL ACAD SCI USA, V96, P10551, DOI 10.1073/pnas.96.19.10551; Arellano M, 1997, INT J BIOCHEM CELL B, V29, P559, DOI 10.1016/S1357-2725(96)00178-1; CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281; Chen SC, 1998, J CLIN INVEST, V102, P653, DOI 10.1172/JCI3483; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Depoortere F, 1996, J CELL SCI, V109, P1759; Fukui R, 1997, ATHEROSCLEROSIS, V132, P53, DOI 10.1016/S0021-9150(97)00086-5; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; HUANG TS, 1995, P NATL ACAD SCI USA, V92, P4793, DOI 10.1073/pnas.92.11.4793; Ishida A, 1997, J BIOL CHEM, V272, P10050; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kusama H, 1999, ATHEROSCLEROSIS, V143, P307, DOI 10.1016/S0021-9150(98)00308-6; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Matsushita H, 1998, HYPERTENSION, V31, P493, DOI 10.1161/01.HYP.31.1.493; Megyesi J, 1999, P NATL ACAD SCI USA, V96, P10830, DOI 10.1073/pnas.96.19.10830; MICHIELI P, 1994, CANCER RES, V54, P3391; Nomura H, 1997, GENE, V191, P211, DOI 10.1016/S0378-1119(97)00062-0; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; ODONNELL ME, 1986, P NATL ACAD SCI USA, V83, P6132, DOI 10.1073/pnas.83.16.6132; Ohtsubo M, 1998, ONCOGENE, V16, P797, DOI 10.1038/sj.onc.1201588; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Perlman H, 1998, J BIOL CHEM, V273, P13713, DOI 10.1074/jbc.273.22.13713; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RAVITZ MJ, 1995, CANCER RES, V55, P1413; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; Smith RC, 1997, GENE DEV, V11, P1674, DOI 10.1101/gad.11.13.1674; Takahashi A, 1999, CIRC RES, V84, P543, DOI 10.1161/01.RES.84.5.543; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WALDMAN T, 1995, CANCER RES, V55, P5187; Weiss RH, 1999, J AM SOC NEPHROL, V10, P1880; Weiss RH, 1998, AM J PHYSIOL-CELL PH, V274, pC1521, DOI 10.1152/ajpcell.1998.274.6.C1521; WEISS RH, 1992, J BIOL CHEM, V267, P5608; Yang Z, 1996, Semin Interv Cardiol, V1, P181; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	42	101	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10285	10290		10.1074/jbc.275.14.10285	http://dx.doi.org/10.1074/jbc.275.14.10285			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744715	hybrid			2022-12-27	WOS:000086345600056
J	Baumann, CA; Chokshi, N; Saltiel, AR; Ribon, V				Baumann, CA; Chokshi, N; Saltiel, AR; Ribon, V			Cloning and characterization of a functional peroxisome proliferator activator receptor-gamma-responsive element in the promoter of the CAP gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RESISTANCE; 3T3-L1 ADIPOCYTES; PROTEIN-KINASE; LESS PROMOTER; C-CBL; THIAZOLIDINEDIONES; INITIATION	c-Cbl-associating protein (CAP) is a multifunctional signaling protein that interacts with c-Cbl, facilitating the tyrosine phosphorylation of c-Cbl in response to insulin, In 3T3-L1 adipocytes and diabetic rodents, CAP gene expression is stimulated by activators of peroxisome proliferator activator receptor gamma (PPAR gamma), such as thiazolidinediones (TZDs), resulting in increased insulin-stimulated c-Cbl phosphorylation, Sequence analysis of 2.5 kilobases of the 5'-flanking region of the CAP gene reveals a predicted peroxisome proliferator response element (PPRE) from -1085 to -1097, The isolated promoter was functional in 3T3 fibroblasts and adipocytes. Co-transfection of the CAP promoter with PPAR gamma and retinoic acid X receptor alpha caused fold stimulation of promoter activity. The TZD rosiglitazone produced an additional 2-3-fold stimulation of the promoter. Deletion of the predicted PPRE from the CAP promoter abolished its ability to respond to rosiglitazone. Gel shift analysis of the putative PPAR gamma site demonstrates direct binding of PPAR/retinoid X receptor heterodimers to the PPRE in the CAP gene. These data demonstrate that TZDs directly stimulate transcription of the CAP gene through activation of PPAR gamma.	Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Cell Biol, Ann Arbor, MI 48105 USA; Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA	Pfizer; University of Michigan System; University of Michigan	Saltiel, AR (corresponding author), Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Cell Biol, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.		Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; Camp HS, 1997, J BIOL CHEM, V272, P10811; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Frohnert BI, 1999, J BIOL CHEM, V274, P3970, DOI 10.1074/jbc.274.7.3970; Johnson EF, 1996, FASEB J, V10, P1241, DOI 10.1096/fasebj.10.11.8836037; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Parks CL, 1996, J BIOL CHEM, V271, P4417; Ribon V, 1997, BIOCHEM J, V324, P839, DOI 10.1042/bj3240839; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; Ribon V, 1998, J BIOL CHEM, V273, P4073, DOI 10.1074/jbc.273.7.4073; Ribon V, 1998, P NATL ACAD SCI USA, V95, P14751, DOI 10.1073/pnas.95.25.14751; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876	14	59	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9131	9135		10.1074/jbc.275.13.9131	http://dx.doi.org/10.1074/jbc.275.13.9131			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734046	hybrid			2022-12-27	WOS:000086206500010
J	Brino, L; Urzhumtsev, A; Mousli, M; Bronner, C; Mitschler, A; Oudet, P; Moras, D				Brino, L; Urzhumtsev, A; Mousli, M; Bronner, C; Mitschler, A; Oudet, P; Moras, D			Dimerization of Escherichia coli DNA-gyrase B provides a structural mechanism for activating the ATPase catalytic center	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-DENSITY MAPS; N-TERMINAL FRAGMENT; TOPOISOMERASE-II; 2-GATE MECHANISM; PROTEIN; MICROSCOPY; NOVOBIOCIN; TRANSPORT; BINDING; MODELS	DNA-gyrase exhibits an unusual ATP-binding site that is formed as a result of gyrase B subunit dimerization, a structural transition that is also essential for DNA capture during the topoisomerization cycle, Previous structural studies on Escherichia coli DNA-gyrase B revealed that dimerization is the result of a polypeptidic exchange involving the N-terminal 14 amino acids. To provide experimental data that dimerization is critical for ATPase activity and enzyme turnover, we generated mutants with reduced dimerization by mutating the two most conserved residues of the GyrB N-terminal arm (Tyr-5 and IIe-10 residues). Our data demonstrate that the hydrophobic IIe-10 residue plays an important role in enzyme dimerization and the nucleotide-protein contact mediated by Tyr-5 side chain residue helps the dimerization process. Analysis of ATPase activities of mutant proteins provides evidence that dimerization enhances the ATP-hydrolysis turnover. The structure of the Y5S mutant of the N-terminal 43-kDa fragment of E. coli DNA GyrB subunit indicates that Tyr-5 residue provides a scaffold for the ATP-hydrolysis center. We describe a channel formed at the dimer interface that provides a structural mechanism to allow reactive water molecules to access the gamma-phosphate group of the bound ATP molecule. Together, these results demonstrate that dimerization strongly contributes to the folding and stability of the catalytic site for ATP hydrolysis. A role for the essential Mg2+ ion for the orientation of the phosphate groups of the bound nucleotide inside the reactive pocket was also uncovered by superposition of the 5'-adenylyl beta-gamma-imidodiphosphate (ADPNP) wild-type structure to the salt-free ADPNP structure.	Univ Strasbourg 1, INSERM, CNRS, IGBMC, F-67404 Illkirch, France; Univ Nancy 1, Fac Sci, Lab Cristallog & Modelisat Mat Mineraux & Biol, F-54506 Vandoeuvre Nancy, France; INSERM, U425, Fac Pharm, F-67401 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite de Lorraine; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Moras, D (corresponding author), Univ Strasbourg 1, INSERM, CNRS, IGBMC, BP 163,1 Rue Laurent Fries, F-67404 Illkirch, France.		Mousli, Marc/Q-1722-2017; Bronner, Christian/R-8488-2016	Mousli, Marc/0000-0001-9759-6864; Bronner, Christian/0000-0002-3101-9279; Ourjoumtsev, Alexandre/0000-0002-1002-3041; Brino, laurent/0000-0002-9036-1461				ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; ALI JA, 1995, BIOCHEMISTRY-US, V34, P9801, DOI 10.1021/bi00030a018; Benedetti P, 1997, J BIOL CHEM, V272, P12132, DOI 10.1074/jbc.272.18.12132; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BOSSEMEYER D, 1994, TRENDS BIOCHEM SCI, V19, P201, DOI 10.1016/0968-0004(94)90022-1; Brino L, 1999, BIOCHIMIE, V81, P973, DOI 10.1016/S0300-9084(99)00222-9; BRINO L, 1997, PLASMID, V38, P1886; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; JANKARIK J, 1991, J APPL CRYSTALLOGR, V24, P409; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; KREUZER KN, 1980, CELL, V20, P245, DOI 10.1016/0092-8674(80)90252-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUNIN VY, 1995, ACTA CRYSTALLOGR A, V51, P880, DOI 10.1107/S010876739500688X; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; MENZEL R, 1994, ADV PHARM A, V29, P201; MOUSLI M, 1990, FEBS LETT, V259, P260, DOI 10.1016/0014-5793(90)80023-C; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; Roca J, 1996, P NATL ACAD SCI USA, V93, P4057, DOI 10.1073/pnas.93.9.4057; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; Schultz P, 1996, P NATL ACAD SCI USA, V93, P5936, DOI 10.1073/pnas.93.12.5936; STAUDENBAUER WL, 1981, NUCLEIC ACIDS RES, V9, P3589, DOI 10.1093/nar/9.15.3589; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; Urzhumtsev AG, 1997, ACTA CRYSTALLOGR D, V53, P540, DOI 10.1107/S0907444997004885; Urzhumtsev AG, 1996, J APPL CRYSTALLOGR, V29, P741, DOI 10.1107/S0021889896007194; URZHUMTSEVA LM, 1996, CCP4 NEWSL PROTEIN B, V32, P41; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0	34	142	144	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9468	9475		10.1074/jbc.275.13.9468	http://dx.doi.org/10.1074/jbc.275.13.9468			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734094	hybrid			2022-12-27	WOS:000086206500058
J	Ding, L; Candido, EPM				Ding, L; Candido, EPM			HSP25, a small heat shock protein associated with dense bodies and M-lines of body wall muscle in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHARACTERIZATION; ALPHA-CRYSTALLIN; SKELETAL-MUSCLE; C-ELEGANS; TNF-ALPHA; EXPRESSION; FAMILY; GENE; CHAPERONE; PATHWAY	HSP25, a previously uncharacterized member of the alpha-crystallin family of small heat shock proteins in Caenorhabditis elegans, has been examined using biochemical and immunological techniques. HSP25 is the second largest of 16 identifiable small heat shock proteins in the nematode and is expressed at all developmental stages under normal growth conditions. Recombinant HSP25 produced in Escherichia coli exists predominantly as small oligomers (dimers to tetramers) and possesses chaperone activity against citrate synthase in vitro. In C. elegans, HSP25 is localized to dense bodies and M-lines in body wall muscle, to the lining of the pharynx, and to the junctions between cells of the spermathecal wall. Affinity chromatography of nematode extracts on a column of immobilized HSP25 resulted in specific binding of vinculin and alpha-actinin but not actin, as revealed by Western blotting. These results suggest a role for HSP25 in the organization or maintenance of the myofilament lattice and adherens junctions in C. elegans.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Candido, EPM (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	epmc@interchange.ubc.ca						ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; ARRIGO AP, 1994, BIOL HEAT SHOCK PROT; BARSTEAD RJ, 1991, CELL MOTIL CYTOSKEL, V20, P69, DOI 10.1002/cm.970200108; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; BRENNER S, 1974, GENETICS, V77, P71; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; EHRNSPERGER M, 1997, MOL CHAPERONES LIFE, P533; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FRANCIS GR, 1985, J CELL BIOL, V101, P1532, DOI 10.1083/jcb.101.4.1532; GETHING MJ, 1997, GUIDEBOOK MOL CHAPER, P269; GETTNER SN, 1995, J CELL BIOL, V129, P1127, DOI 10.1083/jcb.129.4.1127; HAAS AL, 1995, J BIOL CHEM, V270, P9407, DOI 10.1074/jbc.270.16.9407; Harlow E., 1988, ANTIBODIES LABORATOR, P633; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI USA, V79, P855; JONES D, 1989, DNA-J MOLEC CELL BIO, V8, P481, DOI 10.1089/dna.1.1989.8.481; JONES D, 1986, J BIOL CHEM, V261, P2006; Kawazoe Y, 1998, EUR J BIOCHEM, V255, P356, DOI 10.1046/j.1432-1327.1998.2550356.x; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kokke BPA, 1998, FEBS LETT, V433, P228, DOI 10.1016/S0014-5793(98)00917-X; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASZLO A, 1993, INT J RADIAT BIOL, V63, P569, DOI 10.1080/09553009314450751; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Leroux MR, 1997, J BIOL CHEM, V272, P12847, DOI 10.1074/jbc.272.19.12847; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; Lillibridge CD, 1996, EXP PARASITOL, V83, P30, DOI 10.1006/expr.1996.0046; Linder B, 1996, J BIOL CHEM, V271, P30158, DOI 10.1074/jbc.271.47.30158; LOER CM, 1993, J NEUROSCI, V13, P5407, DOI 10.1523/JNEUROSCI.13-12-05407.1993; Mathew A, 1998, MOL CELL BIOL, V18, P5091, DOI 10.1128/MCB.18.9.5091; Mehlen P, 1997, BIOCHEM BIOPH RES CO, V241, P187, DOI 10.1006/bbrc.1997.7635; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Moulder GL, 1996, MOL BIOL CELL, V7, P1181, DOI 10.1091/mbc.7.8.1181; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; ROSENBLUTH J, 1965, J CELL BIOL, V25, P495, DOI 10.1083/jcb.25.3.495; RUSSNAK RH, 1985, MOL CELL BIOL, V5, P1268, DOI 10.1128/MCB.5.6.1268; RUSSNAK RH, 1983, NUCLEIC ACIDS RES, V11, P3187, DOI 10.1093/nar/11.10.3187; Solomon V, 1998, J BIOL CHEM, V273, P25216, DOI 10.1074/jbc.273.39.25216; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; Suzuki A, 1998, J CELL BIOL, V140, P1113, DOI 10.1083/jcb.140.5.1113; Suzuki TC, 1998, PLANT PHYSIOL, V116, P1151, DOI 10.1104/pp.116.3.1151; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; Waterston R., 1988, NEMATODE C ELEGANS, P281; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	52	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9510	9517		10.1074/jbc.275.13.9510	http://dx.doi.org/10.1074/jbc.275.13.9510			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734099	hybrid			2022-12-27	WOS:000086206500063
J	Jaiswal, RK; Jaiswal, N; Bruder, SP; Mbalaviele, G; Marshak, DR; Pittenger, MF				Jaiswal, RK; Jaiswal, N; Bruder, SP; Mbalaviele, G; Marshak, DR; Pittenger, MF			Adult human mesenchymal stem cell differentiation to the osteogenic or adipogenic lineage is regulated by mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; HUMAN BONE-MARROW; MAP KINASE; RECEPTOR-GAMMA; IN-VITRO; ADIPOCYTE DIFFERENTIATION; SIGNAL-TRANSDUCTION; 3T3-L1 ADIPOCYTES; PRECURSOR CELLS	Adult human mesenchymal stem cells are primary, multipotent cells capable of differentiating to osteocytic, chondrocytic, and adipocytic lineages when stimulated under appropriate conditions. To characterize the molecular mechanisms that regulate osteogenic differentiation, we examined the contribution of mitogen-activated protein kinase family members, ERK, JNK, and p38, Treatment of these stem cells with osteogenic supplements resulted in a sustained phase of ERK activation from day 7 to day 11 that coincided with differentiation, before decreasing to basal levels. Activation of JNK occurred much later (day 13 to day 17) in the osteogenic differentiation process. This JNK activation was associated with extracellular matrix synthesis and increased calcium deposition, the two hallmarks of bone formation. Inhibition of ERK activation by PD98059, a specific inhibitor of the ERK signaling pathway, blocked the osteogenic differentiation in a dose-dependent manner, as did transfection with a dominant negative form of MAP kinase kinase (MEK-1), Significantly, the blockage of osteogenic differentiation resulted in the adipogenic differentiation of the stem cells and the expression of adipose-specific mRNAs peroxisome proliferator-activated receptor gamma 2, aP2, and lipoprotein lipase. These observations provide a potential mechanism involving MAP kinase activation in osteogenic differentiation of adult stem cells and suggest that commitment of hMSCs into osteogenic or adipogenic lineages is governed by activation or inhibition of ERK, respectively.	Osiris Therapeut Inc, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA	Osiris Therapeutics; Johns Hopkins University	Pittenger, MF (corresponding author), Osiris Therapeut Inc, 2001 Aliceanna St, Baltimore, MD 21231 USA.	mpittenger@osiristx.com						Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BERESFORD JN, 1992, J CELL SCI, V102, P341; BERG M, 1994, CYTOKINE, V6, P425, DOI 10.1016/1043-4666(94)90067-1; Blanque R, 1997, DRUG EXP CLIN RES, V23, P63; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097-4644(199702)64:2<278::AID-JCB11>3.0.CO;2-F; BRUDER SP, 1994, J CELL BIOCHEM, V56, P283, DOI 10.1002/jcb.240560303; Bruder SP, 1998, CLIN ORTHOP RELAT R, pS247; Camp HS, 1997, J BIOL CHEM, V272, P10811; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P438; Chang SH, 1998, J BIOL CHEM, V273, P19213, DOI 10.1074/jbc.273.30.19213; Chaudhary LR, 1998, MOL CELL BIOCHEM, V178, P59, DOI 10.1023/A:1006807221545; Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295; CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; Dani C, 1997, J CELL SCI, V110, P1279; DAVIS RJ, 1995, TIBS, V19, P470; Erlebacher A, 1998, MOL BIOL CELL, V9, P1903, DOI 10.1091/mbc.9.7.1903; GEHRON R, 1996, OSTEOPOROSIS, P95; GEHRONROBEY P, 1992, DISORDERS BONE MINER, P241; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Hannigan M, 1998, BIOCHEM BIOPH RES CO, V246, P55, DOI 10.1006/bbrc.1998.8570; HAUNER H, 1995, EUR J CLIN INVEST, V25, P90, DOI 10.1111/j.1365-2362.1995.tb01532.x; HAYNESWORTH SE, 1992, BONE, V13, P81, DOI 10.1016/8756-3282(92)90364-3; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; HUWILER A, 1994, FEBS LETT, V354, P255, DOI 10.1016/0014-5793(94)01132-X; Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097-4644(199702)64:2<295::AID-JCB12>3.0.CO;2-I; JAISWAL N, 1996, J BONE MINER RES, P259; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Lau KHW, 1998, J BONE MINER RES, V13, P1660, DOI 10.1359/jbmr.1998.13.11.1660; Lennon DP, 1996, IN VITRO CELL DEV-AN, V32, P602; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; Mackay AM, 1998, TISSUE ENG, V4, P415, DOI 10.1089/ten.1998.4.415; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEUNIER P, 1971, CLIN ORTHOP RELAT R, P147, DOI 10.1097/00003086-197110000-00021; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; NAVRE M, 1989, J CELL BIOL, V109, P1857, DOI 10.1083/jcb.109.4.1857; NOVIKOFF AB, 1980, J CELL BIOL, V87, P180, DOI 10.1083/jcb.87.1.180; Nuttall ME, 1998, J BONE MINER RES, V13, P371, DOI 10.1359/jbmr.1998.13.3.371; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; Rickard DJ, 1996, J BONE MINER RES, V11, P312; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SERRERO G, 1991, P NATL ACAD SCI USA, V88, P3912, DOI 10.1073/pnas.88.9.3912; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; Stein Gary S., 1996, P69; Swarthout JT, 1997, J BONE MINER RES, V12, pP244; Takahashi Y, 1997, J BIOL CHEM, V272, P12897, DOI 10.1074/jbc.272.20.12897; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TORTI FM, 1989, J CELL BIOL, V108, P1105, DOI 10.1083/jcb.108.3.1105; WESTERGRENTHORSSON G, 1991, J CELL PHYSIOL, V147, P523, DOI 10.1002/jcp.1041470319; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, J BIOL CHEM, V269, P19067	62	621	707	0	68	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9645	9652		10.1074/jbc.275.13.9645	http://dx.doi.org/10.1074/jbc.275.13.9645			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734116	hybrid			2022-12-27	WOS:000086206500080
J	Rehli, M; Poltorak, A; Schwarzfischer, L; Krause, SW; Andreesen, R; Beutler, B				Rehli, M; Poltorak, A; Schwarzfischer, L; Krause, SW; Andreesen, R; Beutler, B			PU.1 and interferon consensus sequence-binding protein regulate the myeloid expression of the human toll-like receptor 4 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR KAPPA-B; TRANSCRIPTION FACTOR; DROSOPHILA TOLL; FAMILY MEMBER; MACROPHAGE TRANSCRIPTION; INTERLEUKIN-1 RECEPTOR; ENDOTOXIN RESISTANCE; GAMMA-INTERFERON; IL-1 RECEPTOR	The protein product of the Toll-like receptor (TLR) 4 gene has been implicated in the signal transduction events induced by lipopolysaccharide (LPS). In mice, destructive mutations of Tlr4 impede the normal response to LPS and cause a high susceptibility to Gramnegative infection. Expression of TLR4 mRNA in humans is restricted to a small number of cell types, including LPS-responsive myeloid cells, B-cells, and endothelial cells. To investigate the molecular basis for TLR4 expression in cells of myeloid origin, we cloned the human TLR4 gene and analyzed its putative 5'-proximal promoter. In transient transfections a region of only 75 base pairs upstream of the major transcription initiation site was sufficient to induce maximal luciferase activity in THP-I cells, The sequence of this region is similar in human and mouse TLR4 genes and lacks a TATA box, typical Spl-sites or CCAAT box sequences. Instead, it contains consensus-binding sites for Ets family transcription factors, octamer-binding factors, and a composite interferon response factor/Ets motif. The activity of the promoter in macrophages was strictly dependent on the integrity of both half sites of the composite interferon response factor/Ets motif, which was constitutively bound by the myeloid and B-cell-specific transcription factor PU.1 and interferon consensus sequence-binding protein. These results indicate that the two tissue-restricted transcription factors PU.1 and interferon consensus sequence-binding protein participate in the basal regulation of human TLR4 in myeloid cells. Cloning of the human TLR4 gene provides a basis for further investigation of the possible impact of genetic variations on the susceptibility to infection and sepsis.	Univ Regensburg, Dept Hematol & Oncol, D-93042 Regensburg, Germany; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Regensburg; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Rehli, M (corresponding author), Univ Regensburg, Dept Hematol & Oncol, D-93042 Regensburg, Germany.	Michael.Rehli@klinik.uni-regensburg.de; beutler@howie.swmed.edu	Rehli, Michael/E-9093-2011	Rehli, Michael/0000-0003-3992-932X; Krause, Stefan/0000-0002-5259-4651				ANDREESEN R, 1990, J LEUKOCYTE BIOL, V47, P490, DOI 10.1002/jlb.47.6.490; BERCZI I, 1966, CAN J MICROBIOL, V12, P1070, DOI 10.1139/m66-143; BEUTLER B, 1986, J EXP MED, V164, P1791, DOI 10.1084/jem.164.5.1791; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BOVOLENTA C, 1994, P NATL ACAD SCI USA, V91, P5046, DOI 10.1073/pnas.91.11.5046; CALZONE FJ, 1987, METHOD ENZYMOL, V152, P611; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CHEN HM, 1995, ONCOGENE, V11, P1549; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLART MA, 1986, J EXP MED, V164, P2113, DOI 10.1084/jem.164.6.2113; COUTINHO A, 1977, EUR J IMMUNOL, V7, P325, DOI 10.1002/eji.1830070517; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; Eichbaum Q, 1997, BLOOD, V90, P4135, DOI 10.1182/blood.V90.10.4135; EICHBAUM QG, 1994, J EXP MED, V179, P1985, DOI 10.1084/jem.179.6.1985; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; Giese NA, 1997, J EXP MED, V186, P1535, DOI 10.1084/jem.186.9.1535; GREEN S, 1977, J NATL CANCER I, V59, P1519, DOI 10.1093/jnci/59.5.1519; GutierrezRamos JC, 1997, IMMUNOL TODAY, V18, P329, DOI 10.1016/S0167-5699(97)01085-2; HARANAKA K, 1984, CANCER IMMUNOL IMMUN, V18, P87; HAYES MP, 1993, INFECT IMMUN, V61, P3222, DOI 10.1128/IAI.61.8.3222-3227.1993; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; Himmelmann A, 1997, BLOOD, V90, P3984, DOI 10.1182/blood.V90.10.3984; Hoffmann JA, 1996, CURR OPIN IMMUNOL, V8, P8, DOI 10.1016/S0952-7915(96)80098-7; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Kim YM, 1999, J IMMUNOL, V163, P2000; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; LAU AS, 1989, J CLIN INVEST, V84, P738, DOI 10.1172/JCI114231; Lehtonen A, 1997, J IMMUNOL, V159, P794; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; MATHISON JC, 1990, J CLIN INVEST, V85, P1108, DOI 10.1172/JCI114542; MATSUURA M, 1990, INFECT IMMUN, V58, P935, DOI 10.1128/IAI.58.4.935-937.1990; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; NELSON N, 1993, MOL CELL BIOL, V13, P588, DOI 10.1128/MCB.13.1.588; Ortiz MA, 1999, P NATL ACAD SCI USA, V96, P2740, DOI 10.1073/pnas.96.6.2740; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PACE JL, 1985, J IMMUNOL, V134, P977; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; POLITIS AD, 1994, J IMMUNOL, V152, P2270; Poltorak A, 1998, BLOOD CELL MOL DIS, V24, P340, DOI 10.1006/bcmd.1998.0201; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rehli M, 1999, J IMMUNOL, V162, P1559; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Ross IL, 1998, J BIOL CHEM, V273, P6662, DOI 10.1074/jbc.273.12.6662; ROSS IL, 1994, ONCOGENE, V9, P121; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SchartonKersten T, 1997, J EXP MED, V186, P1523, DOI 10.1084/jem.186.9.1523; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SHARF R, 1995, J BIOL CHEM, V270, P13063, DOI 10.1074/jbc.270.22.13063; Sharf R, 1997, J BIOL CHEM, V272, P9785; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; SULTZER BM, 1968, NATURE, V219, P1253, DOI 10.1038/2191253a0; Suzuki S, 1998, P NATL ACAD SCI USA, V95, P6085, DOI 10.1073/pnas.95.11.6085; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Thomassen E, 1999, CYTOKINE, V11, P389, DOI 10.1006/cyto.1998.0452; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; Torigoe K, 1997, J BIOL CHEM, V272, P25737, DOI 10.1074/jbc.272.41.25737; Ulevitch RJ, 1999, CURR OPIN IMMUNOL, V11, P19, DOI 10.1016/S0952-7915(99)80004-1; VOGEL SN, 1982, J IMMUNOL, V128, P380; VOGEL SN, 1984, INFECT IMMUN, V45, P417, DOI 10.1128/IAI.45.2.417-423.1984; VOGEL SN, 1980, J IMMUNOL, V124, P2004; WEISZ A, 1992, J BIOL CHEM, V267, P25589; WEISZ A, 1994, INT IMMUNOL, V6, P1125; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	77	201	208	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9773	9781		10.1074/jbc.275.13.9773	http://dx.doi.org/10.1074/jbc.275.13.9773			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734131	hybrid			2022-12-27	WOS:000086206500095
J	Tang, Y; Zhou, HL; Chen, A; Pittman, RN; Field, J				Tang, Y; Zhou, HL; Chen, A; Pittman, RN; Field, J			The Akt proto-oncogene links Ras to Pak and cell survival signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; KINASE AKT; PHOSPHORYLATION; ACTIVATION; FAMILY; TRANSFORMATION; PREVENTION; PROTEINS; BAD	The Res oncogene regulates cellular proliferation, differentiation, transformation, and survival through multiple downstream signals. Res signals through its effector phosphoinositide 3 (PI3) kinase to the Pak protein kinase (p65(pak)), but the steps from Res to Pak remain to be elucidated. PI3 kinase can stimulate the small G protein, Rac, a direct activator of Pak, as well as the Akt proto-oncogene, a serine-threonine protein kinase, We found that activated Akt stimulated Pak, whereas a dominant negative Akt inhibited Res activation of Bah in transfection assays. Akt stimulation of Pak was not inhibited by dominant negative mutants of either Rac or Cdc42 suggesting that Akt activated Bah through a GTPase-independent mechanism. We also developed a novel cell-free system to study Res activation of Pak, In this system Res activated Pak only in the presence of a crude cell extract but failed to activate Pak when Akt was immunodepleted from the extract. Akt protects cells from apoptosis through phosphorylation of downstream targets such as the Bcl-2 family member, Bad, We found that activated Bah decreased apoptosis and increased phosphorylation of Bad, whereas dominant negative Pak increased apoptosis and decreased phosphorylation of Bad. These studies define a new oncogene mediated cell survival signal.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Pittman, RN (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.	pittman@pharm.med.upenn.edu; field@pharm.med.upenn.edu	Chen, Albert/AAH-9874-2020; Chen, Albert/E-7397-2014	Chen, Albert/0000-0001-5355-024X; 	NIGMS NIH HHS [R01 GM048241, GM48241] Funding Source: Medline; NINDS NIH HHS [NS32465] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048241] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032465] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Faure S, 1997, EMBO J, V16, P5550, DOI 10.1093/emboj/16.18.5550; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; LOWE PN, 1991, J BIOL CHEM, V266, P1672; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P581; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Ozes ON, 1999, NATURE, V401, P82; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tang Y, 1998, P NATL ACAD SCI USA, V95, P5139, DOI 10.1073/pnas.95.9.5139; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Tang Y, 1999, MOL CELL BIOL, V19, P1881; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568	32	194	203	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9106	9109		10.1074/jbc.275.13.9106	http://dx.doi.org/10.1074/jbc.275.13.9106			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734042	hybrid			2022-12-27	WOS:000086206500006
J	Ferry, G; Loynel, AM; Kucharczyk, N; Bertin, S; Rodriguez, M; Delagrange, P; Galizzi, JP; Jacoby, E; Volland, JP; Lesieur, D; Renard, P; Canet, E; Fauchere, JL; Boutin, JA				Ferry, G; Loynel, AM; Kucharczyk, N; Bertin, S; Rodriguez, M; Delagrange, P; Galizzi, JP; Jacoby, E; Volland, JP; Lesieur, D; Renard, P; Canet, E; Fauchere, JL; Boutin, JA			Substrate specificity and inhibition studies of human serotonin N-acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; MICROSOMAL UDP-GLUCURONOSYLTRANSFERASE(S) ACTIVITIES; COMBINATORIAL PEPTIDE LIBRARIES; MELATONIN RECEPTOR; PINEAL-GLAND; CATALYTIC MECHANISM; MASS-SPECTROMETRY; DRUG DISCOVERY; RHYTHM; ASSAY	Arylalkylamine N-acetyltransferase (AANAT) catalyzes the reaction of serotonin with acetyl-CoA to form N-acetylserotonin and plays a major role in the regulation of the melatonin circadian rhythm in vertebrates. In the present study, the human cloned enzyme has been expressed in bacteria, purified, cleaved, and characterized. The specificity of the human enzyme toward substrates (natural as well as synthetic arylethylamines) and cosubstrates (essentially acyl homologs of acetyl-CoA) has been investigated. Peptide combinatorial libraries of tri-, tetra- and pentapeptides with various amino acid compositions were also screened as potential sources of inhibitors. We report the findings of several peptides with low micromolar inhibitory potency. For activity measurement as well as for specificity studies, an original and rapid method of analysis was developed. The assay was based on the separation and detection of N-[H-3]acetylarylethylamine formed from various arylethylamines and tritiated acetyl-CoA, by means of high performance liquid chromatography with radiochemical detection. The assay proved to be robust and flexible, could accommodate the use of numerous synthetic substrates, and was successfully used throughout this study. me also screened a large number of pharmacological bioamines among which only one, tranylcypromine, behaved as a substrate. The synthesis and survey of simple arylethylamines also showed that AANAT has a large recognition pattern, including compounds as different as phenyl-, naphthyl-, benzothienyl-, or benzofuranyl-ethylamine derivatives. An extensive enzymatic study allowed us to pinpoint the amino acid residue of the pentapeptide inhibitor, S 34461, which interacts with the cosubstrate-binding site area, in agreement with an in silico study based on the available coordinates of the hAANAT crystal.	Inst Rech Servier, Div Pharmacol Mol & Cellulaire, F-78290 Croissy Sur Seine, France; Inst Rech Servier, Div Chim Combinatoire & Peptid, F-92150 Suresnes, France; Inst Rech Servier, Div Physicochim Analyt, F-92150 Suresnes, France; Inst Rech Int Servier, F-92100 Courbevoie, France; Inst Chim Pharmaceut, F-59045 Lille, France	Servier; Institut de Recherches Internationales Servier; Servier; Institut de Recherches Internationales Servier; Servier; Institut de Recherches Internationales Servier; Servier; Institut de Recherches Internationales Servier	Boutin, JA (corresponding author), Inst Rech Servier, Div Pharmacol Mol & Cellulaire, 125 Chemin Ronde, F-78290 Croissy Sur Seine, France.		Boutin, Jean Albert/W-9103-2019	Boutin, Jean Albert/0000-0003-0068-7204				Abe M, 1999, EXP EYE RES, V68, P255, DOI 10.1006/exer.1998.0601; ARENDT S, 1995, MELANTONIN MAMMALIAN; BORJIGIN J, 1995, NATURE, V378, P783, DOI 10.1038/378783a0; BOUTIN JA, 1994, J PHARM SCI, V83, P591, DOI 10.1002/jps.2600830430; Boutin JA, 1998, ARCH BIOCHEM BIOPHYS, V354, P83, DOI 10.1006/abbi.1998.0678; BOUTIN JA, 1984, CHEM-BIOL INTERACT, V52, P173, DOI 10.1016/0009-2797(84)90071-1; Boutin JA, 1996, ANAL BIOCHEM, V234, P126, DOI 10.1006/abio.1996.0064; BOUTIN JA, 1993, EUR J BIOCHEM, V214, P853, DOI 10.1111/j.1432-1033.1993.tb17989.x; Boutin JA, 1996, TRENDS PHARMACOL SCI, V17, P8, DOI 10.1016/0165-6147(96)81563-X; Boutin JA, 1997, MOL DIVERS, V3, P43, DOI 10.1023/A:1009602707067; BOUTIN JA, 1993, DRUG METAB DISPOS, V21, P1157; CHAN JHT, 1975, AUST J CHEM, V28, P1097, DOI 10.1071/CH9751097; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; Coon SL, 1996, GENOMICS, V34, P76, DOI 10.1006/geno.1996.0243; Coon SL, 1999, J BIOL CHEM, V274, P9076, DOI 10.1074/jbc.274.13.9076; Craft CM, 1999, MOL BRAIN RES, V65, P44, DOI 10.1016/S0169-328X(98)00336-2; De Angelis J, 1998, J BIOL CHEM, V273, P3045, DOI 10.1074/jbc.273.5.3045; DEGUCHI T, 1975, J NEUROCHEM, V24, P1083, DOI 10.1111/j.1471-4159.1975.tb03682.x; Delagrange P, 1997, CLIN NEUROPHARMACOL, V20, P482, DOI 10.1097/00002826-199712000-00002; Dolle RE, 1998, MOL DIVERS, V3, P199, DOI 10.1023/A:1009699413828; DOLLE RE, 1996, MOL DIVERS, V2, P223; Dubocovich ML, 1997, N-S ARCH PHARMACOL, V355, P365, DOI 10.1007/PL00004956; DUBOCOVICH ML, 1998, MELATONIN RECEPTORS, P187; Fauchere JL, 1997, CAN J PHYSIOL PHARM, V75, P683, DOI 10.1139/cjpp-75-6-683; FERRY G, 1990, ANAL BIOCHEM, V190, P32, DOI 10.1016/0003-2697(90)90129-W; Fleming JV, 1999, ENDOCRINOLOGY, V140, P972, DOI 10.1210/en.140.2.972; Fourmaintraux E, 1998, BIOORGAN MED CHEM, V6, P9, DOI 10.1016/S0968-0896(97)00175-2; FOURNIER C, 1970, CR ACAD SCI C CHIM, V270, P1179; FREIER SM, 1995, J MED CHEM, V38, P344, DOI 10.1021/jm00002a016; Gastel JA, 1998, SCIENCE, V279, P1358, DOI 10.1126/science.279.5355.1358; Gauer F, 1999, MOL BRAIN RES, V71, P87, DOI 10.1016/S0169-328X(99)00175-8; Gothilf Y, 1999, ENDOCRINOLOGY, V140, P4895, DOI 10.1210/en.140.10.4895; Hamada T, 1999, BIOCHEM BIOPH RES CO, V258, P772, DOI 10.1006/bbrc.1999.0668; Hickman AB, 1999, MOL CELL, V3, P23, DOI 10.1016/S1097-2765(00)80171-9; Hickman AB, 1999, CELL, V97, P361, DOI 10.1016/S0092-8674(00)80745-X; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; HUETHER G, 1993, EXPERIENTIA, V49, P665, DOI 10.1007/BF01923948; Itoh MT, 1999, MOL HUM REPROD, V5, P402, DOI 10.1093/molehr/5.5.402; Itoh MT, 1999, BRAIN RES, V830, P165, DOI 10.1016/S0006-8993(99)01418-3; Khalil EM, 1998, J BIOL CHEM, V273, P30321, DOI 10.1074/jbc.273.46.30321; Khalil EM, 1998, J AM CHEM SOC, V120, P6195, DOI 10.1021/ja981365a; Khalil EM, 1999, P NATL ACAD SCI USA, V96, P12418, DOI 10.1073/pnas.96.22.12418; KLEIN DC, 1970, SCIENCE, V169, P1093, DOI 10.1126/science.169.3950.1093; Lambert PH, 1997, RAPID COMMUN MASS SP, V11, P1971, DOI 10.1002/(SICI)1097-0231(199712)11:18<1971::AID-RCM51>3.0.CO;2-8; LESIEUR D, 1996, Patent No. 0721938; LESIEUR D, 1999, Patent No. 01100; Mahle C D, 1997, Expert Opin Investig Drugs, V6, P399, DOI 10.1517/13543784.6.4.399; Molinari EJ, 1996, EUR J PHARMACOL, V301, P159, DOI 10.1016/0014-2999(95)00870-5; OHKAWA S, 1996, Patent No. 9608466; Paul P, 1999, J PHARMACOL EXP THER, V290, P334; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; REITER RJ, 1993, EXPERIENTIA, V49, P654, DOI 10.1007/BF01923947; REPPERT SM, 1995, P NATL ACAD SCI USA, V92, P8734, DOI 10.1073/pnas.92.19.8734; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; SAM J, 1968, J PHARM SCI-US, V57, P564, DOI 10.1002/jps.2600570403; Segel I.H., 1975, ENZYME KINETICS; Shen SR, 1996, EUR J PHARMACOL, V307, P133, DOI 10.1016/0014-2999(96)00228-2; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Steinhilber D, 1999, EXPERT OPIN THER PAT, V9, P281, DOI 10.1517/13543776.9.3.281; Teh MT, 1998, N-S ARCH PHARMACOL, V358, P522, DOI 10.1007/PL00005288; THOMAS KB, 1990, ANAL BIOCHEM, V184, P228, DOI 10.1016/0003-2697(90)90673-W; Uz T, 1999, BIOL PSYCHIAT, V45, P175, DOI 10.1016/S0006-3223(98)00032-8; VANECEK J, 1980, J NEUROCHEM, V35, P1455, DOI 10.1111/j.1471-4159.1980.tb09024.x; VOISIN P, 1984, J BIOL CHEM, V259, P913; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wallace A, 1996, J BIOL CHEM, V271, P31306, DOI 10.1074/jbc.271.49.31306; WANG SS, 1973, J AM CHEM SOC, V95, P1328, DOI 10.1021/ja00785a602; YANG HYT, 1976, NEUROPHARMACOLOGY, V15, P561, DOI 10.1016/0028-3908(76)90108-8; Zhan-Poe XY, 1999, J PINEAL RES, V27, P49, DOI 10.1111/j.1600-079X.1999.tb00596.x	70	48	49	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8794	8805		10.1074/jbc.275.12.8794	http://dx.doi.org/10.1074/jbc.275.12.8794			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722724	hybrid			2022-12-27	WOS:000086507700074
J	Palenchar, PM; Buck, CJ; Cheng, H; Larson, TJ; Mueller, EG				Palenchar, PM; Buck, CJ; Cheng, H; Larson, TJ; Mueller, EG			Evidence that ThiI, an enzyme shared between thiamin and 4-thiouridine biosynthesis, may be a sulfurtransferase that proceeds through a persulfide intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; ESCHERICHIA-COLI; TRANSFER-RNA; SALMONELLA-TYPHIMURIUM; AZOTOBACTER-VINELANDII; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; NIFS GENE; PROTEIN; SULFUR	ThiI is an enzyme common to the biosynthetic pathways leading to both thiamin and 4-thiouridine in tRNA, Comparison of the ThiI sequence with protein sequences in the data bases revealed that the Escherichia coli enzyme contains a C-terminal extension displaying sequence similarity to the sulfurtransferase rhodanese, Cys-456 of ThiI aligns with the active site cysteine residue of rhodanese that transiently forms a persulfide during catalysis, We investigated the functional importance of this sequence similarity and discovered that, like rhodanese, ThiI catalyzes the transfer of sulfur from thiosulfate to cyanide. Mutation of Cys-456 to alanine impairs this sulfurtransferase activity, and the C456A ThiI is incapable of supporting generation of 4-thiouridine in tRNA both in vitro and in vivo. We therefore conclude that Cys-456 of ThiI is critical for activity and propose that Cys-456 transiently forms a persulfide during catalysis, To accommodate this hypothesis, we propose a general mechanism for sulfur transfer in which the terminal sulfur of the persulfide first acts as a nucleophile and is then transferred as an equivalent of S-2-rather than S-0.	Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA; Virginia Polytech Inst & State Univ, Dept Biochem, Blacksburg, VA 24061 USA	University of Delaware; Virginia Polytechnic Institute & State University	Mueller, EG (corresponding author), Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.	emueller@udel.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059636, T32GM008550] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59636-01, T32 GM08550] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER K, 1987, J BIOL CHEM, V262, P6595; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Begley TP, 1999, CURR OPIN CHEM BIOL, V3, P623, DOI 10.1016/S1367-5931(99)00018-6; BERGSTROM DE, 1971, BIOCHEMISTRY-US, V11, P1; BUCK M, 1983, ANAL BIOCHEM, V129, P1, DOI 10.1016/0003-2697(83)90044-1; Bui BTS, 1998, FEBS LETT, V440, P226, DOI 10.1016/S0014-5793(98)01464-1; CARRE DS, 1974, BIOCHIMIE, V56, P1089, DOI 10.1016/S0300-9084(74)80097-0; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; FAVRE A, 1969, BIOCHEM BIOPH RES CO, V37, P266, DOI 10.1016/0006-291X(69)90729-3; FAVRE A, 1971, J MOL BIOL, V58, P367, DOI 10.1016/0022-2836(71)90252-X; Flint DH, 1996, J BIOL CHEM, V271, P16068; GEHRKE CW, 1982, J CHROMATOGR, V230, P297, DOI 10.1016/S0378-4347(00)80479-X; Gibson KJ, 1999, BIOCHEM BIOPH RES CO, V254, P632, DOI 10.1006/bbrc.1998.9991; Grosjean H., 1998, MODIFICATION EDITING, DOI [10.1128/9781555818296, DOI 10.1128/9781555818296]; HARRIS CL, 1990, J BACTERIOL, V172, P1798, DOI 10.1128/jb.172.4.1798-1803.1990; Hofmann K, 1998, J MOL BIOL, V282, P195, DOI 10.1006/jmbi.1998.1998; Kambampati R, 1999, BIOCHEMISTRY-US, V38, P16561, DOI 10.1021/bi991119r; KRAMER GF, 1988, J BACTERIOL, V170, P2344, DOI 10.1128/jb.170.5.2344-2351.1988; Lacourciere GM, 1998, J BIOL CHEM, V273, P30921, DOI 10.1074/jbc.273.47.30921; LIPSETT MN, 1978, J BACTERIOL, V135, P993, DOI 10.1128/JB.135.3.993-997.1978; Mueller EG, 1998, NUCLEIC ACIDS RES, V26, P2606, DOI 10.1093/nar/26.11.2606; Mueller EG, 1999, PROTEIN SCI, V8, P2424; Nandi DL, 1998, INT J BIOCHEM CELL B, V30, P973, DOI 10.1016/S1357-2725(98)00050-8; Ollagnier-de Choudens S, 1999, FEBS LETT, V453, P25, DOI 10.1016/S0014-5793(99)00694-8; Rajagopalan KV, 1997, BIOCHEM SOC T, V25, P757, DOI 10.1042/bst0250757; RAMABHADRAN TV, 1976, P NATL ACAD SCI USA, V73, P59, DOI 10.1073/pnas.73.1.59; RAY WK, 2000, IN PRESS J BACTERIOL, V182; RYALS J, 1982, J BACTERIOL, V151, P899, DOI 10.1128/JB.151.2.899-904.1982; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Taylor SV, 1998, J BIOL CHEM, V273, P16555, DOI 10.1074/jbc.273.26.16555; Tesmer JG, 1996, NAT STRUCT BIOL, V3, P74, DOI 10.1038/nsb0196-74; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; THOMAS G, 1977, CR ACAD SCI D NAT, V284, P1345; Webb E, 1997, J BACTERIOL, V179, P4399, DOI 10.1128/jb.179.13.4399-4402.1997; Westley J., 1977, BIOORG CHEM, V1, P371; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	37	128	130	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8283	8286		10.1074/jbc.275.12.8283	http://dx.doi.org/10.1074/jbc.275.12.8283			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722656	hybrid			2022-12-27	WOS:000086507700006
J	Toyomura, T; Oka, T; Yamaguchi, C; Wada, Y; Futai, M				Toyomura, T; Oka, T; Yamaguchi, C; Wada, Y; Futai, M			Three subunit a isoforms of mouse vacuolar H+-ATPase - Preferential expression of the a3 isoform during osteoclast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON PUMP; MOLECULAR CHARACTERIZATION; SACCHAROMYCES-CEREVISIAE; CAENORHABDITIS-ELEGANS; 116-KDA POLYPEPTIDE; V-ATPASES; B-SUBUNIT; CELLS; GENES; ACIDIFICATION	Vacuolar H+-ATPase CV-ATPase) is a multi-subunit enzyme with a membrane peripheral catalytic (V-1) and an intrinsic (V-o) sector. We have identified three cDNA clones coding for isoforms of mouse V-o subunit a (a1, a2, and a3). They exhibit 48-52% identity with each other and high similarity to subunit a of other species. The al isoform was mainly expressed in brain and liver. The a2 isoform was observed in heart and kidney in addition to brain and Liver. Transcripts for the a3 isoform were strongly expressed in heart and liver. The a3 isoform was induced during osteoclast differentiation, and localized in the plasma membrane and cytoplasmic filamentous structures. In contrast to a3, the a1 isoform was constitutively expressed and localized in the cytoplasmic endomembrane compartments of the same cells. These findings suggest that the a3 isoform is a component of the plasma membrane V-ATPase essential for bone resorption.	Osaka Univ, Inst Sci & Ind Res, Div Biol Sci, Core Res Evolut Sci & Technol, Osaka 5670047, Japan; Japan Sci & Technol Corp, Osaka 5670047, Japan	Japan Science & Technology Agency (JST); Osaka University; Japan Science & Technology Agency (JST)	Futai, M (corresponding author), Osaka Univ, Inst Sci & Ind Res, Div Biol Sci, Core Res Evolut Sci & Technol, Osaka 5670047, Japan.							AbuAmer Y, 1997, J CELL BIOL, V137, P247, DOI 10.1083/jcb.137.1.247; ANRAKU Y, 1996, HDB BIOL PHYS, V2, P93; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; Brown D, 1997, J EXP BIOL, V200, P257; Brown D, 1996, J EXP BIOL, V199, P2345; Crider BP, 1997, J BIOL CHEM, V272, P10721; Futai M, 1998, J BIOCHEM-TOKYO, V124, P259, DOI 10.1093/oxfordjournals.jbchem.a022105; Futai M, 1996, J BIOENERG BIOMEMBR, V28, P409, DOI 10.1007/BF02113982; HASEBE M, 1992, BIOCHEM BIOPH RES CO, V183, P856, DOI 10.1016/0006-291X(92)90562-Y; HASENFRATZ MP, 1995, PLANT PHYSIOL, V108, P1395, DOI 10.1104/pp.108.4.1395; HEMKEN P, 1992, J BIOL CHEM, V267, P9948; HERNANDO N, 1995, P NATL ACAD SCI USA, V92, P6087, DOI 10.1073/pnas.92.13.6087; Higuchi Y, 1999, BONE, V25, P17, DOI 10.1016/S8756-3282(99)00103-9; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAKKAKORPI PT, 1991, J BONE MINER RES, V6, P817; Lee BS, 1999, J BIOL CHEM, V274, P29164, DOI 10.1074/jbc.274.41.29164; LEE BS, 1996, AM J PHYSIOL, V270, P382; LEE CK, 1990, MOL IMMUNOL, V27, P1137; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; Li YP, 1996, BIOCHEM BIOPH RES CO, V218, P813, DOI 10.1006/bbrc.1996.0145; MANOLSON MF, 1992, J EXP BIOL, V172, P105; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; Mattson NP, 1997, J BONE MINER RES, V12, P753, DOI 10.1359/jbmr.1997.12.5.753; NAKAMURA H, 1994, ARCH HISTOL CYTOL, V57, P535, DOI 10.1679/aohc.57.535; Nakamura I, 1997, FEBS LETT, V401, P207, DOI 10.1016/S0014-5793(96)01454-8; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; Oka T, 1998, J BIOL CHEM, V273, P22570, DOI 10.1074/jbc.273.35.22570; Oka T, 1997, J BIOL CHEM, V272, P24387, DOI 10.1074/jbc.272.39.24387; PENG SB, 1994, J BIOL CHEM, V269, P17262; Peng SB, 1999, J BIOL CHEM, V274, P2549, DOI 10.1074/jbc.274.4.2549; PERIN MS, 1991, J BIOL CHEM, V266, P3877; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P1504, DOI 10.1210/endo-123-3-1504; Tomochika K, 1997, FEBS LETT, V404, P61, DOI 10.1016/S0014-5793(97)00090-2; TURKSEN K, 1988, J BONE MINER RES, V3, P389; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; VANHILLE B, 1993, J BIOL CHEM, V268, P70075; YAMASHITA T, 1990, J CELL PHYSIOL, V145, P587, DOI 10.1002/jcp.1041450327; Zhou ZM, 1998, J BIOL CHEM, V273, P5878, DOI 10.1074/jbc.273.10.5878	45	209	213	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8760	8765		10.1074/jbc.275.12.8760	http://dx.doi.org/10.1074/jbc.275.12.8760			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722719	hybrid			2022-12-27	WOS:000086507700069
J	Gu, F; Gruenberg, J				Gu, F; Gruenberg, J			ARF1 regulates pH-dependent COP functions in the early endocytic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; GOLGI MEMBRANES; PHOSPHOLIPASE-D; VESICLE FORMATION; COATED VESICLES; FUSION INVITRO; LATE ENDOSOMES; ENDOPLASMIC-RETICULUM; MAMMALIAN-CELLS; PLASMA-MEMBRANE	Coat proteins of the COP family were recently shown by us and others to be involved in membrane transport in the endocytic pathway, in addition to their known functions in the biosynthetic pathway. We have also shown that membrane association of endosomal COPs depends on the acidic endosomal pH, in contrast to biosynthetic COPs. In this paper, we report that both membrane recruitment of endosomal COPs and in vitro biogenesis of transport intermediates destined for late endosomes, depend on a cytosolic factor, which we identified as the small GTP-binding protein ARF1. Our data indicate that ARF1 does not act via activation of an endosomal phospholipase D. We also find that ARF1 membrane association is regulated by the endosomal pH, and that this controls the pH-dependent association of endosomal COPs. These studies thus show that ARF1 regulates COP functions in the endocytic pathway, and indicate that ARF1 acts as the cytosolic component of a transmembrane pH-sensing mechanism.	Univ Geneva, Dept Biochem, CH-1211 Geneva 4, Switzerland	University of Geneva	Gruenberg, J (corresponding author), Univ Geneva, Dept Biochem, 30 Quai E Ansermet, CH-1211 Geneva 4, Switzerland.	Jean.Gruenberg@biochem.unige.ch						ANIENTO F, 1993, J BIOL CHEM, V268, P10463; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; Bayer N, 1998, J VIROL, V72, P9645, DOI 10.1128/JVI.72.12.9645-9655.1998; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Daro E, 1997, J CELL BIOL, V139, P1747, DOI 10.1083/jcb.139.7.1747; DASCHER C, 1994, J BIOL CHEM, V269, P1437; Dittie AS, 1996, J CELL BIOL, V132, P523, DOI 10.1083/jcb.132.4.523; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; Faundez V, 1998, CELL, V93, P423, DOI 10.1016/S0092-8674(00)81170-8; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; Gaynor EC, 1998, MOL BIOL CELL, V9, P653, DOI 10.1091/mbc.9.3.653; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GRUENBERG JE, 1986, EMBO J, V5, P3091, DOI 10.1002/j.1460-2075.1986.tb04615.x; Gu F, 1997, J CELL BIOL, V139, P1183, DOI 10.1083/jcb.139.5.1183; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1991, J BIOL CHEM, V266, P2606; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; Le Borgne R, 1998, CURR OPIN CELL BIOL, V10, P499; LeBorgne R, 1997, J CELL BIOL, V137, P335; Liang JO, 1997, J BIOL CHEM, V272, P4141, DOI 10.1074/jbc.272.7.4141; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Lowe M, 1998, BBA-MOL CELL RES, V1404, P53, DOI 10.1016/S0167-4889(98)00046-9; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Ooi CE, 1998, J CELL BIOL, V142, P391, DOI 10.1083/jcb.142.2.391; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Palokangas H, 1998, MOL BIOL CELL, V9, P3561, DOI 10.1091/mbc.9.12.3561; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Piguet V, 1999, CELL, V97, P63, DOI 10.1016/S0092-8674(00)80715-1; Presley JF, 1997, J BIOL CHEM, V272, P13929, DOI 10.1074/jbc.272.21.13929; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; Robinson LJ, 1997, J CELL SCI, V110, P2079; Rojo M, 1997, J CELL BIOL, V139, P1119, DOI 10.1083/jcb.139.5.1119; Song J, 1998, J CELL SCI, V111, P2257; Stamnes M, 1998, P NATL ACAD SCI USA, V95, P13676, DOI 10.1073/pnas.95.23.13676; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; West MA, 1997, J CELL BIOL, V138, P1239, DOI 10.1083/jcb.138.6.1239; WHITNEY JA, 1995, CELL, V83, P703; ZEUZEM S, 1992, P NATL ACAD SCI USA, V89, P6619, DOI 10.1073/pnas.89.14.6619; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289	54	114	116	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8154	8160		10.1074/jbc.275.11.8154	http://dx.doi.org/10.1074/jbc.275.11.8154			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713138	hybrid			2022-12-27	WOS:000085913300098
J	Moolenaar, GF; Herron, MFP; Monaco, V; van der Marel, GA; van Boom, JH; Visse, R; Goosen, N				Moolenaar, GF; Herron, MFP; Monaco, V; van der Marel, GA; van Boom, JH; Visse, R; Goosen, N			The role of ATP binding and hydrolysis by UvrB during nucleotide excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI UVRB; PREINCISION COMPLEX; (A)BC EXCINUCLEASE; ABC EXCINUCLEASE; PROTEIN COMPLEX; CATALYTIC SITE; DNA COMPLEX; INCISION; 3'-INCISION	We have isolated UvrB-DNA complexes by capture of biotinylated damaged DNA substrates on streptavidin-coated magnetic beads. With this method the UvrB-DNA preincision complex remains stable even in the absence of ATP. For the binding of UvrC to the UvrB-DNA complex no cofactor is needed. The subsequent induction of 3' incision does require ATP binding by UvrB but not hydrolysis. This ATP binding induces a conformational change in the DNA, resulting in the appearance of the DNase I-hypersensitive site at the 5' side of the damage. In contrast, the 5' incision is not dependent on ATP binding because it occurs with the same efficiency with ADP. We show with competition experiments that both incision reactions are induced by the binding of the same UvrC molecule. A DNA substrate containing damage close to the 5' end of the damaged strand is specifically bound by UvrB in the absence of UvrA and ATP (Moolenaar, G. F., Monaco, V., van der Marel, C:. A, van Boom, J. H., Visse, R,, and Goosen, N. (2000) J. Biol: Chem. 275, 8038-8043), To initiate the formation of an active UvrBC-DNA incision complex, however, UvrB first needs to hydrolyze ATP, and subsequently a new ATP molecule must be bound. Implications of these findings for the mechanism of the UvrA-mediated formation of the UvrB-DNA preincision complex will be discussed.	Leiden Univ, Leiden Inst Chem, Gorlaeus Labs, Mol Genet Lab, NL-2300 RA Leiden, Netherlands; Leiden Univ, Leiden Inst Chem, Gorlaeus Labs, Lab Bioorgan Synth, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC	Goosen, N (corresponding author), Leiden Univ, Leiden Inst Chem, Gorlaeus Labs, Mol Genet Lab, Einsteinweg 55,POB 9502, NL-2300 RA Leiden, Netherlands.	N.Goosen@chem.Leidenuniv.nl						Alexandrovich A, 1999, FEBS LETT, V451, P181, DOI 10.1016/S0014-5793(99)00542-6; Delagoutte E, 1997, J MOL BIOL, V266, P703, DOI 10.1006/jmbi.1996.0830; GOOSEN N, 1998, NUCL ACID M, V12, P103; LIN JJ, 1992, J BIOL CHEM, V267, P17688; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; Moolenaar GF, 1998, J BIOL CHEM, V273, P34896, DOI 10.1074/jbc.273.52.34896; Moolenaar GF, 2000, J BIOL CHEM, V275, P8038, DOI 10.1074/jbc.275.11.8038; Moolenaar GF, 1997, MUTAT RES-DNA REPAIR, V385, P195, DOI 10.1016/S0921-8777(97)00042-6; Moolenaar GF, 1995, J BIOL CHEM, V270, P30508, DOI 10.1074/jbc.270.51.30508; MOOLENAAR GF, 1994, J MOL BIOL, V240, P294, DOI 10.1006/jmbi.1994.1447; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; OH EY, 1986, NUCLEIC ACIDS RES, V14, P16067; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SEELEY TW, 1990, J BIOL CHEM, V265, P7158; VANHOUTEN B, 1987, J BIOL CHEM, V262, P13180; Verhoeven EEA, 2000, J BIOL CHEM, V275, P5120, DOI 10.1074/jbc.275.7.5120; VISSE R, 1992, J BIOL CHEM, V267, P6736; VISSE R, 1991, J BIOL CHEM, V266, P7609; VOIGT JM, 1989, J BIOL CHEM, V264, P5172	21	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8044	8050		10.1074/jbc.275.11.8044	http://dx.doi.org/10.1074/jbc.275.11.8044			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713125	Green Published, hybrid			2022-12-27	WOS:000085913300085
J	Nuhse, TS; Peck, SC; Hirt, H; Boller, T				Nuhse, TS; Peck, SC; Hirt, H; Boller, T			Microbial elicitors induce activation and dual phosphorylation of the Arabidopsis thaliana MAPK 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; TRANSIENT ACTIVATION; SUSPENSION-CULTURES; TOBACCO CELLS; SIGNAL-TRANSDUCTION; DISEASE RESISTANCE; FUNGAL ELICITOR; PLANT-CELLS; PATHWAYS; TYROSINE	Protein kinases related to the family of mitogen-activated kinases (MAPKs) have been established as signal transduction components in a variety of processes in plants. For Arabidopsis thaliana, however, although one of the genetically best studied plant species, biochemical data on activation of mitogen-activated protein kinases are lacking. A. thaliana MAPK 6 (AtMPK6) is the Arabidopsis orthologue of a tobacco MAPK termed salicylate-induced protein kinase, which is activated by general and race-specific elicitors as well as by physical stress. Using a C terminus-specific antibody, we show that AtMPK6 is activated in elicitor-treated cell cultures of A. thaliana. Four different elicitors from bacteria, fungi, and plants lead to a rapid and transient activation of AtMPK6, indicating a conserved signaling pathway. The induction was equally rapid as medium alkalinization, one of the earliest elicitor response observed in cell cultures. A similarly rapid activation of AtMPK6 was observed in elicitor-treated leaf strips, demonstrating that recognition of the elicitors and activation of the MAPK pathway occurs also in intact plants. We demonstrate by in vivo labeling that AtMPK6 is phosphorylated on threonine and tyrosine residues in elicited cells.	Friedrich Miescher Inst, CH-4058 Basel, Switzerland; Univ Vienna, Vienna Bioctr, Inst Genet & Microbiol, A-1030 Vienna, Austria	Friedrich Miescher Institute for Biomedical Research; University of Vienna; Vienna Biocenter (VBC)	Boller, T (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.	boller@ubaclu.unibas.ch	Hirt, Heribert/A-2061-2013; Boller, Thomas/G-3500-2012	Boller, Thomas/0000-0001-6768-7503				Aarts N, 1998, P NATL ACAD SCI USA, V95, P10306, DOI 10.1073/pnas.95.17.10306; Adam AL, 1997, PLANT PHYSIOL, V115, P853, DOI 10.1104/pp.115.2.853; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; BISHOP PD, 1984, J BIOL CHEM, V259, P3172; Bogre L, 1999, PLANT CELL, V11, P101, DOI 10.1105/tpc.11.1.101; Bogre L, 1997, PLANT CELL, V9, P75, DOI 10.1105/tpc.9.1.75; Bogre L, 1996, NATURE, V383, P489, DOI 10.1038/383489a0; BOLLER T, 1995, ANNU REV PLANT PHYS, V46, P189, DOI 10.1146/annurev.arplant.46.1.189; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Calderini O, 1998, J CELL SCI, V111, P3091; Desikan R, 1998, BIOCHEM J, V330, P115, DOI 10.1042/bj3300115; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; DIETRICH A, 1990, J BIOL CHEM, V265, P6360; DrogeLaser W, 1997, EMBO J, V16, P726, DOI 10.1093/emboj/16.4.726; Felix G, 1999, PLANT J, V18, P265, DOI 10.1046/j.1365-313X.1999.00265.x; FELIX G, 1991, P NATL ACAD SCI USA, V88, P8831, DOI 10.1073/pnas.88.19.8831; Glazebrook J, 1997, ANNU REV GENET, V31, P547, DOI 10.1146/annurev.genet.31.1.547; Gomez-Gomez L, 1999, PLANT J, V18, P277, DOI 10.1046/j.1365-313X.1999.00451.x; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hirt H, 1997, TRENDS PLANT SCI, V2, P11, DOI 10.1016/S1360-1385(96)10048-0; Innes RW, 1998, CURR OPIN PLANT BIOL, V1, P299, DOI 10.1016/1369-5266(88)80050-5; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Jonak C, 1999, CELL MOL LIFE SCI, V55, P204, DOI 10.1007/s000180050285; Jonak C, 1996, P NATL ACAD SCI USA, V93, P11274, DOI 10.1073/pnas.93.20.11274; JONAK C, 1993, PLANT J, V3, P611, DOI 10.1046/j.1365-313X.1993.03040611.x; Knetsch MLW, 1996, PLANT CELL, V8, P1061, DOI 10.1105/tpc.8.6.1061; Kunkel BN, 1996, TRENDS GENET, V12, P63, DOI 10.1016/0168-9525(96)81402-8; Lebrun-Garcia A, 1998, PLANT J, V15, P773, DOI 10.1046/j.1365-313X.1998.00269.x; Ligterink W, 1997, SCIENCE, V276, P2054, DOI 10.1126/science.276.5321.2054; MAY MJ, 1993, PLANT PHYSIOL, V103, P621, DOI 10.1104/pp.103.2.621; Meskiene I, 1998, P NATL ACAD SCI USA, V95, P1938, DOI 10.1073/pnas.95.4.1938; MIZOGUCHI T, 1993, FEBS LETT, V336, P440, DOI 10.1016/0014-5793(93)80852-L; Mizoguchi T, 1997, TRENDS BIOTECHNOL, V15, P15, DOI 10.1016/S0167-7799(96)10074-3; Mizoguchi T, 1996, P NATL ACAD SCI USA, V93, P765, DOI 10.1073/pnas.93.2.765; MIZOGUCHI T, 1994, PLANT J, V5, P111, DOI 10.1046/j.1365-313X.1994.5010111.x; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; Romeis T, 1999, PLANT CELL, V11, P273, DOI 10.1105/tpc.11.2.273; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SCHWACKE R, 1992, PLANTA, V187, P136, DOI 10.1007/BF00201635; Seo S, 1999, PLANT CELL, V11, P289, DOI 10.1105/tpc.11.2.289; SEO S, 1995, SCIENCE, V270, P1988, DOI 10.1126/science.270.5244.1988; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUZUKI K, 1995, PLANT CELL, V7, P639, DOI 10.1105/tpc.7.5.639; Tan PBO, 1999, TRENDS GENET, V15, P145, DOI 10.1016/S0168-9525(99)01694-7; USAMI S, 1995, P NATL ACAD SCI USA, V92, P8660, DOI 10.1073/pnas.92.19.8660; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WurglerMurphy SM, 1997, MOL CELL BIOL, V17, P1289, DOI 10.1128/MCB.17.3.1289; Xing T, 1997, PLANT CELL, V9, P249, DOI 10.1105/tpc.9.2.249; Zhang SQ, 1998, PLANT CELL, V10, P435, DOI 10.1105/tpc.10.3.435; Zhang SQ, 1998, P NATL ACAD SCI USA, V95, P7433, DOI 10.1073/pnas.95.13.7433; Zhang SQ, 1998, P NATL ACAD SCI USA, V95, P7225, DOI 10.1073/pnas.95.12.7225; Zhang SQ, 1997, PLANT CELL, V9, P809, DOI 10.1105/tpc.9.5.809	53	247	265	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7521	7526		10.1074/jbc.275.11.7521	http://dx.doi.org/10.1074/jbc.275.11.7521			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713056	hybrid			2022-12-27	WOS:000085913300016
J	Zhu, YJ; Qi, C; Jia, YZ; Nye, JS; Rao, MS; Reddy, JK				Zhu, YJ; Qi, C; Jia, YZ; Nye, JS; Rao, MS; Reddy, JK			Deletion of PBP/PPARBP, the gene for nuclear receptor coactivator peroxisome proliferator-activated receptor-binding protein, results in embryonic lethality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; HISTONE ACETYLTRANSFERASE; COMPLEX; CBP; DISRUPTION; INTERACTS; BREAST; CANCER; MICE	We previously isolated and identified peroxisome proliferator-activated receptor (PPAR)-binding Protein (PBP) as a coactivator for PPAR gamma, PBP has recently been identified as a component of the multiprotein complexes such as TRAP, DRIP, and ARC that appear to play an important role in the transcriptional activation by several transcriptional factors including nuclear receptors, To assess the biological significance of PBP, we disrupted the PBP gene (PBP/PPARBP) in mice by homologous recombination. PBP+/- mice are healthy, fertile, and do not differ significantly from PBP+/+ control littermates. PBP null mutation (PBP-/-) is embryonically lethal at embryonic day 11.5, suggesting that PBP is an essential gene for mouse embryogenesis, The embryonic lethality is attributed, in part, to defects in the development of placental vasculature similar to those encountered in PPAR gamma mutants. Transient transfection assays using fibroblasts isolated from PBP mutant embryos revealed a decreased capacity for ligand-dependent transcriptional activation of PPAR gamma as compared with fibroblasts derived form the wild type embryos. These observations suggest that there is no functional redundancy between PBP and other coactivators such as steroid receptor coactivator-l and that PBP plays a critical role in the signaling of PPAR gamma and other nuclear receptors.	Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA	Northwestern University	Reddy, JK (corresponding author), Northwestern Univ, Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.		Nye, Jeffrey/G-6520-2012	Nye, Jeffrey/0000-0002-6056-281X	NIGMS NIH HHS [R37 GM23750] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023750] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; COPP AJ, 1995, TRENDS GENET, V11, P87, DOI 10.1016/S0168-9525(00)89008-3; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Lemon BD, 1999, CURR OPIN GENET DEV, V9, P499, DOI 10.1016/S0959-437X(99)00010-6; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; ONATE SA, 1995, SCIENCE, V270, P1354; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Qi C, 1999, P NATL ACAD SCI USA, V96, P1585, DOI 10.1073/pnas.96.4.1585; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Sapin V, 1997, DEV BIOL, V191, P29, DOI 10.1006/dbio.1997.8687; SELFRIDGE J, 1992, SOMAT CELL MOLEC GEN, V18, P325, DOI 10.1007/BF01235756; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhu YJ, 1996, GENE EXPRESSION, V6, P185; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848	24	113	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	2000	275	20					14779	14782		10.1074/jbc.C000121200	http://dx.doi.org/10.1074/jbc.C000121200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	315TD	10747854	hybrid			2022-12-27	WOS:000087128300001
J	Avram, D; Fields, A; Top, KPO; Nevrivy, DJ; Ishmael, JE; Leid, M				Avram, D; Fields, A; Top, KPO; Nevrivy, DJ; Ishmael, JE; Leid, M			Isolation of a novel family of C2H2 zinc finger proteins implicated in transcriptional repression mediated by chicken ovalbumin upstream promoter transcription factor (COUP-TF) orphan nuclear receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; OXYTOCIN GENE PROMOTER; THYROID-HORMONE; ACTIVE REPRESSION; RESPONSE ELEMENTS; BINDING PROTEIN; N-COR; HISTONE DEACETYLASE; ESTROGEN-RECEPTOR; LIGAND-BINDING	Two novel and related C2H2 zinc finger proteins that are highly expressed in the brain, CTIP1 and CTIP2 (COUP TF-interacting proteins 1 and 2, respectively), were isolated and shown to interact with all members of the chicken ovalbumin upstream promoter transcription factor (COUP-TF) subfamily of orphan nuclear receptors, The interaction of CTIP1 with ARP1 was studied in detail, and CTIP1 was found to harbor two independent ARP1 interaction domains, ID1 and ID2, whereas the putative AF-2 of ARP1 was required for interaction with CTIP1. CTIP1, which exhibited a punctate staining pattern within the nucleus of transfected cells, recruited cotransfected ARP1 to these foci and potentiated ARP1-mediated transcriptional repression of a reporter construct. However, transcriptional repression mediated by ARP1 acting through CTIP1 did not appear to involve recruitment of a trichostatin A-sensitive histone deacetylase(s) to the template, suggesting that this repression pathway may be distinct from that utilized by several other nuclear receptors.	Oregon State Univ, Coll Pharm, Mol Pharmacol Lab, Corvallis, OR 97331 USA; Oregon State Univ, Mol & Cellular Biol Program, Corvallis, OR 97331 USA; Oregon State Univ, Environm Hlth Sci Ctr, Corvallis, OR 97331 USA	Oregon State University; Oregon State University; Oregon State University	Leid, M (corresponding author), Oregon State Univ, Coll Pharm, Mol Pharmacol Lab, Corvallis, OR 97331 USA.				NIEHS NIH HHS [ES00210, P30 ES000210, ES00040, P01 ES000040, P01 ES000040-370083] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES000040, P30ES000210] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Achatz G, 1997, MOL CELL BIOL, V17, P4914, DOI 10.1128/MCB.17.9.4914; Aoki K, 1998, J BIOL CHEM, V273, P26698, DOI 10.1074/jbc.273.41.26698; Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709; Avram D, 1999, J BIOL CHEM, V274, P14331, DOI 10.1074/jbc.274.20.14331; Bailey PJ, 1997, J STEROID BIOCHEM, V63, P165, DOI 10.1016/S0960-0760(97)00079-4; Bouvier C, 1998, EUR J PHARMACOL, V348, P85, DOI 10.1016/S0014-2999(98)00132-0; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chu K, 1998, MOL CELL ENDOCRINOL, V137, P145, DOI 10.1016/S0303-7207(97)00241-4; Chu K, 1997, J MOL ENDOCRINOL, V19, P163, DOI 10.1677/jme.0.0190163; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Dowell P, 1999, J BIOL CHEM, V274, P15901, DOI 10.1074/jbc.274.22.15901; Escriva H, 1997, P NATL ACAD SCI USA, V94, P6803, DOI 10.1073/pnas.94.13.6803; Georgopoulos K, 1997, ANNU REV IMMUNOL, V15, P155, DOI 10.1146/annurev.immunol.15.1.155; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Ikeda K, 1998, MOL CELL BIOL, V18, P10, DOI 10.1128/MCB.18.1.10; ISLAM TC, 1994, BIOCHEM BIOPH RES CO, V203, P545, DOI 10.1006/bbrc.1994.2217; JONK LJC, 1994, MECH DEVELOP, V47, P81, DOI 10.1016/0925-4773(94)90098-1; KELLER AD, 1992, MOL CELL BIOL, V12, P1940, DOI 10.1128/MCB.12.5.1940; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; Klinge CM, 1997, J BIOL CHEM, V272, P31465, DOI 10.1074/jbc.272.50.31465; KRONCZYNSKA AM, 1989, NUCLEIC ACIDS RES, V17, P6408; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; Leng X, 1996, MOL CELL BIOL, V16, P2332; Maldonado E, 1999, CELL, V99, P455, DOI 10.1016/S0092-8674(00)81533-0; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Olave I, 1998, GENE DEV, V12, P1621, DOI 10.1101/gad.12.11.1621; Pereira FA, 1999, GENE DEV, V13, P1037, DOI 10.1101/gad.13.8.1037; PEREIRA FA, 1995, J STEROID BIOCHEM, V53, P503, DOI 10.1016/0960-0760(95)00097-J; Pipaon C, 1999, MOL CELL BIOL, V19, P2734; Qiu YH, 1997, GENE DEV, V11, P1925, DOI 10.1101/gad.11.15.1925; QIU YH, 1994, P NATL ACAD SCI USA, V91, P4451, DOI 10.1073/pnas.91.10.4451; Ren B, 1999, GENE DEV, V13, P125, DOI 10.1101/gad.13.1.125; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; Shigeta H, 1996, MOL REPROD DEV, V45, P21, DOI 10.1002/(SICI)1098-2795(199609)45:1&lt;21::AID-MRD3&gt;3.0.CO;2-U; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; SURI C, 1993, J NEUROSCI, V13, P1280; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; UM M, 1995, MOL CELL BIOL, V15, P5007; vanderWees J, 1996, MECH DEVELOP, V54, P173, DOI 10.1016/0925-4773(95)00471-8; Wang Lee-Ho, 1991, Gene Expression, V1, P207; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	58	160	168	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10315	10322		10.1074/jbc.275.14.10315	http://dx.doi.org/10.1074/jbc.275.14.10315			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744719	hybrid, Green Accepted			2022-12-27	WOS:000086345600060
J	Riou, P; Bex, F; Gazzolo, L				Riou, P; Bex, F; Gazzolo, L			The human T cell leukemia/lymphotropic virus type 1 Tax protein represses MyoD-dependent transcription by inhibiting MyoD-binding to the KIX domain of p300 - A potential mechanism for Tax-mediated repression of the transcriptional activity of basic helix-loop-helix factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HTLV-I TAX; SERUM RESPONSE FACTOR; CREB-BINDING; GENE-EXPRESSION; COACTIVATOR CBP; MUSCLE DIFFERENTIATION; 21-BASE-PAIR REPEATS; NUCLEAR INTEGRATION; TRANSACTIVATOR TAX; ONCOPROTEIN TAX	The human T cell leukemia/lymphotropic virus type 1 (HTLV-1) Tax protein strongly activates viral and cellular gene transcription. It mainly functions by interacting with cellular transcription factors and the KIX domain of the p300/CBP coactivators. Tax can also repress the transcription of cellular genes through the basic helix-loop-helix (bHLH) protein family. To investigate the molecular mechanisms of this Tax-mediated inhibition, we analyzed its effect on the transcriptional activity of the myogenic MyoD protein, which was used as a paradigm of bHLH factors. In this study, we show that overexpression of the p300 coactivator in transient transfection assays was sufficient to rescue MyoD repression by Tax. Furthermore, an N-terminal domain of p300 (amino acids 379-654) containing the region of KM serving as the Tax binding site was found, when overexpressed, to potentiate Tax-mediated transactivation of HTLV-1 proviral as well as MyoD-dependent transcription, and to antagonize the inhibition by Tax of the transcriptional activity of MyoD. These results revealing the presence of an N-terminal MyoD binding site mere confirmed by in vitro protein-protein interaction assays that demonstrate that MyoD binds to the KIX domain of p300 and that Tax competes with MyoD binding in a nonreciprocal manner. These observations provide evidence that Tax binding to the KM domain of p300 prevents bHLH proteins from contacting this N-terminal domain of the coactivator, thus resulting in their transcriptional repression. As bHLH proteins are implicated in many developmental fate decisions, especially during thymopoiesis. Tax-mediated inhibition of their transcriptional activity may contribute to the induction of HTLV-l-linked leukemogenesis.	Univ Lyon 1, CNRS, Fac Med Lyon Laennec, UMR 5537, F-69372 Lyon 08, France; Inst Rech Microbiol, B-1070 Brussels, Belgium	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Gazzolo, L (corresponding author), Univ Lyon 1, CNRS, Fac Med Lyon Laennec, UMR 5537, Rue Guillaume Paradin, F-69372 Lyon 08, France.	gazzolo@laennec.univ-lyon1.fr						AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Feigenbaum L, 1996, J VIROL, V70, P3280, DOI 10.1128/JVI.70.5.3280-3285.1996; Feuer G, 1996, J VIROL, V70, P4038, DOI 10.1128/JVI.70.6.4038-4044.1996; FUJII M, 1995, ONCOGENE, V11, P7; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; GESSAIN A, 1985, LANCET, V2, P407; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; GOLGIN MA, 1998, J VIROL, V72, P9396; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; HOLLSBERG P, 1992, J IMMUNOL, V148, P3256; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; JEANG KT, 1988, P NATL ACAD SCI USA, V85, P8291, DOI 10.1073/pnas.85.21.8291; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Johnson SE, 1996, MOL CELL BIOL, V16, P1604; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; KOGA Y, 1989, J IMMUNOL, V142, P4493; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; LACOSTE J, 1994, LEUKEMIA, V8, pS71; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MAGUER V, 1993, J VIROL, V67, P5529, DOI 10.1128/JVI.67.9.5529-5537.1993; MAGUERSATTA V, 1995, BLOOD, V86, P1444, DOI 10.1182/blood.V86.4.1444.bloodjournal8641444; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; Mesnard JM, 1999, VIROLOGY, V257, P277, DOI 10.1006/viro.1999.9685; MOCHIZUKI M, 1992, LANCET, V339, P1110, DOI 10.1016/0140-6736(92)90699-4; MORGAN OS, 1989, LANCET, V2, P1184; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; NYBORG JK, 1990, J BIOL CHEM, V265, P8230; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Sandmoller A, 1996, MOL CELL BIOL, V16, P5846; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Semmes OJ, 1996, J BIOL CHEM, V271, P9730, DOI 10.1074/jbc.271.16.9730; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; SUZUKI T, 1993, ONCOGENE, V8, P2391; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; TEDESCO D, 1995, J VIROL, V69, P6947, DOI 10.1128/JVI.69.11.6947-6957.1995; Tiainen M, 1996, MOL CELL BIOL, V16, P5302; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; Van Orden K, 1999, ONCOGENE, V18, P3766, DOI 10.1038/sj.onc.1202703; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yan JP, 1998, J MOL BIOL, V281, P395, DOI 10.1006/jmbi.1998.1951; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Yoshida M, 1996, J ACQ IMMUN DEF SYND, V13, pS63, DOI 10.1097/00042560-199600001-00012; YOSHIDA M, 1995, CURR TOP MICROBIOL, V193, P79; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	73	38	38	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10551	10560		10.1074/jbc.275.14.10551	http://dx.doi.org/10.1074/jbc.275.14.10551			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744749	hybrid			2022-12-27	WOS:000086345600090
J	Stephanou, A; Brar, BK; Scarabelli, TM; Jonassen, AK; Yellon, DM; Marber, MS; Knight, RA; Latchman, DS				Stephanou, A; Brar, BK; Scarabelli, TM; Jonassen, AK; Yellon, DM; Marber, MS; Knight, RA; Latchman, DS			Ischemia-induced STAT-1 expression and activation play a critical role in cardiomyocyte apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; HEART-FAILURE; CELL-DEATH; PROTEIN; CARDIOTROPHIN-1; MYOCYTES; GP130; REPERFUSION; INFARCTION; CYTOKINE	We show here that exposure of cardiac cells to simulated ischemia results in apoptosis and is accompanied by phosphorylation and increased expression and transcriptional activity of STAT-1, Similarly, interferon-gamma, which is known to induce STAT-1 activation, also induced apoptosis in cardiac cells, STAT-1-transfected cells were more susceptible to ischemia-induced cell death than cells transfected with a control plasmid lacking the STAT-1 coding sequence. Furthermore, an antisense STAT-1 vector reduced both ischemia-and overexpressed STAT-1-induced cell death in cardiac cells. Both STAT-1 overexpression and interferon-gamma treatment or exposure to ischemia activated the promoter of the pro-apoptotic caspase-1 gene in cardiomyocytes. Finally, ischemia/reperfusion also induced STAT-1 activation and caspase-1 processing in ventricular myocytes in the intact heart er vivo. Immunofluorescent staining demonstrated an increase in STAT-1-positive staining in cardiomyocytes in response to ischemia/reperfusion that co-localized with terminal deoxynucleotidyl transferase dVTP nick end-labeling-positive apoptotic cells. These results suggest that STAT-1 plays a critical role in the regulation of ischemia/reperfusion-induced apoptosis in cardiac cells, acting at least in part via a caspase-1 activation-dependent pathway.	Inst Child Hlth, London WC1N 1EH, England; UCL Hosp, Hatter Inst Cardiovasc Studies, London WC1E 6AU, England; St Thomas Hosp, Dept Cardiol, London SE1 7EH, England; Royal Brompton Hosp, Natl Heart & Lung Inst, London SW3 6LR, England	University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; Guy's & St Thomas' NHS Foundation Trust; Imperial College London; Royal Brompton Hospital	Stephanou, A (corresponding author), Inst Child Hlth, 30 Guilford St, London WC1N 1EH, England.	anastasis_Stephanov@yahoo.com	marber, michael/AAW-7916-2021; Yellon, Derek M/ABD-5110-2021	Yellon, Derek/0000-0001-7791-9320; Marber, Michael/0000-0002-3463-7128				Bauer JH, 1998, J BIOL CHEM, V273, P9255, DOI 10.1074/jbc.273.15.9255; BING OHL, 1994, J MOL CELL CARDIOL, V26, P943, DOI 10.1006/jmcc.1994.1115; Black SC, 1998, J MOL CELL CARDIOL, V30, P733, DOI 10.1006/jmcc.1998.0660; Brar BK, 1999, J MOL CELL CARDIOL, V31, P135, DOI 10.1006/jmcc.1998.0857; Cheng W, 1996, EXP CELL RES, V226, P316, DOI 10.1006/excr.1996.0232; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DENT CL, 1993, TRANSCRIPTION FACTOR, P1; Fujio Y, 1997, J CLIN INVEST, V99, P2898, DOI 10.1172/JCI119484; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Kaneko S, 1997, CLIN EXP IMMUNOL, V109, P185, DOI 10.1046/j.1365-2249.1997.4191324.x; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Long XL, 1997, J CLIN INVEST, V99, P2635, DOI 10.1172/JCI119452; MacLellan WR, 1997, CIRC RES, V81, P137, DOI 10.1161/01.RES.81.2.137; MARBER MS, 1993, CIRCULATION, V88, P1264, DOI 10.1161/01.CIR.88.3.1264; Mascareno E, 1998, P NATL ACAD SCI USA, V95, P5590, DOI 10.1073/pnas.95.10.5590; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MIYASHITA T, 1995, CELL, V80, P293; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; Scarabelli TM, 1999, J IMMUNOL METHODS, V228, P23, DOI 10.1016/S0022-1759(99)00090-3; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; Stephanou A, 1998, J MOL CELL CARDIOL, V30, P849, DOI 10.1006/jmcc.1998.0651; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; UMANSKY SR, 1995, CELL DEATH DIFFER, V2, P235; Xu XL, 1998, CANCER RES, V58, P2832; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	36	172	184	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10002	10008		10.1074/jbc.275.14.10002	http://dx.doi.org/10.1074/jbc.275.14.10002			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744676	hybrid			2022-12-27	WOS:000086345600017
J	You, GF; Kuze, K; Kohanski, RA; Amsler, K; Henderson, S				You, GF; Kuze, K; Kohanski, RA; Amsler, K; Henderson, S			Regulation of mOAT-mediated organic anion transport by okadaic acid and protein kinase C in LLC-PK1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION TRANSPORTER; EXPRESSION CLONING; PHORBOL ESTERS; PHOSPHORYLATION; KIDNEY; SECRETION	Organic anion transporters in the kidney proximal tubule play an essential role in eliminating a wide range of organic anions including endogenous compounds, xenobiotics, and their metabolites, thereby preventing their potentially toxic effects within the body. We have previously cloned a cDNA encoding an organic anion transporter from mouse kidney (mOAT) (Lopez-Nieto, C, E., You, G., Bush, K. T., Barros, E. J. G., Beier, D. R., and Nigam, S. K. (1997) J. Biol. Chem. 272, 6471-6478; Kuze, K., Graces, P., Leahy, A, Wilson, P., Stuhlmann, H., and You, G. (1999) J. Biol. Chem, 274, 1519-1524). In the present study, we assessed the potential for regulation of this transporter by heterologous expression of mOAT in the pig proximal tubule-like cell Line, LLC-PK1. We report here that both protein phosphatase (PP1/PP2A) inhibitor, okadaic acid, and protein kinase C (PKC) activators down-regulate mOAT-mediated transport of para-aminohippuric acid (PAH), a prototypic organic anion, in a time- and concentrationdependent manner. However their mechanisms of action for this down-regulation are distinct. Okadaic acid modulated PAH transport, at least in part, through phosphorylation/dephosphorylation of mOAT; phosphoamino acid analysis indicated this phosphorylation occurs on serine. In contrast, PKC activation induced a decrease in the maximum transport velocity (V-max) of PAH transport without direct phosphorylation of the transporter protein. Together these results provide the first demonstration that regulation of organic anion transport by mOAT is likely to be tightly controlled directly and indirectly by phatase PP1/PP2A and PKC. Our results also suggest that kinases other than PKC are involved in this process.	CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Anat & Cell Biol, New York, NY 10029 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Rutgers State University New Brunswick; Rutgers State University Medical Center	You, GF (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, POB 1243,1 Gustave L Levy Pl, New York, NY 10029 USA.	gyou@smtplink.mssm.edu	Henderson, Scott/AAP-2785-2021	Henderson, Scott/0000-0002-1076-3867				BAGGIO B, 1993, BIOCHIM BIOPHYS ACTA, V1148, P157, DOI 10.1016/0005-2736(93)90173-W; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brown D, 1996, PHYSIOL REV, V76, P245, DOI 10.1152/physrev.1996.76.1.245; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COREY JL, 1994, J BIOL CHEM, V269, P14759; Grundemann D, 1997, J BIOL CHEM, V272, P10408; HOHAGE H, 1994, J PHARMACOL EXP THER, V269, P659; HORI R, 1993, AM J PHYSIOL, V264, pF975, DOI 10.1152/ajprenal.1993.264.6.F975; Hosoyamada M, 1999, AM J PHYSIOL-RENAL, V276, pF122, DOI 10.1152/ajprenal.1999.276.1.F122; Huff RA, 1997, J NEUROCHEM, V68, P225; KATSURA T, 1995, P NATL ACAD SCI USA, V92, P7212, DOI 10.1073/pnas.92.16.7212; Kuze K, 1999, J BIOL CHEM, V274, P1519, DOI 10.1074/jbc.274.3.1519; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; Li DL, 1998, AM J PHYSIOL-RENAL, V275, pF863, DOI 10.1152/ajprenal.1998.275.6.F863; LopezNieto CE, 1997, J BIOL CHEM, V272, P6471, DOI 10.1074/jbc.272.10.6471; Lu R, 1999, AM J PHYSIOL-RENAL, V276, pF295, DOI 10.1152/ajprenal.1999.276.2.F295; Miller DS, 1998, AM J PHYSIOL-RENAL, V274, pF156, DOI 10.1152/ajprenal.1998.274.1.F156; MOLLER JV, 1982, PHARMACOL REV, V34, P315; Nagai J, 1997, AM J PHYSIOL-RENAL, V273, pF674, DOI 10.1152/ajprenal.1997.273.5.F674; PRITCHARD JB, 1993, PHYSIOL REV, V73, P765, DOI 10.1152/physrev.1993.73.4.765; Race JE, 1999, BIOCHEM BIOPH RES CO, V255, P508, DOI 10.1006/bbrc.1998.9978; Ramamoorthy S, 1998, J BIOL CHEM, V273, P2458, DOI 10.1074/jbc.273.4.2458; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; Sweet DH, 1999, AM J PHYSIOL-RENAL, V276, pF864, DOI 10.1152/ajprenal.1999.276.6.F864; Sweet DH, 1997, J BIOL CHEM, V272, P30088, DOI 10.1074/jbc.272.48.30088; Takano M, 1996, AM J PHYSIOL-RENAL, V271, pF469, DOI 10.1152/ajprenal.1996.271.2.F469; Tojo A, 1999, J AM SOC NEPHROL, V10, P464; ULLRICH KJ, 1988, AM J PHYSIOL, V254, pF453, DOI 10.1152/ajprenal.1988.254.4.F453; Vaughan RA, 1997, J BIOL CHEM, V272, P15541, DOI 10.1074/jbc.272.24.15541; Wolff NA, 1997, FEBS LETT, V417, P287, DOI 10.1016/S0014-5793(97)01304-5; Yip JW, 1997, J BIOL CHEM, V272, P18473, DOI 10.1074/jbc.272.29.18473	32	78	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10278	10284		10.1074/jbc.275.14.10278	http://dx.doi.org/10.1074/jbc.275.14.10278			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744714	hybrid			2022-12-27	WOS:000086345600055
J	Buchanan, FG; Elliot, CM; Gibbs, M; Exton, JH				Buchanan, FG; Elliot, CM; Gibbs, M; Exton, JH			Translocation of the Rac1 guanine nucleotide exchange factor Tiam1 induced by platelet-derived growth factor and lysophosphatidic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PLECKSTRIN HOMOLOGY DOMAIN; PUTATIVE TARGET; CDC42 GTPASES; RHO; ACTIVATION; BINDING; PHOSPHORYLATION; IDENTIFICATION; SUPERFAMILY	Several guanine nucleotide exchange factors for the Rho family of GTPases that induce activation by exchanging GDP for GTP have been identified. One of these is the tumor invasion gene product Tiam1, which acts on Rad. In this study, we demonstrate that platelet-derived growth factor (PDGF) and lysophosphatidic acid induce the translocation of Tiam1 to the membrane fraction of NIH 3T3 fibroblasts in a time-dependent manner. Previously, we have shown that Tiam1 is phosphorylated by protein kinase C (PKC) and calcium/calmodulin kinase II (CaMK II) after stimulation with agonists, Here we show, by pretreatment of cells with kinase inhibitors, that CaMK II, but not PKC, is involved in the membrane translocation of Tiaml, Addition of the calcium ionophore ionomycin alone induced the translocation of Tiaml, However, the cell-permeable diacylglycerol oleoylacetylglycerol was without effect and did not enhance the effect of ionomycin, These data further indicated a role for CaMK II and not PKC, Inhibition of phosphoinositide S-kinase by wortmannin had little effect on the translocation of Tiaml, The role of phosphorylation was further studied by comparing the phosphorylation pattern of Tiaml in the membranes versus whole cell Tiaml, PDGF-induced phosphorylation of membrane-associated Tiaml occurred more rapidly than that of the total Tiaml pool, and CaMK II, but not PKC, played a significant role in this process, Furthermore, by using the pal-binding domain of PAK-3, we show that PDGF, but not lysophosphatidic acid, activates Rad in vice and that this activation involves CaMK II and PKC, but not 3-phosphoinositides. Our results indicate that Tiaml is translocated to and phosphorylated at membranes after agonist stimulation and that CaMK II, but not PKC, is involved in this process. Also, these kinases are involved in the activation of Rac in vivo.	Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University	Exton, JH (corresponding author), Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, 221 Kirkland Hall, Nashville, TN 37232 USA.							Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Fleming IN, 1998, FEBS LETT, V429, P229, DOI 10.1016/S0014-5793(98)00566-3; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; Flynn P, 1998, J BIOL CHEM, V273, P2698, DOI 10.1074/jbc.273.5.2698; Fujisawa K, 1998, J BIOL CHEM, V273, P18943, DOI 10.1074/jbc.273.30.18943; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Heldin CH, 1997, FEBS LETT, V410, P17, DOI 10.1016/S0014-5793(97)00318-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; LANGLOIS WJ, 1994, ENDOCRINOLOGY, V135, P2412, DOI 10.1210/en.135.6.2412; LEE HC, 1993, J BIOL CHEM, V268, P293; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Michaely PA, 1999, J BIOL CHEM, V274, P21430, DOI 10.1074/jbc.274.30.21430; Michiels F, 1999, BIOCHEM SOC SYMP, V65, P125; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; OVERBECK AF, 1995, MOL REPROD DEV, V42, P468, DOI 10.1002/mrd.1080420415; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Yeo EJ, 1997, BBA-MOL CELL RES, V1356, P308, DOI 10.1016/S0167-4889(97)00006-2	40	72	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9742	9748		10.1074/jbc.275.13.9742	http://dx.doi.org/10.1074/jbc.275.13.9742			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734127	hybrid			2022-12-27	WOS:000086206500091
J	Burgess, JK; Hotchkiss, KA; Suter, C; Dudman, NPB; Szollosi, J; Chesterman, CN; Chong, BH; Hogg, PJ				Burgess, JK; Hotchkiss, KA; Suter, C; Dudman, NPB; Szollosi, J; Chesterman, CN; Chong, BH; Hogg, PJ			Physical proximity and functional association of glycoprotein 1b alpha and protein-disulfide isomerase on the platelet plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; VONWILLEBRAND-FACTOR; PROTEINDISULFIDE ISOMERASE; MULTIFUNCTIONAL PROTEIN; PROLYL 4-HYDROXYLASE; GLUTATHIONE; IB; ANTIBODIES; BINDING; COMPLEX	Platelet function is influenced by the platelet thiol-disulfide balance. Platelet activation resulted in 440% increase in surface protein thiol groups. Two proteins that presented free thiol(s) on the activated platelet surface were protein-disulfide isomerase (PDI) and glycoprotein 1b alpha (GP1b alpha), PDI contains two active site dithiols/disulfides. The active sites of 26% of the PDI on resting platelets was in the dithiol form, compared with 81% in the dithiol form on activated platelets. Similarly, GP1b alpha presented one or more free thiols on the activated platelet surface but not on resting platelets. Anti-PDI antibodies increased the dissociation constant for binding of vWF to platelets by similar to 50% and PDI and GP1b alpha were sufficiently close on the platelet surface to allow fluorescence resonance energy transfer between chromophores attached to PDI and GP1b alpha. Incubation of resting platelets with anti-PDI antibodies followed by activation with thrombin enhanced labeling and binding of monoclonal antibodies to the N-terminal region of GP1b alpha on the activated platelet surface. These observations indicated that platelet activation triggered reduction of the active site disulfides of PDI and a conformational change in GP1b alpha that resulted in exposure of a free thiol(s).	Univ New S Wales, Sch Pathol, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia; Prince Wales Hosp, Dept Haematol, Sydney, NSW 2052, Australia; St Vincents Hosp, Garvan Inst Med Res, Dept Mol & Cellular Oncol, Darlinghurst, NSW 2010, Australia; Prince Henry Hosp, Dept Cardiovasc Med, Little Bay, NSW 2036, Australia; Univ Debrecen, Dept Biophys & Cell Biol, H-4012 Debrecen, Hungary	University of New South Wales Sydney; Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of Debrecen	Hogg, PJ (corresponding author), Univ New S Wales, Sch Pathol, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia.	p.hogg@unsw.edu.au	Chong, Beng/AAE-2617-2019; Chong, Beng/AAM-9010-2021; Burgess, Janette K/A-3597-2010; Burgess, Janette/M-7117-2019	Hogg, Philip/0000-0001-6486-2863; Burgess, Janette/0000-0001-9868-9966				AKAGI S, 1988, J HISTOCHEM CYTOCHEM, V36, P1069, DOI 10.1177/36.8.3292644; BERNDT MC, 1988, BIOCHEMISTRY-US, V27, P633, DOI 10.1021/bi00402a021; Berndt MC, 1998, BLOOD, V92, p703A; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BOSIA A, 1983, THROMB RES, V30, P137, DOI 10.1016/0049-3848(83)90236-0; BOSIA A, 1985, THROMB RES, V37, P423, DOI 10.1016/0049-3848(85)90071-4; BULLEID NJ, 1993, ADV PROTEIN CHEM, V44, P125, DOI 10.1016/S0065-3233(08)60566-5; BURCH PT, 1994, TRANSFUSION, V34, P421, DOI 10.1046/j.1537-2995.1994.34594249055.x; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; CHEN K, 1995, BRIT J HAEMATOL, V90, P425, DOI 10.1111/j.1365-2141.1995.tb05169.x; Couet J, 1996, BIOCHEMISTRY-US, V35, P14800, DOI 10.1021/bi961359w; Dudman NPB, 1996, CLIN CHEM, V42, P2028; ESSEX DW, 1995, BLOOD, V86, P2168, DOI 10.1182/blood.V86.6.2168.bloodjournal8662168; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GINSBERG MH, 1995, THROMB HAEMOSTASIS, V74, P352; HAWKINS HC, 1991, BIOCHEM J, V275, P335, DOI 10.1042/bj2750335; HILL TD, 1989, THROMB RES, V53, P457, DOI 10.1016/0049-3848(89)90200-4; Hotchkiss KA, 1996, BIOCHEMISTRY-US, V35, P9761, DOI 10.1021/bi9603938; Hotchkiss KA, 1998, BBA-PROTEIN STRUCT M, V1388, P478, DOI 10.1016/S0167-4838(98)00211-8; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; INGALLS HM, 1986, P NATL ACAD SCI USA, V83, P4779, DOI 10.1073/pnas.83.13.4779; JIANG XM, 1996, J BIOL CHEM, V35, P9761; KAETZEL CS, 1987, BIOCHEM J, V241, P39, DOI 10.1042/bj2410039; Kenny D, 1998, BLOOD, V92, P175, DOI 10.1182/blood.V92.1.175.413a36_175_183; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; KOKSCH M, 1995, J IMMUNOL METHODS, V187, P53, DOI 10.1016/0022-1759(95)00166-8; KRONING H, 1994, SCAND J IMMUNOL, V39, P346, DOI 10.1111/j.1365-3083.1994.tb03384.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; Lawrence DA, 1996, J LEUKOCYTE BIOL, V60, P611, DOI 10.1002/jlb.60.5.611; Lopez J A, 1997, Curr Opin Hematol, V4, P323; MANDEL R, 1993, P NATL ACAD SCI USA, V90, P4112, DOI 10.1073/pnas.90.9.4112; MANSOOR MA, 1992, ANAL BIOCHEM, V200, P218, DOI 10.1016/0003-2697(92)90456-H; MATSUDA S, 1979, THROMB HAEMOSTASIS, V42, P1324; MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OSTERMANN G, 1982, ACTA HAEMATOL-BASEL, V68, P278, DOI 10.1159/000206993; OWEN W G, 1973, Thrombosis Research, V3, P705, DOI 10.1016/0049-3848(73)90017-0; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; RAO ASMK, 1993, P NATL ACAD SCI USA, V90, P2950, DOI 10.1073/pnas.90.7.2950; ROFFMAN E, 1986, BIOCHEM BIOPH RES CO, V136, P80, DOI 10.1016/0006-291X(86)90879-X; RUGGERI ZM, 1980, J CLIN INVEST, V65, P1318, DOI 10.1172/JCI109795; RYSER HJP, 1994, P NATL ACAD SCI USA, V91, P4559, DOI 10.1073/pnas.91.10.4559; RYSER HJP, 1991, J BIOL CHEM, V266, P18439; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; Sullam PM, 1998, J BIOL CHEM, V273, P5331, DOI 10.1074/jbc.273.9.5331; Szollosi J, 1998, CYTOMETRY, V34, P159; Tager M, 1997, EXP HEMATOL, V25, P601; TERADA K, 1995, J BIOL CHEM, V270, P20410, DOI 10.1074/jbc.270.35.20410; THOMAS G, 1986, THROMB RES, V44, P859, DOI 10.1016/0049-3848(86)90031-9; TITANI K, 1987, P NATL ACAD SCI USA, V84, P5610, DOI 10.1073/pnas.84.16.5610; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; Wolvetang EJ, 1996, CELL GROWTH DIFFER, V7, P1315; WOODS VL, 1986, J BIOL CHEM, V261, P5242; YAMADA K, 1985, THROMB RES, V38, P61, DOI 10.1016/0049-3848(85)90007-6	56	116	121	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9758	9766		10.1074/jbc.275.13.9758	http://dx.doi.org/10.1074/jbc.275.13.9758			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734129	hybrid			2022-12-27	WOS:000086206500093
J	Gu, XJ; Lawrence, R; Krieger, M				Gu, XJ; Lawrence, R; Krieger, M			Dissociation of the high density lipoprotein and low density lipoprotein binding activities of murine scavenger receptor class B type I (mSR-BI) using retrovirus library-based activity dissection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED ENDOCYTOSIS; SR-BI; LIPID TRANSFER; HOST-DEFENSE; CELL MUTANTS; PLASMA HDL; MEMBRANE; CD36; LDL; IDENTIFICATION	The murine class B, type I scavenger receptor (mSRBI) is a receptor for both high density lipoprotein (HDL) and low density lipoprotein (LDL) and mediates selective, rather than endocytic, uptake of lipoprotein lipid. We have developed a "retrovirus library-based activity dissection" method to generate mSR-BI mutants in which some, but not all, of the activities of this multifunctional protein have been disrupted. This method employs three techniques: 1) efficient in vitro cDNA mutagenesis there error-prone PCR was used), 2) efficient retroviral delivery and high expression of single mutant cDNAs into individual cells, and 3) isolation of infected cells expressing the desired mutant phenotype using high sensitivity positive/negative screening by two-color fluorescence-activated cell sorting. A set of mutants, all having arginine substitutions at two common sites (positions 402 or 401 and position 418), were isolated and characterized. Mutation at either site alone did not generate as strong a mutant phenotype (loss of DiI uptake from DiI-HDL) as did the double mutations. "Activity-dissected" double mutants were as effective as wild-type mSR-BI in functioning as LDL receptors, mediating high affinity LDL binding and uptake of metabolically active cholesterol from LDL, but they lost most of their corresponding HDL receptor activity. Thus, these mutants provide support for the proposal that the interaction of SR-BI with HDL differs from that with LDL. Examination of the in vivo function of such mutants may provide insights into the differential roles of the LDL and HDL receptor activities of SR-BI in normal lipoprotein metabolism and in SR-BI's ability to protect against atherosclerosis.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Krieger, M (corresponding author), MIT, Dept Biol, Rm 68-483, Cambridge, MA 02139 USA.	krieger@mit.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484, R01HL052212] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52212, HL41484] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; Arai T, 1999, J BIOL CHEM, V274, P2366, DOI 10.1074/jbc.274.4.2366; ASSMANN G, 1995, METABOLIC MOL BASES, P2053; Berglund L, 1996, BBA-GENE STRUCT EXPR, V1309, P63, DOI 10.1016/S0167-4781(96)00143-1; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CALVO D, 1993, J BIOL CHEM, V268, P18929; Calvo D, 1997, ARTERIOSCL THROM VAS, V17, P2341, DOI 10.1161/01.ATV.17.11.2341; Chase MB, 1998, CIRCULATION, V98, P202; Chatterton JE, 1999, P NATL ACAD SCI USA, V96, P915, DOI 10.1073/pnas.96.3.915; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; Greaves DR, 1998, CURR OPIN LIPIDOL, V9, P425, DOI 10.1097/00041433-199810000-00006; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; KIMELMAN D, 1986, MOL CELL BIOL, V6, P1487, DOI 10.1128/MCB.6.5.1487; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Kozarsky KF, 2000, ARTERIOSCL THROM VAS, V20, P721, DOI 10.1161/01.ATV.20.3.721; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; Krieger M, 1997, CURR OPIN LIPIDOL, V8, P275, DOI 10.1097/00041433-199710000-00006; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Lange Y, 1999, J LIPID RES, V40, P2264; LEITERSDORF E, 1984, BIOCHIM BIOPHYS ACTA, V796, P72, DOI 10.1016/0005-2760(84)90240-6; Leung DW, 1989, TECHNIQUE, V1, P11; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHOUTEN D, 1990, ARTERIOSCLEROSIS, V10, P1127, DOI 10.1161/01.ATV.10.6.1127; Stangl H, 1999, J BIOL CHEM, V274, P32692, DOI 10.1074/jbc.274.46.32692; Stangl H, 1998, J BIOL CHEM, V273, P31002, DOI 10.1074/jbc.273.47.31002; Swarnakar S, 1999, J BIOL CHEM, V274, P29733, DOI 10.1074/jbc.274.42.29733; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Ueda Y, 1999, J BIOL CHEM, V274, P7165, DOI 10.1074/jbc.274.11.7165; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; ZANNIS VI, 1993, ADV HUM GENET, V21, P145	47	84	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9120	9130		10.1074/jbc.275.13.9120	http://dx.doi.org/10.1074/jbc.275.13.9120			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734045	hybrid			2022-12-27	WOS:000086206500009
J	Lee, KB; Ptasienski, JA; Pals-Rylaarsdam, R; Gurevich, VV; Hosey, MM				Lee, KB; Ptasienski, JA; Pals-Rylaarsdam, R; Gurevich, VV; Hosey, MM			Arrestin binding to the M-2 muscarinic acetylcholine receptor is precluded by an inhibitory element in the third intracellular loop of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; VISUAL ARRESTIN; PHOSPHORYLATED RHODOPSIN; BETA-ARRESTIN; PHOTORECEPTOR-MEMBRANES; CHOLINERGIC RECEPTORS; 48-KDA PROTEIN; INTERNALIZATION; DESENSITIZATION; TRANSDUCTION	Desensitization of G protein-coupled receptors (GPCRs) involves the binding of members of the family of arrestins to the receptors, In the model system involving the visual GPCR rhodopsin, activation and phosphorylation of rhodopsin is thought to convert arrestin from a low to high affinity binding state. Phosphorylation of the M-2 muscarinic acetylcholine receptor (mAChR) has been shown to be required for binding of arrestins 2 and 3 in vitro and for arrestin-enhanced internalization in intact cells (Pals-Rylaarsdam, R., and Hosey, M. M. (1997) J. Biol. Chem. 272, 14152-14158), For the M, mAChR, arrestin binding requires phosphorylation at multiple serine and threonine residues at amino acids 307-311 in the third intracellular (i3) loop. Here, we have investigated the molecular basis for the requirement of receptor phosphorylation for arrestin binding. Constructs of arrestin 2 that can bind to other GPCRs in a phosphorylation independent manner were unable to interact with a mutant M, mAChR in which the Ser/Thr residues at 307-311 were mutated to alanines. However, although phosphorylation-deficient mutants of the M, mAChR that lacked 50-157 amino acids from the i3 loop were unable to undergo agonist-dependent internalization when expressed alone in tsA201 cells, co-expression of arrestin 2 or 3 restored agonist-dependent internalization. Furthermore, a deletion of only 15 amino acids (amino acids 304-319) was sufficient to allow for phosphorylation-independent arrestin-receptor interaction. These results indicate that phosphorylation at residues 307-311 does not appear to be required to activate arrestin into a high affinity binding state. Instead, phosphorylation at residues 307-311 appears to facilitate the removal of an inhibitory constraint that precludes receptor-arrestin association in the absence of receptor phosphorylation.	Northwestern Univ, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; Northwestern Univ, Inst Neurosci, Chicago, IL 60611 USA; Sun Hlth Res Inst, Ralph & Muriel Roberts Lab Vis Sci, Sun City, AZ 85732 USA	Northwestern University; Northwestern University; Banner Research; Banner Health; Banner Sun Health Research Institute	Hosey, MM (corresponding author), Northwestern Univ, Dept Mol Pharmacol & Biol Chem, 303 E Chicago Ave,S215, Chicago, IL 60611 USA.	mhosey@nwu.edu	Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NEI NIH HHS [EY 11500] Funding Source: Medline; NHLBI NIH HHS [HL 50121] Funding Source: Medline; NIGMS NIH HHS [T32GM08061] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050121] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008061] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Bunemann M, 1999, ANNU REV PHYSIOL, V61, P169, DOI 10.1146/annurev.physiol.61.1.169; CRAFT CM, 1994, J BIOL CHEM, V269, P4613; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389; KUNKEL MT, 1993, EMBO J, V12, P3809, DOI 10.1002/j.1460-2075.1993.tb06059.x; Lee KB, 1998, J BIOL CHEM, V273, P12967, DOI 10.1074/jbc.273.21.12967; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; McDowell JH, 1999, BIOCHEMISTRY-US, V38, P6119, DOI 10.1021/bi990175p; Molday RS, 1998, INVEST OPHTH VIS SCI, V39, P2493; Mukherjee S, 1999, J BIOL CHEM, V274, P12984, DOI 10.1074/jbc.274.19.12984; Mukherjee S, 1999, P NATL ACAD SCI USA, V96, P493, DOI 10.1073/pnas.96.2.493; Mundell SJ, 1999, BIOCHEMISTRY-US, V38, P8723, DOI 10.1021/bi990361v; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P15334; PALCZEWSKI K, 1992, NEURON, V8, P117, DOI 10.1016/0896-6273(92)90113-R; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451; WILDEN U, 1986, FEBS LETT, V207, P292, DOI 10.1016/0014-5793(86)81507-1; YAMAKI K, 1987, BIOCHEM BIOPH RES CO, V142, P904, DOI 10.1016/0006-291X(87)91499-9	33	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9284	9289		10.1074/jbc.275.13.9284	http://dx.doi.org/10.1074/jbc.275.13.9284			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734068	hybrid			2022-12-27	WOS:000086206500032
J	Wu, L; Davies, SL; North, PS; Goulaouic, H; Riou, JF; Turley, H; Gatter, KC; Hickson, ID				Wu, L; Davies, SL; North, PS; Goulaouic, H; Riou, JF; Turley, H; Gatter, KC; Hickson, ID			The Bloom's syndrome gene product interacts with topoisomerase III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WERNER-SYNDROME PROTEIN; DNA HELICASE; SACCHAROMYCES-CEREVISIAE; SGS1; HOMOLOG; CELLS; EXONUCLEASE; CLONING; RECQ; TOP3	Bloom's syndrome is a rare genetic disorder associated with loss of genomic integrity and a large increase in the incidence of many types of cancer at an early age. The Bloom's syndrome gene product, BLM, belongs to the RecQ family of DNA helicases, which also includes the human Werner's and Rothmund-Thomson syndrome gene products and the Sgs1 protein of Saccharomyces cerevisiae. This family shows strong evolutionary conservation of protein structure and function. Previous studies have shown that Sgs1p interacts both physically and genetically with topoisomerase III. Here, we have investigated whether this interaction has been conserved in human cells. We show that BLM and hTOPO III alpha, one of two human topoisomerase III homologues, co-localize in the nucleus of human cells and can be co-immunoprecipitated from human cell extracts. More over, the purified BLM and hTOPO III alpha proteins are able to bind specifically to each other in vitro indicating that the interaction is direct. We have mapped two independent domains on BLM that are important for mediating the interaction with hTOPO III alpha. Furthermore, through characterizing a genetic interaction between BLM and TOP3 in S. cerevisiae, we have identified a functional role for the hTOPO III alpha interaction domains in BLM.	Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund Labs, Oxford OX3 9DS, England; Rhone Poulenc Rorer, Ctr Rech Vitry Alfortville, F-94403 Vitry Sur Seine, France; Univ Oxford, John Radcliffe Hosp, Dept Cellular Sci, Oxford OX3 9DU, England	Cancer Research UK; University of Oxford; Sanofi-Aventis; Sanofi France; University of Oxford	Hickson, ID (corresponding author), Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund Labs, Oxford OX3 9DS, England.	hickson@icrf.icnet.uk	Hickson, Ian/AAJ-7548-2020	riou, jean-francois/0000-0002-0055-6506; Hickson, Ian/0000-0002-0583-566X				Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; Chakraverty RK, 1999, BIOESSAYS, V21, P286; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Gangloff S, 1999, EMBO J, V18, P1701, DOI 10.1093/emboj/18.6.1701; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Goodwin A, 1999, NUCLEIC ACIDS RES, V27, P4050, DOI 10.1093/nar/27.20.4050; Goulaouic H, 1999, NUCLEIC ACIDS RES, V27, P2443, DOI 10.1093/nar/27.12.2443; Gray MD, 1998, EXP CELL RES, V242, P487, DOI 10.1006/excr.1998.4124; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Hanai R, 1996, P NATL ACAD SCI USA, V93, P3653, DOI 10.1073/pnas.93.8.3653; Harlow E, 1988, ANTIBODIES LAB MANUA, P139; Harmon FG, 1999, MOL CELL, V3, P611, DOI 10.1016/S1097-2765(00)80354-8; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Karow JK, 1999, CURR BIOL, V9, P597, DOI 10.1016/S0960-9822(99)80264-4; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kawasaki K, 1997, GENOME RES, V7, P250, DOI 10.1101/gr.7.3.250; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Li W, 1998, P NATL ACAD SCI USA, V95, P1010, DOI 10.1073/pnas.95.3.1010; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Neff NF, 1999, MOL BIOL CELL, V10, P665, DOI 10.1091/mbc.10.3.665; Ng SW, 1999, NUCLEIC ACIDS RES, V27, P993, DOI 10.1093/nar/27.4.993; SALK D, 1981, CYTOGENET CELL GENET, V30, P108, DOI 10.1159/000131597; Seki T, 1998, J BIOL CHEM, V273, P28553, DOI 10.1074/jbc.273.44.28553; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; VENNOS EM, 1995, DERMATOL CLIN, V13, P143, DOI 10.1016/S0733-8635(18)30117-7; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; Wu L, 1999, CURR BIOL, V9, pR518, DOI 10.1016/S0960-9822(99)80325-X; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	40	269	272	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9636	9644		10.1074/jbc.275.13.9636	http://dx.doi.org/10.1074/jbc.275.13.9636			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734115	hybrid			2022-12-27	WOS:000086206500079
J	Fong, CL; Lentz, A; Mayfield, SP				Fong, CL; Lentz, A; Mayfield, SP			Disulfide bond formation between RNA binding domains is used to regulate mRNA binding activity of the chloroplast poly(A)-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSBA MESSENGER-RNA; CHLAMYDOMONAS-REINHARDTII; CRYSTAL-STRUCTURE; GENE-EXPRESSION; TRANSLATION; ISOMERASE; REQUIRES; REGION	Binding of the chloroplast poly(A)-binding protein, RB47, to the psbA mRNA is regulated in response to light and is required for translation of this mRNA in chloroplasts, The RNA binding activity of RB47 can be modulated in vitro by oxidation and reduction. Site-directed mutations to individual cysteine residues in each of the four RNA binding domains of RB47 showed that changing single cysteines to serines in domains 2 or 3 reduced, but did not eliminate, the ability of RB47 to be redox-regulated. Simultaneously changing cysteines to serines in both domains 2 and 3 resulted in the production of RB47 protein that was insensitive to redox regulation but retained the ability to bind the psbA mRNA at high affinity. The poly(A)-binding protein from Saccharomyces cerevisiae lacks cysteine residues in RNA binding domains 2 and 3, and this poly(A)-binding protein lacks the ability to be regulated by oxidation or reduction. These data show that disulfide bond formation between RNA binding domains in a poly(A)-binding protein can be used to regulate the ability of this protein to bind mRNA and suggest that redox regulation of RNA binding activity may be used to regulate translation in organisms whose poly(A)-binding proteins contain these critical cysteine residues.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Mayfield, SP (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NIGMS NIH HHS [GM54659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bruick RK, 1998, J CELL BIOL, V143, P1145, DOI 10.1083/jcb.143.5.1145; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; DANON A, 1991, EMBO J, V10, P3993, DOI 10.1002/j.1460-2075.1991.tb04974.x; DANON A, 1994, SCIENCE, V266, P1717, DOI 10.1126/science.7992056; Deardorff JA, 1997, J MOL BIOL, V269, P67, DOI 10.1006/jmbi.1997.1013; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Eibl C, 1999, PLANT J, V19, P333, DOI 10.1046/j.1365-313X.1999.00543.x; FREEDMAN RB, 1988, BIOCHEM SOC T, V16, P96, DOI 10.1042/bst0160096; Kim JM, 1997, SCIENCE, V278, P1954, DOI 10.1126/science.278.5345.1954; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; MAYFIELD SP, 1994, J CELL BIOL, V127, P1537, DOI 10.1083/jcb.127.6.1537; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NIETFELD W, 1990, EMBO J, V9, P3699, DOI 10.1002/j.1460-2075.1990.tb07582.x; Rochaix JD, 1996, PLANT MOL BIOL, V32, P327, DOI 10.1007/BF00039389; Siomi H, 1997, CURR OPIN GENET DEV, V7, P345, DOI 10.1016/S0959-437X(97)80148-7; Xu RM, 1997, STRUCTURE, V5, P559, DOI 10.1016/S0969-2126(97)00211-6; Yohn CB, 1998, J CELL BIOL, V142, P435, DOI 10.1083/jcb.142.2.435; Yohn CB, 1998, P NATL ACAD SCI USA, V95, P2238, DOI 10.1073/pnas.95.5.2238	18	28	31	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8275	8278		10.1074/jbc.275.12.8275	http://dx.doi.org/10.1074/jbc.275.12.8275			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722654	hybrid			2022-12-27	WOS:000086507700004
J	Grullich, C; Sullards, MC; Fuks, Z; Merrill, AH; Kolesnick, R				Grullich, C; Sullards, MC; Fuks, Z; Merrill, AH; Kolesnick, R			CD95(Fas/APO-1) signals ceramide generation independent of the effector stage of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; ACID SPHINGOMYELINASE; CASPASE-3 ACTIVATION; CD95 FAS/APO-1; CYTOCHROME-C; CANCER-CELLS; INHIBITION; STRESS; FADD; REQUIREMENT	Although numerous studies document caspase-independent ceramide generation preceding apoptosis upon environmental stress, the molecular ordering of ceramide generation during cytokine-induced apoptosis remains uncertain. Here, we show that CD95-induced ceramide elevation occurs during the initiation phase of apoptosis. We titrated down the amount of FADD transfected into HeLa and 293T cells until it was insufficient for apoptosis, although cycloheximide (CHX) still triggered the effector phase. Even in the absence of CIM, ceramide levels increased rapidly, peaking at 2.7 +/- 0.2-fold of control 8 h post-transfection. Dominant negative FADD failed to confer ceramide generation or CHX-mediated apoptosis, Ceramide generation induced by FADD was initiator caspase-dependent, being blocked by crmA. Limited pro-caspase 8 overexpression also increased ceramide levels 2.7 +/- 0.2-fold, yet failed, without CIM, to initiate apoptosis, Expression of membrane-targeted oligomerized CD-8 caspase 8 induced apoptosis without GEM, yet elevated ceramide only to a level equivalent to limited pro-caspase 8 transfection. Ceramide elevations mere detected concurrently by diacyl-glycerol kinase and electrospray tandem mass spectrometry. These investigations provide evidence that ceramide generation is initiator caspase-dependent and occurs prior to commitment to the effector phase of apoptosis, definitively ordering ceramide as proximal in CD95 signaling.	Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA; Emory Univ, Dept Biochem, Atlanta, GA 30322 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Emory University	Kolesnick, R (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, 1275 York Ave, New York, NY 10021 USA.			Merrill, Alfred/0000-0002-6673-968X; Grullich, Carsten/0000-0002-2783-8220	NCI NIH HHS [CA42385, CA52462] Funding Source: Medline; NIGMS NIH HHS [GM46368] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046368] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boesen-de Cock JGR, 1999, J BIOL CHEM, V274, P14255, DOI 10.1074/jbc.274.20.14255; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Bose R, 1998, J BIOL CHEM, V273, P28852, DOI 10.1074/jbc.273.44.28852; Chen LJ, 1998, MOL IMMUNOL, V35, P195, DOI 10.1016/S0161-5890(98)00044-3; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Gill JS, 1998, CELL DEATH DIFFER, V5, P876, DOI 10.1038/sj.cdd.4400410; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hartfield PJ, 1997, FEBS LETT, V401, P148, DOI 10.1016/S0014-5793(96)01460-3; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P374, DOI 10.1016/S0968-0004(98)01289-4; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huwiler A, 1999, J BIOL CHEM, V274, P7190, DOI 10.1074/jbc.274.11.7190; JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014-5793(94)01428-4; Karasavvas N, 1999, CELL DEATH DIFFER, V6, P115, DOI 10.1038/sj.cdd.4400482; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Laethem RM, 1998, BLOOD, V91, P4350, DOI 10.1182/blood.V91.11.4350.411k27_4350_4360; Lavie Y, 1997, J BIOL CHEM, V272, P1682, DOI 10.1074/jbc.272.3.1682; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140; Lucci A, 1998, ANTICANCER RES, V18, P475; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Moley KH, 1998, NAT MED, V4, P1421, DOI 10.1038/4013; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; Payne SG, 1999, J CELL PHYSIOL, V180, P263, DOI 10.1002/(SICI)1097-4652(199908)180:2<263::AID-JCP14>3.0.CO;2-H; Plo I, 1999, NEUROREPORT, V10, P2373, DOI 10.1097/00001756-199908020-00028; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; Spinedi A, 1999, CELL DEATH DIFFER, V6, P618, DOI 10.1038/sj.cdd.4400533; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Suzuki A, 1997, EXP CELL RES, V233, P41, DOI 10.1006/excr.1997.3498; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Watts JD, 1999, CELL DEATH DIFFER, V6, P105, DOI 10.1038/sj.cdd.4400472; Watts JD, 1997, P NATL ACAD SCI USA, V94, P7292, DOI 10.1073/pnas.94.14.7292; Wiegmann K, 1999, J BIOL CHEM, V274, P5267, DOI 10.1074/jbc.274.9.5267; Xu J, 1998, J BIOL CHEM, V273, P16521, DOI 10.1074/jbc.273.26.16521; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	53	80	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8650	8656		10.1074/jbc.275.12.8650	http://dx.doi.org/10.1074/jbc.275.12.8650			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722705	hybrid			2022-12-27	WOS:000086507700055
J	Jo, MJ; Stolz, DB; Esplen, JE; Dorko, K; Michalopoulos, GK; Strom, SC				Jo, MJ; Stolz, DB; Esplen, JE; Dorko, K; Michalopoulos, GK; Strom, SC			Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR SCATTER FACTOR; FACTOR-ALPHA; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; EPITHELIAL-CELLS; TRANSGENIC MICE; CARCINOMA-CELLS; EGF RECEPTOR; LIVER-REGENERATION; HEPATOPOIETIN-A	In rat liver epithelial cells constitutively expressing transforming growth factor alpha (TGF alpha), c-Met is constitutively phosphorylated in the absence of its ligand, hepatocyte growth factor. We proposed that TGF alpha and the autocrine activation of its receptor, epidermal growth factor receptor (EGFR), Leads to phosphorylation and activation of c-Met. We found that there is constitutive c-Met phosphorylation in human hepatoma cell lines and the human epidermoid carcinoma cell line, A431 which express TGF alpha, but not in normal human hepatocytes, Constitutive c-Met phosphorylation in A431, HepG2, AKN-1, and HuH6 cells was inhibited by neutralizing antibodies against TGFa and/or EGFR, Exposure to exogenous TGF alpha or EGF increased the phosphorylation of c-Met in the human epidermoid carcinoma cell line, A431, The increase of c-Met phosphorylation by TGF alpha in A431 cells was inhibited by neutralizing antibodies against TGF alpha and/or EGFR and by the EGFR-specific inhibitor tyrphostin AG1478, These results indicate that constitutive c-Met phosphorylation, and the increase of c-Met phosphorylation by TGF alpha or EGF, in tumor cell lines is the result of the activation via EGFR, We found that c-Met in tumor cells co-immunoprecipitates with EGFR regardless of the existence of their ligands in tumor cells, but not in normal human hepatocytes. We conclude that c-Met associates with EGFR in tumor cells, and this association facilitates the phosphorylation of c-Met in the absence of hepatocyte growth factor. This cross-talk between c-Met and EGFR may have significant implications for altered growth control in tumorigenesis.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Physiol & Cell Biol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Strom, SC (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, 200 Lothrop St,BST S-450, Pittsburgh, PA 15261 USA.		Strom, Stephen C/A-6501-2008		NATIONAL CANCER INSTITUTE [R29CA076541, R01CA035373, R01CA076541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [N01DK092310] Funding Source: NIH RePORTER; NCI NIH HHS [CA35373, CA76541] Funding Source: Medline; NIDDK NIH HHS [N01-DK-92310] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BROCCACCIO C, 1998, NATURE, V391, P285; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DERYNCK R, 1987, CANCER RES, V47, P707; Fausto N, 1991, Prog Growth Factor Res, V3, P219, DOI 10.1016/0955-2235(91)90008-R; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; Habib AA, 1998, J BIOL CHEM, V273, P6885, DOI 10.1074/jbc.273.12.6885; HU ZY, 1993, AM J PATHOL, V142, P1823; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; KIM HH, 1994, J BIOL CHEM, V269, P24747; KUMAR R, 1990, J BIOL CHEM, V265, P4578; LEE GH, 1992, CANCER RES, V52, P5162; LINDROOS PM, 1991, HEPATOLOGY, V13, P743, DOI 10.1002/hep.1840130422; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; Nussler AK, 1999, IN VITRO CELL DEV-AN, V35, P190, DOI 10.1007/s11626-999-0026-4; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; Presnell SC, 1997, MOL CARCINOGEN, V18, P244, DOI 10.1002/(SICI)1098-2744(199704)18:4<244::AID-MC8>3.3.CO;2-Y; Presnell SC, 1998, HEPATOLOGY, V28, P1253, DOI 10.1002/hep.510280513; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Shima N, 1998, J CELL PHYSIOL, V177, P130, DOI 10.1002/(SICI)1097-4652(199810)177:1<130::AID-JCP14>3.3.CO;2-O; Skouteris GG, 1996, BIOCHEM BIOPH RES CO, V218, P229, DOI 10.1006/bbrc.1996.0040; SMITH JJ, 1987, P NATL ACAD SCI USA, V84, P7567, DOI 10.1073/pnas.84.21.7567; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550; Stolz DB, 1997, J CELL PHYSIOL, V170, P57; Strom SC, 1997, TRANSPLANT P, V29, P2103, DOI 10.1016/S0041-1345(97)00252-2; TSAO MS, 1993, CELL GROWTH DIFFER, V4, P571; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; Velloso LA, 1996, P NATL ACAD SCI USA, V93, P12490, DOI 10.1073/pnas.93.22.12490; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; YEH YC, 1987, CANCER RES, V47, P896; ZARNEGAR R, 1989, CANCER RES, V49, P3314	42	265	278	4	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8806	8811		10.1074/jbc.275.12.8806	http://dx.doi.org/10.1074/jbc.275.12.8806			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722725	hybrid			2022-12-27	WOS:000086507700075
J	Tock, MR; Walsh, AP; Carroll, G; McDowall, KJ				Tock, MR; Walsh, AP; Carroll, G; McDowall, KJ			The CafA protein required for the 5 '-maturation of 16 S rRNA is a 5 '-end-dependent ribonuclease that has context-dependent broad sequence specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDORIBONUCLEASE RNASE-E; ESCHERICHIA-COLI-CELLS; MESSENGER-RNA; RIBOSOMAL-RNA; IN-VITRO; ANTISENSE RNAI; CLEAVAGE SITES; GENE-PRODUCT; STEM-LOOPS; DEGRADATION	The CafA protein, which was initially described as having a role in either Escherichia coli cell division or chromosomal segregation, has recently been shown to be required for the maturation of the 5'-end of 16 S rRNA The sequence of CafA is similar to that of the N-terminal ribonucleolytic half of RNase E, an essential E, coli enzyme that has a central role in the processing of rRNA and the decay of mRNA and RNAI, the antisense regulator of ColE1-type plasmids, We show here that a highly purified preparation of CafA is sufficient in vitro for RNA cutting, We detected CafA cleavage of RNAI and a structured region from the 5'-untranslated region of ompA. mRNA within segments cleavable by RNaseE, but not CafA cleavage of 9 S RNA at its "a" RNase E site. The latter is consistent with the finding that the generation of 5 S rRNA from its 9 S precursor can be blocked by inactivation of RNase E in cells that are wild type for CafA Interestingly, however, a decanucleotide corresponding in sequence to the a site of 9 S RNA was cut efficiently indicating that cleavage by CafA is regulated by the context of sites within structured RNAs, Consistent with this notion is our finding that although 23 S rRNA is stable in vivo, a segment from this RNA is cut efficient by CafA at multiple sites in vitro, We also show that, like RNase E cleavage, the efficiency of cleavage by CafA is dependent on the presence of a monophosphate group on the 5'-end of the RNA. This finding raises the possibility that the context dependence of cleavage by CafA may be due at least in part to the separation of a cleavable sequence from the 5'-end of an RNA, Comparison of the sites surrounding points of CafA cleavage suggests that this enzyme has broad sequence specificity. Together with the knowledge that CafA can cut RNAI and ompA mRNA in vitro within segments whose cleavage in vivo initiates the decay of these RNAs, this finding suggests that CafA may contribute at some point during the decay of many RNAs in E. coli.	Univ Leeds, Fac Biol Sci, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	McDowall, KJ (corresponding author), Univ Leeds, Fac Biol Sci, LC Miall Bldg, Leeds LS2 9JT, W Yorkshire, England.	k.j.mcdowall@leeds.ac.uk	McDowall, Kenneth/GYA-5735-2022	McDowall, Kenneth/0000-0003-2528-2190				APIRION D, 1978, J BIOL CHEM, V253, P1738; BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; BROSIUS J, 1980, P NATL ACAD SCI-BIOL, V77, P201, DOI 10.1073/pnas.77.1.201; Cam K, 1996, NUCLEIC ACIDS RES, V24, P3065, DOI 10.1093/nar/24.15.3065; Carpousis AJ, 1999, TRENDS GENET, V15, P24, DOI 10.1016/S0168-9525(98)01627-8; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; Coburn GA, 1999, PROG NUCLEIC ACID RE, V62, P55; COHEN SN, 1995, CELL, V80, P829, DOI 10.1016/0092-8674(95)90284-8; Cohen SN, 1997, MOL MICROBIOL, V23, P1099, DOI 10.1111/j.1365-2958.1997.tb02593.x; CORMACK RS, 1992, J MOL BIOL, V228, P1078, DOI 10.1016/0022-2836(92)90316-C; CORMACK RS, 1993, P NATL ACAD SCI USA, V90, P9006, DOI 10.1073/pnas.90.19.9006; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; EMORY SA, 1992, GENE DEV, V6, P135, DOI 10.1101/gad.6.1.135; FAUBLADIER M, 1990, J MOL BIOL, V212, P461, DOI 10.1016/0022-2836(90)90325-G; GEGENHEIMER P, 1977, J BIOL CHEM, V252, P3064; GEORGELLIS D, 1992, J BACTERIOL, V174, P5382, DOI 10.1128/JB.174.16.5382-5390.1992; GHORA BK, 1978, CELL, V15, P1055, DOI 10.1016/0092-8674(78)90289-1; Huang HJ, 1998, NATURE, V391, P99, DOI 10.1038/34219; Jansen RP, 1999, FASEB J, V13, P455, DOI 10.1096/fasebj.13.3.455; Kaberdin VR, 1996, J BIOL CHEM, V271, P13103, DOI 10.1074/jbc.271.22.13103; Kaberdin VR, 1998, P NATL ACAD SCI USA, V95, P11637, DOI 10.1073/pnas.95.20.11637; Li ZW, 1999, EMBO J, V18, P2878, DOI 10.1093/emboj/18.10.2878; LINCHAO S, 1994, J BIOL CHEM, V269, P10797; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; LUNDBERG U, 1990, EMBO J, V9, P2731, DOI 10.1002/j.1460-2075.1990.tb07460.x; LUNDBERG U, 1995, MOL MICROBIOL, V17, P595; MACKIE GA, 1992, J BIOL CHEM, V267, P1054; MACKIE GA, 1993, J MOL BIOL, V234, P998, DOI 10.1006/jmbi.1993.1654; Mackie GA, 1997, J BIOL CHEM, V272, P609; Mackie GA, 1998, NATURE, V395, P720, DOI 10.1038/27246; MANLEY JL, 1995, P NATL ACAD SCI USA, V92, P1800, DOI 10.1073/pnas.92.6.1800; MCDOWALL KJ, 1993, J BACTERIOL, V175, P4245, DOI 10.1128/JB.175.13.4245-4249.1993; MCDOWALL KJ, 1995, NATURE, V374, P287, DOI 10.1038/374287a0; MCDOWALL KJ, 1994, J BIOL CHEM, V269, P10790; McDowall KJ, 1996, J MOL BIOL, V255, P349, DOI 10.1006/jmbi.1996.0027; MELEFORS O, 1993, CONTROL MESSENGER RN, P53; MUDD EA, 1993, MOL MICROBIOL, V9, P557, DOI 10.1111/j.1365-2958.1993.tb01716.x; MURRAY J, 1996, THESIS U LEEDS LEEDS; Naureckiene S, 1996, MOL MICROBIOL, V21, P55, DOI 10.1046/j.1365-2958.1996.6121101.x; OKADA Y, 1995, J CELL BIOCHEM, P114; OKADA Y, 1994, J BACTERIOL, V176, P917, DOI 10.1128/jb.176.3.917-922.1994; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; Sambrook J., 2002, MOL CLONING LAB MANU; Sarkar N, 1996, MICROBIOL-UK, V142, P3125, DOI 10.1099/13500872-142-11-3125; Sarkar N, 1997, ANNU REV BIOCHEM, V66, P173, DOI 10.1146/annurev.biochem.66.1.173; SOHLBERG B, 1993, P NATL ACAD SCI USA, V90, P277, DOI 10.1073/pnas.90.1.277; TARASEVICIENE L, 1995, J BIOL CHEM, V270, P26391, DOI 10.1074/jbc.270.44.26391; Vanzo NF, 1998, GENE DEV, V12, P2770, DOI 10.1101/gad.12.17.2770; WACHI M, 1987, J BACTERIOL, V169, P4935, DOI 10.1128/jb.169.11.4935-4940.1987; Wachi M, 1999, BIOCHEM BIOPH RES CO, V259, P483, DOI 10.1006/bbrc.1999.0806; WACHI M, 1991, GENE, V106, P135; Wachi M, 1997, MOL GEN GENET, V253, P515, DOI 10.1007/s004380050352; WACHI M, 1989, J BACTERIOL, V171, P6511, DOI 10.1128/jb.171.12.6511-6516.1989; WACHI M, 1993, J CELL BIOCH SE, V17, P307; WALSH AP, 1995, THESIS U LEEDS LEEDS; XU FF, 1995, NATURE, V374, P180, DOI 10.1038/374180a0; XU FF, 1993, P NATL ACAD SCI USA, V90, P6756, DOI 10.1073/pnas.90.14.6756	57	129	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8726	8732		10.1074/jbc.275.12.8726	http://dx.doi.org/10.1074/jbc.275.12.8726			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722715	hybrid			2022-12-27	WOS:000086507700065
J	Xue, LZ; Murray, JH; Tolkovsky, AM				Xue, LZ; Murray, JH; Tolkovsky, AM			The Ras/phosphatidylinositol 3-kinase and Ras/ERK pathways function as independent survival modules each of which inhibits a distinct apoptotic signaling pathway in sympathetic neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; KILLS POSTMITOTIC NEURONS; PROTEIN-KINASE; CYTOSINE-ARABINOSIDE; PHOSPHATIDYLINOSITOL 3-KINASE; GANGLION NEURONS; MAP KINASES; RAS P21; AKT; ACTIVATION	Ras promotes robust survival of many cell systems by activating the phosphatidylinositol 3-kinase (PIS-kinase)/Akt pathway, but little is understood about the survival functions of the Ras/ERK pathway. We have used three different effector-loop mutant forms of Ras, each of which activates a single downstream effector pathway, to dissect their individual contributions to survival of nerve growth factor (NGF)-dependent sympathetic neurons. The PI3-kinase pathway-selective protein Ras(Val-12)Y40C was as powerful as oncogenic Ras-(Val-12) in preventing apoptosis induced by NGF deprivation but conferred no protection against apoptosis induced by cytosine arabinoside. Identical results were obtained with transfected Akt. In contrast, the ERK pathway-selective protein Ras(Val-12)T35S had no protective effects on NGF-deprived neurons but was almost as strongly protective as Ras(Val-12) against cytosine arabinoside-induced apoptosis, The protective effects of Ras(Val-12)T35S against cytosine arabinoside were completely abolished by the ERK pathway inhibitor PD98059. Ras(Val-12)E37G, an activator of RalGDS, had no survival effect on either death pathway, similar to RasS17N, the full survival antagonist. Thus, Ras provides two independent survival pathways each of which inhibits a distinct apoptotic mechanism. Our study presents one of the few clear-cut cases where only the Ras/ERK, but not the Ras/PI3K/Akt pathway, plays a dominant survival signaling role.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	University of Cambridge	Tolkovsky, AM (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1QW, England.	amt@mole.bio.cam.ac.uk						Adderley SR, 1999, J BIOL CHEM, V274, P5038, DOI 10.1074/jbc.274.8.5038; Anderson CNG, 1999, J NEUROSCI, V19, P664; Borasio GD, 1996, NEUROSCIENCE, V73, P1121, DOI 10.1016/0306-4522(96)00084-X; BORASIO GD, 1989, NEURON, V2, P1087; BORASIO GD, 1993, J CELL BIOL, V121, P665, DOI 10.1083/jcb.121.3.665; Carson JP, 1999, CANCER RES, V59, P1449; Creedon DJ, 1996, J BIOL CHEM, V271, P20713, DOI 10.1074/jbc.271.34.20713; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Enokido Y, 1996, NEUROSCI LETT, V203, P1, DOI 10.1016/0304-3940(95)12247-8; Goi T, 1999, MOL CELL BIOL, V19, P1731; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Klesse LJ, 1998, J NEUROSCI, V18, P10420; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Markus A, 1997, DEV BIOL, V191, P306, DOI 10.1006/dbio.1997.8771; MARTIN DP, 1990, J NEUROSCI, V10, P184; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; NOBES CD, 1995, EUR J NEUROSCI, V7, P344, DOI 10.1111/j.1460-9568.1995.tb01069.x; Nobes CD, 1996, NEUROSCIENCE, V70, P1067, DOI 10.1016/0306-4522(95)00420-3; NOBES CD, 1991, J AUTONOM NERV SYST, V33, P213, DOI 10.1016/0165-1838(91)90218-R; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SanzRodriguez C, 1997, NEUROSCI LETT, V223, P141, DOI 10.1016/S0304-3940(97)13412-7; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; TOMKINS CE, 1994, J CELL SCI, V107, P1499; Virdee K, 1996, J NEUROCHEM, V67, P1801; VIRDEE K, 1995, EUR J NEUROSCI, V7, P2159, DOI 10.1111/j.1460-9568.1995.tb00637.x; Virdee K, 1999, BRAIN RES, V837, P127, DOI 10.1016/S0006-8993(99)01643-1; Vogelbaum MA, 1998, J NEUROSCI, V18, P8928; WALLACE TL, 1989, J NEUROSCI, V9, P115; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780	40	132	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8817	8824		10.1074/jbc.275.12.8817	http://dx.doi.org/10.1074/jbc.275.12.8817			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722727	hybrid			2022-12-27	WOS:000086507700077
J	Jenkins, M; Keir, M; McCune, JM				Jenkins, M; Keir, M; McCune, JM			A membrane-bound Fas decoy receptor expressed by human thymocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; HUMAN T-CELLS; MEDIATED APOPTOSIS; LYMPHOPROLIFERATIVE SYNDROME; DIFFERENTIAL EXPRESSION; LIGAND INTERACTION; PERIPHERAL-BLOOD; IMMUNE-RESPONSES; ACTIVATION; CD95	Human thymocytes at several stages of maturation express Fas, yet resist apoptosis induction through its ligation, A proximal step in apoptotic signaling through Fas is implicated in this resistance, as these cells undergo normal levels of apoptosis induction after exposure to tumor necrosis factor-cu, We studied the Fas receptors expressed in human thymocytes to search for mechanisms of receptor-mediated inhibition of Fas signaling in these cells. We describe here a unique, membrane-bound form of Fas receptor that contained a complete extracellular domain of Fas but that lacked a death domain due to alternative splicing of exon 7. This Fas decoy receptor (FDR) was shown to have nearly wild-type ability to bind native human Fas ligand and was expressed predominantly at the plasma membrane. Unlike soluble forms of Fas receptor, FDR dominantly inhibited apoptosis induction by Fas ligand in transfected human embryonic kidney cells. Titration ofFDR in Fas-expressing cells suggests that FDR may operate through the formation of mixed receptor complexes. FDR also dominantly inhibited Fas-induced apoptosis in Jurkat T cells. In mixing experiments with wild-type Fas, FDR was capable of inhibiting death signaling at molar ratios less than 0.5, and this relative level of FDR: wild type message was observed in at least some thymocytes tested. The data suggest that Fas signal pathways in primary human cells may be regulated by expression of a membrane-bound decoy receptor, analogous to the regulation of tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis by decoy receptors.	Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	McCune, JM (corresponding author), Univ Calif San Francisco, Gladstone Inst Virol & Immunol, POB 419100, San Francisco, CA 94141 USA.	mmccune@gladstone.ucsf.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001425, R01AI040312] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI40312, K08-AI01425] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Cascino I, 1996, J IMMUNOL, V156, P13; CASCINO I, 1995, J IMMUNOL, V154, P2706; CHENG JH, 1995, J IMMUNOL, V154, P1239; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GORCZYCA W, 1993, CANCER RES, V53, P1945; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; HAYASHI Y, 1993, NATURE, V366, P687, DOI 10.1038/366687a0; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; HUGHES DPM, 1995, J EXP MED, V182, P1395, DOI 10.1084/jem.182.5.1395; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jenkins M, 1999, J IMMUNOL, V163, P1195; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; LIU CD, 1995, BIOCHEM J, V310, P957, DOI 10.1042/bj3100957; LYNCH DH, 1995, IMMUNOL TODAY, V16, P569, DOI 10.1016/0167-5699(95)80079-4; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; McLeod JD, 1998, J IMMUNOL, V160, P2072; MIYAWAKI T, 1992, J IMMUNOL, V149, P3753; NAGAFUJI K, 1995, BLOOD, V86, P883, DOI 10.1182/blood.V86.3.883.bloodjournal863883; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Noble A, 1998, J IMMUNOL, V160, P559; Papoff G, 1996, J IMMUNOL, V156, P4622; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Robinson D, 1997, SIGHT SOUND, V7, P5; Schneider P, 1997, J BIOL CHEM, V272, P18827, DOI 10.1074/jbc.272.30.18827; Vaishnaw AK, 1999, J CLIN INVEST, V103, P355, DOI 10.1172/JCI5121; Wallach D, 1998, CURR OPIN IMMUNOL, V10, P279, DOI 10.1016/S0952-7915(98)80166-0; Yang Y, 1998, INT IMMUNOL, V10, P175, DOI 10.1093/intimm/10.2.175	35	29	29	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7988	7993		10.1074/jbc.275.11.7988	http://dx.doi.org/10.1074/jbc.275.11.7988			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713117	hybrid			2022-12-27	WOS:000085913300077
J	Lai, JF; Kao, SC; Jiang, ST; Tang, MJ; Chan, PC; Chen, HC				Lai, JF; Kao, SC; Jiang, ST; Tang, MJ; Chan, PC; Chen, HC			Involvement of focal adhesion kinase in hepatocyte growth factor-induced scatter of Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL-CELLS; C-MET; INTEGRIN EXPRESSION; PROTEIN-KINASE; GRB2 BINDING; MDCK CELLS; 3T3 CELLS; V-SRC	Focal adhesion kinase (FAK) has been implicated to play a critical role in integrin-mediated control of cell behavior. However, it is unclear whether FAK also participates in the regulation of growth factor-elicited. cellular functions. In this study, we have demonstrated that although overexpression of FAK in Madin-Dardy canine kidney cells did not alter their growth property or ability to form tubules within collagen gel upon hepatocyte growth factor (HGF) stimulation, it apparently enhanced HGF-induced cell scattering This enhancement was largely because of an increase in the third phase (i.e. cell migration) of cell scattering rather than the first two phases (i.e. cell spreading and cell-cell dissociation). Conversely, the expression of FAR-related nonkinase significantly (similar to 60%) inhibited HGF-induced cell migration. Moreover, we have found that the effect of FAK on promoting HGF-induced cell motility was greatly dependent on cell-matrix interactions. We showed that HGF treatment selectively increased the expression of integrins alpha(2) and, to a lesser extent, alpha(3) in Madin-Dardy canine kidney cells and that a monoclonal antibody against integrin alpha(2) efficiently blocked HGF-enhanced cell migration on collagen. In our efforts to determine the mechanism. by which FAK promotes HGF-induced cell migration, we found that FAK mutants deficient in phosphatidylinositol 3-kinase or p130(Cas) binding failed to promote HGF-induced cell migration, Interestingly, cells expressing a FAK mutant defective in Grb2 binding exhibited a rate of migration similar to 50% lower than that of cells expressing wild type FAK in response to HGF stimulation, Taken together, our results suggest a link between HGF-increased integrin expression, FAK activation, and enhanced cell motility and implicate a role for FAK in the facilitation of growth factor-induced cell motility.	Natl Chung Hsing Univ, Dept Zool, Taichung 40227, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 70101, Taiwan	National Chung Hsing University; National Cheng Kung University	Chen, HC (corresponding author), Natl Chung Hsing Univ, Dept Zool, Taichung 40227, Taiwan.			Tang, Ming-Jer/0000-0002-0883-4363; Jiang, Si-Tse/0000-0002-5145-258X				Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Chan PC, 1999, J BIOL CHEM, V274, P26901, DOI 10.1074/jbc.274.38.26901; CHEN FA, 1991, J EXP MED, V173, P1111, DOI 10.1084/jem.173.5.1111; Chen HC, 1998, J BIOL CHEM, V273, P25777, DOI 10.1074/jbc.273.40.25777; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GIORDANO S, 1989, ONCOGENE, V4, P1983; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HATAI M, 1994, FEBS LETT, V350, P113, DOI 10.1016/0014-5793(94)00745-4; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilic D, 1998, J CELL BIOL, V143, P547; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; RANKIN S, 1994, J BIOL CHEM, V269, P704; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; SAELMAN EUM, 1995, J CELL SCI, V108, P3531; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHOENENBERGER CA, 1994, J CELL SCI, V107, P527; STOKER M, 1989, J CELL PHYSIOL, V139, P565, DOI 10.1002/jcp.1041390316; Tang MJ, 1998, AM J PHYSIOL-CELL PH, V275, pC921, DOI 10.1152/ajpcell.1998.275.4.C921; Vuori K, 1996, MOL CELL BIOL, V16, P2606; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; ZAMEGAR R, 1995, J CELL BIOL, V129, P1177; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	58	70	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7474	7480		10.1074/jbc.275.11.7474	http://dx.doi.org/10.1074/jbc.275.11.7474			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713050	hybrid			2022-12-27	WOS:000085913300010
J	Beuvink, I; Hess, D; Flotow, H; Hofsteenge, J; Groner, B; Hynes, NE				Beuvink, I; Hess, D; Flotow, H; Hofsteenge, J; Groner, B; Hynes, NE			Stat5a serine phosphorylation - Serine 779 is constitutively phosphorylated in the mammary gland, and serine 725 phosphorylation influences prolactin-stimulated in vitro DNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CASEIN GENE; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; ACTIVATION; TRANSCRIPTION; RECEPTOR; KINASE; INDUCTION; PROTEINS; EXPRESSION	The activity of transcription factors of the Stat family is controlled by phosphorylation of a conserved, carboxyl-terminal tyrosine residue. Tyrosine phosphorylation is essential for Stat dimerization, nuclear translocation, DNA binding, and transcriptional activation. Phosphorylation of Stats on specific serine residues has also been described. We have previously shown that in HC11 mammary epithelial cells Stat5a is phosphorylated on Tyr(694) in a prolactin-sensitive manner, whereas serine phosphorylation is constitutive (Wartmann, M., Cella, N., Hofer, P., Groner, B., Xiuwen, L., Hennighausen, L., and Hynes, N. E. (1996) J. Biol. Chem. 271, 31863-31868). By using mass spectrometry and site-directed mutagenesis, we have now identified Ser(779), located in a unique Stat5a SP motif, as the site of serine phosphorylation. By using phospho-Ser(779)-specific antiserum, we have determined that Ser(779) is constitutively phosphorylated in mammary glands taken from different developmental stages. Stat5a isolated from spleen, heart, brain, and lung was also found to be phosphorylated on Ser(779) Ser(725) in Stat5a has also been identified as a phosphorylation site (Yamashita, H., Xu, J., Erwin, R. A., Farrar, W. L., Kirken, R. A., and Rui, H. (1998) J. Biol. Chem. 273, 30218-30224). Here we show that mutagenesis of Ser(725) Ser(779), or a combination of Ser(725/779) to an Ala had no effect on prolactin-induced transcriptional activation of a beta-casein reporter construct, However, following prolactin induction the Ser(725) mutant displayed sustained DNA binding activity compared with that of wild type Stat5a. The results suggest that Ser(725) phosphorylation has an impact on signal duration.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Roche Discovery Welwyn, Welwyn Garden City AL7 3AY, Herts, England; Georg Speyer Haus, D-60596 Frankfurt, Germany	Friedrich Miescher Institute for Biomedical Research; Roche Holding	Hynes, NE (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.							BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Briscoe J, 1996, TRENDS CELL BIOL, V6, P336, DOI 10.1016/0962-8924(96)10028-3; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Harlow E., 1988, ANTIBODIES LAB MANUA; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; Krieg J, 1998, MOL BIOL CELL, V9, P301, DOI 10.1091/mbc.9.2.301; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; McWhinney CD, 1998, J MOL CELL CARDIOL, V30, P751, DOI 10.1006/jmcc.1998.0639; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; RICHARDSON CD, 1985, J VIROL, V54, P186, DOI 10.1128/JVI.54.1.186-193.1985; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHMITT-NEY M, 1992, MOL ENDOCRINOL, V6, P1988, DOI 10.1210/me.6.12.1988; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Wartmann M, 1996, J BIOL CHEM, V271, P31863, DOI 10.1074/jbc.271.50.31863; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	31	68	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10247	10255		10.1074/jbc.275.14.10247	http://dx.doi.org/10.1074/jbc.275.14.10247			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744710	hybrid			2022-12-27	WOS:000086345600051
J	Huang, TS; Wang, HY; Lee, SY; Johansson, MW; Soderhall, K; Cerenius, L				Huang, TS; Wang, HY; Lee, SY; Johansson, MW; Soderhall, K; Cerenius, L			A cell adhesion protein from the crayfish Pacifastacus leniusculus, a serine proteinase homologue similar to Drosophila masquerade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORSESHOE-CRAB HEMOCYTES; PROPHENOLOXIDASE-ACTIVATING SYSTEM; FRESH-WATER CRAYFISH; BLOOD-CELLS; PROCLOTTING ENZYME; MOLECULAR-BASIS; CDNA CLONING; SEQUENCE; PURIFICATION; COAGULATION	A cDNA encoding a protein resembling masquerade, a serine proteinase homologue expressed during embryogenesis, larval, and pupal development in Drosophila melanogaster, mas identified in hemocytes of the adult freshwater crayfish, Pacifastacus leniusculus. The crayfish protein is similar to Drosophila masquerade in the following aspects: (a) overall sequence of the serine proteinase domain, such as the position of three putative disulfide bridges, glycine in the place of the catalytic serine residue, and the presence of a substrate-lining pocket typical for trypsins; (b) the presence of several copies of a disulfide-knotted motif in the putative propeptide, This masquerade-like protein is cleaved into a 27-kDa fragment, which could be detected by immunoblot analysis using an affinity-purified antibody against a synthetic peptide in the C-terminal domain of the protein. The 27-kDa protein could be immunoaffinity-purified from hemocyte lysate supernatant and exhibited cell adhesion activity in vitro, indicating that the C-terminal domain of the crayfish masquerade-like protein mediates cell adhesion.	Uppsala Univ, Evolut Biol Ctr, Dept Comparat Physiol, SE-75236 Uppsala, Sweden	Uppsala University	Cerenius, L (corresponding author), Uppsala Univ, Evolut Biol Ctr, Dept Comparat Physiol, Norbyvagen 18A, SE-75236 Uppsala, Sweden.			Lee, So Young/0000-0003-3130-785X; Johansson, Mats/0000-0001-5699-978X				ALMEIDA RP, 1991, BIOCHEM BIOPH RES CO, V177, P688, DOI 10.1016/0006-291X(91)91843-2; APPEL LF, 1993, P NATL ACAD SCI USA, V90, P4937, DOI 10.1073/pnas.90.11.4937; ASPAN A, 1990, INSECT BIOCHEM, V20, P709, DOI 10.1016/0020-1790(90)90085-9; BARTHALAY Y, 1990, EMBO J, V9, P3603, DOI 10.1002/j.1460-2075.1990.tb07571.x; Cai TQ, 1996, J EXP MED, V184, P1213, DOI 10.1084/jem.184.4.1213; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dimopoulos G, 1997, P NATL ACAD SCI USA, V94, P11508, DOI 10.1073/pnas.94.21.11508; ElGhmati SM, 1996, J IMMUNOL, V156, P2542; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GAY NJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P290, DOI 10.1016/0167-4781(92)90163-T; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Holmblad T, 1997, J EXP ZOOL, V277, P255, DOI 10.1002/(SICI)1097-010X(19970215)277:3<255::AID-JEZ6>3.0.CO;2-N; HORJUP P, 1985, FEBS LETT, V184, P333; JOHANSSON MW, 1995, BIOCHEM BIOPH RES CO, V216, P1079, DOI 10.1006/bbrc.1995.2731; Johansson MW, 1999, J CELL SCI, V112, P917; JOHANSSON MW, 1988, J CELL BIOL, V106, P1795, DOI 10.1083/jcb.106.5.1795; JOHANSSON MW, 1994, EUR J BIOCHEM, V223, P389, DOI 10.1111/j.1432-1033.1994.tb19005.x; Johansson MW, 1997, J CELL SCI, V110, P1133; Johansson S, 1997, FRONT BIOSCI, V2, P126; Kawabata S, 1996, FEBS LETT, V398, P146, DOI 10.1016/S0014-5793(96)01224-0; KUROSKY A, 1980, P NATL ACAD SCI-BIOL, V77, P3388, DOI 10.1073/pnas.77.6.3388; MURUGASUOEI B, 1995, GENE DEV, V9, P139, DOI 10.1101/gad.9.2.139; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; MUTA T, 1993, J BIOL CHEM, V268, P21384; MUTA T, 1990, J BIOL CHEM, V265, P22426; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; OLSON PF, 1990, EMBO J, V9, P1219, DOI 10.1002/j.1460-2075.1990.tb08229.x; SAITO T, 1995, J BIOCHEM-TOKYO, V117, P1131, DOI 10.1093/oxfordjournals.jbchem.a124818; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH C, 1994, GENETICS, V136, P1355; SMITH VJ, 1983, CELL TISSUE RES, V233, P295; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; TANGEMANN K, 1997, INTEGRIN LIGAND INTE, P85; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	37	85	91	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					9996	10001		10.1074/jbc.275.14.9996	http://dx.doi.org/10.1074/jbc.275.14.9996			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744675	hybrid			2022-12-27	WOS:000086345600016
J	Maingret, F; Patel, AJ; Lesage, F; Lazdunski, M; Honore, E				Maingret, F; Patel, AJ; Lesage, F; Lazdunski, M; Honore, E			Lysophospholipids open the two-pore domain mechano-gated K+ channels TREK-1 and TRAAK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANOSENSITIVE ION CHANNELS; ARACHIDONIC-ACID; FATTY-ACIDS; LIPID BILAYERS; FUNCTIONAL EXPRESSION; BIOLOGICAL-MEMBRANES; POTASSIUM CHANNELS; CELLS; CLONING; ACTIVATION	The two-pore (2P) domain K+ channels TREK-I and TRAAK are opened by membrane stretch as well as arachidonic acid (AA) (Patel, A. J., Honore, E., Maingret, F., Lesage, F., Fink, M., Duprat, F., and Lazdunski, M. (1998) EMBO J. 17, 4283-4290; Maingret, F., Patel, A. J., Lesage, F., Lazdunski, M., and Honore, E. (1999) J. Biol. Chem 274, 26691-26696; Maingret, F., Fosset, M., Lesage, F., Lazdunski, M., and Honore, E. (1999) J. Biol. Chem. 274, 1381-1387. me demonstrate that lysophospholipids (LPs) and platelet-activating factor also produce large specific and reversible activations of TREK-I and TRAAK. LPs activation is a function of the size of the polar head and length of the acyl chain but is independent of the charge of the molecule. Bath application of lysophosphatidylcholine (LPC) immediately opens TREK-1 and TRAAK in the cell-attached patch configuration. In excised patches, LPC activation is lost, whereas AA still produces maximal opening. The carboxyl-terminal region of TREK-I, but not the amino terminus and the extracellular loop M1P1, is critically required for LPC activation. LPC activation is indirect and may possibly involve a cytosolic factor, whereas AA directly interacts with either the channel proteins or the bilayer and mimics stretch. Opening of TREK-1 and TRAAK by fatty acids and LPs may be an important switch in the regulation of synaptic function and may also play a protective role during ischemia and inflammation.	CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Lazdunski, M (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, 660 Route Lucioles, F-06560 Valbonne, France.		Lesage, Florian/D-5097-2011; Lesage, Florian/P-9780-2019	Lesage, Florian/0000-0002-4406-7106; Lesage, Florian/0000-0002-4406-7106; HONORE, Eric/0000-0002-8007-0919				Andersen O S, 1999, Methods Enzymol, V294, P208; Bazan NG, 1996, J LIPID MEDIAT CELL, V14, P321, DOI 10.1016/0929-7855(96)00541-X; Bonventre JV, 1997, J LIPID MEDIAT CELL, V16, P199; Casado M, 1998, J PHYSIOL-LONDON, V513, P317, DOI 10.1111/j.1469-7793.1998.317bb.x; Chavez RA, 1999, J BIOL CHEM, V274, P7887, DOI 10.1074/jbc.274.12.7887; CHERNOMORDIK LV, 1987, BIOCHIM BIOPHYS ACTA, V906, P309, DOI 10.1016/0304-4157(87)90016-5; CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; Hamill OP, 1996, PHARMACOL REV, V48, P231; ISRAELACHVILI JN, 1977, BIOCHIM BIOPHYS ACTA, V470, P185, DOI 10.1016/0005-2736(77)90099-2; KIM D, 1992, J GEN PHYSIOL, V100, P1021, DOI 10.1085/jgp.100.6.1021; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; Kim D, 1998, CIRC RES, V82, P513, DOI 10.1161/01.RES.82.4.513; KIM DH, 1990, CIRC RES, V67, P1040, DOI 10.1161/01.RES.67.4.1040; KIM DH, 1995, J PHYSIOL-LONDON, V484, P643, DOI 10.1113/jphysiol.1995.sp020693; LAURITZEN I, 1994, BRAIN RES, V651, P353, DOI 10.1016/0006-8993(94)90719-6; Leonoudakis D, 1998, J NEUROSCI, V18, P868; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; LUNDBAEK JA, 1994, J GEN PHYSIOL, V104, P645, DOI 10.1085/jgp.104.4.645; Maingret F, 1999, J BIOL CHEM, V274, P26691, DOI 10.1074/jbc.274.38.26691; Maingret F, 1999, J BIOL CHEM, V274, P1381, DOI 10.1074/jbc.274.3.1381; MARKIN VS, 1991, BIOPHYS J, V60, P1120, DOI 10.1016/S0006-3495(91)82147-6; MARTINAC B, 1990, NATURE, V348, P261, DOI 10.1038/348261a0; MARTINAC B, 1992, THERMODYNAMICS CELL, V1, P327; ORDWAY RW, 1989, SCIENCE, V244, P1176, DOI 10.1126/science.2471269; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; PASCHER I, 1992, BIOCHIM BIOPHYS ACTA, V1113, P339, DOI 10.1016/0304-4157(92)90006-V; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; PETROU S, 1994, J GEN PHYSIOL, V103, P471, DOI 10.1085/jgp.103.3.471; Reyes R, 1998, J BIOL CHEM, V273, P30863, DOI 10.1074/jbc.273.47.30863; Salinas M, 1999, J BIOL CHEM, V274, P11751, DOI 10.1074/jbc.274.17.11751; SHEETZ MP, 1974, P NATL ACAD SCI USA, V71, P4457, DOI 10.1073/pnas.71.11.4457	35	274	289	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10128	10133		10.1074/jbc.275.14.10128	http://dx.doi.org/10.1074/jbc.275.14.10128			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744694	hybrid			2022-12-27	WOS:000086345600035
J	Stenberg, G; Dragani, B; Cocco, R; Mannervik, B; Aceto, A				Stenberg, G; Dragani, B; Cocco, R; Mannervik, B; Aceto, A			A conserved "hydrophobic staple motif" plays a crucial role in the refolding of human glutathione transferase P1-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-CAPPING BOX; S-TRANSFERASE; 3-DIMENSIONAL STRUCTURE; ALPHA-HELICES; PROTEINS; MECHANISM; IDENTIFICATION; ISOENZYMES; RESOLUTION; STABILITY	The specific (i, i+5) hydrophobic staple interaction involving a helix residue and a second residue located in the turn preceding the helix is a recurrent motif at the N terminus of alpha-helices, This motif is strictly conserved in the core of all soluble glutathione transferases (GSTs) as well as in other protein structures. Human GSTP1-1 variants mutated in amino acid Ile(149) and Tyr(154) Of the hydrophobic staple motif of the alpha 6-helix were analyzed, In particular, a double mutant cycle analysis has been performed to evaluate the role of the hydrophobic staple motif in the refolding process. The results show that this local interaction, by restricting the number of conformations of the alpha 6-helix relative to the al-helix, favors the formation of essential interdomain interactions and thereby accelerates the folding process, Thus, for the first time it is shown that the hydrophobic staple interaction has a role in the folding process of an intact protein. In P-i class GSTs, Tyr(154) appears to be of particular structural importance, since it interacts with conserved residues Leu(21), Asp(24), and Gln(25) of the adjacent alpha 1-helix which contributes to the active site. Human GSTP1-1 variants L21A and Y154F have also been analyzed in order to distinguish the role of interdomain interactions from that of the hydrophobic staple. The experimental results reported here suggest that the strict conservation of the hydrophobic staple motif reflects an evolutionary pressure for proteins to fold rapidly.	Univ Chieti, Dipartimento Sci Biomed, I-66100 Chieti, Italy; Univ Uppsala, Ctr Biomed, Dept Biochem, S-75123 Uppsala, Sweden	G d'Annunzio University of Chieti-Pescara; Uppsala University	Aceto, A (corresponding author), Univ Chieti, Dipartimento Sci Biomed, Via Vestini 31, I-66100 Chieti, Italy.							ACETO A, 1990, CARCINOGENESIS, V11, P2267, DOI 10.1093/carcin/11.12.2267; Aceto A, 1997, BIOCHEM J, V322, P229, DOI 10.1042/bj3220229; ACETO A, 1992, BIOCHEM J, V285, P241, DOI 10.1042/bj2850241; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; Dragani B, 1997, J BIOL CHEM, V272, P25518, DOI 10.1074/jbc.272.41.25518; Fersht AR, 1997, CURR OPIN STRUC BIOL, V7, P3, DOI 10.1016/S0959-440X(97)80002-4; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HOROVITZ A, 1990, J MOL BIOL, V214, P613, DOI 10.1016/0022-2836(90)90275-Q; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P112; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KOLM RH, 1995, PROTEIN EXPRES PURIF, V6, P265, DOI 10.1006/prep.1995.1034; KOONIN EV, 1994, PROTEIN SCI, V3, P2045, DOI 10.1002/pro.5560031117; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MUNOZ V, 1995, BIOCHEMISTRY-US, V34, P15301, DOI 10.1021/bi00046a039; MUNOZ V, 1995, NAT STRUCT BIOL, V2, P380, DOI 10.1038/nsb0595-380; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Ptitsyn OB, 1996, FASEB J, V10, P3, DOI 10.1096/fasebj.10.1.8566544; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; SEALE JW, 1994, PROTEIN SCI, V3, P1741, DOI 10.1002/pro.5560031014; Shakhnovich E, 1996, NATURE, V379, P96, DOI 10.1038/379096a0; Shakhnovich EI, 1997, CURR OPIN STRUC BIOL, V7, P29, DOI 10.1016/S0959-440X(97)80005-X; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; STACKHOUSE TM, 1988, BIOCHEMISTRY-US, V27, P824, DOI 10.1021/bi00402a050; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x	28	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	2000	275	14					10421	10428		10.1074/jbc.275.14.10421	http://dx.doi.org/10.1074/jbc.275.14.10421			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BT	10744731	hybrid			2022-12-27	WOS:000086345600072
J	Grimes, JA; Nielsen, SJ; Battaglioli, E; Miska, EA; Speh, JC; Berry, DL; Atouf, F; Holdener, BC; Mandel, G; Kouzarides, T				Grimes, JA; Nielsen, SJ; Battaglioli, E; Miska, EA; Speh, JC; Berry, DL; Atouf, F; Holdener, BC; Mandel, G; Kouzarides, T			The co-repressor mSin3A is a functional component of the REST-CoREST repressor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESTRICTIVE SILENCER FACTOR; SODIUM-CHANNEL GENE; TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE; TARGET GENES; IN-VIVO; N-COR; EXPRESSION; PROTEIN	The repressor REST/NRSF restricts expression of a large set of genes to neurons by suppressing their expression in non-neural tissues. We find that REST repression involves two distinct repressor proteins. One of these, CoREST, interacts with the COOH-terminal repressor domain of REST (Andres, M. E., Burger, C., Peral-Rubio, M. J., Battaglioli, E., Anderson, M. E., Grimes, J., Dallmanm J., Ballas, N., and Mandel, G. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 9873-9878). Here we show that the co-repressor mSin3A also interacts with REST. The REST-mSin3A association involves the NH2-terminal repressor domain of REST and the paired amphipathic helix 2 domain of mSin3A REST forms complexes with endogenous mSin3A in mammalian cells, and both mSin3A and CoREST interact with REST in intact mammalian cells. REST repression is blocked in yeast lacking Sin3 and rescued in its presence. In mammalian cells, repression by REST is reduced when binding to mSin3A is inhibited. In mouse embryos, the distribution of mSin3A and REST transcripts is largely coincident. The pattern of CoREST gene expression is more restricted, suggesting that mSin3A is required constitutively for REST repression, whereas CoREST is recruited for more specialized repressor functions.	SUNY Stony Brook, Howard Hughes Med Inst, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Neurobiol & Behav, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Cell Biol & Biochem, Stony Brook, NY 11794 USA; Univ Cambridge, Wellcome Canc Res Campaign Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QR, England	Howard Hughes Medical Institute; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Cambridge; University of Cambridge	Mandel, G (corresponding author), SUNY Stony Brook, Howard Hughes Med Inst, Stony Brook, NY 11794 USA.		battaglioli, elena/H-9350-2017	Kouzarides, Tony/0000-0002-8918-4162; Battaglioli, Elena/0000-0001-9168-7212; Miska, Eric/0000-0002-4450-576X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022518] Funding Source: NIH RePORTER; NINDS NIH HHS [NS22518] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; Chen ZF, 1998, NAT GENET, V20, P136, DOI 10.1038/2431; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HOCKFIELD S, 1993, MOL PROBES NERVOUS S, V1; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; Kadosh D, 1998, MOL CELL BIOL, V18, P5121, DOI 10.1128/MCB.18.9.5121; Kallunki P, 1997, J CELL BIOL, V138, P1343, DOI 10.1083/jcb.138.6.1343; Kasten MM, 1996, MOL CELL BIOL, V16, P4215; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; LAHERTY CD, 1997, MOL ENDOCRINOL, V11, P682; Lavender P, 1997, ONCOGENE, V14, P2721, DOI 10.1038/sj.onc.1201243; Leichter M, 1999, EUR J NEUROSCI, V11, P1937, DOI 10.1046/j.1460-9568.1999.00617.x; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; TapiaRamirez J, 1997, P NATL ACAD SCI USA, V94, P1177, DOI 10.1073/pnas.94.4.1177; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; WILKINSIN DG, 1992, IN SITU HYBRIDIZATIO; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500	25	188	196	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9461	9467		10.1074/jbc.275.13.9461	http://dx.doi.org/10.1074/jbc.275.13.9461			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734093	hybrid			2022-12-27	WOS:000086206500057
J	Hakimi, MA; Privat, I; Valay, JG; Lerbs-Mache, S				Hakimi, MA; Privat, I; Valay, JG; Lerbs-Mache, S			Evolutionary conservation of C-terminal domains of primary Sigma(70)-type transcription factors between plants and bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; SINAPIS-ALBA L; SIGMA-FACTORS; ARABIDOPSIS-THALIANA; POLYPEPTIDES; DNA; CHLOROPLASTS; INITIATION; SEQUENCE; SUBUNIT	Three different cDNAs coding for putative plant plastid sigma(70)-type transcription initiation factors have recently been cloned and sequenced from Arabidopsis thaliana, We have analyzed the evolutionary conservation of function(s) of the N-terminal and C-terminal halves of these three sigma factors by in in vitro transcription studies using heterologous transcription systems and by complementation assays using Escherichia coli thermosensitive rpoD mutants. Our results indicate differences and similarities of the three plant factors and their prokaryotic ancestors. The functions of the N-terminal parts of the plant sigma factors are considerably different from the function of the N-terminal part of the principal sigma(70) factor off. coli, On the other hand, the C-terminal parts have kept at least two characteristics when compared with their prokaryotic ancestors: 1) they can distinguish between different promoter structures, and 2) one of them is capable of fully complementing E. coli rpoD mutants, i,e. recognizing all essential E, coli promoters that are used by the E. coli principal sigma(70) factor. This shows for the first time in vivo a strong evolutionary conservation of cis- and trans-acting elements between the prokaryotic and the plant plastid transcriptional machinery.	Univ Grenoble 1, Lab Genet Mol Plantes Plastes & Differenciat Cell, F-38041 Grenoble, France; Univ Grenoble 1, CNRS, F-38041 Grenoble, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Lerbs-Mache, S (corresponding author), Univ Grenoble 1, Lab Genet Mol Plantes Plastes & Differenciat Cell, BP 53X, F-38041 Grenoble, France.	Silva.Lerbs-Mache@ujf-grenoble.fr	HAKIMI, Mohamed-ali/GYJ-0879-2022; HAKIMI, Mohamed-Ali/F-9806-2014; HAKIMI, Mohamed-ali/Q-6475-2019	HAKIMI, Mohamed-Ali/0000-0002-2547-8233; HAKIMI, Mohamed-ali/0000-0002-2547-8233				Bowers CW, 1999, EMBO J, V18, P709, DOI 10.1093/emboj/18.3.709; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; GRIBSKOV M, 1983, GENE, V26, P109, DOI 10.1016/0378-1119(83)90180-4; Gruber TM, 1997, J BACTERIOL, V179, P1734, DOI 10.1128/jb.179.5.1734-1747.1997; Hedtke B, 1997, SCIENCE, V277, P809, DOI 10.1126/science.277.5327.809; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; Hess WR, 1999, INT REV CYTOL, V190, P1, DOI 10.1016/S0074-7696(08)62145-2; HU J, 1991, NUCLEIC ACIDS RES, V19, P3431, DOI 10.1093/nar/19.12.3431; HU J, 1990, P NATL ACAD SCI USA, V87, P1531, DOI 10.1073/pnas.87.4.1531; IRATNI R, 1994, GENE DEV, V8, P2928, DOI 10.1101/gad.8.23.2928; ISAKSSON LA, 1977, MOL GEN GENET, V156, P233, DOI 10.1007/BF00267177; Isono K, 1997, P NATL ACAD SCI USA, V94, P14948, DOI 10.1073/pnas.94.26.14948; Johnson BD, 1997, J BIOL CHEM, V272, P31029, DOI 10.1074/jbc.272.49.31029; Kaneko T, 1996, DNA Res, V3, P185, DOI 10.1093/dnares/3.3.185; KANETTO M, 1999, J BACTERIOL, V40, P832; LERBS S, 1988, MOL GEN GENET, V211, P459, DOI 10.1007/BF00425701; LERBSMACHE S, 1993, P NATL ACAD SCI USA, V90, P5509, DOI 10.1073/pnas.90.12.5509; LIEBKE H, 1980, MOL GEN GENET, V177, P277, DOI 10.1007/BF00267439; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; Tan S, 1999, P NATL ACAD SCI USA, V96, P5316, DOI 10.1073/pnas.96.9.5316; Tanaka K, 1997, FEBS LETT, V413, P309, DOI 10.1016/S0014-5793(97)00906-X; TILLER K, 1991, EUR J BIOCHEM, V198, P93, DOI 10.1111/j.1432-1033.1991.tb15990.x; TILLER K, 1993, PLANT MOL BIOL, V21, P503, DOI 10.1007/BF00028807; Wilson C, 1997, J MOL BIOL, V267, P60, DOI 10.1006/jmbi.1997.0875	27	54	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9215	9221		10.1074/jbc.275.13.9215	http://dx.doi.org/10.1074/jbc.275.13.9215			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734058	hybrid			2022-12-27	WOS:000086206500022
J	Yang, D; Suzuki, S; Hao, LJ; Fujii, Y; Yamauchi, A; Yamamoto, M; Nakamura, M; Kumatori, A				Yang, D; Suzuki, S; Hao, LJ; Fujii, Y; Yamauchi, A; Yamamoto, M; Nakamura, M; Kumatori, A			Eosinophil-specific regulation of gp91(phox) gene expression by transcription factors GATA-1 and GATA-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT DISPLACEMENT PROTEIN; MAJOR BASIC-PROTEIN; CHRONIC GRANULOMATOUS-DISEASE; MYELOID-LEUKEMIA CELLS; CYTOCHROME B(558); BINDING PROTEIN; MEGAKARYOCYTIC DIFFERENTIATION; ERYTHROID-DIFFERENTIATION; PROMOTER; GP91-PHOX	The glycoprotein gp91(phox) is an essential component of the phagocyte NADPH oxidase and is expressed in eosinophils, neutrophils, monocytes, and B-lymphocytes, We previously suggested an eosinophil-specific mechanism of gp91(phox) gene expression. To elucidate the mechanism, we performed functional assays on deletion mutants of the gp91(phox) promoter in various types of gp91(phox)-expressing cells. A 10-base pair (bp) region from bp -105 to -96 of the promoter activated transcription of the gene in eosinophilic cells, but not in neutrophilic, monocytic, or B-lymphocytic cells, A 2-bp mutation introduced into the GATA site spanning bp -101 to -96 (-98GATA site) of the fragment abolished its activity. Gel shift assays using a GATA competitor and specific antibodies demonstrated that both GATA-1 and GATA-2 specifically bound to the -98GATA site with similar affinities. Individual transfection of GATA-1 and GATA-2 into Jurkat cells, which have neither endogenous GATA-1 nor GATA-2, activated the -105/+12 construct in a -98GATA site-dependent manner. Combined transfection of GATA-1 and GATA-2 activated the promoter less than transfection of GATA-1 alone. These results suggest that GATA-1 is an activator and that GATA-2 is a relative competitive inhibitor of GATA-1 in the expression of the gp91(phox) gene in human eosinophils.	Nagasaki Univ, Inst Trop Med, Dept Host Def Biochem, Nagasaki 8528523, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res, Tsukuba, Ibaraki 3058577, Japan	Nagasaki University; University of Tsukuba	Nakamura, M (corresponding author), Nagasaki Univ, Inst Trop Med, Dept Host Def Biochem, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.		Yamauchi, Akira/F-2202-2010; Yamamoto, Masayuki/A-4873-2010	Yamauchi, Akira/0000-0001-9205-6922; Yamamoto, Masayuki/0000-0002-9073-9436; Yang, Dan/0000-0002-1852-6858				Ariga Tadashi, 1994, European Journal of Haematology, V52, P99; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; Eklund EA, 1997, J BIOL CHEM, V272, P9344; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Eklund EA, 1996, J IMMUNOL, V157, P2418; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; FISCHKOFF SA, 1988, LEUKEMIA RES, V12, P679, DOI 10.1016/0145-2126(88)90103-8; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; GRUART V, 1992, BLOOD, V79, P2592; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; Hung HL, 1999, MOL CELL BIOL, V19, P3496; KOBAYASHI S, 1990, BLOOD, V75, P458; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; Kumatori A, 1998, GENOMICS, V53, P123, DOI 10.1006/geno.1998.5510; KURIBAYASHI F, 1995, BIOCHEM BIOPH RES CO, V209, P146, DOI 10.1006/bbrc.1995.1482; LI MS, 1995, BIOCHEM J, V305, P921, DOI 10.1042/bj3050921; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; Luo W, 1996, J BIOL CHEM, V271, P18203, DOI 10.1074/jbc.271.30.18203; Luo W, 1996, J BIOL CHEM, V271, P23445, DOI 10.1074/jbc.271.38.23445; McNagny KM, 1998, EMBO J, V17, P3669, DOI 10.1093/emboj/17.13.3669; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; NEWBURGER PE, 1991, J BIOL CHEM, V266, P16171; REDONDO JM, 1990, SCIENCE, V247, P1225, DOI 10.1126/science.2156339; Sadat MA, 1998, FEBS LETT, V436, P390; SEGAL AW, 1981, BIOCHEM J, V196, P363, DOI 10.1042/bj1960363; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; Suzuki S, 1998, P NATL ACAD SCI USA, V95, P6085, DOI 10.1073/pnas.95.11.6085; TAUBER AI, 1983, MEDICINE, V62, P286, DOI 10.1097/00005792-198309000-00003; TESLA U, 1993, J IMMUNOL, V150, P2418; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; VISVADER JE, 1992, EMBO J, V11, P4557, DOI 10.1002/j.1460-2075.1992.tb05557.x; WEISS MJ, 1995, EXP HEMATOL, V23, P99; Yamaguchi Y, 1998, BLOOD, V91, P3447, DOI 10.1182/blood.V91.9.3447.3447_3447_3458; YAZDANBAKHSH M, 1987, J IMMUNOL, V138, P3443; Yu LX, 1997, J BIOL CHEM, V272, P27288, DOI 10.1074/jbc.272.43.27288; ZON LI, 1993, BLOOD, V81, P3234	42	29	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 31	2000	275	13					9425	9432		10.1074/jbc.275.13.9425	http://dx.doi.org/10.1074/jbc.275.13.9425			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299PF	10734088	hybrid			2022-12-27	WOS:000086206500052
J	Bakalara, N; Santarelli, X; Davis, C; Baltz, T				Bakalara, N; Santarelli, X; Davis, C; Baltz, T			Purification, cloning, and characterization of an acidic ectoprotein phosphatase differentially expressed in the infectious bloodstream form of Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; BLOOD-STREAM FORMS; EFFECTOR FUNCTIONS; EXTRACELLULAR ATP; SURFACE; KINASES; PHOSPHORYLATION; LEISHMANIA; CRUZI; RHODESIENSE	We purified an ecto-phosphatase of 115 kDa (Try-AcP115) specifically expressed by bloodstream forms of Trypanosoma brucei, The corresponding gene coded for a 45-kDa protein potentially including a signal peptide, a membrane-spanning domain and an N-terminal domain containing 8 N-glycosylation sites. There was no significant sequence homology with other phosphatases, Antiserum to the Escherichia coli recombinant N-terminal domain, Petase7, recognized a protein of 55 kDa in Western blots after deglycosylation of the Try-AcP115 protein by N-glycosidase F. Immunofluorescence and trypsin treatment of living parasites showed that TryAcP115 was localized to the surface of the parasite and that its N-terminal domain was oriented extracellularly. The recombinant N-terminal domains, expressed in E. coli and Leishmania amazonensis, harbored phosphatase activity against Tyr(P)-Raytide, Ser(P)-neurogranin, and ATP, The enzymatic properties of native TryAcP115 and the recombinant proteins for the substrate Tgr(P)-Raytide were virtually identical and included: (i) K-m and V-max values of 15 nM and 200 pmol/min/mg, (ii) no requirement for divalent cations, and (iii) sensitivity to vanadate, sodium fluoride, and tartrate, but insensitivity to okadaic acid and tetramisole. Although the function of TryAcP115 remains unknown, a differentially expressed, unique ecto-phosphatase could regulate growth or influence parasite-host interactions and might provide a useful target for chemotherapy.	Univ Bordeaux 2, Mol Parasitol Lab, CNRS, UMR 5016, F-33076 Bordeaux, France; Univ Bordeaux 2, Ecole Super Technol & Biomol, F-33076 Bordeaux, France; Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA; Univ Calif San Diego, Ctr Genet Mol, San Diego, CA 92103 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; University of California System; University of California San Diego; University of California System; University of California San Diego	Bakalara, N (corresponding author), Univ Bordeaux 2, Mol Parasitol Lab, CNRS, UMR 5016, BP 12,146 Rue Leo Saignat, F-33076 Bordeaux, France.			SANTARELLI, Xavier/0000-0003-1530-4632				Apasov SG, 1996, J BIOL CHEM, V271, P25677, DOI 10.1074/jbc.271.41.25677; Bakalara N, 1995, EXP PARASITOL, V81, P302, DOI 10.1006/expr.1995.1121; Bakalara N, 1995, EUR J BIOCHEM, V234, P871, DOI 10.1111/j.1432-1033.1995.871_a.x; BALTZ T, 1985, EMBO J, V4, P1273, DOI 10.1002/j.1460-2075.1985.tb03772.x; BATES PF, 1983, GENE, V26, P137, DOI 10.1016/0378-1119(83)90183-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Briffeuil P, 1998, BIOINFORMATICS, V14, P357, DOI 10.1093/bioinformatics/14.4.357; CAMPBELL DA, 1989, NUCLEIC ACIDS RES, V17, P458, DOI 10.1093/nar/17.1.458; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; ELMOATASSIM C, 1992, BIOCHIM BIOPHYS ACTA, V1134, P31, DOI 10.1016/0167-4889(92)90025-7; Fernandes EC, 1997, Z NATURFORSCH C, V52, P351; FILIPPINI A, 1990, P NATL ACAD SCI USA, V87, P8267, DOI 10.1073/pnas.87.21.8267; FRIEDBERG I, 1995, J BIOL CHEM, V270, P20560, DOI 10.1074/jbc.270.35.20560; Furuya T, 1998, MOL BIOCHEM PARASIT, V92, P339, DOI 10.1016/S0166-6851(97)00246-6; HAMM B, 1990, MOL BIOCHEM PARASIT, V40, P13, DOI 10.1016/0166-6851(90)90075-W; HERMOSO T, 1991, EMBO J, V10, P4061, DOI 10.1002/j.1460-2075.1991.tb04982.x; HOLDER AA, 1981, MOL BIOCHEM PARASIT, V2, P135, DOI 10.1016/0166-6851(81)90095-5; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KELLY JM, 1992, NUCLEIC ACIDS RES, V20, P3963, DOI 10.1093/nar/20.15.3963; Kyshe-Andersen J, 1984, J BIOCHEM BIOPH METH, V10, P203; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; LESTER D, 1990, BIOCHIM BIOPHYS ACTA, V1025, P293; MABBOTT N, 1995, INFECT IMMUN, V63, P1563, DOI 10.1128/IAI.63.4.1563-1566.1995; MATTHEWS KR, 1994, J CELL BIOL, V125, P1147, DOI 10.1083/jcb.125.5.1147; MCLAUGHLIN J, 1986, MOL CELL BIOCHEM, V70, P177, DOI 10.1007/BF00229432; MeyerFernandes JR, 1997, ARCH BIOCHEM BIOPHYS, V341, P40, DOI 10.1006/abbi.1997.9933; MITSUI H, 1994, PLANT MOL BIOL, V25, P865, DOI 10.1007/BF00028881; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Nickel V, 1998, J BIOL CHEM, V273, P23668, DOI 10.1074/jbc.273.37.23668; NOTHWEHR SF, 1990, J BIOL CHEM, V265, P17202; OGATA S, 1994, J BIOL CHEM, V269, P5210; PAAS Y, 1995, ARCH BIOCHEM BIOPHYS, V316, P780, DOI 10.1006/abbi.1995.1104; Petitfrere E, 1996, BIOCHEM BIOPH RES CO, V220, P746, DOI 10.1006/bbrc.1996.0475; PLESNER L, 1995, INT REV CYTOL, V158, P141; Redegeld FA, 1997, BBA-BIOMEMBRANES, V1328, P151, DOI 10.1016/S0005-2736(97)00082-5; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; Sacerdoti-Sierra N, 1997, J BIOL CHEM, V272, P30760, DOI 10.1074/jbc.272.49.30760; Sambrook J., 2002, MOL CLONING LAB MANU; SEYFANG A, 1993, EUR J BIOCHEM, V214, P593, DOI 10.1111/j.1432-1033.1993.tb17958.x; Smith TM, 1999, BIOCHEMISTRY-US, V38, P5849, DOI 10.1021/bi990171k; Taylor K, 1996, INFECT IMMUN, V64, P4115, DOI 10.1128/IAI.64.10.4115-4122.1996; Tosomba OM, 1996, EXP PARASITOL, V84, P429, DOI 10.1006/expr.1996.0131; ULHAS P, 1991, BIOCHIM BIOPHYS ACTA, V1092, P256; VANDERGEER P, 1994, CELL BIOL, V10, P251; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Walter J, 1996, J BIOL CHEM, V271, P111, DOI 10.1074/jbc.271.1.111; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8	51	48	48	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8863	8871		10.1074/jbc.275.12.8863	http://dx.doi.org/10.1074/jbc.275.12.8863			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722732	hybrid			2022-12-27	WOS:000086507700082
J	Jiang, RF; Gao, BC; Prasad, K; Greene, LE; Eisenberg, E				Jiang, RF; Gao, BC; Prasad, K; Greene, LE; Eisenberg, E			Hsc70 chaperones clathrin and primes it to interact with vesicle membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLES; UNCOATING ATPASE; ASSEMBLY PROTEIN; MEDIATED ENDOCYTOSIS; MOLECULAR CHAPERONE; NERVE-TERMINALS; RECEPTOR; ADAPTERS; AUXILIN; BASKETS	When Hsc70 uncoats clathrin-coated vesicles in an auxilin- and ATP dependent reaction, a single round of rapid uncoating occurs followed by very slow steady-state uncoating. We now show that this biphasic time course occurs because Hsc70 sequentially forms two types of complex with the dissociated clathrin triskelions. The first round of clathrin uncoating is driven by formation of a pre steady-state assembly protein (AP)-clathrin-Hsc70-ADP complex. Then, following exchange of ADP with ATP, a steady-state AP-clathrin-Hsc70-ATP complex forms that ties up Hsc70, preventing further uncoating, This steady-state complex forms only during uncoating in the presence of APs; in the absence of APs, Hsc70 rapidly dissociates from the uncoated clathrin and continues to carry out uncoating, Whether it is complexed with ATP or ADP, the steady-state complex has very different properties from the pre-steady-state complex in that it cannot be immunoprecipitated by anti-clathrin antibodies and is readily dissociated by fast protein liquid chromatography. Remarkably, when the steady-state complex is incubated with uncoated vesicle membranes in ATP, the pre steady state complex reforms, suggesting that the clathrin triskelions in the steady-state complex rebind to the membranes and are again uncoated by Hsc70. We propose that Hsc70 not only uncoats clathrin but also chaperones it to prevent it from inappropriately polymerizing in the cell cytosol and primes it to reform clathrin coated pits.	NHLBI, Cell Biol Lab, Sect Cell Physiol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Eisenberg, E (corresponding author), NHLBI, Cell Biol Lab, Sect Cell Physiol, NIH, Bldg 10,Rm B1-22, Bethesda, MD 20892 USA.	eisenbee@nhlbi.nih.gov	Gimenez, Luis E Diaz/D-9291-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000516, Z01HL000516] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; Barouch W, 1997, BIOCHEMISTRY-US, V36, P4303, DOI 10.1021/bi962727z; BAROUCH W, 1994, J BIOL CHEM, V269, P28563; Bauerfeind R, 1997, J BIOL CHEM, V272, P30984, DOI 10.1074/jbc.272.49.30984; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; BLACK MM, 1991, J NEUROSCI, V11, P1163; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; CHOCK SP, 1979, J BIOL CHEM, V254, P3229; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; Dell'Angelica EC, 1999, J BIOL CHEM, V274, P7278, DOI 10.1074/jbc.274.11.7278; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; EISENBERG E, 1998, MOL BIOL CHAPERONES, P329; GAO BC, 1991, J BIOL CHEM, V266, P19565; GAO BC, 1993, J BIOL CHEM, V268, P8507; GAO BC, 1995, BIOCHEMISTRY-US, V34, P11882, DOI 10.1021/bi00037a028; GREENE LE, 1990, J BIOL CHEM, V265, P6682; Haffner C, 1997, FEBS LETT, V419, P175, DOI 10.1016/S0014-5793(97)01451-8; Hannan LA, 1998, MOL BIOL CELL, V9, P2217, DOI 10.1091/mbc.9.8.2217; HEUSER J, 1989, J CELL BIOL, V109, P1457, DOI 10.1083/jcb.109.4.1457; Hirst J, 1999, MOL BIOL CELL, V10, P2787, DOI 10.1091/mbc.10.8.2787; JADOT M, 1992, J BIOL CHEM, V267, P11069; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; Jiang RF, 1997, J BIOL CHEM, V272, P6141, DOI 10.1074/jbc.272.10.6141; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; McLauchlan H, 1998, CURR BIOL, V8, P34, DOI 10.1016/S0960-9822(98)70018-1; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; NANDI PK, 1982, P NATL ACAD SCI-BIOL, V79, P5881, DOI 10.1073/pnas.79.19.5881; PRASAD K, 1988, BIOCHEMISTRY-US, V27, P6098, DOI 10.1021/bi00416a040; PRASAD K, 1993, J BIOL CHEM, V268, P23758; Prasad K, 1995, J BIOL CHEM, V270, P30551, DOI 10.1074/jbc.270.51.30551; PRASAD K, 1994, J BIOL CHEM, V269, P6931; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; SMYTHE E, 1992, J CELL BIOL, V119, P1163, DOI 10.1083/jcb.119.5.1163; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; UNANUE ER, 1981, CELL, V26, P439, DOI 10.1016/0092-8674(81)90213-0; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; Zhao X, 1998, MOL BIOL CELL, V9, p340A	44	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8439	8447		10.1074/jbc.275.12.8439	http://dx.doi.org/10.1074/jbc.275.12.8439			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722678	hybrid			2022-12-27	WOS:000086507700028
J	Johnson, TW; Shen, GZ; Zybailov, B; Kolling, D; Reategui, R; Beauparlant, S; Vassiliev, IR; Bryant, DA; Jones, AD; Golbeck, JH; Chitnis, PR				Johnson, TW; Shen, GZ; Zybailov, B; Kolling, D; Reategui, R; Beauparlant, S; Vassiliev, IR; Bryant, DA; Jones, AD; Golbeck, JH; Chitnis, PR			Recruitment of a foreign quinone into the A(1) site of photosystem I - I. Genetic and physiological characterization of phylloquinone biosynthetic pathway mutants in Synechocystis sp PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MENAQUINONE VITAMIN-K2 BIOSYNTHESIS; ESCHERICHIA-COLI; ELECTRON-TRANSFER; REACTION CENTERS; SYNECHOCOCCUS SP; COMPLEX; CYANOBACTERIA; SEQUENCE; SUBUNIT	Genes encoding enzymes of the biosynthetic pathway leading to phylloquinone, the secondary electron acceptor of photosystem (PS) I, were identified in Synechocystis sp, PCC 6803 by comparison with genes encoding enzymes of the menaquinone biosynthetic pathway in Escherichia coli, Targeted inactivation of the menA and menB genes, which code for phytyl transferase and 1,4-dihydroxy-2-naphthoate synthase, respectively, prevented the synthesis of phylloquinone, thereby confirming the participation of these two gene products in the biosynthetic pathway. The menA and menB mutants grow photoautotrophically under low light conditions (20 mu E m(-2) s(-1)), with doubling times twice that of the mild type, but they are unable to grow under high light conditions (120 mu E m(-2) s(-1)). The menA and menB mutants grow photoheterotrophically on media supplemented with glucose under low light conditions, with doubling times similar to that of the wild type, but they are unable to grow under high light conditions unless atrazine is present to inhibit PS II activity. The level of active PS II per cell in the menA and menB mutant strains is identical to that of the wild type, but the level of active PS I is about 50-60% that of the wild type as assayed by low temperature fluorescence, P700 photoactivity, and electron transfer rates. PS I complexes isolated from the menA and menB mutant strains contain the full complement of polypeptides, show photoreduction of F-A and F-B at 15 K, and support 82-84% of the wild type rate of electron transfer from cytochrome c(6) to flavodoxin, HPLC analyses show high levels of plastoquinone-g in PS I complexes from the menA and menB mutants but not from the wild type. We propose that in the absence of phylloquinone, PS I recruits plastoquinone-g into the A(1) site, where it functions as an efficient cofactor in electron transfer from A(0) to the iron-sulfur clusters.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Penn State Univ, Dept Chem, University Pk, PA 16802 USA	Iowa State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Chitnis, PR (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.	chitnis@iastate.edu	Jones, Arthur D/C-2670-2013	Jones, A. Daniel/0000-0002-7408-6690; Zybailov, Boris/0000-0003-2432-9145				BIGGINS J, 1988, BIOCHEMISTRY-US, V27, P1494, DOI 10.1021/bi00405a015; BIGGINS J, 1989, FEBS LETT, V250, P271, DOI 10.1016/0014-5793(89)80736-7; CHITNIS VP, 1993, J BIOL CHEM, V268, P11678; CRANE FL, 1960, BIOCHEM BIOPH RES CO, V3, P37, DOI 10.1016/0006-291X(60)90099-1; DRISCOLL JR, 1992, J BACTERIOL, V174, P5063, DOI 10.1128/JB.174.15.5063-5071.1992; Golbeck J. H., 1995, CRC HDB ORGANIC PHOT, P1407; GOLBECK JH, 1993, P NATL ACAD SCI USA, V90, P1642, DOI 10.1073/pnas.90.5.1642; HILL KF, 1990, ARCH MICROBIOL, V153, P355, DOI 10.1007/BF00249005; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; Kaneko T, 1996, DNA Res, V3, P109; LOCKAU W, 1987, PROGR PHOTOSYNTHESIS, V2, P37; MacKinney G, 1941, J BIOL CHEM, V140, P315; MALKIN R, 1986, FEBS LETT, V208, P343, DOI 10.1016/0014-5793(86)81046-8; MAXWELL PC, 1976, BIOCHEMISTRY-US, V15, P3975, DOI 10.1021/bi00663a011; NITSCHKE W, 1991, TRENDS BIOCHEM SCI, V16, P241, DOI 10.1016/0968-0004(91)90095-D; Nugent JHA, 1996, EUR J BIOCHEM, V237, P519, DOI 10.1111/j.1432-1033.1996.00519.x; PALANIAPPAN C, 1992, J BACTERIOL, V174, P8111, DOI 10.1128/JB.174.24.8111-8118.1992; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Redding K, 1999, J BIOL CHEM, V274, P10466, DOI 10.1074/jbc.274.15.10466; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHOEDER HU, 1986, FEBS LETT, V199, P23, DOI 10.1016/0014-5793(86)81216-9; SCHULTZ G, 1985, PHYSIOL PLANTARUM, V64, P123, DOI 10.1111/j.1399-3054.1985.tb01222.x; SETIF P, 1987, BIOCHIM BIOPHYS ACTA, V894, P146, DOI 10.1016/0005-2728(87)90184-8; SHARMA V, 1992, J BACTERIOL, V174, P5057, DOI 10.1128/JB.174.15.5057-5062.1992; Sharma V, 1996, GENE, V168, P43, DOI 10.1016/0378-1119(95)00721-0; SHEN GZ, 1993, BIOCHEMISTRY-US, V32, P5109, DOI 10.1021/bi00070a019; SHEN GZ, 1994, J BIOL CHEM, V269, P13904; SHEN GZ, 1995, PHOTOSYNTH RES, V44, P41, DOI 10.1007/BF00018295; TAKAHASHI Y, 1985, PHOTOSYNTH RES, V6, P183, DOI 10.1007/BF00032792; Yang F, 1998, J PHYS CHEM B, V102, P8288, DOI 10.1021/jp981952i; ZIEGLER K, 1989, Z NATURFORSCH C, V44, P468; Zybailov B, 2000, J BIOL CHEM, V275, P8531, DOI 10.1074/jbc.275.12.8531	33	113	120	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8523	8530		10.1074/jbc.275.12.8523	http://dx.doi.org/10.1074/jbc.275.12.8523			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722690	hybrid			2022-12-27	WOS:000086507700040
J	Kawahara, K; Morishita, T; Nakamura, T; Hamada, F; Toyoshima, K; Akiyama, T				Kawahara, K; Morishita, T; Nakamura, T; Hamada, F; Toyoshima, K; Akiyama, T			Down-regulation of beta-catenin by the colorectal tumor suppressor APC requires association with axin and beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WNT SIGNALING PATHWAY; ADENOMATOUS POLYPOSIS-COLI; GLYCOGEN-SYNTHASE KINASE-3; TRANSCRIPTION FACTOR LEF-1; XENOPUS EMBRYOS; GENE-PRODUCT; FUNCTIONAL INTERACTION; NEGATIVE REGULATOR; SOMATIC MUTATIONS; PROTEIN	The tumor suppressor adenomatous polyposis coli (APC) is mutated in familial adenomatous polyposis and in sporadic colorectal tumors. APC forms a complex with beta-catenin, Axin, and glycogen synthase kinase-3 beta and induces the degradation of beta-catenin. In the present study, me examined whether APC association with Axin is required for degradation of beta-catenin. We found that a fragment of APC that induces beta-catenin degradation was rendered inactive by disruption of its Axin-binding sites. Also, overexpression of an Axin fragment spanning the regulator of the G-protein signaling domain inhibited APC-mediated beta-catenin degradation. An APC fragment with mutated beta-catenin-binding sites but intact Axin-binding sites also failed to induce degradation of beta-catenin. These results suggest that APC requires interaction with Axin and beta-catenin to down-regulate beta-catenin.	Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Tokyo 113, Japan; Osaka Univ, Inst Microbial Dis, Dept Oncogene Res, Suita, Osaka 565, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Higashinari Ku, Osaka 537, Japan	University of Tokyo; Osaka University; Osaka Medical Center for Cancer & Cardiovascular Diseases	Akiyama, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 113, Japan.							Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; MIYASHIRO I, 1995, ONCOGENE, V11, P89; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1997, CANCER RES, V57, P4624; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Senda T, 1996, BIOCHEM BIOPH RES CO, V223, P329, DOI 10.1006/bbrc.1996.0894; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1995, CANCER RES, V55, P2972; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	40	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8369	8374		10.1074/jbc.275.12.8369	http://dx.doi.org/10.1074/jbc.275.12.8369			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722668	hybrid			2022-12-27	WOS:000086507700018
J	Li, XH; Wright, PM; Lu, AL				Li, XH; Wright, PM; Lu, AL			The C-terminal domain of MutY glycosylase determines the 7,8-dihydro-8-oxo-guanine specificity and is crucial for mutation avoidance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI MUTY; DNA-REPAIR ENZYME; NUCLEOTIDE EXCISION-REPAIR; G-A MISPAIRS; MISMATCH REPAIR; ENDONUCLEASE-III; SUBSTRATE-SPECIFICITY; CATALYTIC MECHANISM; DAMAGED DNA; GENE-PRODUCT	Escherichia coli MutY is an adenine DNA glycosylase active on DNA substrates containing A/G, A/8-oxoG, or A/C mismatches and also has a weak guanine glycosylase activity on G/8-oxoG-containing DNA. The N-terminal domain of MutY, residues 1-226, has been shown to retain catalytic activity. Substrate binding, glycosylase, and Schiff base intermediate formation activities of the truncated and intact MutY were compared. MutY has high binding affinity with 8-oxoG when mispaired with A, G, T, C, or inosine, The truncated protein has more than 18-fold Lower affinities for binding various 8-oxoG-containing mismatches when compared with intact MutY. MutY catalytic activity toward A/8-oxoG-containing DNA is much faster than that on A/G-containing DNA whereas deletion of the C-terminal domain reduces its catalytic preference for A/8-oxoG-DNA over A/G-DNA. MutY exerts more inhibition on the catalytic activity of MutM (Fpg) protein than does truncated MutY, The tight binding of MutY with GO mispaired with T, G, and apurinic/apyrimidinic sites may be involved in the regulation of MutM activity. An E. colt mutY strain that produces an N-terminal 249-residue truncated MutY confers a mutator phenotype, These findings strongly suggest that the C-terminal domain of MutY determines the 8-oxoG specificity and is crucial for mutation avoidance by oxidative damage.	Univ Maryland, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Lu, AL (corresponding author), Univ Maryland, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA.				NIGMS NIH HHS [GM 35132] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035132] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA M, 1989, P NATL ACAD SCI USA, V86, P3949, DOI 10.1073/pnas.86.11.3949; AU KG, 1988, P NATL ACAD SCI USA, V85, P9163, DOI 10.1073/pnas.85.23.9163; AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; BAILLY V, 1987, BIOCHEM J, V242, P565, DOI 10.1042/bj2420565; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; Braun JEF, 1997, MUTAT RES-DNA REPAIR, V384, P45, DOI 10.1016/S0921-8777(97)00014-1; Bridges BA, 1996, MOL GEN GENET, V251, P352, DOI 10.1007/BF02172526; Bulychev NV, 1996, BIOCHEMISTRY-US, V35, P13147, DOI 10.1021/bi960694h; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHETSANGA CJ, 1979, NUCLEIC ACIDS RES, V6, P3673, DOI 10.1093/nar/6.11.3673; David SS, 1998, CHEM REV, V98, P1221, DOI 10.1021/cr980321h; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; DODSON ML, 1994, J BIOL CHEM, V269, P32709; Duarte V, 1999, NUCLEIC ACIDS RES, V27, P496, DOI 10.1093/nar/27.2.496; Gogos A, 1996, BIOCHEMISTRY-US, V35, P16665, DOI 10.1021/bi960843w; Golinelli MP, 1999, BIOCHEMISTRY-US, V38, P6997, DOI 10.1021/bi982300n; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; KATCHER HL, 1983, BIOCHEMISTRY-US, V22, P4071, DOI 10.1021/bi00286a013; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; Lu AL, 1996, J BIOL CHEM, V271, P24138, DOI 10.1074/jbc.271.39.24138; Lu AL, 1998, J BIOL CHEM, V273, P25098, DOI 10.1074/jbc.273.39.25098; LU AL, 1995, J BIOL CHEM, V270, P23582, DOI 10.1074/jbc.270.40.23582; LU AL, 1988, GENETICS, V118, P593; LU AL, 1988, CELL, V54, P805, DOI 10.1016/S0092-8674(88)91109-9; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Manuel RC, 1996, J BIOL CHEM, V271, P16218, DOI 10.1074/jbc.271.27.16218; Manuel RC, 1997, BIOCHEMISTRY-US, V36, P11140, DOI 10.1021/bi9709708; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Nash HM, 1997, CHEM BIOL, V4, P693, DOI 10.1016/S1074-5521(97)90225-8; NGHIEM Y, 1988, P NATL ACAD SCI USA, V85, P2709, DOI 10.1073/pnas.85.8.2709; Ni TT, 1999, MOL CELL, V4, P439, DOI 10.1016/S1097-2765(00)80346-9; Noll DM, 1999, BIOCHEMISTRY-US, V38, P6374, DOI 10.1021/bi990335x; Porello SL, 1998, BIOCHEMISTRY-US, V37, P14756, DOI 10.1021/bi981594+; RADICELLA JP, 1988, P NATL ACAD SCI USA, V85, P9674, DOI 10.1073/pnas.85.24.9674; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SU SS, 1988, J BIOL CHEM, V263, P6829; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; TCHOU J, 1993, MUTAT RES, V299, P277, DOI 10.1016/0165-1218(93)90104-L; TCHOU J, 1994, J BIOL CHEM, V269, P15318; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; TSAIWU JYYJ, 1991, J BACTERIOL, V173, P1902, DOI 10.1128/jb.173.6.1902-1910.1991; Williams SD, 1998, NUCLEIC ACIDS RES, V26, P5123, DOI 10.1093/nar/26.22.5123; Williams SD, 1999, BIOCHEMISTRY-US, V38, P15417, DOI 10.1021/bi992013z; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Wright PM, 1999, J BIOL CHEM, V274, P29011, DOI 10.1074/jbc.274.41.29011; Yamagata Y, 1996, CELL, V86, P311, DOI 10.1016/S0092-8674(00)80102-6; Zhang QM, 1998, NUCLEIC ACIDS RES, V26, P4669, DOI 10.1093/nar/26.20.4669; Zharkov DO, 1998, BIOCHEMISTRY-US, V37, P12384, DOI 10.1021/bi981066y	62	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8448	8455		10.1074/jbc.275.12.8448	http://dx.doi.org/10.1074/jbc.275.12.8448			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722679	hybrid			2022-12-27	WOS:000086507700029
J	Mukhopadhyay, A; Manna, SK; Aggarwal, BB				Mukhopadhyay, A; Manna, SK; Aggarwal, BB			Pervanadate-induced nuclear factor-kappa B activation requires tyrosine phosphorylation and degradation of I kappa B alpha - Comparison with tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; TRANSCRIPTION FACTOR; PROTEOLYTIC DEGRADATION; PHOSPHATASE INHIBITORS; INTACT-CELLS; T-CELLS; KINASE; PROTEINS; SIGNAL; EXPRESSION	Tumor necrosis factor activates nuclear transcription factor kappa B (NF-kappa B) by inducing serine phosphorylation of the inhibitory subunit of NF-kappa B (I kappa B alpha), which leads to its ubiquitination and degradation. In contrast, per-vanadate (PV) activates NF-kappa B and induces tyrosine phosphorylation of I kappa B alpha (Singh, S., Darney, B. G., and Aggarwal, B. B. (1996) J. Biol. Chem. 271, 31049-31054; Imbert, V., Rupee, R. A., Antonia, L., Pahl, H. L., Traenckner, E. B.-M., Mueller-Dieckmann, C., Farahifar, D., Rossi, B., Auderger, P., Baeuerle, P. A., and Peyron, J.-F. (1996) Cell 86, 787-798). Whether PV also induces I kappa B alpha degradation and whether degradation is required for NF-kappa B activation are not understood. We investigated the effect of PV-induced tyrosine phosphorylation on I kappa B alpha degradation and NF-kappa B activation. PV activated NF-kappa B, as determined by DNA binding, NF-kappa B-dependent reporter gene expression, and phosphorylation and degradation of I kappa B alpha. Maximum degradation of I kappa B alpha occurred at 180 min, followed by NF-kappa B-dependent I kappa B alpha resynthesis. N-Acetylleucylleucylnorlucinal, a proteasome inhibitor, blocked both I kappa B alpha degradation and NF-kappa B activation, suggesting that the I kappa B alpha degradation is required for NF-kappa B activation. PV did not induce serine phosphorylation of I kappa B alpha but induced phosphorylation at tyrosine residue 42. Unlike tumor necrosis factor (TNF), PV did not induce ubiquitination of I kappa B alpha Like TNF, however, PV induced phosphorylation and degradation of I kappa B alpha, and subsequent NF-kappa B activation, which could be blocked by N-tosyl-L-phenylalanine chloromethyl ketone, calpeptin, and pyrrolidine dithiocarbomate, suggesting a close Link between PV-induced NF-kappa B activation and I kappa B alpha degradation. Overall, our studies demonstrate that PV activates NF-kappa B, which, unlike TNF, requires tyrosine phosphorylation of I kappa B alpha and its degradation.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Aggarwal, Bharat B/G-3388-2013					ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHATURVEDI MM, 1999, IN PRESS METHODS ENZ; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; EICHER DM, 1994, J IMMUNOL, V152, P2710; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GRILLI M, 1993, INT REV CYTOL, V143, P1; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; HEFFETZ D, 1992, BIOCHEM J, V288, P631, DOI 10.1042/bj2880631; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Imbert V, 1996, J INFLAMM, V46, P65; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; KOONG AC, 1994, CANCER RES, V54, P1425; Krejsa CM, 1997, J BIOL CHEM, V272, P11541; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MENON SD, 1995, J BIOL CHEM, V270, P18881; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Natarajan K, 1998, ARCH BIOCHEM BIOPHYS, V352, P59, DOI 10.1006/abbi.1998.0576; RAFIEE P, 1995, J IMMUNOL, V154, P4785; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; SUZUKI K, 1992, ANN NY ACAD SCI, V674, P218, DOI 10.1111/j.1749-6632.1992.tb27490.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Uehara T, 1999, J BIOL CHEM, V274, P15875, DOI 10.1074/jbc.274.22.15875; Vecchi M, 1998, J BIOL CHEM, V273, P20589, DOI 10.1074/jbc.273.32.20589; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VISNITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	45	65	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 24	2000	275	12					8549	8555		10.1074/jbc.275.12.8549	http://dx.doi.org/10.1074/jbc.275.12.8549			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	304WU	10722693	hybrid			2022-12-27	WOS:000086507700043
J	Fujii, T; Garcia-Bermejo, ML; Bernabo, JL; Caamano, J; Ohba, M; Kuroki, T; Li, LW; Yuspa, SH; Kazanietz, MG				Fujii, T; Garcia-Bermejo, ML; Bernabo, JL; Caamano, J; Ohba, M; Kuroki, T; Li, LW; Yuspa, SH; Kazanietz, MG			Involvement of protein kinase C delta (PKC delta) in phorbol ester-induced apoptosis in LNCaP prostate cancer cells - Lack of proteolytic cleavage of PKC delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ICE-LIKE PROTEASE; TYROSINE PHOSPHORYLATION; 12-O-TETRADECANOYLPHORBOL-13-ACETATE-INDUCED APOPTOSIS; HUMAN KERATINOCYTES; TUMOR PROMOTERS; ACTIVATION; EXPRESSION; INDUCTION; OVEREXPRESSION; GROWTH	Phorbol esters, the activators of protein kinase C (PKC), induce apoptosis in androgen-sensitive LNCaP prostate cancer cells. The role of individual PKC isozymes as mediators of this effect has not been thoroughly examined to date. To study the involvement of the novel isozyme PRC delta we used a replication-deficient. adenovirus (PKC delta AdV), which allowed for a tightly controlled expression of PKC delta in LNCaP cells. A significant reduction in cell number was observed after infection of LNCaP cells with PKC delta AdV. Overexpression of PKC delta markedly enhanced the apoptotic effect of phorbol 12-myristate 13-acetate in LNCaP cells. PKC delta-mediated apoptosis was substantially reduced by the pan-caspase inhibitor z-VAD and by Bcl-2 overexpression. Importantly, and contrary to other cell types, PKC delta-mediated apoptosis does not involve its proteolytic cleavage by caspase-3, suggesting that allosteric activation of PHC delta is sufficient to trigger apoptosis in LNCaP cells. In addition, phorbol ester-induced apoptosis was blocked by a kinase-deficient mutant of PHC delta, supporting the concept that PKC delta plays an important role in the regulation of apoptotic cell death in LNCaP prostate cancer cells.	Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA; Showa Univ, Sch Pharmaceut Sci, Dept Microbiol, Shinagawa Ku, Tokyo 1428555, Japan; NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Showa University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kazanietz, MG (corresponding author), Univ Penn, Sch Med, Ctr Expt Therapeut, 816 Biomed Res Bldg 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.		Caamano, Jorge/I-6778-2012; García-Bermejo, María Laura/E-1542-2015; Caamano, Jorge/O-7530-2019; Kuroki, Toshio/A-9500-2011	Caamano, Jorge/0000-0003-3530-7056; García-Bermejo, María Laura/0000-0002-8167-2276; Caamano, Jorge/0000-0003-3530-7056; Kuroki, Toshio/0000-0001-6369-4351				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BERKNER KL, 1992, CURR TOP MICROBIOL, V158, P39; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; BLUMBERG PM, 1988, CANCER RES, V48, P1; Caloca MJ, 1997, J BIOL CHEM, V272, P26488, DOI 10.1074/jbc.272.42.26488; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; DAY ML, 1994, CELL GROWTH DIFFER, V5, P735; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; DENNING MF, 1993, J BIOL CHEM, V268, P26079; DEVENTE JE, 1995, J CLIN INVEST, V96, P1874, DOI 10.1172/JCI118233; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Frutos S, 1999, J BIOL CHEM, V274, P10765, DOI 10.1074/jbc.274.16.10765; Garzotto M, 1998, CANCER RES, V58, P2260; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Griffiths G, 1996, BIOCHEM BIOPH RES CO, V222, P802, DOI 10.1006/bbrc.1996.0830; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; He DL, 1997, CANCER RES, V57, P1868; Heerdt BG, 1999, CANCER RES, V59, P1584; Henkels KM, 1999, CANCER RES, V59, P3077; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; KAZANIETZ MG, 1994, MOL PHARMACOL, V46, P374; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KAZANIETZ MG, 1998, P INT CANC C, P1091; Kiley SC, 1999, CANCER RES, V59, P3230; Li LW, 1999, MOL CELL BIOL, V19, P8547; LI WQ, 1994, J BIOL CHEM, V269, P2349; Marcelli M, 1999, CANCER RES, V59, P382; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Mohr S, 1998, P NATL ACAD SCI USA, V95, P5045, DOI 10.1073/pnas.95.9.5045; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; OJEDA F, 1992, INT J RADIAT BIOL, V61, P663, DOI 10.1080/09553009214551471; Powell CT, 1996, CELL GROWTH DIFFER, V7, P419; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; RAFFO AJ, 1995, CANCER RES, V55, P4438; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Shanmugam M, 1998, ONCOGENE, V16, P1649, DOI 10.1038/sj.onc.1201684; Shao RG, 1997, J BIOL CHEM, V272, P31321, DOI 10.1074/jbc.272.50.31321; SHARKEY NA, 1985, CANCER RES, V45, P19; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; Sternsdorf T, 1999, MOL CELL BIOL, V19, P5170; SZALLASI Z, 1994, J BIOL CHEM, V269, P27159; Tanaka Y, 1999, EXP CELL RES, V247, P514, DOI 10.1006/excr.1998.4376; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Whitman SP, 1997, J BIOL CHEM, V272, P23481, DOI 10.1074/jbc.272.38.23481; YANG CL, 1995, CANCER RES, V55, P4210	55	190	194	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7574	7582		10.1074/jbc.275.11.7574	http://dx.doi.org/10.1074/jbc.275.11.7574			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713064	hybrid			2022-12-27	WOS:000085913300024
J	Gentry, JJ; Casaccia-Bonnefil, P; Carter, BD				Gentry, JJ; Casaccia-Bonnefil, P; Carter, BD			Nerve growth factor activation of nuclear factor kappa B through its p75 receptor is an anti-apoptotic signal in RN22 schwannoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTROPHIN RECEPTOR; PC12 CELLS; DEATH; INDUCTION; NEURONS; NGF; POTENTIATION; HIPPOCAMPAL; SUPPRESSION; INHIBITION	Recent evidence indicates that nerve growth factor (NGF) produces its effects through signaling contributions from both TrkA and the p75 receptor. In contrast to its trophic actions through TrkA, NGF binding to p75 has been shown to activate programmed cell death through a mechanism involving the stress kinase JNK. However, this receptor also activates nuclear factor kappa B (NF-kappa B), the role of which has yet to be determined. We investigated the function of p75-mediated NF-kappa B stimulation in regulating cell survival in the rat schwannoma cell line RN22, which expresses p75, but not TrkA Gel shift assays demonstrated activation of NF-kappa B in response to NGF within 30 min and lasting at least 4 h, NGF also stimulated JNK in the cells (detected by in vitro kinase assays) with a similar time course. Preventing activation of NF-kappa B with the specific inhibitor SN50 resulted in NGF-induced cell loss. Similarly, transfection of the cells with a mutant form of the endogenous NF-kappa B inhibitor (I kappa B alpha Delta N), which cannot be degraded and therefore remains bound to NF-kappa B, preventing its activation, resulted in a significant increase in the number of apoptotic cells following NGF treatment. These results suggest that NGF activation of NF-kappa B through the p75 receptor promotes survival, counterbalancing the pro-apoptotic signal.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Nashville, TN 37232 USA; NYU, Med Ctr, Skirball Inst, Dept Mol Neurobiol, New York, NY 10012 USA	Vanderbilt University; Vanderbilt University; New York University	Carter, BD (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA.	bruce.carter@mcmail.vanderbilt.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038220] Funding Source: NIH RePORTER; NINDS NIH HHS [NS38220] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Chao M, 1998, BRAIN RES REV, V26, P295, DOI 10.1016/S0165-0173(97)00036-2; CHENG B, 1991, NEURON, V7, P1031, DOI 10.1016/0896-6273(91)90347-3; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Davey F, 1998, CURR BIOL, V8, P915, DOI 10.1016/S0960-9822(07)00371-5; Frade JM, 1999, DEVELOPMENT, V126, P683; Frade JM, 1996, NATURE, V383, P166; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Grinspan JB, 1996, J NEUROSCI, V16, P6107; Hamanoue M, 1999, MOL CELL NEUROSCI, V14, P28, DOI 10.1006/mcne.1999.0770; HEUMANN R, 1987, P NATL ACAD SCI USA, V84, P8735, DOI 10.1073/pnas.84.23.8735; Jessen KR, 1997, J ANAT, V191, P501, DOI 10.1046/j.1469-7580.1997.19140501.x; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; Kim WK, 1998, J NEUROSCI RES, V54, P17, DOI 10.1002/(SICI)1097-4547(19981001)54:1<17::AID-JNR3>3.0.CO;2-K; Kuner P, 1998, J NEUROSCI RES, V54, P465, DOI 10.1002/(SICI)1097-4547(19981115)54:4<465::AID-JNR4>3.0.CO;2-T; Ladiwala U, 1998, J NEUROSCI, V18, P1297; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Ozes ON, 1999, NATURE, V401, P82; PFEIFFER SE, 1972, P NATL ACAD SCI USA, V69, P2885, DOI 10.1073/pnas.69.10.2885; Rong YQ, 1996, J NEUROCHEM, V67, P662; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Soilu-Hanninen M, 1999, J NEUROSCI, V19, P4828; Taglialatela G, 1997, J NEUROSCI RES, V47, P155; TAMMARIELLO S, 1999, IN PRESS PROGRAMMED; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P4094, DOI 10.1073/pnas.83.11.4094; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WOOD JN, 1995, NEUROSCI LETT, V192, P41, DOI 10.1016/0304-3940(95)11603-T; Yeo TT, 1997, J NEUROSCI, V17, P7594; Yoon SO, 1998, J NEUROSCI, V18, P3273	39	95	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					7558	7565		10.1074/jbc.275.11.7558	http://dx.doi.org/10.1074/jbc.275.11.7558			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713062	hybrid			2022-12-27	WOS:000085913300022
J	Vestner, B; Waldmann, T; Gruss, C				Vestner, B; Waldmann, T; Gruss, C			Histone octamer dissociation is not required for in vitro replication of simian virus 40 minichromosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; IN-VITRO; CHROMATIN ACCESSIBILITY; TRANSCRIPT ELONGATION; XENOPUS OOCYTES; TOPOISOMERASE-I; NUCLEOSOME CORE; RNA-POLYMERASE; CELL-EXTRACTS; T-ANTIGEN	Replication of chromosomal templates requires the passage of the replication machinery through nucleosomally organized DNA. To gain further insights into these processes we have used chromatin that was reconstituted with dimethyl suberimidate-cross-linked histone octamers as template in the SV40 in vitro replication system. By supercoiling analysis we found that crosslinked histone octamers were reconstituted with the same kinetic and efficiency as control octamers. Minichromosomes with cross-linked nucleosomes were completely replicated, although the efficiency of replication was lower compared with control chromatin. Analysis of the chromatin structure of the replicated DNA revealed that the cross-linked octamer is transferred to the daughter strands. Thus, our data imply that histone octamer dissociation is not a prerequisite for the passage of the replication machinery and the transfer of the parental nucleosomes.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany	University of Konstanz	Gruss, C (corresponding author), Univ Konstanz, Dept Biol, Univ Str 10, D-78457 Constance, Germany.							Alexiadis V, 1998, EMBO J, V17, P3428, DOI 10.1093/emboj/17.12.3428; ALMOUZNI G, 1990, NUCLEIC ACIDS RES, V18, P5767, DOI 10.1093/nar/18.19.5767; BONNEANDREA C, 1990, NATURE, V343, P719, DOI 10.1038/343719a0; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; Fotedar A, 1996, J BIOL CHEM, V271, P31627, DOI 10.1074/jbc.271.49.31627; FOTEDAR R, 1989, P NATL ACAD SCI USA, V86, P6459, DOI 10.1073/pnas.86.17.6459; Gasser R, 1996, J MOL BIOL, V258, P224, DOI 10.1006/jmbi.1996.0245; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GERMOND JE, 1976, NUCLEIC ACIDS RES, V3, P3173, DOI 10.1093/nar/3.11.3173; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; Gruss C, 1996, PROG NUCLEIC ACID RE, V52, P337, DOI 10.1016/S0079-6603(08)60971-X; GRUSS C, 1993, EMBO J, V12, P4533, DOI 10.1002/j.1460-2075.1993.tb06142.x; Halmer L, 1997, MOL CELL BIOL, V17, P2624, DOI 10.1128/MCB.17.5.2624; Halmer L, 1998, J BIOL CHEM, V273, P34792, DOI 10.1074/jbc.273.52.34792; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JACKSON V, 1987, BIOCHEMISTRY-US, V26, P2315, DOI 10.1021/bi00382a037; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; Krude T, 1999, EUR J BIOCHEM, V263, P1, DOI 10.1046/j.1432-1327.1999.00508.x; KRUDE T, 1991, MOL CELL BIOL, V11, P6257, DOI 10.1128/MCB.11.12.6257; KRUDE T, 1995, CURR BIOL, V5, P1232, DOI 10.1016/S0960-9822(95)00245-4; LANFORD RE, 1988, VIROLOGY, V167, P72, DOI 10.1016/0042-6822(88)90055-4; LEFFAK IM, 1984, NATURE, V307, P82, DOI 10.1038/307082a0; LEFFAK IM, 1977, CELL, V12, P837, DOI 10.1016/0092-8674(77)90282-3; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; ONEILL TE, 1992, J MOL BIOL, V223, P67, DOI 10.1016/0022-2836(92)90716-W; ONEILL TE, 1993, P NATL ACAD SCI USA, V90, P6203, DOI 10.1073/pnas.90.13.6203; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Quintini G, 1996, MOL CELL BIOL, V16, P2888; RANDALL SK, 1992, J BIOL CHEM, V267, P14259; SANDALTZOPOULOS R, 1994, EMBO J, V13, P373, DOI 10.1002/j.1460-2075.1994.tb06271.x; SAPP M, 1990, J BIOL CHEM, V265, P9357; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; STEIN A, 1979, P NATL ACAD SCI USA, V76, P5000, DOI 10.1073/pnas.76.10.5000; STEIN A, 1977, P NATL ACAD SCI USA, V74, P2780, DOI 10.1073/pnas.74.7.2780; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Wittmeyer J, 1999, BIOCHEMISTRY-US, V38, P8961, DOI 10.1021/bi982851d; ZUCKER K, 1990, J BIOL CHEM, V265, P14487	44	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2000	275	11					8190	8195		10.1074/jbc.275.11.8190	http://dx.doi.org/10.1074/jbc.275.11.8190			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	294LT	10713143	hybrid			2022-12-27	WOS:000085913300103
